<SEC-DOCUMENT>0001345099-24-000022.txt : 20240229
<SEC-HEADER>0001345099-24-000022.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229153101
ACCESSION NUMBER:		0001345099-24-000022
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		99
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MESOBLAST LTD
		CENTRAL INDEX KEY:			0001345099
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37626
		FILM NUMBER:		24703163

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 38
		STREET 2:		55 COLLINS STREET
		CITY:			MELBOURNE, VICTORIA
		STATE:			C3
		ZIP:			3000
		BUSINESS PHONE:		613 9639 6036

	MAIL ADDRESS:	
		STREET 1:		LEVEL 38
		STREET 2:		55 COLLINS STREET
		CITY:			MELBOURNE, VICTORIA
		STATE:			C3
		ZIP:			3000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>meso-20231231.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:meso="http://www.mesoblast.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>meso-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-10">0001345099</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-11">6/30</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-12">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-42" decimals="INF" name="meso:ConversionRatioOfWarrants" scale="0" id="f-229">0.25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-185" decimals="INF" name="meso:OutstandingCommonShareCapitalPercentage" scale="0" id="f-723">5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-186" decimals="INF" name="meso:OutstandingCommonShareCapitalPercentage" scale="0" id="f-724">10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-283" decimals="INF" name="meso:ConversionRatioOfWarrants" scale="0" id="f-990">0.25</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="meso-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="aud"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:unit id="audPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManufacturingAndCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManufacturingAndCommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManagementAndAdministrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManagementAndAdministrationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RegulatoryEnvironmentsAxis">meso:ClinicalManufacturingRegulatoryAndReimbursementApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TaslyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>meso:milestone</xbrli:measure></xbrli:unit><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TaslyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TaslyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:JCRPharmaceuticalsCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:JCRPharmaceuticalsCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:ManufacturingCommercializationExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:ManufacturingCommercializationExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:QuarterlyPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:November2021WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:November2021WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:December2022WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">meso:UnlistedEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">meso:UnlistedEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:ContingentConsiderationProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:ContingentConsiderationProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedUnitSalesPriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedUnitSalesPriceMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">meso:ExpectedSalesVolumeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedSalesVolumesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">meso:ExpectedSalesVolumeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedSalesVolumesMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">meso:ExpectedSalesVolumeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:PaymentAssumptionsMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:PaymentAssumptionsMeasurementInputMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">meso:WarrantsFairValueAtGrantDateDecember222022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">meso:WarrantsFairValueAtGrantDateDecember222022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:November2021WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="year"><xbrli:measure>meso:Year</xbrli:measure></xbrli:unit><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositoryReceiptMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-05</xbrli:startDate><xbrli:endDate>2024-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-05</xbrli:startDate><xbrli:endDate>2024-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:CardiovascularProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:CardiovascularProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:IntravenousProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:IntravenousProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:MSCProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:MSCProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:EmployeeBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:ProvisionForLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:ProvisionForLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:PlacementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:PlacementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">srt:OtherCurrencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CommodityPriceRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CommodityPriceRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:LonzaBioscienceSingaporePteLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:ManufacturingServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001345099</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:ManufacturingServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>meso:segment</xbrli:measure></xbrli:unit><xbrli:unit id="lawsuit"><xbrli:measure>meso:lawsuit</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Rule 13a-16 or 15d-16 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">under the Securities Exchange Act of 1934 </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Filed in the month of February 2024 for the period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">December 31, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-3">001-37626</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4">Mesoblast Limited</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Translation of Registrant&#8217;s name into English)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Australia</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Silviu Itescu</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer and Executive Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-5">Level 38</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-6">55 Collins Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-7">Melbourne</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-8">3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-9">Australia</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 40-F </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_10">Incorporation by Reference</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_10">Foreword</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_10">Currency of Presentation and Certain Defined Terms</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_13">Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_16">Unaudited Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_79">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_121">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_124">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_124">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i0ca481b9662c4533b1d2a0227d14fda1_127">98</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 2</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT ON FORM 6-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE SIX MONTHS ENDED DECEMBER 2023</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span id="ic02d3d574755462a9976ca9718d8a18d_2500"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incorporation by Reference</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Report on Form 6-K (excluding Exhibit 99.1, 99.2 and 99.3) is hereby incorporated by reference in:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22pt">the Registra</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion Statement on Form F-3 (No. 333-267175) that we filed with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on August 31, 2022;  </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22pt">the Post-Effective Amendment No. 1 to the Registration Statement on Form F-3 (No. 333-262301) that we filed with the SEC on December 20, 2022;  </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22pt">the Registration Statement on Form F-3 (No. 333-268890) that we filed with the SEC on December 20, 2022; </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.33pt">the Registration Statement on Form F-3 (No. 333- 270814) that we filed with U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 24, 2023;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.33pt">the Registration Statement on Form F-3 (No. 333-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">272029) that we filed with U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on May 18, 2023; and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22pt">the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-Effective Amendment No. 1 to the registration statements on (i) Form S-8 (File No. 333-210935) filed with the SEC on April 26, 2016, (ii) Form S-8 (File No. 333-220988) filed with the SEC on October 17, 2017, (iii) Form S-8 (File No. 333-240107) filed with the SEC on July 27, 2020, (iv) Form S-8 (File No. 333-261863) filed with the SEC on December 23, 2021, and (v) Form S-8 (File No. 333-267663) filed with the SEC on September 30, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Form 6-K</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shall be deemed to be a part of such registration statements from the date on which this Report is furnished to the SEC, to the extent not superseded by documents or reports subsequently filed or furnished.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreword</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors of Mesoblast Limited (ABN 68 109 431 870) has resolved to submit the following report of Mesoblast </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limited and its subsidiaries for the six months ended December 31, 2023 in compliance with the provisions of the Corporations Act 2001.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Directors of Mesoblast Limited in office at any time during or since the end of the six months ended December 31, 2023 were:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"/><td style="width:19.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Silviu Itescu</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric Rose</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph Swedish</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">William M Burns</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-executive Director, Vice Chairman, Chair of the Nomination and Remuneration Committee</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Spooner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-executive Director, Chair of Audit and Risk Committee (ceased September 20, 2023)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philip Facchina</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-executive Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philip Krause</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-executive Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jane Bell</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-executive Director, Chair of Audit and Risk Committee (from September 20, 2023)</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Mr. Michael Spooner resigned effective September 26, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Currency Presentation and Certain Defined Terms</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Report on Form 6-K, references to &#8220;U.S.&#8221; or &#8220;United States&#8221; are to the United States of America, its territories and its possessions. References to &#8220;US$&#8221; or &#8220;$&#8221; or &#8220;U.S. dollars&#8221; are to the legal currency of the United States, references to &#8220;&#8364;&#8221; or &#8220;Euro&#8221; are to the legal currency of the European Union, references to &#8220;S$&#8221; or &#8220;SGD&#8221; or &#8220;Singapore dollars&#8221; are to the legal currency of Singapore and references to &#8220;A$&#8221; or &#8220;Australian Dollars&#8221; are to the legal currency of Australia. Our financial statements are presented in U.S. dollars and are prepared in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board, or &#8220;IFRS&#8221;. References to a particular &#8220;fiscal&#8221; year are to our fiscal year ended June 30 of such year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references to &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;Mesoblast&#8221; or &#8220;the Group&#8221; shall mean Mesoblast Limited (ABN 68 109 431 870) and its subsidiaries. We own or have rights to trademarks and trade names that we use in connection with the operation of our business, including our corporate name, logos, product names and website names. Other trademarks and trade names appearing in this Report are the property of their respective owners.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_13"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report on Form 6-K includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;target&#8221;, &#8220;likely&#8221;, &#8220;will&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;may&#8221;, &#8220;goal&#8221;, &#8220;objective&#8221; and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of our preclinical and clinical studies, and our research and development programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to advance our manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to take advantage of the potential benefits of the 21st Century Cures Act;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the impact that any future pandemic and other geopolitical instability could have on business operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the commercialization of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential for our product candidates, if they are approved, to be withdrawn from the market due to patient adverse events or deaths;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential benefits of strategic collaboration agreements and our ability to enter into and maintain established strategic collaborations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain intellectual property on our product candidates and our ability to successfully defend these in cases of alleged infringement;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to obtain additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments relating to our competitors and our industry;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the pricing and reimbursement of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general economic conditions; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors&#8221; included elsewhere in this Report on Form 6-K.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read thoroughly this Report on Form 6-K and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements. Other sections of this Report on Form 6-K include additional factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risk factors emerge from time to time and it is not possible for our management to predict all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this Report on Form 6-K relate only to events or information as of the date on which the statements are made in this Report on Form 6-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 5</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div><span><br/></span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_19"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Income Statement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"><tr><td style="width:1.0%"/><td style="width:62.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except per share amount)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-13">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-14">3,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research &amp; development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-15">12,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-16">13,430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing commercialization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ManufacturingCommercialization" format="ixt:num-dot-decimal" scale="3" id="f-17">6,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:ManufacturingCommercialization" format="ixt:num-dot-decimal" scale="3" id="f-18">12,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management and administration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ManagementAndAdministrationExpense" format="ixt:num-dot-decimal" scale="3" id="f-19">11,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:ManagementAndAdministrationExpense" format="ixt:num-dot-decimal" scale="3" id="f-20">13,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:FairValueRemeasurementOfContingentConsideration" scale="3" id="f-21">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:FairValueRemeasurementOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-22">5,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:FairValueRemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-23">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:FairValueRemeasurementOfWarrantLiability" scale="3" id="f-24">712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-25">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-26">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-27">10,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-28">10,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-29">32,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-30">41,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit/(expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-31">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-32">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss attributable to the owners of Mesoblast Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-33">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-34">41,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses per share from continuing operations attributable to the ordinary equity holders of the Group:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic - losses per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="4" sign="-" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-35">3.82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="4" sign="-" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-36">5.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted - losses per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="4" sign="-" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-37">3.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="4" sign="-" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-38">5.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The above consolidated income statement should be read in conjunction with the accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 6</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statement of Comprehensive Income</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.848%"><tr><td style="width:1.0%"/><td style="width:62.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss for the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-39">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-40">41,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other comprehensive (loss)/income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Items that may be reclassified to profit and loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-41">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" scale="3" id="f-42">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Items that will not be reclassified to profit and loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" scale="3" id="f-43">931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" scale="3" id="f-44">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss)/income for the period, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-45">233</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="f-46">292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total comprehensive losses attributable to the owners of Mesoblast Limited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-47">32,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-48">41,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The above consolidated statement of comprehensive income should be read in conjunction with the accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 7</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statement of Changes in Equity</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"/><td style="width:22.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.302%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.814%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share Option<br/>Reserve</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Investment<br/>Revaluation<br/>Reserve</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Foreign<br/>Currency<br/>Translation Reserve</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant<br/>Reserve</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Accumulated losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of July 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-49">1,165,309</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-50">97,924</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-51">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-52">39,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-53">12,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-54">738,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-55">497,044</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-56">41,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-57">41,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-58">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-59">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-60">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive profit/(loss) for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-61">192</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-62">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-63">41,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-64">41,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transactions with owners in their capacity as owners:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contributions of equity net of transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" format="ixt:num-dot-decimal" scale="3" id="f-65">42,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" format="ixt:num-dot-decimal" scale="3" id="f-66">42,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="f-67">42,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="f-68">42,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax credited / (debited) to equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="meso:TaxCreditedOrDebitedToEquity" scale="3" id="f-69">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:TaxCreditedOrDebitedToEquity" scale="3" id="f-70">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer of exercised options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of share-based payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-74">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-75">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:num-dot-decimal" scale="3" id="f-77">1,631</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">1,631</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-80">1,207,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-81">99,555</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-82">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-83">39,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-84">12,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-85">780,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-86">500,002</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of July 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-87">1,249,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-88">101,367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="f-89">543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-90">40,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-91">12,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-92">820,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-93">501,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-94">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-96">931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-97">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="f-98">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive profit/(loss) for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-99">931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-100">1,164</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-101">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-102">32,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transactions with owners in their capacity as owners:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contributions of equity net of transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" format="ixt:num-dot-decimal" scale="3" id="f-103">37,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" format="ixt:num-dot-decimal" scale="3" id="f-104">37,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="f-105">37,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="f-106">37,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tax credited / (debited) to equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="meso:TaxCreditedOrDebitedToEquity" scale="3" id="f-107">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:TaxCreditedOrDebitedToEquity" scale="3" id="f-108">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transfer of exercised options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fair value of share-based payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-111">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-112">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:fixed-zero" scale="3" id="f-113">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">2,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">2,093</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-116">1,286,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-117">103,460</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-118">1,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-119">39,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-120">12,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-121">853,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-122">508,731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The above consolidated statement of changes in equity should be read in conjunction with the accompanying Notes.</span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:7pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 8</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheet </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-123">77,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-124">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-125">3,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-126">6,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-127">3,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-128">3,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-129">85,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-130">81,658</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-131">1,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-132">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-133">4,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-134">5,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="3" id="f-135">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-136">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-137">2,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:OtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-138">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-139">576,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-140">577,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Non-Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-141">585,131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-142">587,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-143">670,285</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-144">669,415</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-145">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-146">20,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-147">8,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-148">6,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentPortionOfLongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-149">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentPortionOfLongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-150">5,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-151">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-152">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-153">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-154">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-155">31,367</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-156">41,982</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-157">17,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-158">16,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-159">107,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-160">102,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-161">3,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-162">3,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DeferredConsiderationNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DeferredConsiderationNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-164">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Non-Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-165">130,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-166">125,595</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-167">161,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-168">167,577</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-169">508,731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-170">501,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-171">1,286,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-172">1,249,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-173">75,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-174">73,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Accumulated losses)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-175">853,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-176">820,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-177">508,731</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-178">501,838</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The above consolidated balance sheet should be read in conjunction with the accompanying Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 9</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statement of Cash Flows</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:CommercializationRevenueReceived" format="ixt:num-dot-decimal" scale="3" id="f-179">3,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:CommercializationRevenueReceived" format="ixt:num-dot-decimal" scale="3" id="f-180">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government grants and tax incentives and credits received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:GovernmentGrantsAndTaxIncentivesAndCreditsReceived" format="ixt:num-dot-decimal" scale="3" id="f-181">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:GovernmentGrantsAndTaxIncentivesAndCreditsReceived" scale="3" id="f-182">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments to suppliers and employees (inclusive of goods and services tax)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" format="ixt:num-dot-decimal" scale="3" id="f-183">33,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" format="ixt:num-dot-decimal" scale="3" id="f-184">34,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="f-185">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="f-186">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="3" id="f-187">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash (outflows) in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-189">26,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-190">30,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:InvestmentInFixedAssets" scale="3" id="f-191">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:InvestmentInFixedAssets" scale="3" id="f-192">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts from investment in sublease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ReceiptsFromInvestmentInSublease" scale="3" id="f-193">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:ReceiptsFromInvestmentInSublease" format="ixt:fixed-zero" scale="3" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="3" id="f-195">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="3" id="f-196">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash (outflows) in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-197">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-198">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of transaction costs from borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:PaymentsOfTransactionCostsFromBorrowings" scale="3" id="f-199">540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:PaymentsOfTransactionCostsFromBorrowings" scale="3" id="f-200">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other costs of finance paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-201">2,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-202">2,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issue of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-203">39,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-204">45,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for share issue costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-205">2,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-206">2,646</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-207">2,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-208">1,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash inflows by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-209">31,600</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-210">38,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-211">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-212">7,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-213">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-214">60,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FX gains/(losses) on the translation of foreign bank accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-215">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-216">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-217">77,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-218">67,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The above consolidated statement of cash flows should be read in conjunction with the accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 10</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesoblast Limited (the &#8220;Company&#8221;) and its subsidiaries (the &#8220;Group&#8221;) are primarily engaged in the development of regenerative medicine products. The Company&#8217;s primary proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The Company was formed in 2004 as an Australian company and has been listed on the Australian Securities Exchange (the &#8220;ASX&#8221;) since 2004. In November 2015, the Company listed in the United States of America (&#8220;U.S.&#8221;) on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) and from this date has been dual-listed in Australia and the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are presented in U.S. dollars (&#8220;$&#8221; or &#8220;USD&#8221; or &#8220;US$&#8221;), unless otherwise noted, including certain amounts that are presented in Australian dollars (&#8220;AUD&#8221; or &#8220;A$&#8221;) and Singapore dollars (&#8220;SGD&#8221; or &#8220;S$&#8221;).</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_37"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" id="f-220" continuedAt="f-220-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-219" continuedAt="f-219-1" escape="true">Basis of preparation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-220-1" continuedAt="f-220-2"><ix:continuation id="f-219-1" continuedAt="f-219-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. The condensed consolidated financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Accounting Standard IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and are unaudited. These condensed interim financial statements do not include all of the notes and disclosures required by International Financial Reporting Standards, as issued by the IASB, for annual consolidated financial statements and should therefore be read in conjunction with our annual report on Form 20-F for the year ended June&#160;30, 2023. In the opinion of management, the interim financial data includes all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the results for the interim periods.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Going concern </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Group held total cash reserves of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-221">77.6</ix:nonFraction> million. During the six months ended December 31, 2023, the Group executed on reprioritization of projects and operational streamlining activities and as a result has reduced net cash usage for operating activities, which was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="meso:MaximumAmountInCashOutflowsFromOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-222">26.6</ix:nonFraction> million the six months ended December&#160;31, 2023, a reduction of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="meso:PercentageOfReductionInCashOutflowsFromOperatingActivities" scale="-2" id="f-223">14</ix:nonFraction>% compared to the prior period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with the Group's overall commercial strategy to complete additional pivotal clinical studies for both the Group's chronic lower back pain and steroid-refractory acute graft versus host disease ("SR-aGVHD") product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) standards) on the Group&#8217;s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Historical cost convention</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income, financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;New and amended standards adopted by the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new or amended standards adopted by the Group in the six months ended December&#160;31, 2023. These interim financial statements follow the same accounting policies as compared to the June&#160;30, 2023 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;New accounting standards and interpretations not yet adopted by the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting standards and interpretations not yet adopted by the Group for the December&#160;31, 2023 reporting period that are expected to materially impact the Group.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-220-2"><ix:continuation id="f-219-2"><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Use of estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Impact of after effects of COVID-19 and geopolitical instability</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group&#8217;s significant accounting estimates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with relevant collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the effects of the COVID-19 pandemic and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group&#8217;s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.</span></div></ix:continuation></ix:continuation><div id="i0ca481b9662c4533b1d2a0227d14fda1_40"></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" id="f-224" continuedAt="f-224-1" escape="true">Significant changes in the current reporting period</ix:nonNumeric></span></div><ix:continuation id="f-224-1" continuedAt="f-224-2"><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Significant events</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial position and performance of the Group was affected by the following event during the six months ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. Assumptions associated with SR-aGVHD are included within the impairment assessment of MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. The Group assessed and included the impact of the FDA's complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD in these areas within the Form 20-F for the year ended June 30, 2023.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In September 2023, the Group provided an update on the path to approval for lead-product candidate remestemcel-L in the treatment of pediatric and adult SR-aGvHD, following a Type A meeting held with FDA.  Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD within the impairment assessment of MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><ix:continuation id="f-224-2" continuedAt="f-224-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"><ix:continuation id="f-224-3">In December 2023 the Group completed an institutional placement together with a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing eligible shareholders, raising A$<ix:nonFraction unitRef="aud" contextRef="c-42" decimals="-5" name="meso:NumberOfSharesIssuedAndFullyPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-225">60.3</ix:nonFraction>&#160;million at an issue price of A$<ix:nonFraction unitRef="audPerShare" contextRef="c-42" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-226">0.30</ix:nonFraction> per share. In December 2023, proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="meso:ProceedsFromPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-227">39.7</ix:nonFraction>&#160;million (A$<ix:nonFraction unitRef="aud" contextRef="c-42" decimals="-5" name="meso:NumberOfSharesIssuedAndFullyPaidValue" format="ixt:num-dot-decimal" scale="6" id="f-228">60.3</ix:nonFraction>&#160;million) were received and recognized in cash and cash equivalents.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 12</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" id="f-230" continuedAt="f-230-1" escape="true">Loss before income tax</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" id="f-231" continuedAt="f-231-1" escape="true"><ix:continuation id="f-230-1" continuedAt="f-230-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:CommercializationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-232">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:CommercializationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-233">3,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-234">3,388</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-235">3,422</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical trial and research &amp; development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ClinicalTrialRelatedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-236">2,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:ClinicalTrialRelatedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-237">4,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing production &amp; development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ManufacturingProductionAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-238">5,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:ManufacturingProductionAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-239">11,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-240">10,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:WagesAndSalaries" format="ixt:num-dot-decimal" scale="3" id="f-241">9,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined contribution superannuation expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:DefinedContributionSuperannuationExpenses" scale="3" id="f-242">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:DefinedContributionSuperannuationExpenses" scale="3" id="f-243">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity settled share-based payment transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-244">2,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-245">1,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Employee benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-246">12,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-247">11,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation and amortization of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plant and equipment depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-248">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-249">565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-250">1,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-251">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:IntellectualPropertyAmortization" scale="3" id="f-252">742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:IntellectualPropertyAmortization" scale="3" id="f-253">750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Depreciation and amortization of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-254">2,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-255">2,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Management &amp; administration expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overheads &amp; administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:OverheadsAndAdministrationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-256">4,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:OverheadsAndAdministrationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-257">5,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consultancy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ConsultancyExpenses" format="ixt:num-dot-decimal" scale="3" id="f-258">1,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:ConsultancyExpenses" format="ixt:num-dot-decimal" scale="3" id="f-259">1,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal and other professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:LegalAndOtherProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-260">1,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:LegalAndOtherProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="f-261">1,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses (excluding the amount amortized above)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:IntellectualPropertyExpenses" format="ixt:num-dot-decimal" scale="3" id="f-262">1,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:IntellectualPropertyExpenses" format="ixt:num-dot-decimal" scale="3" id="f-263">1,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other Management &amp; administration expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:OtherManagementAndAdministrationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-264">8,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:OtherManagementAndAdministrationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-265">9,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:LossGainOnRemeasurementOfContingentConsideration" scale="3" id="f-266">337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:LossGainOnRemeasurementOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-267">5,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:FairValueRemeasurementOfContingentConsideration" scale="3" id="f-268">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:FairValueRemeasurementOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-269">5,989</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:LossGainOnRemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-270">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:LossGainOnRemeasurementOfWarrantLiability" scale="3" id="f-271">712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:FairValueRemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-272">4,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:FairValueRemeasurementOfWarrantLiability" scale="3" id="f-273">712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromInterest" scale="3" id="f-274">903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:RevenueFromInterest" scale="3" id="f-275">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains/(losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:ForeignExchangeGainsLosses" scale="3" id="f-276">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:ForeignExchangeGainsLosses" scale="3" id="f-277">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other operating income and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-278">1,068</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="f-279">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance (costs)/gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of borrowing arrangements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" scale="3" id="f-280">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-281">1,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-282">10,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-283">9,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Finance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-284">10,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-285">10,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total loss before income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-286">32,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-287">41,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-230-2" continuedAt="f-230-3"><ix:continuation id="f-231-1" continuedAt="f-231-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Share-based payment transactions</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, the share-based payment transactions have been reflected in the Consolidated Income Statement functional expense categories as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-288">1,104,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-289">797,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-290">48,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-291">183,720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management and administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-292">1,043,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-293">1,143,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity settled share-based payment transactions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-294">2,195,436</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" name="ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="0" id="f-295">1,756,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Change in comparative figures</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-231-2">For the six months ended December 31, 2022, the Group reclassified immaterial amounts within Other Management and administration expenses. The Group does not believe these reclassifications to be material to the consolidated financial statements.</ix:continuation> </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gr&#252;nenthal arrangement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Group entered into a strategic partnership with Gr&#252;nenthal for the development and commercialization in Europe and Latin America of the Group&#8217;s allogeneic mesenchymal precursor cell (&#8220;MPC&#8221;) product, MPC-06-ID, receiving exclusive rights to the Phase 3 allogeneic product candidate for the treatment of low back pain due to degenerative disc disease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group received a non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="meso:NonRefundableUpFrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-296">15.0</ix:nonFraction> million in October 2019, on signing of the contract with Gr&#252;nenthal. The Group received a milestone payment in December 2019 of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="meso:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-297">2.5</ix:nonFraction> million in relation to meeting a milestone event as part of the strategic partnership with Gr&#252;nenthal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Group announced its intention to leverage the results from a planned US trial to support potential product approvals in both the US and EU by including <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="meso:PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" scale="-2" id="f-298">20</ix:nonFraction>% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. As a result, the strategic partnership with Gr&#252;nenthal has been amended, and milestone payments relating to R&amp;D and CMC services and other development services which were linked to the Europe trial have been removed, instead the Group is eligible to receive payments up to US$<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="meso:AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" format="ixt:num-dot-decimal" scale="6" id="f-299">112.5</ix:nonFraction> million prior to product launch in the EU, inclusive of US$<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="meso:NonRefundableUpfrontPaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="f-300">17.5</ix:nonFraction> million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach US$<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-9" name="meso:CumulativeMilestonePaymentsReachableAmount" format="ixt:num-dot-decimal" scale="9" id="f-301">1</ix:nonFraction> billion depending on the final outcome of Phase 3 studies and patient adoption. The Group will also receive tiered double-digit royalties on product sales as per the agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="meso:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-302">2.5</ix:nonFraction> million milestone payment received in December 2019 from Gr&#252;nenthal was considered deferred consideration as of December&#160;31, 2023. The performance obligation for the $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="meso:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-303">2.5</ix:nonFraction> million was previously satisfied under the original agreement, however under the amended agreement with Gr&#252;nenthal it is subject to repayment to Gr&#252;nenthal. Revenue will be recognized when the clinical trial has recruited the required amount of European patients, as the $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="meso:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-304">2.5</ix:nonFraction> million will no longer be subject to repayment to Gr&#252;nenthal. For the six months ended December&#160;31, 2023 and 2022, respectively, <ix:nonFraction unitRef="usd" contextRef="c-55" decimals="INF" name="meso:RevenueRecognizedForRightOfUseLicenseOfIP" format="ixt:fixed-zero" scale="0" id="f-305"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="INF" name="meso:RevenueRecognizedForRightOfUseLicenseOfIP" format="ixt:fixed-zero" scale="0" id="f-306">no</ix:nonFraction></ix:nonFraction> milestone revenue was recognized in relation to this strategic partnership with Gr&#252;nenthal.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tasly arrangement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Group entered into a strategic alliance with Tasly Pharmaceutical Group (&#8220;Tasly&#8221;) for the development, manufacture and commercialization in China of the Group&#8217;s allogeneic mesenchymal precursor cell (&#8220;MPC&#8221;) products, MPC-150-IM and MPC-25-IC. Tasly received all exclusive rights for MPC-150-IM and MPC-25-IC in China and Tasly will fund all development, manufacturing and commercialization activities in China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group received a $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="meso:DeferredConsiderationMilestoneConsiderationRecognized" format="ixt:num-dot-decimal" scale="6" id="f-307">20.0</ix:nonFraction> million up-front technology access fee from Tasly upon closing of this strategic alliance in October 2018. The Group recognized  $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" format="ixt:num-dot-decimal" scale="6" id="f-308">10.0</ix:nonFraction> million from this $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="meso:DeferredConsiderationMilestoneConsiderationRecognized" format="ixt:num-dot-decimal" scale="6" id="f-309">20.0</ix:nonFraction> million up-front technology access fee at closing in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-230-3" continuedAt="f-230-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2018 and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" format="ixt:num-dot-decimal" scale="6" id="f-310">10.0</ix:nonFraction> million was recognized in revenue in February 2020. The Group is also entitled to receive $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="meso:AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" format="ixt:num-dot-decimal" scale="6" id="f-311">25.0</ix:nonFraction> million on product regulatory approvals in China, double-digit escalating royalties on net product sales and up to <ix:nonFraction unitRef="milestone" contextRef="c-59" decimals="INF" name="meso:NumberOfEscalatingMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="f-312">six</ix:nonFraction> escalating milestone payments when the product candidates reach certain sales thresholds in China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, respectively, <ix:nonFraction unitRef="usd" contextRef="c-60" decimals="INF" name="meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" format="ixt:fixed-zero" scale="0" id="f-313"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="INF" name="meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" format="ixt:fixed-zero" scale="0" id="f-314">no</ix:nonFraction></ix:nonFraction> revenue was recognized in relation to this strategic alliance with Tasly.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TiGenix arrangement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Group entered into a patent license agreement with TiGenix NV (&#8220;TiGenix&#8221;), now a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived mesenchymal stem cell (&#8220;MSC") product, Alofisel&#174; a registered trademark of TiGenix, previously known as Cx601, for the local treatment of fistulae. The agreement includes the right for Takeda to grant sub-licenses to affiliates and third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group received a $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-315">5.9</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-5" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-316">5.0</ix:nonFraction>&#160;million) up-front payment upon entering the patent license agreement and a further payment of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-317">5.9</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-62" decimals="-5" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-318">5.0</ix:nonFraction>&#160;million) 12 months after the patent license agreement date. In September 2021, the Group received a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-319">1.2</ix:nonFraction>&#160;million (&#8364;<ix:nonFraction unitRef="eur" contextRef="c-63" decimals="-5" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="6" id="f-320">1.0</ix:nonFraction>&#160;million) upon Takeda receiving approval to manufacture and market Alofisel&#174; in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's Disease. The Group is entitled to further payments up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-64" decimals="-5" name="meso:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="f-321">9.0</ix:nonFraction> million when Takeda reaches certain product regulatory milestones. Additionally, the Group receives single digit royalties on net sales of Alofisel&#174;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, the Group earned $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="ifrs-full:RevenueFromRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-322">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="ifrs-full:RevenueFromRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-323">0.2</ix:nonFraction> million, respectively, of royalty income on sales of Alofisel&#174; in Europe by our licensee Takeda.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, respectively, <ix:nonFraction unitRef="usd" contextRef="c-60" decimals="INF" name="meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" format="ixt:fixed-zero" scale="0" id="f-324"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="INF" name="meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" format="ixt:fixed-zero" scale="0" id="f-325">no</ix:nonFraction></ix:nonFraction> milestone revenue was recognized in relation to the Group's patent license agreement with Takeda. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JCR arrangement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Group acquired all of the culture-expanded, MSC-based assets from Osiris Therapeutics, Inc. These assets included assumption of a collaboration agreement with JCR, a research and development oriented pharmaceutical company in Japan. Revenue recognized under this agreement is limited to the amount of cash received or for which the Group is entitled, as JCR has the right to terminate the agreement at any time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JCR Agreement, JCR is responsible for all development and manufacturing costs including sales and marketing expenses. Under the JCR Agreement, JCR has the right to develop our MSCs in two fields for the Japanese market: exclusive in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow, or the First JCR Field; and non-exclusive for developing assays that use liver cells for non-clinical drug screening and evaluation, or the Second JCR Field. With respect to the First JCR Field, the Group are entitled to payments when JCR reaches certain commercial milestones and to escalating double-digit royalties. These royalties are subject to possible renegotiation downward in the event of competition from non-infringing products in Japan. With respect to the Second JCR Field, the Group are entitled to a double-digit profit share. The Group expanded our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (&#8220;EB&#8221;) in October 2018 and for hypoxic ischemic encephalopathy (&#8220;HIE&#8221;), a condition suffered by newborns who lack sufficient blood supply and oxygen to the brain, in June 2020. The Group will receive royalties on TEMCELL&#174; Hs. Inj. (&#8220;TEMCELL&#8221;), a registered trademark of JCR product sales for EB and HIE, if and when JCR begins selling TEMCELL for such indications in Japan. The Group apply the sales-based and usage-based royalty exception for licenses of intellectual property and therefore recognizes royalty revenue at the later of when the subsequent sale or usage occurs and the associated performance obligation has been satisfied. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023, the Group recognized $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="meso:RoyaltiesReceivableUnderSalesBasedMilestones" format="ixt:num-dot-decimal" scale="6" id="f-326">3.2</ix:nonFraction> million in commercialization revenue relating to royalty income earned on sales of TEMCELL in Japan by our licensee JCR, compared with $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="meso:RoyaltiesReceivableUnderSalesBasedMilestones" format="ixt:num-dot-decimal" scale="6" id="f-327">3.2</ix:nonFraction> million for the six months ended December&#160;31, 2022. These amounts were recorded in revenue as there are no further performance obligations required in regard to these items. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-230-4" continuedAt="f-230-5"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are included in the financial statements at the lower of cost (including raw materials, direct labor, other direct costs and related production overheads) and net realizable value. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product in accordance with IAS 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Before that point, a provision is made against the carrying value to its recoverable amount in accordance with IAS 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; the provision is then reversed at the point when a high probability of regulatory approval is determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group considers a number of factors in determining the probability of the product candidate realizing future economic benefit, including the product candidate&#8217;s current status in the regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, the market need, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, commercialization and market trends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a provision is made against the carrying value of pre-launch inventory the costs are recognized within Manufacturing Commercialization expenses. When the high probability threshold is met, the provision will be reversed through Manufacturing Commercialization expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All inventory costs are currently fully provided for and are recognized within Manufacturing Commercialization expenses. Where it is determined that the pre-launch inventory will be used within a clinical trial, that amount is removed from the cost of pre-launch inventory. There is no impact on the consolidated income statement as the carrying value has been previously fully provided for.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="meso:PreLaunchInventoryRecognized" format="ixt:num-dot-decimal" scale="6" id="f-328">21.6</ix:nonFraction> million of pre-launch inventory recognized on the balance sheet that was fully provided for, compared with $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="meso:PreLaunchInventoryRecognized" format="ixt:num-dot-decimal" scale="6" id="f-329">22.4</ix:nonFraction> million at June&#160;30, 2023. The future commercial use of the pre-launch inventory recognized on the consolidated balance sheet will be dependent on future discussions with the FDA and remains fully provided for.  </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-230-5">For the six months ended December&#160;31, 2023, the Group reversed $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" sign="-" name="meso:PreLaunchInventoryRecognized" format="ixt:num-dot-decimal" scale="6" id="f-330">0.8</ix:nonFraction> million of pre-launch inventory costs within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory, primarily due to a reallocation of pre-launch inventory costs for use in clinical trials. For the six months ended December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="meso:PreLaunchInventoryRecognized" format="ixt:num-dot-decimal" scale="6" id="f-331">1.6</ix:nonFraction> million of pre-launch inventory costs have been recognized within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory.</ix:continuation> </span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_46"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-332" continuedAt="f-332-1" escape="true">Income tax benefit/(expense)</ix:nonNumeric></span></div><ix:continuation id="f-332-1" continuedAt="f-332-2"><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" id="f-333" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax (benefit)/expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:IncreaseDecreaseInCurrentTax" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:IncreaseDecreaseInCurrentTax" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current tax (benefit)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Increase)/decrease in deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:IncreaseDecreaseInDeferredTaxAssets" scale="3" id="f-338">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:IncreaseDecreaseInDeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Decrease)/increase in deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:IncreaseDecreaseInDeferredTaxLiabilities" scale="3" id="f-340">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:IncreaseDecreaseInDeferredTaxLiabilities" scale="3" id="f-341">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax (benefit)/expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="f-342">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="3" id="f-343">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax (benefit)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-344">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-345">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets have been brought to account only to the extent that it is foreseeable that they are recoverable against future tax liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized for unused tax losses to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilized. Deferred tax assets are offset against taxable temporary </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-332-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences (deferred tax liabilities) when the deferred tax balances relate to the same tax jurisdiction in accordance with our accounting policy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are measured at the rate in which they are expected to settle within the respective jurisdictions, which can change based on factors such as new legislation or timing of utilization and reversal of associated assets and liabilities. </span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" id="f-346" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets not brought to account</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unused tax losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-347">134,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-348">125,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other temporary differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-349">13,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-350">12,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-351">3,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-352">3,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DeferredTaxAssetsNotBroughtToAccount" format="ixt:num-dot-decimal" scale="3" id="f-353">151,699</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DeferredTaxAssetsNotBroughtToAccount" format="ixt:num-dot-decimal" scale="3" id="f-354">141,266</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0ca481b9662c4533b1d2a0227d14fda1_49"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" id="f-355" continuedAt="f-355-1" escape="true">Financial assets and liabilities</ix:nonNumeric></span></div><ix:continuation id="f-355-1" continuedAt="f-355-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note provides information about the Group's financial instruments, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">an overview of all financial instruments held by the Group;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">specific information about each type of financial instrument;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">accounting policies; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">information used to determine the fair value of the instruments, including judgments and estimation uncertainty involved.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-356" continuedAt="f-356-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group holds the following financial instruments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVTPL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at <br/>amortized cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-357">77,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-358">77,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-359">3,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-360">3,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="3" id="f-361">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" scale="3" id="f-362">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-363">2,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-364">2,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="ifrs-full:FinancialAssets" scale="3" id="f-365">826</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-366">83,793</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-367">84,619</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-368">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-369">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-370">6,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-371">6,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-372">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-373">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-374">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:OtherNoncurrentFinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-375">2,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-376">1,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-377">80,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:FinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-378">82,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through other comprehensive income</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through profit or loss</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-2" continuedAt="f-355-3"><ix:continuation id="f-356-1" continuedAt="f-356-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVTPL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at <br/>amortized cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-379">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-380">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-381">115,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-382">115,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-383">17,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-384">17,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-385">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-386">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-387">18,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-388">126,522</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-389">145,050</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-390">20,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-391">20,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-392">108,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-393">108,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-394">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-395">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-396">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-397">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-398">22,625</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-399">128,908</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:FinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-400">151,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through other comprehensive income </span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><ix:continuation id="f-356-2" continuedAt="f-356-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"><ix:continuation id="f-356-3">Fair value through profit or loss</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s exposure to various risks associated with the financial instruments is discussed in Note 9. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="f-401" escape="true"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Cash and cash equivalents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:BalancesWithBanks" format="ixt:num-dot-decimal" scale="3" id="f-402">77,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:BalancesWithBanks" format="ixt:num-dot-decimal" scale="3" id="f-403">70,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits at call</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DepositsAtCall" scale="3" id="f-404">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DepositsAtCall" scale="3" id="f-405">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-406">77,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-407">71,318</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">As of December&#160;31, 2023 and June&#160;30, 2023, interest-bearing deposits at call include amounts of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="meso:InterestBearingDepositsAtCallHeldAsSecurity" format="ixt:num-dot-decimal" scale="6" id="f-408">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="meso:InterestBearingDepositsAtCallHeldAsSecurity" format="ixt:num-dot-decimal" scale="6" id="f-409">0.4</ix:nonFraction> million, respectively, held as security and restricted for use.</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Classification as cash equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-3" continuedAt="f-355-4"><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" id="f-410" escape="true"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Trade and other receivables and prepayments</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Trade and other receivables</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade debtors</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-411">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-412">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax incentives recoverable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ResearchAndDevelopmentTaxIncentiveCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="f-413">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ResearchAndDevelopmentTaxIncentiveCreditReceivable" format="ixt:num-dot-decimal" scale="3" id="f-414">2,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign withholding tax recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ForeignWithholdingTaxRecoverable" scale="3" id="f-415">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ForeignWithholdingTaxRecoverable" scale="3" id="f-416">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ReceivableFromTaxCredits" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ReceivableFromTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-418">1,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sublease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NetInvestmentInFinanceLease" scale="3" id="f-419">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NetInvestmentInFinanceLease" scale="3" id="f-420">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentInterestReceivable" scale="3" id="f-421">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentInterestReceivable" scale="3" id="f-422">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recoverable taxes (Goods and services tax and value-added tax)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="f-423">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="f-424">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-425">3,998</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-426">6,998</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1) Research and development tax incentive </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group's research and development activities are eligible under the Australian government's Innovation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Australia Research and Development Tax Incentive program for research and development activities conducted in relation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia. The tax incentives recoverable as of December 31, 2023 pertains to an estimate for the year ended June 30, 2023. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Prepayments</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial research and development expenditure</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ClinicalTrialResearchAndDevelopmentExpenditure" scale="3" id="f-427">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ClinicalTrialResearchAndDevelopmentExpenditure" scale="3" id="f-428">950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance and subscriptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:PrepaidInsuranceAndSubscriptions" format="ixt:num-dot-decimal" scale="3" id="f-429">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:PrepaidInsuranceAndSubscriptions" format="ixt:num-dot-decimal" scale="3" id="f-430">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:OtherPrepayments" scale="3" id="f-431">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:OtherPrepayments" scale="3" id="f-432">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Prepayments" format="ixt:num-dot-decimal" scale="3" id="f-433">3,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Prepayments" format="ixt:num-dot-decimal" scale="3" id="f-434">3,342</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Classification as trade and other receivables</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables and other receivables represent the principal amounts due at balance date less, where applicable, any provision for expected credit losses. The Group uses the simplified approach to measuring expected credit losses, which uses a lifetime expected credit loss allowance. Debts which are known to be uncollectible are written off in the consolidated income statement. All trade receivables and other receivables are recognized at the value of the amounts receivable, as they are due for settlement within <ix:nonNumeric contextRef="c-79" name="meso:TradeReceivablesSettlementPeriod" format="ixt-sec:durday" id="f-435">60</ix:nonNumeric> days and therefore do not require remeasurement.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Fair values of trade and other receivables</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of the current receivables, their carrying amount is assumed to be the same as their fair value.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Impairment and risk exposure</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the impairment of trade and other receivables, their credit quality and the Group&#8217;s exposure to credit risk, foreign currency risk and interest rate risk can be found in Note 9.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-4" continuedAt="f-355-5"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="f-436" escape="true"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Trade and other payables</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-437">10,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-438">20,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and other payables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:TradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-439">10,760</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:TradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-440">20,145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of trade and other payables are assumed to be the same as their fair values, due to their short-term nature. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="f-441" escape="true"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.&#160;&#160;&#160;&#160;Borrowings </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Secured liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:SecuredBankLoansReceived" format="ixt:num-dot-decimal" scale="3" id="f-442">81,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:SecuredBankLoansReceived" format="ixt:num-dot-decimal" scale="3" id="f-443">81,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:BorrowingCostsRecognisedAsExpense" format="ixt:num-dot-decimal" scale="3" id="f-444">9,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="ifrs-full:BorrowingCostsRecognisedAsExpense" format="ixt:num-dot-decimal" scale="3" id="f-445">8,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of carrying amount, net of payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:BorrowingCostsCapitalised" format="ixt:num-dot-decimal" scale="3" id="f-446">43,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="ifrs-full:BorrowingCostsCapitalised" format="ixt:num-dot-decimal" scale="3" id="f-447">35,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-448">115,762</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-449">108,763</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="ifrs-full:ShorttermBorrowings" scale="3" id="f-450">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="ifrs-full:ShorttermBorrowings" scale="3" id="f-451">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - Oaktree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="ifrs-full:ShorttermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-452">8,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="ifrs-full:ShorttermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-453">5,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:ShorttermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-454">8,534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:ShorttermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-455">5,952</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-456">60,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-457">55,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - Oaktree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-458">46,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-459">47,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-460">107,228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-461">102,811</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-462">115,762</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-463">108,763</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Borrowing arrangements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funds associated with Oaktree Capital Management, L.P. (&#8220;Oaktree&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Group entered into a $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="meso:BorrowingsPrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="f-464">90.0</ix:nonFraction> million <ix:nonNumeric contextRef="c-86" name="meso:BorrowingsTerm" format="ixt-sec:durwordsen" id="f-465">five-year</ix:nonNumeric> senior debt facility provided by funds associated with Oaktree. The Group drew the first tranche of $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-466">60.0</ix:nonFraction> million on closing. The conditions required to draw down the additional $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-467">30.0</ix:nonFraction> million tranche have not been met. The facility has a <ix:nonNumeric contextRef="c-86" name="meso:BorrowingsInterestOnlyPeriod" format="ixt-sec:durwordsen" id="f-468">three-year</ix:nonNumeric> interest only period, at a fixed rate of  <ix:nonFraction unitRef="number" contextRef="c-87" decimals="INF" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-469">9.75</ix:nonFraction>% per annum, after which time <ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="meso:PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" scale="-2" id="f-470">40</ix:nonFraction>% of the principal amortizes over <ix:nonNumeric contextRef="c-85" name="meso:BorrowingsPrincipalAmortizationPeriod" format="ixt-sec:durwordsen" id="f-471">two years</ix:nonNumeric> and a final payment is due no later than November 2026. The facility also allowed the Group to make quarterly payments of interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-89" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-472">8.0</ix:nonFraction>% per annum for the first <ix:nonNumeric contextRef="c-85" name="meso:BorrowingsPrincipalAmortizationPeriod" format="ixt-sec:durwordsen" id="f-473">two years</ix:nonNumeric>, and the unpaid interest portion (<ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="meso:UnpaidInterestPortionPerAnnum" scale="-2" id="f-474">1.75</ix:nonFraction>% per annum) has been added to the outstanding loan balance and currently accrues further interest at a fixed rate of <ix:nonFraction unitRef="number" contextRef="c-85" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-475">9.75</ix:nonFraction>% per annum.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November&#160;19, 2021, Oaktree were also granted warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-476">1,769,669</ix:nonFraction> American Depositary Shares (&#8220;ADSs&#8221;) at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-477">7.26</ix:nonFraction> per ADS, a <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="meso:PercentageOfPremiumForVolumeWeightedAveragePrice" scale="-2" id="f-478">15</ix:nonFraction>% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the debt facility was signed; consequently, a liability for the warrants was recognized in November 2021. The warrants were legally issued on January&#160;11, 2022 and may be exercised within <ix:nonNumeric contextRef="c-92" name="meso:IssuanceWarrantsExercisedPeriod" format="ixt-sec:duryear" id="f-479">7</ix:nonNumeric> years of issuance. On the issuance date of the Oaktree facility and the warrants, the warrants were initially measured at fair value and the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-5" continuedAt="f-355-6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oaktree borrowing liability measured as the difference between the $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-480">60.0</ix:nonFraction> million received from the Oaktree facility and the fair value of the warrants. In December 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-481">455,000</ix:nonFraction> ADSs at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-95" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-482">3.70</ix:nonFraction> per ADS, a <ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="meso:PercentageOfSharePremiumPrice" scale="-2" id="f-483">15</ix:nonFraction>% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the first amendment to the loan agreement was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within <ix:nonNumeric contextRef="c-97" name="meso:WarrantExerciseTerm" format="ixt-sec:duryear" id="f-484">7</ix:nonNumeric> years of issuance.  Refer to Note 5(e)(vi) for more details on warrants issued. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 5, 2024, the ratio under Mesoblast's American Depository Receipt ("ADR") program was changed from 5 ordinary shares representing 1 ADS (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADS (10:1 ratio). As a result of this ratio change and as a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the number and exercise price for the warrants was adjusted in accordance with the terms of these warrants. The warrants issued in November 2021 changed from <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-485">1,769,669</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-486">7.26</ix:nonFraction> per ADS to <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-487">884,838</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-488">14.36</ix:nonFraction> per ADS. The warrants issued in December 2022 changed from <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-489">455,000</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-490">3.70</ix:nonFraction> per ADS to <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-491">227,502</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-492">7.24</ix:nonFraction> per ADS.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the six months ended December&#160;31, 2023, the Group recognized a minimal loss in the Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of the financial liability to reflect the revised estimated future cash flows from the credit facility. In the six months ended December&#160;31, 2022 the Group recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="INF" sign="-" name="meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" format="ixt:num-dot-decimal" scale="6" id="f-493">1.4</ix:nonFraction> million in the Income Statement as remeasurement of borrowing arrangements within finance costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Within this </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="INF" sign="-" name="meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" format="ixt:num-dot-decimal" scale="6" id="f-494">1.4</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> loss, $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="meso:FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" format="ixt:num-dot-decimal" scale="6" id="f-495">1.0</ix:nonFraction>&#160;million relates to the remeasurement due to additional warrants being issued to Oaktree as a result of the first amendment to the loan agreement and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="meso:FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" format="ixt:num-dot-decimal" scale="6" id="f-496">0.4</ix:nonFraction>&#160;million relates to the adjustment of the carrying amount of the financial liability to reflect the revised estimated future cash flows from the credit facility</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group has pledged substantially all of its assets as collateral under the loan facility with Oaktree. </span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NovaQuest Capital Management, L.L.C.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2018, the Group entered into an <ix:nonNumeric contextRef="c-107" name="meso:BorrowingsTerm" format="ixt-sec:durwordsen" id="f-497">eight-year</ix:nonNumeric>, $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="meso:BorrowingsPrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="f-498">40.0</ix:nonFraction> million loan and security agreement with NovaQuest before drawing the first tranche of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-499">30.0</ix:nonFraction> million of the principal in July 2018. The additional $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-500">10.0</ix:nonFraction>&#160;million from the loan will be drawn on marketing approval of remestemcel-L for the treatment of pediatric patients with SR-aGVHD by the FDA. The loan term included an interest only period of approximately <ix:nonNumeric contextRef="c-107" name="meso:BorrowingsInterestOnlyPeriod" format="ixt-sec:durwordsen" id="f-501">four years</ix:nonNumeric> through until July 8, 2022. All interest and principal payments (i.e. the amortization period) are deferred until the earlier of loan maturity or from after the first commercial sale of remestemcel-L for the treatment in pediatric patients with SR-aGVHD in the United States and other geographies excluding Asia ("remestemcel-L for pediatric SR-aGVHD"). Principal is repayable in equal quarterly instalments over the amortization period of the loan and is subject to the payment cap described below. The loan has a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="c-108" decimals="2" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-502">15</ix:nonFraction>% per annum. If there are no net sales of remestemcel-L for pediatric SR-aGVHD, the loan is only repayable at maturity. The Group can elect to prepay all outstanding amounts owing at any time prior to maturity, subject to a prepayment charge. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval and first commercial sales, repayments commence based on a percentage of net sales and are limited by a payment cap which is equal to the principal due for the next 12 months, plus accumulated unpaid principal and accrued unpaid interest.  During the <ix:nonNumeric contextRef="c-107" name="meso:BorrowingsInterestOnlyPeriod" format="ixt-sec:durwordsen" id="f-503">four-year</ix:nonNumeric> period commencing July 8, 2022, principal amortizes in equal quarterly instalments payable only after approval and first commercial sales. If in any quarterly period, <ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold" scale="-2" id="f-504">25</ix:nonFraction>% of net sales of remestemcel-L for pediatric SR-aGVHD exceed the annual payment cap, the Group will pay the payment cap and an additional portion of excess sales which will be used towards the prepayment amount in the event there is an early prepayment of the loan. If in any quarterly period <ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold" scale="-2" id="f-505">25</ix:nonFraction>% of net sales of remestemcel-L for pediatric SR-aGVHD is less than the annual payment cap, then the payment is limited to <ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold" scale="-2" id="f-506">25</ix:nonFraction>% of net sales of remestemcel-L for pediatric SR-aGVHD. Any unpaid interest will be added to the principal amounts owing and shall accrue further interest. At maturity date, any unpaid loan balances are repaid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of this relationship of net sales and repayments, changes in our estimated net sales may trigger an adjustment of the carrying amount of the financial liability to reflect the revised estimated cash flows. The carrying amount is recalculated by computing the present value of the revised estimated future cash flows at the financial instrument&#8217;s original effective interest rate. The adjustment is recognized in the Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-6" continuedAt="f-355-7"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023 and 2022, the Group recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" sign="-" name="meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" format="ixt:num-dot-decimal" scale="6" id="f-507">0.1</ix:nonFraction> million and a gain of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" format="ixt:num-dot-decimal" scale="6" id="f-508">0.2</ix:nonFraction> million, respectively, in the Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows as a net result of changes to the key assumptions in development timelines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group recognizes a liability as current based on repayments linked to estimates of sales of remestemcel-L. However, if sales of remestemcel-L are higher than estimated, actual repayments will exceed this amount, subject to the annual payment cap described above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the loan and security agreement with NovaQuest is subordinated to the Group&#8217;s fixed rate loan with the senior creditor, Oaktree. The Group have pledged a portion of our assets relating to the SR-aGVHD product candidate as collateral under the loan facility with NovaQuest.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Compliance with loan covenants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loan facilities with Oaktree and NovaQuest contain a number of covenants that impose operating restrictions on us, which may restrict our ability to respond to changes in our business or take specified actions. The Group has an operating objective to at all times maintain unrestricted cash reserves in excess of six months liquidity. The objective aligns with our loan and security agreement with Oaktree where the Group is currently obliged to maintain a minimum unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="meso:MinimumUnrestrictedCashBalance" format="ixt:num-dot-decimal" scale="6" id="f-509">35.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has complied with the financial and other restrictive covenants of its borrowing facilities during the six months ended December&#160;31, 2023 and during the year ended June&#160;30, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" id="f-510" escape="true"><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Net Debt Reconciliation</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-511">77,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-512">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-513">115,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-514">108,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-515">6,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-516">7,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-517">992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-518">5,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NetDebt" format="ixt:num-dot-decimal" scale="3" id="f-519">45,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NetDebt" format="ixt:num-dot-decimal" scale="3" id="f-520">50,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-521">77,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-522">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross debt - fixed interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-523">121,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-524">116,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross debt - variable interest rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="3" id="f-525">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="ifrs-full:Borrowings" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-527">992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-528">5,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NetDebt" format="ixt:num-dot-decimal" scale="3" id="f-529">45,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NetDebt" format="ixt:num-dot-decimal" scale="3" id="f-530">50,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Net debt amount includes leases and borrowing arrangements.</span></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" id="f-531" continuedAt="f-531-1" escape="true"></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-7" continuedAt="f-355-8"><ix:continuation id="f-531-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities from financing activities </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Borrowings </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant liability </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sub-total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and cash<br/>equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Debt as at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-532">108,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-533">7,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-534">5,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-535">121,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-536">71,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NetDebt" format="ixt:num-dot-decimal" scale="3" id="f-537">50,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:CashFlowsAdjustmentsOnDebt" format="ixt:num-dot-decimal" scale="3" id="f-538">3,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-539">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-541">5,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-542">4,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-543">10,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:RemeasurementAdjustmentsOnDebt" scale="3" id="f-544">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:RemeasurementAdjustmentsOnWarrants" format="ixt:num-dot-decimal" scale="3" id="f-545">4,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:RemeasurementAdjustmentsOnDebtAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-546">4,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:RemeasurementAdjustmentsOnDebtAndWarrants" format="ixt:num-dot-decimal" scale="3" id="f-547">4,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Changes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-548">10,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" scale="3" id="f-549">782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:OtherChangesOnDebtAndLeases" format="ixt:num-dot-decimal" scale="3" id="f-550">10,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:OtherChangesOnDebtAndLeases" format="ixt:num-dot-decimal" scale="3" id="f-551">10,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" scale="3" id="f-552">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-554">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-555">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-556">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt as at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-557">115,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-558">6,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-559">992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:LiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-560">122,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-561">77,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NetDebt" format="ixt:num-dot-decimal" scale="3" id="f-562">45,437</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Other changes include modification of leases and accrued interest expenses for borrowings and leases.</span></div></ix:continuation><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Fair values of borrowing arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the borrowings at amortized cost in accordance with our accounting policy is a reasonable approximation of fair value. </span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.&#160;&#160;&#160;&#160;Recognized fair value measurement</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Fair value hierarchy</span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" id="f-563" continuedAt="f-563-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of December&#160;31, 2023 and June&#160;30, 2023 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities - biotech sector</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-564">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="f-566">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="f-567">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="f-570">826</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="f-571">826</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities at fair value through profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="meso:ContingentConsiderations" format="ixt:fixed-zero" scale="3" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="meso:ContingentConsiderations" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-574">17,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-575">17,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:fixed-zero" scale="3" id="f-576">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-578">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-579">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-581">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-582">18,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-583">18,528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-8" continuedAt="f-355-9"><ix:continuation id="f-563-1"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities - biotech sector</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-584">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-586">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-587">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-590">1,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:FinancialAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-591">1,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities at fair value through profit or loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="meso:ContingentConsiderations" format="ixt:fixed-zero" scale="3" id="f-592">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="meso:ContingentConsiderations" format="ixt:fixed-zero" scale="3" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-594">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-595">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:fixed-zero" scale="3" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:fixed-zero" scale="3" id="f-597">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-598">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-599">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-600">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="3" id="f-601">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-602">22,625</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:FinancialLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-603">22,625</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between any of the levels for recurring fair value measurements during the period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s policy is to recognize transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, trading and financial assets at fair value through other comprehensive income securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of financial instruments that are not traded in an active market (for example, foreign exchange contracts) is determined using valuation techniques which maximize the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for provisions (contingent consideration), equity securities (unlisted) and warrant liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Valuation techniques used.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group did <ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="0" id="f-604"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="0" id="f-605"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="0" id="f-606"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="0" id="f-607"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="0" id="f-608"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="ifrs-full:FinancialAssets" format="ixt:fixed-zero" scale="0" id="f-609"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="0" id="f-610"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="ifrs-full:FinancialLiabilities" format="ixt:fixed-zero" scale="0" id="f-611">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> hold any level 1 and level 2 financial instruments as at December&#160;31, 2023 or June&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s level 3 assets consists of an investment in unlisted equity securities in the biotechnology sector. Level 3 assets were <ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="meso:PercentageOfAssetsMeasuredAtFairValue" scale="-2" id="f-612"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="2" name="meso:PercentageOfAssetsMeasuredAtFairValue" scale="-2" id="f-613">100</ix:nonFraction></ix:nonFraction>% of total assets measured at fair value as at December&#160;31, 2023 and June&#160;30, 2023. The Group&#8217;s level 3 liabilities consist of a contingent consideration provision related to the acquisition of the MSC assets and warrant liabilities related to the warrants granted to Oaktree as part of the debt facility. Level 3 liabilities were <ix:nonFraction unitRef="number" contextRef="c-139" decimals="2" name="meso:PercentageOfLiabilitiesMeasuredAtFairValue" scale="-2" id="f-614"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="meso:PercentageOfLiabilitiesMeasuredAtFairValue" scale="-2" id="f-615">100</ix:nonFraction></ix:nonFraction>% of total liabilities measured at fair value as at December&#160;31, 2023 and June&#160;30, 2023. The Group used discounted cash flow analysis to determine the fair value measurements of contingent consideration and used the Black-Scholes valuation method to determine the fair value of warrant liabilities. Refer to Note 5(e)(vi) for the fair value measurement and movements in warrant liability for the period ended December&#160;31, 2023 and June&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Fair value measurements using significant unobservable inputs (level 3)</span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" id="f-616" continuedAt="f-616-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in level 3 instruments for the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-616-1"><ix:continuation id="f-355-9" continuedAt="f-355-10"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent<br/>consideration<br/>provision</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance - July 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="meso:ContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="3" id="f-617">23,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="meso:ContingentConsiderationProvisionAmountUsed" format="ixt:num-dot-decimal" scale="3" id="f-618">2,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to consolidated income statement:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="meso:LossGainOnRemeasurementOfContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="f-619">8,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing balance - June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="meso:ContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="3" id="f-620">17,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance - July 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="meso:ContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="3" id="f-621">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to consolidated income statement:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="meso:LossGainOnRemeasurementOfContingentConsideration" scale="3" id="f-622">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing balance - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="meso:ContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="3" id="f-623">17,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In the year ended June&#160;30, 2023 a gain of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="meso:GainLossOnReMeasurementOfContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="6" id="f-624">8.8</ix:nonFraction> million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, developmental timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines were updated to reflect expectations as a result of the complete response.  </span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In the six months ended December&#160;31, 2023 a minimal gain was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation such as development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-10" continuedAt="f-355-11"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Valuation inputs and relationship to fair </span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" id="f-625" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.935%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of inputs<br/>(weighted average)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value <br/>as of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value <br/>as of <br/>June 30, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation <br/>technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>June 30, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Relationship of <br/>unobservable inputs to <br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="meso:ContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="3" id="f-626">17,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="meso:ContingentConsiderationProvision" format="ixt:num-dot-decimal" scale="3" id="f-627">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-146" name="ifrs-full:DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities" id="f-628">Discounted cash flows</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-146" name="ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities" id="f-629">Risk adjusted discount rate</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-147" decimals="2" name="meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" scale="-2" id="f-630">11</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" scale="-2" id="f-631">13</ix:nonFraction>%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-149" decimals="3" sign="-" name="meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" scale="-2" id="f-632">12.5</ix:nonFraction>%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" scale="-2" id="f-633">11</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" scale="-2" id="f-634">13</ix:nonFraction>%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-152" decimals="3" sign="-" name="meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" scale="-2" id="f-635">12.5</ix:nonFraction>%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the discount rate by <ix:nonFraction unitRef="number" contextRef="c-153" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-636">0.5</ix:nonFraction>% would increase/decrease the fair value by an insignificant amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the discount rate by <ix:nonFraction unitRef="number" contextRef="c-154" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-637">0.5</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-154" decimals="4" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-638">0.01</ix:nonFraction>%.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-143" name="ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities" id="f-639">Expected unit sales price</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the price assumptions by <ix:nonFraction unitRef="number" contextRef="c-155" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-640">10</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-155" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-641">0.1</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the price assumptions by <ix:nonFraction unitRef="number" contextRef="c-156" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-642">10</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-156" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-643">0.1</ix:nonFraction>%.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-157" name="ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities" id="f-644">Expected sales volumes</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the volume assumptions by <ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-645">10</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-646">0.1</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the volume assumptions by <ix:nonFraction unitRef="number" contextRef="c-159" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-647">10</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-159" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-648">0.1</ix:nonFraction>%.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-160" name="ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities" id="f-649">Probability of success and payment</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the probability of success and payment assumptions by <ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-650">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-162" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-651">20</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-161" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-652">10.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-162" decimals="3" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-653">20.0</ix:nonFraction>%, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the probability of success and payment assumptions by <ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-654">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" scale="-2" id="f-655">20</ix:nonFraction>% would increase/decrease the fair value by <ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-656">8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" scale="-2" id="f-657">16</ix:nonFraction>%, respectively.</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">There were no significant inter-relationships between unobservable inputs that materially affect fair values.</span></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Valuation processes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the MSC assets on October 11, 2013 (the &#8220;acquisition date&#8221;), an independent valuation of the contingent consideration was carried out by an independent valuer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023, the Group has adopted a process to value contingent consideration internally. This valuation has been completed by the Group&#8217;s internal valuation team and reviewed by the interim Chief Financial Officer (the "CFO"). The valuation team is responsible for the valuation model. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. For each indication we determine the probability of success based on the current development status within each jurisdiction and payment provisions within the agreement. Cash flows relevant to each jurisdiction are discounted appropriately based on the discount rate assumed. The remeasurement charged to the consolidated income statement in the six months ended December&#160;31, 2023 was a net result of changing the key assumptions of the contingent consideration valuation such as development timelines and the increase </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-11" continuedAt="f-355-12"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration. Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD and a remeasurement of contingent consideration, up or down, could occur. </span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" id="f-658" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The fair value of contingent consideration<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:CashOrStockPayableAtFairValueLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-659">16,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:CashOrStockPayableAtFairValueLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-660">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of royalty payments from commercialization of the intellectual property acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:RoyaltyPaymentsAtFairValueLiabilities" scale="3" id="f-661">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:RoyaltyPaymentsAtFairValueLiabilities" scale="3" id="f-662">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-663">17,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:ContingentConsiderations" format="ixt:num-dot-decimal" scale="3" id="f-664">17,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main level 3 inputs used by the Group are evaluated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk adjusted discount rate:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used in the valuation has been determined based on required rates of returns of listed companies in the biotechnology industry (having regards to their stage of development, their size and number of projects) and the indicative rates of return required by suppliers of venture capital for investments with similar technical and commercial risks. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected unit sales prices:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market sale price of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected sales volumes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected sales volumes of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of success and payment:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected cash flows used to measure contingent consideration are risk adjusted for the probability of successful development of products and payment provisions within the agreement. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Warrant liability </span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" id="f-665" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-666">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-667">2,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants fair value at grant date - December 22, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="meso:WarrantsFairValueAtIssueDate" format="ixt:fixed-zero" scale="3" id="f-668">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="meso:WarrantsFairValueAtIssueDate" format="ixt:num-dot-decimal" scale="3" id="f-669">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:RemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-670">4,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="meso:RemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-671">2,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-672">992</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-673">5,426</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, in connection with the $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-674">60.0</ix:nonFraction> million drawdown of the Oaktree debt, Oaktree were granted the right to warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-675">1,769,669</ix:nonFraction> ADSs at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-676">7.26</ix:nonFraction> per ADS, a <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="meso:PercentageOfPremiumForVolumeWeightedAveragePrice" scale="-2" id="f-677">15</ix:nonFraction>% premium to the 30-day VWAP. Given that Oaktree received an unconditional right to the warrants on November&#160;19, 2021, this date has been determined as the measurement date. The warrants instruments were issued on January&#160;11, 2022, following the required administrative process, and these warrants may be exercised within <ix:nonNumeric contextRef="c-92" name="meso:IssuanceWarrantsExercisedPeriod" format="ixt-sec:duryear" id="f-678">7</ix:nonNumeric> years of issuance of the warrant instruments. The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-679">455,000</ix:nonFraction> ADSs at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-680">3.70</ix:nonFraction> per ADS, a <ix:nonFraction unitRef="number" contextRef="c-170" decimals="2" name="meso:PercentageOfPremiumForVolumeWeightedAveragePrice" scale="-2" id="f-681">15</ix:nonFraction>% premium to the 30-day VWAP.  We determined that an obligation to issue the warrants has arisen from the time the first amendment to the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-355-12"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan agreement was signed; consequently, a liability for the warrants has been recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within <ix:nonNumeric contextRef="c-171" name="meso:IssuanceWarrantsExercisedPeriod" format="ixt-sec:duryear" id="f-682">7</ix:nonNumeric> years of issuance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2024, the ratio under Mesoblast's ADR program was changed from 5 ordinary shares representing 1 ADS (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADS (10:1 ratio). As a result of this ratio change and as a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the number and exercise price for the warrants was adjusted in accordance with the terms of these warrants. The warrants issued in November 2021 changed from <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-683">1,769,669</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-684">7.26</ix:nonFraction> per ADS to <ix:nonFraction unitRef="shares" contextRef="c-172" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-685">884,838</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-686">14.36</ix:nonFraction> per ADS. The warrants issued in December 2022 changed from <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-687">455,000</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-688">3.70</ix:nonFraction> per ADS to <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="0" name="meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-689">227,502</ix:nonFraction> ADSs at US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-690">7.24</ix:nonFraction> per ADS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of the warrants will be received in U.S. dollars, which is different to Mesoblast Limited&#8217;s functional currency of Australian dollars which gives rise to variability in the cash flow. As a result, the warrants are classified as a financial liability in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IAS32 Financial Instruments: Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The financial liability is recorded in warrant liability at fair value at grant date and subsequently remeasured at each reporting period with changes being recorded in the Income Statement as remeasurement of warrant liability. The warrant liabilities are considered level 3 liabilities as the determination of fair value includes various assumptions about the share prices and historical volatility as inputs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2023, and June&#160;30, 2023 the fair value of the warrant liability was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="meso:WarrantsFairValueAtIssueDate" format="ixt:num-dot-decimal" scale="6" id="f-691">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="meso:WarrantsFairValueAtIssueDate" format="ixt:num-dot-decimal" scale="6" id="f-692">5.4</ix:nonFraction> million, respectively. During the six months ended December 31,  2023, a remeasurement gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="meso:GainLossOnRemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-693">4.4</ix:nonFraction> million was recognized on the remeasurement of warrant liability. During the six months ended December 31, 2022, a remeasurement loss of $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" sign="-" name="meso:GainLossOnRemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="6" id="f-694">0.7</ix:nonFraction> million was recognized on the remeasurement of warrant liability.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;Fair value of warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants granted are not traded in an active market and therefore the fair value has been estimated by using the Black-Scholes valuation method based on the following assumptions. Key terms of the warrants are included below. <ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" id="f-695" continuedAt="f-695-1" escape="true">The following assumptions were based on observable market conditions that existed at the issue date and as of December&#160;31, 2023.</ix:nonNumeric></span></div><ix:continuation id="f-695-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"/><td style="width:23.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, except percent data and as otherwise noted) <br/>Assumption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of<br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rationale</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-173" decimals="2" name="meso:WarrantsPricePerShare" scale="0" id="f-696">1.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="2" name="meso:WarrantsPricePerShare" scale="0" id="f-697">3.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Closing share price on valuation date from external market source</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-175" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-698">3.70</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-699">7.26</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-175" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-700">3.70</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-701">7.26</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per subscription agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="year" contextRef="c-178" decimals="0" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-702">5</ix:nonFraction> to <ix:nonFraction unitRef="year" contextRef="c-179" decimals="0" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-703">7</ix:nonFraction> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="year" contextRef="c-180" decimals="0" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-704">6</ix:nonFraction> to <ix:nonFraction unitRef="year" contextRef="c-181" decimals="0" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-705">7</ix:nonFraction> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per subscription agreement</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-706">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-174" decimals="2" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-707">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Company&#8217;s nil dividend history</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-173" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-708">86.71</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-174" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-709">81.26</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on historical volatility data for the Company</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Free Interest Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-173" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-710">3.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-174" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-711">4.01</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing U.S treasury issued <ix:nonNumeric contextRef="c-1" name="meso:IssuanceWarrantsExercisedPeriod" format="ixt-sec:duryear" id="f-712">7</ix:nonNumeric> year bonds on valuation date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value per warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-175" decimals="4" name="meso:FairValuePerWarrant" scale="0" id="f-713">0.4000</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="4" name="meso:FairValuePerWarrant" scale="0" id="f-714">0.6248</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="INF" name="meso:FairValuePerWarrant" scale="0" id="f-715">2.3103</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-177" decimals="INF" name="meso:FairValuePerWarrant" scale="0" id="f-716">2.9401</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determined using Black-Scholes valuation model with the inputs above</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="0" name="meso:FairValueOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-717">992,233</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" name="meso:FairValueOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-718">5,426,212</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-719"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="0" name="meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" format="ixt:num-dot-decimal" scale="0" id="f-720">2,224,669</ix:nonFraction></ix:nonFraction> warrants of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="0" name="meso:FairValueOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-721">992,233</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="0" name="meso:FairValueOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-722">5,426,212</ix:nonFraction> as of December&#160;31, 2023 and June&#160;30, 2023, respectively.</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 28</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-187" name="meso:DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" id="f-725" continuedAt="f-725-1" escape="true">Non-financial assets and liabilities</ix:nonNumeric></span></div><ix:continuation id="f-725-1" continuedAt="f-725-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="f-726" continuedAt="f-726-1" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="f-726-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Acquired licenses<br/>to patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In-process<br/>research and<br/>development<br/>acquired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current marketed<br/>products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-727">134,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-728">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-729">427,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-730">14,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-731">578,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-732">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-733">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-734">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-736">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-737">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-738">1,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-739">1,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-740">134,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-741">1,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-742">427,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-743">13,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-744">577,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-745">134,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-746">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-747">489,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-748">23,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-749">651,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-750">1,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-751">10,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-752">12,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-753">61,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-754">61,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-755">134,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-756">1,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-757">427,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-758">13,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-759">577,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-760">134,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-761">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-762">427,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-763">13,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-764">577,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-765">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-766">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-767">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-770">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-771">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-772">727</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-773">742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-774">134,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-775">1,726</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-776">427,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-777">12,606</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-778">576,564</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-779">134,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-780">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-781">489,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-782">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-783">651,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-784">1,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-785">11,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-786">12,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-787">61,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-788">61,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-789">134,453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-790">1,726</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-791">427,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-792">12,606</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-793">576,564</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" id="f-794" continuedAt="f-794-1" escape="true">Carrying value of in-process research and development acquired by product</ix:nonNumeric></span></div><ix:continuation id="f-794-1" continuedAt="f-794-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-795">254,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-796">254,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous products for metabolic diseases and inflammatory/immunologic conditions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-797">70,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-798">70,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSC products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-799">102,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-800">102,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-801">427,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="ifrs-full:IntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-802">427,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy</span></div></ix:continuation><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><ix:continuation id="f-794-2" continuedAt="f-794-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"><ix:continuation id="f-794-3">Includes remestemcel-L for the treatment of adults and children with SR-aGVHD and remestemcel-L for the treatment of Crohn&#8217;s disease</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-725-2" continuedAt="f-725-3"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all products included within the above balances, the underlying currency of each item recorded is US$.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Significant estimate: Impairment of goodwill and assets with an indefinite useful life</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group tests annually, or more frequently if events or changes in circumstances indicate that they might be impaired, whether goodwill and its assets with indefinite useful lives have suffered any impairment in accordance with its accounting policy stated in Note 23(j) in the Form 20-F for the year ended June 30, 2023. The recoverable amounts of these assets and cash-generating units have been determined based on fair value less costs to dispose calculations, which require the use of market-participant assumptions that are based on development strategies using external data sources as well as past experience. The full annual impairment assessment was performed at March 31, 2023 and <ix:nonFraction unitRef="usd" contextRef="c-231" decimals="INF" name="ifrs-full:ImpairmentLossOnFinancialAssets" format="ixt:fixed-zero" scale="0" id="f-803"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="INF" name="ifrs-full:ImpairmentLossOnFinancialAssets" format="ixt:fixed-zero" scale="0" id="f-804">no</ix:nonFraction></ix:nonFraction> impairment of the in-process research and development and goodwill were identified. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the FDA issued a complete response to the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD and the Group considered this to be an impairment indicator that could cause the carrying amount of its intangible assets to exceed its recoverable amounts. As a result, the Group completed an impairment assessment on its MSC products intangible asset and goodwill. The assumptions used in the impairment assessment were updated from the March 31, 2023 impairment assessment and included changes to the market population and penetration, product pricing and launch timings. There were no other significant changes in key assumptions, including the probability of success. No impairment to the in-process research and development and goodwill was identified. </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Impairment tests for goodwill and intangible assets with an indefinite useful life</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development acquired is considered to be an indefinite life intangible asset on the basis that it is incomplete and cannot be used in its current form (see Note 23(p)(iii) in the Form 20-F for the year ended June 30, 2023). The intangible asset&#8217;s life will remain indefinite until such time it is completed and commercialized or impaired. The carrying value of in-process research and development is a separate asset which has been subject to impairment testing at the cash generating unit level, which has been determined to be at the product level.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On acquisition, goodwill was not able to be allocated to the cash generating unit (&#8220;CGU&#8221;) level or to a group of CGU given the synergies of the underlying research and development. For the purpose of impairment testing, goodwill is monitored by management at the operating segment level. The Group is managed as one operating segment, being the development of cell technology platform for commercialization. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recoverable amount of both goodwill and in-process research and development was assessed as of March 31, 2023 based on the fair value less costs to dispose. As a result of the receipt of the complete response from the FDA in August 2023, an impairment assessment was performed over the in-process research and development value of the MSC asset and goodwill. <ix:nonFraction unitRef="usd" contextRef="c-232" decimals="INF" name="ifrs-full:ImpairmentLossOnFinancialAssets" format="ixt:fixed-zero" scale="0" id="f-805"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="INF" name="ifrs-full:ImpairmentLossOnFinancialAssets" format="ixt:fixed-zero" scale="0" id="f-806">No</ix:nonFraction></ix:nonFraction> impairment was identified as a result of these impairment assessments. Management assessed assets for indicators of impairment as at December&#160;31, 2023 including considering events up to the date of the approval of the financial statements and no indicators of impairment were identified. </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Key assumptions used for fair value less costs to dispose calculations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value less costs to dispose the Group has given consideration to the following internal and external indicators:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">discounted expected future cash flows of programs valued by the Group&#8217;s internal valuation team and reviewed by the interim CFO. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. When determining key assumptions, the business units refer to both external sources and past experience as appropriate. The valuation is considered to be level 3 in the fair value hierarchy due to unobservable inputs used in the valuation; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scientific results and progress of the trials since acquisition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the market capitalization of the Group on the ASX (ASX:MSB); and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the valuation of the Group&#8217;s assets from an independent valuation. An independent valuation was obtained for all assets at March 31, 2023 and for the MSC products an impairment assessment was performed as a result of the receipt of the complete response.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-725-3" continuedAt="f-725-4"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of disposal were assumed to be immaterial.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash-flows used a real post-tax discount rate range of <ix:nonFraction unitRef="number" contextRef="c-233" decimals="3" name="meso:PostTaxDiscountRates" scale="-2" id="f-807">13.8</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-234" decimals="3" name="meso:PostTaxDiscountRates" scale="-2" id="f-808">15.5</ix:nonFraction>%, and include estimated real cash inflows and outflows for each program through to expected patent expiry which ranges from <ix:nonNumeric contextRef="c-233" name="meso:ExpectedPatentExpiry" format="ixt-sec:duryear" id="f-809">9</ix:nonNumeric> to <ix:nonNumeric contextRef="c-234" name="meso:ExpectedPatentExpiry" format="ixt-sec:duryear" id="f-810">25</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to cash outflows consideration has been given to cost of goods sold, selling costs and clinical trial schedules including estimates of numbers of patients and per patient costs. Associated expenses such as regulatory fees and patent maintenance have been included as well as any further preclinical development if applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to cash inflows consideration has been given to product pricing, market population and penetration, sales rebates and discounts, launch timings and probability of success in the relevant applicable markets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no standard growth rates applied, other than our estimates of market penetration which increase initially, plateau and then decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment of the recoverable amount of each product has been made in accordance with the discounted cash-flow assumptions outlined above. The assessments showed that the recoverable amount of each product exceeds the carrying amount and therefore there is no impairment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment of goodwill showed the recoverable amount of the Group's operating segment, including goodwill and remaining in-process research and development, exceeds carrying amounts, and therefore there is no impairment.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Impact of possible changes in key assumptions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has considered and assessed reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amount of our intangible assets to exceed its recoverable amount. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whilst there is no impairment, the key sensitivities in the valuation are dependent on the continued successful development of our technology platforms. Future discussion with the FDA could change the  assumptions used within the impairment assessments. If the Group is unable to successfully develop its technology platforms, an impairment of the carrying amount of our intangible assets may result.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Provisions</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfProvisionsExplanatory" id="f-811" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="f-812">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-813">17,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-814">17,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="ifrs-full:CurrentProvisions" scale="3" id="f-815">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-816">16,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-817">17,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-818">3,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="f-819">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-820">4,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-821">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:NoncurrentProvisions" scale="3" id="f-822">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-823">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for license agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-824">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:fixed-zero" scale="3" id="f-825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-826">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-827">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:fixed-zero" scale="3" id="f-828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-829">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-830">8,230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-831">17,073</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-832">25,303</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-833">6,399</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NoncurrentProvisions" format="ixt:num-dot-decimal" scale="3" id="f-834">16,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:Provisions" format="ixt:num-dot-decimal" scale="3" id="f-835">23,011</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The classification of contingent consideration as current represents the expected payments within the next 12 months based on current development timelines.</span></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Information about individual provisions and significant estimates</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration provision relates to the Group&#8217;s liability for certain milestones and royalty achievements pertaining to the acquired MSC assets. Further disclosures can be found in Note 5(e)(iii).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-725-4"><div style="margin-top:18pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee benefits</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for employee benefits relates to the Group&#8217;s liability for annual leave, short term incentives and long service leave.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits include accrued annual leave. As at December&#160;31, 2023 and June&#160;30, 2023, the entire amount of the annual leave accrual was $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="meso:CurrentProvisionsForAccruedAnnualLeave" format="ixt:num-dot-decimal" scale="6" id="f-836">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="meso:CurrentProvisionsForAccruedAnnualLeave" format="ixt:num-dot-decimal" scale="6" id="f-837">1.1</ix:nonFraction> million respectively, and is presented as current, since the Group does not have an unconditional right to defer settlement for any of these obligations.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Movements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration provision relates to the Group&#8217;s liability for certain milestones and royalty achievements. Refer to Note 5(e)(iii) for movements in contingent consideration for the period ended December&#160;31, 2023 and June&#160;30, 2023.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Deferred tax balances</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" id="f-838" continuedAt="f-838-1" escape="true">Deferred tax balances</ix:nonNumeric></span></div><ix:continuation id="f-838-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance comprises temporary differences attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" format="ixt:num-dot-decimal" scale="3" id="f-839">74,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" format="ixt:num-dot-decimal" scale="3" id="f-840">76,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DeferredTaxAssetsAttributableToOtherTemporaryDifferences" format="ixt:num-dot-decimal" scale="3" id="f-841">13,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DeferredTaxAssetsAttributableToOtherTemporaryDifferences" format="ixt:num-dot-decimal" scale="3" id="f-842">11,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-843">87,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-844">87,992</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance comprises temporary differences attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-845">87,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-846">87,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-847">87,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-848">87,992</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:NetDeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-849">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:NetDeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-850">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" id="f-851" continuedAt="f-851-1" escape="true">Movements </ix:nonNumeric></span></div><ix:continuation id="f-851-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Tax losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(DTA)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">temporary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">differences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(DTA)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible<br/>assets (DTL)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total (DTL) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-852">80,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-853">7,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-854">88,242</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="3" id="f-855">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" format="ixt:num-dot-decimal" scale="3" id="f-856">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" sign="-" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" format="ixt:num-dot-decimal" scale="3" id="f-857">4,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" scale="3" id="f-858">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" sign="-" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" scale="3" id="f-859">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- directly to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" scale="3" id="f-860">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" format="ixt:fixed-zero" scale="3" id="f-861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" scale="3" id="f-863">212</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-864">76,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-865">11,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-866">87,992</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="3" id="f-867">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" format="ixt:num-dot-decimal" scale="3" id="f-868">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" sign="-" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" format="ixt:num-dot-decimal" scale="3" id="f-869">1,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" sign="-" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" scale="3" id="f-870">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" scale="3" id="f-871">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- directly to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" scale="3" id="f-872">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" format="ixt:fixed-zero" scale="3" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" format="ixt:fixed-zero" scale="3" id="f-874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" scale="3" id="f-875">102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-876">74,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-877">13,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-878">87,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="3" id="f-879">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Deferred tax assets are netted against deferred tax liabilities</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 32</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="f-880" continuedAt="f-880-1" escape="true">Cash flow information</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" id="f-881" escape="true"><ix:continuation id="f-880-1"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)<br/>(a) Reconciliation of cash and cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:BalancesWithBanks" format="ixt:num-dot-decimal" scale="3" id="f-882">77,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:BalancesWithBanks" format="ixt:num-dot-decimal" scale="3" id="f-883">70,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits at call</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="meso:DepositsAtCall" scale="3" id="f-884">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="meso:DepositsAtCall" scale="3" id="f-885">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-886">77,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-887">71,318</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(b) Reconciliation of net cash flows used in operations with loss after income tax</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-888">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-889">41,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add/(deduct) net loss for non-cash items as follows:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-890">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" format="ixt:num-dot-decimal" scale="3" id="f-891">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange (gains)/losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-892">159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-893">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForFinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-894">10,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForFinanceIncomeCost" format="ixt:num-dot-decimal" scale="3" id="f-895">10,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="meso:FairValueRemeasurementOfContingentConsiderationAfterTax" scale="3" id="f-896">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:FairValueRemeasurementOfContingentConsiderationAfterTax" format="ixt:num-dot-decimal" scale="3" id="f-897">5,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:RemeasurementOfWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-898">4,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:RemeasurementOfWarrantLiability" scale="3" id="f-899">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity settled share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-900">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-901">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="3" id="f-902">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDeferredTaxExpense" scale="3" id="f-903">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in trade and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="f-904">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="f-905">743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:AdjustmentsForIncreaseDecreaseInPrepayments" scale="3" id="f-906">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="meso:AdjustmentsForIncreaseDecreaseInPrepayments" scale="3" id="f-907">424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in tax incentive recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-908">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="3" id="f-909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in trade creditors and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="meso:AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-910">9,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="meso:AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-911">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForProvisions" format="ixt:num-dot-decimal" scale="3" id="f-912">1,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForProvisions" scale="3" id="f-913">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash outflows used in operations</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-914">26,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-915">30,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i0ca481b9662c4533b1d2a0227d14fda1_58"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-916" continuedAt="f-916-1" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="f-916-1" continuedAt="f-916-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Contributed equity </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-917" continuedAt="f-917-1" escape="true">Share capital </ix:nonNumeric></span></div><ix:continuation id="f-917-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contributed equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Share capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-918">1,015,342,237</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-919">737,121,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="meso:OrdinarySharesPurchasedValue" format="ixt:num-dot-decimal" scale="3" id="f-920">1,286,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="meso:OrdinarySharesPurchasedValue" format="ixt:num-dot-decimal" scale="3" id="f-921">1,207,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Treasury Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="meso:TreasurySharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-922">542,903</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="meso:TreasurySharesPurchased" format="ixt:num-dot-decimal" scale="0" id="f-923">542,903</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="meso:TreasurySharesPurchasedValue" format="ixt:fixed-zero" scale="3" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="meso:TreasurySharesPurchasedValue" format="ixt:fixed-zero" scale="3" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Contributed Equity</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-926">1,014,799,334</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-927">736,578,315</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-928">1,286,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-929">1,207,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-916-2" continuedAt="f-916-3"><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" id="f-930" continuedAt="f-930-1" escape="true">Movements in ordinary share capital</ix:nonNumeric></span></div><ix:continuation id="f-930-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-931">814,204,825</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-932">650,454,551</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-933">1,249,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-934">1,165,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issues of ordinary shares during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Placement of shares under a share placement agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="INF" name="meso:SharesAvailableForIssuanceUnderIssuancePlan" format="ixt:num-dot-decimal" scale="0" id="f-935">201,137,412</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="meso:SharesAvailableForIssuanceUnderIssuancePlan" format="ixt:num-dot-decimal" scale="0" id="f-936">86,666,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="meso:SharesIssuedInPlacementsValue" format="ixt:num-dot-decimal" scale="3" id="f-937">39,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="meso:SharesIssuedInPlacementsValue" format="ixt:num-dot-decimal" scale="3" id="f-938">45,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs arising on share issue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="meso:TransactionCostsArisingOnShareIssueShare" format="ixt:fixed-zero" scale="0" id="f-939">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="meso:TransactionCostsArisingOnShareIssueShare" format="ixt:fixed-zero" scale="0" id="f-940">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="meso:TransactionCostsArisingOnShareIssue" format="ixt:num-dot-decimal" scale="3" id="f-941">2,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="meso:TransactionCostsArisingOnShareIssue" format="ixt:num-dot-decimal" scale="3" id="f-942">2,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total contributions of equity during the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="meso:ContributionsOfEquityDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="f-943">201,137,412</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="meso:ContributionsOfEquityDuringPeriod" format="ixt:num-dot-decimal" scale="0" id="f-944">86,666,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="meso:ContributionsOfValueForEquityDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-945">37,106</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="meso:ContributionsOfValueForEquityDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-946">42,405</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share options reserve transferred to equity on exercise of options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" format="ixt:fixed-zero" scale="0" id="f-947">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-263" decimals="INF" name="meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" format="ixt:fixed-zero" scale="0" id="f-948">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" format="ixt:fixed-zero" scale="3" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" format="ixt:fixed-zero" scale="3" id="f-950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-951">1,015,342,237</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-952">737,121,218</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-953">1,286,229</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-954">1,207,714</ix:nonFraction></span></td></tr></table></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the six months ended December 31,  2023, <ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="ifrs-full:NumberOfSharesIssuedButNotFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-955">201,137,412</ix:nonFraction> shares were issued in a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing shareholders in Australia and certain other countries together with an institutional placement of new fully paid ordinary shares in Mesoblast Limited, at A$<ix:nonFraction unitRef="audPerShare" contextRef="c-42" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-956">0.30</ix:nonFraction> per share.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the six months ended December 31, 2022, <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="ifrs-full:NumberOfSharesIssuedButNotFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-957">86,666,667</ix:nonFraction> shares were issued in an equity purchase of Mesoblast Limited at A$<ix:nonFraction unitRef="audPerShare" contextRef="c-264" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-958">0.75</ix:nonFraction> per share to existing and new institutional investors.</span></div></td></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" id="f-959" continuedAt="f-959-1" escape="true">Movements of shares in share trust </ix:nonNumeric></span></div><ix:continuation id="f-959-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="meso:SharesHeldInTrust" format="ixt:num-dot-decimal" scale="0" id="f-960">542,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="meso:SharesHeldInTrust" format="ixt:num-dot-decimal" scale="0" id="f-961">542,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="INF" name="meso:SharesHeldInTrustValue" format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="INF" name="meso:SharesHeldInTrustValue" format="ixt:fixed-zero" scale="3" id="f-963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Movement of shares in share trust</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-964">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-965">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="INF" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="INF" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="meso:SharesHeldInTrust" format="ixt:num-dot-decimal" scale="0" id="f-968">542,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="meso:SharesHeldInTrust" format="ixt:num-dot-decimal" scale="0" id="f-969">542,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="INF" name="meso:SharesHeldInTrustValue" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="INF" name="meso:SharesHeldInTrustValue" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. From July 1, 2020, unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. Prior to July 1, 2020, the shares issued and share capital received on the exercise of options were recorded in ordinary share capital.</span></div></td></tr></table></div></ix:continuation><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfWarrantReserveExplanatoryTableTextBlock" id="f-972" continuedAt="f-972-1" escape="true">Warrant reserve</ix:nonNumeric></span></div><ix:continuation id="f-972-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant reserve</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-973">12,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-974">12,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movement during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:fixed-zero" scale="3" id="f-975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="ifrs-full:ChangesInEquity" format="ixt:fixed-zero" scale="3" id="f-976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing Balance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-977">12,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-978">12,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-916-3"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Group completed a A$<ix:nonFraction unitRef="aud" contextRef="c-276" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="6" id="f-979">138.0</ix:nonFraction> million (US$<ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="6" id="f-980">110.0</ix:nonFraction> million) private placement of <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-981">60,109,290</ix:nonFraction> new fully-paid ordinary shares at a price of A$<ix:nonFraction unitRef="audPerShare" contextRef="c-277" decimals="2" name="ifrs-full:ParValuePerShare" scale="0" id="f-982">2.30</ix:nonFraction>. As part of this placement, the Group also issued one warrant for every four ordinary shares issued in the placement, which resulted in a further <ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-983">15,027,327</ix:nonFraction> warrants issued. Each warrant has an exercise price of A$<ix:nonFraction unitRef="audPerShare" contextRef="c-278" decimals="INF" name="meso:WarrantExercisePricePerShare" scale="0" id="f-984">2.88</ix:nonFraction> per share and a <ix:nonNumeric contextRef="c-279" name="meso:WarrantExerciseTerm" format="ixt-sec:duryear" id="f-985">7</ix:nonNumeric>-year term.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has a right to compel exercise of the warrants at any time, subject to the price of the Group&#8217;s ordinary shares trading at least A$<ix:nonFraction unitRef="audPerShare" contextRef="c-280" decimals="2" name="meso:SharesPrice" scale="0" id="f-986">4.32</ix:nonFraction> for <ix:nonNumeric contextRef="c-278" name="meso:SharePriceMinimumConsecutiveDay" format="ixt-sec:durday" id="f-987">45</ix:nonNumeric> consecutive days on the ASX. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the exercise price for the warrants was adjusted from A$<ix:nonFraction unitRef="audPerShare" contextRef="c-281" decimals="INF" name="meso:WarrantExercisePricePerShare" scale="0" id="f-988">2.88</ix:nonFraction> per share to A$<ix:nonFraction unitRef="audPerShare" contextRef="c-282" decimals="INF" name="meso:WarrantExercisePricePerShare" scale="0" id="f-989">2.86</ix:nonFraction> per share with effect from January 5, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the warrants include certain anti-dilution clauses, which adjust the exercise price or conversion ratio in the event of a rights issue or bonus issue. Management analyzed these clauses and determined the fixed-for-fixed requirement was still satisfied because the relative rights of shareholders and warrant holders were maintained. Therefore the warrants were classified as equity. The warrants were initially measured in equity at fair value, which was determined using a Monte Carlo simulation (refer to Note 7(b)(iv) in the Form 20-F for the year ended June 30, 2023 for more details), with the residual consideration being attributed to the ordinary shares issued in the same transaction. The warrants are not remeasured for subsequent changes in fair value.</span></div></ix:continuation><div id="i0ca481b9662c4533b1d2a0227d14fda1_64"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="f-991" continuedAt="f-991-1" escape="true">Financial risk management</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfExposureToFinancialRisksTableTextBlock" id="f-992" escape="true"><ix:continuation id="f-991-1" continuedAt="f-991-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note explains the Group&#8217;s exposure to financial risks and how these risks could affect the Group&#8217;s future financial performance. Current year profit and loss information has been included where relevant to add further context.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exposure arising from</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Measurement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Management</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; currency risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future commercial transactions </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow forecasting<br/>Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; interest rate risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term deposits at fixed rates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposits at variable rates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; price risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. </span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; share price risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future exercise of warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise. Therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, and trade and other receivables and other non-current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aging analysis<br/>Credit ratings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rolling cash flow forecasts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future cash flow requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group&#8217;s future commitments.</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-991-2" continuedAt="f-991-3"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Market risk</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Currency risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has foreign currency amounts owing relating to clinical, regulatory and overhead activities and foreign currency deposits held primarily in the Group&#8217;s Australian based entity, whose functional currency is the A$. The Group also has foreign currency amounts owing </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Group&#8217;s Swiss and Singapore based entities, whose functional currencies are the US$.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Group also has foreign currency amounts owing in various other non-US$ currencies in A$ and US$ functional currency entities in the Group relating to clinical, regulatory and overhead activities. These foreign currency balances give rise to a currency risk, which is the risk of the exchange rate moving, in either direction, and the impact it may have on the Group&#8217;s financial performance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency risk is minimized by ensuring the proportion of cash reserves held in each currency matches the expected rate of spend of each currency. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Group held <ix:nonFraction unitRef="number" contextRef="c-284" decimals="2" name="meso:PercentageOfCashHeld" scale="-2" id="f-993">68</ix:nonFraction>% of its cash in US$, <ix:nonFraction unitRef="number" contextRef="c-285" decimals="2" name="meso:PercentageOfCashHeld" scale="-2" id="f-994">31</ix:nonFraction>% in A$ and <ix:nonFraction unitRef="number" contextRef="c-286" decimals="2" name="meso:PercentageOfCashHeld" scale="-2" id="f-995">1</ix:nonFraction>% in other currencies. As of June&#160;30, 2023, the Group held <ix:nonFraction unitRef="number" contextRef="c-287" decimals="2" name="meso:PercentageOfCashHeld" scale="-2" id="f-996">67</ix:nonFraction>% of its cash in US$, and <ix:nonFraction unitRef="number" contextRef="c-288" decimals="2" name="meso:PercentageOfCashHeld" scale="-2" id="f-997">33</ix:nonFraction>% in A$.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Cash flow and fair value interest rate risk </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is exposed to interest rate movements which impacts interest income earned on its deposits and at call accounts. The interest rate risk is managed by spreading the maturity date of our deposits across various periods. The Group ensures that sufficient funds are available, in at call accounts, to meet the working capital requirements of the Group.</span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" id="f-998" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of December&#160;31, 2023 and June&#160;30, 2023. The effect on profit is shown if interest rates change by <ix:nonFraction unitRef="number" contextRef="c-289" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRate" scale="-2" id="f-999"><ix:nonFraction unitRef="number" contextRef="c-290" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRate" scale="-2" id="f-1000">10</ix:nonFraction></ix:nonFraction>%, in either direction, is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"/><td style="width:36.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested - US$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1001">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1002">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="meso:FundsInvestedWhichDerivesInterestRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1003">49,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1004">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1005">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="meso:FundsInvestedWhichDerivesInterestRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1006">40,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increase by <ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1007"><ix:nonFraction unitRef="number" contextRef="c-296" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1008">10</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1009">2.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1010">2.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1011">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1012">1.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1013">1.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1014">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate decrease by <ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1015"><ix:nonFraction unitRef="number" contextRef="c-296" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1016">10</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1017">1.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1018">1.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1019">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1020">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-295" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1021">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1022">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Australian dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested - A$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-297" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1023">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1024">4.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="aud" contextRef="c-299" decimals="-3" name="meso:FundsInvestedWhichDerivesInterestRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1025">35,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1026">3.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-301" decimals="4" name="meso:FundsInvestedPercentage" scale="-2" id="f-1027">4.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="aud" contextRef="c-302" decimals="-3" name="meso:FundsInvestedWhichDerivesInterestRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1028">35,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increase by <ix:nonFraction unitRef="number" contextRef="c-302" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1029"><ix:nonFraction unitRef="number" contextRef="c-299" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1030">10</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-297" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1031">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1032">5.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="aud" contextRef="c-299" decimals="-3" name="meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1033">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1034">3.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-301" decimals="4" name="meso:IncreaseInInterestRatePercentage" scale="-2" id="f-1035">5.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="aud" contextRef="c-302" decimals="-3" name="meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1036">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate decrease by <ix:nonFraction unitRef="number" contextRef="c-299" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1037"><ix:nonFraction unitRef="number" contextRef="c-302" decimals="INF" name="meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" scale="-2" id="f-1038">10</ix:nonFraction></ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-297" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1039">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-298" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1040">4.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="aud" contextRef="c-299" decimals="-3" name="meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1041">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-300" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1042">3.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-301" decimals="4" name="meso:DecreaseInInterestRatePercentage" scale="-2" id="f-1043">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="aud" contextRef="c-302" decimals="-3" name="meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" scale="3" id="f-1044">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A$ deposits held as of June 30, 2023  have been updated to reflect the increasing impact of higher interest rates.</span></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Price risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price risk is the risk that future cash flows derived from financial instruments will be altered as a result of a market price movement, which is defined as movements other than foreign currency rates and interest rates. The Group is exposed to price risk which arises from long-term borrowings under its facility with NovaQuest, where the timing and amounts of principal and interest payments is dependent on net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia. As net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in these territories increase/decrease, the timing and amount of principal and interest payments relating to this type of financing arrangement will also fluctuate, resulting in an adjustment to the carrying amount of the financial liability. The adjustment is recognized in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-991-3" continuedAt="f-991-4"><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" id="f-1045" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exposure of the Group&#8217;s borrowing to price rate changes are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total<br/>borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total<br/>borrowings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="ifrs-full:ShorttermBorrowings" scale="3" id="f-1046">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="2" name="meso:PercentageOfPriceRateChangesInCurrentBorrowings" scale="-2" id="f-1047">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="ifrs-full:ShorttermBorrowings" scale="3" id="f-1048">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-304" decimals="2" name="meso:PercentageOfPriceRateChangesInCurrentBorrowings" scale="-2" id="f-1049">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1050">60,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="2" name="meso:PercentageOfPriceRateChangesInNonCurrentBorrowings" scale="-2" id="f-1051">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-1052">55,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-304" decimals="2" name="meso:PercentageOfPriceRateChangesInNonCurrentBorrowings" scale="-2" id="f-1053">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1054">61,245</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-303" decimals="2" name="meso:PercentageOfPriceRateChangesInBorrowings" scale="-2" id="f-1055">53</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="f-1056">56,075</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-304" decimals="2" name="meso:PercentageOfPriceRateChangesInBorrowings" scale="-2" id="f-1057">51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2023, all other factors held constant, a +/- <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="meso:PercentageOfForecastNetSales" scale="-2" id="f-1058">20</ix:nonFraction>% increase/decrease in the forecast net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia would not have a significant impact on non-current borrowing and profit. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is also exposed to price risk on contingent consideration provision balances, as expected unit revenues are a significant unobservable input used in the level 3 fair value measurements. As at December&#160;31, 2023, all other factors held constant, the increase/decrease in price assumptions adopted in the fair value measurements of the contingent consideration provision are discussed in Note 5(e)(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">iv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group does not consider it has any exposure to price risk other than those already described above. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Share price risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group's exposure to share price risk arises from warrant liabilities held by the Group and classified in the statement of financial position at fair value through profit or loss. The future exercise of these warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise, therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. </span></div><ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" id="f-1059" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the impact of the increase/decrease of Mesoblast's share price on the Group's profit or loss during the period, based on the assumption that the share price had increased/decreased by <ix:nonFraction unitRef="number" contextRef="c-41" decimals="2" name="meso:PercentageOfIncreaseAndDecreaseInSharePrice" scale="-2" id="f-1060">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-29" decimals="2" name="meso:PercentageOfIncreaseAndDecreaseInSharePrice" scale="-2" id="f-1061">10</ix:nonFraction>% with all other variables held constant as of December&#160;31, 2023 and June&#160;30, 2023 respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.696%"><tr><td style="width:1.0%"/><td style="width:63.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.626%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:WarrantLiability" scale="3" id="f-1062">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-1063">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact on profit or (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price increase by 10% (2023: 10%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="0" sign="-" name="meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" scale="3" id="f-1064">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="0" sign="-" name="meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" scale="3" id="f-1065">698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price decrease by 10% (2023: 10%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="0" name="meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" scale="3" id="f-1066">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="0" name="meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" scale="3" id="f-1067">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Credit risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk that one party to a financial instrument will fail to discharge its obligation and cause financial loss to the other party. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets as mentioned in Note 5.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Liquidity risk </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that the Group will not be able to pay its debts as and when they fall due. Liquidity risk has been assessed in Note 1(i). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><ix:continuation id="f-991-4" continuedAt="f-991-5"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial liabilities, excluding contingent consideration, borrowings and lease liabilities held by the Group as of December&#160;31, 2023 and June&#160;30, 2023 mature within <ix:nonNumeric contextRef="c-309" name="meso:NonInterestBearingFinancialLiabilitiesMaturityPeriod" format="ixt-sec:durmonth" id="f-1068"><ix:nonNumeric contextRef="c-310" name="meso:NonInterestBearingFinancialLiabilitiesMaturityPeriod" format="ixt-sec:durmonth" id="f-1069">6</ix:nonNumeric></ix:nonNumeric> months. Trade payables and contingent consideration held by the Group as of December&#160;31, 2023 and June&#160;30, 2023 are non-interest bearing. The total contractual cash flows associated with trade payables equate to the carrying amount disclosed within the financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities" id="f-1070" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which therefore differs from the carrying value, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Within <br/>1 year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Between <br/>1-2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Between <br/>2-5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over <br/>5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>contractual <br/>cash flows</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying <br/>amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1071">9,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1072">18,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1073">143,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1075">171,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="ifrs-full:GrossLoanCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1076">115,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1077">10,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1081">10,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="ifrs-full:GrossLoanCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1082">10,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1083">3,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1084">2,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="f-1085">613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1087">6,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="ifrs-full:GrossLoanCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1088">6,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1089">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="f-1090">881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" scale="3" id="f-1091">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1093">6,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" name="ifrs-full:GrossLoanCommitments" scale="3" id="f-1094">612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1095">28,630</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1096">22,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1097">144,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:fixed-zero" scale="3" id="f-1098">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-1099">195,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="ifrs-full:GrossLoanCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1100">133,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at December&#160;31, 2023 without taking into account drawdowns of further tranches.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD in the United States and other territories excluding Asia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. Product royalties will be payable in cash which will be funded from royalties received from net sales. With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Group commenced production under its manufacturing service agreement with Lonza for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of pediatric SR-aGVHD in the US market. This agreement contains lease and non-lease components. As of December&#160;31, 2023, the agreement contains a minimum remaining financial commitment of the non-lease component of $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="meso:MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" format="ixt:num-dot-decimal" scale="6" id="f-1101">12.7</ix:nonFraction> million, payable until June 2025, which is cancellable in limited circumstances. The Group has accounted for the lease component within the agreement as a lease liability separately from the non-lease components. As of December&#160;31, 2023, the lease component is $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="meso:MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" format="ixt:num-dot-decimal" scale="6" id="f-1102">2.5</ix:nonFraction> million on an undiscounted basis, as disclosed within the total contractual cash flows as lease liabilities in Note 9(c). At the Group's discretion, the minimum financial commitment under this manufacturing services agreement can be reduced by $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="meso:MinimumFinancialCommitmentReductionAmount" format="ixt:num-dot-decimal" scale="6" id="f-1103">7.4</ix:nonFraction>&#160;million under certain conditions, with $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="meso:MinimumFinancialCommitmentReductionAmountOnLeaseComponent" format="ixt:num-dot-decimal" scale="6" id="f-1104">1.5</ix:nonFraction>&#160;million of this reduction relating to the lease component and $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="meso:MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" format="ixt:num-dot-decimal" scale="6" id="f-1105">5.9</ix:nonFraction>&#160;million relating to the non-lease component of the agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group have agreements with third parties related to contract manufacturing and other goods and services. As of December&#160;31, 2023, the Group had $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="meso:NonCancellablePurchaseCommitments" format="ixt:num-dot-decimal" scale="6" id="f-1106">5.7</ix:nonFraction> million of non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services (excluding those with Lonza). This amount represents our minimum contractual obligations, including termination fees. Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Group are contractually obligated to make certain payments, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-991-5">The Group did <ix:nonFraction unitRef="usd" contextRef="c-41" decimals="INF" name="meso:OtherPurchaseCommitments" format="ixt:fixed-zero" scale="0" id="f-1107">not</ix:nonFraction> have any other purchase commitments as of December&#160;31, 2023.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 38</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-1108" continuedAt="f-1108-1" escape="true">(Losses) per share</ix:nonNumeric></span></div><ix:continuation id="f-1108-1" continuedAt="f-1108-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-1109" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in cents)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="4" sign="-" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-1110">3.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="4" sign="-" name="ifrs-full:BasicEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-1111">5.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total basic (losses) per share attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="4" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="-2" id="f-1112">3.82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="4" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="-2" id="f-1113">5.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Diluted (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="4" sign="-" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-1114">3.82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="4" sign="-" name="ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations" scale="-2" id="f-1115">5.64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="4" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="-2" id="f-1116">3.82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="4" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="-2" id="f-1117">5.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) (Losses) used in calculating (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="3" id="f-1118">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" format="ixt:num-dot-decimal" scale="3" id="f-1119">41,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) from continuing operations attributable to the ordinary equity holders of the company:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Used in calculating basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" format="ixt:num-dot-decimal" scale="3" id="f-1120">32,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" format="ixt:num-dot-decimal" scale="3" id="f-1121">41,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" format="ixt:num-dot-decimal" scale="3" id="f-1122">32,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" format="ixt:num-dot-decimal" scale="3" id="f-1123">41,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Shares)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Shares)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares used as the denominator in calculating basic losses per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1124">851,464,145</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1125">733,282,900</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1126">851,464,145</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-1127">733,282,900</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and warrants are considered to be potential ordinary shares. These securities have been excluded from the determination of basic losses per share in the six months ended December&#160;31, 2023 and 2022. Shares that may be paid as contingent consideration have also been excluded from basic losses per share. They have been excluded from the calculation of diluted losses per share because they are anti-dilutive for the six months ended December&#160;31, 2023 and 2022.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1108-2">The calculations for the six months ended December&#160;31, 2023 and 2022 have been adjusted to reflect the bonus element in the entitlement offer to existing eligible shareholders which occurred during December 2023.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 39</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-1128" continuedAt="f-1128-1" escape="true">Events occurring after the reporting period</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1128-1">There were no events that have occurred after December&#160;31, 2023 and prior to the signing of this financial report that would likely have a material impact on the financial results presented.</ix:continuation> </span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_73"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-1129" continuedAt="f-1129-1" escape="true">Segment information</ix:nonNumeric></span></div><ix:continuation id="f-1129-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified on the basis of whether the allocation of resources and/or the assessment of performance of a particular component of the Company&#8217;s activities are regularly reviewed by the Company&#8217;s chief operating decision maker as a separate operating segment. By these criteria, the activities of the Company are considered to be <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="meso:NumberOfOperatingSegment" format="ixt-sec:numwordsen" scale="0" id="f-1130">one</ix:nonFraction> segment being the development of adult stem cell technology platform for commercialization, and the segmental analysis is the same as the analysis for the Company as a whole. The chief operating decision maker (Chief Executive Officer) reviews the consolidated income statement, balance sheet, and statement of cash flows regularly to make decisions about the Company&#8217;s resources and to assess overall performance.</span></div></ix:continuation><div id="i0ca481b9662c4533b1d2a0227d14fda1_76"></div><div style="margin-top:18pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="meso:DisclosureOfLegalProceedingsExplanatoryTextBlock" id="f-1131" continuedAt="f-1131-1" escape="true">Legal proceedings</ix:nonNumeric></span></div><ix:continuation id="f-1131-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A class action proceeding in the Federal Court of Australia was served on the Company in May 2022 by the law firm William Roberts Lawyers on behalf of persons who, between February 22, 2018, and December 17, 2020, acquired an interest in Mesoblast shares, American Depository Receipts, and/or related equity swap arrangements. In June 2022, the firm Phi Finney McDonald commenced a second shareholder class action against the Company in the Federal Court of Australia asserting similar claims arising during the same period. Like the class action lawsuit from October 2020 filed in the U.S. Federal District Court for the Southern District of New York (which had court approval for settlement in August 2022), the Australian class actions relate to the Complete Response Letter released by the FDA in September 2020 in relation to the Company's GvHD product candidate; they also relate to certain representations made by the Company in relation to our COVID-19 product candidate and the decline in the market price of the Company's ordinary shares in December 2020. The Australian class actions have been consolidated into <ix:nonFraction unitRef="lawsuit" contextRef="c-41" decimals="INF" name="meso:NumberOfClassActionLawsuits" format="ixt-sec:numwordsen" scale="0" id="f-1132">one</ix:nonFraction> lawsuit. The Company will continue to vigorously defend against the proceedings. The Company cannot provide any assurance as to the possible outcome or cost to us from the lawsuit, particularly as it is at an early stage, nor how long it may take to resolve such lawsuit. Thus, the Company has not accrued any amounts in connection with such legal proceedings.</span></div></ix:continuation><div id="i0ca481b9662c4533b1d2a0227d14fda1_531"></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%;text-decoration:underline">Australian Disclosure Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%">Directors&#8217; Declaration</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">In accordance with a resolution of directors of Mesoblast Limited,</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">In the director&#8217;s opinion:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">a)&#160;&#160;&#160;&#160;the financial statements and notes set out on pages 6 to 42 are in accordance with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:90%">Corporations Act 2001, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">including:</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">i)&#160;&#160;&#160;&#160;complying with Accounting Standards, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:90%">Corporations Regulations 2001 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">and other mandatory professional reporting requirements, and</span></div><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">ii)&#160;&#160;&#160;&#160;giving a true and fair view of the consolidated entity's financial position as at December 31, 2023 and of its performance for the six months ended on that date, and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">b)  there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This declaration is made in accordance with a resolution of the directors.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.416%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joseph Swedish</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Silviu Itescu</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph Swedish</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Silviu Itescu</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February&#160;29, 2024</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Melbourne</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_536"></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preparation of interim financial statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the interim financial statements to conform to the requirements applicable in both Australia and the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the interim financial statements to conform to the requirements of IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company has labelled the interim financial information &#8220;unaudited&#8221; because the interim financial information is not subject to an audit by our independent registered public accounting firm. Exhibits 99.1, 99.2 and 99.3 are included within this filing to meet the requirements of Australian laws and regulations and are not incorporated in any registration statement under the U.S. Securities Act of 1933.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the interim financial statements to conform to the requirements of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporations Act 2001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AASB 134 Interim Financial Reporting. A review of the interim financial information has been performed by the Company&#8217;s independent auditors to meet the requirements of Australian Auditing Standard on Review Engagements ASRE 2410 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Review of a Financial Report Performed by the Independent Auditor of the Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and users should refer to the auditor&#8217;s independence declaration and independent auditor&#8217;s review report included within this filing.</span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This page is intentionally left blank.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This page is intentionally left blank.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 44</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements included in this Report on Form 6-K. We present our consolidated financial statements in U.S. dollars and in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board, or IFRS, and Australian equivalent International Financial Reporting Standards, as issued by the Australian Accounting Standards Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For us and our subsidiaries that use a functional currency that is not U.S. dollars, the assets and liabilities have been translated at the closing exchange rate, while the income and expenses have been translated at the average exchange rate. The resulting exchange differences are recognized in our consolidated statement of comprehensive income. See note 23(d) in the notes to our consolidated financial statements and the related notes thereto included in our annual report on Form 20-F for the fiscal year ended June 30, 2023 (&#8220;Form 20-F&#8221;), filed with the Securities and Exchange Commission on August 31, 2023, for more information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our fiscal year ends each year on June 30. Reference to a year relates to the fiscal year, ended in June 30 of the year indicated, rather than the calendar year, unless indicated by a specific date. </span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesoblast is a world leader in developing allogeneic cellular medicines. We have developed a range of late-stage product candidates derived from our first and second generation proprietary mesenchymal lineage cell therapy technology platforms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remestemcel-L is our first generation mesenchymal lineage stromal cell product platform and is in late stage development for treatment of systemic inflammatory diseases including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pediatric steroid refractory acute Graft versus Host Disease (&#8220;SR-aGVHD&#8221;); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Acute respiratory distress syndrome (&#8220;ARDS&#8221;); and </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Biologic refractory inflammatory bowel disease (&#8220;IBD&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rexlemestrocel-L is our second generation mesenchymal lineage precursor cell product platform and is in late stage development for treatment of:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Advanced chronic heart failure (&#8220;CHF&#8221;); and </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic low back pain (&#8220;CLBP&#8221;) due to degenerative disc disease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both platforms have life cycle management strategies with promising emerging pipelines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 15, 2024, we announced that the United States Food and Drug Administration (&#8220;FDA&#8221;) granted Mesoblast&#8217;s allogeneic cell therapy Revascor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (rexlemestrocel-L) an Orphan-Drug Designation (&#8220;ODD&#8221;) following submission of results from the randomized controlled trial in children with hypoplastic left heart syndrome (&#8220;HLHS&#8221;), a potentially life threatening congenital heart condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 19, 2024, we announced that the FDA granted Mesoblast&#8217;s cell therapy Revascor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (rexlemestrocel-L) a Rare Pediatric Disease (RPD) designation following submission of results from the randomized controlled trial in children with HLHS, a potentially life-threatening congenital heart condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 28, 2023, we provided an update on a private placement to institutional and sophisticated investors and 1 for 4 pro-rata accelerated non-renounceable entitlement offer to shareholders in Australia and certain other countries that raised A$60.3 million at an issue price of A$0.30 per ordinary share.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 27, 2023, we announced filing for Orphan Drug Designation (&#8220;ODD&#8221;) and Rare Pediatric Disease (&#8220;RPD&#8221;) designation with the FDA for REVASCOR in the treatment of the congenital heart disease hypoplastic left heart syndrome (&#8220;HLHS&#8221;). The filings were based on results from a blinded, randomized, controlled prospective trial of REVASCOR conducted at a single center in the US in 19 children with HLHS and accepted for publication in peer reviewed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The Journal of Thoracic and Cardiovascular Surgery Open (JTCVS Open)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 22. 2023, we announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast&#8217;s lead product candidate Ryoncil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (remestemcel-L) in the treatment of adults with SR-aGvHD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 26, 2023, we announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 21, 2023, we provided an update on the path to approval for lead-product candidate remestemcel-L in the treatment of pediatric and adult SR-aGvHD, following a Type A meeting held with FDA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 4, 2023, the FDA provided a complete response to the Biologics License Application (&#8220;BLA&#8221;) resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. Mesoblast intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. This adult study is in line with our overall commercial strategy, which envisioned a sequenced progression from pediatric to adult SR-aGVHD indications. As part of its review FDA completed the Pre-License Inspection ("PLI") of the manufacturing facility, did not issue any Form 483, and found no objectionable conditions. In addition, FDA acknowledged in the resubmission review that changes implemented appear to improve assay performance relative to the original version of the assay used in the pediatric Phase 3 trial.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the period covered in this Report, no material cybersecurity incidents occurred.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_85"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. For the six months ended December&#160;31, 2023, we had an accumulated deficit of $853.3 million. Our net loss for the six months ended December&#160;31, 2023 was $32.5 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we may continue to incur significant losses for the foreseeable future. There can be no assurance that we will ever achieve or maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our future capital requirements will continue as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue the research and clinical development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiate and advance our product candidates into larger clinical studies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to identify, assess, acquire, and/or develop other product candidates and technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek regulatory and marketing approvals in multiple jurisdictions for our product candidates that successfully complete clinical studies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish collaborations with third parties for the development and commercialization of our product candidates, or otherwise build and maintain a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">further develop and implement our proprietary manufacturing processes and expand our manufacturing capabilities and resources for commercial production;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek coverage and reimbursement from third-party payors, including government and private payors for future products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make interest payments, principal repayments and other charges on our debt financing arrangements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make milestone or other payments under our agreements pursuant to which we have licensed or acquired rights to intellectual property and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to maintain, protect, and expand our intellectual property portfolio; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to attract and retain skilled personnel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development and management and administration expenses to remain relatively consistent over the next 12 months. Subject to us achieving successful regulatory approval, we expect an increase in our total expenses driven by an increase in our product manufacturing and selling, general and administrative expenses as we move towards commercialization. Therefore, we will need additional capital to fund our operations, which we may raise through equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations, strategic alliances and licensing arrangements. We do not know when, or if, we will generate revenues from our product sales significant enough to generate profits. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one or more of our cell-based product candidates. For further discussion on our ability to continue as a going concern, see Note 1(i) in our accompanying financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercialization and Milestone Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Commercialization and milestone revenue relates to upfront, royalty and milestone payments recognized under development and commercialization agreements; milestone payments, the receipt of which is dependent on certain clinical, regulatory or commercial milestones; as well as royalties on product sales of licensed products, if and when such product sales occur; and revenue from the supply of products. Payment is generally due on standard terms of 30 to 60 days.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred consideration in our consolidated balance sheet, depending on the nature of the arrangement. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified within non-current liabilities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenditure is recognized as an expense as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">third party costs comprising all external expenditure on our research and development programs such as fees paid to Contract Research Organizations (&#8220;CROs&#8221;) and on our pre-commercial activities, such as research pertaining to market access and pricing, brand marketing and initiation of trade and distribution contracts. Third party costs also comprise fees paid to consultants who perform research on our behalf and under our direction, rent and utility costs for our research and development facilities, and database analysis fees;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">third party costs under license and/or sub-license arrangements for the research and development, license, manufacture and/or commercialization of products and/or product candidates, such as payments for options to acquire rights to products and product candidates as well as contingent obligations under the agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product support costs consisting primarily of salaries and related overhead expenses for personnel in research and development and pre-commercial functions (for example wages, salaries and associated on costs such as superannuation, share-based incentives and payroll taxes, plus travel costs and recruitment fees for new hires); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">intellectual property support costs comprising payments to our patent attorneys to progress patent applications and all costs of renewing our granted patents; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">amortization of currently marketed products on a straight-line basis over the life of the asset.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses are not charged to specific products or programs, since the number of clinical and preclinical product candidates or development projects tends to vary from period to period and since internal resources are utilized across multiple products and programs over any given period of time. As a result, our management does not maintain and evaluate research and development costs by product or program. Acquired in-process research and development is capitalized as an asset and is not amortized but is subject to impairment review during the development phase. Upon completion of its development, the acquired in-process research and development amortization will commence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing Commercialization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing commercialization expenditure is recognized as an expense as incurred. Our manufacturing commercialization expenses consist primarily of:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">salaries and related overhead expenses including share-based incentives for personnel in manufacturing functions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fees paid to our contract manufacturing organizations, which perform process development on our behalf and under our direction; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs related to laboratory supplies used in our manufacturing development efforts; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provision for the carrying value of pre-launch inventory costs on the balance sheet.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management and Administration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Management and administration expenses consist primarily of salaries and related costs including share-based incentives for directors and employees in corporate and administrative functions, including the executives of those areas. Other significant management and administration expenses include legal and professional services, rent and depreciation of leasehold improvements, insurance and information technology services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Remeasurement of Contingent Consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Remeasurement of contingent consideration pertains to the acquisition of the MSC assets from Osiris Therapeutics, Inc. The fair value remeasurement of contingent consideration is recognized as a net result of changes to the key assumptions of the contingent consideration valuation such as developmental timelines, market growth, probability of success and payment, market penetration, product pricing and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Movement of Warrants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Remeasurement of warrants pertain to the warrants granted to Oaktree Capital Management, L.P ("Oaktree") in relation to the refinancing and amendment of our senior debt facility. The fair value movement of warrants is recognized when there is a change in the valuation assumptions such as share price, risk-free interest rates and volatility.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income and Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other operating income and expenses primarily comprise foreign exchange gains and losses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax incentives comprise payments from the Australian government&#8217;s Innovation Australia Research and Development Tax Incentive program for research and development activities conducted in relation to our qualifying research that meets the regulatory criteria. The research and development tax incentive credit is available for our research and development activities in Australia. Eligible companies can receive a refundable tax offset for a percentage of their research and development spending.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no research and development tax incentive income recognized in the six months ended December 31, 2023 and 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains and losses relate to unrealized foreign exchange gains and losses on our foreign currency amounts in our Australian based entity, whose functional currency is the A$, and foreign currency amounts in our Switzerland and Singapore based entities, whose functional currencies are the US$, plus realized gains and losses on any foreign currency payments to our suppliers due to movements in exchange rates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest revenue is accrued on a time basis by reference to the principal outstanding and at the effective interest rate applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Finance costs primarily consists of remeasurement of borrowing arrangements, interest expense in relation to finance lease charges, accrued interest expense and interest expense in relation to the amortization of transaction costs and other charges associated with the borrowings as represented in our consolidated balance sheet using the effective interest rate method over the period of initial recognition through maturity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of borrowing arrangements recognized pertain to our loan and security agreements with NovaQuest Capital Management, L.L.C. (&#8220;NovaQuest&#8221;) and Oaktree. Remeasurement of borrowing arrangements is recognized when there is a modification of the borrowing arrangement with no significant change to the contractual cash flows of the borrowings at the remeasurement date or when there is a revision in the estimated future cash flows which is recorded as an adjustment of the carrying amount of the financial liability. The carrying amount is recalculated by computing the present value of the revised estimated future cash flows at the financial instrument&#8217;s original effective interest rate. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit/Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income tax benefit/expense consists of net changes in deferred tax assets and liabilities recognized on the balance sheet during the period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 48</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Our Results for the Six Months Ended December 31, 2023 with the Six Months Ended December 31, 2022</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended December&#160;31, 2023 and 2022, together with the changes in those items in dollars and as a percentage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands except per share information)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Income Statement Data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,388</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,422</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(34)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research &amp; development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing commercialization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management and administration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value movement of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32,641)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,496)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,855</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss attributable to the owners of Mesoblast Limited</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:1pt;text-align:justify;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses per share from continuing operations attributable to</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;the ordinary equity holders:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;Cents </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;Cents </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;Cents </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic - losses per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted - losses per share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">NM = not meaningful.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were $3.4 million for the six months ended December&#160;31, 2023 and 2022. The following table shows the movement within revenue for the six months ended December&#160;31, 2023 and 2022, together with the changes in those items.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue from royalty income earned on sales of TEMCELL in Japan and Alofisel&#174; in Europe remained consistent for the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022. Royalty income on sales of TEMCELL in Japan by our licensee JCR were consistent at $3.2 million in the six months ended December&#160;31, 2023 and 2022, with an unfavorable impact of $0.1 million in the six months ended December 31, 2023 due to foreign exchange rate changes as the Japanese Yen depreciated against the U.S. dollar. Royalty income on sales of Alofisel&#174; in Europe by our licensee Takeda were consistent at $0.2 million in the six months ended December&#160;31, 2023 and 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $12.6 million for the six months ended December&#160;31, 2023, compared with $13.4 million for the six months ended December&#160;31, 2022, a decrease of $0.8 million. The $0.8 million decrease in research and development expenses was due to a decrease in third party costs.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third party costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product support costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property support costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of current marketed products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,430</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(783)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third party costs, which consist of all external expenditure on our research and development programs and pre-commercial activities, decreased by $1.8 million in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This $1.8 million decrease was due to a reduction in our third party costs for our Phase 3 clinical trials for the treatment of MPC-06-ID (CLBP) and MPC-150-IM (CHF) as activities and costs decline over time as these trials transitioned into the patient monitoring and data analysis stage. The decrease of these costs were primarily due to higher activities in relation to patient monitoring during follow up visits and higher data analysis being performed in the six months ended December 31, 2022 compared with the six months ended December 31, 2023. In the six months ended December&#160;31, 2023, we also incurred costs of $0.9 million associated with our pre-commercial activities as we prepared for the potential launch of remestemcel-L in the United States. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product support costs, which consist primarily of salaries and related overhead expenses for personnel in research and development and pre-commercial functions, have increased by $1.1 million, for the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022. Within this $1.1 million increase, $0.8 million relates to an increase in product support costs for research and development functions and $0.3 million relates to an increase in product support costs for pre-commercial functions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $0.8 million increase in product support costs for personnel in research and development functions is primarily due to an increase of $0.3 million in share-based payment expenses and $0.3 million in consulting expenses for the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022. There was a decrease in full time equivalents for the six months ended December&#160;31, 2023; however overall costs across salaries and associated expenses increased by $0.2 million due to one-off restructuring costs in the six months ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $0.3 million increase in product support costs for personnel in pre-commercial functions is primarily due to an increase of $0.3 million in salaries and associated expenses including recruitment expenses as we prepared for the potential launch of remestemcel-L in the United States. There was also an increase of $0.2 million due to one-off restructuring costs in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022. These increases were offset with a $0.2 million decrease in consulting expenses in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also included in research and development expenses are intellectual property support costs, which consist of payments to our patent attorneys to progress patent applications and costs of renewing our granted patents. These costs have decreased by $0.1 million in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022 due to decreased activities across our entire patent portfolio.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing commercialization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing commercialization expenses were $6.7 million for the six months ended December&#160;31, 2023, compared with $12.7 million for the six months ended December&#160;31, 2022, a decrease of $6.0 million. This decrease is primarily due to a decrease in platform technology costs. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing commercialization:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing support costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing commercialization</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6,014)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(47</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Platform technology costs decreased by $6.4 million for the six months ended December&#160;31, 2023 compared with six months ended December&#160;31, 2022. These costs consist of fees paid to our contract manufacturing organizations, potency assay work that supported the aGVHD BLA resubmission, process development of our proprietary technology that facilitates the increase in yields necessary for the long-term commercial supply of our product candidates and next generation manufacturing processes to reduce labor, drive down cost of goods and improve manufacturing efficiencies in our MPC and MSC based products. The decrease of these costs was primarily due to lower MSC development activities during the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing support costs, which consist primarily of salaries and related overhead expenses for personnel in manufacturing commercialization functions increased by $0.4 million in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022 primarily due to an increase of $0.2 million across salaries and associated expenses due to one-off restructuring costs and an increase of $0.2 million in share-based payment expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management and administration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Management and administration expenses were $11.5 million for the six months ended December&#160;31, 2023, compared with $13.3 million for the six months ended December&#160;31, 2022, a decrease of $1.8 million. This decrease was primarily due to a decrease in labor and associated expenses and corporate overheads. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management and administration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Labor and associated expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate overheads</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(377)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management and administration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,799)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Labor and associated expenses decreased by $1.5 million from $5.9 million for the six months ended December&#160;31, 2022 to $4.4 million for the six months ended December&#160;31, 2023. This $1.5 million decrease is primarily due to a decrease of $0.8 million in consulting expenses and $0.4 million in overall cost of labor and associated expenses as a result of managements cost containment strategy. There was also a decrease of $0.2 million across recruitment and share-based payment expenses for the six months ended December 31, 2023, compared with the six months ended December 31, 2022. Labor and associated expenses also experienced favorable exchange rate fluctuations of $0.1 million in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022, as the A$ weakened against the US$ given the majority of management and administration expenses are incurred in A$ by our headquarter office located in Australia.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate overhead expenses decreased by $0.4 million from $6.3 million for the six months ended December&#160;31, 2022 to $5.9 million for the six months ended December&#160;31, 2023 primarily due to a decrease of insurance premiums.   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal and professional fees remained relatively consistent for the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value remeasurement of contingent consideration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Fair value remeasurement of contingent consideration recognized a $0.3 million loss for the six months ended December&#160;31, 2023 compared with a $6.0 million gain for the six months ended December&#160;31, 2022. The $0.3 million loss for the six months ended December&#160;31, 2023 was due to the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This loss was a net result of changing the key assumptions of the contingent consideration valuation such as development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The $6.0 million gain for the six months ended December&#160;31, 2022 was due to the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This gain was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. With respect to commercialization, product royalties will be payable in cash which will be funded from royalties received from net sales.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value movement of warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value movement of warrants was a $4.4 million gain for the six months ended December&#160;31, 2023 compared with a $0.7 million loss for the six months ended December&#160;31, 2022. This $4.4 million gain for the six months ended December&#160;31, 2023 is a net result of changes to the key valuation inputs of the warrants such as the share price, risk-free interest rates and volatility. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating income and expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In relation to other operating income and expenses, we recognized an income of $1.1 million for the six months ended December&#160;31, 2023, compared with a minor loss for the six months ended December&#160;31, 2022, an increase in income of $1.1 million. The following table shows movements within other operating income and expenses for the six months ended December&#160;31, 2023 and 2022, together with the changes in those items:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other operating income and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(689)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange (gains)/losses (net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(418)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other operating (income) and expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,068)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">39</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NM</span></td></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">NM = not meaningful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $0.7 million increase in interest revenue for the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022 was primarily driven by higher interest rates on A$ and US$ cash deposits in the six months ended December&#160;31, 2023, when compared to the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to foreign exchange gains and losses on foreign currency cash balances, creditors and debtors. In the six months ended December&#160;31, 2023, we recognized a foreign exchange gain of $0.2 million, primarily due to movements in exchange rates on US$ liabilities held in Mesoblast Limited, whose functional currency is the A$, as the A$ appreciated against the US$. In the six months ended December&#160;31, 2022, we recognized a foreign exchange loss of $0.2 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance costs</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;$ Change </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;% Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of borrowing arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(366)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023, we recognized an overall loss of $0.1 million for remeasurement of borrowing arrangements in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows from our credit facilities with NovaQuest and Oaktree, a decrease in losses of $1.1 million as compared with a $1.2 million loss for the six months ended December&#160;31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the $0.1 million loss in the six months ended December&#160;31, 2023, in relation to our existing credit facility with NovaQuest, we recognized a $0.1 million loss for remeasurement of borrowing arrangements in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows as a net result of changes to the key assumption in development timelines, a decrease in gains of $0.3 million as compared with a $0.2 million gain recognized for the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also within the $0.1 million loss in the six months ended December&#160;31, 2023, in relation to our existing credit facility with Oaktree, we recognized a minimal loss for remeasurement of borrowing arrangements in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows, a decrease in losses of $1.4 million as compared with a loss of $1.4 million for the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased by $0.7 million from $9.5 million for the six months ended December&#160;31, 2022 to $10.2 million for the six months ended December&#160;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023, in relation to our loan and security agreement with Oaktree, we recognized $4.9 million of interest expense, an increase of $0.5 million as compared with $4.5 million for the six months ended December&#160;31, 2022. Within this $4.9 million recognized in the six months ended December&#160;31, 2023, $3.1 million was recognized with regards to interest expense payable on the loan balance within the year of which $2.6 million was paid and $0.5 million was added to the outstanding loan balance and shall accrue further interest. A further $1.8 million of interest expense was recognized with regard to the amortization of transaction costs incurred on the outstanding loan principal for the six months ended December&#160;31, 2023 using the effective interest rate method over the period of initial recognition through maturity. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023, in relation to our loan and security agreement with NovaQuest, we recognized $5.1 million of interest expense, an increase of $0.7 million as compared with $4.4 million for the six months ended December&#160;31, 2022. Interest expense relating to the NovaQuest loan is accrued on the loan principal balance and all interest payments are deferred until the earlier of loan maturity or from after the first commercial sale of our allogeneic product candidate remestemcel-L for the treatment of pediatric patients with SR-aGVHD in the United States and other geographies excluding Asia.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with IFRS 16 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we also recognized interest expenses of $0.2 million and $0.3 million in relation to lease charges for the six months ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2022, we recognized $0.3 million of interest charges primarily in relation to manufacturing payments. Minimal interest charges were recognized in the six months ended December&#160;31, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss after income tax</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;$ Change </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;% Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,641)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,496)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss after income tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,831</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income tax was $32.6 million for the six months ended December&#160;31, 2023 compared with $41.5 million for the six months ended December&#160;31, 2022, a decrease in the loss by $8.9 million. This decrease is the net effect of the changes in revenues and expenses that have been discussed above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-cash income tax benefit of $0.1 million was recognized in the six months ended December&#160;31, 2023, in relation to the net change in deferred tax assets and liabilities recognized on the balance sheet during the period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-cash income tax benefit of $0.1 million was recognized in the six months ended December&#160;31, 2022 in relation to the net change in deferred tax assets and liabilities recognized on the balance sheet during the period.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We held total cash reserves of $77.6 million as of December&#160;31, 2023. During the six months ended December&#160;31, 2023, we executed on reprioritization of projects and operational streamlining activities and as a result have reduced net cash usage for operating activities, which were $26.6 million for the six months ended December&#160;31, 2023, a reduction of 14% compared to the prior period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with our overall commercial strategy to complete additional pivotal clinical studies for both our chronic lower back pain and steroid-refractory acute graft versus host disease product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet our projected expenditure consistent with our business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) standards) on our ability to continue as a going concern and, therefore, that we may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity have historically been equity raisings, upfront and milestone payments from strategic license agreements, and borrowings under our loan agreements. We also expect net sales to become a source of liquidity. While in the long-term we expect to be able to complete transactions, draw upon these facilities and achieve approval of our product candidates to provide liquidity as needed, there can be no assurance as to whether we will be successful or, if successful, what the terms or proceeds may be.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;$ Change </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Data:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (outflows) in operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(30,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (outflows) in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash inflows by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7,308</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,368)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash outflows in operating activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash outflows for operating activities were $26.6 million for the six months ended December&#160;31, 2023, compared with $30.7 million for the six months ended December&#160;31, 2022, a decrease of $4.1 million. The decrease of $4.1 million is due to a decrease in cash outflows of $0.6 million and an increase in cash inflows of $3.5 million in the six months ended December&#160;31, 2023, compared with the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.5 million increase of inflows comprised: inflows from royalty income earned on sales of TEMCELL in Japan and Alofisel&#174; in Europe increased by $0.3 million during the six months ended December&#160;31, 2023, compared with the six months ended December&#160;31, 2022; received $2.5 million of receipts for research and development tax incentive during the six months ended December 31, 2023, compared to $Nil for the six months ended December 31, 2022; and inflows from interest receipts increased by $0.7 million in the six months ended December&#160;31, 2023, compared with the six months ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outflows for payments to suppliers and employees decreased by $0.6 million from $34.6 million for the six months ended December&#160;31, 2022 to $34.0 million for the six months ended December&#160;31, 2023, primarily due to a decrease in payments in relation to research and development costs. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash outflows in investing activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash outflows for investing activities decreased by $0.1 million in the six months ended December&#160;31, 2023, compared with the six months ended December&#160;31, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net cash inflows in financing activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash inflows for financing activities decreased by $6.7 million for the six months ended December&#160;31, 2023, compared with the six months ended December&#160;31, 2022. The decrease of $6.7 million is due to a decrease in cash inflows of $5.4 million and an increase in cash outflows of $1.3 million in the six months ended December&#160;31, 2023 compared with the six months ended December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $5.4 million decrease in inflows comprised: $45.1 million of proceeds received on completion of global private placement during the six months ended December&#160;31, 2022, compared with $39.7 million of proceeds received from an institutional placement and entitlement offer during the six months ended December&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.3 million increase in outflows comprised: payments of $2.1 million and $1.1 million for lease liabilities during the six months ended December&#160;31, 2023 and 2022, respectively; and payments of $0.5 million and $0.2 million for borrowings costs in the six months ended December&#160;31, 2023 and 2022, respectively. </span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_94"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know when, or if, we will generate revenues from our product sales significant enough to generate profits. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize more of our cell-based product candidates. We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our cell-based product candidates, and begin to commercialize any approved products either directly ourselves or through a collaborator or partner. We are subject to all of the risks inherent in the development of new cell-based products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses and our management and administration expenses to remain relatively consistent over the next 12 months. Subject to us achieving successful regulatory approval we expect an increase in our total expenses driven by an increase in our product manufacturing and selling, general and administrative expenses as we move towards commercialization. Therefore, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance of additional debt or equity securities, it could result in dilution to our existing shareholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our ordinary shares. If we incur further indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_97"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our borrowing arrangements, refer to Note 5(d) in the notes to our consolidated financial statements.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_100"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitments means an agreement to purchase goods or services that is enforceable and legally binding that specifies all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations are not recognized as liabilities at December&#160;31, 2023. For a description of our contractual commitments, refer to Note 9(c) in the notes to our consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease and sub-lease commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease various offices under non-cancellable leases expiring within 1 to 4 years. The leases have varying terms, escalation clauses and renewal rights. On renewal, the terms of the leases are renegotiated. We sublease a portion of our office in Melbourne Australia under a non-cancellable lease expiring within 3 years. We also lease a manufacturing suite under a manufacturing services agreement with Lonza for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of pediatric SR-aGVHD in the US market expiring within 2 years from December 31, 2023, which is cancellable in limited circumstances.  </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired certain intellectual property relating to our MPCs, or Medvet IP, pursuant to an Intellectual Property Assignment Deed, or IP Deed, with Medvet Science Pty Ltd, or Medvet. Medvet&#8217;s rights under the IP Deed were transferred to Central Adelaide Local Health Network Incorporated, or CALHNI, in November 2011. In connection with our use of the Medvet IP, on completion of certain milestones we will be obligated to pay CALHNI, as successor in interest to Medvet, (i) certain aggregated milestone payments of up to $2.2 million, and single-digit royalties on net sales of products covered by the Medvet IP, for cardiac muscle and blood vessel applications and bone and cartilage regeneration and repair applications, subject to minimum annual royalties beginning in the first year of commercial sale of those products and (ii) single-digit royalties on net sales of the specified products for applications outside the specified fields.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a number of agreements with other third parties pertaining to intellectual property. Contingent liabilities may arise in the future if certain events or developments occur in relation to these agreements and as of December&#160;31, 2023 we have assessed that the probability of outflows is remote.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any commitments for future capital expenditure outstanding as of December&#160;31, 2023.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_103"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, other than the purchase commitments and contingent liabilities as mentioned above.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_106"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Differences Between IFRS and U.S. GAAP</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS differs from U.S. GAAP in certain respects. Management has not assessed the materiality of differences between IFRS and GAAP. Our significant accounting policies are described in Note 23 to our consolidated financial statements and the related notes thereto included in our Form 20-F.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 56</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosure About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk, share price risk, price risk and foreign currency exchange risk. We make use of sensitivity analyses which are inherently limited in estimating actual losses in fair value that can occur from changes in market conditions. For additional information, refer to Note 9 in the notes to our consolidated financial statements.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_112"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events subsequent to balance date</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any other events subsequent to the balance date, not otherwise disclosed in this report, which significantly affected or may significantly affect our operations, our results of our operations or our state of affairs in subsequent financial periods. </span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_115"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rounding of amounts</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company is of a kind referred to in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASIC Corporations (Rounding in Financial/Directors&#8217; Reports) Instrument 2016/191</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, issued by the Australian Securities and Investments Commission, relating to the &#8216;rounding off&#8217; of amounts in the financial and directors&#8217; reports. Unless mentioned otherwise, amounts within this report have been rounded off in accordance with that Legislative Instrument to the nearest thousand dollars, or in certain cases, to the nearest dollar.</span></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_118"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors&#8217; resolution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report is made in accordance with a resolution of the directors on February&#160;29, 2024.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Nasdaq Stock Market Rule 5615(a)(3), foreign private issuers, such as our company, are permitted to follow certain home country corporate governance practices instead of certain provisions of the Nasdaq Stock Market Rules. For example, we may follow home country practice with regard to certain corporate governance requirements, such as the composition of the board of directors and quorum requirements applicable to shareholders&#8217; meetings. In addition, we may follow home country practice instead of the Nasdaq Stock Market Rules requirement to hold executive sessions and to obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions or private placements of securities. Further, we may follow home country practice instead of the Nasdaq Stock Market Rules requirement to obtain shareholder approval prior to the establishment or amendment of certain share option, purchase or other compensation plans. A foreign private issuer that elects to follow a home country practice instead of any Nasdaq rule must submit to Nasdaq, in advance, a written statement from an independent counsel in such issuer&#8217;s home country certifying that the issuer&#8217;s practices are not prohibited by the home country&#8217;s laws. We submitted such a written statement to Nasdaq.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as set forth below, we currently intend to comply with the corporate governance listing standards in the Nasdaq Stock Market Rules to the extent possible under Australian law. However, we may choose to change such practices to follow home country practice in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nasdaq Stock Market Rules require that a listed company specify that the quorum for any meeting of the holders of share capital be at least 33 1/3% of the outstanding shares of the company&#8217;s common voting stock. We follow our home country practice, rather than complying with this rule. Consistent with Australian law, our constitution does not require a quorum of at least 33 1/3% of the issued voting shares of Mesoblast for any general meeting of its shareholders. Our constitution provides that a quorum for a general meeting of our shareholders constitutes two shareholders present in person, by proxy, by attorney, or, where the shareholders is a body corporate, by representative. This provision and our practice of holding meetings with this quorum are not prohibited by the ASX Listing Rules or any other Australian law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may follow home country practice instead of Nasdaq Rule 5635(d), which requires a company to obtain shareholder approval for an issuance of securities (other than a public offering) that equals of 20% or more of the outstanding voting power in the company before such issuance. This Nasdaq rule is inconsistent with an ASX Listing Rule that provides a company cannot issue a number of securities over any rolling 12-month period exceeding 15% of the outstanding capital of the company without approval of shareholders but subject to certain exceptions such as pro-rata offers of securities to all shareholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This page is intentionally left blank.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 58</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks described below and all other information contained in this Report on Form 6-K before making an investment decision. If any of the following risks actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our ADSs could decline, and you may lose part or all of your investment. This Report on Form 6-K also contains forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including the risks described below and elsewhere in this Report on Form 6-K.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Requirements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company and we have not yet generated significant revenues. We have incurred net losses during most of our fiscal periods since our inception. Our net loss for the six months ended December&#160;31, 2023 was $32.5 million. As of December&#160;31, 2023, we have an accumulated deficit of $853.3 million since our inception. We do not know whether or when we will become profitable. Our losses have resulted principally from costs incurred in clinical development and manufacturing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase as we move toward commercialization, including the scaling up of our manufacturing activities and our establishment of infrastructure and logistics necessary to support potential product launches. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To achieve and maintain profitability, we must successfully develop our product candidates, obtain regulatory approval, and manufacture, market and sell those products for which we obtain regulatory approval. If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve and maintain sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. We may not succeed in these activities, and we may never generate revenue from product sales that is significant enough to achieve profitability. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our company could cause you to lose part or all of your investment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never be profitable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue and achieve profitability depends on our ability, either alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not currently generate revenues from product sales (other than licensing revenue from sales of TEMCELL&#174; HS. Inj. (&#8220;TEMCELL&#8221;), a registered trademark of JCR Pharmaceuticals Co., Ltd. (&#8220;JCR&#8221;), by JCR in Japan, and royalty revenue from net sales of Alofisel&#174; a registered trademark of TiGenix NV (&#8220;TiGenix&#8221;), previously known as Cx601, an adipose-derived mesenchymal stromal cell product developed by TiGenix, now a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) and approved for marketing in the EU), and we may never generate product sales. Our ability to generate future revenues from product sales depends heavily on our success in a number of areas, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completing research, preclinical and clinical development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical studies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing commercial and distribution capabilities necessary to effectively seek and maintain market access and ensure compliance with legal and regulatory requirements relating to interactions with healthcare providers, healthcare organizations and government agencies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining market acceptance of our product candidates as viable treatment options;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">addressing competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and sustaining an adequate level of reimbursement from payors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identifying and validating new cell therapy product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, know-how and trademarks;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">attracting, hiring and retaining qualified personnel; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">implementing additional internal systems and infrastructure, as needed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing and distributing any approved product candidate. Our expenses could increase beyond expectations if we are required by the United States Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;), or other regulatory agencies, to perform clinical and other studies in addition to those that we currently anticipate. We may not become profitable and may need to obtain additional funding to continue operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We require substantial additional financing to achieve our goals, and our failure to obtain this necessary capital or establish and maintain strategic partnerships to provide funding support for our development programs could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception. As of December&#160;31, 2023, our cash and cash equivalents were $77.6 million. We expect to continue to incur significant expenses and increase our cumulative operating losses for the foreseeable future in connection with our planned research, development and product commercialization efforts. In addition, we will require additional financing to achieve our goals and our failure to do so could adversely affect our commercialization efforts. We anticipate that our expenses will increase if and as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue the research and clinical development of our product candidates, including MPC-150-IM (Class II-IV Chronic Heart Failure (&#8220;CHF&#8221;)), MPC-06-ID (Chronic Low Back Pain (&#8220;CLBP&#8221;)), remestemcel-L and MPC-300-IV (inflammatory conditions) product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to identify, assess, acquire, and/or develop other and combination product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek regulatory and marketing approvals in multiple jurisdictions for our product candidates that successfully complete clinical studies and identify and apply for regulatory designations to facilitate development and ultimate commercialization of our products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish and maintain collaborations and strategic partnerships with third parties for the development and commercialization of our product candidates, or otherwise build and maintain a sales, marketing and distribution infrastructure and/or external logistics to commercialize any products for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">further develop and implement our proprietary manufacturing processes in both planar technology and our bioreactor programs and expand our manufacturing capabilities and resources for commercial production;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek coverage and reimbursement from third-party payors, including government and private payors for future products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">make milestone or other payments under our agreements pursuant to which we have licensed or acquired rights to intellectual property and technology;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to maintain, protect and expand our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to attract and retain skilled personnel; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop the compliance and other infrastructure necessary to support product commercialization and distribution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to experience any delays or encounter issues with any of the above, including clinical holds, failed studies, inconclusive or complex results, safety or efficacy issues, or other regulatory challenges that require longer follow-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up of existing studies, additional studies, or additional supportive studies in order to pursue marketing approval, it could further increase the costs associated with the above. Further, the net operating losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder or as a holder of the ADSs. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic collaborations or partnerships, or marketing, distribution or licensing arrangements with third parties, we may be required to do so at an earlier stage than would otherwise be ideal and/or may have to limit valuable rights to our intellectual property, technologies, product candidates or future revenue streams, or grant licenses or other rights on terms that are not favorable to us. Furthermore, any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we held total cash reserves of $77.6 million. During the six months ended December&#160;31, 2023, we executed on reprioritization of projects and operational streamlining activities and as a result have reduced net cash usage for operating activities, which were $26.6 million for the six months ended December&#160;31, 2023, a reduction of 14% compared to the prior period. In line with our overall commercial strategy to complete additional pivotal clinical studies for both our chronic lower back pain and steroid-refractory acute graft versus host disease product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet our projected expenditure consistent with our business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) standards) on our ability to continue as a going concern and, therefore, that we may be unable to realize our assets and discharge our liabilities in the normal course of business. Our consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to obtain adequate funding or partnerships beyond the 12-month period we may not be able to continue as a going concern, and our shareholders and holders of the ADSs may lose some or all of their investment in Mesoblast. See Note 1(i) of our accompanying financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our loan facilities with funds associated with Oaktree Capital Management, L.P. (&#8220;Oaktree&#8221;) and NovaQuest Capital Management, L.L.C. (&#8220;NovaQuest&#8221;) could restrict our operations, particularly our ability to respond to changes in our business or to take specified actions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, we entered into a loan agreement and guaranty with Oaktree, with a secured five-year senior debt facility and drew down $60.0 million on closing. On June 29, 2018, we entered into a loan and security agreement with NovaQuest for a $40.0 million non-dilutive, eight-year term credit facility, repayable from net sales of our allogeneic product candidate remestemcel-L in pediatric patients with steroid-refractory acute graft versus host disease (&#8220;SR-aGVHD&#8221;), in the United States and other geographies excluding Asia. We drew the first tranche of $30.0 million on closing. Our loan facilities with Oaktree and NovaQuest contain a number of covenants that impose operating restrictions on us, which may restrict our ability to respond to changes in our business or take specified actions. Under the terms of our Oaktree agreement the minimum unrestricted cash balance we need to maintain is $35.0 million. Our ability to comply with the various covenants under the agreements may be affected by events beyond our control, and we may not be able to continue to meet the covenants. Upon the occurrence of an event of default, Oaktree or NovaQuest could elect to declare all amounts outstanding under the loan facility to be immediately due and payable and terminate all commitments to extend further credit. If Oaktree or NovaQuest accelerates the repayment, we may not have sufficient funds to repay our existing debt. If we were unable to repay the owed amounts, Oaktree or NovaQuest could proceed against the collateral granted to it to secure such indebtedness. We have pledged substantially all of our assets as collateral under the loan facility with Oaktree, and a portion of our assets relating to the SR-aGVHD product candidate as collateral under the loan facility with NovaQuest.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, a substantial portion of our operating expenses has been denominated in U.S. dollars and our main currency requirements are U.S. dollars, Australian dollars and Singapore dollars. Approximately 68% of our cash and cash equivalents as of December&#160;31, 2023 were denominated in U.S. dollars, 31% were denominated in Australian dollars and 1% were denominated in other currencies. Because we have multiple functional currencies across different jurisdictions, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in the exchange rate between these currencies and the foreign currencies of the transactions recorded in our accounts could materially impact our reported results of operations and distort period-to-period comparisons. For example, a portion of our research and clinical trials are undertaken in Australia. As such, payment will be made in Australian dollar currency, and may exceed the budgeted expenditure if there are adverse currency fluctuations against the U.S. dollar.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically, if we decide to convert our Australian dollars into U.S. dollars for any business purpose, appreciation of the U.S. dollar against the Australian dollar would have a negative effect on the U.S. dollar amount available to us. Appreciation or depreciation in the value of the Australian dollar relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Review and Approval of Our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are based on our novel mesenchymal lineage cell technology, which makes it difficult to accurately and reliably predict the time and cost of product development and subsequently obtaining regulatory approval. At the moment, no industrially manufactured, non-hematopoietic, allogeneic cell products have been approved in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than with respect to sales of products by our licensees, we have not commercially marketed, distributed or sold any products. The success of our business depends on our ability to develop and commercialize our lead product candidates. We have concentrated our product research and development efforts on our mesenchymal lineage cell platform, a novel type of cell therapy. Our future success depends on the successful development of this therapeutic approach. There can be no assurance that any development problems we experience in the future related to our mesenchymal lineage cell platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing sustainable, reproducible and scalable manufacturing processes or transferring these processes to collaborators, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical study requirements of the FDA, the EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer to develop than for other, better known or extensively studied pharmaceutical or other product candidates. In addition, adverse developments in clinical trials of cell therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory agencies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive testing of our product candidates to demonstrate their safety and efficacy, including both preclinical animal testing and evaluation in human clinical trials, before we can obtain regulatory approval to market and sell them. Conducting such testing is a lengthy, time-consuming, and expensive process and there is a high rate of failure. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and completed preclinical and clinical results for our product candidates are not necessarily predictive of the results of our ongoing or future clinical trials. Promising results in preclinical studies of a product candidate may not be predictive of similar results in humans during clinical trials, and successful results from early human clinical trials of a product candidate may not be replicated in later and larger human clinical trials or in clinical trials for different indications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the results of our or our collaborators&#8217; ongoing or future clinical trials are negative or inconclusive with respect to the efficacy of our product candidates, or if these trials do not meet the clinical endpoints with statistical significance, or if there are safety concerns or adverse events associated with our product candidates, we or our collaborators may be prevented or delayed in obtaining marketing approval for our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if ongoing or future clinical studies meet the clinical endpoints with statistical significance, the FDA or other regulatory agencies may still find the data insufficient to support marketing approval based on other factors. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical studies, including as a result of disruptive events beyond our control, including pandemics.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that any preclinical testing or clinical trials will be conducted as planned or completed on schedule, if at all. As a result, we may not achieve our expected clinical milestones. A failure can occur at any stage of testing. Events that may prevent successful or timely commencement, enrollment or completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">problems which may arise as a result of our transition of research and development programs from licensors or previous sponsors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in raising, or inability to raise, sufficient capital to fund the planned trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays by us or our collaborators in reaching a consensus with regulatory agencies on trial design;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in trial design;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">inability to identify, recruit and train suitable clinical investigators;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">inability to add new clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in reaching agreement on acceptable terms for the performance of the trials with contract research organizations (&#8220;CROs&#8221;), and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in obtaining required Institutional Review Board (&#8220;IRB&#8221;), approval at each clinical trial site;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in recruiting suitable clinical sites and patients (i.e., subjects) to participate in clinical trials and delays in accruing medical events necessary to complete any events-driven trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">imposition of a clinical hold by regulatory agencies for any reason, including negative clinical results, safety concerns or as a result of an inspection of manufacturing or clinical operations or trial sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure by CROs, other third parties or us or our collaborators to adhere to clinical trial requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to perform in accordance with the FDA&#8217;s current Good Clinical Practices (&#8220;cGCP&#8221;), or applicable regulatory guidelines in other countries;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in testing, validation, manufacturing and delivery of a product candidate to clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays caused by patients not completing participation in a trial or not returning for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays caused by clinical trial sites not completing a trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to demonstrate adequate efficacy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">occurrence of serious adverse events in clinical trials that are associated with a product candidates and that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disagreements between us and the FDA or other regulatory agencies regarding a clinical trial design, protocol amendments, or interpreting the data from our clinical trials.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ongoing clinical trials may be affected by delays caused by disruptive events outside our control, such as delays in monitoring and data collection as a result of geopolitical instability, significant climate events and pandemics, including due to prioritization of hospital resources, travel restrictions, and the inability to access sites for patient monitoring. In addition, some patients may be unable to comply with clinical trial protocols if quarantines or stay at home orders impede patient movement or interrupt health services.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays, including delays caused by the above factors, can be costly and could negatively affect our or our collaborators&#8217; ability to complete clinical trials for our product candidates. If we or our collaborators are not able to successfully complete clinical trials or are not able to do so in a timely and cost-effective manner, we will not be able to obtain regulatory approval and/or will not be able to commercialize our product candidates and our commercial partnering opportunities will be harmed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates as well as completion of required follow-up periods. In general, if patients are unwilling to participate in our cell therapy trials because of negative publicity from adverse events in the biotechnology or cell therapy industries or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting trials and obtaining regulatory approval for our product candidates may be delayed. Additionally, we or our collaborators generally will have to run multi-site and potentially multi-national trials, which can be time consuming, expensive and require close coordination and supervision. If we have difficulty enrolling a sufficient number of patients or otherwise conducting clinical trials as planned, we or our collaborators may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are delays in accumulating the required number of trial subjects or, in trials where clinical events are a primary endpoint, if the events needed to assess performance of our clinical candidates do not accrue at the anticipated rate, there may be delays in completing the trial. These delays could result in increased costs, delays in advancing development of our product candidates, including delays in testing the effectiveness, or even termination of the clinical trials altogether.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment and completion of clinical trials are affected by factors including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">size of the patient population, particularly in orphan diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">design of the trial protocol;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">eligibility criteria for the particular trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">perceived risks and benefits of the product candidate being tested;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">availability of competing therapies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patient referral practices of physicians and level and effectiveness of study site recruitment efforts; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ability to monitor patients adequately during and after treatment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once enrolled, patients may choose to discontinue their participation at any time during the trial, for any reason. Participants also may be terminated from the study at the initiative of the investigator, for example if they experience serious adverse clinical events or do not follow the study directions. If we are unable to maintain an adequate number of patients in our clinical trials, we may be required to delay or terminate an ongoing clinical trial, which would have an adverse effect on our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct multinational clinical trials, which present additional and unique risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval for our product candidates in the United States and in select non-U.S. jurisdictions such as Europe, Japan and Canada. Conducting trials on a multinational basis requires collaboration with foreign medical institutions and healthcare providers. Our ability to successfully initiate, enroll and complete a clinical trial in multiple countries is subject to numerous risks unique to conducting business internationally, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulty in establishing or managing relationships with physicians, sites and CROs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">standards within different jurisdictions for conducting clinical trials and recruiting patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to effectively interface with non-US regulatory authorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to identify or reach acceptable agreements with qualified local consultants, physicians and partners;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments, and anti-corruption/anti-bribery laws; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differing genotypes, average body weights and other patient profiles within and across countries from our donor profile may impact the optimal dosing or may otherwise impact the results of our clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">global events like geopolitical instability, climate events and pandemics limiting our ability to commence and conduct studies, including recruiting patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of conducting multinational clinical trials could negatively affect our or our collaborators&#8217; ability to complete trials as intended which could have an adverse effect on our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our product candidates, or limit the scope of any approved indication or market acceptance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants in clinical trials of our investigational cell therapy products may experience adverse reactions or other undesirable side effects. While some of these can be anticipated, others may be unexpected. We cannot predict the frequency, duration, or severity of adverse reactions or undesirable side effects that may occur during clinical investigation of our product candidates. If any of our product candidates, prior to or after any approval for commercial sale, cause serious adverse events or are associated with other safety risks, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may suspend (e.g., through a clinical hold) or terminate clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may deny regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulators may restrict the indications or patient populations for which a product candidate is approved;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for use, and/or impose restrictions on distribution in the form of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), in connection with approval, if any;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may withdraw their approval, require more onerous labeling statements or impose a more restrictive REMS than any product that is approved;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be required to change the way the product is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patient recruitment into our clinical trials may suffer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our relationships with our collaborators may suffer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we could be required to provide compensation to subjects for their injuries, e.g., if we are sued and found to be liable or if required by the laws of the relevant jurisdiction or by the policies of the clinical site; or</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that adverse events associated with our product candidates will not be observed, in such settings where no prior adverse events have occurred. As is typical in clinical development, we have a program of ongoing toxicology studies in animals for our clinical-stage product candidates and cannot provide assurance that the findings from such studies or any ongoing or future clinical trials will not adversely affect our clinical development activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants or if preliminary data demonstrate that our product candidates are unlikely to receive regulatory approval or unlikely to be successfully commercialized. In addition, regulatory agencies, IRBs or data safety monitoring boards may at any time recommend the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that they present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate a clinical trial for any of our product candidates, the commercial prospects for that product as well as our other product candidates may be harmed and our ability to generate product revenue from these product candidates may be delayed or eliminated. Furthermore, any of these events could prevent us or our collaborators from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing our product candidates and impair our ability to generate revenue from the commercialization of these product candidates either by us or by our collaborators.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Several of our product candidates are being evaluated for the treatment of patients who are extremely ill, and patient deaths that occur in our clinical trials could negatively impact our business even if they are not shown to be related to our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing MPC-150-IM, which will focus on patients with heart failure with reduced ejection fraction associated with ischemic and/or diabetic etiology, and remestemcel-L, which will focus on SR-aGVHD. We have also been developing remestemcel-L in COVID-19 infected patients with moderate to severe acute respiratory distress syndrome (&#8220;ARDS&#8221;) on ventilator support. The patients who receive our product candidates are very ill due to their underlying diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, patients remain at high risk following their treatment with our product candidates and may more easily acquire infections or other common complications during the treatment period, which can be serious and life threatening. As a result, it is likely that we will observe severe adverse outcomes in patients during our Phase 3 and other trials for these product candidates, including patient death. If a significant number of study subject deaths were to occur, regardless of whether such deaths are attributable to our product candidates, our ability to obtain regulatory approval for the applicable product candidate may be adversely impacted and our business could be materially harmed. Should studies of a candidate product result in regulatory approval, any association with a significant number of study subject deaths could limit the commercial potential of an approved product candidate, or negatively impact the medical community&#8217;s willingness to use our product with patients.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements to obtain regulatory approval of the FDA and regulators in other jurisdictions can be costly, time-consuming, and unpredictable. If we or our collaborators are unable to obtain timely regulatory approval for our product candidates, our business may be substantially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process is expensive and the time and resources required to obtain approval from the FDA or other regulatory authorities in other jurisdictions to sell any product candidate is uncertain and approval may take years. Whether regulatory approval will be granted is unpredictable and depends upon numerous factors, including the discretion of the regulatory authorities. For example, governing legislation, approval policies, regulations, regulatory policies, or the type and amount of preclinical and clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that none of our existing or future product candidates will ever obtain regulatory approval, even if we expend substantial time and resources seeking such approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, regulatory requirements governing cell therapy products in particular have changed and may continue to change in the future. For example, in December 2016, the 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Century Cures Act (&#8220;Cures Act&#8221;) was signed into law in the United States. This law is designed to advance medical innovation, and includes a number of provisions that may impact our product development programs. For example, the Cures Act establishes a new &#8220;regenerative medicine advanced therapy&#8221; designation (&#8220;RMAT&#8221;), and creates a pathway for increased interaction with FDA for the development of products which obtain designations. Although the FDA issued guidance documents in 2019, it remains unclear how and when the FDA will fully implement all deliverables under the Cures Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory review committees and advisory groups and any contemplated new guidelines may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient revenue to maintain our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to successfully complete our ongoing and future clinical trials of product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a product candidate is safe, pure, and potent for any or all of a product candidate&#8217;s proposed indications;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to demonstrate that a product candidate&#8217;s benefits outweigh the risk associated with the product candidate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or other regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or other regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or other regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a decision by the FDA, other regulatory authorities or us to suspend or terminate a clinical trial at any time;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the data collected from clinical trials of our product candidates may be inconclusive or may not be sufficient to support the submission of a Biologics License Application (&#8220;BLA&#8221;), or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our third party manufacturers of supplies needed for manufacturing product candidates may fail to satisfy FDA or other regulatory requirements and may not pass inspections that may be required by FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the failure to comply with applicable regulatory requirements following approval of any of our product candidates may result in the refusal by the FDA or similar foreign regulatory agency to approve a pending BLA or supplement to a BLA submitted by us for other indications or new product candidates; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the approval policies or regulations of the FDA or other regulatory authorities outside of the United States may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may gain regulatory approval for any of our product candidates in some but not all of the territories available and any future approvals may be for some but not all of the target indications, limiting their commercial potential. Regulatory requirements and timing of product approvals vary from country to country and some jurisdictions may require additional testing beyond what is required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our drug candidates may not benefit from an expedited approval path for cellular medicines designated as Regenerative Medicine Advanced Therapies (RMATs) under the 21st Century Cures Act. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, the FDA granted RMAT designation for our novel MPC therapy in the treatment of heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices. The FDA granted RMAT designation for our novel MPC therapy in the treatment of chronic lower back pain due to degenerative disc disease. While the Cures Act offers several potential benefits to drugs designated as RMATs, including eligibility for increased agency support and advice during development, priority review on filing, a potential pathway for accelerated or full approval based on surrogate or intermediate endpoints, and the potential to use patient registry data and other sources of real world evidence for post approval confirmatory studies, there is no assurance that any of these potential benefits will either apply to any or all of our drug candidates or, if applicable, accelerate marketing approval. RMAT designation does not change the evidentiary standards of safety and effectiveness needed for marketing approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there is no certainty as to whether any of our product candidates that have not yet received RMAT designation under the Cures Act will receive such designation under the Cures Act. Designation as an RMAT is within the discretion of the FDA. Accordingly, even if we believe one of our products or product candidates meets the criteria for RMAT designation, the FDA may disagree. Additionally, for any product candidate that receives RMAT designation, we may not experience a faster development, review or approval process compared to conventional FDA procedures. The FDA may withdraw RMAT designation if it believes that the product no longer meets the qualifying criteria for designation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for our product candidates, our products will be subject to ongoing regulatory scrutiny.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of our product candidates that are approved in the United States or in other jurisdictions will continue to be subject to ongoing regulatory requirements relating to the quality, identity, strength, purity, safety, efficacy, testing, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing, marketing, advertising, promotion, distribution, sale, storage, packaging, pricing, import or export, record-keeping and submission of safety and other post-market information for all approved product candidates. In the United States, this includes both federal and state requirements. In particular, as a condition of approval of a BLA, the FDA may require a REMS, to ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. Moreover, regulatory approval may require substantial post-approval (Phase 4) testing and surveillance to monitor the drug&#8217;s safety or efficacy. Delays in the REMS approval process could result in delays in the BLA approval process. In addition, as part of the REMS, the FDA could require significant restrictions, such as restrictions on the prescription, distribution and patient use of the product, which could significantly impact our ability to effectively commercialize our product candidates, and dramatically reduce their market potential thereby adversely impacting our business, results of operations and financial condition. Post-approval study requirements could add additional burdens, and failure to timely complete such studies, or adverse findings from those studies, could adversely affect our ability to continue marketing the product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to comply with ongoing regulatory requirements, as well as post-approval discovery of previously unknown problems, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, may significantly and adversely affect our ability to generate revenue from our product candidates, and may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product candidates, withdrawal of the product candidates from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">suspension or withdrawal of regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costly regulatory inspections;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters, or holds on clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our collaborators, or suspension or revocation of BLAs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on our operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties by FDA or other regulatory bodies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our business and our operating results will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies, or that of the applicable regulatory bodies in other jurisdictions, may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are not able to maintain regulatory compliance, are slow or unable to adopt new requirements or policies, or effect changes to existing requirements, we or our collaborators may no longer be able to lawfully market our product, and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical and other concerns surrounding the use of embryonic stem cell-based therapy may negatively affect regulatory approval or public perception of our non-embryonic stem cell product candidates, which could reduce demand for our products or depress our share price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of embryonic stem cells (&#8220;ESCs&#8221;), for research and therapy has been the subject of considerable public debate, with many people voicing ethical, legal and social concerns related to their collection and use. Our cells are not ESCs, which have been the predominant focus of this public debate and concern in the United States and elsewhere. However, the distinction between ESCs and non-ESCs, such as our mesenchymal lineage cells, may be misunderstood by the public. Negative public attitudes toward cell therapy and publicity and harm from cell therapy usage clinically by others could also result in greater governmental regulation of cell therapies, which could harm our business. The improper use of cells could give rise to ethical and social commentary adverse to us, which could harm the market demand for new products and depress the price of our ordinary shares and ADSs. Ongoing lack of understanding of the difference between </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESCs and non-ESCs could negatively impact the public&#8217;s perception of our company and product candidates and could negatively impact us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional government-imposed restrictions on, or concerns regarding possible government regulation of, the use of cell therapies in research, development and commercialization could also cause an adverse effect on us by harming our ability to establish important partnerships or collaborations, delaying or preventing the development of certain product candidates, and causing a decrease in the price of our ordinary shares and ADSs, or by otherwise making it more difficult for us to raise additional capital. For example, concerns regarding such possible regulation could impact our ability to attract collaborators and investors. Also, existing and potential government regulation of cell therapies may lead researchers to leave the field of cell therapy research altogether in order to assure that their careers will not be impeded by restrictions on their work. This may make it difficult for us to find and retain qualified scientific personnel.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation may not ensure that we will benefit from market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate that receives orphan drug designation can benefit from potential commercial benefits following approval. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, defined as affecting (1) a patient population of fewer than 200,000 in the United States, (2) a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States, or (3) an &#8220;orphan subset&#8221; of a patient population greater than 200,000 in the United States. In the European Union (&#8220;EU&#8221;), the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 10,000 persons in the EU. Currently, this designation provides market exclusivity in the U.S. and the EU for seven years and ten years, respectively, if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve a drug with similar chemical structure for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs. In the EU, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remestemcel-L product candidate has received orphan drug designation for the treatment of aGVHD by the FDA and EMA, and our CHF product candidate, rexlemestrocel-L has received orphan drug designation from the FDA for both the prevention of post-implantation mucosal bleeding in end-stage CHF patients who require a left ventricular assist device (&#8220;LVAD&#8221;) and children with hypoplastic left heart syndrome ("HLHS"). If we seek orphan drug designations for other product candidates in other indications, we may fail to receive such orphan drug designations and, even if we succeed, such orphan drug designations may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face competition from biosimilars due to changes in the regulatory environment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products that are demonstrated to be &#8220;highly similar&#8221;, or biosimilar, to or &#8220;interchangeable&#8221; with an FDA-approved innovator (original) biological product. This pathway could allow competitors to reference data from innovator biological products already approved after 12 years from the time of approval. For several years the annual budget requests of President Obama&#8217;s administration included proposals to cut this 12-year period of exclusivity down to seven years. Those proposals were not adopted by Congress. Under President Biden&#8217;s administration, it is unclear if a similar change will be pursued in the future. In Europe, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data from biological products already approved, but will not be able to get on the market until ten years after the time of approval. This 10-year period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilars in other countries that could compete with our products. If competitors are able to obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars causing the price for our products and our potential market share to suffer, resulting in lower product sales.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our BLA submission for pediatric SR-aGVHD may not be approved and even if it is approved, we will continue to be closely regulated by FDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biological product, our allogeneic cellular medicine, remestemcel-L, for the treatment of children with SR-aGVHD, requires regulatory approval from the FDA before it may legally be distributed in U.S. commerce. In particular, remestemcel-L will require FDA approval of a BLA under Section 351 of the Public Health Service Act to be commercialized. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have received Fast Track designation from the FDA for remestemcel-L in pediatrics with SR-aGVHD. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast Track designation may provide for a more streamlined development or approval process but it does not change the standards for approval and may be rescinded by the FDA if the product no longer meets the qualifying criteria. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biologic product that receives Fast Track designation can be eligible for regulatory benefits, including rolling BLA review. Rolling review of a BLA enables individual modules of the application to be submitted to and reviewed by the FDA on an ongoing basis, rather than waiting for all sections of a BLA to be completed before submission. Note that there is no benefit of Fast Track in relation to the review time for the resubmitted BLA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remestemcel-L was accepted for Priority Review by the FDA with an action date of September 30, 2020, under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;). In August 2020, the Oncologic Drugs Advisory Committee (&#8220;ODAC&#8221;) of the FDA voted in favor that available data from a single-arm Phase 3 trial and evidence from additional studies support the efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remestemcel-L</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in pediatric patients with SR-aGVHD. Although the FDA considers the recommendation of the panel, the final decision regarding the approval of the product is made solely by the FDA, and the recommendations by the panel are non-binding. On September 30, 2020, the FDA issued a Complete Response Letter to our BLA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remestemcel-L</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of pediatric SR-aGVHD. Despite the overwhelming ODAC vote, the FDA recommended that we conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remestemcel-L</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for SR-aGVHD. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, we resubmitted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the BLA and, on </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 1, 2023, the FDA issued a Complete Response Letter in relation to the resubmitted BLA and requires more data to support marketing approval, including potency assay or clinical data. The FDA acknowledged in the resubmission review that changes implemented appeared to improve assay performance relative to the original version of the assay used in the pediatric Phase 3 trial. In line with our overall commercial strategy to progress to adult populations, we intend to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. In connection with its review of the BLA, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he FDA conducted a pre-license inspection of the manufacturing process of remestemcel-L which did not result in the issuance of a Form 483 and there were no observed concerns.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of review of our BLA, the FDA may request or require additional preclinical, clinical, chemistry and manufacturing, controls (or CMC), or other data and information. The development and provision of these data and information may be time consuming and expensive. Our failure to comply, or the failure of our contract manufacturers to satisfy, applicable FDA CMC requirements could result in a delay or failure to obtain approval of our BLA.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in our submission and may request additional testing or information. The testing and approval process requires substantial time, effort and financial resources, and may take several years to complete. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA or other regulatory agencies may find the data from our clinical studies insufficient to support marketing approval. For example, our Phase 3 study for remestemcel-L for the treatment of pediatric SR-aGVHD, which met the primary clinical endpoint with statistical significance, was conducted as a single-arm study due to the seriousness of the condition, the rapid clinical deterioration of affected patients, the mounting literature suggesting a meaningful treatment effect, and the position in the medical community that a randomized controlled trial was neither feasible nor ethical in this patient population. While we have provided the FDA with comparator outcomes from control subjects, it is possible that the FDA requires additional data for approval. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we will have to participate in other Advisory Committee proceedings for other of our product candidates. FDA Advisory Committees are convened to conduct public hearings on matters of importance that come before the FDA, to review the issues involved, and to provide advice and recommendations to the FDA. New product candidates may be referred for review by Advisory Committees whether the FDA has identified issues or concerns in respect of such candidates or not. Advisory Committee input and recommendations may be used at the discretion of the FDA. Advisory Committee proceedings are in part conducted publicly. While the recommendations made by Advisory Committees in respect of marketing applications for any product are not dispositive, such determinations and recommendations are often influential, and may be made available publicly and to the advantage of our competitors. In addition, it is possible that safety findings and recommendations as well as other concerns and considerations raised by Advisory Committee members, who constitute a multi-disciplinary group of experts (including representatives and/or advocates from the consumer sector), may impact the FDA&#8217;s review of our product candidate submissions or labeling unfavorably. Furthermore, commentary from Advisory Committee proceedings can figure into future product and other litigation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive regulatory approval for a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, such approval may entail limitations on the indicated uses for which such product may be marketed and/or require post-marketing testing and surveillance to monitor safety or efficacy of our product. The FDA may limit further marketing of our product based on the results of post-marketing studies, if compliance with pre- and post-marketing regulatory standards is not maintained, or if problems occur after our product reaches the marketplace such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">later discovery of previously unknown problems or concerns with our product, including adverse events of unanticipated severity or frequency, or with our manufacturing processes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Collaborators</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates in a timely and cost-effective manner or at all, and our business could be substantially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party entities, including CROs, academic institutions, hospitals and other third-party collaborators, to monitor, support, conduct and/or oversee preclinical and clinical studies of our current and future product candidates. We rely on these parties for execution of our nonclinical and clinical studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or any of these third-parties fail to comply with the applicable protocol, legal, regulatory, and scientific standards, the clinical data generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical studies before approving our marketing applications.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative parties or do so on commercially reasonable terms. In addition, these parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going nonclinical and clinical programs. If third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical studies may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. Third parties may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with these third parties, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing product development and/or commercialization arrangements, and any that we may enter into in the future, may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to, and continue to seek additional, collaboration arrangements with biopharmaceutical companies for the development and/or commercialization of our current and future product candidates. We may enter into new arrangements on a selective basis depending on the merits of retaining certain development and commercialization rights for ourselves as compared to entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies for each product candidate, both in the United States and internationally. To the extent that we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators. Any failure to meet our clinical milestones with respect to an unpartnered product candidate would make finding a collaborator more difficult. Moreover, collaboration arrangements are complex, costly and time consuming to negotiate, document and implement, and we cannot guarantee that we can successfully maintain such relationships or that the terms of such arrangements will be favorable to us. If we fail to establish and implement collaboration or other alternative arrangements, the value of our business and operating results will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in our efforts to establish, implement and maintain collaborations or other alternative arrangements if we choose to enter into such arrangements. The terms of any collaboration or other arrangements that we may establish may not be favorable to us. The management of collaborations may take significant time and resources that distract our management from other matters.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully collaborate with any existing or future collaborators may be impaired by multiple factors including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator may shift its priorities and resources away from our programs due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator may cease development in therapeutic areas which are the subject of our strategic alliances;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator may change the success criteria for a particular program or product candidate thereby delaying or ceasing development of such program or candidate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a significant delay in initiation of certain development activities by a collaborator will also delay payments tied to such activities, thereby impacting our ability to fund our own activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator could develop a product that competes, either directly or indirectly, with our current or future products, if any;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator may exercise its rights under the agreement to terminate our collaboration;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a dispute may arise between us and a collaborator concerning the research or development of a product candidate or commercialization of a product resulting in a delay in milestones, royalty payments or termination of a program and possibly resulting in costly litigation or arbitration which may divert management attention and resources;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the results of our clinical trials may not match our collaborators&#8217; expectations, even if statistically significant;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator may not adequately protect or enforce the intellectual property rights associated with a product or product candidate; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator may use our proprietary information or intellectual property in such a way as to invite litigation from a third party.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such activities by our current or future collaborators could adversely affect us financially and could harm our business reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Manufacturing and Supply Chain</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing our product candidates at a commercial scale. We may not be able to manufacture our product candidates in quantities sufficient for development and commercialization if our product candidates are approved, or for any future commercial demand for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have manufactured clinical and commercial quantities of our mesenchymal lineage cell product candidates in manufacturing facilities owned by Lonza Walkersville, Inc. and Lonza Bioscience Singapore Pte. Ltd. (collectively referred to as &#8220;Lonza&#8221;). In 2023, FDA conducted a pre-license inspection of the manufacturing process of remestemcel-L which did not result in the issuance of a Form 483 and there were no observed concerns.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The production of any biopharmaceutical, particularly cell-based therapies, involves complex processes and protocols. We cannot provide assurance that such production efforts will enable us to manufacture our product candidates in the quantities and with the quality needed and in a timely manner for clinical trials, regulatory approval(s), and/or any resulting commercialization. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to do so, our clinical trials and commercialization efforts, if any, may not proceed in a timely fashion and our business will be adversely affected. If any of our product candidates are approved for commercialization and marketing, we may be required to manufacture the product in large quantities to meet demand. Producing product in commercial quantities requires developing and adhering to complex manufacturing processes that are different from the manufacture of a product in smaller quantities for clinical trials, including adherence to additional and more demanding regulatory standards. Although we believe that we have developed processes and protocols that will enable us to consistently manufacture commercial-scale quantities of product, we cannot provide assurance that such processes and protocols will enable us to manufacture our product candidates in quantities that may be required for commercialization of the product with yields and at costs that will be commercially attractive. If we are unable to establish or maintain commercial manufacture of the product or are unable to do so at costs that we currently anticipate, our business will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing on the introduction of novel manufacturing approaches with the potential to result in efficiency and yield improvements to our current process. Certain of these novel approaches include modifying the media used in cell production. Another approach includes the development of 3-dimensional (&#8220;3D&#8221;) bioreactor-based production for mesenchymal lineage cells. There is no guarantee that we will successfully complete either of these processes or meet all applicable regulatory requirements. This may be due to multiple factors, including the failure to produce sufficient quantities and the inability to produce cells that are equivalent in physical and therapeutic properties as compared to the products produced using our current manufacturing processes. In the event our transition to these improved manufacturing processes is unsuccessful, we may not be able to produce certain of our products in a cost-efficient manner and our business may be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global events may adversely impact the manufacturing and commercialization of remestemcel-L, and other product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2019, we announced that we had entered into a manufacturing service agreement with Lonza Bioscience Singapore Pte. Ltd. for the supply of commercial product for the potential approval and launch of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remestemcel-L</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently also manufacture our other product candidates with Lonza Singapore.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the after effects of the COVID-19 pandemic, and recent geopolitical instability, countries in which we have operations, including Singapore, have experienced some challenges in the ability of our suppliers and contractors to source, supply or acquire raw materials or components needed for our manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected if those impacts and impacts from other disruptive events such as significant climate and geopolitical events, are experienced, with potential for increased costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on contract manufacturers to supply and manufacture our product candidates. Our business could be harmed if Lonza fails to provide us with sufficient quantities of these product candidates or fails to do so at acceptable quality levels or prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our mesenchymal lineage cell product candidates for use in the conduct of our clinical trials, and we currently lack the internal resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. As a result, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently depend on Lonza to manufacture our mesenchymal lineage cell product candidates. Relying on Lonza to manufacture our mesenchymal lineage cell product candidates entails risks, and Lonza may:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">cease or reduce production or deliveries, raise prices or renegotiate terms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">be unable to meet any product specifications and quality requirements consistently;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delay or be unable to procure or expand sufficient manufacturing capacity, which may harm our reputation or frustrate our customers;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">not have the capacity sufficient to support the scale-up of manufacturing for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">have manufacturing and product quality issues related to scale-up of manufacturing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">experience costs and validation of new equipment facilities requirement for scale-up that it will pass on to us;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fail to comply with cGMP and similar international standards;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">lose its manufacturing facility in Singapore, stored inventory or laboratory facilities through fire or other causes, or other loss of materials necessary to manufacture our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">experience disruptions to its operations by conditions unrelated to our business or operations, including the bankruptcy or interruptions of its suppliers;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">experience carrier disruptions or increased costs that it will pass on to us;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fail to secure adequate supplies of essential ingredients in our manufacturing process;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">experience failure of third parties involved in the transportation, storage or distribution of our products, including the failure to deliver supplies it uses for the manufacture of our product candidates under specified storage conditions and in a timely manner; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">terminate agreements with us; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">appropriate or misuse our trade secrets and other proprietary information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to delays in the development of our product candidates, including delays in our clinical trials, or failure to obtain regulatory approval for our product candidates, or it could impact our ability to successfully commercialize our current product candidates or any future products. Some of these events could be the basis for FDA or other regulatory action, including injunction, recall, seizure or total or partial suspension of production.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the lead time needed to establish a relationship with a new manufacturer can be lengthy and expensive, and we may experience delays in meeting demand in the event we must switch to a new manufacturer. We are expanding our manufacturing collaborations in order to meet future demand and to provide back-up manufacturing options, which also involves risk and requires significant time and resources. Our future collaborators may need to expand their facilities or alter the facilities to meet future demand and changes in regulations. These activities may lead to delays, interruptions to supply, or may prove to be more costly than anticipated. Any problems in our manufacturing process could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manufacture or commercialize our product candidates in a profitable manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to implement a business model under which we control the manufacture and supply of our product candidates, including but not exclusively, through our product suppliers, including Lonza. We and the suppliers of our product candidates, including Lonza, have no experience manufacturing our product candidates at commercial scale. Accordingly, there can be no assurance as to whether we and our suppliers will be able to scale-up the manufacturing processes and implement technological improvements in a manner that will allow the manufacture of our product candidates in a cost effective manner. Our or our collaborators&#8217; inability to sell our product candidates at a price that exceeds our cost of manufacture by an amount that is profitable for us will have a material adverse result on the results of our operations and our financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborators&#8217; ability to identify, test and verify new donor tissue in order to create new master cell banks involves many risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial stage of manufacturing involves obtaining mesenchymal lineage cell-containing bone marrow from donors, for which we currently rely on our suppliers. Mesenchymal lineage cells are isolated from each donor&#8217;s bone </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marrow and expanded to create a master cell bank. Each individual master cell bank comes from a single donor. A single master cell bank can source many production runs, which in turn can produce up to thousands of doses of a given product, depending on the dose level. The process of identifying new donor tissue, testing and verifying its validity in order to create new master cell banks and validating such cell bank with the FDA and other regulatory agencies is time consuming, costly and prone to the many risks involved with creating living cell products. There could be consistency or quality control issues with any new master cell bank. Although we believe we and our collaborators have the necessary know-how and processes to enable us to create master cell banks with consistent quality and within the timeframe necessary to meet projected demand and we have begun doing so, we cannot be certain that we or our collaborators will be able to successfully do so, and any failure or delays in creating new master cell banks may have a material adverse impact on our business, results of operations, financial conditions and growth prospects and could result in our inability to continue operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators depend on a limited number of suppliers for our product candidates&#8217; materials, equipment or supplies and components required to manufacture our product candidates. The loss of these suppliers, or their failure to provide quality supplies on a timely basis, could cause delays in our current and future capacity and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators depend on a limited number of suppliers for the materials, equipment and components required to manufacture our product candidates, as well as various &#8220;devices&#8221; or &#8220;carriers&#8221; for some of our programs (e.g., the catheter for use with MPC-150-IM, and the hyaluronic acid used for chronic lower back pain). The main consumable used in our manufacturing process is our media, which currently is sourced from fetal bovine serum (&#8220;FBS&#8221;). This material comes from limited sources, and as a result is expensive. Consequently, we or our collaborators may not be able to obtain sufficient quantities of our product candidates or other critical materials equipment and components in the future, at affordable prices or at all. A delay or interruption by our suppliers may also harm our business, and operating results. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we or our collaborators may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify for and, in some cases, obtain regulatory approval for a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Our and our collaborators&#8217; dependence on single-source suppliers exposes us to numerous risks, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our or our collaborators&#8217; suppliers may cease or reduce production or deliveries, raise prices or renegotiate terms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our or our collaborators&#8217; suppliers may not be able to source materials, equipment or supplies and components required to manufacture our product candidates as a result of the after effects of the COVID-19 pandemic or geopolitical and/or economic instability adversely or the impact of climate events affecting the supply chain;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we or our collaborators may be unable to locate suitable replacement suppliers on acceptable terms or on a timely basis, or at all; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays caused by supply issues may harm our reputation, frustrate our customers and cause them to turn to our competitors for future needs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators and Lonza are subject to significant regulation with respect to manufacturing our product candidates. The Lonza manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing manufacturers, including Lonza, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with current international Good Manufacturing Practice and other international regulatory requirements. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates. We, our collaborators, or suppliers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to current Good Laboratory Practice and current Good Manufacturing Practice regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Lonza and other suppliers have never produced a commercially approved cellular therapeutic product and therefore have not yet obtained the requisite regulatory authority approvals to do so.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can begin commercial manufacture of our products for sale in the United States, we must obtain FDA regulatory approval for the product, in addition to the approval of the processes and quality systems associated with the manufacturing of such product, which requires a successful FDA inspection of the facility handling the manufacturing of our product, including Lonza&#8217;s manufacturing facilities. The novel nature of our product candidates creates significant challenges in regards to manufacturing. For example, the U.S. federal and state governments and other jurisdictions impose restrictions on the acquisition and use of tissue, including those incorporated in federal Good Tissue Practice regulations. We may not be able to identify or develop sources for the cells necessary for our product candidates that comply with these laws and regulations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory authorities may, at any time before or after product approval, audit or inspect a manufacturing facility involved with the preparation of our product candidates or raw materials or the associated quality systems for compliance with the regulations applicable to the activities being conducted. In 2023, FDA conducted a pre-license inspection of the manufacturing process of remestemcel-L which did not result in the issuance of  a Form 483 and there were no observed concerns. Although we oversee each contract manufacturer involved in the production of our product candidates, we cannot control the manufacturing process of, and are dependent on, the contract manufacturer for compliance with the regulatory requirements. If the contract manufacturer is unable to comply with manufacturing regulations, we may be subject to fines, unanticipated compliance expenses, recall or seizure of any approved products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our business, results of operations and financial condition. If the manufacturer fails to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to perform many necessary services for the commercialization of our product candidates, including services related to the distribution, storage and transportation of our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will rely upon third parties for certain storage, distribution and other logistical services. In accordance with certain laws, regulations and specifications, our product candidates must be stored and transported at extremely low temperatures within a certain range. If these environmental conditions deviate, our product candidates&#8217; remaining shelf-lives could be impaired or their efficacy and safety could become adversely affected, making them no longer suitable for use. If any of the third parties that we intend to rely upon in our storage, distribution and other logistical services process fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties to us, or encounter physical damage or natural disaster at their facilities, our ability to deliver product to meet commercial demand may be significantly impaired. In addition, as our cellular therapies will constitute a new form of product, experience in commercial distribution of such therapies in the United States is extremely limited, and as such is subject to execution risk. While we intend to work closely with our selected distribution logistics providers to define appropriate parameters for their activities to ensure product remains intact throughout the process, there is no assurance that such logistics providers will be able to maintain all requirements and handle and distribute our products in a manner that does not significantly impair them, which may impact our ability to satisfy commercial demand.  Likewise, the after effects from the COVID-19 pandemic, geopolitical and economic instability, and climate events may adversely impact access to raw materials and distribution, storage and transportation of our products, and the cost of those activities.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product recalls or inventory losses caused by unforeseen events may adversely affect our operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are manufactured, stored and distributed using technically complex processes requiring specialized facilities, highly specific raw materials and other production constraints. The complexity of these processes, as well as strict company and government standards for the manufacture, storage and distribution of our product candidates, subjects us to risks. For example, during the manufacturing process we have from time to time experienced several different types of issues that have led to a rejection of various batches. Historically, the most common reasons for batch rejections include major process deviations during the production of a specific batch and failure of manufactured product to meet one or more specifications. While product candidate batches released for the use in clinical trials or for commercialization undergo sample testing, some latent defects may only be identified following product release. In addition, process deviations or unanticipated effects of approved process changes may result in these product candidates not complying with stability requirements or specifications. The occurrence or suspected occurrence of production and distribution difficulties can lead to lost inventories, and in some cases product recalls, with consequential reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause production </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays, substantial expense, lost sales and delays of new product launches. In the event our production efforts require a recall or result in an inventory loss, our operating results and financial condition may be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients and healthcare payors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when product development is successful and regulatory approval has been obtained, our ability to generate significant revenue depends on the acceptance of our products by physicians, payors and patients. Many potential market participants have limited knowledge of, or experience with, cell therapy-based products, so gaining market acceptance and overcoming any safety or efficacy concerns may be more challenging than for more traditional therapies. Our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts to educate the marketplace may require more or different resources than are required by the conventional therapies marketed by our competitors. We cannot assure you that our products will achieve the expected market acceptance and revenue if and when they obtain the requisite regulatory approvals. Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. The market acceptance of each of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efficacy and safety of the product candidate, as demonstrated in clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the clinical indications for which the product is approved, and the label approved by regulatory authorities for use with the product, including any warnings or contraindications that may be required on the label;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acceptance by physicians, patients, and with pediatric indications by parents/caregivers of the product as a safe and effective treatment;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost, safety and efficacy of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the continued projected growth of markets for our various indications;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">relative convenience and ease of administration;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the prevalence and severity of adverse side effects; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effectiveness of our, and our collaborators&#8217; sales and marketing efforts; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sufficient third-party insurance and other payor (e.g., governmental) coverage and reimbursement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance is critical to our ability to generate significant revenue. Any product candidate, if approved and commercialized, may be accepted in only limited capacities or not at all. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate significant revenue and our business would suffer.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish our own commercial capabilities across sales, marketing and distribution, or enter into licensing or collaboration agreements for these purposes, we may not be successful in independently commercializing any future products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited sales, marketing or distribution infrastructure and experience. Commercializing our product candidates, if such product candidates obtain regulatory approval, would require significant sales, distribution and marketing capabilities. Where and when appropriate, we may elect to utilize contract sales forces or distribution collaborators to assist in the commercialization of our product candidates. If we enter into arrangements with third parties to perform sales, marketing and distribution/price reporting services for our product candidates, the resulting revenue or the profitability from this revenue to us may be lower than if we had sold, marketed and distributed that product ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute any future products or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell, market and distribute our current or any future products effectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we are unable to engage third parties to assist us with these functions, we will have to invest significant amounts of financial and management resources, some of which will need to be committed prior to any </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confirmation that any of our proprietary product candidates will be approved. For any future products for which we decide to perform sales, marketing and distribution functions ourselves, we could face a number of additional risks, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel or to develop alternative sales channels;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability of account teams to obtain formulary acceptance for our products, allowing for reimbursement and hence patient access;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with multiple products; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unforeseen costs and expenses associated with creating and maintaining an independent sales and marketing organization.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than we do.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of our potential competitors have significantly greater development, financial, manufacturing, marketing, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in conducting clinical trials, obtaining regulatory approvals, manufacturing pharmaceutical and biologic products and commercializing such therapies. Recent and potential future merger and acquisition activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds that could make our product candidates obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing our product candidates or competitors to our product candidates before we do. Specialized, smaller or early-stage companies may also prove to be significant competitors, particularly those with a focus and expertise in cell therapies. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. If we are not able to compete effectively against potential competitors, our business will not grow and our financial condition and results of operations will suffer.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our marketed products may be used by physicians for indications that are not approved by the FDA. If the FDA finds that we marketed our products in a manner that promoted off-label use, we may be subject to civil or criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), and other laws and regulations, if any of our product candidates are approved by the FDA, we would be prohibited from promoting our products for off-label uses. This means, for example, that we would not be able to make claims about the use of our marketed products outside of their approved indications, and we would not be able to proactively discuss or provide information on off-label uses of such products, with very specific and limited exceptions. The FDA does not, however, prohibit physicians from prescribing products for off-label uses in the practice of medicine. Should the FDA determine that our activities constituted the promotion of off-label use, the FDA could issue a warning or untitled letter or, through the Department of Justice, bring an action for seizure or injunction, and could seek to impose fines and penalties on us and our executives. In addition, failure to follow FDA rules and guidelines relating to promotion and advertising can result in, among other things, the FDA&#8217;s refusal to approve a product, the suspension or withdrawal of an approved product from the market, product recalls, fines, disgorgement of money, operating restrictions, injunctions or criminal prosecutions, and also may figure into civil litigation against us.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, was passed. The Affordable Care Act is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and the health insurance industry, impose new taxes and fees on the healthcare industry and impose additional health policy reforms. There have been a number of judicial and congressional challenges to certain aspects of the Affordable Care Act. We can provide no assurance that laws such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Affordable Care Act, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the outcome of potential reforms and changes to government negotiation/regulation to healthcare costs are unknown. If changes in policy limit reimbursements that we are able to receive through federal programs, it could negatively impact reimbursement levels from those payors and private payors, and our business, revenues or profitability could be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaborators fail to obtain and sustain an adequate level of reimbursement for our products by third-party payors, sales and profitability would be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our collaborators&#8217; ability to commercialize any products successfully will depend, in part, on the extent to which coverage and reimbursement for our products and related treatments will be available from government healthcare programs, private health insurers, managed care plans, and other organizations. Additionally, even if there is a commercially viable market, if the level of third-party reimbursement is below our expectations, our revenue and profitability could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, such as government programs, including Medicare or Medicaid in the United States, or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices charged for medical products and services, and many third-party payors limit or delay coverage of or reimbursement for newly approved healthcare products. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and other factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">appropriate for the specific patient;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">cost-effective; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">neither experimental nor investigational.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A current trend in the U.S. healthcare industry as well as in other countries around the world is toward cost containment. Large public and private payors, managed care organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. In particular, third-party payors may limit the covered indications. Cost-control initiatives could decrease the price we might establish for any product, which could result in product revenue and profitability being lower than anticipated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or other regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also be insufficient to cover our and any collaborator&#8217;s costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments and treatment codes for other services. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, reimbursement systems in international markets vary significantly by country and by region, and reimbursement approvals must be obtained on a country-by-country basis. Our existing or future collaborators, if any, may elect to reduce the price of our products in order to increase the likelihood of obtaining reimbursement approvals which could adversely affect our revenues and profits. In many countries, including for example in Japan, products cannot be commercially launched until reimbursement is approved. Further, the post-approval price negotiation process in some countries can exceed 12 months. In addition, pricing and reimbursement decisions in certain countries can be affected by decisions taken in other countries, which can lead to mandatory price reductions and/or additional reimbursement restrictions across a number of other countries, which may thereby adversely affect our sales and profitability. In the event that countries impose prices which are not sufficient to allow us or our collaborators to generate a profit, our collaborators </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may refuse to launch the product in such countries or withdraw the product from the market, which would adversely affect sales and profitability.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our cell therapy and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our target patient populations for some of our product candidates may be relatively small, and as a result, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. Due to the novel nature of our cell therapy technology, the manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is uncertain. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products. Further, if the results of our clinical trials and related cost benefit analyses do not clearly demonstrate the efficacy or overall value of our product candidates in a manner that is meaningful to prescribers and payors, our pricing and reimbursement may be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly EU member states, Japan, Australia and Canada, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, revenues or profitability could be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer. Because the target patient populations of certain of our product candidates are small, we must be able to successfully identify physicians with access to appropriate patients and achieve a significant market share to maintain profitability and growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of the number of people with diseases targeted by our product candidates are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. In addition, physicians who we believe have access to patients in need of our products may in fact not often treat the diseases targeted by our product candidates, and may not be amenable to use of our product. Further, the number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to risks related to our licensees and our international operations, and failure to manage these risks may adversely affect our operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries operate out of Australia, the United States, Singapore, the United Kingdom and Switzerland. We have licensees, with rights to commercialize products based on our MSC technology, including JCR in Japan. Our primary manufacturing collaborator, Lonza, serves us primarily out of their facilities in Singapore, and through contractual relationships with third parties, has access to storage facilities in the U.S., Europe, Australia and Singapore. As a result, a significant portion of our operations are conducted by and/or rely on entities outside the markets in which certain of our trials take place, our suppliers are sourced, our product candidates are developed, and, if any such product candidates obtain regulatory approval, our products may be sold. Accordingly, we import a substantial number of products and/or materials into such markets. We may be denied access to our customers, suppliers or other collaborators or denied the ability to ship products from any of these sites as a result of a closing of the borders of the countries in which we operate, or in which these operations are located, due to economic, legislative, political, health or military conditions in such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries. If any of our product candidates are approved for commercialization, we may enter into agreements with third parties to market them on a worldwide basis or in more limited geographical regions. We expect that we will be subject to additional risks related to entering into international business relationships, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">logistics and regulations associated with shipping cell samples and other perishable items, including infrastructure conditions and transportation delays;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential import and export issues and other trade barriers and restrictions with the U.S. Customs and Border Protection and similar bodies in other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">tariffs imposed by the U.S. on goods from other countries, including the recently implemented tariffs and additional tariff that have been proposed by the U.S. government on various imports from China and the EU and by the governments of these jurisdictions on certain U.S. goods, and any other possible tariffs that may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">deterioration of political relations, for example between Russia and other nations, and between the U.K. and members of the EU, which could have a material adverse effect on our supply chains, and sales and operations in these countries;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in social, political and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development and investment both domestically as well as in the other countries and jurisdictions into which we sell our products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fluctuations in currency exchange rates and the related effect on our results of operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential increases on tariffs or restrictions on trade generally;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">business interruptions resulting from geopolitical actions, including war (such as Russia&#8217;s invasion of Ukraine) and terrorism, or climate related events and natural disasters including earthquakes, typhoons, floods and fires.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of animal-derived materials could harm our product development and commercialization efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the manufacturing materials and/or components that we use in, and which are critical to, implementation of our technology involve the use of animal-derived products, including FBS. Suppliers or regulatory changes may limit or restrict the availability of such materials for clinical and commercial use. While FBS is commonly used in the production of various marketed biopharmaceuticals, the suppliers of FBS that meet our strict quality standards are limited in number and region. As such, to the extent that any such suppliers or regions face an interruption in supply (for example, if there is a new occurrence of so-called &#8220;mad cow disease&#8221;), it may lead to a restricted supply of the serum currently required for our product manufacturing processes. Any restrictions on these materials would impose a potential competitive disadvantage for our products or prevent our ability to manufacture our cell products. The FDA has issued regulations for controls over bovine material in animal feed. These regulations do not appear to affect our ability to purchase the manufacturing materials we currently use. However, the FDA may propose new regulations that could affect our operations. Our inability to develop or obtain alternative compounds would harm our product development and commercialization efforts. There are certain limitations in the supply of certain animal-derived materials, which may lead to delays in our ability to complete clinical trials or eventually to meet the anticipated market demand for our cell products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the human clinical use of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product design, testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection and other acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">decreased demand for our products, even if such products are approved;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injury to our reputation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs to defend the related litigations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product recalls, withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased cost of liability insurance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability to commercialize our product candidates; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a decline in our ordinary share price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. Additionally, our insurance policies have various exclusions, and we may be subject to a product liability claim for which we have no coverage or reduced coverage. Any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our proprietary technology in the marketplace.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on our ability to obtain patents, protect our trade secrets and operate without infringing on the proprietary rights of others. We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property of our product candidates. Patents might not be issued or granted with respect to our patent applications that are currently pending, and issued or granted patents might later be found to be invalid or unenforceable, be interpreted in a manner that does not adequately protect our current product or any future products, or fail to otherwise provide us with any competitive advantage. As such, we do not know the degree of future protection that we will have on our proprietary products and technology, if any, and a failure to obtain adequate intellectual property protection with respect to our product candidates and proprietary technology could have a material adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents throughout the world would be prohibitively expensive, so our policy is to patent technology in jurisdictions with significant or otherwise relevant commercial opportunities or activities. However, patent protection may not be available for some of the products or technology we are developing. If we must spend significant time and money protecting or enforcing our patents, designing around patents held by others or licensing, potentially for large fees, patents or other proprietary rights held by others, our business, results of operations and financial condition may be harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent positions of biopharmaceutical products are complex and uncertain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and extent of patent protection for our product candidates are particularly uncertain. To date, our principal product candidates have been based on specific subpopulations of known and naturally occurring adult stem cells. We anticipate that the products we develop in the future will continue to include or be based on the same or other naturally occurring stem cells or derivatives or products thereof. Although we have sought and expect to continue to seek patent protection for our product candidates, their methods of use and methods of manufacture, any or all of them may not be subject to effective patent protection. Publication of information related to our product candidates by us or others may prevent us from obtaining or enforcing patents relating to these products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or may design around our patent rights. In addition, any of our issued patents may be declared invalid. If we fail to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product to compete with our product candidates. We may also face competition from companies who develop a substantially similar product to our other product candidates that may not be covered by any of our patents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our current or future products, if any, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain certain of our proprietary know-how and technological advances as trade secrets, especially where we do not believe patent protection is appropriate or obtainable, including, but not exclusively, with respect to certain aspects of the manufacturing of our products. However, trade secrets are difficult to protect. We take a number of measures to protect our trade secrets including, limiting disclosure, physical security and confidentiality and non-disclosure agreements. We enter into confidentiality agreements with our employees, consultants, outside scientific collaborators, contract manufacturing partners, sponsored researchers and other advisors and third parties to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain trade secret protection, or failure to adequately protect our intellectual property could enable competitors to develop generic products or use our proprietary information to develop other products that compete with our products or cause additional, material adverse effects upon our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be forced to litigate to enforce or defend our intellectual property rights, and/or the intellectual property rights of our licensors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be forced to litigate to enforce or defend our intellectual property rights against infringement by competitors, and to protect our trade secrets against unauthorized use. In so doing, we may place our intellectual property at risk of being invalidated, unenforceable, or limited or narrowed in scope and may no longer be used to prevent the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture and sale of competitive product. Further, an adverse result in any litigation or other proceedings before government agencies such as the United States Patent and Trademark Office (&#8220;USPTO&#8221;), may place pending applications at risk of non-issuance. Further, interference proceedings, derivation proceedings, entitlement proceedings, ex parte reexamination, inter partes reexamination, inter partes review, post-grant review, and opposition proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be used to challenge inventorship, ownership, claim scope, or validity of our patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential and proprietary information could be compromised by disclosure during this type of litigation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property disputes could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and/or management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our ADSs and ordinary shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of litigation proceedings more effectively than we can because of their greater financial resources and personnel. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct our clinical trials, continue our internal research programs, in-license needed technology or enter into strategic collaborations that would help us bring our product candidates to market. As a result, uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. patent reform legislation and court decisions could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued U.S. patents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Under the current patent laws, a third party that files a patent application in the USPTO before us for a particular invention could therefore be awarded a patent covering such invention even if we had made that invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent application. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current US legislation allows third party submissions of prior art to the USPTO during patent prosecution and additional procedures for attacking the validity of a patent through USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, and derivation proceedings. Because a lower evidentiary standard applies in USPTO proceedings compared to the evidentiary standards applied in United States federal courts in actions seeking to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if challenged in a district court action. Accordingly, a third party may attempt to use available USPTO procedures to invalidate our patent claims that would not otherwise have been invalidated if first challenged by the third party in a district court action. These post-grant review (PGR) proceedings, which are similar to European &#8220;opposition&#8221; proceedings and provide third-party petitioners with the ability to challenge the validity of a patent on more expansive grounds than those permitted in other USTPO proceedings, allow for validity to be examined by the USPTO based not only on prior art patents and publications, but also on prior invalidating public use and sales, the presence of non-statutory subject matter in the patent claims and inadequate written description or lack of enablement. Discovery for PGR proceedings is accordingly likely to be expansive given that the issues addressed in PGR are more comprehensive than those addressed in other USPTO proceedings. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As compared to intellectual property-reliant companies generally, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. These rulings have created uncertainty with respect to the validity and enforceability of patents, even once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties claim that intellectual property used by us infringes upon their intellectual property, commercialization of our product candidates and our operating profits could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights, or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the future, pursue such infringement claims against us or any third-party proprietary technologies we have licensed. Any such claims could also be expensive and time consuming to defend and divert management&#8217;s attention and resources, and could delay or prevent us from commercializing our product candidates. Our competitive position could suffer as a result. Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our product candidates, we have not conducted a freedom-to-operate search or analysis for our product candidates, and we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product candidates. Thus, we cannot guarantee that our product candidates, or our commercialization thereof, do not and will not infringe any third party&#8217;s intellectual property.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity of our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one of the U.S. patents covering each of such approved product(s) or the use thereof may be eligible for up to five years of patent term restoration under the Hatch-Waxman Act. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates, including by the EMA in the EU or the PMDA in Japan. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. In addition, if a patent we wish to extend is owned by another party and licensed to us, we may need to obtain approval and cooperation from our licensor to request the extension.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period before we might face generic or follow-on competition could be shortened and we may not be able to stop our competitors from launching competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and keep senior management and key scientific, commercial, regulatory affairs and other personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on members of our executive management, particularly Dr. Silviu Itescu, our Chief Executive Officer. Dr. Itescu was an early pioneer in the study and clinical development of cell therapeutics and is globally recognized in the field of regenerative medicine. The loss of the services of Dr. Itescu or any other member of the executive management team could impede the achievement of our research, development and commercialization objectives. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory affairs, sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, consultants and collaboration partners may engage in misconduct or other improper activities, including noncompliance with laws and regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements (including arrangements with healthcare providers, opinion leaders, research institutions, distributors and payors) in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of activity relating to pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation, or, given we are a listed company in Australia and the United States, breach of insider trading or other securities laws and regulations. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire other companies or assets which could divert our management&#8217;s attention, result in additional dilution to our shareholders and otherwise disrupt our operations and harm our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past and may in the future seek to acquire businesses, products or technologies that we believe could complement or expand our product offerings, enhance our technical capabilities or otherwise offer growth opportunities. For example, we acquired MSC assets in 2013. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">incurrence of acquisition-related costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">diversion of management&#8217;s attention from other business concerns;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unanticipated costs or liabilities associated with the acquisition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">harm to our existing business relationships with collaborators as a result of the acquisition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">harm to our brand and reputation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential loss of key employees;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">use of resources that are needed in other parts of our business; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">use of substantial portions of our available cash to consummate the acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results arising from the impairment assessment process. Acquisitions may also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators must comply with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the manufacture, storage, handling, use, transportation and disposal of hazardous and biological materials, and the health and safety of employees with respect to laboratory activities required for the development of products and technologies. In the event of contamination or injury, or failure to comply with environmental, occupational health and safety and export control laws and regulations, it could cause an interruption of our commercialization efforts, research and development efforts, or business operations, and we could be held liable for any resulting damages and any such liability could exceed our assets and resources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We work with outside scientists and their institutions in developing product candidates. These scientists may have other commitments or conflicts of interest, which could limit our access to their expertise and harm our ability to leverage our discovery platform.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors and collaborators at academic research institutions in connection with our product development. These scientific advisors serve as our link to the specific pools of trial participants we are targeting in that these advisors may:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identify individuals as potential candidates for study;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtain their consent to participate in our research;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">perform medical examinations and gather medical histories;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">conduct the initial analysis of suitability of the individuals to participate in our research based on the foregoing; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collect data and biological samples from trial participants periodically in accordance with our study protocols.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These scientists and collaborators are not our employees, rather they serve as either independent contractors or the primary investigators under research collaboration agreements that we have with their sponsoring academic or research institution. Such scientists and collaborators may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if an actual or potential conflict of interest between their work for us and their work for another entity arises, we may lose their services. It is also possible that some of our valuable proprietary knowledge may become publicly known through these scientific advisors if they breach their confidentiality agreements with us, which would cause competitive harm to our business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our ability to use cumulative carry forward net operating losses is or becomes subject to certain limitations or if certain tax incentive credits from which we may benefit expire or no longer apply to us, our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an Australian company subject to taxation in Australia and other jurisdictions. As of December&#160;31, 2023, our cumulative operating losses have a total potential tax benefit of $209.4 million at local tax rates (excluding other temporary differences). These losses may be available for use once we are in a tax profitable position. These losses were incurred in different jurisdictions and can only be offset against profits earned in the relevant jurisdictions. Tax losses are able to be carried forward at their nominal amount indefinitely in Australia and in Singapore, and for up to 20 years in the U.S. as long as certain conditions are met; however, new tax reform legislation in the United States allows for indefinite carryforward of any net operating loss arising in a tax year ending after December 31, 2018, subject to certain conditions. In order to use these tax losses, it is necessary to satisfy certain tests and, as a result, we cannot assure you that the tax losses will be available to offset profits if and when we earn them. Utilization of our net operating loss and research and development credit carryforwards in the U.S. may be subject to substantial annual limitation due to ownership change limitations that could occur in the future generally provided by Section 382 of the Internal Revenue Code of 1986, as amended. In addition, U.S. tax reform introduced a limitation on the amount of net operating losses arising in taxable years beginning after December 31, 2017, that a corporation may deduct in a single tax year equal to the lesser of the available net operating loss carryover or 80 percent of a taxpayer&#8217;s pre-net operating loss deduction taxable income. With respect to carryforward net operating losses in the U.S. that are subject to the 20-year carry-forward limit, our carry forward net operating losses first start to expire in 2032.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be eligible for certain research and development tax incentive refundable credits in Australia that may increase our available cash flow. The Australian federal government's Research and Development Tax Incentive grant is available for eligible research and development purposes based on the filing of an annual application. The Australian government may in the future decide to modify the requirements of, reduce the amounts of the research and development tax incentive credits available under, or discontinue its research and development tax incentive program. For instance, the Australian government undertook a review of its Research and Development Tax Incentive program in the May 2020 Federal budget and in October 2020 introduced new legislation for the tax offset applicable to eligible companies for income tax years commencing from July 1, 2021. One of the legislation changes made was to allow a tax offset for companies with an aggregated turnover of A$20.0 million or more. For companies with an aggregated turnover of A$20.0 million or more, the rate of tax offset is the company&#8217;s corporate tax rate plus a rate between 8.5% and 16.5% depending on the proportion of research and development expenditures in relation to total expenditures. For companies with an aggregated turnover below A$20.0 million, the rate of the refundable research and development tax offset was set as at 18.5% above the company&#8217;s tax rate. If the Research and Development Tax program incentives are revoked or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modified, or if we are no longer eligible for such incentives due to other circumstances, our business, results of operations and financial condition may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess, on an annual basis, the quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia. As of December 31, 2023, tax incentives recoverable of $1.3 million have been recognized within trade and other receivables on our consolidated balance sheet pertaining to an estimate of the research and development tax incentive income from the Research and Development Tax Incentive program relating to a claim for eligible expenditure under the incentive scheme for the year ended June 30, 2023. No income was recognized in the six months ended December 31, 2023. There can be no assurances that we will benefit from these incentives in the future if our activities are not eligible under the incentive scheme or that the tax incentive credit programs will not be revoked or modified in any way in the future.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxing authorities could reallocate our taxable income within our subsidiaries, which could increase our consolidated tax liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct operations in multiple tax jurisdictions and the tax laws of those jurisdictions generally require that the transfer pricing between affiliated companies in different jurisdictions be the same as those between unrelated companies dealing at arms&#8217; length, and that such prices are supported by contemporaneous documentation. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities. If tax authorities in any of these countries were to successfully challenge our transfer pricing as not reflecting arms&#8217; length transactions, they could require us to adjust our transfer pricing and thereby reallocate our income to reflect these revised transfer pricing, which could result in a higher tax liability to us, and possibly interest and penalties, and could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry is highly regulated and pharmaceutical companies are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare fraud and abuse regulations are complex and can be subject to varying interpretations as to whether or not a statute has been violated. The laws that may affect our ability to operate include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which prohibits, among other things, the knowing and willful payment of remuneration to induce or reward patient referrals, prescribing or recommendation of products, or the generation of business involving any item or service which may be payable by the federal health care programs (e.g., drugs, supplies, or health care services for Medicare or Medicaid patients);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal False Claims Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment for government funds (e.g., payment from Medicare or Medicaid) or knowingly making, using, or causing to be made or used a false record or statement, material to a false or fraudulent claim for government funds;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act of 1996</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;HIPAA&#8221;), as amended by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Information Technology for Economic and Clinical Health Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HIPAA imposes civil and criminal liability for the wrongful access or disclosure of protected health information;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Physician Payments Sunshine Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, created under Section 6002 of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Protection and Affordable Care Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ACA&#8221;), as amended, requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, those physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDCA, which, among other things, regulates the testing, development, approval, manufacture, promotion and distribution of drugs, devices and biologics. The FDCA prohibits manufacturers from selling or distributing &#8220;adulterated&#8221; or &#8220;misbranded&#8221; products. A drug product may be deemed misbranded if, among other things, (i) the product labeling is false or misleading, fails to contain requisite information or does not bear adequate directions for use; (ii) the product is manufactured at an unregistered facility; or (iii) the product lacks the requisite FDA clearance or approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Corrupt Practices Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;FCPA&#8221;), which prohibits corrupt payments, gifts or transfers of value to non-U.S. officials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">non-U.S. and U.S. state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to comply with these laws, or the regulations adopted thereunder, could result in administrative, civil, and/or criminal penalties, and could result in a material adverse effect on our reputation, business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal fraud and abuse laws have been interpreted to apply to arrangements between pharmaceutical manufacturers and a variety of health care professionals and healthcare organizations. Although the federal Anti-Kickback Statute has several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, all elements of the potentially applicable exemption or safe harbor must be met in order for the arrangement to be protected, and prosecutors have interpreted the federal healthcare fraud statutes to attack a wide range of conduct by pharmaceutical companies. In addition, most states have statutes or regulations similar to the federal anti-kickback and federal false claims laws, which apply to items and services covered by Medicaid and other state programs, or, in several states, apply regardless of the payor. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the ACA, among other things, amended the intent standard under the Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA makes clear that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the federal False Claims Act. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A failure to adequately protect private health information could result in severe harm to our reputation and subject us to significant liabilities, each of which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the clinical trial process, we may obtain the private health information of our trial subjects. There are a number of state, federal and international laws protecting the privacy and security of health information and personal data. As part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Recovery and Reinvestment Act 2009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ARRA&#8221;), Congress amended the privacy and security provisions of HIPAA. HIPAA imposes limitations on the use and disclosure of an individual&#8217;s healthcare information by healthcare providers conducting certain electronic transactions, healthcare clearinghouses, and health insurance plans, collectively referred to as covered entities. The HIPAA amendments also impose compliance obligations and corresponding penalties for non-compliance on certain individuals and entities that provide services to or perform certain functions on behalf of healthcare providers and other covered entities involving the use or disclosure of individually identifiable health information, collectively referred to as business associates. ARRA also made significant increases in the penalties for improper use or disclosure of an individual&#8217;s health information under HIPAA and extended enforcement authority to state attorneys general. The amendments also create notification requirements to federal regulators, and in some cases local and national media, for individuals whose health information has been inappropriately accessed or disclosed. Notification is not required under HIPAA if the health information that is improperly used or disclosed is deemed secured in accordance with certain encryption or other standards developed by the U.S. Department of Health and Human Services, or HHS. Most states have laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to ensure ongoing protection of personal information. Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for non-compliance. The EU&#8217;s General Data Protection Regulation, Canada&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Information Protection and Electronic Documents Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other data protection, privacy and similar national, state/provincial and local laws and regulations may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers or to alleviate problems caused by such breaches, and the failure to so comply may lead to fines or penalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations are subject to anti-corruption laws, including Australian bribery laws, the United Kingdom Bribery Act, and the FCPA and other anti-corruption laws that apply in countries where we do business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Although we believe that we have adequate policies and enforcement mechanisms to ensure legal and regulatory compliance with the FCPA, the U.K. Bribery Act 2010 and other similar regulations, we participate in collaborations and relationships with third parties, and it is possible that any of our employees, subcontractors, agents or partners may violate any such legal and regulatory requirements, which may expose us to criminal or civil enforcement actions, including penalties and suspension or disqualification from U.S. federal procurement contracting. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws or other laws including trade related laws. If we are not in compliance with these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of these laws by respective government bodies could also have an adverse impact on our reputation, our business, results of operations and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur additional legal, accounting and other expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to maintain our current status as a foreign private issuer, either (1) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United States or (2) (a) a majority of our executive officers or directors must not be U.S. citizens or residents, (b) more than 50 percent of our assets cannot be located in the U.S. and (c) our business must be administered principally outside the U.S. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC rules and Nasdaq listing standards. Further, we would be required to comply with U.S. GAAP, as opposed to IFRS, in the preparation and issuance of our financial statements for historical and current periods. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404(a) of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sarbanes-Oxley Act of 2002</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sarbanes-Oxley Act&#8221;) requires that our management assess and report annually on the effectiveness of our internal controls over financial reporting and identify any material weaknesses in our internal controls over financial reporting. In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended, and anticipate that we will continue to expend, significant resources, including accounting-related costs and significant management oversight. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If either we are unable to conclude that we have effective internal controls over financial reporting or our independent auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal controls over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, the price of the ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to remain listed on Nasdaq Global Select Market (&#8220;Nasdaq&#8221;).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur significant increased costs as a result of operating as a company whose ADSs are publicly traded in the United States, and our management will continue to be required to devote substantial time to compliance initiatives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company whose ADSs are publicly traded in the United States, we have incurred and will continue to incur significant legal, accounting, insurance and other expenses. The Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented by the SEC and Nasdaq, have imposed various requirements on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public companies including requiring establishment and maintenance of effective disclosure and financial controls. Our management and other personnel will need to continue to devote a substantial amount of time to these compliance initiatives, and we will need to add additional personnel and build our internal compliance infrastructure. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These laws and regulations could also make it more difficult and expensive for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our senior management. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of the ADSs, fines, sanctions and other regulatory action and potentially regulatory investigations and enforcement and/or civil litigation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never declared or paid dividends on our ordinary shares, and we do not anticipate paying dividends in the foreseeable future. Therefore, you must rely on price-appreciation of our ordinary shares or ADSs for a return on your investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our ordinary shares. For the foreseeable future, we currently intend to retain all available funds and any future earnings to support our operations and to finance the growth and development of our business. Any future determination to declare cash dividends will be made at the discretion of our board of directors, subject to compliance with applicable laws and covenants under the loan facilities with Oaktree and NovaQuest or other current or future credit facilities, which may restrict or limit our ability to pay dividends, and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. We do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future. As a result, a return on your investment in our ordinary shares or ADSs will likely only occur if our ordinary share or ADS price appreciates. There is no guarantee that our ordinary shares or ADSs will appreciate in value in the future.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares or ADSs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Australian</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Corporations Act 2001</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Corporations Act&#8221;). Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in our issued voting shares if the acquisition of that interest will lead to a person&#8217;s voting power in us increasing to more than 20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our ordinary shares. This may have the ancillary effect of entrenching our board of directors and may deprive or limit our shareholders&#8217; opportunity to sell their ordinary shares or ADSs and may further restrict the ability of our shareholders to obtain a premium from such transactions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of information technology systems, data security breaches or unauthorized disclosure of sensitive data could adversely affect our business by exposing us to liability and affect our business and reputation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is increasingly dependent on critical, complex, and interdependent information technology systems (IT systems), including cloud-based software and external servers, some of which are managed or hosted by third parties, to support business processes as well as internal and external communications. The information and data processed and stored in our IT systems, and those of our research collaborators, CROs, contract manufacturers, suppliers, distributors, or other third parties for which we depend to operate our business, may be vulnerable to cybersecurity breaches from unauthorized activity by our employees, contractors or malware, hacking, business email compromise, phishing or other cyberattacks directed by other parties. Such breaches can result in loss, damage, denial-of-service, unauthorized access or misappropriation and may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public. In addition, our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. The increase in working remotely could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, manufacturing sites, clinical trial sites, and other third parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapidly moving nature of technology and the increasing sophistication of cybersecurity threats, may mean our measures to prevent, respond to and minimize such risks may be ineffective. If a material incident or interruption were to occur, it could result in a disruption of our development programs and future commercial operations, including due to a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss, corruption or unauthorized disclosure of our proprietary or sensitive information. Additionally, the costs to the company to investigate and mitigate cybersecurity incidents could be significant. Any disruption, security breach, or action by the company, its employees, or contractors that might be inconsistent with the rapidly evolving data privacy and security laws and regulations applicable within Australia and the United States and elsewhere where we conduct business, could result in; enforcement actions by both countries state and federal governments or foreign governments, liability or sanctions under data privacy laws including healthcare laws such as the Privacy Act or HIPAA that protect certain types of sensitive information, regulatory penalties, other legal proceedings such as but not limited to private litigation, the incurrence of significant remediation costs, disruptions to our development programs, business operations and collaborations, diversion of management efforts and damage to our reputation which could harm our business and operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Trading Markets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price and trading volume of our ordinary shares and ADSs may be volatile and may be affected by economic conditions beyond our control. Such volatility may lead to securities litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our ordinary shares and ADSs may be highly volatile and subject to wide fluctuations. In addition, the trading volume of our ordinary shares and ADSs may fluctuate and cause significant price variations to occur. We cannot assure you that the market price of our ordinary shares and ADSs will not fluctuate or significantly decline in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some specific factors that could negatively affect the price of our ordinary shares and ADSs or result in fluctuations in their price and trading volume include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">results of clinical trials of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">results of clinical trials of our competitors&#8217; products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">actual or anticipated fluctuations in our quarterly operating results or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">publication of research reports by securities analysts about us or our competitors in the industry;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fluctuations of exchange rates between the U.S. dollar and the Australian dollar;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additions to or departures of our key management personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">issuances by us of debt or equity securities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">litigation or investigations involving our company, including: shareholder litigation; investigations or audits by regulators into the operations of our company; or proceedings initiated by our competitors or clients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the passage of legislation or other regulatory developments affecting us or our industry;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in trading volume of ADSs on the Nasdaq and of our ordinary shares on the ASX;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales or perceived potential sales of the ADSs or ordinary shares by us, our directors, senior management or our shareholders in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">short selling or other market manipulation activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">terrorist acts, acts of war or periods of widespread civil unrest (such as Russia&#8217;s invasion of Ukraine);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">natural disasters, the impact of climate change and other calamities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in market conditions for biopharmaceutical companies; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">conditions in the U.S. or Australian financial markets or changes in general economic conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, shareholders often instituted securities class action litigation against that company. If we were involved in a class action suit, it could divert the attention of senior management, require significant expenditure for defense costs, and, if adversely determined, could have a material adverse effect on our results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A class action proceeding in the Federal Court of Australia was served on the Company in May 2022 by the law firm William Roberts Lawyers on behalf of persons who, between February 22, 2018, and December 17, 2020, acquired an interest in Mesoblast shares, American Depository Receipts, and/or related equity swap arrangements. In June 2022, the firm Phi Finney McDonald commenced a second shareholder class action against the Company in the Federal Court of Australia asserting similar claims arising during the same period. Like the class action lawsuit from October 2020 filed in the U.S. Federal District Court for the Southern District of New York (which had court approval for settlement in August 2022), the Australian class actions relate to the Complete Response Letter released by the FDA in relation to our GvHD product candidate; they also relate to certain representations made by the Company in relation to our COVID-19 product candidate and the decline in the market price of our ordinary shares in December 2020. The Australian class actions have been consolidated into one lawsuit. The Company will continue to vigorously defend against the proceedings. The Company cannot provide any assurance as to the possible outcome or cost to us from the lawsuit, particularly as it is at an early stage, nor how long it may take to resolve such lawsuit. Thus, the Company has not accrued any amounts in connection with such legal proceedings.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of these securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ADSs are listed on the Nasdaq and our ordinary shares are listed on the ASX. We cannot predict the effect of this dual listing on the value of our ordinary shares and ADSs. However, the dual listing of our ordinary shares and ADSs may dilute the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in the United States. The price of the ADSs could also be adversely affected by trading in our ordinary shares on the ASX, and vice versa.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the market price and trading volume of our ordinary shares and/or ADSs could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our ordinary shares and ADSs could be influenced by the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may discontinue research on our company, to the extent such coverage currently exists, or in other cases, may never publish research on our company. If too few securities or industry analysts commence coverage of our company, the trading price for our ordinary shares and ADSs would likely be negatively impacted. If one or more of the analysts who cover us downgrade our ordinary shares or ADSs or publish inaccurate or unfavorable research about our business, the market price of our ADSs would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our ordinary shares and/or ADSs could decrease, which might cause our price and trading volume to decline.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our ADSs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for the ADSs may not develop in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ADSs are listed in the United States on the Nasdaq under the symbol &#8220;MESO.&#8221; However, we cannot assure you that an active public market in the United States for the ADSs will develop on that exchange, or if developed, that this market will be sustained.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently report our financial results under IFRS, which differs in certain significant respect from U.S. GAAP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently we report our financial statements under IFRS. There have been and there may in the future be certain significant differences between IFRS and U.S. GAAP, including differences related to revenue recognition, intangible assets, share-based compensation expense, income tax and earnings per share. As a result, our financial information and reported earnings for historical or future periods could be significantly different if they were prepared in accordance with U.S. GAAP. In addition, we do not intend to provide a reconciliation between IFRS and U.S. GAAP unless it is required under applicable law. As a result, you may not be able to meaningfully compare our financial statements under IFRS with those companies that prepare financial statements under U.S. GAAP.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, we are permitted and expect to follow certain home country corporate governance practices in lieu of certain Nasdaq requirements applicable to domestic issuers and we are permitted to file less information with the Securities and Exchange Commission than a company that is not a foreign private issuer. This may afford less protection to holders of our ADSs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;foreign private issuer&#8221;, as defined in Rule 405 under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Exchange Act of 1933</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as amended (the &#8220;Securities Act&#8221;), whose ADSs will be listed on the Nasdaq, we will be permitted to, and plan to, follow certain home country corporate governance practices in lieu of certain Nasdaq requirements. For example, we may follow home country practice with regard to certain corporate governance requirements, such as the composition of the board of directors and quorum requirements applicable to shareholders&#8217; meetings. This difference may result in a board that is more difficult to remove and less shareholder approvals required generally. In addition, we may follow home country practice instead of the Nasdaq Global Select Market requirement to hold executive sessions and to obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions or private placements of securities. The above differences may result in less shareholder oversight and requisite approvals for certain acquisition or financing related decisions. Further, we may follow home country practice instead of the Nasdaq Global Select Market requirement to obtain shareholder approval prior to the establishment or amendment of certain share option, purchase or other compensation plans. This difference may result in less shareholder oversight and requisite approvals for certain company compensation related decisions. A foreign private issuer must disclose in its annual reports filed with the Securities and Exchange Commission, or SEC, and the Nasdaq Global Select Market, the requirements with which it does not comply followed by a description of its applicable home country practice. The Australian home country practices described above may afford less protection to holders of the ADSs than that provided under the Nasdaq Global Select Market rules.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a foreign private issuer, we are exempt from certain rules under the &#8220;Exchange Act&#8221;, that impose disclosure requirements as well as procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as a company that files as a domestic issuer whose securities are registered under the Exchange Act, nor are we generally required to comply with the SEC&#8217;s Regulation FD, which restricts the selective disclosure of material non-public information. Accordingly, the information may not be disseminated in as timely a manner, or there may be less information publicly available concerning us generally than there is for a company that files as a domestic issuer.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADS holders may be subject to additional risks related to holding ADSs rather than ordinary shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADS holders do not hold ordinary shares directly and, as such, are subject to, among others, the following additional risks.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">As an ADS holder (and not the holder of ordinary shares underlying your ADSs), we will not treat you as one of our shareholders and you will not be able to exercise shareholder rights, except through the American depositary receipt, or ADR, depositary as permitted by the deposit agreement.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Distributions on the ordinary shares represented by your ADSs will be paid to the ADR depositary, and before the ADR depositary makes a distribution to you on behalf of your ADSs, any withholding taxes that must be paid will be deducted. Additionally, if the exchange rate fluctuates during a time when the ADR depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We and the ADR depositary may amend or terminate the deposit agreement without the ADS holders&#8217; consent in a manner that could prejudice ADS holders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADS holders must act through the ADR depositary to exercise your voting rights and, as a result, you may be unable to exercise your voting rights on a timely basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a holder of ADSs (and not the ordinary shares underlying your ADSs), we will not treat you as one of our shareholders, and you will not be able to exercise shareholder rights. The ADR depositary will be the holder of the ordinary shares underlying your ADSs, and ADS holders will be able to exercise voting rights with respect to the ordinary shares represented by the ADSs only in accordance with the deposit agreement relating to the ADSs. There are practical limitations on the ability of ADS holders to exercise their voting rights due to the additional procedural steps involved in communicating with these holders. For example, holders of our ordinary shares will receive notice of shareholders&#8217; meetings by mail or email and will be able to exercise their voting rights by either attending the shareholders meeting in person or voting by proxy. ADS holders, by comparison, will not receive notice directly from us. Instead, in accordance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the deposit agreement, we will provide notice to the ADR depositary of any such shareholders meeting and details concerning the matters to be voted upon. As soon as practicable after receiving notice from us of any such meeting, the ADR depositary will mail to holders of ADSs the notice of the meeting and a statement as to the manner in which voting instructions may be given by ADS holders. To exercise their voting rights, ADS holders must then instruct the ADR depositary as to voting the ordinary shares represented by their ADSs. Due to these procedural steps involving the ADR depositary, the process for exercising voting rights may take longer for ADS holders than for holders of ordinary shares. The ordinary shares represented by ADSs for which the ADR depositary fails to receive timely voting instructions will not be voted. Under Australian law and our Constitution, any resolution to be considered at a meeting of the shareholders shall be decided on a show of hands unless a poll is demanded by the shareholders at or before the declaration of the result of the show of hands. Under voting by a show of hands, multiple &#8220;yes&#8221; votes by ADS holders will only count as one &#8220;yes&#8221; vote and will be negated by a single &#8220;no&#8221; vote, unless a poll is demanded.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are or become classified as a passive foreign investment company, our U.S. securityholders may suffer adverse tax consequences.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon an analysis of our income and assets for the taxable six months ended December&#160;31, 2023, we do not believe we were a passive foreign investment company (a "PFIC") for our most recent tax year. In general, if at least 75% of our gross income for any taxable year consists of passive income or at least 50% of the average quarterly value of assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, then we will be classified as a PFIC for U.S. federal income tax purposes. Passive income for this purpose generally includes dividends, interest, certain royalties and rents, and gains from commodities and securities transactions. Passive assets for this purpose generally includes assets held for the production of passive income. Accordingly, passive assets generally include any cash, cash equivalents and cash invested in short-term, interest bearing, debt instruments or bank deposits that are readily convertible into cash. Since PFIC status depends upon the composition of our income and assets and the market value of our assets from time to time, and since the determination of PFIC status must be made annually at the end of each taxable year, there can be no assurance that we will not be considered a PFIC for any future taxable year. Investors should be aware that our gross income for purposes of the PFIC income test depends on the receipt of active revenue, and there can be no assurances that such active revenue will continue, or that we will receive other gross income that is not considered passive for purposes of the PFIC income test. If we were a PFIC for any taxable year during a U.S. investor&#8217;s holding period for the ordinary shares or ADSs, we would ordinarily continue to be treated as a PFIC for each subsequent year during which the U.S. investor owned the ordinary shares or ADSs. If we were treated as a PFIC, U.S. investors would be subject to special punitive tax rules with respect to any "excess distribution" received from us and any gain realized from a sale or other disposition (including a pledge) of the ordinary shares or ADSs unless a U.S. investor made a timely "qualified electing fund" or "mark-to-market" election. For a more detailed discussion of the U.S. tax consequences to U.S. investors if we were classified as a PFIC, see Item 10.E - "Taxation &#8212; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders &#8212; Passive Foreign Investment Company".</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in foreign currency exchange rates could impact amounts you receive as a result of any dividend or distribution we declare on our ordinary shares.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant change in the value of the Australian dollar may impact amounts you receive in U.S. dollars as a result of any dividend or distribution we declare on our ordinary shares as a holder of our ADSs. More specifically, any dividends that we pay on our ordinary shares will be in Australian dollars. The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses, including any such fees or expenses incurred to convert any such Australian dollars into U.S. dollars. You will receive these distributions in U.S. dollars in proportion to the number of our ordinary shares your ADSs represent. Depreciation of the U.S. dollar against the Australian dollar would have a negative effect on any such distribution payable to you.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You may not receive distributions on our ordinary shares represented by the ADSs or any value for such distribution if it is illegal or impractical to make them available to holders of ADSs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not anticipate paying any dividends on our ordinary shares in the foreseeable future, if such a dividend is declared, the depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution of the ADSs, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ordinary shares, rights or anything else to holders of the ADSs. This means that you may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may have a material adverse effect on the value of your ADSs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You may be subject to limitations on transfers of your ADSs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of our senior management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our officers and directors are non-residents of the United States, and a substantial portion of the assets of such persons are located outside the U.S. As a result, it may be impossible to serve process on such persons in the United States or to enforce judgments obtained in U.S. courts against them based on civil liability provisions of the securities laws of the U.S. Even if you are successful in bringing such an action, there is doubt as to whether Australian courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the U.S. or elsewhere may be unenforceable in Australia or elsewhere outside the U.S. An award for monetary damages under the U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in Australia will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The U.S. and Australia do not currently have a treaty or statute providing for recognition and enforcement of the judgments of the other country (other than arbitration awards) in civil and commercial matters. As a result, our public shareholders and holders of the ADSs may have more difficulty in protecting their interests through actions against us, our management, our directors than would shareholders of a corporation incorporated in a jurisdiction in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 96</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.416%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mesoblast Limited</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;29, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Silviu Itescu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Silviu Itescu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 97</span></div></div></div><div id="i0ca481b9662c4533b1d2a0227d14fda1_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Table </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0ca481b9662c4533b1d2a0227d14fda1_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991app4d.htm">Appendix 4D of Mesoblast Limited ("the Company") for the half-year report for the six months ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991app4d.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit991app4d.htm">.</a></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.2&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex992independentauditors.htm">Independent auditor's review report to the members of Mesoblast Limited, dated February 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex992independentauditors.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex992independentauditors.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex992independentauditors.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex992independentauditors.htm">.</a></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.3&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex993auditorsindependenc.htm">Auditor's independence declaration, dated February 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex993auditorsindependenc.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex993auditorsindependenc.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex993auditorsindependenc.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex993auditorsindependenc.htm">.</a></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page 98</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991app4d.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit991app4d</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:968;"><!-- exhibit991app4d001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit991app4d001.jpg" title="slide1" width="968" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Exhibit 99.1    Mesoblast Limited  ABN 68 109 431 870  and Controlled Entities (Mesoblast Group)        HALF-YEAR INFORMATION   FOR THE SIX MONTHS ENDED DECEMBER 31, 2023    PROVIDED TO THE ASX UNDER LISTING RULE 4.2A          This half-year financial report is to be read in conjunction with the financial  report for the period ended June 30, 2023. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit991app4d002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit991app4d002.jpg" title="slide2" width="968" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">-2-  Rule 4.2A.3  Appendix 4D   Half-Year Report for the six months to December 31, 2023      Name of entity  MESOBLAST LIMITED  ABN 68 109 431 870      1. Reporting period    Report for the half-year ended December 31, 2023  Previous corresponding period is the financial year ended  and half-year ended  June 30, 2023  December 31, 2022    2. Results for announcement to the market      Up/down % change   Amount reported  for the half-year  ended  December 31, 2023  (USD&#8217;000)  Revenues from ordinary activities (item 2.1) Down 1% to 3,388        Loss from ordinary activities after tax attributable to  members (item 2.2) Down *  21% to 32,539        Net loss for the period attributable to members (item 2.3) Down* 21% to 32,539  *decrease in loss        There are no dividends being proposed or declared for the period (item 2.4 and 2.5)    Commentary related to the above results  Please refer to the Directors&#8217; Report (please see the section titled Management&#8217;s Discussion and Analysis  of Financial Condition and Results of Operations) within the Form 6-K for the six months ended December  31, 2023.      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit991app4d003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit991app4d003.jpg" title="slide3" width="968" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">-3-  3. Net tangible assets per security (item 3)   December 31, 2023 December 31, 2022  Net tangible (liability) backing per ordinary security  (in USD cents) (5.38) cents (8.75) cents    A large proportion of the Company&#8217;s assets are intangible in nature, consisting of goodwill, acquired  licenses to patents, in-process research and development acquired, currently marketed products and right- of-use assets. Our intangible assets primarily relate to the acquisition of both Mesoblast, Inc and the  culture-expanded Mesenchymal Stem Cell technology. These assets and the associated provision for  contingent consideration are excluded from the calculation of net tangible assets per security. As at  December 31, 2023 and 2022, the value of deferred tax liabilities was $Nil.    4. Half-Year Financial Statements and Directors&#8217; Report    The financial information provided in the Appendix 4D should be read in conjunction with the Report on  Form 6-K (incorporating the Half-Year Report) for the six months ended December 31, 2023 which has been  prepared in accordance with Australian Accounting Standards.    Directors&#8217; Report - please refer to the section titled Management&#8217;s Discussion and Analysis of Financial  Condition and Results of Operations within the Form 6-K.    Half-Year Financial Statement &#8211; please refer to the Financial Statements within the Form 6-K.      5. Independent review of the financial report (item 9)    The financial report has been independently reviewed. The financial report is not subject to a qualified  independent review statement.  The independent audit review report includes the following statement:     We draw attention to Note 1(i) in the half-year financial report, which indicates that the Group had cash  outflows from operations of $26.6 million for the 6 months ended December 31, 2023. The ability of the  Group to continue as a going concern is dependent upon the Group obtaining additional funding from one  or more sources to meet the Group&#8217;s projected expenditure consistent with its business strategy over at  least the next 12 months. These conditions, along with other matters set forth in Note 1(i), indicate that a  material uncertainty exists that may cast significant doubt on the Group&#8217;s ability to continue as a going  concern. Our conclusion is not modified in respect of this matter.     The independent audit review report is attached to the Financial Statements within the Form 6-K.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992independentauditors.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ex992independentauditors</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:965;"><!-- ex992independentauditors001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex992independentauditors001.jpg" title="slide1" width="965" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">PricewaterhouseCoopers, ABN 52 780 433 757  2 Riverside Quay, SOUTHBANK  VIC  3006, GPO Box 1331, MELBOURNE  VIC  3001  T: 61 3 8603 1000, F: 61 3 8603 1999  Liability limited by a scheme approved under Professional Standards Legislation.  Independent auditor's review report to the members of  Mesoblast Limited  Report on the half-year financial report  Conclusion  We have reviewed the half-year financial report of Mesoblast Limited (the Company) and the entities it  controlled during the half-year (together the Group), which comprises the consolidated balance sheet as  at 31 December 2023, the consolidated statement of comprehensive income, consolidated statement of  changes in equity, consolidated statement of cash flows and consolidated income statement for the half- year ended on that date, material accounting policy information and selected explanatory notes and the  directors' declaration.  Based on our review, which is not an audit, we have not become aware of any matter that makes us  believe that the accompanying half-year financial report of Mesoblast Limited does not comply with the  Corporations Act 2001 including:  1. giving a true and fair view of the Group's financial position as at 31 December 2023 and of its performance for the half-year ended on that date 2. complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. Basis for conclusion  We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by  the Independent Auditor of the Entity (ASRE 2410). Our responsibilities are further described in the  Auditor's responsibilities for the review of the half-year financial report section of our report.  We are independent of the Group in accordance with the auditor independence requirements of the  Corporations Act 2001 and the ethical requirements of the Accounting Professional &amp; Ethical Standards  Board&#8217;s APES 110 Code of Ethics for Professional Accountants (including Independence Standards)  (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled  our other ethical responsibilities in accordance with the Code.  Material uncertainty relating to going concern  We draw attention to Note 1(i) in the half-year financial report, which indicates that the Group had cash  outflows from operating activities of $26.6 million for the 6 months ended December 31, 2023. The ability  of the Group to continue as a going concern is dependent upon the Group obtaining additional funding  from one or more sources to meet the Group&#8217;s projected expenditure consistent with its business  strategy over at least the next 12 months. These conditions, along with other matters set forth in Note  1(i), indicate that a material uncertainty exists that may cast significant doubt on the Group&#8217;s ability to  continue as a going concern. Our conclusion is not modified in respect of this matter.  Exhibit 99.2 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex992independentauditors002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex992independentauditors002.jpg" title="slide2" width="965" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    Responsibilities of the directors for the half-year financial report  The directors of the Company are responsible for the preparation of the half-year financial report that  gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act  2001 and for such internal control as the directors determine is necessary to enable the preparation of  the half-year financial report that gives a true and fair view and is free from material misstatement  whether due to fraud or error.   Auditor's responsibilities for the review of the half-year financial report  Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE  2410 requires us to conclude whether we have become aware of any matter that makes us believe that  the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true  and fair view of the Group's financial position as at 31 December 2023 and of its performance for the  half-year ended on that date, and complying with Accounting Standard AASB 134 Interim Financial  Reporting and the Corporations Regulations 2001.  A review of a half-year financial report consists of making enquiries, primarily of persons responsible for  financial and accounting matters, and applying analytical and other review procedures. A review is  substantially less in scope than an audit conducted in accordance with Australian Auditing Standards  and consequently does not enable us to obtain assurance that we would become aware of all significant  matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  PricewaterhouseCoopers  Jon Roberts Melbourne  Partner     29 February 2024  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993auditorsindependenc.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ex993auditorsindependenc</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:965;"><!-- ex993auditorsindependenc001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex993auditorsindependenc001.jpg" title="slide1" width="965" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">PricewaterhouseCoopers, ABN 52 780 433 757  2 Riverside Quay, SOUTHBANK  VIC  3006, GPO Box 1331, MELBOURNE  VIC  3001  T: 61 3 8603 1000, F: 61 3 8603 1999, www.pwc.com.au  Liability limited by a scheme approved under Professional Standards Legislation.  Auditor&#8217;s Independence Declaration  As lead auditor for the review of Mesoblast Limited for the half-year ended 31 December 2023, I  declare that to the best of my knowledge and belief, there have been:   (a) no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and (b) no contraventions of any applicable code of professional conduct in relation to the review. This declaration is in respect of Mesoblast Limited and the entities it controlled during the period.  Jon Roberts Melbourne  Partner  PricewaterhouseCoopers  29 February 2024  Exhibit 99.3 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>meso-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1c79165c-755b-4603-a45e-827a45827c07,g:19d448ab-9536-4f20-ab7d-76d6f5e0018c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:meso="http://www.mesoblast.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mesoblast.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meso-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meso-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meso-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meso-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.mesoblast.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedIncomeStatement" roleURI="http://www.mesoblast.com/role/ConsolidatedIncomeStatement">
        <link:definition>0000002 - Statement - Consolidated Income Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofComprehensiveIncome" roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome">
        <link:definition>0000003 - Statement - Consolidated Statement of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofChangesinEquity" roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity">
        <link:definition>0000004 - Statement - Consolidated Statement of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheet" roleURI="http://www.mesoblast.com/role/ConsolidatedBalanceSheet">
        <link:definition>0000005 - Statement - Consolidated Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpreparation" roleURI="http://www.mesoblast.com/role/Basisofpreparation">
        <link:definition>0000007 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantchangesinthecurrentreportingperiod" roleURI="http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod">
        <link:definition>0000008 - Disclosure - Significant changes in the current reporting period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Lossbeforeincometax" roleURI="http://www.mesoblast.com/role/Lossbeforeincometax">
        <link:definition>0000009 - Disclosure - Loss before income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxbenefitexpense" roleURI="http://www.mesoblast.com/role/Incometaxbenefitexpense">
        <link:definition>0000010 - Disclosure - Income tax benefit/(expense)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialassetsandliabilities" roleURI="http://www.mesoblast.com/role/Financialassetsandliabilities">
        <link:definition>0000011 - Disclosure - Financial assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Nonfinancialassetsandliabilities" roleURI="http://www.mesoblast.com/role/Nonfinancialassetsandliabilities">
        <link:definition>0000012 - Disclosure - Non-financial assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashflowinformation" roleURI="http://www.mesoblast.com/role/Cashflowinformation">
        <link:definition>0000013 - Disclosure - Cash flow information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.mesoblast.com/role/Equity">
        <link:definition>0000014 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialriskmanagement" roleURI="http://www.mesoblast.com/role/Financialriskmanagement">
        <link:definition>0000015 - Disclosure - Financial risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Lossespershare" roleURI="http://www.mesoblast.com/role/Lossespershare">
        <link:definition>0000016 - Disclosure - (Losses) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Eventsoccurringafterthereportingperiod" roleURI="http://www.mesoblast.com/role/Eventsoccurringafterthereportingperiod">
        <link:definition>0000017 - Disclosure - Events occurring after the reporting period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://www.mesoblast.com/role/Segmentinformation">
        <link:definition>0000018 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Legalproceedings" roleURI="http://www.mesoblast.com/role/Legalproceedings">
        <link:definition>0000019 - Disclosure - Legal proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationPolicies" roleURI="http://www.mesoblast.com/role/BasisofpreparationPolicies">
        <link:definition>9954471 - Disclosure - Basis of preparation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossbeforeincometaxTables" roleURI="http://www.mesoblast.com/role/LossbeforeincometaxTables">
        <link:definition>9954472 - Disclosure - Loss before income tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxbenefitexpenseTables" roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseTables">
        <link:definition>9954473 - Disclosure - Income tax benefit/(expense) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesTables" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables">
        <link:definition>9954474 - Disclosure - Financial assets and liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesTables" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables">
        <link:definition>9954475 - Disclosure - Non-financial assets and liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashflowinformationTables" roleURI="http://www.mesoblast.com/role/CashflowinformationTables">
        <link:definition>9954476 - Disclosure - Cash flow information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.mesoblast.com/role/EquityTables">
        <link:definition>9954477 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementTables" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementTables">
        <link:definition>9954478 - Disclosure - Financial risk management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossespershareTables" roleURI="http://www.mesoblast.com/role/LossespershareTables">
        <link:definition>9954479 - Disclosure - (Losses) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationDetails" roleURI="http://www.mesoblast.com/role/BasisofpreparationDetails">
        <link:definition>9954480 - Disclosure - Basis of preparation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantchangesinthecurrentreportingperiodDetails" roleURI="http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails">
        <link:definition>9954481 - Disclosure - Significant changes in the current reporting period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails" roleURI="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails">
        <link:definition>9954482 - Disclosure - Loss before income tax - Summary of Loss Before Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails" roleURI="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails">
        <link:definition>9954483 - Disclosure - Loss before income tax - Summary of Loss Before Income Tax (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossbeforeincometaxAdditionalInformationDetails" roleURI="http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails">
        <link:definition>9954484 - Disclosure - Loss before income tax - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails" roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails">
        <link:definition>9954485 - Disclosure - Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails" roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails">
        <link:definition>9954486 - Disclosure - Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails">
        <link:definition>9954487 - Disclosure - Financial assets and liabilities - Summary of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails">
        <link:definition>9954488 - Disclosure - Financial assets and liabilities - Summary of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails">
        <link:definition>9954489 - Disclosure - Financial assets and liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails">
        <link:definition>9954490 - Disclosure - Financial assets and liabilities - Summary of Trade and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofPrepaymentsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails">
        <link:definition>9954491 - Disclosure - Financial assets and liabilities - Summary of Prepayments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesAdditionalInformationDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails">
        <link:definition>9954492 - Disclosure - Financial assets and liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails">
        <link:definition>9954493 - Disclosure - Financial assets and liabilities - Summary of Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofBorrowingsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails">
        <link:definition>9954494 - Disclosure - Financial assets and liabilities - Summary of Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofNetDebtDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails">
        <link:definition>9954495 - Disclosure - Financial assets and liabilities - Summary of Net Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails">
        <link:definition>9954496 - Disclosure - Financial assets and liabilities - Summary of Net Debt Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails">
        <link:definition>9954497 - Disclosure - Financial assets and liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails">
        <link:definition>9954498 - Disclosure - Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails">
        <link:definition>9954499 - Disclosure - Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails">
        <link:definition>9954500 - Disclosure - Financial assets and liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails">
        <link:definition>9954501 - Disclosure - Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails">
        <link:definition>9954502 - Disclosure - Financial assets and liabilities - Summary of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails">
        <link:definition>9954503 - Disclosure - Financial assets and liabilities - Summary of Fair Value of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails" roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails">
        <link:definition>9954504 - Disclosure - Financial assets and liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails">
        <link:definition>9954505 - Disclosure - Non-financial assets and liabilities - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails">
        <link:definition>9954506 - Disclosure - Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesAdditionalInformationDetails" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails">
        <link:definition>9954507 - Disclosure - Non-financial assets and liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails">
        <link:definition>9954508 - Disclosure - Non-financial assets and liabilities - Summary of Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails">
        <link:definition>9954509 - Disclosure - Non-financial assets and liabilities - Summary of Deferred Tax Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954510 - Disclosure - Non-financial assets and liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashflowinformationDetails" roleURI="http://www.mesoblast.com/role/CashflowinformationDetails">
        <link:definition>9954511 - Disclosure - Cash flow information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofShareCapitalDetails" roleURI="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails">
        <link:definition>9954512 - Disclosure - Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofMovementsinOrdinaryShareCapitalDetails" roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails">
        <link:definition>9954513 - Disclosure - Equity - Summary of Movements in Ordinary Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails" roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails">
        <link:definition>9954514 - Disclosure - Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofMovementsofSharesinShareTrustDetails" roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails">
        <link:definition>9954515 - Disclosure - Equity - Summary of Movements of Shares in Share Trust (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofWarrantReserveDetails" roleURI="http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails">
        <link:definition>9954516 - Disclosure - Equity - Summary of Warrant Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.mesoblast.com/role/EquityAdditionalInformationDetails">
        <link:definition>9954517 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementAdditionalInformationDetails" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails">
        <link:definition>9954518 - Disclosure - Financial risk management - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails">
        <link:definition>9954519 - Disclosure - Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails">
        <link:definition>9954520 - Disclosure - Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails">
        <link:definition>9954521 - Disclosure - Financial risk management - Summary of Borrowing to Price Rate Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails">
        <link:definition>9954522 - Disclosure - Financial risk management - Schedule of Increase/Decrease of Share Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails" roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails">
        <link:definition>9954523 - Disclosure - Financial risk management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossespershareDetails" roleURI="http://www.mesoblast.com/role/LossespershareDetails">
        <link:definition>9954524 - Disclosure - (Losses) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.mesoblast.com/role/SegmentInformationDetails">
        <link:definition>9954525 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.mesoblast.com/role/LegalProceedingsDetails">
        <link:definition>9954526 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="meso_NumberOfEscalatingMilestonePayments" abstract="false" name="NumberOfEscalatingMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="meso_OtherChangesOnDebtAndLeases" abstract="false" name="OtherChangesOnDebtAndLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_NumberOfSharesIssuedAndFullyPaidValue" abstract="false" name="NumberOfSharesIssuedAndFullyPaidValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IncreaseInInterestRatePercentage" abstract="false" name="IncreaseInInterestRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_PlacementAgreementMember" abstract="true" name="PlacementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_FairValueOfWarrants" abstract="false" name="FairValueOfWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_OrdinarySharesPurchasedValue" abstract="false" name="OrdinarySharesPurchasedValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" abstract="false" name="DisclosureOfWarrantReserveExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfFinancialRiskManagementLineItems" abstract="true" name="DisclosureOfFinancialRiskManagementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_ContingentConsiderationProvision" abstract="false" name="ContingentConsiderationProvision" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ExpectedSalesVolumesMeasurementInputMember" abstract="true" name="ExpectedSalesVolumesMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DeferredConsiderationNonCurrent" abstract="false" name="DeferredConsiderationNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" abstract="false" name="PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" abstract="false" name="MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_TradeReceivablesSettlementPeriod" abstract="false" name="TradeReceivablesSettlementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" abstract="false" name="DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_BorrowingsPrincipalAmortizationPeriod" abstract="false" name="BorrowingsPrincipalAmortizationPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_DefinedContributionSuperannuationExpenses" abstract="false" name="DefinedContributionSuperannuationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PercentageOfForecastNetSales" abstract="false" name="PercentageOfForecastNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" abstract="false" name="InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" abstract="true" name="DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" abstract="false" name="MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IntellectualPropertyExpenses" abstract="false" name="IntellectualPropertyExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IntangibleAssetsMember" abstract="true" name="IntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfNonFinancialAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_LegalAndOtherProfessionalFees" abstract="false" name="LegalAndOtherProfessionalFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_InterestBearingDepositsAtCallHeldAsSecurity" abstract="false" name="InterestBearingDepositsAtCallHeldAsSecurity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_CurrentMarketedProductsMember" abstract="true" name="CurrentMarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_WarrantExerciseTerm" abstract="false" name="WarrantExerciseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_DisclosureOfWarrantReserveLineItems" abstract="true" name="DisclosureOfWarrantReserveLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" abstract="false" name="GovernmentGrantsAndTaxIncentivesAndCreditsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" abstract="true" name="RefinancingAndExpansionOfSeniorDebtFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" abstract="false" name="NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_FundsInvestedWhichDerivesInterestRevenue" abstract="false" name="FundsInvestedWhichDerivesInterestRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_OutstandingCommonShareCapitalPercentage" abstract="false" name="OutstandingCommonShareCapitalPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" abstract="true" name="DisclosureOfSignificantChangesInCurrentReportingPeriodTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_TreasurySharesPurchasedValue" abstract="false" name="TreasurySharesPurchasedValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IncomeStatementFunctionalExpenseCategoriesMember" abstract="true" name="IncomeStatementFunctionalExpenseCategoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DeferredTaxAssetsNotBroughtToAccount" abstract="false" name="DeferredTaxAssetsNotBroughtToAccount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_CurrentTaxAbstract" abstract="true" name="CurrentTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_FairValueRemeasurementOfContingentConsiderationAbstract" abstract="true" name="FairValueRemeasurementOfContingentConsiderationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_TaxCreditedOrDebitedToEquity" abstract="false" name="TaxCreditedOrDebitedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_GainLossOnRemeasurementOfWarrantLiability" abstract="false" name="GainLossOnRemeasurementOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_OtherOperatingIncomeAndExpensesAbstract" abstract="true" name="OtherOperatingIncomeAndExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_TiGenixNVMember" abstract="true" name="TiGenixNVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_PreLaunchInventoryRecognized" abstract="false" name="PreLaunchInventoryRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ManufacturingCommercializationExpensesMember" abstract="true" name="ManufacturingCommercializationExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" abstract="false" name="PercentageOfReductionInCashOutflowsFromOperatingActivities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" abstract="false" name="DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_BorrowingsPrincipalAmount" abstract="false" name="BorrowingsPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_December2022WarrantsMember" abstract="true" name="December2022WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_IncomeStatementLocationMember" abstract="true" name="IncomeStatementLocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfWarrantReserveTable" abstract="true" name="DisclosureOfWarrantReserveTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_CommercializationRevenueReceived" abstract="false" name="CommercializationRevenueReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_MSCProductMember" abstract="true" name="MSCProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_TransactionCostsArisingOnShareIssue" abstract="false" name="TransactionCostsArisingOnShareIssue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ClinicalTrialRelatedResearchAndDevelopment" abstract="false" name="ClinicalTrialRelatedResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_NumberOfOperatingSegment" abstract="false" name="NumberOfOperatingSegment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="meso_GainLossOnReMeasurementOfContingentConsiderationProvision" abstract="false" name="GainLossOnReMeasurementOfContingentConsiderationProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_SharesHeldInTrustValue" abstract="false" name="SharesHeldInTrustValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" abstract="false" name="FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ExpectedPatentExpiry" abstract="false" name="ExpectedPatentExpiry" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_PostTaxDiscountRates" abstract="false" name="PostTaxDiscountRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" abstract="false" name="PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_LossGainOnRemeasurementOfWarrantLiability" abstract="false" name="LossGainOnRemeasurementOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_SharesPrice" abstract="false" name="SharesPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" abstract="false" name="DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_ContributionsOfEquityDuringPeriod" abstract="false" name="ContributionsOfEquityDuringPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="meso_FairValueRemeasurementOfContingentConsiderationAfterTax" abstract="false" name="FairValueRemeasurementOfContingentConsiderationAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" abstract="false" name="MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IntellectualPropertyAmortization" abstract="false" name="IntellectualPropertyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_BorrowingsInterestOnlyPeriod" abstract="false" name="BorrowingsInterestOnlyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_SharesAvailableForIssuanceUnderIssuancePlan" abstract="false" name="SharesAvailableForIssuanceUnderIssuancePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" abstract="false" name="IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsAndLiabilitiesLineItems" abstract="true" name="DeferredTaxAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" abstract="false" name="UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_ConsultancyExpenses" abstract="false" name="ConsultancyExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_GrunenthalGmbHMember" abstract="true" name="GrunenthalGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" abstract="true" name="ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" abstract="false" name="DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_OtherPrepayments" abstract="false" name="OtherPrepayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_WarrantsFairValueAtGrantDateDecember222022Member" abstract="true" name="WarrantsFairValueAtGrantDateDecember222022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DepositsAtCall" abstract="false" name="DepositsAtCall" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PercentageOfPriceRateChangesInCurrentBorrowings" abstract="false" name="PercentageOfPriceRateChangesInCurrentBorrowings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_ProvisionForLicenseAgreementsMember" abstract="true" name="ProvisionForLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_NumberOfClassActionLawsuits" abstract="false" name="NumberOfClassActionLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" abstract="false" name="FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_AmericanDepositoryReceiptMember" abstract="true" name="AmericanDepositoryReceiptMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" abstract="false" name="NonInterestBearingFinancialLiabilitiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_FairValueRemeasurementOfWarrantLiabilityAbstract" abstract="true" name="FairValueRemeasurementOfWarrantLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" abstract="false" name="AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" abstract="true" name="DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_PercentageOfSharePremiumPrice" abstract="false" name="PercentageOfSharePremiumPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" abstract="false" name="DeferredTaxAssetsAttributableToOtherTemporaryDifferences" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_RemeasurementAdjustmentsOnDebtAndWarrants" abstract="false" name="RemeasurementAdjustmentsOnDebtAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ForeignExchangeGainsLosses" abstract="false" name="ForeignExchangeGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_UnlistedEquitySecuritiesMember" abstract="true" name="UnlistedEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_IncreaseDecreaseInCurrentTax" abstract="false" name="IncreaseDecreaseInCurrentTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredConsiderationMilestoneConsiderationRecognized" abstract="false" name="DeferredConsiderationMilestoneConsiderationRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ExpectedSalesVolumeMember" abstract="true" name="ExpectedSalesVolumeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_PaymentAssumptionsMeasurementInputMember" abstract="true" name="PaymentAssumptionsMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_ContingentConsiderationProvisionAmountUsed" abstract="false" name="ContingentConsiderationProvisionAmountUsed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" abstract="true" name="DisclosureOfMovementsOfSharesInShareTrustLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" abstract="false" name="AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_FairValueRemeasurementOfContingentConsideration" abstract="false" name="FairValueRemeasurementOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_MesoblastEmployeeShareTrustMember" abstract="true" name="MesoblastEmployeeShareTrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_NovaQuestCapitalManagementLLCMember" abstract="true" name="NovaQuestCapitalManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfFinancialRiskManagementTable" abstract="true" name="DisclosureOfFinancialRiskManagementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_IncomeStatementLocationsAxis" abstract="true" name="IncomeStatementLocationsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_RoyaltyPaymentsAtFairValueLiabilities" abstract="false" name="RoyaltyPaymentsAtFairValueLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" abstract="false" name="DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_WarrantsPricePerShare" abstract="false" name="WarrantsPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" abstract="false" name="DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_PercentageOfPriceRateChangesInBorrowings" abstract="false" name="PercentageOfPriceRateChangesInBorrowings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_CashFlowsAdjustmentsOnDebt" abstract="false" name="CashFlowsAdjustmentsOnDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ManagementAndAdministrationMember" abstract="true" name="ManagementAndAdministrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_ManagementAndAdministrationExpense" abstract="false" name="ManagementAndAdministrationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_LonzaBioscienceSingaporePteLtdMember" abstract="true" name="LonzaBioscienceSingaporePteLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" abstract="false" name="DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_NonCancellablePurchaseCommitments" abstract="false" name="NonCancellablePurchaseCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" abstract="false" name="NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ManufacturingCommercialization" abstract="false" name="ManufacturingCommercialization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsAndLiabilitiesTable" abstract="true" name="DeferredTaxAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_InvestmentInFixedAssets" abstract="false" name="InvestmentInFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ManufacturingAndCommercializationMember" abstract="true" name="ManufacturingAndCommercializationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_ProbabilityOfSuccessMeasurementInputMember" abstract="true" name="ProbabilityOfSuccessMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_TaxLossesMember" abstract="true" name="TaxLossesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfLossBeforeIncomeTaxAbstract" abstract="true" name="DisclosureOfLossBeforeIncomeTaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfFinancialRiskManagementAbstract" abstract="true" name="DisclosureOfFinancialRiskManagementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_UnpaidInterestPortionPerAnnum" abstract="false" name="UnpaidInterestPortionPerAnnum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" abstract="false" name="PercentageOfPriceRateChangesInNonCurrentBorrowings" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_TradePayablesMember" abstract="true" name="TradePayablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" abstract="true" name="DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_ClinicalTrialResearchAndDevelopmentExpenditure" abstract="false" name="ClinicalTrialResearchAndDevelopmentExpenditure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_WarrantsFairValueAtIssueDate" abstract="false" name="WarrantsFairValueAtIssueDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" abstract="true" name="DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_RemeasurementAdjustmentsOnDebt" abstract="false" name="RemeasurementAdjustmentsOnDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" abstract="false" name="PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_PrivatePlacementOfSharesMember" abstract="true" name="PrivatePlacementOfSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_MilestoneRevenue" abstract="false" name="MilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_AdditionalPotentialMilestonePaymentsReceivable" abstract="false" name="AdditionalPotentialMilestonePaymentsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCreditReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_TaslyMember" abstract="true" name="TaslyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_CumulativeMilestonePaymentsReachableAmount" abstract="false" name="CumulativeMilestonePaymentsReachableAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_PercentageOfLiabilitiesMeasuredAtFairValue" abstract="false" name="PercentageOfLiabilitiesMeasuredAtFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_DisclosureOfMovementsOfSharesInShareTrustTable" abstract="true" name="DisclosureOfMovementsOfSharesInShareTrustTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" abstract="false" name="PercentageOfEntitysRevenueAnnualPaymentCapThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" abstract="true" name="DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_PrepaidInsuranceAndSubscriptions" abstract="false" name="PrepaidInsuranceAndSubscriptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ExercisePriceShareWarrentsIssued" abstract="false" name="ExercisePriceShareWarrentsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="meso_SharesIssuedInPlacementsValue" abstract="false" name="SharesIssuedInPlacementsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_EmployeeBenefitsMember" abstract="true" name="EmployeeBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" abstract="true" name="DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" abstract="false" name="IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_BorrowingsTerm" abstract="false" name="BorrowingsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_DisclosureOfLossBeforeIncomeTaxTable" abstract="true" name="DisclosureOfLossBeforeIncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="meso_FinanceCostsGainsAbstract" abstract="true" name="FinanceCostsGainsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_ForeignWithholdingTaxRecoverable" abstract="false" name="ForeignWithholdingTaxRecoverable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" abstract="false" name="AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_FairValuePerWarrant" abstract="false" name="FairValuePerWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="meso_ContributionsOfValueForEquityDuringPeriod" abstract="false" name="ContributionsOfValueForEquityDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_NonRefundableUpFrontPaymentReceived" abstract="false" name="NonRefundableUpFrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" abstract="false" name="IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PaymentsOfTransactionCostsFromBorrowings" abstract="false" name="PaymentsOfTransactionCostsFromBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IssuanceWarrantsExercisedPeriod" abstract="false" name="IssuanceWarrantsExercisedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_OverheadsAndAdministrationExpenses" abstract="false" name="OverheadsAndAdministrationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ManufacturingServiceAgreementMember" abstract="true" name="ManufacturingServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_ExpectedUnitSalesPriceMeasurementInputMember" abstract="true" name="ExpectedUnitSalesPriceMeasurementInputMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" abstract="false" name="IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DecreaseInInterestRatePercentage" abstract="false" name="DecreaseInInterestRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" abstract="false" name="IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" abstract="false" name="MinimumFinancialCommitmentReductionAmountOnLeaseComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_RoyaltiesReceivableUnderSalesBasedMilestones" abstract="false" name="RoyaltiesReceivableUnderSalesBasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" abstract="false" name="SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_EffectOnProfitFromChangeInInterestRate" abstract="false" name="EffectOnProfitFromChangeInInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_PercentageOfIncreaseAndDecreaseInSharePrice" abstract="false" name="PercentageOfIncreaseAndDecreaseInSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" abstract="false" name="OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsAbstract" abstract="true" name="DeferredTaxAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_BasisOfPreparationAbstract" abstract="true" name="BasisOfPreparationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_RemeasurementOfWarrantLiability" abstract="false" name="RemeasurementOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" abstract="false" name="EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IncreaseDecreaseInDeferredTaxAssets" abstract="false" name="IncreaseDecreaseInDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfLossBeforeIncomeTaxLineItems" abstract="true" name="DisclosureOfLossBeforeIncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_MaximumAmountInCashOutflowsFromOperatingActivities" abstract="false" name="MaximumAmountInCashOutflowsFromOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_WarrantExercisePricePerShare" abstract="false" name="WarrantExercisePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="meso_QuarterlyPaymentsMember" abstract="true" name="QuarterlyPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_SharePriceMinimumConsecutiveDay" abstract="false" name="SharePriceMinimumConsecutiveDay" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="meso_LossGainOnRemeasurementOfContingentConsideration" abstract="false" name="LossGainOnRemeasurementOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxLiabilityAbstract" abstract="true" name="DeferredTaxLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_ReceivableFromTaxCredits" abstract="false" name="ReceivableFromTaxCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_OtherManagementAndAdministrationExpenses" abstract="false" name="OtherManagementAndAdministrationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ManufacturingProductionAndDevelopment" abstract="false" name="ManufacturingProductionAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" abstract="false" name="DisclosureOfLegalProceedingsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" abstract="false" name="NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" abstract="false" name="SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" abstract="true" name="DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_RemeasurementAdjustmentsOnWarrants" abstract="false" name="RemeasurementAdjustmentsOnWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_AdjustmentsForIncreaseDecreaseInPrepayments" abstract="false" name="AdjustmentsForIncreaseDecreaseInPrepayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" abstract="false" name="RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ProceedsFromPrivatePlacement" abstract="false" name="ProceedsFromPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ContingentConsiderationProvisionMember" abstract="true" name="ContingentConsiderationProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_OaktreeCapitalManagementLPMember" abstract="true" name="OaktreeCapitalManagementLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" abstract="false" name="PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_MinimumFinancialCommitmentReductionAmount" abstract="false" name="MinimumFinancialCommitmentReductionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_FundsInvestedPercentage" abstract="false" name="FundsInvestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_License1Member" abstract="true" name="License1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_CardiovascularProductsMember" abstract="true" name="CardiovascularProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" abstract="false" name="ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" abstract="false" name="UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" abstract="true" name="DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" abstract="false" name="DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_CurrentProvisionsForAccruedAnnualLeave" abstract="false" name="CurrentProvisionsForAccruedAnnualLeave" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PercentageOfAssetsMeasuredAtFairValue" abstract="false" name="PercentageOfAssetsMeasuredAtFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" abstract="true" name="DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" abstract="false" name="FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_CommercializationRevenue" abstract="false" name="CommercializationRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_FairValueRemeasurementOfWarrantLiability" abstract="false" name="FairValueRemeasurementOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_PercentageOfCashHeld" abstract="false" name="PercentageOfCashHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_IncreaseDecreaseInDeferredTaxLiabilities" abstract="false" name="IncreaseDecreaseInDeferredTaxLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_SharesHeldInTrust" abstract="false" name="SharesHeldInTrust" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_ConversionRatioOfWarrants" abstract="false" name="ConversionRatioOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" abstract="false" name="DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_OaktreeCapitalManagementMember" abstract="true" name="OaktreeCapitalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" abstract="false" name="AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" abstract="true" name="ChangeInOperatingAssetsAndLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" abstract="false" name="DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_ReceiptsFromInvestmentInSublease" abstract="false" name="ReceiptsFromInvestmentInSublease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" abstract="false" name="AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_TreasurySharesPurchased" abstract="false" name="TreasurySharesPurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_RevenueRecognizedForRightOfUseLicenseOfIP" abstract="false" name="RevenueRecognizedForRightOfUseLicenseOfIP" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_IntravenousProductsMember" abstract="true" name="IntravenousProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" abstract="false" name="DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_MinimumUnrestrictedCashBalance" abstract="false" name="MinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfExposureToFinancialRisksTableTextBlock" abstract="false" name="DisclosureOfExposureToFinancialRisksTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_OtherManagementAndAdministrationExpensesAbstract" abstract="true" name="OtherManagementAndAdministrationExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_DiscountedPercentageOnIssuanceOfEquity" abstract="false" name="DiscountedPercentageOnIssuanceOfEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" abstract="false" name="ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_CashOrStockPayableAtFairValueLiabilities" abstract="false" name="CashOrStockPayableAtFairValueLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_InvestmentRevaluationReserveMember" abstract="true" name="InvestmentRevaluationReserveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_NonRefundableUpfrontPaymentsReceivable" abstract="false" name="NonRefundableUpfrontPaymentsReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_ContingentConsiderations" abstract="false" name="ContingentConsiderations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" abstract="false" name="FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" abstract="false" name="PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" abstract="false" name="PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_OtherPurchaseCommitments" abstract="false" name="OtherPurchaseCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" abstract="false" name="DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="meso_DisclosureOfLossBeforeIncomeTaxLineItem" abstract="true" name="DisclosureOfLossBeforeIncomeTaxLineItem" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_LongTermBorrowingsAbstract" abstract="true" name="LongTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" abstract="true" name="DepreciationAndAmortizationOfNonCurrentAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="meso_JCRPharmaceuticalsCoLTDMember" abstract="true" name="JCRPharmaceuticalsCoLTDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_November2021WarrantsMember" abstract="true" name="November2021WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" abstract="false" name="EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="meso_TransactionCostsArisingOnShareIssueShare" abstract="false" name="TransactionCostsArisingOnShareIssueShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="meso_PercentageOfPremiumForVolumeWeightedAveragePrice" abstract="false" name="PercentageOfPremiumForVolumeWeightedAveragePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>meso-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1c79165c-755b-4603-a45e-827a45827c07,g:19d448ab-9536-4f20-ab7d-76d6f5e0018c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedIncomeStatement" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedIncomeStatement"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_65d6a886-763e-461d-9eb8-8d72a15a1300" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_79e4df19-afa0-4dc8-998b-37e91f65f497" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_65d6a886-763e-461d-9eb8-8d72a15a1300" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_79e4df19-afa0-4dc8-998b-37e91f65f497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f98d6ae-7e1a-40f5-9aab-00bdec987f10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_65d6a886-763e-461d-9eb8-8d72a15a1300" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_6f98d6ae-7e1a-40f5-9aab-00bdec987f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_12878456-88e0-4b99-ad0b-46648828f736" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_ifrs-full_Revenue_12878456-88e0-4b99-ad0b-46648828f736" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_92b2ea9f-84ac-4bdf-a80e-52af2178f1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_92b2ea9f-84ac-4bdf-a80e-52af2178f1be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingCommercialization_e3cf3abd-f3f0-4aa6-a528-0bd6ff2ad681" xlink:href="meso-20231231.xsd#meso_ManufacturingCommercialization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_meso_ManufacturingCommercialization_e3cf3abd-f3f0-4aa6-a528-0bd6ff2ad681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManagementAndAdministrationExpense_71bc4763-a5e6-4e59-b673-a622b38e37ef" xlink:href="meso-20231231.xsd#meso_ManagementAndAdministrationExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_meso_ManagementAndAdministrationExpense_71bc4763-a5e6-4e59-b673-a622b38e37ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsideration_281f7c9c-804b-43a0-9f83-5f266ae7845b" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsideration"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsideration_281f7c9c-804b-43a0-9f83-5f266ae7845b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiability_17c26409-8ef4-49b6-8e58-e3127157f108" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiability"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_meso_FairValueRemeasurementOfWarrantLiability_17c26409-8ef4-49b6-8e58-e3127157f108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_f8e4f75a-b0c4-4005-a922-b90662ce28b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_f8e4f75a-b0c4-4005-a922-b90662ce28b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_a8cae513-fb74-4f6a-b2ee-2ab7e4bf2c4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_5b8e490c-f447-4564-9531-dc108bd476b9" xlink:to="loc_ifrs-full_FinanceCosts_a8cae513-fb74-4f6a-b2ee-2ab7e4bf2c4f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_242ac18f-5899-476b-9360-62e2378e46b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_600331cf-4e1e-4cb5-ba7b-8860061ce23a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_242ac18f-5899-476b-9360-62e2378e46b8" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_600331cf-4e1e-4cb5-ba7b-8860061ce23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_96eee7aa-59d4-4f02-8d07-e813b38918a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_242ac18f-5899-476b-9360-62e2378e46b8" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_96eee7aa-59d4-4f02-8d07-e813b38918a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b536362f-2b4e-41b0-b5f1-a3c42266b12a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_eb112a0d-04da-40c3-bb58-c3b2c33dcdcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b536362f-2b4e-41b0-b5f1-a3c42266b12a" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_eb112a0d-04da-40c3-bb58-c3b2c33dcdcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_e87d2b04-be08-4b07-9624-4375efa03f26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_b536362f-2b4e-41b0-b5f1-a3c42266b12a" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_e87d2b04-be08-4b07-9624-4375efa03f26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofChangesinEquity"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_f4a1a9ba-d50a-4759-b0dd-286c898b1377" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxCreditedOrDebitedToEquity_15523f8c-859a-4f13-bd36-957aff98e225" xlink:href="meso-20231231.xsd#meso_TaxCreditedOrDebitedToEquity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ChangesInEquity_f4a1a9ba-d50a-4759-b0dd-286c898b1377" xlink:to="loc_meso_TaxCreditedOrDebitedToEquity_15523f8c-859a-4f13-bd36-957aff98e225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_6435948c-fd54-4247-b98d-fa9b653d08a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ChangesInEquity_f4a1a9ba-d50a-4759-b0dd-286c898b1377" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_6435948c-fd54-4247-b98d-fa9b653d08a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_57e9c923-4eeb-4ccd-8027-462d2bf27240" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ChangesInEquity_f4a1a9ba-d50a-4759-b0dd-286c898b1377" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_57e9c923-4eeb-4ccd-8027-462d2bf27240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_0625b82c-19fe-41bd-933d-151c8a1b207b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_78208629-dde9-4b54-9c42-c1d8b722d3af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_0625b82c-19fe-41bd-933d-151c8a1b207b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_78208629-dde9-4b54-9c42-c1d8b722d3af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_b354d84d-d82c-474a-b856-9e11822ae669" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_74084b7d-788c-4ef4-adad-2a6de49edf00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_b354d84d-d82c-474a-b856-9e11822ae669" xlink:to="loc_ifrs-full_ProfitLoss_74084b7d-788c-4ef4-adad-2a6de49edf00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_a010e3d8-e476-4b6a-a672-5839bc326ad2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_b354d84d-d82c-474a-b856-9e11822ae669" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_a010e3d8-e476-4b6a-a672-5839bc326ad2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedBalanceSheet"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_6fc04b3e-8f60-4954-9d91-af42028e9e47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_2a4307d4-0615-4756-8bd8-d86b0703110b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_6fc04b3e-8f60-4954-9d91-af42028e9e47" xlink:to="loc_ifrs-full_IssuedCapital_2a4307d4-0615-4756-8bd8-d86b0703110b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_c3e210e2-4054-4e77-bde9-346ac700e579" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_6fc04b3e-8f60-4954-9d91-af42028e9e47" xlink:to="loc_ifrs-full_OtherReserves_c3e210e2-4054-4e77-bde9-346ac700e579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_39df05f1-d7c5-499f-84a9-4b64056c7119" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_6fc04b3e-8f60-4954-9d91-af42028e9e47" xlink:to="loc_ifrs-full_RetainedEarnings_39df05f1-d7c5-499f-84a9-4b64056c7119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_2272df2f-524b-42a8-95a2-d750dc4b5dec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_db725f83-f8af-48e5-bd82-e565a4844c04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities_2272df2f-524b-42a8-95a2-d750dc4b5dec" xlink:to="loc_ifrs-full_Assets_db725f83-f8af-48e5-bd82-e565a4844c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_c5553c80-b382-438c-b1b8-f8fb7cb7f210" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities_2272df2f-524b-42a8-95a2-d750dc4b5dec" xlink:to="loc_ifrs-full_Liabilities_c5553c80-b382-438c-b1b8-f8fb7cb7f210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_17480e45-529f-405d-9f01-3c918779755d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_07bf05f2-6513-42c2-a917-6dee82c63128" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_17480e45-529f-405d-9f01-3c918779755d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_07bf05f2-6513-42c2-a917-6dee82c63128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_01fe4e27-ab2a-4b24-b25b-e55f081f36e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_17480e45-529f-405d-9f01-3c918779755d" xlink:to="loc_ifrs-full_RightofuseAssets_01fe4e27-ab2a-4b24-b25b-e55f081f36e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_24f1eca6-7f01-43eb-b8ae-56f3f8171f62" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_17480e45-529f-405d-9f01-3c918779755d" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_24f1eca6-7f01-43eb-b8ae-56f3f8171f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_c1ba8d6b-fef4-4fb4-bb12-05f2d29feeb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_17480e45-529f-405d-9f01-3c918779755d" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_c1ba8d6b-fef4-4fb4-bb12-05f2d29feeb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_3cb4156e-fb81-45b4-9579-4a11c2525f78" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_17480e45-529f-405d-9f01-3c918779755d" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_3cb4156e-fb81-45b4-9579-4a11c2525f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_9109cdca-22b0-419d-a045-db686d287b86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_2d566801-c32a-45a0-b955-c0417d6b39e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_9109cdca-22b0-419d-a045-db686d287b86" xlink:to="loc_ifrs-full_CashAndCashEquivalents_2d566801-c32a-45a0-b955-c0417d6b39e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_cf3e0ec3-57c8-499d-8e31-27fd970f81bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_9109cdca-22b0-419d-a045-db686d287b86" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_cf3e0ec3-57c8-499d-8e31-27fd970f81bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_fbfee1fc-2887-4e11-887e-73c06419c353" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_9109cdca-22b0-419d-a045-db686d287b86" xlink:to="loc_ifrs-full_CurrentPrepayments_fbfee1fc-2887-4e11-887e-73c06419c353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_dba2d1bc-4a28-4ac3-b351-ce1d5beab58c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_d4ff2be8-d710-4f9f-99ac-8d2f46883660" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_dba2d1bc-4a28-4ac3-b351-ce1d5beab58c" xlink:to="loc_ifrs-full_CurrentAssets_d4ff2be8-d710-4f9f-99ac-8d2f46883660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_6ce039a3-ce5e-4198-a412-32001f220c5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_dba2d1bc-4a28-4ac3-b351-ce1d5beab58c" xlink:to="loc_ifrs-full_NoncurrentAssets_6ce039a3-ce5e-4198-a412-32001f220c5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_55b90b31-24dc-4018-977c-2343741cee52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_5dcf74a9-043a-4365-b6c4-4a4c3c325bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_55b90b31-24dc-4018-977c-2343741cee52" xlink:to="loc_ifrs-full_NoncurrentProvisions_5dcf74a9-043a-4365-b6c4-4a4c3c325bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_3396503e-4046-4a4a-a151-925e4a634890" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_55b90b31-24dc-4018-977c-2343741cee52" xlink:to="loc_ifrs-full_LongtermBorrowings_3396503e-4046-4a4a-a151-925e4a634890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_bed5b9ed-5464-454a-ba0d-f8c73b4f1168" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_55b90b31-24dc-4018-977c-2343741cee52" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_bed5b9ed-5464-454a-ba0d-f8c73b4f1168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredConsiderationNonCurrent_7f161ef5-0f53-459e-8c2b-843a57fce928" xlink:href="meso-20231231.xsd#meso_DeferredConsiderationNonCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_55b90b31-24dc-4018-977c-2343741cee52" xlink:to="loc_meso_DeferredConsiderationNonCurrent_7f161ef5-0f53-459e-8c2b-843a57fce928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_8f355fd4-c2a5-4153-92fc-431ef6655d8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_42440cb0-7557-4bf2-9fae-b8616ecd001e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_8f355fd4-c2a5-4153-92fc-431ef6655d8b" xlink:to="loc_ifrs-full_CurrentLiabilities_42440cb0-7557-4bf2-9fae-b8616ecd001e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_3facdb08-d3df-40ec-8d09-c8ee62526bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_8f355fd4-c2a5-4153-92fc-431ef6655d8b" xlink:to="loc_ifrs-full_NoncurrentLiabilities_3facdb08-d3df-40ec-8d09-c8ee62526bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_91f523d0-68f4-4325-a6af-1b78babdbce7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_3d092e8a-c168-4c68-81e8-135245af86de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_91f523d0-68f4-4325-a6af-1b78babdbce7" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_3d092e8a-c168-4c68-81e8-135245af86de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_d9710f95-cea9-452f-9841-65d05173e658" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_91f523d0-68f4-4325-a6af-1b78babdbce7" xlink:to="loc_ifrs-full_CurrentProvisions_d9710f95-cea9-452f-9841-65d05173e658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_87e9167a-42d2-46cf-aeaf-b07274c21afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_91f523d0-68f4-4325-a6af-1b78babdbce7" xlink:to="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_87e9167a-42d2-46cf-aeaf-b07274c21afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_5a397bdc-eb8a-41c3-9c46-83be6fa6a9cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_91f523d0-68f4-4325-a6af-1b78babdbce7" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_5a397bdc-eb8a-41c3-9c46-83be6fa6a9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_76379344-35d8-4c13-9d3b-a1eab162dd0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_91f523d0-68f4-4325-a6af-1b78babdbce7" xlink:to="loc_ifrs-full_WarrantLiability_76379344-35d8-4c13-9d3b-a1eab162dd0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_905be705-c41d-4bb9-90a2-3f606830585f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CommercializationRevenueReceived_d7040a07-720c-40ee-9011-c90c538af2ec" xlink:href="meso-20231231.xsd#meso_CommercializationRevenueReceived"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_905be705-c41d-4bb9-90a2-3f606830585f" xlink:to="loc_meso_CommercializationRevenueReceived_d7040a07-720c-40ee-9011-c90c538af2ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_0f88eda4-c076-43e2-b25c-7466f173c59e" xlink:href="meso-20231231.xsd#meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_905be705-c41d-4bb9-90a2-3f606830585f" xlink:to="loc_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_0f88eda4-c076-43e2-b25c-7466f173c59e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_d2949804-a5cb-47c5-a870-6b772ff82c1f" xlink:href="meso-20231231.xsd#meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_905be705-c41d-4bb9-90a2-3f606830585f" xlink:to="loc_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_d2949804-a5cb-47c5-a870-6b772ff82c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_8569ccc2-34d3-41cc-8484-504b610aaf17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_905be705-c41d-4bb9-90a2-3f606830585f" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_8569ccc2-34d3-41cc-8484-504b610aaf17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_87ca783a-babc-45d5-b141-3918d7875f3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_905be705-c41d-4bb9-90a2-3f606830585f" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_87ca783a-babc-45d5-b141-3918d7875f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_8395a9fa-b99f-4134-932e-c2d9101d3f17" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InvestmentInFixedAssets_73f4ffb7-975c-4d07-8047-497e76b72011" xlink:href="meso-20231231.xsd#meso_InvestmentInFixedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_8395a9fa-b99f-4134-932e-c2d9101d3f17" xlink:to="loc_meso_InvestmentInFixedAssets_73f4ffb7-975c-4d07-8047-497e76b72011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_3472372a-6cc8-4615-87c1-8636874ee423" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_8395a9fa-b99f-4134-932e-c2d9101d3f17" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_3472372a-6cc8-4615-87c1-8636874ee423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ReceiptsFromInvestmentInSublease_b04ae1f6-9228-4f92-a110-4c964dade7f3" xlink:href="meso-20231231.xsd#meso_ReceiptsFromInvestmentInSublease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_8395a9fa-b99f-4134-932e-c2d9101d3f17" xlink:to="loc_meso_ReceiptsFromInvestmentInSublease_b04ae1f6-9228-4f92-a110-4c964dade7f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_98e9c7db-4102-4e38-ba1d-2dbe7dd13365" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentsOfTransactionCostsFromBorrowings_196f0e27-cf4c-44cb-93cf-13f9d67c4ddf" xlink:href="meso-20231231.xsd#meso_PaymentsOfTransactionCostsFromBorrowings"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_98e9c7db-4102-4e38-ba1d-2dbe7dd13365" xlink:to="loc_meso_PaymentsOfTransactionCostsFromBorrowings_196f0e27-cf4c-44cb-93cf-13f9d67c4ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_f774e8bc-c964-42d1-ad9c-db107b032969" xlink:href="meso-20231231.xsd#meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_98e9c7db-4102-4e38-ba1d-2dbe7dd13365" xlink:to="loc_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_f774e8bc-c964-42d1-ad9c-db107b032969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_4cf500c3-3bf2-4022-9b1c-c11111dee9af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_98e9c7db-4102-4e38-ba1d-2dbe7dd13365" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_4cf500c3-3bf2-4022-9b1c-c11111dee9af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_1079dca3-4bc5-4c8f-b953-b0e65c0d841d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_98e9c7db-4102-4e38-ba1d-2dbe7dd13365" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_1079dca3-4bc5-4c8f-b953-b0e65c0d841d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_3f31d73b-7b22-4d41-b146-6883fb4dc874" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_98e9c7db-4102-4e38-ba1d-2dbe7dd13365" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_3f31d73b-7b22-4d41-b146-6883fb4dc874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_cbd07a53-266e-403c-af34-2eb455a203c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c0a512e5-210b-4553-abfb-d5dda3f4b5a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_cbd07a53-266e-403c-af34-2eb455a203c7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_c0a512e5-210b-4553-abfb-d5dda3f4b5a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fb39ead4-ba93-4878-b679-704b138e9f0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_cbd07a53-266e-403c-af34-2eb455a203c7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_fb39ead4-ba93-4878-b679-704b138e9f0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0586ec0-1824-4df6-97d4-5562484ca157" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_cbd07a53-266e-403c-af34-2eb455a203c7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_b0586ec0-1824-4df6-97d4-5562484ca157" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_1e3d5430-8ba2-483b-8f21-d8bdc81e33ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CommercializationRevenue_07cf5054-7e47-4e52-a6d4-5bb53c1225a9" xlink:href="meso-20231231.xsd#meso_CommercializationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_1e3d5430-8ba2-483b-8f21-d8bdc81e33ea" xlink:to="loc_meso_CommercializationRevenue_07cf5054-7e47-4e52-a6d4-5bb53c1225a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MilestoneRevenue_99b2dcd3-c04f-4e9e-9700-a190f1cf012b" xlink:href="meso-20231231.xsd#meso_MilestoneRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_1e3d5430-8ba2-483b-8f21-d8bdc81e33ea" xlink:to="loc_meso_MilestoneRevenue_99b2dcd3-c04f-4e9e-9700-a190f1cf012b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiability_7eb9d32f-04ba-46ab-8774-2ea512eb7f4c" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfWarrantLiability_84862bcf-8320-4196-a255-6c32e90dfd26" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfWarrantLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_FairValueRemeasurementOfWarrantLiability_7eb9d32f-04ba-46ab-8774-2ea512eb7f4c" xlink:to="loc_meso_LossGainOnRemeasurementOfWarrantLiability_84862bcf-8320-4196-a255-6c32e90dfd26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherManagementAndAdministrationExpenses_8aec336c-d942-4dbf-bd72-5ea11df220f6" xlink:href="meso-20231231.xsd#meso_OtherManagementAndAdministrationExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OverheadsAndAdministrationExpenses_a4a0ec58-cf65-4d1f-9d4c-efcbe3f31922" xlink:href="meso-20231231.xsd#meso_OverheadsAndAdministrationExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_OtherManagementAndAdministrationExpenses_8aec336c-d942-4dbf-bd72-5ea11df220f6" xlink:to="loc_meso_OverheadsAndAdministrationExpenses_a4a0ec58-cf65-4d1f-9d4c-efcbe3f31922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConsultancyExpenses_cabd43cf-2e72-4ea2-8229-dab97440cb58" xlink:href="meso-20231231.xsd#meso_ConsultancyExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_OtherManagementAndAdministrationExpenses_8aec336c-d942-4dbf-bd72-5ea11df220f6" xlink:to="loc_meso_ConsultancyExpenses_cabd43cf-2e72-4ea2-8229-dab97440cb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LegalAndOtherProfessionalFees_26595928-2695-44ca-b4af-8fbbabef8508" xlink:href="meso-20231231.xsd#meso_LegalAndOtherProfessionalFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_OtherManagementAndAdministrationExpenses_8aec336c-d942-4dbf-bd72-5ea11df220f6" xlink:to="loc_meso_LegalAndOtherProfessionalFees_26595928-2695-44ca-b4af-8fbbabef8508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntellectualPropertyExpenses_10cdb462-4393-4d1b-8740-87c08824dff5" xlink:href="meso-20231231.xsd#meso_IntellectualPropertyExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_OtherManagementAndAdministrationExpenses_8aec336c-d942-4dbf-bd72-5ea11df220f6" xlink:to="loc_meso_IntellectualPropertyExpenses_10cdb462-4393-4d1b-8740-87c08824dff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_0e0d0c7f-01eb-48d3-8cb9-6d25564cca74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_ifrs-full_Revenue_0e0d0c7f-01eb-48d3-8cb9-6d25564cca74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalTrialRelatedResearchAndDevelopment_f67a728b-ea29-4e75-919e-609e983d60c3" xlink:href="meso-20231231.xsd#meso_ClinicalTrialRelatedResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_meso_ClinicalTrialRelatedResearchAndDevelopment_f67a728b-ea29-4e75-919e-609e983d60c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingProductionAndDevelopment_192cb7f2-b735-4885-8d42-94996bdde8b5" xlink:href="meso-20231231.xsd#meso_ManufacturingProductionAndDevelopment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_meso_ManufacturingProductionAndDevelopment_192cb7f2-b735-4885-8d42-94996bdde8b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_81205284-0f65-49af-b253-dba3ae12c55c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_81205284-0f65-49af-b253-dba3ae12c55c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_fc144e34-bfbe-40c7-80d7-40685b5e25b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_ifrs-full_AmortisationExpense_fc144e34-bfbe-40c7-80d7-40685b5e25b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherManagementAndAdministrationExpenses_c709efe7-165e-4a52-82cb-b645c3286429" xlink:href="meso-20231231.xsd#meso_OtherManagementAndAdministrationExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_meso_OtherManagementAndAdministrationExpenses_c709efe7-165e-4a52-82cb-b645c3286429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsideration_81501535-bd38-4667-8776-209fbd48167d" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsideration"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsideration_81501535-bd38-4667-8776-209fbd48167d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiability_caa8811f-9864-40c3-9468-858e86533596" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiability"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_meso_FairValueRemeasurementOfWarrantLiability_caa8811f-9864-40c3-9468-858e86533596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_ebb15b8c-ba8a-4405-b993-59cff752084f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_ebb15b8c-ba8a-4405-b993-59cff752084f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_0fcf0697-aee9-48b3-87e1-871f8679991a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_127428a3-446d-4158-8d96-2b9d4ef1952e" xlink:to="loc_ifrs-full_FinanceCosts_0fcf0697-aee9-48b3-87e1-871f8679991a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_cc31b053-1b54-4e0c-930a-5b8fc6b83f44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_4cf592f3-3c43-4c77-9840-df7363523b46" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_cc31b053-1b54-4e0c-930a-5b8fc6b83f44" xlink:to="loc_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_4cf592f3-3c43-4c77-9840-df7363523b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_c96dcd33-d99c-44ce-9b6f-0a5a4f06c04d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_cc31b053-1b54-4e0c-930a-5b8fc6b83f44" xlink:to="loc_ifrs-full_InterestExpense_c96dcd33-d99c-44ce-9b6f-0a5a4f06c04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_722535c0-02e4-4805-b39f-dcf46179fd0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_bd5c6ee6-387a-4e3e-a9b1-7094ec07c98f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_722535c0-02e4-4805-b39f-dcf46179fd0b" xlink:to="loc_ifrs-full_WagesAndSalaries_bd5c6ee6-387a-4e3e-a9b1-7094ec07c98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DefinedContributionSuperannuationExpenses_d6d7200f-458d-49a5-977a-a09ed428345e" xlink:href="meso-20231231.xsd#meso_DefinedContributionSuperannuationExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_722535c0-02e4-4805-b39f-dcf46179fd0b" xlink:to="loc_meso_DefinedContributionSuperannuationExpenses_d6d7200f-458d-49a5-977a-a09ed428345e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_2203f1e6-6e4b-4f8a-942f-4e2e1c8d4067" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense_722535c0-02e4-4805-b39f-dcf46179fd0b" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_2203f1e6-6e4b-4f8a-942f-4e2e1c8d4067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsideration_da7a41c7-05ef-4230-bdc7-795fbe0e6f2c" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfContingentConsideration_60354716-21f5-461c-a9e2-6693ff175724" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfContingentConsideration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_FairValueRemeasurementOfContingentConsideration_da7a41c7-05ef-4230-bdc7-795fbe0e6f2c" xlink:to="loc_meso_LossGainOnRemeasurementOfContingentConsideration_60354716-21f5-461c-a9e2-6693ff175724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_a217f53a-88f5-4a0b-80ab-b6d1bd47862b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_deaf23f2-c525-4a45-b258-e2cc4f2ce303" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AmortisationExpense_a217f53a-88f5-4a0b-80ab-b6d1bd47862b" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_deaf23f2-c525-4a45-b258-e2cc4f2ce303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_d49ccbdc-9259-41c3-b4c0-1b4da9f90fde" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AmortisationExpense_a217f53a-88f5-4a0b-80ab-b6d1bd47862b" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_d49ccbdc-9259-41c3-b4c0-1b4da9f90fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntellectualPropertyAmortization_8fef455d-6218-4268-bfe4-1a4c575d8cb4" xlink:href="meso-20231231.xsd#meso_IntellectualPropertyAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_AmortisationExpense_a217f53a-88f5-4a0b-80ab-b6d1bd47862b" xlink:to="loc_meso_IntellectualPropertyAmortization_8fef455d-6218-4268-bfe4-1a4c575d8cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_9ff68cb0-655b-4347-abce-4dd8f39f9b52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ForeignExchangeGainsLosses_6ed6e249-110d-492b-80e1-1a84be6727ab" xlink:href="meso-20231231.xsd#meso_ForeignExchangeGainsLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense_9ff68cb0-655b-4347-abce-4dd8f39f9b52" xlink:to="loc_meso_ForeignExchangeGainsLosses_6ed6e249-110d-492b-80e1-1a84be6727ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_75311c7b-e8a8-4c4c-a94e-9460b0eeb363" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense_9ff68cb0-655b-4347-abce-4dd8f39f9b52" xlink:to="loc_ifrs-full_RevenueFromInterest_75311c7b-e8a8-4c4c-a94e-9460b0eeb363" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_adcf7b3d-cba7-4175-bf98-92b420b9b488" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_509476b3-dd39-49dd-bacf-dae01a3a7097" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_adcf7b3d-cba7-4175-bf98-92b420b9b488" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_509476b3-dd39-49dd-bacf-dae01a3a7097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_72b61bad-a468-4a77-b417-e81176873114" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInDeferredTaxAssets_f8e37faa-7530-4cc9-b0d2-de255e8bd449" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInDeferredTaxAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_72b61bad-a468-4a77-b417-e81176873114" xlink:to="loc_meso_IncreaseDecreaseInDeferredTaxAssets_f8e37faa-7530-4cc9-b0d2-de255e8bd449" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInDeferredTaxLiabilities_834eff0f-a528-460a-87fc-1ff5e1aade11" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_72b61bad-a468-4a77-b417-e81176873114" xlink:to="loc_meso_IncreaseDecreaseInDeferredTaxLiabilities_834eff0f-a528-460a-87fc-1ff5e1aade11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_f181f663-8af0-47e4-b4e7-47b7be4e641a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInCurrentTax_331c7a15-afc3-4b0f-b157-6020a923bdc3" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInCurrentTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_f181f663-8af0-47e4-b4e7-47b7be4e641a" xlink:to="loc_meso_IncreaseDecreaseInCurrentTax_331c7a15-afc3-4b0f-b157-6020a923bdc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccount_0f7f691b-dccc-4cf8-ace9-e99decef1986" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_c23170d5-2d42-40e0-ab3f-e9737bbf11a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccount_0f7f691b-dccc-4cf8-ace9-e99decef1986" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_c23170d5-2d42-40e0-ab3f-e9737bbf11a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_dc416293-5329-4337-9d23-c8faf9cc55da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccount_0f7f691b-dccc-4cf8-ace9-e99decef1986" xlink:to="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_dc416293-5329-4337-9d23-c8faf9cc55da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_8088e070-3c6e-4984-93b6-4856475fc724" xlink:href="meso-20231231.xsd#meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccount_0f7f691b-dccc-4cf8-ace9-e99decef1986" xlink:to="loc_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_8088e070-3c6e-4984-93b6-4856475fc724" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_764cd067-105d-4cf2-8583-6b57fec6cffd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_bbec024b-d7c6-4c78-9ebe-1344b52445da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssets_764cd067-105d-4cf2-8583-6b57fec6cffd" xlink:to="loc_ifrs-full_CashAndCashEquivalents_bbec024b-d7c6-4c78-9ebe-1344b52445da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_20acd511-7420-4b93-a019-c5e4acd5c473" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssets_764cd067-105d-4cf2-8583-6b57fec6cffd" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_20acd511-7420-4b93-a019-c5e4acd5c473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_13080370-9959-48d8-97b8-867030b5f34d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssets_764cd067-105d-4cf2-8583-6b57fec6cffd" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_13080370-9959-48d8-97b8-867030b5f34d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_a238a58c-5775-4eab-8f27-25f63b42844a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialAssets_764cd067-105d-4cf2-8583-6b57fec6cffd" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_a238a58c-5775-4eab-8f27-25f63b42844a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_87f973e2-161a-46b6-bdca-e50275a4721d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_62c43266-8e9d-4618-a6a2-2df94a009873" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_87f973e2-161a-46b6-bdca-e50275a4721d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_62c43266-8e9d-4618-a6a2-2df94a009873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_55da4f99-3b46-4129-bc80-5012cf4b8b8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_87f973e2-161a-46b6-bdca-e50275a4721d" xlink:to="loc_ifrs-full_Borrowings_55da4f99-3b46-4129-bc80-5012cf4b8b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_09efdb12-7105-458d-9621-a2a5b193a604" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_87f973e2-161a-46b6-bdca-e50275a4721d" xlink:to="loc_meso_ContingentConsiderations_09efdb12-7105-458d-9621-a2a5b193a604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_461108ef-2bbf-40cc-bbd1-cb6a31f0aa7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilities_87f973e2-161a-46b6-bdca-e50275a4721d" xlink:to="loc_ifrs-full_WarrantLiability_461108ef-2bbf-40cc-bbd1-cb6a31f0aa7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_968a5260-2a03-4a40-9d2a-a1d7a7f59189" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BalancesWithBanks_b7bf0da4-78b7-4ccf-b29b-61b123f3837a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_968a5260-2a03-4a40-9d2a-a1d7a7f59189" xlink:to="loc_ifrs-full_BalancesWithBanks_b7bf0da4-78b7-4ccf-b29b-61b123f3837a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DepositsAtCall_583d92c5-b64e-43d9-8fff-351c74861c0c" xlink:href="meso-20231231.xsd#meso_DepositsAtCall"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_968a5260-2a03-4a40-9d2a-a1d7a7f59189" xlink:to="loc_meso_DepositsAtCall_583d92c5-b64e-43d9-8fff-351c74861c0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ForeignWithholdingTaxRecoverable_a53db364-52d5-43df-bbbe-6c50f19359c3" xlink:href="meso-20231231.xsd#meso_ForeignWithholdingTaxRecoverable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_meso_ForeignWithholdingTaxRecoverable_a53db364-52d5-43df-bbbe-6c50f19359c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ReceivableFromTaxCredits_c73fa8bc-aeb3-4a55-a06f-c8391b2cf68a" xlink:href="meso-20231231.xsd#meso_ReceivableFromTaxCredits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_meso_ReceivableFromTaxCredits_c73fa8bc-aeb3-4a55-a06f-c8391b2cf68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_b6e6a749-dedb-45ce-985e-5529d726e78d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_b6e6a749-dedb-45ce-985e-5529d726e78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivables_78aad339-ed3b-4aa4-9bbb-3acc793c62ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_ifrs-full_TradeReceivables_78aad339-ed3b-4aa4-9bbb-3acc793c62ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInterestReceivable_07823125-c7f3-4d34-9738-7f140b8061c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_ifrs-full_CurrentInterestReceivable_07823125-c7f3-4d34-9738-7f140b8061c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_f019b1d9-96f1-4218-8731-7d249c06076f" xlink:href="meso-20231231.xsd#meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_f019b1d9-96f1-4218-8731-7d249c06076f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetInvestmentInFinanceLease_03bca2f2-2a1e-40fc-bdf1-6fe05dda9239" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetInvestmentInFinanceLease"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables_fa8537ac-be17-4344-9bf9-bd4b2201748d" xlink:to="loc_ifrs-full_NetInvestmentInFinanceLease_03bca2f2-2a1e-40fc-bdf1-6fe05dda9239" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofPrepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_a49e80b0-b22c-4254-87fd-7fe113dcaff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalTrialResearchAndDevelopmentExpenditure_ed686370-dbd6-46ac-86ec-a401e7848ab6" xlink:href="meso-20231231.xsd#meso_ClinicalTrialResearchAndDevelopmentExpenditure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Prepayments_a49e80b0-b22c-4254-87fd-7fe113dcaff2" xlink:to="loc_meso_ClinicalTrialResearchAndDevelopmentExpenditure_ed686370-dbd6-46ac-86ec-a401e7848ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrepaidInsuranceAndSubscriptions_7255b2fa-3471-49fb-bdc5-149335f9d607" xlink:href="meso-20231231.xsd#meso_PrepaidInsuranceAndSubscriptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Prepayments_a49e80b0-b22c-4254-87fd-7fe113dcaff2" xlink:to="loc_meso_PrepaidInsuranceAndSubscriptions_7255b2fa-3471-49fb-bdc5-149335f9d607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherPrepayments_46196e40-6474-44c2-b762-e6d3533a2bfd" xlink:href="meso-20231231.xsd#meso_OtherPrepayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Prepayments_a49e80b0-b22c-4254-87fd-7fe113dcaff2" xlink:to="loc_meso_OtherPrepayments_46196e40-6474-44c2-b762-e6d3533a2bfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_2498830e-3275-4ba0-93b3-532b5e91f7f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermBorrowings_c2c36bcd-db81-440a-8d3b-4644eb42bd92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_2498830e-3275-4ba0-93b3-532b5e91f7f5" xlink:to="loc_ifrs-full_ShorttermBorrowings_c2c36bcd-db81-440a-8d3b-4644eb42bd92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_74c2795c-0bd4-4bf0-8e94-5cbb290be578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Borrowings_2498830e-3275-4ba0-93b3-532b5e91f7f5" xlink:to="loc_ifrs-full_LongtermBorrowings_74c2795c-0bd4-4bf0-8e94-5cbb290be578" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofNetDebtDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt_ad709fa1-e056-4c90-8f17-4232c0c2bfe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_40fe767a-3c2d-4a68-adfe-8596c0dbcbec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDebt_ad709fa1-e056-4c90-8f17-4232c0c2bfe9" xlink:to="loc_ifrs-full_CashAndCashEquivalents_40fe767a-3c2d-4a68-adfe-8596c0dbcbec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_cdad89df-ab12-486e-ae5a-746bdf825738" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDebt_ad709fa1-e056-4c90-8f17-4232c0c2bfe9" xlink:to="loc_ifrs-full_Borrowings_cdad89df-ab12-486e-ae5a-746bdf825738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_4497ca20-df1e-4aff-8c49-1223c710dc9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDebt_ad709fa1-e056-4c90-8f17-4232c0c2bfe9" xlink:to="loc_ifrs-full_LeaseLiabilities_4497ca20-df1e-4aff-8c49-1223c710dc9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_db72db55-9616-4cc2-b8c5-18aeecbee8a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDebt_ad709fa1-e056-4c90-8f17-4232c0c2bfe9" xlink:to="loc_ifrs-full_WarrantLiability_db72db55-9616-4cc2-b8c5-18aeecbee8a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt_fe9ae278-37d8-4a0a-bf74-0ae4f384942c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_de934a59-de55-4061-a1f7-ca04088213da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDebt_fe9ae278-37d8-4a0a-bf74-0ae4f384942c" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_de934a59-de55-4061-a1f7-ca04088213da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_45126e24-cce8-467b-ab5f-4a71793c18c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDebt_fe9ae278-37d8-4a0a-bf74-0ae4f384942c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_45126e24-cce8-467b-ab5f-4a71793c18c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_ce0edbeb-a747-4e5c-b820-47ff5ba42f7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_dba1e3d3-2f26-4c98-b25a-12ef306785fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_ce0edbeb-a747-4e5c-b820-47ff5ba42f7c" xlink:to="loc_ifrs-full_WarrantLiability_dba1e3d3-2f26-4c98-b25a-12ef306785fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_d88ff0f2-e6ca-4b56-af05-bc5e18bca098" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_ce0edbeb-a747-4e5c-b820-47ff5ba42f7c" xlink:to="loc_ifrs-full_LeaseLiabilities_d88ff0f2-e6ca-4b56-af05-bc5e18bca098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_303d0a69-3f5d-47e0-946e-cd3e8b75f980" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_ce0edbeb-a747-4e5c-b820-47ff5ba42f7c" xlink:to="loc_ifrs-full_Borrowings_303d0a69-3f5d-47e0-946e-cd3e8b75f980" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_73821dad-dcd7-460d-abd5-29080d25eb60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_2e70f2af-24d7-4acf-8746-6e263351fa4b" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue_73821dad-dcd7-460d-abd5-29080d25eb60" xlink:to="loc_meso_ContingentConsiderations_2e70f2af-24d7-4acf-8746-6e263351fa4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_c3113e93-7fba-4afc-baaa-74370c15322d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue_73821dad-dcd7-460d-abd5-29080d25eb60" xlink:to="loc_ifrs-full_WarrantLiability_c3113e93-7fba-4afc-baaa-74370c15322d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_1b22d5c0-cbd7-45ca-921d-6231808a59b6" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CashOrStockPayableAtFairValueLiabilities_6729a50f-271e-4e1d-9dec-e8748c0eadb3" xlink:href="meso-20231231.xsd#meso_CashOrStockPayableAtFairValueLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_ContingentConsiderations_1b22d5c0-cbd7-45ca-921d-6231808a59b6" xlink:to="loc_meso_CashOrStockPayableAtFairValueLiabilities_6729a50f-271e-4e1d-9dec-e8748c0eadb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RoyaltyPaymentsAtFairValueLiabilities_a7b6908b-ab3b-40ca-aacc-a316ad8b2eef" xlink:href="meso-20231231.xsd#meso_RoyaltyPaymentsAtFairValueLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_ContingentConsiderations_1b22d5c0-cbd7-45ca-921d-6231808a59b6" xlink:to="loc_meso_RoyaltyPaymentsAtFairValueLiabilities_a7b6908b-ab3b-40ca-aacc-a316ad8b2eef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_2c03ca99-4658-4a89-b8ac-617d2f28e689" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_ece29de1-461e-43cf-9ae4-04fb4a8ea819" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_2c03ca99-4658-4a89-b8ac-617d2f28e689" xlink:to="loc_ifrs-full_CurrentProvisions_ece29de1-461e-43cf-9ae4-04fb4a8ea819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_7151d034-fcc5-4d97-9f56-91fbf1d50659" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Provisions_2c03ca99-4658-4a89-b8ac-617d2f28e689" xlink:to="loc_ifrs-full_NoncurrentProvisions_7151d034-fcc5-4d97-9f56-91fbf1d50659" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_10a87dd0-fd13-44c1-afde-67a1283d1f76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_d531e78a-aa93-48ad-b638-c09ccab9e40d" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxAssets_10a87dd0-fd13-44c1-afde-67a1283d1f76" xlink:to="loc_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_d531e78a-aa93-48ad-b638-c09ccab9e40d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_1001b358-98eb-44e0-b3d2-429bcd899d43" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxAssets_10a87dd0-fd13-44c1-afde-67a1283d1f76" xlink:to="loc_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_1001b358-98eb-44e0-b3d2-429bcd899d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_b2e8aa36-82d6-4272-bd8f-723a5c558af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_2e10c265-1343-43bd-add3-b62204a0dfcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDeferredTaxLiabilities_b2e8aa36-82d6-4272-bd8f-723a5c558af4" xlink:to="loc_ifrs-full_DeferredTaxAssets_2e10c265-1343-43bd-add3-b62204a0dfcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_fd51cdb6-1d0a-4723-a7ae-53f641478955" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetDeferredTaxLiabilities_b2e8aa36-82d6-4272-bd8f-723a5c558af4" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_fd51cdb6-1d0a-4723-a7ae-53f641478955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_d93934dc-7580-44e1-bae5-2cf6ae6e4f6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_27dabffd-ef72-4c1c-b1f1-3486694e5fae" xlink:href="meso-20231231.xsd#meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxLiabilities_d93934dc-7580-44e1-bae5-2cf6ae6e4f6f" xlink:to="loc_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_27dabffd-ef72-4c1c-b1f1-3486694e5fae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/CashflowinformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#CashflowinformationDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/CashflowinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_92ab4afe-42df-4365-875c-46571991ba34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_92ab4afe-42df-4365-875c-46571991ba34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_b2f32654-89bb-498c-b73b-3d1f107eb47b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_b2f32654-89bb-498c-b73b-3d1f107eb47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_e4687808-1318-45c4-80d9-99c789855135" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_e4687808-1318-45c4-80d9-99c789855135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_14229ade-ed7f-408c-81b6-8c538a6e4f7b" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsiderationAfterTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_14229ade-ed7f-408c-81b6-8c538a6e4f7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdjustmentsForIncreaseDecreaseInPrepayments_46bcb96c-3b25-48f9-ab1e-73c745c3f21e" xlink:href="meso-20231231.xsd#meso_AdjustmentsForIncreaseDecreaseInPrepayments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_meso_AdjustmentsForIncreaseDecreaseInPrepayments_46bcb96c-3b25-48f9-ab1e-73c745c3f21e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_2a9d153d-cf22-4bdd-863b-06c8d41f744b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_2a9d153d-cf22-4bdd-863b-06c8d41f744b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncomeCost_f9bfd625-d462-4722-92f9-f432328c7d49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncomeCost_f9bfd625-d462-4722-92f9-f432328c7d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_3297fd50-f5b1-4c44-96ca-34ef1e7a305d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_3297fd50-f5b1-4c44-96ca-34ef1e7a305d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_9749b145-7c4c-46c4-90d1-722d0aa000a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_9749b145-7c4c-46c4-90d1-722d0aa000a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementOfWarrantLiability_59afe5b0-1afa-48f2-8721-f307dec4a756" xlink:href="meso-20231231.xsd#meso_RemeasurementOfWarrantLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_meso_RemeasurementOfWarrantLiability_59afe5b0-1afa-48f2-8721-f307dec4a756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_703a42b0-2eec-4c2c-8ea5-839081079759" xlink:href="meso-20231231.xsd#meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_703a42b0-2eec-4c2c-8ea5-839081079759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_36c61322-490c-43e8-94a3-5d8521f015de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_36c61322-490c-43e8-94a3-5d8521f015de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_aa74dfbd-44ef-49ee-a1e8-5f7911aaef2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_60a8cf26-7c24-402b-b5a0-bfc52a7569fe" xlink:to="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_aa74dfbd-44ef-49ee-a1e8-5f7911aaef2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquityScheduleofShareCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_67774461-3587-4b05-8074-dd4108e03489" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OrdinarySharesPurchasedValue_eec388e0-1495-4bc6-aefe-1711140c1c74" xlink:href="meso-20231231.xsd#meso_OrdinarySharesPurchasedValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_67774461-3587-4b05-8074-dd4108e03489" xlink:to="loc_meso_OrdinarySharesPurchasedValue_eec388e0-1495-4bc6-aefe-1711140c1c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchasedValue_b02fd792-1020-40f9-bc20-19f6aa4570e0" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchasedValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_67774461-3587-4b05-8074-dd4108e03489" xlink:to="loc_meso_TreasurySharesPurchasedValue_b02fd792-1020-40f9-bc20-19f6aa4570e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_96a0703f-66fe-4a59-aec4-70fa304a4700" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_fa036e58-8d2d-4d19-879d-103d02b17fc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_96a0703f-66fe-4a59-aec4-70fa304a4700" xlink:to="loc_ifrs-full_NumberOfSharesIssued_fa036e58-8d2d-4d19-879d-103d02b17fc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchased_9c717d71-0a74-4d26-80dc-cc44f085ced9" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchased"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding_96a0703f-66fe-4a59-aec4-70fa304a4700" xlink:to="loc_meso_TreasurySharesPurchased_9c717d71-0a74-4d26-80dc-cc44f085ced9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsinOrdinaryShareCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfEquityDuringPeriod_2fdcb146-02fb-46e4-b35d-d4a12ec5feb3" xlink:href="meso-20231231.xsd#meso_ContributionsOfEquityDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssueShare_8bd36061-1ab0-416a-b823-4fc365941529" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssueShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_ContributionsOfEquityDuringPeriod_2fdcb146-02fb-46e4-b35d-d4a12ec5feb3" xlink:to="loc_meso_TransactionCostsArisingOnShareIssueShare_8bd36061-1ab0-416a-b823-4fc365941529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan_47e56414-56ad-4ba5-9d48-b53fde78432b" xlink:href="meso-20231231.xsd#meso_SharesAvailableForIssuanceUnderIssuancePlan"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_ContributionsOfEquityDuringPeriod_2fdcb146-02fb-46e4-b35d-d4a12ec5feb3" xlink:to="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan_47e56414-56ad-4ba5-9d48-b53fde78432b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfValueForEquityDuringPeriod_2b37125b-1a84-4a21-950d-dd4690640275" xlink:href="meso-20231231.xsd#meso_ContributionsOfValueForEquityDuringPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesIssuedInPlacementsValue_c0440d90-fae8-4ce2-bf0c-50ee010a7800" xlink:href="meso-20231231.xsd#meso_SharesIssuedInPlacementsValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_ContributionsOfValueForEquityDuringPeriod_2b37125b-1a84-4a21-950d-dd4690640275" xlink:to="loc_meso_SharesIssuedInPlacementsValue_c0440d90-fae8-4ce2-bf0c-50ee010a7800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssue_e98eb013-4a88-4246-9044-a05dd4d56f5e" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_ContributionsOfValueForEquityDuringPeriod_2b37125b-1a84-4a21-950d-dd4690640275" xlink:to="loc_meso_TransactionCostsArisingOnShareIssue_e98eb013-4a88-4246-9044-a05dd4d56f5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInBorrowings_9e65ce00-0dd7-48c2-aeca-19083405e606" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInBorrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings_14623d7a-9bb2-459a-8f86-40c8bf6ff180" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInCurrentBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_PercentageOfPriceRateChangesInBorrowings_9e65ce00-0dd7-48c2-aeca-19083405e606" xlink:to="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings_14623d7a-9bb2-459a-8f86-40c8bf6ff180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_d38ca7a5-1e67-44fe-8128-83109a9a8700" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInNonCurrentBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_meso_PercentageOfPriceRateChangesInBorrowings_9e65ce00-0dd7-48c2-aeca-19083405e606" xlink:to="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_d38ca7a5-1e67-44fe-8128-83109a9a8700" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossespershareDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossespershareDetails"/>
  <link:calculationLink xlink:role="http://www.mesoblast.com/role/LossespershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_7190eda7-8d1c-456f-97be-5df3ab832ebe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_b2721d4f-dde9-4d82-b33c-472193ac8564" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare_7190eda7-8d1c-456f-97be-5df3ab832ebe" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_b2721d4f-dde9-4d82-b33c-472193ac8564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_b769b362-e3aa-49ca-a252-1683edc3ffc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_aa3b8802-88cb-4a99-bfde-f0688f2d4f52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_b769b362-e3aa-49ca-a252-1683edc3ffc1" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_aa3b8802-88cb-4a99-bfde-f0688f2d4f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_0b1714c5-e083-468a-9e02-6dfa35126d9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_b3851372-14f9-48ed-bc6c-db6ba80d2cb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare_0b1714c5-e083-468a-9e02-6dfa35126d9a" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_b3851372-14f9-48ed-bc6c-db6ba80d2cb3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>meso-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1c79165c-755b-4603-a45e-827a45827c07,g:19d448ab-9536-4f20-ab7d-76d6f5e0018c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofChangesinEquity"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_9f557775-77c4-4a1b-a9f9-8f8d32b533be_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:to="loc_ifrs-full_EquityMember_9f557775-77c4-4a1b-a9f9-8f8d32b533be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:to="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_d04fe5b2-b43b-4ca1-8f64-df85a7133756" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_IssuedCapitalMember_d04fe5b2-b43b-4ca1-8f64-df85a7133756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember_09fbf569-d408-44ca-abe4-112f2ac7ad7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember_09fbf569-d408-44ca-abe4-112f2ac7ad7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InvestmentRevaluationReserveMember_f08a322d-5005-4d9b-978d-803f8928de71" xlink:href="meso-20231231.xsd#meso_InvestmentRevaluationReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_meso_InvestmentRevaluationReserveMember_f08a322d-5005-4d9b-978d-803f8928de71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_810e5fa0-ce17-4774-8065-7f5c7b1aea8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_810e5fa0-ce17-4774-8065-7f5c7b1aea8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_f171c6fa-9b47-4db9-a950-400a523d5a9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_f171c6fa-9b47-4db9-a950-400a523d5a9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_5291c7f9-9a43-4003-bdfa-92fb4b145ce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_RetainedEarningsMember_5291c7f9-9a43-4003-bdfa-92fb4b145ce1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5266eac8-40d7-4fbf-9615-775262ed6108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_Equity_5266eac8-40d7-4fbf-9615-775262ed6108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_283606ab-2922-48c1-a280-eee0821c1dfa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_ProfitLoss_283606ab-2922-48c1-a280-eee0821c1dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_c925120e-6fdd-427d-b48a-df1a637509bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_c925120e-6fdd-427d-b48a-df1a637509bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_a2e11668-6cfc-491f-89e4-aae421324745" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_ComprehensiveIncome_a2e11668-6cfc-491f-89e4-aae421324745" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_585e5e83-5418-4cda-a6e7-cbb91cf90089" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_585e5e83-5418-4cda-a6e7-cbb91cf90089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_0af9b525-50a7-4e27-9a9e-bb120a8ae5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_0af9b525-50a7-4e27-9a9e-bb120a8ae5f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxCreditedOrDebitedToEquity_673a3d78-8f76-424b-bd48-63e5a43fdaaa" xlink:href="meso-20231231.xsd#meso_TaxCreditedOrDebitedToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_meso_TaxCreditedOrDebitedToEquity_673a3d78-8f76-424b-bd48-63e5a43fdaaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_12ad226c-ea65-418b-984f-2eafb52a8fae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_12ad226c-ea65-418b-984f-2eafb52a8fae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_73c26a43-9707-4c49-84f6-64355f0fd96f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_73c26a43-9707-4c49-84f6-64355f0fd96f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_18364871-a0ab-4361-9669-4d516d25c6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_ChangesInEquity_18364871-a0ab-4361-9669-4d516d25c6e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5c661a98-a4b4-4143-be19-babc7f01b701" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#SignificantchangesinthecurrentreportingperiodDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_6f63899b-3331-4140-8aeb-251444d4c323_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:to="loc_ifrs-full_EquityMember_6f63899b-3331-4140-8aeb-251444d4c323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b76af15f-5a9b-47f1-8bc0-6326a7e2bba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:to="loc_ifrs-full_EquityMember_b76af15f-5a9b-47f1-8bc0-6326a7e2bba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember_7f48f602-5361-460b-908b-603229a55107" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_b76af15f-5a9b-47f1-8bc0-6326a7e2bba8" xlink:to="loc_meso_PrivatePlacementOfSharesMember_7f48f602-5361-460b-908b-603229a55107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConversionRatioOfWarrants_083aeb8d-6b71-43e9-bfdf-db9905bab77d" xlink:href="meso-20231231.xsd#meso_ConversionRatioOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_ConversionRatioOfWarrants_083aeb8d-6b71-43e9-bfdf-db9905bab77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfSharesIssuedAndFullyPaidValue_0cac9dd7-aef5-4ffd-bb14-405ef3f60989" xlink:href="meso-20231231.xsd#meso_NumberOfSharesIssuedAndFullyPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_NumberOfSharesIssuedAndFullyPaidValue_0cac9dd7-aef5-4ffd-bb14-405ef3f60989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_e13533f8-bede-41f6-aab4-e3ff39629cd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_ifrs-full_ParValuePerShare_e13533f8-bede-41f6-aab4-e3ff39629cd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProceedsFromPrivatePlacement_10d5266d-0980-4d69-9b39-5df83d79b21f" xlink:href="meso-20231231.xsd#meso_ProceedsFromPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_ProceedsFromPrivatePlacement_10d5266d-0980-4d69-9b39-5df83d79b21f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem_f8d8f4af-244a-4f34-8688-17d50c18fa42" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxLineItem"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem_f8d8f4af-244a-4f34-8688-17d50c18fa42" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:to="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationMember_addc27a5-326f-4dd1-9217-807f3c0ec67d_default" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:to="loc_meso_IncomeStatementLocationMember_addc27a5-326f-4dd1-9217-807f3c0ec67d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationMember_d29fdd81-4f15-4515-a237-143f2cd354da" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:to="loc_meso_IncomeStatementLocationMember_d29fdd81-4f15-4515-a237-143f2cd354da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementFunctionalExpenseCategoriesMember_c63fef9a-7cb8-40e9-a3f2-083c227f6b2e" xlink:href="meso-20231231.xsd#meso_IncomeStatementFunctionalExpenseCategoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_IncomeStatementLocationMember_d29fdd81-4f15-4515-a237-143f2cd354da" xlink:to="loc_meso_IncomeStatementFunctionalExpenseCategoriesMember_c63fef9a-7cb8-40e9-a3f2-083c227f6b2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f5681258-bdd6-4461-980a-bad580b2251f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f5681258-bdd6-4461-980a-bad580b2251f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ResearchAndDevelopmentMember_bfb228a3-a9fc-4925-8a40-3ba380f4b1b8" xlink:href="meso-20231231.xsd#meso_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:to="loc_meso_ResearchAndDevelopmentMember_bfb228a3-a9fc-4925-8a40-3ba380f4b1b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingAndCommercializationMember_1d78e193-e9d9-44ac-b831-8c4937018135" xlink:href="meso-20231231.xsd#meso_ManufacturingAndCommercializationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:to="loc_meso_ManufacturingAndCommercializationMember_1d78e193-e9d9-44ac-b831-8c4937018135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManagementAndAdministrationMember_9980bd14-8696-4b39-91b2-cc9550dc62d2" xlink:href="meso-20231231.xsd#meso_ManagementAndAdministrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:to="loc_meso_ManagementAndAdministrationMember_9980bd14-8696-4b39-91b2-cc9550dc62d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_62e736c6-ce8f-45ca-b96b-0315472026c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem_f8d8f4af-244a-4f34-8688-17d50c18fa42" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_62e736c6-ce8f-45ca-b96b-0315472026c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_4f912fbd-dce6-4198-9955-dc2b9f612a63_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:to="loc_ifrs-full_CounterpartiesMember_4f912fbd-dce6-4198-9955-dc2b9f612a63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:to="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GrunenthalGmbHMember_9ce5b7b5-183b-48a7-9507-b338e0086f1b" xlink:href="meso-20231231.xsd#meso_GrunenthalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_GrunenthalGmbHMember_9ce5b7b5-183b-48a7-9507-b338e0086f1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaslyMember_125bc0e4-d6a3-4758-9b46-0770bcf5e310" xlink:href="meso-20231231.xsd#meso_TaslyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_TaslyMember_125bc0e4-d6a3-4758-9b46-0770bcf5e310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TiGenixNVMember_d91afdc5-2b57-40b3-8a90-181f75fb68f1" xlink:href="meso-20231231.xsd#meso_TiGenixNVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_TiGenixNVMember_d91afdc5-2b57-40b3-8a90-181f75fb68f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_JCRPharmaceuticalsCoLTDMember_1503e4b4-c51a-493f-bd3e-6b790e6c28e9" xlink:href="meso-20231231.xsd#meso_JCRPharmaceuticalsCoLTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_JCRPharmaceuticalsCoLTDMember_1503e4b4-c51a-493f-bd3e-6b790e6c28e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_36a0f35a-4ba5-4ae0-90c9-beddf07a4852_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:to="loc_ifrs-full_RangesMember_36a0f35a-4ba5-4ae0-90c9-beddf07a4852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5adba0d5-6b42-4bc4-9864-7ca92a518e8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:to="loc_ifrs-full_RangesMember_5adba0d5-6b42-4bc4-9864-7ca92a518e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_fcd782e5-bb64-4335-8bc2-b9d62e1f1c75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_5adba0d5-6b42-4bc4-9864-7ca92a518e8c" xlink:to="loc_ifrs-full_TopOfRangeMember_fcd782e5-bb64-4335-8bc2-b9d62e1f1c75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsMember_40bfc317-a425-4548-b80e-debef8792fd4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:to="loc_ifrs-full_RegulatoryEnvironmentsMember_40bfc317-a425-4548-b80e-debef8792fd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsMember_d3cf1a38-ec91-4ed2-9fc8-2fb22e5104e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:to="loc_ifrs-full_RegulatoryEnvironmentsMember_d3cf1a38-ec91-4ed2-9fc8-2fb22e5104e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_765d005c-9fbb-4ca3-81f1-b0e98a05d692" xlink:href="meso-20231231.xsd#meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsMember_d3cf1a38-ec91-4ed2-9fc8-2fb22e5104e8" xlink:to="loc_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_765d005c-9fbb-4ca3-81f1-b0e98a05d692" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_b629f12a-b3eb-4421-95c6-bb62a73671b7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:to="loc_ifrs-full_ProductsAndServicesMember_b629f12a-b3eb-4421-95c6-bb62a73671b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:to="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingCommercializationExpensesMember_4851fef9-2cc2-4490-ba6b-76a0b133c805" xlink:href="meso-20231231.xsd#meso_ManufacturingCommercializationExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:to="loc_meso_ManufacturingCommercializationExpensesMember_4851fef9-2cc2-4490-ba6b-76a0b133c805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_License1Member_95b853d4-d6ad-430b-86b1-500458f8576b" xlink:href="meso-20231231.xsd#meso_License1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:to="loc_meso_License1Member_95b853d4-d6ad-430b-86b1-500458f8576b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonRefundableUpFrontPaymentReceived_3b61cc22-d751-46ac-8d4a-edf14ad7e379" xlink:href="meso-20231231.xsd#meso_NonRefundableUpFrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_NonRefundableUpFrontPaymentReceived_3b61cc22-d751-46ac-8d4a-edf14ad7e379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MilestonePaymentReceived_cd1a6228-54ad-4992-88e9-f449275b1c7d" xlink:href="meso-20231231.xsd#meso_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_MilestonePaymentReceived_cd1a6228-54ad-4992-88e9-f449275b1c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_c1861b26-f045-4306-a7b6-f40a80ae1924" xlink:href="meso-20231231.xsd#meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_c1861b26-f045-4306-a7b6-f40a80ae1924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_d7f64243-4e36-4d7c-8dc4-acc22011fb41" xlink:href="meso-20231231.xsd#meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_d7f64243-4e36-4d7c-8dc4-acc22011fb41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonRefundableUpfrontPaymentsReceivable_869b0caa-efa5-4a63-9f53-fa7e2128194c" xlink:href="meso-20231231.xsd#meso_NonRefundableUpfrontPaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_NonRefundableUpfrontPaymentsReceivable_869b0caa-efa5-4a63-9f53-fa7e2128194c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CumulativeMilestonePaymentsReachableAmount_3331e9d0-897a-4e6f-8c25-e8e48722eda5" xlink:href="meso-20231231.xsd#meso_CumulativeMilestonePaymentsReachableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_CumulativeMilestonePaymentsReachableAmount_3331e9d0-897a-4e6f-8c25-e8e48722eda5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRecognizedForRightOfUseLicenseOfIP_8120ac3c-85bb-44e2-9b8d-4933646b48b7" xlink:href="meso-20231231.xsd#meso_RevenueRecognizedForRightOfUseLicenseOfIP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RevenueRecognizedForRightOfUseLicenseOfIP_8120ac3c-85bb-44e2-9b8d-4933646b48b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredConsiderationMilestoneConsiderationRecognized_f5237afd-e8a8-4ef8-9456-c998a33b4b2b" xlink:href="meso-20231231.xsd#meso_DeferredConsiderationMilestoneConsiderationRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_DeferredConsiderationMilestoneConsiderationRecognized_f5237afd-e8a8-4ef8-9456-c998a33b4b2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_f9a996c4-af51-483f-9943-477bb94bb973" xlink:href="meso-20231231.xsd#meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_f9a996c4-af51-483f-9943-477bb94bb973" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_5ecf22d5-a84a-4110-bf74-b33b153ed58a" xlink:href="meso-20231231.xsd#meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_5ecf22d5-a84a-4110-bf74-b33b153ed58a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfEscalatingMilestonePayments_fc5428af-4842-40c1-a874-86b847586b30" xlink:href="meso-20231231.xsd#meso_NumberOfEscalatingMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_NumberOfEscalatingMilestonePayments_fc5428af-4842-40c1-a874-86b847586b30" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_138d22bc-893d-4c10-9a5e-0f1413cb9ac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_CurrentContractLiabilities_138d22bc-893d-4c10-9a5e-0f1413cb9ac9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_d8fa1ff2-ed53-4d93-8376-9a4d629e0981" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_d8fa1ff2-ed53-4d93-8376-9a4d629e0981" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_a5fc4304-5f9b-483b-a087-05978497ef60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_a5fc4304-5f9b-483b-a087-05978497ef60" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f0590f98-f2ee-456e-bec9-89f08d345a7d" xlink:href="meso-20231231.xsd#meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f0590f98-f2ee-456e-bec9-89f08d345a7d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_38e83159-08b6-4b8a-93e2-08551ca62b21" xlink:href="meso-20231231.xsd#meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_38e83159-08b6-4b8a-93e2-08551ca62b21" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_e1684ed5-7fac-4757-9ed3-e83299a19e92" xlink:href="meso-20231231.xsd#meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_e1684ed5-7fac-4757-9ed3-e83299a19e92" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdditionalPotentialMilestonePaymentsReceivable_8eeb0f4a-e6f0-4418-aa68-d4da2cf3bfa2" xlink:href="meso-20231231.xsd#meso_AdditionalPotentialMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AdditionalPotentialMilestonePaymentsReceivable_8eeb0f4a-e6f0-4418-aa68-d4da2cf3bfa2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_202a034c-5ede-4777-86b0-e2510ff2697d" xlink:href="meso-20231231.xsd#meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_202a034c-5ede-4777-86b0-e2510ff2697d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_165b31a8-6aec-4a8f-bec4-ffa1190c705b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_RevenueFromRoyalties_165b31a8-6aec-4a8f-bec4-ffa1190c705b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RoyaltiesReceivableUnderSalesBasedMilestones_27d41240-1a85-48c2-bd29-582ecc3b3f80" xlink:href="meso-20231231.xsd#meso_RoyaltiesReceivableUnderSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RoyaltiesReceivableUnderSalesBasedMilestones_27d41240-1a85-48c2-bd29-582ecc3b3f80" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PreLaunchInventoryRecognized_5d928f11-bb8c-4d92-af8c-af9f2951a7e6" xlink:href="meso-20231231.xsd#meso_PreLaunchInventoryRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_PreLaunchInventoryRecognized_5d928f11-bb8c-4d92-af8c-af9f2951a7e6" xlink:type="arc" order="21"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_c7a97f50-2aed-4de7-89a5-34cb4feb8d48_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_c7a97f50-2aed-4de7-89a5-34cb4feb8d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1b8cb5d1-b422-49c0-8c71-11136ba150d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1b8cb5d1-b422-49c0-8c71-11136ba150d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_3c4196d9-4036-4c66-adfa-85d34ea363d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1b8cb5d1-b422-49c0-8c71-11136ba150d2" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_3c4196d9-4036-4c66-adfa-85d34ea363d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_bedb3380-a730-424d-941f-878def10fcd9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:to="loc_ifrs-full_FinancialAssetsMember_bedb3380-a730-424d-941f-878def10fcd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_9176772d-19ab-4557-a6e6-75e785275642" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:to="loc_ifrs-full_FinancialAssetsMember_9176772d-19ab-4557-a6e6-75e785275642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_a3334e0f-15f4-4233-889c-135a1e227f10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_9176772d-19ab-4557-a6e6-75e785275642" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_a3334e0f-15f4-4233-889c-135a1e227f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_fcc454fe-6593-4387-955b-900daf925870" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_fcc454fe-6593-4387-955b-900daf925870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_c92d99da-057d-430a-81de-38aa4ddf42cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_fcc454fe-6593-4387-955b-900daf925870" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_c92d99da-057d-430a-81de-38aa4ddf42cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_10942b81-38ec-4d19-932b-b68c1770ba0e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_10942b81-38ec-4d19-932b-b68c1770ba0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_4b9e5166-15c0-45d8-a934-c588c7f9cc40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_4b9e5166-15c0-45d8-a934-c588c7f9cc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_7cac8061-aae7-4747-aad7-1132bfc08c45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_4b9e5166-15c0-45d8-a934-c588c7f9cc40" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_7cac8061-aae7-4747-aad7-1132bfc08c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_98bb122e-4e82-4dd2-a32c-f42ad6bd49b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_CashAndCashEquivalents_98bb122e-4e82-4dd2-a32c-f42ad6bd49b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_da3cfc6b-301d-487b-9f3f-8f02357e41c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_da3cfc6b-301d-487b-9f3f-8f02357e41c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_87897344-5217-45e2-af3d-6026a53f21aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_87897344-5217-45e2-af3d-6026a53f21aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_577da13d-83e6-4070-a160-bddcf8749e53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_577da13d-83e6-4070-a160-bddcf8749e53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_35c2a666-207b-4b8b-8669-537ac35bf342" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_FinancialAssets_35c2a666-207b-4b8b-8669-537ac35bf342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_a1dd5a00-34ee-4a12-9720-60c52140d03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_a1dd5a00-34ee-4a12-9720-60c52140d03c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_793f959a-6ea3-4814-9932-26f39f1a17f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_Borrowings_793f959a-6ea3-4814-9932-26f39f1a17f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_10bdc3f0-dca9-4cd5-96d3-a4962fbef0e4" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_meso_ContingentConsiderations_10bdc3f0-dca9-4cd5-96d3-a4962fbef0e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_1b938f2f-b1e9-48ab-ad53-44af7653d93c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_WarrantLiability_1b938f2f-b1e9-48ab-ad53-44af7653d93c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_5c9efbae-e8fc-4ff3-8221-1b8d1d3c56c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_FinancialLiabilities_5c9efbae-e8fc-4ff3-8221-1b8d1d3c56c4" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ad4bd092-4fd5-4654-85ae-a44ca849cad3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:to="loc_ifrs-full_RangesMember_ad4bd092-4fd5-4654-85ae-a44ca849cad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_9a14cc1a-778a-445d-947b-e7e393366b13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:to="loc_ifrs-full_RangesMember_9a14cc1a-778a-445d-947b-e7e393366b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_444a5724-0c77-499e-b9b6-ef5827d03409" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_9a14cc1a-778a-445d-947b-e7e393366b13" xlink:to="loc_ifrs-full_TopOfRangeMember_444a5724-0c77-499e-b9b6-ef5827d03409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:to="loc_ifrs-full_CounterpartiesMember_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:to="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementLPMember_630c711f-9888-43f3-94ed-6868935e1542" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:to="loc_meso_OaktreeCapitalManagementLPMember_630c711f-9888-43f3-94ed-6868935e1542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NovaQuestCapitalManagementLLCMember_476ab5ab-8409-4638-8024-3ced25163059" xlink:href="meso-20231231.xsd#meso_NovaQuestCapitalManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:to="loc_meso_NovaQuestCapitalManagementLLCMember_476ab5ab-8409-4638-8024-3ced25163059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementMember_13034a70-4633-4cde-883c-c7fac74a4b65" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:to="loc_meso_OaktreeCapitalManagementMember_13034a70-4633-4cde-883c-c7fac74a4b65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationMember_9dee73c0-869d-468d-a646-4cb428ca2ec5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:to="loc_ifrs-full_MethodsOfGenerationMember_9dee73c0-869d-468d-a646-4cb428ca2ec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:to="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TrancheOneMember_81b37fbd-686a-49c1-a116-4f12f1856795" xlink:href="meso-20231231.xsd#meso_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:to="loc_meso_TrancheOneMember_81b37fbd-686a-49c1-a116-4f12f1856795" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_QuarterlyPaymentsMember_b79c1790-7408-461a-a72d-fcf99c73ce78" xlink:href="meso-20231231.xsd#meso_QuarterlyPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:to="loc_meso_QuarterlyPaymentsMember_b79c1790-7408-461a-a72d-fcf99c73ce78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TrancheTwoMember_8461b123-8392-4151-97c0-b28c615aba1f" xlink:href="meso-20231231.xsd#meso_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:to="loc_meso_TrancheTwoMember_8461b123-8392-4151-97c0-b28c615aba1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_d18b0450-d3a4-4024-8449-ea17c2e8a390_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_d18b0450-d3a4-4024-8449-ea17c2e8a390_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_4b4c6da1-6cfe-403b-97b7-e62699779924" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_ifrs-full_WarrantsMember_4b4c6da1-6cfe-403b-97b7-e62699779924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvisionMember_18db1dcb-8639-4a95-b4d6-dcc521b5608d" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_meso_ContingentConsiderationProvisionMember_18db1dcb-8639-4a95-b4d6-dcc521b5608d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_November2021WarrantsMember_c149e25e-0681-45db-b487-53db946fc994" xlink:href="meso-20231231.xsd#meso_November2021WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_meso_November2021WarrantsMember_c149e25e-0681-45db-b487-53db946fc994" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_December2022WarrantsMember_5a166d92-2a6a-4b57-9a6c-bf5d90908b19" xlink:href="meso-20231231.xsd#meso_December2022WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_meso_December2022WarrantsMember_5a166d92-2a6a-4b57-9a6c-bf5d90908b19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:to="loc_ifrs-full_EquityMember_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:to="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmericanDepositarySharesMember_9322e38d-2bb9-43ea-b493-ec06d1d49051" xlink:href="meso-20231231.xsd#meso_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:to="loc_meso_AmericanDepositarySharesMember_9322e38d-2bb9-43ea-b493-ec06d1d49051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmericanDepositoryReceiptMember_d74b9f21-492b-4105-af92-9b863b033bb4" xlink:href="meso-20231231.xsd#meso_AmericanDepositoryReceiptMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:to="loc_meso_AmericanDepositoryReceiptMember_d74b9f21-492b-4105-af92-9b863b033bb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_097b78dc-908e-4ee1-81c2-936dcdcf9507_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_097b78dc-908e-4ee1-81c2-936dcdcf9507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_80c0b3ae-cd1f-4899-aab6-3137b765b527" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_80c0b3ae-cd1f-4899-aab6-3137b765b527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_15145cdb-bba0-4c18-9394-6f6d688194f0" xlink:href="meso-20231231.xsd#meso_RefinancingAndExpansionOfSeniorDebtFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_80c0b3ae-cd1f-4899-aab6-3137b765b527" xlink:to="loc_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_15145cdb-bba0-4c18-9394-6f6d688194f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cd87f22-2c42-4124-b497-7b27126acbe4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:to="loc_srt_RangeMember_0cd87f22-2c42-4124-b497-7b27126acbe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:to="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3abcc8cb-cf27-45dc-9e50-b8d526fb2291" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:to="loc_srt_MaximumMember_3abcc8cb-cf27-45dc-9e50-b8d526fb2291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5eafbc1-3d7d-4e06-ad06-4c875ea50bfd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:to="loc_srt_MinimumMember_e5eafbc1-3d7d-4e06-ad06-4c875ea50bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:to="loc_ifrs-full_InterestRateTypesMember_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_122f29d0-f5fe-45b2-beaf-03895735d751" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:to="loc_ifrs-full_InterestRateTypesMember_122f29d0-f5fe-45b2-beaf-03895735d751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_bdd67d8a-c8fb-42d6-9d6e-e14bede25558" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_122f29d0-f5fe-45b2-beaf-03895735d751" xlink:to="loc_ifrs-full_FixedInterestRateMember_bdd67d8a-c8fb-42d6-9d6e-e14bede25558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_aea2575d-19a1-42b1-9802-c021af9fbbe5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_aea2575d-19a1-42b1-9802-c021af9fbbe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_ca1cfbff-042f-4864-807f-5aa293e7b07d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_ca1cfbff-042f-4864-807f-5aa293e7b07d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_27595878-314b-4b89-bbea-587ea4c160da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_27595878-314b-4b89-bbea-587ea4c160da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_7db7538a-775d-4435-ac0b-dddd2e1ec26d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_7db7538a-775d-4435-ac0b-dddd2e1ec26d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_4c171e95-44ae-46cf-b72c-f2c450dd1b7b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:to="loc_ifrs-full_FinancialAssetsMember_4c171e95-44ae-46cf-b72c-f2c450dd1b7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_7de40fd8-20a3-4327-aeff-541a01f55a60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:to="loc_ifrs-full_FinancialAssetsMember_7de40fd8-20a3-4327-aeff-541a01f55a60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UnlistedEquitySecuritiesMember_e619c480-f12e-4eb7-a386-e58f6c28104b" xlink:href="meso-20231231.xsd#meso_UnlistedEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsMember_7de40fd8-20a3-4327-aeff-541a01f55a60" xlink:to="loc_meso_UnlistedEquitySecuritiesMember_e619c480-f12e-4eb7-a386-e58f6c28104b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_0aa81fed-04ae-4879-a677-b4cdb9a9aeee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:to="loc_ifrs-full_NonadjustingEventsMember_0aa81fed-04ae-4879-a677-b4cdb9a9aeee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_aecc6102-5df6-43f4-9c86-70c546d80250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:to="loc_ifrs-full_NonadjustingEventsMember_aecc6102-5df6-43f4-9c86-70c546d80250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PotentialOrdinaryShareTransactionsMember_b63d4917-3dba-489a-baee-692c3af24bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PotentialOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_aecc6102-5df6-43f4-9c86-70c546d80250" xlink:to="loc_ifrs-full_PotentialOrdinaryShareTransactionsMember_b63d4917-3dba-489a-baee-692c3af24bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TradeReceivablesSettlementPeriod_0a4924ce-ef7b-4fca-b21d-ce67a61ac936" xlink:href="meso-20231231.xsd#meso_TradeReceivablesSettlementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_TradeReceivablesSettlementPeriod_0a4924ce-ef7b-4fca-b21d-ce67a61ac936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsPrincipalAmount_6814e9c0-2929-4d68-a3f6-9be09b7245b2" xlink:href="meso-20231231.xsd#meso_BorrowingsPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsPrincipalAmount_6814e9c0-2929-4d68-a3f6-9be09b7245b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsTerm_d3b2dfc9-ea46-4aa2-9595-dc19bcad040b" xlink:href="meso-20231231.xsd#meso_BorrowingsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsTerm_d3b2dfc9-ea46-4aa2-9595-dc19bcad040b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_408167a4-6eac-43c5-98ed-bfd5d0d78976" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_Borrowings_408167a4-6eac-43c5-98ed-bfd5d0d78976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsInterestOnlyPeriod_be5f3172-3fcf-43c5-9468-bd79e81fae5c" xlink:href="meso-20231231.xsd#meso_BorrowingsInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsInterestOnlyPeriod_be5f3172-3fcf-43c5-9468-bd79e81fae5c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_5a901763-646f-4d82-b8a7-16ef94797f85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_BorrowingsInterestRate_5a901763-646f-4d82-b8a7-16ef94797f85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_1d14756f-0b88-4e06-aa98-4afa622db76c" xlink:href="meso-20231231.xsd#meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_1d14756f-0b88-4e06-aa98-4afa622db76c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsPrincipalAmortizationPeriod_d80b920b-85e3-4709-93b6-6821db75cfec" xlink:href="meso-20231231.xsd#meso_BorrowingsPrincipalAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsPrincipalAmortizationPeriod_d80b920b-85e3-4709-93b6-6821db75cfec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UnpaidInterestPortionPerAnnum_8c5e69b5-76cc-4676-817f-1e614ca5362a" xlink:href="meso-20231231.xsd#meso_UnpaidInterestPortionPerAnnum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_UnpaidInterestPortionPerAnnum_8c5e69b5-76cc-4676-817f-1e614ca5362a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_4ab2c689-862f-4849-97ae-f949fdbff752" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_4ab2c689-862f-4849-97ae-f949fdbff752" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_f59dd7b7-8d25-4f9a-b5f9-0ba016294f67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_ParValuePerShare_f59dd7b7-8d25-4f9a-b5f9-0ba016294f67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_b3c6d430-9990-47fc-a7d0-3d142eafc3eb" xlink:href="meso-20231231.xsd#meso_PercentageOfPremiumForVolumeWeightedAveragePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_b3c6d430-9990-47fc-a7d0-3d142eafc3eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IssuanceWarrantsExercisedPeriod_9887d3a6-ba90-46e7-ae62-1841b1b12bfa" xlink:href="meso-20231231.xsd#meso_IssuanceWarrantsExercisedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_IssuanceWarrantsExercisedPeriod_9887d3a6-ba90-46e7-ae62-1841b1b12bfa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfSharePremiumPrice_5aabac30-124c-47eb-a761-8169d98391db" xlink:href="meso-20231231.xsd#meso_PercentageOfSharePremiumPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfSharePremiumPrice_5aabac30-124c-47eb-a761-8169d98391db" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExerciseTerm_4ee6855c-ad23-4c80-9606-b2efb87facf2" xlink:href="meso-20231231.xsd#meso_WarrantExerciseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_WarrantExerciseTerm_4ee6855c-ad23-4c80-9606-b2efb87facf2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OutstandingCommonShareCapitalPercentage_394523f5-44a6-4fda-b865-adbab467a05e" xlink:href="meso-20231231.xsd#meso_OutstandingCommonShareCapitalPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_OutstandingCommonShareCapitalPercentage_394523f5-44a6-4fda-b865-adbab467a05e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExercisePriceShareWarrentsIssued_170e4180-d0a0-44bc-903b-46fb4c26f81f" xlink:href="meso-20231231.xsd#meso_ExercisePriceShareWarrentsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_ExercisePriceShareWarrentsIssued_170e4180-d0a0-44bc-903b-46fb4c26f81f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_101cf6d8-e2d2-4680-90e4-10dd80b38d73" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_101cf6d8-e2d2-4680-90e4-10dd80b38d73" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_8554faa0-8243-4dc8-9013-69d413ac888c" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_8554faa0-8243-4dc8-9013-69d413ac888c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_68defdcf-8a1d-4c89-bb9a-0e9327fce77c" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_68defdcf-8a1d-4c89-bb9a-0e9327fce77c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_ac5907b6-a7e8-483c-8f9a-d1dfc475ab7a" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_ac5907b6-a7e8-483c-8f9a-d1dfc475ab7a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_a276c641-e836-4d4c-9210-a1896a117d72" xlink:href="meso-20231231.xsd#meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_a276c641-e836-4d4c-9210-a1896a117d72" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumUnrestrictedCashBalance_611cf4e7-61ee-4e40-81ff-812c756cf262" xlink:href="meso-20231231.xsd#meso_MinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_MinimumUnrestrictedCashBalance_611cf4e7-61ee-4e40-81ff-812c756cf262" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_c1abfe0b-5947-4cce-8325-93c91b833158" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_FinancialAssets_c1abfe0b-5947-4cce-8325-93c91b833158" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_1392c452-ae48-4f26-8b0a-5cd71fe64df0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_FinancialLiabilities_1392c452-ae48-4f26-8b0a-5cd71fe64df0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfAssetsMeasuredAtFairValue_22c84e30-9280-4f67-ba53-56251248ad7e" xlink:href="meso-20231231.xsd#meso_PercentageOfAssetsMeasuredAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfAssetsMeasuredAtFairValue_22c84e30-9280-4f67-ba53-56251248ad7e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfLiabilitiesMeasuredAtFairValue_0d087520-4f4d-4911-9e6f-f7bd8f5db9f6" xlink:href="meso-20231231.xsd#meso_PercentageOfLiabilitiesMeasuredAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfLiabilitiesMeasuredAtFairValue_0d087520-4f4d-4911-9e6f-f7bd8f5db9f6" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtIssueDate_6b69dd74-d565-47d6-a9f7-7084cb4bb0d6" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtIssueDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_WarrantsFairValueAtIssueDate_6b69dd74-d565-47d6-a9f7-7084cb4bb0d6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GainLossOnRemeasurementOfWarrantLiability_7972fff6-1eeb-480c-add7-410c6608cb00" xlink:href="meso-20231231.xsd#meso_GainLossOnRemeasurementOfWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_GainLossOnRemeasurementOfWarrantLiability_7972fff6-1eeb-480c-add7-410c6608cb00" xlink:type="arc" order="28"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_3d2275b7-d060-4a63-93ab-08bbf939e171" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_3d2275b7-d060-4a63-93ab-08bbf939e171" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:to="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_db1b1a26-a51f-4b2a-bba7-b59a379c117b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:to="loc_ifrs-full_CounterpartiesMember_db1b1a26-a51f-4b2a-bba7-b59a379c117b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:to="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NovaQuestCapitalManagementLLCMember_d980d50b-9429-4c21-8c45-e1d633f37a2e" xlink:href="meso-20231231.xsd#meso_NovaQuestCapitalManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:to="loc_meso_NovaQuestCapitalManagementLLCMember_d980d50b-9429-4c21-8c45-e1d633f37a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementLPMember_14580bc0-d5e3-4bde-b337-1da771fbf1db" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:to="loc_meso_OaktreeCapitalManagementLPMember_14580bc0-d5e3-4bde-b337-1da771fbf1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_3d2275b7-d060-4a63-93ab-08bbf939e171" xlink:to="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SecuredBankLoansReceived_2bcb5800-7a30-4f68-b7b5-7eeb88375b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SecuredBankLoansReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_SecuredBankLoansReceived_2bcb5800-7a30-4f68-b7b5-7eeb88375b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_042e3403-6efc-442d-9f95-2a70547a7e95" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsRecognisedAsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_042e3403-6efc-442d-9f95-2a70547a7e95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingCostsCapitalised_9b988419-be85-477d-9aed-ac0f0f4d2890" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_BorrowingCostsCapitalised_9b988419-be85-477d-9aed-ac0f0f4d2890" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_3d347f9f-2f6a-4c3a-b5a1-ba4112605488" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_Borrowings_3d347f9f-2f6a-4c3a-b5a1-ba4112605488" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:href="meso-20231231.xsd#meso_LongTermBorrowingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermBorrowings_1495cb73-6611-4f95-8463-92187106d329" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:to="loc_ifrs-full_ShorttermBorrowings_1495cb73-6611-4f95-8463-92187106d329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_159277d9-4eb6-437d-a023-75a76612efe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:to="loc_ifrs-full_LongtermBorrowings_159277d9-4eb6-437d-a023-75a76612efe6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_240317ee-5e6c-4b9f-b1f7-d27fe759cc54" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofNetDebtDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:to="loc_ifrs-full_InterestRateTypesMember_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:to="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_131d2bac-af11-4e58-8c7f-bab8490deed1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:to="loc_ifrs-full_FixedInterestRateMember_131d2bac-af11-4e58-8c7f-bab8490deed1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_f262091d-4f27-4e43-b8d4-f9ce7a5f75b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:to="loc_ifrs-full_FloatingInterestRateMember_f262091d-4f27-4e43-b8d4-f9ce7a5f75b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_9f60a7c9-a5fc-4dcc-a615-0ea7c03ad4be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_9f60a7c9-a5fc-4dcc-a615-0ea7c03ad4be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_bfe4b4b7-2f31-4efd-9b28-796c56c924fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_Borrowings_bfe4b4b7-2f31-4efd-9b28-796c56c924fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_15516d5b-e357-45d6-9332-7e6eddf94d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_LeaseLiabilities_15516d5b-e357-45d6-9332-7e6eddf94d66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_5ccdee52-dec6-460a-aade-0a603fd98887" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_WarrantLiability_5ccdee52-dec6-460a-aade-0a603fd98887" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt_1e636f70-27c7-49ac-af49-f9d7a5a0758d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_NetDebt_1e636f70-27c7-49ac-af49-f9d7a5a0758d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_278dcbb1-15ef-4254-bc4f-f95053add900_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_278dcbb1-15ef-4254-bc4f-f95053add900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_40e21f4e-1529-47e4-bcd4-ee0fb70f9551" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_40e21f4e-1529-47e4-bcd4-ee0fb70f9551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEquitySecuritiesMember_12f780ed-881f-497f-a27d-a00c84215200" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_40e21f4e-1529-47e4-bcd4-ee0fb70f9551" xlink:to="loc_ifrs-full_OtherEquitySecuritiesMember_12f780ed-881f-497f-a27d-a00c84215200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_67576247-0664-45cb-a797-f336de427c11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_67576247-0664-45cb-a797-f336de427c11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_bf98a028-646e-4b22-9095-fe1961a3937e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_bf98a028-646e-4b22-9095-fe1961a3937e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_b7559a7a-f585-47e8-988d-2b3ea07a2bb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_b7559a7a-f585-47e8-988d-2b3ea07a2bb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_088cd11e-5d0e-414a-b3f9-8c0d24483d56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:to="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_088cd11e-5d0e-414a-b3f9-8c0d24483d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_55b7ed91-bca6-4c48-8b35-95002a684174" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_088cd11e-5d0e-414a-b3f9-8c0d24483d56" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_55b7ed91-bca6-4c48-8b35-95002a684174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:to="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_00bb1024-fa1f-42ba-b10b-3e7b1aed4e3a" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:to="loc_meso_ContingentConsiderations_00bb1024-fa1f-42ba-b10b-3e7b1aed4e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_902fd172-da80-4264-8b02-a58fb4a5189f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:to="loc_ifrs-full_WarrantLiability_902fd172-da80-4264-8b02-a58fb4a5189f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_a53ff678-ba8b-45e6-88a9-604f0dfd2c07" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_a53ff678-ba8b-45e6-88a9-604f0dfd2c07" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_0332c06d-97f1-4ec5-beaf-4392a3675d52_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_0332c06d-97f1-4ec5-beaf-4392a3675d52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5d4d11f1-aa58-4c8b-a419-3e3c42778041" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5d4d11f1-aa58-4c8b-a419-3e3c42778041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_153f96dc-4fd3-4d8c-a78e-3d5caa19edd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5d4d11f1-aa58-4c8b-a419-3e3c42778041" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_153f96dc-4fd3-4d8c-a78e-3d5caa19edd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision_2fdb11ea-485c-482c-acc9-e37e49465598" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_ContingentConsiderationProvision_2fdb11ea-485c-482c-acc9-e37e49465598" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvisionAmountUsed_fce1e11c-b93e-436f-9aa0-9051fd9f2e14" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvisionAmountUsed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_ContingentConsiderationProvisionAmountUsed_fce1e11c-b93e-436f-9aa0-9051fd9f2e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfContingentConsideration_8562ea57-9017-405b-9796-d0ca342e5779" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_LossGainOnRemeasurementOfContingentConsideration_8562ea57-9017-405b-9796-d0ca342e5779" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision_90d2a5df-3aff-45af-aecb-fd320b35c0ce" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ad4e672-8d7f-43f7-8d8f-7b3155bc1dba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ad4e672-8d7f-43f7-8d8f-7b3155bc1dba" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4e182846-15ef-4f0d-8015-269959b6fa74_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_4e182846-15ef-4f0d-8015-269959b6fa74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2ee0302f-1ab5-416d-8785-0559637a4d59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2ee0302f-1ab5-416d-8785-0559637a4d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_70877752-e134-44d8-921d-9671207360b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2ee0302f-1ab5-416d-8785-0559637a4d59" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_70877752-e134-44d8-921d-9671207360b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_c08fb781-a71a-4461-9471-d51dceb7b042" xlink:href="meso-20231231.xsd#meso_GainLossOnReMeasurementOfContingentConsiderationProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ad4e672-8d7f-43f7-8d8f-7b3155bc1dba" xlink:to="loc_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_c08fb781-a71a-4461-9471-d51dceb7b042" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_6ffec991-6bf8-4615-91e5-8bb0407b193a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_6ffec991-6bf8-4615-91e5-8bb0407b193a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3430384c-7e34-4610-811d-6b453984cda0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3430384c-7e34-4610-811d-6b453984cda0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_32c0cbb4-a7c7-4bc3-ac0a-41d842143a6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3430384c-7e34-4610-811d-6b453984cda0" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_32c0cbb4-a7c7-4bc3-ac0a-41d842143a6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_f39a71f3-3158-460c-9b2f-52398c132a66_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:to="loc_ifrs-full_ValuationTechniquesMember_f39a71f3-3158-460c-9b2f-52398c132a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_0d658b2b-3374-4de8-9829-5ec5bc66aa72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:to="loc_ifrs-full_ValuationTechniquesMember_0d658b2b-3374-4de8-9829-5ec5bc66aa72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember_956e85d5-c334-466f-9dbc-c1b9ad2c919f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesMember_0d658b2b-3374-4de8-9829-5ec5bc66aa72" xlink:to="loc_ifrs-full_DiscountedCashFlowMember_956e85d5-c334-466f-9dbc-c1b9ad2c919f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsMember_31fe9869-e944-4ebb-b6b7-323ad9570073_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:to="loc_ifrs-full_SalesChannelsMember_31fe9869-e944-4ebb-b6b7-323ad9570073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsMember_dd350ec0-62a7-4a60-bdf3-93e001bb615f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:to="loc_ifrs-full_SalesChannelsMember_dd350ec0-62a7-4a60-bdf3-93e001bb615f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedSalesVolumeMember_9bb78c0f-388a-4ddb-8ef9-3e449e6d424a" xlink:href="meso-20231231.xsd#meso_ExpectedSalesVolumeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SalesChannelsMember_dd350ec0-62a7-4a60-bdf3-93e001bb615f" xlink:to="loc_meso_ExpectedSalesVolumeMember_9bb78c0f-388a-4ddb-8ef9-3e449e6d424a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProbabilityOfDefaultAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_fec02450-80b1-47b6-b30f-cbc6601e755b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForProbabilityOfDefaultMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:to="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_fec02450-80b1-47b6-b30f-cbc6601e755b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_f3bf3a8b-c118-49bf-a0fc-cbc24d7ffc93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForProbabilityOfDefaultMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:to="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_f3bf3a8b-c118-49bf-a0fc-cbc24d7ffc93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProbabilityOfDefaultMember_a89f6673-aec1-46e6-a843-12540097af9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProbabilityOfDefaultMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_f3bf3a8b-c118-49bf-a0fc-cbc24d7ffc93" xlink:to="loc_ifrs-full_ProbabilityOfDefaultMember_a89f6673-aec1-46e6-a843-12540097af9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_577b3f0d-9aae-4996-b14b-c46d9f55f773_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:to="loc_ifrs-full_RangesMember_577b3f0d-9aae-4996-b14b-c46d9f55f773_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:to="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_51961bd2-8236-4f98-97b2-0ee8da9eebfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:to="loc_ifrs-full_BottomOfRangeMember_51961bd2-8236-4f98-97b2-0ee8da9eebfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e2091fa3-eb39-480d-9a1a-99519730c949" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:to="loc_ifrs-full_TopOfRangeMember_e2091fa3-eb39-480d-9a1a-99519730c949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageMember_41e02f92-7903-4c02-bcf2-a3332965684d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:to="loc_ifrs-full_WeightedAverageMember_41e02f92-7903-4c02-bcf2-a3332965684d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_4c4110d6-6600-43cc-83d3-db933575ae4b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:to="loc_ifrs-full_UnobservableInputsMember_4c4110d6-6600-43cc-83d3-db933575ae4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:to="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_15e41810-d78d-4b25-8586-ba7e0fe16d2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_15e41810-d78d-4b25-8586-ba7e0fe16d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedUnitSalesPriceMeasurementInputMember_88e33d25-841b-4b0c-a7d5-d22ce8636595" xlink:href="meso-20231231.xsd#meso_ExpectedUnitSalesPriceMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_ExpectedUnitSalesPriceMeasurementInputMember_88e33d25-841b-4b0c-a7d5-d22ce8636595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedSalesVolumesMeasurementInputMember_61713752-8e7a-4c52-b115-a5745f8f2f11" xlink:href="meso-20231231.xsd#meso_ExpectedSalesVolumesMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_ExpectedSalesVolumesMeasurementInputMember_61713752-8e7a-4c52-b115-a5745f8f2f11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProbabilityOfSuccessMeasurementInputMember_0ede5770-4587-4843-9be3-a2b0e1ea4021" xlink:href="meso-20231231.xsd#meso_ProbabilityOfSuccessMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_ProbabilityOfSuccessMeasurementInputMember_0ede5770-4587-4843-9be3-a2b0e1ea4021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentAssumptionsMeasurementInputMember_76094b25-018b-49e2-a013-09c1f27fde66" xlink:href="meso-20231231.xsd#meso_PaymentAssumptionsMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_PaymentAssumptionsMeasurementInputMember_76094b25-018b-49e2-a013-09c1f27fde66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision_ca5f25f6-c6d6-4399-9c51-39554a24c7a5" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_ContingentConsiderationProvision_ca5f25f6-c6d6-4399-9c51-39554a24c7a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities_9c731d27-e578-40b2-a953-15a1c0a8b261" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities_9c731d27-e578-40b2-a953-15a1c0a8b261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities_3a3d2d78-01db-4829-9ddc-b237bf7f5e85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities_3a3d2d78-01db-4829-9ddc-b237bf7f5e85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_14350208-3ba5-4bc3-aab7-6c95edd02434" xlink:href="meso-20231231.xsd#meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_14350208-3ba5-4bc3-aab7-6c95edd02434" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_72b2e640-ab3c-4b14-a854-cd97f075528d" xlink:href="meso-20231231.xsd#meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_72b2e640-ab3c-4b14-a854-cd97f075528d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_769bad79-8724-4cb1-acbf-d6acdd95b9a1" xlink:href="meso-20231231.xsd#meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_769bad79-8724-4cb1-acbf-d6acdd95b9a1" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:to="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefaultFinancialStatementsDateMember_1563e06a-1ba5-465d-8834-fc7f7acd6efc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:to="loc_ifrs-full_DefaultFinancialStatementsDateMember_1563e06a-1ba5-465d-8834-fc7f7acd6efc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefaultFinancialStatementsDateMember_ba350bd6-927e-4bc2-b324-b961122fceff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:to="loc_ifrs-full_DefaultFinancialStatementsDateMember_ba350bd6-927e-4bc2-b324-b961122fceff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtGrantDateDecember222022Member_7fc92049-6b5b-47da-82dc-4645e232f200" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtGrantDateDecember222022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DefaultFinancialStatementsDateMember_ba350bd6-927e-4bc2-b324-b961122fceff" xlink:to="loc_meso_WarrantsFairValueAtGrantDateDecember222022Member_7fc92049-6b5b-47da-82dc-4645e232f200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_74e1be39-59b3-4e2b-9a63-ec2aaaaa47b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_ifrs-full_WarrantLiability_74e1be39-59b3-4e2b-9a63-ec2aaaaa47b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtIssueDate_2a5fe21f-c983-49fe-9b3e-e15538c75f63" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtIssueDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_meso_WarrantsFairValueAtIssueDate_2a5fe21f-c983-49fe-9b3e-e15538c75f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementOfWarrantLiability_7a215e56-ac5a-4173-8e38-037a583d64a6" xlink:href="meso-20231231.xsd#meso_RemeasurementOfWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_meso_RemeasurementOfWarrantLiability_7a215e56-ac5a-4173-8e38-037a583d64a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_a0e77ce5-ddb0-43f9-9721-910c23544cb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_94b5b98c-9ac5-49e1-89e5-c68d912cdca8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_94b5b98c-9ac5-49e1-89e5-c68d912cdca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0af87808-5013-46a5-a146-90671feb1df1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0af87808-5013-46a5-a146-90671feb1df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1296d9dc-9412-4d0a-8147-3622326a1cc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0af87808-5013-46a5-a146-90671feb1df1" xlink:to="loc_ifrs-full_WarrantsMember_1296d9dc-9412-4d0a-8147-3622326a1cc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:to="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d763df7-8fa9-43d5-a64d-46ab93d7e123_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:to="loc_srt_RangeMember_2d763df7-8fa9-43d5-a64d-46ab93d7e123_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:to="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ce7aa9ab-96c6-4e16-ad49-042d3636ba75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:to="loc_srt_MinimumMember_ce7aa9ab-96c6-4e16-ad49-042d3636ba75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45f06a71-09ed-417d-85ff-b1af58aff637" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:to="loc_srt_MaximumMember_45f06a71-09ed-417d-85ff-b1af58aff637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsPricePerShare_334de3f1-d529-4cb2-8543-62972d548b8c" xlink:href="meso-20231231.xsd#meso_WarrantsPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_meso_WarrantsPricePerShare_334de3f1-d529-4cb2-8543-62972d548b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_19624ae5-b400-4689-a1b8-87b8314cb014" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_ParValuePerShare_19624ae5-b400-4689-a1b8-87b8314cb014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f52c69bb-d33f-49f9-a6f2-1170771e9979" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f52c69bb-d33f-49f9-a6f2-1170771e9979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24e4d66d-e4fb-4345-bda0-798772a38a8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24e4d66d-e4fb-4345-bda0-798772a38a8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3e29a50c-236c-4b86-bad3-5164cda8869c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3e29a50c-236c-4b86-bad3-5164cda8869c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1f0c745c-e32c-4e2e-97d5-7ceb97674ee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1f0c745c-e32c-4e2e-97d5-7ceb97674ee9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValuePerWarrant_49aca165-873f-4127-abca-3080e6de4d81" xlink:href="meso-20231231.xsd#meso_FairValuePerWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_meso_FairValuePerWarrant_49aca165-873f-4127-abca-3080e6de4d81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueOfWarrants_4c5cc647-8377-4a6b-a52c-8bda0503346d" xlink:href="meso-20231231.xsd#meso_FairValueOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_meso_FairValueOfWarrants_4c5cc647-8377-4a6b-a52c-8bda0503346d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0c42bf53-db86-4216-9a5a-7962f17a71b1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0c42bf53-db86-4216-9a5a-7962f17a71b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_19b6abf9-8f09-4291-b9bc-f401d111860e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_19b6abf9-8f09-4291-b9bc-f401d111860e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_19b628ad-deb5-44d3-9758-9c1921d2c949" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_19b6abf9-8f09-4291-b9bc-f401d111860e" xlink:to="loc_ifrs-full_WarrantsMember_19b628ad-deb5-44d3-9758-9c1921d2c949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:to="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_058da9af-0dc5-418c-aece-471e4b8f8fd5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:to="loc_srt_RangeMember_058da9af-0dc5-418c-aece-471e4b8f8fd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:to="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9577f9cd-58c1-404f-b0f5-44f8ce0e77ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:to="loc_srt_MaximumMember_9577f9cd-58c1-404f-b0f5-44f8ce0e77ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f70cebd4-0f15-457c-9fda-c416eb811c17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:to="loc_srt_MinimumMember_f70cebd4-0f15-457c-9fda-c416eb811c17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IssuanceWarrantsExercisedPeriod_ad48b76d-2598-4d23-8e2d-342eecfa5d5c" xlink:href="meso-20231231.xsd#meso_IssuanceWarrantsExercisedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_meso_IssuanceWarrantsExercisedPeriod_ad48b76d-2598-4d23-8e2d-342eecfa5d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_2c58e03f-91a5-4900-b3d0-d92ed95bbb28" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_2c58e03f-91a5-4900-b3d0-d92ed95bbb28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueOfWarrants_4b1e3317-d573-4411-9d12-31694b40af9c" xlink:href="meso-20231231.xsd#meso_FairValueOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_meso_FairValueOfWarrants_4b1e3317-d573-4411-9d12-31694b40af9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_15ca9a33-d70b-4c20-a05d-ebf3d0f84032" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_ifrs-full_ParValuePerShare_15ca9a33-d70b-4c20-a05d-ebf3d0f84032" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_43746461-9016-47b0-a1f5-b81a3ec8d4f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_43746461-9016-47b0-a1f5-b81a3ec8d4f8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_5d20ced5-d889-4a43-be30-72081bba8e8d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_5d20ced5-d889-4a43-be30-72081bba8e8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_a40a83f7-882c-487f-ab92-c96f2f9e506a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_ifrs-full_GoodwillMember_a40a83f7-882c-487f-ab92-c96f2f9e506a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_a74591fe-9c54-43de-b155-a02a32b4b0cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_ifrs-full_LicencesMember_a74591fe-9c54-43de-b155-a02a32b4b0cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_170b031a-e3d4-4b01-a83b-3c4c226579af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_170b031a-e3d4-4b01-a83b-3c4c226579af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentMarketedProductsMember_53d582b0-b659-4ba9-8b4c-9d53613405da" xlink:href="meso-20231231.xsd#meso_CurrentMarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_meso_CurrentMarketedProductsMember_53d582b0-b659-4ba9-8b4c-9d53613405da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_9428b8b5-3052-4620-b5e7-42807ec8bf5e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:to="loc_ifrs-full_CarryingAmountMember_9428b8b5-3052-4620-b5e7-42807ec8bf5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:to="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_a3f115dd-5289-49a9-9613-0f2db209d84a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_a3f115dd-5289-49a9-9613-0f2db209d84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_5b2b6d21-d6e3-4ae4-8ff8-2159ec030e4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_5b2b6d21-d6e3-4ae4-8ff8-2159ec030e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_ebcf932c-40f3-4a1f-bd40-b224f7e13da3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_ebcf932c-40f3-4a1f-bd40-b224f7e13da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_018a3ff8-f54b-4bbe-b7ae-0f9450a405b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_018a3ff8-f54b-4bbe-b7ae-0f9450a405b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ee52132-f206-493a-be5b-1a2e6cf1620c" xlink:href="meso-20231231.xsd#meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ee52132-f206-493a-be5b-1a2e6cf1620c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_4e575112-4f0c-465e-a0ca-14b483c9f6f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_4e575112-4f0c-465e-a0ca-14b483c9f6f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_02f22cc1-92a6-4a2f-9e00-7ca254f3357d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_02f22cc1-92a6-4a2f-9e00-7ca254f3357d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_d0faa6b7-8b02-4cfc-b01a-5935dae6ea13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b01abb54-fc02-4cd8-86b0-9c71ef2b6f03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b01abb54-fc02-4cd8-86b0-9c71ef2b6f03" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_f4b29eb1-c553-4f84-b3c5-6df21da946e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_f4b29eb1-c553-4f84-b3c5-6df21da946e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_edc41a34-1738-409d-9df0-bdb271a45723" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_f4b29eb1-c553-4f84-b3c5-6df21da946e0" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_edc41a34-1738-409d-9df0-bdb271a45723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_661e6623-4c5c-40ca-bcf7-ff543b12630d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:to="loc_ifrs-full_ProductsAndServicesMember_661e6623-4c5c-40ca-bcf7-ff543b12630d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:to="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CardiovascularProductsMember_d569437c-7497-41cd-af0d-4a1497750a68" xlink:href="meso-20231231.xsd#meso_CardiovascularProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:to="loc_meso_CardiovascularProductsMember_d569437c-7497-41cd-af0d-4a1497750a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntravenousProductsMember_3c389f1e-3f39-45e4-ac50-688ca3bdc2e7" xlink:href="meso-20231231.xsd#meso_IntravenousProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:to="loc_meso_IntravenousProductsMember_3c389f1e-3f39-45e4-ac50-688ca3bdc2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MSCProductMember_5a7e68f1-3d41-43c0-a8e2-7f23e9cf6d8c" xlink:href="meso-20231231.xsd#meso_MSCProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:to="loc_meso_MSCProductMember_5a7e68f1-3d41-43c0-a8e2-7f23e9cf6d8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_7a827cae-a61b-4684-91d6-982b4f10cd0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b01abb54-fc02-4cd8-86b0-9c71ef2b6f03" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_7a827cae-a61b-4684-91d6-982b4f10cd0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c5c6dc45-1204-49d1-8a6a-41e746ad4825_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_c5c6dc45-1204-49d1-8a6a-41e746ad4825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_a6e2a446-9a69-4a75-a2ba-a7e56fc5903b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_a6e2a446-9a69-4a75-a2ba-a7e56fc5903b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_c59599af-1835-4649-982f-53762c1e9760" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:to="loc_ifrs-full_GoodwillMember_c59599af-1835-4649-982f-53762c1e9760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_72e334de-c688-48a8-a0f4-4f7a2fd0df90_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:to="loc_ifrs-full_RangesMember_72e334de-c688-48a8-a0f4-4f7a2fd0df90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:to="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_bfb572f9-dfef-4191-9a43-b749e392d70f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:to="loc_ifrs-full_BottomOfRangeMember_bfb572f9-dfef-4191-9a43-b749e392d70f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_18de07dd-7f54-46dd-8ca7-1c869533faeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:to="loc_ifrs-full_TopOfRangeMember_18de07dd-7f54-46dd-8ca7-1c869533faeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_7521c076-c4ab-4977-95e7-1baa5fccee2c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:to="loc_ifrs-full_ValuationTechniquesMember_7521c076-c4ab-4977-95e7-1baa5fccee2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_acd6c13e-21b2-4271-8f34-d1705fa33a4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:to="loc_ifrs-full_ValuationTechniquesMember_acd6c13e-21b2-4271-8f34-d1705fa33a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember_387b486a-d3b1-4307-89e7-02a7701fa891" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ValuationTechniquesMember_acd6c13e-21b2-4271-8f34-d1705fa33a4c" xlink:to="loc_ifrs-full_DiscountedCashFlowMember_387b486a-d3b1-4307-89e7-02a7701fa891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_d69e3f5a-3414-4ed0-b513-85816947fad9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:to="loc_ifrs-full_OtherProvisionsMember_d69e3f5a-3414-4ed0-b513-85816947fad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_10435533-1efd-43b0-a378-410e134ae6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:to="loc_ifrs-full_OtherProvisionsMember_10435533-1efd-43b0-a378-410e134ae6c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EmployeeBenefitsMember_97e13d44-273f-45d4-895a-d1540798cf89" xlink:href="meso-20231231.xsd#meso_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_10435533-1efd-43b0-a378-410e134ae6c6" xlink:to="loc_meso_EmployeeBenefitsMember_97e13d44-273f-45d4-895a-d1540798cf89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossOnFinancialAssets_48ae8091-71af-4dd1-aee2-7afee89a3dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_ifrs-full_ImpairmentLossOnFinancialAssets_48ae8091-71af-4dd1-aee2-7afee89a3dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PostTaxDiscountRates_f07a3147-e8a5-42a0-8ec9-deb2162b4d07" xlink:href="meso-20231231.xsd#meso_PostTaxDiscountRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_PostTaxDiscountRates_f07a3147-e8a5-42a0-8ec9-deb2162b4d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedPatentExpiry_fdae65af-ada0-4dd9-9594-4d4d1dde84be" xlink:href="meso-20231231.xsd#meso_ExpectedPatentExpiry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_ExpectedPatentExpiry_fdae65af-ada0-4dd9-9594-4d4d1dde84be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentProvisionsForAccruedAnnualLeave_d4dc25f3-7777-434d-b4a5-8db9feaaba83" xlink:href="meso-20231231.xsd#meso_CurrentProvisionsForAccruedAnnualLeave"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_CurrentProvisionsForAccruedAnnualLeave_d4dc25f3-7777-434d-b4a5-8db9feaaba83" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:to="loc_ifrs-full_OtherProvisionsMember_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:to="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_fb12cca9-723a-4ceb-b4c5-f517e81e7e3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:to="loc_ifrs-full_ContingentConsiderationMember_fb12cca9-723a-4ceb-b4c5-f517e81e7e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EmployeeBenefitsMember_0a1a1932-36aa-4154-a8cd-b503d35a3f5c" xlink:href="meso-20231231.xsd#meso_EmployeeBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:to="loc_meso_EmployeeBenefitsMember_0a1a1932-36aa-4154-a8cd-b503d35a3f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProvisionForLicenseAgreementsMember_be187173-cbd1-4f27-a058-e7d2d6c2d1f5" xlink:href="meso-20231231.xsd#meso_ProvisionForLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:to="loc_meso_ProvisionForLicenseAgreementsMember_be187173-cbd1-4f27-a058-e7d2d6c2d1f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_185f9276-9636-4837-a1d1-8d4f0405dc19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_CurrentProvisions_185f9276-9636-4837-a1d1-8d4f0405dc19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_8d18f8e2-6b74-4998-b5e1-d7ca1e29ff49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_NoncurrentProvisions_8d18f8e2-6b74-4998-b5e1-d7ca1e29ff49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_5b1ebff6-2c8b-4786-b692-d3cedfc7fd64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_Provisions_5b1ebff6-2c8b-4786-b692-d3cedfc7fd64" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:to="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_7d3bd989-d772-408a-abdf-a2fd134dbb03_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_7d3bd989-d772-408a-abdf-a2fd134dbb03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxLossesMember_396fb7a9-e1dc-4af4-9f5c-b96e9fcb8512" xlink:href="meso-20231231.xsd#meso_TaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:to="loc_meso_TaxLossesMember_396fb7a9-e1dc-4af4-9f5c-b96e9fcb8512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_63442f67-07f8-432d-ba07-e3550a24e21d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_63442f67-07f8-432d-ba07-e3550a24e21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntangibleAssetsMember_83cbbedd-cab3-4359-b1a6-c12906aba4c1" xlink:href="meso-20231231.xsd#meso_IntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:to="loc_meso_IntangibleAssetsMember_83cbbedd-cab3-4359-b1a6-c12906aba4c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_faff9108-7566-4f3a-9aa2-77c97debaf44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_faff9108-7566-4f3a-9aa2-77c97debaf44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:to="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax_a3b4e09b-f3b1-4d16-880f-3822772f99e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:to="loc_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax_a3b4e09b-f3b1-4d16-880f-3822772f99e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_2ee8c0a5-710f-4c95-a68a-55d005c19b1b" xlink:href="meso-20231231.xsd#meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:to="loc_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_2ee8c0a5-710f-4c95-a68a-55d005c19b1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_bca0d362-c36e-42f7-8ccf-525f47df376c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquityScheduleofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_985ec13f-e041-402f-9559-f7efad709c13_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_985ec13f-e041-402f-9559-f7efad709c13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_7083a868-1383-404c-9061-c156aab68a0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_7083a868-1383-404c-9061-c156aab68a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_70ade9dc-1e67-4b9d-8819-4f382cb9602b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_7083a868-1383-404c-9061-c156aab68a0c" xlink:to="loc_ifrs-full_OrdinarySharesMember_70ade9dc-1e67-4b9d-8819-4f382cb9602b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_61b755d5-a91d-436b-b0a3-1cf0c8c01854" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:to="loc_ifrs-full_NumberOfSharesIssued_61b755d5-a91d-436b-b0a3-1cf0c8c01854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchased_76e4e5ea-a7ae-4c90-82cf-5db85aa1d64b" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:to="loc_meso_TreasurySharesPurchased_76e4e5ea-a7ae-4c90-82cf-5db85aa1d64b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_6d400f81-6d13-4e2c-bb09-7a91f9b076c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_6d400f81-6d13-4e2c-bb09-7a91f9b076c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OrdinarySharesPurchasedValue_84642b8d-5df1-4e7c-a9b2-9e941bf621fa" xlink:href="meso-20231231.xsd#meso_OrdinarySharesPurchasedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_meso_OrdinarySharesPurchasedValue_84642b8d-5df1-4e7c-a9b2-9e941bf621fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchasedValue_beddc3f6-85ff-45c7-9002-16cd5b037387" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchasedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_meso_TreasurySharesPurchasedValue_beddc3f6-85ff-45c7-9002-16cd5b037387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8c46c92b-571b-4cee-9bdc-0ac613a3a1c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_ifrs-full_Equity_8c46c92b-571b-4cee-9bdc-0ac613a3a1c6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsinOrdinaryShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_cade6254-c206-4d57-9ce3-bce7b178ebd3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_cade6254-c206-4d57-9ce3-bce7b178ebd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_353fbc44-6153-4a39-bcb7-f6e0e79bd568" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_353fbc44-6153-4a39-bcb7-f6e0e79bd568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_adb3aea6-19e1-49dc-8d8d-6e220030d7e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_353fbc44-6153-4a39-bcb7-f6e0e79bd568" xlink:to="loc_ifrs-full_OrdinarySharesMember_adb3aea6-19e1-49dc-8d8d-6e220030d7e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember_1bd069ce-322d-422e-b414-03c6b9bea8f2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsMember_1bd069ce-322d-422e-b414-03c6b9bea8f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember_a5f6472b-3672-44ba-917c-9c85b8278721" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsMember_a5f6472b-3672-44ba-917c-9c85b8278721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PlacementAgreementMember_75289446-3ed7-4225-aeb9-2a331f3d15a4" xlink:href="meso-20231231.xsd#meso_PlacementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsMember_a5f6472b-3672-44ba-917c-9c85b8278721" xlink:to="loc_meso_PlacementAgreementMember_75289446-3ed7-4225-aeb9-2a331f3d15a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_31e7dee6-3291-4c59-a8ee-1bcf19c52213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_NumberOfSharesIssued_31e7dee6-3291-4c59-a8ee-1bcf19c52213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e5c360d1-9d45-4edd-ad7e-449f9d9a2902" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_Equity_e5c360d1-9d45-4edd-ad7e-449f9d9a2902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan_4a0ff44b-1f9c-4548-8d83-28bffb9021f4" xlink:href="meso-20231231.xsd#meso_SharesAvailableForIssuanceUnderIssuancePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan_4a0ff44b-1f9c-4548-8d83-28bffb9021f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesIssuedInPlacementsValue_f43b2e4a-54d5-4b52-a18a-6b6c71c48130" xlink:href="meso-20231231.xsd#meso_SharesIssuedInPlacementsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_SharesIssuedInPlacementsValue_f43b2e4a-54d5-4b52-a18a-6b6c71c48130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssueShare_4bfe2e04-b0aa-4a00-ac91-d8592871252e" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssueShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_TransactionCostsArisingOnShareIssueShare_4bfe2e04-b0aa-4a00-ac91-d8592871252e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssue_d825bfbf-3582-4ef3-86d4-d4b323a1271d" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_TransactionCostsArisingOnShareIssue_d825bfbf-3582-4ef3-86d4-d4b323a1271d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfEquityDuringPeriod_5b9fc7eb-92c8-4d6b-b796-2408aef013cf" xlink:href="meso-20231231.xsd#meso_ContributionsOfEquityDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ContributionsOfEquityDuringPeriod_5b9fc7eb-92c8-4d6b-b796-2408aef013cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfValueForEquityDuringPeriod_92b44c5f-bd87-4183-a39b-1cb9ad42f5b5" xlink:href="meso-20231231.xsd#meso_ContributionsOfValueForEquityDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ContributionsOfValueForEquityDuringPeriod_92b44c5f-bd87-4183-a39b-1cb9ad42f5b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_6002d634-a943-4f43-8e86-ffa531bc5a32" xlink:href="meso-20231231.xsd#meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_6002d634-a943-4f43-8e86-ffa531bc5a32" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_a07e439d-2483-480b-9db2-18b6d43034cc" xlink:href="meso-20231231.xsd#meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_a07e439d-2483-480b-9db2-18b6d43034cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_9943fab5-953b-42b8-8d18-ab851e3801e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_42241f43-f6b6-4e77-8c13-6277d5aaa919" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_54ae1e32-aec6-4987-9243-f7c7e1e9feae_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:to="loc_ifrs-full_EquityMember_54ae1e32-aec6-4987-9243-f7c7e1e9feae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a2278a19-371d-4f18-9f3f-6cfdc2663f8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:to="loc_ifrs-full_EquityMember_a2278a19-371d-4f18-9f3f-6cfdc2663f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember_33baad46-310d-4881-b910-18e59b41bf23" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_a2278a19-371d-4f18-9f3f-6cfdc2663f8c" xlink:to="loc_meso_PrivatePlacementOfSharesMember_33baad46-310d-4881-b910-18e59b41bf23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedButNotFullyPaid_fbc198b2-a866-41a4-ae78-2f32ca408efb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_ifrs-full_NumberOfSharesIssuedButNotFullyPaid_fbc198b2-a866-41a4-ae78-2f32ca408efb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_b1e8e3c5-9e21-40c0-8eb3-838eb82e1263" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_ifrs-full_ParValuePerShare_b1e8e3c5-9e21-40c0-8eb3-838eb82e1263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DiscountedPercentageOnIssuanceOfEquity_bcf8014d-f602-4dc8-af88-11c35f79ef84" xlink:href="meso-20231231.xsd#meso_DiscountedPercentageOnIssuanceOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_meso_DiscountedPercentageOnIssuanceOfEquity_bcf8014d-f602-4dc8-af88-11c35f79ef84" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsofSharesinShareTrustDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:to="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_edb02d07-c267-4796-93f8-f6168a2c485e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:to="loc_ifrs-full_CounterpartiesMember_edb02d07-c267-4796-93f8-f6168a2c485e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_7f9dd9e7-b2b3-413a-8595-0d6cf6da58f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:to="loc_ifrs-full_CounterpartiesMember_7f9dd9e7-b2b3-413a-8595-0d6cf6da58f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MesoblastEmployeeShareTrustMember_8e96733d-5fd5-40c3-a01d-37ea39f562c5" xlink:href="meso-20231231.xsd#meso_MesoblastEmployeeShareTrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_7f9dd9e7-b2b3-413a-8595-0d6cf6da58f4" xlink:to="loc_meso_MesoblastEmployeeShareTrustMember_8e96733d-5fd5-40c3-a01d-37ea39f562c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrust_b617fd72-c51f-4a31-9739-20a0d0d1e3c5" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_SharesHeldInTrust_b617fd72-c51f-4a31-9739-20a0d0d1e3c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrustValue_cb07ad54-881b-4af1-8239-c83e465a0d2d" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrustValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_SharesHeldInTrustValue_cb07ad54-881b-4af1-8239-c83e465a0d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_9775a259-1a20-4c10-a785-52e30f03a476" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_9775a259-1a20-4c10-a785-52e30f03a476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_34378901-8285-4913-9f4f-0299fa01f42b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_34378901-8285-4913-9f4f-0299fa01f42b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrust_bcccf66b-b9e6-4370-a7e6-701ab6a82819" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrust"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrustValue_97232985-7607-4cba-a966-94db84f2679e" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrustValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofWarrantReserveDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:to="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b17ed10a-73e4-494e-beb5-bfea11a0db49_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:to="loc_ifrs-full_EquityMember_b17ed10a-73e4-494e-beb5-bfea11a0db49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_7cd8858a-94a1-479b-b300-a0bfc3c0d104" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:to="loc_ifrs-full_EquityMember_7cd8858a-94a1-479b-b300-a0bfc3c0d104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_f1d1e44e-0d7f-4e38-a28f-d9b3939a6d82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_7cd8858a-94a1-479b-b300-a0bfc3c0d104" xlink:to="loc_ifrs-full_WarrantsMember_f1d1e44e-0d7f-4e38-a28f-d9b3939a6d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_171a9f29-3e75-4468-b5a7-f500c03c3cef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:to="loc_ifrs-full_Equity_171a9f29-3e75-4468-b5a7-f500c03c3cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_a92a568e-b758-42cc-a9b4-59148f6a63cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:to="loc_ifrs-full_ChangesInEquity_a92a568e-b758-42cc-a9b4-59148f6a63cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9b5d37af-61ab-41fc-94e3-4a608d36ac33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_028a8185-1531-4333-911c-310485760b2d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:to="loc_ifrs-full_EquityMember_028a8185-1531-4333-911c-310485760b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_aea9b8cd-3756-4692-871f-667e800c79b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:to="loc_ifrs-full_EquityMember_aea9b8cd-3756-4692-871f-667e800c79b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember_881dfeca-40ce-492f-80b8-a01a8a99c76f" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_aea9b8cd-3756-4692-871f-667e800c79b2" xlink:to="loc_meso_PrivatePlacementOfSharesMember_881dfeca-40ce-492f-80b8-a01a8a99c76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_83e69e42-dd7b-46e2-96dc-56f196f3ec1c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:to="loc_ifrs-full_OtherReservesMember_83e69e42-dd7b-46e2-96dc-56f196f3ec1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_e4b9417a-b2ea-49d3-a72d-e8f08ff2fe5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:to="loc_ifrs-full_OtherReservesMember_e4b9417a-b2ea-49d3-a72d-e8f08ff2fe5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_ee64eb17-4023-4cfa-ad09-4e7e230fb3a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherReservesMember_e4b9417a-b2ea-49d3-a72d-e8f08ff2fe5b" xlink:to="loc_ifrs-full_WarrantsMember_ee64eb17-4023-4cfa-ad09-4e7e230fb3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_0d0219f5-e9ca-4673-9a89-926a4108abcd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:to="loc_ifrs-full_RangesMember_0d0219f5-e9ca-4673-9a89-926a4108abcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5464389e-e29d-48aa-85c8-2967cc435acc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:to="loc_ifrs-full_RangesMember_5464389e-e29d-48aa-85c8-2967cc435acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_6f5e1c9c-2c19-4c79-8b49-b5824f449e45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_5464389e-e29d-48aa-85c8-2967cc435acc" xlink:to="loc_ifrs-full_BottomOfRangeMember_6f5e1c9c-2c19-4c79-8b49-b5824f449e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_f1567cd2-5329-4750-a558-c98a4d340446_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:to="loc_ifrs-full_NonadjustingEventsMember_f1567cd2-5329-4750-a558-c98a4d340446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_3166414e-e4ee-4063-8ce5-7be40c823332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:to="loc_ifrs-full_NonadjustingEventsMember_3166414e-e4ee-4063-8ce5-7be40c823332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_073f4191-885f-467e-8e69-9dbef7878c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_3166414e-e4ee-4063-8ce5-7be40c823332" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_073f4191-885f-467e-8e69-9dbef7878c7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_fd381f9b-6cb1-4f5e-a757-57a1c5b53b49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_fd381f9b-6cb1-4f5e-a757-57a1c5b53b49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_2ae277ba-cee0-4c76-97ae-066e57374c79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_2ae277ba-cee0-4c76-97ae-066e57374c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_190105aa-8c32-46b9-8d81-bb30374c4a56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_ParValuePerShare_190105aa-8c32-46b9-8d81-bb30374c4a56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConversionRatioOfWarrants_c99dcd5e-75ac-487f-92f6-d0a56d315082" xlink:href="meso-20231231.xsd#meso_ConversionRatioOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_ConversionRatioOfWarrants_c99dcd5e-75ac-487f-92f6-d0a56d315082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_b03156d5-cb1c-48d1-aace-b19042acbb12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_NumberOfSharesIssued_b03156d5-cb1c-48d1-aace-b19042acbb12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExercisePricePerShare_3409602f-3505-4419-840a-3d4c493874fa" xlink:href="meso-20231231.xsd#meso_WarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_WarrantExercisePricePerShare_3409602f-3505-4419-840a-3d4c493874fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExerciseTerm_e0ef9c37-8eac-4320-a6b8-087390ddb069" xlink:href="meso-20231231.xsd#meso_WarrantExerciseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_WarrantExerciseTerm_e0ef9c37-8eac-4320-a6b8-087390ddb069" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesPrice_99d232e0-b874-4304-9110-d14747e1cdc6" xlink:href="meso-20231231.xsd#meso_SharesPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_SharesPrice_99d232e0-b874-4304-9110-d14747e1cdc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharePriceMinimumConsecutiveDay_54476e53-d6ad-471d-b489-4c6879aea3f4" xlink:href="meso-20231231.xsd#meso_SharePriceMinimumConsecutiveDay"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_SharePriceMinimumConsecutiveDay_54476e53-d6ad-471d-b489-4c6879aea3f4" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_47e5dfaf-bac1-453d-b682-adafbc61b1fb_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:to="loc_currency_AllCurrenciesDomain_47e5dfaf-bac1-453d-b682-adafbc61b1fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:to="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_2fb253c5-8219-4a78-a42d-0560dc54d8a5" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:to="loc_currency_USD_2fb253c5-8219-4a78-a42d-0560dc54d8a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_5c01f305-2def-4e30-bfdf-c1da41e281ab" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:to="loc_currency_AUD_5c01f305-2def-4e30-bfdf-c1da41e281ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OtherCurrencyMember_fc51dd7d-5331-4759-90bd-787fb54069a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OtherCurrencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:to="loc_srt_OtherCurrencyMember_fc51dd7d-5331-4759-90bd-787fb54069a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_392d443a-7d51-47cb-97af-102454f0a448_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:to="loc_ifrs-full_TypesOfRisksMember_392d443a-7d51-47cb-97af-102454f0a448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:to="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_4153ab44-e1a0-4a91-b4e9-deebf4976b01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:to="loc_ifrs-full_CurrencyRiskMember_4153ab44-e1a0-4a91-b4e9-deebf4976b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_e6c9d98c-f481-4bf3-b238-e67d3364f00e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:to="loc_ifrs-full_InterestRateRiskMember_e6c9d98c-f481-4bf3-b238-e67d3364f00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiquidityRiskMember_d153ad71-fbd1-40c6-850f-6330116192f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:to="loc_ifrs-full_LiquidityRiskMember_d153ad71-fbd1-40c6-850f-6330116192f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_78746b3c-abb1-4229-8083-64434a5bac83_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:to="loc_ifrs-full_CounterpartiesMember_78746b3c-abb1-4229-8083-64434a5bac83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_47bac647-f949-4e87-ae32-1594cb5d1b0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:to="loc_ifrs-full_CounterpartiesMember_47bac647-f949-4e87-ae32-1594cb5d1b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LonzaBioscienceSingaporePteLtdMember_ad2cff96-62b4-4481-bc20-f2114baf1afd" xlink:href="meso-20231231.xsd#meso_LonzaBioscienceSingaporePteLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesMember_47bac647-f949-4e87-ae32-1594cb5d1b0b" xlink:to="loc_meso_LonzaBioscienceSingaporePteLtdMember_ad2cff96-62b4-4481-bc20-f2114baf1afd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember_684b36ef-685c-4d82-b239-56164ce36596_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsMember_684b36ef-685c-4d82-b239-56164ce36596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember_cbb170a7-9b3a-48c0-9a2d-7b71b5fde975" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsMember_cbb170a7-9b3a-48c0-9a2d-7b71b5fde975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingServiceAgreementMember_62ef50de-bd30-418a-b890-9d91694b5c08" xlink:href="meso-20231231.xsd#meso_ManufacturingServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsMember_cbb170a7-9b3a-48c0-9a2d-7b71b5fde975" xlink:to="loc_meso_ManufacturingServiceAgreementMember_62ef50de-bd30-418a-b890-9d91694b5c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfCashHeld_e6b0b7f6-36c5-4c7b-a986-a0b94e3d7179" xlink:href="meso-20231231.xsd#meso_PercentageOfCashHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_PercentageOfCashHeld_e6b0b7f6-36c5-4c7b-a986-a0b94e3d7179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOnProfitFromChangeInInterestRate_b2c9ac5a-14bc-48e4-ae99-42dfa0e60ff7" xlink:href="meso-20231231.xsd#meso_EffectOnProfitFromChangeInInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_EffectOnProfitFromChangeInInterestRate_b2c9ac5a-14bc-48e4-ae99-42dfa0e60ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfForecastNetSales_8e628b7e-181d-4f3e-bb64-2de146fef5ca" xlink:href="meso-20231231.xsd#meso_PercentageOfForecastNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_PercentageOfForecastNetSales_8e628b7e-181d-4f3e-bb64-2de146fef5ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_d29b6324-6153-4e5b-98a0-28ad3683f73a" xlink:href="meso-20231231.xsd#meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_d29b6324-6153-4e5b-98a0-28ad3683f73a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_7ae5c9cc-0cb4-40a4-863f-5c4e0c85d787" xlink:href="meso-20231231.xsd#meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_7ae5c9cc-0cb4-40a4-863f-5c4e0c85d787" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_2d8413b7-4573-4618-a138-3e08a65718a6" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_2d8413b7-4573-4618-a138-3e08a65718a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmount_39d5da07-482f-4860-85fe-4d8d692ceaeb" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentReductionAmount_39d5da07-482f-4860-85fe-4d8d692ceaeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_d8403336-6eda-4eb7-b51b-1b4d43802c3d" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_d8403336-6eda-4eb7-b51b-1b4d43802c3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_bb259166-dadf-4a2c-ba83-766dff0ac0ab" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_bb259166-dadf-4a2c-ba83-766dff0ac0ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonCancellablePurchaseCommitments_3e8db371-8ab6-4cdc-9c75-f4e747844f5a" xlink:href="meso-20231231.xsd#meso_NonCancellablePurchaseCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_NonCancellablePurchaseCommitments_3e8db371-8ab6-4cdc-9c75-f4e747844f5a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherPurchaseCommitments_3f6a8072-1007-4699-ad9f-1de1ee23cb10" xlink:href="meso-20231231.xsd#meso_OtherPurchaseCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_OtherPurchaseCommitments_3f6a8072-1007-4699-ad9f-1de1ee23cb10" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_cf9b5aa3-c804-4dfe-ac35-a403515deb76_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:to="loc_currency_AllCurrenciesDomain_cf9b5aa3-c804-4dfe-ac35-a403515deb76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:to="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_d5792d89-6374-41b9-9a60-e73ebbd040bd" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:to="loc_currency_USD_d5792d89-6374-41b9-9a60-e73ebbd040bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_58f9e750-0198-4c79-9f47-6fd56243ca68" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:to="loc_currency_AUD_58f9e750-0198-4c79-9f47-6fd56243ca68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_021b707e-6bd8-4f34-83c4-059c72dc1601_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:to="loc_ifrs-full_RangesMember_021b707e-6bd8-4f34-83c4-059c72dc1601_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:to="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_e0fd2dcc-38a6-4713-910e-89f6506111d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:to="loc_ifrs-full_BottomOfRangeMember_e0fd2dcc-38a6-4713-910e-89f6506111d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_f13b5992-dbd6-40b1-a88d-3a5d261bb215" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:to="loc_ifrs-full_TopOfRangeMember_f13b5992-dbd6-40b1-a88d-3a5d261bb215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_ca88ef55-3dbe-4122-923d-6bf33baca866_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:to="loc_ifrs-full_TypesOfRisksMember_ca88ef55-3dbe-4122-923d-6bf33baca866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_bd2ef2f1-0d89-46f1-9a61-9dd377e73146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:to="loc_ifrs-full_TypesOfRisksMember_bd2ef2f1-0d89-46f1-9a61-9dd377e73146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_fb80cd13-3c0c-4a51-8e37-5f55d95c66f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_bd2ef2f1-0d89-46f1-9a61-9dd377e73146" xlink:to="loc_ifrs-full_InterestRateRiskMember_fb80cd13-3c0c-4a51-8e37-5f55d95c66f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FundsInvestedPercentage_bfb305d7-ed08-49a5-afa5-d530dff2372f" xlink:href="meso-20231231.xsd#meso_FundsInvestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_FundsInvestedPercentage_bfb305d7-ed08-49a5-afa5-d530dff2372f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseInInterestRatePercentage_032f171c-8d2b-4f49-8a99-a24e660d2f96" xlink:href="meso-20231231.xsd#meso_IncreaseInInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_IncreaseInInterestRatePercentage_032f171c-8d2b-4f49-8a99-a24e660d2f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DecreaseInInterestRatePercentage_8029451e-d3a9-43d9-9e53-9a662bd118f1" xlink:href="meso-20231231.xsd#meso_DecreaseInInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_DecreaseInInterestRatePercentage_8029451e-d3a9-43d9-9e53-9a662bd118f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FundsInvestedWhichDerivesInterestRevenue_4477a2b8-b179-424a-b4ec-4554ce4843ea" xlink:href="meso-20231231.xsd#meso_FundsInvestedWhichDerivesInterestRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_FundsInvestedWhichDerivesInterestRevenue_4477a2b8-b179-424a-b4ec-4554ce4843ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_5755ae1f-3333-4282-a8b7-19a58b1fc2ff" xlink:href="meso-20231231.xsd#meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_5755ae1f-3333-4282-a8b7-19a58b1fc2ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_74401eff-c46b-41a1-b95c-dff6fd328dd2" xlink:href="meso-20231231.xsd#meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_74401eff-c46b-41a1-b95c-dff6fd328dd2" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_4248efb9-7ee1-4138-b790-bc679abd39b9" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_4248efb9-7ee1-4138-b790-bc679abd39b9" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_7bbc2edf-165a-4ae8-bcff-62520223a2ea_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:to="loc_ifrs-full_TypesOfRisksMember_7bbc2edf-165a-4ae8-bcff-62520223a2ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_0f6c96e7-f81f-4faa-829d-ad72583d7c1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:to="loc_ifrs-full_TypesOfRisksMember_0f6c96e7-f81f-4faa-829d-ad72583d7c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_f8edab20-482e-4796-9c76-446cf621530b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_0f6c96e7-f81f-4faa-829d-ad72583d7c1c" xlink:to="loc_ifrs-full_InterestRateRiskMember_f8edab20-482e-4796-9c76-446cf621530b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:to="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_a42d4518-0f0b-45b8-9a6d-160a274741e5_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:to="loc_currency_AllCurrenciesDomain_a42d4518-0f0b-45b8-9a6d-160a274741e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:to="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_a7bdd39b-57fc-4827-8ab4-f321af107f70" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:to="loc_currency_USD_a7bdd39b-57fc-4827-8ab4-f321af107f70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_34d166da-d2d7-4328-95f1-0899b63245c7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:to="loc_currency_AUD_34d166da-d2d7-4328-95f1-0899b63245c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_25549b8b-d66f-4487-bcaa-ac4b283ba60d" xlink:href="meso-20231231.xsd#meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_4248efb9-7ee1-4138-b790-bc679abd39b9" xlink:to="loc_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_25549b8b-d66f-4487-bcaa-ac4b283ba60d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_ea9dac77-5a14-4711-a64f-801cceb9b940_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:to="loc_ifrs-full_TypesOfRisksMember_ea9dac77-5a14-4711-a64f-801cceb9b940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_32e282ce-f386-4d3c-9ced-705b7ad99152" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:to="loc_ifrs-full_TypesOfRisksMember_32e282ce-f386-4d3c-9ced-705b7ad99152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommodityPriceRiskMember_bba759fc-70b2-4ea1-a593-193ef844edf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommodityPriceRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_32e282ce-f386-4d3c-9ced-705b7ad99152" xlink:to="loc_ifrs-full_CommodityPriceRiskMember_bba759fc-70b2-4ea1-a593-193ef844edf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermBorrowings_677ad2ad-c713-40da-97ca-16573ca0d82f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_ifrs-full_ShorttermBorrowings_677ad2ad-c713-40da-97ca-16573ca0d82f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_53faa67e-8249-47d9-a46c-060aacd23e53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_ifrs-full_LongtermBorrowings_53faa67e-8249-47d9-a46c-060aacd23e53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_02f5dda1-f963-478f-a9fe-f5544fe1f16a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_ifrs-full_Borrowings_02f5dda1-f963-478f-a9fe-f5544fe1f16a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings_01243005-3bab-4d7e-b3ea-f6abaca6faa6" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInCurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings_01243005-3bab-4d7e-b3ea-f6abaca6faa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_5be9528b-a4e0-4adf-bcfb-a47acdff2321" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInNonCurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_5be9528b-a4e0-4adf-bcfb-a47acdff2321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInBorrowings_2b67d976-6ab8-4698-941a-c51eec684727" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_PercentageOfPriceRateChangesInBorrowings_2b67d976-6ab8-4698-941a-c51eec684727" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:to="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e4e49aaf-3dbf-4150-afef-1899c5fca8e9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:to="loc_ifrs-full_RangesMember_e4e49aaf-3dbf-4150-afef-1899c5fca8e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:to="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_a97a204c-e571-42e5-ae7a-18c58fc8c54e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:to="loc_ifrs-full_TopOfRangeMember_a97a204c-e571-42e5-ae7a-18c58fc8c54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_5b96563d-880d-4949-9f16-48426073652d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:to="loc_ifrs-full_BottomOfRangeMember_5b96563d-880d-4949-9f16-48426073652d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_ac056eb6-4524-4e1f-94b0-718d5d5f9847" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_ifrs-full_WarrantLiability_ac056eb6-4524-4e1f-94b0-718d5d5f9847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_6b304ab3-cf73-4984-94b4-f76c8121453a" xlink:href="meso-20231231.xsd#meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_6b304ab3-cf73-4984-94b4-f76c8121453a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_a49b3d29-ea91-4d95-a1dc-522c802a7cba" xlink:href="meso-20231231.xsd#meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_a49b3d29-ea91-4d95-a1dc-522c802a7cba" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ca084746-a85a-42a2-bacb-b54b33d95627_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_ca084746-a85a-42a2-bacb-b54b33d95627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_879a42b6-ced8-44c6-9221-c98d1c7ad148" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_879a42b6-ced8-44c6-9221-c98d1c7ad148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TradePayablesMember_08398287-24e0-4b43-a812-44ea47b724c7" xlink:href="meso-20231231.xsd#meso_TradePayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_meso_TradePayablesMember_08398287-24e0-4b43-a812-44ea47b724c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_13ccf2f7-25d0-4836-aa85-6e6e562bcfa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_13ccf2f7-25d0-4836-aa85-6e6e562bcfa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_ec361d1c-5d5c-44fe-b18b-4aa556a66f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_ifrs-full_ContingentConsiderationMember_ec361d1c-5d5c-44fe-b18b-4aa556a66f0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:to="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_377fc04d-d61a-43e7-bad5-c7a02b9979a5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_377fc04d-d61a-43e7-bad5-c7a02b9979a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_0ec7840e-263e-49f8-b98d-36726c125f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_0ec7840e-263e-49f8-b98d-36726c125f1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2236282d-a67d-4dc3-b6a1-70703dcdb6d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2236282d-a67d-4dc3-b6a1-70703dcdb6d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3ee0e023-d839-4388-a207-cb8225b03dae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3ee0e023-d839-4388-a207-cb8225b03dae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_4ded5142-abe4-44c8-ae6e-9a094a29bdd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_4ded5142-abe4-44c8-ae6e-9a094a29bdd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_c75231c8-a2e9-4123-822d-21b11b111546" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_c75231c8-a2e9-4123-822d-21b11b111546" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLoanCommitments_09917ab8-f5f8-4377-b945-6df443d198ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLoanCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:to="loc_ifrs-full_GrossLoanCommitments_09917ab8-f5f8-4377-b945-6df443d198ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>meso-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1c79165c-755b-4603-a45e-827a45827c07,g:19d448ab-9536-4f20-ab7d-76d6f5e0018c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_4bbb31bb-d39e-45d3-b563-34900f2a2796_terseLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of contingent consideration</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_label_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Remeasurement Of Contingent Consideration After Tax</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_documentation_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration after tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsiderationAfterTax" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsiderationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValueRemeasurementOfContingentConsiderationAfterTax" xlink:to="lab_meso_FairValueRemeasurementOfContingentConsiderationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_64039e69-3835-458c-98db-ba31fdbff130_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_e4e27f42-d7b2-4b54-af2f-13f92a847d2e_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock_098dad41-3625-447f-9eb9-5791c3acca56_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Movements Related to Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Net Movement Related To Deferred Tax Assets And Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of net movement related to deferred tax assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxLiabilityAbstract_4011cd81-7636-41ce-bcac-f47a3f36416e_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_meso_DeferredTaxLiabilityAbstract_label_en-US" xlink:label="lab_meso_DeferredTaxLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability [Abstract]</link:label>
    <link:label id="lab_meso_DeferredTaxLiabilityAbstract_documentation_en-US" xlink:label="lab_meso_DeferredTaxLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxLiabilityAbstract" xlink:href="meso-20231231.xsd#meso_DeferredTaxLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxLiabilityAbstract" xlink:to="lab_meso_DeferredTaxLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cb76f12b-1823-4d0c-b3d4-e350f14a1e11_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncomeStatementLocationsAxis_ab3013fe-bbb2-46d2-949f-90099bdedb55_terseLabel_en-US" xlink:label="lab_meso_IncomeStatementLocationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Locations</link:label>
    <link:label id="lab_meso_IncomeStatementLocationsAxis_label_en-US" xlink:label="lab_meso_IncomeStatementLocationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Locations [Axis]</link:label>
    <link:label id="lab_meso_IncomeStatementLocationsAxis_documentation_en-US" xlink:label="lab_meso_IncomeStatementLocationsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income statement locations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationsAxis" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncomeStatementLocationsAxis" xlink:to="lab_meso_IncomeStatementLocationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_9fc5c214-f371-43c6-ab6d-288e5db399c5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_95b1d52b-b5c9-4820-8b50-1353cbdf6104_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FairValuePerWarrant_1e1f77ce-93fa-41a0-af87-63d61301eb5e_terseLabel_en-US" xlink:label="lab_meso_FairValuePerWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per warrant (in dollars per share)</link:label>
    <link:label id="lab_meso_FairValuePerWarrant_label_en-US" xlink:label="lab_meso_FairValuePerWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Per Warrant</link:label>
    <link:label id="lab_meso_FairValuePerWarrant_documentation_en-US" xlink:label="lab_meso_FairValuePerWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value per warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValuePerWarrant" xlink:href="meso-20231231.xsd#meso_FairValuePerWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValuePerWarrant" xlink:to="lab_meso_FairValuePerWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_dad15acd-1937-409c-85e6-0d84f96a0501_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RegulatoryEnvironmentsAxis_9beadfea-7df1-4084-9a5d-5ad8168e3224_terseLabel_en-US" xlink:label="lab_ifrs-full_RegulatoryEnvironmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory environments [axis]</link:label>
    <link:label id="lab_ifrs-full_RegulatoryEnvironmentsAxis_label_en-US" xlink:label="lab_ifrs-full_RegulatoryEnvironmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory environments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsAxis" xlink:to="lab_ifrs-full_RegulatoryEnvironmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_1a105f81-a41d-41b0-bdfe-2497e679de07_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingCostsCapitalised_94ca11f0-be1a-4b81-aa2d-579a03cb2975_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of carrying amount, net of payments made</link:label>
    <link:label id="lab_ifrs-full_BorrowingCostsCapitalised_label_en-US" xlink:label="lab_ifrs-full_BorrowingCostsCapitalised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing costs capitalised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingCostsCapitalised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingCostsCapitalised" xlink:to="lab_ifrs-full_BorrowingCostsCapitalised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentProvisions_3ca1a42e-62df-4135-8eca-47893fa05c2f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_ca5be75b-685a-4ead-8b91-e28da87e7dc8_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_CurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_CurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentProvisions" xlink:to="lab_ifrs-full_CurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_973d1260-8a44-45a3-aa60-8e2c82fff553_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8014be8f-cd0a-4068-8de6-9c8e437b5890_negatedLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization charge</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities_368778a1-917d-4a79-add0-2cff910e2941_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation technique</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of valuation techniques used in fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WagesAndSalaries_b48bdd2d-883c-43bb-9152-aba0d811c793_negatedLabel_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and employee benefits</link:label>
    <link:label id="lab_ifrs-full_WagesAndSalaries_label_en-US" xlink:label="lab_ifrs-full_WagesAndSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wages and salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WagesAndSalaries" xlink:to="lab_ifrs-full_WagesAndSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_f59a93fc-fdb2-4b1e-b672-8a486cecfbc3_totalLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Contributed Equity (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_06cac3d3-e4b7-47f0-a158-9997c5ee1224_negatedLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit/(expense)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_a22581af-34b8-4b9d-82b5-54990340edc9_totalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit)/expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock_fc790d69-680e-40f1-b1a3-858b3ce3cdbd_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Carrying Value of In Process Research and Development Acquired by Product</link:label>
    <link:label id="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Carrying Value Of In Process Research And Development Acquired By Product Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of carrying value of in process research and development acquired by product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_8bd37829-47e6-4ab1-a693-8dfd124f3944_terseLabel_en-US" xlink:label="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Manufacturing, Regulatory and Reimbursement Approval</link:label>
    <link:label id="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_label_en-US" xlink:label="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Manufacturing Regulatory And Reimbursement Approval [Member]</link:label>
    <link:label id="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_documentation_en-US" xlink:label="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, manufacturing, regulatory and reimbursement approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" xlink:href="meso-20231231.xsd#meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" xlink:to="lab_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepayments_11ae6436-21bb-4c0f-9dcb-eff64d08e0d3_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepayments_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepayments" xlink:to="lab_ifrs-full_CurrentPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_f78dc0e9-b740-4fe0-b68d-72f308d77a29_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of employee benefits expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:to="lab_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock_f0fd6971-8e8c-4c36-8762-32c305b42757_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Detailed Information About Valuation Processes of Contingent Consideration at Fair Value Explanatory</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Valuation Processes Of Contingent Consideration At Fair Value Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about valuation processes of contingent consideration at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a299615e-9565-4748-9371-3c78ff4d0a1f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Term</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DefinedContributionSuperannuationExpenses_65de0ea2-14d0-4d31-ae3f-59dbd939e189_negatedLabel_en-US" xlink:label="lab_meso_DefinedContributionSuperannuationExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution superannuation expenses</link:label>
    <link:label id="lab_meso_DefinedContributionSuperannuationExpenses_label_en-US" xlink:label="lab_meso_DefinedContributionSuperannuationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Superannuation Expenses</link:label>
    <link:label id="lab_meso_DefinedContributionSuperannuationExpenses_documentation_en-US" xlink:label="lab_meso_DefinedContributionSuperannuationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution superannuation expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DefinedContributionSuperannuationExpenses" xlink:href="meso-20231231.xsd#meso_DefinedContributionSuperannuationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DefinedContributionSuperannuationExpenses" xlink:to="lab_meso_DefinedContributionSuperannuationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_4530f025-e492-4882-9bd5-853bbb5af5eb_terseLabel_en-US" xlink:label="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities</link:label>
    <link:label id="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_label_en-US" xlink:label="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Reasonably Possible Increase (Decrease) In Fair Value Measurement Due To Change In Unobservable Input, Liabilities</link:label>
    <link:label id="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_documentation_en-US" xlink:label="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Reasonably Possible Increase (Decrease) In Fair Value Measurement Due To Change In Unobservable Input, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" xlink:href="meso-20231231.xsd#meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" xlink:to="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract_54193abf-d5f5-4c09-8f3a-05f60c4167f7_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Not Brought To Account For Unused Tax Losses [Abstract]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not brought to account for unused tax losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" xlink:to="lab_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_fe8e9ff8-20b4-415c-aef3-558105b5390e_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ReceiptsFromInvestmentInSublease_d1095e07-d9d5-42f8-a257-385449021662_verboseLabel_en-US" xlink:label="lab_meso_ReceiptsFromInvestmentInSublease" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts from investment in sublease</link:label>
    <link:label id="lab_meso_ReceiptsFromInvestmentInSublease_label_en-US" xlink:label="lab_meso_ReceiptsFromInvestmentInSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts From Investment In Sublease</link:label>
    <link:label id="lab_meso_ReceiptsFromInvestmentInSublease_documentation_en-US" xlink:label="lab_meso_ReceiptsFromInvestmentInSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts From Investment In Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ReceiptsFromInvestmentInSublease" xlink:href="meso-20231231.xsd#meso_ReceiptsFromInvestmentInSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ReceiptsFromInvestmentInSublease" xlink:to="lab_meso_ReceiptsFromInvestmentInSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_df119366-c1fe-4fbc-a543-89454b6d8c5c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Used in calculating basic (losses) per share</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_f9cdade8-591e-4c46-ac45-e70e8b5f9dbd_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax losses</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Attributable To Temporary Differences From Tax Losses</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets attributable to temporary differences from tax losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" xlink:to="lab_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_a9daddd6-f135-4695-854f-799b8de7a044_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions with owners in their capacity as owners</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManufacturingServiceAgreementMember_fd78b1fc-a5ac-4569-aa2e-dcd04f442c17_terseLabel_en-US" xlink:label="lab_meso_ManufacturingServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Service Agreement</link:label>
    <link:label id="lab_meso_ManufacturingServiceAgreementMember_label_en-US" xlink:label="lab_meso_ManufacturingServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Service Agreement [Member]</link:label>
    <link:label id="lab_meso_ManufacturingServiceAgreementMember_documentation_en-US" xlink:label="lab_meso_ManufacturingServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing service agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingServiceAgreementMember" xlink:href="meso-20231231.xsd#meso_ManufacturingServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManufacturingServiceAgreementMember" xlink:to="lab_meso_ManufacturingServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TrancheTwoMember_5d9233fc-1b2f-4df2-a86a-4317038fef47_terseLabel_en-US" xlink:label="lab_meso_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_meso_TrancheTwoMember_label_en-US" xlink:label="lab_meso_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_meso_TrancheTwoMember_documentation_en-US" xlink:label="lab_meso_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TrancheTwoMember" xlink:href="meso-20231231.xsd#meso_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TrancheTwoMember" xlink:to="lab_meso_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PostTaxDiscountRates_70955cef-918f-4191-8e7d-f3b716475a5e_terseLabel_en-US" xlink:label="lab_meso_PostTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post tax discount rates</link:label>
    <link:label id="lab_meso_PostTaxDiscountRates_label_en-US" xlink:label="lab_meso_PostTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Tax Discount Rates</link:label>
    <link:label id="lab_meso_PostTaxDiscountRates_documentation_en-US" xlink:label="lab_meso_PostTaxDiscountRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post tax discount rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PostTaxDiscountRates" xlink:href="meso-20231231.xsd#meso_PostTaxDiscountRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PostTaxDiscountRates" xlink:to="lab_meso_PostTaxDiscountRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_e2d9f4a8-0c56-4618-80e6-e7049c0061a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted - losses per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_a17cd7ac-a8f0-432b-a4b2-e8370f325636_verboseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_71086642-a98e-4ce6-849d-daf751e33325_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities at FVTPL</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_1969128e-c73d-42c1-b269-764ed411897b_terseLabel_en-US" xlink:label="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- directly to equity</link:label>
    <link:label id="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_label_en-US" xlink:label="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Movement In Regulatory Deferral Account Balances Related To Directly To Equity</link:label>
    <link:label id="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_documentation_en-US" xlink:label="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net movement in regulatory deferral account balances related to directly to equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" xlink:href="meso-20231231.xsd#meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" xlink:to="lab_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_30a62c6c-cc06-409a-900d-620b38a199d9_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types</link:label>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_a6c94186-d90c-43f2-825f-5e7d4382b9f8_terseLabel_en-US" xlink:label="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines</link:label>
    <link:label id="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_label_en-US" xlink:label="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patients To Provide Regulatory Harmonization Cost Efficiencies And Streamlined Timelines</link:label>
    <link:label id="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_documentation_en-US" xlink:label="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" xlink:href="meso-20231231.xsd#meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" xlink:to="lab_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_cb0d7585-5b20-4a5c-b522-ff2cb9368869_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_db00f6cc-0ab7-4dbb-974b-87a2fd57f380_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_0aec600a-a420-481a-be04-fa083af6368d_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentProvisions_label_en-US" xlink:label="lab_ifrs-full_NoncurrentProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentProvisions" xlink:to="lab_ifrs-full_NoncurrentProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue_f1acb121-1a06-4de6-930a-b3fbf1155f47_terseLabel_en-US" xlink:label="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liabilities measured at fair value</link:label>
    <link:label id="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue_label_en-US" xlink:label="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Liabilities Measured At Fair Value</link:label>
    <link:label id="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue_documentation_en-US" xlink:label="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liabilities measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfLiabilitiesMeasuredAtFairValue" xlink:href="meso-20231231.xsd#meso_PercentageOfLiabilitiesMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfLiabilitiesMeasuredAtFairValue" xlink:to="lab_meso_PercentageOfLiabilitiesMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_BorrowingsPrincipalAmortizationPeriod_6489a2f6-302c-4e73-8fe8-a73e2ed07154_terseLabel_en-US" xlink:label="lab_meso_BorrowingsPrincipalAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_meso_BorrowingsPrincipalAmortizationPeriod_label_en-US" xlink:label="lab_meso_BorrowingsPrincipalAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Principal Amortization Period</link:label>
    <link:label id="lab_meso_BorrowingsPrincipalAmortizationPeriod_documentation_en-US" xlink:label="lab_meso_BorrowingsPrincipalAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Principal Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsPrincipalAmortizationPeriod" xlink:href="meso-20231231.xsd#meso_BorrowingsPrincipalAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_BorrowingsPrincipalAmortizationPeriod" xlink:to="lab_meso_BorrowingsPrincipalAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock_2b44719f-6c50-4c80-83e8-858eef1fd12c_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings</link:label>
    <link:label id="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Legal Proceedings Explanatory [Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of legal proceedings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfLegalProceedingsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" xlink:to="lab_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_579b1de3-696d-45da-87e4-ecdf9973c107_terseLabel_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of borrowing arrangements within finance gains (loss)</link:label>
    <link:label id="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_label_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains (Loss) On Remeasurement Of Borrowing Arrangements</link:label>
    <link:label id="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_documentation_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs gains (loss) on remeasurement of borrowing arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" xlink:to="lab_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_4ed40413-5148-4b12-a192-fdedcd909eca_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities at amortized cost</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at amortised cost, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_a0439519-1c80-4518-b6bc-6523df5753d3_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade &amp; other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_85a9daa0-a802-4b18-b072-d05ce770d0cd_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillMember_ba72102c-5501-4e4b-9c66-31efb6d0da08_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_4e4489fa-7aff-45f5-90b9-ef82b067f764_terseLabel_en-US" xlink:label="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount entitled to be received upon reaching product clinical and regulatory milestones and reimbursement targets are achieved</link:label>
    <link:label id="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_label_en-US" xlink:label="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Entitled To Be Received Upon Reaching Product Clinical And Regulatory Milestones And Reimbursement Targets Are Achieved</link:label>
    <link:label id="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_documentation_en-US" xlink:label="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Entitled To Be Received Upon Reaching Product Clinical And Regulatory Milestones And Reimbursement Targets Are Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" xlink:href="meso-20231231.xsd#meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" xlink:to="lab_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_7d99c103-0e28-417b-a8c9-25e276035145_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock_86b94805-fce9-44ce-99ad-816c37d3b2dc_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Loss Before Income Tax Explanatory [Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about loss before income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_d73b17e2-3d5a-4b4f-9317-fa1489ef8ab7_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_dfdaba6a-6044-433c-8f63-b88ea80bb01b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProbabilityOfDefaultAxis_1a61e0b0-9773-407b-952f-00221bfd2d27_terseLabel_en-US" xlink:label="lab_ifrs-full_ProbabilityOfDefaultAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of default [axis]</link:label>
    <link:label id="lab_ifrs-full_ProbabilityOfDefaultAxis_label_en-US" xlink:label="lab_ifrs-full_ProbabilityOfDefaultAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of default [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProbabilityOfDefaultAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProbabilityOfDefaultAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProbabilityOfDefaultAxis" xlink:to="lab_ifrs-full_ProbabilityOfDefaultAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities_225c2f43-e6de-44e4-af63-66e5a0479f7e_terseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Changes, Leases</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease)in lease liabilities arising from financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" xlink:to="lab_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_9677d48d-1090-485a-bb36-04e3a7ad2b24_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic - losses per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_a733cd73-7981-4374-b26e-eb166926599e_verboseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lab_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_366c629b-60ff-408c-b97a-0fc26842ad94_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets and liabilities table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:to="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_3978b04f-8228-45fd-8a00-22903790f562_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of exercised options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_6ad97113-ec20-42d4-9ee1-b02fbadb08f6_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities_1db2c4ce-922a-4aaa-85ee-5141ce219d65_terseLabel_en-US" xlink:label="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount paid in cash outflows from operating activities</link:label>
    <link:label id="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities_label_en-US" xlink:label="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount In Cash Outflows From Operating Activities</link:label>
    <link:label id="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities_documentation_en-US" xlink:label="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount in cash outflows from operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MaximumAmountInCashOutflowsFromOperatingActivities" xlink:href="meso-20231231.xsd#meso_MaximumAmountInCashOutflowsFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MaximumAmountInCashOutflowsFromOperatingActivities" xlink:to="lab_meso_MaximumAmountInCashOutflowsFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfForecastNetSales_78686ee4-d75c-4b06-80e5-7d91e3e755d8_terseLabel_en-US" xlink:label="lab_meso_PercentageOfForecastNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of forecast net sales</link:label>
    <link:label id="lab_meso_PercentageOfForecastNetSales_label_en-US" xlink:label="lab_meso_PercentageOfForecastNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Forecast Net Sales</link:label>
    <link:label id="lab_meso_PercentageOfForecastNetSales_documentation_en-US" xlink:label="lab_meso_PercentageOfForecastNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of forecast net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfForecastNetSales" xlink:href="meso-20231231.xsd#meso_PercentageOfForecastNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfForecastNetSales" xlink:to="lab_meso_PercentageOfForecastNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_61cc0fb6-c498-4837-92a9-e56607a0e92c_terseLabel_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</link:label>
    <link:label id="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_label_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques used in fair value measurement [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:to="lab_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases_7d820850-3fb7-4211-8068-6ce6dca93053_verboseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange adjustments, Leases</link:label>
    <link:label id="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases_label_en-US" xlink:label="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease Through Effect Of Changes In Foreign Exchange Rates Liabilities Arising From Leases</link:label>
    <link:label id="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" xlink:to="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_029d7d6b-562d-41de-b6f1-a99463dce7a3_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_5c7bdf05-8102-49eb-a129-bf3c884940d3_terseLabel_en-US" xlink:label="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten percent of increase in share price</link:label>
    <link:label id="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_label_en-US" xlink:label="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of net income risk based on increase in share price</link:label>
    <link:label id="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_documentation_en-US" xlink:label="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of net income risk based on increase in share price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" xlink:href="meso-20231231.xsd#meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" xlink:to="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_3ddfb35d-4d03-4c53-881c-06f53781c6d4_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManagementAndAdministrationMember_dff0715c-ebd4-47ba-8e11-51da4e0c2f9d_terseLabel_en-US" xlink:label="lab_meso_ManagementAndAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management and administration</link:label>
    <link:label id="lab_meso_ManagementAndAdministrationMember_label_en-US" xlink:label="lab_meso_ManagementAndAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management And Administration [Member]</link:label>
    <link:label id="lab_meso_ManagementAndAdministrationMember_documentation_en-US" xlink:label="lab_meso_ManagementAndAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management and administration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManagementAndAdministrationMember" xlink:href="meso-20231231.xsd#meso_ManagementAndAdministrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManagementAndAdministrationMember" xlink:to="lab_meso_ManagementAndAdministrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RoyaltyPaymentsAtFairValueLiabilities_cf40d17c-dc7f-4dbe-9032-72116c1c0c0a_terseLabel_en-US" xlink:label="lab_meso_RoyaltyPaymentsAtFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of royalty payments from commercialization of the intellectual property acquired</link:label>
    <link:label id="lab_meso_RoyaltyPaymentsAtFairValueLiabilities_label_en-US" xlink:label="lab_meso_RoyaltyPaymentsAtFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payments At Fair Value Liabilities</link:label>
    <link:label id="lab_meso_RoyaltyPaymentsAtFairValueLiabilities_documentation_en-US" xlink:label="lab_meso_RoyaltyPaymentsAtFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments at fair value, liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RoyaltyPaymentsAtFairValueLiabilities" xlink:href="meso-20231231.xsd#meso_RoyaltyPaymentsAtFairValueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RoyaltyPaymentsAtFairValueLiabilities" xlink:to="lab_meso_RoyaltyPaymentsAtFairValueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_BorrowingsTerm_078f2735-555b-408e-8f67-82a7799c3ac0_terseLabel_en-US" xlink:label="lab_meso_BorrowingsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings term</link:label>
    <link:label id="lab_meso_BorrowingsTerm_label_en-US" xlink:label="lab_meso_BorrowingsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Term</link:label>
    <link:label id="lab_meso_BorrowingsTerm_documentation_en-US" xlink:label="lab_meso_BorrowingsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsTerm" xlink:href="meso-20231231.xsd#meso_BorrowingsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_BorrowingsTerm" xlink:to="lab_meso_BorrowingsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock_f4136588-b1da-499e-bfc3-683bbbc483d8_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements</link:label>
    <link:label id="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Significant Unobservable Inputs Used In Fair Value Measurements Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about significant unobservable inputs used in fair value measurements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_ed222200-a525-420e-8eb0-c5995bc40f5a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions of equity net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through other contributions by owners, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_ff6e21df-ae34-49fa-a585-606ff43e11a8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManufacturingAndCommercializationMember_77f64e05-cd31-4e87-bf4b-684730603123_terseLabel_en-US" xlink:label="lab_meso_ManufacturingAndCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and commercialization</link:label>
    <link:label id="lab_meso_ManufacturingAndCommercializationMember_label_en-US" xlink:label="lab_meso_ManufacturingAndCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing And Commercialization [Member]</link:label>
    <link:label id="lab_meso_ManufacturingAndCommercializationMember_documentation_en-US" xlink:label="lab_meso_ManufacturingAndCommercializationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and commercialization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingAndCommercializationMember" xlink:href="meso-20231231.xsd#meso_ManufacturingAndCommercializationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManufacturingAndCommercializationMember" xlink:to="lab_meso_ManufacturingAndCommercializationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_c0ba77f4-9e95-466e-8830-0f5897750634_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FX gains/(losses) on the translation of foreign bank accounts</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_168aacb6-fb5d-4985-8389-4484a14741b1_verboseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange adjustments, cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_f759f9a5-fa5f-431b-9851-2fe8e0cad210_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_e6e0c4f4-9f82-440c-8510-c479e1dee337_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_9720ab8f-2102-4ca3-a08c-3e5e856245f8_terseLabel_en-US" xlink:label="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on re-measurement of contingent consideration provision</link:label>
    <link:label id="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_label_en-US" xlink:label="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Loss On Re Measurement Of Contingent Consideration Provision</link:label>
    <link:label id="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_documentation_en-US" xlink:label="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on re-measurement of contingent consideration provision.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GainLossOnReMeasurementOfContingentConsiderationProvision" xlink:href="meso-20231231.xsd#meso_GainLossOnReMeasurementOfContingentConsiderationProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_GainLossOnReMeasurementOfContingentConsiderationProvision" xlink:to="lab_meso_GainLossOnReMeasurementOfContingentConsiderationProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_b40f8818-4689-4e0a-b746-eb354453b606_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Trade and Other Payables</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FundsInvestedPercentage_32b3ce7b-7bb7-4d7c-9342-7e71e95bc267_terseLabel_en-US" xlink:label="lab_meso_FundsInvestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds invested percentage</link:label>
    <link:label id="lab_meso_FundsInvestedPercentage_label_en-US" xlink:label="lab_meso_FundsInvestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds Invested Percentage</link:label>
    <link:label id="lab_meso_FundsInvestedPercentage_documentation_en-US" xlink:label="lab_meso_FundsInvestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds invested percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FundsInvestedPercentage" xlink:href="meso-20231231.xsd#meso_FundsInvestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FundsInvestedPercentage" xlink:to="lab_meso_FundsInvestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_9c8f87e2-a76a-48d5-aa03-3f8fa7e8acd0_negatedLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for intellectual property</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_c3fa976f-6864-49f3-a913-34dda4d831b9_totalLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total basic (losses) per share attributable to the ordinary equity holders of the company (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfSharePremiumPrice_d999a721-b82c-4492-8eb0-7e4f64e2ffa4_terseLabel_en-US" xlink:label="lab_meso_PercentageOfSharePremiumPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share premium price</link:label>
    <link:label id="lab_meso_PercentageOfSharePremiumPrice_label_en-US" xlink:label="lab_meso_PercentageOfSharePremiumPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Share Premium Price</link:label>
    <link:label id="lab_meso_PercentageOfSharePremiumPrice_documentation_en-US" xlink:label="lab_meso_PercentageOfSharePremiumPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share premium price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfSharePremiumPrice" xlink:href="meso-20231231.xsd#meso_PercentageOfSharePremiumPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfSharePremiumPrice" xlink:to="lab_meso_PercentageOfSharePremiumPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentInterestReceivable_c2f49fa8-f5b9-4c2b-b182-13dce153a902_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentInterestReceivable_label_en-US" xlink:label="lab_ifrs-full_CurrentInterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current interest receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInterestReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInterestReceivable" xlink:to="lab_ifrs-full_CurrentInterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManufacturingCommercializationExpensesMember_10c53648-d02b-49ef-91cb-f18240e58fe0_terseLabel_en-US" xlink:label="lab_meso_ManufacturingCommercializationExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Commercialization Expenses</link:label>
    <link:label id="lab_meso_ManufacturingCommercializationExpensesMember_label_en-US" xlink:label="lab_meso_ManufacturingCommercializationExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Commercialization Expenses [Member]</link:label>
    <link:label id="lab_meso_ManufacturingCommercializationExpensesMember_documentation_en-US" xlink:label="lab_meso_ManufacturingCommercializationExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Commercialization expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingCommercializationExpensesMember" xlink:href="meso-20231231.xsd#meso_ManufacturingCommercializationExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManufacturingCommercializationExpensesMember" xlink:to="lab_meso_ManufacturingCommercializationExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock_98327c3e-e280-4284-aff5-12bceef11924_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Liability</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Warrant Liability Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities_2ce711e9-a4f3-4351-9ef8-cb430baf41de_verboseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows, Warrants liability</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Warrant Liabilities Arising From Financing Activities</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in warrant liabilities arising from financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" xlink:to="lab_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_cd38f3fd-fe08-4aaa-8f85-3f50c3e5de42_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OrdinarySharesPurchasedValue_918b26cc-627b-405f-9623-8be6381358ee_terseLabel_en-US" xlink:label="lab_meso_OrdinarySharesPurchasedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_meso_OrdinarySharesPurchasedValue_label_en-US" xlink:label="lab_meso_OrdinarySharesPurchasedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares Purchased Value</link:label>
    <link:label id="lab_meso_OrdinarySharesPurchasedValue_documentation_en-US" xlink:label="lab_meso_OrdinarySharesPurchasedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OrdinarySharesPurchasedValue" xlink:href="meso-20231231.xsd#meso_OrdinarySharesPurchasedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OrdinarySharesPurchasedValue" xlink:to="lab_meso_OrdinarySharesPurchasedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossOnFinancialAssets_6a854d25-9700-4e4f-b648-e8993d5a7e89_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossOnFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossOnFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss on financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossOnFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossOnFinancialAssets" xlink:to="lab_ifrs-full_ImpairmentLossOnFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PlacementAgreementMember_e860f751-09ec-420a-8daa-b647de8ed45e_terseLabel_en-US" xlink:label="lab_meso_PlacementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agreement</link:label>
    <link:label id="lab_meso_PlacementAgreementMember_label_en-US" xlink:label="lab_meso_PlacementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Agreement [Member]</link:label>
    <link:label id="lab_meso_PlacementAgreementMember_documentation_en-US" xlink:label="lab_meso_PlacementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PlacementAgreementMember" xlink:href="meso-20231231.xsd#meso_PlacementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PlacementAgreementMember" xlink:to="lab_meso_PlacementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnWarrants_1af4809d-7842-40c9-ad88-9c5e3ec74df6_terseLabel_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement adjustments, Warrant liability</link:label>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnWarrants_label_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Adjustments On Warrants</link:label>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnWarrants_documentation_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement adjustments on warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementAdjustmentsOnWarrants" xlink:href="meso-20231231.xsd#meso_RemeasurementAdjustmentsOnWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RemeasurementAdjustmentsOnWarrants" xlink:to="lab_meso_RemeasurementAdjustmentsOnWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_c2de367e-bf0f-4d0f-b8e3-f4e526d3af1c_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesMember_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesMember" xlink:to="lab_ifrs-full_ProductsAndServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems_c18e2565-292b-4c06-ace8-ff4e68000bfe_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems" xlink:to="lab_meso_DeferredTaxAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock_8b1ec920-20bb-4d0f-8cea-4d02d5377f41_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Debt</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Net Debt Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about net debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock_ce88d2f6-1240-4a17-9f90-92eb507305cb_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-financial assets and liabilities</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Non Financial Liabilities Explanatory [Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non financial assets and non financial liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" xlink:to="lab_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_4f221c89-b52d-4815-bcc0-1c60d8106266_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity settled share-based payment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDeferredTaxLiabilities_c0509516-d514-4a20-8250-0522cd5dd45f_totalLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDeferredTaxLiabilities" xlink:to="lab_ifrs-full_NetDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_fe11808d-64c9-420f-b8b3-671c3d1da9ef_terseLabel_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs loss on adjustment of carrying amount on financial liability</link:label>
    <link:label id="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_label_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains (Loss) On Adjustment Of Carrying Amount On Financial Liability</link:label>
    <link:label id="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_documentation_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains (Loss) On Adjustment Of Carrying Amount On Financial Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" xlink:to="lab_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_63a5cd25-2c97-468b-877c-085cbf62112a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_5ddaa0e1-655f-4406-b319-4347e28878a8_terseLabel_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum financial commitment reduction amount on lease component</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_label_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Reduction Amount on Lease Component</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_documentation_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Reduction Amount on Lease Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" xlink:to="lab_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_d2885daa-95e8-4621-a327-8820bc9b9937_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_5e7ca019-bbff-498a-9380-228290fb58ca_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock_e644806c-4a52-4c14-9556-51624d128473_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Flow Information</link:label>
    <link:label id="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Summary Of Cash Flow Information Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of summary of cash flow information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_b43fd1ba-61b6-4963-9b94-dd4b070d0a6d_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock_014bb8d1-1431-43fd-a056-9d44a95798c0_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movements of Shares in Share Trust</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movements Of Shares In Share Trust Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of movements of shares in share trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicencesMember_858fcf21-6af7-4ea5-a16c-8dfe7d69e75d_terseLabel_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired licenses to patents</link:label>
    <link:label id="lab_ifrs-full_LicencesMember_label_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivables_e0cae39f-1ef9-484b-8b9b-c1ae90919863_verboseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade debtors</link:label>
    <link:label id="lab_ifrs-full_TradeReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivables" xlink:to="lab_ifrs-full_TradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLoanCommitments_a00a291a-ee39-44f8-bc26-45b7dd2d86c1_negatedLabel_en-US" xlink:label="lab_ifrs-full_GrossLoanCommitments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_GrossLoanCommitments_label_en-US" xlink:label="lab_ifrs-full_GrossLoanCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross loan commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLoanCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLoanCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLoanCommitments" xlink:to="lab_ifrs-full_GrossLoanCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_3f63a3dc-da51-48e5-903a-3ff4a1e65016_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfWarrantReserveTable_b47d8a02-a0f1-4496-a546-c337c7f5fd94_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrant Reserve [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfWarrantReserveTable_label_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrant Reserve [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfWarrantReserveTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of warrant reserve.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfWarrantReserveTable" xlink:to="lab_meso_DisclosureOfWarrantReserveTable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_JCRPharmaceuticalsCoLTDMember_58ebdce9-6749-4279-b02f-1335c846e914_terseLabel_en-US" xlink:label="lab_meso_JCRPharmaceuticalsCoLTDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JCR Pharmaceuticals Co. Ltd</link:label>
    <link:label id="lab_meso_JCRPharmaceuticalsCoLTDMember_label_en-US" xlink:label="lab_meso_JCRPharmaceuticalsCoLTDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J C R Pharmaceuticals Co L T D [Member]</link:label>
    <link:label id="lab_meso_JCRPharmaceuticalsCoLTDMember_documentation_en-US" xlink:label="lab_meso_JCRPharmaceuticalsCoLTDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JCR Pharmaceuticals Co LTD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_JCRPharmaceuticalsCoLTDMember" xlink:href="meso-20231231.xsd#meso_JCRPharmaceuticalsCoLTDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_JCRPharmaceuticalsCoLTDMember" xlink:to="lab_meso_JCRPharmaceuticalsCoLTDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_8445b00f-b461-4fcd-b422-519a50a1843a_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsMember" xlink:to="lab_ifrs-full_FinancialAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ReceivableFromTaxCredits_966a954c-7f0f-4fad-a80e-f78ed3171e1b_terseLabel_en-US" xlink:label="lab_meso_ReceivableFromTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Tax credits</link:label>
    <link:label id="lab_meso_ReceivableFromTaxCredits_label_en-US" xlink:label="lab_meso_ReceivableFromTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable From Tax Credits</link:label>
    <link:label id="lab_meso_ReceivableFromTaxCredits_documentation_en-US" xlink:label="lab_meso_ReceivableFromTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from tax credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ReceivableFromTaxCredits" xlink:href="meso-20231231.xsd#meso_ReceivableFromTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ReceivableFromTaxCredits" xlink:to="lab_meso_ReceivableFromTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherChangesOnDebtAndLeases_3eaf0757-212f-477b-b90f-8ffc4352e6dc_terseLabel_en-US" xlink:label="lab_meso_OtherChangesOnDebtAndLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Changes</link:label>
    <link:label id="lab_meso_OtherChangesOnDebtAndLeases_label_en-US" xlink:label="lab_meso_OtherChangesOnDebtAndLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Changes On Debt And Leases</link:label>
    <link:label id="lab_meso_OtherChangesOnDebtAndLeases_documentation_en-US" xlink:label="lab_meso_OtherChangesOnDebtAndLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes on debt and leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherChangesOnDebtAndLeases" xlink:href="meso-20231231.xsd#meso_OtherChangesOnDebtAndLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherChangesOnDebtAndLeases" xlink:to="lab_meso_OtherChangesOnDebtAndLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PreLaunchInventoryRecognized_2c94cb46-6228-42f6-9ef5-c842c3a8554f_terseLabel_en-US" xlink:label="lab_meso_PreLaunchInventoryRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-launch inventory recognized</link:label>
    <link:label id="lab_meso_PreLaunchInventoryRecognized_label_en-US" xlink:label="lab_meso_PreLaunchInventoryRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Launch Inventory Recognized</link:label>
    <link:label id="lab_meso_PreLaunchInventoryRecognized_documentation_en-US" xlink:label="lab_meso_PreLaunchInventoryRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre launch inventory recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PreLaunchInventoryRecognized" xlink:href="meso-20231231.xsd#meso_PreLaunchInventoryRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PreLaunchInventoryRecognized" xlink:to="lab_meso_PreLaunchInventoryRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_b81fee4b-8b16-4eef-a26c-f5f2e7f16b71_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (gains)/losses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_4505eca2-c307-4037-8c46-6e589a4faf6c_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ConsultancyExpenses_379e54c4-5b37-4135-8366-1ff7f7991051_negatedLabel_en-US" xlink:label="lab_meso_ConsultancyExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy</link:label>
    <link:label id="lab_meso_ConsultancyExpenses_label_en-US" xlink:label="lab_meso_ConsultancyExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultancy Expenses</link:label>
    <link:label id="lab_meso_ConsultancyExpenses_documentation_en-US" xlink:label="lab_meso_ConsultancyExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to consultancy expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConsultancyExpenses" xlink:href="meso-20231231.xsd#meso_ConsultancyExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ConsultancyExpenses" xlink:to="lab_meso_ConsultancyExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_58b40604-785b-4f61-95b3-40f2305648af_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInEquity_87a20fbf-587f-4334-b62b-f2acc7a993f2_totalLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in equity</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquity_668bdb90-ec28-4faf-b10a-c5260127016a_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement during the period</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquity_label_en-US" xlink:label="lab_ifrs-full_ChangesInEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquity" xlink:to="lab_ifrs-full_ChangesInEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OutstandingCommonShareCapitalPercentage_6ec6d226-4953-42e4-8648-3a5e5885470b_terseLabel_en-US" xlink:label="lab_meso_OutstandingCommonShareCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding common share capital, percentage</link:label>
    <link:label id="lab_meso_OutstandingCommonShareCapitalPercentage_label_en-US" xlink:label="lab_meso_OutstandingCommonShareCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Common Share Capital, Percentage</link:label>
    <link:label id="lab_meso_OutstandingCommonShareCapitalPercentage_documentation_en-US" xlink:label="lab_meso_OutstandingCommonShareCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Common Share Capital, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OutstandingCommonShareCapitalPercentage" xlink:href="meso-20231231.xsd#meso_OutstandingCommonShareCapitalPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OutstandingCommonShareCapitalPercentage" xlink:to="lab_meso_OutstandingCommonShareCapitalPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_LossGainOnRemeasurementOfContingentConsideration_1a51241f-0c37-4647-ba36-fc3eceb1895b_negatedLabel_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of contingent consideration</link:label>
    <link:label id="lab_meso_LossGainOnRemeasurementOfContingentConsideration_c24861f0-6d13-4f51-91b7-30878f168fb3_verboseLabel_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement</link:label>
    <link:label id="lab_meso_LossGainOnRemeasurementOfContingentConsideration_label_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Gain On Remeasurement Of Contingent Consideration</link:label>
    <link:label id="lab_meso_LossGainOnRemeasurementOfContingentConsideration_documentation_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on remeasurement of contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:to="lab_meso_LossGainOnRemeasurementOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized_d0ed93c5-cbcb-47ee-8368-8da54f1b7c82_terseLabel_en-US" xlink:label="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration milestone consideration recognized</link:label>
    <link:label id="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized_label_en-US" xlink:label="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration Milestone Consideration Recognized</link:label>
    <link:label id="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized_documentation_en-US" xlink:label="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration milestone consideration recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredConsiderationMilestoneConsiderationRecognized" xlink:href="meso-20231231.xsd#meso_DeferredConsiderationMilestoneConsiderationRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredConsiderationMilestoneConsiderationRecognized" xlink:to="lab_meso_DeferredConsiderationMilestoneConsiderationRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_3476d915-afec-4e10-b8a2-0c1d55bc066c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Changes In Equity [Line Items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_93b63814-1762-428c-8e06-59173d7120d2_negatedLabel_en-US" xlink:label="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to suppliers and employees (inclusive of goods and services tax)</link:label>
    <link:label id="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_label_en-US" xlink:label="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Suppliers And Employees Inclusive Of Goods And Services Tax</link:label>
    <link:label id="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_documentation_en-US" xlink:label="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to suppliers and employees inclusive of goods and services tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" xlink:href="meso-20231231.xsd#meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" xlink:to="lab_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_dd6e6841-086c-4a57-87b7-3fe151fa2adb_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_b27b92a1-dd0c-407d-b95d-fd4c56947aac_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss)/income</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ResearchAndDevelopmentMember_15b9979b-de56-4a90-bd9f-5d1d1b112a6a_terseLabel_en-US" xlink:label="lab_meso_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_meso_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_meso_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_meso_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_meso_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ResearchAndDevelopmentMember" xlink:href="meso-20231231.xsd#meso_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ResearchAndDevelopmentMember" xlink:to="lab_meso_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_bab39f5f-b776-439b-862b-2f2e5fcd4d63_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_UnlistedEquitySecuritiesMember_b29acd5b-b131-4671-862c-e2a42bd64ee6_terseLabel_en-US" xlink:label="lab_meso_UnlistedEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unlisted Equity Securities</link:label>
    <link:label id="lab_meso_UnlistedEquitySecuritiesMember_label_en-US" xlink:label="lab_meso_UnlistedEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unlisted Equity Securities [Member]</link:label>
    <link:label id="lab_meso_UnlistedEquitySecuritiesMember_documentation_en-US" xlink:label="lab_meso_UnlistedEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unlisted equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UnlistedEquitySecuritiesMember" xlink:href="meso-20231231.xsd#meso_UnlistedEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_UnlistedEquitySecuritiesMember" xlink:to="lab_meso_UnlistedEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_1a5d20ec-8ffe-464c-9b0f-52327fc8166b_terseLabel_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross debt - variable interest rates</link:label>
    <link:label id="lab_ifrs-full_FloatingInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FloatingInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FloatingInterestRateMember" xlink:to="lab_ifrs-full_FloatingInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_72e062dd-beef-4504-958b-f0c5e1788f85_terseLabel_en-US" xlink:label="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of principal amount payable over two year</link:label>
    <link:label id="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_label_en-US" xlink:label="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Borrowing Principal Amount Payable Over Two Year</link:label>
    <link:label id="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_documentation_en-US" xlink:label="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of borrowing principal amount payable over two year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" xlink:href="meso-20231231.xsd#meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" xlink:to="lab_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_46c2a375-e7b8-4e5a-9e04-3c3a302f1e60_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_0414bce1-3988-48f6-969b-ae965c4bbaf3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_32b3362b-80c9-4863-98a8-9d3ad979fe1a_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForProbabilityOfDefaultMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for probability of default</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForProbabilityOfDefaultMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for probability of default [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForProbabilityOfDefaultMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember" xlink:to="lab_ifrs-full_EntitysTotalForProbabilityOfDefaultMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_632717be-cb01-4fff-b59e-80e47b16658e_terseLabel_en-US" xlink:label="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential tax benefit at local tax rates</link:label>
    <link:label id="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Credits For Which No Deferred Tax Asset Recognised</link:label>
    <link:label id="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_documentation_en-US" xlink:label="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax credits for which no deferred Tax Asset Recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:href="meso-20231231.xsd#meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_a9fc8a01-5b3b-4aec-bc37-f5c5a07b1eb5_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_977dab55-ad5e-4596-93f3-827b05b01357_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non financial assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" xlink:to="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseInCurrentTax_a595b28f-1a5b-41ad-bfc7-956942b2fc60_terseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseInCurrentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInCurrentTax_label_en-US" xlink:label="lab_meso_IncreaseDecreaseInCurrentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Current Tax</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInCurrentTax_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseInCurrentTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in current tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInCurrentTax" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInCurrentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseInCurrentTax" xlink:to="lab_meso_IncreaseDecreaseInCurrentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_a6d89125-1d7c-4be6-94f4-3c8808614ad3_terseLabel_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum financial commitment reduction amount on non lease component</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_label_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Reduction Amount on Non Lease Component</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_documentation_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Reduction Amount on Non Lease Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" xlink:to="lab_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_3a02134f-0f46-4df6-82d7-a8a452d5f30c_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SecuredBankLoansReceived_536e4fd1-005c-4b9e-956d-1beeb19e3faf_terseLabel_en-US" xlink:label="lab_ifrs-full_SecuredBankLoansReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing arrangements</link:label>
    <link:label id="lab_ifrs-full_SecuredBankLoansReceived_label_en-US" xlink:label="lab_ifrs-full_SecuredBankLoansReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured bank loans received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SecuredBankLoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SecuredBankLoansReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SecuredBankLoansReceived" xlink:to="lab_ifrs-full_SecuredBankLoansReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock_b1276ccc-4a5a-41a7-9d4e-49402700c0ed_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Borrowing to Price Rate Changes</link:label>
    <link:label id="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Borrowings Deriving Price Risk Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of borrowings deriving price risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_584a2456-bca6-4e34-9a17-035918601ce4_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_519c1c1a-36e4-411d-b653-0621a47ec080_terseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in australian dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_2a1d2fc0-d91e-4862-9e7d-8f7f7ca3db88_verboseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_609a429c-1df8-4014-a908-c39f57e64298_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowingsMember_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term borrowings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowingsMember" xlink:to="lab_ifrs-full_LongtermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_bb449c5d-ecd5-4026-ae87-a5af513e349c_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock_a2e5127c-4d4b-4c6d-8ff7-c0b0d998efe2_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Movements in Ordinary Share Capital</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movements In Ordinary Share Capital Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of movements in ordinary share capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SharesIssuedInPlacementsValue_38b5f08e-3951-4df1-82af-6debffa368c7_terseLabel_en-US" xlink:label="lab_meso_SharesIssuedInPlacementsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement of shares under a share placement agreement</link:label>
    <link:label id="lab_meso_SharesIssuedInPlacementsValue_label_en-US" xlink:label="lab_meso_SharesIssuedInPlacementsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued In Placements Value</link:label>
    <link:label id="lab_meso_SharesIssuedInPlacementsValue_documentation_en-US" xlink:label="lab_meso_SharesIssuedInPlacementsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in placements value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesIssuedInPlacementsValue" xlink:href="meso-20231231.xsd#meso_SharesIssuedInPlacementsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SharesIssuedInPlacementsValue" xlink:to="lab_meso_SharesIssuedInPlacementsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CashFlowsAdjustmentsOnDebt_a11113d8-fee8-42fc-b046-9ada0deb30d5_verboseLabel_en-US" xlink:label="lab_meso_CashFlowsAdjustmentsOnDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows, Borrowings</link:label>
    <link:label id="lab_meso_CashFlowsAdjustmentsOnDebt_label_en-US" xlink:label="lab_meso_CashFlowsAdjustmentsOnDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Adjustments On Debt</link:label>
    <link:label id="lab_meso_CashFlowsAdjustmentsOnDebt_documentation_en-US" xlink:label="lab_meso_CashFlowsAdjustmentsOnDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows adjustments on debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CashFlowsAdjustmentsOnDebt" xlink:href="meso-20231231.xsd#meso_CashFlowsAdjustmentsOnDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CashFlowsAdjustmentsOnDebt" xlink:to="lab_meso_CashFlowsAdjustmentsOnDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MethodsOfGenerationAxis_bf312a43-8b8c-423e-91e1-298209b84131_terseLabel_en-US" xlink:label="lab_ifrs-full_MethodsOfGenerationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methods of generation [axis]</link:label>
    <link:label id="lab_ifrs-full_MethodsOfGenerationAxis_label_en-US" xlink:label="lab_ifrs-full_MethodsOfGenerationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methods of generation [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis" xlink:to="lab_ifrs-full_MethodsOfGenerationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_19190047-b034-42b3-acce-eac647f3b627_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Provisions [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInBorrowings_45bc2bee-de8c-4b4a-92d0-8c8f655dbbdf_totalLabel_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInBorrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total borrowings</link:label>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInBorrowings_label_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Price Rate Changes In Borrowings</link:label>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInBorrowings_documentation_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of price rate changes in borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInBorrowings" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfPriceRateChangesInBorrowings" xlink:to="lab_meso_PercentageOfPriceRateChangesInBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_11c42ce7-23ce-469f-85bf-1c3a6ad0109c_terseLabel_en-US" xlink:label="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of entity's revenue, annual payment cap threshold</link:label>
    <link:label id="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_label_en-US" xlink:label="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Entity's Revenue, Annual Payment Cap Threshold</link:label>
    <link:label id="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_documentation_en-US" xlink:label="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Entity's Revenue, Annual Payment Cap Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" xlink:href="meso-20231231.xsd#meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" xlink:to="lab_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherPrepayments_d7f2b06c-bab5-48e5-96c3-e69b5ce8889c_terseLabel_en-US" xlink:label="lab_meso_OtherPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_meso_OtherPrepayments_label_en-US" xlink:label="lab_meso_OtherPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepayments</link:label>
    <link:label id="lab_meso_OtherPrepayments_documentation_en-US" xlink:label="lab_meso_OtherPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherPrepayments" xlink:href="meso-20231231.xsd#meso_OtherPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherPrepayments" xlink:to="lab_meso_OtherPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OaktreeCapitalManagementMember_cf48c4f8-2fd9-42db-bf41-afac4abd00c2_terseLabel_en-US" xlink:label="lab_meso_OaktreeCapitalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oaktree Capital Management</link:label>
    <link:label id="lab_meso_OaktreeCapitalManagementMember_label_en-US" xlink:label="lab_meso_OaktreeCapitalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oaktree Capital Management [Member]</link:label>
    <link:label id="lab_meso_OaktreeCapitalManagementMember_documentation_en-US" xlink:label="lab_meso_OaktreeCapitalManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oaktree Capital Management.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementMember" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OaktreeCapitalManagementMember" xlink:to="lab_meso_OaktreeCapitalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_0d2fa505-bfa5-43e9-b3d0-d6b208fb0f42_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Employee benefits</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_7b866ca9-9436-4532-a5f8-a2a788831120_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_f5c93ea4-dbaf-409a-bfd9-f4066b32a26d_terseLabel_en-US" xlink:label="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in trade creditors and accruals</link:label>
    <link:label id="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_label_en-US" xlink:label="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Increase Decrease In Trade Creditors And Accruals</link:label>
    <link:label id="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_documentation_en-US" xlink:label="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade creditors and accruals to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" xlink:href="meso-20231231.xsd#meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" xlink:to="lab_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_335834a5-0e38-4336-ac2f-322bddf3d3a4_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_label_en-US" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments on exchange differences on translation of foreign operations, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CommodityPriceRiskMember_e4fd65cb-5898-43d9-b4fa-2b196a1a9bb6_terseLabel_en-US" xlink:label="lab_ifrs-full_CommodityPriceRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity price risk</link:label>
    <link:label id="lab_ifrs-full_CommodityPriceRiskMember_label_en-US" xlink:label="lab_ifrs-full_CommodityPriceRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commodity price risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommodityPriceRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommodityPriceRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CommodityPriceRiskMember" xlink:to="lab_ifrs-full_CommodityPriceRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_f3a744c5-8f5b-4844-a261-a81eaf46333a_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities_aa2304b6-1b24-4549-ba6e-00676639c461_verboseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/increase in deferred tax liabilities</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities_label_en-US" xlink:label="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Deferred Tax Liabilities</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in deferred tax liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInDeferredTaxLiabilities" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseInDeferredTaxLiabilities" xlink:to="lab_meso_IncreaseDecreaseInDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RegulatoryEnvironmentsMember_579f0e5a-a0ff-4b05-9c8e-75890f4bccc6_terseLabel_en-US" xlink:label="lab_ifrs-full_RegulatoryEnvironmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory environments</link:label>
    <link:label id="lab_ifrs-full_RegulatoryEnvironmentsMember_label_en-US" xlink:label="lab_ifrs-full_RegulatoryEnvironmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory environments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsMember" xlink:to="lab_ifrs-full_RegulatoryEnvironmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_0a8971d1-b813-4bae-a94d-2bc8c33fab7e_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_136db191-5e4a-401f-a7a4-14ad7909aebd_verboseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over 5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_96d3586e-9416-4c07-9a1b-2d66bab213cc_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock_45692ea9-1e97-4aee-806e-cc4cbe2e69dd_terseLabel_en-US" xlink:label="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for basis of preparation explanatory</link:label>
    <link:label id="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Basis Of Preparation Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for basis of preparation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" xlink:href="meso-20231231.xsd#meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" xlink:to="lab_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_50f0b074-6dca-493b-8537-e29d6ae422e1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_fdb15fdc-a3aa-4a68-a9e9-95ace6138b9b_negatedLabel_en-US" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity settled share-based payment transactions</link:label>
    <link:label id="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_d504db8b-6eaa-41ce-aba8-9556f6fb0149_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity settled share-based payment transactions</link:label>
    <link:label id="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) through tax on share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a63bad08-001d-4c1d-950f-14283850e17b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_f9245020-a5d3-4190-9fcf-842742e7ccc4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_ff33b68b-caf6-4a4c-b59e-170eba0a98ec_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major components of tax expense (income) [abstract]</link:label>
    <link:label id="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major components of tax expense (income) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MilestonePaymentReceived_58c696d6-121f-4644-aff2-9f099200cd34_terseLabel_en-US" xlink:label="lab_meso_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_meso_MilestonePaymentReceived_label_en-US" xlink:label="lab_meso_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_meso_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_meso_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MilestonePaymentReceived" xlink:href="meso-20231231.xsd#meso_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MilestonePaymentReceived" xlink:to="lab_meso_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_35eff520-378c-42bf-a499-c2adadf60656_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movements Of Shares In Share Trust [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movements Of Shares In Share Trust [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of movements of shares in share trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" xlink:to="lab_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfAssetsMeasuredAtFairValue_8bb45d9e-c519-434b-b2c0-57d5e0a57f4d_terseLabel_en-US" xlink:label="lab_meso_PercentageOfAssetsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets measured at fair value</link:label>
    <link:label id="lab_meso_PercentageOfAssetsMeasuredAtFairValue_label_en-US" xlink:label="lab_meso_PercentageOfAssetsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Assets Measured At Fair Value</link:label>
    <link:label id="lab_meso_PercentageOfAssetsMeasuredAtFairValue_documentation_en-US" xlink:label="lab_meso_PercentageOfAssetsMeasuredAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets measured at fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfAssetsMeasuredAtFairValue" xlink:href="meso-20231231.xsd#meso_PercentageOfAssetsMeasuredAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfAssetsMeasuredAtFairValue" xlink:to="lab_meso_PercentageOfAssetsMeasuredAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_812f7bcb-128c-4887-a61e-0cdb1768dff4_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_51cb032f-a325-4cfa-aa36-e2b4723da0d0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_aefd452e-dcda-442f-9b67-9e32c05ec22a_negatedLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_973d4f20-1b71-4846-9a21-070078c7855f_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e55faacd-3730-4ef9-9f19-0640b8e344c8_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract_d4bf570a-34a2-4a4b-92e3-540ab8cc1c88_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Not Brought To Account For Other Temporary Differences [Abstract]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not brought to account for other temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" xlink:to="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a401c97f-592d-4050-9a93-3326821c2741_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_b77962ec-2778-4be5-85f5-b935c0811154_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_d534ff0a-0ab5-417c-b911-42b211ed6518_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other operating income and expenses</link:label>
    <link:label id="lab_ifrs-full_OtherOperatingIncomeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherOperatingIncomeExpense" xlink:to="lab_ifrs-full_OtherOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_2c29c1f8-0743-44bd-96cb-edf1727b17f4_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:to="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_BorrowingsPrincipalAmount_3ad3962a-cd8c-46c6-9a3a-0b00248439c5_terseLabel_en-US" xlink:label="lab_meso_BorrowingsPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings principal amount</link:label>
    <link:label id="lab_meso_BorrowingsPrincipalAmount_label_en-US" xlink:label="lab_meso_BorrowingsPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Principal Amount</link:label>
    <link:label id="lab_meso_BorrowingsPrincipalAmount_documentation_en-US" xlink:label="lab_meso_BorrowingsPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings principal amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsPrincipalAmount" xlink:href="meso-20231231.xsd#meso_BorrowingsPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_BorrowingsPrincipalAmount" xlink:to="lab_meso_BorrowingsPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_d4def5ae-71dc-4fe2-b5c0-10f56b449ecf_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets at amortized cost</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MethodsOfGenerationMember_73b1e1c0-ce35-4d70-830c-76d038cab300_terseLabel_en-US" xlink:label="lab_ifrs-full_MethodsOfGenerationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methods of generation</link:label>
    <link:label id="lab_ifrs-full_MethodsOfGenerationMember_label_en-US" xlink:label="lab_ifrs-full_MethodsOfGenerationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methods of generation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MethodsOfGenerationMember" xlink:to="lab_ifrs-full_MethodsOfGenerationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_031774f8-5c1d-4618-870c-5a99fc404f4a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SharesHeldInTrust_111ff637-7415-4c32-8cf9-0f7805e6a38a_periodStartLabel_en-US" xlink:label="lab_meso_SharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance (in shares)</link:label>
    <link:label id="lab_meso_SharesHeldInTrust_537109a7-db0c-4733-bee1-1456fd67b724_periodEndLabel_en-US" xlink:label="lab_meso_SharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_meso_SharesHeldInTrust_label_en-US" xlink:label="lab_meso_SharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held In Trust</link:label>
    <link:label id="lab_meso_SharesHeldInTrust_documentation_en-US" xlink:label="lab_meso_SharesHeldInTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held in trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrust" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SharesHeldInTrust" xlink:to="lab_meso_SharesHeldInTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_97624e6a-73d6-4dbb-9dea-b56ca98898df_terseLabel_en-US" xlink:label="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received In relation to patent license agreement</link:label>
    <link:label id="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_label_en-US" xlink:label="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received In Relation To Patent License Agreement</link:label>
    <link:label id="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_documentation_en-US" xlink:label="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received In Relation To Patent License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" xlink:href="meso-20231231.xsd#meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" xlink:to="lab_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_d01f59f4-3140-4649-984b-4175fe009f1c_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0f29507d-cb6d-4aaf-98ac-1bc327242322_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of share-based payments</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_8829a7e5-542e-4a7d-aa71-02270a6d7bd5_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_1daa8e30-4490-4b5a-b478-ee710da842fe_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_e00de0db-d21b-4c2a-a31c-1515ac901f69_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in deferred tax liability (asset) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:to="lab_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_76992e81-c759-44e1-ba27-f81843ef529a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_94b59c1a-616e-436b-8790-13f1119bd069_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_4f91d1f3-143c-4416-9df3-9793aafbfd27_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of Range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_fefd1b20-0002-41de-a20a-e19de6ef1ffc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(increase) in tax incentive recoverable</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_addaa69b-0902-46d8-bcb1-1563c605dd0f_negatedLabel_en-US" xlink:label="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other costs of finance paid</link:label>
    <link:label id="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Costs Of Finance Paid Classified As Financing Activities</link:label>
    <link:label id="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other costs of finance paid classified as financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" xlink:href="meso-20231231.xsd#meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" xlink:to="lab_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CommercializationRevenueReceived_7d453b4d-368c-4a3c-bd04-cc3e68014507_terseLabel_en-US" xlink:label="lab_meso_CommercializationRevenueReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization revenue received</link:label>
    <link:label id="lab_meso_CommercializationRevenueReceived_label_en-US" xlink:label="lab_meso_CommercializationRevenueReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Revenue Received</link:label>
    <link:label id="lab_meso_CommercializationRevenueReceived_documentation_en-US" xlink:label="lab_meso_CommercializationRevenueReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization revenue received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CommercializationRevenueReceived" xlink:href="meso-20231231.xsd#meso_CommercializationRevenueReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CommercializationRevenueReceived" xlink:to="lab_meso_CommercializationRevenueReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ProbabilityOfSuccessMeasurementInputMember_1882a085-4a34-4f5f-86e1-6ef621570026_terseLabel_en-US" xlink:label="lab_meso_ProbabilityOfSuccessMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of success</link:label>
    <link:label id="lab_meso_ProbabilityOfSuccessMeasurementInputMember_label_en-US" xlink:label="lab_meso_ProbabilityOfSuccessMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Of Success, Measurement Input [Member]</link:label>
    <link:label id="lab_meso_ProbabilityOfSuccessMeasurementInputMember_documentation_en-US" xlink:label="lab_meso_ProbabilityOfSuccessMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Of Success, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProbabilityOfSuccessMeasurementInputMember" xlink:href="meso-20231231.xsd#meso_ProbabilityOfSuccessMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ProbabilityOfSuccessMeasurementInputMember" xlink:to="lab_meso_ProbabilityOfSuccessMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_cae62c90-0860-4fe1-bac0-819d2f7164a7_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_a5bfd58d-ef06-4ecc-87aa-aa2d82b8f95f_verboseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within 1 year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DiscountedCashFlowMember_913ea1b4-706a-4031-8945-605f3beb57a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_ifrs-full_DiscountedCashFlowMember_label_en-US" xlink:label="lab_ifrs-full_DiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash flow [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountedCashFlowMember" xlink:to="lab_ifrs-full_DiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnDebt_1dbc5491-51b8-47e4-b44c-e5e3f766ada7_terseLabel_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement adjustments, Borrowings</link:label>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnDebt_label_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Adjustments On Debt</link:label>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnDebt_documentation_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement adjustments on debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementAdjustmentsOnDebt" xlink:href="meso-20231231.xsd#meso_RemeasurementAdjustmentsOnDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RemeasurementAdjustmentsOnDebt" xlink:to="lab_meso_RemeasurementAdjustmentsOnDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure_a6731e88-814d-4b3e-b1ed-b51a18452e3a_terseLabel_en-US" xlink:label="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial research and development expenditure</link:label>
    <link:label id="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure_label_en-US" xlink:label="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Research And Development Expenditure</link:label>
    <link:label id="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure_documentation_en-US" xlink:label="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for clinical trial research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalTrialResearchAndDevelopmentExpenditure" xlink:href="meso-20231231.xsd#meso_ClinicalTrialResearchAndDevelopmentExpenditure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ClinicalTrialResearchAndDevelopmentExpenditure" xlink:to="lab_meso_ClinicalTrialResearchAndDevelopmentExpenditure" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_f696329b-ca14-4262-b678-ce2950d6efd9_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged/(credited) to:</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets And Liabilities Relating To Charged Or Credited [Abstract]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities relating to charged or credited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" xlink:to="lab_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ProvisionForLicenseAgreementsMember_5ae0c7a5-ef31-40e8-b475-a13dfa7deec0_terseLabel_en-US" xlink:label="lab_meso_ProvisionForLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for license agreements</link:label>
    <link:label id="lab_meso_ProvisionForLicenseAgreementsMember_label_en-US" xlink:label="lab_meso_ProvisionForLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For License Agreements [Member]</link:label>
    <link:label id="lab_meso_ProvisionForLicenseAgreementsMember_documentation_en-US" xlink:label="lab_meso_ProvisionForLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProvisionForLicenseAgreementsMember" xlink:href="meso-20231231.xsd#meso_ProvisionForLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ProvisionForLicenseAgreementsMember" xlink:to="lab_meso_ProvisionForLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock_cf28dd11-6053-43ef-a062-5adbc9caa896_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Level 3 Instruments</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets And Liabilities Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MinimumUnrestrictedCashBalance_e566be2c-2aa1-4ce4-81d4-80d9ce8f656f_terseLabel_en-US" xlink:label="lab_meso_MinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash balance</link:label>
    <link:label id="lab_meso_MinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_meso_MinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_meso_MinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_meso_MinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum unrestricted cash balance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumUnrestrictedCashBalance" xlink:href="meso-20231231.xsd#meso_MinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MinimumUnrestrictedCashBalance" xlink:to="lab_meso_MinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_37f3e465-e727-4dcf-a40c-697918c2aa09_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows, Sub-total</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through financing cash flows, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MSCProductMember_7ceae6e1-00c5-4bbe-855e-891f08606bdc_terseLabel_en-US" xlink:label="lab_meso_MSCProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSC Products</link:label>
    <link:label id="lab_meso_MSCProductMember_label_en-US" xlink:label="lab_meso_MSCProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M S C Product [Member]</link:label>
    <link:label id="lab_meso_MSCProductMember_documentation_en-US" xlink:label="lab_meso_MSCProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSC Product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MSCProductMember" xlink:href="meso-20231231.xsd#meso_MSCProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MSCProductMember" xlink:to="lab_meso_MSCProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_25d854c3-3370-45c0-a835-5db39c2f8ab7_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_8ba243bc-409e-4cac-b5ba-13884d7d6a4d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items that may be reclassified to profit and loss</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_22fe4849-4d40-4b73-bdec-2508d8a71b87_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 1-2 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_47da26af-3eb6-4638-bd56-5fe6082dff0e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPortionOfLongtermBorrowings_8701efbb-c214-45d7-96d4-39d323b54764_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_CurrentPortionOfLongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:to="lab_ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_da66381a-468c-4181-afcc-a5d4948c1cac_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets and liabilities line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:to="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FairValueOfWarrants_2aa326fe-11d6-455d-b919-80fd43a25865_terseLabel_en-US" xlink:label="lab_meso_FairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_meso_FairValueOfWarrants_label_en-US" xlink:label="lab_meso_FairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants</link:label>
    <link:label id="lab_meso_FairValueOfWarrants_documentation_en-US" xlink:label="lab_meso_FairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueOfWarrants" xlink:href="meso-20231231.xsd#meso_FairValueOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValueOfWarrants" xlink:to="lab_meso_FairValueOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_043d001c-37f5-4008-af4a-07a45645b184_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_e0acaa1e-a02e-4782-a2fb-a2684678bc6d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening net book amount</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_2fcac606-bd4d-4b34-9de5-fdac985554dd_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing net book amount</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_7e4b3b4f-6165-4b92-8760-278b5ceebacd_verboseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of in process research and development</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AmericanDepositarySharesMember_50a1f6be-b06f-4610-9d08-d574accce357_terseLabel_en-US" xlink:label="lab_meso_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_meso_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_meso_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:label id="lab_meso_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_meso_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American depositary shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmericanDepositarySharesMember" xlink:href="meso-20231231.xsd#meso_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AmericanDepositarySharesMember" xlink:to="lab_meso_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_37268fb6-72db-4252-a255-1cee891169a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NumberOfSharesIssuedAndFullyPaidValue_b54a1a29-c3e3-438e-b563-dca9ee77e9d9_terseLabel_en-US" xlink:label="lab_meso_NumberOfSharesIssuedAndFullyPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued, value</link:label>
    <link:label id="lab_meso_NumberOfSharesIssuedAndFullyPaidValue_label_en-US" xlink:label="lab_meso_NumberOfSharesIssuedAndFullyPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued And Fully Paid, Value</link:label>
    <link:label id="lab_meso_NumberOfSharesIssuedAndFullyPaidValue_documentation_en-US" xlink:label="lab_meso_NumberOfSharesIssuedAndFullyPaidValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Issued And Fully Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfSharesIssuedAndFullyPaidValue" xlink:href="meso-20231231.xsd#meso_NumberOfSharesIssuedAndFullyPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NumberOfSharesIssuedAndFullyPaidValue" xlink:to="lab_meso_NumberOfSharesIssuedAndFullyPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_5ad4ef43-3f73-4295-9f04-08baae292d00_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential tax benefit at local tax rates</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:to="lab_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PaymentsOfTransactionCostsFromBorrowings_35ae5d5d-cc04-47c8-be38-035b5b4073b8_negatedLabel_en-US" xlink:label="lab_meso_PaymentsOfTransactionCostsFromBorrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of transaction costs from borrowings</link:label>
    <link:label id="lab_meso_PaymentsOfTransactionCostsFromBorrowings_label_en-US" xlink:label="lab_meso_PaymentsOfTransactionCostsFromBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Transaction Costs From Borrowings</link:label>
    <link:label id="lab_meso_PaymentsOfTransactionCostsFromBorrowings_documentation_en-US" xlink:label="lab_meso_PaymentsOfTransactionCostsFromBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of transaction costs from borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentsOfTransactionCostsFromBorrowings" xlink:href="meso-20231231.xsd#meso_PaymentsOfTransactionCostsFromBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PaymentsOfTransactionCostsFromBorrowings" xlink:to="lab_meso_PaymentsOfTransactionCostsFromBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_e7a83f67-7614-4082-814f-0cc4e24e4a6c_terseLabel_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_ifrs-full_Level1OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level1OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivables_c7f76a21-9b07-4aed-ae76-e2e1530e275a_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade &amp; other receivables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherReceivables" xlink:to="lab_ifrs-full_TradeAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TrancheOneMember_154764f7-2ebf-47ec-914d-fab6a8f040dc_terseLabel_en-US" xlink:label="lab_meso_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_meso_TrancheOneMember_label_en-US" xlink:label="lab_meso_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_meso_TrancheOneMember_documentation_en-US" xlink:label="lab_meso_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TrancheOneMember" xlink:href="meso-20231231.xsd#meso_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TrancheOneMember" xlink:to="lab_meso_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7adee7b8-adfe-4ca0-8752-34cf370b3b12_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Classes Of Share Capital [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_LonzaBioscienceSingaporePteLtdMember_a7142ab9-9f71-403e-b03b-b9eccfd0603c_terseLabel_en-US" xlink:label="lab_meso_LonzaBioscienceSingaporePteLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Bioscience Singapore Pte. Ltd</link:label>
    <link:label id="lab_meso_LonzaBioscienceSingaporePteLtdMember_label_en-US" xlink:label="lab_meso_LonzaBioscienceSingaporePteLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Bioscience Singapore Pte Ltd [Member]</link:label>
    <link:label id="lab_meso_LonzaBioscienceSingaporePteLtdMember_documentation_en-US" xlink:label="lab_meso_LonzaBioscienceSingaporePteLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Bioscience Singapore Pte. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LonzaBioscienceSingaporePteLtdMember" xlink:href="meso-20231231.xsd#meso_LonzaBioscienceSingaporePteLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_LonzaBioscienceSingaporePteLtdMember" xlink:to="lab_meso_LonzaBioscienceSingaporePteLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_5fee82c7-68d1-476d-9076-c7c74357d586_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to the owners of Mesoblast Limited</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_7092ba6f-009b-4d42-bccf-a6944ef4e82b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_484173e4-cdcc-4387-804b-7f6b4bb3f3a1_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_2cd6abbe-c9c6-4735-b7a8-8ab901b31a44_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_label_en-US" xlink:label="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Attributable To Temporary Differences From Intangible Assets</link:label>
    <link:label id="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_documentation_en-US" xlink:label="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities attributable to temporary differences from intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" xlink:href="meso-20231231.xsd#meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" xlink:to="lab_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_91911615-1635-41f4-a7b3-046fd83c6f1f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember_61a52152-d957-458e-8925-3344f5ef1c86_terseLabel_en-US" xlink:label="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected unit sales price</link:label>
    <link:label id="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember_label_en-US" xlink:label="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Unit Sales Price, Measurement Input [Member]</link:label>
    <link:label id="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember_documentation_en-US" xlink:label="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Unit Sales Price, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedUnitSalesPriceMeasurementInputMember" xlink:href="meso-20231231.xsd#meso_ExpectedUnitSalesPriceMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ExpectedUnitSalesPriceMeasurementInputMember" xlink:to="lab_meso_ExpectedUnitSalesPriceMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_bdd2b295-7ff8-4ef6-9a1e-5ca08577da31_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherPayables_562f0d1c-bc72-4587-8887-6c53f1b2903c_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayables" xlink:to="lab_ifrs-full_TradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_15cd2839-52d5-4bf3-9d25-a10036fa737f_terseLabel_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjusted discount rate</link:label>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:to="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP_573ef6e4-17f8-446e-9c48-1106c06efef6_terseLabel_en-US" xlink:label="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized for right of use license of IP</link:label>
    <link:label id="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP_label_en-US" xlink:label="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized For Right Of Use License of IP</link:label>
    <link:label id="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP_documentation_en-US" xlink:label="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized for right of use license of IP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRecognizedForRightOfUseLicenseOfIP" xlink:href="meso-20231231.xsd#meso_RevenueRecognizedForRightOfUseLicenseOfIP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RevenueRecognizedForRightOfUseLicenseOfIP" xlink:to="lab_meso_RevenueRecognizedForRightOfUseLicenseOfIP" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_12267317-86d4-4edd-8b2d-ff8ff9389f40_verboseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions with owners in their capacity as owners:</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_cca3acbb-94de-4c22-bc25-2d79220e2b33_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issues of ordinary shares during the period</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquityAbstract" xlink:to="lab_ifrs-full_ChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TreasurySharesPurchased_cf9cfb40-458e-4047-97eb-7620a36a4c30_negatedLabel_en-US" xlink:label="lab_meso_TreasurySharesPurchased" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Treasury Shares (in shares)</link:label>
    <link:label id="lab_meso_TreasurySharesPurchased_label_en-US" xlink:label="lab_meso_TreasurySharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares Purchased</link:label>
    <link:label id="lab_meso_TreasurySharesPurchased_documentation_en-US" xlink:label="lab_meso_TreasurySharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchased" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TreasurySharesPurchased" xlink:to="lab_meso_TreasurySharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantsMember_656c2771-368f-4aae-9e06-58d510ca72f9_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_label_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember" xlink:to="lab_ifrs-full_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock_9e2a2837-6736-406a-867c-35188e737682_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Tax Assets Not Brought to Account</link:label>
    <link:label id="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Deferred Tax Assets Not Brought To Account Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of deferred tax assets not brought to account.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OaktreeCapitalManagementLPMember_23648a90-0611-4f43-a9d3-e8e5d47dec83_terseLabel_en-US" xlink:label="lab_meso_OaktreeCapitalManagementLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings - Oaktree</link:label>
    <link:label id="lab_meso_OaktreeCapitalManagementLPMember_label_en-US" xlink:label="lab_meso_OaktreeCapitalManagementLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oaktree Capital Management L P [Member]</link:label>
    <link:label id="lab_meso_OaktreeCapitalManagementLPMember_documentation_en-US" xlink:label="lab_meso_OaktreeCapitalManagementLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oaktree Capital Management, L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementLPMember" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OaktreeCapitalManagementLPMember" xlink:to="lab_meso_OaktreeCapitalManagementLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_6c1e6199-478b-4b60-a809-732f4cdba755_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_BorrowingsInterestOnlyPeriod_d2a67f53-5f99-476d-8c9c-b375336f87e5_terseLabel_en-US" xlink:label="lab_meso_BorrowingsInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Interest Only Period</link:label>
    <link:label id="lab_meso_BorrowingsInterestOnlyPeriod_label_en-US" xlink:label="lab_meso_BorrowingsInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Interest Only Period</link:label>
    <link:label id="lab_meso_BorrowingsInterestOnlyPeriod_documentation_en-US" xlink:label="lab_meso_BorrowingsInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Interest Only Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsInterestOnlyPeriod" xlink:href="meso-20231231.xsd#meso_BorrowingsInterestOnlyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_BorrowingsInterestOnlyPeriod" xlink:to="lab_meso_BorrowingsInterestOnlyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a59970ec-f949-4a75-b19a-4edb0a218c06_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract_66e43830-c7fa-489e-9f2e-55587fad5e5e_terseLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract_label_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Remeasurement Of Contingent Consideration [Abstract]</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract_documentation_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsiderationAbstract" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsiderationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValueRemeasurementOfContingentConsiderationAbstract" xlink:to="lab_meso_FairValueRemeasurementOfContingentConsiderationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccount_16739101-70f8-4d00-aa3e-59db72f79764_totalLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not brought to account</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccount_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Not Brought To Account</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccount_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not brought to account.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccount" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccount" xlink:to="lab_meso_DeferredTaxAssetsNotBroughtToAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock_3230bc6c-515b-4f12-84c3-8507be5ceb19_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant changes in the current reporting period</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period Explanatory [Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant changes in current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" xlink:to="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TransactionCostsArisingOnShareIssue_9cebe06f-1b42-4aee-93a1-3240220f0d3b_negatedLabel_en-US" xlink:label="lab_meso_TransactionCostsArisingOnShareIssue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs arising on share issue</link:label>
    <link:label id="lab_meso_TransactionCostsArisingOnShareIssue_label_en-US" xlink:label="lab_meso_TransactionCostsArisingOnShareIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Arising On Share Issue</link:label>
    <link:label id="lab_meso_TransactionCostsArisingOnShareIssue_documentation_en-US" xlink:label="lab_meso_TransactionCostsArisingOnShareIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs arising on share issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssue" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TransactionCostsArisingOnShareIssue" xlink:to="lab_meso_TransactionCostsArisingOnShareIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_43c2ce2d-c374-40b6-b28f-b392a59c3d3a_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_5626cc8b-96d3-43ed-a054-f8a78370b339_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_a79d9d04-cce1-4911-9ef9-0da64c1970a6_terseLabel_en-US" xlink:label="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government grants and tax incentives and credits received</link:label>
    <link:label id="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_label_en-US" xlink:label="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants And Tax Incentives And Credits Received</link:label>
    <link:label id="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_documentation_en-US" xlink:label="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government grants and tax incentives received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" xlink:href="meso-20231231.xsd#meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" xlink:to="lab_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CumulativeMilestonePaymentsReachableAmount_23e93a9c-187d-4730-82f5-1017baa9939e_terseLabel_en-US" xlink:label="lab_meso_CumulativeMilestonePaymentsReachableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative milestone payments reachable amount</link:label>
    <link:label id="lab_meso_CumulativeMilestonePaymentsReachableAmount_label_en-US" xlink:label="lab_meso_CumulativeMilestonePaymentsReachableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Milestone Payments Reachable Amount</link:label>
    <link:label id="lab_meso_CumulativeMilestonePaymentsReachableAmount_documentation_en-US" xlink:label="lab_meso_CumulativeMilestonePaymentsReachableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative milestone payments reachable amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CumulativeMilestonePaymentsReachableAmount" xlink:href="meso-20231231.xsd#meso_CumulativeMilestonePaymentsReachableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CumulativeMilestonePaymentsReachableAmount" xlink:to="lab_meso_CumulativeMilestonePaymentsReachableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_238fa827-7393-4a75-9073-ec42ab60b2f4_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_b5c7b6f7-7490-441f-a8ee-9769aa08efc6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit/(expense)</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_2c42c078-7c03-4c7f-a0fd-698e7655925b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Instruments [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiability_394e7295-1de5-49fb-9fb1-94df7250b2c5_negatedLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of warrant liability</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiability_33b6a0a7-9643-4b85-bf41-6c3cd33ba106_negatedTotalLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair value remeasurement of warrant liability</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiability_label_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Remeasurement Of Warrant Liability</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiability_documentation_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiability" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValueRemeasurementOfWarrantLiability" xlink:to="lab_meso_FairValueRemeasurementOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CurrentProvisionsForAccruedAnnualLeave_15a2316f-adb2-4106-96f4-dc7e5b4cccd5_terseLabel_en-US" xlink:label="lab_meso_CurrentProvisionsForAccruedAnnualLeave" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions for accrued annual leave</link:label>
    <link:label id="lab_meso_CurrentProvisionsForAccruedAnnualLeave_label_en-US" xlink:label="lab_meso_CurrentProvisionsForAccruedAnnualLeave" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions For Accrued Annual Leave</link:label>
    <link:label id="lab_meso_CurrentProvisionsForAccruedAnnualLeave_documentation_en-US" xlink:label="lab_meso_CurrentProvisionsForAccruedAnnualLeave" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions for accrued annual leave.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentProvisionsForAccruedAnnualLeave" xlink:href="meso-20231231.xsd#meso_CurrentProvisionsForAccruedAnnualLeave"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CurrentProvisionsForAccruedAnnualLeave" xlink:to="lab_meso_CurrentProvisionsForAccruedAnnualLeave" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_28900cc0-91b8-4a14-b2b6-56f61139a01a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_a192b24f-619b-4bbd-af4f-c99d0a352001_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_94f41786-16ec-4457-9fc7-70cc2a109ae8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_10aed1af-4c43-4f63-a044-4d54b2597ee8_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_90722887-14d2-41e5-a2f7-1dd801ba573e_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OtherCurrencyMember_dc905e8e-8c69-4cfc-9261-a30bca1fd2c5_terseLabel_en-US" xlink:label="lab_srt_OtherCurrencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Currency</link:label>
    <link:label id="lab_srt_OtherCurrencyMember_label_en-US" xlink:label="lab_srt_OtherCurrencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Currency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OtherCurrencyMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OtherCurrencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OtherCurrencyMember" xlink:to="lab_srt_OtherCurrencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_14fb0a0b-ad05-4e7b-b5c9-7dfe1d9c74bb_terseLabel_en-US" xlink:label="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of borrowing arrangements</link:label>
    <link:label id="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_label_en-US" xlink:label="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains On Remeasurement Of Borrowing Arrangements</link:label>
    <link:label id="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_documentation_en-US" xlink:label="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance (costs) gains on remeasurement of borrowing arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" xlink:to="lab_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_337320e7-6fbd-487a-b2d7-2327f836bf53_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets and liabilities abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="lab_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_GainLossOnRemeasurementOfWarrantLiability_ad3abd5f-1e7b-4762-ae7b-77181e9c17bf_terseLabel_en-US" xlink:label="lab_meso_GainLossOnRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on remeasurement of warrant liability</link:label>
    <link:label id="lab_meso_GainLossOnRemeasurementOfWarrantLiability_label_en-US" xlink:label="lab_meso_GainLossOnRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Warrant Liability</link:label>
    <link:label id="lab_meso_GainLossOnRemeasurementOfWarrantLiability_documentation_en-US" xlink:label="lab_meso_GainLossOnRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on remeasurement of warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GainLossOnRemeasurementOfWarrantLiability" xlink:href="meso-20231231.xsd#meso_GainLossOnRemeasurementOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_GainLossOnRemeasurementOfWarrantLiability" xlink:to="lab_meso_GainLossOnRemeasurementOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_803d9b53-0c95-4610-be00-bf11132b14dc_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value</link:label>
    <link:label id="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_28a8a8c4-22e4-4bdd-a1c3-ec82df46dfdb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not brought to account</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_b8cb29b1-0ba1-4d28-9373-a6f57634813a_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive losses attributable to the owners of Mesoblast Limited</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IntangibleAssetsMember_27b76b89-1e1d-4b39-8b2e-158729273edd_terseLabel_en-US" xlink:label="lab_meso_IntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets (DTL)</link:label>
    <link:label id="lab_meso_IntangibleAssetsMember_label_en-US" xlink:label="lab_meso_IntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Member]</link:label>
    <link:label id="lab_meso_IntangibleAssetsMember_documentation_en-US" xlink:label="lab_meso_IntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntangibleAssetsMember" xlink:href="meso-20231231.xsd#meso_IntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IntangibleAssetsMember" xlink:to="lab_meso_IntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_d4e499db-7230-4f8a-bb2a-2cb03455377f_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Liabilities [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Liabilities [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non financial assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" xlink:to="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingCostsRecognisedAsExpense_80c6726b-e1f3-46d9-8ee5-ada8640503b9_negatedLabel_en-US" xlink:label="lab_ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: transaction costs</link:label>
    <link:label id="lab_ifrs-full_BorrowingCostsRecognisedAsExpense_label_en-US" xlink:label="lab_ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing costs recognised as expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsRecognisedAsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:to="lab_ifrs-full_BorrowingCostsRecognisedAsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_LegalAndOtherProfessionalFees_56c29df3-e318-4f2a-9b39-238061c954d4_negatedLabel_en-US" xlink:label="lab_meso_LegalAndOtherProfessionalFees" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and other professional fees</link:label>
    <link:label id="lab_meso_LegalAndOtherProfessionalFees_label_en-US" xlink:label="lab_meso_LegalAndOtherProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Other Professional Fees</link:label>
    <link:label id="lab_meso_LegalAndOtherProfessionalFees_documentation_en-US" xlink:label="lab_meso_LegalAndOtherProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to Legal, patent and other professional fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LegalAndOtherProfessionalFees" xlink:href="meso-20231231.xsd#meso_LegalAndOtherProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_LegalAndOtherProfessionalFees" xlink:to="lab_meso_LegalAndOtherProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DefaultFinancialStatementsDateMember_3236ec8e-2456-4e5c-aba2-4a1690a85121_terseLabel_en-US" xlink:label="lab_ifrs-full_DefaultFinancialStatementsDateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default financial statements date</link:label>
    <link:label id="lab_ifrs-full_DefaultFinancialStatementsDateMember_label_en-US" xlink:label="lab_ifrs-full_DefaultFinancialStatementsDateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default financial statements date [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefaultFinancialStatementsDateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DefaultFinancialStatementsDateMember" xlink:to="lab_ifrs-full_DefaultFinancialStatementsDateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AmericanDepositoryReceiptMember_3c5bb986-c421-40ae-ba8b-9293692b41dd_terseLabel_en-US" xlink:label="lab_meso_AmericanDepositoryReceiptMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Receipt</link:label>
    <link:label id="lab_meso_AmericanDepositoryReceiptMember_label_en-US" xlink:label="lab_meso_AmericanDepositoryReceiptMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Receipt [Member]</link:label>
    <link:label id="lab_meso_AmericanDepositoryReceiptMember_documentation_en-US" xlink:label="lab_meso_AmericanDepositoryReceiptMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">American Depository Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmericanDepositoryReceiptMember" xlink:href="meso-20231231.xsd#meso_AmericanDepositoryReceiptMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AmericanDepositoryReceiptMember" xlink:to="lab_meso_AmericanDepositoryReceiptMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_e726b9f8-5673-4260-947b-4a722e18ca77_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_04d11b53-9446-4187-88e3-dd7c8475ed21_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Equity</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember_312da050-a136-4447-9694-65504b11a5e4_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Option Reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of gains and losses from investments in equity instruments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember" xlink:to="lab_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_QuarterlyPaymentsMember_b5bf6285-6d8c-4a3c-a7e3-ea8e79e56f19_terseLabel_en-US" xlink:label="lab_meso_QuarterlyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Payments</link:label>
    <link:label id="lab_meso_QuarterlyPaymentsMember_label_en-US" xlink:label="lab_meso_QuarterlyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Payments [Member]</link:label>
    <link:label id="lab_meso_QuarterlyPaymentsMember_documentation_en-US" xlink:label="lab_meso_QuarterlyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_QuarterlyPaymentsMember" xlink:href="meso-20231231.xsd#meso_QuarterlyPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_QuarterlyPaymentsMember" xlink:to="lab_meso_QuarterlyPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseInInterestRatePercentage_96da8447-a214-4907-a308-12154d1b19a0_terseLabel_en-US" xlink:label="lab_meso_IncreaseInInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate increase</link:label>
    <link:label id="lab_meso_IncreaseInInterestRatePercentage_label_en-US" xlink:label="lab_meso_IncreaseInInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Interest Rate Percentage</link:label>
    <link:label id="lab_meso_IncreaseInInterestRatePercentage_documentation_en-US" xlink:label="lab_meso_IncreaseInInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in interest rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseInInterestRatePercentage" xlink:href="meso-20231231.xsd#meso_IncreaseInInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseInInterestRatePercentage" xlink:to="lab_meso_IncreaseInInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManufacturingCommercialization_613eb472-84bc-4d6d-a7c9-008fa61253be_negatedLabel_en-US" xlink:label="lab_meso_ManufacturingCommercialization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing commercialization</link:label>
    <link:label id="lab_meso_ManufacturingCommercialization_label_en-US" xlink:label="lab_meso_ManufacturingCommercialization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Commercialization</link:label>
    <link:label id="lab_meso_ManufacturingCommercialization_documentation_en-US" xlink:label="lab_meso_ManufacturingCommercialization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to Manufacturing commercialization activities, recognized in profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingCommercialization" xlink:href="meso-20231231.xsd#meso_ManufacturingCommercialization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManufacturingCommercialization" xlink:to="lab_meso_ManufacturingCommercialization" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ServiceConcessionArrangementsAxis_50cabd5e-5874-4a52-b859-3545b45e7a31_terseLabel_en-US" xlink:label="lab_ifrs-full_ServiceConcessionArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service concession arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_ServiceConcessionArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_ServiceConcessionArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service concession arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis" xlink:to="lab_ifrs-full_ServiceConcessionArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_6b744ee3-b55e-48fb-9246-fdd203824ced_totalLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilities" xlink:to="lab_ifrs-full_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PotentialOrdinaryShareTransactionsMember_48b7b33a-791a-4975-a8e5-c025b67ee504_terseLabel_en-US" xlink:label="lab_ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Ordinary Share Transactions</link:label>
    <link:label id="lab_ifrs-full_PotentialOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PotentialOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CommercializationRevenue_0d36ae61-5891-4ca3-8c78-422a44304279_terseLabel_en-US" xlink:label="lab_meso_CommercializationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization revenue</link:label>
    <link:label id="lab_meso_CommercializationRevenue_label_en-US" xlink:label="lab_meso_CommercializationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Revenue</link:label>
    <link:label id="lab_meso_CommercializationRevenue_documentation_en-US" xlink:label="lab_meso_CommercializationRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization revenue generally includes non-refundable up-front license and collaboration fees, royalties on product sales of licensed products, if and when such product sales occur and revenue from the supply of products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CommercializationRevenue" xlink:href="meso-20231231.xsd#meso_CommercializationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CommercializationRevenue" xlink:to="lab_meso_CommercializationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SharePriceMinimumConsecutiveDay_d006d490-4a97-42d1-b010-577e255f7a26_terseLabel_en-US" xlink:label="lab_meso_SharePriceMinimumConsecutiveDay" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price, minimum consecutive day</link:label>
    <link:label id="lab_meso_SharePriceMinimumConsecutiveDay_label_en-US" xlink:label="lab_meso_SharePriceMinimumConsecutiveDay" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price, Minimum Consecutive Day</link:label>
    <link:label id="lab_meso_SharePriceMinimumConsecutiveDay_documentation_en-US" xlink:label="lab_meso_SharePriceMinimumConsecutiveDay" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price, Minimum Consecutive Day</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharePriceMinimumConsecutiveDay" xlink:href="meso-20231231.xsd#meso_SharePriceMinimumConsecutiveDay"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SharePriceMinimumConsecutiveDay" xlink:to="lab_meso_SharePriceMinimumConsecutiveDay" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock_e82a93ae-60fc-497a-9e69-dc8680f2e63a_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deposits Held which Derive Interest Revenue with Maximum and Minimum Interest Rates Being Earned</link:label>
    <link:label id="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Deposits Held Which Derive Interest Revenue With Maximum And Minimum Interest Rates Being Earned Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of deposits held which derive interest revenue with maximum and minimum interest rates being earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_f6421987-73cd-49b1-94cd-279b61c011e4_terseLabel_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IntellectualPropertyExpenses_b8016f8b-9908-4d51-ad35-20ba22900f4a_negatedLabel_en-US" xlink:label="lab_meso_IntellectualPropertyExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property expenses (excluding the amount amortized above)</link:label>
    <link:label id="lab_meso_IntellectualPropertyExpenses_label_en-US" xlink:label="lab_meso_IntellectualPropertyExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Expenses</link:label>
    <link:label id="lab_meso_IntellectualPropertyExpenses_documentation_en-US" xlink:label="lab_meso_IntellectualPropertyExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to intellectual property expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntellectualPropertyExpenses" xlink:href="meso-20231231.xsd#meso_IntellectualPropertyExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IntellectualPropertyExpenses" xlink:to="lab_meso_IntellectualPropertyExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_5a1456bf-27f1-49cd-b85b-d299bc5c40c6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_b3cf9612-8d1d-44cf-91b6-33462acfb215_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development acquired</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets under development [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:to="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_86f26139-149a-46e9-a170-5109600bce5c_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_71c10a04-0e60-47e5-8f9a-ee397103487f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fully-paid ordinary shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued and fully paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_ea6d5642-e840-406a-9a19-718409d83698_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss)/income for the period, net of tax</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherOperatingIncomeAndExpensesAbstract_9db849fe-23df-4cc5-8065-4289625f14b1_terseLabel_en-US" xlink:label="lab_meso_OtherOperatingIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income and expenses</link:label>
    <link:label id="lab_meso_OtherOperatingIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_meso_OtherOperatingIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income And Expenses [Abstract]</link:label>
    <link:label id="lab_meso_OtherOperatingIncomeAndExpensesAbstract_documentation_en-US" xlink:label="lab_meso_OtherOperatingIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income And Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherOperatingIncomeAndExpensesAbstract" xlink:href="meso-20231231.xsd#meso_OtherOperatingIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherOperatingIncomeAndExpensesAbstract" xlink:to="lab_meso_OtherOperatingIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_c86811be-8f90-4b24-981a-86816a67a727_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Between 2-5 years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_e8d3eb77-999f-4a93-b8fa-b00e7f033812_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_bf6c85f7-0ded-4608-b67f-639ef4081d47_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherPurchaseCommitments_da6a652c-dc99-4289-8fc9-ffb2ee404f37_terseLabel_en-US" xlink:label="lab_meso_OtherPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other purchase commitments</link:label>
    <link:label id="lab_meso_OtherPurchaseCommitments_label_en-US" xlink:label="lab_meso_OtherPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Purchase Commitments</link:label>
    <link:label id="lab_meso_OtherPurchaseCommitments_documentation_en-US" xlink:label="lab_meso_OtherPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other purchase commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherPurchaseCommitments" xlink:href="meso-20231231.xsd#meso_OtherPurchaseCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherPurchaseCommitments" xlink:to="lab_meso_OtherPurchaseCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredConsiderationNonCurrent_12cec3ae-440d-44dc-82d9-3e2df4f0e671_terseLabel_en-US" xlink:label="lab_meso_DeferredConsiderationNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred consideration</link:label>
    <link:label id="lab_meso_DeferredConsiderationNonCurrent_label_en-US" xlink:label="lab_meso_DeferredConsiderationNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Consideration Non Current</link:label>
    <link:label id="lab_meso_DeferredConsiderationNonCurrent_documentation_en-US" xlink:label="lab_meso_DeferredConsiderationNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of deferred consideration on customer receipts expected to be accounted for after one year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredConsiderationNonCurrent" xlink:href="meso-20231231.xsd#meso_DeferredConsiderationNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredConsiderationNonCurrent" xlink:to="lab_meso_DeferredConsiderationNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments_4ebb63d2-8297-4686-af6b-574d8327f2ab_terseLabel_en-US" xlink:label="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(increase) in prepayments</link:label>
    <link:label id="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments_label_en-US" xlink:label="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Increase Decrease In Prepayments</link:label>
    <link:label id="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments_documentation_en-US" xlink:label="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for (increase) decrease in prepayments to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdjustmentsForIncreaseDecreaseInPrepayments" xlink:href="meso-20231231.xsd#meso_AdjustmentsForIncreaseDecreaseInPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AdjustmentsForIncreaseDecreaseInPrepayments" xlink:to="lab_meso_AdjustmentsForIncreaseDecreaseInPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_90e91d1d-1c88-44dc-b3d0-027212cc00a2_verboseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of Range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_1df6860b-27d4-4a43-9154-a3e5fe1c6eb0_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of Range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_586a6656-c55c-4b0b-9120-38d3543c8ef0_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_19cd25e8-6afe-400e-ae12-5e382316f393_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for lease liabilities</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ExpectedSalesVolumesMeasurementInputMember_260600c5-0df8-418d-9847-ef8a7a86b77f_terseLabel_en-US" xlink:label="lab_meso_ExpectedSalesVolumesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected sales volumes</link:label>
    <link:label id="lab_meso_ExpectedSalesVolumesMeasurementInputMember_label_en-US" xlink:label="lab_meso_ExpectedSalesVolumesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Sales Volumes, Measurement Input [Member]</link:label>
    <link:label id="lab_meso_ExpectedSalesVolumesMeasurementInputMember_documentation_en-US" xlink:label="lab_meso_ExpectedSalesVolumesMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Sales Volumes, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedSalesVolumesMeasurementInputMember" xlink:href="meso-20231231.xsd#meso_ExpectedSalesVolumesMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ExpectedSalesVolumesMeasurementInputMember" xlink:to="lab_meso_ExpectedSalesVolumesMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_c09bf770-57ce-4b01-b1f7-707735f8c0d6_terseLabel_en-US" xlink:label="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term</link:label>
    <link:label id="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_label_en-US" xlink:label="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Remaining Financial Commitment Of Non Lease Component On Exercise Of Option To Extend Non Cancellable Term</link:label>
    <link:label id="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_documentation_en-US" xlink:label="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:href="meso-20231231.xsd#meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:to="lab_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxTable_ccdccaf3-e6d2-4148-82b0-d267504e2dca_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxTable_label_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Table].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable" xlink:to="lab_meso_DisclosureOfLossBeforeIncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_5fce8286-2de6-4654-a2ff-dc288c85a2ca_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SharesPrice_bda96dc4-c9ea-4cb5-9fa8-78aa97689177_terseLabel_en-US" xlink:label="lab_meso_SharesPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price for right exercise of the warrants (in australian dollar per shares)</link:label>
    <link:label id="lab_meso_SharesPrice_label_en-US" xlink:label="lab_meso_SharesPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Price</link:label>
    <link:label id="lab_meso_SharesPrice_documentation_en-US" xlink:label="lab_meso_SharesPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesPrice" xlink:href="meso-20231231.xsd#meso_SharesPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SharesPrice" xlink:to="lab_meso_SharesPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpense_0c49339a-e7af-4471-83af-96bbbbd18b3c_negatedLabel_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_ifrs-full_InterestExpense_label_en-US" xlink:label="lab_ifrs-full_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpense" xlink:to="lab_ifrs-full_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_c8754bca-1f0d-41c5-8166-ac3487c3cb23_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows, Leases</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsPerShareAbstract_0f14e730-9819-474a-bfca-f87dab854615_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(b) Diluted (losses) per share</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsPerShareAbstract" xlink:to="lab_ifrs-full_DilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_9cbd15d4-ab9b-498f-b7c5-1413bcfc08a3_terseLabel_en-US" xlink:label="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of inputs (weighted average)</link:label>
    <link:label id="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_label_en-US" xlink:label="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Weighted Average Of Significant Unobservable Inputs Liabilities</link:label>
    <link:label id="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_documentation_en-US" xlink:label="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of weighted average of significant unobservable inputs liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" xlink:href="meso-20231231.xsd#meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" xlink:to="lab_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_a8985595-f857-49c7-a311-ae204e8a4bdc_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_b33e7014-366f-4aea-bf5e-50e6dbf6d8b8_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange adjustments, Sub-total</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromRoyalties_1a9743ef-2fe8-45d4-a504-01a68d7934c4_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty income</link:label>
    <link:label id="lab_ifrs-full_RevenueFromRoyalties_label_en-US" xlink:label="lab_ifrs-full_RevenueFromRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromRoyalties" xlink:to="lab_ifrs-full_RevenueFromRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock_9cb58e7f-d26f-471f-939f-8f862a30de9f_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Expense/(Benefit)</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Income Tax Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice_8a2c0bf5-ce83-47c6-8564-cbf3b5e1638f_terseLabel_en-US" xlink:label="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of increase and decrease in share price</link:label>
    <link:label id="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice_label_en-US" xlink:label="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Increase And Decrease In Share Price</link:label>
    <link:label id="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice_documentation_en-US" xlink:label="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Increase And Decrease In Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfIncreaseAndDecreaseInSharePrice" xlink:href="meso-20231231.xsd#meso_PercentageOfIncreaseAndDecreaseInSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfIncreaseAndDecreaseInSharePrice" xlink:to="lab_meso_PercentageOfIncreaseAndDecreaseInSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_f15f1d6d-724b-410f-8ae6-ed9cefdab0b3_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_c30033df-da96-4698-ba53-94d67e79f3ce_verboseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_7cd3746e-9581-4a01-90ac-78ca0608975c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Provisions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a35d49e9-b688-4546-adb5-7f2bcb80ea4b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_56b5dce1-21fc-4ab9-ace5-8f13834b6fac_terseLabel_en-US" xlink:label="lab_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities at fair value through profit or loss:</link:label>
    <link:label id="lab_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_label_en-US" xlink:label="lab_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated financial liabilities at fair value through profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract" xlink:to="lab_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_a0f916e1-7526-4dd8-bb42-c873122d752a_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash inflows by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_6f8601d4-17a0-4386-ac65-6e34736bec8c_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accumulated losses)</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FundsInvestedWhichDerivesInterestRevenue_a80a14f7-2e6c-48fc-8b90-d2e14aa7b458_terseLabel_en-US" xlink:label="lab_meso_FundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds invested</link:label>
    <link:label id="lab_meso_FundsInvestedWhichDerivesInterestRevenue_label_en-US" xlink:label="lab_meso_FundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds Invested Which Derives Interest Revenue</link:label>
    <link:label id="lab_meso_FundsInvestedWhichDerivesInterestRevenue_documentation_en-US" xlink:label="lab_meso_FundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds invested which derives interest revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FundsInvestedWhichDerivesInterestRevenue" xlink:href="meso-20231231.xsd#meso_FundsInvestedWhichDerivesInterestRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FundsInvestedWhichDerivesInterestRevenue" xlink:to="lab_meso_FundsInvestedWhichDerivesInterestRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DecreaseInInterestRatePercentage_77022b32-f2b1-45ad-bbf7-c62b9b34854a_terseLabel_en-US" xlink:label="lab_meso_DecreaseInInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate decrease</link:label>
    <link:label id="lab_meso_DecreaseInInterestRatePercentage_label_en-US" xlink:label="lab_meso_DecreaseInInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Interest Rate Percentage</link:label>
    <link:label id="lab_meso_DecreaseInInterestRatePercentage_documentation_en-US" xlink:label="lab_meso_DecreaseInInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in interest rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DecreaseInInterestRatePercentage" xlink:href="meso-20231231.xsd#meso_DecreaseInInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DecreaseInInterestRatePercentage" xlink:to="lab_meso_DecreaseInInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_7a4c4748-db90-462e-8574-ea02ae937abf_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add/(deduct) net loss for non-cash items as follows:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProbabilityOfDefaultMember_7340e2af-a76f-465a-9e97-0e58ca69d417_terseLabel_en-US" xlink:label="lab_ifrs-full_ProbabilityOfDefaultMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Success</link:label>
    <link:label id="lab_ifrs-full_ProbabilityOfDefaultMember_label_en-US" xlink:label="lab_ifrs-full_ProbabilityOfDefaultMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of default [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProbabilityOfDefaultMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProbabilityOfDefaultMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProbabilityOfDefaultMember" xlink:to="lab_ifrs-full_ProbabilityOfDefaultMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_e374eb6c-e5a9-427a-8a57-aa0ed761970a_terseLabel_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [axis]</link:label>
    <link:label id="lab_ifrs-full_ProductsAndServicesAxis_label_en-US" xlink:label="lab_ifrs-full_ProductsAndServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProductsAndServicesAxis" xlink:to="lab_ifrs-full_ProductsAndServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock_2edb34df-726c-4886-a54a-4ecaf8de7e3a_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Warrants</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Fair Value Of Warrants Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about fair value of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock_f96d9314-a724-409f-8328-182e183bc1c2_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Trade and Other Receivables and Prepayments</link:label>
    <link:label id="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Trade And Other Receivables And Prepayments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of trade and other receivables and prepayments explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfWarrantReserveLineItems_19814b05-f7e3-4cba-87be-9dad14c29552_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrant Reserve [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfWarrantReserveLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrant Reserve [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfWarrantReserveLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of warrant reserve.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems" xlink:to="lab_meso_DisclosureOfWarrantReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_e26bf484-9104-487f-bc33-254afcc6224b_terseLabel_en-US" xlink:label="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refinancing and Expansion of Senior Debt Facility</link:label>
    <link:label id="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_label_en-US" xlink:label="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refinancing And Expansion Of Senior Debt Facility [Member]</link:label>
    <link:label id="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_documentation_en-US" xlink:label="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refinancing and expansion of senior debt facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" xlink:href="meso-20231231.xsd#meso_RefinancingAndExpansionOfSeniorDebtFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" xlink:to="lab_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_8d13ac3f-a593-4c45-90bf-ddfa5b46b222_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Borrowings</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_beced4ac-79c1-4c64-bb08-8fbc71bfe70c_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValue" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_2c4279ab-dd9e-4cac-b490-90399f3275c7_terseLabel_en-US" xlink:label="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ten percent of decrease in share rice</link:label>
    <link:label id="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_label_en-US" xlink:label="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of net income risk based on decrease in share price</link:label>
    <link:label id="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_documentation_en-US" xlink:label="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of net income risk based on decrease in share price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" xlink:href="meso-20231231.xsd#meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" xlink:to="lab_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_cfe6cb5d-2b42-46f1-9350-56d682440620_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset depreciation</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementAbstract_fef17a06-680d-4b6e-81b6-b68fe72effb2_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Risk Management [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementAbstract_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Risk Management [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementAbstract_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial risk management.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract" xlink:to="lab_meso_DisclosureOfFinancialRiskManagementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseInDeferredTaxAssets_97854d11-d01a-4284-906c-6a5135195d65_terseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseInDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/decrease in deferred tax assets</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInDeferredTaxAssets_label_en-US" xlink:label="lab_meso_IncreaseDecreaseInDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Deferred Tax Assets</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInDeferredTaxAssets_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseInDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInDeferredTaxAssets" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseInDeferredTaxAssets" xlink:to="lab_meso_IncreaseDecreaseInDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem_a3a0a148-311c-422b-a00d-72519d538757_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax Line Item</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem_label_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax Line Item</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem_documentation_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax Line Item.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxLineItem"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem" xlink:to="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItem" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_4b3ad5df-4ef4-4a44-9324-018f345b1bd7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReservesMember_675dc0f0-c780-44ad-bfc9-236815f7cce1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReservesMember_label_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_0a4c52ca-374f-41dc-958c-d90836966ba6_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_5de5a85a-fb3a-4dc2-9cd8-38bdb46bdc20_verboseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_5db393e4-6a34-44d0-82e6-28dcee9e0050_netLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current borrowings</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AdditionalPotentialMilestonePaymentsReceivable_43b984ae-a8a5-41b1-a16d-981560af6523_terseLabel_en-US" xlink:label="lab_meso_AdditionalPotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional potential milestone payments receivable</link:label>
    <link:label id="lab_meso_AdditionalPotentialMilestonePaymentsReceivable_label_en-US" xlink:label="lab_meso_AdditionalPotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Milestone Payments Receivable</link:label>
    <link:label id="lab_meso_AdditionalPotentialMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_meso_AdditionalPotentialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Potential Milestone Payments Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdditionalPotentialMilestonePaymentsReceivable" xlink:href="meso-20231231.xsd#meso_AdditionalPotentialMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AdditionalPotentialMilestonePaymentsReceivable" xlink:to="lab_meso_AdditionalPotentialMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ContributionsOfValueForEquityDuringPeriod_4481779f-cecc-447f-b0ab-fe3606074fb1_totalLabel_en-US" xlink:label="lab_meso_ContributionsOfValueForEquityDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contributions of equity during the period</link:label>
    <link:label id="lab_meso_ContributionsOfValueForEquityDuringPeriod_label_en-US" xlink:label="lab_meso_ContributionsOfValueForEquityDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions Of Value For Equity During Period</link:label>
    <link:label id="lab_meso_ContributionsOfValueForEquityDuringPeriod_documentation_en-US" xlink:label="lab_meso_ContributionsOfValueForEquityDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions of value for equity during period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfValueForEquityDuringPeriod" xlink:href="meso-20231231.xsd#meso_ContributionsOfValueForEquityDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ContributionsOfValueForEquityDuringPeriod" xlink:to="lab_meso_ContributionsOfValueForEquityDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NovaQuestCapitalManagementLLCMember_89237d07-86fb-4c4f-b73a-20d23b6048c3_terseLabel_en-US" xlink:label="lab_meso_NovaQuestCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings - NovaQuest</link:label>
    <link:label id="lab_meso_NovaQuestCapitalManagementLLCMember_label_en-US" xlink:label="lab_meso_NovaQuestCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nova Quest Capital Management L L C [Member]</link:label>
    <link:label id="lab_meso_NovaQuestCapitalManagementLLCMember_documentation_en-US" xlink:label="lab_meso_NovaQuestCapitalManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NovaQuest Capital Management, L.L.C.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NovaQuestCapitalManagementLLCMember" xlink:href="meso-20231231.xsd#meso_NovaQuestCapitalManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NovaQuestCapitalManagementLLCMember" xlink:to="lab_meso_NovaQuestCapitalManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PrepaidInsuranceAndSubscriptions_1c4738a8-3256-4948-950e-f1ecd115b469_terseLabel_en-US" xlink:label="lab_meso_PrepaidInsuranceAndSubscriptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance and subscriptions</link:label>
    <link:label id="lab_meso_PrepaidInsuranceAndSubscriptions_label_en-US" xlink:label="lab_meso_PrepaidInsuranceAndSubscriptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance And Subscriptions</link:label>
    <link:label id="lab_meso_PrepaidInsuranceAndSubscriptions_documentation_en-US" xlink:label="lab_meso_PrepaidInsuranceAndSubscriptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance and subscriptions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrepaidInsuranceAndSubscriptions" xlink:href="meso-20231231.xsd#meso_PrepaidInsuranceAndSubscriptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PrepaidInsuranceAndSubscriptions" xlink:to="lab_meso_PrepaidInsuranceAndSubscriptions" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NumberOfClassActionLawsuits_ebb357f2-5d29-4419-a1a1-25a987f3a30b_terseLabel_en-US" xlink:label="lab_meso_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of action lawsuits</link:label>
    <link:label id="lab_meso_NumberOfClassActionLawsuits_label_en-US" xlink:label="lab_meso_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:label id="lab_meso_NumberOfClassActionLawsuits_documentation_en-US" xlink:label="lab_meso_NumberOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfClassActionLawsuits" xlink:href="meso-20231231.xsd#meso_NumberOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NumberOfClassActionLawsuits" xlink:to="lab_meso_NumberOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_fc06102b-cfaa-43d8-b465-43bd06c2620c_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsMember" xlink:to="lab_ifrs-full_UnobservableInputsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BalancesWithBanks_6670e31a-268c-4b6f-8da1-a683b9418a30_terseLabel_en-US" xlink:label="lab_ifrs-full_BalancesWithBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash at bank</link:label>
    <link:label id="lab_ifrs-full_BalancesWithBanks_9ace0a76-a8ff-4d09-82e5-bc6391c28c08_verboseLabel_en-US" xlink:label="lab_ifrs-full_BalancesWithBanks" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash at bank</link:label>
    <link:label id="lab_ifrs-full_BalancesWithBanks_label_en-US" xlink:label="lab_ifrs-full_BalancesWithBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances with banks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BalancesWithBanks" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BalancesWithBanks" xlink:to="lab_ifrs-full_BalancesWithBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ServiceConcessionArrangementsMember_65e43def-1308-456a-bb81-4b60b9f1579d_terseLabel_en-US" xlink:label="lab_ifrs-full_ServiceConcessionArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service concession arrangements</link:label>
    <link:label id="lab_ifrs-full_ServiceConcessionArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_ServiceConcessionArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service concession arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsMember" xlink:to="lab_ifrs-full_ServiceConcessionArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_0865c6eb-4d6e-4865-b15f-0208e5835954_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_f0db711a-536f-421c-9aea-08a5db458a94_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CreationDateAxis_efb02862-642c-45dc-bde5-152be59072b0_terseLabel_en-US" xlink:label="lab_ifrs-full_CreationDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creation date [axis]</link:label>
    <link:label id="lab_ifrs-full_CreationDateAxis_label_en-US" xlink:label="lab_ifrs-full_CreationDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Creation date [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreationDateAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreationDateAxis" xlink:to="lab_ifrs-full_CreationDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SharesHeldInTrustValue_021e0940-b8b8-4882-b01d-3c2829dcfdc9_periodStartLabel_en-US" xlink:label="lab_meso_SharesHeldInTrustValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance</link:label>
    <link:label id="lab_meso_SharesHeldInTrustValue_de8f1cbc-32fc-4a04-ae24-6d5a0daaaef7_periodEndLabel_en-US" xlink:label="lab_meso_SharesHeldInTrustValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_meso_SharesHeldInTrustValue_label_en-US" xlink:label="lab_meso_SharesHeldInTrustValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held In Trust Value</link:label>
    <link:label id="lab_meso_SharesHeldInTrustValue_documentation_en-US" xlink:label="lab_meso_SharesHeldInTrustValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held in trust, value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrustValue" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrustValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SharesHeldInTrustValue" xlink:to="lab_meso_SharesHeldInTrustValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_5a280403-28de-46fa-b945-b4931dae7b62_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, class</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents_8a9c707e-0570-41e3-93fa-a20522d81540_verboseLabel_en-US" xlink:label="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange adjustments, Total</link:label>
    <link:label id="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents_label_en-US" xlink:label="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Foreign Exchange Adjustments On Liabilities Arising From Financing Activities And Cash And Cash Equivalents</link:label>
    <link:label id="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents_documentation_en-US" xlink:label="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange adjustments on liabilities arising from financing activities and cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" xlink:href="meso-20231231.xsd#meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" xlink:to="lab_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_b4a9295d-fa9a-4bd6-a7f8-d4450be6c43e_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_24d1cd92-ce7e-46f0-a7e8-075c2be9764d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock_389bb564-5482-4067-b370-65d204433b6d_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Increase/Decrease of Share Price</link:label>
    <link:label id="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis effect of increase (decrease) in share price [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of sensitivity analysis effect of increase (decrease) in share price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" xlink:to="lab_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_d058c414-db5e-4d94-a083-8656a7a26903_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Risk</link:label>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateRiskMember" xlink:to="lab_ifrs-full_InterestRateRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_InvestmentRevaluationReserveMember_cbf2cc5d-8a05-4d31-ba37-31a35fa751a1_terseLabel_en-US" xlink:label="lab_meso_InvestmentRevaluationReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Revaluation Reserve</link:label>
    <link:label id="lab_meso_InvestmentRevaluationReserveMember_label_en-US" xlink:label="lab_meso_InvestmentRevaluationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Revaluation Reserve [Member]</link:label>
    <link:label id="lab_meso_InvestmentRevaluationReserveMember_documentation_en-US" xlink:label="lab_meso_InvestmentRevaluationReserveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment revaluation reserve.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InvestmentRevaluationReserveMember" xlink:href="meso-20231231.xsd#meso_InvestmentRevaluationReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_InvestmentRevaluationReserveMember" xlink:to="lab_meso_InvestmentRevaluationReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ForeignWithholdingTaxRecoverable_81483667-85b6-4c14-a3d6-5b3b34285c1b_terseLabel_en-US" xlink:label="lab_meso_ForeignWithholdingTaxRecoverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign withholding tax recoverable</link:label>
    <link:label id="lab_meso_ForeignWithholdingTaxRecoverable_label_en-US" xlink:label="lab_meso_ForeignWithholdingTaxRecoverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Withholding Tax Recoverable</link:label>
    <link:label id="lab_meso_ForeignWithholdingTaxRecoverable_documentation_en-US" xlink:label="lab_meso_ForeignWithholdingTaxRecoverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign withholding tax recoverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ForeignWithholdingTaxRecoverable" xlink:href="meso-20231231.xsd#meso_ForeignWithholdingTaxRecoverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ForeignWithholdingTaxRecoverable" xlink:to="lab_meso_ForeignWithholdingTaxRecoverable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_8a756c33-7d7a-4ed1-a969-a2fe4656f8a7_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_d6a1736b-029d-4bac-ba06-dbebf6654cc4_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedImpairmentMember_3219c97a-e78a-4826-92f9-1b3a918e8a56_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment</link:label>
    <link:label id="lab_ifrs-full_AccumulatedImpairmentMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedImpairmentMember" xlink:to="lab_ifrs-full_AccumulatedImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_e19d34a8-5a13-4372-9bab-c7a8e4a11c4a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Fair Value Measurement Of Assets [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_d478cc6a-80f6-4cd4-a0b8-b8c2a0332bf7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Instruments [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_9b11a5be-990a-43f2-ad76-af92dfa66f98_totalLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax (benefit)/expense</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_December2022WarrantsMember_3fc1b4e2-e6b9-4e55-a5de-94e5372722a3_terseLabel_en-US" xlink:label="lab_meso_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2022 warrants</link:label>
    <link:label id="lab_meso_December2022WarrantsMember_label_en-US" xlink:label="lab_meso_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2022 warrants [Member]</link:label>
    <link:label id="lab_meso_December2022WarrantsMember_documentation_en-US" xlink:label="lab_meso_December2022WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2022 warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_December2022WarrantsMember" xlink:href="meso-20231231.xsd#meso_December2022WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_December2022WarrantsMember" xlink:to="lab_meso_December2022WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_61297731-a98a-429f-a01d-54bc6e5e16bf_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement Of Changes In Equity [Table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillMember_b43674ca-384f-4c29-adc5-c33450546306_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillMember_label_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillMember" xlink:to="lab_ifrs-full_GoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_a48adf7e-32f7-4de0-a816-b2c94d6e6d03_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issue of shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_7eb33529-40fe-4700-b4f8-ef4d84250127_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_3aefe16f-cdf3-4a49-8842-32ff1a5b1e5d_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ContingentConsiderationProvisionAmountUsed_24a923f1-8d7f-4cb5-9fc1-0b5dc9bc718f_negatedLabel_en-US" xlink:label="lab_meso_ContingentConsiderationProvisionAmountUsed" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification during the period</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvisionAmountUsed_label_en-US" xlink:label="lab_meso_ContingentConsiderationProvisionAmountUsed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Provision Amount Used</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvisionAmountUsed_documentation_en-US" xlink:label="lab_meso_ContingentConsiderationProvisionAmountUsed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration provision amount used.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvisionAmountUsed" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvisionAmountUsed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ContingentConsiderationProvisionAmountUsed" xlink:to="lab_meso_ContingentConsiderationProvisionAmountUsed" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_480cf648-fdc2-4c53-811d-5f642eee226c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of liabilities arising from financing activities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract_b5d3b93f-2a6a-4da9-9fbe-8074118a7633_terseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit)/expense</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense (income) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:to="lab_ifrs-full_DeferredTaxExpenseIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_d9647544-d00e-4920-8048-681f317fed2e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDeferredTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for deferred tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_e586b99d-82be-4707-b481-27d8580f4e17_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (outflows) in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_5c5dfc35-263c-4bf3-9c57-de86ffc07c6c_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities_4fa0590b-0dd9-4fc2-a56f-1266a38ef3a7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of inputs used in fair value measurement, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities" xlink:to="lab_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_e57803ef-e2d8-4d30-9502-a5239f4957a0_terseLabel_en-US" xlink:label="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options reserve transferred to equity on exercise of options</link:label>
    <link:label id="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_label_en-US" xlink:label="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options Reserve Transferred To Equity On Exercise Of Options Value</link:label>
    <link:label id="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_documentation_en-US" xlink:label="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options reserve transferred to equity on exercise of options value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" xlink:href="meso-20231231.xsd#meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" xlink:to="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TransactionCostsArisingOnShareIssueShare_fa7a269f-0ff2-4126-94af-f07c0f184dc3_terseLabel_en-US" xlink:label="lab_meso_TransactionCostsArisingOnShareIssueShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs arising on share issue (in shares)</link:label>
    <link:label id="lab_meso_TransactionCostsArisingOnShareIssueShare_label_en-US" xlink:label="lab_meso_TransactionCostsArisingOnShareIssueShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Arising On Share Issue Share</link:label>
    <link:label id="lab_meso_TransactionCostsArisingOnShareIssueShare_documentation_en-US" xlink:label="lab_meso_TransactionCostsArisingOnShareIssueShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Arising On Share Issue Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssueShare" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssueShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TransactionCostsArisingOnShareIssueShare" xlink:to="lab_meso_TransactionCostsArisingOnShareIssueShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_bef6fff9-7e82-41b5-b1aa-bc6a88df77be_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Intangible Assets [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_d4291bd7-edac-4979-80b2-a24d70894417_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_907753af-d974-4fab-9388-c2625854c911_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ContributionsOfEquityDuringPeriod_2df1acd5-c62f-432a-a940-ca31cd7f8407_totalLabel_en-US" xlink:label="lab_meso_ContributionsOfEquityDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contributions of equity during the period (in shares)</link:label>
    <link:label id="lab_meso_ContributionsOfEquityDuringPeriod_label_en-US" xlink:label="lab_meso_ContributionsOfEquityDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions Of Equity During Period</link:label>
    <link:label id="lab_meso_ContributionsOfEquityDuringPeriod_documentation_en-US" xlink:label="lab_meso_ContributionsOfEquityDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions of equity during period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfEquityDuringPeriod" xlink:href="meso-20231231.xsd#meso_ContributionsOfEquityDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ContributionsOfEquityDuringPeriod" xlink:to="lab_meso_ContributionsOfEquityDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsAbstract_13753be2-f0c1-4889-b8f4-3a82621b027f_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_BorrowingsAbstract_label_en-US" xlink:label="lab_ifrs-full_BorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAbstract" xlink:to="lab_ifrs-full_BorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_6ac605a9-a9ed-4022-b047-fd2240a016ac_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_label_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_documentation_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant changes in current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" xlink:to="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_ce713c76-889d-4722-a117-6e9cda6bbd96_periodStartLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_64048bd1-c97b-4af6-af01-0341e05f529b_periodEndLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable_21bae523-4dfd-4eca-b289-a302b5a3d366_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movements Of Shares In Share Trust [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable_label_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Movements Of Shares In Share Trust [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of movements of shares in share trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable" xlink:to="lab_meso_DisclosureOfMovementsOfSharesInShareTrustTable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock_9c91d21f-33eb-4aa3-bf5a-5436ccf61326_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Reserve</link:label>
    <link:label id="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrant Reserve Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of warrant reserve.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_ba8601bb-0261-4dfc-a4cc-fadf4d85a243_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_BasisOfPreparationAbstract_89be2357-4ffa-474e-a1fa-1ef91d30f859_terseLabel_en-US" xlink:label="lab_meso_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Preparation [Abstract]</link:label>
    <link:label id="lab_meso_BasisOfPreparationAbstract_label_en-US" xlink:label="lab_meso_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Preparation [Abstract]</link:label>
    <link:label id="lab_meso_BasisOfPreparationAbstract_documentation_en-US" xlink:label="lab_meso_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BasisOfPreparationAbstract" xlink:href="meso-20231231.xsd#meso_BasisOfPreparationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_BasisOfPreparationAbstract" xlink:to="lab_meso_BasisOfPreparationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PrivatePlacementOfSharesMember_a4204c10-50c6-4b59-809b-07aa92136d2c_terseLabel_en-US" xlink:label="lab_meso_PrivatePlacementOfSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_meso_PrivatePlacementOfSharesMember_label_en-US" xlink:label="lab_meso_PrivatePlacementOfSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Of Shares [Member]</link:label>
    <link:label id="lab_meso_PrivatePlacementOfSharesMember_documentation_en-US" xlink:label="lab_meso_PrivatePlacementOfSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PrivatePlacementOfSharesMember" xlink:to="lab_meso_PrivatePlacementOfSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetInvestmentInFinanceLease_f63541b8-596d-4f2d-aa1b-60f13fd75e15_terseLabel_en-US" xlink:label="lab_ifrs-full_NetInvestmentInFinanceLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment in sublease</link:label>
    <link:label id="lab_ifrs-full_NetInvestmentInFinanceLease_label_en-US" xlink:label="lab_ifrs-full_NetInvestmentInFinanceLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net investment in finance lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetInvestmentInFinanceLease" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetInvestmentInFinanceLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetInvestmentInFinanceLease" xlink:to="lab_ifrs-full_NetInvestmentInFinanceLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_cd055f6b-06c6-4ab3-9529-2f4774247a4a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock_19876ad1-de17-4ce2-bf9b-b01aff505a2c_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Fair Value Measurement Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about fair value measurement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5e9598f2-f575-4da0-8a6b-960d3f81dc2d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_5121581d-c999-419b-965f-0a427040fcab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementTable_68c33a5d-0207-4f15-82a2-bd5309b67633_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Risk Management [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementTable_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Risk Management [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial risk management.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable" xlink:to="lab_meso_DisclosureOfFinancialRiskManagementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax_06a56763-8d56-4431-a6a7-879d3d19bdd5_terseLabel_en-US" xlink:label="lab_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- profit or loss</link:label>
    <link:label id="lab_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax_label_en-US" xlink:label="lab_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net movement in regulatory deferral account balances related to profit or loss and net movement in related deferred tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" xlink:to="lab_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member_cca6355b-f5c6-4449-bf59-0de19862676b_terseLabel_en-US" xlink:label="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value at Grant Date December 22, 2022</link:label>
    <link:label id="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member_label_en-US" xlink:label="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value at Grant Date December 22, 2022 [Member]</link:label>
    <link:label id="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member_documentation_en-US" xlink:label="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value at Grant Date December 22, 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtGrantDateDecember222022Member" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtGrantDateDecember222022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_WarrantsFairValueAtGrantDateDecember222022Member" xlink:to="lab_meso_WarrantsFairValueAtGrantDateDecember222022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ContingentConsiderations_58eebc07-2a4d-4e8e-923c-ed5009c4eeec_terseLabel_en-US" xlink:label="lab_meso_ContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_meso_ContingentConsiderations_a2698662-b757-43e0-91d1-1e5e417aab08_verboseLabel_en-US" xlink:label="lab_meso_ContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_meso_ContingentConsiderations_5f1fc805-0208-4e8c-9621-1294ecefdb1f_totalLabel_en-US" xlink:label="lab_meso_ContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_meso_ContingentConsiderations_label_en-US" xlink:label="lab_meso_ContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Considerations</link:label>
    <link:label id="lab_meso_ContingentConsiderations_documentation_en-US" xlink:label="lab_meso_ContingentConsiderations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent considerations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ContingentConsiderations" xlink:to="lab_meso_ContingentConsiderations" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TreasurySharesPurchasedValue_52fe0b92-bfa2-459d-b038-42c1f206cb11_negatedTerseLabel_en-US" xlink:label="lab_meso_TreasurySharesPurchasedValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Treasury Shares</link:label>
    <link:label id="lab_meso_TreasurySharesPurchasedValue_label_en-US" xlink:label="lab_meso_TreasurySharesPurchasedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares Purchased Value</link:label>
    <link:label id="lab_meso_TreasurySharesPurchasedValue_documentation_en-US" xlink:label="lab_meso_TreasurySharesPurchasedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares purchased value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchasedValue" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchasedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TreasurySharesPurchasedValue" xlink:to="lab_meso_TreasurySharesPurchasedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PaymentAssumptionsMeasurementInputMember_e285b585-4f5d-4e24-ae10-577e44b6a99a_terseLabel_en-US" xlink:label="lab_meso_PaymentAssumptionsMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment assumptions</link:label>
    <link:label id="lab_meso_PaymentAssumptionsMeasurementInputMember_label_en-US" xlink:label="lab_meso_PaymentAssumptionsMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Assumptions, Measurement Input [Member]</link:label>
    <link:label id="lab_meso_PaymentAssumptionsMeasurementInputMember_documentation_en-US" xlink:label="lab_meso_PaymentAssumptionsMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Assumptions, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentAssumptionsMeasurementInputMember" xlink:href="meso-20231231.xsd#meso_PaymentAssumptionsMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PaymentAssumptionsMeasurementInputMember" xlink:to="lab_meso_PaymentAssumptionsMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_EmployeeBenefitsMember_6dadba65-03da-40f3-9a82-15a0cb6d6c46_terseLabel_en-US" xlink:label="lab_meso_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_meso_EmployeeBenefitsMember_label_en-US" xlink:label="lab_meso_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits [Member]</link:label>
    <link:label id="lab_meso_EmployeeBenefitsMember_documentation_en-US" xlink:label="lab_meso_EmployeeBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EmployeeBenefitsMember" xlink:href="meso-20231231.xsd#meso_EmployeeBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_EmployeeBenefitsMember" xlink:to="lab_meso_EmployeeBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_32ce1313-9108-4cc4-a6e5-602269dfb122_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_311b0a00-c1a4-49df-a059-b18fd7400ddc_terseLabel_en-US" xlink:label="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants granted to purchase american depositary shares (in shares)</link:label>
    <link:label id="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_label_en-US" xlink:label="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted To Purchase American Depositary Shares</link:label>
    <link:label id="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_documentation_en-US" xlink:label="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants granted to purchase American Depositary Shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" xlink:to="lab_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory_24421b2a-c003-45bf-9b35-13b5548d36f5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Tax Balances</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of deferred taxes [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_2f6e487c-1dd4-4503-87dc-bdf0870ee2ce_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants_92ac3fd9-d65c-401a-b6b1-6b833a799887_verboseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange adjustments, Warrant liability</link:label>
    <link:label id="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants_label_en-US" xlink:label="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease Through Effect Of Changes In Foreign Exchange Rates Liabilities Arising From Warrants</link:label>
    <link:label id="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates liabilities arising from warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" xlink:to="lab_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_036bc0f5-e9cc-4807-bfa8-985c9dea266a_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current financial assets at fair value through other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:to="lab_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_167b7824-246b-4851-a7da-391deb3ff37a_negatedLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research &amp; development</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromInterest_4f1b6e21-b6f8-47f1-bc9f-f2acba9519d5_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromInterest_label_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest" xlink:to="lab_ifrs-full_RevenueFromInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CurrentTaxAbstract_aadfb3fd-b917-4448-a9a5-7ef65a588cc9_terseLabel_en-US" xlink:label="lab_meso_CurrentTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax</link:label>
    <link:label id="lab_meso_CurrentTaxAbstract_label_en-US" xlink:label="lab_meso_CurrentTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax [Abstract]</link:label>
    <link:label id="lab_meso_CurrentTaxAbstract_documentation_en-US" xlink:label="lab_meso_CurrentTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentTaxAbstract" xlink:href="meso-20231231.xsd#meso_CurrentTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CurrentTaxAbstract" xlink:to="lab_meso_CurrentTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_9c76a9a8-36c5-43fa-97c5-c9c7c45bef6e_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, category</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TaxLossesMember_2fffa08f-8d2d-4538-99a0-316364fc2e82_terseLabel_en-US" xlink:label="lab_meso_TaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax losses (DTA)</link:label>
    <link:label id="lab_meso_TaxLossesMember_label_en-US" xlink:label="lab_meso_TaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Losses [Member]</link:label>
    <link:label id="lab_meso_TaxLossesMember_documentation_en-US" xlink:label="lab_meso_TaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxLossesMember" xlink:href="meso-20231231.xsd#meso_TaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TaxLossesMember" xlink:to="lab_meso_TaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_f14c3feb-667b-42e1-9ef9-5c092b60bbbe_terseLabel_en-US" xlink:label="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate increase on funds invested</link:label>
    <link:label id="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_label_en-US" xlink:label="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Interest Rate On Funds Invested Which Derives Interest Revenue</link:label>
    <link:label id="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_documentation_en-US" xlink:label="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in interest rate on funds invested which derives interest revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:href="meso-20231231.xsd#meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:to="lab_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_27c4a614-d04e-48b0-9acc-ce47db2f3220_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantLiability_5d95eca0-c11a-43ea-af59-fba5b481d9c3_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_e570c031-6eeb-4baf-9e94-569bd50ec9ef_negatedLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_938c4fed-fea3-4b1e-975c-eda384ae27b3_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability at beginning of period</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_94c645b9-99a9-41ef-a480-165add908538_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability at end of period</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_e3751e8e-0378-4f61-a8af-f3c3254ca6d4_verboseLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liabilities</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_dbbd3f29-ddc8-46c0-a1b6-2ddc2b887d91_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_c83fd0f6-9a0a-407b-9d93-196b4f15f569_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Balance</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_label_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantLiability" xlink:to="lab_ifrs-full_WarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CurrentMarketedProductsMember_081d5cc9-ec1a-47bb-b5ce-23657deaf003_terseLabel_en-US" xlink:label="lab_meso_CurrentMarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current marketed products</link:label>
    <link:label id="lab_meso_CurrentMarketedProductsMember_label_en-US" xlink:label="lab_meso_CurrentMarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketed Products [Member]</link:label>
    <link:label id="lab_meso_CurrentMarketedProductsMember_documentation_en-US" xlink:label="lab_meso_CurrentMarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current marketed products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentMarketedProductsMember" xlink:href="meso-20231231.xsd#meso_CurrentMarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CurrentMarketedProductsMember" xlink:to="lab_meso_CurrentMarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_WarrantExerciseTerm_b782aa5e-6111-4c31-b60a-185aa78fe73e_terseLabel_en-US" xlink:label="lab_meso_WarrantExerciseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise term</link:label>
    <link:label id="lab_meso_WarrantExerciseTerm_label_en-US" xlink:label="lab_meso_WarrantExerciseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Term</link:label>
    <link:label id="lab_meso_WarrantExerciseTerm_documentation_en-US" xlink:label="lab_meso_WarrantExerciseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExerciseTerm" xlink:href="meso-20231231.xsd#meso_WarrantExerciseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_WarrantExerciseTerm" xlink:to="lab_meso_WarrantExerciseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesTable_434c6fca-6eb6-47c3-adff-546e02204287_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets And Liabilities [Table]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets And Liabilities [Table]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule disclosing information related to deferred tax assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesTable" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesTable" xlink:to="lab_meso_DeferredTaxAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_8e03b96f-81f7-4b17-986f-d90b4d19ac88_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_a1208ac0-8f79-4b22-8a87-64f7dbf086d7_terseLabel_en-US" xlink:label="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of premium for volume-weighted average price</link:label>
    <link:label id="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_label_en-US" xlink:label="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Premium For Volume Weighted Average Price</link:label>
    <link:label id="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_documentation_en-US" xlink:label="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of premium for volume-weighted average price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPremiumForVolumeWeightedAveragePrice" xlink:href="meso-20231231.xsd#meso_PercentageOfPremiumForVolumeWeightedAveragePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfPremiumForVolumeWeightedAveragePrice" xlink:to="lab_meso_PercentageOfPremiumForVolumeWeightedAveragePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_UnpaidInterestPortionPerAnnum_dddda236-a06a-415b-afa1-67920d659e44_terseLabel_en-US" xlink:label="lab_meso_UnpaidInterestPortionPerAnnum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Interest Portion Per Annum</link:label>
    <link:label id="lab_meso_UnpaidInterestPortionPerAnnum_label_en-US" xlink:label="lab_meso_UnpaidInterestPortionPerAnnum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid Interest Portion Per Annum</link:label>
    <link:label id="lab_meso_UnpaidInterestPortionPerAnnum_documentation_en-US" xlink:label="lab_meso_UnpaidInterestPortionPerAnnum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid interest portion per annum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UnpaidInterestPortionPerAnnum" xlink:href="meso-20231231.xsd#meso_UnpaidInterestPortionPerAnnum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_UnpaidInterestPortionPerAnnum" xlink:to="lab_meso_UnpaidInterestPortionPerAnnum" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ProceedsFromPrivatePlacement_a0dd7d35-ba46-45f3-9835-6e5a5dcee42a_terseLabel_en-US" xlink:label="lab_meso_ProceedsFromPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from private placement</link:label>
    <link:label id="lab_meso_ProceedsFromPrivatePlacement_label_en-US" xlink:label="lab_meso_ProceedsFromPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from private placement</link:label>
    <link:label id="lab_meso_ProceedsFromPrivatePlacement_documentation_en-US" xlink:label="lab_meso_ProceedsFromPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from private placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProceedsFromPrivatePlacement" xlink:href="meso-20231231.xsd#meso_ProceedsFromPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ProceedsFromPrivatePlacement" xlink:to="lab_meso_ProceedsFromPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDebt_72daff78-a67a-41bb-985e-70a87a1fc2f2_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_NetDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Debt</link:label>
    <link:label id="lab_ifrs-full_NetDebt_6085ef27-5b79-4c2e-a1f5-7283db4155b9_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_NetDebt" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt total at beginning of period</link:label>
    <link:label id="lab_ifrs-full_NetDebt_7f24c8a4-f878-41ec-bb87-f2ea45301cb8_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_NetDebt" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt total at end of period</link:label>
    <link:label id="lab_ifrs-full_NetDebt_label_en-US" xlink:label="lab_ifrs-full_NetDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDebt" xlink:to="lab_ifrs-full_NetDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_a808fe23-9b59-4d51-9072-ca7fcd4a90eb_terseLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_a29ebe5c-6570-48fc-8498-9ecb3422c504_totalLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember_8c4073ab-0797-419f-9abd-95508be7463a_terseLabel_en-US" xlink:label="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Functional Expense Categories</link:label>
    <link:label id="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember_label_en-US" xlink:label="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Functional Expense Categories [Member]</link:label>
    <link:label id="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember_documentation_en-US" xlink:label="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income statement functional expense categories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementFunctionalExpenseCategoriesMember" xlink:href="meso-20231231.xsd#meso_IncomeStatementFunctionalExpenseCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncomeStatementFunctionalExpenseCategoriesMember" xlink:to="lab_meso_IncomeStatementFunctionalExpenseCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2ddb5237-1829-4ff1-9589-3d06b4bdd561_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_e4094b3d-43e9-474a-806d-e0657581af1b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Provisions [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherProvisionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="lab_ifrs-full_DisclosureOfOtherProvisionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_ea5953ac-5e6c-4ec6-8486-907314662743_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(increase) in trade and other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in trade and other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_b61ef61e-f2b9-401f-869e-7c2e623e1546_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_2f7c8bff-e716-4f96-ba36-b4acbf8d851d_terseLabel_en-US" xlink:label="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue relating to non-refundable up-front payment</link:label>
    <link:label id="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_label_en-US" xlink:label="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Royalties Entitled To Be Received Upon Reaching Sales Based Milestones</link:label>
    <link:label id="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_documentation_en-US" xlink:label="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Royalties Entitled To Be Received Upon Reaching Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" xlink:href="meso-20231231.xsd#meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" xlink:to="lab_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_f9593053-999d-4d13-bba8-aa73acfd50f7_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities_9cacfea1-1059-4b09-8fc3-b8558cd4d6bc_terseLabel_en-US" xlink:label="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Changes, Borrowings</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Borrowing Liabilities Classified As Financing Activities</link:label>
    <link:label id="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities_documentation_en-US" xlink:label="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in borrowing liabilities classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_87a95449-a158-4073-8cd7-ce63d81316cd_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_1f6967de-1955-4a1f-8fd0-7ba182595196_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_912c0435-0b77-4a98-986a-32a1d89a074a_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases at end of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DepositsAtCall_36b466f5-1dfd-4d24-b46d-451fb996e00e_terseLabel_en-US" xlink:label="lab_meso_DepositsAtCall" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits at call</link:label>
    <link:label id="lab_meso_DepositsAtCall_label_en-US" xlink:label="lab_meso_DepositsAtCall" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits At Call</link:label>
    <link:label id="lab_meso_DepositsAtCall_documentation_en-US" xlink:label="lab_meso_DepositsAtCall" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits at call.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DepositsAtCall" xlink:href="meso-20231231.xsd#meso_DepositsAtCall"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DepositsAtCall" xlink:to="lab_meso_DepositsAtCall" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilities_9241fc4b-79d6-4585-8a27-b33bb9255b4e_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, Total</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_d96c4939-c441-4fa3-8571-fec94da27708_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilities" xlink:to="lab_ifrs-full_FinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_313b47c3-c0fd-4101-88cb-55ad49851dd1_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_35486507-37ed-4c97-b730-dfdd23259dc4_terseLabel_en-US" xlink:label="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on profit from change in interest rate increase or decrease</link:label>
    <link:label id="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_label_en-US" xlink:label="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect On Profit From Change In Interest Rate Increase Or Decrease</link:label>
    <link:label id="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_documentation_en-US" xlink:label="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on profit from change in interest rate increase or decrease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" xlink:href="meso-20231231.xsd#meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" xlink:to="lab_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones_07e62d64-1e5a-4254-b633-022d5f35bf01_terseLabel_en-US" xlink:label="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties receivable under sales-based milestones</link:label>
    <link:label id="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones_label_en-US" xlink:label="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties Receivable Under Sales Based Milestones</link:label>
    <link:label id="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones_documentation_en-US" xlink:label="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties receivable under salesbased milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RoyaltiesReceivableUnderSalesBasedMilestones" xlink:href="meso-20231231.xsd#meso_RoyaltiesReceivableUnderSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RoyaltiesReceivableUnderSalesBasedMilestones" xlink:to="lab_meso_RoyaltiesReceivableUnderSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_59eabc99-3dc2-4794-9c95-715e1dffc9a9_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-total at beginning of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_1e06ec40-25cd-475f-99ab-3432b3b37ceb_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-total at end of period</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_70a83e89-fbb6-4851-8b0f-f08733bd1e82_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Non Financial Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_documentation_en-US" xlink:label="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non financial assets and liabilities,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" xlink:to="lab_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock_81e60817-0c87-4b2c-aeb6-240017495c21_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Debt Reconciliation</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Net Debt Reconciliation Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The disclosure of detailed information about net debt reconciliation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_69b5f2b5-418c-4e42-8fcf-0085a0e5fd9a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Intangible Assets [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ContingentConsiderationProvision_52e9c596-c28a-422a-a41b-f06e2195be04_periodStartLabel_en-US" xlink:label="lab_meso_ContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvision_aa169df8-6014-478c-b80f-96564f54b3e3_periodEndLabel_en-US" xlink:label="lab_meso_ContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing balance</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvision_dfa824d9-0e89-409b-a625-d1d8a791af5d_verboseLabel_en-US" xlink:label="lab_meso_ContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration provision</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvision_label_en-US" xlink:label="lab_meso_ContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Provision</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvision_documentation_en-US" xlink:label="lab_meso_ContingentConsiderationProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration provision.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ContingentConsiderationProvision" xlink:to="lab_meso_ContingentConsiderationProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_f9535594-d137-4655-9816-6864e1e64a07_terseLabel_en-US" xlink:label="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Operating Assets And Liabilities [Abstract]</link:label>
    <link:label id="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_documentation_en-US" xlink:label="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:href="meso-20231231.xsd#meso_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:to="lab_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_41db0f04-2671-409f-bce5-fb338badc902_terseLabel_en-US" xlink:label="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options reserve transferred to equity on exercise of options (in shares)</link:label>
    <link:label id="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_label_en-US" xlink:label="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options Reserve Transferred To Equity On Exercise Of Options Share</link:label>
    <link:label id="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_documentation_en-US" xlink:label="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options Reserve Transferred To Equity On Exercise Of Options Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" xlink:href="meso-20231231.xsd#meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" xlink:to="lab_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TaslyMember_a36db11b-54f1-4526-a64c-dca86cf8c973_terseLabel_en-US" xlink:label="lab_meso_TaslyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tasly</link:label>
    <link:label id="lab_meso_TaslyMember_label_en-US" xlink:label="lab_meso_TaslyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tasly [Member]</link:label>
    <link:label id="lab_meso_TaslyMember_documentation_en-US" xlink:label="lab_meso_TaslyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tasly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaslyMember" xlink:href="meso-20231231.xsd#meso_TaslyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TaslyMember" xlink:to="lab_meso_TaslyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiquidityRiskMember_1ec2d7c6-fe60-4cb4-9150-44dd6037b8f3_terseLabel_en-US" xlink:label="lab_ifrs-full_LiquidityRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity Risk</link:label>
    <link:label id="lab_ifrs-full_LiquidityRiskMember_label_en-US" xlink:label="lab_ifrs-full_LiquidityRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiquidityRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiquidityRiskMember" xlink:to="lab_ifrs-full_LiquidityRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_9928772f-8d49-4e43-9c3b-6a00b712744a_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items that will not be reclassified to profit and loss</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TaxCreditedOrDebitedToEquity_7c781bcc-50f4-483e-949c-0ed06eef9245_negatedLabel_en-US" xlink:label="lab_meso_TaxCreditedOrDebitedToEquity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credited / (debited) to equity</link:label>
    <link:label id="lab_meso_TaxCreditedOrDebitedToEquity_label_en-US" xlink:label="lab_meso_TaxCreditedOrDebitedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credited Or Debited To Equity</link:label>
    <link:label id="lab_meso_TaxCreditedOrDebitedToEquity_documentation_en-US" xlink:label="lab_meso_TaxCreditedOrDebitedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credited or debited to equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxCreditedOrDebitedToEquity" xlink:href="meso-20231231.xsd#meso_TaxCreditedOrDebitedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TaxCreditedOrDebitedToEquity" xlink:to="lab_meso_TaxCreditedOrDebitedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_856afdb2-1b25-4584-af3a-c09485abcc9b_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_c452a13f-0ee2-4f50-ac0a-53cccd753c41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ExpectedSalesVolumeMember_524948a1-681e-4eef-bae7-7d0c0832fb98_terseLabel_en-US" xlink:label="lab_meso_ExpectedSalesVolumeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Sales Volume</link:label>
    <link:label id="lab_meso_ExpectedSalesVolumeMember_label_en-US" xlink:label="lab_meso_ExpectedSalesVolumeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Sales Volume [Member]</link:label>
    <link:label id="lab_meso_ExpectedSalesVolumeMember_documentation_en-US" xlink:label="lab_meso_ExpectedSalesVolumeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected sales volume.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedSalesVolumeMember" xlink:href="meso-20231231.xsd#meso_ExpectedSalesVolumeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ExpectedSalesVolumeMember" xlink:to="lab_meso_ExpectedSalesVolumeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities_ae8708dd-6d3b-412b-8f4f-11a5d09f832b_terseLabel_en-US" xlink:label="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reduction in cash outflows from operating activities</link:label>
    <link:label id="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities_label_en-US" xlink:label="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Reduction In Cash Outflows From Operating Activities</link:label>
    <link:label id="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities_documentation_en-US" xlink:label="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reduction in cash outflows from operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" xlink:href="meso-20231231.xsd#meso_PercentageOfReductionInCashOutflowsFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" xlink:to="lab_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_18baa17d-3879-4ecb-a712-3a4d35578855_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_6710e5f3-521e-4070-865c-4487d6d541c1_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income:</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets designated as measured at fair value through profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract" xlink:to="lab_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_November2021WarrantsMember_f5588456-8031-4ddc-a892-eae5c82407fb_terseLabel_en-US" xlink:label="lab_meso_November2021WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2021 warrants</link:label>
    <link:label id="lab_meso_November2021WarrantsMember_label_en-US" xlink:label="lab_meso_November2021WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2021 warrants [Member]</link:label>
    <link:label id="lab_meso_November2021WarrantsMember_documentation_en-US" xlink:label="lab_meso_November2021WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2021 warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_November2021WarrantsMember" xlink:href="meso-20231231.xsd#meso_November2021WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_November2021WarrantsMember" xlink:to="lab_meso_November2021WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_e046ddf4-8f9d-40ed-89dd-edb2c26cb52a_totalLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_3ff80014-794c-4ff8-97ed-706be67542ef_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of (Losses) Earnings Per Share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TradePayablesMember_4aa6ac92-0bca-4436-9766-a582bf3e6f31_terseLabel_en-US" xlink:label="lab_meso_TradePayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_meso_TradePayablesMember_label_en-US" xlink:label="lab_meso_TradePayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Payables [Member]</link:label>
    <link:label id="lab_meso_TradePayablesMember_documentation_en-US" xlink:label="lab_meso_TradePayablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TradePayablesMember" xlink:href="meso-20231231.xsd#meso_TradePayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TradePayablesMember" xlink:to="lab_meso_TradePayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock_a96a2a94-ad0b-4ec4-a9e8-93885d5990dc_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Assets And Financial Liabilities Explanatory [Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial assets and financial liabilities explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" xlink:to="lab_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CashOrStockPayableAtFairValueLiabilities_012910d4-7626-4d33-be00-b92467aa5bc2_terseLabel_en-US" xlink:label="lab_meso_CashOrStockPayableAtFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets</link:label>
    <link:label id="lab_meso_CashOrStockPayableAtFairValueLiabilities_label_en-US" xlink:label="lab_meso_CashOrStockPayableAtFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Or Stock Payable At Fair Value Liabilities</link:label>
    <link:label id="lab_meso_CashOrStockPayableAtFairValueLiabilities_documentation_en-US" xlink:label="lab_meso_CashOrStockPayableAtFairValueLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash or stock payable at fair value, liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CashOrStockPayableAtFairValueLiabilities" xlink:href="meso-20231231.xsd#meso_CashOrStockPayableAtFairValueLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CashOrStockPayableAtFairValueLiabilities" xlink:to="lab_meso_CashOrStockPayableAtFairValueLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_WarrantsFairValueAtIssueDate_ea0608ec-9a71-4edc-80e2-ee5f43603e68_terseLabel_en-US" xlink:label="lab_meso_WarrantsFairValueAtIssueDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants fair value at issue date</link:label>
    <link:label id="lab_meso_WarrantsFairValueAtIssueDate_ebe87201-5768-4521-947a-9c2580992884_verboseLabel_en-US" xlink:label="lab_meso_WarrantsFairValueAtIssueDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants fair value at grant date - December 22, 2022</link:label>
    <link:label id="lab_meso_WarrantsFairValueAtIssueDate_label_en-US" xlink:label="lab_meso_WarrantsFairValueAtIssueDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value At Issue Date</link:label>
    <link:label id="lab_meso_WarrantsFairValueAtIssueDate_documentation_en-US" xlink:label="lab_meso_WarrantsFairValueAtIssueDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants fair value at issue date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtIssueDate" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtIssueDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_WarrantsFairValueAtIssueDate" xlink:to="lab_meso_WarrantsFairValueAtIssueDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEquitySecuritiesMember_c16e9cac-8813-4e89-a713-7f83324c0bce_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_ifrs-full_OtherEquitySecuritiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equity securities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEquitySecuritiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEquitySecuritiesMember" xlink:to="lab_ifrs-full_OtherEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities_3665979c-f0ef-49f4-bb0e-4196ed33f19f_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows, Total</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ForeignExchangeGainsLosses_9219696c-c449-40c9-9677-6caf0d0ec692_terseLabel_en-US" xlink:label="lab_meso_ForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains/(losses)</link:label>
    <link:label id="lab_meso_ForeignExchangeGainsLosses_label_en-US" xlink:label="lab_meso_ForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Gains Losses</link:label>
    <link:label id="lab_meso_ForeignExchangeGainsLosses_documentation_en-US" xlink:label="lab_meso_ForeignExchangeGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains/(losses).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ForeignExchangeGainsLosses" xlink:href="meso-20231231.xsd#meso_ForeignExchangeGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ForeignExchangeGainsLosses" xlink:to="lab_meso_ForeignExchangeGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_55a9562a-371e-4745-b0aa-df5b5f272d60_terseLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of warrant liability</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_label_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Remeasurement Of Warrant Liability [Abstract]</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_documentation_en-US" xlink:label="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiabilityAbstract" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValueRemeasurementOfWarrantLiabilityAbstract" xlink:to="lab_meso_FairValueRemeasurementOfWarrantLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsAbstract_a1919abd-c423-4730-ab95-6b9101370440_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets [Abstract]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAbstract_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAbstract" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsAbstract" xlink:to="lab_meso_DeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ClinicalTrialRelatedResearchAndDevelopment_023bf790-9721-46e4-a67b-9943c6203b81_negatedLabel_en-US" xlink:label="lab_meso_ClinicalTrialRelatedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and research &amp; development</link:label>
    <link:label id="lab_meso_ClinicalTrialRelatedResearchAndDevelopment_label_en-US" xlink:label="lab_meso_ClinicalTrialRelatedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Related Research And Development</link:label>
    <link:label id="lab_meso_ClinicalTrialRelatedResearchAndDevelopment_documentation_en-US" xlink:label="lab_meso_ClinicalTrialRelatedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to clinical trial related research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalTrialRelatedResearchAndDevelopment" xlink:href="meso-20231231.xsd#meso_ClinicalTrialRelatedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ClinicalTrialRelatedResearchAndDevelopment" xlink:to="lab_meso_ClinicalTrialRelatedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_fe6621c8-6c33-45d0-9043-2581e92c254c_terseLabel_en-US" xlink:label="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of reasonably possible increase (decrease) in unobservable input, liabilities</link:label>
    <link:label id="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_label_en-US" xlink:label="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Reasonably Possible Increase (Decrease) In Unobservable Input, Liabilities</link:label>
    <link:label id="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_documentation_en-US" xlink:label="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Reasonably Possible Increase (Decrease) In Unobservable Input, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" xlink:href="meso-20231231.xsd#meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" xlink:to="lab_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OverheadsAndAdministrationExpenses_1c13f6d0-bb17-4cef-8b60-57064528502a_negatedLabel_en-US" xlink:label="lab_meso_OverheadsAndAdministrationExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overheads &amp; administration</link:label>
    <link:label id="lab_meso_OverheadsAndAdministrationExpenses_label_en-US" xlink:label="lab_meso_OverheadsAndAdministrationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overheads And Administration Expenses</link:label>
    <link:label id="lab_meso_OverheadsAndAdministrationExpenses_documentation_en-US" xlink:label="lab_meso_OverheadsAndAdministrationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to overheads and administration expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OverheadsAndAdministrationExpenses" xlink:href="meso-20231231.xsd#meso_OverheadsAndAdministrationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OverheadsAndAdministrationExpenses" xlink:to="lab_meso_OverheadsAndAdministrationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IssuanceWarrantsExercisedPeriod_94ebfceb-d0c8-4557-b50f-2508068f89b8_terseLabel_en-US" xlink:label="lab_meso_IssuanceWarrantsExercisedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance warrants exercised period</link:label>
    <link:label id="lab_meso_IssuanceWarrantsExercisedPeriod_label_en-US" xlink:label="lab_meso_IssuanceWarrantsExercisedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Warrants Exercised Period</link:label>
    <link:label id="lab_meso_IssuanceWarrantsExercisedPeriod_documentation_en-US" xlink:label="lab_meso_IssuanceWarrantsExercisedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance warrants exercised period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IssuanceWarrantsExercisedPeriod" xlink:href="meso-20231231.xsd#meso_IssuanceWarrantsExercisedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IssuanceWarrantsExercisedPeriod" xlink:to="lab_meso_IssuanceWarrantsExercisedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReservesWithinEquityAxis_b459f0b3-ce46-4ba7-a47d-7cda7877a583_terseLabel_en-US" xlink:label="lab_ifrs-full_ReservesWithinEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves within equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ReservesWithinEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ReservesWithinEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves within equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReservesWithinEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReservesWithinEquityAxis" xlink:to="lab_ifrs-full_ReservesWithinEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_f183c8b7-758b-494e-9d87-089468837dc9_terseLabel_en-US" xlink:label="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions Reversal Other Than Through Business Combinations Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions (reversal) other than through business combinations intangible assets other than goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="meso-20231231.xsd#meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Prepayments_bf63b835-15b5-4ae4-b6b0-0378b170cf04_totalLabel_en-US" xlink:label="lab_ifrs-full_Prepayments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_ifrs-full_Prepayments_label_en-US" xlink:label="lab_ifrs-full_Prepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Prepayments" xlink:to="lab_ifrs-full_Prepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfCashHeld_87e58263-004d-492f-a9a9-418f9684f9bb_terseLabel_en-US" xlink:label="lab_meso_PercentageOfCashHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held</link:label>
    <link:label id="lab_meso_PercentageOfCashHeld_label_en-US" xlink:label="lab_meso_PercentageOfCashHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Cash Held</link:label>
    <link:label id="lab_meso_PercentageOfCashHeld_documentation_en-US" xlink:label="lab_meso_PercentageOfCashHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfCashHeld" xlink:href="meso-20231231.xsd#meso_PercentageOfCashHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfCashHeld" xlink:to="lab_meso_PercentageOfCashHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AUD_b21c2d14-6f5c-4b0b-9614-6a8d40f14ed7_terseLabel_en-US" xlink:label="lab_currency_AUD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUD</link:label>
    <link:label id="lab_currency_AUD_label_en-US" xlink:label="lab_currency_AUD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AUD" xlink:to="lab_currency_AUD" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_b3ae3138-98a2-448c-bc1c-7452abc530eb_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Attributable To Other Temporary Differences</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets attributable to other temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" xlink:to="lab_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmount_b1099491-58c9-49ce-ac9a-dfe44aad6237_terseLabel_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum financial commitment reduction amount</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmount_label_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Reduction Amount</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentReductionAmount_documentation_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentReductionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Reduction Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmount" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MinimumFinancialCommitmentReductionAmount" xlink:to="lab_meso_MinimumFinancialCommitmentReductionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentConsiderationMember_7eb0ee33-3045-43d5-8625-045cc345ce03_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_ifrs-full_ContingentConsiderationMember_label_en-US" xlink:label="lab_ifrs-full_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentConsiderationMember" xlink:to="lab_ifrs-full_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NonRefundableUpfrontPaymentsReceivable_d61f92e8-e00e-4e61-9b85-5337aa8ca10a_terseLabel_en-US" xlink:label="lab_meso_NonRefundableUpfrontPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payments receivable</link:label>
    <link:label id="lab_meso_NonRefundableUpfrontPaymentsReceivable_label_en-US" xlink:label="lab_meso_NonRefundableUpfrontPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Upfront Payments Receivable</link:label>
    <link:label id="lab_meso_NonRefundableUpfrontPaymentsReceivable_documentation_en-US" xlink:label="lab_meso_NonRefundableUpfrontPaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonRefundableUpfrontPaymentsReceivable" xlink:href="meso-20231231.xsd#meso_NonRefundableUpfrontPaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NonRefundableUpfrontPaymentsReceivable" xlink:to="lab_meso_NonRefundableUpfrontPaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_5fc4c464-e1cc-4237-b500-a0b785e766e4_terseLabel_en-US" xlink:label="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount</link:label>
    <link:label id="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, variable consideration amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="meso-20231231.xsd#meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_c53f57c5-481e-41d0-9591-18be05e8a7cb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial risk management</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial risk management [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_aff54463-3097-4adf-8fa2-f28cd22bfcdc_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Depreciation and amortization of non-current assets</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_ba6fcfc0-bb5d-45e9-a942-92c8e3a4778b_terseLabel_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs loss on remeasurement due to additional warrants issued</link:label>
    <link:label id="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_label_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains (Loss) On Remeasurement Due To Additional Warrants Issued</link:label>
    <link:label id="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_documentation_en-US" xlink:label="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains (Loss) On Remeasurement Due To Additional Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" xlink:to="lab_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock_c332eb64-4345-44da-ac51-2ac29846770c_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Exposure to Financial Risks</link:label>
    <link:label id="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of exposure to financial risks [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of exposure to financial risks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfExposureToFinancialRisksTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfExposureToFinancialRisksTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfExposureToFinancialRisksTableTextBlock" xlink:to="lab_meso_DisclosureOfExposureToFinancialRisksTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_1804b52b-a729-486a-88ab-3aeaf9f7a36f_negatedLabel_en-US" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="lab_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_97e544b4-f181-4266-b1f6-d70657ce373d_terseLabel_en-US" xlink:label="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt on non refundable up-front payment upon reaching product regulatory milestone</link:label>
    <link:label id="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_label_en-US" xlink:label="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Entitled To Be Received On Non Refundable Upfront Payment Upon Reaching Product Regulatory Milestone</link:label>
    <link:label id="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_documentation_en-US" xlink:label="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Entitled to be received on non refundable up-front payment upon reaching product regulatory milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" xlink:href="meso-20231231.xsd#meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" xlink:to="lab_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1fc1c14f-6761-4c32-900f-e967e98050f0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract_f3535caf-fbc8-465e-94b9-ffffd76c136f_terseLabel_en-US" xlink:label="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure - Non-financial Assets and Liabilities - Additional Information (Details) [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract_label_en-US" xlink:label="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Non Financial Assets And Liabilities Additional Information Details [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract_documentation_en-US" xlink:label="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Non Financial Assets And Liabilities Additional Information Details [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" xlink:href="meso-20231231.xsd#meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" xlink:to="lab_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_b946bac8-1381-42eb-97ec-86ded68e81fa_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract" xlink:to="lab_ifrs-full_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NumberOfOperatingSegment_1b503ec6-2540-4149-8478-b5b8fbc7e3bb_terseLabel_en-US" xlink:label="lab_meso_NumberOfOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_meso_NumberOfOperatingSegment_label_en-US" xlink:label="lab_meso_NumberOfOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Segment</link:label>
    <link:label id="lab_meso_NumberOfOperatingSegment_documentation_en-US" xlink:label="lab_meso_NumberOfOperatingSegment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfOperatingSegment" xlink:href="meso-20231231.xsd#meso_NumberOfOperatingSegment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NumberOfOperatingSegment" xlink:to="lab_meso_NumberOfOperatingSegment" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_LongTermBorrowingsAbstract_171b03ca-ab4d-4f6e-89d7-01a458990abf_terseLabel_en-US" xlink:label="lab_meso_LongTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_meso_LongTermBorrowingsAbstract_label_en-US" xlink:label="lab_meso_LongTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Borrowings [Abstract]</link:label>
    <link:label id="lab_meso_LongTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_meso_LongTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LongTermBorrowingsAbstract" xlink:href="meso-20231231.xsd#meso_LongTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_LongTermBorrowingsAbstract" xlink:to="lab_meso_LongTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NonCancellablePurchaseCommitments_59d803f3-7823-41fb-90fb-3c832bf875f3_terseLabel_en-US" xlink:label="lab_meso_NonCancellablePurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services</link:label>
    <link:label id="lab_meso_NonCancellablePurchaseCommitments_label_en-US" xlink:label="lab_meso_NonCancellablePurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancellable Purchase Commitments</link:label>
    <link:label id="lab_meso_NonCancellablePurchaseCommitments_documentation_en-US" xlink:label="lab_meso_NonCancellablePurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable purchase commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonCancellablePurchaseCommitments" xlink:href="meso-20231231.xsd#meso_NonCancellablePurchaseCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NonCancellablePurchaseCommitments" xlink:to="lab_meso_NonCancellablePurchaseCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_44d2b617-cb1e-4104-b500-9382de8b6a04_terseLabel_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross debt - fixed interest rates</link:label>
    <link:label id="lab_ifrs-full_FixedInterestRateMember_label_en-US" xlink:label="lab_ifrs-full_FixedInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FixedInterestRateMember" xlink:to="lab_ifrs-full_FixedInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_54aeeb8b-d593-46aa-aef2-8bf5bc638bb0_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_719db44a-41a5-4a69-bb53-b116481edafe_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of equity component of convertible instruments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:to="lab_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ecaa2607-8538-40dc-9984-71113c09b3ee_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NonRefundableUpFrontPaymentReceived_6c6461b6-fa68-4989-a846-09c8516bdc98_terseLabel_en-US" xlink:label="lab_meso_NonRefundableUpFrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment received</link:label>
    <link:label id="lab_meso_NonRefundableUpFrontPaymentReceived_label_en-US" xlink:label="lab_meso_NonRefundableUpFrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Refundable Up Front Payment Received</link:label>
    <link:label id="lab_meso_NonRefundableUpFrontPaymentReceived_documentation_en-US" xlink:label="lab_meso_NonRefundableUpFrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non refundable up front payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonRefundableUpFrontPaymentReceived" xlink:href="meso-20231231.xsd#meso_NonRefundableUpFrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NonRefundableUpFrontPaymentReceived" xlink:to="lab_meso_NonRefundableUpFrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MesoblastEmployeeShareTrustMember_c6c4036a-0cec-42c4-9f68-933311b672a7_terseLabel_en-US" xlink:label="lab_meso_MesoblastEmployeeShareTrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mesoblast Employee Share Trust</link:label>
    <link:label id="lab_meso_MesoblastEmployeeShareTrustMember_label_en-US" xlink:label="lab_meso_MesoblastEmployeeShareTrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mesoblast Employee Share Trust [Member]</link:label>
    <link:label id="lab_meso_MesoblastEmployeeShareTrustMember_documentation_en-US" xlink:label="lab_meso_MesoblastEmployeeShareTrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mesoblast Employee Share Trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MesoblastEmployeeShareTrustMember" xlink:href="meso-20231231.xsd#meso_MesoblastEmployeeShareTrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MesoblastEmployeeShareTrustMember" xlink:to="lab_meso_MesoblastEmployeeShareTrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_CardiovascularProductsMember_6b4550fc-b44e-4956-8b4f-dd74bd129dd3_terseLabel_en-US" xlink:label="lab_meso_CardiovascularProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Products</link:label>
    <link:label id="lab_meso_CardiovascularProductsMember_label_en-US" xlink:label="lab_meso_CardiovascularProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Products [Member]</link:label>
    <link:label id="lab_meso_CardiovascularProductsMember_documentation_en-US" xlink:label="lab_meso_CardiovascularProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CardiovascularProductsMember" xlink:href="meso-20231231.xsd#meso_CardiovascularProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_CardiovascularProductsMember" xlink:to="lab_meso_CardiovascularProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TradeReceivablesSettlementPeriod_44f77270-8b38-4146-aa8f-5b5928af0b10_terseLabel_en-US" xlink:label="lab_meso_TradeReceivablesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables settlement period</link:label>
    <link:label id="lab_meso_TradeReceivablesSettlementPeriod_label_en-US" xlink:label="lab_meso_TradeReceivablesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables Settlement Period</link:label>
    <link:label id="lab_meso_TradeReceivablesSettlementPeriod_documentation_en-US" xlink:label="lab_meso_TradeReceivablesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables settlement period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TradeReceivablesSettlementPeriod" xlink:href="meso-20231231.xsd#meso_TradeReceivablesSettlementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TradeReceivablesSettlementPeriod" xlink:to="lab_meso_TradeReceivablesSettlementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesMember_3eeaaed0-6a77-49fb-a862-0528c56821f0_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesMember_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesMember" xlink:to="lab_ifrs-full_CounterpartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_05e5fde4-e84c-459d-8298-151102050287_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_c214d270-08ee-4d0a-9911-baa882e2f68c_verboseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables and other payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6bba61c8-3b8f-439f-a167-84e5407c59f2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ExpectedPatentExpiry_2b321b3a-7bab-4b2e-9e61-af0818eecbb6_terseLabel_en-US" xlink:label="lab_meso_ExpectedPatentExpiry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected patent expiry</link:label>
    <link:label id="lab_meso_ExpectedPatentExpiry_label_en-US" xlink:label="lab_meso_ExpectedPatentExpiry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Patent Expiry</link:label>
    <link:label id="lab_meso_ExpectedPatentExpiry_documentation_en-US" xlink:label="lab_meso_ExpectedPatentExpiry" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected patent expiry.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedPatentExpiry" xlink:href="meso-20231231.xsd#meso_ExpectedPatentExpiry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ExpectedPatentExpiry" xlink:to="lab_meso_ExpectedPatentExpiry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_13be6398-11f0-4f40-bd24-a056999933d9_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential tax benefit at local tax rates</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_0d73d620-d3e2-4b2e-85d4-f839974bec75_terseLabel_en-US" xlink:label="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other recoverable taxes (Goods and services tax and value-added tax)</link:label>
    <link:label id="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_label_en-US" xlink:label="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables from taxes other than income tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:to="lab_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9ffed617-f174-428b-ad6f-fede630c912a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Classes Of Share Capital [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_c23b6d3a-c96b-4a3e-b147-70c30301e053_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets at FVOCI</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherManagementAndAdministrationExpenses_3b805ade-8b1a-424a-a595-d40832eef78f_negatedTotalLabel_en-US" xlink:label="lab_meso_OtherManagementAndAdministrationExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other Management &amp; administration expenses</link:label>
    <link:label id="lab_meso_OtherManagementAndAdministrationExpenses_label_en-US" xlink:label="lab_meso_OtherManagementAndAdministrationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Management And Administration Expenses</link:label>
    <link:label id="lab_meso_OtherManagementAndAdministrationExpenses_documentation_en-US" xlink:label="lab_meso_OtherManagementAndAdministrationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other management &amp; administration expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherManagementAndAdministrationExpenses" xlink:href="meso-20231231.xsd#meso_OtherManagementAndAdministrationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherManagementAndAdministrationExpenses" xlink:to="lab_meso_OtherManagementAndAdministrationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract_ed54fc68-7642-40a7-a35e-bb7930ffe271_terseLabel_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax credits</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract_label_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Not Brought To Account For Other Tax Credits [Abstract]</link:label>
    <link:label id="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract_documentation_en-US" xlink:label="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets not brought to account for other tax credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" xlink:to="lab_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_0e050e06-bd88-45c8-84df-948e0b422d24_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">From continuing operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="lab_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_e178bbf7-a4a3-4ac2-8e4d-9d34e882bd58_terseLabel_en-US" xlink:label="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non interest bearing financial liabilities maturity period</link:label>
    <link:label id="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_label_en-US" xlink:label="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Interest Bearing Financial Liabilities Maturity Period</link:label>
    <link:label id="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_documentation_en-US" xlink:label="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non interest bearing financial liabilities maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" xlink:href="meso-20231231.xsd#meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" xlink:to="lab_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_7ede20e7-e759-489e-a8ee-c3011db62402_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_GrunenthalGmbHMember_d5ddcb4f-49bc-4494-aa63-0e981712090c_terseLabel_en-US" xlink:label="lab_meso_GrunenthalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grunenthal</link:label>
    <link:label id="lab_meso_GrunenthalGmbHMember_label_en-US" xlink:label="lab_meso_GrunenthalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grunenthal Gmb H [Member]</link:label>
    <link:label id="lab_meso_GrunenthalGmbHMember_documentation_en-US" xlink:label="lab_meso_GrunenthalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gr&#252;nenthal GmbH.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GrunenthalGmbHMember" xlink:href="meso-20231231.xsd#meso_GrunenthalGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_GrunenthalGmbHMember" xlink:to="lab_meso_GrunenthalGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_c90135b4-909b-4498-ae79-8254e9e88244_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_85cc6644-05e8-49b2-8a27-1eaac2bd74fe_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_3f68b3f3-af3e-439e-b708-d00c04926972_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_22eafe04-330e-40fd-a19b-d2a8747719b0_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4381a86d-6bce-4f1b-8adf-f95194be36f5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedButNotFullyPaid_31813e95-133f-40c5-bfc5-a740b6e084b6_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued and fully paid (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedButNotFullyPaid_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued but not fully paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedButNotFullyPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan_a04f714d-384f-4da3-af47-c8bb2c89d64e_terseLabel_en-US" xlink:label="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement of shares under a share placement agreement (in shares)</link:label>
    <link:label id="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan_label_en-US" xlink:label="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available For Issuance Under Issuance Plan</link:label>
    <link:label id="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan_documentation_en-US" xlink:label="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance under issuance plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan" xlink:href="meso-20231231.xsd#meso_SharesAvailableForIssuanceUnderIssuancePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan" xlink:to="lab_meso_SharesAvailableForIssuanceUnderIssuancePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_84152eb9-902f-4b43-9679-8077f1e59281_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_269f2d4b-252b-440f-8651-21452c170ed0_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows, Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_TiGenixNVMember_7092d7b7-3fe7-4193-82ac-3fb02eabcd36_terseLabel_en-US" xlink:label="lab_meso_TiGenixNVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TiGenix NV</link:label>
    <link:label id="lab_meso_TiGenixNVMember_label_en-US" xlink:label="lab_meso_TiGenixNVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ti Genix N V [Member]</link:label>
    <link:label id="lab_meso_TiGenixNVMember_documentation_en-US" xlink:label="lab_meso_TiGenixNVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This member stands for TiGenix NV.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TiGenixNVMember" xlink:href="meso-20231231.xsd#meso_TiGenixNVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_TiGenixNVMember" xlink:to="lab_meso_TiGenixNVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_LossGainOnRemeasurementOfWarrantLiability_f06eb0bc-0a5f-444a-aebc-5dd838932dcf_negatedLabel_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of warrant liability</link:label>
    <link:label id="lab_meso_LossGainOnRemeasurementOfWarrantLiability_label_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Gain On Remeasurement Of Warrant Liability</link:label>
    <link:label id="lab_meso_LossGainOnRemeasurementOfWarrantLiability_documentation_en-US" xlink:label="lab_meso_LossGainOnRemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss&#8203; gain&#8203; on remeasurement&#8203; of warrant &#8203;liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfWarrantLiability" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_LossGainOnRemeasurementOfWarrantLiability" xlink:to="lab_meso_LossGainOnRemeasurementOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ConversionRatioOfWarrants_1fa87680-eeac-472a-ad1e-41c767e86d8e_terseLabel_en-US" xlink:label="lab_meso_ConversionRatioOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio of warrants</link:label>
    <link:label id="lab_meso_ConversionRatioOfWarrants_label_en-US" xlink:label="lab_meso_ConversionRatioOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio of warrants</link:label>
    <link:label id="lab_meso_ConversionRatioOfWarrants_documentation_en-US" xlink:label="lab_meso_ConversionRatioOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio of warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConversionRatioOfWarrants" xlink:href="meso-20231231.xsd#meso_ConversionRatioOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ConversionRatioOfWarrants" xlink:to="lab_meso_ConversionRatioOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_WarrantsPricePerShare_c97aa517-2c38-47a6-89cc-7670b82ce55f_terseLabel_en-US" xlink:label="lab_meso_WarrantsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_meso_WarrantsPricePerShare_label_en-US" xlink:label="lab_meso_WarrantsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Price Per Share</link:label>
    <link:label id="lab_meso_WarrantsPricePerShare_documentation_en-US" xlink:label="lab_meso_WarrantsPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsPricePerShare" xlink:href="meso-20231231.xsd#meso_WarrantsPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_WarrantsPricePerShare" xlink:to="lab_meso_WarrantsPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_ea8fb7b2-e2a0-4fd7-9239-d4756e3ade47_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_c1f3a039-72d0-436c-a95f-5fa210c36210_negatedLabel_en-US" xlink:label="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate decrease on funds invested</link:label>
    <link:label id="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_label_en-US" xlink:label="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Interest Rate On Funds Invested Which Derives Interest Revenue</link:label>
    <link:label id="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_documentation_en-US" xlink:label="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in interest rate on funds invested which derives interest revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:href="meso-20231231.xsd#meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:to="lab_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_b9553a00-214b-484c-a739-474c17855b17_totalLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_OtherManagementAndAdministrationExpensesAbstract_7f34de73-1bcd-441f-9ff7-534ac74790de_terseLabel_en-US" xlink:label="lab_meso_OtherManagementAndAdministrationExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Management &amp; administration expenses</link:label>
    <link:label id="lab_meso_OtherManagementAndAdministrationExpensesAbstract_label_en-US" xlink:label="lab_meso_OtherManagementAndAdministrationExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Management And Administration Expenses [Abstract]</link:label>
    <link:label id="lab_meso_OtherManagementAndAdministrationExpensesAbstract_documentation_en-US" xlink:label="lab_meso_OtherManagementAndAdministrationExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other management and administration expenses abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherManagementAndAdministrationExpensesAbstract" xlink:href="meso-20231231.xsd#meso_OtherManagementAndAdministrationExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_OtherManagementAndAdministrationExpensesAbstract" xlink:to="lab_meso_OtherManagementAndAdministrationExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementLineItems_16c8f840-4f15-4267-a4cc-1914289b666a_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Financial Risk Management [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Financial Risk Management [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfFinancialRiskManagementLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfFinancialRiskManagementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial risk management.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems" xlink:to="lab_meso_DisclosureOfFinancialRiskManagementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_7440cc7e-c372-4950-a2b8-840a22f4d3f3_totalLabel_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Assets</link:label>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_label_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets (liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="lab_ifrs-full_NetAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_License1Member_b0f05a08-092c-4e5c-bf5f-777371bb3f8c_terseLabel_en-US" xlink:label="lab_meso_License1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_meso_License1Member_label_en-US" xlink:label="lab_meso_License1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License 1 [Member]</link:label>
    <link:label id="lab_meso_License1Member_documentation_en-US" xlink:label="lab_meso_License1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_License1Member" xlink:href="meso-20231231.xsd#meso_License1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_License1Member" xlink:to="lab_meso_License1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_e3ec5e14-83de-4b29-be44-83caca2b73ba_terseLabel_en-US" xlink:label="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from up-front payment as deferred consideration</link:label>
    <link:label id="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_label_en-US" xlink:label="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized From Upfront Payment As Deferred Consideration</link:label>
    <link:label id="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_documentation_en-US" xlink:label="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from up-front payment as deferred consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" xlink:href="meso-20231231.xsd#meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" xlink:to="lab_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_0eb3de1e-d550-446f-a62c-906a2f099f7b_terseLabel_en-US" xlink:label="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of non-current assets</link:label>
    <link:label id="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_label_en-US" xlink:label="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization Of Non Current Assets [Abstract]</link:label>
    <link:label id="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_documentation_en-US" xlink:label="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization of Non-current Assets Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" xlink:href="meso-20231231.xsd#meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" xlink:to="lab_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManufacturingProductionAndDevelopment_47aed197-28c8-40e4-82fd-c4e8f353f0ab_negatedLabel_en-US" xlink:label="lab_meso_ManufacturingProductionAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing production &amp; development</link:label>
    <link:label id="lab_meso_ManufacturingProductionAndDevelopment_label_en-US" xlink:label="lab_meso_ManufacturingProductionAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Production And Development</link:label>
    <link:label id="lab_meso_ManufacturingProductionAndDevelopment_documentation_en-US" xlink:label="lab_meso_ManufacturingProductionAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to manufacturing production and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingProductionAndDevelopment" xlink:href="meso-20231231.xsd#meso_ManufacturingProductionAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManufacturingProductionAndDevelopment" xlink:to="lab_meso_ManufacturingProductionAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_e1eb1d22-a88a-4083-bbe2-fd07ca7ff6c7_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtFairValue_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities, at fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_a2e16edd-bfab-4cf2-85ed-73718616381a_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_4cc5e2dd-b72a-4359-9185-5848db190ecb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_0d126c6a-939a-4e91-a07a-6617f44191ee_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants_9b29bf4e-5b42-4d97-b04c-cb70078248d7_terseLabel_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement adjustments</link:label>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants_label_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Adjustments On Debt And Warrants</link:label>
    <link:label id="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants_documentation_en-US" xlink:label="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement adjustments on debt and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementAdjustmentsOnDebtAndWarrants" xlink:href="meso-20231231.xsd#meso_RemeasurementAdjustmentsOnDebtAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RemeasurementAdjustmentsOnDebtAndWarrants" xlink:to="lab_meso_RemeasurementAdjustmentsOnDebtAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValuationTechniquesMember_3b246c70-c385-4cfb-bc1d-07c2fa935f64_terseLabel_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques</link:label>
    <link:label id="lab_ifrs-full_ValuationTechniquesMember_label_en-US" xlink:label="lab_ifrs-full_ValuationTechniquesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValuationTechniquesMember" xlink:to="lab_ifrs-full_ValuationTechniquesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_a939d246-e0ed-406a-beb7-3a7b89099ff1_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive profit/(loss) for the period</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_9e723f0b-772e-427f-91ee-c2977d96162f_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_3d292494-3b6f-4de8-8e8a-d1d4ae3e7b1d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_398621f5-f3be-4349-80e3-96a248930fb4_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_12484fd2-95eb-469b-b7d4-cd21211c29c5_totalLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_ca71d3ee-7bdc-4226-9d46-54a089a713e6_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_WarrantExercisePricePerShare_ab541539-5119-4fdb-917b-f2d1292f56a5_terseLabel_en-US" xlink:label="lab_meso_WarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price per share (in australian dollar per shares)</link:label>
    <link:label id="lab_meso_WarrantExercisePricePerShare_label_en-US" xlink:label="lab_meso_WarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_meso_WarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_meso_WarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExercisePricePerShare" xlink:href="meso-20231231.xsd#meso_WarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_WarrantExercisePricePerShare" xlink:to="lab_meso_WarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract_9fe06184-7790-493f-886d-947fbd5d3275_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract_label_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Abstract]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract_documentation_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of loss before income tax [Abstract].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract" xlink:to="lab_meso_DisclosureOfLossBeforeIncomeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_d5e1272e-d57f-4ce0-afec-bf86b8568177_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_16833615-4f32-44bc-8e3f-58927ec969a7_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Non-Current Liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_59f86fab-9bcb-4b83-9933-7fa4ded477a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contractual cash flows</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial liabilities, undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_ae99fdec-02f7-489a-aaff-3f502e36b1be_negatedLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of share options (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DiscountedPercentageOnIssuanceOfEquity_3311924c-7de1-4b9a-bb79-ffae7e6c2640_terseLabel_en-US" xlink:label="lab_meso_DiscountedPercentageOnIssuanceOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted percentage on issuance of equity</link:label>
    <link:label id="lab_meso_DiscountedPercentageOnIssuanceOfEquity_label_en-US" xlink:label="lab_meso_DiscountedPercentageOnIssuanceOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted Percentage On Issuance Of Equity</link:label>
    <link:label id="lab_meso_DiscountedPercentageOnIssuanceOfEquity_documentation_en-US" xlink:label="lab_meso_DiscountedPercentageOnIssuanceOfEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted percentage on issuance of equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DiscountedPercentageOnIssuanceOfEquity" xlink:href="meso-20231231.xsd#meso_DiscountedPercentageOnIssuanceOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DiscountedPercentageOnIssuanceOfEquity" xlink:to="lab_meso_DiscountedPercentageOnIssuanceOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_2aaba8b1-9444-4ed9-b5f2-310885de55d7_terseLabel_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of non-current borrowings</link:label>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_label_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Price Rate Changes In Non Current Borrowings</link:label>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_documentation_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of price rate changes in non-current borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInNonCurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" xlink:to="lab_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_RemeasurementOfWarrantLiability_236ceb5a-70d2-4d32-8420-68bd143d0cbe_terseLabel_en-US" xlink:label="lab_meso_RemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of warrant liability</link:label>
    <link:label id="lab_meso_RemeasurementOfWarrantLiability_4bbed0f9-f882-45bd-8cad-a8ebde72d4b1_verboseLabel_en-US" xlink:label="lab_meso_RemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of warrant liabilities</link:label>
    <link:label id="lab_meso_RemeasurementOfWarrantLiability_label_en-US" xlink:label="lab_meso_RemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Warrant Liability</link:label>
    <link:label id="lab_meso_RemeasurementOfWarrantLiability_documentation_en-US" xlink:label="lab_meso_RemeasurementOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementOfWarrantLiability" xlink:href="meso-20231231.xsd#meso_RemeasurementOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_RemeasurementOfWarrantLiability" xlink:to="lab_meso_RemeasurementOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fe973133-8d47-4273-b8de-f7622b81b35b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings_f1c54c93-f376-4a85-aa79-eca45de535ac_terseLabel_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of current borrowings</link:label>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings_label_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Price Rate Changes In Current Borrowings</link:label>
    <link:label id="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings_documentation_en-US" xlink:label="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of price rate changes in current borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInCurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings" xlink:to="lab_meso_PercentageOfPriceRateChangesInCurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_2bb3b38a-1eba-4ee1-bc32-a1e4203fc422_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_081c300e-89dd-4a28-bf48-671ca14ea39c_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_bb16f080-e33f-4352-b0e3-97e5810b2d3f_verboseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of loans</link:label>
    <link:label id="lab_ifrs-full_Borrowings_e3ccd547-1b87-434a-b2e7-4f5455534eb1_totalLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_d2ea4a91-13c7-484d-a6d9-68a3062ff7cb_negatedLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_ab12c202-8731-4cc7-a1d2-c9531f4a84b2_negatedPeriodStartLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Borrowings_1a26a86e-9caa-4303-b798-acaf6ccd6d91_negatedPeriodEndLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings at end of period</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_EffectOnProfitFromChangeInInterestRate_09cb4a99-1f4b-430a-a5dc-dde5cfd6be13_terseLabel_en-US" xlink:label="lab_meso_EffectOnProfitFromChangeInInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on profit from change in interest rates</link:label>
    <link:label id="lab_meso_EffectOnProfitFromChangeInInterestRate_label_en-US" xlink:label="lab_meso_EffectOnProfitFromChangeInInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect On Profit From Change In Interest Rate</link:label>
    <link:label id="lab_meso_EffectOnProfitFromChangeInInterestRate_documentation_en-US" xlink:label="lab_meso_EffectOnProfitFromChangeInInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect on profit from change in interest rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOnProfitFromChangeInInterestRate" xlink:href="meso-20231231.xsd#meso_EffectOnProfitFromChangeInInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_EffectOnProfitFromChangeInInterestRate" xlink:to="lab_meso_EffectOnProfitFromChangeInInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_c61e4ba1-37a0-45c0-a862-d6fde2d9f75f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_3fafccd6-5b2a-4ea6-a4f7-ef23d664dd96_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(a) Basic (losses) per share</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:to="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_4707e3da-508f-4b00-a4fe-0e906deba8ed_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_label_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period [Table]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_documentation_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant changes in current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" xlink:to="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_71167d5e-3ba0-48b3-81ab-eb15153ed50e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Cash Equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IncomeStatementLocationMember_d155b06c-d3e7-457c-a6cb-ae684539aa5d_terseLabel_en-US" xlink:label="lab_meso_IncomeStatementLocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_meso_IncomeStatementLocationMember_label_en-US" xlink:label="lab_meso_IncomeStatementLocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Member]</link:label>
    <link:label id="lab_meso_IncomeStatementLocationMember_documentation_en-US" xlink:label="lab_meso_IncomeStatementLocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income statement location.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationMember" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IncomeStatementLocationMember" xlink:to="lab_meso_IncomeStatementLocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IntravenousProductsMember_5b965084-ba06-490e-8d3d-24fd0890c4ee_terseLabel_en-US" xlink:label="lab_meso_IntravenousProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intravenous products for metabolic diseases and inflammatory/immunologic conditions</link:label>
    <link:label id="lab_meso_IntravenousProductsMember_label_en-US" xlink:label="lab_meso_IntravenousProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intravenous Products [Member]</link:label>
    <link:label id="lab_meso_IntravenousProductsMember_documentation_en-US" xlink:label="lab_meso_IntravenousProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intravenous products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntravenousProductsMember" xlink:href="meso-20231231.xsd#meso_IntravenousProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IntravenousProductsMember" xlink:to="lab_meso_IntravenousProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageMember_1c97c77b-fd5f-429e-82de-04a9cd88d580_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageMember_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageMember" xlink:to="lab_ifrs-full_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsideration_e6624ea6-81c2-46b8-ab3c-adb2e5bede9b_negatedLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsideration_fd669e30-b0a8-4fd4-aa28-cadbdccb064c_negatedTotalLabel_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsideration_label_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Remeasurement Of Contingent Consideration</link:label>
    <link:label id="lab_meso_FairValueRemeasurementOfContingentConsideration_documentation_en-US" xlink:label="lab_meso_FairValueRemeasurementOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value remeasurement of contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsideration" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FairValueRemeasurementOfContingentConsideration" xlink:to="lab_meso_FairValueRemeasurementOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_5745b1a4-18c4-417a-87af-33a0cff4e133_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax (benefit)/expense</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax expense (income) and adjustments for current tax of prior periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ccd17b6d-7d38-4e8d-b582-02ffb02bac20_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_440aa2af-99d2-4797-8a4f-fec919490962_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_3bf23269-752a-4d05-b129-ab92ff3a07a5_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(c) (Losses) used in calculating (losses) per share</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to ordinary equity holders of parent entity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:to="lab_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_dde03fbf-f934-4420-bfbf-07a850c581cd_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_315b4fa5-9d48-48bc-ac8b-460fed50726a_terseLabel_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum financial commitment of lease component on exercise of option to extend non-cancellable term</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_label_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Financial Commitment Of Lease Component On Exercise Of Option To Extend Non Cancellable Term</link:label>
    <link:label id="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_documentation_en-US" xlink:label="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum financial commitment of lease component on exercise of option to extend non-cancellable term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:to="lab_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_FinanceCostsGainsAbstract_f4850879-041a-41f3-b53d-8559f44b991f_terseLabel_en-US" xlink:label="lab_meso_FinanceCostsGainsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance (costs)/gains</link:label>
    <link:label id="lab_meso_FinanceCostsGainsAbstract_label_en-US" xlink:label="lab_meso_FinanceCostsGainsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Costs Gains [Abstract]</link:label>
    <link:label id="lab_meso_FinanceCostsGainsAbstract_documentation_en-US" xlink:label="lab_meso_FinanceCostsGainsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance (costs) gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsAbstract" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_FinanceCostsGainsAbstract" xlink:to="lab_meso_FinanceCostsGainsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_85dc52d4-97f9-486d-b11f-68bab136cc86_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Significant Changes In Current Reporting Period [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant changes in current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" xlink:to="lab_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_c5d737f0-1cc1-4084-8655-4eb7d855638a_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plant and equipment depreciation</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ExercisePriceShareWarrentsIssued_e6529c47-bf1f-4afa-9c13-3b01a75feb61_terseLabel_en-US" xlink:label="lab_meso_ExercisePriceShareWarrentsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, share warrents issued (in dollars per share)</link:label>
    <link:label id="lab_meso_ExercisePriceShareWarrentsIssued_label_en-US" xlink:label="lab_meso_ExercisePriceShareWarrentsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price, Share Warrents Issued</link:label>
    <link:label id="lab_meso_ExercisePriceShareWarrentsIssued_documentation_en-US" xlink:label="lab_meso_ExercisePriceShareWarrentsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price, Share Warrents Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExercisePriceShareWarrentsIssued" xlink:href="meso-20231231.xsd#meso_ExercisePriceShareWarrentsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ExercisePriceShareWarrentsIssued" xlink:to="lab_meso_ExercisePriceShareWarrentsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermBorrowings_0650a81b-5320-4594-ac37-3712b119e91b_verboseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_ShorttermBorrowings_f772e057-597f-4355-91e6-f6ab173a7c3f_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowings</link:label>
    <link:label id="lab_ifrs-full_ShorttermBorrowings_label_en-US" xlink:label="lab_ifrs-full_ShorttermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermBorrowings" xlink:to="lab_ifrs-full_ShorttermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_8eff5500-8a8f-4fd4-bb08-34f5ccf2ecc0_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_e02b24b7-f29f-4869-833f-b4aafae1c532_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_8ee9b04e-eb00-49cf-ac04-f72f393abdb4_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accumulated losses)</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock_ff87f8c5-f37e-45fe-86fa-36259b659bba_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Loss Before Income Tax</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock_label_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax Explanatory [Table Text Block]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of loss before income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" xlink:to="lab_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity_fb94d443-dc8f-4441-8988-3210d4f978e4_terseLabel_en-US" xlink:label="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest-bearing deposits at call held as security</link:label>
    <link:label id="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity_label_en-US" xlink:label="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Bearing Deposits At Call Held As Security</link:label>
    <link:label id="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity_documentation_en-US" xlink:label="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest bearing deposits at call held as security.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InterestBearingDepositsAtCallHeldAsSecurity" xlink:href="meso-20231231.xsd#meso_InterestBearingDepositsAtCallHeldAsSecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_InterestBearingDepositsAtCallHeldAsSecurity" xlink:to="lab_meso_InterestBearingDepositsAtCallHeldAsSecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems_8812b034-0035-4fe1-a787-bc915f97db75_terseLabel_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems_label_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Line Items]</link:label>
    <link:label id="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems_documentation_en-US" xlink:label="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Loss Before Income Tax [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems" xlink:to="lab_meso_DisclosureOfLossBeforeIncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_65655329-c328-4553-ad70-e0c27e3aec3e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used as the denominator in calculating basic losses per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LegalProceedingsProvisionAbstract_22b6ad96-ec13-4296-8390-ac0e26d48443_terseLabel_en-US" xlink:label="lab_ifrs-full_LegalProceedingsProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings provision [abstract]</link:label>
    <link:label id="lab_ifrs-full_LegalProceedingsProvisionAbstract_label_en-US" xlink:label="lab_ifrs-full_LegalProceedingsProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings provision [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvisionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LegalProceedingsProvisionAbstract" xlink:to="lab_ifrs-full_LegalProceedingsProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_d5e96773-761c-4b44-835b-6d81c8229f1a_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (outflows) in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ContingentConsiderationProvisionMember_61c0d838-aac2-4421-8d90-ca8e007bdc57_terseLabel_en-US" xlink:label="lab_meso_ContingentConsiderationProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Provision</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvisionMember_label_en-US" xlink:label="lab_meso_ContingentConsiderationProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Provision [Member]</link:label>
    <link:label id="lab_meso_ContingentConsiderationProvisionMember_documentation_en-US" xlink:label="lab_meso_ContingentConsiderationProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration provision.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvisionMember" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ContingentConsiderationProvisionMember" xlink:to="lab_meso_ContingentConsiderationProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_7e66be14-0720-4a13-afaa-8f28d3b60e43_terseLabel_en-US" xlink:label="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received, after the patent license agreement</link:label>
    <link:label id="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_label_en-US" xlink:label="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received, After the Patent License Agreement</link:label>
    <link:label id="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_documentation_en-US" xlink:label="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received, After the Patent License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" xlink:href="meso-20231231.xsd#meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" xlink:to="lab_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ManagementAndAdministrationExpense_26ab7039-40e8-44ae-8205-17499cf7e0aa_negatedLabel_en-US" xlink:label="lab_meso_ManagementAndAdministrationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management and administration</link:label>
    <link:label id="lab_meso_ManagementAndAdministrationExpense_label_en-US" xlink:label="lab_meso_ManagementAndAdministrationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management And Administration Expense</link:label>
    <link:label id="lab_meso_ManagementAndAdministrationExpense_documentation_en-US" xlink:label="lab_meso_ManagementAndAdministrationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of expenditure directly attributable to Management and administration activities, recognized in profit or loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManagementAndAdministrationExpense" xlink:href="meso-20231231.xsd#meso_ManagementAndAdministrationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ManagementAndAdministrationExpense" xlink:to="lab_meso_ManagementAndAdministrationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_fc564c39-0d03-4b83-bd2d-de85ea8964c2_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesChannelsAxis_6e4e0e07-9abe-459e-b69e-71ab0daf4201_terseLabel_en-US" xlink:label="lab_ifrs-full_SalesChannelsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales channels [axis]</link:label>
    <link:label id="lab_ifrs-full_SalesChannelsAxis_label_en-US" xlink:label="lab_ifrs-full_SalesChannelsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales channels [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesChannelsAxis" xlink:to="lab_ifrs-full_SalesChannelsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_a6fc8398-b284-455a-b371-8447ff9416d9_terseLabel_en-US" xlink:label="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants issued to purchase american depositary shares</link:label>
    <link:label id="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_label_en-US" xlink:label="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Issued To Purchase American Depositary Shares</link:label>
    <link:label id="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_documentation_en-US" xlink:label="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Issued To Purchase American Depositary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" xlink:to="lab_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_a1701cfa-405b-420f-b82e-149a0f8767b2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(decrease) in provisions</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForProvisions_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForProvisions" xlink:to="lab_ifrs-full_AdjustmentsForProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_3cec65eb-4e55-41c1-b79c-4b863f59fb1b_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange differences</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_27958f7c-1625-457b-91a5-d8d75881b471_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_8387d47f-e8b1-4dcf-bc56-68de2a88ddc2_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_2526f3f2-16da-4f45-9aca-b52a3f6bbe50_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_NumberOfEscalatingMilestonePayments_176090a0-bda9-4a38-a48f-5e5bac28c8e5_terseLabel_en-US" xlink:label="lab_meso_NumberOfEscalatingMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escalating milestone payments</link:label>
    <link:label id="lab_meso_NumberOfEscalatingMilestonePayments_label_en-US" xlink:label="lab_meso_NumberOfEscalatingMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Escalating Milestone Payments</link:label>
    <link:label id="lab_meso_NumberOfEscalatingMilestonePayments_documentation_en-US" xlink:label="lab_meso_NumberOfEscalatingMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Escalating Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfEscalatingMilestonePayments" xlink:href="meso-20231231.xsd#meso_NumberOfEscalatingMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_NumberOfEscalatingMilestonePayments" xlink:to="lab_meso_NumberOfEscalatingMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_3cddfaa1-b0b9-4285-8dfc-3fecc7b2c4ae_terseLabel_en-US" xlink:label="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax incentives recoverable</link:label>
    <link:label id="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_label_en-US" xlink:label="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive Credit Receivable</link:label>
    <link:label id="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_documentation_en-US" xlink:label="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive Credit Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" xlink:href="meso-20231231.xsd#meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" xlink:to="lab_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssets_5c2589df-a4ff-43e5-9086-ac07aae38a98_totalLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets, Total</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_c595c977-e161-428e-b49a-caaf0458314b_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_FinancialAssets_label_en-US" xlink:label="lab_ifrs-full_FinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssets" xlink:to="lab_ifrs-full_FinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAbstract_1c6c9fa2-a918-4bde-ad41-3a0be0adcfd6_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributed equity</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAbstract_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncomeCost_609caca7-3d01-4f0f-a6c5-c806373f52c6_negatedLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncomeCost_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for finance income (cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_IntellectualPropertyAmortization_bef3f6cd-608c-47cb-980c-d9a28c059a4c_negatedLabel_en-US" xlink:label="lab_meso_IntellectualPropertyAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortization</link:label>
    <link:label id="lab_meso_IntellectualPropertyAmortization_label_en-US" xlink:label="lab_meso_IntellectualPropertyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Amortization</link:label>
    <link:label id="lab_meso_IntellectualPropertyAmortization_documentation_en-US" xlink:label="lab_meso_IntellectualPropertyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntellectualPropertyAmortization" xlink:href="meso-20231231.xsd#meso_IntellectualPropertyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_IntellectualPropertyAmortization" xlink:to="lab_meso_IntellectualPropertyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Provisions_f45d6b35-93b4-4f69-a407-6c00ff3bdec4_totalLabel_en-US" xlink:label="lab_ifrs-full_Provisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_Provisions_label_en-US" xlink:label="lab_ifrs-full_Provisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Provisions" xlink:to="lab_ifrs-full_Provisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0c64d704-cfad-4b89-87e7-831cbc365054_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events occurring after the reporting period</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_meso_InvestmentInFixedAssets_df255f22-b24a-4c59-89ca-e29be3c87fc7_terseLabel_en-US" xlink:label="lab_meso_InvestmentInFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in fixed assets</link:label>
    <link:label id="lab_meso_InvestmentInFixedAssets_label_en-US" xlink:label="lab_meso_InvestmentInFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Fixed Assets</link:label>
    <link:label id="lab_meso_InvestmentInFixedAssets_documentation_en-US" xlink:label="lab_meso_InvestmentInFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in fixed assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InvestmentInFixedAssets" xlink:href="meso-20231231.xsd#meso_InvestmentInFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_meso_InvestmentInFixedAssets" xlink:to="lab_meso_InvestmentInFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesChannelsMember_0be948d8-9309-48a6-8e65-b09688938408_terseLabel_en-US" xlink:label="lab_ifrs-full_SalesChannelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales channels</link:label>
    <link:label id="lab_ifrs-full_SalesChannelsMember_label_en-US" xlink:label="lab_ifrs-full_SalesChannelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales channels [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesChannelsMember" xlink:to="lab_ifrs-full_SalesChannelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_17c6b0b0-b84d-4d27-84f5-1dd85fdc81c8_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share (in shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_e4a703fc-2251-4f23-9358-5040b91d5a72_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_c8418b1b-52f9-4c81-8c94-3da8b85c5f47_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Temporary Differences (DTA)</link:label>
    <link:label id="lab_ifrs-full_OtherTemporaryDifferencesMember_label_en-US" xlink:label="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTemporaryDifferencesMember" xlink:to="lab_ifrs-full_OtherTemporaryDifferencesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>meso-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:1c79165c-755b-4603-a45e-827a45827c07,g:19d448ab-9536-4f20-ab7d-76d6f5e0018c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mesoblast.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="meso-20231231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e9bffcb1-3dfb-4777-9acf-a5fae9dd5b04" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_DocumentType_e9bffcb1-3dfb-4777-9acf-a5fae9dd5b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_00204a3e-5482-4ebf-a018-ff33aefaad87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_DocumentPeriodEndDate_00204a3e-5482-4ebf-a018-ff33aefaad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7eb81e53-489d-41b2-9ac8-671fc145c07b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityFileNumber_7eb81e53-489d-41b2-9ac8-671fc145c07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_449a8605-ffa9-4006-b595-146bcfa110f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityRegistrantName_449a8605-ffa9-4006-b595-146bcfa110f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_eaedb1e8-d079-4986-90d4-430998250cbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityAddressAddressLine1_eaedb1e8-d079-4986-90d4-430998250cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_df49395e-3ced-44d0-bbdd-cd52dd5e48f8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityAddressAddressLine2_df49395e-3ced-44d0-bbdd-cd52dd5e48f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cff207ba-aebd-430d-968e-f6fbd6055af7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityAddressCityOrTown_cff207ba-aebd-430d-968e-f6fbd6055af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_128ffc90-06ad-4898-b676-8e081ea7de33" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityAddressPostalZipCode_128ffc90-06ad-4898-b676-8e081ea7de33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_350b0af2-c6d7-4076-a22d-3f884feaa389" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityAddressCountry_350b0af2-c6d7-4076-a22d-3f884feaa389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6b7eeb85-97c0-4b47-bfa1-60c151d541d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_EntityCentralIndexKey_6b7eeb85-97c0-4b47-bfa1-60c151d541d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_24a7f62e-2f51-4b0a-a453-4a8d88631054" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_CurrentFiscalYearEndDate_24a7f62e-2f51-4b0a-a453-4a8d88631054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b864fc1d-7d35-48c8-bd6e-c958a1e93dc1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e63c87e1-8cf1-4890-bc24-b2bc4f2c4029" xlink:to="loc_dei_AmendmentFlag_b864fc1d-7d35-48c8-bd6e-c958a1e93dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedIncomeStatement" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedIncomeStatement"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_1bd8997d-760f-4210-ad03-0983ddb43924" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_Revenue_1bd8997d-760f-4210-ad03-0983ddb43924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_246fde10-86b7-4a30-9777-ecfb52f70f12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_246fde10-86b7-4a30-9777-ecfb52f70f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingCommercialization_a4432257-b262-48ea-922e-85e68dabf23c" xlink:href="meso-20231231.xsd#meso_ManufacturingCommercialization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_meso_ManufacturingCommercialization_a4432257-b262-48ea-922e-85e68dabf23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManagementAndAdministrationExpense_b768c5c0-d41e-4edb-ad9d-ded48f61945c" xlink:href="meso-20231231.xsd#meso_ManagementAndAdministrationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_meso_ManagementAndAdministrationExpense_b768c5c0-d41e-4edb-ad9d-ded48f61945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsideration_9fd1e9c9-3434-4af4-ad7f-0cd61b08372b" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsideration_9fd1e9c9-3434-4af4-ad7f-0cd61b08372b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiability_3a532582-75f0-4c01-93ec-4828805fbd90" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_meso_FairValueRemeasurementOfWarrantLiability_3a532582-75f0-4c01-93ec-4828805fbd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_faf09761-caa6-43da-896d-d5886f5c4621" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_faf09761-caa6-43da-896d-d5886f5c4621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_3156a6d0-372b-45e7-b14f-4b582cbb906d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_FinanceCosts_3156a6d0-372b-45e7-b14f-4b582cbb906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_26295ce3-4c8d-41d5-8d6a-03fa28e6048e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_26295ce3-4c8d-41d5-8d6a-03fa28e6048e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_60031d63-f563-47ad-9695-985256666fd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_60031d63-f563-47ad-9695-985256666fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_43533b62-a021-4629-b2e4-b0464796e0a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_43533b62-a021-4629-b2e4-b0464796e0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_572210aa-009d-49b1-8b08-2e622fb9a36e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_649f991c-a283-46fa-b50e-64a9a727effa" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_572210aa-009d-49b1-8b08-2e622fb9a36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_0f28caef-3035-4102-8617-0b7a5846d82e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_572210aa-009d-49b1-8b08-2e622fb9a36e" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_0f28caef-3035-4102-8617-0b7a5846d82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_185fb06c-0817-4ed3-8317-2757afc57fda" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_572210aa-009d-49b1-8b08-2e622fb9a36e" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_185fb06c-0817-4ed3-8317-2757afc57fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_6d99c319-6131-4b66-892f-28f352a58f95" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_fbabd4ab-a39c-44b4-9802-a74566b2c319" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_6d99c319-6131-4b66-892f-28f352a58f95" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_fbabd4ab-a39c-44b4-9802-a74566b2c319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_213af1ba-f7a1-4efd-ae6f-577076b24e91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_6d99c319-6131-4b66-892f-28f352a58f95" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_213af1ba-f7a1-4efd-ae6f-577076b24e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_5d3fb860-7b56-4161-8273-0c8083a36c5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_213af1ba-f7a1-4efd-ae6f-577076b24e91" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_5d3fb860-7b56-4161-8273-0c8083a36c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_8e9a985c-955d-4442-895b-6811d3fc8e66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_5d3fb860-7b56-4161-8273-0c8083a36c5a" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax_8e9a985c-955d-4442-895b-6811d3fc8e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_23b51a93-f35b-4ff2-998e-dc0b15f4a61e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_213af1ba-f7a1-4efd-ae6f-577076b24e91" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_23b51a93-f35b-4ff2-998e-dc0b15f4a61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_320c186c-c903-44ee-bdad-fb61eeadeb64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_23b51a93-f35b-4ff2-998e-dc0b15f4a61e" xlink:to="loc_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_320c186c-c903-44ee-bdad-fb61eeadeb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c5522b3e-145d-4859-a42f-e6709e276b75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_213af1ba-f7a1-4efd-ae6f-577076b24e91" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_c5522b3e-145d-4859-a42f-e6709e276b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_854b7d28-5eb5-4cad-b68a-ce2158fb41b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfComprehensiveIncomeAbstract_6d99c319-6131-4b66-892f-28f352a58f95" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_854b7d28-5eb5-4cad-b68a-ce2158fb41b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofChangesinEquity"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_5179ce90-bf51-43b6-82b1-7c1186e720ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_5179ce90-bf51-43b6-82b1-7c1186e720ab" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9f557775-77c4-4a1b-a9f9-8f8d32b533be" xlink:to="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_d04fe5b2-b43b-4ca1-8f64-df85a7133756" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_IssuedCapitalMember_d04fe5b2-b43b-4ca1-8f64-df85a7133756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember_09fbf569-d408-44ca-abe4-112f2ac7ad7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember_09fbf569-d408-44ca-abe4-112f2ac7ad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InvestmentRevaluationReserveMember_f08a322d-5005-4d9b-978d-803f8928de71" xlink:href="meso-20231231.xsd#meso_InvestmentRevaluationReserveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_meso_InvestmentRevaluationReserveMember_f08a322d-5005-4d9b-978d-803f8928de71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_810e5fa0-ce17-4774-8065-7f5c7b1aea8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_810e5fa0-ce17-4774-8065-7f5c7b1aea8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_f171c6fa-9b47-4db9-a950-400a523d5a9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_f171c6fa-9b47-4db9-a950-400a523d5a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_5291c7f9-9a43-4003-bdfa-92fb4b145ce1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a706cf62-8c07-405d-94c7-93c6c7c15b20" xlink:to="loc_ifrs-full_RetainedEarningsMember_5291c7f9-9a43-4003-bdfa-92fb4b145ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_4fc5ff11-af01-4276-879e-ad4c6fc6717f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5266eac8-40d7-4fbf-9615-775262ed6108" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_Equity_5266eac8-40d7-4fbf-9615-775262ed6108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_283606ab-2922-48c1-a280-eee0821c1dfa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_ProfitLoss_283606ab-2922-48c1-a280-eee0821c1dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_c925120e-6fdd-427d-b48a-df1a637509bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_c925120e-6fdd-427d-b48a-df1a637509bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_a2e11668-6cfc-491f-89e4-aae421324745" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_ComprehensiveIncome_a2e11668-6cfc-491f-89e4-aae421324745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_7c46c2b2-18e1-40bb-9cd7-c27b4ef809d6" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_585e5e83-5418-4cda-a6e7-cbb91cf90089" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_585e5e83-5418-4cda-a6e7-cbb91cf90089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_0af9b525-50a7-4e27-9a9e-bb120a8ae5f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_0af9b525-50a7-4e27-9a9e-bb120a8ae5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxCreditedOrDebitedToEquity_673a3d78-8f76-424b-bd48-63e5a43fdaaa" xlink:href="meso-20231231.xsd#meso_TaxCreditedOrDebitedToEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_meso_TaxCreditedOrDebitedToEquity_673a3d78-8f76-424b-bd48-63e5a43fdaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_12ad226c-ea65-418b-984f-2eafb52a8fae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_12ad226c-ea65-418b-984f-2eafb52a8fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_73c26a43-9707-4c49-84f6-64355f0fd96f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_73c26a43-9707-4c49-84f6-64355f0fd96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_18364871-a0ab-4361-9669-4d516d25c6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_ChangesInEquity_18364871-a0ab-4361-9669-4d516d25c6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5c661a98-a4b4-4143-be19-babc7f01b701" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_e6f67635-fe5f-4426-b614-d201e82b69b4" xlink:to="loc_ifrs-full_Equity_5c661a98-a4b4-4143-be19-babc7f01b701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedBalanceSheet"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_965a0c5c-915d-4d99-98c6-e7d243f30c5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_d68e88ca-c8d1-4d07-9641-f88b0e73a85f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_965a0c5c-915d-4d99-98c6-e7d243f30c5b" xlink:to="loc_ifrs-full_AssetsAbstract_d68e88ca-c8d1-4d07-9641-f88b0e73a85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_1fbc02e4-555f-45bc-bc4a-d840dea196ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_d68e88ca-c8d1-4d07-9641-f88b0e73a85f" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_1fbc02e4-555f-45bc-bc4a-d840dea196ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_20c2fa11-2c15-491c-86a3-895a2ba213cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1fbc02e4-555f-45bc-bc4a-d840dea196ca" xlink:to="loc_ifrs-full_CashAndCashEquivalents_20c2fa11-2c15-491c-86a3-895a2ba213cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_a04b0543-11dc-4b88-ba5d-0e5b57e43f13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1fbc02e4-555f-45bc-bc4a-d840dea196ca" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_a04b0543-11dc-4b88-ba5d-0e5b57e43f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_aeda3741-e526-4680-bfec-0a7eea08ac2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1fbc02e4-555f-45bc-bc4a-d840dea196ca" xlink:to="loc_ifrs-full_CurrentPrepayments_aeda3741-e526-4680-bfec-0a7eea08ac2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_f021b4a1-6972-4571-969d-cb8e84b2494f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_1fbc02e4-555f-45bc-bc4a-d840dea196ca" xlink:to="loc_ifrs-full_CurrentAssets_f021b4a1-6972-4571-969d-cb8e84b2494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_d68e88ca-c8d1-4d07-9641-f88b0e73a85f" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_eeaaf42c-fb21-4aac-8361-e2b50d17e831" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_eeaaf42c-fb21-4aac-8361-e2b50d17e831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_0c00cd5e-0d77-45ef-8db4-836643bd91cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:to="loc_ifrs-full_RightofuseAssets_0c00cd5e-0d77-45ef-8db4-836643bd91cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_cf8108ac-5233-4e17-a8ad-e43d3dc828bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:to="loc_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome_cf8108ac-5233-4e17-a8ad-e43d3dc828bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_f7b5df69-de04-4ba5-b774-3b0a7cb977af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_f7b5df69-de04-4ba5-b774-3b0a7cb977af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_97b89a61-0f64-43b3-a61f-fb8edc34c0e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_97b89a61-0f64-43b3-a61f-fb8edc34c0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_64f60624-a61f-4267-9abd-ebf8233bdbab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_c762605d-f391-448f-bcf6-b6d4a5a7f881" xlink:to="loc_ifrs-full_NoncurrentAssets_64f60624-a61f-4267-9abd-ebf8233bdbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_733a9841-66ca-4738-a650-22b670919266" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_d68e88ca-c8d1-4d07-9641-f88b0e73a85f" xlink:to="loc_ifrs-full_Assets_733a9841-66ca-4738-a650-22b670919266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract_a403870e-294c-46e5-9310-efec0cbe06d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_965a0c5c-915d-4d99-98c6-e7d243f30c5b" xlink:to="loc_ifrs-full_LiabilitiesAbstract_a403870e-294c-46e5-9310-efec0cbe06d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_a403870e-294c-46e5-9310-efec0cbe06d5" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_476102e6-7f1e-420e-a919-a61263458e14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_476102e6-7f1e-420e-a919-a61263458e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_1bd63857-e03a-4af0-ba04-73b6d27de615" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:to="loc_ifrs-full_CurrentProvisions_1bd63857-e03a-4af0-ba04-73b6d27de615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_ff4d86f3-261c-444a-aadf-6e29d9baf5b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:to="loc_ifrs-full_CurrentPortionOfLongtermBorrowings_ff4d86f3-261c-444a-aadf-6e29d9baf5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6a54c5de-7b41-4170-ac68-773eff0179ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_6a54c5de-7b41-4170-ac68-773eff0179ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_c193be55-c70b-4d17-a07e-4a8133e634a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:to="loc_ifrs-full_WarrantLiability_c193be55-c70b-4d17-a07e-4a8133e634a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_65494a4e-fbe1-475f-a626-57d205d49460" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_86e5106a-4cba-44d1-a858-2e7f5f51243b" xlink:to="loc_ifrs-full_CurrentLiabilities_65494a4e-fbe1-475f-a626-57d205d49460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_a403870e-294c-46e5-9310-efec0cbe06d5" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_061611ca-9fe8-4d90-82d7-2e4295441859" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:to="loc_ifrs-full_NoncurrentProvisions_061611ca-9fe8-4d90-82d7-2e4295441859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_281a1ac4-43d8-489a-860f-e4441983dc37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:to="loc_ifrs-full_LongtermBorrowings_281a1ac4-43d8-489a-860f-e4441983dc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_55ae6799-3922-4eaa-ad59-cfe66b3383e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_55ae6799-3922-4eaa-ad59-cfe66b3383e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredConsiderationNonCurrent_ce367fe4-adda-49a9-8c17-eac3824b620f" xlink:href="meso-20231231.xsd#meso_DeferredConsiderationNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:to="loc_meso_DeferredConsiderationNonCurrent_ce367fe4-adda-49a9-8c17-eac3824b620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_4cc9a6ae-431b-413a-9fe9-318bd2f2b61b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_7f7429bd-1dd1-4f28-bfdc-8802ebe28e21" xlink:to="loc_ifrs-full_NoncurrentLiabilities_4cc9a6ae-431b-413a-9fe9-318bd2f2b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_17b2f572-b8b6-4ec0-ae34-2b2862609883" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_a403870e-294c-46e5-9310-efec0cbe06d5" xlink:to="loc_ifrs-full_Liabilities_17b2f572-b8b6-4ec0-ae34-2b2862609883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_b6d30002-fda9-4297-9014-e45cea098f49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_965a0c5c-915d-4d99-98c6-e7d243f30c5b" xlink:to="loc_ifrs-full_NetAssetsLiabilities_b6d30002-fda9-4297-9014-e45cea098f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_b6a3bcb1-a86b-49b6-b632-a7cf480abfd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_965a0c5c-915d-4d99-98c6-e7d243f30c5b" xlink:to="loc_ifrs-full_EquityAbstract_b6a3bcb1-a86b-49b6-b632-a7cf480abfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_077d18ec-9bb6-4816-9163-ec64b3cdce76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b6a3bcb1-a86b-49b6-b632-a7cf480abfd0" xlink:to="loc_ifrs-full_IssuedCapital_077d18ec-9bb6-4816-9163-ec64b3cdce76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_e4669530-d64f-4bb7-b30d-fe04628764e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b6a3bcb1-a86b-49b6-b632-a7cf480abfd0" xlink:to="loc_ifrs-full_OtherReserves_e4669530-d64f-4bb7-b30d-fe04628764e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_af1e8b86-a2c7-4e13-95f6-7a3decf512b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b6a3bcb1-a86b-49b6-b632-a7cf480abfd0" xlink:to="loc_ifrs-full_RetainedEarnings_af1e8b86-a2c7-4e13-95f6-7a3decf512b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3f8f08a6-db48-4084-8b5e-dead87b942d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_b6a3bcb1-a86b-49b6-b632-a7cf480abfd0" xlink:to="loc_ifrs-full_Equity_3f8f08a6-db48-4084-8b5e-dead87b942d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="meso-20231231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CommercializationRevenueReceived_63a6ba60-66ae-4612-a3e8-ab1ff0deaab9" xlink:href="meso-20231231.xsd#meso_CommercializationRevenueReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:to="loc_meso_CommercializationRevenueReceived_63a6ba60-66ae-4612-a3e8-ab1ff0deaab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_4b8a7b8a-aadd-4cec-98d4-fdf37c939e9b" xlink:href="meso-20231231.xsd#meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:to="loc_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived_4b8a7b8a-aadd-4cec-98d4-fdf37c939e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_c13949d7-3e2d-47e0-9dac-6077ebf0a7b2" xlink:href="meso-20231231.xsd#meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:to="loc_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax_c13949d7-3e2d-47e0-9dac-6077ebf0a7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b0f2dba6-052a-4e46-9775-af293e397306" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_b0f2dba6-052a-4e46-9775-af293e397306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_7e8c6d43-0439-43b3-8f54-d77033a48c59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_7e8c6d43-0439-43b3-8f54-d77033a48c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_fc4989ea-37ac-4933-a25f-5078cbd7d633" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9566c479-ccb4-4198-a279-c4405297037e" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_fc4989ea-37ac-4933-a25f-5078cbd7d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_32eba080-b8a4-41ea-a373-d95c6481b09b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_32eba080-b8a4-41ea-a373-d95c6481b09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InvestmentInFixedAssets_9c578287-c7e4-4174-9f33-9b317ffe3243" xlink:href="meso-20231231.xsd#meso_InvestmentInFixedAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_32eba080-b8a4-41ea-a373-d95c6481b09b" xlink:to="loc_meso_InvestmentInFixedAssets_9c578287-c7e4-4174-9f33-9b317ffe3243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ReceiptsFromInvestmentInSublease_c6182fdf-83f4-46ff-a1da-8185802427ef" xlink:href="meso-20231231.xsd#meso_ReceiptsFromInvestmentInSublease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_32eba080-b8a4-41ea-a373-d95c6481b09b" xlink:to="loc_meso_ReceiptsFromInvestmentInSublease_c6182fdf-83f4-46ff-a1da-8185802427ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_913ab0d9-ffb4-42e2-ba97-e2201a1fbe92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_32eba080-b8a4-41ea-a373-d95c6481b09b" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_913ab0d9-ffb4-42e2-ba97-e2201a1fbe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_77af78dc-cdc9-4482-a427-91eff5943926" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_32eba080-b8a4-41ea-a373-d95c6481b09b" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_77af78dc-cdc9-4482-a427-91eff5943926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentsOfTransactionCostsFromBorrowings_113800f2-c537-4d21-b14a-8c4b1bd2a494" xlink:href="meso-20231231.xsd#meso_PaymentsOfTransactionCostsFromBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:to="loc_meso_PaymentsOfTransactionCostsFromBorrowings_113800f2-c537-4d21-b14a-8c4b1bd2a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_3ab9578d-97cd-4f36-9f69-08b6a2b087b4" xlink:href="meso-20231231.xsd#meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:to="loc_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities_3ab9578d-97cd-4f36-9f69-08b6a2b087b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_7ddecc51-ffbb-41a2-b4d9-31ebdda25a8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_7ddecc51-ffbb-41a2-b4d9-31ebdda25a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_a897f6fc-1880-428e-8711-50dfef9cb86e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_a897f6fc-1880-428e-8711-50dfef9cb86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_5812f4e9-8ff0-46fe-ab45-800fdf54a0d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_5812f4e9-8ff0-46fe-ab45-800fdf54a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e096f748-6ada-4d9f-adaf-36f1ef960481" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_627fc68b-04d4-495d-a00a-f60085eaa1ce" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_e096f748-6ada-4d9f-adaf-36f1ef960481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_b9e972b0-f54d-4575-bfa7-709507e7efea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_b9e972b0-f54d-4575-bfa7-709507e7efea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_c3cf2178-147f-4a9a-94ae-30d9df67d887" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_CashAndCashEquivalents_c3cf2178-147f-4a9a-94ae-30d9df67d887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_9bd6bc55-6a58-4162-8321-afadb814cf0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_9bd6bc55-6a58-4162-8321-afadb814cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_bbc03af8-2c83-49b8-ae1e-1ff7e1474242" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_35d1e706-d4b1-4140-9ee9-c60b4e2bb213" xlink:to="loc_ifrs-full_CashAndCashEquivalents_bbc03af8-2c83-49b8-ae1e-1ff7e1474242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Basisofpreparation" xlink:type="simple" xlink:href="meso-20231231.xsd#Basisofpreparation"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Basisofpreparation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_BasisOfPreparationAbstract_356479b6-225c-4979-b1cf-17b965af6516" xlink:href="meso-20231231.xsd#meso_BasisOfPreparationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_508c4173-62ef-46c3-adf4-22a1d295ac43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_BasisOfPreparationAbstract_356479b6-225c-4979-b1cf-17b965af6516" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_508c4173-62ef-46c3-adf4-22a1d295ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod" xlink:type="simple" xlink:href="meso-20231231.xsd#Significantchangesinthecurrentreportingperiod"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_e782a919-2dca-4ea6-8b0a-6b06ed735436" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock_dbeba16e-eea8-42a3-8f58-8ce6df69977c" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_e782a919-2dca-4ea6-8b0a-6b06ed735436" xlink:to="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock_dbeba16e-eea8-42a3-8f58-8ce6df69977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Lossbeforeincometax" xlink:type="simple" xlink:href="meso-20231231.xsd#Lossbeforeincometax"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Lossbeforeincometax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_8a44fd56-c0cd-405a-8f4a-157d8abdf574" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock_903e2cd9-0ea8-4b55-bdc5-92b5a4405464" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_8a44fd56-c0cd-405a-8f4a-157d8abdf574" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock_903e2cd9-0ea8-4b55-bdc5-92b5a4405464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Incometaxbenefitexpense" xlink:type="simple" xlink:href="meso-20231231.xsd#Incometaxbenefitexpense"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Incometaxbenefitexpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1bce679c-b677-42d1-8c5b-2d653f51edf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_d0fb6def-95fa-4170-a152-8047956e23bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1bce679c-b677-42d1-8c5b-2d653f51edf4" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_d0fb6def-95fa-4170-a152-8047956e23bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Financialassetsandliabilities" xlink:type="simple" xlink:href="meso-20231231.xsd#Financialassetsandliabilities"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Financialassetsandliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_c616eac1-e1e2-4466-9f92-7db216fd52de" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock_cd8c3edb-76fc-40f3-ba11-a05e2de192bb" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_c616eac1-e1e2-4466-9f92-7db216fd52de" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock_cd8c3edb-76fc-40f3-ba11-a05e2de192bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Nonfinancialassetsandliabilities" xlink:type="simple" xlink:href="meso-20231231.xsd#Nonfinancialassetsandliabilities"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Nonfinancialassetsandliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_1233fb91-f85f-4eea-bb73-764f487c0227" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock_18079cf3-124c-4045-8d22-746224348af3" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_1233fb91-f85f-4eea-bb73-764f487c0227" xlink:to="loc_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock_18079cf3-124c-4045-8d22-746224348af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Cashflowinformation" xlink:type="simple" xlink:href="meso-20231231.xsd#Cashflowinformation"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Cashflowinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_183c6849-bee3-4857-8a13-26738d9bf1d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_e106f0f1-6c9e-470e-a651-8bdff31c0c01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_183c6849-bee3-4857-8a13-26738d9bf1d1" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_e106f0f1-6c9e-470e-a651-8bdff31c0c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Equity" xlink:type="simple" xlink:href="meso-20231231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_b6b5fa48-8fa9-4834-bed6-4e2dc76c9843" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_67075966-fcc9-4760-a6e2-82d588805b4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_b6b5fa48-8fa9-4834-bed6-4e2dc76c9843" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_67075966-fcc9-4760-a6e2-82d588805b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Financialriskmanagement" xlink:type="simple" xlink:href="meso-20231231.xsd#Financialriskmanagement"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Financialriskmanagement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_5809356f-d4ea-4a13-b514-60b53815d637" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_654ddd5e-7939-45cd-a782-0e08910f87d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_5809356f-d4ea-4a13-b514-60b53815d637" xlink:to="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_654ddd5e-7939-45cd-a782-0e08910f87d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Lossespershare" xlink:type="simple" xlink:href="meso-20231231.xsd#Lossespershare"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Lossespershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_dd024387-aca0-4d6d-825b-ccc2c4778fcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1ba9f743-fa93-4917-a32b-f5b29abbe03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_dd024387-aca0-4d6d-825b-ccc2c4778fcc" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1ba9f743-fa93-4917-a32b-f5b29abbe03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Eventsoccurringafterthereportingperiod" xlink:type="simple" xlink:href="meso-20231231.xsd#Eventsoccurringafterthereportingperiod"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Eventsoccurringafterthereportingperiod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_41831c65-dcc9-45f7-b0f1-5d5ae6cb5aa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2c622db0-484f-4993-906f-9f11ff57f183" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_41831c65-dcc9-45f7-b0f1-5d5ae6cb5aa5" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2c622db0-484f-4993-906f-9f11ff57f183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Segmentinformation" xlink:type="simple" xlink:href="meso-20231231.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_931bf8b5-096e-4c56-a8d0-412d0634de0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_344faad0-9bd3-4b2e-ba05-704e0ea5deb7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_931bf8b5-096e-4c56-a8d0-412d0634de0d" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_344faad0-9bd3-4b2e-ba05-704e0ea5deb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/Legalproceedings" xlink:type="simple" xlink:href="meso-20231231.xsd#Legalproceedings"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/Legalproceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvisionAbstract_1d20b7ff-0bac-4ec4-99af-d64a197bbce9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvisionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock_a50d5990-8269-4149-9fbf-3ccf4aae5629" xlink:href="meso-20231231.xsd#meso_DisclosureOfLegalProceedingsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LegalProceedingsProvisionAbstract_1d20b7ff-0bac-4ec4-99af-d64a197bbce9" xlink:to="loc_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock_a50d5990-8269-4149-9fbf-3ccf4aae5629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/BasisofpreparationPolicies" xlink:type="simple" xlink:href="meso-20231231.xsd#BasisofpreparationPolicies"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/BasisofpreparationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_BasisOfPreparationAbstract_37d564fb-b192-4607-a21b-4c1f8b88508b" xlink:href="meso-20231231.xsd#meso_BasisOfPreparationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock_2214faa1-a729-4fb0-b5cf-ec471ee04d9a" xlink:href="meso-20231231.xsd#meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_BasisOfPreparationAbstract_37d564fb-b192-4607-a21b-4c1f8b88508b" xlink:to="loc_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock_2214faa1-a729-4fb0-b5cf-ec471ee04d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxTables" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_0acac720-dd90-405f-b2d1-b663f779e606" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock_3a7d26f4-40e2-4e96-8f84-e1eac7869c22" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_0acac720-dd90-405f-b2d1-b663f779e606" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock_3a7d26f4-40e2-4e96-8f84-e1eac7869c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseTables" xlink:type="simple" xlink:href="meso-20231231.xsd#IncometaxbenefitexpenseTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/IncometaxbenefitexpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_9095d188-eddb-43ae-b82b-849dab44b40a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock_351a585f-5d18-4031-bf2a-98b73d1f7527" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_9095d188-eddb-43ae-b82b-849dab44b40a" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock_351a585f-5d18-4031-bf2a-98b73d1f7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock_62c6f11b-eb32-4034-91f7-58a79448ecaf" xlink:href="meso-20231231.xsd#meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_9095d188-eddb-43ae-b82b-849dab44b40a" xlink:to="loc_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock_62c6f11b-eb32-4034-91f7-58a79448ecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_8ea87f3a-7c8b-450f-ab0b-6c57869a70ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_8ea87f3a-7c8b-450f-ab0b-6c57869a70ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_6319e022-0218-486d-9ffc-745a88b5f335" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_6319e022-0218-486d-9ffc-745a88b5f335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock_c0e936f9-eec2-4d31-8ae0-33e1d2aaf9af" xlink:href="meso-20231231.xsd#meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock_c0e936f9-eec2-4d31-8ae0-33e1d2aaf9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_4f57144f-e005-46f9-8152-659ec0bd92a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_4f57144f-e005-46f9-8152-659ec0bd92a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_d246d93a-1fe5-4b4a-ade9-3ebce1df2c72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_d246d93a-1fe5-4b4a-ade9-3ebce1df2c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock_2db23ee6-08d8-43cc-9138-edef021166e1" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock_2db23ee6-08d8-43cc-9138-edef021166e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock_1d749d6b-4402-4069-8c41-265b345762e0" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock_1d749d6b-4402-4069-8c41-265b345762e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock_4b52727e-8205-41a6-8871-2114af01a596" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock_4b52727e-8205-41a6-8871-2114af01a596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock_a9c164c0-ee28-462b-aceb-a368ebd844dc" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock_a9c164c0-ee28-462b-aceb-a368ebd844dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock_28d13973-8bec-4259-bdbe-a340f14f39ed" xlink:href="meso-20231231.xsd#meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock_28d13973-8bec-4259-bdbe-a340f14f39ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock_ba719c3c-aed0-4aa9-b7a2-b62abbd73a03" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock_ba719c3c-aed0-4aa9-b7a2-b62abbd73a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock_702a7117-d3b2-4342-b081-99d1f7daf4b2" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock_702a7117-d3b2-4342-b081-99d1f7daf4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock_ef5eaf35-6121-45f2-8435-3436bfa73a6d" xlink:href="meso-20231231.xsd#meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7f7aed3d-a5af-4a38-b071-0945e068d0dd" xlink:to="loc_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock_ef5eaf35-6121-45f2-8435-3436bfa73a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a5c779dd-a80e-4976-b437-7c0ecb60da9f" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_9641842c-b943-4a64-8735-2732c3504af6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a5c779dd-a80e-4976-b437-7c0ecb60da9f" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_9641842c-b943-4a64-8735-2732c3504af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock_94bdf744-9abf-4a7f-8868-13e544179901" xlink:href="meso-20231231.xsd#meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a5c779dd-a80e-4976-b437-7c0ecb60da9f" xlink:to="loc_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock_94bdf744-9abf-4a7f-8868-13e544179901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfProvisionsExplanatory_c338ae82-a663-4b3e-82ec-224031a29e5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfProvisionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a5c779dd-a80e-4976-b437-7c0ecb60da9f" xlink:to="loc_ifrs-full_DisclosureOfProvisionsExplanatory_c338ae82-a663-4b3e-82ec-224031a29e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_b83a9bdd-df0c-448f-b0b3-7b6f050cabfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a5c779dd-a80e-4976-b437-7c0ecb60da9f" xlink:to="loc_ifrs-full_DisclosureOfDeferredTaxesExplanatory_b83a9bdd-df0c-448f-b0b3-7b6f050cabfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock_22aa4da3-3785-47ad-a210-0c7a05e41c01" xlink:href="meso-20231231.xsd#meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a5c779dd-a80e-4976-b437-7c0ecb60da9f" xlink:to="loc_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock_22aa4da3-3785-47ad-a210-0c7a05e41c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/CashflowinformationTables" xlink:type="simple" xlink:href="meso-20231231.xsd#CashflowinformationTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/CashflowinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_6ff0904b-e0a1-49dc-ac02-3d0cc01637da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock_7b33024f-e318-4f09-8aa6-17c8eb10490e" xlink:href="meso-20231231.xsd#meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_6ff0904b-e0a1-49dc-ac02-3d0cc01637da" xlink:to="loc_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock_7b33024f-e318-4f09-8aa6-17c8eb10490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquityTables" xlink:type="simple" xlink:href="meso-20231231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_f830087f-e839-442c-91ed-2211e5339b3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_7f5396a4-fd25-447b-a432-cb383085852a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_f830087f-e839-442c-91ed-2211e5339b3b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_7f5396a4-fd25-447b-a432-cb383085852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock_82cdb389-0083-49b0-9a53-7ae7c41d7a00" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_f830087f-e839-442c-91ed-2211e5339b3b" xlink:to="loc_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock_82cdb389-0083-49b0-9a53-7ae7c41d7a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock_429a9989-3759-47fc-a5f3-2ef8e83f217b" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_f830087f-e839-442c-91ed-2211e5339b3b" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock_429a9989-3759-47fc-a5f3-2ef8e83f217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock_63d37a09-0d61-4852-9cbc-1a6678ffbea5" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_f830087f-e839-442c-91ed-2211e5339b3b" xlink:to="loc_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock_63d37a09-0d61-4852-9cbc-1a6678ffbea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementTables" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_733f1f88-f1ac-402b-8054-12f8b6b22426" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfExposureToFinancialRisksTableTextBlock_2de7341b-fca8-4a9d-9971-bae465ce884c" xlink:href="meso-20231231.xsd#meso_DisclosureOfExposureToFinancialRisksTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_733f1f88-f1ac-402b-8054-12f8b6b22426" xlink:to="loc_meso_DisclosureOfExposureToFinancialRisksTableTextBlock_2de7341b-fca8-4a9d-9971-bae465ce884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock_24132165-00d0-43af-b5dc-de02de6b3c33" xlink:href="meso-20231231.xsd#meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_733f1f88-f1ac-402b-8054-12f8b6b22426" xlink:to="loc_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock_24132165-00d0-43af-b5dc-de02de6b3c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock_c04a889e-5c13-4cdb-bdc6-9eb674207cdf" xlink:href="meso-20231231.xsd#meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_733f1f88-f1ac-402b-8054-12f8b6b22426" xlink:to="loc_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock_c04a889e-5c13-4cdb-bdc6-9eb674207cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock_66b9d0df-6083-4463-803d-2ffe06ca2600" xlink:href="meso-20231231.xsd#meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_733f1f88-f1ac-402b-8054-12f8b6b22426" xlink:to="loc_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock_66b9d0df-6083-4463-803d-2ffe06ca2600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_73c5171e-76d6-491e-8560-da89c87f894a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_733f1f88-f1ac-402b-8054-12f8b6b22426" xlink:to="loc_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities_73c5171e-76d6-491e-8560-da89c87f894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossespershareTables" xlink:type="simple" xlink:href="meso-20231231.xsd#LossespershareTables"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LossespershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_4f8e33a6-044c-4afc-85ce-8f1f1bf95bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_bbb46047-adcd-4db5-aa6b-9f60e3df9160" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_4f8e33a6-044c-4afc-85ce-8f1f1bf95bf0" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_bbb46047-adcd-4db5-aa6b-9f60e3df9160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/BasisofpreparationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#BasisofpreparationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/BasisofpreparationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_BasisOfPreparationAbstract_c66e8285-d0bd-405a-a969-a65d00958272" xlink:href="meso-20231231.xsd#meso_BasisOfPreparationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_376bc461-7759-4751-ab42-63b19e1a695a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_BasisOfPreparationAbstract_c66e8285-d0bd-405a-a969-a65d00958272" xlink:to="loc_ifrs-full_CashAndCashEquivalents_376bc461-7759-4751-ab42-63b19e1a695a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MaximumAmountInCashOutflowsFromOperatingActivities_e76f2dc1-6c08-447f-a882-f5f3573d77c7" xlink:href="meso-20231231.xsd#meso_MaximumAmountInCashOutflowsFromOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_BasisOfPreparationAbstract_c66e8285-d0bd-405a-a969-a65d00958272" xlink:to="loc_meso_MaximumAmountInCashOutflowsFromOperatingActivities_e76f2dc1-6c08-447f-a882-f5f3573d77c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities_d96cf6a7-5b39-402c-88ca-1c1ae41ad5ed" xlink:href="meso-20231231.xsd#meso_PercentageOfReductionInCashOutflowsFromOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_BasisOfPreparationAbstract_c66e8285-d0bd-405a-a969-a65d00958272" xlink:to="loc_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities_d96cf6a7-5b39-402c-88ca-1c1ae41ad5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#SignificantchangesinthecurrentreportingperiodDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_5cb3f7f5-0c4a-4dde-953a-90d0b4b5d3fd" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract_5cb3f7f5-0c4a-4dde-953a-90d0b4b5d3fd" xlink:to="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_b76af15f-5a9b-47f1-8bc0-6326a7e2bba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6f63899b-3331-4140-8aeb-251444d4c323" xlink:to="loc_ifrs-full_EquityMember_b76af15f-5a9b-47f1-8bc0-6326a7e2bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember_7f48f602-5361-460b-908b-603229a55107" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_b76af15f-5a9b-47f1-8bc0-6326a7e2bba8" xlink:to="loc_meso_PrivatePlacementOfSharesMember_7f48f602-5361-460b-908b-603229a55107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:href="meso-20231231.xsd#meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable_3935e2a5-e3b5-4573-9796-93fafdbcdbe2" xlink:to="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConversionRatioOfWarrants_083aeb8d-6b71-43e9-bfdf-db9905bab77d" xlink:href="meso-20231231.xsd#meso_ConversionRatioOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_ConversionRatioOfWarrants_083aeb8d-6b71-43e9-bfdf-db9905bab77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfSharesIssuedAndFullyPaidValue_0cac9dd7-aef5-4ffd-bb14-405ef3f60989" xlink:href="meso-20231231.xsd#meso_NumberOfSharesIssuedAndFullyPaidValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_NumberOfSharesIssuedAndFullyPaidValue_0cac9dd7-aef5-4ffd-bb14-405ef3f60989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_e13533f8-bede-41f6-aab4-e3ff39629cd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_ifrs-full_ParValuePerShare_e13533f8-bede-41f6-aab4-e3ff39629cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProceedsFromPrivatePlacement_10d5266d-0980-4d69-9b39-5df83d79b21f" xlink:href="meso-20231231.xsd#meso_ProceedsFromPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems_dcb590a2-7cb0-4d7a-98b6-aadfe70810c5" xlink:to="loc_meso_ProceedsFromPrivatePlacement_10d5266d-0980-4d69-9b39-5df83d79b21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_fcdc0d66-743a-4b7c-a091-eb017d390dcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_ifrs-full_RevenueAbstract_fcdc0d66-743a-4b7c-a091-eb017d390dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CommercializationRevenue_fa2d847a-8402-46b4-bbb5-5da98848a10d" xlink:href="meso-20231231.xsd#meso_CommercializationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_fcdc0d66-743a-4b7c-a091-eb017d390dcc" xlink:to="loc_meso_CommercializationRevenue_fa2d847a-8402-46b4-bbb5-5da98848a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_1cf3b9e6-c015-461e-b815-4239b35fd9ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_fcdc0d66-743a-4b7c-a091-eb017d390dcc" xlink:to="loc_ifrs-full_Revenue_1cf3b9e6-c015-461e-b815-4239b35fd9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalTrialRelatedResearchAndDevelopment_109e7035-ac44-487f-b298-081b08a8ecd4" xlink:href="meso-20231231.xsd#meso_ClinicalTrialRelatedResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_ClinicalTrialRelatedResearchAndDevelopment_109e7035-ac44-487f-b298-081b08a8ecd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingProductionAndDevelopment_2dcbf355-4ae3-4831-8dca-5070d87cb404" xlink:href="meso-20231231.xsd#meso_ManufacturingProductionAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_ManufacturingProductionAndDevelopment_2dcbf355-4ae3-4831-8dca-5070d87cb404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_5f618329-77b0-4a30-b8bc-f16ce7d1a093" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_5f618329-77b0-4a30-b8bc-f16ce7d1a093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WagesAndSalaries_1478ef0e-ef45-405f-badf-02f3d153156b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_5f618329-77b0-4a30-b8bc-f16ce7d1a093" xlink:to="loc_ifrs-full_WagesAndSalaries_1478ef0e-ef45-405f-badf-02f3d153156b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DefinedContributionSuperannuationExpenses_32b162ad-435c-424f-b960-2a04b8dfee71" xlink:href="meso-20231231.xsd#meso_DefinedContributionSuperannuationExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_5f618329-77b0-4a30-b8bc-f16ce7d1a093" xlink:to="loc_meso_DefinedContributionSuperannuationExpenses_32b162ad-435c-424f-b960-2a04b8dfee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_dcaa7b0c-86cc-453a-b02e-435eca82bf09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_5f618329-77b0-4a30-b8bc-f16ce7d1a093" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_dcaa7b0c-86cc-453a-b02e-435eca82bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_92e4d2a3-adf1-44f8-9258-2284914ea132" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract_5f618329-77b0-4a30-b8bc-f16ce7d1a093" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_92e4d2a3-adf1-44f8-9258-2284914ea132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_34514675-8cef-4e8c-b084-a14543606d2d" xlink:href="meso-20231231.xsd#meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_34514675-8cef-4e8c-b084-a14543606d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_721c49ba-3bd5-499e-a754-3b3c328e4f44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_34514675-8cef-4e8c-b084-a14543606d2d" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_721c49ba-3bd5-499e-a754-3b3c328e4f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_e19bce09-7ce2-40e0-a5ed-84f8e1b50660" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_34514675-8cef-4e8c-b084-a14543606d2d" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_e19bce09-7ce2-40e0-a5ed-84f8e1b50660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntellectualPropertyAmortization_4cccd519-9cc1-4289-b096-01caf8a4177c" xlink:href="meso-20231231.xsd#meso_IntellectualPropertyAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_34514675-8cef-4e8c-b084-a14543606d2d" xlink:to="loc_meso_IntellectualPropertyAmortization_4cccd519-9cc1-4289-b096-01caf8a4177c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_509b6a2f-8c41-49a5-99b2-b4786e8fbd7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract_34514675-8cef-4e8c-b084-a14543606d2d" xlink:to="loc_ifrs-full_AmortisationExpense_509b6a2f-8c41-49a5-99b2-b4786e8fbd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:href="meso-20231231.xsd#meso_OtherManagementAndAdministrationExpensesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OverheadsAndAdministrationExpenses_a49f0a79-d178-42c5-bbff-f952ea660b4a" xlink:href="meso-20231231.xsd#meso_OverheadsAndAdministrationExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:to="loc_meso_OverheadsAndAdministrationExpenses_a49f0a79-d178-42c5-bbff-f952ea660b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConsultancyExpenses_a732e170-c260-4e1c-9789-67385747c9a8" xlink:href="meso-20231231.xsd#meso_ConsultancyExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:to="loc_meso_ConsultancyExpenses_a732e170-c260-4e1c-9789-67385747c9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LegalAndOtherProfessionalFees_9176c22d-eeaa-4da9-a8a6-8689622d4fe5" xlink:href="meso-20231231.xsd#meso_LegalAndOtherProfessionalFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:to="loc_meso_LegalAndOtherProfessionalFees_9176c22d-eeaa-4da9-a8a6-8689622d4fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntellectualPropertyExpenses_b2b4c9ad-9aa6-43ac-a5c1-c796bea15998" xlink:href="meso-20231231.xsd#meso_IntellectualPropertyExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:to="loc_meso_IntellectualPropertyExpenses_b2b4c9ad-9aa6-43ac-a5c1-c796bea15998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherManagementAndAdministrationExpenses_249e5874-69dd-4094-8924-9e319afc15cc" xlink:href="meso-20231231.xsd#meso_OtherManagementAndAdministrationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherManagementAndAdministrationExpensesAbstract_2f90ea0b-45c5-4a2c-ae43-d2afc627cf07" xlink:to="loc_meso_OtherManagementAndAdministrationExpenses_249e5874-69dd-4094-8924-9e319afc15cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsiderationAbstract_21be6fed-c629-4f32-af12-d628fa11eb49" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsiderationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsiderationAbstract_21be6fed-c629-4f32-af12-d628fa11eb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfContingentConsideration_cb08bb06-4bb2-40d3-bec7-ccb54ee6aefb" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfContingentConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FairValueRemeasurementOfContingentConsiderationAbstract_21be6fed-c629-4f32-af12-d628fa11eb49" xlink:to="loc_meso_LossGainOnRemeasurementOfContingentConsideration_cb08bb06-4bb2-40d3-bec7-ccb54ee6aefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsideration_9820db4a-2f8f-4b83-b8a2-3567a4aff29a" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FairValueRemeasurementOfContingentConsiderationAbstract_21be6fed-c629-4f32-af12-d628fa11eb49" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsideration_9820db4a-2f8f-4b83-b8a2-3567a4aff29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_e5806a6b-c7c9-4478-82a8-d1d03a588916" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiabilityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_e5806a6b-c7c9-4478-82a8-d1d03a588916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfWarrantLiability_fad1e1b9-6e41-4774-a515-091c6f2ecb2d" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfWarrantLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_e5806a6b-c7c9-4478-82a8-d1d03a588916" xlink:to="loc_meso_LossGainOnRemeasurementOfWarrantLiability_fad1e1b9-6e41-4774-a515-091c6f2ecb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfWarrantLiability_2bc8a138-8d26-41f4-8c40-bd881d6f2479" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfWarrantLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FairValueRemeasurementOfWarrantLiabilityAbstract_e5806a6b-c7c9-4478-82a8-d1d03a588916" xlink:to="loc_meso_FairValueRemeasurementOfWarrantLiability_2bc8a138-8d26-41f4-8c40-bd881d6f2479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherOperatingIncomeAndExpensesAbstract_45686fa4-4287-4cb8-b13d-d15b64c7c096" xlink:href="meso-20231231.xsd#meso_OtherOperatingIncomeAndExpensesAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_OtherOperatingIncomeAndExpensesAbstract_45686fa4-4287-4cb8-b13d-d15b64c7c096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_9adbbf05-f62a-4e51-9366-4df25a71dbe3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherOperatingIncomeAndExpensesAbstract_45686fa4-4287-4cb8-b13d-d15b64c7c096" xlink:to="loc_ifrs-full_RevenueFromInterest_9adbbf05-f62a-4e51-9366-4df25a71dbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ForeignExchangeGainsLosses_c284558f-c742-4907-9f8a-c2c0e9b29106" xlink:href="meso-20231231.xsd#meso_ForeignExchangeGainsLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherOperatingIncomeAndExpensesAbstract_45686fa4-4287-4cb8-b13d-d15b64c7c096" xlink:to="loc_meso_ForeignExchangeGainsLosses_c284558f-c742-4907-9f8a-c2c0e9b29106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherOperatingIncomeExpense_afd12baf-7da9-4500-9d85-780a081687bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_OtherOperatingIncomeAndExpensesAbstract_45686fa4-4287-4cb8-b13d-d15b64c7c096" xlink:to="loc_ifrs-full_OtherOperatingIncomeExpense_afd12baf-7da9-4500-9d85-780a081687bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsAbstract_36480ba4-fb22-4270-9b0e-adc863f8cded" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_meso_FinanceCostsGainsAbstract_36480ba4-fb22-4270-9b0e-adc863f8cded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_b9f6213b-0aea-47f4-bc11-c70e665e0826" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FinanceCostsGainsAbstract_36480ba4-fb22-4270-9b0e-adc863f8cded" xlink:to="loc_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements_b9f6213b-0aea-47f4-bc11-c70e665e0826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpense_4c95bf06-595a-4462-95ed-57372ba442f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FinanceCostsGainsAbstract_36480ba4-fb22-4270-9b0e-adc863f8cded" xlink:to="loc_ifrs-full_InterestExpense_4c95bf06-595a-4462-95ed-57372ba442f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_3c42ca85-60f7-4ba2-b7b6-9551bc14c856" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_FinanceCostsGainsAbstract_36480ba4-fb22-4270-9b0e-adc863f8cded" xlink:to="loc_ifrs-full_FinanceCosts_3c42ca85-60f7-4ba2-b7b6-9551bc14c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_e59c0ae6-28e5-4f72-96d6-204a54bb07c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_090f1fe5-6041-4383-acbe-6613986a5241" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_e59c0ae6-28e5-4f72-96d6-204a54bb07c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_5f430ac2-19d5-449d-bff4-0387e0a08d32" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_5f430ac2-19d5-449d-bff4-0387e0a08d32" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:to="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementLocationMember_d29fdd81-4f15-4515-a237-143f2cd354da" xlink:href="meso-20231231.xsd#meso_IncomeStatementLocationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_IncomeStatementLocationsAxis_addc27a5-326f-4dd1-9217-807f3c0ec67d" xlink:to="loc_meso_IncomeStatementLocationMember_d29fdd81-4f15-4515-a237-143f2cd354da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncomeStatementFunctionalExpenseCategoriesMember_c63fef9a-7cb8-40e9-a3f2-083c227f6b2e" xlink:href="meso-20231231.xsd#meso_IncomeStatementFunctionalExpenseCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_IncomeStatementLocationMember_d29fdd81-4f15-4515-a237-143f2cd354da" xlink:to="loc_meso_IncomeStatementFunctionalExpenseCategoriesMember_c63fef9a-7cb8-40e9-a3f2-083c227f6b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f5681258-bdd6-4461-980a-bad580b2251f" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ResearchAndDevelopmentMember_bfb228a3-a9fc-4925-8a40-3ba380f4b1b8" xlink:href="meso-20231231.xsd#meso_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:to="loc_meso_ResearchAndDevelopmentMember_bfb228a3-a9fc-4925-8a40-3ba380f4b1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingAndCommercializationMember_1d78e193-e9d9-44ac-b831-8c4937018135" xlink:href="meso-20231231.xsd#meso_ManufacturingAndCommercializationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:to="loc_meso_ManufacturingAndCommercializationMember_1d78e193-e9d9-44ac-b831-8c4937018135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManagementAndAdministrationMember_9980bd14-8696-4b39-91b2-cc9550dc62d2" xlink:href="meso-20231231.xsd#meso_ManagementAndAdministrationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d7317d90-3c8b-4d17-9dea-92b5456d3798" xlink:to="loc_meso_ManagementAndAdministrationMember_9980bd14-8696-4b39-91b2-cc9550dc62d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem_f8d8f4af-244a-4f34-8688-17d50c18fa42" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxLineItem"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_0925a464-6c0c-4880-a9e9-c55b27de06f0" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem_f8d8f4af-244a-4f34-8688-17d50c18fa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_62e736c6-ce8f-45ca-b96b-0315472026c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItem_f8d8f4af-244a-4f34-8688-17d50c18fa42" xlink:to="loc_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions_62e736c6-ce8f-45ca-b96b-0315472026c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossbeforeincometaxAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_947450cd-00c6-4fc3-8a3f-c7a9d54ca972" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxAbstract_947450cd-00c6-4fc3-8a3f-c7a9d54ca972" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_4f912fbd-dce6-4198-9955-dc2b9f612a63" xlink:to="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GrunenthalGmbHMember_9ce5b7b5-183b-48a7-9507-b338e0086f1b" xlink:href="meso-20231231.xsd#meso_GrunenthalGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_GrunenthalGmbHMember_9ce5b7b5-183b-48a7-9507-b338e0086f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaslyMember_125bc0e4-d6a3-4758-9b46-0770bcf5e310" xlink:href="meso-20231231.xsd#meso_TaslyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_TaslyMember_125bc0e4-d6a3-4758-9b46-0770bcf5e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TiGenixNVMember_d91afdc5-2b57-40b3-8a90-181f75fb68f1" xlink:href="meso-20231231.xsd#meso_TiGenixNVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_TiGenixNVMember_d91afdc5-2b57-40b3-8a90-181f75fb68f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_JCRPharmaceuticalsCoLTDMember_1503e4b4-c51a-493f-bd3e-6b790e6c28e9" xlink:href="meso-20231231.xsd#meso_JCRPharmaceuticalsCoLTDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_5cbe9248-2fb6-4cbe-9f3e-1fe206f6063c" xlink:to="loc_meso_JCRPharmaceuticalsCoLTDMember_1503e4b4-c51a-493f-bd3e-6b790e6c28e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5adba0d5-6b42-4bc4-9864-7ca92a518e8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_36a0f35a-4ba5-4ae0-90c9-beddf07a4852" xlink:to="loc_ifrs-full_RangesMember_5adba0d5-6b42-4bc4-9864-7ca92a518e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_fcd782e5-bb64-4335-8bc2-b9d62e1f1c75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_5adba0d5-6b42-4bc4-9864-7ca92a518e8c" xlink:to="loc_ifrs-full_TopOfRangeMember_fcd782e5-bb64-4335-8bc2-b9d62e1f1c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RegulatoryEnvironmentsMember_d3cf1a38-ec91-4ed2-9fc8-2fb22e5104e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RegulatoryEnvironmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsAxis_40bfc317-a425-4548-b80e-debef8792fd4" xlink:to="loc_ifrs-full_RegulatoryEnvironmentsMember_d3cf1a38-ec91-4ed2-9fc8-2fb22e5104e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_765d005c-9fbb-4ca3-81f1-b0e98a05d692" xlink:href="meso-20231231.xsd#meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RegulatoryEnvironmentsMember_d3cf1a38-ec91-4ed2-9fc8-2fb22e5104e8" xlink:to="loc_meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember_765d005c-9fbb-4ca3-81f1-b0e98a05d692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_b629f12a-b3eb-4421-95c6-bb62a73671b7" xlink:to="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingCommercializationExpensesMember_4851fef9-2cc2-4490-ba6b-76a0b133c805" xlink:href="meso-20231231.xsd#meso_ManufacturingCommercializationExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:to="loc_meso_ManufacturingCommercializationExpensesMember_4851fef9-2cc2-4490-ba6b-76a0b133c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_License1Member_95b853d4-d6ad-430b-86b1-500458f8576b" xlink:href="meso-20231231.xsd#meso_License1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_21cbcaac-67d4-4f9e-8cbd-480edb1ec5ae" xlink:to="loc_meso_License1Member_95b853d4-d6ad-430b-86b1-500458f8576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:href="meso-20231231.xsd#meso_DisclosureOfLossBeforeIncomeTaxLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxTable_12c267db-fbe0-4be3-8638-5b73ab44fa8e" xlink:to="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonRefundableUpFrontPaymentReceived_3b61cc22-d751-46ac-8d4a-edf14ad7e379" xlink:href="meso-20231231.xsd#meso_NonRefundableUpFrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_NonRefundableUpFrontPaymentReceived_3b61cc22-d751-46ac-8d4a-edf14ad7e379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MilestonePaymentReceived_cd1a6228-54ad-4992-88e9-f449275b1c7d" xlink:href="meso-20231231.xsd#meso_MilestonePaymentReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_MilestonePaymentReceived_cd1a6228-54ad-4992-88e9-f449275b1c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_c1861b26-f045-4306-a7b6-f40a80ae1924" xlink:href="meso-20231231.xsd#meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines_c1861b26-f045-4306-a7b6-f40a80ae1924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_d7f64243-4e36-4d7c-8dc4-acc22011fb41" xlink:href="meso-20231231.xsd#meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved_d7f64243-4e36-4d7c-8dc4-acc22011fb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonRefundableUpfrontPaymentsReceivable_869b0caa-efa5-4a63-9f53-fa7e2128194c" xlink:href="meso-20231231.xsd#meso_NonRefundableUpfrontPaymentsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_NonRefundableUpfrontPaymentsReceivable_869b0caa-efa5-4a63-9f53-fa7e2128194c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CumulativeMilestonePaymentsReachableAmount_3331e9d0-897a-4e6f-8c25-e8e48722eda5" xlink:href="meso-20231231.xsd#meso_CumulativeMilestonePaymentsReachableAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_CumulativeMilestonePaymentsReachableAmount_3331e9d0-897a-4e6f-8c25-e8e48722eda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRecognizedForRightOfUseLicenseOfIP_8120ac3c-85bb-44e2-9b8d-4933646b48b7" xlink:href="meso-20231231.xsd#meso_RevenueRecognizedForRightOfUseLicenseOfIP"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RevenueRecognizedForRightOfUseLicenseOfIP_8120ac3c-85bb-44e2-9b8d-4933646b48b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredConsiderationMilestoneConsiderationRecognized_f5237afd-e8a8-4ef8-9456-c998a33b4b2b" xlink:href="meso-20231231.xsd#meso_DeferredConsiderationMilestoneConsiderationRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_DeferredConsiderationMilestoneConsiderationRecognized_f5237afd-e8a8-4ef8-9456-c998a33b4b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_f9a996c4-af51-483f-9943-477bb94bb973" xlink:href="meso-20231231.xsd#meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration_f9a996c4-af51-483f-9943-477bb94bb973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_5ecf22d5-a84a-4110-bf74-b33b153ed58a" xlink:href="meso-20231231.xsd#meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone_5ecf22d5-a84a-4110-bf74-b33b153ed58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfEscalatingMilestonePayments_fc5428af-4842-40c1-a874-86b847586b30" xlink:href="meso-20231231.xsd#meso_NumberOfEscalatingMilestonePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_NumberOfEscalatingMilestonePayments_fc5428af-4842-40c1-a874-86b847586b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_138d22bc-893d-4c10-9a5e-0f1413cb9ac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_CurrentContractLiabilities_138d22bc-893d-4c10-9a5e-0f1413cb9ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_d8fa1ff2-ed53-4d93-8376-9a4d629e0981" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_d8fa1ff2-ed53-4d93-8376-9a4d629e0981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_a5fc4304-5f9b-483b-a087-05978497ef60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_a5fc4304-5f9b-483b-a087-05978497ef60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f0590f98-f2ee-456e-bec9-89f08d345a7d" xlink:href="meso-20231231.xsd#meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f0590f98-f2ee-456e-bec9-89f08d345a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_38e83159-08b6-4b8a-93e2-08551ca62b21" xlink:href="meso-20231231.xsd#meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement_38e83159-08b6-4b8a-93e2-08551ca62b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_e1684ed5-7fac-4757-9ed3-e83299a19e92" xlink:href="meso-20231231.xsd#meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement_e1684ed5-7fac-4757-9ed3-e83299a19e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdditionalPotentialMilestonePaymentsReceivable_8eeb0f4a-e6f0-4418-aa68-d4da2cf3bfa2" xlink:href="meso-20231231.xsd#meso_AdditionalPotentialMilestonePaymentsReceivable"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AdditionalPotentialMilestonePaymentsReceivable_8eeb0f4a-e6f0-4418-aa68-d4da2cf3bfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_202a034c-5ede-4777-86b0-e2510ff2697d" xlink:href="meso-20231231.xsd#meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones_202a034c-5ede-4777-86b0-e2510ff2697d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromRoyalties_165b31a8-6aec-4a8f-bec4-ffa1190c705b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRoyalties"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_ifrs-full_RevenueFromRoyalties_165b31a8-6aec-4a8f-bec4-ffa1190c705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RoyaltiesReceivableUnderSalesBasedMilestones_27d41240-1a85-48c2-bd29-582ecc3b3f80" xlink:href="meso-20231231.xsd#meso_RoyaltiesReceivableUnderSalesBasedMilestones"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_RoyaltiesReceivableUnderSalesBasedMilestones_27d41240-1a85-48c2-bd29-582ecc3b3f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PreLaunchInventoryRecognized_5d928f11-bb8c-4d92-af8c-af9f2951a7e6" xlink:href="meso-20231231.xsd#meso_PreLaunchInventoryRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfLossBeforeIncomeTaxLineItems_060c9b80-e8ba-4935-ae45-13a28cd625f6" xlink:to="loc_meso_PreLaunchInventoryRecognized_5d928f11-bb8c-4d92-af8c-af9f2951a7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_4b9822ac-25a7-47c2-afad-cd1f95f94cd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_7612fbd2-6e0c-4e3b-ad8a-73edce2daa13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_4b9822ac-25a7-47c2-afad-cd1f95f94cd4" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_7612fbd2-6e0c-4e3b-ad8a-73edce2daa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentTaxAbstract_38c46a27-a1b1-4982-a3b0-469c5328ffba" xlink:href="meso-20231231.xsd#meso_CurrentTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_7612fbd2-6e0c-4e3b-ad8a-73edce2daa13" xlink:to="loc_meso_CurrentTaxAbstract_38c46a27-a1b1-4982-a3b0-469c5328ffba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInCurrentTax_1e21055b-c3c0-4a22-9771-abe062923776" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInCurrentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_CurrentTaxAbstract_38c46a27-a1b1-4982-a3b0-469c5328ffba" xlink:to="loc_meso_IncreaseDecreaseInCurrentTax_1e21055b-c3c0-4a22-9771-abe062923776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_4e9af944-592c-4e49-bfcf-9a5dcd919b61" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_CurrentTaxAbstract_38c46a27-a1b1-4982-a3b0-469c5328ffba" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_4e9af944-592c-4e49-bfcf-9a5dcd919b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_6f2ddc7b-0c53-416d-92f9-687ecfe7daf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_7612fbd2-6e0c-4e3b-ad8a-73edce2daa13" xlink:to="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_6f2ddc7b-0c53-416d-92f9-687ecfe7daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInDeferredTaxAssets_77c8f1ce-449c-475b-97ec-b7c4d670ef62" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInDeferredTaxAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_6f2ddc7b-0c53-416d-92f9-687ecfe7daf4" xlink:to="loc_meso_IncreaseDecreaseInDeferredTaxAssets_77c8f1ce-449c-475b-97ec-b7c4d670ef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInDeferredTaxLiabilities_92ee1095-4351-4a06-9080-7762db5dc1d8" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInDeferredTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_6f2ddc7b-0c53-416d-92f9-687ecfe7daf4" xlink:to="loc_meso_IncreaseDecreaseInDeferredTaxLiabilities_92ee1095-4351-4a06-9080-7762db5dc1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_d70de47f-1add-472c-a715-bff8bbd06ba8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract_6f2ddc7b-0c53-416d-92f9-687ecfe7daf4" xlink:to="loc_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_d70de47f-1add-472c-a715-bff8bbd06ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_dc557d8d-c632-49a7-919f-069b7bff9472" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DeferredTaxExpenseIncomeAbstract_7612fbd2-6e0c-4e3b-ad8a-73edce2daa13" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_dc557d8d-c632-49a7-919f-069b7bff9472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_231d0360-476c-4d0f-81f8-2589cffabc93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_2684b6f3-d5ac-45c4-9abb-ee7d685c79a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_231d0360-476c-4d0f-81f8-2589cffabc93" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_2684b6f3-d5ac-45c4-9abb-ee7d685c79a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract_8784721c-16b9-48ed-aac9-82cb972817cb" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_2684b6f3-d5ac-45c4-9abb-ee7d685c79a3" xlink:to="loc_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract_8784721c-16b9-48ed-aac9-82cb972817cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_20c7b270-92db-48f3-b3bd-7dd908036113" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract_8784721c-16b9-48ed-aac9-82cb972817cb" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_20c7b270-92db-48f3-b3bd-7dd908036113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract_9a74d19a-b49e-4616-8dc5-c1217f5f48cb" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_2684b6f3-d5ac-45c4-9abb-ee7d685c79a3" xlink:to="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract_9a74d19a-b49e-4616-8dc5-c1217f5f48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_e40adf7a-f1cf-4a8b-a5bb-8ad423e61ece" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract_9a74d19a-b49e-4616-8dc5-c1217f5f48cb" xlink:to="loc_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures_e40adf7a-f1cf-4a8b-a5bb-8ad423e61ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract_400aff93-cea3-424e-ae3d-0037981b4ab1" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_2684b6f3-d5ac-45c4-9abb-ee7d685c79a3" xlink:to="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract_400aff93-cea3-424e-ae3d-0037981b4ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_adc45f58-6f48-4f08-93ed-ea09fba87e22" xlink:href="meso-20231231.xsd#meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract_400aff93-cea3-424e-ae3d-0037981b4ab1" xlink:to="loc_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised_adc45f58-6f48-4f08-93ed-ea09fba87e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsNotBroughtToAccount_254f8155-0a1b-492b-a6f7-5d4ecf8a85fd" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsNotBroughtToAccount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract_2684b6f3-d5ac-45c4-9abb-ee7d685c79a3" xlink:to="loc_meso_DeferredTaxAssetsNotBroughtToAccount_254f8155-0a1b-492b-a6f7-5d4ecf8a85fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_fbacbdaa-1c9b-447f-80dc-439f2843c124" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_fbacbdaa-1c9b-447f-80dc-439f2843c124" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsCategoryMember_1b8cb5d1-b422-49c0-8c71-11136ba150d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_c7a97f50-2aed-4de7-89a5-34cb4feb8d48" xlink:to="loc_ifrs-full_FinancialAssetsCategoryMember_1b8cb5d1-b422-49c0-8c71-11136ba150d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_3c4196d9-4036-4c66-adfa-85d34ea363d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsCategoryMember_1b8cb5d1-b422-49c0-8c71-11136ba150d2" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_3c4196d9-4036-4c66-adfa-85d34ea363d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_9176772d-19ab-4557-a6e6-75e785275642" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_bedb3380-a730-424d-941f-878def10fcd9" xlink:to="loc_ifrs-full_FinancialAssetsMember_9176772d-19ab-4557-a6e6-75e785275642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_a3334e0f-15f4-4233-889c-135a1e227f10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_9176772d-19ab-4557-a6e6-75e785275642" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostMember_a3334e0f-15f4-4233-889c-135a1e227f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesCategoryMember_fcc454fe-6593-4387-955b-900daf925870" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_8c8a22ed-c266-40fb-9f5c-67e9bc58b4f7" xlink:to="loc_ifrs-full_FinancialLiabilitiesCategoryMember_fcc454fe-6593-4387-955b-900daf925870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_c92d99da-057d-430a-81de-38aa4ddf42cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesCategoryMember_fcc454fe-6593-4387-955b-900daf925870" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_c92d99da-057d-430a-81de-38aa4ddf42cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_4b9e5166-15c0-45d8-a934-c588c7f9cc40" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_10942b81-38ec-4d19-932b-b68c1770ba0e" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_4b9e5166-15c0-45d8-a934-c588c7f9cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_7cac8061-aae7-4747-aad7-1132bfc08c45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_4b9e5166-15c0-45d8-a934-c588c7f9cc40" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_7cac8061-aae7-4747-aad7-1132bfc08c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_da018c1b-1a2f-4d81-995a-3236aea625f8" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_98bb122e-4e82-4dd2-a32c-f42ad6bd49b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_CashAndCashEquivalents_98bb122e-4e82-4dd2-a32c-f42ad6bd49b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherReceivables_da3cfc6b-301d-487b-9f3f-8f02357e41c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_TradeAndOtherReceivables_da3cfc6b-301d-487b-9f3f-8f02357e41c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_87897344-5217-45e2-af3d-6026a53f21aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome_87897344-5217-45e2-af3d-6026a53f21aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentFinancialAssets_577da13d-83e6-4070-a160-bddcf8749e53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_OtherNoncurrentFinancialAssets_577da13d-83e6-4070-a160-bddcf8749e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_35c2a666-207b-4b8b-8669-537ac35bf342" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_FinancialAssets_35c2a666-207b-4b8b-8669-537ac35bf342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_a1dd5a00-34ee-4a12-9720-60c52140d03c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_a1dd5a00-34ee-4a12-9720-60c52140d03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_793f959a-6ea3-4814-9932-26f39f1a17f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_Borrowings_793f959a-6ea3-4814-9932-26f39f1a17f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_10bdc3f0-dca9-4cd5-96d3-a4962fbef0e4" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_meso_ContingentConsiderations_10bdc3f0-dca9-4cd5-96d3-a4962fbef0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_1b938f2f-b1e9-48ab-ad53-44af7653d93c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_WarrantLiability_1b938f2f-b1e9-48ab-ad53-44af7653d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_5c9efbae-e8fc-4ff3-8221-1b8d1d3c56c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_e5cadec9-4e26-4ce4-b001-b10ea6d007c2" xlink:to="loc_ifrs-full_FinancialLiabilities_5c9efbae-e8fc-4ff3-8221-1b8d1d3c56c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_5569da7d-755a-4999-b86e-ed0dce75851d" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BalancesWithBanks_6ce31ba6-50bd-446c-8539-404e564b3e97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_5569da7d-755a-4999-b86e-ed0dce75851d" xlink:to="loc_ifrs-full_BalancesWithBanks_6ce31ba6-50bd-446c-8539-404e564b3e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DepositsAtCall_f766c64a-481b-4d7b-8f62-3bb42b470a15" xlink:href="meso-20231231.xsd#meso_DepositsAtCall"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_5569da7d-755a-4999-b86e-ed0dce75851d" xlink:to="loc_meso_DepositsAtCall_f766c64a-481b-4d7b-8f62-3bb42b470a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_f156897d-66e6-4225-b167-b9b9c7032f7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_5569da7d-755a-4999-b86e-ed0dce75851d" xlink:to="loc_ifrs-full_CashAndCashEquivalents_f156897d-66e6-4225-b167-b9b9c7032f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_ea3a6c1c-53f1-4a7d-9c85-8edb1b65202e" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_InterestBearingDepositsAtCallHeldAsSecurity_165dedda-6feb-4834-aea1-dafde2de20b7" xlink:href="meso-20231231.xsd#meso_InterestBearingDepositsAtCallHeldAsSecurity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_ea3a6c1c-53f1-4a7d-9c85-8edb1b65202e" xlink:to="loc_meso_InterestBearingDepositsAtCallHeldAsSecurity_165dedda-6feb-4834-aea1-dafde2de20b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivables_b4ba9ea0-321b-4a9c-a09c-e2cc4035c3fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_ifrs-full_TradeReceivables_b4ba9ea0-321b-4a9c-a09c-e2cc4035c3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_ecdca1d7-c2fd-4115-bc5c-2627a4c5419f" xlink:href="meso-20231231.xsd#meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable_ecdca1d7-c2fd-4115-bc5c-2627a4c5419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ForeignWithholdingTaxRecoverable_822eae9e-ab37-4a68-9d4e-da4a784b1018" xlink:href="meso-20231231.xsd#meso_ForeignWithholdingTaxRecoverable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_meso_ForeignWithholdingTaxRecoverable_822eae9e-ab37-4a68-9d4e-da4a784b1018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ReceivableFromTaxCredits_38b122a6-7440-4de2-a1f6-3dbde395a025" xlink:href="meso-20231231.xsd#meso_ReceivableFromTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_meso_ReceivableFromTaxCredits_38b122a6-7440-4de2-a1f6-3dbde395a025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetInvestmentInFinanceLease_90fba07b-6520-48d4-b098-409bedcc9628" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetInvestmentInFinanceLease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_ifrs-full_NetInvestmentInFinanceLease_90fba07b-6520-48d4-b098-409bedcc9628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInterestReceivable_ac9dd9b0-c3d8-4063-be7d-cd58291db98d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_ifrs-full_CurrentInterestReceivable_ac9dd9b0-c3d8-4063-be7d-cd58291db98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_1439fc71-27c6-4ef6-9efe-a7c7288856d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_1439fc71-27c6-4ef6-9efe-a7c7288856d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_fb749486-7764-44d3-a4f9-2064d13a931f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_b4a73278-e434-4d64-a728-1a43c06f4ccd" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_fb749486-7764-44d3-a4f9-2064d13a931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofPrepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4439ac67-70f6-40fb-b093-cdffa271a09f" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ClinicalTrialResearchAndDevelopmentExpenditure_c9ba3343-8e87-4c0b-847b-045e155fe92b" xlink:href="meso-20231231.xsd#meso_ClinicalTrialResearchAndDevelopmentExpenditure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4439ac67-70f6-40fb-b093-cdffa271a09f" xlink:to="loc_meso_ClinicalTrialResearchAndDevelopmentExpenditure_c9ba3343-8e87-4c0b-847b-045e155fe92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrepaidInsuranceAndSubscriptions_4bca9c42-a0dc-4c29-a6fd-cc4cf52cd6db" xlink:href="meso-20231231.xsd#meso_PrepaidInsuranceAndSubscriptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4439ac67-70f6-40fb-b093-cdffa271a09f" xlink:to="loc_meso_PrepaidInsuranceAndSubscriptions_4bca9c42-a0dc-4c29-a6fd-cc4cf52cd6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherPrepayments_533593fc-48bb-4c7a-8e4d-9d9d4894ce4f" xlink:href="meso-20231231.xsd#meso_OtherPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4439ac67-70f6-40fb-b093-cdffa271a09f" xlink:to="loc_meso_OtherPrepayments_533593fc-48bb-4c7a-8e4d-9d9d4894ce4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_b55aa973-de67-405e-851a-20f4dc2a104b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4439ac67-70f6-40fb-b093-cdffa271a09f" xlink:to="loc_ifrs-full_Prepayments_b55aa973-de67-405e-851a-20f4dc2a104b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_c394759f-795c-44f7-adcb-894b4084e5e2" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_c394759f-795c-44f7-adcb-894b4084e5e2" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_9a14cc1a-778a-445d-947b-e7e393366b13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_ad4bd092-4fd5-4654-85ae-a44ca849cad3" xlink:to="loc_ifrs-full_RangesMember_9a14cc1a-778a-445d-947b-e7e393366b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_444a5724-0c77-499e-b9b6-ef5827d03409" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_9a14cc1a-778a-445d-947b-e7e393366b13" xlink:to="loc_ifrs-full_TopOfRangeMember_444a5724-0c77-499e-b9b6-ef5827d03409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_ea0f75a2-2a7f-4472-a0e2-e3ecafedf5a7" xlink:to="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementLPMember_630c711f-9888-43f3-94ed-6868935e1542" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:to="loc_meso_OaktreeCapitalManagementLPMember_630c711f-9888-43f3-94ed-6868935e1542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NovaQuestCapitalManagementLLCMember_476ab5ab-8409-4638-8024-3ced25163059" xlink:href="meso-20231231.xsd#meso_NovaQuestCapitalManagementLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:to="loc_meso_NovaQuestCapitalManagementLLCMember_476ab5ab-8409-4638-8024-3ced25163059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementMember_13034a70-4633-4cde-883c-c7fac74a4b65" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_30c10a06-a710-4145-9fd5-717ca9d8078d" xlink:to="loc_meso_OaktreeCapitalManagementMember_13034a70-4633-4cde-883c-c7fac74a4b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MethodsOfGenerationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MethodsOfGenerationAxis_9dee73c0-869d-468d-a646-4cb428ca2ec5" xlink:to="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TrancheOneMember_81b37fbd-686a-49c1-a116-4f12f1856795" xlink:href="meso-20231231.xsd#meso_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:to="loc_meso_TrancheOneMember_81b37fbd-686a-49c1-a116-4f12f1856795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_QuarterlyPaymentsMember_b79c1790-7408-461a-a72d-fcf99c73ce78" xlink:href="meso-20231231.xsd#meso_QuarterlyPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:to="loc_meso_QuarterlyPaymentsMember_b79c1790-7408-461a-a72d-fcf99c73ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TrancheTwoMember_8461b123-8392-4151-97c0-b28c615aba1f" xlink:href="meso-20231231.xsd#meso_TrancheTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MethodsOfGenerationMember_82cf2132-8bba-4272-961d-3613f99255dd" xlink:to="loc_meso_TrancheTwoMember_8461b123-8392-4151-97c0-b28c615aba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_d18b0450-d3a4-4024-8449-ea17c2e8a390" xlink:to="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_4b4c6da1-6cfe-403b-97b7-e62699779924" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_ifrs-full_WarrantsMember_4b4c6da1-6cfe-403b-97b7-e62699779924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvisionMember_18db1dcb-8639-4a95-b4d6-dcc521b5608d" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvisionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_meso_ContingentConsiderationProvisionMember_18db1dcb-8639-4a95-b4d6-dcc521b5608d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_November2021WarrantsMember_c149e25e-0681-45db-b487-53db946fc994" xlink:href="meso-20231231.xsd#meso_November2021WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_meso_November2021WarrantsMember_c149e25e-0681-45db-b487-53db946fc994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_December2022WarrantsMember_5a166d92-2a6a-4b57-9a6c-bf5d90908b19" xlink:href="meso-20231231.xsd#meso_December2022WarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialLiabilitiesMember_fe366236-cf2d-473a-afce-c8be2d655f86" xlink:to="loc_meso_December2022WarrantsMember_5a166d92-2a6a-4b57-9a6c-bf5d90908b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8db262a0-e7bc-46b1-87b2-9ef86ddb9ed5" xlink:to="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmericanDepositarySharesMember_9322e38d-2bb9-43ea-b493-ec06d1d49051" xlink:href="meso-20231231.xsd#meso_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:to="loc_meso_AmericanDepositarySharesMember_9322e38d-2bb9-43ea-b493-ec06d1d49051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AmericanDepositoryReceiptMember_d74b9f21-492b-4105-af92-9b863b033bb4" xlink:href="meso-20231231.xsd#meso_AmericanDepositoryReceiptMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_2772f8ec-b3c6-4bb9-b998-7881f2127061" xlink:to="loc_meso_AmericanDepositoryReceiptMember_d74b9f21-492b-4105-af92-9b863b033bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_80c0b3ae-cd1f-4899-aab6-3137b765b527" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_097b78dc-908e-4ee1-81c2-936dcdcf9507" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_80c0b3ae-cd1f-4899-aab6-3137b765b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_15145cdb-bba0-4c18-9394-6f6d688194f0" xlink:href="meso-20231231.xsd#meso_RefinancingAndExpansionOfSeniorDebtFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_80c0b3ae-cd1f-4899-aab6-3137b765b527" xlink:to="loc_meso_RefinancingAndExpansionOfSeniorDebtFacilityMember_15145cdb-bba0-4c18-9394-6f6d688194f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0cd87f22-2c42-4124-b497-7b27126acbe4" xlink:to="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3abcc8cb-cf27-45dc-9e50-b8d526fb2291" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:to="loc_srt_MaximumMember_3abcc8cb-cf27-45dc-9e50-b8d526fb2291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5eafbc1-3d7d-4e06-ad06-4c875ea50bfd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae903436-0a1e-4a17-b6cb-6ec3e01081bb" xlink:to="loc_srt_MinimumMember_e5eafbc1-3d7d-4e06-ad06-4c875ea50bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_122f29d0-f5fe-45b2-beaf-03895735d751" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_a897ad4f-8a0e-489a-9a79-f2ef18d1e5da" xlink:to="loc_ifrs-full_InterestRateTypesMember_122f29d0-f5fe-45b2-beaf-03895735d751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_bdd67d8a-c8fb-42d6-9d6e-e14bede25558" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_122f29d0-f5fe-45b2-beaf-03895735d751" xlink:to="loc_ifrs-full_FixedInterestRateMember_bdd67d8a-c8fb-42d6-9d6e-e14bede25558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_aea2575d-19a1-42b1-9802-c021af9fbbe5" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_ca1cfbff-042f-4864-807f-5aa293e7b07d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_ca1cfbff-042f-4864-807f-5aa293e7b07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_27595878-314b-4b89-bbea-587ea4c160da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_27595878-314b-4b89-bbea-587ea4c160da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_7db7538a-775d-4435-ac0b-dddd2e1ec26d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_d1865be7-06b3-4501-954e-cd04e17965ef" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_7db7538a-775d-4435-ac0b-dddd2e1ec26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsMember_7de40fd8-20a3-4327-aeff-541a01f55a60" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_4c171e95-44ae-46cf-b72c-f2c450dd1b7b" xlink:to="loc_ifrs-full_FinancialAssetsMember_7de40fd8-20a3-4327-aeff-541a01f55a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UnlistedEquitySecuritiesMember_e619c480-f12e-4eb7-a386-e58f6c28104b" xlink:href="meso-20231231.xsd#meso_UnlistedEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsMember_7de40fd8-20a3-4327-aeff-541a01f55a60" xlink:to="loc_meso_UnlistedEquitySecuritiesMember_e619c480-f12e-4eb7-a386-e58f6c28104b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_aecc6102-5df6-43f4-9c86-70c546d80250" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_0aa81fed-04ae-4879-a677-b4cdb9a9aeee" xlink:to="loc_ifrs-full_NonadjustingEventsMember_aecc6102-5df6-43f4-9c86-70c546d80250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PotentialOrdinaryShareTransactionsMember_b63d4917-3dba-489a-baee-692c3af24bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PotentialOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_aecc6102-5df6-43f4-9c86-70c546d80250" xlink:to="loc_ifrs-full_PotentialOrdinaryShareTransactionsMember_b63d4917-3dba-489a-baee-692c3af24bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_1fd8f38c-162d-4573-b34e-bccf774a7354" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TradeReceivablesSettlementPeriod_0a4924ce-ef7b-4fca-b21d-ce67a61ac936" xlink:href="meso-20231231.xsd#meso_TradeReceivablesSettlementPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_TradeReceivablesSettlementPeriod_0a4924ce-ef7b-4fca-b21d-ce67a61ac936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsPrincipalAmount_6814e9c0-2929-4d68-a3f6-9be09b7245b2" xlink:href="meso-20231231.xsd#meso_BorrowingsPrincipalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsPrincipalAmount_6814e9c0-2929-4d68-a3f6-9be09b7245b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsTerm_d3b2dfc9-ea46-4aa2-9595-dc19bcad040b" xlink:href="meso-20231231.xsd#meso_BorrowingsTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsTerm_d3b2dfc9-ea46-4aa2-9595-dc19bcad040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_408167a4-6eac-43c5-98ed-bfd5d0d78976" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_Borrowings_408167a4-6eac-43c5-98ed-bfd5d0d78976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsInterestOnlyPeriod_be5f3172-3fcf-43c5-9468-bd79e81fae5c" xlink:href="meso-20231231.xsd#meso_BorrowingsInterestOnlyPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsInterestOnlyPeriod_be5f3172-3fcf-43c5-9468-bd79e81fae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_5a901763-646f-4d82-b8a7-16ef94797f85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_BorrowingsInterestRate_5a901763-646f-4d82-b8a7-16ef94797f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_1d14756f-0b88-4e06-aa98-4afa622db76c" xlink:href="meso-20231231.xsd#meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear_1d14756f-0b88-4e06-aa98-4afa622db76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_BorrowingsPrincipalAmortizationPeriod_d80b920b-85e3-4709-93b6-6821db75cfec" xlink:href="meso-20231231.xsd#meso_BorrowingsPrincipalAmortizationPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_BorrowingsPrincipalAmortizationPeriod_d80b920b-85e3-4709-93b6-6821db75cfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_UnpaidInterestPortionPerAnnum_8c5e69b5-76cc-4676-817f-1e614ca5362a" xlink:href="meso-20231231.xsd#meso_UnpaidInterestPortionPerAnnum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_UnpaidInterestPortionPerAnnum_8c5e69b5-76cc-4676-817f-1e614ca5362a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_4ab2c689-862f-4849-97ae-f949fdbff752" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_4ab2c689-862f-4849-97ae-f949fdbff752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_f59dd7b7-8d25-4f9a-b5f9-0ba016294f67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_ParValuePerShare_f59dd7b7-8d25-4f9a-b5f9-0ba016294f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_b3c6d430-9990-47fc-a7d0-3d142eafc3eb" xlink:href="meso-20231231.xsd#meso_PercentageOfPremiumForVolumeWeightedAveragePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfPremiumForVolumeWeightedAveragePrice_b3c6d430-9990-47fc-a7d0-3d142eafc3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IssuanceWarrantsExercisedPeriod_9887d3a6-ba90-46e7-ae62-1841b1b12bfa" xlink:href="meso-20231231.xsd#meso_IssuanceWarrantsExercisedPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_IssuanceWarrantsExercisedPeriod_9887d3a6-ba90-46e7-ae62-1841b1b12bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfSharePremiumPrice_5aabac30-124c-47eb-a761-8169d98391db" xlink:href="meso-20231231.xsd#meso_PercentageOfSharePremiumPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfSharePremiumPrice_5aabac30-124c-47eb-a761-8169d98391db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExerciseTerm_4ee6855c-ad23-4c80-9606-b2efb87facf2" xlink:href="meso-20231231.xsd#meso_WarrantExerciseTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_WarrantExerciseTerm_4ee6855c-ad23-4c80-9606-b2efb87facf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OutstandingCommonShareCapitalPercentage_394523f5-44a6-4fda-b865-adbab467a05e" xlink:href="meso-20231231.xsd#meso_OutstandingCommonShareCapitalPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_OutstandingCommonShareCapitalPercentage_394523f5-44a6-4fda-b865-adbab467a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExercisePriceShareWarrentsIssued_170e4180-d0a0-44bc-903b-46fb4c26f81f" xlink:href="meso-20231231.xsd#meso_ExercisePriceShareWarrentsIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_ExercisePriceShareWarrentsIssued_170e4180-d0a0-44bc-903b-46fb4c26f81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_101cf6d8-e2d2-4680-90e4-10dd80b38d73" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares_101cf6d8-e2d2-4680-90e4-10dd80b38d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_8554faa0-8243-4dc8-9013-69d413ac888c" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements_8554faa0-8243-4dc8-9013-69d413ac888c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_68defdcf-8a1d-4c89-bb9a-0e9327fce77c" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued_68defdcf-8a1d-4c89-bb9a-0e9327fce77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_ac5907b6-a7e8-483c-8f9a-d1dfc475ab7a" xlink:href="meso-20231231.xsd#meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability_ac5907b6-a7e8-483c-8f9a-d1dfc475ab7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_a276c641-e836-4d4c-9210-a1896a117d72" xlink:href="meso-20231231.xsd#meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold_a276c641-e836-4d4c-9210-a1896a117d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumUnrestrictedCashBalance_611cf4e7-61ee-4e40-81ff-812c756cf262" xlink:href="meso-20231231.xsd#meso_MinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_MinimumUnrestrictedCashBalance_611cf4e7-61ee-4e40-81ff-812c756cf262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssets_c1abfe0b-5947-4cce-8325-93c91b833158" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_FinancialAssets_c1abfe0b-5947-4cce-8325-93c91b833158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilities_1392c452-ae48-4f26-8b0a-5cd71fe64df0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_ifrs-full_FinancialLiabilities_1392c452-ae48-4f26-8b0a-5cd71fe64df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfAssetsMeasuredAtFairValue_22c84e30-9280-4f67-ba53-56251248ad7e" xlink:href="meso-20231231.xsd#meso_PercentageOfAssetsMeasuredAtFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfAssetsMeasuredAtFairValue_22c84e30-9280-4f67-ba53-56251248ad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfLiabilitiesMeasuredAtFairValue_0d087520-4f4d-4911-9e6f-f7bd8f5db9f6" xlink:href="meso-20231231.xsd#meso_PercentageOfLiabilitiesMeasuredAtFairValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_PercentageOfLiabilitiesMeasuredAtFairValue_0d087520-4f4d-4911-9e6f-f7bd8f5db9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtIssueDate_6b69dd74-d565-47d6-a9f7-7084cb4bb0d6" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtIssueDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_WarrantsFairValueAtIssueDate_6b69dd74-d565-47d6-a9f7-7084cb4bb0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GainLossOnRemeasurementOfWarrantLiability_7972fff6-1eeb-480c-add7-410c6608cb00" xlink:href="meso-20231231.xsd#meso_GainLossOnRemeasurementOfWarrantLiability"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_abd3fb53-9a66-4274-af6d-9c42c06cd5ef" xlink:to="loc_meso_GainLossOnRemeasurementOfWarrantLiability_7972fff6-1eeb-480c-add7-410c6608cb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_d28d4b26-a6ae-4808-bc8d-3bd5f7bb9224" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_a4de8746-732f-4a6a-96f2-746938daa39c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_d28d4b26-a6ae-4808-bc8d-3bd5f7bb9224" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_a4de8746-732f-4a6a-96f2-746938daa39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayables_747e2a4b-d8b9-4a90-88b5-bb998d153a12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_d28d4b26-a6ae-4808-bc8d-3bd5f7bb9224" xlink:to="loc_ifrs-full_TradeAndOtherPayables_747e2a4b-d8b9-4a90-88b5-bb998d153a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_da7e6392-96cb-4630-958a-487736bc6b79" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_da7e6392-96cb-4630-958a-487736bc6b79" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:to="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_db1b1a26-a51f-4b2a-bba7-b59a379c117b" xlink:to="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NovaQuestCapitalManagementLLCMember_d980d50b-9429-4c21-8c45-e1d633f37a2e" xlink:href="meso-20231231.xsd#meso_NovaQuestCapitalManagementLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:to="loc_meso_NovaQuestCapitalManagementLLCMember_d980d50b-9429-4c21-8c45-e1d633f37a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OaktreeCapitalManagementLPMember_14580bc0-d5e3-4bde-b337-1da771fbf1db" xlink:href="meso-20231231.xsd#meso_OaktreeCapitalManagementLPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_d4167613-2415-46f4-a13c-f0c11d8e70b4" xlink:to="loc_meso_OaktreeCapitalManagementLPMember_14580bc0-d5e3-4bde-b337-1da771fbf1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_3d2275b7-d060-4a63-93ab-08bbf939e171" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesTable_8ee554fe-5360-4607-a7c9-2249634311a3" xlink:to="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_3d2275b7-d060-4a63-93ab-08bbf939e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_3d2275b7-d060-4a63-93ab-08bbf939e171" xlink:to="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SecuredBankLoansReceived_2bcb5800-7a30-4f68-b7b5-7eeb88375b6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SecuredBankLoansReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_SecuredBankLoansReceived_2bcb5800-7a30-4f68-b7b5-7eeb88375b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_042e3403-6efc-442d-9f95-2a70547a7e95" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsRecognisedAsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_BorrowingCostsRecognisedAsExpense_042e3403-6efc-442d-9f95-2a70547a7e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingCostsCapitalised_9b988419-be85-477d-9aed-ac0f0f4d2890" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsCapitalised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_BorrowingCostsCapitalised_9b988419-be85-477d-9aed-ac0f0f4d2890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_3d347f9f-2f6a-4c3a-b5a1-ba4112605488" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_Borrowings_3d347f9f-2f6a-4c3a-b5a1-ba4112605488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:href="meso-20231231.xsd#meso_LongTermBorrowingsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermBorrowings_1495cb73-6611-4f95-8463-92187106d329" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:to="loc_ifrs-full_ShorttermBorrowings_1495cb73-6611-4f95-8463-92187106d329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_159277d9-4eb6-437d-a023-75a76612efe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_LongTermBorrowingsAbstract_dcb344ed-d14c-45e2-8586-182f1c479042" xlink:to="loc_ifrs-full_LongtermBorrowings_159277d9-4eb6-437d-a023-75a76612efe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_240317ee-5e6c-4b9f-b1f7-d27fe759cc54" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsAbstract_494843f3-c1ef-45be-9f8b-02fd9acf08f7" xlink:to="loc_ifrs-full_Borrowings_240317ee-5e6c-4b9f-b1f7-d27fe759cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofNetDebtDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_855d87f1-36a3-42b3-a657-37c1fb74378f" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_855d87f1-36a3-42b3-a657-37c1fb74378f" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_115aa49c-dc0c-4a43-95c4-c2f233b6ddf5" xlink:to="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FixedInterestRateMember_131d2bac-af11-4e58-8c7f-bab8490deed1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:to="loc_ifrs-full_FixedInterestRateMember_131d2bac-af11-4e58-8c7f-bab8490deed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FloatingInterestRateMember_f262091d-4f27-4e43-b8d4-f9ce7a5f75b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FloatingInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_bd25ca96-ccd6-4e0e-ae90-4117fc7b6fce" xlink:to="loc_ifrs-full_FloatingInterestRateMember_f262091d-4f27-4e43-b8d4-f9ce7a5f75b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable_488098e2-2d8d-43de-89ff-905461b7192a" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_9f60a7c9-a5fc-4dcc-a615-0ea7c03ad4be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_9f60a7c9-a5fc-4dcc-a615-0ea7c03ad4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_bfe4b4b7-2f31-4efd-9b28-796c56c924fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_Borrowings_bfe4b4b7-2f31-4efd-9b28-796c56c924fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_15516d5b-e357-45d6-9332-7e6eddf94d66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_LeaseLiabilities_15516d5b-e357-45d6-9332-7e6eddf94d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_5ccdee52-dec6-460a-aade-0a603fd98887" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_WarrantLiability_5ccdee52-dec6-460a-aade-0a603fd98887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt_1e636f70-27c7-49ac-af49-f9d7a5a0758d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems_36fecc62-9120-4781-8c10-72bb53d0eb2c" xlink:to="loc_ifrs-full_NetDebt_1e636f70-27c7-49ac-af49-f9d7a5a0758d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_1cb25e53-bbe7-40d8-923b-09ad9bbf5777" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_Borrowings_1cb25e53-bbe7-40d8-923b-09ad9bbf5777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_ce29ae32-aba8-4e7b-8f76-cb718cd356e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_LeaseLiabilities_ce29ae32-aba8-4e7b-8f76-cb718cd356e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_ee84ddae-d3d4-401c-a8f7-5b09de4a9702" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_WarrantLiability_ee84ddae-d3d4-401c-a8f7-5b09de4a9702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_4fcd4cd2-a82a-4387-b666-7625809dde42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_4fcd4cd2-a82a-4387-b666-7625809dde42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_65a6458c-d064-44c2-bd58-43bc36d07492" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_CashAndCashEquivalents_65a6458c-d064-44c2-bd58-43bc36d07492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt_ea6fae39-6d9c-4a8e-a2b6-9cd7e5ed6ec7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_NetDebt_ea6fae39-6d9c-4a8e-a2b6-9cd7e5ed6ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CashFlowsAdjustmentsOnDebt_33aed00a-9f73-4c3e-84e9-f3b86fe6bd6c" xlink:href="meso-20231231.xsd#meso_CashFlowsAdjustmentsOnDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_CashFlowsAdjustmentsOnDebt_33aed00a-9f73-4c3e-84e9-f3b86fe6bd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_404a85ff-fb4d-4d48-8db5-f722a0dfb220" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_404a85ff-fb4d-4d48-8db5-f722a0dfb220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities_22a96220-14f2-47be-8209-1c82e2340d08" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities_22a96220-14f2-47be-8209-1c82e2340d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_d4b9021d-d54e-434b-9e84-8e95fb4f579d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_d4b9021d-d54e-434b-9e84-8e95fb4f579d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_f3f8af15-8b53-4626-bb3b-d447ef47925e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_f3f8af15-8b53-4626-bb3b-d447ef47925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities_66cc9e93-7bfe-4b3c-9702-c67c051b84d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities_66cc9e93-7bfe-4b3c-9702-c67c051b84d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementAdjustmentsOnDebt_43f5abe6-c994-4e0b-be57-c8cad1c0d676" xlink:href="meso-20231231.xsd#meso_RemeasurementAdjustmentsOnDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_RemeasurementAdjustmentsOnDebt_43f5abe6-c994-4e0b-be57-c8cad1c0d676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementAdjustmentsOnWarrants_590a2d53-6fa1-4b1f-a0a7-036d74bebe9a" xlink:href="meso-20231231.xsd#meso_RemeasurementAdjustmentsOnWarrants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_RemeasurementAdjustmentsOnWarrants_590a2d53-6fa1-4b1f-a0a7-036d74bebe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementAdjustmentsOnDebtAndWarrants_07b3267b-fa8f-4223-8bf7-c7b74d6ac6e8" xlink:href="meso-20231231.xsd#meso_RemeasurementAdjustmentsOnDebtAndWarrants"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_RemeasurementAdjustmentsOnDebtAndWarrants_07b3267b-fa8f-4223-8bf7-c7b74d6ac6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities_e9ba8c33-d6c7-4b48-b2f0-96dd5f76e17f" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities_e9ba8c33-d6c7-4b48-b2f0-96dd5f76e17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities_6d697ffe-44c6-4df7-b9e8-3d5a4a911918" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities_6d697ffe-44c6-4df7-b9e8-3d5a4a911918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherChangesOnDebtAndLeases_672c5c91-10d5-4453-a16c-12549a2b47be" xlink:href="meso-20231231.xsd#meso_OtherChangesOnDebtAndLeases"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_OtherChangesOnDebtAndLeases_672c5c91-10d5-4453-a16c-12549a2b47be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases_39e58619-a79c-4ff0-95a3-10c469eed966" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases_39e58619-a79c-4ff0-95a3-10c469eed966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants_ab22e23d-5e69-4e54-9fc8-fe6e9375b90f" xlink:href="meso-20231231.xsd#meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants_ab22e23d-5e69-4e54-9fc8-fe6e9375b90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_e7301a81-3425-4558-bdee-5043363879bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_e7301a81-3425-4558-bdee-5043363879bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_6f51a33b-4398-4325-84da-1e03c3049f2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_6f51a33b-4398-4325-84da-1e03c3049f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents_f46537df-ef8b-4f71-aaf8-fab8a58b11dd" xlink:href="meso-20231231.xsd#meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents_f46537df-ef8b-4f71-aaf8-fab8a58b11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_692d44f8-936e-4d37-bdbb-09fca4524d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_Borrowings_692d44f8-936e-4d37-bdbb-09fca4524d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_54533866-1cc0-4a9f-9490-abfa03cd5ab6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_LeaseLiabilities_54533866-1cc0-4a9f-9490-abfa03cd5ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_6f4ef865-d19c-4528-9288-4fa729bfcb3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_WarrantLiability_6f4ef865-d19c-4528-9288-4fa729bfcb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1c1d3318-9d1c-4373-91fb-b66728ab88be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivities_1c1d3318-9d1c-4373-91fb-b66728ab88be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d45d0970-5eae-4212-97b9-e621e29b213a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d45d0970-5eae-4212-97b9-e621e29b213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDebt_3ad3e50a-673b-4a3c-8ec4-aa8b3608b1e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDebt"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_4621d7ee-8930-4c11-aff5-04261d84b083" xlink:to="loc_ifrs-full_NetDebt_3ad3e50a-673b-4a3c-8ec4-aa8b3608b1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_915f792c-64c5-4900-ab2f-ad7c7c485541" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_915f792c-64c5-4900-ab2f-ad7c7c485541" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_40e21f4e-1529-47e4-bcd4-ee0fb70f9551" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_278dcbb1-15ef-4254-bc4f-f95053add900" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_40e21f4e-1529-47e4-bcd4-ee0fb70f9551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEquitySecuritiesMember_12f780ed-881f-497f-a27d-a00c84215200" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_40e21f4e-1529-47e4-bcd4-ee0fb70f9551" xlink:to="loc_ifrs-full_OtherEquitySecuritiesMember_12f780ed-881f-497f-a27d-a00c84215200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5c17acb1-cf7b-4abb-90e8-b5452b25dc6e" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level1OfFairValueHierarchyMember_67576247-0664-45cb-a797-f336de427c11" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:to="loc_ifrs-full_Level1OfFairValueHierarchyMember_67576247-0664-45cb-a797-f336de427c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_bf98a028-646e-4b22-9095-fe1961a3937e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_bf98a028-646e-4b22-9095-fe1961a3937e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_b7559a7a-f585-47e8-988d-2b3ea07a2bb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_487caffc-e126-4cfe-83ba-60a208797db4" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_b7559a7a-f585-47e8-988d-2b3ea07a2bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_d3b6f4db-a1e9-45e9-9007-cc7372fbc893" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_088cd11e-5d0e-414a-b3f9-8c0d24483d56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:to="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_088cd11e-5d0e-414a-b3f9-8c0d24483d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValue_55b7ed91-bca6-4c48-8b35-95002a684174" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract_088cd11e-5d0e-414a-b3f9-8c0d24483d56" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValue_55b7ed91-bca6-4c48-8b35-95002a684174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_4a206364-3d82-4a3a-8ed8-387739c4a5ff" xlink:to="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_00bb1024-fa1f-42ba-b10b-3e7b1aed4e3a" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:to="loc_meso_ContingentConsiderations_00bb1024-fa1f-42ba-b10b-3e7b1aed4e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_902fd172-da80-4264-8b02-a58fb4a5189f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:to="loc_ifrs-full_WarrantLiability_902fd172-da80-4264-8b02-a58fb4a5189f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtFairValue_a53ff678-ba8b-45e6-88a9-604f0dfd2c07" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract_34bd72a5-603f-446c-8dbe-399ca7b58dd1" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtFairValue_a53ff678-ba8b-45e6-88a9-604f0dfd2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_28425ab0-d39e-488c-92cc-a9d2b3f34212" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_28425ab0-d39e-488c-92cc-a9d2b3f34212" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5d4d11f1-aa58-4c8b-a419-3e3c42778041" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_0332c06d-97f1-4ec5-beaf-4392a3675d52" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5d4d11f1-aa58-4c8b-a419-3e3c42778041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_153f96dc-4fd3-4d8c-a78e-3d5caa19edd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5d4d11f1-aa58-4c8b-a419-3e3c42778041" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_153f96dc-4fd3-4d8c-a78e-3d5caa19edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_4b403217-584e-4b0b-aa01-7fced0726634" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision_2fdb11ea-485c-482c-acc9-e37e49465598" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_ContingentConsiderationProvision_2fdb11ea-485c-482c-acc9-e37e49465598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvisionAmountUsed_fce1e11c-b93e-436f-9aa0-9051fd9f2e14" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvisionAmountUsed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_ContingentConsiderationProvisionAmountUsed_fce1e11c-b93e-436f-9aa0-9051fd9f2e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LossGainOnRemeasurementOfContingentConsideration_8562ea57-9017-405b-9796-d0ca342e5779" xlink:href="meso-20231231.xsd#meso_LossGainOnRemeasurementOfContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_LossGainOnRemeasurementOfContingentConsideration_8562ea57-9017-405b-9796-d0ca342e5779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision_90d2a5df-3aff-45af-aecb-fd320b35c0ce" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_21363641-1b20-405c-b9d6-531fe363554a" xlink:to="loc_meso_ContingentConsiderationProvision_90d2a5df-3aff-45af-aecb-fd320b35c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_9cb1ae13-d50e-4484-8dc3-49554e719f5e" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_9cb1ae13-d50e-4484-8dc3-49554e719f5e" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2ee0302f-1ab5-416d-8785-0559637a4d59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_4e182846-15ef-4f0d-8015-269959b6fa74" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2ee0302f-1ab5-416d-8785-0559637a4d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_70877752-e134-44d8-921d-9671207360b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_2ee0302f-1ab5-416d-8785-0559637a4d59" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_70877752-e134-44d8-921d-9671207360b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ad4e672-8d7f-43f7-8d8f-7b3155bc1dba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ba21c76a-fcfd-474d-a929-12121fe0cf48" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ad4e672-8d7f-43f7-8d8f-7b3155bc1dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_c08fb781-a71a-4461-9471-d51dceb7b042" xlink:href="meso-20231231.xsd#meso_GainLossOnReMeasurementOfContingentConsiderationProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ad4e672-8d7f-43f7-8d8f-7b3155bc1dba" xlink:to="loc_meso_GainLossOnReMeasurementOfContingentConsiderationProvision_c08fb781-a71a-4461-9471-d51dceb7b042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_5c40ab2e-393d-4fe5-9564-9dc0a64da849" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_5c40ab2e-393d-4fe5-9564-9dc0a64da849" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3430384c-7e34-4610-811d-6b453984cda0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_6ffec991-6bf8-4615-91e5-8bb0407b193a" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3430384c-7e34-4610-811d-6b453984cda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_32c0cbb4-a7c7-4bc3-ac0a-41d842143a6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_3430384c-7e34-4610-811d-6b453984cda0" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_32c0cbb4-a7c7-4bc3-ac0a-41d842143a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_0d658b2b-3374-4de8-9829-5ec5bc66aa72" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_f39a71f3-3158-460c-9b2f-52398c132a66" xlink:to="loc_ifrs-full_ValuationTechniquesMember_0d658b2b-3374-4de8-9829-5ec5bc66aa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember_956e85d5-c334-466f-9dbc-c1b9ad2c919f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesMember_0d658b2b-3374-4de8-9829-5ec5bc66aa72" xlink:to="loc_ifrs-full_DiscountedCashFlowMember_956e85d5-c334-466f-9dbc-c1b9ad2c919f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesChannelsMember_dd350ec0-62a7-4a60-bdf3-93e001bb615f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesChannelsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SalesChannelsAxis_31fe9869-e944-4ebb-b6b7-323ad9570073" xlink:to="loc_ifrs-full_SalesChannelsMember_dd350ec0-62a7-4a60-bdf3-93e001bb615f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedSalesVolumeMember_9bb78c0f-388a-4ddb-8ef9-3e449e6d424a" xlink:href="meso-20231231.xsd#meso_ExpectedSalesVolumeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SalesChannelsMember_dd350ec0-62a7-4a60-bdf3-93e001bb615f" xlink:to="loc_meso_ExpectedSalesVolumeMember_9bb78c0f-388a-4ddb-8ef9-3e449e6d424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProbabilityOfDefaultAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_f3bf3a8b-c118-49bf-a0fc-cbc24d7ffc93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForProbabilityOfDefaultMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProbabilityOfDefaultAxis_fec02450-80b1-47b6-b30f-cbc6601e755b" xlink:to="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_f3bf3a8b-c118-49bf-a0fc-cbc24d7ffc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProbabilityOfDefaultMember_a89f6673-aec1-46e6-a843-12540097af9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProbabilityOfDefaultMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForProbabilityOfDefaultMember_f3bf3a8b-c118-49bf-a0fc-cbc24d7ffc93" xlink:to="loc_ifrs-full_ProbabilityOfDefaultMember_a89f6673-aec1-46e6-a843-12540097af9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_577b3f0d-9aae-4996-b14b-c46d9f55f773" xlink:to="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_51961bd2-8236-4f98-97b2-0ee8da9eebfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:to="loc_ifrs-full_BottomOfRangeMember_51961bd2-8236-4f98-97b2-0ee8da9eebfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e2091fa3-eb39-480d-9a1a-99519730c949" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:to="loc_ifrs-full_TopOfRangeMember_e2091fa3-eb39-480d-9a1a-99519730c949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageMember_41e02f92-7903-4c02-bcf2-a3332965684d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e0988037-0e56-40f5-95e7-6252da0ec79a" xlink:to="loc_ifrs-full_WeightedAverageMember_41e02f92-7903-4c02-bcf2-a3332965684d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_4c4110d6-6600-43cc-83d3-db933575ae4b" xlink:to="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_15e41810-d78d-4b25-8586-ba7e0fe16d2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_15e41810-d78d-4b25-8586-ba7e0fe16d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedUnitSalesPriceMeasurementInputMember_88e33d25-841b-4b0c-a7d5-d22ce8636595" xlink:href="meso-20231231.xsd#meso_ExpectedUnitSalesPriceMeasurementInputMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_ExpectedUnitSalesPriceMeasurementInputMember_88e33d25-841b-4b0c-a7d5-d22ce8636595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedSalesVolumesMeasurementInputMember_61713752-8e7a-4c52-b115-a5745f8f2f11" xlink:href="meso-20231231.xsd#meso_ExpectedSalesVolumesMeasurementInputMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_ExpectedSalesVolumesMeasurementInputMember_61713752-8e7a-4c52-b115-a5745f8f2f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProbabilityOfSuccessMeasurementInputMember_0ede5770-4587-4843-9be3-a2b0e1ea4021" xlink:href="meso-20231231.xsd#meso_ProbabilityOfSuccessMeasurementInputMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_ProbabilityOfSuccessMeasurementInputMember_0ede5770-4587-4843-9be3-a2b0e1ea4021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PaymentAssumptionsMeasurementInputMember_76094b25-018b-49e2-a013-09c1f27fde66" xlink:href="meso-20231231.xsd#meso_PaymentAssumptionsMeasurementInputMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_fe8b85d0-c9e0-45a7-8c07-0171c42c0269" xlink:to="loc_meso_PaymentAssumptionsMeasurementInputMember_76094b25-018b-49e2-a013-09c1f27fde66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_f2aa65be-5389-4be4-aa06-6c17ee99e7c4" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderationProvision_ca5f25f6-c6d6-4399-9c51-39554a24c7a5" xlink:href="meso-20231231.xsd#meso_ContingentConsiderationProvision"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_ContingentConsiderationProvision_ca5f25f6-c6d6-4399-9c51-39554a24c7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities_9c731d27-e578-40b2-a953-15a1c0a8b261" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities_9c731d27-e578-40b2-a953-15a1c0a8b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities_3a3d2d78-01db-4829-9ddc-b237bf7f5e85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities_3a3d2d78-01db-4829-9ddc-b237bf7f5e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_14350208-3ba5-4bc3-aab7-6c95edd02434" xlink:href="meso-20231231.xsd#meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities_14350208-3ba5-4bc3-aab7-6c95edd02434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_72b2e640-ab3c-4b14-a854-cd97f075528d" xlink:href="meso-20231231.xsd#meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities_72b2e640-ab3c-4b14-a854-cd97f075528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_769bad79-8724-4cb1-acbf-d6acdd95b9a1" xlink:href="meso-20231231.xsd#meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_4aa4c313-ce16-43a3-b68e-3475db0463e3" xlink:to="loc_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities_769bad79-8724-4cb1-acbf-d6acdd95b9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_220fab81-98b8-4b8d-a56c-78114a694d48" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CashOrStockPayableAtFairValueLiabilities_10867126-99cb-4cdf-85a2-afc0b718aa65" xlink:href="meso-20231231.xsd#meso_CashOrStockPayableAtFairValueLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_220fab81-98b8-4b8d-a56c-78114a694d48" xlink:to="loc_meso_CashOrStockPayableAtFairValueLiabilities_10867126-99cb-4cdf-85a2-afc0b718aa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RoyaltyPaymentsAtFairValueLiabilities_e461ceb4-9c1f-4331-9e69-efd2a6f82e6c" xlink:href="meso-20231231.xsd#meso_RoyaltyPaymentsAtFairValueLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_220fab81-98b8-4b8d-a56c-78114a694d48" xlink:to="loc_meso_RoyaltyPaymentsAtFairValueLiabilities_e461ceb4-9c1f-4331-9e69-efd2a6f82e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContingentConsiderations_24df10ea-53f8-4a1c-802c-20505f420712" xlink:href="meso-20231231.xsd#meso_ContingentConsiderations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_220fab81-98b8-4b8d-a56c-78114a694d48" xlink:to="loc_meso_ContingentConsiderations_24df10ea-53f8-4a1c-802c-20505f420712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7585650b-48c1-435e-bd65-2a2e58209f3f" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_7585650b-48c1-435e-bd65-2a2e58209f3f" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreationDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:to="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DefaultFinancialStatementsDateMember_ba350bd6-927e-4bc2-b324-b961122fceff" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefaultFinancialStatementsDateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CreationDateAxis_1563e06a-1ba5-465d-8834-fc7f7acd6efc" xlink:to="loc_ifrs-full_DefaultFinancialStatementsDateMember_ba350bd6-927e-4bc2-b324-b961122fceff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtGrantDateDecember222022Member_7fc92049-6b5b-47da-82dc-4645e232f200" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtGrantDateDecember222022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DefaultFinancialStatementsDateMember_ba350bd6-927e-4bc2-b324-b961122fceff" xlink:to="loc_meso_WarrantsFairValueAtGrantDateDecember222022Member_7fc92049-6b5b-47da-82dc-4645e232f200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_67031160-f5fb-4736-b238-b903105d5578" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_74e1be39-59b3-4e2b-9a63-ec2aaaaa47b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_ifrs-full_WarrantLiability_74e1be39-59b3-4e2b-9a63-ec2aaaaa47b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsFairValueAtIssueDate_2a5fe21f-c983-49fe-9b3e-e15538c75f63" xlink:href="meso-20231231.xsd#meso_WarrantsFairValueAtIssueDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_meso_WarrantsFairValueAtIssueDate_2a5fe21f-c983-49fe-9b3e-e15538c75f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementOfWarrantLiability_7a215e56-ac5a-4173-8e38-037a583d64a6" xlink:href="meso-20231231.xsd#meso_RemeasurementOfWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_meso_RemeasurementOfWarrantLiability_7a215e56-ac5a-4173-8e38-037a583d64a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_a0e77ce5-ddb0-43f9-9721-910c23544cb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_46fc25d5-cb69-4c14-9082-cbd3d8477834" xlink:to="loc_ifrs-full_WarrantLiability_a0e77ce5-ddb0-43f9-9721-910c23544cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_fcfb1554-c91c-4232-94ec-bb2adeb68944" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_fcfb1554-c91c-4232-94ec-bb2adeb68944" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0af87808-5013-46a5-a146-90671feb1df1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_94b5b98c-9ac5-49e1-89e5-c68d912cdca8" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0af87808-5013-46a5-a146-90671feb1df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1296d9dc-9412-4d0a-8147-3622326a1cc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_0af87808-5013-46a5-a146-90671feb1df1" xlink:to="loc_ifrs-full_WarrantsMember_1296d9dc-9412-4d0a-8147-3622326a1cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:to="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2d763df7-8fa9-43d5-a64d-46ab93d7e123" xlink:to="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ce7aa9ab-96c6-4e16-ad49-042d3636ba75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:to="loc_srt_MinimumMember_ce7aa9ab-96c6-4e16-ad49-042d3636ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_45f06a71-09ed-417d-85ff-b1af58aff637" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d81be8e7-aed7-48f8-9c98-81e8d2778020" xlink:to="loc_srt_MaximumMember_45f06a71-09ed-417d-85ff-b1af58aff637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea8796ec-3ef8-4168-a09e-d0a0ec8ceb2d" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantsPricePerShare_334de3f1-d529-4cb2-8543-62972d548b8c" xlink:href="meso-20231231.xsd#meso_WarrantsPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_meso_WarrantsPricePerShare_334de3f1-d529-4cb2-8543-62972d548b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_19624ae5-b400-4689-a1b8-87b8314cb014" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_ParValuePerShare_19624ae5-b400-4689-a1b8-87b8314cb014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f52c69bb-d33f-49f9-a6f2-1170771e9979" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f52c69bb-d33f-49f9-a6f2-1170771e9979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24e4d66d-e4fb-4345-bda0-798772a38a8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_24e4d66d-e4fb-4345-bda0-798772a38a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3e29a50c-236c-4b86-bad3-5164cda8869c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3e29a50c-236c-4b86-bad3-5164cda8869c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1f0c745c-e32c-4e2e-97d5-7ceb97674ee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1f0c745c-e32c-4e2e-97d5-7ceb97674ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValuePerWarrant_49aca165-873f-4127-abca-3080e6de4d81" xlink:href="meso-20231231.xsd#meso_FairValuePerWarrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_meso_FairValuePerWarrant_49aca165-873f-4127-abca-3080e6de4d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueOfWarrants_4c5cc647-8377-4a6b-a52c-8bda0503346d" xlink:href="meso-20231231.xsd#meso_FairValueOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_ac61fa7c-efa8-44d0-8567-15c9654f86b6" xlink:to="loc_meso_FairValueOfWarrants_4c5cc647-8377-4a6b-a52c-8bda0503346d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_6b171a34-89d8-467e-aa0e-6009226ce9eb" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract_6b171a34-89d8-467e-aa0e-6009226ce9eb" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_19b6abf9-8f09-4291-b9bc-f401d111860e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_0c42bf53-db86-4216-9a5a-7962f17a71b1" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_19b6abf9-8f09-4291-b9bc-f401d111860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_19b628ad-deb5-44d3-9758-9c1921d2c949" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsMember_19b6abf9-8f09-4291-b9bc-f401d111860e" xlink:to="loc_ifrs-full_WarrantsMember_19b628ad-deb5-44d3-9758-9c1921d2c949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:to="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_058da9af-0dc5-418c-aece-471e4b8f8fd5" xlink:to="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9577f9cd-58c1-404f-b0f5-44f8ce0e77ab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:to="loc_srt_MaximumMember_9577f9cd-58c1-404f-b0f5-44f8ce0e77ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f70cebd4-0f15-457c-9fda-c416eb811c17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0de3fcf6-677e-4213-9b17-6b259019241a" xlink:to="loc_srt_MinimumMember_f70cebd4-0f15-457c-9fda-c416eb811c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_ea6acb0f-db03-48f3-a18b-e43893a0b296" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IssuanceWarrantsExercisedPeriod_ad48b76d-2598-4d23-8e2d-342eecfa5d5c" xlink:href="meso-20231231.xsd#meso_IssuanceWarrantsExercisedPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_meso_IssuanceWarrantsExercisedPeriod_ad48b76d-2598-4d23-8e2d-342eecfa5d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_2c58e03f-91a5-4900-b3d0-d92ed95bbb28" xlink:href="meso-20231231.xsd#meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares_2c58e03f-91a5-4900-b3d0-d92ed95bbb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueOfWarrants_4b1e3317-d573-4411-9d12-31694b40af9c" xlink:href="meso-20231231.xsd#meso_FairValueOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_meso_FairValueOfWarrants_4b1e3317-d573-4411-9d12-31694b40af9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_15ca9a33-d70b-4c20-a05d-ebf3d0f84032" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_ifrs-full_ParValuePerShare_15ca9a33-d70b-4c20-a05d-ebf3d0f84032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_43746461-9016-47b0-a1f5-b81a3ec8d4f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_bdd6ddf0-d9e8-4cb3-a59f-073a05f6fd75" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_43746461-9016-47b0-a1f5-b81a3ec8d4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_eafd324f-95bb-42ba-93b5-43524c5f3550" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_eafd324f-95bb-42ba-93b5-43524c5f3550" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_5d20ced5-d889-4a43-be30-72081bba8e8d" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_a40a83f7-882c-487f-ab92-c96f2f9e506a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_ifrs-full_GoodwillMember_a40a83f7-882c-487f-ab92-c96f2f9e506a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_a74591fe-9c54-43de-b155-a02a32b4b0cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_ifrs-full_LicencesMember_a74591fe-9c54-43de-b155-a02a32b4b0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_170b031a-e3d4-4b01-a83b-3c4c226579af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_170b031a-e3d4-4b01-a83b-3c4c226579af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentMarketedProductsMember_53d582b0-b659-4ba9-8b4c-9d53613405da" xlink:href="meso-20231231.xsd#meso_CurrentMarketedProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_827cfcf7-b9fa-4053-9cfd-e1aa0d1957ce" xlink:to="loc_meso_CurrentMarketedProductsMember_53d582b0-b659-4ba9-8b4c-9d53613405da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_9428b8b5-3052-4620-b5e7-42807ec8bf5e" xlink:to="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_a3f115dd-5289-49a9-9613-0f2db209d84a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_a3f115dd-5289-49a9-9613-0f2db209d84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_5b2b6d21-d6e3-4ae4-8ff8-2159ec030e4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_5b2b6d21-d6e3-4ae4-8ff8-2159ec030e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedImpairmentMember_ebcf932c-40f3-4a1f-bd40-b224f7e13da3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_5f80d3fe-7dd2-4812-9d49-9f79bd361e82" xlink:to="loc_ifrs-full_AccumulatedImpairmentMember_ebcf932c-40f3-4a1f-bd40-b224f7e13da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_729fbc7f-c6be-4b11-9586-5e578f319613" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_018a3ff8-f54b-4bbe-b7ae-0f9450a405b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_018a3ff8-f54b-4bbe-b7ae-0f9450a405b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ee52132-f206-493a-be5b-1a2e6cf1620c" xlink:href="meso-20231231.xsd#meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ee52132-f206-493a-be5b-1a2e6cf1620c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_4e575112-4f0c-465e-a0ca-14b483c9f6f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_4e575112-4f0c-465e-a0ca-14b483c9f6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_02f22cc1-92a6-4a2f-9e00-7ca254f3357d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_02f22cc1-92a6-4a2f-9e00-7ca254f3357d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_d0faa6b7-8b02-4cfc-b01a-5935dae6ea13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_d09a389a-63dd-442d-bd15-d422c7b5bb99" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_d0faa6b7-8b02-4cfc-b01a-5935dae6ea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a8886f91-34e3-444c-bee0-9c8da0fc7e2d" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_a8886f91-34e3-444c-bee0-9c8da0fc7e2d" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_f4b29eb1-c553-4f84-b3c5-6df21da946e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_adf3f5fa-86a0-4a19-bc39-984b5cf93bcb" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_f4b29eb1-c553-4f84-b3c5-6df21da946e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_edc41a34-1738-409d-9df0-bdb271a45723" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_f4b29eb1-c553-4f84-b3c5-6df21da946e0" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_edc41a34-1738-409d-9df0-bdb271a45723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:to="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesAxis_661e6623-4c5c-40ca-bcf7-ff543b12630d" xlink:to="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CardiovascularProductsMember_d569437c-7497-41cd-af0d-4a1497750a68" xlink:href="meso-20231231.xsd#meso_CardiovascularProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:to="loc_meso_CardiovascularProductsMember_d569437c-7497-41cd-af0d-4a1497750a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntravenousProductsMember_3c389f1e-3f39-45e4-ac50-688ca3bdc2e7" xlink:href="meso-20231231.xsd#meso_IntravenousProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:to="loc_meso_IntravenousProductsMember_3c389f1e-3f39-45e4-ac50-688ca3bdc2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MSCProductMember_5a7e68f1-3d41-43c0-a8e2-7f23e9cf6d8c" xlink:href="meso-20231231.xsd#meso_MSCProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProductsAndServicesMember_ac5bb330-7cb5-4f06-9b98-60da64a1b623" xlink:to="loc_meso_MSCProductMember_5a7e68f1-3d41-43c0-a8e2-7f23e9cf6d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b01abb54-fc02-4cd8-86b0-9c71ef2b6f03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_0c623a4b-7a0e-49aa-93c5-713b95d1f507" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b01abb54-fc02-4cd8-86b0-9c71ef2b6f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwill_7a827cae-a61b-4684-91d6-982b4f10cd0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_b01abb54-fc02-4cd8-86b0-9c71ef2b6f03" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwill_7a827cae-a61b-4684-91d6-982b4f10cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract_5127c8c7-5f9b-4480-aeec-fcd570cc8dd1" xlink:href="meso-20231231.xsd#meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract_5127c8c7-5f9b-4480-aeec-fcd570cc8dd1" xlink:to="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_c5c6dc45-1204-49d1-8a6a-41e746ad4825" xlink:to="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_a6e2a446-9a69-4a75-a2ba-a7e56fc5903b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_a6e2a446-9a69-4a75-a2ba-a7e56fc5903b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_c59599af-1835-4649-982f-53762c1e9760" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsAndGoodwillMember_365d963b-41d1-4ece-979e-0a01ecfa6007" xlink:to="loc_ifrs-full_GoodwillMember_c59599af-1835-4649-982f-53762c1e9760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_72e334de-c688-48a8-a0f4-4f7a2fd0df90" xlink:to="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_bfb572f9-dfef-4191-9a43-b749e392d70f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:to="loc_ifrs-full_BottomOfRangeMember_bfb572f9-dfef-4191-9a43-b749e392d70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_18de07dd-7f54-46dd-8ca7-1c869533faeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e20a8251-b971-427b-be79-71bfe37bc092" xlink:to="loc_ifrs-full_TopOfRangeMember_18de07dd-7f54-46dd-8ca7-1c869533faeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValuationTechniquesMember_acd6c13e-21b2-4271-8f34-d1705fa33a4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_7521c076-c4ab-4977-95e7-1baa5fccee2c" xlink:to="loc_ifrs-full_ValuationTechniquesMember_acd6c13e-21b2-4271-8f34-d1705fa33a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountedCashFlowMember_387b486a-d3b1-4307-89e7-02a7701fa891" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ValuationTechniquesMember_acd6c13e-21b2-4271-8f34-d1705fa33a4c" xlink:to="loc_ifrs-full_DiscountedCashFlowMember_387b486a-d3b1-4307-89e7-02a7701fa891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_10435533-1efd-43b0-a378-410e134ae6c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_d69e3f5a-3414-4ed0-b513-85816947fad9" xlink:to="loc_ifrs-full_OtherProvisionsMember_10435533-1efd-43b0-a378-410e134ae6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EmployeeBenefitsMember_97e13d44-273f-45d4-895a-d1540798cf89" xlink:href="meso-20231231.xsd#meso_EmployeeBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_10435533-1efd-43b0-a378-410e134ae6c6" xlink:to="loc_meso_EmployeeBenefitsMember_97e13d44-273f-45d4-895a-d1540798cf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable_43f59d7c-4e15-4d29-964a-b43b1c0f5773" xlink:to="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossOnFinancialAssets_48ae8091-71af-4dd1-aee2-7afee89a3dfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ImpairmentLossOnFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_ifrs-full_ImpairmentLossOnFinancialAssets_48ae8091-71af-4dd1-aee2-7afee89a3dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PostTaxDiscountRates_f07a3147-e8a5-42a0-8ec9-deb2162b4d07" xlink:href="meso-20231231.xsd#meso_PostTaxDiscountRates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_PostTaxDiscountRates_f07a3147-e8a5-42a0-8ec9-deb2162b4d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ExpectedPatentExpiry_fdae65af-ada0-4dd9-9594-4d4d1dde84be" xlink:href="meso-20231231.xsd#meso_ExpectedPatentExpiry"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_ExpectedPatentExpiry_fdae65af-ada0-4dd9-9594-4d4d1dde84be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_CurrentProvisionsForAccruedAnnualLeave_d4dc25f3-7777-434d-b4a5-8db9feaaba83" xlink:href="meso-20231231.xsd#meso_CurrentProvisionsForAccruedAnnualLeave"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems_0ca830cc-5d06-4123-a4de-1d5c3af2f4b1" xlink:to="loc_meso_CurrentProvisionsForAccruedAnnualLeave_d4dc25f3-7777-434d-b4a5-8db9feaaba83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_e2c7e0b8-0386-4e23-bffd-f423fda20181" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_e2c7e0b8-0386-4e23-bffd-f423fda20181" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_e1b3806d-cc07-4a42-9f23-5fa7e5ed8573" xlink:to="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_fb12cca9-723a-4ceb-b4c5-f517e81e7e3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:to="loc_ifrs-full_ContingentConsiderationMember_fb12cca9-723a-4ceb-b4c5-f517e81e7e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EmployeeBenefitsMember_0a1a1932-36aa-4154-a8cd-b503d35a3f5c" xlink:href="meso-20231231.xsd#meso_EmployeeBenefitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:to="loc_meso_EmployeeBenefitsMember_0a1a1932-36aa-4154-a8cd-b503d35a3f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ProvisionForLicenseAgreementsMember_be187173-cbd1-4f27-a058-e7d2d6c2d1f5" xlink:href="meso-20231231.xsd#meso_ProvisionForLicenseAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_f1c810e5-99b5-425f-a92a-0b41841b3516" xlink:to="loc_meso_ProvisionForLicenseAgreementsMember_be187173-cbd1-4f27-a058-e7d2d6c2d1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsTable_38636577-7a0f-4a3d-af22-7f1678828d29" xlink:to="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentProvisions_185f9276-9636-4837-a1d1-8d4f0405dc19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_CurrentProvisions_185f9276-9636-4837-a1d1-8d4f0405dc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentProvisions_8d18f8e2-6b74-4998-b5e1-d7ca1e29ff49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_NoncurrentProvisions_8d18f8e2-6b74-4998-b5e1-d7ca1e29ff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Provisions_5b1ebff6-2c8b-4786-b692-d3cedfc7fd64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Provisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOtherProvisionsLineItems_a8621cb2-b48c-4ae9-abd9-e92ff8d20a2d" xlink:to="loc_ifrs-full_Provisions_5b1ebff6-2c8b-4786-b692-d3cedfc7fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_f181f48e-885e-4e67-bf05-17a79fd7c051" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAbstract_7afeddb8-f863-4514-9f4f-73f91778ca8d" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_f181f48e-885e-4e67-bf05-17a79fd7c051" xlink:to="loc_meso_DeferredTaxAssetsAbstract_7afeddb8-f863-4514-9f4f-73f91778ca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_beb5adc0-77d7-4411-8f0b-7ef6d3d8bf3e" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAbstract_7afeddb8-f863-4514-9f4f-73f91778ca8d" xlink:to="loc_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses_beb5adc0-77d7-4411-8f0b-7ef6d3d8bf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_aa3145d3-a459-4f12-a28d-796505f94531" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAbstract_7afeddb8-f863-4514-9f4f-73f91778ca8d" xlink:to="loc_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences_aa3145d3-a459-4f12-a28d-796505f94531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_16db201f-7e39-465d-9e6b-0bed975aa691" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAbstract_7afeddb8-f863-4514-9f4f-73f91778ca8d" xlink:to="loc_ifrs-full_DeferredTaxAssets_16db201f-7e39-465d-9e6b-0bed975aa691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxLiabilityAbstract_0f0767d9-b71d-4f0d-bbda-0b665a4e7149" xlink:href="meso-20231231.xsd#meso_DeferredTaxLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_f181f48e-885e-4e67-bf05-17a79fd7c051" xlink:to="loc_meso_DeferredTaxLiabilityAbstract_0f0767d9-b71d-4f0d-bbda-0b665a4e7149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_2ccab0ed-f71a-4425-be01-5f03a5020d63" xlink:href="meso-20231231.xsd#meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxLiabilityAbstract_0f0767d9-b71d-4f0d-bbda-0b665a4e7149" xlink:to="loc_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets_2ccab0ed-f71a-4425-be01-5f03a5020d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilities_5c28d68f-e911-465d-b4ca-b748ce20f4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxLiabilityAbstract_0f0767d9-b71d-4f0d-bbda-0b665a4e7149" xlink:to="loc_ifrs-full_DeferredTaxLiabilities_5c28d68f-e911-465d-b4ca-b748ce20f4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxLiabilities_c6d48796-f38c-4982-8366-2a00706505d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_f181f48e-885e-4e67-bf05-17a79fd7c051" xlink:to="loc_ifrs-full_NetDeferredTaxLiabilities_c6d48796-f38c-4982-8366-2a00706505d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_aaa89dec-a453-4c07-9930-99b6fbe37b86" xlink:href="meso-20231231.xsd#meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract_aaa89dec-a453-4c07-9930-99b6fbe37b86" xlink:to="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7d3bd989-d772-408a-abdf-a2fd134dbb03" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TaxLossesMember_396fb7a9-e1dc-4af4-9f5c-b96e9fcb8512" xlink:href="meso-20231231.xsd#meso_TaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:to="loc_meso_TaxLossesMember_396fb7a9-e1dc-4af4-9f5c-b96e9fcb8512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTemporaryDifferencesMember_63442f67-07f8-432d-ba07-e3550a24e21d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTemporaryDifferencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:to="loc_ifrs-full_OtherTemporaryDifferencesMember_63442f67-07f8-432d-ba07-e3550a24e21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IntangibleAssetsMember_83cbbedd-cab3-4359-b1a6-c12906aba4c1" xlink:href="meso-20231231.xsd#meso_IntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ba562d5e-d674-4e15-be61-db492e15f84d" xlink:to="loc_meso_IntangibleAssetsMember_83cbbedd-cab3-4359-b1a6-c12906aba4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesTable_ddf0958a-c43b-4fef-b18b-3ef251cf0b32" xlink:to="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_faff9108-7566-4f3a-9aa2-77c97debaf44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_faff9108-7566-4f3a-9aa2-77c97debaf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:href="meso-20231231.xsd#meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:to="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax_a3b4e09b-f3b1-4d16-880f-3822772f99e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:to="loc_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax_a3b4e09b-f3b1-4d16-880f-3822772f99e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_2ee8c0a5-710f-4c95-a68a-55d005c19b1b" xlink:href="meso-20231231.xsd#meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract_0d414ac5-6b4c-4798-a103-c8efad32f414" xlink:to="loc_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity_2ee8c0a5-710f-4c95-a68a-55d005c19b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_bca0d362-c36e-42f7-8ccf-525f47df376c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DeferredTaxAssetsAndLiabilitiesLineItems_a15a027b-a2ee-4a75-b910-e19aab3da333" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_bca0d362-c36e-42f7-8ccf-525f47df376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/CashflowinformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#CashflowinformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/CashflowinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_e58129e8-70ea-466b-885a-447e7918f30a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_6ce50a52-9061-4e47-8d0e-7f1b0981b668" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_e58129e8-70ea-466b-885a-447e7918f30a" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAbstract_6ce50a52-9061-4e47-8d0e-7f1b0981b668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BalancesWithBanks_4594ccfd-0662-438c-a833-392707417266" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_6ce50a52-9061-4e47-8d0e-7f1b0981b668" xlink:to="loc_ifrs-full_BalancesWithBanks_4594ccfd-0662-438c-a833-392707417266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DepositsAtCall_6c9a65f5-8150-4e53-97cd-4f8ec39ba5f2" xlink:href="meso-20231231.xsd#meso_DepositsAtCall"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_6ce50a52-9061-4e47-8d0e-7f1b0981b668" xlink:to="loc_meso_DepositsAtCall_6c9a65f5-8150-4e53-97cd-4f8ec39ba5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1769a82f-12ea-4a5a-8472-7ea6489accaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_6ce50a52-9061-4e47-8d0e-7f1b0981b668" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1769a82f-12ea-4a5a-8472-7ea6489accaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52f87ec7-757d-4bcf-b9ea-45748615d29b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_e58129e8-70ea-466b-885a-447e7918f30a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52f87ec7-757d-4bcf-b9ea-45748615d29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_ff59ef41-5838-4384-b522-d26d8e3b99bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52f87ec7-757d-4bcf-b9ea-45748615d29b" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_ff59ef41-5838-4384-b522-d26d8e3b99bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52f87ec7-757d-4bcf-b9ea-45748615d29b" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_d6fc119c-edaa-4b7e-84e2-bc1c2df027c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_d6fc119c-edaa-4b7e-84e2-bc1c2df027c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_9740e64b-0881-4e39-92e2-97f5cb811ecd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_9740e64b-0881-4e39-92e2-97f5cb811ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncomeCost_356368cf-0e3f-4274-b3fa-0761a610cc7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncomeCost_356368cf-0e3f-4274-b3fa-0761a610cc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_5eddc4b4-8e3e-4d80-b240-b302fa74cab9" xlink:href="meso-20231231.xsd#meso_FairValueRemeasurementOfContingentConsiderationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_meso_FairValueRemeasurementOfContingentConsiderationAfterTax_5eddc4b4-8e3e-4d80-b240-b302fa74cab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_RemeasurementOfWarrantLiability_87fbb86e-6ebf-4a67-af1d-42a7d0c35519" xlink:href="meso-20231231.xsd#meso_RemeasurementOfWarrantLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_meso_RemeasurementOfWarrantLiability_87fbb86e-6ebf-4a67-af1d-42a7d0c35519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_4723682c-ff45-4bd6-b25f-d6aad8cb61e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_4723682c-ff45-4bd6-b25f-d6aad8cb61e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_1000ce75-02d8-498c-9f72-eec56d2d30bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_4eb272e3-909e-48c3-b172-0e8296f352eb" xlink:to="loc_ifrs-full_AdjustmentsForDeferredTaxExpense_1000ce75-02d8-498c-9f72-eec56d2d30bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:href="meso-20231231.xsd#meso_ChangeInOperatingAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52f87ec7-757d-4bcf-b9ea-45748615d29b" xlink:to="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_b380c84c-24c4-4aba-8407-2852d3ca9707" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_b380c84c-24c4-4aba-8407-2852d3ca9707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdjustmentsForIncreaseDecreaseInPrepayments_835fd43a-524f-4d63-8980-f695d89b91a2" xlink:href="meso-20231231.xsd#meso_AdjustmentsForIncreaseDecreaseInPrepayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:to="loc_meso_AdjustmentsForIncreaseDecreaseInPrepayments_835fd43a-524f-4d63-8980-f695d89b91a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_0af2db91-13fc-4dd6-9a2b-b172c03ab864" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:to="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_0af2db91-13fc-4dd6-9a2b-b172c03ab864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_7487dcd7-6fb0-4dbd-baf9-ad4971dbd67d" xlink:href="meso-20231231.xsd#meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:to="loc_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals_7487dcd7-6fb0-4dbd-baf9-ad4971dbd67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForProvisions_1386854e-5108-4963-91df-e3ef1336dfcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract_5441726a-9177-4d60-b76f-2478dff153a4" xlink:to="loc_ifrs-full_AdjustmentsForProvisions_1386854e-5108-4963-91df-e3ef1336dfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_e2308342-71b8-48c9-8b13-5581c9262dc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_52f87ec7-757d-4bcf-b9ea-45748615d29b" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_e2308342-71b8-48c9-8b13-5581c9262dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquityScheduleofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_462e1092-6afd-4bee-a9d8-6102b7eb3e10" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_462e1092-6afd-4bee-a9d8-6102b7eb3e10" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_7083a868-1383-404c-9061-c156aab68a0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_985ec13f-e041-402f-9559-f7efad709c13" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_7083a868-1383-404c-9061-c156aab68a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_70ade9dc-1e67-4b9d-8819-4f382cb9602b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_7083a868-1383-404c-9061-c156aab68a0c" xlink:to="loc_ifrs-full_OrdinarySharesMember_70ade9dc-1e67-4b9d-8819-4f382cb9602b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_01a6823e-75fc-489d-a872-39ebb13032aa" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_61b755d5-a91d-436b-b0a3-1cf0c8c01854" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:to="loc_ifrs-full_NumberOfSharesIssued_61b755d5-a91d-436b-b0a3-1cf0c8c01854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchased_76e4e5ea-a7ae-4c90-82cf-5db85aa1d64b" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:to="loc_meso_TreasurySharesPurchased_76e4e5ea-a7ae-4c90-82cf-5db85aa1d64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_6d400f81-6d13-4e2c-bb09-7a91f9b076c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_9a9cad39-0ada-4fee-a9e1-8e65ec10ebd8" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_6d400f81-6d13-4e2c-bb09-7a91f9b076c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OrdinarySharesPurchasedValue_84642b8d-5df1-4e7c-a9b2-9e941bf621fa" xlink:href="meso-20231231.xsd#meso_OrdinarySharesPurchasedValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_meso_OrdinarySharesPurchasedValue_84642b8d-5df1-4e7c-a9b2-9e941bf621fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TreasurySharesPurchasedValue_beddc3f6-85ff-45c7-9002-16cd5b037387" xlink:href="meso-20231231.xsd#meso_TreasurySharesPurchasedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_meso_TreasurySharesPurchasedValue_beddc3f6-85ff-45c7-9002-16cd5b037387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8c46c92b-571b-4cee-9bdc-0ac613a3a1c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_25b72c93-df84-424f-b31c-98f35f90613c" xlink:to="loc_ifrs-full_Equity_8c46c92b-571b-4cee-9bdc-0ac613a3a1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsinOrdinaryShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1615e4bf-b687-46b8-b8a1-d5d9b3074dac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1615e4bf-b687-46b8-b8a1-d5d9b3074dac" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_353fbc44-6153-4a39-bcb7-f6e0e79bd568" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_cade6254-c206-4d57-9ce3-bce7b178ebd3" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_353fbc44-6153-4a39-bcb7-f6e0e79bd568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_adb3aea6-19e1-49dc-8d8d-6e220030d7e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_353fbc44-6153-4a39-bcb7-f6e0e79bd568" xlink:to="loc_ifrs-full_OrdinarySharesMember_adb3aea6-19e1-49dc-8d8d-6e220030d7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember_a5f6472b-3672-44ba-917c-9c85b8278721" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis_1bd069ce-322d-422e-b414-03c6b9bea8f2" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsMember_a5f6472b-3672-44ba-917c-9c85b8278721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PlacementAgreementMember_75289446-3ed7-4225-aeb9-2a331f3d15a4" xlink:href="meso-20231231.xsd#meso_PlacementAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsMember_a5f6472b-3672-44ba-917c-9c85b8278721" xlink:to="loc_meso_PlacementAgreementMember_75289446-3ed7-4225-aeb9-2a331f3d15a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_b1a7332f-d493-4122-bc67-abada505b572" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_31e7dee6-3291-4c59-a8ee-1bcf19c52213" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_NumberOfSharesIssued_31e7dee6-3291-4c59-a8ee-1bcf19c52213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_e5c360d1-9d45-4edd-ad7e-449f9d9a2902" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_Equity_e5c360d1-9d45-4edd-ad7e-449f9d9a2902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan_4a0ff44b-1f9c-4548-8d83-28bffb9021f4" xlink:href="meso-20231231.xsd#meso_SharesAvailableForIssuanceUnderIssuancePlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_SharesAvailableForIssuanceUnderIssuancePlan_4a0ff44b-1f9c-4548-8d83-28bffb9021f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesIssuedInPlacementsValue_f43b2e4a-54d5-4b52-a18a-6b6c71c48130" xlink:href="meso-20231231.xsd#meso_SharesIssuedInPlacementsValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_SharesIssuedInPlacementsValue_f43b2e4a-54d5-4b52-a18a-6b6c71c48130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssueShare_4bfe2e04-b0aa-4a00-ac91-d8592871252e" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssueShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_TransactionCostsArisingOnShareIssueShare_4bfe2e04-b0aa-4a00-ac91-d8592871252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TransactionCostsArisingOnShareIssue_d825bfbf-3582-4ef3-86d4-d4b323a1271d" xlink:href="meso-20231231.xsd#meso_TransactionCostsArisingOnShareIssue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_TransactionCostsArisingOnShareIssue_d825bfbf-3582-4ef3-86d4-d4b323a1271d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfEquityDuringPeriod_5b9fc7eb-92c8-4d6b-b796-2408aef013cf" xlink:href="meso-20231231.xsd#meso_ContributionsOfEquityDuringPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ContributionsOfEquityDuringPeriod_5b9fc7eb-92c8-4d6b-b796-2408aef013cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ContributionsOfValueForEquityDuringPeriod_92b44c5f-bd87-4183-a39b-1cb9ad42f5b5" xlink:href="meso-20231231.xsd#meso_ContributionsOfValueForEquityDuringPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ContributionsOfValueForEquityDuringPeriod_92b44c5f-bd87-4183-a39b-1cb9ad42f5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_6002d634-a943-4f43-8e86-ffa531bc5a32" xlink:href="meso-20231231.xsd#meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare_6002d634-a943-4f43-8e86-ffa531bc5a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_a07e439d-2483-480b-9db2-18b6d43034cc" xlink:href="meso-20231231.xsd#meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_5be4989a-b691-436c-9c90-8a6288327945" xlink:to="loc_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue_a07e439d-2483-480b-9db2-18b6d43034cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_9943fab5-953b-42b8-8d18-ab851e3801e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_NumberOfSharesIssued_9943fab5-953b-42b8-8d18-ab851e3801e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_42241f43-f6b6-4e77-8c13-6277d5aaa919" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5b4ededa-8aae-4cbe-ae6f-a1d108cd9dd0" xlink:to="loc_ifrs-full_Equity_42241f43-f6b6-4e77-8c13-6277d5aaa919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a0943610-1d97-45ae-91e6-c86475dafcc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a0943610-1d97-45ae-91e6-c86475dafcc1" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_a2278a19-371d-4f18-9f3f-6cfdc2663f8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_54ae1e32-aec6-4987-9243-f7c7e1e9feae" xlink:to="loc_ifrs-full_EquityMember_a2278a19-371d-4f18-9f3f-6cfdc2663f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember_33baad46-310d-4881-b910-18e59b41bf23" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_a2278a19-371d-4f18-9f3f-6cfdc2663f8c" xlink:to="loc_meso_PrivatePlacementOfSharesMember_33baad46-310d-4881-b910-18e59b41bf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_10691a3e-67c9-4417-90c9-6040c4ecad3d" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedButNotFullyPaid_fbc198b2-a866-41a4-ae78-2f32ca408efb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedButNotFullyPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_ifrs-full_NumberOfSharesIssuedButNotFullyPaid_fbc198b2-a866-41a4-ae78-2f32ca408efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_b1e8e3c5-9e21-40c0-8eb3-838eb82e1263" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_ifrs-full_ParValuePerShare_b1e8e3c5-9e21-40c0-8eb3-838eb82e1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DiscountedPercentageOnIssuanceOfEquity_bcf8014d-f602-4dc8-af88-11c35f79ef84" xlink:href="meso-20231231.xsd#meso_DiscountedPercentageOnIssuanceOfEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_6b546ea5-14e8-4f3c-9458-9fc3b6367723" xlink:to="loc_meso_DiscountedPercentageOnIssuanceOfEquity_bcf8014d-f602-4dc8-af88-11c35f79ef84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofMovementsofSharesinShareTrustDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1a978e1a-ab09-48b0-ac43-dfb62e4df1ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_1a978e1a-ab09-48b0-ac43-dfb62e4df1ce" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:to="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_7f9dd9e7-b2b3-413a-8595-0d6cf6da58f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_edb02d07-c267-4796-93f8-f6168a2c485e" xlink:to="loc_ifrs-full_CounterpartiesMember_7f9dd9e7-b2b3-413a-8595-0d6cf6da58f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MesoblastEmployeeShareTrustMember_8e96733d-5fd5-40c3-a01d-37ea39f562c5" xlink:href="meso-20231231.xsd#meso_MesoblastEmployeeShareTrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_7f9dd9e7-b2b3-413a-8595-0d6cf6da58f4" xlink:to="loc_meso_MesoblastEmployeeShareTrustMember_8e96733d-5fd5-40c3-a01d-37ea39f562c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:href="meso-20231231.xsd#meso_DisclosureOfMovementsOfSharesInShareTrustLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustTable_6a234cc2-cf15-4122-86ee-abc54a6a0033" xlink:to="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrust_b617fd72-c51f-4a31-9739-20a0d0d1e3c5" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrust"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_SharesHeldInTrust_b617fd72-c51f-4a31-9739-20a0d0d1e3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrustValue_cb07ad54-881b-4af1-8239-c83e465a0d2d" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrustValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_SharesHeldInTrustValue_cb07ad54-881b-4af1-8239-c83e465a0d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_9775a259-1a20-4c10-a785-52e30f03a476" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_9775a259-1a20-4c10-a785-52e30f03a476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_34378901-8285-4913-9f4f-0299fa01f42b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_34378901-8285-4913-9f4f-0299fa01f42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrust_bcccf66b-b9e6-4370-a7e6-701ab6a82819" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrust"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_SharesHeldInTrust_bcccf66b-b9e6-4370-a7e6-701ab6a82819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesHeldInTrustValue_97232985-7607-4cba-a966-94db84f2679e" xlink:href="meso-20231231.xsd#meso_SharesHeldInTrustValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems_9b76d828-df7b-48bc-b14b-c9eeb897d92b" xlink:to="loc_meso_SharesHeldInTrustValue_97232985-7607-4cba-a966-94db84f2679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquitySummaryofWarrantReserveDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_353d5370-216a-4242-b614-41b50769383c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_353d5370-216a-4242-b614-41b50769383c" xlink:to="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_7cd8858a-94a1-479b-b300-a0bfc3c0d104" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b17ed10a-73e4-494e-beb5-bfea11a0db49" xlink:to="loc_ifrs-full_EquityMember_7cd8858a-94a1-479b-b300-a0bfc3c0d104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_f1d1e44e-0d7f-4e38-a28f-d9b3939a6d82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_7cd8858a-94a1-479b-b300-a0bfc3c0d104" xlink:to="loc_ifrs-full_WarrantsMember_f1d1e44e-0d7f-4e38-a28f-d9b3939a6d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:href="meso-20231231.xsd#meso_DisclosureOfWarrantReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfWarrantReserveTable_166ff2fb-9eaa-4196-a9e4-661b7e29642b" xlink:to="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_171a9f29-3e75-4468-b5a7-f500c03c3cef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:to="loc_ifrs-full_Equity_171a9f29-3e75-4468-b5a7-f500c03c3cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquity_a92a568e-b758-42cc-a9b4-59148f6a63cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:to="loc_ifrs-full_ChangesInEquity_a92a568e-b758-42cc-a9b4-59148f6a63cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9b5d37af-61ab-41fc-94e3-4a608d36ac33" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfWarrantReserveLineItems_8e4d9546-c0f3-4805-a1ea-4763d62a8287" xlink:to="loc_ifrs-full_Equity_9b5d37af-61ab-41fc-94e3-4a608d36ac33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2e61f082-98f2-471d-96cc-69168110c126" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2e61f082-98f2-471d-96cc-69168110c126" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_aea9b8cd-3756-4692-871f-667e800c79b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_028a8185-1531-4333-911c-310485760b2d" xlink:to="loc_ifrs-full_EquityMember_aea9b8cd-3756-4692-871f-667e800c79b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PrivatePlacementOfSharesMember_881dfeca-40ce-492f-80b8-a01a8a99c76f" xlink:href="meso-20231231.xsd#meso_PrivatePlacementOfSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_aea9b8cd-3756-4692-871f-667e800c79b2" xlink:to="loc_meso_PrivatePlacementOfSharesMember_881dfeca-40ce-492f-80b8-a01a8a99c76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReservesWithinEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_e4b9417a-b2ea-49d3-a72d-e8f08ff2fe5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReservesWithinEquityAxis_83e69e42-dd7b-46e2-96dc-56f196f3ec1c" xlink:to="loc_ifrs-full_OtherReservesMember_e4b9417a-b2ea-49d3-a72d-e8f08ff2fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_ee64eb17-4023-4cfa-ad09-4e7e230fb3a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherReservesMember_e4b9417a-b2ea-49d3-a72d-e8f08ff2fe5b" xlink:to="loc_ifrs-full_WarrantsMember_ee64eb17-4023-4cfa-ad09-4e7e230fb3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_5464389e-e29d-48aa-85c8-2967cc435acc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_0d0219f5-e9ca-4673-9a89-926a4108abcd" xlink:to="loc_ifrs-full_RangesMember_5464389e-e29d-48aa-85c8-2967cc435acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_6f5e1c9c-2c19-4c79-8b49-b5824f449e45" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_5464389e-e29d-48aa-85c8-2967cc435acc" xlink:to="loc_ifrs-full_BottomOfRangeMember_6f5e1c9c-2c19-4c79-8b49-b5824f449e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_3166414e-e4ee-4063-8ce5-7be40c823332" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_f1567cd2-5329-4750-a558-c98a4d340446" xlink:to="loc_ifrs-full_NonadjustingEventsMember_3166414e-e4ee-4063-8ce5-7be40c823332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_073f4191-885f-467e-8e69-9dbef7878c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_3166414e-e4ee-4063-8ce5-7be40c823332" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_073f4191-885f-467e-8e69-9dbef7878c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c55945c1-d13b-4af7-b369-fb2dde08cf21" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_fd381f9b-6cb1-4f5e-a757-57a1c5b53b49" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_fd381f9b-6cb1-4f5e-a757-57a1c5b53b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_2ae277ba-cee0-4c76-97ae-066e57374c79" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_2ae277ba-cee0-4c76-97ae-066e57374c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_190105aa-8c32-46b9-8d81-bb30374c4a56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_ParValuePerShare_190105aa-8c32-46b9-8d81-bb30374c4a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ConversionRatioOfWarrants_c99dcd5e-75ac-487f-92f6-d0a56d315082" xlink:href="meso-20231231.xsd#meso_ConversionRatioOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_ConversionRatioOfWarrants_c99dcd5e-75ac-487f-92f6-d0a56d315082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_b03156d5-cb1c-48d1-aace-b19042acbb12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_ifrs-full_NumberOfSharesIssued_b03156d5-cb1c-48d1-aace-b19042acbb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExercisePricePerShare_3409602f-3505-4419-840a-3d4c493874fa" xlink:href="meso-20231231.xsd#meso_WarrantExercisePricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_WarrantExercisePricePerShare_3409602f-3505-4419-840a-3d4c493874fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_WarrantExerciseTerm_e0ef9c37-8eac-4320-a6b8-087390ddb069" xlink:href="meso-20231231.xsd#meso_WarrantExerciseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_WarrantExerciseTerm_e0ef9c37-8eac-4320-a6b8-087390ddb069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharesPrice_99d232e0-b874-4304-9110-d14747e1cdc6" xlink:href="meso-20231231.xsd#meso_SharesPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_SharesPrice_99d232e0-b874-4304-9110-d14747e1cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SharePriceMinimumConsecutiveDay_54476e53-d6ad-471d-b489-4c6879aea3f4" xlink:href="meso-20231231.xsd#meso_SharePriceMinimumConsecutiveDay"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_54789f84-c577-4d5f-a890-2c641e533fab" xlink:to="loc_meso_SharePriceMinimumConsecutiveDay_54476e53-d6ad-471d-b489-4c6879aea3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_5bdbc055-17b1-4546-8074-8425c6107b2a" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_5bdbc055-17b1-4546-8074-8425c6107b2a" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_47e5dfaf-bac1-453d-b682-adafbc61b1fb" xlink:to="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_2fb253c5-8219-4a78-a42d-0560dc54d8a5" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:to="loc_currency_USD_2fb253c5-8219-4a78-a42d-0560dc54d8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_5c01f305-2def-4e30-bfdf-c1da41e281ab" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:to="loc_currency_AUD_5c01f305-2def-4e30-bfdf-c1da41e281ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OtherCurrencyMember_fc51dd7d-5331-4759-90bd-787fb54069a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OtherCurrencyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_bf5913d9-c536-4fc2-88e0-c19b75b130a7" xlink:to="loc_srt_OtherCurrencyMember_fc51dd7d-5331-4759-90bd-787fb54069a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_392d443a-7d51-47cb-97af-102454f0a448" xlink:to="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_4153ab44-e1a0-4a91-b4e9-deebf4976b01" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:to="loc_ifrs-full_CurrencyRiskMember_4153ab44-e1a0-4a91-b4e9-deebf4976b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_e6c9d98c-f481-4bf3-b238-e67d3364f00e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:to="loc_ifrs-full_InterestRateRiskMember_e6c9d98c-f481-4bf3-b238-e67d3364f00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiquidityRiskMember_d153ad71-fbd1-40c6-850f-6330116192f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_f2420866-fb37-44e4-8b79-73f9b8eaa60f" xlink:to="loc_ifrs-full_LiquidityRiskMember_d153ad71-fbd1-40c6-850f-6330116192f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesMember_47bac647-f949-4e87-ae32-1594cb5d1b0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_78746b3c-abb1-4229-8083-64434a5bac83" xlink:to="loc_ifrs-full_CounterpartiesMember_47bac647-f949-4e87-ae32-1594cb5d1b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_LonzaBioscienceSingaporePteLtdMember_ad2cff96-62b4-4481-bc20-f2114baf1afd" xlink:href="meso-20231231.xsd#meso_LonzaBioscienceSingaporePteLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesMember_47bac647-f949-4e87-ae32-1594cb5d1b0b" xlink:to="loc_meso_LonzaBioscienceSingaporePteLtdMember_ad2cff96-62b4-4481-bc20-f2114baf1afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ServiceConcessionArrangementsMember_cbb170a7-9b3a-48c0-9a2d-7b71b5fde975" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServiceConcessionArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsAxis_684b36ef-685c-4d82-b239-56164ce36596" xlink:to="loc_ifrs-full_ServiceConcessionArrangementsMember_cbb170a7-9b3a-48c0-9a2d-7b71b5fde975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_ManufacturingServiceAgreementMember_62ef50de-bd30-418a-b890-9d91694b5c08" xlink:href="meso-20231231.xsd#meso_ManufacturingServiceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ServiceConcessionArrangementsMember_cbb170a7-9b3a-48c0-9a2d-7b71b5fde975" xlink:to="loc_meso_ManufacturingServiceAgreementMember_62ef50de-bd30-418a-b890-9d91694b5c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_b895eb8f-7c8e-415e-91ed-e90855921527" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfCashHeld_e6b0b7f6-36c5-4c7b-a986-a0b94e3d7179" xlink:href="meso-20231231.xsd#meso_PercentageOfCashHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_PercentageOfCashHeld_e6b0b7f6-36c5-4c7b-a986-a0b94e3d7179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOnProfitFromChangeInInterestRate_b2c9ac5a-14bc-48e4-ae99-42dfa0e60ff7" xlink:href="meso-20231231.xsd#meso_EffectOnProfitFromChangeInInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_EffectOnProfitFromChangeInInterestRate_b2c9ac5a-14bc-48e4-ae99-42dfa0e60ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfForecastNetSales_8e628b7e-181d-4f3e-bb64-2de146fef5ca" xlink:href="meso-20231231.xsd#meso_PercentageOfForecastNetSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_PercentageOfForecastNetSales_8e628b7e-181d-4f3e-bb64-2de146fef5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_d29b6324-6153-4e5b-98a0-28ad3683f73a" xlink:href="meso-20231231.xsd#meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod_d29b6324-6153-4e5b-98a0-28ad3683f73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_7ae5c9cc-0cb4-40a4-863f-5c4e0c85d787" xlink:href="meso-20231231.xsd#meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_7ae5c9cc-0cb4-40a4-863f-5c4e0c85d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_2d8413b7-4573-4618-a138-3e08a65718a6" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm_2d8413b7-4573-4618-a138-3e08a65718a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmount_39d5da07-482f-4860-85fe-4d8d692ceaeb" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentReductionAmount_39d5da07-482f-4860-85fe-4d8d692ceaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_d8403336-6eda-4eb7-b51b-1b4d43802c3d" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent_d8403336-6eda-4eb7-b51b-1b4d43802c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_bb259166-dadf-4a2c-ba83-766dff0ac0ab" xlink:href="meso-20231231.xsd#meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent_bb259166-dadf-4a2c-ba83-766dff0ac0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NonCancellablePurchaseCommitments_3e8db371-8ab6-4cdc-9c75-f4e747844f5a" xlink:href="meso-20231231.xsd#meso_NonCancellablePurchaseCommitments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_NonCancellablePurchaseCommitments_3e8db371-8ab6-4cdc-9c75-f4e747844f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_OtherPurchaseCommitments_3f6a8072-1007-4699-ad9f-1de1ee23cb10" xlink:href="meso-20231231.xsd#meso_OtherPurchaseCommitments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_303c1a6f-8453-46d4-9646-5363c69d50f9" xlink:to="loc_meso_OtherPurchaseCommitments_3f6a8072-1007-4699-ad9f-1de1ee23cb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_e550a1bf-136d-43d4-82e8-54a69f85c3b9" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_e550a1bf-136d-43d4-82e8-54a69f85c3b9" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_cf9b5aa3-c804-4dfe-ac35-a403515deb76" xlink:to="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_d5792d89-6374-41b9-9a60-e73ebbd040bd" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:to="loc_currency_USD_d5792d89-6374-41b9-9a60-e73ebbd040bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_58f9e750-0198-4c79-9f47-6fd56243ca68" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f7ee8c27-7395-4ce3-8581-6e71eb09abc4" xlink:to="loc_currency_AUD_58f9e750-0198-4c79-9f47-6fd56243ca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_021b707e-6bd8-4f34-83c4-059c72dc1601" xlink:to="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_e0fd2dcc-38a6-4713-910e-89f6506111d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:to="loc_ifrs-full_BottomOfRangeMember_e0fd2dcc-38a6-4713-910e-89f6506111d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_f13b5992-dbd6-40b1-a88d-3a5d261bb215" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_773c4e43-fa2b-47cf-afb0-d5b6796c37ed" xlink:to="loc_ifrs-full_TopOfRangeMember_f13b5992-dbd6-40b1-a88d-3a5d261bb215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_bd2ef2f1-0d89-46f1-9a61-9dd377e73146" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_ca88ef55-3dbe-4122-923d-6bf33baca866" xlink:to="loc_ifrs-full_TypesOfRisksMember_bd2ef2f1-0d89-46f1-9a61-9dd377e73146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_fb80cd13-3c0c-4a51-8e37-5f55d95c66f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_bd2ef2f1-0d89-46f1-9a61-9dd377e73146" xlink:to="loc_ifrs-full_InterestRateRiskMember_fb80cd13-3c0c-4a51-8e37-5f55d95c66f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_30b4c666-f230-4f3d-b6fb-edcf79c6434c" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FundsInvestedPercentage_bfb305d7-ed08-49a5-afa5-d530dff2372f" xlink:href="meso-20231231.xsd#meso_FundsInvestedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_FundsInvestedPercentage_bfb305d7-ed08-49a5-afa5-d530dff2372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseInInterestRatePercentage_032f171c-8d2b-4f49-8a99-a24e660d2f96" xlink:href="meso-20231231.xsd#meso_IncreaseInInterestRatePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_IncreaseInInterestRatePercentage_032f171c-8d2b-4f49-8a99-a24e660d2f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DecreaseInInterestRatePercentage_8029451e-d3a9-43d9-9e53-9a662bd118f1" xlink:href="meso-20231231.xsd#meso_DecreaseInInterestRatePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_DecreaseInInterestRatePercentage_8029451e-d3a9-43d9-9e53-9a662bd118f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_FundsInvestedWhichDerivesInterestRevenue_4477a2b8-b179-424a-b4ec-4554ce4843ea" xlink:href="meso-20231231.xsd#meso_FundsInvestedWhichDerivesInterestRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_FundsInvestedWhichDerivesInterestRevenue_4477a2b8-b179-424a-b4ec-4554ce4843ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_5755ae1f-3333-4282-a8b7-19a58b1fc2ff" xlink:href="meso-20231231.xsd#meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_5755ae1f-3333-4282-a8b7-19a58b1fc2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_74401eff-c46b-41a1-b95c-dff6fd328dd2" xlink:href="meso-20231231.xsd#meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_7eeae795-d781-465d-943b-8bdd42940bed" xlink:to="loc_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue_74401eff-c46b-41a1-b95c-dff6fd328dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_41b4c8b1-cf51-49d3-b886-692fd89e6f6b" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_41b4c8b1-cf51-49d3-b886-692fd89e6f6b" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_0f6c96e7-f81f-4faa-829d-ad72583d7c1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_7bbc2edf-165a-4ae8-bcff-62520223a2ea" xlink:to="loc_ifrs-full_TypesOfRisksMember_0f6c96e7-f81f-4faa-829d-ad72583d7c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_f8edab20-482e-4796-9c76-446cf621530b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_0f6c96e7-f81f-4faa-829d-ad72583d7c1c" xlink:to="loc_ifrs-full_InterestRateRiskMember_f8edab20-482e-4796-9c76-446cf621530b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:to="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_a42d4518-0f0b-45b8-9a6d-160a274741e5" xlink:to="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_a7bdd39b-57fc-4827-8ab4-f321af107f70" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:to="loc_currency_USD_a7bdd39b-57fc-4827-8ab4-f321af107f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AUD_34d166da-d2d7-4328-95f1-0899b63245c7" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AUD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_623009dd-b1e8-4959-afbb-272d89b2d80b" xlink:to="loc_currency_AUD_34d166da-d2d7-4328-95f1-0899b63245c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_4248efb9-7ee1-4138-b790-bc679abd39b9" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_7a758e39-1c92-456c-8ae0-20f8c5b0cc4b" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementLineItems_4248efb9-7ee1-4138-b790-bc679abd39b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_25549b8b-d66f-4487-bcaa-ac4b283ba60d" xlink:href="meso-20231231.xsd#meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_4248efb9-7ee1-4138-b790-bc679abd39b9" xlink:to="loc_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease_25549b8b-d66f-4487-bcaa-ac4b283ba60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_5d974f9e-a8f9-4c68-a83a-e852b4d98a00" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_5d974f9e-a8f9-4c68-a83a-e852b4d98a00" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:to="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_32e282ce-f386-4d3c-9ced-705b7ad99152" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_ea9dac77-5a14-4711-a64f-801cceb9b940" xlink:to="loc_ifrs-full_TypesOfRisksMember_32e282ce-f386-4d3c-9ced-705b7ad99152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CommodityPriceRiskMember_bba759fc-70b2-4ea1-a593-193ef844edf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CommodityPriceRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_32e282ce-f386-4d3c-9ced-705b7ad99152" xlink:to="loc_ifrs-full_CommodityPriceRiskMember_bba759fc-70b2-4ea1-a593-193ef844edf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_c09f41c6-3728-4a65-a4a0-ccfab48df2f1" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermBorrowings_677ad2ad-c713-40da-97ca-16573ca0d82f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_ifrs-full_ShorttermBorrowings_677ad2ad-c713-40da-97ca-16573ca0d82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_53faa67e-8249-47d9-a46c-060aacd23e53" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_ifrs-full_LongtermBorrowings_53faa67e-8249-47d9-a46c-060aacd23e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_02f5dda1-f963-478f-a9fe-f5544fe1f16a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_ifrs-full_Borrowings_02f5dda1-f963-478f-a9fe-f5544fe1f16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings_01243005-3bab-4d7e-b3ea-f6abaca6faa6" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInCurrentBorrowings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_PercentageOfPriceRateChangesInCurrentBorrowings_01243005-3bab-4d7e-b3ea-f6abaca6faa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_5be9528b-a4e0-4adf-bcfb-a47acdff2321" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInNonCurrentBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings_5be9528b-a4e0-4adf-bcfb-a47acdff2321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfPriceRateChangesInBorrowings_2b67d976-6ab8-4698-941a-c51eec684727" xlink:href="meso-20231231.xsd#meso_PercentageOfPriceRateChangesInBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_f5a70b5e-45a9-4975-bc53-26252125a1c7" xlink:to="loc_meso_PercentageOfPriceRateChangesInBorrowings_2b67d976-6ab8-4698-941a-c51eec684727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_4066b465-64ea-4348-ad12-db87f14d7bf0" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_4066b465-64ea-4348-ad12-db87f14d7bf0" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:to="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_e4e49aaf-3dbf-4150-afef-1899c5fca8e9" xlink:to="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_a97a204c-e571-42e5-ae7a-18c58fc8c54e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:to="loc_ifrs-full_TopOfRangeMember_a97a204c-e571-42e5-ae7a-18c58fc8c54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_5b96563d-880d-4949-9f16-48426073652d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_e5bde79a-37e2-415f-87a5-13eff755ffd5" xlink:to="loc_ifrs-full_BottomOfRangeMember_5b96563d-880d-4949-9f16-48426073652d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:to="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_ac056eb6-4524-4e1f-94b0-718d5d5f9847" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_ifrs-full_WarrantLiability_ac056eb6-4524-4e1f-94b0-718d5d5f9847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_6b304ab3-cf73-4984-94b4-f76c8121453a" xlink:href="meso-20231231.xsd#meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice_6b304ab3-cf73-4984-94b4-f76c8121453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_a49b3d29-ea91-4d95-a1dc-522c802a7cba" xlink:href="meso-20231231.xsd#meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementLineItems_6a601cff-31ec-44d0-9780-909aecb956ac" xlink:to="loc_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice_a49b3d29-ea91-4d95-a1dc-522c802a7cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_PercentageOfIncreaseAndDecreaseInSharePrice_546527c7-ea62-485d-84f9-dbc2a224f713" xlink:href="meso-20231231.xsd#meso_PercentageOfIncreaseAndDecreaseInSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementTable_a9d2bce3-6dbc-475b-845d-52a977dd0d77" xlink:to="loc_meso_PercentageOfIncreaseAndDecreaseInSharePrice_546527c7-ea62-485d-84f9-dbc2a224f713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_meso_DisclosureOfFinancialRiskManagementAbstract_4f0b14b5-3bd1-4417-a915-859d86a9f96f" xlink:href="meso-20231231.xsd#meso_DisclosureOfFinancialRiskManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_meso_DisclosureOfFinancialRiskManagementAbstract_4f0b14b5-3bd1-4417-a915-859d86a9f96f" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_ca084746-a85a-42a2-bacb-b54b33d95627" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowingsMember_879a42b6-ced8-44c6-9221-c98d1c7ad148" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_ifrs-full_LongtermBorrowingsMember_879a42b6-ced8-44c6-9221-c98d1c7ad148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_TradePayablesMember_08398287-24e0-4b43-a812-44ea47b724c7" xlink:href="meso-20231231.xsd#meso_TradePayablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_meso_TradePayablesMember_08398287-24e0-4b43-a812-44ea47b724c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_13ccf2f7-25d0-4836-aa85-6e6e562bcfa2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_13ccf2f7-25d0-4836-aa85-6e6e562bcfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentConsiderationMember_ec361d1c-5d5c-44fe-b18b-4aa556a66f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContingentConsiderationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_7b851b49-2239-440f-ae7c-c554acec462d" xlink:to="loc_ifrs-full_ContingentConsiderationMember_ec361d1c-5d5c-44fe-b18b-4aa556a66f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:to="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_377fc04d-d61a-43e7-bad5-c7a02b9979a5" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_0ec7840e-263e-49f8-b98d-36726c125f1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_0ec7840e-263e-49f8-b98d-36726c125f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2236282d-a67d-4dc3-b6a1-70703dcdb6d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_2236282d-a67d-4dc3-b6a1-70703dcdb6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3ee0e023-d839-4388-a207-cb8225b03dae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_3ee0e023-d839-4388-a207-cb8225b03dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_4ded5142-abe4-44c8-ae6e-9a094a29bdd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_edb4d081-981d-4c3c-a078-78b9b39b052e" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_4ded5142-abe4-44c8-ae6e-9a094a29bdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_25a57afc-163a-4f4c-8e66-cfdc68a5f18d" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_c75231c8-a2e9-4123-822d-21b11b111546" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows_c75231c8-a2e9-4123-822d-21b11b111546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLoanCommitments_09917ab8-f5f8-4377-b945-6df443d198ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLoanCommitments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_cfcac133-9869-4c17-b3b2-cc5b3d44365d" xlink:to="loc_ifrs-full_GrossLoanCommitments_09917ab8-f5f8-4377-b945-6df443d198ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LossespershareDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LossespershareDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LossespershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_7a21351a-9160-4d72-899b-31256498e425" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_57b8486c-ff34-412b-b83c-4ed8edec361d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7a21351a-9160-4d72-899b-31256498e425" xlink:to="loc_ifrs-full_BasicEarningsPerShareAbstract_57b8486c-ff34-412b-b83c-4ed8edec361d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_de89266a-eb0c-4144-83da-cab0989428a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_57b8486c-ff34-412b-b83c-4ed8edec361d" xlink:to="loc_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations_de89266a-eb0c-4144-83da-cab0989428a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_92a9666d-61ca-47c3-8853-efd2047bc5ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_57b8486c-ff34-412b-b83c-4ed8edec361d" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_92a9666d-61ca-47c3-8853-efd2047bc5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsPerShareAbstract_e9ca21ed-0115-478d-9960-9512f28e0dd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7a21351a-9160-4d72-899b-31256498e425" xlink:to="loc_ifrs-full_DilutedEarningsPerShareAbstract_e9ca21ed-0115-478d-9960-9512f28e0dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_3ecf2f53-e7d7-448a-b14b-84394050013d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DilutedEarningsPerShareAbstract_e9ca21ed-0115-478d-9960-9512f28e0dd3" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations_3ecf2f53-e7d7-448a-b14b-84394050013d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_62c733ab-f4b2-4a40-8b6d-777d8d7e48cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DilutedEarningsPerShareAbstract_e9ca21ed-0115-478d-9960-9512f28e0dd3" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_62c733ab-f4b2-4a40-8b6d-777d8d7e48cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7a21351a-9160-4d72-899b-31256498e425" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_62edd3bc-d9b5-4fb9-bf10-e82c23bb1191" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity_62edd3bc-d9b5-4fb9-bf10-e82c23bb1191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_4b7132e5-5d07-48e7-a804-a7a98461776b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:to="loc_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_4b7132e5-5d07-48e7-a804-a7a98461776b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_9b9a1cab-ab2d-4496-97fc-53c9f6f2379f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:to="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects_9b9a1cab-ab2d-4496-97fc-53c9f6f2379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_aaf5a408-f0a0-48df-84ea-7683794f81ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:to="loc_ifrs-full_WeightedAverageShares_aaf5a408-f0a0-48df-84ea-7683794f81ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_d5552f95-374d-4423-9e59-7e2fd47de93c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract_4c73503d-6760-460c-ad79-a7b1785d6d06" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_d5552f95-374d-4423-9e59-7e2fd47de93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/SegmentInformationDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#SegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_cc3d19e1-e5e9-4c88-8892-fc21861a7397" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfOperatingSegment_e08dbe3d-0d5f-45c9-9254-c44acdda9879" xlink:href="meso-20231231.xsd#meso_NumberOfOperatingSegment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsAbstract_cc3d19e1-e5e9-4c88-8892-fc21861a7397" xlink:to="loc_meso_NumberOfOperatingSegment_e08dbe3d-0d5f-45c9-9254-c44acdda9879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mesoblast.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="meso-20231231.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.mesoblast.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LegalProceedingsProvisionAbstract_d85366f0-18ee-4ad7-9e7a-0acb679e2c8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LegalProceedingsProvisionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_meso_NumberOfClassActionLawsuits_56d54695-2f54-41d1-a45a-5f0445a8750f" xlink:href="meso-20231231.xsd#meso_NumberOfClassActionLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LegalProceedingsProvisionAbstract_d85366f0-18ee-4ad7-9e7a-0acb679e2c8d" xlink:to="loc_meso_NumberOfClassActionLawsuits_56d54695-2f54-41d1-a45a-5f0445a8750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex992independentauditors001.jpg
<TEXT>
begin 644 ex992independentauditors001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KG;[P-X?U'7X]=N;6X;5(UVQW*7LR,B\\+M<8'S-
MP/4UT5% &):^$](L[B\N84N_M-Y&(IIWOIWD* D@!V<E>IZ$5!'X%\.PZQ8Z
MM'92+?V,*V]O,+J7*1J" OWL$8)ZYSWKHJ* .5;X<^%7MM3MFTZ1H=4E$UZI
MNYOW[ABP+?/ZG-67\$>'Y+S2KM[.4SZ4@CLG-U+F%1V'S<^G.<UT-% ',R^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6X@FD",K 8.,]1WS6A'XY\.W&O6^BVNHQW5].2%2#YPN 2<L.!TI@=%1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<,4.TLI#CAE.#@X_IG#TOXDZ]XDT"+5O#O@R2\AVDS>;?K$ X)RD>5RYQCG
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M.=$\-&S,AU2*:07'F8\ORU+8VXYSCU%'B+Q6- U[P]I9LS.=8N&@$GF;?*P
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M@!A@.Q'\QGBOB#-JE]\7_#-G-X8AU*WA2Y:UM9KM-EY^[R6(8$)M(S@YSMH
M]HCD26-9(W5T<!E93D,#T(-.J&T!6R@#6ZVY$:@PJ01'Q]T8XP.G%34 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!Z@4 >9?%'_D@D)_Z8V7\TKU>,AHU8$$$ @CO5"^T+3-2T-M%O+-)M.:-8C
MV<;5Q@9Z\8'/7BF:!X=TKPQIO]GZ/:_9K7>7V>8S_,0 3EB3V'>@#F_B;XDU
M/0-*TJWTF>*UNM5U&*Q%Y*@9;</G+X/!/'?WKS[XQ:,^A^#56^\8:QJ-W//'
MMM+AX_+8 _,^Q4! ''.<9('>O:=:T/3/$6F2:=J]G'=VCD$QOGJ.A!'(/N*Q
MK7X;^$;/3KNPBT6%H+Q D_FN\CNH((&]F+  @$8/4"@#G?%<B0_&_P !S2L$
MC>"\C5B>"QC( ^N2/SJ+XB7MNWQ,^']BLJM<)>R2N@/**0H!/IG!Q]#767G@
M'PQ?Z!:Z)=:4DNGVA+6\;2/NC)))P^[<.3ZTEA\/_"VF&T:TTB*-[2?[1%)O
M=G$F,;BQ.6X]2: .6U:1;+]HC1)KI@D5UHKV]NS< RAW8J/?!'YBHOB#>VLG
MQ8^'UBCJUU#<S22*#RBL%"Y^NT_E7>>(?"VB>*K1+76]/CNXHVW1[B59#ZJR
MD$?@:H:?\/O"NEO:26>CQ1RVDQGADWNSB0C&XL22W'J30!SNM?\ )?O#/_8*
MN/\ V:D0A?VC7!(&[PW@9[_OQ7<S:'IMQKEOK4MJK:C;1-%#/N.51NHQG'?T
MK/U_P/X;\3WMO>ZQI:7-S;KMCE\QT8+G.#M(R,D\'/4T <BCKI_[1<S7A"#4
M-#"6;-T9E=2RCW^5CBCQZZWWQ4\ :?:L'O(+B:YE5>L<6U>3Z [3^5=OK_AC
M1?%%M';ZSI\5VD;;HRQ*LA]592"/P-0:!X,\/>%Y99M(TV.">88DF9VDD8>A
M=R3CVS0!R<ZAOVCK4D E?#9(]CY[#^M>E5GG0]-;7UUTVJ_VFMO]E%QN.1%N
MW;<9QU.>F:T* ."\1>'M$\2^,/\ 0-?NM)\5V5L TEF^US"3D!U(PZY/;UY[
M57\,ZYXCTSX@R^#-?U&VU@&P^VPWT4(BD0!MNV11P/\ ]77/'3>(/!7AWQ1+
M%-K&F1W$\0VQS*[1R*/3<A!Q[9[U)X?\(:!X6$O]C:;';/-_K)-S/(_U=B6(
M]LT ;=>:_!]0(O&+8&X^)+H$^PV_XFO2JS]*T/3=#6[73;5;<7=PUU/AB=\K
M8W-R3UP.E 'E6H:7>3_'S4X%U^ZT62^TV)[66%$)G5=H9!O![J3@>E;</A2V
M@^(6B2ZKXVO-1UFS26:UM)TC#%&7:_W0./KZ?6NRU_PKH?BFWCAUK3HKM8CN
MC9B5=#_LLI##MT/:H?#_ (+\/>%Y99M'TR.WGF&))F=I)&'IO<DX]LT >=:U
MK0^&?C;Q9-PMKK&G?VC: _=^UK\A4>[%@Q_"NL\)>'F\,_"E;&8'[6]G)<71
M;J974LV?<9Q^%;^N>%M$\226<FL:=%=M9N9("Y(V$XST(ST'!XXK5FB2>&2&
M5=T<BE67U!&"* /'=$M+B]_9;:"U5FF-A<,%7J0)G) _ &KGA+0K_4/ FEZG
M;?$34K>Q%DA95C@V6X50&0DKP%P1SZ5Z9I.D6&A:7!IFFVZV]G "(X@20N22
M>22>I-<W<?"KP3=7DES)H,0>1M[I'+(D;'U,:L%_2@#BM4\.6&D_!2WO/#NH
MOJ<.D7JZO9W##&=DGSXP.  7_*H+Z#_A,=$^(/BFR.XQRPIITG=1: 2$K_O,
M6KV-M-LGTMM,-K$+%H3 ;=5VIY9&TJ .@QQ5;2?#VDZ'HW]D:;91V]A\W[D$
MD'=][))).<T <-X$O8_%_C_7/%L?S6L-E;:?:-UQN42R#\&8"O3*S-!\.Z3X
M8T\V&C626EJ7,AC0DY8X!.22>P_*M.@#S7X-*!IGBE@!N/B.[!/X)6'=Z5>W
M'Q[UJW3Q!=:++?:?#+:O"B$SJJJK*-X/0JQP/0UZMI.AZ;H45S'IEJMNES<-
M<S!6)WRMC<W)/7 JMX@\*:'XIABBUK3HKH1',;DE70_[+*0P[=#VH X^U\*V
MMO\ $71Y]3\:WFHZU912RVUI.D8)C92K$[0..>_I5;X:W=L/B+\0K,NHNFU$
M2A2>60;AD>N"?_'AZUVOA_P9X>\+O+)H^F1V\TPQ),6:21AZ%W);'MFN%\-^
M";+6_$OC7_A(-'E:)M6\VTED5XF((()C<8.#QG!P>* +.@,MY\?_ !/<VI#P
M6VF0VT[KR/-)4@9]0%(_ T?!UUM4\5Z3<$+J-OKD\DT9^\58+M;Z':>:[G0/
M#6C>%[%K/1;".TA9M[A269V]68DDGZFJ&N> ?#'B.^%]J>E))=[=IGCE>%V'
MHQ1@3^- '*^%'6_^.'C._M"'M(;:WM9)%Y4RA5R,]R-K _2I/A&H$WC9L#<?
M$ET"?88_Q-=UHNA:7X=T];#2+&&SME.[9&.I]2>I/N>:-+T/3=%-X=.M5@^V
M7#75QAB=\K?>;DGKCM0!PVH$#]HC2,D#=H,@'N?,>O2:P/$7@GP[XKFMYM;T
MQ+J6W!$3^8Z,H/494@D>QK>50BA5& !@"@#S?4"!^T3I.2!G0' SW/FO46JN
MMA^T-HUS>$)!>Z,]M;._ ,H=F*@^N"/^^A77^(O!/ASQ7-;S:WIB74MN"(G\
MQT90>HRI&1[&K6M^&]'\1Z>MCJ^GQ7=NA#(KY!0^JL,%3[@T <-\3W6[\7^
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MS/,=TIBFDB60^K*C '\10!P6KZ/I6D_ KQ6VCZV^L6]W<FX>Y8 ?O3)&& P
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MT_Y)IX<_Z\(_Y5U5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!Y]\0H)I?%O@-XXG=8]5+.54D*-O4^E<OX]\/Z
MLGCF;2M*BE&G>,5ACO)8P<0M$X\QO09C_/)KVFB@#SK5[$P?&7P:+>W9;2WT
M^ZC!53L0;, 9[5RQTKPYX3\=>)/^$UT&.XT_4[HWMCJ4EB;A!O)+QDJI*D$]
M/Q[BO;J* //?!LNB7%UJNH^%_!4=G!!#LM;XP"U-ZQ&2B@J"%R!\Q_*N7U?6
M/AOXDM'D\1^'+O3O$+ ^9;16,RW(E_V9$4!SGH6_$5[510!Y*WACQ+XB_9]&
MCZH)FUPP^9&DY_>$))N1&)_B* #GU&>]6;KXH6%UX/EL(K'4V\2RVA@_LO[#
M+YBS%=O)V[=H/.<]/?BO4:* /(]<\-WGA_\ 9NET.2)I+V*U0R1QC<0[3J[*
M,=<%B/PJ6^^(-K;_  _;1)K'45\2OI_V1=.%G(6:4Q[ RL%VE.^0>GOQ7J]%
M 'D'BCP]>Z+^S6VBO"[WL-O;^9%&-Q#F='8<=<$G\JT/BM;7DW@?0P(+J?2X
M[VV;58;8$NUL!\PP.<=/QQZ5Z?10!X#\0!X>U[P-<1^!?"\<B6QCEN+V#3#!
MY:!@-JDH&=N03C.%!)-=WKWC70+N*Q_MC0)KWPO?0M(NHR6;RI'*&*['B*;D
MZ'#?EZUZ'10!XUX/M=,_X6?:W/@&"^A\.FVE_M4M'*EL[X/E[!(!\V<=.W3O
M6@^IP^&OCMJ=QJ<5S';ZI800VDJ6[R+(X*C;E0<<@]>G>O5:* "O'M0UZW\*
M?'75]3U&VOFM)M*B@1[>V>7+Y0XX'H#7L-% '(Z'\1M$\0ZM%IME#J2SRABI
MGLGC3@$G+$8' K)\'6\T?Q<^($KPR+'(;+8[*0&Q$<X/>O1** /._AC;S0:S
MXZ,L4D8DU^=D+J1N&>H]11\+8)H+_P ;F6*2,2>([ITWJ1N4G@CU%>B44 ><
M_"ZWF@3QKYL,D?F>(;MTWJ1N4[<$>HJ#X3V5R/@K%:/!(EPZ72B-U*G)=\<'
MZUZ;10!Y;\);^SU/X<Q^$Y5NH-1M;>:&[BEMW3R][N.I&"<-T!S7+^%H?!?A
M;1?[#\=>&88M:LY'3SI-,:87B[B59'53G@@<^GY>]44 >2:MX=7Q-\'=:BT/
MPF-"FN9!-;V8C5)+A8W#*S* ,,R@@*?UHU?XBVOB#X=W^E:98ZC+KL^G/#/9
MFSD7[.?+(D+,1MP!NQSDG QDUZW10!R_PXC>+X<>'HY$9'6QC#*PP0<=Q744
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M88!(]K$/C;DY9=N..N:Z^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;B1!*@;:PZ,,]"/6@#RC1O[2MO%OC2,^)M-TB=M1,SQWUD)&D@*+Y;AC(OR
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M.<8&>E=<;BVO_C992:=-%-Y&B2K>20L& 5I5\M6([YR0/2MOQ%X:?6+[P])
M8([?3+WSY(G'#)Y;)M4 8_B'7C%;%AI.FZ4CIIVGVMFDAW.MO"L88^IV@9H
M\O\ #.HZ3I_P;UFRUBYMX[Z'[='J,,K@2-,SOU!Y)8%<>O%/:QF%I\)K74XB
M9XW7S$D'*LML2 ?<$#\17I4^AZ1<WZW\^E6,MXF-MQ);HT@QTPQ&:M2VT$TL
M4LL$<DD)+1.R E"1@D'L<<<4 <3XQN(;3XB^!)[F:.&%9+X&21@J@F#C)-=W
M56^TVPU2)8M0LK:[C5MRI<1+( WJ 0>:M4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*U_PYI?B:Q6TU.
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MFM_C[;!9W1BBN>,9=1W(X)&,]ZZ#3M1M-6L(KZQF$UM*"4D (#8)!Z^X-6J
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M6V3[TL\@11^)JKI/B+1M>$ATG5+2]\O[X@E#%?J!R* -.BBB@ HHHH ****
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M32KF"#:60G>YD=2W0 #E?E.1S7=>%Y=6F\,Z>^NQ"/5/* N "IRP.-WRDKR
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M//)+@8 9W)8@#( S@9J"W\(Z%:^&QX?AL FE[MWD>8YR=^_);.X_, >OMTH
MXB]U#Q#K.M^)5LX==+:?<?9;(V%S;Q0PL(U8-(LCJ7)+9.01C '>I+O6O$$,
MEUI%Y<R6NJ:O!I[6H1@WV9Y#Y=P$(R/DV,_?K78ZEX.T35KV:[NK:82W"A+C
MR+J6%9U P!(J, _''S \<=*M3>'M)GU+3=0DLH_M6F*R6;J2HB#+M("@X/'
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MQ+&>SG"S[]^8XE5EX'78W':J.I> [Z[^UW+6]M<NGB"34HK664JL\+PK&5+
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M GDLPMF=@IV^: =ON!70^"[>PL_B#XRMM-8?9HDL5"*^Y8SLDRJ^@![=LD4
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M4M0AO[5I=1&;6[>6.2)1E(V<@%PO"G/7;SWH ].N)+#3YA<S>3#+<O';^:5
M:1B2$7/4\DX^IJ<6\*W#7 AC$[*$:0*-Q49(!/7 R>/>O&[S3+ [M.FB5K"S
M\9Q6\$3L2L43PQLR#)X7<3Q[UWOQ#N)K+P'>O:320+N@CDEB8AHX6E19&!'3
M"%N>W6@#J)94@A>:1ML<:EF/H!R:H:#K4/B#2(=3M[>Y@MYP'B^T(%9T(!#@
M G@@\9Y]JX+5=*TJP\3+I>CQ1BQN]$NY;^VB<F,A2GE2$9^\26&[J>:Z;P!:
M16/PWT/['"J-)IT,Q4?Q2&-22?J: .IHKS+P9;Z%)HWAK6[R_EC\07DI$LJS
M,9;F<AO,BD7G*CG@@!=HZ5C(D'_"NK?Q()6_X2YM153-YI\XW!NMIAQG[NW*
M[,8V]N] 'LU%>-ZYI\4WASQYK#/-_:%CJ[?8YQ*P-N0L)RG. <DY]>]6_%5A
M!H%[XFM=,\RWAF\*7%Q*HD8[Y58@2$D\M@GGJ: /6:*\P@MM/T[7_!L^C3%I
MM2MY_MKK,7-S$+<MODYY(?;SZG%85O9O9_##PC-;89]7N;5-2EN;IXUF38^Q
M'< E4W;5X'H.] 'KFN:Q;>']%NM5O%D:WMEW.(P"V,@< D>M:%>-ZYIUWIWA
M3QI;^9I=M:FT@/\ 9UA>//\ 9I"YR^&1=@88XQU7/>M?7;(^%_$S'P]')%<W
M'A^_E90[.9YH_+,;-DG<^6//4YH ])N+>"[@>"YACFA<8>.10RL/0@\&I*\F
M\,:==1W'A74;671;1KC#2S1ZI++/J*&(EPRM& [9^;)/RE:I:?IT$'@+P[KZ
MF4ZK_;$"?:FE8OL:[,93K]S:2-O3OUH ]FJO:W1N3.#;SP^5*8QYJ@>9C'S+
M@G*G/7V->77T$&E:C>:[=+:ZO9G5<C4;6^:.]M&,H41;.C*I^7:&&1_#3EEF
ML;F_\1>:^S2_%,T=P"QQ]FE2.-\CT4LK^VTT >KT5XYJ$M_?:58:ME&MO$>N
M[G2XN'AC:V6-UMXW902JML5N!R6P>M=?X)L+K3=8UJ!I=+AM/W)73K&[><6L
MF&W'#*NP,-IP/0GO0!UD=T7OIK;[/.HB16$S*/+?=GA3G)(QSQW%6*\G\;RS
M"^\:I'/+'BSTG8R,04)N'!(]#4OB*U;PMKVJCPXDEO++X9N[@HCLV^:-T"R<
MDY<!FYZF@#U.BO.%MM#T?2!>^'+V0:U/HL\UO%#,9/MA$8(DD!SE@V,,<'+$
M<]*I6EMING0^!-0T.8MJ.H7$2W,JS%WNXFA9I6DY^;! .3T/I0!ZI17BUII%
MO)X1\,ZF7N!?W.O&VDN5G<.86N)4:,$'A2O&!]>O-2Z\)=#/BG3-)/V73AJ&
MF"2/SVBCBCEP)?F&3&K8 8@< DT >R45P/ABQFT7Q3>M))HNG6 T\23V%G?O
M*%8-Q.5=%"#;N!/? ]*[2XN&?2Y;BQ*S.82\!4[E<[<K@]P>* +5%>9>%;?0
MTT'PUK,=])_PD5[ 6++.S/>7!B)D24<Y 8$\XVE1R*RK**TA\&>$]>LYF;Q)
M>7]JL\_FDRSN\@$\;\\J!ORIX7;VQ0![%17C6H:= ?!'BW76,K:G9:S=M:7!
ME;=;[;C@)S\HZY]<\UH^*K..'5?$&N3K9:S9V^UIE6_:WO--V1KE8OX?]L#*
MDEN] 'JE9%YXAM[359],%M=7%W%9?;?+@0$NF[;M7)&6R.GZUQD<&D>(?$7B
MF7Q Y,=I#;M9BXD*&WMV@#&1>1M8N7RPYRN,\5R=U>ZA<^&I[R^DE^W/X&#O
M(Q(<GS3AB?4C!_&@#W&>X6WM)+B0-LC0NP YP!FH-*U&#6-'LM3M@X@O($N(
MPXPP5U##(]<&O.+F#3M1U/QM<:W+B?3X(EM&>4J;>(VX8-'SP2Y;D=2,>U4[
M#[/JFE>%-+DL;6Y:U\-6]W)_:-XT5LB,JKN"*IW/\AY. H^M 'K$UY;V]Q;0
M33*DMRY2%#U=@I8@?@I/X5/7BWA^.VUB#X=7&I%+EQ=:A#OD<M\L?G>6N3R<
M;5QGGBH[:UU74]'O-6>31K35UU.5#J=WJ<L<]O(LY58B@C("X"J$S@@Y[T >
MRW]Y%IVG7-],&,5M$\SA1D[5!)Q[\46%Y'J.G6U["&$5Q$LR!A@[6 (S[\UY
M=JT&FZA;_$2^UF7&H6+R0VK-*5:"'[.ICV#/ 9F;I]XD@YKM+';_ ,*RM=]]
M]@4Z.@-WG'D?N1\__ >OX4 =(2%!). .2345G=P7]E!>6LJRV\\:RQ2+T96&
M01]0:\JL;"VTN5-*O],M/.OM,N%BO=-OGDBO J!BTL;8(/0ALMR<9YJ'2X-/
MN/#G@G1+;3[:YDETK[=(EU=M%:DB.,,SJH;S'RW [<F@#UJYO+>S,(N)EC,\
MHACW?Q.<X4>_!J>O#[2*TU;0M"COO(N+>W\72VD6)6>-(2LA"*S<E.%QGL!5
MBYM;_5AXKO9VTF"[M=0GBAU&\U.6&:P5<>254(0JXVMP?FR<]: /:**\NO\
M28M7UWQB-6_TB2UTFU= LC"-)3'*2ZCCG*C!ZC\:BT^V;3[GP/J=D97U/4]-
MF:[E>1F:Z?[,)!OR>?GQCTZ"@#U:BO&?"]E?W&F^%]92;1[6]N+F%Y[Y]3E-
MS=D_ZV%T,>"Q^8;,X4@8Z4:CIT!\$>+]=8RMJ=EK-VUI<&5MUOMN. G/RCKG
MUSS0!Z_%>6\UU<6L<RM/;[?-0=4W#(S]14]<-X8L+&'XE^,ITAC6Y$EM@Y^;
M#PAF_-N:9>6=CK7Q(U.QU\++:VVFP2V5O,Y$>&:3S9 ,X+ A!GJ./6@#I]6U
M^VTF^TZR>"YN+K4)&2&*! QPHRS') "@=?T!K5KQS0;.'5]0\ W.H(;M\ZBD
M4\S%FDAB8^22>_RX(/?K7L= !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4;[1=*U26&74--L[N2 YB
M>X@60QG_ &20<?A4<OA[1)D=)='T^17G^T.&MD(:7_GH>.6_VNM9VK:]J">(
M8]"T6RMKB]^RF\F>[G:*../=M4?*K$L2#VX -8$VK:_/XYT8V^FB"\GT6X:6
MRNKK$4+":(%F*@[O08&3N'3G !WEU:6U];/;7=O%<6\@P\4R!U8>X/!JI!X?
MT6UT^73[?2+"&RE_UEM';(L;_50,&N<C\:7TWAQ+Y;"QM[I+Z6QNS=7PBM[=
MHV96?>1E@2HP N>><8S56'XC23:*]S#86MW=Q:O%I3+:78>&5GV[723;R/G'
M4<'/I0!U=CX<T/2[C[1I^C:=:3X*^;;VJ1M@]1D '%2ZCHVEZN(QJ>FV=Z(L
M^7]I@639G&<;@<9P/RKE;KQS>Z*-;AUG2X/M>GV\%Q"EG<%TG$SF-%RR@J=X
MP3@\'-22^,M1T?5Q8^(-,MX$73;C47N+2X,J[(MN5 95.[YC[=/4@ '666GV
M6FVXM["T@M80<^7!&$7/T Q5:UT#1K&_DOK32;&WO),[[B*W1)&SURP&37)Z
M3\0VN]1TB&\32A%JS;(5L]1$\UNY0NJRIM'4 C(/!P.^:L>&O&FH>([B&2&Q
MT[[+)(R301W^;NT R 98BHQR " <C(ZT =,FAZ3'JC:HFEV2Z@W6[%N@E/\
MP/&?UIIT#1FU0:HVDV)U '(NC;IYN?\ ?QG]:H^)[Z*RN- 66W:8W&JQPH5F
M:/RV*2'<<?>'!&T\<^U8">/-6;1TUQM%MDTE;\V4Q-T3-_Q\>1O1=F" <<$@
M]?0$@':/IMA)#<PO96S173;KA&B4K*< 9<8^8X '/H*=-8V=Q(TD]I!*[Q-
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MU2,#J>E:%<I>^)=8EUC5+'0=)MKT:4J?:?/N3$TKLN\1Q@*1G:1RQ RP'J:
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M$*MM4DX)QQW]N:HKXSU[4K[PREG9VEN;J_N[2]ADG)!>!9 P#;#\N5W \'(
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MNIVKV+2+$LT4RLK,S   @X/7)] ">U:\<T4T"3Q2H\+J'616!5E(R"#W&.]
M'*OX:UK3]6O;_1=4M@^H0Q)=&^@+D21IL$J[2HR5QE2,9 Y%.T#P5'X?U/39
M[>Z,D%EI)T_:Z_,[&17+D].2#Q[U:;QAITNNZ5INGSVU^M\\R/-;W*N(3&F[
M! SR>G45IP:UI5S?O80:G92WD>=]O'.K2+CKE0<B@#FX/"NKZ=IK6ME?:?/%
M)=W4\]M>VN^*59I3(O0Y!7..X.3QTJK9> ;O2[?3[FPOK6/4K*[N+F-/LY%J
M$G&'A5 V5484@@]1TYQ71Z9XJT35[6]N;/4;9H+*5HYY#*NU-I(W$YX4X.#W
MQ6A8ZC8ZI;_:-/O+>[ASM\RWE61<^F02* .2;P/=W/G7=[J$+ZE=:K::A.\<
M16,) 5VQJ"2>B]2>I)Q2-X'O;=X[VPU"!=1M]7NM1@,T1:,I/N#1L 0>C=1W
M'2NU=TCC:21E1%!+,QP !W)K/'B'12TRC6-/+0QB64"Y3*(<89N>!R.3ZT <
ME=> =2OXM9EN]5M9;S4+RTO OV<^0#!C$;)NRR':!USW]JDN/!&JW]_J5U=Z
ME9*-2TF33)HH+8JL*G=M*?-S@L2<]>V*Z\:OIITW^TAJ%I]@QG[5YR^5C.,[
M\XZ^]4;_ ,6:'I^AG69-3MI+#>(Q-#,KJS$XP"#@G^@- &#_ ,(?JR7&GZF+
MC29=3@L183I/:LT$L:MN1E^;<K#)]0=QZ<58G\*:JKZ-J-KJ-E_:^G>>KEK3
M9!*DN-R[%.5QM7!R3\O.<UT%QKVCVD=O)<ZM8PI<@- TEPBB4'H5)/S?A4MS
MJFGV;JEU?6L#L 56695)R<#&3W/'UH RO"V@7>AMJ\M]?1W<^HWQO&:.(QA2
M8T7: 2>!LXYZ8K)\2^$-6\1K=65Q>:7)93/NAN)K(FZM%XXC8,!D8X;@C/.:
MZ*+7+6/39+[4KFQLH4F>+S#=JT?RL5&7. "<<KV.1VJOJGB:VL;/3+NU\J^@
MO[Z&S22&8%1YC;=P(R#CT_6@##U?P-?:E)XFACU&".SUI87P\+-)'+&J* ?F
M 9"$Y'!Y-/3PCJ\VOVNK75]IZ;;.:QDM;:V9(UB?:<H2V=V5[\8P,#&3V-Q<
M06EN\]S-'##&,O)(P55'J2>!4%EJFGZC:M=6-]:W5NI(,L$RN@QUY!Q0!QEK
MX%U2TL="<7FF3:AH]LUBGFVK-#/;D( &&[*N"@.1QU&*TQX5O9UT:2[O;0SV
M.I&^D%O:B*,KY;H(U .>-X^8DDX_+?LM7TW4XI);#4;2ZCB.)'@F5PA]R#Q1
M8ZOINII(]AJ%I=I$<2-;S+($/O@\4 <]?>#I;S3O%]J+Q%.ODE&*$^3^X2+G
MGG[N?QJ.Z\(WT&MW>IZ5-IC-?0Q1W$>H6IE"O&NU70AA_#@%3Z#D5T=EK6E:
MD918:G971A_UGD3J^SZX/'XU,+ZS,,$PNH#%<$"!Q(-LI(R I[Y SQ0!BV/A
MN:U\16.JR7B2FWTMK%P(1'YCF1'+@+PH^4\#UK)C\$W]G)IUS9ZA;?:;/5;N
M^ FB8HR7!?*\$'(#]?45U!UW2!=16IU6Q^T3,5BB^T)O<@E2 ,Y)!!''<&LY
M_%^FS-JL&GW-I<7FFNL<T4MTL2Y.W)W<X W@9Q]X8ZT 3^)M"?7;&V6"Y%M>
M6=U'>6LK)O42(3@,N1E2"P/(ZUAWW@S4=:AUVXU2_M?[0U+33IL/V>)A%;Q_
M,<\DEB6;)Z= *Z:ZUW2+&3R[O5;&W??Y>V6X1#OP#MP3UP0<>XJ6ZU33[&:&
M&\O[6WEG.(DFF5&D/HH)Y_"@!EWI<-_H4^DW)+07%LUM*5X)5EVG'X&N=M?#
M7B*2P33-1U^'[!#926B_9+8I)-N38KR%F."HYPN,GG..*ZR"XANH5FMYHYHF
M^Z\;!E/T(JG'KND2W<5I'JMB]S*,QPK<(7<<\@9R>A_*@#D+7P1K4(\/$ZAI
M<7]AR*8HK>S9$F7RVC9G^;.[#9&. <YSGBS+X/U;4-7TVZU.]TR5M/NEN%OH
M;(QW<H7.$9@V "#AL#!'85U$^M:5:W\=A<:G9Q7DF-EO).JR-GIA2<FLN7Q.
MRZOJ^GQVL.[3C:#S)KD1K()R1U(X(QP.=QP.* *#>"ICX'F\/?;4\R2^-WYV
MPX -UY^W&?3Y:V?%>B/XC\,7^D1SK UU&$$C+D+R#T_"K<NKZ9;ZA'83:C:1
MWLGW+=YU$C_12<FI1?6;6DET+J VT>[?,)!L7;D-D]!C!SZ8H YC6_!!UJ_U
MJY:^\DW]O:)"RQY,$L$CR*_7D;F'''0^M3VOAS4+S7TU?Q!<V<[P6DEI!;VL
M+*@$A4R,Q9B22% QT SUK;U*_-EICWD(@DQMV^;.(D(+ 9WD$#KQZ\#O3+G7
M=(LY!'=:K8P.9/*"RW"*=^ =N">N"#CW% '$#X8W2^#6T==9 O\ [2)%OO*.
M5C$/V<+C/7R>,^IS70:SH&I72K:V3:1/I?D+"+'4K/S4C*Y&Y2",Y&!@^G!'
M-/U/Q=;V/B_3?#D2VTES=(TLK272Q^4@*@ #!+.=W"\9P>:UHM:TJXU!]/AU
M.SDO4SOMDG4R+CKE0<B@"IH^@?V5X1MM!^V2R^3:_9_M'1NF,CKC&>!VP*Y6
MV\!ZU!I^@6HU'2XUT.>.6!8;-E$^U2A:0[L[BK$\=R2<]NU.MZ4)7B.IV0DC
M!9T^T+E0&V$D9X ;Y?KQUJ(^(]"6&>8ZUIPBMW$<SFZ3$;'HK'/!X/!H P9?
M!4TG@O4=!^VH'N[Z2[$VPX4-<>=MQGTXJ#4/!FL/%XBT_3=5M(--UQI)9?-M
MV:6%Y(PCA2& (. >1QD]:ZN[U?3+"SCO+S4;2WMI,;)IIU1&R,C#$X-4]1\5
M:)I2Z<UUJ-LB:A+Y=N_FKM?Y2V[.<;>.OJ1ZT /GT*&\\)/H%VY:*6R^R2.G
M!P4VDC^=8T7AG7+ZQ;3-=UFWFTW[#)9-':6YC:XWKMWR%BV"!G 7C)S[5NQ:
MO"MO>W%]+:6L%K.T1E-TK* ,<N> AY^Z>G'K4T.KZ;<V2WD&H6DMJS!%G296
M0L2  &!QDD@8]Z .;M/"VL37.B+K6IVEQ::,XD@%O;LCSR!"BO(2Q P&)P.I
M/X4D/@J:+P;I6A?;4+V-]%=F78<.$G\W;C/&1Q72V.JZ=J?F_P!GW]K=^4=L
MGV>99-A]#@\&EU#5=.TF)9=1O[6SC<[5:XF6,$^@+$4 <IJ_@_5M<N4COKW3
M)((KM9X;T616\B19 X16#8!XV[L=.V:2[\&:J;36M(L=4M8=(UB>6:;S(&:>
M'S?]:J$,%.<L02.-W?%=9+JFGP01SS7UM'%(A=)'F4*R@9)!)Y '.::FLZ7)
MIK:DFI6;6"\FZ6=3$.WWLX_6@#E]0\!M=2:J(+Q(HKPZ=Y:%"?+6U?=@\\Y
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M!YS!;2S^+-!DCC'VEO"\VV5EZ2;H-I)]<UAV$NG7'A3P;HNGQJOB.SOK1KF
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC-E4,?S @J058YXJI-\.[>X36!-K&H2-J\40NG?RR3+&P*2#Y>,8 VCY<=J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW+:=93_VIP/WLRR^0F[TR8Y6_*NSU."XN=*O(+2=H+F2%TAF7K&Y4A6_ X-
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M/ 8.@Z'MUQ4OP\UC5->TV^U'4_MBF2\F2*.9(5CC5)'0*FPEC@* Q;OTR.:
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M1/MAG$5R(VN/M36JW4@MS+NW;S%NVYW<],9YQFEO_!.AZE?S7=Q!/_I#J]S
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MC&[>0&."P4@'O4=YX\L;1KZ4:=J,^G:?,8+S4(D0PPNN-W!<.P7/)52!@^E
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M6#*XLHP01SG..M7;KP[HM]J46I7>DV,]]%CR[B6!6=<=,,1GCMZ4 <?X(?\
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M!TQVH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;-:W$D#1JV-R[D8$@X&03S1:^#- LI%>VL/*"W2WB(LS[$F52@=4W;0=K$'
MYXSG K>HH CG@BN;>2">-)895*.CC*LI&"".XQ6-IO@_1-)NDN;6WF,L49BA
M,]U+,(4/58P[$(.,?+CBMVB@#*C\-Z3%ING:<EH!::;(DMI'O;]VR?=.<Y.,
MGKFJ%SX"\-W<UQ)/8.RW$OGR0_:91$92<EQ&&VAL_P 0&?SKI** ,+4O!^B:
MM>RW=U;3":= D_D74L(G4< 2*C .,<?,#QQ3K_PCHFHW,%Q-:,DL,(MU-O/)
M!F(=(V", R?[)R*VZ* *>EZ79:+IT6GZ= (+2'/EQ*20N22>ON368O@O0$U
M7@LGW"?[2(?M$GD";.?,$.[RPV><[<YYZUOT4 9C>'M*>QU.R:U!M]4=WO$W
MM^]9U"L<YR,@ <8JW/86MSITFGS0J]I)$8'B;HR$8(_*K%% &3IOAK2M)FMI
MK2"42VUNUK%)+<22LL3,&*Y=CD94=>F,#BJ\_@S0KB.-#:2Q-'<RW4<D%S+%
M(DDI)D(=6# ,2<C./:MZB@#G#X#\.&"Y@6P:.*Y>.618[F5/WD>-L@PWRO\
M*/F&"<<DUL7.FV=YI<FF74(GLY(O)>.4EMRXQ@D\GZYS5NB@#G[7P3H%I.)U
MLY)IA ]MYES<RSL8G #(2['*\#CH.<8R:C@\!^';?[*4M+@O:.KVTCWL[/#M
M! 5&+DJN"1M!VGN*Z2B@#G_^$*T#['/:"S<037'VK8+F7]U+DG?'\W[HY8GY
M,=35_2="T_1$F%C$X>=@\TLTSS22$# +.Y+' X&3Q6C10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUF>)$Q.B DRNW<(4SR>""*T+9O["T*#Q<$?&E:YJ"784<M:RW#J_'?:VQ_\
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M5'48 )]A2ZIJVE-XI\0ZIH5E!J5N/#+!Q;@^5<,)<$97[V%(R1S@8[<>O44
M>.V-Y:1^-/#TL&JZ;=6S6-U:>=I]IY$ 8JA2'?N;<?E.%)R,>]%I8V6F_#7P
M#=SVT<>G)=6T^I.8^,>4^UY/50[+UX''I7L5% ' >#)]-N_B'XMNM)$9LY;>
MQ*RQ+B.5L3 LIZ$=LCN#2ZQ_:^N_$.)-(6S:'P_#OD^V;PC7$RD#&WJ5C_\
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M6"]',1D\M%W*>0,\!@,]:]&HH \5OX(Q<>+].UK6M.L)KV_E*PW&F-/=31,
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M,><DD]R223[F@#Q>]U2"XT>WO1-IUG-#K<=U<Z?;V9\^S NANDFE+$J<<DD
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MV,N1C[W YH Z.BJVGV2:;I\%E'+-*D*!!)/(7=@.[,>2?>K- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX$OEQ*"$0D'&2PR<9P* .RHKC;DZOX)\,^(K^?5)-5MK6W:XL!=#,R$(<J[
M#<N[&#U S7/:L=<\+^";+Q>?$>HWE[&;::\MYF0V\RR,JNBH%&S&_@CGB@#U
M.BN#U9M4U/XIC0H=8N['33H@NI5MB [/YQ7Y6(.W/&2.<#'>LZS\3ZGX?\*>
M.&GNY=1ET&YDCM)KG!=E,:L@<@#=@MU[B@#TVL^PUJRU*_U&RMI&:?3Y5BN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPH!/<DD\FNDCDCFB26)U>-P&5U.0P/0@]Z=0!F>'='7P_P"'-.TA9C.ME;I
M)2NTOM&,X[52\2>&3KD^G7]I?OI^J:;(SVMTL8D #C:ZLAQN4C'<'@<UT%%
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MA8 @$@$]!GK0 M%%% !103@9/2D!! (((/<4 +11FB@ HHI&8*I9B H&22>
M* %HIL<B31+)$ZO&X#*RG(8'H0:=0 4444 %%,EFB@B:6:1(XU&6=V  'N32
MHZR(KHP9&&593D$>HH =1110 44R2:*%0TLJ1J6"@LP ))P!]2:?0 4444 %
M%%,::))(XWD19),[%+ %L#)P._% #Z**9'-%,&,4B.%8HVU@<,.H/N* 'T49
M'K10 4444 %%%% !111F@ HHHH **B@N8+E&:WFCE56*DQL& (ZCCO4M !11
M10 444R6:*",R32)'&,99V  R<#DT /HIDTT5O$TLTB1QK]YW8 #ZDT^@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH XC6+J+PU\1H-5G;99:GI<T4Y["2WS*I/OY9D'
M_ :X_3-2U#POX7\0QSLYU#5[&+5K92>1<W1,3*/]US%Q[UZ3XL\)V/C#2H]/
MOY)XHXY1*'@8*WW2I&2#P59@?8TFM>$-.US6-'U*X:9)=+<O$D1 6095@KC'
M(#(K#IR* ./&M7.B7S>$]/O7L+?1+&WB$D>DS7IGE9,_-L!"K@#W))YXKMO#
M^LW&I>$[35M0LY+.X> O/ R,I1ER&P&Y X)&>Q%0:AX7-QK$VJ:?JU[I=U<Q
M+#<FV6-EF5<[20ZL PR0".WK6Q9V:6=A#9B6:=8HQ'YEQ(9'? QEF/4F@#D_
M#NH>)]4TW2_$4UW8-I][']HFL?)*M!"REEV2 DLX^7(( .3C%9EOXH\0IX:T
MGQ=<7-HUC?W$ DTY;?!BAFD"*5DW9+C<I.1@\C K>TSP1#IDUG&FKZC)IMBY
MDM-/=D$<1(( )"AW4!C@,Q ]\"H[;P%:VZVEH=3OY=(LK@7%MIK^7Y:,K;E!
M8+O95/(4MV'7% &%J'B;Q.FB^*-:M[RRB@T.]GCCMFMMQG2/:2&;<,<' P/?
MVJ_>ZKKFM7WB6'3[NVM;/2HEB$4D&\W#M")&W-D;1A@!CW//2MF;P=8S:%KN
MDM/<"'69IIIV!7<AD !"\8QQQG-0WO@J*YU"^N;?5K^RCU&)(KZ" Q[9PJ[
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M)5078*2 6)Z^O-51\/+86\=D=8U+^S8+U;VWLP8PD3B7S<;MFYEW9X). ?4
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M@1"A+MLCXX7=(YP<\F@#D+7QM>W$>CZ=#.--0:):WLTEKI,MUEY5X14C!"(
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M(H%G")L'S%=RY4 ':1^%2Z#X.MM!N;*>.^N[E[/3_P"SHO.V?ZD,&7.U1DC
M&?2@#GM.\6:[K$.B:5'/:VVHW<U\ES>"#<H2VDV$HA/WF)7J2!S[5I/>ZS9>
M(?#%CK TZ>>>XNT-S%$03&L19&&?]6Q'# $CWJS_ ,(+:16UJ+/4+RUO+2ZN
M+FWNX]A=#.Q:1"&4J5.[H1V'.14MMX,LX9M/GFO;VZGM)9YFDG<$S/,A1]V
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MJVXMZ8)Y^M95]8ZQ#\/]6\)KH-_<7YOI9%G6(&&6-KGSA('SR=IQMZY'3'-
M'H&I>,-$TF\FM;NYE\RW4/<&*VEE6W4\@R,BD(,<_,1QSTI;_P 8:)IUV;26
MZDDN1"EQY-M;23N8FR X"*<K\IY'3C/49XJ]T6\L-=\2BYA\130ZG/Y]N-+*
MF.96B5"CY!V$%2,L0,$5O>'-"FTKQA(RVDT=E%H5E:0R2,'.4:7*;NY *YH
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M+&#(V",X(YSD=.\/ARXN;KQ#XFAN=$U>U@UFX#PS3VVU546Z(=QSP<J0/PH
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M/$\>]5_BVE@<#FN1U71-9UZ?Q1J$&E7MLLMYIMW;Q-MCEN$@^_C/ ? R ?\
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MI;I!&8Y6CVK%&.=^3G)! X'7-2G2;Q;OP 4M)!'8*XN<+Q#_ *(R#/I\Q H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M21H6"+(8F"[L <;\<XZC'2NE\?VC7>J>$$%Y=6X?5]A\B3;U@E.>G4;>/J:
M.ML]0M-0^T?9)EE^SS-;RXS\DBXROX9%6:\@F2_LO#?CG7;/5[RUGT_5KN:"
M&%E$99=I.\$'?GI@\8Z<Y)T]0U76M7\6ZW901:\8-/2".W&DRV\85WC#EW\U
MU+'+  <KA3W- 'I;,%4LQP ,DU!87]KJEA!?64RS6MP@DBD7.&4]#S6?HLVI
MS^$[276H!!J;6H^TQJ00),<XVDCGKQZUYWX9&H:-X/\  .HPZO>/]LFMK26U
M9E\CR71N N.", [LYSGZ4 >N5EW7B31[*&_EN;^*)+"18KDMG]V[!2J^Y(9<
M 9ZUYQK/B'4XK>Z\0:;=ZW/!%J:Q1W#&".RV>>L31"(MO<?>7?MR3SG%5_$=
MI]JU#Q$/M%Q#CQ1IB_N7VYW);C/U'4>] 'L$,T=Q!'/$VZ.10ZG!&01D<&J^
MGZ;9Z5;M!90^6C2-*^6+%W8Y9F8DDDD]2:RKF[NKAKCP_!9ZO YMVBCU<JAC
M5MG#[MVXG/\ L]?:N7L?%FIZNFC)&SI=:?9W%WK,2<%I8MT0B/H&D#M]$H ]
M(HKRKPYJ'BR^@\/:M%;ZY/)>/#)?/<36WV-X)!EC&@?<NW(*X&2%P>M0ZKXA
MU.*&3Q!IUWK=Q;C54ACN)#!'9-&9Q$T8BW;V&-PW[<DC.<4 >MU1U#6=.TJ:
MTAO;I(9;N3RK=#DM(WH .?J>@KF_#IO]1\8^(YKG5+IK73[_ ,BWM%8",!H(
MV.[C)Y;(YX.?6H/$MA]H^)_A&3[7=1?N;L[8I,+\HC/3'?.#Z@"@#L;*]M]1
MLX[NTD\R"3.U\$9P<'@\]0:L5Y5X?U'6=>E\*VD^LWD4=Y87TMTT+ /(4G15
M^;'! .,CG&:EAUJ_;21I$NJ:K/>+KES90"T6,W5U#%EMID8JJ8&,OP<#WH ]
M0JI?Z99ZHD"7D/FK!/'<QC<1MD1MRMP>Q'3I7F#:_KT/A[Q!:I>7MM<6.LV5
MM;R73QRS1)*T.Y79"5;[[=R<'!JWX@UC5?!M]K\5KJ=W>I'H?VZ+[:PD,4WF
MF/<, ?+@@E>G% 'I-W=0V-G-=W+[((4,DCX)VJ!DG YJ2-UEC61#E6 8'U!K
MA=<M-1\->&]9O;?Q3>7#C2+B18KHJ[F94R)8R,;0.Z@$<CICG/UC5+Z^GNUL
M[S79I+#3XGE73VA@BMI&C+[I&D8&0D;3M ( ^M 'H;:A:+J:::9E%X\+3K%S
MDQ@A2WYL!^-6:\Z\-ZC/J_B[POJ5T0;BZ\*M-*5& 6:2 GCMR:T]9-_??$73
MM)BU2ZL[%M-ENIDMV"EV26,#D@X^]SCMD=Z .RHKR.+6/%NL6=_JVFVNN2WZ
M7TR6J1RVRV02.4H(V1G#'(4Y8C.3QQBM:0:IJ^M>-%.OW]E'IC1FTBMW51$Q
MMD<EL@[AGMT^]^ !Z-17F^@ZGJ?C74+2&[U&[T^&/0[.]9+-Q$TLTV[<Q."=
MHV<#ISSFJ.G:KK?B"X\+Z=-K5U;K.=3AN[BVVH]P+>5$1P<84G') [MC&> #
MU175BP5@2IPP!Z'&<'\"*=7$> K1HM6\6S->74Q_MF2+;+)N7 BB(.,=<''T
M JMXJ?6[76[VZGEUM=&6!#;3:.T;?9F )=I8C\S\X/ 88&,4 >@45YA<:YJ>
MN>);JTLVUN[L+6PM989-'D@A\QI5+>:_F,I(( PHR.#FK.GW7B+6M4T;0=;N
MKK3+A=*DO+O[*Z))-(LHC7++D ;?F(4]6'88H ]$+J'5"P#-G )Y.*ALKVWU
M&TCN[23S(),[7P1G!(/!YZ@UP#Z?<_\ "?\ A*.YU^YOGBM+W=-$5C60QO'@
M,HR,X.UNF=O053\-:KJWB5] TJZU:[@CDT^YO;B:!PDL[+<>6J[L9  .>,9X
MH ]3HKRP:QK<RV6E+K%PK0^*9-*:\ 7S);<0.X#<8+#(&<=5!KIO"LMW;^)?
M$FC37]S>6UD]N]NURP>11)&2REL<C(R,^M '6U1O=9T[3KRSL[NZ2*YO7*6\
M1R6D(QG '89&3T&17+;;[Q'XM\1V;:S?:?!I8@BMDM'"?,\0D,CY!W<D  \?
M*>.:Y[P_<77B3Q3X)UF]N[E+FXT6>:58GVHS))"#QC[K=2/I0!ZQ17)^*+J\
MF\2^'=!@O9[.WU W$EQ+;D+(PB12$5B#MR6R2.<+7.3ZWJVFZA=:.NIW$\=E
MXATZWCN)2#(T,P1FB8@?-C)&>N"* /3Z*\U\:^(-4TZ\\6K9WTD0L]#M[B *
M?]7*TLH+?4@+^5=[I5A+IUD(9[ZXO92Q=YK@@DD]0,  #T':@"[17DD.L:];
M?#R#6O[4O[J_U._6Q4*8SY"&Y:/,8;"[R!C+'&2.PJQ?WWBC2='\23)#K5KI
M\6CRSPS:G/!)+%<KTV&-V."ISST*\=: /4Z*\XOK_5?#&HZ'=+JUWJ0U&TN6
MN8)RI1GC@,JM& !L&5Q@<88=^:CM[K5=.T?PAK[:Y>7EQJ]U:QWD$K*876=<
MG8@'R;201CLO.: /27=8T+NP51U). *=7CFIQZCJ?PSUG5;W6]0D?^T)+>.%
M9 L:QK>; " .3CN3TP.U>O6T/V:VB@\V27RU"^9*VYFQW)[F@"6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH I1Z591:Q/JRP_Z=/"D#REB?
MW:DD* 3@#+$\=>]5-3\+Z-K$]S-?V8E>YM1:3'>R[X@V\# /4-R#U'8UL44
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MUUC[5'#=RQ1W&!@>8BL%?CCD<C@\5>E\/Z7/K5EJ\EHIOK*-HK>0$C8K#!&
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M0N)(H1$NQ&#;@P&, @\Y]>:KW'AW1+S4DU*YT>PFODP5N9+=&D&.GS$9X[4
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M+:XBOV>9V-R/L^[Y\GDY&1Z=J[:S\-Z'IUM<VUEHVGVT%RI6>.*V15E4C!#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR AZ)"L93ZY7.:K>+?"_F)XCU>2ZD07$-D\/D6YE>&2VD9PVT<L,L,@<X!H
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M3[D+RJ';Z G)JS7C'C%["QU[Q#*)M.N;F:2-Y-'U6U(GN2L:!?LLJ'>0<
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M9-<?:IFC#G[A_=IRHQDGD^G/8:)J\NK^%K/59+5[6>>V$KP2 @QOCE3GG@T
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M<:O' 43$<N]G9=V,E26[]*V=5\0Z7HCPQW]R4EGR8HHXWED<#J0B M@9&3C
MS1;>(=(O!IYMK^*4:AO^RE,GS=@RV/0C!R#Z4 9^J>#=/U>[U:>[EG(U*UAM
MW5"%,?E,SHZGLP9L_@*M:5H]_9WAN;_7KS4&$7E)&Z)'&HR"6*H!N;CJ>G.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!P'Q!\:ZCX2UW0$MXX7TZ?S9=0WH2ZPHT2EE.>,"0G\
M*U/B#XGN?#'A9KO35BEU&>18K19!N4GEF8@=@BN?PK.\6V,&I_$7PU872;[>
MYT[4H9%]598@?T-<EIBZCK%EJ4&JHY/A'2+K3][#B6X977S!Z_N40_\ ;0T
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MRPMI2IBAA\F-'P"'>) ,D@$*3GY: .@T[X@:#J]O/<:<]Y=0P6YN'>*SE8
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M],MM0:^(M[FX-K'^YDW^< Q,93;N#_(PVD YP.I% &\ %&  !Z"D6.-0P5%
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MQ^4]#S@XS4<_C[P[;RSH]U.4M[@VUQ,MI*T4$@;;B1PNU>>Y/OTYH Z0@'J
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MX[ \\4 ;]%<?-\1M(%UI45K!?W,6H7+0),EE-MPL9?>OR?.,@#CL2<X4UV%
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M*UU%[*6YE#1S+;RSK;2-!%*V,(\H78K<C@GN,T ;]%<]>^-]"L+V>VGN)_\
M1I%BN)TM97A@=L85Y0I13\PZGC(SBFQ>,[!O$VK:/-%/ NFVZ3RW4D+B( AR
MV6*[5 "@@D_-DX^Z: .CHK"T[QAHVIW"P133Q.\)GB^U6LD EC&,NA=0& R#
MQV.:33/&.C:M=V]M:RW(:Y4O;/-:2Q)<*!DF-W4!N.>#TYZ4 ;U%8&N^*K;0
M=8T?3IK:ZF?4IGC#0P22! J,V?E4Y.0!CL"6Z UC:1\0K(I>+K$CQO#JD]EY
ML5K*T,068I&)) "JD\=2.H/ (H [BBL#5/&>B:1>7%K=37!>U17NF@M)94MU
M(R#(R*0G'/)Z<]*;_P )=9GQC%X=2"X=Y;3[4+A(9&CP2,?,%VX(S\V<9XZF
M@#H:*P-8\56VC^(M(T>6VNI9-1+XDB@D=4"C_94@\XSR-HY.!6-X?^(5E=6$
M1U:1X[E[Z:T,D5K+Y",)F2-6D *JQ 7@GN.F10!W%%<_?^--#TV\N+:XN)O]
M&*K<S1VTDD5N2 0))%4JG!!Y/&><5JZEJ5MI6DW6IW3XMK6%IY&'/RJ,G'KP
M* +=%<9#JGCF[TQ-6M]*T=8I$$T>FR32"=D(R%,GW0Y';& >]:^I^*]-T464
M>I^?!=WD3216D<#32L5V[E C#9(WCI[GH": -RBN>OO&VA:?=W%O<7$^+5PE
MS/':RO#;L<8$DBJ54\C.3QGG%:D.KV-QJ%Y8Q3[KBR2.2=-I^57!*G.,'(4]
M/2@"[17.-XZ\/^79-'<SSM?6WVJUB@M)9))H\XR%52>_3J!S6MI.KV.N:='?
MZ?/YUNY(#%2I!!(*E2 000001F@"[17#Z/\ $*R:.[76)'C>+5)[+S8K64PQ
MA9C'&)) "JL1MZD=0> 16SJGC/1-(O+BUNIK@O:HKW30VDLJ6RD9!D9%(3CG
MD].>E &_16+J'BO2-.O(;26::6>6'[0$M;:2<K%G'F-L4[5SW-1>"M:G\1>$
MK+5;DQ&6<R9,0PI"R,HQR>P% &_16!!XTT*YU*.QCN92TLS6\4YMI!!+*N<H
MLI78S<'@'L::GC?0I-02T6XG^>X-HEQ]EE$#39QY8EV["V01UZ\=: .AHKGY
M_&NAVU]+:R3W'[F86\UPMI*T$4AP-C2A=@.2!R>,\UDP?$"TL[_Q!#K#2)'I
MU^85>WM)9!%#Y<;!Y64$*-S-R<=/8T =M12*RNBNC!E89!!X(I: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH X;XCZ9K$L&GZKX?MGN-3M3-;A$(!\N:)D+?17$;?\!K*\2>#;U+S1
M]*TJU:32KRSM],U%UP!'#!*CJQ^J&5?^!5Z=10!YQJVC7ECXWU?4WBU^2TU"
M& PMH\H&'C4J4=<@CL0>G)Y%=;X;TI-+\)V6FQ6\MF$AQY,DHE>(MDD%AP2"
M>U:EQ=06B(]Q,D2O(L2ESC+L0JJ/<D@5AZEXUTG2[G4X9UNF_LR));N2.$E(
M]V-J[NFX@@X]* .(MK'6O^$3\*^'#X?O5N=(U.S-U.RKY(CBE&9$;/S9'/ X
M&<X[[,>G:_I_A#Q=_9EJ\>IW.JW,]L-JEGC9U^90W!.P'&>X%>@44 >7VVBW
M%YXQM+B73M=DTFZTRYT^:;49=[AG*$DH2=BD C.!D]L8)SX-%\5VWA]M<_LZ
M5_$-C-%:P0@C=+#';M!NZ]"\KR?0"O8** ,>QTN;0_!\.EZ:$:YM+$0P;_NM
M(J8!/U;D_6O/+>PUJ6Z\*:A-I_B&>>QNUDU(W<@VJ[1.A\N(';M#-U4# QC/
M./1[S7K.SUNRT=EGEO;M&D5(HBP2-2 7<]%7+ 9]ZU* /*QIVK6_AY;8Z-?-
M+IOB;[>ZH@/G0FY>3='S\WRL"123Z'>6VH>(EN;'Q)/%JEPUS;II\ZI%*LD:
MJ8Y,GY&!!!)XQBO5:* ./\/:'-I?C&\<6LD=DFCV5I#([;LF,RY7=W(!7)[Y
MKG_"^DZKHMQX+ENM+NBL-A=6=QY:@F!Y)8V4N,\+A3S7J%% 'EGAO2=6\-/X
M?U6ZTJ[GCBL+JRN(8%#RP,]QYB-MSR"!@XZ<5/:^']6DGT^_ET^6(7/BM]4:
M!L%K> V[QJ7P2 20I(!."U>F44 <UHUA=6_CCQ/>2P,EM=+:>3(>C[48-CZ$
MBN;\3:#JFI:KXPL(+*8C6=,MTM;G \K?%YF4=L_+G('XUZ310!Q -_XC\6>'
M+P:->Z?!I0GEN7NU5/F>(QB-,$[N6))''RCGFM37["ZNO$_A6XAA9X;6[G>=
MQT13;R*"?Q('XUK7&J6\,-T\8DNGM9%CFAME\R168*0-H]G5OH<U=H \TC\+
MZKIWCO3[&V@<^'HA=S6TZG_CT,T9#0D>@;YE]FQVJ&UTW5[CPCX>\(MHMW;W
M6GW5K]INV"B!4@D#&1'S\Q8*, #/S<XQ7J-% 'E-]H&KW6F:Q9II]\LUMXD_
MM9#$RI]HA,@;]TY.-X&2 <<@5T?A734/B"YU7[)KJN+5;9;C5I@2X+;BJIU
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MQK81V,AN[[4;N6WB &95:0%2/J!7;ZWKUGH,%O)=+/(]S.+>"*WB,CR2$$X
M'LK'\*TZ .#W:IX<USQ-LT"[U4:K,EQ:-#M,;GREC,<C$_( 4ZD$8/?I5#4]
M/\1VU_XBNK*SN(DNKK3S(;3:TA@6,";R=W!8=!QGTYKTNH9+J"*YAMY)D6:8
M,8XR>7V]<#VR* /)K[1-6FE\5&WTK6'AU/0#;6CWLOFR-(ID^5LL2F=PPO\
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MB[$(/?!%):KJGAC6-8N#H5YJ2:G;6S6XMPI DCA$;129(V#(!R>,,?2O0J*
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M[#2=7M=:LWNK,N8EFE@.]<'=&Y1OPRIJO>>(;2PF6.YANH]][%91NT1"R22
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M]'T,R'2],M;-I<!VAB"E@.@)'4"@#C]:TRUD^*J7++)YRZ!<3!A*XPZRQ@'
M..AZ=*Q-.M3'X/\  R37EYY>NS6XU.X:ZDW2CR'9(]V?E!8*O&,XQWKU5[&T
MDN_M;VT37'E&#S2@+>62"5SZ$@''M4,NC:9/I*Z5+I]L^GJBQK:M$#&%'0!>
M@Q@8]* /+_$33:1!XTTK2KNYBL;>"PEC"S,QMII)<,J$DD94*V.G/O6R/#5@
MWQ%N=',M\=-ETA+J2V-[*5>;S63S"=V<X]\9P>H!KLH/#NBVNFR:=!I5G'92
M-OD@6%0CMD'+#N<@<GT%7?L=M]N-[Y$?VHQ^49MHW[,YVYZXR<XH YSX?WEU
M=_#C1[F>1[BY-KR\C99R,@9/<\#FN)M/W7@/PYXHAO;J3Q#=WUJ)9#<.3.\D
MP66$IG&T L-N.-O;%>LVEG;6%I':V<$<%O&,)%&H55'L!TJA#X9T*WU4ZI#I
M%E'?%BQN%@4/N/4YQU/<]30!Y?=112>#_&VN-J5W_:FF:K>?9)!=N/LS+)E$
M50<8)(&".=V.@%7;Q-7U_P 4^)([BSBF^Q) D/F:Q)9_8U:$.9%5489+%OG)
M_AQVKK=(\"Z7:W%W=:C8V-[=R:C/>0S/ "T8>0NHR>ZY_/I6OJ?AK0]9N$GU
M/2;*\F1=JO/"KG;G.,D=,]NE '$:39W6K>,M'@UJ_-VT'A^"Y?[)<MY,\XE(
M$N5(W#OZ'/3@5A75]*;?2_$UC') E[K<217MUJTC7,R-/L9/)"; FW<-N[@
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M"..:X(::15 :0@;06/?  %0WVD:=J<MM+?6-O<R6LGFP-+&&,3>JD]#P/RH
M\FM=.CLOAU%X@@FNDU*'6SY4BW#A44Z@49 H.W:06R,<Y-6+R+5];U#Q=.\4
M'G6-V\-O>3:S):&P18U*.J*A4#G>6)^;)!X%>H_V/IOV#[!]@MOLGF>;Y'EC
M9OW[]V.F=WS9]>:KW_AC0M4O5O+_ $>QN;E0 )9H%9L#H"2.<=LT 9VOC49O
MAEJ0WI+J3Z1)EK<Y5I3"<E#W!/2N>TF]O]+F\&>7K":C9ZJGD_9!!&JPJ("X
M>$J P5=H4[BW#>M>CUEV'AK0]*OI;W3](LK6ZER'FA@56()R1D#N>: ,'QC"
M;SQ-X1L&GGCM[F[N%G6&5H_,46\C;200<9 KC+W3UL_"?C"]AN[X3:+JC)II
M^UR8ME'E/A1NY&7;.<\<=J]>FL[:XN+>XF@CDFMF+0R,H+1DJ5)4]L@D?0U"
M^D:;+;75N]C;M#=N9+B,Q@K*QQ\S#N?E'7T% '#R6EMKNO>,GUJZN(SIIC2U
M"W+Q"UB\A7\U0I&"6+'=_LX[5G^'(Y_%6M:0NO374BR^%[:XF@$SQK)*9&&]
M@I&3CG\?88]!U+PUH>L7*7.I:397<Z#:LDT*N<9SC)'(SVJZME:K>?;%MXA<
M^4(?-"C=L!R%SZ9).* /)/#ULFI:GX"EOI)YY8SJ<0DDG?<5AE(CR<\X []>
M^:CBTZ.T^'EQX@@FNDU*WUR0PR+<.!&IU H5"@[=I!;((YR?:O4Y/#FBS0VL
M,FE6;1VLIGMU,*XBD)+%EXX)))/O4QT?338-8&PM_LC2>:T'EC87W[]V.F=W
MS9]>: /.-<A?3;[6->OC)J>G17>_[?I^J,EQIX7:#%Y6=A"D'(!R<G()KJ?B
M/?WNG> ]0N=/E:*;,2&57V%$:5%=MV#MPI/S8XZ]JU)_"OA^ZU/^TKC1;"6]
MW!S.\"EBPZ$G')'8UJ30Q7$+PS1I)%(I5T=058'J"#U% 'E\EAJND-JC11VF
MF6KZ)=-)9Q:Q)=/(P4;)E5T4J1R"P/.X9Y J:PL_[+O_  #?6]Q=O=:DC1WK
MR7+O]H!M&D^8$XX901@<=J[>Q\+Z#ID5Q%8Z/96Z7*>7,(X%'F)TVGCD<GCI
M5S^S;+_1/]$A_P!#_P"/;Y!^Y^4K\OI\I(X[&@#QX6]M<^ /"^O7-W.VKW^L
MVC7#O<.?-D-R"T94G&%QP .-OUJ>:/6]83Q1J&VVBN[34;B&#4;C6I+?["L;
M8C_=A"H7&UCD_-N.>M>F#PGX=6]DO1HFGBYDD$KR_9UW%PP8-G'7< <^H!IU
MWX8T&_U$:C=Z/8SW@*GSI(%9B1T))'..V>E '#30)J]_XUN-;NY8[G3((T@\
MJY=$MD-L'+J 0#N<MR0<XQTXKKO O_)._#G_ &"[;_T4M7;[PWHFIW\=]?:3
M97-W& JS2PJS #D#)'8\CTJ_;6T%G:Q6MM$D,$*"..-%PJ*!@ #L * ."\%7
M^E6'P7TV;6)8$L!9.)A*1AERV5P>I/3'>N8TFWUV=O"V@WMD+N.+0!<"SN=0
MDM 7\S;EBJL79$V#:>FXFO2[7P1X5LKI+FV\.:5%.AW)(EH@93Z@XX-7]4T3
M2];CCCU33[:\6,[D\Z,-L/<C/2@#SFTCOYI_#.@ZS?I-IUQ>7X86U^\H<1C,
M4#S#:S%<N"#U\L9Z4NN#[/=:'H&BWDNI:=+J5S'<07&HO$HD2/<ML9@I;:"2
M0ISG&,XXKT*?P]HUSI,>E3:59OI\>/+MC"OEICH0N, _2D;P[HKZ0NDMI-D=
M.0Y6U\A?+4YSD+C .><]: /-[RWU:RTR:QENTM+=]?T^.&WL]3>XDM%=T$B%
MRJLH.0P';=Z58F\/VAUCQI8":]6RL;&&YM8!>2[8IGCDW./FSG]VIY]_4UZ#
M;^']'M+*.SM]+M(K:.83I$D*A1(#D/C'W@0#GKQ5DZ?9F:YE-K"9+I!'.^P9
ME4 @!CW #'\S0!YCI-K;^)/&6C#5YY96G\)6T[QB9H_.<R'+':03C)..F3GL
M*S;6^U;4+?PSI"EM0L)+O4HT%Q?O +M89-L(:559FPNXX_BVY/2O4KKPMH%]
M'''=:/8S+'$L$8>!3LC7.U1QP!DX ]34UQH&CW>EQ:9<:9:26,6/*MVA79'C
MIM&,#'M0!YK<VNJ0Z;;:;<WRPVTGB6"!(;/4GGDMHF0[X6D(5AR20.H##T%>
MDW,>EZ/X=FCND5=*M;<B590TH$0'.X')88ZYS3H-!TBUM+>TM]-M(K>WE$T,
M20J%20?Q@8^]R>>M7V574JP#*1@@C((H \_O'G3X@>%[J[N[2]T^X>=-*BM$
M\LP;H2=[<MYB[ 5R"H&X'![7K.*WMOBS=16Z111#0H<)& H&;B4]!6YIOA;0
M-&NWN]-T:PM+AP09((%1L'J 0.!["JT7@7PG!=)=1>&]*2X1Q(DBVJ!E8'((
M..N>: -V.:*8N(I4<QML<*P.UO0^AY'%<GKMVUYJ-]X>T""W34;J)?[2OV0;
M;9&7:I;N\A7[J]A@G QGH=.TJWTR?4)8!AKZY-S*, #>45.,>R#\<U1O_!GA
MC5+V2]O] TVZNI<;YIK9&=L# R2.> !0!@Z!96VB?$*YTU6Q%#H-G%9%VR3%
M&\JOSWP2A/U%9OAK5K73/#L$]O8)?:A>ZGJ T:$ !C$T[L2'/W(\8)/ICJ2!
M7;7?A;0+^QMK*[T:QGM;4;;>*2!2L0QC"C' QV%)J'A;0-6CMX]0T6PNDMDV
M0+-;JPB7CA01P.!P/2@#'L-/LO#NG1KJMY9OJVJ:@\Z3O"6B%ZZG 0=@%7:,
MD$@'G)JEX6FDT_QEXGCUJZMYM0$-K-/>Q?NX1%APB%#G81\QY9L[@<]JZ6+P
MIX>@TJ;2XM$T]+"9]\MLMNHC=N.2N,9X'/M3K;PQH5GID^FV^D645C<?ZZ!8
M%"2?[PQS^- &K7'^&_\ DH7C;_KK9?\ I.*[   8'2H(K*U@NKBYBMXTGN"I
MFD50&DVC"[CWP.* /(K_ $V)?"7CW6UFNDO[+5+N6UDCN'00LNT@A00,D]20
M<].@K1U!-3U[QMXAMI;*.[ALH+<6XDU>2S\A7BW-(H1&R2VX;STV 5Z,VD:<
M]I=6C6-NUO=LSW$1C&V5F^\6'<GOFH-3\-Z)K,L<NIZ397<D:[4::%6(7^[D
MCI[=* *WA^YNK;P38W.K7D-W<168>>YMG\Q9<+G>IQ\V0,Y[YKSFPGN+34/!
MFJ6\36RZM>K^^GU>2XN;J%XW8^;'L" <H>"=IP!7L*1I'$L2(JQJ-JHHP /0
M#TK%C\&^&88GBCT#341W61E%LH&Y3D'IV)./J: /+UM8+;X=:[K]K=W"ZQ9:
MQ<_9F2Y<>4_VHXC" [2&W<@CG?\ 2M759Y9?$=^DDKND7B[35C5F)"#R8S@>
MG))_&N_'A3P\+R*\&B6 N8G,B2_9UW*Y8MNSCKN).?4FK;Z/ILDSRO86[2/.
MERS&,9,J@!7/^T   ?:@#RI;6/5==T;[<TTN/%FI0C,SC"!)B%&#Q@J,?ETK
M1\^\%V_P_-S/YYU42+-YAW_V<<SD[NO4&'/TKOKKPYHM[:FVN=*LYH#<&Y,;
MPJ1YI))?&/O')Y]ZI:7H-TGB6[U_59K:6]D@%I;K;QE5A@#%L9))9F8Y)Z<#
M% '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '-:IK6J2>*8_#^C)9I.MG]MGN+M6=50N45552"22&Y
MR, =\UQ>M:GJ7BV7PU:2PV,936KBSO;:0.\3S0QR\\$93Y=P!YSCTKN=5\/7
M5QKT6N:3J*6-^ML;23SK?SXY8MVX J&4@@Y((/<\&JEEX(BL_P"QW%_))-8W
M\VH3RO&,W,LJ.KDX.%&9,C&> ![T )X\O]7L+/2/[(N(87N-5MK>1I58Y#..
M.".#C!]0:YR'4?$&F:CX\OM/33V2RN5N)A<ASYI6UB)1,$;>!U.>HXKM?$VA
M2:_I]O#!>"TN+:[ANX93%YBAXVW ,N1D'ZBJL?A0BS\20RWV]]<R9'$6!$3
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M!:K#:^0D8<KO8C<Q+':!G( &>* $UG6M2'B.TT#1DM!=RVLEY+/=AF2.-65
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M^7$J(7=V Y/ P ",D]:S;OQ#XBL18:9<6-B-8O[YK:WF#L;=HEC,C3%<[A@
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MAIH+NW:"9KZ[D*L,$AKB1E/XJ0:KG3+L^,_$MY]F?R+G2K>&&3'#N#-N4?\
M?2_F* -"P\9:'J>HV]E:7;R272,]M(;>18IPHRVR0KM8@=0">_H:9;^-M!N;
MV*VBNI2)IC;PW!MI1!+*"1L64KL8Y!'!Y(XKG-/T'44TWX<PM:2Q-80,EX0.
M8";-TY_X$0/K5"VTW5YO!FA>#FT6[@O+&ZMA<794"!(X90YD5\_,6"\ <Y;G
M% ':Q^,]!EN+^);UL:>)3=RM"ZQ0F-MK!G*[0<]LY(Y'%2Z5XITK6+PVEM)<
M)<^5YRQ7-K+ SQYQO42*-RY(Y'3(]:X^X\+:I?> ?%NF16[17EYJUS<P*S!/
M.7S@ZX/;<%P"?6KWA_3ENO$UIJ$EIXDWVD$F)]6F 6-GV@HJ]6)QDD<#:.30
M!TVL>(],T)X([Z:433AC%#!;R3R,%QN.R-6.!D9.,<U!/XQT&#2[/43?B2WO
M21:B")Y7F(ZA44%B1@YXX[XK%\;6#3:KIUVMCK(,44J+J.BR_OX22IV-&1AT
M;&<X."HX&<UD:;;>(]-NM \0:OIMS>F""[M9HH(D\^)))%:.5HU.W<53#!>F
M?K0!VMOXJT2[L[6[AOU:&ZN19Q'8P;SN?W;*1E6X/# 8IU]XFT;33?B\ODA^
MP)$]T65L1+(2J$G'<@].G?%<%<:1K,BW/B(:/<J)/$-OJ2Z<NWS_ "(XA$6V
MYQO/WMN<_C4>LZ;K'B!?&%RFAWD,5_#IJ6L4Z@/*(Y6+Y4$XP#G!YQCZ4 =F
M?'GAW[%;W0O)V6X=TAC2SF:63;C<5C";RHR/FQCGK4TWC/0(=.LK[[?YL-[D
M6RV\+RR2[?O;8T4MQWXX[XK-UE+S2?'=OX@73KJ_LGTUK)Q:('DA?S X.W()
M5AQD="HS7.:AI6L2ZUIGB*?2]2T^W:WN()+;1F3S[??*'1G7D,6 ^;;G#8H
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MD"W!"6DSF*)NCR!4)C'^_BK*Z[;MK8B74;(V1TW[:.&W;=V/,W_<V8_'OTK
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M()/OMR,'DK@?2O2: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *A>[MX[R*S:9
M!<2H\D<9/+*I4,1[ LOYBN*\7:5/J7B:*2 6.JK!9?O-'N+UK=ERYQ,A7(R<
M%?F ^[P1S6-H:Z5K'C/PGJ$45R4.BW)B-W,7E#1S1*,MGYB/FYYR.>: /5*A
MN[NWL+.:\NYEAMX$,DLCG 50,DFO)=&AMK3X6:)-(EY=ZAKL]O:NQOGB\UMS
M%4=^=D852#M&3TZFLS5XC'HOQ%TB1+6*"TL+:=+2TNGFBAE/F;BI8*03M7(Q
MCB@#W.BO+-1T^>\\<SZ-!I]C=Z=9Z9#)9VMWJ4MN@#,^^1=J/O.0!DXV\8ZT
MS2;:74=6\-:/XCU*#4+-=,NIXF@O&DBN)%F54R_RF1DC/<=<F@#U:BO'M(N&
MT_2W\1VU_/<VFD^([F*6228OOLG*QL22?FVY1P?12>]=SX(\V]L+W7IG<G5[
MIKB%6)^2W'R0@#ME%#?5S0!U%%>37L-K>^'_ !SK6I7,J:OIUW=I:S?:&1[4
M1J/(" 'C/RG_ &BQZU)J.K:IH3:E9%G6_P#$=C;RV"$D>7>/L@E ';!:.3'^
M]0!ZK17DLNDW=QXLU316M+2^M-*L+6.T6_U26V,<9C.Z50D;98L""Y.1M%6-
M(T^?5?$OAJSUO45U$1Z"\[R6MRS17+K-&$<L,;^"#DCD\T >I5#=W=O86<UW
M=S+#;PH7DD<X"J.I-<WX\N8X](LK)H9II-0OXK6*)+DVZNQRV)) "0A"G( R
M>G>O-=6CVZ%\0])E2VCM[*WM)H[6UNGFBAD;>&*E@",[1D8QF@#VZZN8[.SG
MNI<^7#&TC;1DX R<?E4>FW\.JZ7::A;[O(NH4GCWC!VLH89'K@U1U.VM[/PA
M?V]JH6".RE"*"3@;#W->8:5#?ZQ>:3ITEE97MK;^&K&6WMKW4)+9/F4AY%"(
MVY@0HR<;>,=: /9Z*\J07-YIOAC0;Q[;6KUX[J<.-4<6DD4;;5WR!"TK*&48
MQU!)JGI$=UK?A?[!%J5B3;>()XX+&>]D\F[B52?(60?.RC=N'!X4<8H ];N;
MNWLUC:XF2(22+$A8_>=CA5'N31=W=O86DEU=3)#!$-SR.<!17D5_!IM[9V.F
MSZ;-9R67B:V@N+1[PSQ1>8@8B)\_=(VG'&"3P*Z_XI6L$OPWU%9$!2+RF7DC
M'[Q1_(F@#I8-8M;C7+S2$\S[3:0Q3297Y=LA8+@^OR&K]><V_AK2M2^(>NV5
MQ"SV<&EV2QPB5@O6;!.#R1C@GIDUS>EW.K:[#X,L+B.#48)=&DF$-_?26Z7$
MRNJY9E1S(RIS@CN3VH ]JHKE_ D%Y;:)<P7=W:7"QWLRP+:W;7(@CR,1&1E4
MDJ=PY' P*X35+".3P=XXUMYKDZC8:I=M9S>>X-OL92-@!P.<Y]>G3% 'L=%>
M5:E;ZAKOC3Q+#<6MC<Q644 M_M>JRVGV:-H@QD0)&PR7+9?((VX[5%K5[K.E
MZ3H5Q8ZE]MUZ;2RFH261,\;VBKDW2YQEU)!4X^8L1SV /5&N[=;V.R:9!<R1
MM*L6?F**5#-] 64?C576=;TWP_I[W^J7:6UNO&YLDL?10.6/!X )KA]/TG15
M^)6@O9$3VR^'WDMIC*6,F)8@KYS\Q(8GWS77>+!;_P#"+ZH\PBWK9SF-GQD$
MQL.,]\$C\: );OQ'I5EH<&LSW)6RN%C:%A&S-)OQL"H!N+'(X S1HWB+3M=:
MYCM&G2XM2HGM[F!X98]PRN4< X(Z'H:PK+6=+TGX<Z#>WJ)<F*UM5MX4"N[S
MF,!%0'HW7GC R>!FKOAC3IQ?ZAK>I36[:IJ"QJ\%N^Y+:),[(P?XC\S$MW)X
MX H Z6BN U32K;6_B-J]I?F:6UCT2W=81*RIO,DXWX!'S #@UA^'X&M[/X=:
MPL]Q)J.HDQW<\D[,9U-M(VULG! *KCTQ0!ZW17CENJ+\/-)\3QW$S>*)]0@#
MS&9M\DS7 22$KG&T*6&S& %Z<4NJ6$<OA#QWK4DMR=0L-2NVLYO/<?9RFUAL
M .!SG/KTZ8H ]0U+7K#2K/4KF>7=_9MO]IN8X^75,,1Q[A6Q]*OPRK/!',F=
MLBAAGT(S7DFN6%F+CXGW0C N!H\;!MQ_C@D+<9[D5J/IUMH/B/PN]G<RVAOK
M&Z6]N'F9O,VPJP=]QQE3SGM]* /2J*\O\,6PT#6M AO[9)9KU7B@U>PU%Y4O
MCY98M-&W/(4MD%@#CD5Z9;W$%W"LUM-'-$V0'C8,IP<'D>X(H YFX^(>A6MX
MEG-'JRW$C,L<?]D769"OWMO[OYL#GBK.FZGHU]XF=K:VN$U.?3HYGDFA>(F
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MO P,<8%5M/M];U/0WUHMI5KJO]I.#J=WK$L<D,BSE1"T7E%0N $";L$$'J:
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MZ@OK.&[MI5EMYXUDBD7HZL,@CV(->8C0[JUNYXO*TBPL9])N#/8VNK2W+70
M!24*T:\J>"V>=_-=9X LK2/X<:%#%&!'/IT#R ,3N9HEW=Z -31=?M=>%T]G
M%<>1;S-!YTD>U)65BK;#W *D9XK4KQ?0K"UATOPW8,'@TS4M<OHKW;*RB8QO
M/Y,;'/0D#CO@=:GUM6LV\2Z/IMU/#IL&I:2L(BF;_1Y))5\U4.>.-AQT!;WH
M ]7GU&UMYG@DF7SU@:X\H?>,:\$X^I INDZE!K.D6>IVN_[/=PI/'O&&VL 1
MD>N#7G\_A_2=.^(LD5M;"-8?#LDD0,C$AO-(SR>>#WK.T73(-)\._#?5+1ID
MO;J:V@GE,S'S(GMW)0C.-HPN!CC Q0!ZK=77V7R/W$\WFRK%^Z3=LSGYF]%&
M.35BN4\;RR1-X:\MV3=KELK;3C((?@^U<-+8HG@#4?$/G7)U2UUN7[/<&=\P
MJ+[;M49P%()R.^: /5]6U6ST/2KC4]0E,5I;KOE<*6P.G0 DU#-X@TN'0HM;
M:Z4Z=*(V29%+!A(P5. ,\EA6/\2O^2=ZS_UQ7_T-:X_QDI\*V%[H)!&DZI=0
M7&FGM#-]HC:6#V!YD7_@8["@#UNH?M=O]M^Q><GVGR_-\K/S;,XW?3/%>=S6
MECK.J^-I]=GD6;37"6Q,[)]D@\A761,$;26+G=ZC':L;33=2ZHFMRPL^O_\
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M)6.) JC)). ..22?QK@=#^(%S?:]9:3->Z)>2ZA%)Y3:<7;[-*J;ML@8_,I
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M0L$(X3 Z9SD]A6WXH\:7VD7L\<%YH-E'' LL$=_*7FNR020J(P* =,D')[4
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MF;5].%A*5@6-8@"V"@R< ;CP2>>]="NE2S^&WTG4;QKEY;=[>:XC01%@P(R
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M@GC26&12CQNN592,$$'J#69I/A?1-#N&GT[3XX9F3RO,RS,$SG:"Q.U?88%
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MCUK>HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.)%L)4,#LJ;8FX.22V0W .X8H KZCX.;4=(MH(H['2KB&^6Z L8\*BD;)!G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQM3)Y^X92^WZX.*ZNB@#@(/ ^J266D:3>75F--TR.>W5XMWFS1R0O$I((PK
M,,C)SR<CI48^']W)H=W820Z7%,VFR645U&\SL[, "Y#<1J=O*C=VYXY]#HH
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M9P&$AY&2#SS5JU\*WYU^#6[R:V6Y.HM>311%BBK]E-NJ*2 6/0DD#OQ77T4
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MU,L&F?8E68-M+[T;)QVPI_2NCHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex992independentauditors002.jpg
<TEXT>
begin 644 ex992independentauditors002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+:#4)[%&T&4S26Y D*>>ORJQ!VY.WGK@'US0!Z%=7"6EI-<R*[)$C2,$4LQ
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M-&F]@B[F W,>@'O[4 <M/X1U"UUC4-0\/Z\=,747$MU!):+.AE V^8F2-K$
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MXMXP[X!8EB!C.<8SQ6AX?\/IH,NL.MPTW]I:C)?$%=OEEU4;>O.-O7WK9HH
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MMJJ\]]:6KA+BZ@A8JSA9) I*J,D\]@.2: ,3P;X8N/"6D'26U0WME$Q^R*T
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MS>QAF7YGGW[@>.@\PX^@ZT 4]<\8*=&U&YT%Y)KO2]L]Q#):2('B5OWBJ64
MG:&Q@GD"L_Q#XZNK ZQ?Z:(KC3M-TZ%\E2?,N9V'EC(YVA"K$#D[Q79ZI=&S
MTZ:86-Q?$#'V>W56=\\8PQ _,URWA;P+;V7P^?0-5A)-Z&>Z02EBA. JA_\
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M_<JQ+;054$C)/7)K.?P-:.]\IU"]^S76HQZE]G_=[8YE=7)4[=V"5&02?;%
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M2!/O,$"%B@R/FQCD<\UG:-X[M+C2+S4M1G00_P!JS6-F+>%W>8*WR (H+,Q
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M2"W9B/W,2%Y&X[\*H]V%:=SXETJTT6UU::Y/V2["?9S'&TCS%QE51%!9B1V
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MR8H)'V+(V.%+8XS7FEWI4-U-!-X8\):KH6O-<1,\ZH+>",!P9/,VMLD7;N&
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MTF/"^<TBE4)]P#4<4FHZSXE\&3+X?O[.'3C,+N2YB"")FMV4*.>1GC(XZ?@
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MG=6Q\486F\#3;9YH2MW:\Q/M)!G12#[?-GZ@4 =1#J-I<7]U8Q3!KFU"&>,
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M<[R@MZ\A5_*GZKXP33M8NM*M](U"_N[:U2\D6V$87RF+#.7=>1L/'4Y&,\X
M-*TT#3K(W;0PN7O(TBN'DF=VD5$V+DL2<[>_4]3DU2F\&Z)+;V$*6\]O]@MQ
M;6TEK=2PR)$ !LWHP9EX'!)]>M5-,\=V>J7FE1QZ=?Q6FK*QL;R54$<K*A<K
M@,67@'!( .#CMFKIGC6%]/TR"QM=5U>\O$N)41_)27RXY2C,Q+*@ )  '.,>
M] '5:;IMGI&GQ6-A L%M$"$0$G&3DDD\DDDDD\DFN1T#X?64%FYU>!I)SJ,]
MV8DNI/)DS,SQL\8(1F *]0>@]!6E-XQ1?[.@@T74YM0ODED2Q9$BEC6,@.7W
MN%')&,$YSD9'-5;KQG>)J_AZTM] OPNIO,LR3JD<D7E@Y&"X'! ;(R"OW<DB
M@#HH-'T^W;4&CME_XF,GF788EA*VP)R#QC:H&!Q6?IO@[1=)NX;JU@G,ENI2
MV$]W+,MNI&"(U=B$XXX XXZ55N/&B6ET/M.BZI#IYNULOM\B(L?F%]@.TMOV
M%B &VXY].:IP^/&AN_$IU/3+BWLM)N4@CE78S2LRQ[4P')+LS_+P!@C)!R*
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M/UBUMHY[3[!+93YE"-%ND1P^"/F'RD8%95IX3U2'P5X/TIUB^TZ5=VLUR _
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M(O Y&3GGC%=OK&J6^B:->:I=AS;VD+32",9;:HR<#UJW'()8DD7.UU##/H:
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MER"T)4CYQQ\P('0<BHO#O@F?3SH]G=^&M.+Z>Z&34C=LP?RQ\KQQ]0Y(4\X
MYZUZ510!P,OA+5'^'VI:,%A^V7&IR72#?\NPW?FC)]=OZU1U_P &:QK%SXCA
MGT^TOGU#<+'4+JZ.VTC,04((L<,&#'(X.[)/&*],HH Y#PQHFIV>O-J-];QP
M*^D6EF464.1)$TF[IVPRG/O5P:+>?\)EJ^J83[-=:9#:QG=SO5I2<CTPZUT=
M% '#Z;X6U*UTSP'!(L6_1<?:\/P/]&>/Y?7YF%9T/A*_M_#>E:=J'AZQU9;8
MSL=MT89X'>5F5HY.."IYP0<@=:])HH \[/AK6&T#3;36-'M=>\EIFQ)>LMS:
M[GS&$F(!;"84G()('6G6?ASQ)9-X9O)E6^ET^ZNC)#)=EGB@E!"+YC#,A08!
M)Y->A44 >27?@;7[K3&CETJSN-6AOUNVU.>\+/<JLX<*@(_=_* .>!C SG(T
M]5\':QJH\36C6MNL6H7=OJ5M*\_RF2-80874#(!\MAN'K7I%% 'GUOX3FEMM
M6:+PU9:7+-ILUK"YNS-*SN,$9Z*G ]S[8K4@\/7\>I>#YV$>S2K*6"Y^;HS1
M1J,>O*FNMHH \SO/ =_*4O)+2WO'M]:O;P6;SE!-!.3T8=''RG!XX(S5G_A#
M[J33T-MHMEIDK:O97311W!D<PPR*Q+L>"WWL <8QS7H=% '$^)O"NHZQJ?B&
M6W\H1ZAX>_LZ%G;'[[?*>?0?.O-=1HQNSH]J+ZU%K<K&%DA$@D"D<?>'7(&?
MQJ]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'G'C2XN-+\075K!-(A\26$=E
M!AC\LXF$98>A\N?=_P!L_:L&XEFO=)U32'ED9?#.BZE%-EB=S-OB@+>O[I&/
M/]ZO7I[*UNI8);BVAFDMVWPO)&&,;8QE2>AQW%,_LRPS=G[#;9O!BZ/E+^_&
M-N'X^;CCG/% 'G4&FQ:'JO@BXTQ9!=WMM,ERQE8FYQ:EU#Y//S*"/3H,"L?P
MS::G=:3X;UL2Z1:W\]W$T^H2ZK*;BY8M^]A:,QX)(W*$SA2!CI7L!LK0O;N;
M6$M;9\AO+&8LC:=O]WCCCM52+P_HL&J-J<6D6$>H,26NEMD$I)ZG=C/- 'DP
MTBP32KJ&!#"TOC9(':*0AP@GP #G(P"<$<\U>\2";PO-XSM?#YDM(AH]K<A(
MY&Q&S2R))(O7:=@R2/[N>U>FC0M'%W+=C2K'[3+(DLDWV=-[NO*L6QDD=CVJ
MT;.V-Q)<&VA\^2,1/)L&YT&2%)ZD#)X]S0!YI:Z7=Z9J:R6O]C:=;RZ9<F6V
ML]4EN'NUVC9*%:-<E3CY\Y(8UTWPYTVWL_!&D72>8]S>V-O-<322%FD8QCKD
M]LX'M6S8>'M$TLS'3](L+3SQME\BV1/,'HV!R*O000VUO'!;Q)%#$H2..-0J
MHH&  !P !VH \;U^WT^^\%_$#5=3F/\ :L%Y=VT<C3$/'&N%BC49X5EQQWW&
MNITN_2U\0^,/M-R(XXM/LI%#O@*ODODC\1767/AS0[V]>]NM&T^>Z=#&\\ML
MC.RD8*EB,D8XQZ4^YT'1[V\@O+K2K&>YMP!#-+;HSQ@= I(R/PH \FTW^T-7
M_P"$.TZ6WM+ZT;PW'<1V^H7DD$<LV5#M\J-O95V\'IN)KT/P)#=6_AQH;F]M
M;M4NIE@:VN6N%CCWG$9D8 L4Y7D=A6K=>']&OK"&PN])L9[.  16\MNC1QX&
M!M4C X]*N6UM!9V\=O:P1P01C:D<2!54>@ X% 'CEO:6ECIEU!#FVM+OQ@]G
MJ#QR%3]G#OM1CG(4MM7MPV.]=EH$$&E_$;5=)TGY-+73H)Y8$<M'#<%W' _A
M+( 2!UP#73'0M'9[QSI5B7O0!=,;=,S@=-_'S?CFI-.TG3M'MS;Z986ME"3N
M,=M"L:D^N !S0!PFOZ99O\2[R[: >>OAR68/DY#A]H/Y<5G6UG9V_@?PA9+;
M2W=]KHMY)?/OGBCF=8"Y\U\,2H'1 .< =J]1>RM99VGDMH7F:(PF1HP6,9.2
MF>NW/;I4%UHNE7VG1Z?=Z99SV4041VTL"M&FT87"D8&!P* /(EO);32O$MHD
MT$-K8Z[II6.UN&>&!6DA\P*S $+G.1T!W5K^.]7N;?7?$K:9=N)[;PQN/DOD
MQ,9CEN.C!3GUZ&O0O^$?T7$@_LC3\20BW?\ T9/FB'1#QRH].E.LM"TC34V6
M.E65LNPQXAMT3Y"<E>!T)YQ0!P@TS0]*^(W@Z+1G4+):W<C(DQ<.OEKMD.2>
M3S\W\6.^*V/&"I>>*O"VEWS-_9-T]R9XRY5)I5C!C1L=1RYV]ROM70V/AW1-
M+=7T_1]/M'5BRM!;(A!(P2"!W'%6;_3K'5+5K74+.WN[=B"8KB,2*2.AP1B@
M#R6_CQ<:AHME<SKH\7B:PMX/*F;]WO1?.C1LY !)X!X)/2O1=<CDT/P+J::)
M$8Y;2PF-HB98JP0E<9Z\UHPZ/IEO:06D.G6D=M XDAA2!0D;@Y#* , @\Y%7
M: /*O#.FW<-_X7O[5]'LQ<+NEECU:6:;4HS$2V4:,!F!P^<\8-9MIIL8^%VE
M7PGN1?:AJMK%/<B=M^S[7M"@Y^4 >GUKU6R\/Z+IMY)>6.D6%K=29WS06R([
M9ZY(&35@:9IZVD=H+&V%M$XDCA$2[$8-N#!<8!#<Y]>: .'ET;3)?'\7A^]A
M']D6NCB:RLWD;RVD,K"1\9^9@-G7.-WO7/:7!_;EUX7TZ\N+BXTHW^JPQ$S-
M_I%M&3Y89@<LO '7D#TKU74M&TO68TCU33;.^2,Y1;F!9 I]1N!Q4RZ?9(UL
M5M+=3:J5MR(P/)!&"$X^48XXH =!/;,\EM!-$SV^U9(U<%H\C(##J..>:FJ&
M*UMX9YIXK>*.:<@S2(@#2$# +'J<#CGM4U !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %74]1M](TN[U&[?9;VL332-Z*HR?Y5F^%?%%IXMT<ZA:P3VY2
M9X)8+A0)(G7LP!(Z$'Z$5S'Q0OY;G^R/#%K97-^VH7 N+RVM=N]K6)@SCYB
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M="\/:!H.B:?''I]]K$4-Q:I,85G4AF\MGY(#E1D]_P :ET3P_JNG>-;2]M-
MT[P[I[VLL5[#:7JNLW ,;B,(HW*W\7HU 'H_F1F0QAUW@9*YY_*AG1 2S*H
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M9YH [OPCXA'BKPO9:V+8VPN@Q\DOOVX<KUP,]/2MAI$0$NZJ!U).*XOX0_\
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M!%Y0*B-UD9EY[%@"1W(H ].HIL4:0Q)%$BI&BA551@ #H!3J "BBB@ HHHH
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M'((B+;>O.,8]JZIT62-D895@0?I3J* ,-O".C/X1'A<VS?V2(Q%Y/FMG:#N
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MSTX X%3ZEJ%OI.EW>HW;%;:UA>:5@,D*H)/'?@5/#,EQ!'-&<I(H=2?0C(H
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M''<%LD#IG- !XN\8ZC+X7\52Z1ITRVNG)/:G4([D)(LRK@LB8SM5C@MN!X.
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M<6TNE7:Z?H>K30:3!IUQ;ZDIV!HAQ)&^QB.K C:,C'2M>R\*7-MJ7AR[*Z;
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M$T:&U=R]R\D?E%F!4!!M+< MR>M "6/Q -U_9=U/I?D:7JDR0VMQ]J5I<O\
MZLR1 ?*&XQ@G&1D"K5KXOO+^<7%EH,]QHYO&M/MD<P,A*N4:018SY88$9SG
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M2"-5SU9V/W5&.3@]N*Y^U\?+),;>YTX17$6HPV%QY5R)8T\Y<QNK@#<"<+C
M()JYXQ\/W>O1Z6ULEG<K978N)+*]8B&Y&QE 8A6Y!8,.",BL"+P'J@B\21DZ
M5 -52&>W%L&1;6YBQL&W;RN54EL@D@_+SP :DGQ M(T\2L;*7_B2C*?./]*^
M9DPO''[Q&3OS1KOC6\T%;NYN-"(L+)5::5[Q$D<8!8Q1D?.%SC)*Y(.*S_\
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M<6A_9[&=Y]7EE6.+S$7RUB8J[L21QQP!R:ZUF085F4;C@ GK7COA?3K*YN_
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M4#  & *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M( DXZ\4 .TSPEJ5DEI:W'B.XN-/LH&@M[=81&64KL7SF!_>;1TX7GD\U5L/
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M]E:=W\H.KQ,4! <E@2. <UZ%<7=M:*C7-Q%"LDBQ(9'"AG8X51GJ2> .]34
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MD!42H&0@D=<98$>HK4H \QU33+@>.)O"L<1.E:W<Q:O,1]U%C_UZ'_?=(/\
MOXU0WFE7<U[?!["=XW\:6T^#$2&B$467Z<J"#STXKNM+TS2X-9U*^M[IKO4'
M817#R7'FM /OB(#^!?FSMXZ@\\5M4 >6^,M(U"\U;Q6UK83SH]EIDFQ(R?M
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M1MH<,WS;3QQWKUNB@#QFSLKR?S[2XL]3F=_%UK?;KNTVM) 4CQ(VU @Y4Y&
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MNXXRQ8BN?\'> !9^&]!BUB6^66Q*SG3VN T"3@DAL#.<$YQNVYYQ0!2N=?\
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M"Y\M)GZ%BI! 8]V7!- &7.C:1?Z!X1\.W[V5I<F[D>X4K.\*1%28DWAE'S2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M?W]KI=A-?7T
MZ06L"[Y)7/"BGVMU!?6D-W:RK+;SHLD4B'(=2,@CZBN*\>:@\^LZ)H$-A=WZ
M&4:A?06BJS^3$1L!#,HPTNWOT4T_X<WKQ0ZGX>GM+FS;3;@O:P7042"UE):/
M."1P=Z\'HHH [BBN&9;J[^(^N%KV^:WTVQM;B"SCN'2-I3YO)4'D';C'0]P<
M#'->&Y?$U_IOA[78EO3<W<\,MU=7&K@P3QN?G00%MJX!.T* 05'O0!Z]5>UO
M(KQ93$)0(I6B;S(V3YE.#C(&1Z$<'M7G":EJ95/!7V^Z_M-=:,+7/G-YQL1_
MI&_?G.2A6//J:SY]8UJYN[?2XY;ZYBN_$.I12+%>&"1HXLE(EE)RB]\ @X7
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M+$G'H.@Z"O/[/4=0M[SPIJT#ZLL.K:@B&>_U/S#=0R([#-N"43C:1MQC ]:
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MQZ$=NW%4-&O;_5O^$:T*^U.^^R2SZHDLR7+QS7 MY2D:-(I#?=))P<G;SWH
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M--+!N)$?EE<*W(!;<>!G%9&F?#EM+\NP'ASPM=P1W)==4NH=\YA+EMK1[.7
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MV%[K3Q)XI.K2)+(A/VLW'G, C;?FV;<#!^7;[5Z@+: 1Q1B"/9"08UV#"$#
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M/W<Y^;;CIWS71:WH-QJ6LZ-JEG?1VT^FO(=LL'FK(DBA6& RD' X.?P-8O\
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M"9#=".*GBNK/3?$>A:\^D76G:$;*[AB1K5O]'F>56#LB@E/,56(R!UP<$XH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8WSRI9WMM</$<2+#*KE#Z'!XKSGQCITT&NWEEH-L()?^$4O4MXK9 F"98^%
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M'O;VVMD<X5IY50,?09/-4-<\26FAQV@:*>\NKU_+M+2U4-).<9.,D  #DL2
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MBFHQS-,,M&V=Q"GYAE<;1][%>P4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@ &<
M#K2T4 (  20!D]:6BB@ (!ZBC&:** $P"0<#(Z4M%% !28&<XY]:6B@ P,YQ
MS2$ XR <=*6B@!" >H!I:** $  &  ![48 ).!D]:6B@!,#.<<^M9NEZ)!I5
MYJES'([MJ-U]J</C"-L1,#VP@_.M.B@!" >H!I:** $P,YP,^M+110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M')_G,?B+2P>J@1WB#Z<(_P"A-;VC>)M+UUI(K.<BZB'[ZUE4I-%_O(>?QZ4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %'5M272-/>\:UNKI4ZQVL>]\>N,C@4FEZO::MHMIJUN
MY2UNHEFC,ORG:PR,^AK+U[Q7HVFO?Z9?WL=I<)8M<#SSL61#N'R$_>((Y YY
M'K7":!:60N?!UEXHA@^P)X:5K:&_ \K[3E=_#<;PA7KR 3[T >N[@.I%(CK(
MH9&#*>A!R#7C>EV=MJ5YX<LG03Z(?$&HK91DYC>V$4A51ZQ[@P Z$<=*[/P5
M:P:=XB\8:?90I;V4.H1-%!$H5(RUO&S;5' R>>* +UWXSMK?6KW2H-*U:]N+
M+9YYM+<.J[UW+SN':M+1-?L=?M99[,RHT$IAGAGC,<D,@ )5E/0X(/XUQ=M:
M:[<_$/QF=&U6VLF7['E9[3S@[>1QSN&T?@:PLQOX*%QJ$\IGNO$$"^)Q-A1'
MA@CHP7 $7RQ_53D]30!ZAKNNVVA>'KW695:>WM(C(RPD$L!V':M)9$<D*RDK
MU /3ZUXQXOCTZW7QC!X=2V33/^$?5KI+(*(5N/,.SA?E#E,Y[X K4NHM,M?$
MVCMX*%M]LETJ]:X-I@M(HC4Q-+CJWF8P6YR3[T >IB1&=D#J67JH/(JMJ&J6
M6EV<EW>W"101@%F/.,G X'/4XKR/PI8PRIX1NK>_\/6U\94>1[<.;VY.P^='
M*<Y)/S;MW 8#IQ4-QH>DGX1:OJ<]C;273:I+NN)8PS*@OR, GHN-W'3EO4T
M>UF1%*@NH+?=R>OTIU>1^)+'0HM2U2^MF\,ZE:PV<2OIM^?):WC5"5^S2#(4
M,#D8&-PZCMZAI%PEWHMA<Q12Q1S6\<BQS$ET!4$!B><COF@"Y1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@E&5@#@X.<&A9$?=L=6VG!P<X->.>)$MK&_\2)X-$,-M_P (\'NUTS 17\[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )N&[;D;L9QGFC< P7(R>@KS
M.[\-Z0OB#3].\/PM/KMM?QWFH:NQW2PQ[MS++* ,EU^41^AS@ 5A^(H;6QTS
MQ==:GIEZ?%$-U/=V%^MJ[%(E^:%DFQM1%4 %=PZ$8)/(![317+>-)7G^%NNS
M2+M>32)F8>A,1-<[X8T_PL)-*>#P'=VUV!&RWC::JJCX!W[\\<\YH ]+ID<T
M4Q<12(YC;8^U@=K=<'T/(X]Z\LL_B%J]]9PZS;&>99;K:-*CT>X8>1YFS(G
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MMK77%U99KAYQ8)88D??E%8L&)/);).23S6M110 4444 %%%% !1110 4444
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M=6M\PA26W<# V[4"D8+ AE.0Q%5I_ EO=Z-JUE<ZMJ$MUJQ3[7?YC$KJF,(
M%V!,9&-O(9L]:ZRB@# T[PW/:$QWVN7FJ69C\O['=P6XBQQCA(E/&.F<>U+'
MX/T6#Q%!K4%C!#/#;O B1PHJ?,RMOX&=PVX!ST)K>HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex993auditorsindependenc001.jpg
<TEXT>
begin 644 ex993auditorsindependenc001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q_Q#;;I
M-MSC]]_0UV%<3\2_^0-:?]=_Z&N3'J^&F=V6J^*@O,\_\T?W_P!:/-']_P#6
ML^BODN0^U]FCK/#EP$:XS+MR%_B^M>H07EO]GBS<1YV#^(>E>)Z7UE_"NOB_
MU2?[HK6GFTL'[BC<\3,<%&K.]ST2.:*7/ER*^.NTYI]<UX6_UMS_ +J_UKI:
M^GP&*>*P\:S5KW_,^=Q%+V51P3"BBBNPQ"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"%,WG_ $&(/^_)_P :<OP;O /^0Q!_WY/^->NT53PM)]#*.=8V+NI?@O\
M(\GB^$-W'G_B;P'/_3$_XU:'PLN@ /[4A_[]'_&O3J*AX&@^GXC>=XV6\OP7
M^1YS;?#2Y@+$ZE$<_P#3,_XUW.DV+:;I=O9LX<Q+@L!C/.:NT5T4X1IQY(['
M)B,=7Q"M5=PHHHJSD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM6+V[OP#G[RD^AP/Q KYTME\2>!M?CNEM;FRO8&X\R,X8=QZ,#0!]3:GX/\
M#FL7GVO4=%L[FX[RO$-Q^I[_ (UKPP16T"001I%%&H5$08"@= !7@L7Q?\=:
MU"+32M"B:Y(P98+>1R/?!.!^->L> X=>A\+Q'Q([-J4DCR/O8$@$\#C@?2F!
MTU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1S316\+33R
M)%$@RSNP  ]R:DJIJFEV>LZ;/IVH0B:TG 62,L5W#.>H(/4"@#Y2^)5U;WOQ
M$UFXM9XYX'E7;)&P96^11P17O?PDU.PF^'^DV,5Y ]W%&_F0+("Z_O&/(Z]"
M*L?\*C\"_P#0!3_P(F_^+K0T7X?^%_#VHKJ&E:4MM=*I42":1N#UX9B* .EH
MHHH **** "BBB@ IKHLB[74,/0C-.HH 155%"JH4#H ,4M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HKC_&_B/5M*>ULM @AN-1:*:]FCD4
ML/L\2Y8#!X9F**#[GTK2NO%NGP6&E74$5S>MJH#64%J@9Y1LWD\D  +R<D4
M;U%4-)U2/5[1ITMKJV9)&CDANHMCHPZCT(Y'()!]:YK3O&+6T>K'4FFNI5UR
M;3[&WMX@9) %5@B@8!P-Q))X Y- ':45ST7C'3WT[4;F6WOH)M.94N;-X,SJ
MS8V *I(;=D8()'OP:;!XTTX_V@NH6]YI<MA;?:YXKV-0WD\_.-K,",J1P<Y[
M4 ='17$#QC<WWB[PW8PV=_86]\MQ))%>0*IF18]RD$$XP>HR#R,BNDUC6H]'
M6W4VEY>3W+F.&"TCW,Q )/)(50 .I(H TZ*YV#QIIDUE#<&.ZB9]173'@DC
MDAN&(&UQG&.0<@D8(J;4?%NE:3<:G#>/+&=.M8[N=MF04=F50N.2Q*$8]Q0!
MN45PDWC"[F\66UB8+_3+?^RKJ[FAN8$WY4Q['!!8' +\9^HZ5-I7C@3ZQ9:<
M]O=2VCZ/%J#ZC*B("K#.]@&PHX.<#AN.G- ':T5S-AXWL+^XL$-EJ-K;ZB<6
M-U<PA8K@[2P"_,2I*@D;@N<<5:\/^*;3Q*9FL;6]$$19#<31!8V=6*LH.>2"
M/I[YR  ;E%<,_BJ[C^(6J6MVUS::+I5BD\Q,,9C;(D)=VR6"X0;0O4@YK7T[
MQC:7]_9V<MAJ-B]\C26;7<(5;@*-QVX8D';SAL'':@#HJ*P_#/BFT\5V1O;"
MUO4M"JM'/<1!%ESG(7DD[2,'MGIFN6\0^/-0AL?%\=I9SV<NBF-8[MT1E).P
MG()/4/D<=.N#Q0!Z+17.VOC&PFU&:RNK6]T]TM6O%>]B$:R0J0&<8)QC(R&P
M1GI3=.\:6.H7=E UEJ%HFH FQGNH0D=SA=V%P202H) 8*2!0!TE%9'B#Q'9^
M'(;22[BN)3=W MH4MX][/(59@N,]]I ]R*HW/C2V@F>"/2]5N9X($N+N*WA5
MFM%<9 DRP^;&?E7<>/I0!TM%8^F>)],U>^:ULY6<_9(KV.0KA989,[64]^5(
M.<8K)L_&VEWEVMZ+VX@L/[,EO=DT*A#$DNTR[N6[<#H0<]: .NHKEXO'-D2!
M<Z;JEFTEM)<VRW$"J;E$7<P3#'YL<[6VGVJT/%^E-J6BV*O(TNL0&>U8+\NW
M9O&X]B0#CUP: -ZBJ&DZM;:S;37%H)/*CN);?<XP&:-RC%?49!Y]JQ;?Q[IE
MP]M(MK?KIUU<"VM]2:$"WDD+;0 =VX MP&*@'UH ZFBN-\'Z]J>N^(?$)NTN
MX;2TNS;00/#&J(%5#RP)8N=Q..F"*CA\6WR?%*Z\/7*0C3&C1+:0*0PG,8DV
ML<X.5#D?[M ';45Q%MXPN[GXG76C 0+HMM9REI2/F,\9B+G=G&T"4#IU4UHV
M'CC3[Z>Q'V/4+>UU!]EE>3PA8;AL$@*<[AD D;@,]J .FHKF[+QG9ZA<PBWT
M_4VLYYVMXK\6X,#N"5['<!D$;BH'O44GCW3(GEE-K?G38KG[+)J:PC[.LF[8
M1G=NP&^4L%VY[T =317!P^.9;#5_%$5]:7][;:9=CYK2W4BV@\F-LL<@MR7/
M&XX'3&*N#Q6(O$^JM)<-+HUOH]M?1"*+>Q+O+DK@;FR%7 H ["BN<M_&=@TM
MW#?VE]I<MK:-?.E[$ 6@7[SC:S X[CKR.*CB\:12V\DQT76(A]F:ZA\VW4"=
M% /RD,0#@@X;:: .GHK&\*:U+XB\+Z?JL]I):R7,"2-&P&"2H.5Y/RG/&>:@
M\&ZS=:[H+WMYY?FB\N8?W:X&V.9T7\<** .@HKDSXRL=.-V;F:]NB=8.FQQI
M;KE)?*#B-0OWEXX8\Y;TJ*3XCZ=#;WTLNE:PATYL:A&;==UHN P9\-@J0<_*
M6. >* .QHKB?$7C4:%_;=Q;?:+Y[."U<6PB01Q^:S@,&R&(..<],#'4UIW/C
M"""Y^R1:5JEU>) MQ<6]O"K/;(V=N_+ ;C@X522<=* .CHKG)?&NF,FF_P!G
MPW>IR:C ;F"*SC!;RAC+MN*A0"P')SGC%,\$:Y<:_INI7=Q(SJFJ7,,(>/8R
MQ*^%4C .0..>?6@#IJ*\]TGQQ<#4/$5[JZW\5E:7PL;2T%M&=SD1[5&TEVE8
MOT^[@CWQM2>.M.MK74Y;^TO[&;3K<74]K<1J)#$20'7:Q5AD$<'@CG% '445
M0TW5%U/3S>QV=W"F3L2>,(\BCHP&>A[9P?4"N&D^(5[=:'I&J)97-DDVNFRD
M3RE<S1!IEVJ 2=WR*#C'S9QQ0!Z117,Q^.-,%IJDU[!>6$FF>7]IM[F(>9^\
M_P!7M"%@VX\#!Z\5;TOQ-;ZEJ3Z;+97NGWRP_:%@O(U4R1YQN4JS X) (SD9
M&1S0!MT5R.L>);O2_'EGIJPW-W;3:9+,+2VB5G>59$ .3C "ENK ?CBK<?C2
MPGT6VU&VM-0N&N+AK9+2.#]\)5+!E8$@+C:V22!QUY% '1T5Q6J>,FN-,M9M
M,\^TN4UNUT^\@N8E$D>^1 RD<CE6!!!/7@T_P;KVIZ]K?B![Q+N&VM;QK:W@
MDAC5(PH7JP)8OR2<G&",4 =E16?'K-J_B";12)$NXK=;D;E^5XV8KE3WP1@^
MF1ZUCIXZTZYALVL+2_OIKP2O!;V\2EVCC?8TOS,%"9Q@DC.1@4 =117.CQEI
M\FDV]];6U]=//<-;+:0P?OEE7.]&!("E=IR6('OR*A?Q[I,.DR7\\-["8;U;
M":V:',T4S8PI4$YR&4@J3G(QF@#J**JVU\LVFK?3PRV:%#(\=R K1@==V"0/
MSK$T_P ;Z??W%BGV/4+:WU$[;&[N(0L5R=I8!3DD94$C<%R!Q0!TM%<E%\0]
M+ECAN%LM2%C)=?8VO# !%'+YGE@,=V<%L#(!'(R0<U3\6>/%L="\1-I5O?--
MIL,D9OT@5X(K@)D*<G)()7/RD#/)H [FBN;G\70VLR6<=CJ&I7D=LEQ<I91*
MWDJPX+98#)P<*,GCI1)XUTU_[.&G0W>IR:A;FZACLXP6$(P"[;BH49(&"<YX
MQ0!TE%<SX&UNX\0:-=WMQ*9 -1NHHBT>PB)96" C Y"@#GGUK&\2:[XFT..Z
MU)[W2X]EP$L]'\HO+=Q[PHP^X'>W) "D#OGDT =_17*>(];UO3/$&B0P0VB:
M9=W\=I([DM+(61V. ,!0-G4Y)SVQSTMU(T-G/*N-R1LPSZ@4 345YYI&J>-[
MOP;9^)H[W2KTS6BW3:>UDT18%=Q591(<-V!*XK<3QQ83VVF/8V=]?W&H6:WL
M=M:QJ72$X^9RS!5Y..O)SC.* .GHKFV\;:6VGV%S:Q7=W-?2/%!9PQ?OR\>?
M,!5B NT@@Y( _$4A\;:<;*VECMKZ2[N;A[:.P6'%QYJ9+J5) &T#)8G;C'/(
MH Z6BN8?QWI,.G-=3PWL3QWJ6$MJT.9HIGP54J"<Y!!!4G.1C-5I/B'8Q+?J
M^CZR+C3AOO+?[.I>"/;N$A(?:5(SC!)X/'% '845P[>,YHO&EW9PV]YJ5DVE
MVUY;06<"LWSM)N?+%>,!."?H.M:?_"<:7-9Z;-I\-YJ$NI1M+;VUM$/,V(<.
M6W%0H4D Y(YXYH Z6BN6E\?:3%8V=R(;Z1[JZDLUMD@S,LZ!B8V7/#?+CTY!
MSCFMRZN;PZ++<V%IOO3!OAM[A@GSD9"N1G'/6@"[17#_ -NZ[X?\06UEK5]9
MZC#/87%Y.+:V,36OE!3G[S90Y*C.#D=>M0VGB'Q';6?A_6]3GLI+'69X8GLH
MK<JUJ)A^[(DW'<02H;(YR<8Q0!WU%<)K.K>+-%A75KJ?3A$^H1VT6DI"6>6-
MY0@Q+NYDVG?@+@8([9I_BK5O$>D1:GJ0U/2=/M;52UC:3Q>8][M4$@G>""6.
MT!03TZYQ0!W%%064\ES86\\L+022Q*[Q-U0D9*GZ=*QM4UFZL_&?A_2HO+^S
M7\5T\V5RV8U0K@]OO&@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XF/
MPC>:MXHU?6]3O;^P=V6TLDL[D)_HR#(+$9^\Y=L=N*RXO"M]IVBC0KG0#K.E
MV-](UE(EXL5RD+#<A1MRX969T/S+QC&:]$N[F*RLY[N8D101M(Y R=JC)_E3
M;&\AU'3[:^MR3!<Q+-&2,$JP!''T- &)X,LM7L=+N8]6>XVM=,UI%=7 GFA@
MPN%>09W'.X]3P0,FN3OO!.IRS27[637!@U^YO5M8KOR7GMY8@F5=6&U@><$C
M."#UKT^J-QJUK:ZO8Z7*S"ZO4E>$!<@B/;NR>WWQ0!PTGAO5%T'5)=(T:YTR
M[NKBW\R-M5:2ZN;>-LNOF%V6-B"X&'[]16;>>"-5U"\UA;;1WT^TU31FLH_.
MO1,\,JL74RY=N&/'R%L=^IKUFB@#AH[?Q%K'BSPUJ-YH?]GVVG)<"X\RYC=B
M[Q[05"$_+D?7GH,5<\8Z?JM[J&D/;6MW?:7$9?MMG:78MWD8@>6Q)9=R@[LK
MN[@X.*ZVHFN8$NH[9ID$\B,Z1EOF95(#$#N!N7/U% 'EUMX3\066FWT4>D+O
MB\00:S;Q)=JRRQ@1AH@['.]=IY; /8U:UGPUXA\1W'B.[;3DLFO+*S6SBFG1
MB7@F:0H^TD#/'0D88<]<=]H^K6NN:1;:G8LS6URF^,LNTD?2KU ' 7>G^(==
M\2QZE-HIL+>/2+NT"2W$;R&6381G8Q&T[>#GL<XXJI;>$]80V-G-9GR+GPJF
MC7,Z2I_HLH!R2"<L/F_ASTKT6.Y@EGF@CF1I8<>:BMDID9&1VR*/M,'VH6OG
M)]H*>9Y6[YMN<;L>F>* .$@TKQ!JD/A?3+[2/L,6C7$,]S=FXC=)C%&541!2
M6PQ(/S!<#UK?\$:5=Z+X5@L;Z,1W"SW+LH8-P\\CKR/]EA70U%/<P6WE^?,D
M?FN(TWMC<QZ*/4T <9K?A*^UG4?%Z?+#!JNDP6EO,6!'F+YV<@<@#>OYTY+/
M7==USP[-J&CG3(=(=YYG>XCD\Z0Q-&%C"$G;\Q.6VG@<5U&GZM:ZG-?Q6S,7
ML;@VTVY<8<*K<>HPPJ]0!SW@72KO0_ ^CZ9?1B.ZMK<)*@8, W/<<&N8U_PY
MKEX_C6SMM.,L6K_9YK6X$T84E$C1D()R#\I.<8QWKTBJ.CZM:Z[I-OJ=BS-;
M7"[HRR[21G'3\* .;\5>%[S7]=!CPEI+HE]8/-N'R/-Y87CJ>%8_A69X=\,3
M17NCK>^&+B"2QP\MW/K#S1"14*AH8_,;.2?XE7 )KT6B@#GO$VE7>I7_ (<E
MMHPZ66J+<SDL!M012KGGKRR\"N;U7PM=0>+=9U,:+>:K!J0BDB-IJAM3"Z1A
M"KCS$!4[00PW$9(Q7H"7,$ES+;I,C31!6DC#99 V<$CMG!_*I: /.M=\(:K#
MI&CCPU:P6EW'9R:9<11SDK#!,HW,K-RWENH([GFI-?\  D^HW$]A8JD&GGPX
M^EP2%AA)/,4H".N,+R<5UVKZ]9:*UFER)GFO)O)@A@B:1W;!8X [  DGMBM.
M@#@= \/-_;-A<W?A:YLWM$=FN;O5WN%60KM_=)YC9!!898+QVK)M/!GB&PTF
M^ECMXY-0TVXMXM&0S+B2V@E=ER<_+N25E.?2O5** ,?PYHQT?PI8:3(V9(K8
M),X/WI",NWXL6/XUQEOX>\02>$])\&SZ6(X;*X@\W4Q/&8GAAE#@HH._>P4#
M!4 $GFO1;JYCL[.>ZF)$4,;2.0,G &3_ "IMA>PZEIUK?VQ)@N8DFC)&"58
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M&2:*1V:)MV]00"02NX=1UQBN^L]6M;[4-0L8&8SZ?(D<X*X 9D#C![\,*O4
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M?ZITA *'&,CWQQGKB@#S7&OZQ9:[JL82'4+?4KB*&_GUEX$L_+DVHABV[-N
M,@_>W9/6M/Q%;W=M?:UK=[Y^HZ?#M=I],U9HI]+"1KO419"-@Y?KD[N0>*[J
MY\*Z!>:G_:-QI%G+>;E8RO$"69?ND^I'8GI3;WPGX?U&_-]>:/93W+8+R21
ME\=-W]['OF@#G?"UG:/\1_%5]$9F8QV;(S2OC#QEC\I./TX[8J6^MDUWXD7&
MDZE-<?8;;2X[BWMH[AXED=Y'5W.P@L0%4#/3/O74#1]-&K_VL+* :@8_*-R$
M&\KZ$U'JN@:1KGE?VGIUO=&+/EM*@)7/4 ]<'N.] 'EVGP#6[OP4]_/<W0CU
M74+6&X-S(&EAB6;RV)!&3A1\W4XY)S7:_$ S&QT6&&YGM_/UFUAD>"0HQ1F(
M89'/(KHDTG3XQ9!+*W06.?LH6, 0Y4J=H'3Y21QV-2W5E;7HB%S!',(95FCW
MKG:Z_=8>XH \ON]$A2X\=VB7FI+;:9:1W-C$+Z;$$K0,Q<'=DG*@X)('.!R:
MFN/$>H>&P+^6:6X.NZ-#+9H[$C[>JJFQ1T&_S$./56->C-IEB[WCM:0EKU E
MR2H_?* 5 ;U&"1^-8MYX;FU'7=+><VB:-I+B>TMHXSO,H0JI8G@*N20!U./2
M@!\NG/I/P\GT^6XDN);?3'22:1BS2,(SN8D\\G)KB/!U_=WFG*FK-<65S9:#
M&VEV:R8CD@,(!GR#\[Y&,'[@QW.:]6EBCGA>&5 \<BE75AD,#P0:IMHNF.EH
MK6%N19H8[;Y!^Z0KM*KZ KQCTH \YTNV>PTKX=:S'>WTE_J,EO%=R2W4CB9)
M+5V*E2=O!5<<=L]:J*\W_"N8_%_VZ\_X2-KY26^U/@N;KRS!Y>=NW;\NW'OU
MYKU0:3IXM[* 6<(BL2K6J;!B$JI5=OIA21]#50>%]!&J_P!J#2+/[=O\WSO*
M&[?_ '_][WZT >;ZI>ZLHN_#UI>7/VW1KV\U/(E;?) BK+#&Q[J3.JX[^61V
MJQ/>MK>K:?KB3O)97/BFW@LU+$J(XH)%) Z#,ADSCT%>F+I=@NH3:@+.$7D\
M8BEFV#>Z#HI/<5%!H6E6UG9V<&GVT=M92>;;1+& L3\_,H['YF_,T >4VH\1
M:MHUWK<2QPZHNHRA;^XUIXD@*3E1"8=NT+@!=IZYSU-7M7@BU;1OB'J6I7MS
M'=V$EQ;6X6Y=%AB6W4H @.TARQSD'=G%>@R^%= FU3^TY-(LWO=XD\XQ#)<=
M&/JP]>M%[X5T#4K]KZ]TBSN+IUV-+)$"6&,#/K@=,]* .&T."+6=4O(]3O[J
MWATO1[!K0173PK"'B9GFPI )R,9.1\N*Q=&O=7UBQ\&:=(LNH03Z3-=/')J#
MVOVF59%7+. 2VU3G;[Y[5W6O^$KF]U.VNK"VT*2."W$$*7]GO:W(.0R,O)'3
MY#QD9!%7K#P9I$'A?3-"OK:+4(K"-522>,9W <L/[I.3T/?% $?@>+4;?2+N
MWU&>*7RKV5+=4O#<M#%QB-Y" 2RDL.>< 5Y_XMU"<Z7XB\2:<MRALKYH8K^Z
MU=XVCDC=4*10(NTID$88@MDDUZ[8:?9Z79QV=A:PVUM']V*% JC/)X'O6?+X
M2\.SW=S=2Z+8R3W(83.T(._<,,3[D<$]30!RTVF)KGC/Q=!?75Z;>UMK5H(8
MKJ2)8W:-\L I'/ K+\,2R^*M1T"VUJ\NI(E\,P7BJER\7FS,Y5Y"4(+, J_3
M<3WKTFTTC3[#S/LMG#"9(TB<HN-RH"%!]0 2!52Z\*>'[VVL[:YT>SEALUV6
MZ-$,1+C&T>@X''3B@##^%A4^"%*3F=#?7FV4G)D'VB3YL^_6N(2VCM/AUK?B
M"TOKI=6LM7N3;E+IPL;?:SB/8#M(;=R"#G?],>QV5A::;;_9[*VBMX=S/Y<2
MA5W,26.!ZDDUFCPCX=%Y'=C1;(7$<AE5_)&0Y8MN]SDDY[$T <!>IJ^N:UXM
M9H2SV%QY%M.VL/:"R01*RN$52.22Q8]>G054\0W6HP0^);F:Y"ZB/#&GM)/:
MR8!D\R7<R,,<$YP1VKTW4?"^@ZO=B[U#2+.YN  IDEB!+ = ?4#T.:L7.B:7
M>&X-S86\OVB)8)M\8/F1J254^H!)./>@#S>_35M<\1^*PT#/]@E6&VD.L268
MLT\E7$@15(.22VX]<8Z"KVC:<9OB3IMYJ4@EU'_A'(YIY8+ES$\H<*64 A2I
MZXQCOC/-=GJ7A?0M8NENM1TFTNIPH7?+$"2HY /J/8\5=_L^S%W]K%M$+@0^
M0) HR(\YV_3/:@"57BN8 T;K)%(O#(V01[$5XU9:3;CPAH4<4ES&;CQ;(DCK
M<.6 6:X7Y22=IQW&#WZ\UZWHVE0:)HUIIEMDPVT8C4D 9Q[#@5!%X:T2">2>
M+2[5)9+@73LL8&9AG#_[WS-S[F@#S?7[F\\-?\)C8:/<W45M&NFLF^Z<FW$T
MC)*RNQ8IE5'/;K5B\L]8T:VUUHDCTVT.@W;M:C6'NI#(J_),@8 KCD$@\Y'<
M5Z5)I=A++=R26<#O=QK%<%XP?-1<X5L]0-S<'U-4K+PKH&G07,-II%I#'=1F
M*<+&/WB8QM/^S@GCI0!P.H6UY:6_@_3+4W-W'JWF7-\)M1DA-S,(5(4R<E0>
M3L7 .W&*ZKP3;ZE9OJ]K>O"MLERIMK9;XW;VP* LC.P! S\P!Z!O3%;U[HNF
M:EIZ6%[8P3VB;=D4B JFWH1Z$=B*=INE6&CVGV73K.&U@W%RD2!06/4GU/N:
M /.KO1X-0UGXBW4TUVLEL8W@\FY>(1N+-"'^0C)R!USC'N<HUU)XC;3(GAN+
MZX@T.WN[OS]5>RMHS*,^9F-2S/\ *W)X ]S7I']FV0:\;[+%F]_X^3M'[[Y0
MOS>OR@#Z52N/"N@7<MK)<:19RO:QK# 6B!V(O1?]T=ATH \^\/\ B"ZT_0_"
M'BC4[^:2RGM9["_>20LN06:*0^K?NRI;J=XJ G79W\+VEU'-<G61>:G<VKW[
MVP9R4:.+> 3A$;[@X)7/:O2F\,Z&VF3Z8VE6AL9Y3-+;F(>6SY!W%>F<@&K&
MI:/INLVRVVHV4%U"C!T65 =K#H1Z'W% &'X'@U*UM-2MK^6)HHKQA;1+>FZ:
MW0JI,3.0#D,20#R 0*XU]-L[J/XC7TU]=07-C>2S0F&Z>+[.PMHV63"D DD8
MYS]W'K7J.GZ;8Z39K::?:0VMNI)$<2!1D]3QW/K6?=^$?#M]</<76BV4TKR>
M:[O""7;CEO7[HZ^E 'GT,^M>)M?DAO;)KOR-)LID@_M22R"-*A,D@" [CN&W
M/\.WWIJR^(+^_P##>C:@8M57^RI;AA#JC0QW4BRA QE1?WA5-IQZL3VKTG5?
M#FC:V\;ZGIEM=/&I5&DC!(4]5SUQ[=*6^\.Z-J5G;VEWIEK+;VV/(C,8 BXQ
M\F/N\<<4 >>0V^JM/X:TK4-1D$,FLWD.VUU%I6$ @D80O*,,2I!4YY  YS6U
MH-C!_:'BS0IKRZCTVSO[9K<-=ONBW112;0Y.[:7[9[D=ZZVWT/2K6.RCM]/M
MHDLF9K94C"B$D$$KCH2&.?J:)]$TNY%T)["WD^UR1RW&Y ?-=,;"WJ1M7'T%
M %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_H\FD'5DU2S;3@,FZ$Z^4.<<MG'7BFVWB+1;S3Y+^WU:REM(F"23+.I1&)
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M167;\AG<C ]/2NKH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD<YK2HH YB+X?^'HI8&6VN/+M[E;JW@:[E,4$@;?NCC+;5Y]!W(Z$BNGHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6\I\(2:>S.PPEP7C(0X/^R:ZB35O$NHZ7<0:;X<FL+V'3I=D]ZT8VW.T!$C
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M_P!O@>1II)4+K'\KKL 7&6YY/3BDTV]U^?XF7%M=W5O%9II-O/)9+&S;'=I
M0'WXR&7[VWE<# QDW]1\)W$VJW6HZ5K5QIDU[ D%WLB63S F0KC=]UP&(SSV
MXXJ6U\+FQ\1V^K6VI7&U+&.QGBF E,ZH6*,7/.[+DD]Z (M8UC5'\4VGAW1W
MM;>:2T>]GN;J%I0D:LJ!50,N22W4G@#O7$^(;[5/%,&C:?>'35DMO$C:?=QR
M6C303ND3NC[#(/DVD$H2><?-QSW^L>'I+[5K75[#4'L-2MXG@\T1"19(F()1
ME/7E0001BJ=OX(MH(; &]GEN+?5&U6:=U7=<3,KJ<@8"C#\ = H% %;XG6[7
M/@A[19I(?M%Y9P&2(E64-<1J<8]C7-^(-?OM7^&]MI7FM%K$PF@U!D;#1_90
M3.V>VXHH'M**]#UW1H]=TY+.25HE6Y@N-RC)S%(L@'XE<?C66_@BP;6-=U)9
MI5EU:U-NR\;8=RA791ZMMCS_ +@H YA/&MQ:C2M%@U"RL##H]M<S75Y:R7!D
M9UPJ*J,N/NDEB>XP*FD\?ZG-H^BWK+;Z3!="=;N_N+.6XABDC<*%"J5*A_F8
M,Q P,=:WSX/EM;BTN](U>2QNXK&.PE<P+*D\<?W25.,,"6P0>Y'-69= U1(+
M(6?B2\CG@C:.62XC29;C)SN9>,,#T(Q@'% &2/$NL7LNAZ78W.CO?:A%/<27
M\(:>W$,; !D7<I)8NO&["\\G%8.O:WJNH0V5C/':-J^F>*+:UWH&6&7,9=)-
MI)*C#C*Y/0\UTD'@*.Q@L)=/U.:WU.SEN)1=F)&$AG;=*K1\#:3@@#&,#GKE
M)? $4^GK&^JW7VYM375)KU44.\RC:N%Q@* % &#P.<Y- '.>,=7U4:-XB\/Z
MR]I/-!!9WD%S:PM$'C>X"D,C,V"&3UY!K3\6>,]1T6\U8VNH:0JZ= )5LS;3
M7$LWR;B)&0@0YZ#(/J>.*T+CP'_:,&JMJ>K2W-[J*P1-<+"J"**)]ZHJCU))
M))YS3KSP*;E];@CUFY@TW67:6[MHXTW%V0(VV0\A2%&1CUY&: ,[6?&FH6^H
MPH+O3]%L9;**XM[K4K626*XD?.4\Q758]ORYSDG=D"K-C?Z[<_$J.WEO[,6/
M]C17,EM"C.A9G93M?< ?F&0VWE>,#K5S_A%=7CLDM8?$\RQ&V6VE22TCD1@H
M(W*I^Z2.#U!QG%/T[P9%H^K:9=Z=?S1PV6G)IKP2('\Z)"2I+=0V2<D?I0!#
MK\LB_$7P=&KL$=;[<H/#8C7&1WJWXFO1::MX8B-K;3?:=3\K?,FYHOW$K;D.
M>&^7&?0FG^(?#4^LZGI>HVFJR:?=Z=YOEND*R!A(H4Y#<=!^M1CPQ>7,VFS:
MIK<M[+I][]KB;[.D>?W;)M(7M\Y.: .93QCXJDT?3]85-),%UJK:8ML8I QS
M,\2R;]_&"!E=IR >1G ?J_B/4[:Q\0:?J\&F:A+IUUIVQ_LS)%(D\R 9C+MA
ME()!W=0IKH(O!=O%H6GZ4+N4I9ZF-15]HRS"=IMI]LMBDU3P7;ZI<:O*]Y*A
MU)[-G"J#L^SOO7'UQ@T <U-XKUG07\9ZC>7=M=PVFHQ6EI;M"ZA'D2$*=V\X
M0;\L ,DY((SBI(_B+<:>=2^U3VFK0V^F2WR3V=I+;A7CQF)@[-UR"&!['BMV
M\\#0WMQKGF:C.MIJSQW#0HBAH+A @61'Z\>6IP1C-6?^$9NKZUO[77=:GU&"
M[M6M#"L*PHJMU; SE_?.!V% '-SMK[>,_ TFLS6$WG27,@^RPM%Y3&V;*'<[
M;AS][CITYKI_%FLW&CV-LUM>:?://.(C->JSX&"3LC4@R-Q]T$=SVJE9>#+J
M/5M&U#4-?N+Y](#K;H8$C!5HRAW8ZM@CGVZ#)K1U_P //J]YIE_:W[65]ITC
MO#+Y0D4AUVL"IZ\=\C% ')1^/]6;0[UXH[*ZOK36+;3UD,,D$<Z2F/#;&)9#
MA\=2.,\BK&J>,=;\,RZW:ZF+&_GM=/AO+1[>%H%+22M$$<%VX# '(/3-75^'
MP\^[>36;J875];:A+YD:[C-"4.01C"ML QCCM5_7/!=EK][J%Q=SS*M[IR6#
M+'@% LC2*X/]X,WTXH Q"FM1?$[PVFL7%E<-_9]ZR2VL#1#),.Y2K,W3C!SS
MGH,<Z'B6ZUF/QQX6M+"_AM[6Y:X,T;PL^_9'DYPZY&#QZ'GGI5FR\*7:>(;+
M6]2UR:_NK2"6W1?(2-"K[<G _B^7D]_08JYK6@/JNIZ3J,%\]I<Z;([(1&'#
MJZ[64@^W?M0!P.AZOKN@>#9-6@:P;3(-9GBDMGA<RRK)>LC,) P"D%^!M/3K
MS@7-4^(MXE[K9LKK3XETJ=X([*>UEDEO&0 MB12%CR<JO#=,FNE;P5;MX1F\
M/_;)?*ENS=&7:-P)N//QCTSQ]*)?"5W%>:@^E:]<Z=;:C*9[F&.%'(D( 9HW
M/W"P SP>>1B@#0U#7X;#PA<>(6AD,,5D;SRCPQ 3=M]CVKD]"\=7UUK.D6US
M=6%]'J65DCL[2:)K-]A<99F(=>-N<+R0?:NZOM/M]2TJXTV[4R6UQ"T$H)Y9
M6&#SZX-9&D>']2T^>U%SXBNKRTM(S'% 843>,8!D8<N0/ISS0!S.G>,/$LVA
MZ!K]V-+%GJ-]%9R6D<#AU$DAC$@D+XZX.W;T[U3@U?6$TO4I]5EL-31?%$5G
M%'+:L!%^_1-RYD.,9!4?PD9R<UU</@JWA\,:1H@O)3'IMW#=))M&7,<OF $>
MA/%0MX%#&]C.J2_9+C58]56'RES'*LBR,-W<$K^% '-1ZOK"6NJS:G+8:E$G
MBB"SBBEM6Q%^]B7<N9#C (*C'# G)SBI-1^)%ZD^M3V=QIZ)IEU+;QZ?+:RO
M-=^4</B13M0DA@HVMT&>O'0R>!1)-?#^U)?LESJD6J"#RERDJ.C$;NI!V#CM
MFI6\(W<%U?\ ]EZ_=:?9W\YN9X(X49ED;&\QN>4W8R>#@DD8H QM7\:ZE!K4
MUNMYIFCVWDQ263:K:R[+TNNXCS@RK'@G;C#'/..U=-XKNVM/ VLWDEO;3M%I
MTTK02CS(G(C)VGIN4].V15;6?#%_JAOH(_$$\.GWT?ES6TD"2[05VGRV;[N1
MSSN&<FM"^T&WO/"=QX>61XK:6R:R#_>94*;,\]3B@#F_#5[K%WXZU.&6]MQI
ML.G63I:) P";Q(1M._ .1R<'("CC'.EJNKZO/XJ3P]HTEG;2I9?;9[F[A:88
M+E$155UY)5B3G@#IS4]CX9;3O$;:K;Z@XCEM(;:XMVC!$GE!@C!NJ_?.1WI=
M7\-S7NLPZSINIR:=J*6YM7D$2RK)$6W %6[@\@@]SUS0!F'6_$EWK%CH$::=
M8:E]@-[>S.C7$:C?L58U#(3N()R3P..36>GC37+D:98PP6"ZE+J]QI5T[*YB
M!BC=O,0;@<853M)]1D=:V/\ A#9;>2PN]/UN\BU.UMFM7N[E1<&XC9MY#@XY
M#<C!&,XZ<4ZR\$6MFVE2"\GDGLKZ:_EED W7,TJ.KEL8 ^_P!TP!0!R^N^(O
M$PT[4].^W64-_IVL6%LUW!;.JRQ3-$P^7S,J?FPWS'(R.,Y&Q_PDVMPZYKZ7
M!L/[,T"!)KED@<27&;?S"$^<A,,"><\$#U-7=4\$0ZD=9D6_E@FU*YM;I75
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MJ=B_F6=W& ?+;CJIX8<#BLRW\1^)]$8Q>)M!-Q HXO\ 2095/^]']X?4?E0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4A(4$D@ <DFEI'19$9'4,K#!!&
M010!SVI^&_#OB@BY>.)[B,_)>6DNV5#_ +ZGV[U1>;Q)X7??<LVN:.O+R*F+
MN >I4<2 >V#]:@N_A/X6G<R6D-UILI.?,L9S&?ISD8_"F1> -6LV(LO'6N1Q
M\#9.5FPH[#=TH Z[2]4L]9TZ&_L)A-;2C*L!CV((/0@]JN5D>'] A\.Z=+:P
M7$]P\TSW$LTY!9Y&ZG@ =NE6=*CU..T8:M/;S7)D8@V\910F?E&"2<XH Y72
M_+T#XG:IIG$=OK,"WT )P#,I*R >I(PWX5K>-]/35/"]Q:S74MM;,Z&<Q0&9
MG0,"4"KSSTR.E9GQ'M)5TW3M=MEW7&C7L=SM"DEXR0KJ,<\@C\J[6@!L:+'$
MB(NU5 "@#&!7->.="\/ZOH,MQXAC8V]DCRB5'*M'QSCU)P.#73UQGBS3KCQ3
MK=CX<>.5-(5/ME_, 0)0#A(@W3)/)]A0!YGX%\'._@ZY\2VLVG8+R-Y&J6@E
MC$<9/.\<J>O(_*G^#M%CU"WNO$-SX'BU&SNIB8193[/)"_*0L1(R"<GK^%;V
MD>"O%:Z5<>"[@Q6GA\3N[WZ-NEGB+9V*,_+GN2/7KW]1TC2K71-)MM-LD*VU
ML@1 3DX]3ZD]: ./U35?"/BG3%T.\N7TVXX^S+>1-;RPNOW2N\#D8'0\U)X5
M\4WUOJ/_  C7BED34U&;2['$=]'V*GIN]17975G:WT)AN[>*>,C!25 P_6O/
M]3^"OAF^F$MM+>V+#[J0R@HI]0&!(_ T >CT5!90/:V%O;RSM/)%$J-,XP9"
M  6/N>M3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45SOC'Q
M%>^%]'.J6^F1WUM$1]HW7/E,@+*H*C:V[D^W2K>I^*-"T:Y%MJ.J6UM,5WE)
M'Y5>FYO[H]S@4 :]%96H>)M$TMPE[J=M"[1K*JL_+(<X( Y(X/3T-7K*]M=1
MLHKRRN([BVF7='+&P96'J"* )Z*XO3_%GB+6(;JYTWPQ:S6T-U-;J7U38[F-
MRA.WRL#)7U_&M.Q\::-<^&;+7;FX%C;W9*(EP0'\P$JR #[Q!5NF>F: .AHK
ME]7\:V%EIVE:C9W5I<6-YJ"VDMP9<)$I5RQ)[$;>0>E:ECXDT74K.YN[34[:
M2WM<_:'W@"+ S\V?N\<\T :E%9%CXIT+4H;F6SU2VE2VC\V;#X*)@G<0>=O!
MYZ<5FW7Q#\,VUQ90KJ<,WVJY-L&B;*HP0N23Z< <=V'O0!U-%8Y\5Z -5_LP
MZO:?;/,\GRO,'^L_N9Z;O]GK6Q0 4444 %%%% !1110 4444 %%%% !1110
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M!_BR*MP&WL;GP9K4.C7EGHUI:7-M);?9I'>RE<)@LH!8\HZ[\'KG.&S7I=%
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MW2%]SXC.W@N 0,"O7J* /,IEDUW4O"UGI-E>6D^F6MP+EY;5XEM=UL8U3<0
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M'/'K0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SGQ=H>CWCZGHFFZ='
M>^(]8_>R7$@WFR4@*)6<\HJ[<JHY)' ZFF:CI45OXIULZYX?NM:AOK2"*RG6
MW$P550J\98\1$OEMQP/FSGBM\^!;==1O[ZVUK6K62^F,\X@N54%L #JI.
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MNY8L26$S30[  "Q1D.>.1AC^.* -*BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:O($#D*>F2,,>0>10!V%%<OIOB6VCMKR2XOKJZD;59+.&![81R+)@$0J!]X
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M1/$#:S=7EN^CZAI\EKLWB[\K!+ D &-VYP 2#C@CUH VJ*** "BBB@ HHHH
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M1FPB2^@N'D5IIMOS[VCZK[ @'G.0<5V%LTEAHJ->1PH]O!F1+1"4&T=$7KC
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MSU8K([623AV\M9"@<< E3@'..] &!I?A_5/#VMB[TFUM$TV_B!O]/\[:(9U
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M0M:2:L=+: 2'[1&V\IO88P.1N*]EYSVK5@\2)?:_-IMD+?R[:3R9YIIMI>0
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M?Y;>6)O^>?F8V[NVW.<\=:)/$FD1WAM7N\.LXMF?RV,:RG&(S)C:&.1P3G)
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M)'Y2&1I&<@*%"Y)))%47\6:;'#"QCO3-+(\:6HLY/.)0 M\F,X (YZ<CGD4
M;E%<@WCZQAU2[6199--BTZWODG@MI'8([2AV< ?*%$:]0#R?PT[GQ;I%K=O
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M!!]Z -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exhibit991app4d001.jpg
<TEXT>
begin 644 exhibit991app4d001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J&[_ ./.?_KFW\JFIDT,=Q"\,JAXW&UE/<>E 'C'P8^U1> [2YOY
M;?\ X1^**[:92I#+()8RI8YP> V, $>];NOZSJVB?%&PTVYUJ9=#UA42,A5S
M:3[LA,[>DFTJ,Y/S''2NPC\%>&8K<6\>A6"0!PXB$(";NN<=,U8O/#.B:CO^
MVZ7:W&^43MYL8;,@& W/<#@'TH \>\67FHZ5XW^(FJ:9J,UG<V>GV4B-&J'<
M<(,-N!XY/3%;M]K=_=>.OLTDJ_9[KP:UX\?EKQ(20<-C<!QTSBO0KCPKH-W+
M=RW&D6DLEVJI<L\0)F5<8#9^\!@8SZ4X>&M$6Y6Y&F6PG6W^RK)Y8W"'&/+!
M_NX[=* /(_!&J:MH]A\-K:TOIYK35X[F&YLV52J*AR'3 R",DDY.:SI-5U34
M_!6@--J,R&3QDMK(842,.F\L"0J@$AE!Y[\G/%>WV?AW1M.F6:RTVVMW5#&A
MBC"[%)R0H'W03R<8R>M0CPGX>73FT\:+8_8VF$Y@\E=GF?W\?WO>@#-\>>%[
MKQ7X"O-#L[P+<R+&8YICPY1E;YL#OCL/PKS8^&-8\?ZKX],9ALA<V]K9;TE+
MPR7,6QF&X 9 V%2<<;N]>W2VL$UK]F>,>1C;Y8X&/3CM[4Q;"T2Q%C';QQ6H
M7:(8AL4#T &./:@#R[PA<7"_$7Q/XCU5K:QT^TL(+&[F$^8#.H7=AR #MP0?
M3.*N?$QH)]=^'US"8Y%DUR$I*F"&4X((/<=*]!ET?3)]);2I+"V.GLFPVOE
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0(6(RS C/L?J*S/@6NES7/C&\LA;$7%WL@LT==RVZ[MORG^$[P,G@XH Z_\
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M?8_RE61NN"#R.M>;^ HHO$'QC\8:Y<(ACT<KIUFI'RQ*"RDKZ<1G_OL^M/\
M@6HNCXOU>%=MG>ZLWD # P-S<?@ZT >O4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7;($#'D@*HZ#+'\_H*K^//"7B7Q8DEEIWB:+3=)GM_*N+4V:R&0Y))WYR!C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2CNXO)\F&Z(MRH,SJ"2F3RN<\YZ5YIX7MIKG]FOQ;#!$TCB_=@BC)VJ8&/Y
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M-.8--&;N!HMLT7L5]_KC@^AJ;4_B%H>D^$+'Q/<FY_LZ],8BVQ9?YP2,C/'
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M%<_0,!^%>BUY+\!%,OA[7M0 (ANM7E:+W&U>?U_2O6J "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX+N;/[%J%Z?!@\+>5CS-\$<1E0 G.5 R!SUKP;4"=2T?4/B='=Q)JZZZD]O
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M:CXA^&B:SJES'+?_ +_+A%3.TG' P.U<1#\6/$5K\%!XCG:&YU:?46LHYFB
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M=+;*$*L'( 4C Z+SCM6W\./&TWB#P7=7VNO'%J&ERRPZ@0NT*4YW8[?+^H-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ-I^G^)M0\9SRV?G2+)I[6J$2!<K]\$8YYZ5Z?XB_P"19U7_ *\YO_0#7#?
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MRGMHRLF& P&/<YZ8KW/PAJ]QK_A#2=6NX1#<7=LDLB*,#)'4>QZCV-?.&B^
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MJ$T)+XAE7<BD$\OQZ4 =OXJ\16GA3PU>ZS>',=O'E4S@R.>%4>Y.!7F'PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$ XR
M<<\TM% !2  9P ,\G%+10 @4+T 'TIBP0K*95B02'JX49/XU)10 4@55SM4#
M/7 I:* $P,YP,^M 50<A1GUQ2T4 '6FA$!R%7\J=10 A52<E1GUQ2T44 %(
M%&  ![4M% $<L$4P EB20#D;U!Q4@&!@=*** "D "C   ]!2T4 ( %&  /I0
M%4 @ 8/7BEHH :$0'(5?RI2H888 CWI:* "F-#$\?EO&C(?X2H(_*GT4 -"(
M$"!5VC@+CBE(!&" 1Z4M%    , 8%1R0138\V)),'(W*#BI** #'&.U(  ,
M #T%+10 @50, #'IB@*%Z #Z4M% "$!A@@'ZT!57HH'T%+10 @4 8  'H!0
M%&  !Z"EHH 0HI.2H)^E&U<@X&1TXZ4M% ###$91*8D,@X#E1D?C3R 1@C(H
MHH 3  P!QZ4;%V[=HP.V*6B@!" 1@@$>]+110!&D$,;LZ1(KMU95 )J2BB@!
M H P  /04!0HPH 'H*6B@".."*$L8XD0MR2J@9IY56Z@'ZBEHH 3:N,;1CTQ
M0%4'(4#Z"EHH *3 SG R>]+10 T(H! 4#)R>.M&Q/[J_E3J* $"@9P ,\G%&
MT;MV!D=\4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQJVFG3SJ U"T-DIP;@3+Y8YQ][..O% %RBJDVJZ=;MMFO[6(^5YV'F5?W?\
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MG(2V&W^N ./4UR?@#5[GXD>.-$U"=&:/PWI&)-_1KMLIN_$ -_P&O>7W;&V
M%L< G S7%?#7P3<>#-,U#^T);:;4M0NVN)WM@0@'\*C(' RQZ?Q4 >'Z!H]Q
MXE\':LEW<^$K:_EO7>ZO=5G>.^AD# D[L<+P1Z<FNZ\07=G=^+;?1)](\.7^
MK6NC1-=ZMKL["!U R?+&#W8G<,'D^E>FWO@?PKJ.HMJ%[X>TV>[8[FEDMU)<
M^K<<GZU/J?A3P_K5Q!<:GHUC=S0 +&\T"L5 Z#D=/;I0!\Z&61OV:T7S#B/7
M-L>"?E'7C\23^-?1?ASPOH_A33S8Z-9K;0L0SX8DNV -Q)[X I6\+: ^F-IK
M:-8FQ:;SS;F!=AD_O;<8S[UKT >,>$_#FC)\>/%R+IMN%L8X)K4!.(G9%+,O
MH22?SK@L9_9TMP"0?^$@Z@X(X-?3$.DZ=;ZE<ZE#96\=[=!5GN%C >0 8 8]
M3@ 53_X13P]_98TO^Q;#[ )?.%MY"^6'_O;<8S[T >8R^'-*\)?'?PA;:%:+
M90W%C.LR1L?WFU'P6R>3P.?85P?BZ_TS7/!^O:GIN@>'=-@34"@EFF9M2ED\
MQ2S*,< Y)()P!NQTKZ6FTG3[C4[?4IK*"2^ME98;AHP7C!X(5NHSD_G69-X'
M\*W%Y<7DWA[39+BXSYTC6RDOGJ3QU/<T >6ZGI-EXE^,OA&UU>'[7;R^'(Y9
M8W8XD8&1AN]1G!Q[5SSI<:-X.^+&G:-YD-K;:C&B11D_NXFD*OCVV@ ^PKZ$
M&BZ6NHP:@-/MA>6\/D0SB(;XX_[@/4#D\>])!HNEVKWKP:=:QM?L6NRL0'GG
MGE_[W4]?4T >66MGX M_ -Y)X?;3O[7?PU<!OL\F963R@7,@!Z[L?>YZX[UA
M6VIZ=#\/_AYI=QH>G:E?7JS"U?5)2EM!AOF+]0V<CC%>QV'@WPUI8N18Z%I]
MN+J-HI_+MU'F(>JGC[I].E/NO"7AZ]TJ#2[G1;&6PM^88&A7;'_NCM^% '@V
MA_NM"^+5LGV!(4@C(CTUBULK8DSY>>W^%>U_#G_DFWAO_L'0_P#H K0@\*^'
M[6WNK>WT6PBANXUBN(TMU5944856 '( K1M;6WL;2*UM88X+>% D<4:[511P
M  .@H \9^%7AC2]1UWQ7K=S:"XU&SUJ9;1W8XB().0,XR2>3["N$T#1[CQ+X
M+U-;JZ\)6M])>/)<WVJSO'?PR!@2=V.!QCTY/>OINPTG3]+^T?8+*WM?M$IF
MF\F,+YCGJQQU-9EYX'\*ZCJ+:A>>'M-GNV.YI9+=26/JW')^M 'DFO6VB/\
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MA@:RT+3X&@D,L3) H9'(QN!QG.*T=1TRQUBR>RU*SAN[5R"T,R!U)!R.#[T
M>.ZQHFG^(/CAX:L=4MQ<6A\.H[0L2%<JTI&['49P<>U:WP=MHM.U_P >:7:J
M8[*TU8K!""2$&7&!^"J/PKTK^Q]-_M.+4OL%M]NAA\B.X\L;TCY^4'J!R>/>
MEL])T_3KBZGLK*"WFNY/-N'BC"F5_P"\Q'4\G\Z /)?%PTF[^/.GVOBUK?\
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MT"-%TL:A;Z@-/MA>6T7D0S^4-\<?]U3V')X]Z(-%TNUEO98-/MHY+XYNV6(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*[\84OM'&X@$@]B<C%>QV6@FT\*C0CJFH2D0/!]N:7_2!NS\P?\ O#/!]A0
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MH:MIDFB2Z@L6H3&9XI$#D8;L#L]OO>U 'I7C#Q1;^#O#-SKEU;RSPP% 8XB
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MW\([^F: /2/$_CO0O"2VHU":62>[S]GM[6,RR2 =2 .WO5KPOXLTCQAIAO\
M1[@RQHYCD1T*/&X[,#TKS73+RUU+X\Z'=PJRV<GAM);!9!RJ,"1^."WZU>^%
MN$^(?Q)\O M1J*$8^Z'W2[O_ *] 'J]>>+\;?!#ZJEB+^<+(_EK=-;L(2<X^
M\><9[XQ7H?49%>*^.HH?B7XFT[P-H$*?V?I4XFU*]B4".WP"OEJ1QG!88'?'
M]TX /0O%/C_0O"-S;VFH23RWEPI>.UM83+(4'5L#H.#U]#Z&F+\2/"[^$/\
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M"R2:=]E6TP6^?8J@ Y]1@'/K4'A+PG:^#]);3K2^U"[A+[E-[-YA0  !5P
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M&(U>9R[L .K,>I]ZX*X^"^@7<P6YU37IM/$GF#39+XFW!ST"XR!^.?>O1Z*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit991app4d002.jpg
<TEXT>
begin 644 exhibit991app4d002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445SOCOQ /"_@C5M7#!988"(?^NK?*G_CQ% '@/CSXM>+'\::Q%H&JS0:7
M8R>4JQ1(P 4A"Y)4\%_YBO=/AMXG?Q=X$T[5)W#W>TQ7)  _>J<$X' SPW_
MJ\@^$7@,:_\ #;Q3<W"9FU53:VS/V*?,&^GF;?\ OBI/V<M?:VU/5_#-P2ID
M'VJ%&XPZ_*X^I&W_ +Y- 'T/3))HHMOF2(FXX&Y@,U\__M(W$MOJGAEXG92B
M3.,'N&3FJ6H?!_Q1XI\-3>+=:U_SM8E@-U'9LFX;,;@@;.%..@ P.E 'TA17
MAO[//BZ^U*UU#P]?W#SK9HLUJTC9*H3AESZ [<>F37F_ARW\2ZY\0=;T#0-2
M>S;49YA=S[R"L2R$DYZ^@P.3G'3- 'UNDT4CLB2(S+]Y0P)'UI]?)GCGP)JW
MPCU32]5TW6I)O.8^7<QIY3)(N"5(R<@@^O/((]?6?'/Q-NM/^$.EZYIY$.I:
MS'&B,O/DDKF1A],$#Z@T >K//#'(L;RHKMT4L 3^%25\S^'/A9HGB;PJFM:W
MXR$6M7J&5%>YC(3/W?,W'<Q/!/(ZUT?P \7ZG>76I>%]2NGNEM8O/MG=]Q0!
M@K*#W7YE(].: /=:8LT3R-&LB%U^\H89'U%?)R+XDU'XR^(](\.WS6MWJ5]=
MVTDV\KLB$I9CGJ,!.W..!UI/'G@'5?A3J&E:I9ZX]P\[,4N8T,3QR+@D'YCD
M'/KSSD>H!]:TSSHO-\KS$\S&=FX9Q]*\R\<?$"\TOX,V/B"U80ZCJL$"1NO_
M "S>1-S$?0!L>^*\N\$?![5_&7AW_A*FU][.\FD9[0LK.SLI(WL^X%<L#R,G
MC- %WP?+(?VG[\&1R#?7RD9Z@+)@?H*[7QSX*\?:Q\1K;5-$U=H-*7RMH%VT
M8AV_>R@ZYY/?.<5YI\*X]0A^/<46K.7U%)KM;IBP),@CD#'(Z\YYK5^+<TJ_
M';2 LC@+]DQACQ^\H ^E:*\0_:#\(S7.GVOBRQW^;9 0W04G_5D_*X^C'!_W
MAZ5Q7BCXI:AXT\#:#X7LUF?5KEUBO]O!F92%C ]=QPQ]P* /J2BN>\$>&(_"
M'A&PT9&WR1)NFDS]^1N6/TSP/8"M#7];M/#F@WNKWS[;:UB,C>K'LH]R< >Y
MH \T^,?Q#U+0)M/\.^&9BNM7;!W:-%=D0G"J 01EC^0'O67\"_''B3Q3K6JV
MNMZF]Y%#;K)&'1 5;=CJ #5'X5Z)=^+=9USXC:XFYY/-2R4] VT@D>RKA!^/
M<5F?LU_\C+K?_7FG_H= &S\;_B!XG\+>++"PT35&L[=[%9G58D8LYD<9RP/9
M15.Y;X^:3;M>/*US$@W,D:6TI(_W0-Q_#FL;]H__ )'[3O\ L%I_Z-EKZ<3[
MB_2@#R/X7?&0^+M0&A:Y;Q6VJE289(LA)\#)7!^ZV 3Z'!Z=*]=KY6\=0)X?
M_:$2;3P(\W]K<[5X^9MA;\R2?QKZIH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%<A?^+;NT^*>E^%%MX3:7E@]T\QSO5@7P!SC'R^G>@#KZ*XVT\9SR?$
MS6O#=Q';16&G6"7?V@DAN=I.XDX  8_E5W2/B!X4U[5/[-TS7+6YO#G;$I(+
MXY.TD -QSQF@#1U?PWHFOF$ZOI5G?&'/EFXA#E,]<9]<#\JTHXTBC6.-%1$
M5548  Z "O'W^*FH:=X.\7ZE>SVS7UEJ\UAIL;1X#8(P"!UP"6YZXKN?A]JE
MWK/A*WO[W6+;59I6),]O#Y2KP,H1W*G(SWH ZFLFQ\+Z#I>I2ZC8:/8VU[-G
MS)XH%5VR<GD#N>M<C+\29=%\1>*-+\16\%N-,MOMUB\61]J@[#D_>R57COGT
MK2T;QL+?P-8>(/&,UEI+W@WI&NX?*W*  Y)8KS@>M '945A0^,_#=QH$FNQ:
MS:'2XSM>X+X5&X^4@\@\CC&>13-'\<>&=?MKNXTO6+>XCLT,EQC(,: 9+$$
MXX/- '045B:/XP\/^(+U[/2=5@O+A(5G9(B3M1L8)X]QQUYKE_$OC'Q-;_$.
M#PIX=L-+FDDT\7ADOG=?XF4C*_0=J /0Z*XCP9\08M>\.ZGJ.M0PZ5+I5R]M
M>DR@Q!EQR&/;G&/YYK7T?QOX:UZ&ZETS6+>X6T0R3@9!1!SN((!Q[T =!17,
M6_Q%\(7>HVNGP>(+*2ZN@IAC#'YMW09Q@$^AYYJ;7?'7ACPU=I::QK-M:W#@
M,(F)9@#T) !P/K0!T-%8M[XN\/Z=9V=Y=ZO:16MXI:WF,GR2 +N)!''2N4O?
MC/X5M?$&F6"7D,ME>1/)+?;RJP8!*@J5R=V,=J /1:*PO%WB2W\+>%+[699(
MP8H6, ?.))=IV+QZG KD_ GCQ)O!$GB'Q1XFTZ6-I%5MD7E?9G*Y\H_WVP0>
M!GKUH ])HK!TSQKX;UG2[S4M/UBWGM+-#)<NI(,2@$DLI&0, ]NQJ71O%F@^
M(;F:WTC4X+R6&-)9%B).U7&5.>GX=N] &S17"M\5-"B^(,OA2:6.,I& +HR<
M-.7"^3MQ][G.<]JR= ^*EC;ZOXEM/%.LVEJ+75Y;2R1EPWEJ2!G SC_:- 'J
M%%8^M>*]!\/64%YJNJ6]M!/_ *EBV[S>,_*!DL,$=/6K6DZQIVNZ='?Z5>17
M=K)D++$V1D=0?0^QH O45S\_CGPQ;>($T*76;9=3>18A;Y).]NBD@8!/H3FL
MJP\8BSN_$T_B#6-)73M/O%AB-L)-\ 8D!9LC&X\=.,Y]J .UHK.CU[2IM732
MHKZ*2^>W%T(4.X^43@/D<8J#6/%6A>'YDBU?5+>S=XVE43-C<J]2/S''4T ;
M%%<DWQ/\$I96]VWB2R$,[E(SN.<CKE<97J.2!UK4UOQ;H'ARSAN]6U6VM89^
M869MQD'7*@9)'(Y'J* -FBL*/QGX<E\/MKT>KVS:6KA&N5;*JQ( !'4')'!'
M>H;/Q[X5U&ZO+:TUVSFFLHVEG5&SM1?O,#T8#OC- '1T5YG8_%NP\1>%/$MS
MIC1VVJZ;;74T$#/YA=(TRLO0#!)'%:/@GXD:+KFFZ/97FM6;Z_=6R/+ O&7(
MR1Z _P"SG/M0!W=%<_+XY\,0>(%T&36;8:FT@B%N"2=YZ*2!@-[$YJOX\\;6
M?@3P\VIW,8GE9U2"V\S8922,X.#T!)_"@#J**YU/'7AH^&TU^35[6/3G;9YS
M-QO[J!U)]@.U6] \4:)XHMI+C1-2@O8XR%D\LG*$],J<$9]Q0!KT5P'C#QAX
MATSQMH_AGP_8Z=/<:A;R3![UG51LR2,K[*:F\*^.=0OO%%WX5\2Z5'INM00_
M:(S#+OAN(_[RGJ.O3GOTQB@#N:*YNR\?^%-2UG^R+/7;.:^+%5B5CAF'4*W1
MC[ FGZAXZ\+Z7K2:/>ZW:0Z@Y"^2S<@GH&(X4G(ZD=: .AHKG=6\>>%M"U,:
M;J>MVMM=G&8G8DIGIN(&%_'%3:MXR\.:%-Y6J:Q:VLAM_M(5V^]&3M##UR>P
MYH W**Y1OB9X*2*TE;Q)8A+O_5?.?7'S#'R\_P![%8NM_$!?#WQ372]4U&VM
M-!_L@71:11DRF0J,'J>!T% 'HM%8\'BO0;CP\VO1:M:G2E!+71?"+@XP<]#G
MC'6J^E>-_#6MV5Y>:=K%O/!9(9+DC(,2 $EBI ., \X[4 =!16+HWBW0/$%W
M+:Z3JD%Y-%$DSK$2=J-T.<8_#J.]<[XX\0>-="BU#4=(TS1SI%A")9);V9_,
MF&,ML5< 8Z?,><<4 =Y17!WGC[4O^%<V/B73/#\UU<W=JUPT)<+';A5+,SL<
M?+P< <M[5N>"->N/$_@S3-:NHHHI[N,NZ19V@[B.,DGM0!T%%17,DD5K-)#"
M9I41F2(-C>P' SVSTKR[_A8/C+1?&>A:3XHT+3(+76I/*@^QS,\D1R!\QR0<
M%ES@#V/% 'JU%>4ZO\1_$\MWXCN?#>DZ;/I'AUS'>/=R.)9F7/F>7MX&W!Z_
M7OBM/5?&'BZ_T&RUGPEHNGRV$NGK>RS7\YX)R3$JJ02P ZDXYH ]#HKS_P /
M^-?$/B_P!9:SH.D6?]ISSM!*EU,5@B"YS)Q\S#@# Y^;VJ3P!XTU?Q!K&O:'
MKME9PZAH\BI)+8LQA?=G@;LD'Y?7\!B@#O**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "O(/&_A>U\4_&[0K/4K6>73FTIR[1LR ,&D(^9>G:
MO7Z* /#M(\/#P;\1O&<.A:1+<6\.@[K>"8-*LSD(=F3][)R,?A6/I6HZAX@\
M9> [V6[GNW@N&%Q%'I/V6*Q9E'[H/@;NA[D<>]?1-% 'S[/IUP_PK^)2-92M
M*VOR/"IB)8CS8^5X],\BO3'\-:Y?:1HYT?Q--H44=E&LEO#91R!WP"6.[D'M
M7;44 >2?&+P[!J^N^"WDLWG\W4TM+ED4\P,RDAL=NI]LFF_%BUOK/Q9X3UN.
M:YM=+LO.22ZMK07/V1V VL8R",'@9QQCCG%>NT4 >%+.=%\&>(M>\/3W.NRW
MVH0/<3WNDF..(C):9(L#=C(YQP<&JNBM=:CXV\57RW=WJD-QX7G6.^?3C:"<
MY485,#.,$ ]3@^E>_P!% '!_"#2+;3OAOH\JV$=O=RQ,TSF+;(Q+G[QZ]A^0
MKF?%OA?_ (2?XY06LTE_:V[:$<7-H[1E7$CX&X<=^E>Q44 ?.,FFZM+\'=2\
M-1:7(E_H.L*;Q;>WYNH@3^\Q_&<@>O" UOZ4NG:UJ>KZY#XBU+5;Z'0;B!_,
MTG[)&J8X5B%4%@3P.>G7BO;Z@OK2/4-/N;*8L(KB)HG*G! 8$''OS0!\RV<]
MIKGPV\+^%](T2Z7Q";]9OM M"HV[FS+YG<8('MM/H*[0ZC9>#_B!XW?Q3I=U
M<#5@C6$JVC3+/'M(\H$ XZJ/3Y>>@KUCPWH%KX7\/V>BV+S/;6JE4:9@7.23
MR0 .I]*U: /GBT\+:A!X:^&.FZSI\C@ZK))-;2QEA'&SA@KCMD<D'UP:ZGQ\
MECX<^)GA#6;G2V_L>&&YBF-O:;U#,I"@JHZY88_'TKUZB@#F_'L/VKX=^($6
M$R,VG3E$V9.[RSC ]:\JU'3Y=.\*?##6+C3)IM*T[;)J444!8HS*FV1D R<;
M3R?IWKWFB@#PHJ?$6M?$#Q+HUC<Q:-/X>EM4D:W:+[5/L!RJD G 4CI_.O0_
MA;I-KIOP\T1HK&.VN);1&F(CVNS'D[CU/)[UV5% 'DFI2VV@_M 1WVH6$QM=
M0TM+:VECMC(IG,J]P.",')[<5AV^A1S>'OBW//I8>Y>^NO(=X,N0"S+M)&>O
M/%>[T4 ?/FHP:GI5U\/]<N+J]T[3X= CMFO8K$71M9MISN0@XR"HSC/'M7HW
MPKT^PM-&U2YT[4+R^BO=0>=I;FS^RAG*KN*)@?*?7 '&.U=[10!X;>7SZ!\1
MYE\)W-[=7&HZN/[3T6[TYB@.X[ITE(P%[@@]P>@Q0)(]-M/BN]_IL]U'=WHA
M@@$3$SNP<+MP.Q(.1TQFO<J* /&/@_IE_P"%/%&J:%K]K(=4GL[>:"\.YE:%
M4 \H,>!LSC'^R?05L^+]-74/C7X)\^S^T6J07+/OCW(&"$KGMG(!'OBO3J*
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M)/N1Q6]X;U*Q\*^)_%>E>)=$O+K4M1U9I[8K9&8743-\F#C&!UYZ9]17MU%
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MXL<8]:\6\,>*[/7?'Z^)O%5KJ2WP?[-I5BEE(T5HC'&YFQRQR>>W7T ][
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWL=YX[[1W[UL#P\PUS2M0-P"MCI\UF4V\OO,1W9SQCR^GO5?^T?&?_0M:/\
M^#I__D>C^T?&?_0M:/\ ^#I__D>@"EIG@V_M-(\/Z==:C;RQZ'>)+ \<#*9(
MDB>,*V6/S?/G(XXZ4K^&);70O$]A>SI=:5?FYN4BAMV\]#*6=A]XAB"?EP >
ME7/[1\9_]"UH_P#X.G_^1Z/[1\9_]"UH_P#X.G_^1Z #P%I=WI?A&T_M(LVJ
M7>;N]9QAC-)\Q!'J!A?^ UTM<U_:/C/_ *%K1_\ P=/_ /(]']H^,_\ H6M'
M_P#!T_\ \CT =+17-?VCXS_Z%K1__!T__P CT?VCXS_Z%K1__!T__P CT =+
M17-?VCXS_P"A:T?_ ,'3_P#R/1_:/C/_ *%K1_\ P=/_ /(] '2T5S7]H^,_
M^A:T?_P=/_\ (]']H^,_^A:T?_P=/_\ (] '2T5S7]H^,_\ H6M'_P#!T_\
M\CT?VCXS_P"A:T?_ ,'3_P#R/0!TM%<U_:/C/_H6M'_\'3__ "/1_:/C/_H6
MM'_\'3__ "/0!TM%<U_:/C/_ *%K1_\ P=/_ /(]']H^,_\ H6M'_P#!T_\
M\CT =+17-?VCXS_Z%K1__!T__P CT?VCXS_Z%K1__!T__P CT =+17-?VCXS
M_P"A:T?_ ,'3_P#R/1_:/C/_ *%K1_\ P=/_ /(] '2T5S7]H^,_^A:T?_P=
M/_\ (]']H^,_^A:T?_P=/_\ (] '2T5S7]H^,_\ H6M'_P#!T_\ \CT?VCXS
M_P"A:T?_ ,'3_P#R/0!TM%<U_:/C/_H6M'_\'3__ "/1_:/C/_H6M'_\'3__
M "/0!TM%<U_:/C/_ *%K1_\ P=/_ /(]']H^,_\ H6M'_P#!T_\ \CT =+17
M-?VCXS_Z%K1__!T__P CT?VCXS_Z%K1__!T__P CT =+17-?VCXS_P"A:T?_
M ,'3_P#R/1_:/C/_ *%K1_\ P=/_ /(] '2T5S7]H^,_^A:T?_P=/_\ (]']
MH^,_^A:T?_P=/_\ (] '2T5S7]H^,_\ H6M'_P#!T_\ \CT?VCXS_P"A:T?_
M ,'3_P#R/0!TM%<U_:/C/_H6M'_\'3__ "/1_:/C/_H6M'_\'3__ "/0!TM%
M<U_:/C/_ *%K1_\ P=/_ /(]']H^,_\ H6M'_P#!T_\ \CT =+17-?VCXS_Z
M%K1__!T__P CT?VCXS_Z%K1__!T__P CT =+17-?VCXS_P"A:T?_ ,'3_P#R
M/1_:/C/_ *%K1_\ P=/_ /(] '2T5S7]H^,_^A:T?_P=/_\ (]']H^,_^A:T
M?_P=/_\ (] '2T5S7]H^,_\ H6M'_P#!T_\ \CT?VCXS_P"A:T?_ ,'3_P#R
M/0!TM%<U_:/C/_H6M'_\'3__ "/1_:/C/_H6M'_\'3__ "/0!TM%<U_:/C/_
M *%K1_\ P=/_ /(]']H^,_\ H6M'_P#!T_\ \CT =+17-?VCXS_Z%K1__!T_
M_P CT?VCXS_Z%K1__!T__P CT =+17-?VCXS_P"A:T?_ ,'3_P#R/1_:/C/_
M *%K1_\ P=/_ /(] '2T5S7]H^,_^A:T?_P=/_\ (]']H^,_^A:T?_P=/_\
M(] '2T5S7]H^,_\ H6M'_P#!T_\ \CT?VCXS_P"A:T?_ ,'3_P#R/0!TM%<U
M_:/C/_H6M'_\'3__ "/1_:/C/_H6M'_\'3__ "/0!TM%<U_:/C/_ *%K1_\
MP=/_ /(]']H^,_\ H6M'_P#!T_\ \CT =+17-?VCXS_Z%K1__!T__P CT?VC
MXS_Z%K1__!T__P CT =+17-?VCXS_P"A:T?_ ,'3_P#R/1_:/C/_ *%K1_\
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M% !1110 4444 %%%% !7->#/^/;6?^PS>?\ HPUTM<UX,_X]M9_[#-Y_Z,-
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MH77.V,3IM4-QU'?% &!H'C75[WP;JVN'Q3I6HW5MH[W9L8+/8UM-LW#>=YR
M01C S3[7Q?XNT33O#&N:W<Z=J.D:V]O'*L-L89;5IEW*0=Q# =^*T],\)>*D
M\&WGAG4)M!%JVDM8036D<HE+[-BM(3P1C).!UJM8^ /$=]!X>T[Q'JFFG2-"
M:&2*VL(7W7#Q+M0R,Y[=\#GG\ #TRBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH YKP7_ ,>>K_\ 89O?_1S5TM<U
MX+_X\]7_ .PS>_\ HYJZ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO!G_'MK/_89O/\
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MF"4[6'49"XKQWQ+>QKK'BB:.]ACLDU^+[1X9ED_?ZBZLH,B<;@&.#@9!QUX
MKTGQD_\ PEGCW0O!D8+6=N1JNJCML0_NXS]6ZCW!H Z34_'_ (6T?5UTK4-8
MAAO#MRA1R$W?=WL 53/^T172U\_>(;ZSL],^)NB7[J-8O]2C:TMF'[RX5BGE
M[!U;'MTKWC3HI8-+M(ISF9(45SG^(* ?UH LT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^A(UC_P*L_\ X_1_PD>N?]"1K'_@59__ !^NEHH YK_A(]<_Z$C6/_ JS_\
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M]"1K'_@59_\ Q^NEHH YK_A(]<_Z$C6/_ JS_P#C]'_"1ZY_T)&L?^!5G_\
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MO^$CUS_H2-8_\"K/_P"/T?\ "1ZY_P!"1K'_ (%6?_Q^NEHH YK_ (2/7/\
MH2-8_P# JS_^/T?\)'KG_0D:Q_X%6?\ \?KI:* .=\'6M];:9>/J%E)937.H
M7-R()'1V57D++DHS+G![&NBHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ(U?Q)HF@&$:OJMG8F<XC%Q,$+?3/;WK!^'/BN]\6Z9J]U>BWS:ZI-:0F!2
M8U"E2>3D_-UKS:Z:Q\,_$72)_']OYUF?#4-K#)- 9T^T*%#K@ Y;[_\ WT/6
MNH^!*)'X6UQ([>2VC&MSA(9%*M&-D>%(/0CI0!ZG1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 8SUHHHH **** "BBB@ HHHH 0(H8L% 8]3CDUS_ (;\)6GANZUFX@GEF;5+
M][Z02@8C=CG"X'3FNAHH 1E5E*L 0>H(I< # '%%%  0",'D4@      Z8I:
M* "N.U?P M]XFG\0:;KVI:3?W,*P7#6VQED1>G#*<'@<CTKL:* ,7PMX8T_P
MAH<>DZ;YK0HS.TDS;GD=CDLQ]:@\)^$;3PE:7UO;3RSB[OI+UFE RK. "!@=
M/EKH:* $95==K*&'H1FEQ110 4FU=P;:-PXSCFEHH 0JK8R <'(R.E+110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )[:I_X-;K_XY1_PC.G_ //;5/\ P:W7_P <H V**Q_^$9T__GMJG_@UNO\
MXY1_PC.G_P#/;5/_  :W7_QR@#8HK'_X1G3_ /GMJG_@UNO_ (Y1_P (SI__
M #VU3_P:W7_QR@#8HK'_ .$9T_\ Y[:I_P"#6Z_^.4?\(SI__/;5/_!K=?\
MQR@#8HK'_P"$9T__ )[:I_X-;K_XY1_PC.G_ //;5/\ P:W7_P <H V**Q_^
M$9T__GMJG_@UNO\ XY1_PC.G_P#/;5/_  :W7_QR@#8HK'_X1G3_ /GMJG_@
MUNO_ (Y1_P (SI__ #VU3_P:W7_QR@#8HK'_ .$9T_\ Y[:I_P"#6Z_^.4?\
M(SI__/;5/_!K=?\ QR@#8HK'_P"$9T__ )[:I_X-;K_XY1_PC.G_ //;5/\
MP:W7_P <H V**Q_^$9T__GMJG_@UNO\ XY1_PC.G_P#/;5/_  :W7_QR@#8H
MK'_X1G3_ /GMJG_@UNO_ (Y1_P (SI__ #VU3_P:W7_QR@#8HK'_ .$9T_\
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M"Q')P.IP.OI4%YXHT+3X(9[O5[.**>+SH6:48E3@;E_O#YAT]:YWQ3I6I?\
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M/_0;TW_P*3_&M#[/#_SQC_[Y%'V>'_GC'_WR* ,__A)=!_Z#>F_^!2?XT?\
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M#[/#_P \8_\ OD4?9X?^>,?_ 'R* ,__ (270?\ H-Z;_P"!2?XT?\)+H/\
MT&]-_P# I/\ &M#[/#_SQC_[Y%'V>'_GC'_WR* ,_P#X270?^@WIO_@4G^-'
M_"2Z#_T&]-_\"D_QK0^SP_\ /&/_ +Y%'V>'_GC'_P!\B@#/_P"$ET'_ *#>
MF_\ @4G^-'_"2Z#_ -!O3?\ P*3_ !K0^SP_\\8_^^11]GA_YXQ_]\B@#/\
M^$ET'_H-Z;_X%)_C1_PDN@_]!O3?_ I/\:T/L\/_ #QC_P"^11]GA_YXQ_\
M?(H S_\ A)=!_P"@WIO_ (%)_C1_PDN@_P#0;TW_ ,"D_P :T/L\/_/&/_OD
M4?9X?^>,?_?(H S_ /A)=!_Z#>F_^!2?XT?\)+H/_0;TW_P*3_&M#[/#_P \
M8_\ OD4?9X?^>,?_ 'R* ,__ (270?\ H-Z;_P"!2?XT?\)+H/\ T&]-_P#
MI/\ &M#[/#_SQC_[Y%'V>'_GC'_WR* ,_P#X270?^@WIO_@4G^-'_"2Z#_T&
M]-_\"D_QK0^SP_\ /&/_ +Y%'V>'_GC'_P!\B@#/_P"$ET'_ *#>F_\ @4G^
M-'_"2Z#_ -!O3?\ P*3_ !K0^SP_\\8_^^11]GA_YXQ_]\B@#/\ ^$ET'_H-
MZ;_X%)_C1_PDN@_]!O3?_ I/\:T/L\/_ #QC_P"^11]GA_YXQ_\ ?(H S_\
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MZ?9R3<QK/(B%ATSSV]Z;J.N^'-'N(;?4M2TVTFF ,:3RHA8$X!P>V>] $O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKQPH[#I6N %    '  H 6BBB@ HHHH **** "BBB@ HHHH QO"?_ "*>E_\
M7NO\JV:QO"?_ "*>E_\ 7NO\JV: "BBB@ HHHH **** "BBB@ HHHH ****
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MO&=(GL;R;P'>MK5S=ZW=7QEO[>2\:3;)Y,N_,1)$>UCM  7CCGM[-0 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K&T;_D+^(?^O\
M3_TF@K9K)G\.V4][<7?G7T4MPP>7R+V6)68*%!VJP&<*!^% &C/;6]TJK<01
M3*K!E$B!@#ZC/>E6"%2I6) 4SM(4?+GKCZUE?\(U:?\ /[JW_@SG_P#BZ/\
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M&K3_ )_=6_\ !G/_ /%T?\(U:?\ /[JW_@SG_P#BZ --+.VCC$:6\*H"I"A
M!QTX]L#%35C?\(U:?\_NK?\ @SG_ /BZ/^$:M/\ G]U;_P &<_\ \70!HQV%
MG#YOE6D">=_K-L8&_P"O'-2^5'O5_+7<@*J<<J#C('Y#\JR?^$:M/^?W5O\
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M #^ZM_X,Y_\ XN@#9HK&_P"$:M/^?W5O_!G/_P#%T?\ "-6G_/[JW_@SG_\
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M  9S_P#Q='_"-6G_ #^ZM_X,Y_\ XN@#9HK&_P"$:M/^?W5O_!G/_P#%T?\
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M'4^M!C0DDHI)QG(ZXZ5D?\(U:?\ /[JW_@SG_P#BZ/\ A&K3_G]U;_P9S_\
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MNK?^#.?_ .+H /"?_(IZ7_U[K_*MFJ]C90:=8065LK+! @1 S%B /4GDU8H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&0<5\_W/A#05@^%)73HU;5-OVY@2&N-R1L0YSDC+'\#CI3]1L)M*'Q<TSP]
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MGYOPKS/6=#TS7_VA8K35;..[MDT$2B*494L)" 2._P!X]:\X3PWI*? SQ#K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5C?\(['_ -!/5O\ P->C_A'8_P#H)ZM_X&O0!LT5C?\ ".Q_]!/5O_ UZ/\
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M &S16-_PCL?_ $$]6_\  UZ/^$=C_P"@GJW_ (&O0!LT5C?\(['_ -!/5O\
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M *)BH V:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;0O^/W7?^PB?_1,5;-8VA?\?NN_]A$_^B8J -FBBB@ HHHH **** "BBB@
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M<X)8=PN<5!K'Q2TC2+R]@.G:K=)8QPS7,]M;JT<4<H!5R2PXYZ8SUXXK$O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L;0O^/W7?^PB?_1,5;-8VA?\ '[KO_81/_HF*@#9HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=
M\6^*'\,Q::(--?4+G4+Q;.&%)5C^9E8@EFX_A_6NBKCO'VCZMJ8T"ZT>TBNY
M]-U2.\>&2<1!U56&-Q!QR1VH GT?QS97O]JPZM;OHEYI05KR&\D3:B,,JX<'
M:RGU]:T(_%WAZ71I=836;(Z="VR2X\X!4;^Z?0\CCKR*\^UKX?\ B7Q'!KNL
M7OV2VU6]>U^SV,-P2BQ0-NVM)MY9CSG& 0/P6?P-K4UB-2@TMUU./6+;49;6
M_P!26<W@B0K@N%"J<-QU^[S0!WD_C7PQ;6-I?3:]8):W>3!*9QB0 X)'L#P?
M3O3]1\8^&])E$6H:Y86TA5&"R3J"5?.T_0X//M7!Z[X3\1ZIKMOKC:3L6YTV
M2QNM.LM26(Q9E9\ERF'#!OF '7UIUW\.[Z1-92"Q@"3>&8=,LUDF$C)*H/R[
MB!P/E^; SB@#J=:\?:1:>'=;U'2+VRU.YTJ(O+;Q3@X.<8)&>.O/M5_2O&&@
M:O97%S;:O8R"TC#W>R=2(.,G<>PX//3BN#UCX>:O/%>QV-K;(LWA6'3 JNJ@
MW"R;C^&.]5-1^'?B3Q!%K#S6=AI,ATB#3;:*"?>EPT<RR%R0HV@A=H!&0#[4
M >DV_C'PY=:=)J$.MV+6<<BQ23>< J.QPH/IG(QFIVUJ.ZT#^U=%B_M9'7,"
M6\B@3'=MX9B  #G)]C7FUUX"U;5-$U,2Z5+#?WMS9&;[;J2W/G1POD]%  "D
M@=2?;'/I&N6TA\/75K8Z9;WI=-GV*27R4D0G#+N ..">W6@# TKQ_)?Z?K<D
M^@7L>H:1<"WFLK=UG+L>FUQ@8]2<8'6MOPIX@3Q3X8L-;CMVMTNT+B)FW%<,
M1U_"N,\(^'/$7AG3O$<UOH\$,-],C6&AB_W+!QMD8RD$ MG.!Z8IWA67Q)X.
M\)^'?#MSHL+7IO%M/DN/,!@.YY)C@?+M'&#UX]<4 =3XL\0ZCX=L?M5AH$^J
MJD<DTY2=(EA1 "22W))!.  >AK!E^)Z3V>G2:-H=SJ-Q=::VJ20&98C! IVD
MDG.3NR !UQ5CXCZ=XFUFQM-+T6UCGTZ=C_:2BZ$$DD8QB-6(. W.3C.!CO6-
M>>'O$]OJ=MK6D^'[*-Y=$?1Y-.^W +: 2$QN'VX9<=0 #0!H:S\3GTS0+7Q%
M:^'+R\T*2WBGFO!/''Y0D. H0G+,"0#CCGK5WQ%X[N?#MQ;32^'[B72)IH8?
MMPN$!+28QMB^\V,X/3D&N5O?!OBFWL_#N@KI=MJV@:5;QO-;_;A;BZN1SE\J
M28U/(7'/?TJUXV\+>(/%&I6TMGX?M+'48V@>#6UU$[K4+AF7RPHW$$N!V(YX
MH ]3HH'2B@#&\,?\@F;_ +"%[_Z52ULUC>&/^03-_P!A"]_]*I:V: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L;0O^/W7?^PB?_1,5;-8VA?\ '[KO_81/_HF*@#9HHHH
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MY;>(P1/L\PN5.-V054 \'KQ0!T'D^)?^@AI/_@#)_P#':/)\2_\ 00TG_P
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M!&%DPN.3@Y'&#UH W?)\2_\ 00TG_P  9/\ X[1Y/B7_ *"&D_\ @#)_\=K
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MQO#'_()F_P"PA>_^E4M;- !1110 4444 %%%% !1110 4444 %%%% !1110
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MV)^0LJ@'ANF1BNNHH BM;:*SM(;6!-D,*+'&H[*!@#\A4M%% !1110 4444
M%%%% !1110 5GZK::C=11_V;J8L)4;+%K=9E<8Z$$@_D16A10!R5GX>U/15M
M+?3KUY'N]3:_U6]D1!Y@(^9 G;<0BC'0 G.>LM]X5O\ 5;Z#^TM=>XTVWO%O
M([5;5$<LC;D5I >5!QT )QR:ZBB@#C)? <LL-SIW]LN-%N;TWLMJ;93)N,GF
ME1+G[I?_ &<XXS1<^ Y;B*_T\:RZZ-?WC7D]K]F4R;F<.RK+GA2P_ND@=#79
MT4 %%%% &-X8_P"03-_V$+W_ -*I:V:QO#'_ ""9O^PA>_\ I5+6S0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5C:%_Q^Z[_P!A$_\ HF*MFL;0O^/W7?\ L(G_ -$Q4 ;-
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>&/\
MD$S?]A"]_P#2J6MFL;PQ_P @F;_L(7O_ *52ULT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+&P\*IX=.^XL5MVMF$I&YT8$$'&.Q-4=+\'I8WUE<W6KW^H_V?&T5DESY8$
M9=I/R*"S;?ERV>"?4T 8UAXWUNZ\+:?K$ND64<FK200:= +EB2[YRTAV_*H
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M;G2]1N-.6/3!=V-I'/<K/<.HED8$^7%A2>@^\?[PXZXO6GBG4]6\10V&FZ;
M+3[%:WT\]U*R.D<Q?Y @!R^%XS@<'/:K<WA64W_]H6FNZA9WLMO'!=S1)"WV
MG9G:[*R%0W)Y4 <].E:%IHL-IK5SJHGFDN+FVAMGWD8Q$7(;@#D^8<_ATH Q
M/$VHZ_:^+O#MGI36GV:Z,XE2=V&\K&3@X4X ZC'?KQ4.J>-9M+\2VVGR-I$D
M4U[%9^1%>%KI/,("NR[<#DC*^G.:W-;T!=8N=/NH[ZYLKNPE:2&: (3AE*LI
M#JP((/I66_@2W:^:4:K?K:G4EU3[&OE[//#AR2=FXJ2.F>,_3  VT\7W=SXL
M?PR=.5=0@F>2X;>?+6TP"DH..68LJ[>Q#=AS>\4:Y<:*EN8;C1X/-W?-J5T8
MMQ&,*B@$MU.3VQT.:C@\%V-OJL.K)<W/]II=27$ET2N^97&TQ-QCRPH0 =MB
MGKDFQJ_AL:EJUMJD&I7=A>00O;^9;B,[HG*EAAU8 Y48(YH YF+Q5KNLZOX0
MN=,CM8;'5;&:XEMYI6SN79D$A?X=WRXZY.<<4VU\5>(=.TKQEJFHQV=Q;Z5<
MS"&-)&W JD;!!\H^7#$YZY/I6Y%X)MK2UT**RU&]MI-&1HH)5V,SQL &5@RD
M'.T<@ C%%WX)M[N/7[<ZE>)9:TK&>V41[4D954NI*[LX0<$D<GB@"#^T-1_X
M2#P_%K%E#!=7)NC&EM=R,L:"-3AQ@*[<D="!C(ZU@^!O$.KZ=X7\(1W]A;?V
M9J"I9Q3)<,TROL9E9EVXPVPC .1D?0=Y>:/!>ZQIVI222"6P$HC52-K>8H4Y
MX]JPM'\ VVDG2HVU?4;RRTH[[.TN&0I')M*[R0H8X#-@$X&>.V !;?QC-/H6
MCZB;- VH:H;!DWG"#S9$W XY/R9Q[U3\/ZYXB:#Q+<:BVEF*RO9HHFEN6C6,
MJ$.&;9P@!)SR:MQ> ;:*YMB-6U$V5I?&_MK'<@BBD+%R,A=S#+-@$G&:ENO
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M65M@;#,OK5^U\)V?]MZ!9-974^D:;97%]FZAX>XFD4@,N NX?O#L &,C@8%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M45G)K^CR:0=635+)M.'6Z$Z^4.<?>SCKQ2+XAT5M-741JUB;)V*+<?:%\LL
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MY49>15"X4DNVXC"C !/JR^M3WGB70M/N8+>\UBPMYIP&BCEN$5G!Z$ GH>U
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M*** ,;PQ_P @F;_L(7O_ *52ULUC>&/^03-_V$+W_P!*I:V: "BBB@ HHHH
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M*\]JIC0]9T'P]I)L;'4%\0V]G+'$+=(YK8K)(7%M+N/"K\HW#& .">E>JT4
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M:IH5]#:ZC>R70%W I22(Q1)M(!.2=K<8Z5W-% 'F$GAZ_M8K?58+"^M4N9)
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M-0:]X975KZYTS3--URV%W?I-=N\Y2R #JSRA=WS%@O"@=3D@8KTRB@ HHHH
MQO#'_()F_P"PA>_^E4M;-8WAC_D$S?\ 80O?_2J6MF@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &-X8_Y!,W_ &$+W_TJEK9K&\,?\@F;_L(7
MO_I5+6S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5C:%_Q^Z[_V$3_Z)BK9K&T+_C]UW_L(
MG_T3%0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<@XS@GGGY30!ZA17+Z]JNJZ'\.+G4W=#JMO9"5BZ#'F8&00..N161J.N>(-
MN]3M+O4+>]<Z%<ZE!(EL(_(EBP-N,G*'>,9Y^4\F@#OZ*X3^TO$BIH&GR:K;
M_;=;9Y6N%M1MM8UBWE$4GYCG !;MDX[55G\3>(8%FTI;NU>_M]=@TW[:UO\
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M_P#V%/XL2]@%C%J!MQIGV<?-$MQY!R^=PD/+#MT&.] 'HU(S*BEF("@9))X
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M%-0MOA=JVS4G6[@LR9+E(PIDP.< ?=S[=* .M:ZMUNDM6GC%PZ-(D1<;V52
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M*I:V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0$GD0/".D;A6 D7V;(Z^II9O!VB2VUA MM- -/@%O;26UU+#(D0 &S>C!BO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K&T+_C]UW_ +")_P#1,5;-8VA?\?NN_P#81/\
MZ)BH X?QZMI>?%3P;8:Z(VT5TN)%CGQY,EP%^4-G@X^7 /KCO4OB"ZATO7=
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M+K;!KY#(K-N5BRAV"%BOR[MNW..^: 'Z;XI\/ZQ=&UTS6].O+@*6\JWN4D;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P (Q8?\_&K?^#>Z_P#CE &7=:+K[WVE:W;#2X]5M(9K6:V+N()(7*D -MW
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M7_QR@#9HK&_X1BP_Y^-6_P#!O=?_ !RC_A&+#_GXU;_P;W7_ ,<H V:*QO\
MA&+#_GXU;_P;W7_QRC_A&+#_ )^-6_\ !O=?_'* -FBL;_A&+#_GXU;_ ,&]
MU_\ '*/^$8L/^?C5O_!O=?\ QR@#9HK&_P"$8L/^?C5O_!O=?_'*/^$8L/\
MGXU;_P &]U_\<H V:*QO^$8L/^?C5O\ P;W7_P <H_X1BP_Y^-6_\&]U_P#'
M* -FBL;_ (1BP_Y^-6_\&]U_\<H_X1BP_P"?C5O_  ;W7_QR@#9HK&_X1BP_
MY^-6_P#!O=?_ !RC_A&+#_GXU;_P;W7_ ,<H V:*QO\ A&+#_GXU;_P;W7_Q
MRC_A&+#_ )^-6_\ !O=?_'* -FBL;_A&+#_GXU;_ ,&]U_\ '*/^$8L/^?C5
MO_!O=?\ QR@#9HK&_P"$8L/^?C5O_!O=?_'*/^$8L/\ GXU;_P &]U_\<H V
M:*QO^$8L/^?C5O\ P;W7_P <H_X1BP_Y^-6_\&]U_P#'* -FBL;_ (1BP_Y^
M-6_\&]U_\<H_X1BP_P"?C5O_  ;W7_QR@#9HK&_X1BP_Y^-6_P#!O=?_ !RC
M_A&+#_GXU;_P;W7_ ,<H V:*QO\ A&+#_GXU;_P;W7_QRC_A&+#_ )^-6_\
M!O=?_'* -FBL;_A&+#_GXU;_ ,&]U_\ '*/^$8L/^?C5O_!O=?\ QR@#9HK&
M_P"$8L/^?C5O_!O=?_'*/^$8L/\ GXU;_P &]U_\<H V:*QO^$8L/^?C5O\
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M_GXU;_P;W7_QRC_A&+#_ )^-6_\ !O=?_'* -FBL;_A&+#_GXU;_ ,&]U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit991app4d003.jpg
<TEXT>
begin 644 exhibit991app4d003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 \@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGDY&.,G?TGQ)KDOC)-$U?3;.W6XT]KZ(6\S2/"%=5V2$@ GYNJ\9!'/6H8O
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW/#W_?4W^%9^MZMXST+0[W59X-!DBM(6E9$>;<P Z#(H [6BN:SXX_N>'O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKV%:?_">:#ZZG_X*;O\ ^-T?\)YH/KJ?_@IN_P#XW0!FZ+\+](T74K.ZCO\
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M1K8W$:)%$H "IE"0.,D9ZDUI_P#">:#ZZG_X*;O_ .-T?\)YH/KJ?_@IN_\
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M)(&TX(R,@5%-XZL;.QU"?4-/U&SFT\P&>UDC1Y=LK[$==C,K G/0D_*>,\4
M;5QHNE7=DEE<Z99S6B'*020*R*?4*1@5:@MX;6!(+>&.*%!M2.-0JJ/0 =*Y
M#4O'C6^@^(+B#1K^'4M*M/M/V2[1 2C*Q23Y7P4RC9P=PVGC/%7/^$Q*QZ=$
M^AZFVH7L+SK9H(=ZQIM#.29-N,NN &+<]* -+1M M-%TZVLHP)DM'D-LTB M
M"K,2%4]@ =OT J>71-)GCMXYM,LI$MCF!7MT(B/JH(^7\*RX]0N(/B ^G22N
MUK>Z:+J&-_\ EF\;A7 ^HDC./53ZUT5 %"?1-)NK=+>XTNRFA1/+6.2W1E5<
M@[0", 9 X]JL"SM5,)%M"# I2(A!^[4@ A?08 X'I4]% %>&QM+<Q&"U@B,4
M?DQE(PNQ./E&.B\#CIP*RM5\*:=J.@3:+!##8V=Q,DDZ6\*J) '5F! P,L%P
M3UQ6[10!FWFCQ7VKZ9?2R-C3S(\4( VF1EV!C]%+@?[QJU=V%G?QB.\M(+E!
MG"S1AP,C!Z^H)%6** *+Z+I4FFKIKZ99M8+]VU:!3$._"8Q^E*^CZ9)8O8OI
MUHUHYRT#0*8V/NN,'H*NT4 5H=.LK81""SMXA#&8XO+B5=B$@E5P. 2!P/04
MQ=)TU(3"NGVBQ-%Y!00J%,?)V8Q]WD\=.35RB@#-UC1+36M,N[.93$;BV>U,
M\0 D1''(5L<#@''3@5F:1X2^P:U%JMW?+<W,%LUK"(K5(%5&*DY"_>/R+WP.
M<#FNEHH P[CPKIM]X@N-5OX(+SSK:& 07$*NJ&-I&##.>?WA_*M"^TG3=4B2
M+4-/M+N.,Y1+B%9 I]@0<5<HH ACL[6%T>*VA1TC\I&5 "J?W1Z#VI+RQM-1
MMFMKVUAN8&^]%/&'4_4'BIZ* *T>G6,-O!;Q65ND$#!H8UB4+&1T*C& >3TI
MMUI>GWT\,]W8VUQ- <PR2PJ[1GU4D9'X5;HH JC3;$($%E;A%A^SA1$N!%_<
MZ?=X''2I/LEMOB?[/%OA0I&VP913C('H#@<>PJ:B@"A:Z'I-B6-II=E;E@P;
MRK=$R&QNS@=\#/K@5#K>AQ:QX;N=$23[);W$(@)B0?+'P"JCH,KD>V:U:* &
M1Q1PPI#&BK&BA54#@ < 55LM'TS3DF2QTZTM5F.91! J!_\ >P.?QJ[10!1L
M]$TK3DE2QTRRM5FXE$%NJ!_][ Y_&DBT+2(+&6QATJQCLYCF2W2W01O]5 P:
MOT4 4XM(TV& P1:?:1PG83&L*A3M.5XQC@@8],58,$)N!<&*,SJA02;1N"D@
MD9ZXR!Q["I** ,+5?"FG:CX?N-%@AAL;2ZE5[A;:%5$@#*S @8&6"X)ZX-;H
M    P!T HHH *YKQ5_R%O"?_ &&/_;:XKI:YKQ5_R%O"?_88_P#;:XH N^+-
M1ETGP?K6HP'$UM8S2QGT94)'ZUR>I>%[@6OAF.VTE]4TZPTZ2&2W2\\@F0B+
M:^<C<?E?J?XJ[K4["+5=)O-.GSY-W \#X_NLI4_H:PK;PY?7>AZ9#?ZMJ%E>
MV]JL$YT^X"I*0,%N5.,XSD8(SC- &AX8U"QU3PU8W>FQRQ6;1[8XY<[X]I*E
M3DGD$$=3TKC+&"/2/B5IT*6-_H]O+;W,9DNKKSAJ;C# Y#N 556?+D,0<8ZU
MV=IX;L;"/3H;)[FVMK")XH[>*=@CAP,EQ_$PQD$\Y)/>JEIX.LX-2@OKJ^U'
M49;972V6^G\Q80XVL0,#)*\9;)P3S0!Y]X3DD7Q#H$TZW$ EGN =::61H]9R
MK;% /W<YWC< /W?R9!S7<^"&,2Z_IR_ZFQUB>.$=E1PLV![ RD5)I_@?3M/E
ML<7>H3VNGOOLK.>?=%;D J"HQDX!(&XG%6_"^DW&E6-V]YL^V7U[->3!#E5+
MM\J@]\($'X4 9NC:_K&J02ZXRV$>A+)<*(=CFX\N(NN_=G:263[NT8!ZYK,\
M-^.-5UB^TMI;1'M-2B:3;#8W$9L_D+KOE<;) 0-N5"\D8R*Z&Q\(V6GZ@]Q;
MW=^ML\LDWV#S_P#1P\F=YV8S@EF.TG;DY I=(\*P:*T:6NHZDUG"I2&RDG#1
M1*1@ <;B .@).* .=T'Q=XBOD\,W5_!IB6VOQLL:0+)OAD$+2AB2V&4[#\N
M1D<GK5?1==\4VG@J]U*=X-0E749H59+:5VA073H[LH8LZJ!D*N" ,9/6NMM/
M"NG6=KH5O%YVS1/^/3+Y/^K:/YN.?E<^G-0P^$8+2*\BL]4U2UCN;AKD+%.
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MD*W!Z$G!&",G!J.X\)6TFHS7MKJ&I6$EP$%RMK/M$^T;06R"0VT ;@0< <T
M86K^+/$,,WB2;3[;3A9Z'#'<.MRLGFS*81(R<$!3C/S<]ACO4]M?Z[<_$J:*
M*[M_[+.E07(MFC;=AGD'!W8#Y'WL8Q@8XS6]<>&;"Z37%D\[&M1>5=8?^'R_
M+^7CCY?KS39/#-HVL6VIQW-Y!/#;"T80R[5EB!)4.,=B201@\T 9W@WQ%>ZX
M)UU*6SBO(U5I=.6"2*>T))^5]['>..'  .#BNKK%TKPW;Z7J$NH->7M[>/"(
M!-=RAV2,$G:, =SG)R3ZUM4 %%%% !1110 4444 %%%% !1110!S7@'_ )%"
MW_Z^+K_THDKI:YKP#_R*%O\ ]?%U_P"E$E=+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R
M\UI-;?$=;L1.;?4=*-L9%4D))%(64,>V5E;'^[7444 <CX;\(W.B7&AR2W,4
M@T[1?[-<(#\[[HVW#V^0_G6MX7T:30?#EMIDTJ2O$9"70'!W.S=_]ZMBB@#@
M8O!>MC0H/"TM_8G0(9$Q*(W^TM"CAUC(SM!X"EO3MFK_ (E\/:YXD$FFSSZ6
MNE/<1RK,(G^TQ!6#87G;NXQOR, ]*Z^B@#C!X>\36E_K@TS4=-M[;5;HW'GR
M1.\T.8T0[5R%)^3(R>]:<_A*R?P')X3A=XK0V)LTD/+ ;<;CZG//O7044 <;
MJ7AO7?$GAV?3=<N=*\Q6AD@,,+NC21N'S(&/*M@ J.@)Y-0?\(3-+H5]9KI^
MA:9/<2VSAM/A8!A%*LAWM@$]#@8XR>3FNYHH Y?5_"DNJWWB"0W*1Q:KHZZ:
MORDM&P\[+'U'[T?D:H:SX9US6] M+&ZCT0W,43(+D>:'MGQA98F'.<<XXY[X
MKMZ* .5M;*XE^(,<\GFR0Z9I MOM$BX\V65U9L>I"Q*3C^_75444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<UXJ_Y"WA/_L,?^VUQ72UB^(]$N=973GL[];*YL;L74<C0
M>:"?+=,%=P[2'OVH VJ*YK^R?%O_ $-5I_X*1_\ ':/[)\6_]#5:?^"D?_':
M .EHKFO[)\6_]#5:?^"D?_':/[)\6_\ 0U6G_@I'_P =H Z6BN:_LGQ;_P!#
M5:?^"D?_ !VC^R?%O_0U6G_@I'_QV@#I:*YK^R?%O_0U6G_@I'_QVC^R?%O_
M $-5I_X*1_\ ': .EHKFO[)\6_\ 0U6G_@I'_P =H_LGQ;_T-5I_X*1_\=H
MZ6BN:_LGQ;_T-5I_X*1_\=H_LGQ;_P!#5:?^"D?_ !V@#I:*YK^R?%O_ $-5
MI_X*1_\ ':/[)\6_]#5:?^"D?_': .EHKFO[)\6_]#5:?^"D?_':/[)\6_\
M0U6G_@I'_P =H Z6BN:_LGQ;_P!#5:?^"D?_ !VC^R?%O_0U6G_@I'_QV@#I
M:*YK^R?%O_0U6G_@I'_QVC^R?%O_ $-5I_X*1_\ ': .EKFOB%_R3S7_ /KR
MD_E1_9/BW_H:K3_P4C_X[5/5?"WB76=)NM-N_%-L;>YC,4FS2P#@^A\R@#L:
M*YK^R?%O_0U6G_@I'_QVC^R?%O\ T-5I_P""D?\ QV@#I:*YK^R?%O\ T-5I
M_P""D?\ QVC^R?%O_0U6G_@I'_QV@#I:*YK^R?%O_0U6G_@I'_QVC^R?%O\
MT-5I_P""D?\ QV@#I:*YK^R?%O\ T-5I_P""D?\ QVC^R?%O_0U6G_@I'_QV
M@#I:*YK^R?%O_0U6G_@I'_QVC^R?%O\ T-5I_P""D?\ QV@#I:*YK^R?%O\
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M>IV;K>?V?*898E;:=P8*?PYZ]#57X=Z3%I7AR4#3TLYI+Z[W@0B-F47,NS/
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MS7J^("W\(0?>C_&X"OCT)H [;2->CU/3[F_EC6UM([F2&*620;9D1MHD!.,
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MDL9C%W;QSA"<[=ZAL9[XS7F>B:9?QZ;X=5[&Y5H_#5_$X:)@5=GAVJ>."<'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO[V2TO!>QS3NFXN%*@$*H&W#'@ <U6U#Q'/IO@2X\0.EE=30PF7%I.7AD^;
MVOCD8QVZUL66KZ;J3SI8ZA:736[;9E@F5S&?1L'@_6@#,OO".G7\&L12R7*_
MVK/%<3.C@-')&J!&3CC'EJ><\_E5FVT&"VU ZB\]S=W1LELW:<J?,169LD
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MUWL"/*0D@GC[W/7]*S5\":?!;:7%97^HV4FG6ILX[BWE4220G!*.2I!Y .0
M0>A%;MEJVFZDTXL=0M+HP-LF$$ROY;>C8/!^M)8:QI>JF4:=J5G>&$[9!;SK
M)L/H=I.* (='T*ST/0X]'M#*;6/>%\Q]S?.Q8\]^6-5T\+6":+H^E!Y_L^DO
M ]N=PW$Q#"[CCGWZ5MT4 >:Z-X8\2:;J%L(A/;.NH//=7 O@]M) TK.R)"1D
M9#8 P,'G)[];'X3TZ/3+73U>X\FVOSJ"$N,^;YK2X/'W=S'CT[UNT4 9.GZ!
M!IFLW^H6]U=!;Y_-EM693"),*I<#&X$A .N.O%:U%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5P^I))IGC?4M1OM$N]4M+W3X8+9K>W$WEE6DWQ$?PAMRG)X..3Q
M7<44 >=^'?#6HZ=?>#DO;4[K+2;J*>0 .(79H2B;O4 $#_=-7O$6DZM::?IU
MT]Y?ZV;/5(+MT\F(2+&NY6V+&J[OO9QR>.*[:FK)&TCQJZETQN4'E<],CM0!
MYM)92ZDWB2_OM+UFSBN=2M;FS:&W#SH8XD"R>7SD;DY7!//(!SB&YMO$5R?#
MFL:A!>P+:F\CE-A91M*N]AY4S0,'P653N !*E^V37J-% '.^&-/&E>$S#9QW
M;LS3S)%?HL3EG=FP54 (I)X&!@'H*XS2+/5;[7-/N]2TW4?*31[JWNX5L4MD
MC=O+/DQ8P6'RL 22.F#UKU6B@#S&TL;F?P_J&F7EKK$FCVOV3[!<BP6.]1HV
M+ %,?O%C*H<[><G@]:CN[;Q'>P^']4O8+V-+*[NA(UG9)YY1AB*=H&# ,0&!
M &1OS@<@>I44 >9OHO\ 9VGZ!?V]AJM[!!K,UY<1S6JB=5DBE4D1*!A=[ XQ
MGG.*T88KVS\=;M*L[_[/>79EU".[M!Y*?NMOG13=03M1=N3U/"UW=% %*RNC
MJNFF5[2YLS(7C,5PH6088KG )X.,CV(K@;"XUG3/ (\(GP[J$NK0VC6$4B1C
M[+(,%5E\W. N,,0?FZC%>ETWS$\TQ;U\P#=MSSCUQZ4 >=G3[_PQJ4UO'IE[
MJ,4^@6NGP2VL88&6'S00Y)&P$.IR>.M2>&?#TRZOX:GU#3#BS\,Q6Y:://E3
M93*\]&QG]:]"IID02B(NOF$%@N>2!U./3D4 <]XAL[FY\1>%9X87DBMK^629
MU&1&IMIE!/H,L!^-<OIGANYM?#GA?;I9BO8-<:XN"(L.J%Y@68]<%2H^F*]+
MHH \X2+4]*TSQ7:V>A22WS:@]U 9+4/%)"[IRO(#LJ[F"9ZK65/HFJ:CIOB_
M=9:A<)?G3_)-U:+"TX23Y_D4#& .X!P.>U>N44 >7^.-,:R;Q--!9^39W.BV
MELAB0!9)?/D4*!T9L,H"]\@9 -5+BWN[_3_$]K<6ER/$5[;VLIM19K"IA23:
M"@620$YW9);/ XP*]3O;&UU*SEL[VWCN+:48>*50RL/<&JVEZ#I>C&5M/LHH
M'EQYC@99P.@+'D@9.!VS0!Y]KVGSC4O',+>&+N]EUF.."RN8X%9'/V=$ +$_
M(JOSN/'!QR*=K?AK6[BW\1P11332266E*'4#_2?)=VF5=W!)'8\'(!ZUZ=)(
MD4;22.J(H)9F. !ZDTX'(R.E '(>$K%#J^H:H7UEIYH(87.H6:6RL%+D8547
M)&X@DCH0 :YWQ3!KNI:E>VJZ==J$U2TEMUM;)#%+$CQ,9GF/.X888!!  X(R
M:]1HH \_MH+NS\774%AI^HR:9=37,U_%=6H58V*'YX)LC.\@#;D\,?NXQ6,^
MD:W=^$=7T+3K6^?38+>U%FUY:I!<LJ2Y>#D 2 (N Q !+8.[DUZS3?,C\WRM
MZ^9MW;,\X]<>E 'F%]H$NL>'?%,UJFLW&H7>F"V5+^SCMA(5WE0JJJY89(R?
M4 &KOB1YY_LFL:'I6K0ZJ+22*"WDT\-#,I?)AF4_ZO)4'=E>#G)Z5Z)10!QO
MQ,!?P(XEM1<%KRR#6XP?,_TF+*<X'/3GBN<UK2;W78/%=YI^B7=I;76FVUFE
MO+!Y4EQ*DC,S!.N K!<]\<<"O3;RRMM0@$%W"LT0=) K=-R,&4_@P!_"K% '
M):KH[Q^*=!:PL0EG;V5[&WDQA4C++$$''3.TX^E8.A^$_(MOAV)M%1&L;5S=
MAH1^ZD,(^_[[^?K7I=% 'F4-MK.CV,-O#IT\-H=8U!FF@LA/-!&TC-%Y:'.%
M;/7! &/7-,\/>&[PP>#8]2TN4I97FHRS)<1+^ZW-(8RP'RCJ",<=,=J]0J(7
M,#%0)HR6<H ''+#.1]1@\>U 'GVIZ+J$FI:TT-C*8Y=?TN>(JG#11B#>P]EV
MMGZ&HX=,N/\ A93^'@F=(BN?^$ASG@,P*"/_ +_;Y!]*]*JO%86L-]<7L<"+
M<W"HLTH'S.%SM!]AD_F: .?\2:2=3\4^%I'L_M-K:W$\DQ9-RQGR6"$_\"QC
MWQ7)ZQX?N7UOQ+:7RZU]BU5XS"=.LHIE>,1(@7>R$QLK*V,E0,@CG->J4V.2
M.9 \3JZ'HRG(- 'GVHVNLV%]XEN;33Y)UGO[(K*UN)F$2PHKRHG\;*0?Q['&
M*RAHVJ2>&O$<CZ=?3M)KEI?0I-;HDLT2&W+L$7 R0C\8!.,'G->L44 >9ZQ8
M74WB>XU*2'6(M-U#3(;>(6FGQS,@!??%(CHQ3.Y3T /.>@KI-2T1W^%]UH=I
M'/-+_8[6L"7)7S&;R2JAB.-V<9]ZZ99(W=T5U9D.' .2IQGGTX-.H \\8RKJ
M/AK6WT+4)-/M;.>VDMA:$RV\S>7B3RNI!".N0._H:W/ ^G7%CH]Z;BT:SCN]
M0N+J"T< &&)VRJD#@$\MCMNQ73T4 >6KHMS/X)N- ET2X\Z'7$DF5[?]W/"U
M^9,J>CJ(SD^@JQXF\-:C=2^,(M-LG2.[M].:,1*JB?RY',JKGY2Q0!<'CD \
M5Z536DC1D5W56<X0$X+'&<#UX!/X4 <CX2L4.LWVJE]9:>6WB@<ZA9QVRD*6
M(PJHNXC<1G'0@ USWBV#7=2O]1LTTZ[4+J%K);+:V2&.:-&B8RR3'G<,,,#!
M 4<$9->HT4 <-I4;Z9XDUBVU#0;N[EOM56Z@O$MUDB\O:@0LY/RF/:>#SQE<
MYKEEMY-/L?#&E7NA7,>HVGB!&FOGA41N6E8[UDZMO!!XZ=\8%>Q57NK&VOA"
M+F%91#*LT>[^%UZ,/<4 >:W]KJL>GZKH2:)J$LTWB%+U9TC!A\@W,<N[=GD@
M @J.1UQCFKE[I$@;7IKJVU2)CKZ7EE/96XF9"MM&HDV$'<F0RG@\^G4>C44
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M.:0(,[464%F/L!7,7WANY?P_XL=-+)O[G6UG@81?O'17A*LIZX&&(_&O2Z*
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MPEIZMKD6H2#7$GM[ VNR]L8K>)%+(=GR(N\@KQC( SSS7=44 %%%% !1110
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ML%JT\5A>BT-I'I5S*]QM*B1A.O[M#R< @_=Y//&WXA\;6^D:3JD]O:WLES9
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MTP6SVJ'=QY;,K'CURB\T <=>_$"YGTJ_U/1XK=[6ST'^TI#*I8B9P3'&<$=
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M6OI6EVVC6"V5F&$(DDD 9LG+NSMS]6- %VBBB@ HHHH **** "BBB@ HHHH
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M>QQQF@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWUC38=3AL=1OK+2K:6(2M*//=4CC4YR2%"@]@.P!H ]+EGB@C\R65(T_O.P
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M,079OG=BS'))/))XZ5;HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQMTV]U7X=2VVGV=Q=SFZA/E6\32-@'DX S7.^,?AMI6BZSX/N_#/AZ1)%UF
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M;F]E:4/*55<[9& X4 = *X'PY:ZMJ'Q.@U9X_$5W:G19H#>:I9"$F3DE%"J
M%RW&><YQFNV^#5A>:;\+]+M;^TGM;A'F+13QE'7,KD9!Y'% &'H?C3Q?XO\
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M((D)Y.3SVX S0!K>&?B?H6N>#I-?O+F.R6U1?MRLK[87;HH) WY_V<U>\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/JFE+8726R7<7EW(F#QLQ7!.T;6!'(&1SP34>L>#X=7EUJ1[N2/^U+2"V8!
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M!!M;+'!..!QR>E=)XG\/7'B.RDL?[2%O93Q-%/"UJDNX'^)2WW6'8\CVIO\
MPB< _ML+=2[=4LX[1MPR8U2-D!SW.&SSZ4 5YO%=[=WYL_#^DQZA)'9Q7D[7
M%U]G5%DR40?(V7(4G' ''-2:%XQM]?OK."VM72*ZTT7X=V^9?GV&,KCJ#GG/
M:H6\'W-M<I<Z/K<MA.UE%97!\A91*L8(1P#]UQN;GD<].*:O@9;%M-;1-5N-
M.:SLC8,WEK*98BP;/S<!]P)W8QR>* ,J+Q4+_5O#>NRB2ULY=&O[J: 2%@ C
M0<GID@9QQWHAU[6=4\7>$I+O3#IUI=I<31!+SS?,4PY D7:N&'!Q\P]ZUK+P
M'96MKI=K)<RSP6.GW&GE64 RI,4W$GL1L_6DTOP9<V6HZ1=7>O7%ZFDQO%:Q
M- B#8R;/F(Y9L8Y]N@R: (?$=]JEKX_T*+3+7[6\NGWF8)+GR8LAX/F<X;IR
M!A2?F^IJ"7XD01Z?IQ:VM;;4;N>XMW@O[Y8(8'@;;+NEVG/.,87)W#@<XVM;
M\.7&IZS8:M9:K)87=E#+"A6%9%<2%"=P/4?)V(YQSQS03P(EM::<UEJ<L>I6
M4L\OVR6)9/.:<[I=Z<#!.#P1C:.: -;PQXAA\3:,+^)%0K+)!(J2B50Z,5.U
MQPRG&0>X(Z5SD'Q%G/A6+Q#?:-%96MVT45D);Y09'<D'>2H$:#!.[).!G /%
M=EIUM<6MDD-U=?:I@26E\I8P<G/"C@ =*P1X+@'@_3M!6]E5].:.2VNPB[ED
M0Y5MIR".H(/4$T 5M-\<-J=AJC6]OILEWITD:R&/4U:U*N,A_/V< <@C;D$=
M.]0VWQ!^U:.\T%A!/J']IC2XH+>\$D,LI4.&$VW[FPY)VY&",5>OO"EYJFE)
M;7VL+)<174=U#(EFBQJR= T>3N!YSD^F,8JNO@,BRN5.KS?;Y-375(KL0(/*
MF6-8\!!P5PI&/1NN>: #PC>ZC>>*/%*ZE ;:6*6V46XG\U$_=#E&P.#UZ ^H
MJ&7Q6^EOJS06-U>S?VY'IR0O=C!9XHV!3(PB_-]WZG/.*VM!\/2:/>ZE>W&I
M2WUUJ#QO,[QJ@!1=H"@=!C''MU/6J\G@^&2XGF^UR RZQ%JQ&P<,B(FSZ'9G
M/O0!9\/Z[<ZK<:E97]@EE?Z?,L<L<4_G1L&0.K*VU2<@]"!@BH+/Q%J&I:Q=
M0V&D1RZ;:79LY[M[O8^]<;RL>T@JI."2P/!P#WT+'1TL=9U74EF9VU%HF9",
M!-B!./7.,UGVOAFZT_6+FYL=9F@T^ZNC=SV7D(V9#C< YY"L1DC&>3@C- &=
M:^.KF>+3M2DT98]"U&Z6VMKL769<NVV-VBVX"L<=&)&1D4U?'=Z9C.^A!-+3
M5CI4ET;L%]_G>4KK'MY7=MSE@1DX!QDS67@0VJV%D^L3S:+I]R+FUL3"H*LK
M%D5I.K*I.0, \#).*MMX/A.D2Z?]KDVR:M_:F_8,AOM GV?3(QF@"G#XF6RO
M=1407$V[7XM-/FW.X*7BB.Y!M^51N^[ZY.>:EU?QK_98US;IKW#:7/:0A$F
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MCQP0SHV[/K\GZUJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(67[+ABPP.<\$]S5+PYX?ATW2? FHV^G-#J;WS1W<_EGS3$T,V5<]=N53 /
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MJ^KVVBV:75T)#&\\5N/+&3ND=47\,L,^U$NKVT.NVNCL)/M-S!+<(0/EVQE
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ME>82$.%X;84!)(.,5@^%O#T.E:9\/K^VTTP:A),R7LPC(D9&MY25D/7;N5,
M\# QB@#U<.I<H&&X#)7/(H9U09=@HSC).*\A\*:7(VJZ8=0O+>UUZWOI);D)
MH\PNICE]RO<;RK1LIX.-N-N,8%='\1X;3?87DWD3W%K%,8;"\L'N;>ZW!<K\
MH^63@!3R>3P1F@#LX[POJ$]J;:9%B1&$[@>7)NSPISG(QSD#J.M6LC)&>17E
M^K0_:9?%+WFE70-UI6FK;V\0.];C,VQ4;'#(Y7GMC)XK?^'\-W;6FIPZPCG7
MUNV-_<$?+.2!Y;H<#Y-FT =B".N: .OWIN"[EW'.!GDXI5=77<K CU!KR*X\
M+VMQI\][)IKF^E\6LC3A6$HMWN]K ,.5C*,V<8')/O4^JZ0=.;Q)8V.G2Q:&
MNI:?-<6EI"0K6Y5?/V(HY!P-P7J : /55D1TWJZLO]X'(IDUU!!;S3R2*(X5
M+2-UV@#)Z5Y-JMG;3Z5XSE\,6+P:++I$<8C@MFBCEN@7W&-,#D(4!(')QW%;
M-WX6L;7Q)J&GV&D1+97F@.)8A%F.:99!L+YX9^3R>: .KD\2V8GT)8 9H=8+
M>3,. JB%I0Q!YY"_K6P9$$?F%UV8SNSQCZUY1I>CZ/J>D^ ;.'24%HDS?VA"
M+0Q*9A9MN\P8&26 !)R#T.:6;2;.#0[ZSG9+&TLO$,TEE!<6+SVC+LR$>-1C
MRR78CH P&.1B@#U@'(R.E-$B-NVNIVG#8/3ZURL;ZE??"R1M.T[^S-2DTR06
MUI$"GE2;"$"@@%><$ @8R*XO2=,MFTZ_FL+FV2=-"N(9K*ST::U:0E1CSF9V
M#2*0<9^8[FZ\T >O!U9BJL"1U /2LV^UN&RU?2].*&1]0FDB5E88C*1M(<_@
MN/QKAK/0/[(O_#DFB6/V6\NM#NDN950@R2[(2AE8]6W%L%N>M9GANTTG^VO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !12$A022 !R2: 0RAE(((R".] "T
M444 %%%% !1110 4444 %%(K*XRI!'J#2T %%%% !1110 44UY$B7=(ZH,XR
MQQS3J "BBB@ HHHH **0,K9P0<'!P>AI: "BBB@ HHHH **** "BBB@ HH)
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M>V1P",@8'%6],\*7MYIK)K5U=PS0WIN=-=+KS+BS78%VF4C#9R^00PPV.<4
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M?L8#1I,J2*Z,Q(V@%P03U'3)XIK^'M3N+>\@%D^Z;PA%8IO  \_]Y\F?49%
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M0V5M;W5Q<Q0HD]R5:9P.7*C:,_0 "IZ* "BBB@ HHHH **** "BBB@ HHHH
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MJ:Z=<ZE!'=EE7RV;[I;[H8]%)[ XSVH UJ*R)/%&B0ZLNER:E MZT@B$9/\
M&1D)GH&/IG-2PZ_I4^K/I<5]$][&2K1+DX(&2N>F0.2,YH TJ*R;'Q-HFIW[
M6-EJ4$]P Q"(WW@IPVT]&P>N,XIVJ>(]'T2:*'4M0AMI91NC1S\SC(' []:
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M'R*H.6;G 'K@5UB;S&OF!0^!N"G(![XH =1110 4444 %%%% !1110 4444
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MCTV:4SSR,-RJ8CM)Z;OW@0\#J :ZNB@#S;6?#5^WB#Q%Y]EK-]I^L["!IUS
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M[.$]P*9=>%KXZKKEG>66M7ECJ=]]I1[&ZA2$J0@Q('8,"I7J,Y &.>*],HH
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M<=LXS69K^AZUXFB\1ZA'H\UD]SHXT^WM;B2+S9WWLY9MK%0!G RW<]*]*HH
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MYN$R5R>0>HH ZZBL[0M8BU_1H-3@MKJVCFW8BNXO+D7#%>5[=/RK1H ****
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M%O[W'3W%;% !17.>'O%L7B#7?$&EQVCPMH]PL#2,X(E)!Y QQ]VNCH ****
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M##[I /&3R./[IZ5Z'61=^%M"OM+M=,N-*M7L+219(+?R\)&RYP0!]3^9K7H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ"">,'GUP* /3**X+0?$.OM=>&9M6N[*:VUVR>8Q10&/[.RQK(#N+'<""<Y
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MK%8UNK9[&V%I!+:W<D,@A &$+*P+#@=<\\U9T[Q-HFK2W,=CJ5O.ULN^7:V
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M;G[#=/))-'YC99I'+L<YR,L2:R[3QWIKZMI6D7,L?VR^L4NA)!N:(LVP!5)
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M7#>(]Y&2K1J"0& R5W8QN Y(SF@"C?\ @O1-2OI[NX@GS<E3<PQW,B0W!4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5STOB1K+Q+JFGWZ1QVMMIR
M:A!*N<L@+"4'_=(7IV:NAKB_'GA;4/$$NG2:8T:L?,LKW>VW-I-M\S'J1L7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC+SPQPR.#C;MW C;D#&5SCM74>#;N]FAUBSO;R2\;3M2DM8YY0H=XPB.N[:
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MY&64[/F&)"HQMQUY[:.J:CJMXWB^^CUZ?3/[!)2VMXTCV'; LN^7<I+!BQ&
M1P..>: /0Z3(SC(SZ5YQ-J&O:U>:N\>L76EI9Z+:WR001QG$TBRL0Q=2=H*
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M1&UT^WGA6R>W4&656;=)YQRR@@+@<<-GG% 'I55K^_M=,LWN[V98;=" SMG
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ME(RA@X8^82RY;(]5QQU]+H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(88)#*5QG<""".N167#XSTYI;J.[M[[3VM[1[UA>0%-T"_><8STR,@X/(XH
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MO[MVVYR-OW<[N>F,<TW1O$5MKLC_ &.VO/LXW>7=21;8I=K;3M.<]?4#/44
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M5PD]M<Q[)(R1E2>2"".A!(_*M.@ HHHH **** "BBB@ HHHH **** "BBB@
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M7*+E]HR-K #G@BM#PUX0OM%F\.-//;NNEZ5/92["WS.[Q,"N1TQ&>OM79T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT^HVI\V"&2X9UYM8FWE"?FVG./0+CM7I5AIEAI<)ATZQMK.(MN*6\2QJ3ZX
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MH=-LXX&54:)(%"E020" ,8!)('N:E;3[)[]+]K.W:\1"B7!B4R*I[!L9 ]J
M.'TCQ&U[?> H(M5\^2ZTV2:[C6;<9"(4PSC_ 'MW7OFL.WO-8L_AEI&K_P!L
M7]S=ZM-:PW4T]UL6&-F(^4X(C)X4OC/.>M>GVNC:78RF6TTVSMY"Q<O% J$L
M>"<@=3ZU-]AL_L/V'[+!]DV[/(\L>7M]-O3'M0!SW@^+5;>34XKZ=7M1(C6L
M37YNY(LK\P:0@$@D C.3R?:LO0[O[?J&I:C>ZW=1ZA;ZI<6L.GB["1[4)6./
MRCPQ90&SC)SP:[.PTRPTJ P:=8VUG$3N,=O$L:D^N% IITG33J7]I'3[4WX&
MW[3Y*^;CIC=C/ZT >;Z1J=T;#PCK,6O7=WJNK7<<=[9O<;HRK*QE41=$\O'4
M $;><YI;*?4X]/TS76UK49)Y?$3V30O-F'R#=21;-G0X'()Y&  <#%>C0:/I
MEK?2WUOIUI%>2Y\RXC@59'^K 9-2BPLQ$L0M(!&DGG*GEC ?=NW ?WMQ)SUS
MS0!PMI?W-AXHO(+^]N;F:]^UR6-Q;WV^#RTY$;0_\LV08&X Y(.3DXK+_M6^
M@T+PWKNHZA=W&GII%H]U':WYBGCF?&9F3(\X-D#:3V. <UZ3!H^F6UW/=V^G
M6<5S/D331P*KR9Z[F R?QIKZ'I$DUM,^E6+2VJA;=S;H6A Z!#CY0/:@#SYA
M)HNM_$34K&ZNI-1MHA/;V\EPSJS&V# ["?FP00/0# IMG-KMOI-[?Q:D6M7T
M.XF8OJQNI'E"@I-&-HV8RV0OR\CCBO23I]D;\7YL[<WH3RQ<>4OF;?[N[&<>
MU06V@Z/9M.UKI-C UPI68Q6Z*9 >H; Y!]Z .+TN&]@UG0+:76M3N4UO2)Y+
MOS;@\2*(2'CQCRS^\8?+CMWYJ_\ "FWA@^'^F&*ZFF=X09%DG,@C(R-H!/RC
MCI77BUMQ)#(+>(/"I2)@@S&IQD+Z X' ]!3+33[*P,IL[.WMS,YDE\F)4WM_
M>; Y/N: /*I_$VLV%['8&_F;_A&[Z6757=B6FM6E01;O7]U,S\]XJU]+O]2U
M"Z\-S3W]VL&N3W]QY:RE=L!0F$#TPFUAZ$DUWSZ=92-<L]G;LUT@2X)B4F90
M, /Q\PP2,'UIXL[93 1;P@VXVPX0?NQC&%]...* /(-/T^/_ (5QHD-OJ5V)
MIM=@1V,_F- 1=.N5#9"GOTY-=UX6-Q:>(?$6CO>W5U:VDD#P&ZE,KIYD>67<
M>2,C(STS6]'H^F12221Z=:(\LHGD98%!>0'(<G'+ ]^M64@ACFDF2*-99<>8
MZJ SXX&3WQ0!Y9XG,NI6NNK>7]VD-GXHL8XRD[((HS]EST/ !9F'H3FM;5[B
M31O$-G=S:C=W>C)]EMHQ;:B1)!*SXW2QY_?*^Y,DDD ' [UW$NG6,\-Q#+9V
M\D5R=TZ/$I64X RPQ\W  Y]!4"Z%HZW,%RNE6(GMU"02BW3=$HZ!3C( ]!0!
MS/Q&\K'A@37S6,;:U&K7".$* PS#ACP">F>V:PVUB\TXZA;P:Q<SZ98^(K"!
M+N:<N5C?RS+&TA^\H+8Y/&[!Z5Z7=6=K>QB.[MH9T!)"RH' )!!X/L2/H342
M:3IL6FG3H]/M$L2"#;+"HB(/4;<8_2@#A;W4K_5]4\4VFDZS&!!/8I$OVORU
M;@M+$D@SL9@",CD'])M)UQKO4?"L5G-?QP/-?P7,-U<>:Q>($$,^3O 8'!R>
M,5V!T'1S9M9G2;$VKA0T/V9-C!>@*XQQGBIXM/LK=;=8;.WC6V!$ 2)0(@>"
M%P/ES[4 >:^&9]3ALO VK3:UJ-W-JTA@NX[B;=&R&"5QA>@(,:_-U/.2<TGA
M:]\1ZM/INK-=B.22^D2]2;4R4*!G4PBWVX5EP,8.?EY)S7IB6%G'';QI:0*E
ML<P*L8 B.",J/X>"1QV)J%=%TI=2.I+IEF+X];D0+YI_X%C/ZT <!I]UJ,:Z
MKI,NLNFM7-A+<6VIF_\ .LW4N%5PI_U)!=1@#'7&[%=+X*OEGMK^R=;U+NRN
M!'<)<WANPK%%8;)222I!!P<$$G@5L0Z%H]LEPD&E6,27/$ZQVZ*)?][ ^;\:
ML66GV6F6PMK"TM[6 '(B@C$:@_0#% 'GMM).;W5-)U.^O;BZOK2[GMKJTU O
M!+$K@@",']RRAE7@8//)JEI4,G_"(_#_ $^PUN_BCU!HUNGBNBS ?8V8QJ3G
M8,J, ?=ZC!KTNTTC3;"XFN+/3[2VFG.99(851I/]X@9/XTEMI&F6846NG6D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME7)5UVNI0D,I'9@5(/N*R-&\<V.LW.GQ)I^I6L6I0&:RN+J)52<!0S 88D$
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MB#B,>5$F&_&,GCUJX^AZA'XMU#4K>:U-EJ-I'!.D@;S$:,2;2N."#Y@SGTH
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MWS0&-!G*".,)S^5 ''_\)UJ=[X1\/ZT^GWEI)<:E!'+'"BM]I1M^5C 9C@D
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M,,4GVP[ J!A(2S_/G:=@VX7/7.*Q/$O@'5_$$NHF:ZTRX-Y!$B37,<A:T95
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ME[J>H^1<V.H27(BNY(VG*2Q!=S*0W&>Q![9P2" >H2W,$$D,<T\<;SOLB5V
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M@A1U=>Y.6+=>!CL_&]_;VFGV,$ZS,;R\6",)?-9INVLW[R5>57"G@9R<#!H
MZ>BO(["[N]0\*;3K%OY=IK-PJV\NL2(MU JG$2W7#L%+ @GJ%&>*[2+7K/\
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MR>)=9?QSJ6D1:1Y]E;V4-Q$ZS(I)8R\\GHQ0*!VP2>#0!T[65HTDDC6T)>4
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MY4 <'W&#74T4 51IMD!;YM(6-LH6%G0,T8'3!/(J9[>"0N7AC8N K[E!W =
M?7J:DHH S=;T2TU[2KJPNMR+<1B-I8L!P <C!(/<9P<CU%5=,\.?8M8?5KS4
MKG4+XV_V99)4C0)'NW$ (JC)(!R<].,5N44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<U?^'M4'B&XU?1=5@LGO+>."Z2XM3,#L+;'3#KA@'8<Y!XX
MXKI:* .,OO!>H3#6;*SUF*WTG69&DNXFM=\REU"R"-]X W =U."3BKTGA)2/
M$2Q70CCU>S2U1?+SY 6)HP>OS?>SVZ5TM% ')#PIJEA?_:]%UF"U:>S@M+H3
MV9EW>4"%D3YUVMAB,'<.GIS%_P (3+;ZU>W=G+I36U[<_:I5O=-\Z6-R &V/
MO7@XSR#@D]>E=E10!@1>&C';>)(?M8/]LS/*#Y?^IW0I%CK\WW,]NN*2#PR8
M;OP[/]K!_L>TDML>7_K=R(N[KQC9G'/6N@HH HVEE<'15LM6N4OIFB,=Q*L7
ME++G(/R@G'!]:Y4>"=8?0T\-W'B&.3P^J"$H+,BZ> =(FEW[<8&TL$R1^==Q
M10!QVM>#;^^N]7.FZO#8VNKVBVUW&]IYC+M5D!C;< N5;!!!Z<8K4TOPZ=.U
MMM1^U>9G3;>P\OR\?ZIG.[.>^_IVQUK=HH P-<T*\O=5T_5]*OH;34+-)81Y
M\!ECDCDV[E90RG.44@@]O>J<OAK6X-4;5-.URVCOKFTCMKUI[$NDA0L5D10Z
M[2-[#!)&,>F:ZNB@#F=%\'0Z'J&ESV]T[Q6.FR6.QU^:0O(CF0G/7*'C'\7M
M5&W\$WNF0Z3-I6K0QZAIZW,1DGM2\4T4TGF%2H<$$$+@ANWO7:44 <E?^"WU
M;^TSJ&IF1]0TA--E=( A#*TC&0#..LGW?;J:+3PSKJZQ)K%[KMK-?'3VLHA'
M8;8DRRL'*ER6Y'(R.O&,<];10!Q%KX!DCAG\R]M8I)M3M=0:*SM#% AA96PJ
M%S@MMY;/7MQ3KGP/>S0:AI2:O$F@:A=O=3VYM29QO??)&LF_ 5FSU4D D5VM
M% '+:AX.-]I_BNU%\$_MXY#>5GR/W*1=,_-]S/;KBM/Q#HIUW09-,$_D;WB;
MS-F[&R17Z9'7;C\:UJ* .7G\+7=YXNL]:N;RR"6<KO$8+,I<.I4KY3R[R&0;
MLXVC) ].=.[T8W/B?3-8\_:+*WN(?*V9W^:8SG.>,>7Z<YK5HH XU/!-U91V
M$^G:I%'J-C=WD\<DUL7C=+B1G:-D# \97!##E>G.*'\$W?\ 9P=-5B.L'55U
M5[E[8F)I0NS;Y8?(39A1\V>,YKLJ* ,?7M%DUW01ITERL4AEMY6E6/()CE20
MX7/&=F.O&>]5KOPP;J\\13_:PO\ ;%A'9A?+SY6U91NZ_-GS>G'3WKH:* .0
M7PEJNG737.B:S;VLEQ9P6MU]HLS*"8E*K(F'7:V">#D=/3ED'@BYT::PD\/:
MJEH8-.33I?M-MY_F1JQ97&&7#@L_7(.[IQ7944 <IHO@PZ.WA\_;_.&D6=Q:
M\Q8,OFLAW=>,;.G.<]J33O!8L;+PO;/>B5=#C>-OW6//#1&/U^7KGO7644 <
M;X=\$RZ";:U\W2IM/ME:.-O[-VW3)@A0TH?&0#R0N3CM46G>"-3M#H-M/KL4
MVG:'/YEI"MGMD=1&\:B1]YR55\ @ <'(.>.WHH RM0T8WVO:/J?G[/[.,Q\O
M9GS/,3;USQCKWK*L?!IL])\+V/VX/_8<_G%_*QYW[J2/&,_+_K,]^E=510!E
M7^C&]U_2-4\_9_9_G?N]F?,\Q-O7/&/QK#G\%2IKE_>V4NE&&_F$\R7VF_:'
MC?:JL4?>N 0H."#@Y/?%=C10!R]SX6N[WQ99ZQ<7=DL=E*TD1@LRERRE2OE/
M+O(*?-G&T9P/2N?\*>$]9N-$T6/5;X16%E>->K9-:%)_,61RBLY;&P$AONY/
M'->D44 <=I/@J71M0 MI=*?3UNGN$\[3=URFYRY02[P."3@E<@<>]6]"\.ZI
MH4PM(=6@?1$FEECMC:?O@'+-L,F_&T,Q(^7/ &?7IJ* ,/PGHEWX=T.'2;B]
MANX;4>7;.D!C81CH'^8AF]QCZ5C1^!KU;6/1FU>)O#T=X+M;;[*1.0)?-$1D
MWXV!\<[<X&,]Z[6B@#*T?1CI5[K%QY_F_P!HWOVK;LQY?[J--O7G[F<\=:SK
MCPQ=OK&MW,.H0I9ZO;"*>%[<LZ.(S&&5@P&,$$@@].HS7344 <[#X7,5QX=E
M^U@_V/:26Q'E_P"MW(B[NOR_<SCGK6+=?#^[N/"NF>'?[2LC:VEK' 9Y+ M.
MCK_RUA?S!Y;8QV.,9YZ5WE% &5K^C'6[&VMA/Y/DWEO=;BN[=Y4JR;>HZ[<9
M[9K.U#PD;Y?%(^VA/[=M5MQ^ZSY.(F3/7YOO9QQTKIJ* .!\0_#F;6I;_;J%
MF$O;%+1GN;#SI;?8I&86WC8#G)&#SW]-]=!NX/%PUFUOH5@EM([6ZMY("S.(
MR[*R,&&TYD.<@]*WZ* .&'@&Y;P[;Z1+J5K*NGW@NM.=[+<%Y<[9E+XD!#E>
M-OKUJ^/"=Q-9V<=S/IT,EOJ,5]_H%CY*$1_P8WDDGGYL_A7544 5!#>_VL9S
M>)]A\@(+7ROF$FXDOOSTQ@;<>]6Z** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAO&=E>
M0ZMHTUKKVJVJZCJ<=K+##,H14,3D[05.#E >_4UW-9>LZ*NKS:5(TYB_L^]6
M\ "YWD(Z[?;[^<^U '(2:GK&@^,-7MK*VNM9BM=(M9F^TW@3: \^XYQR[ #&
M  =O)&!5^_\ B':Q/8Q6,-M)+=6":CB]O4M56)_N $@Y<X/'3CDCBMM_#Z/K
M.JZC]H;.H645H4V_<"&0[LYYSYO3VK'7P-)9_P!FS:;J445U::=%ITK7%F)D
MFCC^ZVW<"K EN0>_>@"[=^(+;4/AS=>(;8W*6\FF272^6XCE4>66P&P0K#IG
MG!]:H77C&]MI[FST_0Y+\V.GPWLTLEVL?R.'X^Z27^0XXP><D=]_4-'.H^%K
MK19KG#7-F]J\ZQ@<LA4L%''?.*J0^%TBN]3G^U,?MUA#8D;/N",2#=UYSYG3
MVH IR^,9KJYMK?1-(?4&DL(]1EW3K#Y<4F=@&0=SG#<<#CDBN?T#QN=.\(>&
M+21H;G4KO3OM+R:A?"W0("!EI&#$L2<  'H<XQ6ZG@NYLI+&72];>SEBTV+3
M;A_LZR>=''G:R@GY'&6Y^8<]#BH8/ )L+71_[.U)([S3;,V7FW%J)DFB)#?,
MFX8((R"&[GKF@!8/'LFIC2$T?1VNYM3M9KA5>Y6-8O*=4<,V#QEB,J#G XP<
MB.3XC6XL-.9;6*'4+R2>)K>]NU@C@:!MLNZ3!Z-@# ).1P.<)J&@:X_BW0Y;
M+4/(:UTVZ22]%HIB9VDA(1H\C (#$ $'Y>IYS,/ *V]KIK6>I%=2LGGD:ZN+
M=95G:=M\N],CJV",$8P* &0^/VOX-*&FZ2;J[U"6X@\H72A(I(3ALR8(*=2&
M&<C''.*E3QQ)/I]D+?2&?5[J]FL18M<!522'=YA,F#\H"$Y R<CBM*+P[*;[
M1KVZOEEGT[S\^7;B-9/,&.%!^4#\<UGR>"601SV6J-;W\.IW&H03M '5?.W;
MXV3(W+AL=0> : ,73/&4VDV.NWFJP.EU+X@^Q6]K<72A(V,$1V^8>%08=LXZ
M=LG%:"?$5'L'>/3EN;V/48M/:"TNTE1GD7<C))@ KR.H!!SGI4O_  @);3[B
M.75Y);Z35!JL=V\"$)-Y:QD%.A4@,,<<-UR,U?;PQ<W5K9QW^HPR2VVH17H:
MWM!"AV=$V[CU]230!B:YXUUF#PWK#V^EQ6NKZ9=P03QM<"1 DFPAU;;\V0P&
M"!C)].>S2XO!I1N)K)5O!&6-M',&!89PH<@#GU..M8FI^#8]2C\0J;UXVUAH
M7W+&#Y+1*H4]?FY4'''I6AJ&C2ZOX6NM&U"^+2W5N\$MS!'Y?W@1D+DXZ],F
M@#GQ\0O)MM=-U86_VC2K'[=LM+Y9TD3YOEWA1M8%.01W'6MC4/%5MIFI&VN8
M66%-+FU.28-G:D10%<=SA\]>U9</@!9!J8U'4(Y1J&F_V:Z6MHMND<?S<J 3
MS\QZY_+BGP^"+BXNY9];UI]1\W2Y=+9$MUA7RI"I+#!)W?*<GOG@#% %"'7=
M8U'QGX:%YILVF6US:74RHMV)!*-L9 < ##KGI@@9X)YJ#1_%.M3W?A""PM#/
M8:CIDEQ(UY=@S,08N6;9R5#^V[=VQ6UIOA"_M]5TR^U#7GOCIL$EO!&+98P5
M90,L022WRC)Z<< <Y;:>"I=.@\-"RU4QS:+;M:EWMPXGB;9N!&X;3^[&#DX]
M#0!H^)/$,VAOID-MIKW]SJ%R;:*-91'AO+=\DD=/DY]!SST.%J_Q&32;F[@D
MLK7S=.@CEOXY-02-U9DWE(5(_>D+_N@Y '/%=/J>C+J6HZ1>&8QG3;EK@*%S
MYF8GCQ[??S^%95[X3N&UR]U/3-2AM6OPGVF.>R6X!9%VAD)8;3M !SD<#B@"
M.?QS;P66M3"S=YM/: 0PA^;H3A?)*G'&YF*]\%352?QA;Z*=:DF$TDJZM'8Q
M1W%TJQ^8T,;\,0!&@!).<]">^*TM3\'6^I^*],UQ[J1/LBJ);=5&VX*%C$6/
M;8S,P^OM4-]X(BO/M\BWS1W,^IIJ<$GE!A#(L2QX*GAU(4YZ?>]LT 5['X@P
M73Q126D6\:E'I]P]M=+-%&9$+1NK@#<I.%Z @GI2VGQ"M;V&Z-O92--%JZ:7
M%$7QYVY@!*#C[NW>WT0U=NO"]SJ/AJ\TN^U*(SSNLD5Q:V8A$#J59&";CDAE
M!Y-5-.^']GIVN:1J45Y*5TZS2W\@J-LTB*Z+,QS][;+(/^!>U &GXD\0S:$V
MF0VVFO?W.H7)MHHEE$>&\MWR21T^3GT&3SC!P]7^(R:3<W=O+96OG:=!'+?Q
MR:@D;JS)O*0J1^]8+S_"#D8YXKIM4T9=3U'2+LS&,Z;=-<!0N?,S$\>/;[^?
MPK*O?"=PVNWNJ:9J,-JU^$^TQSV2W +(NT,A+#:=H YR.!Q0!6O/&UV+O48M
M*T)[^*PMHKJ64W*Q!HW0N H()+8!XX''45*?&,^H3I#X=TG^TB+**]E:2X$
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MX:HL)F"QNF6(&W!PYQC=D\=N*T-(\3W5]KJZ7?Z0]A)-9F]MF,ZR%XPRJP8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@
MOB']IL+!]1M_%4VFZCYB)IUL9TBAD<D#:ZM]_))R2< >F#D [VBD7=L7=C=C
MG'3-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &'K7ALZS=QS_P!MZS8;$V>78W7EHW).2,'GG]!6
M=XE9=?T[5O#TOAZ]N'>(Q0R3Q+Y$C,O#B3)V[2<Y.&&. 376T4 <Q)X/>XT_
M3;=_$&LVS6=I';L;*Y\I92HQO88.2:Z91M4#).!C)ZFEHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556202752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Mesoblast Limited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Level 38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">55 Collins Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melbourne<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">AU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001345099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575930288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Income Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="nump">$ 3,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="num">(12,647)<span></span>
</td>
<td class="num">(13,430)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ManufacturingCommercialization', window );">Manufacturing commercialization</a></td>
<td class="num">(6,746)<span></span>
</td>
<td class="num">(12,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ManagementAndAdministrationExpense', window );">Management and administration</a></td>
<td class="num">(11,482)<span></span>
</td>
<td class="num">(13,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfContingentConsideration', window );">Fair value remeasurement of contingent consideration</a></td>
<td class="num">(337)<span></span>
</td>
<td class="nump">5,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfWarrantLiability', window );">Fair value remeasurement of warrant liability</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="num">(712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income and expenses</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="num">(10,319)<span></span>
</td>
<td class="num">(10,685)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">(32,641)<span></span>
</td>
<td class="num">(41,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/(expense)</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Loss attributable to the owners of Mesoblast Limited</a></td>
<td class="num">$ (32,539)<span></span>
</td>
<td class="num">$ (41,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">Basic - losses per share (in dollars per share)</a></td>
<td class="num">$ (0.0382)<span></span>
</td>
<td class="num">$ (0.0564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">Diluted - losses per share (in dollars per share)</a></td>
<td class="num">$ (0.0382)<span></span>
</td>
<td class="num">$ (0.0564)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ManagementAndAdministrationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to Management and administration activities, recognized in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ManagementAndAdministrationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ManufacturingCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to Manufacturing commercialization activities, recognized in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ManufacturingCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576509568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Loss for the period</a></td>
<td class="num">$ (32,539)<span></span>
</td>
<td class="num">$ (41,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified to profit and loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange differences on translation of foreign operations</a></td>
<td class="nump">1,164<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that will not be reclassified to profit and loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax', window );">Financial assets at fair value through other comprehensive income</a></td>
<td class="num">(931)<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive (loss)/income for the period, net of tax</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Total comprehensive losses attributable to the owners of Mesoblast Limited</a></td>
<td class="num">$ (32,306)<span></span>
</td>
<td class="num">$ (41,078)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 48<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_48&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification adjustments related to financial assets measured at fair value through other comprehensive income, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 92<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_92&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554792288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Issued Capital</div></th>
<th class="th"><div>Share Option Reserve</div></th>
<th class="th"><div>Investment Revaluation Reserve</div></th>
<th class="th"><div>Foreign Currency Translation Reserve</div></th>
<th class="th"><div>Warrant Reserve</div></th>
<th class="th"><div>(Accumulated losses)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">$ 497,044<span></span>
</td>
<td class="nump">$ 1,165,309<span></span>
</td>
<td class="nump">$ 97,924<span></span>
</td>
<td class="num">$ (542)<span></span>
</td>
<td class="num">$ (39,700)<span></span>
</td>
<td class="nump">$ 12,969<span></span>
</td>
<td class="num">$ (738,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(41,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive profit/(loss) for the period</a></td>
<td class="num">(41,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Contributions of equity net of transaction costs</a></td>
<td class="nump">42,405<span></span>
</td>
<td class="nump">42,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Transactions with owners in their capacity as owners</a></td>
<td class="nump">42,405<span></span>
</td>
<td class="nump">42,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TaxCreditedOrDebitedToEquity', window );">Tax credited / (debited) to equity</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Transfer of exercised options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Fair value of share-based payments</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Increase (decrease) in equity</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">500,002<span></span>
</td>
<td class="nump">1,207,714<span></span>
</td>
<td class="nump">99,555<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="num">(39,600)<span></span>
</td>
<td class="nump">12,969<span></span>
</td>
<td class="num">(780,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">497,044<span></span>
</td>
<td class="nump">1,165,309<span></span>
</td>
<td class="nump">97,924<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="num">(39,700)<span></span>
</td>
<td class="nump">12,969<span></span>
</td>
<td class="num">(738,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">501,838<span></span>
</td>
<td class="nump">1,249,123<span></span>
</td>
<td class="nump">101,367<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="num">(40,273)<span></span>
</td>
<td class="nump">12,969<span></span>
</td>
<td class="num">(820,805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(32,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive profit/(loss) for the period</a></td>
<td class="num">(32,306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="nump">1,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Transactions with owners in their capacity as owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Contributions of equity net of transaction costs</a></td>
<td class="nump">37,106<span></span>
</td>
<td class="nump">37,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Transactions with owners in their capacity as owners</a></td>
<td class="nump">37,106<span></span>
</td>
<td class="nump">37,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TaxCreditedOrDebitedToEquity', window );">Tax credited / (debited) to equity</a></td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Transfer of exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Fair value of share-based payments</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Increase (decrease) in equity</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 508,731<span></span>
</td>
<td class="nump">$ 1,286,229<span></span>
</td>
<td class="nump">$ 103,460<span></span>
</td>
<td class="num">$ (1,474)<span></span>
</td>
<td class="num">$ (39,109)<span></span>
</td>
<td class="nump">$ 12,969<span></span>
</td>
<td class="num">$ (853,344)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_TaxCreditedOrDebitedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credited or debited to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_TaxCreditedOrDebitedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554689328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheet - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash &amp; cash equivalents</a></td>
<td class="nump">$ 77,554<span></span>
</td>
<td class="nump">$ 71,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade &amp; other receivables</a></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">6,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepayments</a></td>
<td class="nump">3,602<span></span>
</td>
<td class="nump">3,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total Current Assets</a></td>
<td class="nump">85,154<span></span>
</td>
<td class="nump">81,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="nump">5,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Financial assets at fair value through other comprehensive income</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">576,564<span></span>
</td>
<td class="nump">577,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total Non-Current Assets</a></td>
<td class="nump">585,131<span></span>
</td>
<td class="nump">587,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total Assets</a></td>
<td class="nump">670,285<span></span>
</td>
<td class="nump">669,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">10,760<span></span>
</td>
<td class="nump">20,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">8,230<span></span>
</td>
<td class="nump">6,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">8,534<span></span>
</td>
<td class="nump">5,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total Current Liabilities</a></td>
<td class="nump">31,367<span></span>
</td>
<td class="nump">41,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">17,073<span></span>
</td>
<td class="nump">16,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">107,228<span></span>
</td>
<td class="nump">102,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,386<span></span>
</td>
<td class="nump">3,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredConsiderationNonCurrent', window );">Deferred consideration</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total Non-Current Liabilities</a></td>
<td class="nump">130,187<span></span>
</td>
<td class="nump">125,595<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">161,554<span></span>
</td>
<td class="nump">167,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net Assets</a></td>
<td class="nump">508,731<span></span>
</td>
<td class="nump">501,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued Capital</a></td>
<td class="nump">1,286,229<span></span>
</td>
<td class="nump">1,249,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">75,846<span></span>
</td>
<td class="nump">73,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">(Accumulated losses)</a></td>
<td class="num">(853,344)<span></span>
</td>
<td class="num">(820,805)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total Equity</a></td>
<td class="nump">$ 508,731<span></span>
</td>
<td class="nump">$ 501,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredConsiderationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred consideration on customer receipts expected to be accounted for after one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredConsiderationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576245056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CommercializationRevenueReceived', window );">Commercialization revenue received</a></td>
<td class="nump">$ 3,971<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived', window );">Government grants and tax incentives and credits received</a></td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax', window );">Payments to suppliers and employees (inclusive of goods and services tax)</a></td>
<td class="num">(33,994)<span></span>
</td>
<td class="num">(34,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash (outflows) in operating activities</a></td>
<td class="num">(26,572)<span></span>
</td>
<td class="num">(30,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_InvestmentInFixedAssets', window );">Investment in fixed assets</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ReceiptsFromInvestmentInSublease', window );">Receipts from investment in sublease</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Payments for intellectual property</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash (outflows) in investing activities</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PaymentsOfTransactionCostsFromBorrowings', window );">Payment of transaction costs from borrowings</a></td>
<td class="num">(540)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities', window );">Interest and other costs of finance paid</a></td>
<td class="num">(2,845)<span></span>
</td>
<td class="num">(2,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issue of shares</a></td>
<td class="nump">39,708<span></span>
</td>
<td class="nump">45,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="num">(2,578)<span></span>
</td>
<td class="num">(2,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments for lease liabilities</a></td>
<td class="num">(2,145)<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash inflows by financing activities</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">38,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">7,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">71,318<span></span>
</td>
<td class="nump">60,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">FX gains/(losses) on the translation of foreign bank accounts</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 77,554<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CommercializationRevenueReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercialization revenue received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CommercializationRevenueReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government grants and tax incentives received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other costs of finance paid classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_InvestmentInFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_InvestmentInFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PaymentsOfTransactionCostsFromBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of transaction costs from borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PaymentsOfTransactionCostsFromBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to suppliers and employees inclusive of goods and services tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ReceiptsFromInvestmentInSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipts From Investment In Sublease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ReceiptsFromInvestmentInSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556430784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BasisOfPreparationAbstract', window );"><strong>Basis Of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text">Basis of preparation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. The condensed consolidated financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Accounting Standard IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and are unaudited. These condensed interim financial statements do not include all of the notes and disclosures required by International Financial Reporting Standards, as issued by the IASB, for annual consolidated financial statements and should therefore be read in conjunction with our annual report on Form 20-F for the year ended June&#160;30, 2023. In the opinion of management, the interim financial data includes all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the results for the interim periods.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Going concern </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Group held total cash reserves of $77.6 million. During the six months ended December 31, 2023, the Group executed on reprioritization of projects and operational streamlining activities and as a result has reduced net cash usage for operating activities, which was $26.6 million the six months ended December&#160;31, 2023, a reduction of 14% compared to the prior period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with the Group's overall commercial strategy to complete additional pivotal clinical studies for both the Group's chronic lower back pain and steroid-refractory acute graft versus host disease ("SR-aGVHD") product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) standards) on the Group&#8217;s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Historical cost convention</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income, financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;New and amended standards adopted by the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new or amended standards adopted by the Group in the six months ended December&#160;31, 2023. These interim financial statements follow the same accounting policies as compared to the June&#160;30, 2023 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;New accounting standards and interpretations not yet adopted by the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting standards and interpretations not yet adopted by the Group for the December&#160;31, 2023 reporting period that are expected to materially impact the Group.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Use of estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Impact of after effects of COVID-19 and geopolitical instability</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group&#8217;s significant accounting estimates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with relevant collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the effects of the COVID-19 pandemic and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group&#8217;s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of preparation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556158160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant changes in the current reporting period<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract', window );"><strong>Disclosure Of Significant Changes In Current Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock', window );">Significant changes in the current reporting period</a></td>
<td class="text">Significant changes in the current reporting period<div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Significant events</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial position and performance of the Group was affected by the following event during the six months ended December&#160;31, 2023.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. Assumptions associated with SR-aGVHD are included within the impairment assessment of MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. The Group assessed and included the impact of the FDA's complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD in these areas within the Form 20-F for the year ended June 30, 2023.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In September 2023, the Group provided an update on the path to approval for lead-product candidate remestemcel-L in the treatment of pediatric and adult SR-aGvHD, following a Type A meeting held with FDA.  Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD within the impairment assessment of MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span>In December 2023 the Group completed an institutional placement together with a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing eligible shareholders, raising A$60.3&#160;million at an issue price of A$0.30 per share. In December 2023, proceeds of $39.7&#160;million (A$60.3&#160;million) were received and recognized in cash and cash equivalents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant changes in current reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant changes in current reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576098512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss before income tax<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxAbstract', window );"><strong>Disclosure Of Loss Before Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock', window );">Loss before income tax</a></td>
<td class="text">Loss before income tax<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical trial and research &amp; development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing production &amp; development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined contribution superannuation expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity settled share-based payment transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Employee benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12,490)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,785)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation and amortization of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plant and equipment depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Depreciation and amortization of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,190)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Management &amp; administration expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overheads &amp; administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consultancy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal and other professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses (excluding the amount amortized above)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other Management &amp; administration expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,413)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,712)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(337)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(712)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains/(losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other operating income and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance (costs)/gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of borrowing arrangements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Finance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10,319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10,685)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total loss before income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32,641)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,496)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Share-based payment transactions</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, the share-based payment transactions have been reflected in the Consolidated Income Statement functional expense categories as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,104,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">797,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management and administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,143,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity settled share-based payment transactions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,195,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,756,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Change in comparative figures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December 31, 2022, the Group reclassified immaterial amounts within Other Management and administration expenses. The Group does not believe these reclassifications to be material to the consolidated financial statements. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gr&#252;nenthal arrangement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Group entered into a strategic partnership with Gr&#252;nenthal for the development and commercialization in Europe and Latin America of the Group&#8217;s allogeneic mesenchymal precursor cell (&#8220;MPC&#8221;) product, MPC-06-ID, receiving exclusive rights to the Phase 3 allogeneic product candidate for the treatment of low back pain due to degenerative disc disease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group received a non-refundable upfront payment of $15.0 million in October 2019, on signing of the contract with Gr&#252;nenthal. The Group received a milestone payment in December 2019 of $2.5 million in relation to meeting a milestone event as part of the strategic partnership with Gr&#252;nenthal.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Group announced its intention to leverage the results from a planned US trial to support potential product approvals in both the US and EU by including 20% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. As a result, the strategic partnership with Gr&#252;nenthal has been amended, and milestone payments relating to R&amp;D and CMC services and other development services which were linked to the Europe trial have been removed, instead the Group is eligible to receive payments up to US$112.5 million prior to product launch in the EU, inclusive of US$17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach US$1 billion depending on the final outcome of Phase 3 studies and patient adoption. The Group will also receive tiered double-digit royalties on product sales as per the agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $2.5 million milestone payment received in December 2019 from Gr&#252;nenthal was considered deferred consideration as of December&#160;31, 2023. The performance obligation for the $2.5 million was previously satisfied under the original agreement, however under the amended agreement with Gr&#252;nenthal it is subject to repayment to Gr&#252;nenthal. Revenue will be recognized when the clinical trial has recruited the required amount of European patients, as the $2.5 million will no longer be subject to repayment to Gr&#252;nenthal. For the six months ended December&#160;31, 2023 and 2022, respectively, no milestone revenue was recognized in relation to this strategic partnership with Gr&#252;nenthal.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tasly arrangement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Group entered into a strategic alliance with Tasly Pharmaceutical Group (&#8220;Tasly&#8221;) for the development, manufacture and commercialization in China of the Group&#8217;s allogeneic mesenchymal precursor cell (&#8220;MPC&#8221;) products, MPC-150-IM and MPC-25-IC. Tasly received all exclusive rights for MPC-150-IM and MPC-25-IC in China and Tasly will fund all development, manufacturing and commercialization activities in China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group received a $20.0 million up-front technology access fee from Tasly upon closing of this strategic alliance in October 2018. The Group recognized  $10.0 million from this $20.0 million up-front technology access fee at closing in </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 2018 and the remaining $10.0 million was recognized in revenue in February 2020. The Group is also entitled to receive $25.0 million on product regulatory approvals in China, double-digit escalating royalties on net product sales and up to six escalating milestone payments when the product candidates reach certain sales thresholds in China.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, respectively, no revenue was recognized in relation to this strategic alliance with Tasly.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TiGenix arrangement </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Group entered into a patent license agreement with TiGenix NV (&#8220;TiGenix&#8221;), now a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived mesenchymal stem cell (&#8220;MSC") product, Alofisel&#174; a registered trademark of TiGenix, previously known as Cx601, for the local treatment of fistulae. The agreement includes the right for Takeda to grant sub-licenses to affiliates and third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group received a $5.9&#160;million (&#8364;5.0&#160;million) up-front payment upon entering the patent license agreement and a further payment of $5.9&#160;million (&#8364;5.0&#160;million) 12 months after the patent license agreement date. In September 2021, the Group received a milestone payment of $1.2&#160;million (&#8364;1.0&#160;million) upon Takeda receiving approval to manufacture and market Alofisel&#174; in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's Disease. The Group is entitled to further payments up to &#8364;9.0 million when Takeda reaches certain product regulatory milestones. Additionally, the Group receives single digit royalties on net sales of Alofisel&#174;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, the Group earned $0.2 million and $0.2 million, respectively, of royalty income on sales of Alofisel&#174; in Europe by our licensee Takeda.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, respectively, no milestone revenue was recognized in relation to the Group's patent license agreement with Takeda. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JCR arrangement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Group acquired all of the culture-expanded, MSC-based assets from Osiris Therapeutics, Inc. These assets included assumption of a collaboration agreement with JCR, a research and development oriented pharmaceutical company in Japan. Revenue recognized under this agreement is limited to the amount of cash received or for which the Group is entitled, as JCR has the right to terminate the agreement at any time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JCR Agreement, JCR is responsible for all development and manufacturing costs including sales and marketing expenses. Under the JCR Agreement, JCR has the right to develop our MSCs in two fields for the Japanese market: exclusive in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow, or the First JCR Field; and non-exclusive for developing assays that use liver cells for non-clinical drug screening and evaluation, or the Second JCR Field. With respect to the First JCR Field, the Group are entitled to payments when JCR reaches certain commercial milestones and to escalating double-digit royalties. These royalties are subject to possible renegotiation downward in the event of competition from non-infringing products in Japan. With respect to the Second JCR Field, the Group are entitled to a double-digit profit share. The Group expanded our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (&#8220;EB&#8221;) in October 2018 and for hypoxic ischemic encephalopathy (&#8220;HIE&#8221;), a condition suffered by newborns who lack sufficient blood supply and oxygen to the brain, in June 2020. The Group will receive royalties on TEMCELL&#174; Hs. Inj. (&#8220;TEMCELL&#8221;), a registered trademark of JCR product sales for EB and HIE, if and when JCR begins selling TEMCELL for such indications in Japan. The Group apply the sales-based and usage-based royalty exception for licenses of intellectual property and therefore recognizes royalty revenue at the later of when the subsequent sale or usage occurs and the associated performance obligation has been satisfied. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023, the Group recognized $3.2 million in commercialization revenue relating to royalty income earned on sales of TEMCELL in Japan by our licensee JCR, compared with $3.2 million for the six months ended December&#160;31, 2022. These amounts were recorded in revenue as there are no further performance obligations required in regard to these items. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are included in the financial statements at the lower of cost (including raw materials, direct labor, other direct costs and related production overheads) and net realizable value. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product in accordance with IAS 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Before that point, a provision is made against the carrying value to its recoverable amount in accordance with IAS 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; the provision is then reversed at the point when a high probability of regulatory approval is determined. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group considers a number of factors in determining the probability of the product candidate realizing future economic benefit, including the product candidate&#8217;s current status in the regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, the market need, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, commercialization and market trends.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a provision is made against the carrying value of pre-launch inventory the costs are recognized within Manufacturing Commercialization expenses. When the high probability threshold is met, the provision will be reversed through Manufacturing Commercialization expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All inventory costs are currently fully provided for and are recognized within Manufacturing Commercialization expenses. Where it is determined that the pre-launch inventory will be used within a clinical trial, that amount is removed from the cost of pre-launch inventory. There is no impact on the consolidated income statement as the carrying value has been previously fully provided for.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $21.6 million of pre-launch inventory recognized on the balance sheet that was fully provided for, compared with $22.4 million at June&#160;30, 2023. The future commercial use of the pre-launch inventory recognized on the consolidated balance sheet will be dependent on future discussions with the FDA and remains fully provided for.  </span></div>For the six months ended December&#160;31, 2023, the Group reversed $0.8 million of pre-launch inventory costs within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory, primarily due to a reallocation of pre-launch inventory costs for use in clinical trials. For the six months ended December 31, 2022, $1.6 million of pre-launch inventory costs have been recognized within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about loss before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfLossBeforeIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of loss before income tax [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfLossBeforeIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576638640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit/(expense)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax benefit/(expense)</a></td>
<td class="text">Income tax benefit/(expense)<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax (benefit)/expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current tax (benefit)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Increase)/decrease in deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Decrease)/increase in deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax (benefit)/expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(126)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax (benefit)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(126)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets have been brought to account only to the extent that it is foreseeable that they are recoverable against future tax liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized for unused tax losses to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilized. Deferred tax assets are offset against taxable temporary </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences (deferred tax liabilities) when the deferred tax balances relate to the same tax jurisdiction in accordance with our accounting policy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes are measured at the rate in which they are expected to settle within the respective jurisdictions, which can change based on factors such as new legislation or timing of utilization and reversal of associated assets and liabilities. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets not brought to account</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unused tax losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other temporary differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">151,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">141,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556200832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock', window );">Financial assets and liabilities</a></td>
<td class="text">Financial assets and liabilities<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note provides information about the Group's financial instruments, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">an overview of all financial instruments held by the Group;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">specific information about each type of financial instrument;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">accounting policies; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">information used to determine the fair value of the instruments, including judgments and estimation uncertainty involved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group holds the following financial instruments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVTPL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at <br/>amortized cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">83,793</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">84,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">80,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">82,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through other comprehensive income</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through profit or loss</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVTPL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at <br/>amortized cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,522</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">145,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">128,908</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">151,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through other comprehensive income </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through profit or loss </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s exposure to various risks associated with the financial instruments is discussed in Note 9. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above.</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Cash and cash equivalents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits at call</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">77,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">71,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">As of December&#160;31, 2023 and June&#160;30, 2023, interest-bearing deposits at call include amounts of $0.4 million and $0.4 million, respectively, held as security and restricted for use.</span></div></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Classification as cash equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition. </span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Trade and other receivables and prepayments</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Trade and other receivables</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade debtors</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax incentives recoverable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign withholding tax recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sublease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recoverable taxes (Goods and services tax and value-added tax)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,998</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,998</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1) Research and development tax incentive </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group's research and development activities are eligible under the Australian government's Innovation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Australia Research and Development Tax Incentive program for research and development activities conducted in relation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia. The tax incentives recoverable as of December 31, 2023 pertains to an estimate for the year ended June 30, 2023. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Prepayments</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial research and development expenditure</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance and subscriptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,602</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Classification as trade and other receivables</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade receivables and other receivables represent the principal amounts due at balance date less, where applicable, any provision for expected credit losses. The Group uses the simplified approach to measuring expected credit losses, which uses a lifetime expected credit loss allowance. Debts which are known to be uncollectible are written off in the consolidated income statement. All trade receivables and other receivables are recognized at the value of the amounts receivable, as they are due for settlement within 60 days and therefore do not require remeasurement.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Fair values of trade and other receivables</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of the current receivables, their carrying amount is assumed to be the same as their fair value.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Impairment and risk exposure</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the impairment of trade and other receivables, their credit quality and the Group&#8217;s exposure to credit risk, foreign currency risk and interest rate risk can be found in Note 9.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Trade and other payables</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and other payables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of trade and other payables are assumed to be the same as their fair values, due to their short-term nature. </span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.&#160;&#160;&#160;&#160;Borrowings </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Secured liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of carrying amount, net of payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">115,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">108,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - Oaktree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - Oaktree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">107,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">102,811</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">115,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">108,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Borrowing arrangements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funds associated with Oaktree Capital Management, L.P. (&#8220;Oaktree&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Group entered into a $90.0 million five-year senior debt facility provided by funds associated with Oaktree. The Group drew the first tranche of $60.0 million on closing. The conditions required to draw down the additional $30.0 million tranche have not been met. The facility has a three-year interest only period, at a fixed rate of  9.75% per annum, after which time 40% of the principal amortizes over two years and a final payment is due no later than November 2026. The facility also allowed the Group to make quarterly payments of interest at a rate of 8.0% per annum for the first two years, and the unpaid interest portion (1.75% per annum) has been added to the outstanding loan balance and currently accrues further interest at a fixed rate of 9.75% per annum.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November&#160;19, 2021, Oaktree were also granted warrants to purchase 1,769,669 American Depositary Shares (&#8220;ADSs&#8221;) at US$7.26 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the debt facility was signed; consequently, a liability for the warrants was recognized in November 2021. The warrants were legally issued on January&#160;11, 2022 and may be exercised within 7 years of issuance. On the issuance date of the Oaktree facility and the warrants, the warrants were initially measured at fair value and the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oaktree borrowing liability measured as the difference between the $60.0 million received from the Oaktree facility and the fair value of the warrants. In December 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the first amendment to the loan agreement was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance.  Refer to Note 5(e)(vi) for more details on warrants issued. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 5, 2024, the ratio under Mesoblast's American Depository Receipt ("ADR") program was changed from 5 ordinary shares representing 1 ADS (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADS (10:1 ratio). As a result of this ratio change and as a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the number and exercise price for the warrants was adjusted in accordance with the terms of these warrants. The warrants issued in November 2021 changed from 1,769,669 ADSs at US$7.26 per ADS to 884,838 ADSs at US$14.36 per ADS. The warrants issued in December 2022 changed from 455,000 ADSs at US$3.70 per ADS to 227,502 ADSs at US$7.24 per ADS.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the six months ended December&#160;31, 2023, the Group recognized a minimal loss in the Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of the financial liability to reflect the revised estimated future cash flows from the credit facility. In the six months ended December&#160;31, 2022 the Group recognized a loss of $1.4 million in the Income Statement as remeasurement of borrowing arrangements within finance costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Within this </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$1.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> loss, $1.0&#160;million relates to the remeasurement due to additional warrants being issued to Oaktree as a result of the first amendment to the loan agreement and $0.4&#160;million relates to the adjustment of the carrying amount of the financial liability to reflect the revised estimated future cash flows from the credit facility</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Group has pledged substantially all of its assets as collateral under the loan facility with Oaktree. </span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NovaQuest Capital Management, L.L.C.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2018, the Group entered into an eight-year, $40.0 million loan and security agreement with NovaQuest before drawing the first tranche of $30.0 million of the principal in July 2018. The additional $10.0&#160;million from the loan will be drawn on marketing approval of remestemcel-L for the treatment of pediatric patients with SR-aGVHD by the FDA. The loan term included an interest only period of approximately four years through until July 8, 2022. All interest and principal payments (i.e. the amortization period) are deferred until the earlier of loan maturity or from after the first commercial sale of remestemcel-L for the treatment in pediatric patients with SR-aGVHD in the United States and other geographies excluding Asia ("remestemcel-L for pediatric SR-aGVHD"). Principal is repayable in equal quarterly instalments over the amortization period of the loan and is subject to the payment cap described below. The loan has a fixed interest rate of 15% per annum. If there are no net sales of remestemcel-L for pediatric SR-aGVHD, the loan is only repayable at maturity. The Group can elect to prepay all outstanding amounts owing at any time prior to maturity, subject to a prepayment charge. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval and first commercial sales, repayments commence based on a percentage of net sales and are limited by a payment cap which is equal to the principal due for the next 12 months, plus accumulated unpaid principal and accrued unpaid interest.  During the four-year period commencing July 8, 2022, principal amortizes in equal quarterly instalments payable only after approval and first commercial sales. If in any quarterly period, 25% of net sales of remestemcel-L for pediatric SR-aGVHD exceed the annual payment cap, the Group will pay the payment cap and an additional portion of excess sales which will be used towards the prepayment amount in the event there is an early prepayment of the loan. If in any quarterly period 25% of net sales of remestemcel-L for pediatric SR-aGVHD is less than the annual payment cap, then the payment is limited to 25% of net sales of remestemcel-L for pediatric SR-aGVHD. Any unpaid interest will be added to the principal amounts owing and shall accrue further interest. At maturity date, any unpaid loan balances are repaid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of this relationship of net sales and repayments, changes in our estimated net sales may trigger an adjustment of the carrying amount of the financial liability to reflect the revised estimated cash flows. The carrying amount is recalculated by computing the present value of the revised estimated future cash flows at the financial instrument&#8217;s original effective interest rate. The adjustment is recognized in the Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the six months ended December&#160;31, 2023 and 2022, the Group recognized a loss of $0.1 million and a gain of $0.2 million, respectively, in the Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows as a net result of changes to the key assumptions in development timelines.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group recognizes a liability as current based on repayments linked to estimates of sales of remestemcel-L. However, if sales of remestemcel-L are higher than estimated, actual repayments will exceed this amount, subject to the annual payment cap described above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the loan and security agreement with NovaQuest is subordinated to the Group&#8217;s fixed rate loan with the senior creditor, Oaktree. The Group have pledged a portion of our assets relating to the SR-aGVHD product candidate as collateral under the loan facility with NovaQuest.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Compliance with loan covenants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loan facilities with Oaktree and NovaQuest contain a number of covenants that impose operating restrictions on us, which may restrict our ability to respond to changes in our business or take specified actions. The Group has an operating objective to at all times maintain unrestricted cash reserves in excess of six months liquidity. The objective aligns with our loan and security agreement with Oaktree where the Group is currently obliged to maintain a minimum unrestricted cash balance of $35.0 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has complied with the financial and other restrictive covenants of its borrowing facilities during the six months ended December&#160;31, 2023 and during the year ended June&#160;30, 2023.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Net Debt Reconciliation</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115,762)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(50,603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross debt - fixed interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(121,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross debt - variable interest rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,437)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(50,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Net debt amount includes leases and borrowing arrangements.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities from financing activities </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Borrowings </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant liability </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sub-total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and cash<br/>equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Debt as at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108,763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,426)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(121,921)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Changes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt as at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(115,762)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6,237)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(992)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(122,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">77,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,437)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Other changes include modification of leases and accrued interest expenses for borrowings and leases.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Fair values of borrowing arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the borrowings at amortized cost in accordance with our accounting policy is a reasonable approximation of fair value. </span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">e.&#160;&#160;&#160;&#160;Recognized fair value measurement</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Fair value hierarchy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of December&#160;31, 2023 and June&#160;30, 2023 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities - biotech sector</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities at fair value through profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities - biotech sector</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities at fair value through profit or loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between any of the levels for recurring fair value measurements during the period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s policy is to recognize transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, trading and financial assets at fair value through other comprehensive income securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of financial instruments that are not traded in an active market (for example, foreign exchange contracts) is determined using valuation techniques which maximize the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for provisions (contingent consideration), equity securities (unlisted) and warrant liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Valuation techniques used.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group did not hold any level 1 and level 2 financial instruments as at December&#160;31, 2023 or June&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s level 3 assets consists of an investment in unlisted equity securities in the biotechnology sector. Level 3 assets were 100% of total assets measured at fair value as at December&#160;31, 2023 and June&#160;30, 2023. The Group&#8217;s level 3 liabilities consist of a contingent consideration provision related to the acquisition of the MSC assets and warrant liabilities related to the warrants granted to Oaktree as part of the debt facility. Level 3 liabilities were 100% of total liabilities measured at fair value as at December&#160;31, 2023 and June&#160;30, 2023. The Group used discounted cash flow analysis to determine the fair value measurements of contingent consideration and used the Black-Scholes valuation method to determine the fair value of warrant liabilities. Refer to Note 5(e)(vi) for the fair value measurement and movements in warrant liability for the period ended December&#160;31, 2023 and June&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Fair value measurements using significant unobservable inputs (level 3)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in level 3 instruments for the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent<br/>consideration<br/>provision</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance - July 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to consolidated income statement:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing balance - June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance - July 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to consolidated income statement:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing balance - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In the year ended June&#160;30, 2023 a gain of $8.8 million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, developmental timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines were updated to reflect expectations as a result of the complete response.  </span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In the six months ended December&#160;31, 2023 a minimal gain was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation such as development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.</span></div></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Valuation inputs and relationship to fair </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of inputs<br/>(weighted average)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value <br/>as of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value <br/>as of <br/>June 30, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation <br/>technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>June 30, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Relationship of <br/>unobservable inputs to <br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discounted cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk adjusted discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11%-13%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12.5%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11%-13%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12.5%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the discount rate by 0.5% would increase/decrease the fair value by an insignificant amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.01%.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected unit sales price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected sales volumes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Probability of success and payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 10.0% and 20.0%, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8% and 16%, respectively.</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">There were no significant inter-relationships between unobservable inputs that materially affect fair values.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Valuation processes </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the MSC assets on October 11, 2013 (the &#8220;acquisition date&#8221;), an independent valuation of the contingent consideration was carried out by an independent valuer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023, the Group has adopted a process to value contingent consideration internally. This valuation has been completed by the Group&#8217;s internal valuation team and reviewed by the interim Chief Financial Officer (the "CFO"). The valuation team is responsible for the valuation model. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. For each indication we determine the probability of success based on the current development status within each jurisdiction and payment provisions within the agreement. Cash flows relevant to each jurisdiction are discounted appropriately based on the discount rate assumed. The remeasurement charged to the consolidated income statement in the six months ended December&#160;31, 2023 was a net result of changing the key assumptions of the contingent consideration valuation such as development timelines and the increase </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration. Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD and a remeasurement of contingent consideration, up or down, could occur. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The fair value of contingent consideration<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of royalty payments from commercialization of the intellectual property acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main level 3 inputs used by the Group are evaluated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk adjusted discount rate:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used in the valuation has been determined based on required rates of returns of listed companies in the biotechnology industry (having regards to their stage of development, their size and number of projects) and the indicative rates of return required by suppliers of venture capital for investments with similar technical and commercial risks. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected unit sales prices:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected market sale price of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected sales volumes:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected sales volumes of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of success and payment:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected cash flows used to measure contingent consideration are risk adjusted for the probability of successful development of products and payment provisions within the agreement. This assumption is reviewed as part of the valuation process outlined above.</span></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Warrant liability </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants fair value at grant date - December 22, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,426</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, in connection with the $60.0 million drawdown of the Oaktree debt, Oaktree were granted the right to warrants to purchase 1,769,669 ADSs at $7.26 per ADS, a 15% premium to the 30-day VWAP. Given that Oaktree received an unconditional right to the warrants on November&#160;19, 2021, this date has been determined as the measurement date. The warrants instruments were issued on January&#160;11, 2022, following the required administrative process, and these warrants may be exercised within 7 years of issuance of the warrant instruments. The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP.  We determined that an obligation to issue the warrants has arisen from the time the first amendment to the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loan agreement was signed; consequently, a liability for the warrants has been recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2024, the ratio under Mesoblast's ADR program was changed from 5 ordinary shares representing 1 ADS (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADS (10:1 ratio). As a result of this ratio change and as a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the number and exercise price for the warrants was adjusted in accordance with the terms of these warrants. The warrants issued in November 2021 changed from 1,769,669 ADSs at US$7.26 per ADS to 884,838 ADSs at US$14.36 per ADS. The warrants issued in December 2022 changed from 455,000 ADSs at US$3.70 per ADS to 227,502 ADSs at US$7.24 per ADS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of the warrants will be received in U.S. dollars, which is different to Mesoblast Limited&#8217;s functional currency of Australian dollars which gives rise to variability in the cash flow. As a result, the warrants are classified as a financial liability in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IAS32 Financial Instruments: Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The financial liability is recorded in warrant liability at fair value at grant date and subsequently remeasured at each reporting period with changes being recorded in the Income Statement as remeasurement of warrant liability. The warrant liabilities are considered level 3 liabilities as the determination of fair value includes various assumptions about the share prices and historical volatility as inputs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2023, and June&#160;30, 2023 the fair value of the warrant liability was $1.0 million and $5.4 million, respectively. During the six months ended December 31,  2023, a remeasurement gain of $4.4 million was recognized on the remeasurement of warrant liability. During the six months ended December 31, 2022, a remeasurement loss of $0.7 million was recognized on the remeasurement of warrant liability.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;Fair value of warrants</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants granted are not traded in an active market and therefore the fair value has been estimated by using the Black-Scholes valuation method based on the following assumptions. Key terms of the warrants are included below. The following assumptions were based on observable market conditions that existed at the issue date and as of December&#160;31, 2023.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:23.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, except percent data and as otherwise noted) <br/>Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of<br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rationale</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Closing share price on valuation date from external market source</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.70 to $7.26</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.70 to $7.26</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per subscription agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 to 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 to 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per subscription agreement</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Company&#8217;s nil dividend history</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.71%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on historical volatility data for the Company</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Free Interest Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.01%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing U.S treasury issued 7 year bonds on valuation date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value per warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.4000 to $0.6248</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3103 to $2.9401</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determined using Black-Scholes valuation model with the inputs above</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$992,233</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,426,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of 2,224,669 warrants of $992,233 and $5,426,212 as of December&#160;31, 2023 and June&#160;30, 2023, respectively.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and financial liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576664320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-financial assets and liabilities<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock', window );">Non-financial assets and liabilities</a></td>
<td class="text">Non-financial assets and liabilities<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Intangible assets</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Acquired licenses<br/>to patents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In-process<br/>research and<br/>development<br/>acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current marketed<br/>products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">578,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">577,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">489,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">651,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">577,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">577,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">576,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">489,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">651,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">576,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Carrying value of in-process research and development acquired by product</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous products for metabolic diseases and inflammatory/immunologic conditions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSC products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes remestemcel-L for the treatment of adults and children with SR-aGVHD and remestemcel-L for the treatment of Crohn&#8217;s disease </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all products included within the above balances, the underlying currency of each item recorded is US$.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Significant estimate: Impairment of goodwill and assets with an indefinite useful life</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group tests annually, or more frequently if events or changes in circumstances indicate that they might be impaired, whether goodwill and its assets with indefinite useful lives have suffered any impairment in accordance with its accounting policy stated in Note 23(j) in the Form 20-F for the year ended June 30, 2023. The recoverable amounts of these assets and cash-generating units have been determined based on fair value less costs to dispose calculations, which require the use of market-participant assumptions that are based on development strategies using external data sources as well as past experience. The full annual impairment assessment was performed at March 31, 2023 and no impairment of the in-process research and development and goodwill were identified. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the FDA issued a complete response to the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD and the Group considered this to be an impairment indicator that could cause the carrying amount of its intangible assets to exceed its recoverable amounts. As a result, the Group completed an impairment assessment on its MSC products intangible asset and goodwill. The assumptions used in the impairment assessment were updated from the March 31, 2023 impairment assessment and included changes to the market population and penetration, product pricing and launch timings. There were no other significant changes in key assumptions, including the probability of success. No impairment to the in-process research and development and goodwill was identified. </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Impairment tests for goodwill and intangible assets with an indefinite useful life</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development acquired is considered to be an indefinite life intangible asset on the basis that it is incomplete and cannot be used in its current form (see Note 23(p)(iii) in the Form 20-F for the year ended June 30, 2023). The intangible asset&#8217;s life will remain indefinite until such time it is completed and commercialized or impaired. The carrying value of in-process research and development is a separate asset which has been subject to impairment testing at the cash generating unit level, which has been determined to be at the product level.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On acquisition, goodwill was not able to be allocated to the cash generating unit (&#8220;CGU&#8221;) level or to a group of CGU given the synergies of the underlying research and development. For the purpose of impairment testing, goodwill is monitored by management at the operating segment level. The Group is managed as one operating segment, being the development of cell technology platform for commercialization. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recoverable amount of both goodwill and in-process research and development was assessed as of March 31, 2023 based on the fair value less costs to dispose. As a result of the receipt of the complete response from the FDA in August 2023, an impairment assessment was performed over the in-process research and development value of the MSC asset and goodwill. No impairment was identified as a result of these impairment assessments. Management assessed assets for indicators of impairment as at December&#160;31, 2023 including considering events up to the date of the approval of the financial statements and no indicators of impairment were identified. </span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Key assumptions used for fair value less costs to dispose calculations </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value less costs to dispose the Group has given consideration to the following internal and external indicators:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">discounted expected future cash flows of programs valued by the Group&#8217;s internal valuation team and reviewed by the interim CFO. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. When determining key assumptions, the business units refer to both external sources and past experience as appropriate. The valuation is considered to be level 3 in the fair value hierarchy due to unobservable inputs used in the valuation; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scientific results and progress of the trials since acquisition;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the market capitalization of the Group on the ASX (ASX:MSB); and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the valuation of the Group&#8217;s assets from an independent valuation. An independent valuation was obtained for all assets at March 31, 2023 and for the MSC products an impairment assessment was performed as a result of the receipt of the complete response.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of disposal were assumed to be immaterial.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash-flows used a real post-tax discount rate range of 13.8% to 15.5%, and include estimated real cash inflows and outflows for each program through to expected patent expiry which ranges from 9 to 25 years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to cash outflows consideration has been given to cost of goods sold, selling costs and clinical trial schedules including estimates of numbers of patients and per patient costs. Associated expenses such as regulatory fees and patent maintenance have been included as well as any further preclinical development if applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In relation to cash inflows consideration has been given to product pricing, market population and penetration, sales rebates and discounts, launch timings and probability of success in the relevant applicable markets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no standard growth rates applied, other than our estimates of market penetration which increase initially, plateau and then decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment of the recoverable amount of each product has been made in accordance with the discounted cash-flow assumptions outlined above. The assessments showed that the recoverable amount of each product exceeds the carrying amount and therefore there is no impairment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment of goodwill showed the recoverable amount of the Group's operating segment, including goodwill and remaining in-process research and development, exceeds carrying amounts, and therefore there is no impairment.</span></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Impact of possible changes in key assumptions</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has considered and assessed reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amount of our intangible assets to exceed its recoverable amount. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whilst there is no impairment, the key sensitivities in the valuation are dependent on the continued successful development of our technology platforms. Future discussion with the FDA could change the  assumptions used within the impairment assessments. If the Group is unable to successfully develop its technology platforms, an impairment of the carrying amount of our intangible assets may result.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Provisions</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for license agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,011</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The classification of contingent consideration as current represents the expected payments within the next 12 months based on current development timelines.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Information about individual provisions and significant estimates</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration provision relates to the Group&#8217;s liability for certain milestones and royalty achievements pertaining to the acquired MSC assets. Further disclosures can be found in Note 5(e)(iii).</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee benefits</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for employee benefits relates to the Group&#8217;s liability for annual leave, short term incentives and long service leave.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits include accrued annual leave. As at December&#160;31, 2023 and June&#160;30, 2023, the entire amount of the annual leave accrual was $1.2 million and $1.1 million respectively, and is presented as current, since the Group does not have an unconditional right to defer settlement for any of these obligations.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Movements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration provision relates to the Group&#8217;s liability for certain milestones and royalty achievements. Refer to Note 5(e)(iii) for movements in contingent consideration for the period ended December&#160;31, 2023 and June&#160;30, 2023.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Deferred tax balances</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Deferred tax balances</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance comprises temporary differences attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance comprises temporary differences attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Movements </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Tax losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(DTA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">temporary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">differences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(DTA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible<br/>assets (DTL)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total (DTL) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(80,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- directly to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(76,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- directly to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(74,684)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13,185)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Deferred tax assets are netted against deferred tax liabilities</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non financial assets and liabilities,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non financial assets and non financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556178816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash flow information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Cash flow information</a></td>
<td class="text">Cash flow information<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)<br/>(a) Reconciliation of cash and cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits at call</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">77,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">71,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(b) Reconciliation of net cash flows used in operations with loss after income tax</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add/(deduct) net loss for non-cash items as follows:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange (gains)/losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,989)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity settled share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in trade and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in tax incentive recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in trade creditors and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash outflows used in operations</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(26,572)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(30,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556301328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Contributed equity </span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Share capital </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contributed equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Share capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,015,342,237</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">737,121,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,286,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,207,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Treasury Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(542,903)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(542,903)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Contributed Equity</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,014,799,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">736,578,315</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,286,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,207,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Movements in ordinary share capital</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">814,204,825</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650,454,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,249,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,165,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issues of ordinary shares during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Placement of shares under a share placement agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201,137,412</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,666,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs arising on share issue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total contributions of equity during the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201,137,412</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,666,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,106</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,405</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share options reserve transferred to equity on exercise of options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,015,342,237</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">737,121,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,286,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,207,714</span></td></tr></table></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the six months ended December 31,  2023, 201,137,412 shares were issued in a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing shareholders in Australia and certain other countries together with an institutional placement of new fully paid ordinary shares in Mesoblast Limited, at A$0.30 per share.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the six months ended December 31, 2022, 86,666,667 shares were issued in an equity purchase of Mesoblast Limited at A$0.75 per share to existing and new institutional investors.</span></div></td></tr></table></div><div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Movements of shares in share trust </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Movement of shares in share trust</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. From July 1, 2020, unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. Prior to July 1, 2020, the shares issued and share capital received on the exercise of options were recorded in ordinary share capital.</span></div></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Warrant reserve</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant reserve</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movement during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing Balance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Group completed a A$138.0 million (US$110.0 million) private placement of 60,109,290 new fully-paid ordinary shares at a price of A$2.30. As part of this placement, the Group also issued one warrant for every four ordinary shares issued in the placement, which resulted in a further 15,027,327 warrants issued. Each warrant has an exercise price of A$2.88 per share and a 7-year term.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has a right to compel exercise of the warrants at any time, subject to the price of the Group&#8217;s ordinary shares trading at least A$4.32 for 45 consecutive days on the ASX. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the exercise price for the warrants was adjusted from A$2.88 per share to A$2.86 per share with effect from January 5, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the warrants include certain anti-dilution clauses, which adjust the exercise price or conversion ratio in the event of a rights issue or bonus issue. Management analyzed these clauses and determined the fixed-for-fixed requirement was still satisfied because the relative rights of shareholders and warrant holders were maintained. Therefore the warrants were classified as equity. The warrants were initially measured in equity at fair value, which was determined using a Monte Carlo simulation (refer to Note 7(b)(iv) in the Form 20-F for the year ended June 30, 2023 for more details), with the residual consideration being attributed to the ordinary shares issued in the same transaction. The warrants are not remeasured for subsequent changes in fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554180032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementAbstract', window );"><strong>Disclosure Of Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial risk management</a></td>
<td class="text">Financial risk management<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note explains the Group&#8217;s exposure to financial risks and how these risks could affect the Group&#8217;s future financial performance. Current year profit and loss information has been included where relevant to add further context.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exposure arising from</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Measurement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Management</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; currency risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future commercial transactions </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow forecasting<br/>Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; interest rate risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term deposits at fixed rates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposits at variable rates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; price risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. </span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; share price risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future exercise of warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise. Therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, and trade and other receivables and other non-current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aging analysis<br/>Credit ratings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rolling cash flow forecasts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future cash flow requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group&#8217;s future commitments.</span></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Market risk</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Currency risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group has foreign currency amounts owing relating to clinical, regulatory and overhead activities and foreign currency deposits held primarily in the Group&#8217;s Australian based entity, whose functional currency is the A$. The Group also has foreign currency amounts owing </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Group&#8217;s Swiss and Singapore based entities, whose functional currencies are the US$.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Group also has foreign currency amounts owing in various other non-US$ currencies in A$ and US$ functional currency entities in the Group relating to clinical, regulatory and overhead activities. These foreign currency balances give rise to a currency risk, which is the risk of the exchange rate moving, in either direction, and the impact it may have on the Group&#8217;s financial performance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currency risk is minimized by ensuring the proportion of cash reserves held in each currency matches the expected rate of spend of each currency. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Group held 68% of its cash in US$, 31% in A$ and 1% in other currencies. As of June&#160;30, 2023, the Group held 67% of its cash in US$, and 33% in A$.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Cash flow and fair value interest rate risk </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is exposed to interest rate movements which impacts interest income earned on its deposits and at call accounts. The interest rate risk is managed by spreading the maturity date of our deposits across various periods. The Group ensures that sufficient funds are available, in at call accounts, to meet the working capital requirements of the Group.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of December&#160;31, 2023 and June&#160;30, 2023. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:36.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested - US$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increase by 10%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate decrease by 10%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Australian dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested - A$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increase by 10%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate decrease by 10%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A$ deposits held as of June 30, 2023  have been updated to reflect the increasing impact of higher interest rates.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Price risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price risk is the risk that future cash flows derived from financial instruments will be altered as a result of a market price movement, which is defined as movements other than foreign currency rates and interest rates. The Group is exposed to price risk which arises from long-term borrowings under its facility with NovaQuest, where the timing and amounts of principal and interest payments is dependent on net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia. As net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in these territories increase/decrease, the timing and amount of principal and interest payments relating to this type of financing arrangement will also fluctuate, resulting in an adjustment to the carrying amount of the financial liability. The adjustment is recognized in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exposure of the Group&#8217;s borrowing to price rate changes are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total<br/>borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total<br/>borrowings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">61,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">56,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2023, all other factors held constant, a +/- 20% increase/decrease in the forecast net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia would not have a significant impact on non-current borrowing and profit. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is also exposed to price risk on contingent consideration provision balances, as expected unit revenues are a significant unobservable input used in the level 3 fair value measurements. As at December&#160;31, 2023, all other factors held constant, the increase/decrease in price assumptions adopted in the fair value measurements of the contingent consideration provision are discussed in Note 5(e)(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">iv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group does not consider it has any exposure to price risk other than those already described above. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Share price risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group's exposure to share price risk arises from warrant liabilities held by the Group and classified in the statement of financial position at fair value through profit or loss. The future exercise of these warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise, therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the impact of the increase/decrease of Mesoblast's share price on the Group's profit or loss during the period, based on the assumption that the share price had increased/decreased by 10% and 10% with all other variables held constant as of December&#160;31, 2023 and June&#160;30, 2023 respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.696%"><tr><td style="width:1.0%"></td><td style="width:63.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact on profit or (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price increase by 10% (2023: 10%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price decrease by 10% (2023: 10%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Credit risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk that one party to a financial instrument will fail to discharge its obligation and cause financial loss to the other party. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets as mentioned in Note 5.</span></div><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Liquidity risk </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that the Group will not be able to pay its debts as and when they fall due. Liquidity risk has been assessed in Note 1(i). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial liabilities, excluding contingent consideration, borrowings and lease liabilities held by the Group as of December&#160;31, 2023 and June&#160;30, 2023 mature within 6 months. Trade payables and contingent consideration held by the Group as of December&#160;31, 2023 and June&#160;30, 2023 are non-interest bearing. The total contractual cash flows associated with trade payables equate to the carrying amount disclosed within the financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which therefore differs from the carrying value, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Within <br/>1 year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Between <br/>1-2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Between <br/>2-5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over <br/>5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>contractual <br/>cash flows</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying <br/>amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,739)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(171,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115,763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(28,630)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(144,455)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(195,085)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(133,372)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at December&#160;31, 2023 without taking into account drawdowns of further tranches.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD in the United States and other territories excluding Asia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. Product royalties will be payable in cash which will be funded from royalties received from net sales. With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Group commenced production under its manufacturing service agreement with Lonza for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of pediatric SR-aGVHD in the US market. This agreement contains lease and non-lease components. As of December&#160;31, 2023, the agreement contains a minimum remaining financial commitment of the non-lease component of $12.7 million, payable until June 2025, which is cancellable in limited circumstances. The Group has accounted for the lease component within the agreement as a lease liability separately from the non-lease components. As of December&#160;31, 2023, the lease component is $2.5 million on an undiscounted basis, as disclosed within the total contractual cash flows as lease liabilities in Note 9(c). At the Group's discretion, the minimum financial commitment under this manufacturing services agreement can be reduced by $7.4&#160;million under certain conditions, with $1.5&#160;million of this reduction relating to the lease component and $5.9&#160;million relating to the non-lease component of the agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group have agreements with third parties related to contract manufacturing and other goods and services. As of December&#160;31, 2023, the Group had $5.7 million of non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services (excluding those with Lonza). This amount represents our minimum contractual obligations, including termination fees. Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Group are contractually obligated to make certain payments, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation.</span></div>The Group did not have any other purchase commitments as of December&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556418000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Losses) per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">(Losses) per share</a></td>
<td class="text">(Losses) per share<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in cents)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total basic (losses) per share attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3.82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5.64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Diluted (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3.82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5.64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) (Losses) used in calculating (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) from continuing operations attributable to the ordinary equity holders of the company:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Used in calculating basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Shares)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Shares)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares used as the denominator in calculating basic losses per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851,464,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733,282,900</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851,464,145</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733,282,900</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and warrants are considered to be potential ordinary shares. These securities have been excluded from the determination of basic losses per share in the six months ended December&#160;31, 2023 and 2022. Shares that may be paid as contingent consideration have also been excluded from basic losses per share. They have been excluded from the calculation of diluted losses per share because they are anti-dilutive for the six months ended December&#160;31, 2023 and 2022.</span></div>The calculations for the six months ended December&#160;31, 2023 and 2022 have been adjusted to reflect the bonus element in the entitlement offer to existing eligible shareholders which occurred during December 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556184976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events occurring after the reporting period<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events occurring after the reporting period</a></td>
<td class="text">Events occurring after the reporting periodThere were no events that have occurred after December&#160;31, 2023 and prior to the signing of this financial report that would likely have a material impact on the financial results presented.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576443824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment information</a></td>
<td class="text">Segment information<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified on the basis of whether the allocation of resources and/or the assessment of performance of a particular component of the Company&#8217;s activities are regularly reviewed by the Company&#8217;s chief operating decision maker as a separate operating segment. By these criteria, the activities of the Company are considered to be one segment being the development of adult stem cell technology platform for commercialization, and the segmental analysis is the same as the analysis for the Company as a whole. The chief operating decision maker (Chief Executive Officer) reviews the consolidated income statement, balance sheet, and statement of cash flows regularly to make decisions about the Company&#8217;s resources and to assess overall performance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556406880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal proceedings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LegalProceedingsProvisionAbstract', window );"><strong>Legal proceedings provision [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock', window );">Legal proceedings</a></td>
<td class="text">Legal proceedings<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A class action proceeding in the Federal Court of Australia was served on the Company in May 2022 by the law firm William Roberts Lawyers on behalf of persons who, between February 22, 2018, and December 17, 2020, acquired an interest in Mesoblast shares, American Depository Receipts, and/or related equity swap arrangements. In June 2022, the firm Phi Finney McDonald commenced a second shareholder class action against the Company in the Federal Court of Australia asserting similar claims arising during the same period. Like the class action lawsuit from October 2020 filed in the U.S. Federal District Court for the Southern District of New York (which had court approval for settlement in August 2022), the Australian class actions relate to the Complete Response Letter released by the FDA in September 2020 in relation to the Company's GvHD product candidate; they also relate to certain representations made by the Company in relation to our COVID-19 product candidate and the decline in the market price of the Company's ordinary shares in December 2020. The Australian class actions have been consolidated into one lawsuit. The Company will continue to vigorously defend against the proceedings. The Company cannot provide any assurance as to the possible outcome or cost to us from the lawsuit, particularly as it is at an early stage, nor how long it may take to resolve such lawsuit. Thus, the Company has not accrued any amounts in connection with such legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LegalProceedingsProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LegalProceedingsProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfLegalProceedingsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of legal proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfLegalProceedingsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576237696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BasisOfPreparationAbstract', window );"><strong>Basis Of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock', window );">Description of accounting policy for basis of preparation explanatory</a></td>
<td class="text">Basis of preparation<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. The condensed consolidated financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Accounting Standard IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as issued by the International Accounting Standards Board (&#8220;IASB&#8221;), and are unaudited. These condensed interim financial statements do not include all of the notes and disclosures required by International Financial Reporting Standards, as issued by the IASB, for annual consolidated financial statements and should therefore be read in conjunction with our annual report on Form 20-F for the year ended June&#160;30, 2023. In the opinion of management, the interim financial data includes all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the results for the interim periods.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Going concern </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Group held total cash reserves of $77.6 million. During the six months ended December 31, 2023, the Group executed on reprioritization of projects and operational streamlining activities and as a result has reduced net cash usage for operating activities, which was $26.6 million the six months ended December&#160;31, 2023, a reduction of 14% compared to the prior period. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with the Group's overall commercial strategy to complete additional pivotal clinical studies for both the Group's chronic lower back pain and steroid-refractory acute graft versus host disease ("SR-aGVHD") product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) standards) on the Group&#8217;s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Historical cost convention</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income, financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;New and amended standards adopted by the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new or amended standards adopted by the Group in the six months ended December&#160;31, 2023. These interim financial statements follow the same accounting policies as compared to the June&#160;30, 2023 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;New accounting standards and interpretations not yet adopted by the Group</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting standards and interpretations not yet adopted by the Group for the December&#160;31, 2023 reporting period that are expected to materially impact the Group.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Use of estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Impact of after effects of COVID-19 and geopolitical instability</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group&#8217;s significant accounting estimates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with relevant collaborators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the effects of the COVID-19 pandemic and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group&#8217;s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of preparation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for basis of preparation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576633152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss before income tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxAbstract', window );"><strong>Disclosure Of Loss Before Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock', window );">Summary of Loss Before Income Tax</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical trial and research &amp; development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing production &amp; development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defined contribution superannuation expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity settled share-based payment transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Employee benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12,490)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,785)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation and amortization of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plant and equipment depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Depreciation and amortization of non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,443)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,190)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Management &amp; administration expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overheads &amp; administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consultancy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal and other professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses (excluding the amount amortized above)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other Management &amp; administration expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8,413)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,712)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Fair value remeasurement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(337)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,989</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Fair value remeasurement of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(712)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains/(losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other operating income and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,068</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(39)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance (costs)/gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of borrowing arrangements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Finance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10,319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10,685)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total loss before income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(32,641)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(41,496)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Share-based payment transactions</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended December&#160;31, 2023 and 2022, the share-based payment transactions have been reflected in the Consolidated Income Statement functional expense categories as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,104,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">797,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing and commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(183,720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management and administration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,143,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity settled share-based payment transactions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,195,436</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,756,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Change in comparative figures</span></div>For the six months ended December 31, 2022, the Group reclassified immaterial amounts within Other Management and administration expenses. The Group does not believe these reclassifications to be material to the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfLossBeforeIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of loss before income tax [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfLossBeforeIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of loss before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576197840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit/(expense) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Major components of tax expense (income) [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock', window );">Summary of Income Tax Expense/(Benefit)</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax (benefit)/expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current tax (benefit)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Increase)/decrease in deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Decrease)/increase in deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax (benefit)/expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(126)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax (benefit)/expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(126)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock', window );">Summary of Deferred Tax Assets Not Brought to Account</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets not brought to account</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unused tax losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other temporary differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential tax benefit at local tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">151,699</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">141,266</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred tax assets not brought to account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576137072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Summary of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group holds the following financial instruments:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial assets<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVTPL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets at <br/>amortized cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">83,793</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">84,619</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash &amp; cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade &amp; other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">80,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">82,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through other comprehensive income</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through profit or loss</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Financial liabilities<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FVTPL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities at <br/>amortized cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126,522</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">145,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">128,908</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">151,533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Fair value through other comprehensive income </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span>Fair value through profit or loss<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.&#160;&#160;&#160;&#160;Cash and cash equivalents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits at call</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">77,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">71,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">As of December&#160;31, 2023 and June&#160;30, 2023, interest-bearing deposits at call include amounts of $0.4 million and $0.4 million, respectively, held as security and restricted for use.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock', window );">Summary of Trade and Other Receivables and Prepayments</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.&#160;&#160;&#160;&#160;Trade and other receivables and prepayments</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Trade and other receivables</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade debtors</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax incentives recoverable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign withholding tax recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sublease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recoverable taxes (Goods and services tax and value-added tax)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,998</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,998</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1) Research and development tax incentive </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group's research and development activities are eligible under the Australian government's Innovation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Australia Research and Development Tax Incentive program for research and development activities conducted in relation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia. The tax incentives recoverable as of December 31, 2023 pertains to an estimate for the year ended June 30, 2023. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Prepayments</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial research and development expenditure</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid insurance and subscriptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,602</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,342</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Summary of Trade and Other Payables</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">c.&#160;&#160;&#160;&#160;Trade and other payables</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables and other payables</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade and other payables</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Summary of Borrowings</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">d.&#160;&#160;&#160;&#160;Borrowings </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Secured liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowing arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of carrying amount, net of payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">115,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">108,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - Oaktree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - Oaktree</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">107,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">102,811</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">115,762</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">108,763</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock', window );">Summary of Net Debt</a></td>
<td class="text"><div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Net Debt Reconciliation</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115,762)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108,763)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(50,603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross debt - fixed interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(121,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(116,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross debt - variable interest rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,437)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(50,603)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Net debt amount includes leases and borrowing arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock', window );">Summary of Net Debt Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities from financing activities </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other assets </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Borrowings </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Leases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant liability </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Sub-total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and cash<br/>equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Debt as at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108,763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,426)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(121,921)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Changes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Debt as at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(115,762)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6,237)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(992)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(122,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">77,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,437)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Other changes include modification of leases and accrued interest expenses for borrowings and leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of December&#160;31, 2023 and June&#160;30, 2023 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities - biotech sector</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">826</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities at fair value through profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets at fair value through other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities - biotech sector</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,757</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities at fair value through profit or loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(iii)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5(e)(vi)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,625</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock', window );">Summary of Changes in Fair Value of Level 3 Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in level 3 instruments for the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent<br/>consideration<br/>provision</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance - July 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to consolidated income statement:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing balance - June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance - July 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to consolidated income statement:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing balance - December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In the year ended June&#160;30, 2023 a gain of $8.8 million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, developmental timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines were updated to reflect expectations as a result of the complete response.  </span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In the six months ended December&#160;31, 2023 a minimal gain was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation such as development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock', window );">Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of inputs<br/>(weighted average)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value <br/>as of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value <br/>as of <br/>June 30, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation <br/>technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended <br/>June 30, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Relationship of <br/>unobservable inputs to <br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Discounted cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Risk adjusted discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11%-13%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12.5%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11%-13%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12.5%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the discount rate by 0.5% would increase/decrease the fair value by an insignificant amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.01%.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected unit sales price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected sales volumes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Probability of success and payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six months ended December 31,  2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 10.0% and 20.0%, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Year ended 30 June, 2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8% and 16%, respectively.</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">There were no significant inter-relationships between unobservable inputs that materially affect fair values.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock', window );">Disclosure of Detailed Information About Valuation Processes of Contingent Consideration at Fair Value Explanatory</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">The fair value of contingent consideration<br/>(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of royalty payments from commercialization of the intellectual property acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock', window );">Summary of Warrant Liability</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant liability</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants fair value at grant date - December 22, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing Balance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,426</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock', window );">Summary of Fair Value of Warrants</a></td>
<td class="text">The following assumptions were based on observable market conditions that existed at the issue date and as of December&#160;31, 2023.<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:23.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, except percent data and as otherwise noted) <br/>Assumption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of<br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Rationale</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Closing share price on valuation date from external market source</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.70 to $7.26</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.70 to $7.26</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per subscription agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 to 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 to 7 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per subscription agreement</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Company&#8217;s nil dividend history</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.71%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.26%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on historical volatility data for the Company</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Free Interest Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.01%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the closing U.S treasury issued 7 year bonds on valuation date</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value per warrant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.4000 to $0.6248</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3103 to $2.9401</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determined using Black-Scholes valuation model with the inputs above</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$992,233</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,426,212</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of 2,224,669 warrants of $992,233 and $5,426,212 as of December&#160;31, 2023 and June&#160;30, 2023, respectively.</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about net debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about net debt reconciliation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about valuation processes of contingent consideration at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of quantitative information about significant unobservable inputs used in fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and other receivables and prepayments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576159840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-financial assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Summary of Intangible Assets</a></td>
<td class="text">Intangible assets<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Acquired licenses<br/>to patents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">In-process<br/>research and<br/>development<br/>acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current marketed<br/>products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">578,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">577,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">489,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">651,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,618</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">577,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">427,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">577,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">576,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">489,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">651,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,919)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">134,453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,726</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">576,564</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock', window );">Summary of Carrying Value of In Process Research and Development Acquired by Product</a></td>
<td class="text">Carrying value of in-process research and development acquired by product<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous products for metabolic diseases and inflammatory/immunologic conditions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSC products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">427,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span>Includes remestemcel-L for the treatment of adults and children with SR-aGVHD and remestemcel-L for the treatment of Crohn&#8217;s disease<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Summary of Provisions</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for license agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,230</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17,073</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">25,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,399</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23,011</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The classification of contingent consideration as current represents the expected payments within the next 12 months based on current development timelines.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Summary of Deferred Tax Balances</a></td>
<td class="text">Deferred tax balances<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance comprises temporary differences attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance comprises temporary differences attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock', window );">Schedule of Movements Related to Deferred Tax Assets and Liabilities</a></td>
<td class="text">Movements <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Tax losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(DTA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">temporary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">differences</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(DTA)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intangible<br/>assets (DTL)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total (DTL) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(80,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- directly to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">212</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(76,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11,972)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,992</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charged/(credited) to:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- directly to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(74,684)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13,185)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Deferred tax assets are netted against deferred tax liabilities</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of carrying value of in process research and development acquired by product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of net movement related to deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non financial assets and liabilities,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110556155536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash flow information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Statement of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock', window );">Summary of Cash Flow Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)<br/>(a) Reconciliation of cash and cash equivalents</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, <br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, <br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash at bank</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deposits at call</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">77,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">71,318</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(b) Reconciliation of net cash flows used in operations with loss after income tax</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add/(deduct) net loss for non-cash items as follows:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange (gains)/losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,989)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remeasurement of warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity settled share-based payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in trade and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease/(increase) in tax incentive recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in trade creditors and accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in provisions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash outflows used in operations</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(26,572)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(30,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of summary of cash flow information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576571008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of Share Capital</a></td>
<td class="text">Share capital <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contributed equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Share capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,015,342,237</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">737,121,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,286,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,207,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Treasury Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(542,903)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(542,903)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Contributed Equity</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,014,799,334</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">736,578,315</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,286,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,207,714</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock', window );">Summary of Movements in Ordinary Share Capital</a></td>
<td class="text">Movements in ordinary share capital<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">814,204,825</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650,454,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,249,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,165,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issues of ordinary shares during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Placement of shares under a share placement agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201,137,412</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,666,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs arising on share issue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total contributions of equity during the period</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201,137,412</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,666,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,106</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,405</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share options reserve transferred to equity on exercise of options</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending balance</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,015,342,237</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">737,121,218</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,286,229</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,207,714</span></td></tr></table></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the six months ended December 31,  2023, 201,137,412 shares were issued in a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing shareholders in Australia and certain other countries together with an institutional placement of new fully paid ordinary shares in Mesoblast Limited, at A$0.30 per share.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the six months ended December 31, 2022, 86,666,667 shares were issued in an equity purchase of Mesoblast Limited at A$0.75 per share to existing and new institutional investors.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock', window );">Summary of Movements of Shares in Share Trust</a></td>
<td class="text">Movements of shares in share trust <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br/>December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares No. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(U.S. dollars, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Movement of shares in share trust</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">542,903</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. From July 1, 2020, unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. Prior to July 1, 2020, the shares issued and share capital received on the exercise of options were recorded in ordinary share capital.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock', window );">Summary of Warrant Reserve</a></td>
<td class="text">Warrant reserve<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant reserve</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opening balance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Movement during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Closing Balance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of movements in ordinary share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements of shares in share trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of warrant reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554791424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementAbstract', window );"><strong>Disclosure Of Financial Risk Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfExposureToFinancialRisksTableTextBlock', window );">Schedule of Exposure to Financial Risks</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This note explains the Group&#8217;s exposure to financial risks and how these risks could affect the Group&#8217;s future financial performance. Current year profit and loss information has been included where relevant to add further context.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exposure arising from</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Measurement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Management</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; currency risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future commercial transactions </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow forecasting<br/>Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; interest rate risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Term deposits at fixed rates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposits at variable rates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; price risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. </span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk &#8211; share price risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sensitivity analysis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future exercise of warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise. Therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. </span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, and trade and other receivables and other non-current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aging analysis<br/>Credit ratings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rolling cash flow forecasts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future cash flow requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group&#8217;s future commitments.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock', window );">Schedule of Deposits Held which Derive Interest Revenue with Maximum and Minimum Interest Rates Being Earned</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of December&#160;31, 2023 and June&#160;30, 2023. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"><tr><td style="width:1.0%"></td><td style="width:36.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested - US$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increase by 10%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate decrease by 10%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in Australian dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Low </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">High </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">A$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested - A$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,707&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate increase by 10%</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rate decrease by 10%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A$ deposits held as of June 30, 2023  have been updated to reflect the increasing impact of higher interest rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock', window );">Summary of Borrowing to Price Rate Changes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exposure of the Group&#8217;s borrowing to price rate changes are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands, except percent data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total<br/>borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% of total<br/>borrowings</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings - NovaQuest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">61,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">53</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">56,075</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">51</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock', window );">Schedule of Increase/Decrease of Share Price</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the impact of the increase/decrease of Mesoblast's share price on the Group's profit or loss during the period, based on the assumption that the share price had increased/decreased by 10% and 10% with all other variables held constant as of December&#160;31, 2023 and June&#160;30, 2023 respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.696%"><tr><td style="width:1.0%"></td><td style="width:63.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of <br/>June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact on profit or (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price increase by 10% (2023: 10%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share price decrease by 10% (2023: 10%)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities', window );">Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which therefore differs from the carrying value, is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Within <br/>1 year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Between <br/>1-2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Between <br/>2-5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Over <br/>5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total <br/>contractual <br/>cash flows</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying <br/>amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,739)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(143,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(171,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115,763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(28,630)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22,000)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(144,455)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(195,085)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(133,372)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at December&#160;31, 2023 without taking into account drawdowns of further tranches.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD in the United States and other territories excluding Asia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. Product royalties will be payable in cash which will be funded from royalties received from net sales. With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings deriving price risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deposits held which derive interest revenue with maximum and minimum interest rates being earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfExposureToFinancialRisksTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of exposure to financial risks</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfExposureToFinancialRisksTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of sensitivity analysis effect of increase (decrease) in share price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554670240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Losses) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of (Losses) Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cents</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in cents)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total basic (losses) per share attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3.82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5.64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Diluted (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations attributable to the ordinary equity holders of the company</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3.82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5.64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c) (Losses) used in calculating (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in U.S. dollars, in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From continuing operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) from continuing operations attributable to the ordinary equity holders of the company:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Used in calculating basic (losses) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,539)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Shares)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Shares)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares used as the denominator in calculating basic losses per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851,464,145</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733,282,900</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">851,464,145</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">733,282,900</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576148528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BasisOfPreparationAbstract', window );"><strong>Basis Of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash &amp; cash equivalents</a></td>
<td class="nump">$ 77,554<span></span>
</td>
<td class="nump">$ 71,318<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
<td class="nump">$ 60,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MaximumAmountInCashOutflowsFromOperatingActivities', window );">Maximum amount paid in cash outflows from operating activities</a></td>
<td class="nump">$ 26,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities', window );">Percentage of reduction in cash outflows from operating activities</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of preparation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MaximumAmountInCashOutflowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount in cash outflows from operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MaximumAmountInCashOutflowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfReductionInCashOutflowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in cash outflows from operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfReductionInCashOutflowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554801920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant changes in the current reporting period (Details)<br> $ / shares in Units, $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>AUD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems', window );"><strong>Disclosure Of Significant Changes In Current Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ProceedsFromPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="nump">$ 39.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems', window );"><strong>Disclosure Of Significant Changes In Current Reporting Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ConversionRatioOfWarrants', window );">Conversion ratio of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfSharesIssuedAndFullyPaidValue', window );">Number of shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ConversionRatioOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion ratio of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ConversionRatioOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant changes in current reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfSharesIssuedAndFullyPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued And Fully Paid, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfSharesIssuedAndFullyPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ProceedsFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ProceedsFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554142064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss before income tax - Summary of Loss Before Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CommercializationRevenue', window );">Commercialization revenue</a></td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="nump">$ 3,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ClinicalTrialRelatedResearchAndDevelopment', window );">Clinical trial and research &amp; development</a></td>
<td class="num">(2,045)<span></span>
</td>
<td class="num">(4,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ManufacturingProductionAndDevelopment', window );">Manufacturing production &amp; development</a></td>
<td class="num">(5,484)<span></span>
</td>
<td class="num">(11,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract', window );"><strong>Employee benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries and employee benefits</a></td>
<td class="num">(10,096)<span></span>
</td>
<td class="num">(9,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DefinedContributionSuperannuationExpenses', window );">Defined contribution superannuation expenses</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Equity settled share-based payment transactions</a></td>
<td class="num">(2,195)<span></span>
</td>
<td class="num">(1,757)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total Employee benefits</a></td>
<td class="num">(12,490)<span></span>
</td>
<td class="num">(11,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract', window );"><strong>Depreciation and amortization of non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Plant and equipment depreciation</a></td>
<td class="num">(281)<span></span>
</td>
<td class="num">(565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Right of use asset depreciation</a></td>
<td class="num">(1,420)<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IntellectualPropertyAmortization', window );">Intellectual property amortization</a></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Total Depreciation and amortization of non-current assets</a></td>
<td class="num">(2,443)<span></span>
</td>
<td class="num">(2,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherManagementAndAdministrationExpensesAbstract', window );"><strong>Other Management &amp; administration expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OverheadsAndAdministrationExpenses', window );">Overheads &amp; administration</a></td>
<td class="num">(4,594)<span></span>
</td>
<td class="num">(5,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ConsultancyExpenses', window );">Consultancy</a></td>
<td class="num">(1,285)<span></span>
</td>
<td class="num">(1,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LegalAndOtherProfessionalFees', window );">Legal and other professional fees</a></td>
<td class="num">(1,124)<span></span>
</td>
<td class="num">(1,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IntellectualPropertyExpenses', window );">Intellectual property expenses (excluding the amount amortized above)</a></td>
<td class="num">(1,410)<span></span>
</td>
<td class="num">(1,505)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherManagementAndAdministrationExpenses', window );">Total Other Management &amp; administration expenses</a></td>
<td class="num">(8,413)<span></span>
</td>
<td class="num">(9,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfContingentConsiderationAbstract', window );"><strong>Fair value remeasurement of contingent consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LossGainOnRemeasurementOfContingentConsideration', window );">Remeasurement of contingent consideration</a></td>
<td class="num">(337)<span></span>
</td>
<td class="nump">5,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfContingentConsideration', window );">Total Fair value remeasurement of contingent consideration</a></td>
<td class="num">(337)<span></span>
</td>
<td class="nump">5,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfWarrantLiabilityAbstract', window );"><strong>Fair value remeasurement of warrant liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LossGainOnRemeasurementOfWarrantLiability', window );">Remeasurement of warrant liability</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="num">(712)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfWarrantLiability', window );">Total Fair value remeasurement of warrant liability</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="num">(712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherOperatingIncomeAndExpensesAbstract', window );"><strong>Other operating income and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest revenue</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ForeignExchangeGainsLosses', window );">Foreign exchange gains/(losses)</a></td>
<td class="nump">165<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Total Other operating income and expenses</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FinanceCostsGainsAbstract', window );"><strong>Finance (costs)/gains</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements', window );">Remeasurement of borrowing arrangements</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(10,199)<span></span>
</td>
<td class="num">(9,455)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total Finance costs</a></td>
<td class="num">(10,319)<span></span>
</td>
<td class="num">(10,685)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">$ (32,641)<span></span>
</td>
<td class="num">$ (41,496)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ClinicalTrialRelatedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to clinical trial related research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ClinicalTrialRelatedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CommercializationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercialization revenue generally includes non-refundable up-front license and collaboration fees, royalties on product sales of licensed products, if and when such product sales occur and revenue from the supply of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CommercializationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ConsultancyExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to consultancy expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ConsultancyExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DefinedContributionSuperannuationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution superannuation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DefinedContributionSuperannuationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Amortization of Non-current Assets Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfContingentConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of contingent consideration abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfContingentConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FinanceCostsGainsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance (costs) gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FinanceCostsGainsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance (costs) gains on remeasurement of borrowing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ForeignExchangeGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange gains/(losses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ForeignExchangeGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IntellectualPropertyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual property amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IntellectualPropertyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IntellectualPropertyExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to intellectual property expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IntellectualPropertyExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_LegalAndOtherProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to Legal, patent and other professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_LegalAndOtherProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_LossGainOnRemeasurementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss (gain) on remeasurement of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_LossGainOnRemeasurementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_LossGainOnRemeasurementOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss&#8203; gain&#8203; on remeasurement&#8203; of warrant &#8203;liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_LossGainOnRemeasurementOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ManufacturingProductionAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to manufacturing production and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ManufacturingProductionAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherManagementAndAdministrationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other management &amp; administration expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherManagementAndAdministrationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherManagementAndAdministrationExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other management and administration expenses abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherManagementAndAdministrationExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherOperatingIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Operating Income And Expenses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherOperatingIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OverheadsAndAdministrationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to overheads and administration expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OverheadsAndAdministrationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575763936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss before income tax - Summary of Loss Before Income Tax (Parenthetical) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItem', window );"><strong>Disclosure Of Loss Before Income Tax Line Item</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Equity settled share-based payment transactions</a></td>
<td class="nump">$ 2,195,000<span></span>
</td>
<td class="nump">$ 1,757,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncomeStatementLocationsAxis=meso_IncomeStatementFunctionalExpenseCategoriesMember', window );">Income Statement Functional Expense Categories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItem', window );"><strong>Disclosure Of Loss Before Income Tax Line Item</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Equity settled share-based payment transactions</a></td>
<td class="nump">2,195,436<span></span>
</td>
<td class="nump">1,756,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncomeStatementLocationsAxis=meso_IncomeStatementFunctionalExpenseCategoriesMember', window );">Income Statement Functional Expense Categories | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItem', window );"><strong>Disclosure Of Loss Before Income Tax Line Item</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Equity settled share-based payment transactions</a></td>
<td class="nump">1,104,007<span></span>
</td>
<td class="nump">797,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncomeStatementLocationsAxis=meso_IncomeStatementFunctionalExpenseCategoriesMember', window );">Income Statement Functional Expense Categories | Manufacturing and commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItem', window );"><strong>Disclosure Of Loss Before Income Tax Line Item</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Equity settled share-based payment transactions</a></td>
<td class="nump">48,064<span></span>
</td>
<td class="num">(183,720)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncomeStatementLocationsAxis=meso_IncomeStatementFunctionalExpenseCategoriesMember', window );">Income Statement Functional Expense Categories | Management and administration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItem', window );"><strong>Disclosure Of Loss Before Income Tax Line Item</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions', window );">Equity settled share-based payment transactions</a></td>
<td class="nump">$ 1,043,365<span></span>
</td>
<td class="nump">$ 1,143,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfLossBeforeIncomeTaxLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Loss Before Income Tax Line Item.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfLossBeforeIncomeTaxLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncomeStatementLocationsAxis=meso_IncomeStatementFunctionalExpenseCategoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncomeStatementLocationsAxis=meso_IncomeStatementFunctionalExpenseCategoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=meso_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=meso_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=meso_ManufacturingAndCommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=meso_ManufacturingAndCommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=meso_ManagementAndAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=meso_ManagementAndAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110552749008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss before income tax - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration', window );">Revenue recognized from up-front payment as deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone', window );">Receipt on non refundable up-front payment upon reaching product regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfEscalatingMilestonePayments', window );">Escalating milestone payments | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PreLaunchInventoryRecognized', window );">Pre-launch inventory recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=meso_ManufacturingCommercializationExpensesMember', window );">Manufacturing Commercialization Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PreLaunchInventoryRecognized', window );">Pre-launch inventory recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_GrunenthalGmbHMember', window );">Grunenthal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NonRefundableUpFrontPaymentReceived', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MilestonePaymentReceived', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines', window );">Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payments receivable</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CumulativeMilestonePaymentsReachableAmount', window );">Cumulative milestone payments reachable amount</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RevenueRecognizedForRightOfUseLicenseOfIP', window );">Revenue recognized for right of use license of IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_GrunenthalGmbHMember', window );">Grunenthal | Top of Range | Clinical, Manufacturing, Regulatory and Reimbursement Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved', window );">Amount entitled to be received upon reaching product clinical and regulatory milestones and reimbursement targets are achieved</a></td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_TaslyMember', window );">Tasly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredConsiderationMilestoneConsiderationRecognized', window );">Deferred consideration milestone consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration', window );">Revenue recognized from up-front payment as deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_TaslyMember', window );">Tasly | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration', window );">Revenue recognized from up-front payment as deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember', window );">TiGenix NV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember', window );">TiGenix NV | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Current contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Non-current contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">&#8364; 5.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">&#8364; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember', window );">TiGenix NV | Top of Range | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Revenue, remaining performance obligation, variable consideration amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_JCRPharmaceuticalsCoLTDMember', window );">JCR Pharmaceuticals Co. Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems', window );"><strong>Disclosure Of Loss Before Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RoyaltiesReceivableUnderSalesBasedMilestones', window );">Royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Entitled to be received on non refundable up-front payment upon reaching product regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Entitled To Be Received Upon Reaching Product Clinical And Regulatory Milestones And Reimbursement Targets Are Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CumulativeMilestonePaymentsReachableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative milestone payments reachable amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CumulativeMilestonePaymentsReachableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredConsiderationMilestoneConsiderationRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred consideration milestone consideration recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredConsiderationMilestoneConsiderationRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfLossBeforeIncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Loss Before Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfLossBeforeIncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NonRefundableUpFrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable up front payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NonRefundableUpFrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NonRefundableUpfrontPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NonRefundableUpfrontPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfEscalatingMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Escalating Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfEscalatingMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PreLaunchInventoryRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre launch inventory recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PreLaunchInventoryRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RevenueRecognizedForRightOfUseLicenseOfIP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized for right of use license of IP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RevenueRecognizedForRightOfUseLicenseOfIP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized from up-front payment as deferred consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, remaining performance obligation, variable consideration amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RoyaltiesReceivableUnderSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties receivable under salesbased milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RoyaltiesReceivableUnderSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=meso_ManufacturingCommercializationExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=meso_ManufacturingCommercializationExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_GrunenthalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_GrunenthalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RegulatoryEnvironmentsAxis=meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RegulatoryEnvironmentsAxis=meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_TaslyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_TaslyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=meso_License1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=meso_License1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_TiGenixNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_JCRPharmaceuticalsCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_JCRPharmaceuticalsCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576150528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CurrentTaxAbstract', window );"><strong>Current tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseInCurrentTax', window );">Current tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Total current tax (benefit)/expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract', window );"><strong>Deferred tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseInDeferredTaxAssets', window );">(Increase)/decrease in deferred tax assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseInDeferredTaxLiabilities', window );">(Decrease)/increase in deferred tax liabilities</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Total deferred tax (benefit)/expense</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax (benefit)/expense</a></td>
<td class="num">$ (102)<span></span>
</td>
<td class="num">$ (126)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CurrentTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CurrentTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseInCurrentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in current tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseInCurrentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575733568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract', window );"><strong>Unused tax losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Potential tax benefit at local tax rates</a></td>
<td class="nump">$ 134,682<span></span>
</td>
<td class="nump">$ 125,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract', window );"><strong>Other temporary differences</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures', window );">Potential tax benefit at local tax rates</a></td>
<td class="nump">13,797<span></span>
</td>
<td class="nump">12,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract', window );"><strong>Other tax credits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Potential tax benefit at local tax rates</a></td>
<td class="nump">3,220<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsNotBroughtToAccount', window );">Deferred tax assets not brought to account</a></td>
<td class="nump">$ 151,699<span></span>
</td>
<td class="nump">$ 141,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsNotBroughtToAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets not brought to account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsNotBroughtToAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets not brought to account for other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets not brought to account for other temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets not brought to account for unused tax losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other tax credits for which no deferred Tax Asset Recognised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576036048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash &amp; cash equivalents</a></td>
<td class="nump">$ 77,554<span></span>
</td>
<td class="nump">$ 71,318<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
<td class="nump">$ 60,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade &amp; other receivables</a></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">6,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Financial assets at fair value through other comprehensive income</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Total</a></td>
<td class="nump">84,619<span></span>
</td>
<td class="nump">82,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">10,760<span></span>
</td>
<td class="nump">20,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">115,762<span></span>
</td>
<td class="nump">108,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent consideration</a></td>
<td class="nump">17,536<span></span>
</td>
<td class="nump">17,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Total</a></td>
<td class="nump">145,050<span></span>
</td>
<td class="nump">151,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Liabilities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">10,760<span></span>
</td>
<td class="nump">20,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">115,762<span></span>
</td>
<td class="nump">108,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Total</a></td>
<td class="nump">126,522<span></span>
</td>
<td class="nump">128,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Liabilities at FVTPL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent consideration</a></td>
<td class="nump">17,536<span></span>
</td>
<td class="nump">17,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities, Total</a></td>
<td class="nump">18,528<span></span>
</td>
<td class="nump">22,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Assets at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash &amp; cash equivalents</a></td>
<td class="nump">77,554<span></span>
</td>
<td class="nump">71,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade &amp; other receivables</a></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">6,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Total</a></td>
<td class="nump">83,793<span></span>
</td>
<td class="nump">80,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Assets at FVOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome', window );">Financial assets at fair value through other comprehensive income</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets, Total</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContingentConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContingentConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576699856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Cash at bank</a></td>
<td class="nump">$ 77,144<span></span>
</td>
<td class="nump">$ 70,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DepositsAtCall', window );">Deposits at call</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,554<span></span>
</td>
<td class="nump">$ 71,318<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
<td class="nump">$ 60,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DepositsAtCall">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits at call.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DepositsAtCall</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576557424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_InterestBearingDepositsAtCallHeldAsSecurity', window );">Interest-bearing deposits at call held as security</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_InterestBearingDepositsAtCallHeldAsSecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest bearing deposits at call held as security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_InterestBearingDepositsAtCallHeldAsSecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575955424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Trade and Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade debtors</a></td>
<td class="nump">$ 1,804<span></span>
</td>
<td class="nump">$ 2,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable', window );">Tax incentives recoverable</a></td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ForeignWithholdingTaxRecoverable', window );">Foreign withholding tax recoverable</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ReceivableFromTaxCredits', window );">U.S. Tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetInvestmentInFinanceLease', window );">Net investment in sublease</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInterestReceivable', window );">Interest receivables</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax', window );">Other recoverable taxes (Goods and services tax and value-added tax)</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">$ 3,998<span></span>
</td>
<td class="nump">$ 6,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest receivable. [Refer: Interest receivable]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetInvestmentInFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross investment in the finance lease discounted at the interest rate implicit in the lease. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset. Gross investment in the finance lease is the sum of: (a) the lease payments receivable by a lessor under a finance lease; and (b) any unguaranteed residual value accruing to the lessor. Interest rate implicit in the lease is the rate of interest that causes the present value of (a) the lease payments and (b) the unguaranteed residual value to equal to the sum of (i) the fair value of the underlying asset and (ii) the initial direct costs of the lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 94<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_94&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetInvestmentInFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ForeignWithholdingTaxRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign withholding tax recoverable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ForeignWithholdingTaxRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ReceivableFromTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable from tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ReceivableFromTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive Credit Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575742096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Prepayments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ClinicalTrialResearchAndDevelopmentExpenditure', window );">Clinical trial research and development expenditure</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PrepaidInsuranceAndSubscriptions', window );">Prepaid insurance and subscriptions</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherPrepayments', window );">Other</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">$ 3,602<span></span>
</td>
<td class="nump">$ 3,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ClinicalTrialResearchAndDevelopmentExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for clinical trial research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ClinicalTrialResearchAndDevelopmentExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PrepaidInsuranceAndSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid insurance and subscriptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PrepaidInsuranceAndSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110548889280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2024</div></th>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,762,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,763,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IssuanceWarrantsExercisedPeriod', window );">Issuance warrants exercised period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,399,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,533,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantsFairValueAtIssueDate', window );">Warrants fair value at issue date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_GainLossOnRemeasurementOfWarrantLiability', window );">Gain (loss) on remeasurement of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,400,000)<span></span>
</td>
<td class="num">$ (700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Unlisted Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfAssetsMeasuredAtFairValue', window );">Percentage of assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Gross debt - fixed interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,495,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=meso_AmericanDepositarySharesMember', window );">American Depositary Shares | Potential Ordinary Share Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OutstandingCommonShareCapitalPercentage', window );">Outstanding common share capital, percentage</a></td>
<td class="nump">1000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=meso_AmericanDepositoryReceiptMember', window );">American Depository Receipt | Potential Ordinary Share Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OutstandingCommonShareCapitalPercentage', window );">Outstanding common share capital, percentage</a></td>
<td class="nump">500.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsPrincipalAmount', window );">Borrowings principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsTerm', window );">Borrowings term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsInterestOnlyPeriod', window );">Borrowings, Interest Only Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear', window );">Percentage of principal amount payable over two year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsPrincipalAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_UnpaidInterestPortionPerAnnum', window );">Unpaid Interest Portion Per Annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfPremiumForVolumeWeightedAveragePrice', window );">Percentage of premium for volume-weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IssuanceWarrantsExercisedPeriod', window );">Issuance warrants exercised period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements', window );">Remeasurement of borrowing arrangements within finance gains (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued', window );">Finance costs loss on remeasurement due to additional warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability', window );">Finance costs loss on adjustment of carrying amount on financial liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | Refinancing and Expansion of Senior Debt Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfSharePremiumPrice', window );">Percentage of share premium price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantExerciseTerm', window );">Warrant exercise term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | American Depositary Shares | Potential Ordinary Share Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share)</a></td>
<td class="nump">$ 14.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | American Depositary Shares | Refinancing and Expansion of Senior Debt Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares', window );">Number of warrants granted to purchase american depositary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="nump">1,769,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | Warrants | Refinancing and Expansion of Senior Debt Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares', window );">Number of warrants granted to purchase american depositary shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | November 2021 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares', window );">Number of warrants issued to purchase american depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | November 2021 warrants | Potential Ordinary Share Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares', window );">Number of warrants issued to purchase american depositary shares</a></td>
<td class="nump">884,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | December 2022 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares', window );">Number of warrants issued to purchase american depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | December 2022 warrants | Potential Ordinary Share Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares', window );">Number of warrants issued to purchase american depositary shares</a></td>
<td class="nump">227,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | December 2022 warrants | American Depositary Shares | Potential Ordinary Share Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share)</a></td>
<td class="nump">$ 7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree | Quarterly Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements', window );">Remeasurement of borrowing arrangements within finance gains (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold', window );">Percentage of entity's revenue, annual payment cap threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest | Gross debt - fixed interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsPrincipalAmount', window );">Borrowings principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsTerm', window );">Borrowings term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_BorrowingsInterestOnlyPeriod', window );">Borrowings, Interest Only Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest | Contingent Consideration Provision | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfLiabilitiesMeasuredAtFairValue', window );">Percentage of liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest | Tranche One | Gross debt - fixed interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest | Tranche Two | Gross debt - fixed interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementMember', window );">Oaktree Capital Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MinimumUnrestrictedCashBalance', window );">Minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TradeReceivablesSettlementPeriod', window );">Trade receivables settlement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BorrowingsInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BorrowingsInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BorrowingsPrincipalAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Principal Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BorrowingsPrincipalAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BorrowingsPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BorrowingsPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_BorrowingsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_BorrowingsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Costs Gains (Loss) On Adjustment Of Carrying Amount On Financial Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Costs Gains (Loss) On Remeasurement Due To Additional Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance costs gains (loss) on remeasurement of borrowing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_GainLossOnRemeasurementOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on remeasurement of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_GainLossOnRemeasurementOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IssuanceWarrantsExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance warrants exercised period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IssuanceWarrantsExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum unrestricted cash balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants granted to purchase American Depositary Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Issued To Purchase American Depositary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OutstandingCommonShareCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Outstanding Common Share Capital, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OutstandingCommonShareCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfAssetsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of assets measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfAssetsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of borrowing principal amount payable over two year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Entity's Revenue, Annual Payment Cap Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfLiabilitiesMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of liabilities measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfLiabilitiesMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfPremiumForVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium for volume-weighted average price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfPremiumForVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfSharePremiumPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share premium price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfSharePremiumPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_TradeReceivablesSettlementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade receivables settlement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_TradeReceivablesSettlementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_UnpaidInterestPortionPerAnnum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid interest portion per annum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_UnpaidInterestPortionPerAnnum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_WarrantExerciseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_WarrantExerciseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_WarrantsFairValueAtIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants fair value at issue date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_WarrantsFairValueAtIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=meso_UnlistedEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=meso_UnlistedEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=meso_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=meso_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=meso_AmericanDepositoryReceiptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=meso_AmericanDepositoryReceiptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=meso_RefinancingAndExpansionOfSeniorDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=meso_RefinancingAndExpansionOfSeniorDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=meso_November2021WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=meso_November2021WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=meso_December2022WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=meso_December2022WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MethodsOfGenerationAxis=meso_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MethodsOfGenerationAxis=meso_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MethodsOfGenerationAxis=meso_QuarterlyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MethodsOfGenerationAxis=meso_QuarterlyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=meso_ContingentConsiderationProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=meso_ContingentConsiderationProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MethodsOfGenerationAxis=meso_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MethodsOfGenerationAxis=meso_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576606176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Trade and Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payables and other payables</a></td>
<td class="nump">$ 10,760<span></span>
</td>
<td class="nump">$ 20,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">$ 10,760<span></span>
</td>
<td class="nump">$ 20,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110552610992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Borrowings (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SecuredBankLoansReceived', window );">Borrowing arrangements</a></td>
<td class="nump">$ 81,919<span></span>
</td>
<td class="nump">$ 81,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsRecognisedAsExpense', window );">Less: transaction costs</a></td>
<td class="num">(9,215)<span></span>
</td>
<td class="num">(8,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Amortization of carrying amount, net of payments made</a></td>
<td class="nump">43,058<span></span>
</td>
<td class="nump">35,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Principal amount of loans</a></td>
<td class="nump">115,762<span></span>
</td>
<td class="nump">108,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LongTermBorrowingsAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Current</a></td>
<td class="nump">8,534<span></span>
</td>
<td class="nump">5,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Non-current</a></td>
<td class="nump">107,228<span></span>
</td>
<td class="nump">102,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total borrowings</a></td>
<td class="nump">115,762<span></span>
</td>
<td class="nump">108,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember', window );">Borrowings - NovaQuest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LongTermBorrowingsAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Current</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Non-current</a></td>
<td class="nump">60,878<span></span>
</td>
<td class="nump">55,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember', window );">Borrowings - Oaktree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Principal amount of loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LongTermBorrowingsAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Current</a></td>
<td class="nump">8,167<span></span>
</td>
<td class="nump">5,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Non-current</a></td>
<td class="nump">$ 46,350<span></span>
</td>
<td class="nump">$ 47,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2023-01-01<br> -Paragraph 26<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsRecognisedAsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are recognised as an expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsRecognisedAsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SecuredBankLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received from banks that have been secured by collateral. [Refer: Loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SecuredBankLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_LongTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_LongTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_NovaQuestCapitalManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_OaktreeCapitalManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554394272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Net Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,554<span></span>
</td>
<td class="nump">$ 71,318<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
<td class="nump">$ 60,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="num">(115,762)<span></span>
</td>
<td class="num">(108,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(6,237)<span></span>
</td>
<td class="num">(7,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="num">(992)<span></span>
</td>
<td class="num">(5,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net Debt</a></td>
<td class="num">(45,437)<span></span>
</td>
<td class="num">(50,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Gross debt - fixed interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="num">(121,999)<span></span>
</td>
<td class="num">(116,495)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember', window );">Gross debt - variable interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems', window );"><strong>Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FloatingInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554093232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Net Debt Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at beginning of period</a></td>
<td class="num">$ (108,763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Leases at beginning of period</a></td>
<td class="num">(7,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability at beginning of period</a></td>
<td class="num">(5,426)<span></span>
</td>
<td class="num">$ (2,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Sub-total at beginning of period</a></td>
<td class="num">(121,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">71,318<span></span>
</td>
<td class="nump">60,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt total at beginning of period</a></td>
<td class="num">(50,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CashFlowsAdjustmentsOnDebt', window );">Cash Flows, Borrowings</a></td>
<td class="nump">3,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Cash Flows, Leases</a></td>
<td class="nump">2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities', window );">Cash Flows, Warrants liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Cash Flows, Sub-total</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Cash Flows, Cash and cash equivalents</a></td>
<td class="nump">4,940<span></span>
</td>
<td class="nump">7,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities', window );">Cash Flows, Total</a></td>
<td class="nump">10,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RemeasurementAdjustmentsOnDebt', window );">Remeasurement adjustments, Borrowings</a></td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RemeasurementAdjustmentsOnWarrants', window );">Remeasurement adjustments, Warrant liability</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RemeasurementAdjustmentsOnDebtAndWarrants', window );">Remeasurement adjustments</a></td>
<td class="nump">4,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities', window );">Other Changes, Borrowings</a></td>
<td class="num">(10,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities', window );">Other Changes, Leases</a></td>
<td class="num">(782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherChangesOnDebtAndLeases', window );">Other Changes</a></td>
<td class="num">(10,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases', window );">Foreign exchange adjustments, Leases</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants', window );">Foreign exchange adjustments, Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Foreign exchange adjustments, Sub-total</a></td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Foreign exchange adjustments, cash and cash equivalents</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents', window );">Foreign exchange adjustments, Total</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings at end of period</a></td>
<td class="num">(115,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Leases at end of period</a></td>
<td class="num">(6,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability at end of period</a></td>
<td class="num">(992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Sub-total at end of period</a></td>
<td class="num">(122,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">77,554<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt total at end of period</a></td>
<td class="num">$ (45,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CashFlowsAdjustmentsOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flows adjustments on debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CashFlowsAdjustmentsOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of foreign exchange adjustments on liabilities arising from financing activities and cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in borrowing liabilities classified as financing activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease)in lease liabilities arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in warrant liabilities arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through effect of changes in foreign exchange rates liabilities arising from warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherChangesOnDebtAndLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other changes on debt and leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherChangesOnDebtAndLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RemeasurementAdjustmentsOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement adjustments on debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RemeasurementAdjustmentsOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RemeasurementAdjustmentsOnDebtAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement adjustments on debt and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RemeasurementAdjustmentsOnDebtAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RemeasurementAdjustmentsOnWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement adjustments on warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RemeasurementAdjustmentsOnWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554230688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract', window );"><strong>Financial liabilities at fair value through profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent consideration</a></td>
<td class="nump">17,536<span></span>
</td>
<td class="nump">17,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
<td class="nump">$ 2,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total Financial Liabilities</a></td>
<td class="nump">18,528<span></span>
</td>
<td class="nump">22,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract', window );"><strong>Financial liabilities at fair value through profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total Financial Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract', window );"><strong>Financial liabilities at fair value through profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total Financial Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract', window );"><strong>Financial liabilities at fair value through profit or loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent consideration</a></td>
<td class="nump">17,536<span></span>
</td>
<td class="nump">17,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">992<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Total Financial Liabilities</a></td>
<td class="nump">18,528<span></span>
</td>
<td class="nump">22,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherEquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherEquitySecuritiesMember', window );">Equity Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherEquitySecuritiesMember', window );">Equity Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherEquitySecuritiesMember', window );">Equity Securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract', window );"><strong>Financial assets at fair value through other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Total Financial Assets</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContingentConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContingentConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575894800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LossGainOnRemeasurementOfContingentConsideration', window );">Remeasurement</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="num">$ (5,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderationProvision', window );">Opening balance</a></td>
<td class="nump">17,199<span></span>
</td>
<td class="nump">$ 23,284<span></span>
</td>
<td class="nump">$ 23,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderationProvisionAmountUsed', window );">Reclassification during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_LossGainOnRemeasurementOfContingentConsideration', window );">Remeasurement</a></td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderationProvision', window );">Closing balance</a></td>
<td class="nump">$ 17,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContingentConsiderationProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContingentConsiderationProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContingentConsiderationProvisionAmountUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration provision amount used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContingentConsiderationProvisionAmountUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_LossGainOnRemeasurementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss (gain) on remeasurement of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_LossGainOnRemeasurementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576142720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Parenthetical) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_GainLossOnReMeasurementOfContingentConsiderationProvision', window );">Gain on re-measurement of contingent consideration provision</a></td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_GainLossOnReMeasurementOfContingentConsiderationProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on re-measurement of contingent consideration provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_GainLossOnReMeasurementOfContingentConsiderationProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110547184832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details) - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderationProvision', window );">Contingent consideration provision</a></td>
<td class="nump">$ 17,536<span></span>
</td>
<td class="nump">$ 17,199<span></span>
</td>
<td class="nump">$ 23,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities', window );">Unobservable inputs</a></td>
<td class="text">Expected unit sales price<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Expected unit sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in unobservable input, liabilities</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Probability of Success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities', window );">Unobservable inputs</a></td>
<td class="text">Probability of success and payment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Probability of Success | Probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in unobservable input, liabilities</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities</a></td>
<td class="nump">0.100<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Probability of Success | Payment assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in unobservable input, liabilities</a></td>
<td class="nump">0.20<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities</a></td>
<td class="nump">0.200<span></span>
</td>
<td class="nump">0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Expected Sales Volume</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities', window );">Unobservable inputs</a></td>
<td class="text">Expected sales volumes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Expected Sales Volume | Expected sales volumes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in unobservable input, liabilities</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderationProvision', window );">Contingent consideration provision</a></td>
<td class="nump">$ 17,536<span></span>
</td>
<td class="nump">$ 17,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities', window );">Valuation technique</a></td>
<td class="text">Discounted cash flows<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities', window );">Unobservable inputs</a></td>
<td class="text">Risk adjusted discount rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Discounted cash flow | Risk adjusted discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in unobservable input, liabilities</a></td>
<td class="nump">0.005<span></span>
</td>
<td class="nump">0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Discounted cash flow | Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities', window );">Range of inputs (weighted average)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Discounted cash flow | Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities', window );">Range of inputs (weighted average)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Discounted cash flow | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities', window );">Range of inputs (weighted average)</a></td>
<td class="num">(12.50%)<span></span>
</td>
<td class="num">(12.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of inputs used in the fair value measurement of liabilities. Inputs are the assumptions that market participants would use when pricing the liability, including assumptions about risk such as the risk inherent in a particular valuation technique used to measure fair value (such as a pricing model) and the risk inherent in the inputs to the valuation technique.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the valuation techniques (for example, the market approach, cost approach and income approach) used for the fair value measurement of liabilities. [Refer: Valuation techniques [member]; Cost approach [member]; Income approach [member]; Market approach [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContingentConsiderationProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContingentConsiderationProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reasonably Possible Increase (Decrease) In Fair Value Measurement Due To Change In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Reasonably Possible Increase (Decrease) In Unobservable Input, Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of weighted average of significant unobservable inputs liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=meso_ExpectedUnitSalesPriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=meso_ExpectedUnitSalesPriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProbabilityOfDefaultAxis=ifrs-full_ProbabilityOfDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProbabilityOfDefaultAxis=ifrs-full_ProbabilityOfDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=meso_ProbabilityOfSuccessMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=meso_ProbabilityOfSuccessMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=meso_PaymentAssumptionsMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=meso_PaymentAssumptionsMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesChannelsAxis=meso_ExpectedSalesVolumeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesChannelsAxis=meso_ExpectedSalesVolumeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=meso_ExpectedSalesVolumesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=meso_ExpectedSalesVolumesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576683248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure Of Financial Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CashOrStockPayableAtFairValueLiabilities', window );">Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets</a></td>
<td class="nump">$ 16,924<span></span>
</td>
<td class="nump">$ 16,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RoyaltyPaymentsAtFairValueLiabilities', window );">Fair value of royalty payments from commercialization of the intellectual property acquired</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContingentConsiderations', window );">Contingent Consideration</a></td>
<td class="nump">$ 17,536<span></span>
</td>
<td class="nump">$ 17,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CashOrStockPayableAtFairValueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash or stock payable at fair value, liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CashOrStockPayableAtFairValueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContingentConsiderations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContingentConsiderations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial assets and liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RoyaltyPaymentsAtFairValueLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payments at fair value, liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RoyaltyPaymentsAtFairValueLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554560720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Warrant Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Opening balance</a></td>
<td class="nump">$ 5,426<span></span>
</td>
<td class="nump">$ 2,185<span></span>
</td>
<td class="nump">$ 2,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantsFairValueAtIssueDate', window );">Warrants fair value at grant date - December 22, 2022</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RemeasurementOfWarrantLiability', window );">Remeasurement of warrant liability</a></td>
<td class="num">(4,434)<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">2,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Closing Balance</a></td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreationDateAxis=meso_WarrantsFairValueAtGrantDateDecember222022Member', window );">Warrants Fair Value at Grant Date December 22, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantsFairValueAtIssueDate', window );">Warrants fair value at grant date - December 22, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RemeasurementOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RemeasurementOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_WarrantsFairValueAtIssueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants fair value at issue date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_WarrantsFairValueAtIssueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreationDateAxis=meso_WarrantsFairValueAtGrantDateDecember222022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreationDateAxis=meso_WarrantsFairValueAtGrantDateDecember222022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110580450976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Fair Value of Warrants (Details) - Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Year </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantsPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected Volatility</a></td>
<td class="nump">86.71%<span></span>
</td>
<td class="nump">81.26%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk Free Interest Rate</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueOfWarrants', window );">Fair value | $</a></td>
<td class="nump">$ 992,233<span></span>
</td>
<td class="nump">$ 5,426,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected Term | Year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValuePerWarrant', window );">Fair value per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.4000<span></span>
</td>
<td class="nump">$ 2.3103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected Term | Year</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValuePerWarrant', window );">Fair value per warrant (in dollars per share)</a></td>
<td class="nump">$ 0.6248<span></span>
</td>
<td class="nump">$ 2.9401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValuePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValuePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_WarrantsPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_WarrantsPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554615504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Year </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Year </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IssuanceWarrantsExercisedPeriod', window );">Issuance warrants exercised period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares', window );">Number of warrants granted to purchase american depositary shares (in shares) | shares</a></td>
<td class="nump">2,224,669<span></span>
</td>
<td class="nump">2,224,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueOfWarrants', window );">Fair value | $</a></td>
<td class="nump">$ 992,233<span></span>
</td>
<td class="nump">$ 5,426,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected Term | Year</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember', window );">Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure Of Financial Instruments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected Term | Year</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IssuanceWarrantsExercisedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance warrants exercised period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IssuanceWarrantsExercisedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants granted to purchase American Depositary Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554851344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-financial assets and liabilities - Summary of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">$ 577,183<span></span>
</td>
<td class="nump">$ 578,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(1,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">576,564<span></span>
</td>
<td class="nump">577,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">651,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">651,282<span></span>
</td>
<td class="nump">651,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="num">(12,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="num">(12,799)<span></span>
</td>
<td class="num">(12,041)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Accumulated impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="num">(61,919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="num">(61,919)<span></span>
</td>
<td class="num">(61,919)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">134,453<span></span>
</td>
<td class="nump">134,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">134,453<span></span>
</td>
<td class="nump">134,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">134,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">134,453<span></span>
</td>
<td class="nump">134,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember', window );">Acquired licenses to patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember', window );">Acquired licenses to patents | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">2,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">3,131<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember', window );">Acquired licenses to patents | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="num">(1,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="num">(1,405)<span></span>
</td>
<td class="num">(1,375)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">427,779<span></span>
</td>
<td class="nump">427,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">427,779<span></span>
</td>
<td class="nump">427,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">489,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">489,698<span></span>
</td>
<td class="nump">489,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired | Accumulated impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="num">(61,919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="num">(61,919)<span></span>
</td>
<td class="num">(61,919)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=meso_CurrentMarketedProductsMember', window );">Current marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">13,333<span></span>
</td>
<td class="nump">14,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(727)<span></span>
</td>
<td class="num">(1,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">12,606<span></span>
</td>
<td class="nump">13,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=meso_CurrentMarketedProductsMember', window );">Current marketed products | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="nump">23,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">23,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=meso_CurrentMarketedProductsMember', window );">Current marketed products | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Opening net book amount</a></td>
<td class="num">(10,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Closing net book amount</a></td>
<td class="num">$ (11,394)<span></span>
</td>
<td class="num">$ (10,666)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions (reversal) other than through business combinations intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=meso_CurrentMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=meso_CurrentMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554801616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Carrying value of in process research and development</a></td>
<td class="nump">$ 576,564<span></span>
</td>
<td class="nump">$ 577,183<span></span>
</td>
<td class="nump">$ 578,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Carrying value of in process research and development</a></td>
<td class="nump">427,779<span></span>
</td>
<td class="nump">427,779<span></span>
</td>
<td class="nump">$ 427,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired | Cardiovascular Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Carrying value of in process research and development</a></td>
<td class="nump">254,351<span></span>
</td>
<td class="nump">254,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired | Intravenous products for metabolic diseases and inflammatory/immunologic conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Carrying value of in process research and development</a></td>
<td class="nump">70,730<span></span>
</td>
<td class="nump">70,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired | MSC Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure Of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Carrying value of in process research and development</a></td>
<td class="nump">$ 102,698<span></span>
</td>
<td class="nump">$ 102,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=meso_CardiovascularProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=meso_CardiovascularProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=meso_IntravenousProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=meso_IntravenousProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=meso_MSCProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=meso_MSCProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554536752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-financial assets and liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=meso_EmployeeBenefitsMember', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_CurrentProvisionsForAccruedAnnualLeave', window );">Current provisions for accrued annual leave</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PostTaxDiscountRates', window );">Post tax discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ExpectedPatentExpiry', window );">Expected patent expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range | Discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PostTaxDiscountRates', window );">Post tax discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ExpectedPatentExpiry', window );">Expected patent expiry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">In-process research and development acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossOnFinancialAssets', window );">Impairment loss recognised in profit or loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure Of Non Financial Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossOnFinancialAssets', window );">Impairment loss recognised in profit or loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossOnFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss on financial assets. [Refer: Financial assets; Impairment loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossOnFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_CurrentProvisionsForAccruedAnnualLeave">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current provisions for accrued annual leave.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_CurrentProvisionsForAccruedAnnualLeave</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of non financial assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ExpectedPatentExpiry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected patent expiry.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ExpectedPatentExpiry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PostTaxDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post tax discount rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PostTaxDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=meso_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=meso_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis=ifrs-full_DiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110548825184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-financial assets and liabilities - Summary of Provisions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure Of Other Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="nump">$ 8,230<span></span>
</td>
<td class="nump">$ 6,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current</a></td>
<td class="nump">17,073<span></span>
</td>
<td class="nump">16,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total</a></td>
<td class="nump">25,303<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure Of Other Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current</a></td>
<td class="nump">17,036<span></span>
</td>
<td class="nump">16,563<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total</a></td>
<td class="nump">17,536<span></span>
</td>
<td class="nump">17,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=meso_EmployeeBenefitsMember', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure Of Other Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="nump">3,980<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total</a></td>
<td class="nump">4,017<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=meso_ProvisionForLicenseAgreementsMember', window );">Provision for license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure Of Other Provisions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Current</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Total</a></td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount, including provisions for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=meso_EmployeeBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=meso_EmployeeBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=meso_ProvisionForLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=meso_ProvisionForLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575915680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-financial assets and liabilities - Summary of Deferred Tax Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses', window );">Tax losses</a></td>
<td class="nump">$ 74,684<span></span>
</td>
<td class="nump">$ 76,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences', window );">Other temporary differences</a></td>
<td class="nump">13,185<span></span>
</td>
<td class="nump">11,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Total deferred tax assets</a></td>
<td class="nump">87,869<span></span>
</td>
<td class="nump">87,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxLiabilityAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">87,869<span></span>
</td>
<td class="nump">87,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">87,869<span></span>
</td>
<td class="nump">87,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets attributable to other temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets attributable to temporary differences from tax losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities attributable to temporary differences from intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110553148496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-financial assets and liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesLineItems', window );"><strong>Deferred Tax Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract', window );"><strong>Charged/(credited) to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax', window );">- profit or loss</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity', window );">- directly to equity</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=meso_TaxLossesMember', window );">Tax losses (DTA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesLineItems', window );"><strong>Deferred Tax Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance</a></td>
<td class="num">(76,020)<span></span>
</td>
<td class="num">(80,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract', window );"><strong>Charged/(credited) to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax', window );">- profit or loss</a></td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity', window );">- directly to equity</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance</a></td>
<td class="num">(74,684)<span></span>
</td>
<td class="num">(76,020)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other Temporary Differences (DTA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesLineItems', window );"><strong>Deferred Tax Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance</a></td>
<td class="num">(11,972)<span></span>
</td>
<td class="num">(7,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract', window );"><strong>Charged/(credited) to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax', window );">- profit or loss</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="num">(4,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity', window );">- directly to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance</a></td>
<td class="num">(13,185)<span></span>
</td>
<td class="num">(11,972)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=meso_IntangibleAssetsMember', window );">Intangible assets (DTL)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesLineItems', window );"><strong>Deferred Tax Assets And Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Beginning balance</a></td>
<td class="nump">87,992<span></span>
</td>
<td class="nump">88,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract', window );"><strong>Charged/(credited) to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax', window );">- profit or loss</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity', window );">- directly to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Ending balance</a></td>
<td class="nump">$ 87,869<span></span>
</td>
<td class="nump">$ 87,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the net movement in regulatory deferral account balances related to profit or loss and the net movement in related deferred tax. [Refer: Net movement in regulatory deferral account balances related to profit or loss; Net movement in deferred tax arising from regulatory deferral account balances related to profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 14<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=14&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 14<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=14&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities relating to charged or credited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net movement in regulatory deferral account balances related to directly to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=meso_TaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=meso_TaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=meso_IntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=meso_IntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110548681936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash flow information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Cash at bank</a></td>
<td class="nump">$ 77,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DepositsAtCall', window );">Deposits at call</a></td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">77,554<span></span>
</td>
<td class="nump">$ 67,619<span></span>
</td>
<td class="nump">71,318<span></span>
</td>
<td class="nump">$ 60,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Loss for the period</a></td>
<td class="num">(32,539)<span></span>
</td>
<td class="num">(41,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Add/(deduct) net loss for non-cash items as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange (gains)/losses</a></td>
<td class="num">(159)<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance costs</a></td>
<td class="nump">10,319<span></span>
</td>
<td class="nump">10,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FairValueRemeasurementOfContingentConsiderationAfterTax', window );">Remeasurement of contingent consideration</a></td>
<td class="nump">337<span></span>
</td>
<td class="num">(5,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_RemeasurementOfWarrantLiability', window );">Remeasurement of warrant liabilities</a></td>
<td class="num">(4,434)<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">$ 2,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Equity settled share-based payment</a></td>
<td class="nump">2,195<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Deferred tax benefit</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease/(increase) in trade and other receivables</a></td>
<td class="nump">2,084<span></span>
</td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_AdjustmentsForIncreaseDecreaseInPrepayments', window );">Decrease/(increase) in prepayments</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Decrease/(increase) in tax incentive recoverable</a></td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals', window );">Increase/(decrease) in trade creditors and accruals</a></td>
<td class="num">(9,500)<span></span>
</td>
<td class="nump">2,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Increase/(decrease) in provisions</a></td>
<td class="nump">1,821<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash (outflows) in operating activities</a></td>
<td class="num">$ (26,572)<span></span>
</td>
<td class="num">$ (30,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_AdjustmentsForIncreaseDecreaseInPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for (increase) decrease in prepayments to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_AdjustmentsForIncreaseDecreaseInPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade creditors and accruals to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ChangeInOperatingAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in operating assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ChangeInOperatingAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DepositsAtCall">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits at call.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DepositsAtCall</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FairValueRemeasurementOfContingentConsiderationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value remeasurement of contingent consideration after tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FairValueRemeasurementOfContingentConsiderationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_RemeasurementOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_RemeasurementOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575733616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Schedule of Share Capital (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Contributed equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total Equity</a></td>
<td class="nump">$ 508,731<span></span>
</td>
<td class="nump">$ 501,838<span></span>
</td>
<td class="nump">$ 500,002<span></span>
</td>
<td class="nump">$ 497,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Contributed equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in shares)</a></td>
<td class="nump">1,015,342,237<span></span>
</td>
<td class="nump">814,204,825<span></span>
</td>
<td class="nump">737,121,218<span></span>
</td>
<td class="nump">650,454,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TreasurySharesPurchased', window );">Less: Treasury Shares (in shares)</a></td>
<td class="num">(542,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Total Contributed Equity (in shares)</a></td>
<td class="nump">1,014,799,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,578,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OrdinarySharesPurchasedValue', window );">Ordinary shares</a></td>
<td class="nump">$ 1,286,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,207,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TreasurySharesPurchasedValue', window );">Less: Treasury Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total Equity</a></td>
<td class="nump">$ 1,286,229<span></span>
</td>
<td class="nump">$ 1,249,123<span></span>
</td>
<td class="nump">$ 1,207,714<span></span>
</td>
<td class="nump">$ 1,165,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OrdinarySharesPurchasedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OrdinarySharesPurchasedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_TreasurySharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_TreasurySharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_TreasurySharesPurchasedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares purchased value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_TreasurySharesPurchasedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110554541296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Movements in Ordinary Share Capital (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance</a></td>
<td class="nump">$ 501,838<span></span>
</td>
<td class="nump">$ 497,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Issues of ordinary shares during the period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance</a></td>
<td class="nump">$ 508,731<span></span>
</td>
<td class="nump">$ 500,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Issued Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Beginning balance (in shares)</a></td>
<td class="nump">814,204,825<span></span>
</td>
<td class="nump">650,454,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance</a></td>
<td class="nump">$ 1,249,123<span></span>
</td>
<td class="nump">$ 1,165,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Issues of ordinary shares during the period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TransactionCostsArisingOnShareIssueShare', window );">Transaction costs arising on share issue (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_TransactionCostsArisingOnShareIssue', window );">Transaction costs arising on share issue</a></td>
<td class="num">$ (2,602)<span></span>
</td>
<td class="num">$ (2,660)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContributionsOfEquityDuringPeriod', window );">Total contributions of equity during the period (in shares)</a></td>
<td class="nump">201,137,412<span></span>
</td>
<td class="nump">86,666,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ContributionsOfValueForEquityDuringPeriod', window );">Total contributions of equity during the period</a></td>
<td class="nump">$ 37,106<span></span>
</td>
<td class="nump">$ 42,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare', window );">Share options reserve transferred to equity on exercise of options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue', window );">Share options reserve transferred to equity on exercise of options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ending balance (in shares)</a></td>
<td class="nump">1,015,342,237<span></span>
</td>
<td class="nump">737,121,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance</a></td>
<td class="nump">$ 1,286,229<span></span>
</td>
<td class="nump">$ 1,207,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Issued Capital | Placement Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Issues of ordinary shares during the period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesAvailableForIssuanceUnderIssuancePlan', window );">Placement of shares under a share placement agreement (in shares)</a></td>
<td class="nump">201,137,412<span></span>
</td>
<td class="nump">86,666,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesIssuedInPlacementsValue', window );">Placement of shares under a share placement agreement</a></td>
<td class="nump">$ 39,708<span></span>
</td>
<td class="nump">$ 45,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContributionsOfEquityDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributions of equity during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContributionsOfEquityDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ContributionsOfValueForEquityDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributions of value for equity during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ContributionsOfValueForEquityDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Options Reserve Transferred To Equity On Exercise Of Options Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share options reserve transferred to equity on exercise of options value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SharesAvailableForIssuanceUnderIssuancePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares available for issuance under issuance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SharesAvailableForIssuanceUnderIssuancePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SharesIssuedInPlacementsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued in placements value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SharesIssuedInPlacementsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_TransactionCostsArisingOnShareIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs arising on share issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_TransactionCostsArisingOnShareIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_TransactionCostsArisingOnShareIssueShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Arising On Share Issue Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_TransactionCostsArisingOnShareIssueShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServiceConcessionArrangementsAxis=meso_PlacementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServiceConcessionArrangementsAxis=meso_PlacementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110548853456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details) - Private Placement - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems', window );"><strong>Disclosure Of Movements Of Shares In Share Trust [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid', window );">Number of shares issued and fully paid (in shares)</a></td>
<td class="nump">201,137,412<span></span>
</td>
<td class="nump">86,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share)</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedButNotFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has not been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedButNotFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements of shares in share trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfMovementsOfSharesInShareTrustLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575787840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Movements of Shares in Share Trust (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems', window );"><strong>Disclosure Of Movements Of Shares In Share Trust [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_MesoblastEmployeeShareTrustMember', window );">Mesoblast Employee Share Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems', window );"><strong>Disclosure Of Movements Of Shares In Share Trust [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesHeldInTrust', window );">Opening balance (in shares) | shares</a></td>
<td class="nump">542,903<span></span>
</td>
<td class="nump">542,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesHeldInTrustValue', window );">Opening balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercise of share options (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesHeldInTrust', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">542,903<span></span>
</td>
<td class="nump">542,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesHeldInTrustValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfMovementsOfSharesInShareTrustLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements of shares in share trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfMovementsOfSharesInShareTrustLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SharesHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in trust.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SharesHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SharesHeldInTrustValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares held in trust, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SharesHeldInTrustValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_MesoblastEmployeeShareTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_MesoblastEmployeeShareTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110552972160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Warrant Reserve (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfWarrantReserveLineItems', window );"><strong>Disclosure Of Warrant Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance</a></td>
<td class="nump">$ 501,838<span></span>
</td>
<td class="nump">$ 497,044<span></span>
</td>
<td class="nump">$ 497,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Movement during the period</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance</a></td>
<td class="nump">508,731<span></span>
</td>
<td class="nump">500,002<span></span>
</td>
<td class="nump">501,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfWarrantReserveLineItems', window );"><strong>Disclosure Of Warrant Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance</a></td>
<td class="nump">12,969<span></span>
</td>
<td class="nump">$ 12,969<span></span>
</td>
<td class="nump">12,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Movement during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance</a></td>
<td class="nump">$ 12,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfWarrantReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of warrant reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfWarrantReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576002912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br> $ / shares in Units, $ in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>AUD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 05, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issue of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,708<span></span>
</td>
<td class="nump">$ 45,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReservesWithinEquityAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,027,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantExercisePricePerShare', window );">Warrant exercise price per share (in australian dollar per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantExerciseTerm', window );">Warrant exercise term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharePriceMinimumConsecutiveDay', window );">Share price, minimum consecutive day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReservesWithinEquityAxis=ifrs-full_WarrantsMember', window );">Warrants | Major ordinary share transactions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_WarrantExercisePricePerShare', window );">Warrant exercise price per share (in australian dollar per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReservesWithinEquityAxis=ifrs-full_WarrantsMember', window );">Warrants | Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SharesPrice', window );">Share price for right exercise of the warrants (in australian dollar per shares)</a></td>
<td class="nump">4.32<span></span>
</td>
<td class="nump">4.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure Of Classes Of Share Capital [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issue of shares</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">$ 138.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Fully-paid ordinary shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,109,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Exercise price (in australian dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_ConversionRatioOfWarrants', window );">Conversion ratio of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_ConversionRatioOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion ratio of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_ConversionRatioOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SharePriceMinimumConsecutiveDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price, Minimum Consecutive Day</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SharePriceMinimumConsecutiveDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_WarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_WarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_WarrantExerciseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_WarrantExerciseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReservesWithinEquityAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReservesWithinEquityAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=meso_PrivatePlacementOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576010048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfForecastNetSales', window );">Percentage of forecast net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NonCancellablePurchaseCommitments', window );">Non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_OtherPurchaseCommitments', window );">Other purchase commitments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServiceConcessionArrangementsAxis=meso_ManufacturingServiceAgreementMember', window );">Manufacturing Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MinimumFinancialCommitmentReductionAmount', window );">Minimum financial commitment reduction amount</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent', window );">Minimum financial commitment reduction amount on lease component</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent', window );">Minimum financial commitment reduction amount on non lease component</a></td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=meso_LonzaBioscienceSingaporePteLtdMember', window );">Lonza Bioscience Singapore Pte. Ltd | Manufacturing Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm', window );">Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm', window );">Minimum financial commitment of lease component on exercise of option to extend non-cancellable term</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest Rate Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_EffectOnProfitFromChangeInInterestRate', window );">Effect on profit from change in interest rates</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod', window );">Non interest bearing financial liabilities maturity period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Currency Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfCashHeld', window );">Percentage of cash held</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">AUD | Currency Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfCashHeld', window );">Percentage of cash held</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=srt_OtherCurrencyMember', window );">Other Currency | Currency Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfCashHeld', window );">Percentage of cash held</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_EffectOnProfitFromChangeInInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect on profit from change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_EffectOnProfitFromChangeInInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum financial commitment of lease component on exercise of option to extend non-cancellable term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MinimumFinancialCommitmentReductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Financial Commitment Reduction Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MinimumFinancialCommitmentReductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Financial Commitment Reduction Amount on Lease Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Financial Commitment Reduction Amount on Non Lease Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NonCancellablePurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cancellable purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NonCancellablePurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non interest bearing financial liabilities maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_OtherPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_OtherPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfCashHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfCashHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfForecastNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of forecast net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfForecastNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServiceConcessionArrangementsAxis=meso_ManufacturingServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServiceConcessionArrangementsAxis=meso_ManufacturingServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=meso_LonzaBioscienceSingaporePteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=meso_LonzaBioscienceSingaporePteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=srt_OtherCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=srt_OtherCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110548701264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details) - Interest Rate Risk<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FundsInvestedWhichDerivesInterestRevenue', window );">Funds invested</a></td>
<td class="nump">$ 49,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue', window );">Rate increase on funds invested</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue', window );">Rate decrease on funds invested</a></td>
<td class="num">$ (92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FundsInvestedPercentage', window );">Funds invested percentage</a></td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseInInterestRatePercentage', window );">Rate increase</a></td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DecreaseInInterestRatePercentage', window );">Rate decrease</a></td>
<td class="nump">1.66%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD | Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FundsInvestedPercentage', window );">Funds invested percentage</a></td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.84%<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseInInterestRatePercentage', window );">Rate increase</a></td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">2.02%<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
<td class="nump">1.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DecreaseInInterestRatePercentage', window );">Rate decrease</a></td>
<td class="nump">1.66%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">AUD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FundsInvestedWhichDerivesInterestRevenue', window );">Funds invested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue', window );">Rate increase on funds invested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue', window );">Rate decrease on funds invested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (143)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">AUD | Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FundsInvestedPercentage', window );">Funds invested percentage</a></td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseInInterestRatePercentage', window );">Rate increase</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">3.96%<span></span>
</td>
<td class="nump">3.96%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DecreaseInInterestRatePercentage', window );">Rate decrease</a></td>
<td class="nump">3.47%<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">AUD | Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_FundsInvestedPercentage', window );">Funds invested percentage</a></td>
<td class="nump">4.88%<span></span>
</td>
<td class="nump">4.88%<span></span>
</td>
<td class="nump">4.59%<span></span>
</td>
<td class="nump">4.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_IncreaseInInterestRatePercentage', window );">Rate increase</a></td>
<td class="nump">5.37%<span></span>
</td>
<td class="nump">5.37%<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DecreaseInInterestRatePercentage', window );">Rate decrease</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
<td class="nump">4.13%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in interest rate on funds invested which derives interest revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DecreaseInInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DecreaseInInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FundsInvestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds invested percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FundsInvestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_FundsInvestedWhichDerivesInterestRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funds invested which derives interest revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_FundsInvestedWhichDerivesInterestRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in interest rate on funds invested which derives interest revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_IncreaseInInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_IncreaseInInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110580294800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details) - Interest Rate Risk<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease', window );">Effect on profit from change in interest rate increase or decrease</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">AUD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease', window );">Effect on profit from change in interest rate increase or decrease</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect on profit from change in interest rate increase or decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110552666416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial risk management - Summary of Borrowing to Price Rate Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Current borrowings</a></td>
<td class="nump">$ 8,534<span></span>
</td>
<td class="nump">$ 5,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Non-current borrowings</a></td>
<td class="nump">107,228<span></span>
</td>
<td class="nump">102,811<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total borrowings</a></td>
<td class="nump">115,762<span></span>
</td>
<td class="nump">108,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CommodityPriceRiskMember', window );">Commodity price risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Current borrowings</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Non-current borrowings</a></td>
<td class="nump">60,878<span></span>
</td>
<td class="nump">55,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total borrowings</a></td>
<td class="nump">$ 61,245<span></span>
</td>
<td class="nump">$ 56,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfPriceRateChangesInCurrentBorrowings', window );">Percent of current borrowings</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings', window );">Percent of non-current borrowings</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfPriceRateChangesInBorrowings', window );">Percent of total borrowings</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfPriceRateChangesInBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of price rate changes in borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfPriceRateChangesInBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfPriceRateChangesInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of price rate changes in current borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfPriceRateChangesInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfPriceRateChangesInNonCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of price rate changes in non-current borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfPriceRateChangesInNonCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CommodityPriceRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CommodityPriceRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110576571264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial risk management - Schedule of Increase/Decrease of Share Price (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 992,000<span></span>
</td>
<td class="nump">$ 5,426,000<span></span>
</td>
<td class="nump">$ 2,185,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_PercentageOfIncreaseAndDecreaseInSharePrice', window );">Percentage of increase and decrease in share price</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice', window );">Ten percent of increase in share price</a></td>
<td class="num">$ (144,000)<span></span>
</td>
<td class="num">$ (698,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_DisclosureOfFinancialRiskManagementLineItems', window );"><strong>Disclosure of Financial Risk Management [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice', window );">Ten percent of decrease in share rice</a></td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="nump">$ 686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_DisclosureOfFinancialRiskManagementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of financial risk management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_DisclosureOfFinancialRiskManagementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_PercentageOfIncreaseAndDecreaseInSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Increase And Decrease In Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_PercentageOfIncreaseAndDecreaseInSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity analysis for types of net income risk based on decrease in share price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity analysis for types of net income risk based on increase in share price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110553214912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial risk management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">$ (195,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLoanCommitments', window );">Carrying amount</a></td>
<td class="num">(133,372)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(28,630)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Between 1-2 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between 2-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(144,455)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(171,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLoanCommitments', window );">Carrying amount</a></td>
<td class="num">(115,763)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Borrowings | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(9,739)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Borrowings | Between 1-2 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(18,242)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Borrowings | Between 2-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(143,701)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Borrowings | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(10,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLoanCommitments', window );">Carrying amount</a></td>
<td class="num">(10,760)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember', window );">Trade payables | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(10,760)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember', window );">Trade payables | Between 1-2 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember', window );">Trade payables | Between 2-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember', window );">Trade payables | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(6,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLoanCommitments', window );">Carrying amount</a></td>
<td class="num">(6,237)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(3,131)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Between 1-2 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(2,877)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Between 2-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(6,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLoanCommitments', window );">Carrying amount</a></td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Within 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Between 1-2 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(881)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Between 2-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember', window );">Contingent consideration | Over 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows', window );">Total contractual cash flows</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLoanCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows for gross commitments to receive a loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLoanCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=meso_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110580543168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Losses) per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>(a) Basic (losses) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations', window );">From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)</a></td>
<td class="num">$ (0.0382)<span></span>
</td>
<td class="num">$ (0.0564)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Total basic (losses) per share attributable to the ordinary equity holders of the company (in dollars per share)</a></td>
<td class="num">(0.0382)<span></span>
</td>
<td class="num">(0.0564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsPerShareAbstract', window );"><strong>(b) Diluted (losses) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations', window );">From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)</a></td>
<td class="num">(0.0382)<span></span>
</td>
<td class="num">(0.0564)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company (in dollars per share)</a></td>
<td class="num">$ (0.0382)<span></span>
</td>
<td class="num">$ (0.0564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract', window );"><strong>(c) (Losses) used in calculating (losses) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity', window );">From continuing operations</a></td>
<td class="num">$ (32,539)<span></span>
</td>
<td class="num">$ (41,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects', window );">Used in calculating basic (losses) per share</a></td>
<td class="num">(32,539)<span></span>
</td>
<td class="num">(41,370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects', window );">(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share</a></td>
<td class="num">$ (32,539)<span></span>
</td>
<td class="num">$ (41,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares used as the denominator in calculating basic losses per share (in shares)</a></td>
<td class="nump">851,464,145<span></span>
</td>
<td class="nump">733,282,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share (in shares)</a></td>
<td class="nump">851,464,145<span></span>
</td>
<td class="nump">733,282,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110548826912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfOperatingSegment', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfOperatingSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfOperatingSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140110575745632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LegalProceedingsProvisionAbstract', window );"><strong>Legal proceedings provision [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_meso_NumberOfClassActionLawsuits', window );">Number of action lawsuits</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LegalProceedingsProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LegalProceedingsProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_meso_NumberOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">meso_NumberOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>meso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M84J2]P)#[0&%%Q%@J5T]ATP9S^$9>DT09XE8:&S=G;%$F.7N05&OG4 'XWE
MN<!T5&:FV/Y]P'D/)[\FI68TJM+X8'"Y% N3[VQZW)P,GI]Q\8(?V:,X25ZB
MNU^[=_P3>;[NM\M_ GQ"WP]/8RR;X^CNSJM?1RK(P[I\2;[BQVQ,Q\F7_!%Q
M#1*A#5B?>W0QS1>ZH/O?C>/_ E!+ P04    " #<>UU8,K2XC+8$  #G"P
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M-;(*C@[@_LK@B&\7Y*![V\_^ 5!+ P04    " #<>UU8#H&1HPP3  !L-@
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M'E/^2:-";)A=>&IN!0M#SQZ1Z(-S$AWL3\"^4^FN$(>#83P^[WM!IQ-B$]X
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M]YG=)=1^WAF)["Y(I)"Z.2*#9<A)D"S+.N6>]Y&=!^,(F :(A6R8+ 7T$2V
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MV)*5\(YDNV %4HIO1"%IO4*X]%@K-J0OV)?8RQ2-+QP[M)2/]L,@(345+)-
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M>&)-K^OPF($2Q 5T8//XO?@Q6_%LO#9GRP4;J00K@Y$$[1=**W765BS"47!
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M'4T\OAB)OX./#Z8DG"3N%0&O6Q@./JV(0M"Y\XEXHZC+VW,8@N!6>MQ=%L!
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M=S\?78LW.?2-5M[E00^YXK$;9#)%36/GYKT'%G7T'.1CH(GVH7%NV;CX M"
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M^'Q9 D.K/W !_#Y[ N^;_P-02P,$%     @ W'M=6(*Y-PT"$0  B3$  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULQ5MI<]M(DOTK%9I+C( H N#I
M*T*6VQ[-ML:.EMVS$Q/SH0@4R9H&4.P"()GSZ_=E%DX*M.2>W=@O(@F@LO)\
M>:#TZL'87_*=4H7XFB99_OIL5Q3[%Y>7>;13J<S'9J\RW-D8F\H"/^WV,M];
M)6->E":7P60ROTRESL[>O.)KG^R;5Z8L$IVI3U;D99I*>WBK$O/P^LP_JR_\
MI+>[@BY<OGFUEUMUIXHO^T\6ORX;*K%.599KDPFK-J_/KOP7;T-ZGA_X6:N'
MO/-=D"1K8WZA'S?QZ[,),:02%15$0>+C7EVK)"%"8./7BN99LR4M['ZOJ;]G
MV2'+6N;JVB1_TW&Q>WVV/!.QVL@R*7XR#W]6E3PSHA>9).>_XL$].P_.1%3F
MA4FKQ> @U9G[E%\K/706+"<G%@35@H#Y=ALQE^]D(=^\LN9!6'H:U.@+B\JK
MP9S.R"AWA<5=C77%F[^:[&*C,YE%6B9"YKDJ<B&S6"1:KG6B"ZWR5Y<%=J+G
M+Z.*ZEM'-3A!]2]E-A;AQ!/!) C[RR_!8,-ET' 9,+WP!+UW.H\2DY=6B8\;
M 9[%^X;G*\?S%7C^L>59_.-JG1<61O_G$/MNN^GP=A0(+_*]C-3K,WAZKNR]
M.GOSQ]_Y\\G+;P@3-L*$WZ+^FU7^GU,5<BQNLD)F6[U.5/W0N<[$E_'=6,0F
M2:3-/8$+Q<Z4.9;G(_'!F/A!)]!T]&NIK2*2$<(2]&ZRB[TUD<IS<5U:J[("
MOFE_404>^FP*,/)W):WX(8MQ 4ZA&J<0'P$K.MN*#,!#02MD:DJL]\.I-YV%
MPO?F82"FP<);+%;"GWJ+Y5+,%DMO/@O$51QK"NI<_/%WR\ /7@I0K+]V+OWP
M-=I!6B5BO=DH\ =6F_O^HQ6^N$J-+?2_)2,&UEJLK>^>A\M1^\,'E[,1?Z["
MD;B&>SXACK]LQ0F], PASL+SER%<6)C-D7ZN3=ZN#KS5*A33Y<J;KY80##]7
M8C[S/7^*U5%4IF4B2>FRRW^'UW QZ_(^\>;S.3$?>).I/^J1T.E>:IN2+8_U
M<S[WO96_&CV^\-??(O:=_BIN35;L\LI#WJE(I6ME1>@_WTN^H=9'7N('P6.C
MX]K_KI_X75TO@@44O9@&S_&113!OA0F\^60.8>;>;#ZM?.2QAGI^$GI^Z+=^
M,O4FDPG[2; ,GN4GTTG/3^ XJZGSD\5J]7_J)]\0_5Q#=]+: RGO7B:E(E7H
M%GL(HZ6-=HQWL;I'J;%GQF2-6.N#P,-Q&15/PIU3M/N+76-M[F4>06A;DP!D
M(F:"V=0+9W[S"6"U\EYE(-0^B*I)I*J0:P/,A'>!3\)-XE-GFT2B$BJ,/5SJ
M-"TSDY@MGHI,5OOM.;QF,?$6X:3^N+V[[K !X/$G 1N[_JQU6'\2JS=9E)0Q
M]KW]='WASR87-[?,6;%3HD I5["R# D(Y67L%) ^VEF3@:$=E%N(C=0))6#B
MG>@$LXN;Z^>0D5%9*)$>3$3:1$Z Y+ 6WR8!>]R%$W#W\Q#9C5AKIZ$+%&Z4
MV:$X87>J)!UJ^+0M=A:*<^K%3FM5@/M,[2''7A:[ RNLV<ZJ5.6%2B.57/PX
MO*.,4=PY>M%.)S&0 ?59L1-W/UW(#S__^1W?>@:A:VMV&4?#XF5>^X% 72DD
M$FMC4.UXBWD3=DOH>VWN%2K/1!(J>7RM!%S:A.,AXKP;'6@7)1$#&IR I<A8
M(@1M?+G[_1A>CR"ZT]M,;W0DP10XUE"<>B%NVD &C6V=[4FRJD)@D64&]E#O
MZ@P[B#)7FS)!);!1XC,X^F!-N1<%J)*ZLA)B'3SR!0"-$ANK?BVQ07(0&FR2
M<^1TTZ$NR2TB;8$M><%2TDY@$_L4.UF0R <4OZBOQ5I5P*-B3SSL%&[9/L^:
M..CP/<3T/;;8(5C1BS#>0]+LT$4T3?T"J9#8J>@075P#;)'>]Q31!P&&&0PS
M5*78(0C/_S42E>6H;0!(7[QO?.) U9!Z7 V-68=DM'ME)==FC(\,0EB8JVY%
M%\E\=[%5&1YE5LJ,>&-YU@H>&J/^LN@5"/?@9K% H"%Z;86="4%F9,A2A2%?
MW!O0CV1"(,>X0YK5<"6R&C3M7"YGU'7EW<4>P:8CO2=/ F=ENG> Q>:25K4;
M=^&8"O)";:D2+3D3JJ_@- ,DQ.A=1&Y*2\:7L)PB:P)();*;^KI75E-2=GJ"
M#9/*R;HV(PWE.7]]H*7*4L]*MBW$+:>')FF2%C/37>ST_+RD@M^-QSW >X2.
M">TV6L547XNK<HO&C7=RX?K^W14",2^)%V@^W2>P$&VPA\X46:&H0^A/N7C[
MXQ4[S#-@9:\ <X4%RO4 J:%&N20'=^3A !0V^%IQ*'=]G6.-Z4-5\/"$?(P,
M3H2B.O-6*9M2+T/5<1\!VNIKI)0+P0%G'E-6E20W4-7K<>E4$A]QUK$H/(FH
M]M+?,0L]RSA7Z?IFF;M 93L/NPT9L]S''-(;:U)^]LAWAI>ZC%ZA=PUKE6%=
MS  Q]E6 \=.H;!7% WY[37&RARU9U]2XR3+#QH!I7,E9'K#'/,)W#2-?WD'T
M#IC^ KSLB.Y5K!%E8@B[K5U3R&DC+R/R^#$@K"M=Q?WWAP2"KQL12#W(/9TL
MX[($.70?N!]YU!-YY^9[*D"=]X*AB8.6---\Y%/&.0SP3%?PI@LB!HW6@>PP
M.<L,IZ?:S<A=HZHI)B 2Y[E239;8CYQ:OCM5C)QC'_/9U!8L!>L4^"%U7WFP
M24+F9J]2E23=Z(OI5ZHL#1'TOPG!;9-OW<;1;RK$J2@3N4+:H*3N-.MRS [>
MPEDK+]?_4A&[G>[["@=$48%1OA-'J0\)#1MYQ_0Z6;"R=E$[/X<:KQJ+CYGS
MD5R[2.RY,9F4$:RBD"0F8G"H8F.0G7.R13!Y>?WA"W_S7X[<9J1,+)1BRZA'
M9>&'+V*+:L0Y07X (<Z.53;JE'FG-#OF(I+E*BTG<K+((_UUY((I4I3UP'O7
M%Z4RDUOE@L5IR.QK>7*UY1N5KMI"CXCP.JH1$2,#BSQHK :<KBM08T'9O5#1
MCEL>M&: 10X1<OZN S(ZGBJ.N"4 #!ZCR-/>2*9UV%WQOSD&^:9\(>Z?JIUZ
M>:VV'?A5>M_\?)SUF_S"U<%1U7 R#_8K&]+(LT&Z"5A.:DBD0TFSGP+Z4$ZJ
M.A(S/Y%*D4QN.W[5ZIIQG<S<5!WYD<?2)L7 H*--836.<P7I>@GJ/5Q(4O*N
MA91[* 5BU[_;^2B7[<QH4PN>XN=1A7>N[T?BO_H9UJ$^R?5=A395BS5.U;'R
M)(&V;B*L<_!1J\25%Y4J-@9X]4!TD2U<G4W"-D5W*_(+GM0$\Y>T";<X*N:R
M.^)*J"RH\6>PVX B:PB:W5J9YHY51I*&L289-?O20Q5O2J95UWROU4.[DI_5
MJ;A^_]%%_/&:)#<5Z) ;UNX.62$\@(=;3GI/!,AG@D=%4+>G3DWL\(P2.?IQ
M K"J6=R711N:5@'YJ+9:4[]"VW&OY?@[IM^EW>G&H@3A",XX"U=)UM%F(-!5
M'>8J_DWM!R;O%Z]-6L-%U'QM"DII_G>2S[_M5-_#'E6&7-ST5A$;BC,5HVOC
M+DU[1L5KOR_CH*5@0_V*P#JVWU#MY3)B6&NMX_4[#3\&@$%E)6?>,C-K>@G#
MV,\6ZA?SS48O&S?F=!II%[11A5D5Z^2X)&P%"FB?X%JHI%F.MA3H$ZMJ^$CN
M==%DIIJ$B\8J6US=_;<XQY\7MW=O1R]YRRZA5BO=Q4W$U A)'EB5IWNJ BO\
MKA+BU8D[#-AF74CVM$TU7JI'!X-M<%UO]CJK9Z:?Q_G@R;0WYH$U*]_AF:QZ
M:';*QCLT#485668LWK60Q),/!T'L +0["(!,<5'(KPUZ"2XS+8_TL9,?CI=_
M(,K^;#S[@]=MUIHY6.Q(,<C1:);VH.=,6;@?I"@>L%7(!_E@N>W.];T55.Y!
M*>/(T/903U%<6\8F7='3P8RK^YR'!0C=!K1Y\V;#/J8W %#5BX830SVQ@_^:
M)/90>R6)2Y%Y/2S";Z!\XOQ<T%O]N$Q4WLFGM0K8*EE):==!/'9N4B2L7E]P
MU*GJR4VD99TK^(T@-Q>2,&1+28Y&M!O5@$;AWA 2U&<\66MALFF>.],?&LIM
M2LN=[AZ>58O2ZRPVA#P)K@,=AC5:F_,IA1XUX=YS&G?X+X^2UZP_-WAV/@AL
M[7?P-?H,M-XUDC4XWHI4,='T_]*U_S0HC:6-J9=X*';L\+E;1I-1-QU NPJ8
M*6W?PK54K1B5H\($EN?2U"UJ-\&ETES)LLY:E$S(#*H9KS0#FB;^!\KT.FY8
MO8WB4QFKH4DKEW$#0=]+B-4!D]C-QX_9@2/NS -/O:JFYAF,N>E5/CCUJN1'
M:C1N($I%8=X?(@[II.E-&GY.L=(= 0XT4VVX]MH=U^2[&N_)%L!K1#P2+_>>
M*>#YO9OD1&[\:%",D!2G1T^=GI'LWBD#ZO<+W!B0WYD,&CD,$ATJYVC]KNK1
MNST*#?*S^CW"<R>:%"3?/]&D^DHG>7%"75[#=TZGF I][TYA')<M'--M-J_J
MB*JJQ>852-#<ZZB1)K8'^FB Q7M7LU,8E3F?H&I"B_K-2B7NI7<Q-"CM5,NG
M.KR;;O6CJ7JL9R4MQUSX,L^LPR%FC[O=NG1XKI52>:B*D+%8C\4GM'PZ9T&Z
MKW*?>NU;GU^A<S3UV,X=8?G&'3;1UJ7$;FZAEZZSR43X"V\2SNECAH\Y?:57
MVB%=\5<K\0.J(W-0E (SU/X0)O16RXD(%V+J3?R%"/ W%-,5?9D'K6Q<C53'
M<(1$/5LULZ&WF$V:U^[NU]"UI1>$CKU%B'K$"R>AF'LA6 *#<S^@,R83WV=!
M>.J74-]!@^;FY? IV64[]K2*CT\18V313I5T<.QVG"Q#GR&P<>H.A#0#F)I6
MU_-I>$G@GX_Y;,!-Y@XG\NYK) ;N;.]U3"^(]JT[$&+D Z] \].&_-P$XL#-
MAK0K.=J!?[^DKP]@N1XO4I;*<Y%J% X%&D_'ES4'F> 1Y",-29UZ]NY9[@@=
MY6:<W<QO.-9=B10WI^0(X#.JHS<(G?;MY.Q<N;'S>,#S/KO9:,>_U*-GOD/.
MZOT<FM][Y5'VLS2,M"DE,@+K^TKPQ'"6L_=P9O?T$'-UM8Y2P?)KM YU-WX;
M&AD1_=[PW"$R;6^/4V^7HMM&NAGP[_UQ0-9*ZOH/%_SF O4UBD^64K7$C04=
M_V"O=\5LY<!>U6&VB!D;Y;(7%\&P%XK%^N@']K;\OIOF/MR.P]1%XL9I3KV'
M=@1GUHG>NHE2]:;_UM0^]/_JP6/Q4SU+Z#N@.QC3,*FSTSS6#2K-&DQ<O1)Y
MAJW'(D+O2-OST '=87V&@D'CU)WG'P[J4:ART>==<U2#>U^KJ2DJ$$G&2O1"
MW?-ELD!+MBZ+*FF^$)]!!_%+*Q93;[Z<BL7<FP03\=%5\X-4_-#SES/A^]YJ
M$51Y*1[@;+GPEO,5?:Q609_W[@G1_TB QV=+^[L.<-?=N_\P'14[^>BC$V=]
MIW_*C!U-4X8[?_?Y:O1-+;=/=61TXN#RCZ.!(YR!.%].O*E/*R%8B,\ETNZT
M/8%XS><&X\MSM%T(>Q6/6(L7%)9 /7I=1$RB%/#I(!<^Z*SF>3";T%\_&.'1
M&$@6T;D:JE61&Q" N//X+"RN#9TR/7<>-N*S?G"@4:W][^711T$QI1.$@1_R
M@4'^.SG%(^X\/E4Y"4Z><CQW 4$TV=]'M;.T9Q5'@P')[3*@D[!X*ZDQ..E4
M0T>[+SLGZ^F?%&ZA#1!!FM@4K\\FX\7LS %U_:,P>SYLOS9%85+^NE/H<RT]
M@/L; QRL?M#Y_>:_+][\#U!+ P04    " #<>UU83*LO@@L$  "M"   &0
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M6-$$_+Y2"%#]00K:^]K+_P!02P,$%     @ W'M=6/W'C1FT$0  (3<  !D
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M-'\AMT"<QA6"G8V3'$@^NOQ3_J#^HV*I:_*P(0+#Q17;<Q>SFU/6)O<J2J)
MV1>[DJ@/*JG(?$30I(#;DIZE;Q%H\5XJ)576S+015H?5H5\1=DL,>.KXE9DK
MVW7]NO "2'^B< ?R8>^]K+9P\"3A,';L-@'YG>T)/&N #!O8/BLA]SWJ%I&N
M2VX-1I7A(&*V+10'-=3[#XDIU#AYP8IB7-/@P:?.FS(:..BV-H>:2/D<D@+A
M];9,T>%(FF>FS M[9 .'S@AZ!N=R"_?S=9KF#Q+.P.H'75M-[$D([NRU/]$Z
M8XC$!"&!CHVS' <H!0SKCV(?U&B'4!"J4+'F3SE#/EQ6XXDU>6I[-<NS)Y'+
M,@Z#;^[9C1H#.^PF.1!/)CDT&H(AK&.F8-6M5?;1CTX8B-DO]#W)"'L2:20?
M:Q ;(CC<VHN:%L7"K\!8DN-+X/G&X%M,FOR2UMJP#YWV=NK "@N!::B .ZF)
M:2"-XGE27E>H]WF2L*@G2<<VZ;&YY?/;R30Z=ISN3$E%AI+L3#5:"8UJ>1JE
M2I;AT18*;;6!EQOMW!QF2:B>L"X# 2'Q3U:DU/^<+4LHA9O2*5)U@6-@+EU]
M4N?]-D:H'"$A$&]>^DL%XP7Z4)DHSL!@(H*N".]#<I0*U_/B(#[ZH(LM.B[I
M85J]G]!N\A2[1>NI?@70"'=3D09ARXS[FMB5#"%JIMSV%Q=&POWFD8\$*K'Y
MUXC:R\3=WE@1Y@[/J!V!E<>-(:<[QT]M>:+Z\]VW\D3Y/*^L!P2@Y6^!9VX>
M,8MTHT\M-:L=$;_9M"R'U:>L-_Y+"8%\C?.^ZI:=I"X#K'&F8H]TH*H_15O*
MLU+Z (G!7,C@9%CV&-''LH5-;>> W5 -<>A ]E&@?*YPKP,#+*& -2G7O.N#
MA&E=%P#X8/PZ!_2 7 VBC;2H^2,HRHFV ^NN:","=J=)NT<%[#"XX?H$G:5.
MUQ"Y[BY#SVZ\VV+UF!ZD6&)>L#NL'V+!8\\AY(MX3NLQ]2[_7J&RG8[.[;#L
MWX'H3J=NER'PA0"F 4D.>V4*3IFZMYIMMC&N31.(ZS[:YF'G+FQHVSZ%#BI/
MI9:42HP8;>M@L*$(5E&&U%6KQ%\/1V1W5^_#ZC(\JLT.(\('D)5B9[B\*KQM
M(B[YZQ"5]-\I0P3JZT*C!7R$:2SHT*1A=O5CIL,.^M,$2?*52S5^2G)1Q/L*
M"UVX%44B]U%TMFK0*-XJJ;UB;:/"K-L&KN3R8$VC,6+D7K,G-75%JCZ9%%F?
MM,V1@\]'+<!:$[_.2JK?N7E]QQF%?2W=>%NUP5 6C3MLO3G>QR$'[#<>/3X#
M&H;J1\!60C7L4Q<$\O^ O'MX-PQBW%6%#44#,"IXPS= D]Z59."(K =G4)?H
M1/;!C^9^R[C;^?**K6LR@ ,%_1.^.!ZN9L'C^L_L.KR>C_!M><T7^<]L%,X7
MU\%[\C4X>,'5C,@43(:C2=#\N9Y@S?62E_*?Y526Q;J[;#Q<+(+FS^!Z<DF?
MQW*)_@R6T\N.+CJ6" ;C2]:.EXV_24<WCSJ?3S2$:]/A:DY*&*Y6^#.=AS/P
M/!TN1GQQ?BT7EZ-EOX)FPPDI=CZ<LEKF8ZR]7O"5$=$=S\ZH:#J<+7F+*6TQ
MP,I+7&-BL^%XRM=F4!*I FQVHTKUZ(SS$,]YZDX108Q.)ZF'2XYUSO"N-=D$
M6Z@&#MMU; 98(.R[MN/S/OI)E!'FM%63>(]E5M2F09/!G)5#6->LJ81V9I$4
M);<J8;Y4W9]W.R0OD<=Z8UQ\M[@M60=<9:>5@AL/9/&)M.>R@]?QRK8T P,-
M%BOI&PEP7\]98:,BZ=$8N)H&/W3#-P8Z9'WNIN*V -O0IM#6CN9>/JMH-T1$
M%IT2.?D[8*HS8R!8AF^GD4Z>O.$Q$V\$NW.E3H_<O7^B_O[+CS]0(.W0,:H2
M4H)\:82\@/#/:&2AA+NR49I3K2X*:G&IL$/L)14GK1MK%"?X_Q5FJ*3SMJU#
M\*H.J;!?FU^C3+\<+6G$6QYVG'&=TQ[-8=AIN8S>)&A(:=P2.J=UA3,<3\7_
M!&SQ\ZY__2/S%_)%CX(A'IN9J#/.+?K)/#$2Y:^E)F%+R;#(LN;; 2VVZQTK
MV7H0*HQ02V=;#Y"Z0D)=/Q@^<.*B)=8N4]:38;\&:(K?=L<VD @')6>Z*N1_
M,C%^R*DXX?*QY(\G%UZ=Z)O<J9ZC>U'\LOWXQ)O-31?+@-+"=+K@OS]Y\Y$O
MKUZ,PM5R%<P)VN?(*,#].:7"Q3B<S.;N^B(<+>=R_88'JSU%.55J$HS &)XV
M<4Z@(4.I"")5\&]73_#PX]-0:8;D];SZ_PMZH,JDLQ :!G(B4YV!7#M*R_IT
M+J-A+M>.P)QCM1_10>SLB :TG,?7[65(SMHT5%5FFB+6N7*'WRK+U]2FN4'7
MKL(EV\9O@I5),/5[%B]>I57Z1MM[B;YK=9%<65NE.SEK47&^\\]-^IFIH_LK
M=,75O+%199VL/]%YV7R@+P>!>0@N?=O$N3O!J8E1.TVS"94=.N=HOL7:Y%[R
M]$,EU#4=O!9"K5$*4/GR<!G<'4^MF]V_ZQ[5G8RW_31_/'0U=>N-.JYM7GD4
MET"[\(!6I;;!Y#:CT#2 *CE66.EKO=R"% K5[K1X>&Z*WIU"_U_,TD.9H/\K
MSM(_=/M0]WH&<G"7G<V9>,.-M]KF:WA$^9WM\.=/BG#K2)S8F_TP*Z$;_+EE
M;?R*Y.QE'O6MBAMVXH:?N&XZ>#R#OZSZ%DOJT[LC-/GZUIEJ(()&^%%R&'XA
M?W<;O_ZD?'K =(WF$\W99!&\[O&% 6FO&_+'G=J &'U*'ZFIFLWP_^)ZU5US
MW*3Y:\:S4;!8+8+UT4F+]_FD,\HSBJ "[/-,LJ\3DD@##"3T#,$G^+G7W$/
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MWW_=R,^>VL?EQV-OT1=(!ME@Z6BXG%^(&NLO9;[C'T&M\[+,4_Y(K]WI@A[
M_4T.E'%?:(/F5W$O_AM02P,$%     @ W'M=6)XO!Q#A P  4 P  !D   !X
M;"]W;W)K<VAE971S+W-H965T,38N>&ULQ5=1C]HX$/XKHYQ4@<012("E'""5
MW5:M=-6M2K=].-V#209BU;%3VUF6?W]C)YMEM0$57:M[(7;L^>;[9L;.,-\K
M_<UDB!8><B'-(LBL+69A:)(,<V;ZJD!)*UNE<V9IJG>A*32RU!OE(HP&@TF8
M,RZ#Y=R_N]7+N2JMX!)O-9@RSYD^K%"H_2(8!H\O/O%=9MV+<#DOV [7:.^*
M6TVSL$%)>8[2<"5!XW81O!G.5B.WWV_XPG%OCL;@E&R4^N8F'])%,'"$4&!B
M'0*CQSU>HQ .B&A\KS&#QJ4S/!X_HK_SVDG+AAF\5N(K3VVV"*8!I+AEI;"?
MU/X]UGK&#B]1POA?V%=[XT$ 26FLRFMC8I!S63W90QV'(X/I*8.H-H@\[\J1
M9WG#+%O.M=J#=KL)S0V\5&]-Y+AT25E;3:N<[.RR\Z<R!DT7"J1494SC/+2$
MZU;#I,9851C1"8P)?%329@;>RA33Y_8A\6E(18^D5M%9P!M,^A />Q -HO@,
M7MR(C#U>? +O+=.2RYUY$@E_LXVQFFKBGS:]%=RH'<Z=DYDI6(*+@ Z"07V/
MP?+5;\/)X(\S9$<-V=$Y]!_,R*48L.8/S]($%&3,-[3N OUL<HW2FOJW!:G#
M)21NL0L=UH45,SR!CGBQ[YU6.23DDLN2H@]TD6CFCJ(!9JWFF]*RC4"P"FR&
MH'3*)=T+@-]+;@^0*9&B-J"V?CE1><'D 3IQ?QJ1YW%_,NK"9V69<,>RG<)/
M\]/9=.&&B])2X/Y7J>EI$C]/;-)]RGMIR)O+.!-)*4@4R6MQ[HKBKK_N0ZJ$
M8-KTG(W-5&F83,V9*FD<_0?Z;1Q/U<3L7+(Z<=0;QZ])_FC8BZ\&9Y/>,-_^
MBNS/X.X"52W,?U5@'RNPXG"6P@5W3N>#A+6#<;?*T?BK_ZR2*;NGH.X09.EM
MB&BCP;LW%5EFO( 4I:*O);-*MX?P!?OI>-@;34:]X6@,5W'<BZ91[_5@< D!
MJG0HE*6KD=-);:7WH[$\Q>:OHJJKG6;2&5(Z,2^$.F#M?\^T6Z*)=FFDYHGR
M6FW<X&EV??B<T9<,#":EYI836D:"R08EX$,B2I<^7^A5>"UJ'U_765$H3@35
MWP&$2G605W6 +^O ?>0]=QI$_3KS9,<L-3H'3YMQG]GJC.U(0B.M8N"Y,F%4
M&^%V;E[QX:S*)E.5QI/)VF#"*+O.YN#C3@G@O_OMU'$"=<X71Z&MCPB/NKP<
M]<[WLBXHI;15P]>\;=KE-U67^+2]ZK4_,KWC5$8"MV0ZZ%^- ]!5_UI-K"I\
MS[A1ECI0/\RHY4?M-M#Z5E$EU1/GH/D3L?P74$L#!!0    ( -Q[75@V </P
M? (  -8%   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*U4R6[;,!#]
M%4(%>FHM6W;<-+4-Q$F*]A @2+H<BAYH:62QH3@J.;*2O^^0E%4C2'QI+^(V
M[[U9-+/HT-Z["H#$0ZV-6R8547.6IBZOH)9NA T8?BG1UI+X:+>I:RS((H!J
MG6;C\3RMI3+):A'N;NQJ@2UI9>#&"M?6M;2/:]#8+9-)LK^X5=N*_$6Z6C1R
M"W= 7YL;RZ=T8"E4#<8I-,)"N4S.)V?KF;</!M\4=.Y@+WPD&\1[?_A<+).Q
M=P@TY.09)"\[N "M/1&[\;OG3 9)#SS<[]D_AM@YEHUT<('ZNRJH6B:GB2B@
ME*VF6^P^01_/B>?+4;OP%5VTG;]/1-XZPKH'LP>U,G&5#WT>#@"GXQ< 60_(
M@M]1*'AY*4FN%A8[8;TUL_E-"#6@V3EE?%'NR/*K8ARMKG9@R G,\]9:9;9"
ME@164 6<\@8M^;L&K,)BD1(+>EB:]^3K2)Z]0#X7UVBH<N+*%/ $G[*C@[?9
MWMMU=I3P$O*1F$[>B&R<38_P38?HIX%O^A*?<KE&UUH06 J#YJTL?G'2?= 0
M,Q/S\307XH?<.++\3_U\+BU1=?:\JN^S,]?(')8)-Y(#NX-D]?K59#[^<"2F
MV1#3[!C[OU;TOY%_J8#3VOF/P7TVJ9(D*KF#G@**GH$K"_4&;$S#OL1"FD(T
MS,82&%2<VAJOP>6B2CE1*B--KJ3N]:-"AZTNA%;WH!^CG.2F81UOJ&K./0D>
M"9[PD,!Q*SL1:F((BM%SU4@/>JT&NPT3Q8D<6T.Q[8;;86B=QU[]:QXGWK6T
M6V6<T% R=#QZ=Y((&Z=(/! VH7,W2#P'PK;BP0O6&_![B4C[@Q<81OGJ#U!+
M P04    " #<>UU8)-#%T&(#  #&!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6R556UOVS@,_BN$!PP;4,2)DW5%EP18NAWN/@PKUGOY<-@'1:9M
MH;+DD^2DV:\_4G*\%$M[-R!P))%\^/!%U')OW;UO$ ,\M-KX5=:$T%WGN9<-
MML)/;(>&))5UK0BT=77N.X>BC$:MSHOI]#)OA3+9>AG/;MUZ:?N@E<%;![YO
M6^$.&]1VO\IFV?'@BZJ;P ?Y>MF)&N\P_-'=.MKE(TJI6C1>60,.JU7V?G:]
M6;!^5/A3X=Z?K($CV5I[SYO?RE4V94*H409&$/2WPQO4FH&(QC\#9C:Z9,/3
M]1']EQ@[Q;(5'F^L_DN5H5EE5QF46(E>AR]V_RL.\;QA/&FUCU_8)]W%(@/9
M^V#;P9@8M,JD?_$PY.'$X&KZA$$Q&!21=W(467X00:R7SN[!L3:A\2*&&JV)
MG#)<E+O@2*K(+JSOL*84!U F%9@RM<P# ;,XEP/()H$43X!<PB=K0N/AHRFQ
M?&R?$Z&157%DM2F>!?R <@+SV044TV+^#-Y\C'(>\>9/X2DOM?6]0[ 54$<[
MBM34X%/T'OX66Q\<M<C7<]$G\,5Y<+XVU[X3$E<9W0N/;H?9^N6+V>7TW3/4
M%R/UQ7/H_[= /PT"GW_,@J#\J)*6JE)8 BF%!KGIE>>\[1NDO8N'0FLK$Q!)
M*&S;.XD$8<K<#BK>H_?1+ZF0M^C;R%@# 9UP0<E>"P?2MITU@R*;WM"!,(>7
M+ZZ*V=MW/MU=%10FC@YKMM,'6NWHGA+7[>&LH6P4GA:\1*GB/&G%/44B"(_"
M)RHBX(]],8%-A/4(TJF 3HF+%-IW/H\91WK2TLPJT1&M8&%+P :/D+1E!VQ2
MXHYF8G=,D"AID( /V(*D(04!96.LMO4!.BT")P_HP\EJT4DEM/H6"W#!28^(
M@P^AZ43H Y>-?E$B6BY((G^454.A1NZ<C7UC-4[@=SK_C^2]NHGRCP\H>QZM
M\+FJE$3W>JA*\L;)L%J5E."2^H_8$YM .V9Z0<VE8TO$"98B&:6<%2E\ Q4]
M'?ZDZI15IC 2(MY;>G#.=L"CUF3+U)9@=Q06I?FD+R?GKFM^,ELI[W5\0:BQ
M;&]"&K/CZ?A(O4^S^;MZ>N$^"5<K(JNQ(M/IY.V;#%QZ-=(FV"Y.ZJT--/?C
MLJ&'%ATKD+RR-APW[&!\NM?_ E!+ P04    " #<>UU87 !G!<0$  !W"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R55FMOVS84_2L7&K 'X/F5
M])T8<.)ES9"L0;*V&(9]H*5KBPA%JB05U?]^YU*R:W=MUGVQ)9+W\)S[TCUI
MG;\/)7.DCY6QX30K8ZQ?CD8A+[E28>AJMMA9.5^IB%>_'H7:LRJ2465&T_'X
MZ:A2VF:SD[1VXV<GKHE&6[[Q%)JJ4GYSQL:UI]DDVR[<ZG4996$T.ZG5FN\X
MOJUO/-Y&.Y1"5VR#=I8\KTZS^>3EV;&<3P?>:6[#WC.)DJ5S]_)R69QF8R'$
MAO,H" I_#WS.Q@@0:'SH,;/=E6*X_[Q%OTC:H66I I\[\UX7L3S-GF=4\$HU
M)MZZ]C7W>IX(7NY,2+_4=F>/7F24-R&ZJC<&@TK;[E]][/VP9_!\_!6#:6\P
M3;R[BQ++A8IJ=N)=2UY. TT>DM1D#7+:2E#NHL>NAEV<7?%:&:J]RYD+;=?A
M9!0!*YNCO(<XZR"F7X%X2M?.QC+0+[;@XM!^!#H[3M,MI[/IHX +SH=T-!G0
M=#P]>@3O:*?Q*.$=?:M&>7[0*:_^4LL0/7+C[R\)[W"/OXPK]?(RU"KGTPP%
M$=@_<#;[_KO)T_&K1U@?[U@?/X;^;9'YGQ TI]RH$%(Q0/VG+=*68LETP05[
M&)V[QD=R*YHWXA^C%;4J4!)9D.L.G[NJ5G8CMM=J(^&:TG*3MHQJ::5]1>^U
M@7%%MV[)/@:Z4NV&?1"()9?*K.22&BO.!FI+-\!R;)DMJ"Q]@T9!TZFDPN3Y
M@)0M"-G!%;!H\BQER!C+^8=&>_!2%EPB(Q@QD>+@EM ;*90*BP.:5^QUCF,+
MKEW0T0'^%H"ZCB'!CYQ'KS$J HV!&C<46E63\E[9-:,=H0?2I:7?&LM)\2#I
M35IO2DT7VEK>T'6^<%:9@G)7P2@7<O!>[J @D2F=@:</PZ'6Z*)@^YEO_R,N
M (!G)89!5]JH!*HKH'KD.):+QLN?P 15L7A;NV)(5_J>T^H!"40N0#>MO*OH
M31XE;LG/T&@@HR?T=G@WW+%::)#1>>SIX5N1SMSA*U"RMY_V0?QW=.H_T:GI
MQ[;4>4FE$B>)F:JE+@$G]H%C-,G?<N.\64-O\O=/G<-W^NT!_=!'CZ+;N=$P
MWF\YU-AFN@(PIR SNGFQ3=B+Q5PNNN,Z=NF5)&O;X8EC]A 1F!\"_?KP>B$E
M5#10AJ0J=(&;7\FI#2D3W!Z7'"%2"2VU"AM5Q[92!6\I[(5\_U+XAL[?O+M<
M_#QY\>_K4DV(=<&YU/\V/OC$WN.;7L/M+&X_I.X\BEYJJRL,,=K5E0@?TA^/
M^;A4#V M18J$#LXD)I(:0M?R-H<ZE*VL%IU SB-5F^23![UVWC7!;.0[RM"Q
M7P![;>L0!]*MBUT/+T3_1DJ@07U"*7I4'R?4=]!+ _%-1!'B'X7A!-Q1$[KT
M[CN5<!U0K5!%>8,",H)(J $-R5&Z"J?%$#&G#,@"J40S-T[Z9H2K$3]UGS3!
MF<[ .:%!:N^YH0F#@QB7N$!4J#SW3>I<N+-R#=J+! -NLOW<TNI8]G"?M_/A
MESXSH[UA -UNG4:>("5F8S<7[%9W4]6\&R8^'>]&LFOEUX@'+E[!=#Q\]B0C
MWXTYW4MT=1HMEBYB4$F/)29#]G( ^ROGXO9%+MC-FK-_ %!+ P04    " #<
M>UU8WQ/E4?8)   E&0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RM
M6=MR&SD._1669G;6KI(M6_8DF<1VE1WGMC69N.),]F%K'ZAN2F+<3?:0;,N:
MK]\#H&^VY<O#OB222(+  7  T$<K'Z[BTIBD;LK"Q>/1,J7J]602LZ4I==SU
ME7%8F?M0ZH2O83&)53 ZYT-E,9GN[;V8E-JZT<D1_W813HY\G0KKS$50L2Y+
M'=9GIO"KX]'^J/WAJUTL$_TP.3FJ],)<FO1G=1'P;=))R6UI7+3>J6#FQZ/3
M_==GA[2?-WRW9A4'GQ59,O/^BKY\RH]'>Z20*4R62(+&?]?FK2D*$@0U_FID
MCKHKZ>#P<RO]/=L.6V8ZFK>^^+?-T_)X]&JD<C/7=9&^^M5'T]CS*\G+?!'Y
M7[62O2_W1BJK8_)E<Q@:E-;)__JFP6%PX-5#!Z;-@2GK+1>QEN<ZZ9.CX%<J
MT&Y(HP]L*I^&<M:14RY3P*K%N71RIJ.-RL\57%KIH!FJK0M?V,R:N'TT2;B$
MMDZR1N"9")P^(/"%^NQ=6D;USN4FOWU^ N4Z#:>MAF?31P6>FVQ7'>R/U71O
M>O"(O(/.X@.6=_"HQ5_FZF)@\7].9S$%A,A_-UDL @\W"Z2T>1TKG9GC$4",
M)ER;T<DO/^V_V'OSB+J'G;J'CTF'^3$+MF(MX2:=9;YVR;J%JLA):X7$I+B\
M[T5S4Q7:Z>3#>I-1CU^[,2X^F^AGA8Y)_6Y+FTRNL$>3!CM5\'.;E(%J271*
M2Z.J.E0^FEX.Z4T+<^NTRZPN5$PZ&60YJ$5]PTKF$3<N0C8^19B8:[IHTP$2
M>U\E[: 6%F,]BS:WN--$M=371LV,<8T>I+IC,$,.N099EY;JDTLF.+85%YWV
M4%\F2-4A5Y].+]7!H6RTI7K?:?755#[PWK'2$;C$&G?,UFSMDW*C.O,D?NN7
MGUY-IWMO<,T9?]Q_LSUFBZ"RJIVN<[*1D8I#K&RCT$:8<J^<3]B3%75NE"X*
M0HX4P\\ A^3G-F:%CS4"&%S[5VV#J'];]4WV=C9L,AQVC#D:M',UCCWM4U(F
M+GU=Y"0!%.T#>4Y1Q2&?0<*/V@FEL]-\W4D/K)3""C$V"&/G?1>*:Z,#PA.<
MI/Y5.Z,.]H11=F$B;_"5=4V2E4B;!>LSYJ7[Z,( W0(:&5&=_P!;LPUC-M-&
MAL>[8DTR'=404C&K Z?!X(!R)C,QHB@*5FJN;>A!:;T%WZ#6Q,ZD5JT*__H<
M^;-EM]4'3\*A0 :_J5-.$E"H*6<F=#0J9GT(OJ[4TA#4/I%W=%RJAL+XX,\O
M7^Z^0-DI"B"SJ\[K+H&CO5&E$+V ^N@=Y@9FD\NYDE=0-]AD_]8MJX$]?J!,
MB_?1<(0VX$#*1I<@)T:,*CC.-2&KB7L$$^0WA6U>9[C#H95A2^H(+S):C<A;
M,L9JM;394JUP].?IB][.9]NGY<K6B/W#?P#W4M@E>2% ,K5Q$$<:\:S$;8?.
M/P'U-?0K*#W*TH0F):"Q6:Q)$DDM3$+JYLA_0::RU^(S B?C R '(]$Q\W<N
MR);!8YM"#V:H7&17JM+$@)1MB")O\QWD&E5 E N@!&^I1=#SI*!:K,&@'AP+
MEC!H@=36Z/+KCO[P_>/Y:)N<1R@ <Y=S9A,3](I:-\>MT"OX$GLJ2UJC ;PR
ME"G!KW6!B@&L31L1X]9X* PTDX,&2UL!IM!=%BN3V3DV-#D)UZ[@/F&*AKZ
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M7SL2/:V)->%NIRZI\Q&7O[M!DKJ%81&T;;!&/W7K8*42'24W'UOVNO%);\X
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M0A,![I<*2U=_( &'S[;9?U!+ P04    " #<>UU8XQ\V@U4#  !D"   &0
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MLM25_#2GWP#43H#.,T5>-@MGH/VQ6/X+4$L#!!0    ( -Q[75BRRO)#"1$
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MJK"O4#M![L$!\'^ME-E]X +]]>/%?P!02P,$%     @ W'M=6-ON&M$:!
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M 6^QOH \C2!+LOP-O/SH<.[Q\C-X2\LL4E594&NH#]X;^)NMC-54)/^\YO2
M6;R.Z2[.I=FR&N<!W0R#^A&#Q?MWZ3CY^ ;CXLBX> M]L1SNB^/KL_799>OK
M2[9>X_LVXHA+^'ZQO(!&"<&TB2CY8%O5&R8;$\*5<<:&KS?)+)6^?("JBM*B
M@"J)IED"M[A5AEOCCFLF!!1I OETXL3*DL32*$\G\'_6EOSIIZ*!T2J$>ZR5
MK+G@0T$2$8GV-%^](4D"HN=)>QE#-\>V()0A0FN+FDYKU2%8]N2+QWTR^,V=
M4^R( 0+I<D4&\RPJ\VD(HX(H5PE%H&GB$7'I:QMZR^*@)I7\X&EP*B.RY':%
M8W3IXJ&QWC,FWX!U2EO^[["1145!'*)TF@ ]*/1<2,"GNF5R@S#:T/MIPMB9
M00.CM"0VZ32'SUPR62/4RE"@TX0B.G7#>%)2C#IDIM<OY4Q1Y 1'*YH:WNQ#
M WE>P:B,II-I^*O6CFG-:$JQ7E' +7<$BJC(BY!2F,&G'SVWSV#06D$Q-RW3
M^,&]A ULV;-'<5Z5D$9565$4UJ@U';JXKU#BFEMR*,DHO&DV#N%F</DE=W)#
M821XXX-V0L.%M*968S"F(AIFH:\>S1KTTHK2J*D[U,@?_9M%7))) :.JR,-S
MZI2F/7,7ZCQUB<^*L^+.$=H@<6H@SI9Z)-YDC#Q.I@6\?S?)TNPCW<F#>H._
MD*6-AENE!R=97>N>"3(_C<J$"BZ+QLGD',)6JT=N?(VG$=F"4>:2\_OA1E"S
M/7LI1MDX*BL7_#R)JB(-7WN1XI,&TJ'>^#9IJ(AZ:8=><MP]=N*KH0&]B ]M
M_!O3&RIE$+@FU>2BHL:GA]8X+*S:^G:T4I::FY^V]#>!V@G0^5HI>U@X \?_
MD\5_4$L#!!0    ( -Q[75A&#@1XY04  .\0   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;+U86V_;-A3^*P?N4"2 :NMN.TT,)&F*=6B6H$[7AV$/
MM$3;1"51):DX^?<[A[K$BAUWV8 ]Q*(H\CO?N9,YW4CU7:\Y-_"09X4^&ZR-
M*4]&(YVL><[T4):\P"]+J7)F\%6M1KI4G*5V4YZ-?->-1SD3Q6!V:N=NU>Q4
M5B83!;]5H*L\9^KQ@F=R<S;P!NW$%[%:&YH8S4Y+MN)S;KZ6MPK?1AU**G)>
M:"$+4'QY-CCW3B[&M-XN^$/PC=X: VFRD/([O7Q*SP8N$>(93PPA,'S<\TN>
M902$-'XTF(-.)&W<'K?H'ZWNJ,N":7XILV\B->NSP60 *5^R*C-?Y.97WN@3
M$5XB,VU_85.OC=P!))4V,F\V(X-<%/63/31VV-HP>6F#WVSP+>]:D&7Y@1DV
M.U5R XI6(QH-K*IV-Y(3!3EE;A1^%;C/S*Y^5,(\PM$=6V1<'Y^.#(+2IU'2
M %S4 /X+ #%<R\*L-5P5*4_[^T=(IF/DMXPN_(. 'W@RA,!SP'?]X !>T&D8
M6+S@)3RADTSJ2G&02T@RIC77--1KAG,)*X5A&?S)%MHH#)*_]MF@%A'N%T&)
M<Z)+EO"S 6:&YNJ>#V9OWWBQ^_Z  F&G0'@(?3;'1$RKS-*?6\Z7->=]1 ]"
M[2<Z[]GAW-H&G<#S!5>=(^C'WQK931I^ET,X^CJ<#R&56<:4=D 48-:RTJQ(
M]3%<8G HL:@,3X$WL2:.H2_S1J6BP))0NT2#Y[A>Y 2A[_C!&,;!V/%\S_&]
M"7[Q)['C^U,:N6-G[(7PF6M] G=8DM#)CRVSHPBW3]W@>&OT]LW$]_SWW?-.
MDO1MBDTZ$('0&4^G3A"$2"!VHO'$";QH+X$#/HXZ'T>'?5S71#+]M;SG6/6,
M)DMVEOFIXP_C]T!ES]R=%^;BH9?+NQ/_)1!NL(V(8H4E-&-%PF&"!O;=T)GX
M$<21ZX11Z$211V8-I^CO $=>C%'@3N&3UE6=L_)9I*25(E"SYE!R)60*MQF&
M-ZG:I;B&"MDK8(V^9;>"K12O1T?>\9%_C!JA4 RWT/,!W1S']#>&8.J,W0F$
MD>/&$48:*S2KFTHB-=J4*:&)!D[4(@01W@FW(]^)791"S]@];L(O:<,/\:R.
M39KLJO82.TP/-P8,\M"-FD"190W7)#D8XKSD2J$7C6Q%(%_^P%4BM"TN[:;G
MO)\_,1BV/?FZ;$5+PX<GU33&6%['&+<QME-YG)[>C4<WO+5R2G'&P ,\H$ (
MI9+O%#9";/<)MGX<XHI"%N\4+V2%=*G/H2@C3-:&"=J%U"_P"+&LLNP12B;2
MG5!#,==<RP4V$ .?12Y,8\L'H0VI8]>M98:Q9E>?5]10,H%<BA02K@RCY$.M
M%3J](J\CK)$K;J<VPJQQ)>Y$.&/# :.CW [G?\'0 6;@_!=W&+@41O523%7_
M=5[PG>V(>\$)11M79:62-:N#:M=F#:%Q]$2H9T>R%FG:-X0H[CF>AI0>'BBW
M<5=NX]>7V[:]6D/6:72GT(?[JNUA^![FDW,:50GS?RZV30?LGL\SNB7\,M^K
MK3JA>R6&$OJ5%>-G= CRIH%G3S%&09*7F7SD'#5.A<*3/09$G5ZX%@_BK&EQ
MF/V8'5:8S2L*\J=(O&I0&B_7HJAS%$/XJ&0.OU49'0+(Z*Z#[<.F6V.8/B&;
M/5MV(HZ%K3'+RE2=F;HZ2PD/"]S##1:@= @W>VNP4]=])1/.4QM&]-XM)'FH
M/:I8I]X+'7UOR2)K]<"$;MG XK'K%*W,1NLEF66/LA:I,><0;K%/*9KN&W +
MI[$<D>AS174XWL]2:DH]>EN-R1:<G^M]J$*,NPHQ_J<5XAM3:!,#7^I>NJ\<
M',3:?^IN4=L.?83J'$KI^EQ>_S[?VQ:(8"?Q/4RP>-H^NC3?/5L\3\%+O#+1
MDHN]0/L,/-JZA.9<K>Q56]>=KKZ/=K/=;?Z\OL0^+:__%7#-U JK/V1\B5NI
M50Q U=?K^L7(TEYI%]+@!=D.UYQAXZ4%^'TII6E?2$#W/X[9WU!+ P04
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M L)TT-<WG*MCPP2H]X<6_P!02P,$%     @ W'M=6!1$]ES<!@  !B   !D
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M@NA8CW6:9:[>/M>)UV@X@_ &=3O?D.=ZW0J>Z>5RKP&G6W9]U_IU:_RF:R&
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M9-W'ZXD61=4*%T)C8ZV&*5Y]0)H ?)\(+$DS,=VUO4R%?P%02P,$%     @
MW'M=6#TZ<R=9!@  _BX  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
MO9KO;YLX&,?_%2LW39NT+=C\2K8T4A=274\[K5J[[<7I7KC$;=  9[;3KO?7
MGR$4 G:]6'+ZIH7D>;X\_AIL?V)F]Y3]X&M"!/A5Y"4_&:V%V+P?CWFZ)@7F
M[^B&E/*;&\H*+.0INQWS#2-X52<5^1AY7C0N<%:.YK/ZLPLVG]&MR+.27##
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M.](V<_V?!,( ]/R,<_7<,1=E\^>5_ =02P,$%     @ W'M=6&4@GU%L @
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ML/=J?8-]/>>.+U?"^"^L^]PH@+PU5M4]F!347'9_]MS[L 48GNT!Q#T@_E=
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M9:GS?%C1VXC:)=!ZJ91]';CVV[RVV6]02P,$%     @ W'M=6,T1'Q)> P
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MK+J?JSJ";LH+J#D5@N9E<PUX 4P9R/=+2L5S1]UI-;>DDV]02P,$%     @
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M9C/=21@ZQ42@.TQS, /GL "*?'3&I!*Y7A>::3\"A0F5!YKC]B9"^WL':,]
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M"+QP;&_V!3E<Y+GG@^:B^ ^+&@$,Z@ &O0%4!2[1 A.!-ICF@+!"RZ+J4ZQ
ME[G.9LCF()#G'<WH:6DFW'/.=1RG%6:O+X_=]T.+@V#/8D..L)8C[)7C!C+
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M$&:!_K[@7.T&QD!]#XM^ U!+ P04    " #<>UU8.?-7M2 $   )$0  &0
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M$2E28<XN@3"35.P1';73M2H(83"$]"S/TY]7P_/V7J-#W!AA"H#8L#=&F%,
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ME&\4)0QN!9*;HL#B[Q50OIM9KO7TX(ZL<V4>V/&TQ&M8@GHH;X7NV6V6E!3
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M>)V#=)J%N=@KS#\WQ@E=:\C4OZX2;._0==\A%YISM:(S& =&213()P@F/_Z
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MX+<!ZJLXLE?Q8=L)_@%WN2H_^I<SN%IR4E^9H-O#OK0LGBK:4(2^14 _M$5
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MH!R#KV,<]3L1=SIMC""Z0-P&])H/V#2 L@*U#7)>^3K&4;\3\9SFN*D+Q&U
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M":<G3!K59[7J>(OJ$=PHHC=P(5-,._#G_?A!W$,04@K:/,0O>3B+>QGGF!S
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MC%AQU"T&@J[RT^*4"GGVS"^7\O, ,64@G\\I%=N!.H!6'QS1'U!+ P04
M" #<>UU8 3!.=4 #  !F#@  &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6R]5UU/VS 4_2M6-DT@#?+1M+2LC32(T)B&5-$Q'J8]F/2VM7#LS'8I_/M=
M)R&T-,T 1;PTMG//\;TG/JX]7$EUJQ< AMRG7.B1LS F.W9=G2P@I?I09B#P
MS4RJE!KLJKFK,P5TFH-2[@:>UW-3RH03#?.QL8J&<FDX$S!61"_3E*J'$^!R
M-7)\YW'@DLT7Q@ZXT3"C<YB N<K&"GMNQ3)E*0C-I" *9B/GJW\<^YX%Y!&_
M&*ST6IO84FZDO+6=\^G(\6Q&P"$QEH+BXPY.@7/+A'G\+4F=:DX+7&\_LI_E
MQ6,Q-U3#J>37;&H6(Z?OD"G,Z)*;2[GZ!F5!7<N72*[S7[(J8SV')$MM9%J"
M,8.4B>))[TLAU@!^N ,0E(#@I8!.">B\%!"6@#!7IB@EUR&FAD9#)5=$V6AD
MLXU<S!R-Y3-AO_O$*'S+$&>B,R:H2!CE1#%]B\P"OS9^5T,.R 07V73)@<@9
M.1<)+BL-;@Q%PPY.%E0!&2N6 -F+P5#&]3X"KR8QV?NX/W0-9FCG<9,RFY,B
MFV!'-DA^2#K^9Q)X0:<&?MH,_[X4"/=VPN.7PX--N(NR5MH&E;9!SM?950W3
M"9=ZJ7*QGI2^M$I?/"G]^P<"R;F!5/^ITZR8):R?Q6X,QSJC"8P<=+X&=0=.
M].F#W_.^U"G8)EG<$MF&NIU*W4X3>W1-E:*H'F?TAG%F'NJD*RBZ.87= N^B
MP0"W1&_HWJV+LAW6#8/>5ER\'1?X_>YZW$8I855*V%C*&%2""P'7@UTHK+0:
MH6**6UC988+HW&Z9M5M=K<4<_;7DO$/_6:$OB(D;<WWC1^U62G0;E?@I,RO!
M)17SVAH;T:^U0IMD<4MD&ZKU*M5Z[[+1]-I4MTVRN"6R#76/*G6/FM<D")(5
M#MVPY_\=>;2U71SX8;B]_=3$]0;][>VG,<\WJM"O5.@WJG B#9Y%&LW92/#:
MY=,F6=P2V89P@TJXP;N8<]"FNFV2Q2V1;:CK>T\'6.\U]MS^P]SESI)WW7:^
M->=S=];$]?HUAX/F/%^K@[MVIK<WL NJYDQHPF&&]-[A$>:CBDM-T3$RRX_Y
M-[E1\^8"+X*@; "^GTEI'COVYE!=+:-_4$L#!!0    ( -Q[75A^XEF<N@8
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MMSTH((WZD;9GCV,5KU^K[BTK("#%S^\,V@8X*8"3>J%U^HTY4K7BI3OW!H^
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MS-[?8*3C8$3#JCXTXUY9U]IAV;E_"6COX,X;I>S)\ FFOU/Y%U!+ P04
M" #<>UU8*:4HC/0!   4!   &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q]5%&/TS ,_BM1D!!(:.E:;L!H*[&;$$B ICL!#XB'K'7;Z)*F).YZ_'N2
MM*N*M-M+8R?^/G^.G::#-@^V 4#RJ&1K,]H@=EO&;-& XG:E.VC=2:6-XNA<
M4S/;&>!E "G)XBC:,,5%2_,T[!U,GNH>I6CA8(CME>+F[PZD'C*ZIN>-.U$W
MZ#=8GG:\AGO []W!.(_-+*50T%JA6V*@RNB']7:7^/@0\$/ 8!<V\94<M7[P
MSN<RHY$7!!(*] S<+2>X!2D]D9/Q9^*D<TH/7-IG]H^A=E?+D5NXU?*G*+')
MZ%M*2JAX+_%.#Y]@JN?&\Q5:VO EPQB;O*.DZ"UJ-8&= B7:<>6/TSTL ''\
M!""> ''0/28**O<<>9X:/1#CHQV;-T*I >W$B=8WY1Z-.Q4.A_D7J+DD!Z,+
M@%*TM24O]H!<2/LR9>@2^#!63&2[D2Q^@FP/Q8HDZU<DCN*$2#[87N#_-,SI
MFT7&L\@X\"97178+D<X^B3 8O_C1HG'-_7U)[\C[^C*O'_BM[7@!&743;<&<
M@.;/GZTWT?LKJI-9=7*-/?_6JR,8HJLP>D[J="'VDM"1:A.H_$,ZY>N4G9;9
MV:+)_KU\Y:86K242*H>)5F]N*#'C#(X.ZB[T_:C135$P&_=LP?@ =UYIC6?'
MC]+\(\C_ 5!+ P04    " #<>UU8F@2].FX#  "R%@  #0   'AL+W-T>6QE
M<RYX;6S=6-%NVC 4_94H7:=6FAH@:R K(&U(E29M4Z7V86^5(0Y8<IS,,1WT
M<=^SK]J7S-<."5!?1/NPPH)*['MRSCVV;XC3?JF6G-[.*%7>(N.B'/@SI8H/
M05!.9C0CY45>4*&1-)<94;HKIT%92$J2$D@9#SJM5A1DA E_V!?S[#I3I3?)
MYT(-_+@.>?;T.1GX[>B][UFY49[0@7]_]O;'/%=7;SQ[/GEW<M*Z/[_:CI\9
MX-P/G**7>XA>M/2!*AL4DX\VY0WA5$M9ZBE&Z^[E:H<E3+BWWW!W#1:3CMW2
M?W[]1A:H078N4;?EF$/MHYE&Z&#DMIO<6B>CF3L(>9-MZ4%5Q,-^FHNFED/?
M!K0^R:CW0/C 'Q'.QI(!*R49XTL;[D!@DO-<>DK?1#IA&R+EHX7;M@?W5Z63
M,9%+D]MFL-_CZO(M8-4#@XSSVF#'MX%AOR!*42FN=<=<;()/(*]JWRT+[7 J
MR;+=N?0;@CGI).-<)E36:=K^*C3L<YJ"'<FF,SBKO @ 5"K/="-A9)H+8CRL
M&%5#RTXHY[?PX_,]W=!>I&LK9RI&U$UMJ&I:&=L!_74UJ[TN&[U(URO80ZX^
MS?5PA.E#B=,;25.V,/U%6AO U-NX.BD*OOS(V51DU Y^[X3#/EGQO%DNV:/.
M!J4RT0$J?>^!2L4FZY&?DA1W=*%6Y;1(<<^=(_3\;^=Y2@65A*^;UK5_R+/\
M8L?5T_HU/)N?E6W'3I-A]_ ]5CN40S<9'8/)(UCN,#Y\C]4N\M!-'L-,=E_M
ME_TY)MO'8+)SD":#:D^YMG'=V+;640]>#P;^-WC=X$U2;SQG7#%1]68L2:AX
MLGO5\HJ,]0OYAKZ^/J$IF7-U5X,#OVE_I0F;9W%]U0U,1'55T_X"P]-;X=6[
MB<[%1$(7-!E573D=FZ:G&SIK=0!A&[DVAQO!.!9S(X!A>3 '&,>RL#S_TWAZ
MZ'@LAGGK.9$>RNFA',MR(2/SP?*X.;$^W".-XS",(FQ&1R.G@Q$V;U$$?VXU
MS!LPL#R0Z7ESC:\V7B&[ZP!;TUT5@HT4KT1LI/A< ^*>-V#$L7NUL3S P%8!
MJQW([\X#->7FA"&L*N8-NX-Q)(XQ!&K17:-1A,Q.!!_W^F!W21C&L1L!S.T@
M##$$[D8<P1R !PP)0_,<W'H>!:OG5-#\EWKX%U!+ P04    " #<>UU8EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M -Q[75BO:@K82P4  .4Q   /    >&PO=V]R:V)O;VLN>&ULQ9O=<^(V$,#_
M%0U/N8<4_)UD0F9Z2:[-S-TU<W2NCXRP!6AB2U0R2>[^^JY-2=:)V?9E\1/X
M _&SL/:W6HO+)^L>%M8^B.>J-'XZ6M?UYF(\]OE:5=+_8C?*P)&E=96L8=.M
MQG[CE"S\6JFZ*L?A9)*.*ZG-Z.IRW]:]&^,-6ZN\UM; SF;'=ZV>_.OQ9E,\
M:J\7NM3UC^FH?5^JD:BTT97^J8KI:#(2?FV??K=._[2FEN4L=[8LIZ-@=^"[
M<K7.W^V>-9!_RH5O]]1R\4T"R'243J#!I7:^;L]HVY? ^*C@Y-W6MK:?=%DK
M=R-K]9NSVXTVJZ89N(HQNHRV'_:ONTZ\</^G&^URJ7-U8_-MI4R]ZT>GR@;0
M^+7>^)$PLE+3T?X4(4TA;DT-G23NS*XI.+>Y4OCJNV)WU37@HCYT%QH.N+NB
M!>>#O(9M6^H"OKT NMQ62LP:EN9S"#$D$,,C(KZP";L4U[;:. 09$9#18)!K
M:58(,B8@XR-"?I2E-#G\VLW7(;Z$X$L&ZT3IUP)!I@1DR@OY47KM&R8(IQOI
MWH[EC"#+>,EF>F4TG"NAS_+FKE->:"/JM1+YUN&!<D9 GO%"?K;>BX6"SRJ
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ W'M=6.KZY(+N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MW'M=6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #<>UU8B"*(W#\#   A"P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MW'M=6'%! #!E!   %0\  !@              ("!@@L  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( -Q[75CR#P ,E0,  !\+   8
M          " @1T0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #<>UU8FW&7])H'  #".   &               @('H$P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ W'M=6+^V%3["!0  +1H
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M965T.2YX;6Q02P$"% ,4    " #<>UU84*T#64P$  #;"@  &0
M    @(&F20  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M -Q[75A:!9FF$B,  *5_   9              " @2E.  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ W'M=6(*Y-PT"$0  B3$  !D
M             ("!<G$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #<>UU83*LO@@L$  "M"   &0              @(&K@@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -Q[75@\*1EZ70@
M +L5   9              " @>V&  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ W'M=6/W'C1FT$0  (3<  !D              ("!
M@8\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #<>UU8
MGB\'$.$#  !0#   &0              @(%LH0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( -Q[75@V </P? (  -8%   9
M      " @82E  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ W'M=6"30Q=!B P  Q@<  !D              ("!-Z@  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #<>UU87 !G!<0$  !W"@
M&0              @('0JP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( -Q[75C?$^51]@D  "49   9              " @<NP  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ W'M=6$^.IK2V
M!0  P@T  !D              ("!^+H  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #<>UU8XQ\V@U4#  !D"   &0
M@('EP   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -Q[
M75BRRO)#"1$  '$[   9              " @7'$  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ W'M=6)2$O=U1!P  BA0  !D
M         ("!L=4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " #<>UU8V^X:T1H$  "K"   &0              @($YW0  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( -Q[75A&#@1XY04  .\0
M   9              " @8KA  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ W'M=6*D5"%27"P  TQ\  !D              ("!IN<
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #<>UU8.;4+
MZ%8#  !Q"@  &0              @(%T\P  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( -Q[75AA9&"$! ,  'L*   9
M  " @0'W  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MW'M=6)_4F@3, P  *Q(  !D              ("!//H  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #<>UU8%$3V7-P&   &(   &0
M            @($__@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( -Q[75C/7L/>V@,  -<1   9              " @5(% 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ W'M=6",:H7B;#
MU*@  !D              ("!8PD! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #<>UU8]Z.(Q@4#   4"@  &0              @($U
M%@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -Q[75A5
MY*VPY0(  %@)   9              " @7$9 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ W'M=6#TZ<R=9!@  _BX  !D
M     ("!C1P! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -Q[75B4D;0D?Q8  (56 0 9              "
M@5@O 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ W'M=
M6$T@WEUF @   P8  !D              ("!#D8! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " #<>UU8#R6.QK($  #N&0  &0
M        @(&K2 $ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( -Q[75AV%6ON!00  #$5   9              " @91- 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ W'M=6-+R[F5]!0  %AT
M !D              ("!T%$! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " #<>UU89/'4R=8%  #/,   &0              @(&$5P$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -Q[75B15%50
M=@,  (L-   9              " @9%= 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ W'M=6+$=^(.5 @  W 4  !D
M ("!/F$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #<
M>UU8*FK8!5D'  " /   &0              @($*9 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( -Q[75@W&>>T!0,  %X'   9
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M970U-"YX;6Q02P$"% ,4    " #<>UU8LTZ3>PL$  #P%0  &0
M    @(%A@P$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M -Q[75A-E/#I> 0   H:   9              " @:.' 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ W'M=6+FCA@'# P  K1$  !D
M             ("!4HP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " #<>UU83>Z[:-8"  !7"0  &0              @(%,D $ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( -Q[75AB\6,XY00
M (T9   9              " @5F3 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ W'M=6'\[%!4N!@  2B$  !D              ("!
M=9@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #<>UU8
M(C-3U)P#  #N$   &0              @(':G@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( -Q[75AGMF?WV 0  *X5   9
M      " @:VB 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ W'M=6)4HG4C! @  ;@<  !D              ("!O*<! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #<>UU894YO2RP#   ?#
M&0              @(&TJ@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( -Q[75A54=M#50,  ,X-   9              " @1>N 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ W'M=6$0W#).^
M!@  "CX  !D              ("!H[$! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " #<>UU88YRX8HL%  ":'P  &0
M@(&8N $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( -Q[
M75B%&5-\#@8  )0L   9              " @5J^ 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ W'M=6,O:]C$7 P  .@H  !D
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M=#<S+GAM;%!+ 0(4 Q0    ( -Q[75BJ;V8:'@(  *D$   9
M  " @0': 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @
MW'M=6"FE*(ST 0  % 0  !D              ("!5MP! 'AL+W=O<FMS:&5E
M=',O<VAE970W-2YX;6Q02P$"% ,4    " #<>UU8F@2].FX#  "R%@  #0
M            @ &!W@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -Q[75B7
MBKL<P    !,"   +              "  1KB 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( -Q[75BO:@K82P4  .4Q   /              "  0/C 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #<>UU89_Q20DP"  !H+   &@
M        @ %[Z $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #<>UU8AJ9C2 P"  !A*P  $P              @ '_Z@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     4P!3 +P6   \[0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>336</ContextCount>
  <ElementCount>357</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Income Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Income Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statement of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome</Role>
      <ShortName>Consolidated Statement of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity</Role>
      <ShortName>Consolidated Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Basisofpreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Significant changes in the current reporting period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod</Role>
      <ShortName>Significant changes in the current reporting period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Loss before income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Lossbeforeincometax</Role>
      <ShortName>Loss before income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Income tax benefit/(expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Incometaxbenefitexpense</Role>
      <ShortName>Income tax benefit/(expense)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Financial assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Financialassetsandliabilities</Role>
      <ShortName>Financial assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Non-financial assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Nonfinancialassetsandliabilities</Role>
      <ShortName>Non-financial assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Cash flow information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Cashflowinformation</Role>
      <ShortName>Cash flow information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Financial risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Financialriskmanagement</Role>
      <ShortName>Financial risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - (Losses) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Lossespershare</Role>
      <ShortName>(Losses) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Events occurring after the reporting period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Eventsoccurringafterthereportingperiod</Role>
      <ShortName>Events occurring after the reporting period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Legal proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/Legalproceedings</Role>
      <ShortName>Legal proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Basis of preparation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/BasisofpreparationPolicies</Role>
      <ShortName>Basis of preparation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Loss before income tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LossbeforeincometaxTables</Role>
      <ShortName>Loss before income tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Lossbeforeincometax</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Income tax benefit/(expense) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/IncometaxbenefitexpenseTables</Role>
      <ShortName>Income tax benefit/(expense) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Incometaxbenefitexpense</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Financial assets and liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables</Role>
      <ShortName>Financial assets and liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Financialassetsandliabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Non-financial assets and liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables</Role>
      <ShortName>Non-financial assets and liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Nonfinancialassetsandliabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Cash flow information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/CashflowinformationTables</Role>
      <ShortName>Cash flow information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Cashflowinformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Equity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Financial risk management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementTables</Role>
      <ShortName>Financial risk management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Financialriskmanagement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - (Losses) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LossespershareTables</Role>
      <ShortName>(Losses) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Lossespershare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Basis of preparation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/BasisofpreparationDetails</Role>
      <ShortName>Basis of preparation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/BasisofpreparationPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Significant changes in the current reporting period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails</Role>
      <ShortName>Significant changes in the current reporting period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Loss before income tax - Summary of Loss Before Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails</Role>
      <ShortName>Loss before income tax - Summary of Loss Before Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Loss before income tax - Summary of Loss Before Income Tax (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails</Role>
      <ShortName>Loss before income tax - Summary of Loss Before Income Tax (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Loss before income tax - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails</Role>
      <ShortName>Loss before income tax - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails</Role>
      <ShortName>Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Financial assets and liabilities - Summary of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Financial assets and liabilities - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Financial assets and liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Financial assets and liabilities - Summary of Trade and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Trade and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Financial assets and liabilities - Summary of Prepayments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Prepayments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Financial assets and liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails</Role>
      <ShortName>Financial assets and liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Financial assets and liabilities - Summary of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Financial assets and liabilities - Summary of Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Financial assets and liabilities - Summary of Net Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Net Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Financial assets and liabilities - Summary of Net Debt Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Net Debt Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Financial assets and liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Financial assets and liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Financial assets and liabilities - Summary of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Financial assets and liabilities - Summary of Fair Value of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Fair Value of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Financial assets and liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails</Role>
      <ShortName>Financial assets and liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Non-financial assets and liabilities - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Non-financial assets and liabilities - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails</Role>
      <ShortName>Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Non-financial assets and liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails</Role>
      <ShortName>Non-financial assets and liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Non-financial assets and liabilities - Summary of Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails</Role>
      <ShortName>Non-financial assets and liabilities - Summary of Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Non-financial assets and liabilities - Summary of Deferred Tax Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails</Role>
      <ShortName>Non-financial assets and liabilities - Summary of Deferred Tax Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Non-financial assets and liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Non-financial assets and liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Cash flow information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/CashflowinformationDetails</Role>
      <ShortName>Cash flow information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/CashflowinformationTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails</Role>
      <ShortName>Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Equity - Summary of Movements in Ordinary Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails</Role>
      <ShortName>Equity - Summary of Movements in Ordinary Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails</Role>
      <ShortName>Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Equity - Summary of Movements of Shares in Share Trust (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails</Role>
      <ShortName>Equity - Summary of Movements of Shares in Share Trust (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Equity - Summary of Warrant Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails</Role>
      <ShortName>Equity - Summary of Warrant Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Financial risk management - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails</Role>
      <ShortName>Financial risk management - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails</Role>
      <ShortName>Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails</Role>
      <ShortName>Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Financial risk management - Summary of Borrowing to Price Rate Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails</Role>
      <ShortName>Financial risk management - Summary of Borrowing to Price Rate Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Financial risk management - Schedule of Increase/Decrease of Share Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails</Role>
      <ShortName>Financial risk management - Schedule of Increase/Decrease of Share Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Financial risk management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails</Role>
      <ShortName>Financial risk management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - (Losses) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LossespershareDetails</Role>
      <ShortName>(Losses) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mesoblast.com/role/LossespershareTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="meso-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mesoblast.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="meso-20231231.htm">meso-20231231.htm</File>
    <File>meso-20231231.xsd</File>
    <File>meso-20231231_cal.xml</File>
    <File>meso-20231231_def.xml</File>
    <File>meso-20231231_lab.xml</File>
    <File>meso-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="691">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "meso-20231231.htm": {
   "nsprefix": "meso",
   "nsuri": "http://www.mesoblast.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "meso-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "meso-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "meso-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "meso-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "meso-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meso-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 170,
   "keyCustom": 187,
   "axisStandard": 33,
   "axisCustom": 1,
   "memberStandard": 48,
   "memberCustom": 45,
   "hidden": {
    "total": 7,
    "http://www.mesoblast.com/20231231": 4,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 336,
   "entityCount": 1,
   "segmentCount": 97,
   "elementCount": 620,
   "unitCount": 11,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 691,
    "http://xbrl.sec.gov/dei/2023": 12
   },
   "report": {
    "R1": {
     "role": "http://www.mesoblast.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
     "longName": "0000002 - Statement - Consolidated Income Statement",
     "shortName": "Consolidated Income Statement",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome",
     "longName": "0000003 - Statement - Consolidated Statement of Comprehensive Income",
     "shortName": "Consolidated Statement of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
     "longName": "0000004 - Statement - Consolidated Statement of Changes in Equity",
     "shortName": "Consolidated Statement of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
     "longName": "0000005 - Statement - Consolidated Balance Sheet",
     "shortName": "Consolidated Balance Sheet",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:CurrentPrepayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows",
     "longName": "0000006 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:CommercializationRevenueReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:CommercializationRevenueReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.mesoblast.com/role/Basisofpreparation",
     "longName": "0000007 - Disclosure - Basis of preparation",
     "shortName": "Basis of preparation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod",
     "longName": "0000008 - Disclosure - Significant changes in the current reporting period",
     "shortName": "Significant changes in the current reporting period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.mesoblast.com/role/Lossbeforeincometax",
     "longName": "0000009 - Disclosure - Loss before income tax",
     "shortName": "Loss before income tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.mesoblast.com/role/Incometaxbenefitexpense",
     "longName": "0000010 - Disclosure - Income tax benefit/(expense)",
     "shortName": "Income tax benefit/(expense)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.mesoblast.com/role/Financialassetsandliabilities",
     "longName": "0000011 - Disclosure - Financial assets and liabilities",
     "shortName": "Financial assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.mesoblast.com/role/Nonfinancialassetsandliabilities",
     "longName": "0000012 - Disclosure - Non-financial assets and liabilities",
     "shortName": "Non-financial assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-187",
      "name": "meso:DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "meso:DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.mesoblast.com/role/Cashflowinformation",
     "longName": "0000013 - Disclosure - Cash flow information",
     "shortName": "Cash flow information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.mesoblast.com/role/Equity",
     "longName": "0000014 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.mesoblast.com/role/Financialriskmanagement",
     "longName": "0000015 - Disclosure - Financial risk management",
     "shortName": "Financial risk management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.mesoblast.com/role/Lossespershare",
     "longName": "0000016 - Disclosure - (Losses) per share",
     "shortName": "(Losses) per share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.mesoblast.com/role/Eventsoccurringafterthereportingperiod",
     "longName": "0000017 - Disclosure - Events occurring after the reporting period",
     "shortName": "Events occurring after the reporting period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.mesoblast.com/role/Segmentinformation",
     "longName": "0000018 - Disclosure - Segment information",
     "shortName": "Segment information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.mesoblast.com/role/Legalproceedings",
     "longName": "0000019 - Disclosure - Legal proceedings",
     "shortName": "Legal proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfLegalProceedingsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfLegalProceedingsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.mesoblast.com/role/BasisofpreparationPolicies",
     "longName": "9954471 - Disclosure - Basis of preparation (Policies)",
     "shortName": "Basis of preparation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.mesoblast.com/role/LossbeforeincometaxTables",
     "longName": "9954472 - Disclosure - Loss before income tax (Tables)",
     "shortName": "Loss before income tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.mesoblast.com/role/IncometaxbenefitexpenseTables",
     "longName": "9954473 - Disclosure - Income tax benefit/(expense) (Tables)",
     "shortName": "Income tax benefit/(expense) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables",
     "longName": "9954474 - Disclosure - Financial assets and liabilities (Tables)",
     "shortName": "Financial assets and liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables",
     "longName": "9954475 - Disclosure - Non-financial assets and liabilities (Tables)",
     "shortName": "Non-financial assets and liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.mesoblast.com/role/CashflowinformationTables",
     "longName": "9954476 - Disclosure - Cash flow information (Tables)",
     "shortName": "Cash flow information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.mesoblast.com/role/EquityTables",
     "longName": "9954477 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementTables",
     "longName": "9954478 - Disclosure - Financial risk management (Tables)",
     "shortName": "Financial risk management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfExposureToFinancialRisksTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:DisclosureOfExposureToFinancialRisksTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.mesoblast.com/role/LossespershareTables",
     "longName": "9954479 - Disclosure - (Losses) per share (Tables)",
     "shortName": "(Losses) per share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.mesoblast.com/role/BasisofpreparationDetails",
     "longName": "9954480 - Disclosure - Basis of preparation (Details)",
     "shortName": "Basis of preparation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:MaximumAmountInCashOutflowsFromOperatingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails",
     "longName": "9954481 - Disclosure - Significant changes in the current reporting period (Details)",
     "shortName": "Significant changes in the current reporting period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:ProceedsFromPrivatePlacement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:ProceedsFromPrivatePlacement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails",
     "longName": "9954482 - Disclosure - Loss before income tax - Summary of Loss Before Income Tax (Details)",
     "shortName": "Loss before income tax - Summary of Loss Before Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:CommercializationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:CommercializationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails",
     "longName": "9954483 - Disclosure - Loss before income tax - Summary of Loss Before Income Tax (Parenthetical) (Details)",
     "shortName": "Loss before income tax - Summary of Loss Before Income Tax (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-49",
      "name": "ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
     "longName": "9954484 - Disclosure - Loss before income tax - Additional Information (Details)",
     "shortName": "Loss before income tax - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-58",
      "name": "meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-58",
      "name": "meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails",
     "longName": "9954485 - Disclosure - Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details)",
     "shortName": "Income tax benefit/(expense) - Summary of Income Tax Expense/(Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:IncreaseDecreaseInCurrentTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:IncreaseDecreaseInCurrentTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails",
     "longName": "9954486 - Disclosure - Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details)",
     "shortName": "Income tax benefit/(expense) - Summary of Deferred Tax Assets Not Brought to Account (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails",
     "longName": "9954487 - Disclosure - Financial assets and liabilities - Summary of Financial Instruments (Details)",
     "shortName": "Financial assets and liabilities - Summary of Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:TradeAndOtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails",
     "longName": "9954488 - Disclosure - Financial assets and liabilities - Summary of Cash and Cash Equivalents (Details)",
     "shortName": "Financial assets and liabilities - Summary of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:BalancesWithBanks",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails",
     "longName": "9954489 - Disclosure - Financial assets and liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details)",
     "shortName": "Financial assets and liabilities - Summary of Cash and Cash Equivalents (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "meso:InterestBearingDepositsAtCallHeldAsSecurity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "meso:InterestBearingDepositsAtCallHeldAsSecurity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails",
     "longName": "9954490 - Disclosure - Financial assets and liabilities - Summary of Trade and Other Receivables (Details)",
     "shortName": "Financial assets and liabilities - Summary of Trade and Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:TradeReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:TradeReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails",
     "longName": "9954491 - Disclosure - Financial assets and liabilities - Summary of Prepayments (Details)",
     "shortName": "Financial assets and liabilities - Summary of Prepayments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "meso:ClinicalTrialResearchAndDevelopmentExpenditure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "meso:ClinicalTrialResearchAndDevelopmentExpenditure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
     "longName": "9954492 - Disclosure - Financial assets and liabilities - Additional Information (Details)",
     "shortName": "Financial assets and liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:GainLossOnRemeasurementOfWarrantLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails",
     "longName": "9954493 - Disclosure - Financial assets and liabilities - Summary of Trade and Other Payables (Details)",
     "shortName": "Financial assets and liabilities - Summary of Trade and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:TradeAndOtherCurrentPayables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:TradeAndOtherPayables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
     "longName": "9954494 - Disclosure - Financial assets and liabilities - Summary of Borrowings (Details)",
     "shortName": "Financial assets and liabilities - Summary of Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:SecuredBankLoansReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:SecuredBankLoansReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails",
     "longName": "9954495 - Disclosure - Financial assets and liabilities - Summary of Net Debt (Details)",
     "shortName": "Financial assets and liabilities - Summary of Net Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-117",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails",
     "longName": "9954496 - Disclosure - Financial assets and liabilities - Summary of Net Debt Reconciliation (Details)",
     "shortName": "Financial assets and liabilities - Summary of Net Debt Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails",
     "longName": "9954497 - Disclosure - Financial assets and liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)",
     "shortName": "Financial assets and liabilities - Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
     "longName": "9954498 - Disclosure - Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Details)",
     "shortName": "Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:LossGainOnRemeasurementOfContingentConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "meso:ContingentConsiderationProvisionAmountUsed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails",
     "longName": "9954499 - Disclosure - Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Parenthetical) (Details)",
     "shortName": "Financial assets and liabilities - Summary of Changes in Fair Value of Level 3 Instruments (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "meso:GainLossOnReMeasurementOfContingentConsiderationProvision",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "meso:GainLossOnReMeasurementOfContingentConsiderationProvision",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
     "longName": "9954500 - Disclosure - Financial assets and liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details)",
     "shortName": "Financial assets and liabilities - Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "meso:ContingentConsiderationProvision",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-143",
      "name": "ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails",
     "longName": "9954501 - Disclosure - Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details)",
     "shortName": "Financial assets and liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "meso:CashOrStockPayableAtFairValueLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "meso:CashOrStockPayableAtFairValueLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails",
     "longName": "9954502 - Disclosure - Financial assets and liabilities - Summary of Warrant Liability (Details)",
     "shortName": "Financial assets and liabilities - Summary of Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:WarrantLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-165",
      "name": "meso:WarrantsFairValueAtIssueDate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
     "longName": "9954503 - Disclosure - Financial assets and liabilities - Summary of Fair Value of Warrants (Details)",
     "shortName": "Financial assets and liabilities - Summary of Fair Value of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-173",
      "name": "meso:WarrantsPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "meso:WarrantsPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails",
     "longName": "9954504 - Disclosure - Financial assets and liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details)",
     "shortName": "Financial assets and liabilities - Summary of Fair Value of Warrants (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:IssuanceWarrantsExercisedPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails",
     "longName": "9954505 - Disclosure - Non-financial assets and liabilities - Summary of Intangible Assets (Details)",
     "shortName": "Non-financial assets and liabilities - Summary of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
     "longName": "9954506 - Disclosure - Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details)",
     "shortName": "Non-financial assets and liabilities - Summary of Carrying Value of In Process Research and Development Acquired by Product (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-225",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
     "longName": "9954507 - Disclosure - Non-financial assets and liabilities - Additional Information (Details)",
     "shortName": "Non-financial assets and liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-237",
      "name": "meso:CurrentProvisionsForAccruedAnnualLeave",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-237",
      "name": "meso:CurrentProvisionsForAccruedAnnualLeave",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails",
     "longName": "9954508 - Disclosure - Non-financial assets and liabilities - Summary of Provisions (Details)",
     "shortName": "Non-financial assets and liabilities - Summary of Provisions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:Provisions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfProvisionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails",
     "longName": "9954509 - Disclosure - Non-financial assets and liabilities - Summary of Deferred Tax Balances (Details)",
     "shortName": "Non-financial assets and liabilities - Summary of Deferred Tax Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954510 - Disclosure - Non-financial assets and liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Non-financial assets and liabilities - Schedule of Movements Related to Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ifrs-full:DeferredTaxLiabilityAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.mesoblast.com/role/CashflowinformationDetails",
     "longName": "9954511 - Disclosure - Cash flow information (Details)",
     "shortName": "Cash flow information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:BalancesWithBanks",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
     "longName": "9954512 - Disclosure - Equity - Schedule of Share Capital (Details)",
     "shortName": "Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-256",
      "name": "meso:TreasurySharesPurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails",
     "longName": "9954513 - Disclosure - Equity - Summary of Movements in Ordinary Share Capital (Details)",
     "shortName": "Equity - Summary of Movements in Ordinary Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-262",
      "name": "meso:TransactionCostsArisingOnShareIssueShare",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
     "longName": "9954514 - Disclosure - Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details)",
     "shortName": "Equity - Summary of Movements in Ordinary Share Capital (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-42",
      "name": "ifrs-full:NumberOfSharesIssuedButNotFullyPaid",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "ifrs-full:NumberOfSharesIssuedButNotFullyPaid",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails",
     "longName": "9954515 - Disclosure - Equity - Summary of Movements of Shares in Share Trust (Details)",
     "shortName": "Equity - Summary of Movements of Shares in Share Trust (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IncreaseDecreaseThroughExerciseOfOptions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-265",
      "name": "meso:SharesHeldInTrust",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails",
     "longName": "9954516 - Disclosure - Equity - Summary of Warrant Reserve (Details)",
     "shortName": "Equity - Summary of Warrant Reserve (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-29",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-273",
      "name": "ifrs-full:ChangesInEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
     "longName": "9954517 - Disclosure - Equity - Additional Information (Details)",
     "shortName": "Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-278",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
     "longName": "9954518 - Disclosure - Financial risk management - Additional Information (Details)",
     "shortName": "Financial risk management - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:PercentageOfForecastNetSales",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:PercentageOfForecastNetSales",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
     "longName": "9954519 - Disclosure - Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details)",
     "shortName": "Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-293",
      "name": "meso:FundsInvestedWhichDerivesInterestRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-293",
      "name": "meso:FundsInvestedWhichDerivesInterestRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails",
     "longName": "9954520 - Disclosure - Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details)",
     "shortName": "Financial risk management - Schedule of Deposits Held which Derive Interest Revenue Together with the Maximum and Minimum Interest Rates Being Earned (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-293",
      "name": "meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-293",
      "name": "meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails",
     "longName": "9954521 - Disclosure - Financial risk management - Summary of Borrowing to Price Rate Changes (Details)",
     "shortName": "Financial risk management - Summary of Borrowing to Price Rate Changes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:ShorttermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-303",
      "name": "ifrs-full:ShorttermBorrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
     "longName": "9954522 - Disclosure - Financial risk management - Schedule of Increase/Decrease of Share Price (Details)",
     "shortName": "Financial risk management - Schedule of Increase/Decrease of Share Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:WarrantLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "meso:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "meso:PercentageOfIncreaseAndDecreaseInSharePrice",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "meso:DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails",
     "longName": "9954523 - Disclosure - Financial risk management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details)",
     "shortName": "Financial risk management - Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.mesoblast.com/role/LossespershareDetails",
     "longName": "9954524 - Disclosure - (Losses) per share (Details)",
     "shortName": "(Losses) per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:BasicEarningsLossPerShareFromContinuingOperations",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:BasicEarningsLossPerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.mesoblast.com/role/SegmentInformationDetails",
     "longName": "9954525 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "meso:NumberOfOperatingSegment",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "meso:NumberOfOperatingSegment",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.mesoblast.com/role/LegalProceedingsDetails",
     "longName": "9954526 - Disclosure - Legal Proceedings (Details)",
     "shortName": "Legal Proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "meso:NumberOfClassActionLawsuits",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "meso:NumberOfClassActionLawsuits",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "meso-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "currency_AUD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AUD",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AUD",
        "label": "Australia, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r54",
      "r243",
      "r246",
      "r249",
      "r250"
     ]
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedImpairmentMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated impairment",
        "label": "Accumulated impairment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r143",
      "r151",
      "r218",
      "r243",
      "r246",
      "r249",
      "r250"
     ]
    },
    "meso_AdditionalPotentialMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AdditionalPotentialMilestonePaymentsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional potential milestone payments receivable",
        "label": "Additional Potential Milestone Payments Receivable",
        "documentation": "Additional Potential Milestone Payments Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "meso_AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions Reversal Other Than Through Business Combinations Intangible Assets Other Than Goodwill",
        "documentation": "Additions (reversal) other than through business combinations intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease/(increase) in trade and other receivables",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDeferredTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax benefit",
        "label": "Adjustments for deferred tax expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance costs",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "meso_AdjustmentsForIncreaseDecreaseInPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease/(increase) in prepayments",
        "label": "Adjustments For Increase Decrease In Prepayments",
        "documentation": "Adjustments for (increase) decrease in prepayments to reconcile profit (loss) to net cash flow from (used in) operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in trade creditors and accruals",
        "label": "Adjustments For Increase Decrease In Trade Creditors And Accruals",
        "documentation": "Adjustments for increase (decrease) in trade creditors and accruals to reconcile profit (loss) to net cash flow from (used in) operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in provisions",
        "label": "Adjustments for provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Add/(deduct) net loss for non-cash items as follows:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity settled share-based payment",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange (gains)/losses",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r253"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands [member]",
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r121",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r146",
      "r195",
      "r221",
      "r224"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All levels of fair value hierarchy",
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r111"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "meso_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares",
        "label": "American Depositary Shares [Member]",
        "documentation": "American depositary shares."
       }
      }
     },
     "auth_ref": []
    },
    "meso_AmericanDepositoryReceiptMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AmericanDepositoryReceiptMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depository Receipt",
        "label": "American Depository Receipt [Member]",
        "documentation": "American Depository Receipt"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Depreciation and amortization of non-current assets",
        "label": "Amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization charge",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "meso_AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receipt on non refundable up-front payment upon reaching product regulatory milestone",
        "label": "Amount Entitled To Be Received On Non Refundable Upfront Payment Upon Reaching Product Regulatory Milestone",
        "documentation": "Amount Entitled to be received on non refundable up-front payment upon reaching product regulatory milestone."
       }
      }
     },
     "auth_ref": []
    },
    "meso_AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount entitled to be received upon reaching product clinical and regulatory milestones and reimbursement targets are achieved",
        "label": "Amount Entitled To Be Received Upon Reaching Product Clinical And Regulatory Milestones And Reimbursement Targets Are Achieved",
        "documentation": "Amount Entitled To Be Received Upon Reaching Product Clinical And Regulatory Milestones And Reimbursement Targets Are Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "meso_AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "AmountOfRoyaltiesEntitledToBeReceivedUponReachingSalesBasedMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue relating to non-refundable up-front payment",
        "label": "Amount Of Royalties Entitled To Be Received Upon Reaching Sales Based Milestones",
        "documentation": "Amount Of Royalties Entitled To Be Received Upon Reaching Sales Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r113",
      "r172",
      "r175"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash at bank",
        "verboseLabel": "Cash at bank",
        "label": "Balances with banks"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "calculation": {
      "http://www.mesoblast.com/role/LossespershareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total basic (losses) per share attributable to the ordinary equity holders of the company (in dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "calculation": {
      "http://www.mesoblast.com/role/LossespershareDetails": {
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic - losses per share (in dollars per share)",
        "verboseLabel": "From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)",
        "label": "Basic earnings (loss) per share from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsPerShareAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(a) Basic (losses) per share",
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_BasisOfPreparationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "BasisOfPreparationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis Of Preparation [Abstract]",
        "label": "Basis Of Preparation [Abstract]",
        "documentation": "Basis of preparation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingCostsCapitalised",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of carrying amount, net of payments made",
        "label": "Borrowing costs capitalised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_BorrowingCostsRecognisedAsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingCostsRecognisedAsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: transaction costs",
        "label": "Borrowing costs recognised as expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are recognised as an expense."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails": {
       "parentTag": "ifrs-full_NetDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails": {
       "parentTag": "ifrs-full_LiabilitiesArisingFromFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "verboseLabel": "Principal amount of loans",
        "totalLabel": "Total borrowings",
        "negatedLabel": "Borrowings",
        "negatedPeriodStartLabel": "Borrowings at beginning of period",
        "negatedPeriodEndLabel": "Borrowings at end of period",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_BorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_BorrowingsInterestOnlyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "BorrowingsInterestOnlyPeriod",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, Interest Only Period",
        "label": "Borrowings, Interest Only Period",
        "documentation": "Borrowings, Interest Only Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings, interest rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "meso_BorrowingsPrincipalAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "BorrowingsPrincipalAmortizationPeriod",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period",
        "label": "Borrowings Principal Amortization Period",
        "documentation": "Borrowings Principal Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "meso_BorrowingsPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "BorrowingsPrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings principal amount",
        "label": "Borrowings Principal Amount",
        "documentation": "Borrowings principal amount."
       }
      }
     },
     "auth_ref": []
    },
    "meso_BorrowingsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "BorrowingsTerm",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings term",
        "label": "Borrowings Term",
        "documentation": "Borrowings term."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Bottom of Range",
        "terseLabel": "Bottom of Range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r140",
      "r210",
      "r212",
      "r260"
     ]
    },
    "meso_CardiovascularProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CardiovascularProductsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardiovascular Products",
        "label": "Cardiovascular Products [Member]",
        "documentation": "Cardiovascular products."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r68",
      "r71",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r143",
      "r151",
      "r152"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r71",
      "r75",
      "r77",
      "r78",
      "r143",
      "r151",
      "r152"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails": {
       "parentTag": "ifrs-full_NetDebt",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails": {
       "parentTag": "ifrs-full_NetDebt",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/BasisofpreparationDetails",
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash &amp; cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "totalLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r89",
      "r106"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash and cash equivalents",
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_CashFlowsAdjustmentsOnDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CashFlowsAdjustmentsOnDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows, Borrowings",
        "label": "Cash Flows Adjustments On Debt",
        "documentation": "Cash flows adjustments on debt."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash inflows by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (outflows) in investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (outflows) in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_CashOrStockPayableAtFairValueLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CashOrStockPayableAtFairValueLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails": {
       "parentTag": "meso_ContingentConsiderations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets",
        "label": "Cash Or Stock Payable At Fair Value Liabilities",
        "documentation": "Cash or stock payable at fair value, liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "meso_ChangeInOperatingAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ChangeInOperatingAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Change In Operating Assets And Liabilities [Abstract]",
        "documentation": "Change in operating assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInDeferredTaxLiabilityAssetAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax",
        "label": "Changes in deferred tax liability (asset) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in equity",
        "terseLabel": "Movement during the period",
        "label": "Increase (decrease) in equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInEquityAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transactions with owners in their capacity as owners:",
        "terseLabel": "Issues of ordinary shares during the period",
        "label": "Changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r114",
      "r126"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r114",
      "r126"
     ]
    },
    "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfEmployeeBenefitsExpenseAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Classes of employee benefits expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r158",
      "r159",
      "r182",
      "r183"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r155"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments, class",
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r155"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r182",
      "r183"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets and goodwill [axis]",
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "meso_ClinicalManufacturingRegulatoryAndReimbursementApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ClinicalManufacturingRegulatoryAndReimbursementApprovalMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical, Manufacturing, Regulatory and Reimbursement Approval",
        "label": "Clinical Manufacturing Regulatory And Reimbursement Approval [Member]",
        "documentation": "Clinical, manufacturing, regulatory and reimbursement approval."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ClinicalTrialRelatedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ClinicalTrialRelatedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Clinical trial and research &amp; development",
        "label": "Clinical Trial Related Research And Development",
        "documentation": "The amount of expenditure directly attributable to clinical trial related research and development."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ClinicalTrialResearchAndDevelopmentExpenditure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ClinicalTrialResearchAndDevelopmentExpenditure",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails": {
       "parentTag": "ifrs-full_Prepayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial research and development expenditure",
        "label": "Clinical Trial Research And Development Expenditure",
        "documentation": "Amount of asset related to consideration paid in advance for clinical trial research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "meso_CommercializationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CommercializationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization revenue",
        "label": "Commercialization Revenue",
        "documentation": "Commercialization revenue generally includes non-refundable up-front license and collaboration fees, royalties on product sales of licensed products, if and when such product sales occur and revenue from the supply of products."
       }
      }
     },
     "auth_ref": []
    },
    "meso_CommercializationRevenueReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CommercializationRevenueReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization revenue received",
        "label": "Commercialization Revenue Received",
        "documentation": "Commercialization revenue received."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CommodityPriceRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CommodityPriceRiskMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commodity price risk",
        "label": "Commodity price risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of other price risk that represents the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in commodity prices. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r227"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of equity [axis]",
        "terseLabel": "Components Of Equity",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items that may be reclassified to profit and loss",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items that will not be reclassified to profit and loss",
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive profit/(loss) for the period",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r30",
      "r96",
      "r98",
      "r103",
      "r207"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive losses attributable to the owners of Mesoblast Limited",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r32"
     ]
    },
    "meso_ConsultancyExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ConsultancyExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "meso_OtherManagementAndAdministrationExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Consultancy",
        "label": "Consultancy Expenses",
        "documentation": "The amount of expenditure directly attributable to consultancy expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Contingent consideration [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an obligation of the acquirer to transfer additional assets or equity interests to the former owners of an acquiree as part of the exchange for control of the acquiree if specified future events occur or conditions are met."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "meso_ContingentConsiderationProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ContingentConsiderationProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Opening balance",
        "periodEndLabel": "Closing balance",
        "verboseLabel": "Contingent consideration provision",
        "label": "Contingent Consideration Provision",
        "documentation": "Contingent consideration provision."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ContingentConsiderationProvisionAmountUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ContingentConsiderationProvisionAmountUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification during the period",
        "label": "Contingent Consideration Provision Amount Used",
        "documentation": "Contingent consideration provision amount used."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ContingentConsiderationProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ContingentConsiderationProvisionMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Provision",
        "label": "Contingent Consideration Provision [Member]",
        "documentation": "Contingent consideration provision."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ContingentConsiderations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ContingentConsiderations",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtFairValue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration",
        "totalLabel": "Contingent Consideration",
        "label": "Contingent Considerations",
        "documentation": "Contingent considerations."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ContributionsOfEquityDuringPeriod": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ContributionsOfEquityDuringPeriod",
     "calculation": {
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total contributions of equity during the period (in shares)",
        "label": "Contributions Of Equity During Period",
        "documentation": "Contributions of equity during period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ContributionsOfValueForEquityDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ContributionsOfValueForEquityDuringPeriod",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total contributions of equity during the period",
        "label": "Contributions Of Value For Equity During Period",
        "documentation": "Contributions of value for equity during period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ConversionRatioOfWarrants": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ConversionRatioOfWarrants",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion ratio of warrants",
        "label": "Conversion ratio of warrants",
        "documentation": "Conversion ratio of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties",
        "label": "Counterparties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CreationDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CreationDateAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Creation date [axis]",
        "label": "Creation date [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "meso_CumulativeMilestonePaymentsReachableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CumulativeMilestonePaymentsReachableAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative milestone payments reachable amount",
        "label": "Cumulative Milestone Payments Reachable Amount",
        "documentation": "Cumulative milestone payments reachable amount."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency Risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r166"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r99",
      "r207"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInterestReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivables",
        "label": "Current interest receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current interest receivable. [Refer: Interest receivable]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r101",
      "r207"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_CurrentMarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CurrentMarketedProductsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current marketed products",
        "label": "Current Marketed Products [Member]",
        "documentation": "Current marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPortionOfLongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPortionOfLongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "verboseLabel": "Current",
        "label": "Current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "meso_CurrentProvisionsForAccruedAnnualLeave": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CurrentProvisionsForAccruedAnnualLeave",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provisions for accrued annual leave",
        "label": "Current Provisions For Accrued Annual Leave",
        "documentation": "Current provisions for accrued annual leave."
       }
      }
     },
     "auth_ref": []
    },
    "meso_CurrentTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "CurrentTaxAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax",
        "label": "Current Tax [Abstract]",
        "documentation": "Current tax."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax (benefit)/expense",
        "label": "Current tax expense (income) and adjustments for current tax of prior periods"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "meso_December2022WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "December2022WarrantsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2022 warrants",
        "label": "December 2022 warrants [Member]",
        "documentation": "December 2022 warrants"
       }
      }
     },
     "auth_ref": []
    },
    "meso_DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Rate decrease on funds invested",
        "label": "Decrease In Interest Rate On Funds Invested Which Derives Interest Revenue",
        "documentation": "Decrease in interest rate on funds invested which derives interest revenue."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DecreaseInInterestRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DecreaseInInterestRatePercentage",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate decrease",
        "label": "Decrease In Interest Rate Percentage",
        "documentation": "Decrease in interest rate percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity settled share-based payment transactions",
        "terseLabel": "Equity settled share-based payment transactions",
        "label": "Decrease (increase) through tax on share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in equity resulting from tax on transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_DefaultFinancialStatementsDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefaultFinancialStatementsDateMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Default financial statements date",
        "label": "Default financial statements date [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Creation date' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "meso_DeferredConsiderationMilestoneConsiderationRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredConsiderationMilestoneConsiderationRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred consideration milestone consideration recognized",
        "label": "Deferred Consideration Milestone Consideration Recognized",
        "documentation": "Deferred consideration milestone consideration recognized."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredConsiderationNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredConsiderationNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred consideration",
        "label": "Deferred Consideration Non Current",
        "documentation": "The amount of deferred consideration on customer receipts expected to be accounted for after one year."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails": {
       "parentTag": "ifrs-full_NetDeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r15",
      "r46"
     ]
    },
    "meso_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets [Abstract]",
        "documentation": "Deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets And Liabilities [Line Items]",
        "label": "Deferred Tax Assets And Liabilities [Line Items]",
        "documentation": "Deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsAndLiabilitiesRelatingToChargedOrCreditedAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charged/(credited) to:",
        "label": "Deferred Tax Assets And Liabilities Relating To Charged Or Credited [Abstract]",
        "documentation": "Deferred tax assets and liabilities relating to charged or credited."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets And Liabilities [Table]",
        "label": "Deferred Tax Assets And Liabilities [Table]",
        "documentation": "Schedule disclosing information related to deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsAttributableToOtherTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsAttributableToOtherTemporaryDifferences",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails": {
       "parentTag": "ifrs-full_DeferredTaxAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences",
        "label": "Deferred Tax Assets Attributable To Other Temporary Differences",
        "documentation": "Deferred tax assets attributable to other temporary differences."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails": {
       "parentTag": "ifrs-full_DeferredTaxAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses",
        "label": "Deferred Tax Assets Attributable To Temporary Differences From Tax Losses",
        "documentation": "Deferred tax assets attributable to temporary differences from tax losses."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsNotBroughtToAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsNotBroughtToAccount",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets not brought to account",
        "label": "Deferred Tax Assets Not Brought To Account",
        "documentation": "Deferred tax assets not brought to account."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsNotBroughtToAccountForOtherTaxCreditsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax credits",
        "label": "Deferred Tax Assets Not Brought To Account For Other Tax Credits [Abstract]",
        "documentation": "Deferred tax assets not brought to account for other tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsNotBroughtToAccountForOtherTemporaryDifferencesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences",
        "label": "Deferred Tax Assets Not Brought To Account For Other Temporary Differences [Abstract]",
        "documentation": "Deferred tax assets not brought to account for other temporary differences."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxAssetsNotBroughtToAccountForUnusedTaxLossesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses",
        "label": "Deferred Tax Assets Not Brought To Account For Unused Tax Losses [Abstract]",
        "documentation": "Deferred tax assets not brought to account for unused tax losses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit)/expense",
        "label": "Deferred tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax (benefit)/expense",
        "label": "Deferred tax expense (income) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails": {
       "parentTag": "ifrs-full_NetDeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r15",
      "r46"
     ]
    },
    "meso_DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails": {
       "parentTag": "ifrs-full_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities Attributable To Temporary Differences From Intangible Assets",
        "documentation": "Deferred tax liabilities attributable to temporary differences from intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DeferredTaxLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DeferredTaxLiabilityAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liability [Abstract]",
        "documentation": "Deferred tax liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "meso_DefinedContributionSuperannuationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DefinedContributionSuperannuationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Defined contribution superannuation expenses",
        "label": "Defined Contribution Superannuation Expenses",
        "documentation": "Defined contribution superannuation expenses."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DepositsAtCall": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DepositsAtCall",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits at call",
        "label": "Deposits At Call",
        "documentation": "Deposits at call."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DepreciationAndAmortizationOfNonCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DepreciationAndAmortizationOfNonCurrentAssetsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization of non-current assets",
        "label": "Depreciation And Amortization Of Non Current Assets [Abstract]",
        "documentation": "Depreciation and Amortization of Non-current Assets Abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_AmortisationExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Plant and equipment depreciation",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r51",
      "r53"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_AmortisationExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use asset depreciation",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total contractual cash flows",
        "label": "Derivative financial liabilities, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "meso_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/BasisofpreparationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of accounting policy for basis of preparation explanatory",
        "label": "Description Of Accounting Policy For Basis Of Preparation Explanatory [Policy Text Block]",
        "documentation": "Description of accounting policy for basis of preparation."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementLiabilities": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfInputsUsedInFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs",
        "label": "Description of inputs used in fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of inputs used in the fair value measurement of liabilities. Inputs are the assumptions that market participants would use when pricing the liability, including assumptions about risk such as the risk inherent in a particular valuation technique used to measure fair value (such as a pricing model) and the risk inherent in the inputs to the valuation technique."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Term",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk Free Interest Rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation technique",
        "label": "Description of valuation techniques used in fair value measurement, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the valuation techniques (for example, the market approach, cost approach and income approach) used for the fair value measurement of liabilities. [Refer: Valuation techniques [member]; Cost approach [member]; Income approach [member]; Market approach [member]]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DesignatedFinancialLiabilitiesAtFairValueThroughProfitOrLossAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value through profit or loss:",
        "label": "Designated financial liabilities at fair value through profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "calculation": {
      "http://www.mesoblast.com/role/LossespershareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total diluted (losses) per share attributable to the\u00a0ordinary equity holders of the\u00a0company (in dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "calculation": {
      "http://www.mesoblast.com/role/LossespershareDetails": {
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted - losses per share (in dollars per share)",
        "verboseLabel": "From continuing operations attributable to the ordinary equity holders of the company (in dollars per share)",
        "label": "Diluted earnings (loss) per share from continuing operations"
       }
      },
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61"
     ]
    },
    "ifrs-full_DilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsPerShareAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(b) Diluted (losses) per share",
        "label": "Diluted earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureNonFinancialAssetsAndLiabilitiesAdditionalInformationDetailsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure - Non-financial Assets and Liabilities - Additional Information (Details) [Abstract]",
        "label": "Disclosure Non Financial Assets And Liabilities Additional Information Details [Abstract]",
        "documentation": "Disclosure Non Financial Assets And Liabilities Additional Information Details [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Basisofpreparation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "meso_DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Borrowing to Price Rate Changes",
        "label": "Disclosure Of Borrowings Deriving Price Risk Explanatory [Table Text Block]",
        "documentation": "The disclosure of borrowings deriving price risk."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Carrying Value of In Process Research and Development Acquired by Product",
        "label": "Disclosure Of Carrying Value Of In Process Research And Development Acquired By Product Explanatory [Table Text Block]",
        "documentation": "Disclosure of carrying value of in process research and development acquired by product."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Cash Equivalents",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Cashflowinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow information",
        "label": "Disclosure of cash flow statement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [abstract]",
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Classes Of Share Capital [Table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "meso_DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Assets Not Brought to Account",
        "label": "Disclosure Of Deferred Tax Assets Not Brought To Account Explanatory [Table Text Block]",
        "documentation": "The disclosure of deferred tax assets not brought to account."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Balances",
        "label": "Disclosure of deferred taxes [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "meso_DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deposits Held which Derive Interest Revenue with Maximum and Minimum Interest Rates Being Earned",
        "label": "Disclosure Of Deposits Held Which Derive Interest Revenue With Maximum And Minimum Interest Rates Being Earned Explanatory [Table Text Block]",
        "documentation": "Disclosure of deposits held which derive interest revenue with maximum and minimum interest rates being earned."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Borrowings",
        "label": "Disclosure of detailed information about borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "meso_DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Assets and Liabilities Measured and Recognized at Fair Value",
        "label": "Disclosure Of Detailed Information About Fair Value Measurement Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about fair value measurement."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Warrants",
        "label": "Disclosure Of Detailed Information About Fair Value Of Warrants Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about fair value of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Income Tax Expense/(Benefit)",
        "label": "Disclosure Of Detailed Information About Income Tax Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about income tax."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/Lossbeforeincometax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before income tax",
        "label": "Disclosure Of Detailed Information About Loss Before Income Tax Explanatory [Text Block]",
        "documentation": "Disclosure of detailed information about loss before income tax."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Debt",
        "label": "Disclosure Of Detailed Information About Net Debt Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about net debt."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Debt Reconciliation",
        "label": "Disclosure Of Detailed Information About Net Debt Reconciliation Explanatory [Table Text Block]",
        "documentation": "The disclosure of detailed information about net debt reconciliation."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Detailed Information About Valuation Processes of Contingent Consideration at Fair Value Explanatory",
        "label": "Disclosure Of Detailed Information About Valuation Processes Of Contingent Consideration At Fair Value Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about valuation processes of contingent consideration at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Warrant Liability",
        "label": "Disclosure Of Detailed Information About Warrant Liability Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Lossespershare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Losses) per share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Segmentinformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Eventsoccurringafterthereportingperiod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events occurring after the reporting period",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "meso_DisclosureOfExposureToFinancialRisksTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfExposureToFinancialRisksTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exposure to Financial Risks",
        "label": "Disclosure of exposure to financial risks [Table Text Block]",
        "documentation": "Disclosure of exposure to financial risks"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Fair Value Measurement Of Assets [Line Items]",
        "label": "Disclosure of fair value measurement of assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Fair Value Measurement Of Assets [Table]",
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "meso_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/Financialassetsandliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets and liabilities",
        "label": "Disclosure Of Financial Assets And Financial Liabilities Explanatory [Text Block]",
        "documentation": "Disclosure of financial assets and financial liabilities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfFinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Assets And Liabilities [Abstract]",
        "label": "Disclosure Of Financial Assets And Liabilities [Abstract]",
        "documentation": "Disclosure of financial assets and liabilities abstract."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Assets And Liabilities [Line Items]",
        "label": "Disclosure Of Financial Assets And Liabilities [Line Items]",
        "documentation": "Disclosure of financial assets and liabilities line items."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfFinancialAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Assets And Liabilities [Table]",
        "label": "Disclosure Of Financial Assets And Liabilities [Table]",
        "documentation": "Disclosure of financial assets and liabilities table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Instruments",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Instruments [Line Items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Instruments [Table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r153",
      "r160"
     ]
    },
    "meso_DisclosureOfFinancialRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Risk Management [Abstract]",
        "label": "Disclosure Of Financial Risk Management [Abstract]",
        "documentation": "Disclosure of financial risk management."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Financialriskmanagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial risk management",
        "label": "Disclosure of financial risk management [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "meso_DisclosureOfFinancialRiskManagementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialRiskManagementLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Risk Management [Line Items]",
        "label": "Disclosure Of Financial Risk Management [Line Items]",
        "documentation": "Disclosure of financial risk management."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfFinancialRiskManagementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfFinancialRiskManagementTable",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Financial Risk Management [Table]",
        "label": "Disclosure Of Financial Risk Management [Table]",
        "documentation": "Disclosure of financial risk management."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Incometaxbenefitexpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit/(expense)",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Intangible Assets",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Intangible Assets [Line Items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Intangible Assets [Table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "meso_DisclosureOfLegalProceedingsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfLegalProceedingsExplanatoryTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/Legalproceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal proceedings",
        "label": "Disclosure Of Legal Proceedings Explanatory [Text Block]",
        "documentation": "The disclosure of legal proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfLossBeforeIncomeTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfLossBeforeIncomeTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Loss Before Income Tax [Abstract]",
        "label": "Disclosure Of Loss Before Income Tax [Abstract]",
        "documentation": "Disclosure of loss before income tax [Abstract]."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Loss Before Income Tax",
        "label": "Disclosure Of Loss Before Income Tax Explanatory [Table Text Block]",
        "documentation": "Disclosure of loss before income tax."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfLossBeforeIncomeTaxLineItem": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfLossBeforeIncomeTaxLineItem",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Loss Before Income Tax Line Item",
        "label": "Disclosure Of Loss Before Income Tax Line Item",
        "documentation": "Disclosure Of Loss Before Income Tax Line Item."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfLossBeforeIncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfLossBeforeIncomeTaxLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Loss Before Income Tax [Line Items]",
        "label": "Disclosure Of Loss Before Income Tax [Line Items]",
        "documentation": "Disclosure Of Loss Before Income Tax [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfLossBeforeIncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfLossBeforeIncomeTaxTable",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Loss Before Income Tax [Table]",
        "label": "Disclosure Of Loss Before Income Tax [Table]",
        "documentation": "Disclosure Of Loss Before Income Tax [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Table]",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "meso_DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in Ordinary Share Capital",
        "label": "Disclosure Of Movements In Ordinary Share Capital Explanatory [Table Text Block]",
        "documentation": "The disclosure of movements in ordinary share capital."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements of Shares in Share Trust",
        "label": "Disclosure Of Movements Of Shares In Share Trust Explanatory [Table Text Block]",
        "documentation": "Disclosure of movements of shares in share trust."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfMovementsOfSharesInShareTrustLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfMovementsOfSharesInShareTrustLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Movements Of Shares In Share Trust [Line Items]",
        "label": "Disclosure Of Movements Of Shares In Share Trust [Line Items]",
        "documentation": "Disclosure of movements of shares in share trust."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfMovementsOfSharesInShareTrustTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfMovementsOfSharesInShareTrustTable",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Movements Of Shares In Share Trust [Table]",
        "label": "Disclosure Of Movements Of Shares In Share Trust [Table]",
        "documentation": "Disclosure of movements of shares in share trust."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movements Related to Deferred Tax Assets and Liabilities",
        "label": "Disclosure Of Net Movement Related To Deferred Tax Assets And Liabilities Explanatory [Table Text Block]",
        "documentation": "The disclosure of net movement related to deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfNonFinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non Financial Assets And Liabilities [Abstract]",
        "label": "Disclosure Of Non Financial Assets And Liabilities [Abstract]",
        "documentation": "Disclosure of non financial assets and liabilities,"
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfNonFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non Financial Assets And Liabilities [Line Items]",
        "label": "Disclosure Of Non Financial Assets And Liabilities [Line Items]",
        "documentation": "Disclosure of non financial assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfNonFinancialAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfNonFinancialAssetsAndLiabilitiesTable",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non Financial Assets And Liabilities [Table]",
        "label": "Disclosure Of Non Financial Assets And Liabilities [Table]",
        "documentation": "Disclosure of non financial assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/Nonfinancialassetsandliabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-financial assets and liabilities",
        "label": "Disclosure Of Non Financial Assets And Non Financial Liabilities Explanatory [Text Block]",
        "documentation": "Disclosure of non financial assets and non financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]",
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [abstract]",
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Provisions [Line Items]",
        "label": "Disclosure of other provisions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsTable",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Other Provisions [Table]",
        "label": "Disclosure of other provisions [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_DisclosureOfProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfProvisionsExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Provisions",
        "label": "Disclosure of provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "meso_DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Quantitative Information About the Significant Unobservable Inputs Used in Level 3 Fair Value Measurements",
        "label": "Disclosure Of Quantitative Information About Significant Unobservable Inputs Used In Fair Value Measurements Explanatory [Table Text Block]",
        "documentation": "Disclosure of quantitative information about significant unobservable inputs used in fair value measurements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Table]",
        "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "meso_DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Increase/Decrease of Share Price",
        "label": "Disclosure of sensitivity analysis effect of increase (decrease) in share price [Table Text Block]",
        "documentation": "Disclosure of sensitivity analysis effect of increase (decrease) in share price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "meso_DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSignificantChangesInCurrentReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Significant Changes In Current Reporting Period [Abstract]",
        "label": "Disclosure Of Significant Changes In Current Reporting Period [Abstract]",
        "documentation": "Disclosure of significant changes in current reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/Significantchangesinthecurrentreportingperiod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant changes in the current reporting period",
        "label": "Disclosure Of Significant Changes In Current Reporting Period Explanatory [Text Block]",
        "documentation": "Disclosure of significant changes in current reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSignificantChangesInCurrentReportingPeriodLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Significant Changes In Current Reporting Period [Line Items]",
        "label": "Disclosure Of Significant Changes In Current Reporting Period [Line Items]",
        "documentation": "Disclosure of significant changes in current reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfSignificantChangesInCurrentReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSignificantChangesInCurrentReportingPeriodTable",
     "presentation": [
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Significant Changes In Current Reporting Period [Table]",
        "label": "Disclosure Of Significant Changes In Current Reporting Period [Table]",
        "documentation": "Disclosure of significant changes in current reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Fair Value of Level 3 Instruments",
        "label": "Disclosure Of Significant Unobservable Inputs Used In Fair Value Measurement Of Assets And Liabilities Explanatory [Table Text Block]",
        "documentation": "Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash Flow Information",
        "label": "Disclosure Of Summary Of Cash Flow Information Explanatory [Table Text Block]",
        "documentation": "The disclosure of summary of cash flow information."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets not brought to account",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Trade and Other Payables",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "meso_DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Trade and Other Receivables and Prepayments",
        "label": "Disclosure Of Trade And Other Receivables And Prepayments Explanatory [Table Text Block]",
        "documentation": "Disclosure of trade and other receivables and prepayments explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfWarrantReserveExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfWarrantReserveExplanatoryTableTextBlock",
     "presentation": [
      "http://www.mesoblast.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Warrant Reserve",
        "label": "Disclosure Of Warrant Reserve Explanatory [Table Text Block]",
        "documentation": "Disclosure of warrant reserve."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfWarrantReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfWarrantReserveLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrant Reserve [Line Items]",
        "label": "Disclosure Of Warrant Reserve [Line Items]",
        "documentation": "Disclosure of warrant reserve."
       }
      }
     },
     "auth_ref": []
    },
    "meso_DisclosureOfWarrantReserveTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DisclosureOfWarrantReserveTable",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrant Reserve [Table]",
        "label": "Disclosure Of Warrant Reserve [Table]",
        "documentation": "Disclosure of warrant reserve."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DiscountRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DiscountRateMeasurementInputMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk adjusted discount rate",
        "label": "Discount rate, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ifrs-full_DiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DiscountedCashFlowMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted cash flow",
        "label": "Discounted cash flow [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future cash flow amounts through the application of present value techniques and inputs (for example, weighted average cost of capital, long-term revenue growth rate, long-term pre-tax operating margin, discount for lack of marketability, control premium). [Refer: Income approach [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r212"
     ]
    },
    "meso_DiscountedPercentageOnIssuanceOfEquity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "DiscountedPercentageOnIssuanceOfEquity",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounted percentage on issuance of equity",
        "label": "Discounted Percentage On Issuance Of Equity",
        "documentation": "Discounted percentage on issuance of equity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [abstract]",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of (Losses) Earnings Per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FX gains/(losses) on the translation of foreign bank accounts",
        "verboseLabel": "Foreign exchange adjustments, cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83"
     ]
    },
    "meso_EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange adjustments, Total",
        "label": "Effect Of Foreign Exchange Adjustments On Liabilities Arising From Financing Activities And Cash And Cash Equivalents",
        "documentation": "Effect of foreign exchange adjustments on liabilities arising from financing activities and cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "meso_EffectOnProfitFromChangeInInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "EffectOnProfitFromChangeInInterestRate",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect on profit from change in interest rates",
        "label": "Effect On Profit From Change In Interest Rate",
        "documentation": "Effect on profit from change in interest rate."
       }
      }
     },
     "auth_ref": []
    },
    "meso_EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect on profit from change in interest rate increase or decrease",
        "label": "Effect On Profit From Change In Interest Rate Increase Or Decrease",
        "documentation": "Effect on profit from change in interest rate increase or decrease."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Employee benefits",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r38",
      "r186"
     ]
    },
    "meso_EmployeeBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "EmployeeBenefitsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Employee Benefits [Member]",
        "documentation": "Employee benefits."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mesoblast.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_EntitysTotalForProbabilityOfDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForProbabilityOfDefaultMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity's total for probability of default",
        "label": "Entity's total for probability of default [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Probability of default' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r225"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "totalLabel": "Total Equity",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r21",
      "r95",
      "r97",
      "r110",
      "r111",
      "r113"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "meso_ExercisePriceShareWarrentsIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ExercisePriceShareWarrentsIssued",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, share warrents issued (in dollars per share)",
        "label": "Exercise Price, Share Warrents Issued",
        "documentation": "Exercise Price, Share Warrents Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "meso_ExpectedPatentExpiry": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ExpectedPatentExpiry",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected patent expiry",
        "label": "Expected Patent Expiry",
        "documentation": "Expected patent expiry."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ExpectedSalesVolumeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ExpectedSalesVolumeMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Sales Volume",
        "label": "Expected Sales Volume [Member]",
        "documentation": "Expected sales volume."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ExpectedSalesVolumesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ExpectedSalesVolumesMeasurementInputMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected sales volumes",
        "label": "Expected Sales Volumes, Measurement Input [Member]",
        "documentation": "Expected Sales Volumes, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "meso_ExpectedUnitSalesPriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ExpectedUnitSalesPriceMeasurementInputMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected unit sales price",
        "label": "Expected Unit Sales Price, Measurement Input [Member]",
        "documentation": "Expected Unit Sales Price, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Fair Value Of Warrants",
        "documentation": "Fair value of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValuePerWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValuePerWarrant",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per warrant (in dollars per share)",
        "label": "Fair Value Per Warrant",
        "documentation": "Fair value per warrant."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValueRemeasurementOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValueRemeasurementOfContingentConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurement of contingent consideration",
        "negatedTotalLabel": "Total Fair value remeasurement of contingent consideration",
        "label": "Fair Value Remeasurement Of Contingent Consideration",
        "documentation": "Fair value remeasurement of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValueRemeasurementOfContingentConsiderationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValueRemeasurementOfContingentConsiderationAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurement of contingent consideration",
        "label": "Fair Value Remeasurement Of Contingent Consideration [Abstract]",
        "documentation": "Fair value remeasurement of contingent consideration abstract."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValueRemeasurementOfContingentConsiderationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValueRemeasurementOfContingentConsiderationAfterTax",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of contingent consideration",
        "label": "Fair Value Remeasurement Of Contingent Consideration After Tax",
        "documentation": "Fair value remeasurement of contingent consideration after tax."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValueRemeasurementOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValueRemeasurementOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fair value remeasurement of warrant liability",
        "negatedTotalLabel": "Total Fair value remeasurement of warrant liability",
        "label": "Fair Value Remeasurement Of Warrant Liability",
        "documentation": "Fair value remeasurement of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FairValueRemeasurementOfWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FairValueRemeasurementOfWarrantLiabilityAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value remeasurement of warrant liability",
        "label": "Fair Value Remeasurement Of Warrant Liability [Abstract]",
        "documentation": "Fair value remeasurement of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      },
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance costs",
        "negatedTotalLabel": "Total Finance costs",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "meso_FinanceCostsGainsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FinanceCostsGainsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance (costs)/gains",
        "label": "Finance Costs Gains [Abstract]",
        "documentation": "Finance (costs) gains."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance costs loss on adjustment of carrying amount on financial liability",
        "label": "Finance Costs Gains (Loss) On Adjustment Of Carrying Amount On Financial Liability",
        "documentation": "Finance Costs Gains (Loss) On Adjustment Of Carrying Amount On Financial Liability"
       }
      }
     },
     "auth_ref": []
    },
    "meso_FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance costs loss on remeasurement due to additional warrants issued",
        "label": "Finance Costs Gains (Loss) On Remeasurement Due To Additional Warrants Issued",
        "documentation": "Finance Costs Gains (Loss) On Remeasurement Due To Additional Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "meso_FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of borrowing arrangements within finance gains (loss)",
        "label": "Finance Costs Gains (Loss) On Remeasurement Of Borrowing Arrangements",
        "documentation": "Finance costs gains (loss) on remeasurement of borrowing arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FinanceCostsGainsOnRemeasurementOfBorrowingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FinanceCostsGainsOnRemeasurementOfBorrowingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of borrowing arrangements",
        "label": "Finance Costs Gains On Remeasurement Of Borrowing Arrangements",
        "documentation": "Finance (costs) gains on remeasurement of borrowing arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial assets, Total",
        "terseLabel": "Financial assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r151",
      "r152",
      "r154",
      "r218"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets at amortized cost",
        "label": "Financial assets at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Financial Assets",
        "label": "Financial assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value through other comprehensive income",
        "label": "Financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets at FVOCI",
        "label": "Financial assets at fair value through other comprehensive income, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsCategoryMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, category",
        "label": "Financial assets, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsDesignatedAsMeasuredAtFairValueAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value through other comprehensive income:",
        "label": "Financial assets designated as measured at fair value through profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, class",
        "label": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r158",
      "r159",
      "r182",
      "r183"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial liabilities, Total",
        "terseLabel": "Financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities at amortized cost",
        "label": "Financial liabilities at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Financial Liabilities",
        "label": "Financial liabilities, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities at FVTPL",
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, category",
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, class",
        "label": "Financial liabilities, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r182",
      "r183"
     ]
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross debt - fixed interest rates",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "ifrs-full_FloatingInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FloatingInterestRateMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross debt - variable interest rates",
        "label": "Floating interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a non-fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "meso_ForeignExchangeGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ForeignExchangeGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange gains/(losses)",
        "label": "Foreign Exchange Gains Losses",
        "documentation": "Foreign exchange gains/(losses)."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ForeignWithholdingTaxRecoverable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ForeignWithholdingTaxRecoverable",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign withholding tax recoverable",
        "label": "Foreign Withholding Tax Recoverable",
        "documentation": "Foreign withholding tax recoverable."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FundsInvestedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FundsInvestedPercentage",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds invested percentage",
        "label": "Funds Invested Percentage",
        "documentation": "Funds invested percentage."
       }
      }
     },
     "auth_ref": []
    },
    "meso_FundsInvestedWhichDerivesInterestRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "FundsInvestedWhichDerivesInterestRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds invested",
        "label": "Funds Invested Which Derives Interest Revenue",
        "documentation": "Funds invested which derives interest revenue."
       }
      }
     },
     "auth_ref": []
    },
    "meso_GainLossOnReMeasurementOfContingentConsiderationProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "GainLossOnReMeasurementOfContingentConsiderationProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on re-measurement of contingent consideration provision",
        "label": "Gain Loss On Re Measurement Of Contingent Consideration Provision",
        "documentation": "Gain (loss) on re-measurement of contingent consideration provision."
       }
      }
     },
     "auth_ref": []
    },
    "meso_GainLossOnRemeasurementOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "GainLossOnRemeasurementOfWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on remeasurement of warrant liability",
        "label": "Gain (Loss) On Remeasurement Of Warrant Liability",
        "documentation": "Gain (loss) on remeasurement of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "meso_GovernmentGrantsAndTaxIncentivesAndCreditsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "GovernmentGrantsAndTaxIncentivesAndCreditsReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants and tax incentives and credits received",
        "label": "Government Grants And Tax Incentives And Credits Received",
        "documentation": "Government grants and tax incentives received."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r50",
      "r68",
      "r76",
      "r79",
      "r143",
      "r152",
      "r154",
      "r218"
     ]
    },
    "ifrs-full_GrossLoanCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossLoanCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Carrying amount",
        "label": "Gross loan commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows for gross commitments to receive a loan."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "meso_GrunenthalGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "GrunenthalGmbHMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grunenthal",
        "label": "Grunenthal Gmb H [Member]",
        "documentation": "Gr\u00fcnenthal GmbH."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ImpairmentLossOnFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ImpairmentLossOnFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss recognised in profit or loss",
        "label": "Impairment loss on financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss on financial assets. [Refer: Financial assets; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit or loss [abstract]",
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncomeStatementFunctionalExpenseCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncomeStatementFunctionalExpenseCategoriesMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Functional Expense Categories",
        "label": "Income Statement Functional Expense Categories [Member]",
        "documentation": "Income statement functional expense categories."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncomeStatementLocationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncomeStatementLocationMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Member]",
        "documentation": "Income statement location."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncomeStatementLocationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncomeStatementLocationsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Locations",
        "label": "Income Statement Locations [Axis]",
        "documentation": "Income statement locations."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit/(expense)",
        "totalLabel": "Income tax (benefit)/expense",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r41",
      "r42",
      "r43",
      "r59",
      "r109",
      "r171"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes paid",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r198"
     ]
    },
    "meso_IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Changes, Borrowings",
        "label": "Increase Decrease In Borrowing Liabilities Classified As Financing Activities",
        "documentation": "Increase decrease in borrowing liabilities classified as financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "verboseLabel": "Cash Flows, Cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "meso_IncreaseDecreaseInCurrentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseInCurrentTax",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax",
        "label": "Increase Decrease In Current Tax",
        "documentation": "Increase decrease in current tax."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncreaseDecreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseInDeferredTaxAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Increase)/decrease in deferred tax assets",
        "label": "Increase Decrease In Deferred Tax Assets",
        "documentation": "Increase decrease in deferred tax assets."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncreaseDecreaseInDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Decrease)/increase in deferred tax liabilities",
        "label": "Increase Decrease In Deferred Tax Liabilities",
        "documentation": "Increase decrease in deferred tax liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease/(increase) in tax incentive recoverable",
        "label": "Increase (decrease) in deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "meso_IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Changes, Leases",
        "label": "Increase Decrease In Lease Liabilities Arising From Financing Activities",
        "documentation": "Increase (decrease)in lease liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows, Total",
        "label": "Increase (decrease) in liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "meso_IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows, Warrants liability",
        "label": "Increase Decrease In Warrant Liabilities Arising From Financing Activities",
        "documentation": "Increase (decrease) in warrant liabilities arising from financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange adjustments, Sub-total",
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange adjustments, Leases",
        "label": "Increase Decrease Through Effect Of Changes In Foreign Exchange Rates Liabilities Arising From Leases",
        "documentation": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from leases."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange adjustments, Warrant liability",
        "label": "Increase Decrease Through Effect Of Changes In Foreign Exchange Rates Liabilities Arising From Warrants",
        "documentation": "Increase (decrease) through effect of changes in foreign exchange rates liabilities arising from warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": "ifrs-full_ChangesInEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer of exercised options",
        "verboseLabel": "Exercise of share options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows, Sub-total",
        "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherContributionsByOwners",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributions of equity net of transaction costs",
        "label": "Increase through other contributions by owners, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": "ifrs-full_ChangesInEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of share-based payments",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Transactions with owners in their capacity as owners",
        "label": "Increase (decrease) through transactions with owners, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "meso_IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate increase on funds invested",
        "label": "Increase In Interest Rate On Funds Invested Which Derives Interest Revenue",
        "documentation": "Increase in interest rate on funds invested which derives interest revenue."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IncreaseInInterestRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IncreaseInInterestRatePercentage",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate increase",
        "label": "Increase In Interest Rate Percentage",
        "documentation": "Increase in interest rate percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows, Leases",
        "label": "Increase through new leases, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r204"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "periodStartLabel": "Opening net book amount",
        "periodEndLabel": "Closing net book amount",
        "verboseLabel": "Carrying value of in process research and development",
        "label": "Intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets and goodwill",
        "label": "Intangible assets and goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "meso_IntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IntangibleAssetsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets (DTL)",
        "label": "Intangible Assets [Member]",
        "documentation": "Intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsUnderDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsUnderDevelopmentMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development acquired",
        "label": "Intangible assets under development [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "meso_IntellectualPropertyAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IntellectualPropertyAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_AmortisationExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intellectual property amortization",
        "label": "Intellectual Property Amortization",
        "documentation": "Intellectual property amortization."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IntellectualPropertyExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IntellectualPropertyExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "meso_OtherManagementAndAdministrationExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intellectual property expenses (excluding the amount amortized above)",
        "label": "Intellectual Property Expenses",
        "documentation": "The amount of expenditure directly attributable to intellectual property expenses."
       }
      }
     },
     "auth_ref": []
    },
    "meso_InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest and other costs of finance paid",
        "label": "Interest And Other Costs Of Finance Paid Classified As Financing Activities",
        "documentation": "Interest and other costs of finance paid classified as financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_InterestBearingDepositsAtCallHeldAsSecurity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "InterestBearingDepositsAtCallHeldAsSecurity",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofCashandCashEquivalentsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest-bearing deposits at call held as security",
        "label": "Interest Bearing Deposits At Call Held As Security",
        "documentation": "Interest bearing deposits at call held as security."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r170",
      "r177"
     ]
    },
    "ifrs-full_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Risk",
        "label": "Interest rate risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r166"
     ]
    },
    "ifrs-full_InterestRateTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateTypesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate types",
        "label": "Interest rate types [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "meso_IntravenousProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IntravenousProductsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intravenous products for metabolic diseases and inflammatory/immunologic conditions",
        "label": "Intravenous Products [Member]",
        "documentation": "Intravenous products."
       }
      }
     },
     "auth_ref": []
    },
    "meso_InvestmentInFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "InvestmentInFixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in fixed assets",
        "label": "Investment In Fixed Assets",
        "documentation": "Investment in fixed assets."
       }
      }
     },
     "auth_ref": []
    },
    "meso_InvestmentRevaluationReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "InvestmentRevaluationReserveMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Revaluation Reserve",
        "label": "Investment Revaluation Reserve [Member]",
        "documentation": "Investment revaluation reserve."
       }
      }
     },
     "auth_ref": []
    },
    "meso_IssuanceWarrantsExercisedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "IssuanceWarrantsExercisedPeriod",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance warrants exercised period",
        "label": "Issuance Warrants Exercised Period",
        "documentation": "Issuance warrants exercised period."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued Capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "meso_JCRPharmaceuticalsCoLTDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "JCRPharmaceuticalsCoLTDMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JCR Pharmaceuticals Co. Ltd",
        "label": "J C R Pharmaceuticals Co L T D [Member]",
        "documentation": "JCR Pharmaceuticals Co LTD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Over 5 years",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r137",
      "r221",
      "r223",
      "r226"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 2-5 years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r226"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Between 1-2 years",
        "label": "Later than one year and not later than two years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r137",
      "r221",
      "r226",
      "r234"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails": {
       "parentTag": "ifrs-full_LiabilitiesArisingFromFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails": {
       "parentTag": "ifrs-full_NetDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease liabilities",
        "negatedPeriodStartLabel": "Leases at beginning of period",
        "negatedPeriodEndLabel": "Leases at end of period",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r205"
     ]
    },
    "meso_LegalAndOtherProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "LegalAndOtherProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "meso_OtherManagementAndAdministrationExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Legal and other professional fees",
        "label": "Legal And Other Professional Fees",
        "documentation": "The amount of expenditure directly attributable to Legal, patent and other professional fees."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LegalProceedingsProvisionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LegalProceedingsProvisionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal proceedings provision [abstract]",
        "label": "Legal proceedings provision [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r111"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy [axis]",
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r111"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r113",
      "r172",
      "r176"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails": {
       "parentTag": "ifrs-full_NetDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Sub-total at beginning of period",
        "negatedPeriodEndLabel": "Sub-total at end of period",
        "label": "Liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [axis]",
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities",
        "label": "Liabilities arising from financing activities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_LicencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LicencesMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired licenses to patents",
        "label": "Licences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "meso_License1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "License1Member",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License 1 [Member]",
        "documentation": "License 1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity Risk",
        "label": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r216"
     ]
    },
    "meso_LongTermBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "LongTermBorrowingsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Long Term Borrowings [Abstract]",
        "documentation": "Long Term Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "verboseLabel": "Non-current",
        "netLabel": "Non-current borrowings",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowingsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Long-term borrowings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r205"
     ]
    },
    "meso_LonzaBioscienceSingaporePteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "LonzaBioscienceSingaporePteLtdMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lonza Bioscience Singapore Pte. Ltd",
        "label": "Lonza Bioscience Singapore Pte Ltd [Member]",
        "documentation": "Lonza Bioscience Singapore Pte. Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "meso_LossGainOnRemeasurementOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "LossGainOnRemeasurementOfContingentConsideration",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "meso_FairValueRemeasurementOfContingentConsideration",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofChangesinFairValueofLevel3InstrumentsDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Remeasurement of contingent consideration",
        "verboseLabel": "Remeasurement",
        "label": "Loss Gain On Remeasurement Of Contingent Consideration",
        "documentation": "Loss (gain) on remeasurement of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "meso_LossGainOnRemeasurementOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "LossGainOnRemeasurementOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "meso_FairValueRemeasurementOfWarrantLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Remeasurement of warrant liability",
        "label": "Loss Gain On Remeasurement Of Warrant Liability",
        "documentation": "Loss\u200b gain\u200b on remeasurement\u200b of warrant \u200bliability."
       }
      }
     },
     "auth_ref": []
    },
    "meso_MSCProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MSCProductMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSC Products",
        "label": "M S C Product [Member]",
        "documentation": "MSC Product."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major components of tax expense (income) [abstract]",
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorOrdinaryShareTransactionsMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major ordinary share transactions [member]",
        "label": "Major ordinary share transactions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "meso_ManagementAndAdministrationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManagementAndAdministrationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Management and administration",
        "label": "Management And Administration Expense",
        "documentation": "The amount of expenditure directly attributable to Management and administration activities, recognized in profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ManagementAndAdministrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManagementAndAdministrationMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management and administration",
        "label": "Management And Administration [Member]",
        "documentation": "Management and administration."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ManufacturingAndCommercializationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManufacturingAndCommercializationMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing and commercialization",
        "label": "Manufacturing And Commercialization [Member]",
        "documentation": "Manufacturing and commercialization."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ManufacturingCommercialization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManufacturingCommercialization",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Manufacturing commercialization",
        "label": "Manufacturing Commercialization",
        "documentation": "The amount of expenditure directly attributable to Manufacturing commercialization activities, recognized in profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ManufacturingCommercializationExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManufacturingCommercializationExpensesMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Commercialization Expenses",
        "label": "Manufacturing Commercialization Expenses [Member]",
        "documentation": "Manufacturing Commercialization expenses."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ManufacturingProductionAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManufacturingProductionAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Manufacturing production &amp; development",
        "label": "Manufacturing Production And Development",
        "documentation": "The amount of expenditure directly attributable to manufacturing production and development."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ManufacturingServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ManufacturingServiceAgreementMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing Service Agreement",
        "label": "Manufacturing Service Agreement [Member]",
        "documentation": "Manufacturing service agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAnalysisForDerivativeFinancialLiabilities",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity Profile of Anticipated Future Contractual Cash Flows Carrying Value",
        "label": "Disclosure of maturity analysis for derivative financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r121",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r146",
      "r157",
      "r195",
      "r221"
     ]
    },
    "meso_MaximumAmountInCashOutflowsFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MaximumAmountInCashOutflowsFromOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount paid in cash outflows from operating activities",
        "label": "Maximum Amount In Cash Outflows From Operating Activities",
        "documentation": "Maximum amount in cash outflows from operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_MesoblastEmployeeShareTrustMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MesoblastEmployeeShareTrustMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mesoblast Employee Share Trust",
        "label": "Mesoblast Employee Share Trust [Member]",
        "documentation": "Mesoblast Employee Share Trust."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MethodsOfGenerationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MethodsOfGenerationAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Methods of generation [axis]",
        "label": "Methods of generation [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_MethodsOfGenerationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MethodsOfGenerationMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Methods of generation",
        "label": "Methods of generation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all methods of generation. It also represents the standard value for the 'Methods of generation' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "meso_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment received",
        "label": "Milestone Payment Received",
        "documentation": "Milestone payment received."
       }
      }
     },
     "auth_ref": []
    },
    "meso_MilestoneRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MilestoneRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "auth_ref": []
    },
    "meso_MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum financial commitment of lease component on exercise of option to extend non-cancellable term",
        "label": "Minimum Financial Commitment Of Lease Component On Exercise Of Option To Extend Non Cancellable Term",
        "documentation": "Minimum financial commitment of lease component on exercise of option to extend non-cancellable term."
       }
      }
     },
     "auth_ref": []
    },
    "meso_MinimumFinancialCommitmentReductionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MinimumFinancialCommitmentReductionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum financial commitment reduction amount",
        "label": "Minimum Financial Commitment Reduction Amount",
        "documentation": "Minimum Financial Commitment Reduction Amount"
       }
      }
     },
     "auth_ref": []
    },
    "meso_MinimumFinancialCommitmentReductionAmountOnLeaseComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MinimumFinancialCommitmentReductionAmountOnLeaseComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum financial commitment reduction amount on lease component",
        "label": "Minimum Financial Commitment Reduction Amount on Lease Component",
        "documentation": "Minimum Financial Commitment Reduction Amount on Lease Component"
       }
      }
     },
     "auth_ref": []
    },
    "meso_MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum financial commitment reduction amount on non lease component",
        "label": "Minimum Financial Commitment Reduction Amount on Non Lease Component",
        "documentation": "Minimum Financial Commitment Reduction Amount on Non Lease Component"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term",
        "label": "Minimum Remaining Financial Commitment Of Non Lease Component On Exercise Of Option To Extend Non Cancellable Term",
        "documentation": "Minimum remaining financial commitment of non-lease component on exercise of option to extend non-cancellable term."
       }
      }
     },
     "auth_ref": []
    },
    "meso_MinimumUnrestrictedCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "MinimumUnrestrictedCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum unrestricted cash balance",
        "label": "Minimum Unrestricted Cash Balance",
        "documentation": "Minimum unrestricted cash balance."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Assets",
        "label": "Assets (liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r234"
     ]
    },
    "ifrs-full_NetDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net Debt",
        "negatedPeriodStartLabel": "Net debt total at beginning of period",
        "negatedPeriodEndLabel": "Net debt total at end of period",
        "label": "Net debt"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "ifrs-full_NetDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax liabilities",
        "label": "Net deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_NetInvestmentInFinanceLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetInvestmentInFinanceLease",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment in sublease",
        "label": "Net investment in finance lease"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross investment in the finance lease discounted at the interest rate implicit in the lease. Finance lease is a lease that transfers substantially all the risks and rewards incidental to ownership of an underlying asset. Gross investment in the finance lease is the sum of: (a) the lease payments receivable by a lessor under a finance lease; and (b) any unguaranteed residual value accruing to the lessor. Interest rate implicit in the lease is the rate of interest that causes the present value of (a) the lease payments and (b) the unguaranteed residual value to equal to the sum of (i) the fair value of the underlying asset and (ii) the initial direct costs of the lessor."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "meso_NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- directly to equity",
        "label": "Net Movement In Regulatory Deferral Account Balances Related To Directly To Equity",
        "documentation": "Net movement in regulatory deferral account balances related to directly to equity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "- profit or loss",
        "label": "Net movement in regulatory deferral account balances related to profit or loss and net movement in related deferred tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the net movement in regulatory deferral account balances related to profit or loss and the net movement in related deferred tax. [Refer: Net movement in regulatory deferral account balances related to profit or loss; Net movement in deferred tax arising from regulatory deferral account balances related to profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r115",
      "r117"
     ]
    },
    "meso_NonCancellablePurchaseCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NonCancellablePurchaseCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services",
        "label": "Non Cancellable Purchase Commitments",
        "documentation": "Non-cancellable purchase commitments."
       }
      }
     },
     "auth_ref": []
    },
    "meso_NonInterestBearingFinancialLiabilitiesMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NonInterestBearingFinancialLiabilitiesMaturityPeriod",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non interest bearing financial liabilities maturity period",
        "label": "Non Interest Bearing Financial Liabilities Maturity Period",
        "documentation": "Non interest bearing financial liabilities maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_NonRefundableUpFrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NonRefundableUpFrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payment received",
        "label": "Non Refundable Up Front Payment Received",
        "documentation": "Non refundable up front payment received."
       }
      }
     },
     "auth_ref": []
    },
    "meso_NonRefundableUpfrontPaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NonRefundableUpfrontPaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payments receivable",
        "label": "Non Refundable Upfront Payments Receivable",
        "documentation": "Non-refundable upfront payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period",
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r100",
      "r207"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Assets",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current contract liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets at fair value through other comprehensive income",
        "label": "Non-current financial assets at fair value through other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets at fair value through other comprehensive income. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r102",
      "r207"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails": {
       "parentTag": "ifrs-full_Provisions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "verboseLabel": "Non-current",
        "label": "Non-current provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Within 1 year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r127",
      "r128",
      "r137",
      "r221",
      "r226"
     ]
    },
    "meso_NovaQuestCapitalManagementLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NovaQuestCapitalManagementLLCMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings - NovaQuest",
        "label": "Nova Quest Capital Management L L C [Member]",
        "documentation": "NovaQuest Capital Management, L.L.C."
       }
      }
     },
     "auth_ref": []
    },
    "meso_November2021WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "November2021WarrantsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2021 warrants",
        "label": "November 2021 warrants [Member]",
        "documentation": "November 2021 warrants"
       }
      }
     },
     "auth_ref": []
    },
    "meso_NumberOfClassActionLawsuits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NumberOfClassActionLawsuits",
     "presentation": [
      "http://www.mesoblast.com/role/LegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of action lawsuits",
        "label": "Number Of Class Action Lawsuits",
        "documentation": "Number Of Class Action Lawsuits"
       }
      }
     },
     "auth_ref": []
    },
    "meso_NumberOfEscalatingMilestonePayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NumberOfEscalatingMilestonePayments",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escalating milestone payments",
        "label": "Number Of Escalating Milestone Payments",
        "documentation": "Number Of Escalating Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "meso_NumberOfOperatingSegment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NumberOfOperatingSegment",
     "presentation": [
      "http://www.mesoblast.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segment",
        "label": "Number Of Operating Segment",
        "documentation": "Number of operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of share options (in shares)",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "calculation": {
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails": {
       "parentTag": "ifrs-full_NumberOfSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contributed equity",
        "label": "Number of shares issued [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fully-paid ordinary shares (in shares)",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "meso_NumberOfSharesIssuedAndFullyPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NumberOfSharesIssuedAndFullyPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued, value",
        "label": "Number Of Shares Issued And Fully Paid, Value",
        "documentation": "Number Of Shares Issued And Fully Paid, Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssuedButNotFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssuedButNotFullyPaid",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued and fully paid (in shares)",
        "label": "Number of shares issued but not fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has not been received."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "calculation": {
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Contributed Equity (in shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "meso_NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants granted to purchase american depositary shares (in shares)",
        "label": "Number Of Warrants Granted To Purchase American Depositary Shares",
        "documentation": "Number of warrants granted to purchase American Depositary Shares."
       }
      }
     },
     "auth_ref": []
    },
    "meso_NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants issued to purchase american depositary shares",
        "label": "Number Of Warrants Issued To Purchase American Depositary Shares",
        "documentation": "Number Of Warrants Issued To Purchase American Depositary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "meso_OaktreeCapitalManagementLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OaktreeCapitalManagementLPMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings - Oaktree",
        "label": "Oaktree Capital Management L P [Member]",
        "documentation": "Oaktree Capital Management, L.P."
       }
      }
     },
     "auth_ref": []
    },
    "meso_OaktreeCapitalManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OaktreeCapitalManagementMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oaktree Capital Management",
        "label": "Oaktree Capital Management [Member]",
        "documentation": "Oaktree Capital Management."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "verboseLabel": "Issued Capital",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r237"
     ]
    },
    "meso_OrdinarySharesPurchasedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OrdinarySharesPurchasedValue",
     "calculation": {
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Ordinary Shares Purchased Value",
        "documentation": "Ordinary shares value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_OtherChangesOnDebtAndLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherChangesOnDebtAndLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Changes",
        "label": "Other Changes On Debt And Leases",
        "documentation": "Other changes on debt and leases."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income/(loss)",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r29",
      "r36",
      "r105"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss)/income",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive (loss)/income for the period, net of tax",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192"
     ]
    },
    "srt_OtherCurrencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OtherCurrencyMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Currency",
        "label": "Other Currency [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEquitySecuritiesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities",
        "label": "Other equity securities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r211"
     ]
    },
    "meso_OtherManagementAndAdministrationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherManagementAndAdministrationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total Other Management &amp; administration expenses",
        "label": "Other Management And Administration Expenses",
        "documentation": "Other management &amp; administration expenses."
       }
      }
     },
     "auth_ref": []
    },
    "meso_OtherManagementAndAdministrationExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherManagementAndAdministrationExpensesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Management &amp; administration expenses",
        "label": "Other Management And Administration Expenses [Abstract]",
        "documentation": "Other management and administration expenses abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "meso_OtherOperatingIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherOperatingIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "label": "Other Operating Income And Expenses [Abstract]",
        "documentation": "Other Operating Income And Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income and expenses",
        "totalLabel": "Total Other operating income and expenses",
        "label": "Other operating income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "meso_OtherPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails": {
       "parentTag": "ifrs-full_Prepayments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Prepayments",
        "documentation": "Other prepayments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "meso_OtherPurchaseCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherPurchaseCommitments",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other purchase commitments",
        "label": "Other Purchase Commitments",
        "documentation": "Other purchase commitments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other reserves",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r26"
     ]
    },
    "meso_OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails": {
       "parentTag": "meso_DeferredTaxAssetsNotBroughtToAccount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential tax benefit at local tax rates",
        "label": "Other Tax Credits For Which No Deferred Tax Asset Recognised",
        "documentation": "Other tax credits for which no deferred Tax Asset Recognised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTemporaryDifferencesMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Temporary Differences (DTA)",
        "label": "Other temporary differences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "meso_OutstandingCommonShareCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OutstandingCommonShareCapitalPercentage",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding common share capital, percentage",
        "label": "Outstanding Common Share Capital, Percentage",
        "documentation": "Outstanding Common Share Capital, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "meso_OverheadsAndAdministrationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "OverheadsAndAdministrationExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "meso_OtherManagementAndAdministrationExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Overheads &amp; administration",
        "label": "Overheads And Administration Expenses",
        "documentation": "The amount of expenditure directly attributable to overheads and administration expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails",
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in australian dollars per share)",
        "verboseLabel": "Exercise price (in dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "meso_PaymentAssumptionsMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PaymentAssumptionsMeasurementInputMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment assumptions",
        "label": "Payment Assumptions, Measurement Input [Member]",
        "documentation": "Payment Assumptions, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for share issue costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for lease liabilities",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "meso_PaymentsOfTransactionCostsFromBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PaymentsOfTransactionCostsFromBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of transaction costs from borrowings",
        "label": "Payments Of Transaction Costs From Borrowings",
        "documentation": "Payments of transaction costs from borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments to suppliers and employees (inclusive of goods and services tax)",
        "label": "Payments To Suppliers And Employees Inclusive Of Goods And Services Tax",
        "documentation": "Payments to suppliers and employees inclusive of goods and services tax."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfAssetsMeasuredAtFairValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfAssetsMeasuredAtFairValue",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of assets measured at fair value",
        "label": "Percentage Of Assets Measured At Fair Value",
        "documentation": "Percentage of assets measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfBorrowingPrincipalAmountPayableOverTwoYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfBorrowingPrincipalAmountPayableOverTwoYear",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of principal amount payable over two year",
        "label": "Percentage Of Borrowing Principal Amount Payable Over Two Year",
        "documentation": "Percentage of borrowing principal amount payable over two year."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfCashHeld": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfCashHeld",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of cash held",
        "label": "Percentage Of Cash Held",
        "documentation": "Percentage of cash held."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfEntitysRevenueAnnualPaymentCapThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfEntitysRevenueAnnualPaymentCapThreshold",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of entity's revenue, annual payment cap threshold",
        "label": "Percentage Of Entity's Revenue, Annual Payment Cap Threshold",
        "documentation": "Percentage Of Entity's Revenue, Annual Payment Cap Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfForecastNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfForecastNetSales",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of forecast net sales",
        "label": "Percentage Of Forecast Net Sales",
        "documentation": "Percentage of forecast net sales."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfIncreaseAndDecreaseInSharePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfIncreaseAndDecreaseInSharePrice",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of increase and decrease in share price",
        "label": "Percentage Of Increase And Decrease In Share Price",
        "documentation": "Percentage Of Increase And Decrease In Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfLiabilitiesMeasuredAtFairValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfLiabilitiesMeasuredAtFairValue",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of liabilities measured at fair value",
        "label": "Percentage Of Liabilities Measured At Fair Value",
        "documentation": "Percentage of liabilities measured at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines",
        "label": "Percentage Of Patients To Provide Regulatory Harmonization Cost Efficiencies And Streamlined Timelines",
        "documentation": "Percentage of patients to provide regulatory harmonization, cost efficiencies and streamlined timelines."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfPremiumForVolumeWeightedAveragePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfPremiumForVolumeWeightedAveragePrice",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of premium for volume-weighted average price",
        "label": "Percentage Of Premium For Volume Weighted Average Price",
        "documentation": "Percentage of premium for volume-weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfPriceRateChangesInBorrowings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfPriceRateChangesInBorrowings",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Percent of total borrowings",
        "label": "Percentage Of Price Rate Changes In Borrowings",
        "documentation": "Percentage of price rate changes in borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfPriceRateChangesInCurrentBorrowings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfPriceRateChangesInCurrentBorrowings",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails": {
       "parentTag": "meso_PercentageOfPriceRateChangesInBorrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of current borrowings",
        "label": "Percentage Of Price Rate Changes In Current Borrowings",
        "documentation": "Percentage of price rate changes in current borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfPriceRateChangesInNonCurrentBorrowings": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfPriceRateChangesInNonCurrentBorrowings",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails": {
       "parentTag": "meso_PercentageOfPriceRateChangesInBorrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of non-current borrowings",
        "label": "Percentage Of Price Rate Changes In Non Current Borrowings",
        "documentation": "Percentage of price rate changes in non-current borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase (decrease) in fair value measurement due to change in unobservable input, liabilities",
        "label": "Percentage Of Reasonably Possible Increase (Decrease) In Fair Value Measurement Due To Change In Unobservable Input, Liabilities",
        "documentation": "Percentage Of Reasonably Possible Increase (Decrease) In Fair Value Measurement Due To Change In Unobservable Input, Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase (decrease) in unobservable input, liabilities",
        "label": "Percentage Of Reasonably Possible Increase (Decrease) In Unobservable Input, Liabilities",
        "documentation": "Percentage Of Reasonably Possible Increase (Decrease) In Unobservable Input, Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfReductionInCashOutflowsFromOperatingActivities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfReductionInCashOutflowsFromOperatingActivities",
     "presentation": [
      "http://www.mesoblast.com/role/BasisofpreparationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reduction in cash outflows from operating activities",
        "label": "Percentage Of Reduction In Cash Outflows From Operating Activities",
        "documentation": "Percentage of reduction in cash outflows from operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfSharePremiumPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfSharePremiumPrice",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of share premium price",
        "label": "Percentage Of Share Premium Price",
        "documentation": "Percentage of share premium price."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of inputs (weighted average)",
        "label": "Percentage Of Weighted Average Of Significant Unobservable Inputs Liabilities",
        "documentation": "Percentage of weighted average of significant unobservable inputs liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PlacementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PlacementAgreementMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agreement",
        "label": "Placement Agreement [Member]",
        "documentation": "Placement agreement."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PostTaxDiscountRates": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PostTaxDiscountRates",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post tax discount rates",
        "label": "Post Tax Discount Rates",
        "documentation": "Post tax discount rates."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PotentialOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PotentialOrdinaryShareTransactionsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential Ordinary Share Transactions",
        "label": "Potential ordinary share transactions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for potential ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "meso_PreLaunchInventoryRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PreLaunchInventoryRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-launch inventory recognized",
        "label": "Pre Launch Inventory Recognized",
        "documentation": "Pre launch inventory recognized."
       }
      }
     },
     "auth_ref": []
    },
    "meso_PrepaidInsuranceAndSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PrepaidInsuranceAndSubscriptions",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails": {
       "parentTag": "ifrs-full_Prepayments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance and subscriptions",
        "label": "Prepaid Insurance And Subscriptions",
        "documentation": "Prepaid insurance and subscriptions."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofPrepaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Prepayments",
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "meso_PrivatePlacementOfSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "PrivatePlacementOfSharesMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalParentheticalDetails",
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement Of Shares [Member]",
        "documentation": "Private placement of shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProbabilityOfDefaultAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProbabilityOfDefaultAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of default [axis]",
        "label": "Probability of default [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r225"
     ]
    },
    "ifrs-full_ProbabilityOfDefaultMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProbabilityOfDefaultMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of Success",
        "label": "Probability of default [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all probabilities of default."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r225"
     ]
    },
    "meso_ProbabilityOfSuccessMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ProbabilityOfSuccessMeasurementInputMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of success",
        "label": "Probability Of Success, Measurement Input [Member]",
        "documentation": "Probability Of Success, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows",
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "meso_ProceedsFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ProceedsFromPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/SignificantchangesinthecurrentreportingperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from private placement",
        "label": "Proceeds from private placement",
        "documentation": "Proceeds from private placement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services [axis]",
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r213"
     ]
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofCarryingValueofInProcessResearchandDevelopmentAcquiredbyProductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and services",
        "label": "Products and services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r213"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r28",
      "r81",
      "r96",
      "r98",
      "r172",
      "r174",
      "r207",
      "r215"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(c) (Losses) used in calculating (losses) per share",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossespershareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share",
        "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss attributable to the owners of Mesoblast Limited",
        "terseLabel": "Loss for the period",
        "verboseLabel": "Loss for the period",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r186",
      "r187",
      "r228",
      "r229"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From continuing operations",
        "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity. [Refer: Continuing operations [member]; Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossespershareDetails": {
       "parentTag": "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Used in calculating basic (losses) per share",
        "label": "Profit (loss) from continuing operations attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss) from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r52"
     ]
    },
    "meso_ProvisionForLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ProvisionForLicenseAgreementsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for license agreements",
        "label": "Provision For License Agreements [Member]",
        "documentation": "Provision for license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Provisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Provisions",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesSummaryofProvisionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for intellectual property",
        "label": "Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "meso_QuarterlyPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "QuarterlyPaymentsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly Payments",
        "label": "Quarterly Payments [Member]",
        "documentation": "Quarterly payments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r140",
      "r210",
      "r212",
      "r260"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges",
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r140",
      "r210",
      "r212",
      "r260"
     ]
    },
    "meso_ReceiptsFromInvestmentInSublease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ReceiptsFromInvestmentInSublease",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Receipts from investment in sublease",
        "label": "Receipts From Investment In Sublease",
        "documentation": "Receipts From Investment In Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "meso_ReceivableFromTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ReceivableFromTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Tax credits",
        "label": "Receivable From Tax Credits",
        "documentation": "Receivable from tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReceivablesFromTaxesOtherThanIncomeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other recoverable taxes (Goods and services tax and value-added tax)",
        "label": "Receivables from taxes other than income tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exchange differences on translation of foreign operations",
        "label": "Reclassification adjustments on exchange differences on translation of foreign operations, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r56"
     ]
    },
    "ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financial assets at fair value through other comprehensive income",
        "label": "Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to financial assets measured at fair value through other comprehensive income, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "meso_RefinancingAndExpansionOfSeniorDebtFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RefinancingAndExpansionOfSeniorDebtFacilityMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refinancing and Expansion of Senior Debt Facility",
        "label": "Refinancing And Expansion Of Senior Debt Facility [Member]",
        "documentation": "Refinancing and expansion of senior debt facility."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RegulatoryEnvironmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RegulatoryEnvironmentsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory environments [axis]",
        "label": "Regulatory environments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ifrs-full_RegulatoryEnvironmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RegulatoryEnvironmentsMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory environments",
        "label": "Regulatory environments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all regulatory environments. It also represents the standard value for the 'Regulatory environments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "meso_RemeasurementAdjustmentsOnDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RemeasurementAdjustmentsOnDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement adjustments, Borrowings",
        "label": "Remeasurement Adjustments On Debt",
        "documentation": "Remeasurement adjustments on debt."
       }
      }
     },
     "auth_ref": []
    },
    "meso_RemeasurementAdjustmentsOnDebtAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RemeasurementAdjustmentsOnDebtAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement adjustments",
        "label": "Remeasurement Adjustments On Debt And Warrants",
        "documentation": "Remeasurement adjustments on debt and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "meso_RemeasurementAdjustmentsOnWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RemeasurementAdjustmentsOnWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement adjustments, Warrant liability",
        "label": "Remeasurement Adjustments On Warrants",
        "documentation": "Remeasurement adjustments on warrants."
       }
      }
     },
     "auth_ref": []
    },
    "meso_RemeasurementOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RemeasurementOfWarrantLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/CashflowinformationDetails": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/CashflowinformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement of warrant liability",
        "verboseLabel": "Remeasurement of warrant liabilities",
        "label": "Remeasurement Of Warrant Liability",
        "documentation": "Remeasurement of warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research &amp; development",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "meso_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research And Development [Member]",
        "documentation": "Research and development."
       }
      }
     },
     "auth_ref": []
    },
    "meso_ResearchAndDevelopmentTaxIncentiveCreditReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ResearchAndDevelopmentTaxIncentiveCreditReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax incentives recoverable",
        "label": "Research And Development Tax Incentive Credit Receivable",
        "documentation": "Research And Development Tax Incentive Credit Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfEquityComponentOfConvertibleInstrumentsMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Reserve",
        "label": "Reserve of equity component of convertible instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing components of convertible instruments classified as equity."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation Reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r188"
     ]
    },
    "ifrs-full_ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Option Reserve",
        "label": "Reserve of gains and losses from investments in equity instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated gains and losses from investments in equity instruments that the entity has designated at fair value through other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ifrs-full_ReservesWithinEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReservesWithinEquityAxis",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves within equity [axis]",
        "label": "Reserves within equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Accumulated losses)",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r192"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Accumulated losses)",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r188"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedIncomeStatement",
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "totalLabel": "Total Revenue",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r104",
      "r144",
      "r168",
      "r173",
      "r178",
      "r179",
      "r180",
      "r186",
      "r187",
      "r207"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from contracts with customers",
        "label": "Revenue from contracts with customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest revenue",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r169",
      "r177",
      "r234"
     ]
    },
    "ifrs-full_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty income",
        "label": "Royalty income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "meso_RevenueRecognizedForRightOfUseLicenseOfIP": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RevenueRecognizedForRightOfUseLicenseOfIP",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized for right of use license of IP",
        "label": "Revenue Recognized For Right Of Use License of IP",
        "documentation": "Revenue recognized for right of use license of IP."
       }
      }
     },
     "auth_ref": []
    },
    "meso_RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from up-front payment as deferred consideration",
        "label": "Revenue Recognized From Upfront Payment As Deferred Consideration",
        "documentation": "Revenue recognized from up-front payment as deferred consideration."
       }
      }
     },
     "auth_ref": []
    },
    "meso_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, variable consideration amount",
        "label": "Revenue, remaining performance obligation, variable consideration amount",
        "documentation": "Revenue, remaining performance obligation, variable consideration amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r125"
     ]
    },
    "meso_RoyaltiesReceivableUnderSalesBasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RoyaltiesReceivableUnderSalesBasedMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties receivable under sales-based milestones",
        "label": "Royalties Receivable Under Sales Based Milestones",
        "documentation": "Royalties receivable under salesbased milestones."
       }
      }
     },
     "auth_ref": []
    },
    "meso_RoyaltyPaymentsAtFairValueLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "RoyaltyPaymentsAtFairValueLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails": {
       "parentTag": "meso_ContingentConsiderations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofValuationProcessesofContingentConsiderationatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of royalty payments from commercialization of the intellectual property acquired",
        "label": "Royalty Payments At Fair Value Liabilities",
        "documentation": "Royalty payments at fair value, liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesChannelsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesChannelsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales channels [axis]",
        "label": "Sales channels [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_SalesChannelsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesChannelsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales channels",
        "label": "Sales channels [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all sales channels. It also represents the standard value for the 'Sales channels' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_SecuredBankLoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SecuredBankLoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing arrangements",
        "label": "Secured bank loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received from banks that have been secured by collateral. [Refer: Loans received]"
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ten percent of decrease in share rice",
        "label": "Sensitivity analysis for types of net income risk based on decrease in share price",
        "documentation": "Sensitivity analysis for types of net income risk based on decrease in share price"
       }
      }
     },
     "auth_ref": []
    },
    "meso_SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ten percent of increase in share price",
        "label": "Sensitivity analysis for types of net income risk based on increase in share price",
        "documentation": "Sensitivity analysis for types of net income risk based on increase in share price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServiceConcessionArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ServiceConcessionArrangementsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service concession arrangements [axis]",
        "label": "Service concession arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_ServiceConcessionArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ServiceConcessionArrangementsMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service concession arrangements",
        "label": "Service concession arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for arrangements in which an entity (the operator) may enter into an arrangement with another entity (the grantor) to provide services that give the public access to major economic and social facilities. The grantor may be a public or private sector entity, including a governmental body. Examples of service concession arrangements involve water treatment and supply facilities, motorways, car parks, tunnels, bridges, airports and telecommunication networks. Examples of arrangements that are not service concession arrangements include an entity outsourcing the operation of its internal services (for example, employee cafeteria, building maintenance, and accounting or information technology functions). It also represents the standard value for the 'Service concession arrangements' axis if no other member is used. [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options reserve transferred to equity on exercise of options (in shares)",
        "label": "Share Options Reserve Transferred To Equity On Exercise Of Options Share",
        "documentation": "Share Options Reserve Transferred To Equity On Exercise Of Options Share"
       }
      }
     },
     "auth_ref": []
    },
    "meso_ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options reserve transferred to equity on exercise of options",
        "label": "Share Options Reserve Transferred To Equity On Exercise Of Options Value",
        "documentation": "Share options reserve transferred to equity on exercise of options value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_SharePriceMinimumConsecutiveDay": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SharePriceMinimumConsecutiveDay",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price, minimum consecutive day",
        "label": "Share Price, Minimum Consecutive Day",
        "documentation": "Share Price, Minimum Consecutive Day"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangements",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "meso_SharesAvailableForIssuanceUnderIssuancePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SharesAvailableForIssuanceUnderIssuancePlan",
     "calculation": {
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails": {
       "parentTag": "meso_ContributionsOfEquityDuringPeriod",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement of shares under a share placement agreement (in shares)",
        "label": "Shares Available For Issuance Under Issuance Plan",
        "documentation": "Shares available for issuance under issuance plan."
       }
      }
     },
     "auth_ref": []
    },
    "meso_SharesHeldInTrust": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SharesHeldInTrust",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Opening balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares Held In Trust",
        "documentation": "Shares held in trust."
       }
      }
     },
     "auth_ref": []
    },
    "meso_SharesHeldInTrustValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SharesHeldInTrustValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsofSharesinShareTrustDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Opening balance",
        "periodEndLabel": "Ending balance",
        "label": "Shares Held In Trust Value",
        "documentation": "Shares held in trust, value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_SharesIssuedInPlacementsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SharesIssuedInPlacementsValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails": {
       "parentTag": "meso_ContributionsOfValueForEquityDuringPeriod",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement of shares under a share placement agreement",
        "label": "Shares Issued In Placements Value",
        "documentation": "Shares issued in placements value."
       }
      }
     },
     "auth_ref": []
    },
    "meso_SharesPrice": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "SharesPrice",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price for right exercise of the warrants (in australian dollar per shares)",
        "label": "Shares Price",
        "documentation": "Shares price."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofBorrowingsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current",
        "terseLabel": "Current borrowings",
        "label": "Current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Of Changes In Equity [Line Items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement Of Changes In Equity [Table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of comprehensive income [abstract]",
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "meso_TaslyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TaslyMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tasly",
        "label": "Tasly [Member]",
        "documentation": "Tasly."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TaxCreditedOrDebitedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TaxCreditedOrDebitedToEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity": {
       "parentTag": "ifrs-full_ChangesInEquity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedStatementofChangesinEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credited / (debited) to equity",
        "label": "Tax Credited Or Debited To Equity",
        "documentation": "Tax credited or debited to equity."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TaxLossesMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses (DTA)",
        "label": "Tax Losses [Member]",
        "documentation": "Tax losses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesScheduleofMovementsRelatedtoDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits",
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails": {
       "parentTag": "meso_DeferredTaxAssetsNotBroughtToAccount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential tax benefit at local tax rates",
        "label": "Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements, for which deferred tax liabilities have not been recognised as a result of satisfying both of the following conditions: (a) the parent, investor, joint venturer or joint operator is able to control the timing of the reversal of the temporary difference; and (b) it is probable that the temporary difference will not reverse in the foreseeable future. [Refer: Associates [member]; Subsidiaries [member]; Temporary differences [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "meso_TiGenixNVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TiGenixNVMember",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TiGenix NV",
        "label": "Ti Genix N V [Member]",
        "documentation": "This member stands for TiGenix NV."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails",
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of Range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r140",
      "r210",
      "r212",
      "r260"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "verboseLabel": "Trade payables and other payables",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade &amp; other receivables",
        "totalLabel": "Trade and other receivables",
        "label": "Trade and other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade &amp; other receivables",
        "label": "Trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20"
     ]
    },
    "meso_TradePayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TradePayablesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofMaturityProfileofAnticipatedFutureContractualCashFlowsCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Trade Payables [Member]",
        "documentation": "Trade payables."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofTradeandOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade debtors",
        "label": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "meso_TradeReceivablesSettlementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TradeReceivablesSettlementPeriod",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables settlement period",
        "label": "Trade Receivables Settlement Period",
        "documentation": "Trade receivables settlement period."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Tranche One [Member]",
        "documentation": "Tranche one."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche two."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TransactionCostsArisingOnShareIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TransactionCostsArisingOnShareIssue",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails": {
       "parentTag": "meso_ContributionsOfValueForEquityDuringPeriod",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction costs arising on share issue",
        "label": "Transaction Costs Arising On Share Issue",
        "documentation": "Transaction costs arising on share issue."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TransactionCostsArisingOnShareIssueShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TransactionCostsArisingOnShareIssueShare",
     "calculation": {
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails": {
       "parentTag": "meso_ContributionsOfEquityDuringPeriod",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquitySummaryofMovementsinOrdinaryShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs arising on share issue (in shares)",
        "label": "Transaction Costs Arising On Share Issue Share",
        "documentation": "Transaction Costs Arising On Share Issue Share"
       }
      }
     },
     "auth_ref": []
    },
    "meso_TreasurySharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TreasurySharesPurchased",
     "calculation": {
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails": {
       "parentTag": "ifrs-full_NumberOfSharesOutstanding",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Treasury Shares (in shares)",
        "label": "Treasury Shares Purchased",
        "documentation": "Treasury shares purchased."
       }
      }
     },
     "auth_ref": []
    },
    "meso_TreasurySharesPurchasedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "TreasurySharesPurchasedValue",
     "calculation": {
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/EquityScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Treasury Shares",
        "label": "Treasury Shares Purchased Value",
        "documentation": "Treasury shares purchased value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r136",
      "r145",
      "r149",
      "r150"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementSummaryofBorrowingtoPriceRateChangesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks",
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r136",
      "r145",
      "r149",
      "r150"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialriskmanagementAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofDepositsHeldwhichDeriveInterestRevenueTogetherwiththeMaximumandMinimumInterestRatesBeingEarnedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "meso_UnlistedEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "UnlistedEquitySecuritiesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unlisted Equity Securities",
        "label": "Unlisted Equity Securities [Member]",
        "documentation": "Unlisted equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [axis]",
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r257"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs",
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r257"
     ]
    },
    "meso_UnpaidInterestPortionPerAnnum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "UnpaidInterestPortionPerAnnum",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid Interest Portion Per Annum",
        "label": "Unpaid Interest Portion Per Annum",
        "documentation": "Unpaid interest portion per annum."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "calculation": {
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails": {
       "parentTag": "meso_DeferredTaxAssetsNotBroughtToAccount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/IncometaxbenefitexpenseSummaryofDeferredTaxAssetsNotBroughttoAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential tax benefit at local tax rates",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "meso_UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "UpfrontMilestonePaymentReceivedAfterThePatentLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront milestone payment received, after the patent license agreement",
        "label": "Upfront Milestone Payment Received, After the Patent License Agreement",
        "documentation": "Upfront Milestone Payment Received, After the Patent License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "meso_UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "UpfrontMilestonePaymentReceivedInRelationToPatentLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront milestone payment received In relation to patent license agreement",
        "label": "Upfront Milestone Payment Received In Relation To Patent License Agreement",
        "documentation": "Upfront Milestone Payment Received In Relation To Patent License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValuationTechniquesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ValuationTechniquesMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation techniques",
        "label": "Valuation techniques [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails",
      "http://www.mesoblast.com/role/NonfinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation techniques used in fair value measurement [axis]",
        "label": "Valuation techniques used in fair value measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/LossbeforeincometaxSummaryofLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Salaries and employee benefits",
        "label": "Wages and salaries"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "meso_WarrantExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "WarrantExercisePricePerShare",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price per share (in australian dollar per shares)",
        "label": "Warrant Exercise Price Per Share",
        "documentation": "Warrant exercise price per share."
       }
      }
     },
     "auth_ref": []
    },
    "meso_WarrantExerciseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "WarrantExerciseTerm",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise term",
        "label": "Warrant Exercise Term",
        "documentation": "Warrant exercise term."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails": {
       "parentTag": "ifrs-full_LiabilitiesArisingFromFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails": {
       "parentTag": "ifrs-full_FinancialLiabilitiesAtFairValue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails": {
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails": {
       "parentTag": "ifrs-full_NetDebt",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mesoblast.com/role/ConsolidatedBalanceSheet",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialAssetsandLiabilitiesMeasuredandRecognizedatFairValueDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFinancialInstrumentsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofNetDebtReconciliationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails",
      "http://www.mesoblast.com/role/FinancialriskmanagementScheduleofIncreaseDecreaseofSharePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "negatedLabel": "Warrant liability",
        "negatedPeriodStartLabel": "Warrant liability at beginning of period",
        "negatedPeriodEndLabel": "Warrant liability at end of period",
        "verboseLabel": "Warrant liabilities",
        "periodStartLabel": "Opening balance",
        "periodEndLabel": "Closing Balance",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "meso_WarrantsFairValueAtGrantDateDecember222022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "WarrantsFairValueAtGrantDateDecember222022Member",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Fair Value at Grant Date December 22, 2022",
        "label": "Warrants Fair Value at Grant Date December 22, 2022 [Member]",
        "documentation": "Warrants Fair Value at Grant Date December 22, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "meso_WarrantsFairValueAtIssueDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "WarrantsFairValueAtIssueDate",
     "crdr": "debit",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fair value at issue date",
        "verboseLabel": "Warrants fair value at grant date - December 22, 2022",
        "label": "Warrants Fair Value At Issue Date",
        "documentation": "Warrants fair value at issue date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.mesoblast.com/role/EquityAdditionalInformationDetails",
      "http://www.mesoblast.com/role/EquitySummaryofWarrantReserveDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesAdditionalInformationDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails",
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "meso_WarrantsPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.mesoblast.com/20231231",
     "localname": "WarrantsPricePerShare",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofFairValueofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in dollars per share)",
        "label": "Warrants Price Per Share",
        "documentation": "Warrant price per share."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.mesoblast.com/role/FinancialassetsandliabilitiesSummaryofQuantitativeInformationAbouttheSignificantUnobservableInputsUsedinLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted average [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r131",
      "r210",
      "r212",
      "r260"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.mesoblast.com/role/LossespershareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used as the denominator in calculating basic losses per share (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "92",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_92&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "48",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_48&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "23",
   "IssueDate": "2023-01-01",
   "Paragraph": "26",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2023-en-r&anchor=para_26_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_24&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "SIC",
   "Number": "29",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=SIC&num=29&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_e&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG20C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG32&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001345099-24-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001345099-24-000022-xbrl.zip
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M'VAUGH$\&W&#?6XT>FX*J'6X>&YBL<]/(]S-ENV,G;65UST0CE4AWB&8R.M
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M*8=GFK=_W/9KEJ';MG\#4$L#!!0    ( -U[75BXVT-(Q@<  +03   3
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MQ6I6#YLSN^*CP)-P] WYA&1Q#^&@U-%LGJ)#[[G>YS))R,MHID&:Z;S)VK6
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MSRBT^!=S7GCG$PMQKT4N$Z]SHUZ;^H6I(51 '&QJL1X\Z]?"_?>[9$C([4O
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M!W@L*<.#OOF:[NS-5Q8_MFKR'KXZ6!RCR/W=TW-,@VG4BI5J9D4P@^3R#@O
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MBD)Q5'%4<51Q5'%4<51V]VQ.H+^1=]:0WCL[D9U5<T)FS,UTJ,_K\S^H;[$
M8F>OSY,UTNZ@.OE67!O7A=S&/'[H/ @>3Z;A.NR#VJ5_4]]+D^7F6/)9BL9=
M"E-98FKIT<H[P)1>5IC*&:940T?%'<4=Q1W%'<6=D^'.2:^KWA'F:V_$B2B&
MB4&7^+34)A@H]LF@!R-6>[=S( EJB],1Q5S/*(1<!A^%"(X7V:Q;6J/KA991
MU)NSAXTKB$D),:4 %'<4=Q1W%'<4=V1U;3:M%L[6LS'D\FS4_NT\+:7O8__V
M=9>XKS2X=Y,E]-673LSY2R>J(EYM#MDSTI=&L@N1OH(JKZ J+S=G#XU28%=@
M5]OJ%)@4F!28%)@4F!28%)@4F&0+$);F@[:-#ZHJ/E!E#(O0^H4XQ+4H/R*D
MH]U0B_;:U-=,O:@99</,HH8A16@M( 7U9<KB-L[(S/:+?>:]8W@+$ER: "?;
MB]H.%1 _5?UH5I<IR WU8@U/*#0:M:)AS!ZNE1_=F"%X<K VI&0D549J.Y(1
MWD/ +%9J924A2D(DDY#U6FO45SX[;T-9P1V=Q4I]]L3;3?=T*J2>)E(;NT9J
ML] RFT6]G-V9H@JJQP+5M9#:W(W;8>#AX4:Q65-^N1(0V01D+5U>6?VPZ U%
M12^T&E6S:%:4WZ&PNHTRKRQ-1&^(4*/0JI8;Q;JI*VV^57[Z(B3P*OC79F^M
MS_"?9+@]XK\R5[S7F(3D'U$0LLX@:_CQ'+?XB$^\9"&\SEJ!["]=JI&V]T81
M?9Q !)N2!B'\@T6MF(&VQ((''F(='XT:=+W(L;4VU7Q*;/P![OXC<@6J^<'7
M(3[8LKP>3', I-:^>R$-SH<,7D2SQB*:M3ZW_8O62L\!VJ]]4WV+=\>4K53A
M&7TO8$B-2Y\Z)&1O]-,[L\,N<(HK@K&[8O"61[>0-G B"N??,I.VWQV>%J+G
MD;Q2K3%)C_'_XI!1[;"R12H-O=VLU0RK4C7-MFX;I&P8=5NO=&RB_\N :#V^
MJ>LGT^C#XTMM@-C/$NG +"^)\TX& 0K@./. <^.4GT>T*83-)UFGLS.2"6B!
M<O9\PED-*HWZ>!4,AT@S%JWKHQ'ZRW*^U;&;,2K<SQ<DMS/P.GD>?:Y)C\??
MB8W9I)6F1S:Q$/O6@M?CEC-9O'WN4AIJ<TV%-(,_BUP2\39YP_"$NS4CZ\1]
M*!B.0_H!O4S^^&2SH.^0P25S^4/Y39]B'L4FK3J[KL[G+7X>*>KSLE#6\8)_
M_.;XYW/XZ6+V^VKC7*\8J3^5S_74[^<]2C?.RXWT6^8]:O[WE7+MR =56?BH
M)94;"PH0>%V&1,':&;BU/\Z?SR&D ,C[01']W! \7WBF':Q2F2!IM47Z=-$_
M7V-.2W9HY6KJ5[S0AOOV$]4V_)L52VZ.G"Y_CURJF>5Y-,FH7NLPZF#&4LZC
M1D"WZR"S/!^QD]XRIS*RC!KD2@W"Z\CW,2VS!1CSL%7W$/<?EPZ;$ZJ0H*O]
M-^GU/VD6_HGYO#?B9-4:Z\!6;44B5 ]<5RK3NL6*),MVX0)1>.7:^,_M"(!K
M+V28A5:]7JQ69U?:5%N._,/(6%K,D!&,*@ CO6CJ#4E@=%QNS-QV_C:-#9$7
M=B'>\B'P A:V'9J)5Y,72]3>S!)EM,?KR%7(<DO$<0@ZY $Q&/O63R,DKJU+
MJH6666PVMU8EZ6B6?<O@D<-IN47*&DZU0JLF$9Q.(4)Z]&F6S8*/W XI5S:C
MB$CHBC'PK:TKZFAZ:BE'6*E@*/\(6B$8VAY!#42069$%0<<5!Z6G<U^\D#A:
M3I*Z1],T8D7F[$3%"QZO+9M-+"LOZBFYKIW4[*ZHPF1K&Z'0OA^TKVR.-D.[
M60:TZ\5:=3;P46B?,9!3U<=ZE=>V[GF9]M#WJP7LG'@\WSVWE!-_)X_WGT:*
MQNO#< 9%K>\0@!%Q;;Z0W<>P1YWP)&T0N]Q'3CC[B'R]<NW;A*MK>Q Z-G_0
MZ[-;W%0V)/] 6NY^9@<D X%D5NN2 .FX7(1T*#SAWR6O4XH";((GM8^@5L66
M:W7.3Z\#W-PP'#0+K4K13.D*IU95\X^?Y<I\:_Q4"JUJ$?Z1!#^GX*/?,9>X
M%B-.K, U$FJ=T?&LH3A#*:[]P5WB/NU2-V!O5&,N?%YE*XKRXV75^!#D6R+&
M'^) B.Y5B&?T_@,Q$!^C)4HEQ@%PS_F?)L?50JMAU"3QQ!2F]FL%,L'4FH:#
MMZ2M*^=_CZ#AO-. UJ68VRH"D%UVE]L#SM21 &_HQM6Q<;Y1V3JGH\( "4&T
MW !D Z(&@LC<WHM0L<#*,+AW0^*^,FPJL84NSV5A94UM-3NLY1EA+W867?LW
MS[/?F>.LK3J:A5:U7BM6:VK#V3&":;D%RA!,E3*"J5[4&[/G *G@8K?EECDJ
M05!%:-FDH39S%N$-K2J67>ZK56I."]$4XF4IN]P:\=@<N%%/S7DIQ!]KV+;(
M6&[?]>C0JS$GJRZ6&\@-E80)@6V]7#0:U3PKB;7@D8/P[&1QOMPL;HCS"N"\
MUBQ6=(7SG>]#D+6@>LW[=[ /8?\C.P7OYBLC;>:PD&W8;T:2?2_2W7\*::0D
M>;0MAB316=+=?USZ9U$'+-RZ(FK@^F2P>?.K7*Z-5<\LM38F6_.KQQB&:_O*
M53R9N%A/.9A8K8WE'TR;M;[:&$RU0LLH%P%4DH#IN)R:N;LJWU@ -#ZA_HLU
MU7_QL"9HV+4HP=[:JJ)>:#6*AKFUV5%%@1(":(VV5QL#J($]%LVF+)O+3B'V
M^>+YOO<.HSVI:,=6T8X,IL;S\6$/G:^>^PH@Z8W N+;JP*9<Q>KV^PI5R",A
MHE:W/=DAJHI5@<5F5;5@W!\FOE(24,W)02I7^8,K:WG.U+'T_-J"J.,VD495
M[34Z1ABMK-JWAI&!G2O*VR=%57"Q,A!^)[Z/7<$2C3XXI1B#JACCD-8GQEZB
M,09I*L$LM)I-61P\!9#]VI59@*QI4'@KFXHT33".*T!8I4=['FH^U!Z*+$*(
M+=P^/ 9*+YHUM8E"HJ#F9"&_>KBS!>1K$.GHQ69CUK-1D%<MVS<K2,_!R$[!
M 1K?+YT']R>/]Y]"9F;+"J-<IF0VKC!2$7?6/0 VKQ&IU@LMO5XLUV7IU:%
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MUNGLC&9"@$"E>3Y/?ER"(J ^7@7#(=*,1>OZJ,K_LIQOX+6\H.[0/E^0W,[
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MT/O+R!PB:]&V#=UY#IE@'#0LID4J7FP/#6AL/<$G=!S>Y+0K[&K GV\/%58
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MSG5#!06BY*,K1"S0!(@M7E?DEB#,\[!FE:\-\'V93K)_J@./P4U80 O<Q#+
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MB9V>]58RTJ(  4V!X8>Q9X<L!)_A*0#"2F 87P&O2V67J*J)T UN3UW/MFA
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M-+(<1C(W7)#B^2MJ,NS:2V1L,)=XFVH &CR<;5%+N86KQ48V"[( K,OE&>5
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MYS2<:I8TJ?/S7*']JH&=?;G VR;?RP5>9U]A?W#@G9=9?J0<KG)/.$2J]'I
M,T>L\UR9-+]VB.; XW;>\<1[(,[#0C363F7,[KX:H<PMK('9+Z&ZMS[9%:IZ
M20[#R:#*5,P[5AT2K=6,5M;4LM/"QV2@/5*A-F)="ECK7NQGPQJ+6]A$E9><
MP2NPC!2L.N;5]=A2QZ645=[XY?6KH'X_Z)(C"M1$\>Q:1.D<&EBDD76MBP$K
MDK18=P%& +"^J)M-6=YNPB=K2#GVF6B,[%<HDQ=BF#%*AVW?DX\<8\M/^,(#
M^O^%/7*R%F]/I]BP*B@O% _WZ'QA.SB 4?:HW-:CLB=[5,H>E55Y ]FCLF8]
M*OT2W$(J\43R;F*P5O76&&[Y)NOPZ&W8_3SV$]%XPQ7-OWRMZ!+A ?]WZ1CN
MQ."6;4JS/6Q?+0P6-IG -HUQSB'2];$K1&?,.2588AUTR<,QVDB30.5S^PM#
M!6,Q)P:TN&=2O^D ;[+F3[^*T=;U9R*CC3">X70AA;?)Q]8GHL^<W[<,1RJ8
MV.U?]"7 1@_&7+15X]9%V+*,-_(@;'Y/I*&];VW +Z(6X9IEL6L)^MI1]%?;
M^\ -W"?[EJ-E>Q5ZMU?E*G10_ZTV-P$*EJ$/.\7*T#?4:;<'Y16/]\I;5*>,
MXO&+JGFN144O[P664M&.GUQPI7.$+FS("_;*2J?))9RBIOFTENVE1#CV.4N]
MA(+F.NWZ;^O!CK/*+SXOOLT(FP0M="/MC=#4Q59D_$,T>+,W5B9L=K?6J7$V
MP;0?QB2?;></M/J_VNLF<WALG*]I6N0$ )Q>M=-M]@8R*_@<0;;6(?1$(!O@
M,9/>[&O)SHLR8?A02O:!#<X(3P$BD1^I;BN[EU+=GDS=/OFL\C'DE-L@!H8S
M4[%+J2B!O;>^+T>N,3$(CNGXX! +9\1BF:Q_!?[C'KU/N 1^_A^<DO$[7+IT
M\D[,BTC0(:KI9G_8KX@ E5KZN%JZPMC46;5"LZ-*Y7YTY0YR?PPFFK%C&:94
MZ5*EUUAL9JET=L3$. 1\ESO.'X?P:W2U<=-I:EJ[(H)/*N5C*.6CH4NK%KKV
M5:L'3P^N?[5):<(OSYEZ83QBP8FN-GO#X?FTZ]D+5>>46W]9S+-1MA^$>; H
MI*LVM5XRVUXR3XG9_NG9S3E'I S/<D2*GCDB9;_1*8E,KL_^\&?.-K?6)/@D
M4K@>S>5*I''I>G+ B:XG9ZL$-\Y(3=MIO@I_4,KCLY,[JSVM^VG&9AAZU)]N
MAA.*@D$O"L%)+^$4KW^ZD?'=6$K@+%DX*3)7]CKO!/,8D^C='"QR0C)A,QNM
M]_YT<CA.+DT("\)'FK\8\ A,QS3-]/WAL\M'JW GW\MM.MXV88:N,04QF60M
M2C#5=[5@ [[2]DYNU#'Y:2WS'-3$>]0;<@^.MP=1'N$Y8'8X^I>/_":&$T[%
MPT_259'RW^7DF<L_U/T4R._?UQJ# 4D,RUOA*#W;?*&3U@Z9ZNFCX0++XSY<
M5MJ4.+V78DKTDI9,/0L>PF'W.%Z;CSV>VJ9IO^+6I*JI7+9#G;+S.WI+ZVW.
M7L^=Z-\:#LL;-U=2<G[QX@.YJ(HMZE)J*];=0990?V$%%U_M3:>%9195;-S]
M8]9XYZVXX!$"+V5V;K56^OGWA[O[@YALH*IRK""EY!^5\I76&B3U*!8<\E+Q
M-^K;.&4E^NJ)OJ?'+S5$GW9,]%5/[D< AEJ/S&U8&G8RP;GF%UIDQYIS7EPQ
M'2\MC%5;YBRT/._*.;FR<UK9>:5W9@SW).Y,^1\R7[Q7QO@G_7-IO!"3MR;9
M/]'SQ#(\)Q'T-R2/DR;;D<>COJKV?K=3_9JEMLCMD=MSNNS0_O8IDR"X;ZT)
M_L^G4'P73ASJ-V[Z_::N)\=!2!C5'T;;J])*@M&@8C Z+W\LXY#,(1,JS#B;
M%>PXX)O!%H[,'6MPMQ.ADG;<:#<[[G+K%'8S%&09B=P>N3UEVW%,BH,&9B4_
MWT(!7E@%#[&>9SBL2IFLQ-%Q#;FR<-1K5PM')<7C."3:*29=+*5NF'(4=$J,
M)!/1O6@*FS=CA2/"_!O;\X5#9]1RL:.KP88V5+9P6SIG_8R9JB%/KU<\>)]A
MZW_'G7_B&\^8_2ZZ[7Q41QI?JXV;0<HP#NGF5Q-),I@GMT=N3S5LJU+EL%8E
M.7P)<3+>S 9H?35>.@X.V!%9G(<*&DEW1T8UY/;([:ENT(F)Q*^V)03BFGXK
M'#+H-&ZTIM95*Q(RD&@ZKGE4,IJZU4+301H3G?KZ_+U=+J][2^&X3!J(]70K
MO[;-6,ZF5]%YX%E8:Q).$DY'%X]%PR6%#8 >R$[L1MV1XE/B_>1X+QP>+(SW
M/N"]V^RI9]3X\%#=V<XF5+FIQ"H8W+9O>56%RF[6N_C)I9W[TF0AE2RDDL>3
M\O18;H_<GA.>A72.4P'3PPH8M8PQ-1)&%831]A%*)<%H6#$8G9?7)0NI9"'5
MZ0T%><PMMT=N3]EV7%D%,/UVXZ97H0(8B:/C&G*EX4BM%HYD(94LI#I/GNYW
M#YC 7Y#IM<:-VNSK>P]2EE& 2MN(<GOD]LCM*=OT.IZ8[E1+3%]"E$V6855B
M&V1,1&Z/W)YJA*S*+9SIL\*9SOZUQ1)-%433=NNI9#3IU4+3A9=AR1';>\9\
M"N._E^4BU#8I6TZC/QM6J7O]EX3BV4"Q7)-X7ZF-M33M9J^K2;$M>:76O%(X
M7%J85P98H][L#,^H[NSHO,+<DG=L-G#!$=\X7KG*([XC8Q>/__@XJ52]U>DB
M(3[O=&)_5KNBU6)7%HX]-3S%=A33=MWX3KR+C4?G_Q:CS F7/I&]$D_OXJ3M
MY #'8,#V/^+#.848:(>7D!$P_=++ON3@4S)S;O C>::*VE\C6>2_,\=?T@)^
M>C5R*/EQ1::PXFMBOI*5BV(IBG: >I2*602(CDD?;,+W='HX@+%= )5E.PP*
MUR#HJ<,'<?Z+5&8MRLQ!'?TWHSTFW8$Z&O9ZVKBK=SHC=:*1MJ;U)VIW.B'J
M_X$Y^L2&S?_K':GM&]C3.J^^UJ2_0Y.059.2FS21L"8Z@V$ ^I7&[4GXADYN
M/?_33B/[FMZ5FG)-#^Z4*2<T)B>8]1.*7F9JC7$H^L*EU_X?[R>&NS#)ZMJP
M&+'81>_%S82\UI-)@XR._.M0<K7:7'J)<+!X\N:!]9UNJZ?W-PZLSWNK?FLX
M3/\FZT[9GW?;O5+6I&JM]J#HP^6B*K6HS;?:<@!2B520G)/ @UQ<TR CPP0+
MC;ILNO0;PU)^:WUO@?,&4L-QFV#*@TUI+^%I$S=/=5)%2J[R$>*K[>4J,,MY
M!K4K!*HW*_Y+B(MZC+9_N+NOX6A[]9BC[24$#PO!I\<O-82@=DP(5D\#K*,,
ME2"9V["^ORB^G>L=13U4CS!/MD?,V+N?5X[LIOY?'^F8SD?443KJ_CW MH>^
M*]!,2J[LDE9V"9W!>$\)\%K$ <6"K'9O)[']_2O93F(LVX+)8B>Y/7)[JI=-
MW=<+M0&XXRG5CT*(%\ZT&#9NU':SWVM7I-Y,@JE,,!4<SKLGF ;MBH'IO!RS
M=#A\L!W'?H757E0_L(GL!R:K]^3VR.VIGL[=;L"%(KNPAE5!PZHZJ-AD%KG$
M3OVQL]U>VP,[6M6P<PG1MCN6M?2,325@JUUC0GG:U25%V^C;-X9AR)";C.F<
MT?84,@EZZ6(=EF-?AQ+B+BH@BLMW[!S4;^J=JDQPEQB2+%[K[2G#<BN7Q;L5
M8_%+"+#]01R'@/GF9X2N+BG.!J;;RXZ6V^5Z?#*84^GM*<-R"QUR(1[\=+E5
MFMC6&S?#856\;@D0R;^UWIYR VIY^+=7)?Z]\'9CY]%NH^Y=DLZFM\MYP*E<
MDR:H@HO4 !1V5?O@J@Z:NI8<,B)!+T%_=-!O/90M!?0# +W6 ]2?49,OB?K:
MHGZ[]5L*ZC&'M*LWVWHR[T^B_ER#I9O*Q/ZSM*C2:>]?(E:ATJ'UQFUR:>>^
MM$M(3Y'%8+(83!Y;R^V1VU/)\'6_?\SZG6&[<:.UFV#+5R2]0(*I3# 5'#"\
M+YC4BH'IO-PO60PFB\'D ;?<'KD]E=:YVPVXW0MZAEC0TQXT^[U.15(3)':.
M:Z_M@9U.U;!S"=$V60PFB\%D3.<,MZ>023 X0J7(D%>*J"D3E"2&JHDAR>*5
MWIXR++=R65RO&(M?0H!-%H/)6-NY9WK+8$ %54J6U;BID*6@/ND!CS>[VMZU
MQ1(_4K1(:-1'M&R/,^XM6OK5$BT77D)W"?.LZR<;2]RC&D0 +@B*Y9IY951L
M# >-&TUK]K1D;HYD&,DPM6*8K0?LI3 ,ECAI@^:P?4;EK))C+I)CMIO[)7 ,
MP!4X1E>;>B>98" YII"C\HX-I$X9\!B9=]V#EQ</N\*@^;76CV/VOTO7,Z8K
M_I%A3:CE75_ACT[DH$8F?![_\7%2J7JKTT5"?":&H[P0<TD5;P8P>)Z)JJBQ
M/5\X=$8MUWBABF'!O^G:W,UW:[/+#[)1V?/1TV:J]]A,]9-L;F1V9H(NE=GN
M#>3LI()AX=A3PU-L1S%MUTV^6O8HUK7)]-OV^X1\^32CRB_PN@OF0/??NPK]
MN;#=I0-DL($>CF$O7<4QW!^N0ES7!C7AT8GR:G@SH!-5IL$$;<-R/6<YA_=Q
M%<-5)H8[7KHN_-:P%!POK0Q;"CYM3GX:\^4\]IRQ0R= :7P,#A_%&U.L49RR
M/QVZP#FDUK.R@)>T)WA[_'Q,'&>%'Y,YR' /?T[)>*:,35@I_BM<''Q 85VX
M.M@Y6!09V2^T%=] KK:^PCLXQGA-BZI)M?D1WM!DK_ PO2/N[-::X/]\^G-I
M (Z0#I]^+DQB$<]V5J&BA#M14)\+N!?0BS8V J>B,C[=*B$MKFV3_T6ZL*K3
M,?Y!0PKEY2!X(Z85 \W-5? 8A[,O7'KM__$>8 <T7UT;%EL?N^B]N)E0Y_HB
MH8$9!?G7[_FL>[7=;@&UT-82@4/Q9/%U"[YZE_R\K[:&G?2OVBTU]?.L6ZE:
MJSU(OR3K5MF?=]N]\A;5V7BK+<'62IS^YYO\^P8DUV^M[RTP_@!=CMM$4>;-
M0" "E-T\!^,5.?'/][J\EP,;_!R;^\L^R=G9(6?$NZYT"1I=I-/D$C)BN"CW
ME!&Q?F0"(L<A6TW]\:/,?"%@-8RI^P<861^ S,6=<:UQT^\WU6ZWI .XT\>(
M2CK:O5C4Y2@NV1MUX$7UV\VAMO<XR(.C[MC%)\RZ/05$/H+KY!K@^8#$AG69
M!XG!]%IZ+J\<5P)HN':H"0[T"WV/.WO5::48Y"/B4KQ!+' D(B]%E,UEY!]O
M'$;A0^#6NP, I/%MMW'35:LRPU5FIA\M,WT[,O3&36>8/ *K9[[YGC:#/%<J
M:L>F!\4*FQ4]9LSJ>M*8K='!4HE8JH^9+5FFJ!%>$LOT@6749D>M=?;"B5FF
MR%EL7<+3PT%KV-X<GCZ2:P2$BY]\5/2DHSZGV3Q,Z4=N.:]A^!:CE.SL!8.7
MXF/1JA<#VAYUJ OHHL3!H[3)FL.(I]_F$GN&LC,V]HR_[V$FZ#$+]%X\_@-_
M>MP@_3<U)[?N=SI>.KEST'NA#!PT;MJMI,V@P'Z8N&@D2:$W69/>QWN3X>8W
M:2KPX 4=HTMMKIK*#)ZF$%=QQ?/8F^+:'&.,9[?P=&7IKA]^A@'LN,Q[%SL5
MS3RC&ZP?5K)/MK$P_NAP+,SN>&UXL(!Q'J8VWF:>7^*)LC$%^<50 L3=]2"S
MRJD U)E'^-^AR@)0@\<QD[0W5@QV.K]29N0%Q(,"B.9P8Z?V#J7*'!XY<UG^
M!'5=9>K8<W9N/R$>Q5^1,=R-QX1:1=)KQ*J[J"F30:5 0?XCKF"$>FV'EY 1
MF M++_N2Q+'4B7;FD3Q3!8VY&(DB_YTYH1I]IE<CAY(?5V0**[XFYBM9N:C9
MHZ $1$:IF$6 -0[/?OWI]'#JCNT"B$>;%\Y?@^U!'1X<_!>IS%H4@#RHB;\9
M[3'I#M31L-?3QEV]TQFI$XVT-:T_4;O3"5'_#XSS)V8L_NL=J>T;V-,ZK[[6
MI,>&$ESED)LTD9"5YJ:CPYG(&M2ONHV<J4\\:!C)>HKUC_T&EB?H!NP="Q\]
M.G1!5O.U+"B&^R>X]0?3'O\(+!RUG3<G*F%F5,=32 \/C#)SHM9;\3LA_=BG
MBY"">8R+1*+I61E@&X@E4\AD"IE,(:O&Z\H4,IE"EL/19,)\0D=@$F0W+I?9
M//N<O3$:1TRRHD<(JMJX49N#MLP@DY@K-$YB'\QIC1NMJ?7+:ALB\\?V%]7D
M)YX 8-G,"]P5S&X;UBBB%S*5[/RX?&,JV3?J4N*,\83Z(WVAIKU ]Q0P<N]#
MY(X5<H4RH+ (P#[E( +4BN0<R6RTHV6C'0%<7=0OG?U;X%<DH:T.MOYGVX%_
M6JQ@=&:;N&[% Z42T23[> !GSC ;I;$@[1\A98%9OH5T3>, O7'3W5^XRK9^
M%<3*1N&Z"U9Z5<+*)8P+88%"M+AY.?QNH9'+L"2VF*F^A?#9L>= 4&XXK/FC
M4^,GG5S]11T[#?S]2$O!2A@+TA(]HB6:!S\Y[,T!.C/=OK0WCP>"K]13#.N%
MNAYZ#WC:XF*R,'&EF;E/.!G(>A]0]=[B'</H%Z1K&O"'X&BI5>G^*\W,XX:!
MBV%%P\9QP[V'!DLS,_=N^ZG*J4D4TM3<H<Z-3\[VZ1H-4"7ACN=J,KIYCD#)
M4=U5!"@X[?5<2F_K(!8?_,2RX(3+(S_A]F]^L>T)3\F#.[\88_@,(YCX >L7
M> 4O22?X678^C[0;MHO1R,FQ\+NHRS;E:4:L>]:$$SY+8Y4.MC>OB@DAS<WC
M"M7=88/'06VM(K Y+\LS/0TN3Q;ON1F@QVBT$,O#%T;&'GDX&K;]: Y3&G_4
MJ'I<FL@5A'+.'+(2H=QKW/0DE*,:9JV*4M5Y:<0^N=B11+OU_@P%L[E+?-#F
M_@T9I3+'J8O) D>[SWL+*'XN#-.5DS ;ACD>03[>6?4?_R=F%V:\-;+L"QM+
MP<J2*;R(@1O/"NA82?$MO)4#+P@O\(S^FX77P2WO+<M^865PF;1*TN;XI%!U
M+!+PWR&^_9%D*'8X'*1#87_Z9X?,64%_'MJ!+)XL60L PU)XYF0=Z.+9RI]+
M6,B4]7H/7M2;$4^94VSKSIO$/R]-5F2HC!W#@T>1EO(KL<@S9728$=; GK*6
M]'"!2V.P JK1GPMJ30QOZ:"';U>?,!,*KSF'CY77F8%][VU7%.Z;Q@]JKK"S
M_BB574(1XHYG0!_>F9_QH4\DMZFP)AGP?Q907QD1UX#/X.KJ$P;@8GG+.=;<
M+!SZPD<8;!*I8Y,8<XX"V[IZMA%HG&QL_B4;48 _@=<WW#4A#+P4<"ZGHY>=
M-$UB35J4H#_+ I0V,2S$'=*< O7FV"4!61LW; 5KQY$(E+=Q4?P.+NM]$\ZY
M.T=V=>ACL5)960TJJT%E-:BL!JT 760UZ,T=?(1K43P')_5DZNF(>29K1LM.
MF?0WX0GW(+T2XU-(_[1 2[]QH^V=Z":+1<\$;!OS*_<'VZ!Q,]3EF($JH(+9
MW@:&%-RE@XE>_*1\.7+!#5_@MISOV<Z!A;(@[;U/66"1[U&Z%@Z&#_%<1U.'
M%<DJD6<K1Q.Y94.IT\92RO;^21<R0:E8@I+,,-I-EC+B1>)$:9A603SVRK(J
M:F:IGCDV-@K'/-C0$!O]BF#CO.S*]"!)6DQW!_M13J+8,:<HQ@\%C8,.VIF]
ME-2Z^B5=5'U@2TFVL623'?.5]F&3+K))IRO9I-0A+9<TL&##F6AR9(&W?P_=
M*B<2L;=;;Z*<;*T,_,JG&K!S]85C6&-C0<Q@OLED2?EX8S8-E<\JP/$%3>45
M;@7?+1:P.WBO)CQAA4DX+X:+),:S>CRD8!DVO(6#8MJ82A%-KUBZE">LN,8<
M[C0U<+K" NY",*?%5N:4@(_.$A!2[]44R1[L/D2!.U /Z)CZ:X68IOV*[]%2
M/M(1O!V_%E-$?ECVJR4R1)86'G?C!!&6HP#?OCJ&YU%+L:=3?D9)43(RQB4\
M@0CSZF&/X5\H_%K*K6D*A&W? WP"9D4\6[#!$R0W/H 5T_#I$>&XF?"R)L,P
M#IS RW&;D. N]3R39_A@BR%8Z\9>YOUAS/)?[UCX/;C;(UQL3V(B'9 YOIXL
MG0E9A3)<;]R$+J,O<P U*_[N^.H4[@$+MA7+QIK+/Y<&>WV^T9QZEY/$\9(I
ML#X3P^$88,>CYRVM/@)\@?>8')C9CG>%F5R 3#SP\%E@S+.?HV_.\J^ 3&/B
M."P;CK.)8K#<-D#?1' TNS'@7/ ,7#(-R'LY:,L&V_U\ ?3@"9(X'<EP?Z $
M97,-S@!>]Q:76TSSC^PE%[!&^-*;&2R &5<E+/M2S)'R?$7&NN/TW[L!V5B2
M'+\ R=E$T<E:OW$<CU><RG@3(ZA 1^W*/AX#D48HTI?L>^6K#=\,UV=4R:E
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M]MR9L4@JSE#G-D46 Q/TZ#6$@<OP$DS_@\U\?F;6V('CI6&@5'0X6+LW>SG
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M^8T7.O(,)8'K%.GR(T[S1*F*:/''LV%LIYG6O(\U@?/3+$@TVH5\+M(KN)Q
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M=/=/BY)XNQR\143;K6.X0(S/CCW_[$>Y;H,@5V$@ZJ)T2$O.Q))0/ LH5K&
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MY,MU)#7]F#94A]E0>B<9CJ^1(UDBHG86!O$&';5/^Q@.6L-V^E<Y<S7*DH%
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MV82M;!) (Z #M\/YU)NIF(,QL]WXT4NPF? A\ >?3L,?YWK9ZT3<4C+&%YN
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M8(S%1D\6S $,S:".QFG3?L 6C;[QS* O@4DTY<88>/[TRL4C,64,3\'74UC
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M24UCO00TF269R3YJ3]^04^%3.TAVN_7N77=)/P*AXWPT-7[2R=5?U+'36&B
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M25TM>]3A2"QJ]Z+Z8'9-MO=):D/7EWV;&]&?&EUYZ MJ048?B?@=)?8+QA5
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M(T5;&*;N4$MZ,;R%]/CMEOS^SW^\8W\J<:-[QUY8K/QU])L;GA%D:2A5P%Y
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MY:4@90V0!+AK0&DN,5R6[0^@_$&]VQ7!T(BQ0E: E?G+%;N0;Q=Q:/S@9!F
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MS*%HU9BCH+ESS!SW"TP<<S]:>5RR/?J^)7MLOPAXRTY]+AX\_2."I[YDM)K
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M'L^W,MQXBY*,!(^VP]PIVZ+22W#JBBWE*=AR:_C)=[+]UJ/VS2Q>&M_Y96$
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MC "=F03',U<T_O"&QG)%X#%!&I8&]V+/(DO4$.%B8K\^=.;7W=Q&2D+ 7[N
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MJ$G,8'(Y36)XKY8915R ;0"+AQND=WI>8%7 'SX#I6? ;!Y .[GUP5Z'J-]
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M,YU,E(:,S!0(J1,A2L%PKFT(J9AT,,3<T4Y?.=G,ZX;-7#V'XOZ8$S)ZA9&
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M,)/%*';D#^^1SK8D+*LW&'&[-4E5[4U2[M07.YI>_Y82S(N,TAP^Q>O\C \
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M=A/;^0;-^[$[.I^PQ:=SN5TIG&J 3=!A?S7?)$%[=O@7^ 2G'/%9 L0KFAV
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M\E\#YX6@Q^@&/@5*/T9K2Z/X*^'SRM'E<:3,^/9[GO+W?_XR5N31;W!7#9P
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MF^7/'?C3S\N_/SSJ'!T?-_[IH--M_/VJ1QUU3KJG/^1)L*C#[LV+VJQIMM7
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M<DL)^YH&G ,V>-BC:8NN:#Z3;L\_/CS9HF[B'TB:)W(DG4 Z@;Q!(/O^8?_
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MAVU3I<&4?7%X9.DLAEQC@!1C_L'O!1E&/C*)D@%B=*7A59 K;QX%0\*JV=Q
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M^=Y>^-(\/IB 0N(G-4P-@W44<ZIB[I65+9+W!J)':G\43L)<.@[0/H'%E^/
MN%J*D]88ATBY<+"V==10PR %C33T9D4V%%-O$(%5Z%W!3A2I.I,>ED%EL1*8
M$]#[$<:X81]<QJ!]ZU11],+^KF^'1K1=%\0QLF*Y"<K&QY( IB*",(4C1/U7
M4\ZX3Z9F4HYKY!7NA7#,:YX2*7^Q8JU$/YY,9>=)D6?(FM7/P_]$HYU(BN'\
M5S0C*%]"\Y*ICC,N2*PPW&>FT(E E4E)JF_ PYTS:XM2:E1;':]9<W-) 5:>
M&<I3R0@FW+3$E),DK;P6_'N(@:[EB<V5(7MZ&NS*N;4HXW0".)V1!ISG>F <
MK'V@(U1DY.BB=ZQ$G(%1L!-6N"[TVC7+>Q2.R+-CXL:+BGM,]=;,:#I3:X]2
M1:G'T: 48+IIZ/'=PT3]K0H3?1J/]]_($/-+&F)^9L7==H]?ED:T@Y+#NIR8
MC!"IN9*B/M!"6+@5<<;>)UX#9VB_.O2]&J?46C1@G3=O"N%P 5^CT@PPP!.C
MSL-XQ0 N^GMPXO%6<>*Y7 IO0ZR<452W\@9,1:QUNWCWY9*.C<:?_79V]GG[
M.9/V-*+-BB=H-D?%<G(<4JT,;MZ'LBALBG-5D]R^VI29VRRWVL@ZQT']'/$M
M'0\GYMHQOJ <LSQ/(BQMX6 !!\(&9$5P@ NNUW4C6B::IT=(2T ,J[(XJX5S
MC$>Z-.Q=DLY !>^_6WT'/].ZD^/5=2>;:(57/[EJE=:LQ56K;-'JM_KHMP1/
MY483X7\XP<15P'BMP"\B_>^W83:,D@RM_+,!V/EP7U+P]4N8?=M^:T$:#<"7
M23(.596X!]32 KOTN<Q%$FK\F_)G.C L@X;=B6D[7, #ASQH$C]"8?E9\$WI
MR%J&%</4LHIEW$&TP/0!1Z?Q1;JU 2QD'9I&KQX.;F8P7C!6("TAV/6+4:2K
M("JD@P#'P;.[3Q80KX4^*:%S4^*125:N+'\),:$Y(Z%8RK\]=G% M[=5MO:O
M''C!E@WU5R$Y9.W6X/GL0 ",RO[9Z>-*<!6S!T<>FFHZ >08^Q1\^B9]X1H#
M62-6,<SF^93"19@LTQF;:ND2=]%(BCQ8-/YUJ=- ^D2*B$/&M:*RA O(B&,I
MAC=&@<JX&-WLI&1M<7'OWN78[1YM%6-_2:3=" ^':_*W7_=_DII!Y-Z0V"+P
MOH44E2]S+L "#XPHNC+\N*(KX_+BW#N7# ]Q[YZA#BSVG6;2G]]2\UV29I)L
M\KZ04&4OO8LXR]."/-[>0??XY^ZK[E.BIOH>ELN6B1>3!(^]R[)$%:_9"T(3
M8?>7BJVR3&ZI,L6'3Z ='[].2ZX=ZT,H&;C,G&BQYM:@VJFQ*@)9_X,[2LLX
MDE%@OGFD)*(M'<::DK0D+0>_-T: +(H*I"-2BH*Y !?W>S4),_:X;3+)OF(5
M<*9,AM.7$^LYE::#&\. &AAKW^(/W^,R/MTJG;7$_W ("5=4;[_N^FIQ6(A)
MH9%JXJG VK3.XAD.QQS?.S5(BR!=<)B^]XK"](?MS-/<4N<@.6_O-TSCHDCO
M@K7U!Q4&? RR4?"7=YDGPV_&_RHB#%YUC_:"EWO]E[[Q033$""G5U"J#3\K[
MSB<_ \P8\"XD13\&[9!<&Q4RQ2)]"ENFF G2ASLQAPOOP4+!(;D56:Z"D5T3
M4)8=:K9;M0=Q0-3W &L+3#.?+*>R#/U&:5=0DR"EI1NUU[3,U,)C*,\"5X1G
M(3%+O<A!@H^D**\6$E2S?Q4)*.+*HW366]H0[98,K6]FBCI.,ZJST [6>ANT
M3O3&L[.7A,O %<!1PJU)-PA&L<O^CT0#(%B++2NT@&UTIP?S3K#<)M+0;&ZJ
M-+ 8AP^3[.DEH)NL^BR@.O>)/.R!K+UCN""!EF$VU3V@ ?PPTM5H>I<<"$CF
M3$F3A4+_09J&9]A#S=EUV#JZUV<K)),O?(6)_\P2P.#V$T"#54X@12TP YV%
MC@H(,[GJ]">J]PE&5TA&1%Z]3E'4X](MMT"!1@I3N0R^5\18S4*>#Q7+X5)-
MN5)5*R"R_'AABIPUXUB?+W6$KAN&LY^& XIIB+EG/]-\,0JN,UT_*3J*1;=A
M'V;+NU!?\JE,=&*AE**J2I"S@0+FX#8JDS[%4!4+-A5F+4KLKD9-&.GV,<S4
M4U>_6,"KI4D+QW?"/0!MF86H\+A<S;+3@5P=[_?D&MS_4J"'TP1+CG!Y' LC
M"I8L4?+\*HZWZEMV@;9?U]%<+$L!44N-C(/*M52+4M+D3J("+/B[7#9:0<I5
M1#J7=):NVL#._9S*@W.OW_>Z/_?_IK]C%W%P8Y_^BRS"2"=FW4'!727"3[ 7
M$E8A)QH:C23U,:AJ^)N95M?OBM,$1T&E3QIK@_Y4Y33?1!TUEAFX-BJ3M@0^
MQ$"?3S)>N5_Q.O4NS(X_@,D\B/ +^G U:(9UR"%&N:Q+G[.^E461#332K2)!
MA6)-CZ00E/7(\FGXC.NJD:'+*PAB%?Z-]]$ 3SKYOJ"?@AS,EU@MT#?$0!K5
MDV)1GOT0./$ C)Z19>+1E\&SX,>3)XI%]&%6VG0&3\6(*JP>'XD;T5:/1539
M^.HKX.SR_WKO13NQ,,C!\ZU:4S0[H GN8Q"*!A'[OX\]>SI0*MR?,7H*Z8U;
M;"#F\%7VWIY5=A. N0,&TM @L+P4 ^:O J&DX(NP,QL@HZY21,[F<$ND6K?K
M50X(2*8T.7 MPG6VH1,2"'5-.<#:ZOS#*S/R5Y[&,(B1 TGR*U6;UJ8)W0<_
MG":$F>-U>_L$\"-A7\SM*$5;ZAXU*D^M:ZO:DU:+"30;=*PBC8,BK_1%ZW+.
M[PAX0H:U=E_@ ?L@K $3HV9::[BLBGIR51_5JH\3AS;BZC?:L@-7O[$;]1MM
M,2_87$,]1S=FSBD+:DO&F7 >6+?Q-W<EU*Z$TQ]2"-CKND+ +=4%[B)Q%\D3
M7R2/I 975'E<7/ZW]^[L_.NG+Y?;X61O6#OQOTD!7A'!(0W!-QH7D09VU>VW
MC"U<%N93V)5[XA#G28"M3($<]9N CV:5+G&5!>56L>3^>/^_M7<["[XQ *E,
M16'X?S6DF IA: 4&O4FB 00014OBDC]LO<>R/G]-[":[Y*DL=]) 7*:U >NF
MXM$24C%"&%S$XN9C89>O04+(S>4:2 E<G;V]U ^&+>'1<]O/ HX<HQL1=9\&
M*>=6&,QYD12I=1;B\#<<($$:R%%3+QJ"TNY'2?*-JUY*>C J2WR5$-BT'!UA
M@(LWS;DGC-5)$:4^(ED[=7?8!T-9$FZ>+7&:A=S8.EE?C=VAD7$"'O'<8+LS
M)*_ 0UN(+[?PG8HRQ=&[U1RVA?GZ+[3A+]*[DB=$$E.\Y'W6B5G"5?JAT/JM
M:235K<0$0(?E9B4HG%3V9B'%Y$A*) 8D@V#6A9JWT<.7'K\:@%XJEA=>K"@:
M1DC6E.?,X! EP3^&G7*W[P[,@)%"\,!#W47SLF&?X!4,PB17PVD,RY@L3"A/
M&AI-%>Q"Y69"P:AI1 $G,ZODQOYZH82T3\Z2+-<*=1PB,HWIIFQ@!59C^BF;
MSC?RKD$]O>A;8PH[WMD-K;M^V?A-=4;%K&#9'2E$:Z9UOS@]ZEN#4QK7O#Q1
M@@$14QHN82%($$RD9C/,"GTJ1R?0.EBS$AH!/!_$P:AK/<E$#AK+%H2J%:1G
MI&(-*MT,DMJ%+$/#: '&$16<=SKHVC0)"_5]&0:[?FLAA^+/Q5QS[:KC-"FC
M6IT%C0I- RQT'%(G.0$%)1,,Y@\S8&[$"4&D49F/B!=?"2^D@8<860B%[$V8
MS!';,ABJ@L;>F\_8A*>TUQ1.*N+$:B$5EV3ZY]I,&Y6&1%!1I".%< D$9$3=
M'5\3HR&9I<)X64=RGH<K-?0T ((GIV6M@!/W;YA9XM?X5VF4>P/X7\?\&).0
M">3^Z@=K.-<;QJ4@-(F\:WG5;)P*6H >T4*\QG4FP"Z)'C+T+Z4+6OAY5)/
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M8?EB3MZ$C?$N,Z"YDECOWMIM7A[*N%A"0J/J*7X230YE/@V&4SK-E*X:-)A
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M(;QWDVM[I,0*YZ0]@81.9"O7JM=5UPH<YF4?R+)5.Y2%\6)KC5^X=5VN"NI
MX2%IPP@Y^74AKK@0/K:X*R5U%/A'0\=,L&0KG.;Z7?.NW;D2Y-\B9%D7 3D1
MKI\)&G'KR.."Z'*Q+M=U20Y^00#'.4W1_>%S-?'H;(VS;;A#X#Y6,M=UN^*Z
M35:*$S8<MK3Y20F:1S[YND;7O*2$^Q[\$"QA3,!K+B&82&J:15V7Z9HF4(*A
MUH&BGCPZ;9= &NUP[LI=F8O*7X6\@E($Q]0 H12)5)T2AI+PM H(?\&7UF6]
MHH6,E45!XIC$O(![26X^H)$(N+$)P/GGD+?Y'LD[-C5(ZR:@H]VA:82@O^R
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MN'BXR:LJLZ+@WC')^X- @!C^,T\U, 44"B[78OR8Q%2=5_5-NT/S4(MW3UZ
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M#X=$^+?_;_/*+^#@U_/5 )*VE_Z@:*07_B:$>P]Y1RX:%;C\.E7YPRS-'")
M^/GXYTXTFT6"AH1<G&%\J_TA$;-&W'34AM>EW4(H?G=L_K55RF0_](!;2R)5
M^;%!Q4CCBP9:,/X]/Z'RYGZ;<_J,!  Q5"A>R=@+W=XR+?)^[,<&6/-W+W^,
ML&:RJA03X8>\;W@ 5')/:KVJ>4-,2+D!/N.25+]^I'H3SA7'86+$S#C\>[^L
M_*V"/AR]<,N.P$1!4;UH=L-1R2W]$?HSA6<<A=(U6CF<U>:!AN]CF3H\BA,5
MS+>'B67CC=C=[VFDT;9H36=1BV3*GX,Q?)EVR+3NOH3NO \3RKYW$G[[O5)V
M^.<[[Q:<Y.]JMG+.3QDEC+#CL!QD"-C!K%Q]U^M43W]%O+$(LN:N5E%TLJA:
MVZ3-M4,B C#[2$26_"H;'&\WBMC4I"ESI*BKJZ<QT52TXI?SF>:%G 7:$V0D
M-@@\08PS/#1I8&B3S@1*-#R$0[KHTFN^88QB9MH5/GF<-[ ^P71%LT@L>9[4
M]^.B:JB";&*0''TG;:SE[7V<2N7F2_VNYBV#_YTQR$/;6J5^#/=:)?FRB4>J
M$YXX?ULF5)YQNXE(EXK<*K5I]MQ<4<((VVE]PI+Q/C=9N._G]SQ/EFZ-2S"=
M/9-6*A?S)+X(><*U)_:#-$3$A,.\&#%!7P2%1VC>>1A>O-K7!LNGLZ0)[JYA
MD@=_"75[\=9,ONM=20T&N\XG+@#KRC:G@:%(*DP:T5@M>5CO"*O]OZ"CRA).
MK+R98Z#0?ZQ H14H]%3>8 4*?61 H?6JO=)5NW!7AKLNJL\-/?TZAS&HFX]1
M&;/B=*MC=64:S<=X2$1"4G9$DQK73O4YVYAONM0#L*[LE5?6$$/.=0T#A79T
MC@OKK+1%97UXT;TT'&K.9V=R(M*F^)A]0VZRA,OK\G\4!YOIX&Q&$;N"BHY4
M*;9U2=/1MI[U#ZB]AM0>E6+,V<PN+SRQRCR^^\BTA:U+>^5S3&</<!K.%-,I
M7.!Q7&ZU*NM=@^0D(46$35B:=$W:E_8#P44YH3)LCV77B0W(-U\06!;4M-^6
M.U=W;O/R%,")H<KVQ;<O8Y$MDH":9[7OP"K-BF11DUCGJ&]XW8-7;H'O#V7+
M5/=GI+P'9-F&%@R=<!D&[ (_B-JY0N#W\4.$YYS?EYIDY\3=>?'&2E -"DV@
M!NR<Q+U8'#FI1&]3A^41=^&ZIZYLUTQ-;*%BM[0%(@#;PALO=L<J,Y_ 7]D]
MW@\=U ,2?[8K_13D;5 +&/=34\E,L*L(A!WU^6^\T=L(V%XJ[_@8_359OK[G
MC3@(U0!MQ!$37,VUY'&E825PO_[>G(#YN+(=X'SO4UYHAIZ(A>4KZ:U&A"*Q
MM%Z=#<PJAQ6MZ<%(I2FZ/D4">NL7[V\;;SV'$NW/"W!BS-K=)=C]95L ,A)T
MSVR'GODUJH"/]CYP2[0(@(RPZKM 2_%(J1#J3P7O"C^Y^$0_VZZW9SV+S/[<
M0#*'DK_=_'#A NS1+7]G2Y-Q3(339"^11">$MI[_B"_32%, KZ6U-'B5WC%N
M<^O.#<&-F.AO!DY,N'+=>7 +>2V,;2T:> A^;KSC:"<1GWD7VCBJ9S0CZ'&6
M HK1"%F[6>,MSSW_?@.)+\?-57._.D9L$TJ.X71VDS W_H1A1[$@Z?0^A^X%
M@"^*=K@;7]$<DU *60@<:L+Y%F0TXW3F+%1+R%:"KRH@L N(.WR^PRF*J,'O
M%#7X4E&#/Q)J$ OZ"="!W:<&(/?9BZZ?(C%O'RW'\W3MZO<6I_LB ]#P/[-P
M4A5ACPE)<)3:E5$W2!9^]_I5P!2+2Y4TW*8=FVF[(RY<:E)L!7W<G;L>5^VF
M.'?[H=X%FMK))_TA*3O"E?H8M..3]SN.>G=H&W^];KR#B0[K?/?6#QTXSD%J
M(68[ 1&F'9 J;9""61M0A77</Y?T0(4R"9[IS\%DVV(S6D"1\_NH%-!6BE$5
MMU0#=X7%[0+^/^'((KHM/$3 BYB@LN*6'C,^"X<%1TI%$+&"$?SH] A&D\8
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M[Z0A)WB^,%L$;CLS+2RX@ QZQF*_5?/ 9'WZK;QH3CUUZR0Y4X(@FOW Z>%
MX8B$L?(@IUF[I=$R_$GQ1#A4,H J?V J,\D8F]7CG6.P4RR Y\0QI)=%4:;L
M)9L69$Z6TZ_O1_KWU$%*_2%P:BNF'^3D_C01@G6H W^?U C<<=N>"1,,11="
MG-\PZE5QQ#374:] IFY!V?,T;(%S]I83RH.&+J-NZIN9WYK/>IE2A=00"G=D
M2>IV O(KW(ED8_#WW8'K<N7./0/(U(\7EZF+%<4WK[K8E+QGFE*7MZ@CU7$A
M#WG'4C[2_4S8*+@5WMB6!5/HZ@(6;DM:%9KL/OLE;7P(M[EOJ$:]<;S30.9Z
MI_7?1BLQO..,\)-V E&;MU:K!N#*T2K!;Z/F"V^C>X 0JF',L-(-'!]J!B/-
MHCT7I9-1"TTJC6+>GG*I5MJM;S=_:QX<52P%@>JM&(]RZ_H'_#B&1%_"+N;Q
M:94.N^X(T=3=X7PDOMC: ?%$[Y3I'78L.ZJU=KV_5H(4.@WZUN\6/ESZ%GG?
MESV5V/OF(6^+E."<ZGSTP5+J_1"$D)8H^T'O[=]%OD=_<M$^A'\,!3!H.\5J
MYQVQ1;?F?D/!/-YPV"GQ^>7XH-(H$H-*H%/OP;9PI'0C\UKS5^Z(>Q37):X/
M8[K"3CK2,-I0)&1 _<P/Q_2W-16FY[13!06R%;R;REUP_@A=3'!S6!#^\,LO
MW_B7^%[*4A6:):A,1.N8LR55S$&)5@C"\.J>61& *0+POU8$X(H ?"IOL"(
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MJ*ZDS<MI9YHQ )W^"(@Z-=+5S;5PB5'D0%UB)/" ;QA&!WX^4PGPS;YT%Y9
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M7:*/JX@I[G "*3;Z4Y)@O-7+(SPP3A>C"=U]X,)U1:+05IWC=D%9!=I*\Q9
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M9,G.LT!K3WRZF@L,V(?%/"LG*@/: >7Z0[D-@M<S2;^0FXD)Y=O-R]#K!0)
MIA?5X8:6!>IL48B-^V57#5ULE;')ZTCNLS1PH[G\()28=1,%:1NEIX]:SIQT
MYB_;7JYIX60BNTU:HVV_^?M0W"GW.V1]*U&+J6DYB/L\R(^0Q GKA6=,\]<P
M;[I0GF3*"QSGJ8GB)24+9,8\)R5A [%]_$Y\NY^%'8GF@IB,SZRC>V0&>O*S
MA9Y2WH?H>5F>@.%(N7TM&HO(=#*'OTRNQ5'HF%514B72QR^7K#$^B&%FDFU.
M)88R>PQ4CU=>B*&8_$9/$_IXL8SW Q%4_1 )JH"/^<8V4[^69NI?7TQ[,C7+
MG^-BFS56$R7WKK?K' 8F2$-#D$K4I\^@MO@]U5R8N)3.:>%.KF;;P/:@F<"(
MY(( *(CZJ>W<<?= A[QZ;YO^F)L#K+M@U_'W+$5FH;P5YEOZ\U6-EMG6B+!V
M.(F\\G%;UM'JZR#L#YO25:;M_WOF[V;@HR&+,VO/+MD<A<"%FM)K'L#FB('K
MKA*,'9C"48%34B)OND]R@]#CZ*LJ)F^P:X0."P XK >%M-0F-WGR*1E 157:
MK4NJI8"$5R5]:ZB9+L&Q>/V6W[CU%VVPM5:PJD!_/.'Z1/FK.B?++:,,,R,B
MZ5%Q*3*NH]X9=$ZH="M:9KC:6#:!]*,C&#(@(0WZ%)<[(PW?U@U+-Q8.JXDU
MBC^KA<N$H(^N(-G.=L\EXND)_[1(<7-A=3]UD50.;7[7F'',+O]\[7W!^EQN
MPBV/ISPVRKT?D?P3=TQ+SN?X:?&'>PA]9ISDIGJ_'  AZB;E@(-C>D<I[&YI
M4Y #R?*&8/6K.Z(I[F0UX V>X>2PW *Y&HGQ3]M+F67,%(J5VIFVMK=8#IO7
M(K]3X92&:NGE?<GU^0!PE9^V#!?FM@I*-U;4T4 $V/.)PQ:Y1/&'_6QI[9Z$
M33J8EN0E0C8:>="X@SF+%HE6HO7J,H$TT+JT9'1T00ZN8H^++#F+\P@C1Q9C
M +\:>\K<M8 \.Y8QXP<$MNR9&R)]^%2L9TEH88;S7UUNP'HO2?;\BT)8/ULA
MK"N$]:F\P0IA72&LOVLXB-88O7/%0-.U,>FP2L$_TM!.5TJ4R/WXX\$?$X(@
M:?(*<=:8Q^T"@W<B16I$A']L-@7+3+"(2XV::C7WE$C(%$1BX#_#54$N;J3L
MAG"@MNVKZ)^AUC'R3 KDS+K>':E?A</*V-O"<4+B1QE8J@3^$EU0*!'4,HF_
MF^&@G#0*8Z4^GOSHHA<S-[ X)!8!:<M[<B=49I '0RUQS=['016"Z+N87>PD
M2\@,J!)=V-%USKU]K]7+1!3GZ/Q/%32W  PS0U#X*]-PEC$]5:LJ6,2P;IQ6
MDS<-<IC3$4U$*DMXFT?^SW?K6V_1*!:F6D7=.'L\*'$816T39U:]3?;DP"+6
MI&KQ(2Z;!/^B?'8DL2#SRSC'\*TY@-=]I-2Q,2S&9XM!55LG(F7TS^1=JVMM
MT@;L!X\$Y0RSOF0*0GI I6IV?@@4ZE-.0.,!C<X7XOS9 #= =PDI'B)W["Y,
M-XFAULS6Z1_<^YU^XNU)6'(?QA+)A#_-1GN<G^(FJFW)M$L*CV#,C_GM@"^W
M\&*(W*<+HMLKQ!P3E5;-S\O.-EEE*VG ,_ZO%7Q'RKFQ #I92Z5I^I4QNM6&
M>P_>4*MK191ZHOI,2&VZV_!XIHKUEHVZT>.'QZK1S!A,/<A'%]BMXJ])7DJ/
MS<6Q2A,UW0]RR>;>2CE(43/2G,'X])-V4-X)Z_P))<.2V<)%DLMFNY=*8-"Y
M$!95C>%!NE6'SM-TJ<:3QTD\/ 1<6F)%F?_0=%W T%!*;^$GB.E+WIZY'=LY
M FV\*!]I%6:FIA7;^B_LVZ.L#'77QM);'Q2K9^Y T_?+5QX\B,3F[U79DL1&
MF%4T)GE,)CO>U WQ;&#<D:=8QS,90K;9^I,@&5DNVDFZM4-_1\.ZX5Q],YO@
MQ_1V8OGND=W4S"P6;9R-M7E-8['B6ES<NV;'Q?L<Z:A8'DLVH?<&@DTF1-9S
ML(S?:;*:;QE:7E?3Z:$K(5'H:QM_,H^T74U&+36D[S)M:F]&QP3^.KJ0JDUW
MAB^9J!Q/;-,^OZ?*J$OVW%(9Q3+COBO#G:4./UM3ZU'Y>,KD)>->M!231X@*
MEKW1786;.JB$XDDJ-'3J4CWPN($-[F\?MUP\+'Y:[LNF&O<*C=.+@?_J%K5/
M%)O]4SH6[V%N\HDKMKA*D\*]!9PR:IOV I#"[&X)6P 7'OJ>#:AEO\VIDA *
M[S'Q*;B)H4_F)8\-@UO'NXV\/W*JA8];:T!UWK;-0W4>68>T3&4>B'T%7U.W
MM"(WFOOFK9O*,''/F<(\(KHA>'5\ASIDNOG&,!VE6LXID40G'U)P[D5^)*ZL
M8,% ]DP"#8(OB$8O\=\T.>]?]^ARQ ;[H1K)1MH%&:W_Q4,K+GOT<Y2EMPYU
M(U-*2BR&J1H8.A L_W*-4N?&4%F(&NO31"3\NK+]%AV?ZN@DP0I?-T790?R2
M>%#VB];,'G@39SZ#_ U-DXC&3\7NPTLC6W)S:![2DB?S%6'#[1RIBB;SEVVH
M?LFG)3@V<K.H;OG4RP*1SXE_FX)<95CA G2@9&)7"(\2!!9B@&Q2. U\*-$
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MT"B\EOOM'= N&7$U]HPNITZ^=V[CKRQUF0++^:.MH7>PP9M9<BPN_7,3XH:
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M4UOU15,4)Z_\[]YG/U'@^%W?TN9_RQK:X,3T-F-8^X<94!:Y9R%C0[87%]A
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M#.)2[X9..8CN(.J-XD>&Z$!&LQS1UO4ISERTBT&?L'^L_4.,TG'WVXX]/\W
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M&_XZSN$V,89RAYB-(8<;.(;6'='% RI(_G<\=!C%GC$>1@9I-(SVC:Y)BQP
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M.C/-K42C!^QY>TBP8O"'K'80.8X=/>!BL:P'<5+VN,BN3L,S-H 268 RJ4!
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MV6!OY_N;\7R'9;'$'TK!M#XIEP.4WX<U[N:J35+,S :Z5L*86CXI$X1"_I_
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ME-C)FYI&)2%[OZGS1O#1%&!!!T7W-S$U7(GB'>+&\$3>$"YMF#! !- *0;Y
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MD"*Q1#8)#AJ JD3U5O&K6$%K+%G02610P3@(N2 X[4UB.::(P[T(-:GX[7L
MYB$PZ5SJ^QQV]%/$D7+(SN<"H6:9*W*?(: .8)6)N3BAK1Q."XU5^[3!P(&G
MWM(*J1'<FVGI2GF;@J@#56LPESPY<*EV@A=")LM93GXX<7"7NG%YQ&TP<!0'
M^BSPR-&*'+4&;WC=5G7-70VMN(!(8@A=&*[J;]P%'FV0<!0'1F2&UCPZ^N79
M=I#.4$;I_E6'-U$[[+ZYP4JP"BBL VES;9E++FPL5@$+J(ITRJN[(PJ_!H/U
MAE!\O9RN2$W6#*L=,^8?7Z?U]--69&;T4@5=LZOHMBAF. 3R^B %IIAS@LL!
MN]9T)GM<,99#L+1'F_7"LY;Y3@^8W9J+.O(&4L+:$MI&,L1TJ>VG><V^XBX-
M9_0>[@6)X;V@X_#2@!TMK>'.Z$W(,$<DLJPB_8XZD6JN'7=L*3H&)8H=T$P^
M3.(TLA(#1YF)JB(V)H^K Q4#6:M8)#/6Z0&[I!UB)0XG8?M!5R<[LCN/^O0M
MLW.U[7Y]W4L!5"0;.90Z:#IIY"Z2Y/<#QK</\"V'BR\,A96C>-1/_$DRF5DP
M'F2I;84LLCI0#"%EB2Y:7;QC@Z'D>?&GX6(/0^'C0+Z,P1N]TU&*?NO&H?V\
MG;N=Z:>[!K'_0]]<MS8;KLWJ,=2]1#_69J?9OG'KS4MQO?C$2O(F<LB04[9U
MW$LF8[)V7??,L2PT1C.<0'F"V'XZ\0BT)-)# :'J"=0Q8\XJ V1B&RDU+T%U
M&YAZ3">>EVV\=2@@NC7E><X!]QFS39)S28XUV!)#C1V3L ]U*I:2EB6NI1#C
MML9?M@W7L2!IQ)DQ:,]Z")NUWBT7">M(BT5Y /Y#JLWCR!I07S8\OQ8C=1Z4
M7#P2\'1BD&*%N2:CWQ/NP1!?''-!^ZZ9ZIU4PW/)#JO3D^6OZT7ZUZ[-X8TK
M>M-M,5;XH!D)8%L?S9!V4 <( )(8=HEAR+%;@X2N*XY!X[7C[&TMU\>A-ZHZ
M7'P)L_67=[OTX0?H"C8:DM(U9ECS^!CM/(24($AN0G91('8L-.RRW!C46D](
M:'_<_:JV7Q;STK$P:O&)O&8ZG",TUA&K-5%$K7;;L KL<IV)2$RFX#T93KJ^
M"C@/T84$AMLLBG!H!NPI=TU7LWKY&UO%A(+$'J\==VN_*[+]?4 %3)5(&\?@
M^(#M\^Z2-P8]=31"'BR%/Y -+0N9KSJ8WZ#%<LTSDPI*2AI4]A9\T08\+['P
MK)G1 R:0[J%P##JK!U0<S8R1J*<;,ZPNFR0.H:<>6798A=5U_\TTU_V!XIP%
M9W-F4#*7M3"-0R@9P=C A9.9%VL&N\)/C()_IA%][]->K]?+:;Q85U/_PV+?
M.+]=:Z/M;,M)UK(6TU8SS]/9N) A&ND@,9]2B!X5ZU;Q>"PEXU)NQX'H3DO-
M 5G4JI/JHR1O>V+MH9L.B?$H2=I[A^0^*&0091:@A(\I.^^SZN:Z'TK!N)3A
M<"AJPY*V36%ND'S3Q20?TH4@#3A1R_J%%1"S*V"%##II[4)1PQE4#Y%Y_ G<
M9[Y SI(PNLYZ(^;+F"'D+.DV"\%48+FD.!8]-([*G*,!=-^N/(XM#6_( [LK
M6?.4HP$R= ,HVA0$&Q"T+$9Q99W7PY5.=[D;+RUD!P#*H?SI'RW92R]53F"U
M8U6Z<X@!-=1.IP$-JG*W#]L+H^5P2^36VUX7"^KM?!WF'Z<UYKV[Z#:'6$H&
M+ 0%TKT)(B\<I'+&>(6ZA"<=L.94C=;N/11F#YDMP_*O7^^_/JN464VF*HOE
MV;&U,8]\6A-?O2NU38>3_$@+;MCXVPKSV_G)^>8)XU8ZFR%C.-4T5IN$ L5$
MA*@#V:<E:1&L-KX,-W:H&\W'"_+7^;\NMJWWZJ#S[_%\B6E;7_1ZGE^?+9;K
MZ6KS[:85U@HG7H2H0D%28+F0>4*&BK,ZU:B:Y=[S&.1P]O)SJ1^7=.L!E_?M
MAEX9W-"BN$WG;_,EAMF4SF373_^'S^F4Q"]N@Q#_#--Y-:B*)$-9@?.1?$GO
M2 !;&:'ZK9Q9C,H.Y\ \G_YQV:TO ,;F3.X-CC<?@Y1QUC%'[AEW]<6;*&.U
MR:U/9&P[K;D<SB%ZB,IQ992_ +0.9%B;>.55*L-[/-NF+U>R3AY*TGI=UKBL
MG?RY$L*'C(#9UD%[!'7'R;5S24L7JEE[5YX]-(KE, +&5?G>(VH&XU(;/-V&
M]MMY6M;2FN]Q^_?;^>VNAS%%;Q+(*#0H5WQM^X%@9;*$?5D$[^94/F/1<37*
M[QLW?7&C-^5UP^F]M/%$\)EKF8%.@%S7F#,X0TJ5F>2RXL6JNUG[ QKQ=ZD=
M5X?]%S':CV)@;\#:M6K?CJ)YLUBM)\7'D@U!/2LC:C12@!<$^J*DD,(EF]5P
MV2E/$/O,'OM]/S"\ *Z.XU]#6)&U5J;K:O7?>4;\8X[+U4EY%VKBS40*;TO6
M#(J.'%2J<P9J*:E46#C:()D>K@2E&\U=0.;^7+*K!V;V)L%^/25B(JGM?)F(
M//%6^<B5ILVK&O0@=\&SS('N0F8A,,;"2\6W[E/;!5[^SP6OI@QL-;#HE@-Q
MKT!+^U!01P8\E%"M0 '."@Y%,ILQJ;KG;D4#CR_4*;K)_@QP:'[LPSAJFT$Z
MVSE)B^6JQE]36EZ$V6IBF0Q*$*T"D4";!#F5&#0XZ9GCS'I[-ZWW0+?M01(Z
M@>=/$1L?D%4]^G27A-XB^/7].<L3:9+ALGH)GA&]$AUX%23H[+3@A7&=AWO6
M.G07G=#YIPZ6]\3QA@B]?XGV/+=_V3R>3T*P*I>8Z^-](3H1(7"B4Q?K.0\!
MBQ@.E,\@O!,.Y9_,:^R+L?TF1=2F;^LOOZ93S!<S7)2-J?@FG$_7879$=D27
MCVV2)O%L^IOE2VQ7GAAKK5*&@]3.@HJ,=!RS"G)6G#ED4@U8:+>EZ;CQ2LL\
MG8?EE\U!KMY=+--I=1RV/1E(ETM'FZKCG>J@AV2 L(K +>=<L<2359T,L,=6
M&5?ZP0%LOCUQJ=5YMC&^/RPWWL!^<B(3)5LO@+/:H(K5Z92)ON*^F!"4M@Q9
M)_8^MLJX'O2/96^S\VR9QG]Q%G%YLI6%JY.+]6H=YH3"CQ-O B/+O( Q-76E
M=G\-Y..!925(IH*R;+A.3 ^2V?H$WJY6%Y@G)3!I4#MPN4YVR-R3I^LS,4=F
MTO7<EC1<1=D^"L<E^-J@:$^-Z+&\Z5403GRRW&;+@84Z$"^3.>A83I"24H4Y
MG3!WBS$\L,#8N@@WY7*SDQW$Z+VL=OUY\6D3'5M-Y[>T=3,S^)D+M32,C]EC
MJ[Y'F^>-FF5T4K94?7^Q)(2]P^5TD2>D(E/DR@ IRSKT#15$J3-D%;C I MV
M[1STU%)'RHLP7X54/[P^ EYV_3R9;XYQ(\8V7TU<S-+4;NH\1%+ZW(3:[U."
M*DD:[177HJL Z;;B&-1&#[R^(U-Z./TVBF0KYEY_HOM3 TLU3DKDU"?CW^CR
M7'WS;A;F$V51UX(CT";D.BA/@\_*0=2RY#H>68INN6O/6'0,]G;?\.B+!VT0
M<F?C&]^ 2-QW %%:+G0D]#I2D4%P\)KEZH88SXQBPNI#9.'#2S: _M:$>SNG
MTTU;';/U?A)3BF7/H(0Z0R"A@%A8 LT0&2<CP-UU-AX%^P/+C%7Z->+R'IBW
M..]6-O234GF"M82=U;KYX(@J0;?;$Z$0F*;]9FV*[I9JV6&Q4=C60X&A]>$/
MU/24J/S769B'CQOHWI]WO5Z\6TX3O@]K?+,I<V@RZ/OP5=NV+&VT^Q:6.>$O
M$0U$RDFYN^C;^8V^\QX-^6:, <NU>Z%+HCJ" ;AG3BJFD>RM3C>XZXI'R:3'
M%]FU+;NQ.S(WA,PV@(]1@-(^@"O.U#:*+A93"K\[[>"@W=U;>#1ZJQ<<W))4
M?;*DC2)[G,)?%GN(S-*E8,EXY&CH-%0=$<N% R<Y\\$'=R^4>A!N]JT]&HO^
MI:%S-&/ZU7G; KUS7*ZJ1CY"C>W_H"::J0.-[9J\36<7:\P_A.6\<JHN3?S=
M^NV6H( Y6'"9)[KSIH"W$4'G(D-T4F <+M7A$4(;- 5Y^,-K>L*VL.JB6G+G
M5PV$H[""9U7(*D0/*CLR[:5,-?><>QF2(X]V#*?ST ;&H.S:XW!/^YF>>3M$
M-<$N.KQU5?[O8I9OY*/_0/2OO[R=I]E%?2/8;'?Z"7\H!=.:MF*-C]((0!D"
M*%\;40LM@!LG,2=92N(O7WIP^ 9;GOI#>&C'C1!D=(X)<"Y%\@"]AUC;UA5F
MG"N"(*?%"W"C]XV/2]B\]#U[K/1D7!AL.<TNK*9IKWQGD5NND@8DRQ.4<>1E
M(-%G<@FR#CW-?KA)Q0^2V>,)/*R'I--<6D*1*J2''&:(R23(T<10)^ZDN^]P
M+W$R7X>%T09_>Z8!]LK5CM[0[N?UCUI3](^__']02P,$%     @ W7M=6 *.
M$0=6=P  NET% !4   !M97-O+3(P,C,Q,C,Q7V1E9BYX;6SLO6MW&T>2+?I]
M?H6OS]<;K7P_>DW/6;0D]^@NV=+(<O>YG[@B7R)NDX & &5I?OV-+!)\X$$6
M@*H"";EGC<V743MC[\J,B(R,_/?__?7B_(<O>3H;3<9_^Y'_A?WX0Q['21J-
M/_WMQ]\__@SNQ__]'__V;__^?P'\GY\^O/WAU21>7N3Q_(>7TXSSG'[X8S0_
M^V%^EG_XYV3ZK]$7_.'].<[+9'H!\!_-?_9R\OG;=/3I;/Z#8$(M_FSQV^E?
M>;2>&QW!:AU &28!E<[@A*5_TS\CL__WI[]RGY1R&,!K:4 5P0"#36!-,D5G
MQKB+S8>>C\;_^FO]1\!9_H&&-YXUW_[MQ[/Y_/-?7[SXXX\__O(U3,__,IE^
M>B$8DR\6?_WC]9]_7?G[/V3SU]Q[_Z+Y[<V?SD;K_I ^EK_X/[^\_2V>Y0N$
MT7@VQW&\?0 ]/LUO_L.[:/2+JU_2G\Y&?YTU__W;2<1Y0]"C0_AAXU_4[V#Q
M9U!_!%R Y'_Y.DL__L>__?##E>5P&J>3\_PAEQ^NO_S]PYM5I*/Q_$4:7;RX
M_IL7>'Y.B)M/F'_[G/_VXVQT\?D\+WYV-LUE(_K%D"LH7>'\K_II+_;&=$9
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MP+DH J/%9(?S-?8<S#/7UY!4=C@GU<#V]!;@A_P%SR^;+-SU@*[A%>90"I%
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M5,-[GT^C3^BP+NBNK&QL3CU@@X#;KDQOQDV_P?I-7XT!'GQ8[PT!V@_U0(T
M,"19 DTL'FMUD;"U([])X*,2D1E:EW)IM;@_[48 O"17I(O C4B@M)40R..&
M$&.Q5J&5NIT/<QR- +9A?9]& -N8_>DT OB Y+$UV[^85$C,"YI4R4%31BMP
MFB9:5"JB4YZF\N$2=3>PGD/ISE;,K[;$VHF!7G89&BB+7=PV: 8ORKF+\%!E
M.#L2MI[X?:S=OP8\<A4C1[#6(?GCNIYJL@&RS;+>G&4"'WA..&P132_4;V/D
M7BC_./G\KC20%@4<%'EI*Q2P:&V]ZYCF,A\,Y**=L(E)Q88[<[R,[A#%+KOS
MM9HAW<?8_52QU#:?>?H9IS>E8!E9L1H%"+2%AF@%(,L"LLP12TY%XX 5+"OX
MCM\IV).37C9Z[V.Z5F\;5(-[">N0'JQH=T\F'Y'&'C3TLI:L12=9Y R;B\@Y
M \65!E^73<MM1)\<LVZX,RO#B>/QFMQ!M+&-]3O41#-IOL-_S:<YO\3/HSF>
M_X)C_-1$L&_?7X,SA,YR7L [YT#)0G&ZR@F,,\Y+G;E>WN/?D*QX[$F'<!OV
MIV/2ERT[]"2N+^S^@O]UF6?S57AO7RX\'6LP: S@R*4AGUDZ<(P<'QES$IH3
M?.U;<=WB8<^?[JXM.M2KO3@Q(LES1<LJ*EDW_3(X)R/$>B4%^3\JF'9WGC_\
MG.?/<X=V[,7M^R7/SR9I]J[\/8\7-R+5E<JGG*VL+;N,)P?7N 1H5-WF"4JX
MB"+'X2HH-H \_D"A"W9Z*>9; VP1/[> -GC(L!'NH>*&3HAM(Y<]6.DE@M@,
MT8E8!)<"7*@]YP7YQM[P!-)P6;P76J?APHB!!?-H+#&T7K8AHVO7X^.4)M6S
M_&Z\R*$Y'J0MH7%UZVT$]<9BSFF0A8O"G3;6MW,VEC_Y$.Y%1S:?=&6PKD.%
M_[HDQRE/S[\M;J5:],6S!,-Z!E8Q"E\,1_*E:$DLD<862</9MFM@O^$!1\)E
M%^;KZ87\^,=D,3IZ?B!6P,FZ1\(U!V]I$@HTY1A.$0OR=J46RY]\)"3N9;!^
MLKN/G@]/W 6F-(,D48&J<:93RD-&"G%$=BC]<.?KCZ+GQYY[!)TR-G3/CS;8
M_NSYT37)V[1MV(6AH7M^E"R-$=( S</T!EE)BUZ)&:(+622C=7'F:-730<^/
MWL2S#3&]B.:ZRORV)X6*)B$'$TNNG=X#K:_!0C;">&\M+=;#57/?Q_;$NG=L
MQ=RFXOY=S-YUG+'A/,K[Z>3+:';KPW&7 D^QGF>4'A1Z#4$E RG64VE!&[:\
M.;G=D9^EYQT!VWU9M^NHY-?)EP8$4<67=!FY\EGH#,PX7EO4!(+E+&B9@E>F
M1._;U4AO?L:Q$-V1%3L,6JY<[1P7L,02+(W<F'IWI,":W CU]G,T$4+1R3//
M7.#M]ADW/^-8R.W(BKWL(-1N%Y-QS7"\*[6)S_S;58_8%(01R"#;$$&9P,'9
M0(%WID$F$EY.P^T[K<?X'<2>^W/3RPGO*RR+G$H+-(.'F'<1'JXF;7_V5B2Q
MM^E["0/NH1+6BE*;&P89#4UIP4/PWH%UCA?!A66&'Y$06M2?]:V#;2S>M?MW
M<I&GHXCC5_GS9#::X_3;;V<XO2WCED)DZ1*(BDK)C.2\> DY,I-X4IYIWLI+
M>/@YA_ 4=J=@TH_]N@[MEJ!=72*>1Y\713/)JN!I<*"\"* XT_4*<5)PH# D
M,"E#:.?>/_*@HR%W+POV4TB\DKNZ<[UX,TVQFDEP*0+YHK6C8Z9IBD>"*$V*
M*1:OV8"'%!Z#^QWXA)TRUF'+EY80KY7?!N3P)QH>!_YT=BCVHGT[6>W!V?"S
MUL(W9I$%B12=)UY .>\!,1B07-(HC Y:/)%YZXEM7@ROJVVHZMI]_5 -78&-
M/]%<_?KK9VPL]Z[\EL>CR?15#O.?,38==!:Y5LV5CC4)%\AY5Y$[,H578(I)
MAAP"KPIKY?5L_>B#5&%WS=]D,.-WZ [/IO,[IY)93,X6(4!$5:M(A*H^N06*
MWBP7!F-8;E]V;VHI. L-*?2IS:SR(I_/9_6[1B2-0.X]\%B=FMVMVF'_LAL0
MBT6N!8P6CLE6)!_"M=C#^,OT[6&Y#J?S93B8/9-*&F#(FSZ8%H*) 4R.,C/.
M' _A.1"X80GOGK]M#-8Q;[_@U]'%Y<7BD _2K.'HR;&(VFR[^AY9,P@N:6%*
M$,(_E$!LR]R]APZWMNYE]DD7-NMX8?R%3'4+).N,)40.,M5KU7(]JY58K81W
MEGZE62@/'1]H3=[=ASY#\G:V63^]2>@OR<=[4P_<Y=G\ \ZO*Y?0>8M)%7#(
M<G7M$#Q:#T7DPEWB6:?A[C78A/)8_:..^>FEJ>==2 W*Q8O1 MC@^9T-8 ^5
MT^F&U16Q=$E)+[/-)H!<B")\8E!T+6/304"@B9&H=)Y>&)WL\E[1L6CET33-
MP%+9AHF>BI&_YG07W>+X34K&)H<070F@1#+@D\F0N0HY9:&U=H-)9 /(0Z1I
M.B%R3>7Q_BSTTDSK;?Z2SVM2:G%_SW^.\I2><7:UM8X9A;8Z ??("5_@X!T3
M$)G@6'P)(0]7O/0PUN/W73KD:F.KZ7VT=')^OAGBC9O_.,C!O9D6P _EV73)
M^8J@^B*LEX6L#=C$G=$A6V F2'J_&('5JJ;3F<K<>K/2,?L85?6H#W1P46W#
M4R]B:A"*!Q!&Y+&$0NN[JM>;.Z/ ,5M (PHOLPW,#M>[X3&TA_"3.J=Y_7+7
M%4?].4_\ 83":J^==2#)GZNWD'F@EP>!?I9116[8@$F?Q] >L8JZXJB_N4@^
M@-"F8+5TM8$O3<I*20T868!$_Q.9YRC,P'/1 VB/6$5=<310/X3K,*2NZ"1C
MR[/7]8HB"EY-+!!LO4=:1+)$2CS8AW;P^B[AN45Z_$%<9SRMF8LZ6-*64"V.
MQ;; =;CF!W>A/IVJPEUI?>QJTSTHZ;?;P3UX-F7%Z$4!P>IMB5)8P$RNFE8<
M&2]:HQFN^<J 2MFA3+!GH6S#1-<U@;^/ST>S>4Y79P!^R_%R>O<8:#;<1^48
M%"YJ060@:-(9R-H5$X7C3"TM2QL* !]^SD$/O^[.Q:0?0_82"?TZ&6/Z_RYG
M]8C]ZR]-Q6N9Y^F'_'DRK3][GZ>C2;HJL$%TO.1$45O5N+,>T%@+0<44/'K,
M.0\V,[3'??R>24\<KIE3.EAU5L$N:N=:0!O<5=F$]E#>2E]4M]#4'C3UXKYL
M1(@Y1L.9 )V*J=WI%?A(<ZIE42N3'!-Z. ]F6 $]ZL0<7C_;L-.+;MY/Y@2'
MIN-WTT0S\_5AT]HG<8:QN4=ZL<5K9%*>6Y"I]ERL=06!!@W&BRBQ"!7*<'L2
M;5$?PF7JANL5"?5"5-<'A E.RLV)UB]U)9_]EN?SJ[LSKUXE>HV4%RIFR,4&
M4"42.,$3Q&PL&H[12]/*57[L24__EN:=+TCMU,A=*^"GR70Z^8.D/WL_'9$5
M/I,9+NK%#:?&<95]9""\\*"2<>3<TXO@0V:>PL-:B]**^HV/.&+.NS%KUW'Q
M+:J/>7IQFF00J<3:QK!V.D<4X+77D"+W(6)BBK6+@^]_[G=!Z]8&["7[?HOG
M5#'':;I08#)&6JVB!N_(_PDEZ<22==X.U^+S%M=QBF%O!CKL!+8DS$6UW[OQ
M^;?K]25D722W F2)Y1J8HGDG).LS><F8==SR/5]]RG$2W:UQ>VD>O8JN%GJ>
M:O2,6R/!*$.XDA,0'%K@)A>OK+?%#5="N1[C<4JF4V8Z[/[6V(!$&\GQQ$]D
M@QMX2R[*>_Q6_=1W7_+TXQ^3_S?C])0GKJPFM"S4*_.:\TWHZ2LL:(1(P9IV
M,\ANSS].H0Q%2(<M8A[P;:?ST?]<M;:]FA<I/@Y>L !.9PG*,@]>!@/&46@3
MK(XE;[OH//"X(U9(]^;N\/#]]2[19QS='#-X7[$UN$[&X\N+4Q=U-CYH($G6
M-GG6@..V ,^&JXA:&H&MA/#@8XY8 -V9M\,#A%<]CR^KB=Z514O<O]=_YO1Q
M\OYR&L]PEC?UQCM5&$0TSH,S30VE(KE:S$ +H"\IE&)UN^3"SA".6###T-++
M68[W>%7G1O)N()T6[5.JK?!=$AI4J=E173RM>\BX$5X5,UP7J&5TQZFACMCH
MLE!LQ55Z/\T7H\N+GR?3?TS.+R_R/_/HTQEI_(1\)/H#6BEC/JW-'I.2#+SW
MC-;$$@%M8B#)>1(92Y2Y77YKVR<?IR[Z)Z'+/?L&[9O9[)+,D1<SX>NO!'\T
MR^G::_+.V2310, *SN1:&&,$<*=XJ!>-A=+.-WGD04<LB"Y-O(;__6X_N*O6
M9@:[ENR5-#5BP$C2Y$*1ZV1S(&F:VAW/^.2=].0Y;ST_K#SFB+GOSKQKF-\O
M(7HMQX4:FW2]RMDXK6D"2J+>$>YH4C(4.0>12W#UHO#2SNE<\^%'S/*^IES#
M[<YISZNKX"_GLSF.$\7$+R<7%Y-QH[WKF^%O-7DJO=)"EJ:LM=[9FLA;<483
MYH"!(B5D.K?BN^4#CU@#?9A\C2[V2VXN%-I,/PW *MU:T5$7J9Q.N659<=)J
M8K7YI JU)ZH,M"J5H*(PQ;6\;O6Q)QVQ$CHU\AH)[)>;7 Y]KS"UB'PYXY'&
M[R"+).K]WS2AT3B LU13:](E*W=*2+1%<,22&824-5+:+ZMY997\<C*;S_Y.
M]IR]G<QF[\8?\D7&:K=:P',G9W]2Q_:I^>GLE)9&59#D[X2BY3%%1\"Y!')\
M%)<8G7/MDM][@#AB00U%S1I-[9<P;0/\U67^.#E)J2$+S^^_-*?&$9,IUG91
M/%7'JQX;]@@L>RDHN,[6=J>L!Z%\Y_KJCJ8U*MLYD_H0_).FRO7JW7A)<+_5
M5Z/98'PW7KDT[]LI1NV9#8:"MNQ .1G!U81?XJE$934&VRXWT@F<[T]M/=*U
MIA:MN]3LZ_&<\,P^Y"]Y?)GK)A5%"/BM#H3BA8\DE=G9Y#R=HK F&L4A.TGV
M2HK\1,$9('?>(.<VV7;1^ X//V(U]4W%&NWLEZ.][J3[^[CN;I(?.,_I)<[.
M?L+S^E:<&DX^H,H6#,_UC*&BE9L7FEBYB%:;6(1I)Y.'GW/$BNC0P&O([Z"*
M=<D IY%C*)D%T%Y96CQC!B>%!B^CY\%)R0?M$7D/W''JI!LNUJBC@_MM5]:Z
M48T,I:]GTP5@5K3:D4;!!8:@8[*\9*/2\ATN0TCD#L+O1B>[LK)&+/MEA>\N
M?(O3[XVWGD[F-_US3H6(3N6Z'2D<@[I?#0')"-H(S85RF&R[G'"KQQVG"GHR
M]QI%=%?L>N\R\%6<+#%GM:@0%<5KGG/PV10H-B17= J^M#OGUOZ9WXDV.C3\
M&H'LERU>!.TW<$[F3?S^JI9IFV!JL8N"I(T&91.%5KY8L,RI&%0(++63Q$-/
M.6(1=&;<-;3OE]FM0?;:C.$UY-N@VGHK2BD&R#4.%%2SNN&9;+WH-1K#7 RL
MW55QK1]YQ(+HQ^QKU'&=H_WW%TLVI#'\J_E%\_-JHP^Y_%#__?N'-S?V_../
M/_Y2\89SG,W_$B<7+QIKWE@'&^O@.)W?6N>WRXL+G'Z;W.:<9Z_R'$?GL_LP
M9Z.+S^>/^A>[/NK%[>#N#_KZ>?=DT^<P\]=Y'J><?MSC)=U!F3()876PD)BA
M!04-:51B .9"*%[ZS&V[J\JW?_9>\]&6[79<SG4/(X.6=9B&64 ;/0BAO)%*
M<H[MMBJW>VZ',Q.>GW<W'VW#^KWYJ$>SKSNX_4,U1YK_M3XSI[_].)]>YML?
M3L9S>FM>7_4%H(DB?ZI?=-"?LR:,\_0S3NM(FM8HJ9;=(<5FJ.MMGT%@O8R3
M''/M45H?.1^R*^<*ON?0\6HK+:SVXMR/DWYN9+Z':=&\M@6JX>_X7H/T8.TW
M]V3R$6GL0<. (E'<6,.)*<5UK?(A?Y#+"(41L.2R9>&ARW2?JS@>[[@YC#:V
ML'[7[41^G7S!_[K,L_EU'> O.,:K,HNW;U\N\'G'DF8!O*KM3J+@X*+2D'DR
M4A9I4;3+M[5XV$&NU]Z;E$F/%NVZ6] [_-=\FO,JNO>+ZZJ4=BQ$1G%]/88:
M4H8@I06>T%I>0FE;4O_8DYX_UYW:LI?I_C;*.PFS^13C_%1YY12)#"+/I5Y'
MEL$71\ZV*,EC+,R5X8[CK>)[^MF37:*5SACII0=OTQ4XIY]P_*^W$QS/KCJ=
MY70J0@RD8 8699/[=Q!L/:B<<W!.DA7,<''&)I2'F$?V97%%%IU0T.\4TE0W
M$:[)IW$]''8R>_WU,[E2^90ID:4BRDPN$902B4;N-0BT3"N+-OL#]*G9!/<H
MY-(M*?TV-FL@7J^1%>.I#]XYQ3V$[.K.@25HF%.]]J2PHI)P?KB=_XTPCU G
MNY+08:NSM6W79)+*%E] %(/D#\MZ)ATY!%2<"T-Z=<-5"QVB\=T0"MC.S!WV
M.6O\K+>3\:=Z['#-^%(,4BF27N+UD*G. IQV!K@3A4=E/4UEK0*.S<]XQDQV
M:;T.6Y'=\5S.)M/Y_!XXBGN\CL'2XF,XKTTF-#A5_63!G>7,)"G\<'[C*L"!
M@XRNZ%OU&O>T?3^WTM%HES%I+VB%\?6"D=J'FQ8;K'19C99@BESR<)U-5_$=
MBQSVM'S?_6T%N:.<XA;0V=#@ JU$@1>*HX4MV6H?HQXNS;S,_B%*#7[-\U<Y
MS'NO,UAZSG!%!@\-<,\*@ULF[Z9P:B1$L A+'=.]TK63Z6A&=/],[^(U^/&G
MDS@??5E.[YA2;PT0X'FM:;.N)F<YQ=\B!"T3RT'$P53:[=CV?YL[P7.U 4O.
M)O..)CB17**9*65POA3PY(<:'BSWRTT%G[J=!ZFQ>!*Z7UUZ#B2,IU.E\9'^
M<O:NW&T3?+5CR+E&5#Y"BHQ6/53DBNFH((HBI PFI3)<=FP3RJ$K-@XOG!4%
M=T)@+P[U74@-RL7N4@M@@]=V; ![J/*.;EA=$4N7E RJF9"$CN@-Q)A,[3J=
M 7/MZL:Y+=$&4^)P=R@.JI5'JST&ELHV3/1T_>[7G.ZB6VA8\B0"1L!2$PA9
M.W($+,5J&)SR+.6<^& 2V0#R$ F]3HA<<PIO?Q9ZV13^^7R"]4*U-=CJ>6+F
M:U>,(FP];RPAN*2@^)@MZF+U@/5BFW$>D4BZX:*?BD*<G9V,F_/H]8[A+WC>
M-.GQQ;"FH)8PQ-JDAY1LN :6Z:=,8E)AN(5F/<9#Z.-)!6T=4-?+U',G9QA*
M5D$%"Z+(.@V6!#X(!]:;J$WT0I7A*E .NS7XI*2S(T7];#ADG.5[A]BUYB;I
M %EJFA,US;A>2@$VFTS.FE?)#+C=L(3NNY?.7G3ULD>Q<GI1TRJ=LQ848493
M#X<@(*8,# V3)7GGW' UDH<[7_I$!;077;W4LESO<YSR;&AHEH&PD93L&_==
M>7+&$OEBR*QV:3#=7(/Z[N6R"SD;RU\.L4VX5)>,]^J2%QT9Z*?798#_0]_<
MMF?H?7.Q$W3#;4EV;\Q>-C)O'OG+W6/V5YAO7PR%@I&H%<AZ!:%"B>!R<B"=
MM=)'10[\<#?$;PV_V^W(AQYYM3^0)(79*@5 GGTMKO#@&;,4DEMI10G1>?GD
MK'7 3<7N-?CPOF&W##Z=K<&7S8PT6PRER2D+ZU(,@0/7M110: 4AJD*+D6::
M0NSDE]N2])D>607X-#8$.U;$:@)D3V;Z2:C=!W6=YVL#:_B#W.N@'NPD][YD
M/B://9@84"B*9<&+R@2O'BZUN<)+"G)F)5A&*/5PVS<#"N3QT]P#Z6,; GK1
MQ;OY69[6A.[\6W.L;'3GK"L7Q3J6$SA7SZ][6P!%4Q3*HE."( ^X[CP ]""'
M@_>G<T4B77'12Y[];?Z2SV=WEMG_'.4I/>/L6_-RZ,@M1GHY8K&!/+L0ZMT=
M#H)66@2A4S3#;>$\C/7[<%<ZY*N7/.K)^?EFB->B;P-R<#^F!?!#>35=<KXB
MJ+X(ZV59:P-6.1NQE B9"P,JEMKK.B 81E&JL]ZF 2L3#J:J1UVA@XMJ&YYZ
MVC,DA/P!A,9J:X2RP(Q1-%/'>O6EMU"D-"DK82,?SHU^#.TAO*7.:5Z_W'7%
M47\.E'@ 82C>(1,.C#*YMHL2]"9Y#25S;SA*+Y=[E?>MH@?0'K&*NN*HO[E(
M/H30:NW1(A3=G-6GJ=@[ET $F9%9%"$,E[A^#.T1JZ@KCGIQOI<VME[EV>C3
M&.M=[NNZMM^<.&7.Q<1Y!IT8J9\KA""+!Q=9$DHYF?1PM3*[C>'0.]Q#[),,
MP&X_5<1+/;7NW!N@=; Y>0XAUHN&HW+@@M3@-6,"C5/<#EA%O!'G(=0U!-N/
M26Q7JGI9(F\ML.[6FCM0/YY-)Y>?SMY/)V4T?S>MS>IOS"-52%:@AEH5!$J9
M""Z%#-+[B#9HEP8\V-#%B+Z'B6]PYKMNL?IR,JZE^_7"O@G%Y_2)32'4[)2Q
M$#@3"@K6]*\@7X2^#R"S#1QS4EFVNYUSTQ,.(H_!Z9IT;>M>)K"5FD5?F_YP
M*R!AO59)T/OA A. VI5 [P1W?KC2G2=18GHHY71$4K]._7I3G**6I1CK(* +
M=3_!@'/H:?BJL%22B&RX0N5'P'ZGHNJ2PHW%RX<H2WUY5J]DGXW&-V.9E*LP
M^<V8+'?97-;>>_GI5BB&*S/=W3C]E),N0-]Y^JV')KBL#AH''FI]-=,1@D\&
MM.0ETZ^T5H=IQ?(@[([+1]<\ZKJM1%!,"FY!.U7S@^0V(#(.]0[XQ*PP1@X7
MI[:"?*!RT<XT]DB9:"=,/9WRT$<VXYB4]5*V!-Z6>KPN:@@9:1V27J T5B<M
M!I/?LZC"Z$8?VU9?;,/3P?;'VX#\L_JB'\YWVBC?A;"#J4LGE3@GG$@!$JA(
M_BS6%M,RRZB$M8ZIX1)LS[;ZHG]1;</3878\.05%WJ0(JB0)*KD(:!V%7$E'
M1.YS2G_N>'9*\_8[GMMPU/4M1AL2?12^?QG5M_!4E!0XSPC*D:>IG"!P,7K(
MTF;EE=':N\<"T%9/.G@.OG.ONWL##\W^R46]YNGW>LT!>78\<UZ'+<GEDZ:
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MB>Q 5'7NOM\9P0=Z%R9CPOCM_60V&S58XY1^F%_EJW^_&:^,Y.Y K @B&\4
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M%SVE<9JBFYL!_S8G:%==MYL=]NL=]<=1#EY1U0;YH:JK]N-Y34:F)Y(.)ZF
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M)!B*X7J"_/_M?5ES6TFRWKO_2_K6OKPX0BVU;$5TMQ3=&D_XB9&U2;BF@+X
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M^/%S3C?7>59^GWU=7X=_YM5LU>7L32Z9]#Q]Q'^_VORG#QY&Q@ST'X^JR8/
MP,(;I,_8]KI/O68AU\AJK1&*G-<M!(+G##+WB*$.RI4=NVUU7/&X;F+[%UF'
M$U,JS&N'$%6MK*_5;X'3-U'F(C2/A04IAMA2PYYA8[#Y?9NPH05[/D'[C_G+
MW[,YSK_=SZ;\Q_1FL=IK3:W)=:]W?_*:A$#^W[KZ($FZ )RGZ]L*4(QV3C<"
M.1NB)"Y5"J'A4+&#MW&:5.S!]>EQQ6,37D>QT@Z"OBF"Z@"^^?O!$1LZU2M#
M(_491FV/X/[L%#B@-B)I.D-,]9%JX47(AGRDH+R@WQ6GVL6KSTYQGWWY>(EZ
MVX?RH<.H=_ V95W>E&"1_#J>JIM7%/BB(]E))OL2@].\FW6X]<&G\&N;<3(;
M2*"CA,76DYX?B^)NSHI42A1C@=GB0,DZ8QJ9A2RU)J=>9<';'3C/@/T1M&@<
MYH8^-[:;M]U"<C*&D%."2/X40=*>;%8T$+GPS&! %;NUXM[]^3\"_T.)=Y37
MEP>.R\9?^;9">%6P%/*E'5AM#'DK$H&<:@'61F]3#G3PM8NG/@FS=0KUF)&)
MH5D9^K7]F<VO@H"3Z:>/L]>?<?XII_?S]9<GIU=AL9QC7%ZQI+C".KDP*+H\
MK7> G B/CJSX)$6AOQXB5M4!RR5ISBGH&<71^B,O-T'E=],_\Z>;Z_J??%MO
M#:]?Q57!T"]XC?7:O T[?YQ]F,_*9/E^7H]OVO76IZS^T0/I7*$,*C,?H*Q:
M'21NP#E60#HA;.TAYG.[IA--MGQ>RCZX*CY^K3P[/1K:7CMPAV\F\QR7U]\^
MSG[]KQNZ5:[HD'&189T&6I.1H]> AEQEK1-C.G(?>.AT(@\$Z,?0U)-1V-B(
M#!%9DD9 E(8N,U$LN!@+:*&+LJE(:]KUAWK&B!SV"7K-S?U;Z5^D/_DU_CU9
MXO41;\A=/G:(1^#>\$<I_[I+>WZX_+VI)'2P(GH)J4[$5D(5"))'\*Y(7<B!
MXK*A=G7&/6PIV,ZU;@<_DROIA,SD+!0ZF9Q/@,X*D#Z'P"63 O%\Y'/"LK !
M]6Q_<=A 9)W/:_/.#:W"[][I'+DLD%F=(LE$ :^UAV+KM6B9I[]L7R2V#?,\
MRL2&4HNGB\6.HF><*H]=T#;-8SJ :_[HNP?PR4O'CJ.WF]H<P4US!;+,273&
M 9=.$D@RS.LQ#9%K@QC(.F;M+(/FBM.]G*RAWO2A9)R2PWF:3''^;87M+L6
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M,KK2SI)^%NZ%&S7#TC5*$&DOQ,V8K@X@FQLY'8"?RM@9F/9^:G4$9Z-<9EW
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M/&HRG^B'I"5+A>Y-*[8:5S[QCOO$ N><#G/P ^X0PAR:X'?3.*_I=]]7[CT
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MXL1/Q:*710 B[ $4I<)9H9QZ/N1!"K4R+X>+LC0OI%7FE7.@SBNGDWHH>>5
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M:/M299V7"JF7:I\<\-BE(;)_J<A+&MJG#$QQ)C*SS;2/2.:2ZSHG)C.C?O8
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MJL::N4: MG<2&_+\^>:S$5 XF-K&>-ZXZ;/U*JMB5,K4Q$++'"L7>@$(/9@
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M;'>4=ZB-R?@7X9B<G,]+,#./7H3BF/(NWS*PMW%3[IH]9-N'II9\FJ8H]CV
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MXB??!Z&7HM!%7@(#P\2-D^,LC4+WF:KU2O"50];(O(7T:4QU%]F#D9J8.,^
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M1(BEL6XCJ<,:49U?[J68O[ZNRR4-:RFC917=O;YIL9Z8JU^VG=GNQ)?_/+1
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MEW^3TW</C^OBF<FQR'I;94_LEO]>%%3^[2LKGS+"JCOT<Y4&. H2#P(OCGP
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M-!? F+XQS3D!YFY,<P&($XUI+MUA?V2WS<6C'U$I%TZJ+%\:T2!,(@92Z$4
M$C>6O3XQ\&D4881]+R!:V;M]@RQM57,HH66=PQ-8ZI_0#4%H\K,Y$W"LSN3.
M:3_#:=S1T+.?PYU3_M0)W-EK;1K5L(J4V:/<1;OE-X3(A\O.PL4Z(\_"0?D-
M55DE2]8P,:#:;.M$4M=7[?MGP#!*?892X+$T!A Q!A)7D @AD&#FLRBE!@WN
M1Y1L:533T4T>.Z&==LZC$EPY\5@J6!=PVJDH$Z5:'4VZHXQI98T-]6O9;F(2
M[)KMECM[Q9Q:9A5#K72KZYOMS7;0YZ:YV++1S9BF-&EX<R63SK31;_U%CM;\
M9@)\^YO@C#G@C,UP)L#IL"G.% .8S<Q5N5E]$A[6P_:A/6]PN8O=&(*($K%\
M3P,,DC"( ?-3&B$&?9]IU2 _>O+29L9&.#U"/,:I?VX:I/W$<TLCU^6*$MJT
M<E;;$PXU1Q56LHJ;E"_]FJTWE?R78@[%&L?/F^6K/ZM&^]6>O\ Z57EWMEC_
M]^Y[66SOO]^AG[>YVK$3$P&CS3:>"J*5*3)%7JTXQ5[(*0$H0.([15$"4,I2
MD(;"ZI$7)#C%IGOWUM(L;VN_#L5Q*K;9K!FMMZF!$G]747'34< XU=G:;C1T
M(<4)!A&3=O,( PBC1-@MC'C$L>O!U##G?%*KS<C(B[69[K[*+):8?.71YOZU
M852_RKJC4@\5A2*\UDN&>=6$-(Z:W3X4VNG3W:TEG#O_?2B4)Q+B!S_2; *E
M+%N];99K=^+6%8H"C*B; -?U*(!$_%\J/%G@03\)DM!E7HQU6/7E@Y=&D:UL
MCA1.CP"/L.IGLR$(3$U-6LIKD\LY34\P1<7(7^^+I]?BEMIG%3_LW=6C!\WR
M09\3O_TZS_Y]C+(ZQTO36_X^RU%.,K3>A497W:(O//5AZ/HN0"$-A..3NB#E
MA(,$^C'T64P(@?;%=LP%6MJG_=N)+9\A%7@L3*3MY\P&_-2,<E"MY^0VN$R-
M;=795_&I9BGC8X_MK,5]+,2\8LD?>U#["P$->*YU'T'TGT7YIGAX+'*5>RO3
M:ILB:L(3*Q[8/J&-!P&.Q*J3(!X!B" !.$P9\&)7^&8N2A-F>,JN/?;2>%8)
M[I"=Y$V&>UL84*U[A/B_#LAPT[>++N-.@O;D^XSC 6W3O= 4LNG[&6I+-'>'
M0U.H3O0\-'Z$10C!IVS-JHT8H5E)?F&$94^,KL*$1&E$(^#Y'@<PDOFZG/O"
MP7335&!":*#E6_:.LC@B:^7<;<*4C:0&A[QG(=4X>Q\#J*DY:(=1VS_DRX@8
M&1QJCX'53 ?4Y]^KL4Z@+X'1>YI\]N;Y3H8OR7]PRGOQ8IM8JH[?^:EXJCW+
M6ZZVVJH/]9;;7;FM-A]W'4F#D'$>BN5W$*O>TI@#!-,4$!]11'GD1J%6'IGE
M^$LCS\,&L3L=Y#]J+626J_K)48I8M(RUM90&\TZ+_WR+[J5!;Q*E-*D)YHI%
M.MC_>-B90ORCJDV1-<<]SD;J,EH(DC5X_8%&YH^=,9S(6N?#H"'[QPQL]'A3
M54QF)2(Y.+W9O$=9^6]HO66K!&,8TI0!$GHI@ '$ /O$!6%,0^:B,.90/QI7
M:\BE32>'S1R1$MMY:.1VT,;A0G+G28INV3_P//H:\\7HF$X\11SV!*PE=EJ1
MG9N-(X5V_FT2."T;,(X"ZU6Z]O:^K5.T[+T(E793Q?-/NDX;Q8N:G6V<>/G.
M,8[MWK7M&1^+<H/PFGUE]T>G0(GG\Q@3##Q?KA22) 8H\AAP"<5>'"64\P$'
M=3HB+(W=&Q''ZHVA906;L[BQL9WU](VUG5_WY<"K1OQ9#MM,P)OU>$U+L"L>
MJ)D UW^$9O0D6SY4G1^_L(J53ZQ:A1[!;N!S@ (_!)!P!! *(L!\#&,_H,BE
MABV #IZ_-"9KY3*EKT/0=+G)&HJ)B>=_4_=NRXWC6MK@JS#F8B(K(M%%D."I
MY\IYZIT36>7\,UV]HZ,N%#BFV5NFW**<AW[Z 4!2HBR)!"@"YO2.SK)ED5CK
M _EA86$=FE:IVS$L)A#*68V=L\7QJ)ZIX*S*I^_Y^:]-?8F;@_6VN@KF@J$D
MXH!1A@%"\FTN2)J!@L=R%YIP&D78-A2^/X#1D^LUNKV5;EJ=FB/LBBQF2$0A
M@"2#JM)M"@H<01!F89CE-,N31$QJJ'@E@/ZZ*,Z'I2DM6D/CAQ7-@)A BN?T
M=<Z)1X-ZIL1S"I\RXMEOV<=!-T;3#6/R6:C;_RC?'UQQ^>YB3!F(LS@$B(L"
M% (6($Q12'(>(T1SLTH\@^/8/,)^BO TH@:MD*^['P)]CG!;601.7P9W^&6?
M#3#'[_QDI*RBK$>1F!1R??FNWN*O1Q7K!V./?WE258U]2=+&A?3G9O=&)U_L
M[C9M3O&'S59;7W?\06ZL\/97KS7'/A*-(2*2+,0@1CA2$8($%!&/08)"3')*
M(<USBXH:\TBUM.U3LW'8=1+W6^I8%5:8:<Y,3HI?8"9<NXWZM:?;LP&I5="J
M%=QMNGH9NDI&,V=[W8*><L'?-W8AGC._<C8U,?Q/H[=Z&+T:U^U91"6GD[33
MN=MT-3)T98S-Y5=PO@(9\X(]4AQCIL%\%L:8%Y]G13%FOOE\%G6TPBB$M,@$
M2(J( 10FH=PM%S&(XRC-(TBC#!D5QQ@<96F+WJ"->/=C<[TU'5UA35O!]9+6
M]!!2LUC3T?_EPIJ.7MZ:CIX3A=F7KSH@N.T.H9KH]3:4?46RK$@C3D&493E
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MPJPGTSP"3:!+QTS9J:2K>79[G+IIOBW:5CR/4C&+6/3KIVV8,CU.A2\.;>=
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MS8:IX[55B&(6AI"".!,)0&&82],881!F&"4I2@C,+??K Z,MC=@.HH[%:DQ
MEH>88@PYP&'$ <KR".!($/E/FJ,TRPE-V>J1;\L-^[K#VYUG?)^/[ [EVT=>
MJ7AD=4Q+-IM_!5C7;IL3ZTC('5P:IH"PIO0C @7C"1 ,TR)/D@2Q#NOWU4CK
M7$=(=^,Z=*)(J\@QSAF7V!(D0 I3%71;1"#/TA!$\G%.*.<$4V:??#$+RKZR
M*+;;7PKD_?)65BH>0;7ZN5A'<,X9,'7_S82J8WOJA( U=-]:0>=-6QC%PT/^
MP649O"<2C,)Q+B-@_*()6ZR;!TF0%%?O^*,D,+D@_?IZC^53UE6<"C$4*>&
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MY04'A8@X2)(DEY^PA"?<V)J<*,32*/##H<?;MJ^(?E/WJJ@?#[I8F%)3I\K
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M_3I$AX_?)][;XVG\==H?'\Y?>:\K"_L^KS,A-Z*]Y(BNY4$<9W$4\@RD@C"
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MK= U*-1YD YV5'TQ/U;?>;W3YO3'JAFR5].W,X%AQ'"8A ##6-()0JJM3X%
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M8>O")6$'E'/J-!3',RW:@71*>9;73W:0]I([\E1$*8P+ %&! 4IY 3#,0I#
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M\N?,F!69(P?'O'>>7I+S<<OE^JP>_"^JM?Q&/-6\6:Q75/"4DH2!2!5C0ZF
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M>?FK4RFS;23\5@E;JSKJ-ZHI1^-QW"<:)%P:6EP &(<Y0$F* 2$Y5'0:DD+
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MI#+%<8K,OBTV7RD'I,PUJ#F!>J8HP3+E5 U@]%<:H0C  :!OIP;4PAR9 J;
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MB$'I=@GU7#=.Y!3A1NI.QL-E]DW27%1U-4'.PBI(R2$I". 09@ JJET45&5
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M?)*\-E+--='K(60CDKT>-3.Z(F5[%^J=W"SO:G.V>[/Y15*3;T/<;'>[IKO
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MYRU=WTFG<RKKD;18,D.,3^!%L0V\72>-T+W;DMQLDV;,&L$/U\(0P+HDJ0X
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MD@,.3:KME!- RJH"):<J%:GD);'?I+[<S]QLMT[21':B)G=&UK_V<;P.3MT
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M@0PSF2*):<6M#G)]!9C;.KC?@UQKD9/'G<RN.RZ.XV"[!1,.W=#GMA>*:+^
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MHTX;/8Y8T^H%#\+\LJ9"[FL5;GZ3V^V#W.]5+"!45957J:9*LSN8P1)0BA5
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MV[GN"T/@.=Z*%23._)S&P>?T4:>1Y_(YA4_G\-FGW%-DW6@O1!A/Y,,#O5O
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MW/P@]YJY6L;3C69>$I4+R$".<G/(E2J 2Y2!/(,HYUF52I&Z9O5_E?&,4P+
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M=@GP*U5 (:L"9(P+ &&F %&J JB E%>P(JFP/PAR[7UNOOZK%PYR*1P1$NS
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MH!"1"<<&D%.VL7IKBJ0''[7-7=\MM;';^LZ']^PAYTCFAG5,(BQ8( )(AA%
M&&+!,I)*;K6OZMSS[ AHG^Q@+[5GI),M^+8L% #2T+ND1U&3RSV@M-L1C9#<
MP *IJ(D-AN1YQ:0&%C -)S2P:<"7QMX^F ]F<]J)]@M_7JW$G\N'AYMOR\TB
M%5E>\I("4A#-8Y)D@*85!66950K"C&32ZC*7>]=S([).[O/SSFQHW'7":^M
MB^]L5UD/B2V[A0 Z,+U-AK$'Q;G"%9SCK 6*3'*N0)VRG',+7B%>!SE0;\1_
M/6^V34J8V_J=9.:RTRYS)&$Y80I*@!C, 12D BR%''!6I6F%<VVP6>6F<NMV
M;O1VG$Z9[B5W"@2RQ=SB["$(DH'YZQC$ Z%--A4C=G,0\2_WO*?VR#I%5 5
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M2(-Z08,WQO32MUT/Y/\EJON'C>!7+V)-[D7WDTQ86;!"M[SC2 *8ELJ2IER
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MG>MNZQ">PE 612IB5 !4%DVW503*1.1 YH0F148*EEFVH!F)8) ,IZ,>Z5-
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MUI70O!%](M;7BM!JT?2$:*I4!21%G$D&TA3IE :%=IDA#% ,8UHF')'"NDO
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M#BYZ!6@+VAOPN%[?ZGW"KV]HR>DJI_>+GW*H?_@TWX;@QDJ4R3IPQ1IR:56
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M Z"2 F*0)#ZGG1;]V?1C*!_:M'6#PV?>7[:IS3$%(K<NZO+=[/TBD7>\^':
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MEK_G&6U=XG+U[=4,K[XMI\N?2\EQ5<N<XB+C,O^4-[]O [NU,'9=:Q-\8JF
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MYM1[]&:Z$/](XJ^W.-V\8/M(O&$-,;9#;N>S^NJ)_EQ/Z6G*._W-! _9E)R
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M@QMI)WC4&5CABLL8/,:=V[4N'[T?I+,9Z%[@E4OK2AH%X,A"Q\/L)%>0ER*
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MU:VSK%15L0BHMK5ZV*0@\5%B-(3(PK+%;V>#3PBW'42.'=_T@X)'X.I#)9/
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M4<HH#TV8[D=)-XB>?7%J4(6-C<[K/:?7D?O=I7!=P[AP7F6;HP0IBF5FV.M
MZ3)(94U$E5H>N!/PGOE(-TR=<[&H5S&/#9<=>=/;=- -AV_G/R^6-/LT?Y@>
MVI%*O1&"CF2#DQ'0MW:!VHRY1<TRR<9%HA*W7_YU-')]4=@-J'^Y8M$H"AX_
M;=*_&.X<;4RJU<Q*&WO9AJ5: ['F )4<Q;;3(HK#W,[^:.S6DG[.E: I*7FB
M.?#CI?&DY^ZUD!@D:*/XLK.6/??29L *H[73P<>TA?[A:ZC]LMSM,/TUBTCC
M8V@BA^N9>MG['86V"U>M1*T3&!U;]ZUJP]D+@B2ALQ8FUNU=G2<\*@<PT WX
M?XV"TJGU.[Y'=,OAUM'](:?8^0C?2.,)H53CK/:E K69XJ9Z5@-6OC@Q!;0A
M25E*)^]H&'J[8?SL"UL35/Y$#/N#1[,NJF(,DQNU(S!%>[Z64GLT6S,:JTRQ
MTYV7=,ZULZ.UT<_[@Y_F)YN+9(W5.C@',N>VLC-6B"8*P%21+XMB,4U\+I(Z
MYU):3YJ9&LP>/9-UU;#E=1:*;#D:J]JS_\"^246OV*G.20]GP0YZOZS.N4#6
MDV:F!K/N@9W,LF@MF;<B<ULAI"'*FMK#5Z\".P%AP+&7/0?XYUP6.[4NIX;8
M'>YI,;:(Z 580G8IE%00?8I +%+B4ZBD'FZ3RC'QR#F7TWK5TI'/E_M#W.VK
M68U%DQ4(SK?$ .H,@;+A,"@D[02'0 .NLMOG\;(ZY\K7<7HXA?4:9]+;EH3Q
M!PG_<MU(5OA/;_9F_V_^S?IGG"W_@9=7=/*)<+U0-^3DN/[%.<Z$N2AM]5%E
M<"9;X.BFA3>J A:??3;!6B-?4O$4%JG=R?:7^Y[(]_7Z^]?#[(M.[&F7!"@I
MMJ68$9A;#SE[[55-F8W*8.9W+]+/:D[=/H!Z?F= ORJ=QDJ C5%9W7*QV8^D
M?"@Y)0G2MIV;RAI(V52HT0K+=U5AEH;S/!\3.*5E #U#XK';>:1^I@BRFXTS
M1I"2U1"SH5@PGAH;Q0"1J,D+YL8.-R?Q21+'!MK1RG\)3@=H8A* VC0XMC!L
M_?UWRE?+&Q_G>EF6JCX(*A""9 %%SY9>;=9#BQPX0+-J0.OU#*$3 ]<A4'@$
MK[[T,@F0O:-O=+EZ8.+_YXR63-/G[YN#:+/TF/D@YNI;T)82VW4*D*RQ*BE;
MLALP??@LK5-:8G+J"[-'K4T"A:\N+W>S='MH@\]8:P:2RH')E2#HA. $*A%\
M]&7 G7H="![;]/6)D4< [%MADT#AAB/Y#$?.6^^4\2!<&^-H<VJMUQZJUJX-
M#_59#CGT^GEJQ\9?[Q!YV@KVI:_I(% ]PU&J,:!0@</\UH*1E.)3&RU4DM%)
MU%'[@>_C9Z@=^T8>"(%]Z6LZ"-3/<>2MC>@1J@VV^<X!8@@%5-*$PJ-*:;A\
MWDO4CKU?;" $]J6O22"PJQ_][FX+D6%!.<T67I>@6F4)(5 )H(/W.F:#M@[W
M &)O\L?&Z)!QRVEU.PGX;J7KW]!J]FG>:I*O[NI3K^Y+4G?Y>Q%"+E(2V"+X
MHI &(>D:(611E#%!%SM<E?HP'L9V.$\,KB<6V9]<TU-$] .>+JQ-GDJ4D#*V
MNZM-VDW:0K1"*'3!2#_@GON==(Z-S"&0\A(\#U7;)"!X+[$[KAX60>]9NWD=
M]V&YJ+/U^^6[Q>J^1*I-*EZAA;:Y$HQQN8V%)M Q9O3)AE*&B][[X&CL^&IH
M@SLX"L8>#?%Z,5_/YI]8E/RKU8SUN='NZD*(E*10!BJV,H/B<(%_GT"33Q*I
M&-INF]RU-6''%\:VF,.K>M&WW"?RFNI1WWL4JA;I%10,@GG@TQB24( VU,0G
M4(8X7+1TV(N$OR#N>E+81$#W@O NT.I:G0^0L+U*M.0@!(PL,%-%J45E,=R
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MDLC5;$4._RYWG A AY8[]E'A)!(M+R1'#<F@@G$WPPRJ*!"$M*!<C#8F5W'
M)MF_0KEC+X#L6^[81UN30%^7U*@B$EJH"A*3!2,=,^6#!<&QO=,>3;%Q, B>
M?[EC+XP<5.[81V&30.&+Z7,O@O?>*N#;P_#-4=JX75D@.B^5\-J)-!P$_PKE
MCKT@LG^Y8Q]]30*!>P216 PYK]AU\:U&63W_*E3P24MK4Y8E_;O<,<K=?!H=
MCEWN:#FLELMJ>:Q?.N2Q[I,2682:?)" 7F)KVY00C9?L?<N2*?DD3+?VM(-)
M&-L2G@@1B\'5TQL(Q\D7_><5LC#:Y[[1VWE=++]<@R MKM;KS_3[[--\5F>9
M_Z4_YHNTHN6W9@[>SK]>K5>M#L BWMPX3[T3.GV_["#4#YF%&EX=XR2L;#8"
MDVJ-ZIJODTKMD:(S$$L6Z$S!8+J55R:;L*H*T=E$8'6(8!*UB=C"@<O2$\5(
M/O^[/W<8 !V:L-I'A9-PE5\(;UU;31:C!)=J +[56&:2!1<27VC")QD'7,KP
M5TA8[060?1-6^VAK$NCK$MQJHX4.)H.G%GTZ*2!(CCY=,E9'_HN"P\TW/?^$
MU5X8.2AAM8_")H'"%Q,@K:,YI\1'U6?/AS9K0+XSP+25%TH:C6ZXS5U_A835
M7A#9/V&UC[XF@<#&Q49%'RE_GL_^^XHVKOG;^5-.^>885QTYTJP:.*)MQUAD
MB&W(OU4LORRU0C?<D*"]R3^/!-9Q=_5I=3I5V-Z<0%&<#4DET-KS 2^;47,J
M@J5L4W8.T0_WKFLGF6.;RA-#I LD#]#7)*#73G!K+*7-AK*?+Q?_NN&$0SH*
MMEC(>G.UM";3DC)DF2(6E:,<<*;%+BHG"+Q#@/!DD'RT5B:!K]_QDE:MP6O.
MGLSFZ+6VPAA<!(J&6:#4MBTF#UII+-%Z(?QPC[0>D3?U'N ^;M3C=#(]6-V<
MC5*T%90%.(7LK:(3D J;^*A)")D2AVC#6:PG"!S;6!VI]N=A=( .QJXA_O3G
M5\IL8C=\_&-QR0?LULJFY$,6%70('.V4DB!0;<\>C8GDBE';C_=VI,AW?F)2
M6#A$=XO>!3D)N_)AN4@W0Z+>US=4\>KRQF%DP2AC.;X628+QR4'2S%ANE[F0
MY*T=+G6QB\JI/SKHX_+J14.3P-I/K=SX??6Q#6'Z>;%\BK&;8U1UJKK-@<I2
M<K024P44-3?6E"F^UCS@PL?.9(]MX_I!RB, GD9MDT#D,[Q@B-4YK]L+'I:9
M(P<8C :IK!$B>JRQC&K_IH&Y$X&CDQ4\0%.30-UO[?7/]0(E[Y-NK;\1VU+T
M&/E@2L,B,J[$:FWU X:&=V1UPI0][UOU,!U,!SZW/BR)&(+0'@19!T;4UIM
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M^>FW<#[SS2$K UU9'Z<X4'--? <:OA@E1XX<-4(TE"$EA862"]%TZ_6=;'&
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M/HG+\,G4?6/QHF*M3'H ;YUC86D$YD&!]SGZ0HDO^N$:A'>2.=VX]$!0=*F
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M.X_+FC#W?3WD(V*8))UL>027JNM1E >'-<]%J&P,2Z+L]I%Y!B4OK=3V:^$
M<!F4U5/CYN?\ C&.$2\TSY D^AK8]^#K>"JZTXT(B7-7>+<+ZH65VO:V!L#-
MH*R>&C??Z<P_OV4QK7;2F*Z4LA9%<!"XK778"FL77++AM%8Q*Z=D[I;IVG7%
MMHV;H:^KH5@_-9[V*]7W\\[$:JLU9EY TC]$;)U2XX(%3M>V"[Q$4;I90:?N
MY%(*10>^_\XDJJEQN5]I]R#6*L5X+@6B,F0,<.00R&$%,B!-25*XE+K-@C]U
M)Y=2VCGP_7HF4?7'I;_#Y3Q?TZ[2CYL'_F&#AT]Y/8MX<[E)X7O)^"$RQ%\6
MT-CIXHH'%4GS0RQU@H=/$H)S!HP7)3F?33'=RN^:2Q>W:+7+T@./7I#A9<@I
MQ,QHZ\5%'5B,:C#*+BE=O(_$CTL7[\/Y)H(03^(R-H0H<BK C490F,F0CW0[
M&:$)'T*BV/6<6HN-3IQBW@L"+\=&^\BC.43=QU%8,=&;;*$XLK]5000G? ),
M5F@GDXT\3H*I]L)9_67>)3;:1P!-@.BY@)S+"8-@M3M%!F6]J26U!I0RL1C!
MM1QQ0L+%Q$9[2;]S;+2'*%HJC*K37Y7F#EAAY&[IX.I+9Z*CQE!8917/A]+&
MSE88-7$F\S&WUDF\;:+\84\A@!&2O.:4(/!<PV_:UV2Y ,+6PHY 7PZJF!^H
M,*J7-+L41O5A;0OPJ!4]:$-*T@?0MM36KL+6=@X*BA0<"V>VV$/9.#](850O
MR>TKC.K#QA9$7RMZI$K<F(201+*@I"#\ZYIAY/Q=.TT=[:":H,G"J)-$WY>-
MD[^[]WDR5D*Y7(('FS,'51OO!>L9F>K&>@P5[A.U])\X._@86^*\[)\:5]WZ
MB&]#7.^7VZ#"E=!:^> ")&-*'2UEB3ZRWY%8*)P,:%BW1+UC=]#VB\N1:.C?
MXOU$T5Q<]Y[;SY]Q^751?EHLEXN_9_/K]>+#<A9SY<4=?U9G"++T6/6\,9%C
MR1\[A*&3MZKX#.B*!Q6-HY\D0G9:!)5JD^]NW;F:"V%$YHOBT8"T9# H-+4A
M S*(L9#=Z%+-]?Y7#&'TD?AQ(8P^G&_BK?#)\VE&GS!:"QJYJM6-'-"H H[Q
M&'.@FT"-5T%QB2&,7A!X.8311Q[-(>K^N5.*+)R(F3Q69T E69LYY@26Z6 Q
M><^UF 13[;TZ]Y=YEQ!&'P$T :+:Z7%1YY_?60[?7LY#(/_(ETA;#^0>9236
M:"^!>YF+4RJG,E[A\G.[; E0QR!@SZCG <0QM1_9RR4J&HDDG<D#KXG=WFIR
M4#1AH(81N:"#N?M^-=;[Q,2QCF.NM_.ROPF%]<>GQ7)-'_CYP>M971E+)TM@
M@EA[1"B6$+R-6 /35D9DR>U6>9US ._3#;9M31T)AJ=C=T^43!/P>K<@-_I[
M&K0LB,9F<**.9;?)TT$T$9AAB#$)F?5X76">[J]M7384N$Z4RPDIR>O!&@P]
M[)R)HE.B*[QX0Z?"N@+H"YD,6BM5,B_<C)>]UA-)#529G8:D(^5PO'9:K/'F
M=*/J\;C&W5>^M_.[@-CZ,6U<*,F8!ADPD!U*YR3(C% ,UKX5IIZ=3G95SX4O
MI<3L&!"=71!36^Z'::O#))Z0IT/V6KA NC<S,E-3J5F ]8^6E'"M!!?=GD#[
MKWTIU61G@MK)XF@;;8^($L'0[6X-T)%Q=02% Z\X0M0\YVB<LJ*;C]AUQ4NI
M!SL3LHYD_6!7Y.A57]O Z39LNBA_?")1;3ASSC*M+NN.5%?5FP6C%T(Q8X(R
M&HRBVU-)Y0 3K_W]G"V<[M6PVW'J4J*(Z),(M9>S274PN]6A3N])H 5Z:U-B
MR0[V!'9)4<0^$C\NBMB'\TT\3WSKU9M55AZQU,YT!137#+#D MQY'W6)Z/).
M7E<S[; GCAOV$OJ!=MA])- .>+9QBJQ#RM8C2)M%W7T!9U$#E[D4JW4I:;SX
M3IOML'L)^' [[#[<;@(K3_KITME P52$K"T');(&S!:)&5&[$NFKRJ/AY:A&
MQF,UPNXEZY<;&?=A?!/0V=?*6P=OM)$)G&.)'!55YTYP \HI89B51HOQFN\?
MVTE]K$[8IP'H5/9/_2K0RP$V:!BO1:>2U^9-*C'PUM$7YC''X+7!P4;.O;ND
MZ/$Q1LYYV=^$;OH3ETNL%&"8W<S67Z\P,FURG7RKA0)5.R]Y%1A8[I).NGBG
M#I7/#*N8=G?7MC5]) R>**R39#*UMOHCSU>S]>P+[?O5'&^^KF:K-XOE?5[0
M;WG]=AX7GS>)/#_A*J?W\V\=PKZ]KUR9()G"("$6*TD_.U4I5E"LB8X+KK3L
MU@APD.VTK=].@]U$0KLXF'YK&/:(8E0^R"0\9/1DBB9/IBA/D2X5$1T3:&,X
M$TSW;>=2PM7CP?1DH4T-T\=AB>V9>S5/>^G2BJQ6&RW19<A*=F3<.%4\D+TC
M4 A5+)>=P-ACT;8A=Z+E=R[F7UQ9V4-,Y%=<WRXWR;B+,JO_X=5\/8NSOVJ3
MPC>W]+O\>C'?O%7?XLUK7'UZ<[/X>_6:[)FOL_GU_\:;V[-&CP;<WDA!IG,Q
M=/185&&!JU!S.A+I5,4MD'+5X+1/SJ OWG1KJ#M"+.J;H?UXL:TD'ETLFT:*
M)/8O^6$G6YM\EE=WRD5HU!9+!&XDUO;M$5PVADR@%(U#7<A$'\U=.IV>MAVL
MH^#VU+\:6>Q-^/F/*'A%RHB41ZV9OB=P?OTJ;LRJ^MN[*4^,7$IE %WM9$8W
M& 2, 8)604JRF,QN?LDY,WS[;'WJA^^QL?4T+_AL@KXL'&^'* :G>5 >A)">
M- 4K-5@0(6JM,.:HS(CO[#TW/S66SPBEXV%[A%S; .Z3?/U[2ISUJ$2@\YWK
MC&$5#7@A.$3O$H\6$U>'!KF?NYKBPJ!X##PZU%8<(:NIGPX^+C'E#_BUWBD/
M+26=]$XX"V*3#!N4I-/*R5]5&94-5JB.M85[/GSJB.$8$!F$L6VHH_J"\8AE
M]W1P&6,1A>C0J?8(E:3.29^#R2:3 @^QX'CU\OOW.,V3TV2JZ'0Y-8&W^HQ!
MW"$.TT^K&0EI([)M@#]*PTF#@DZZO@B7#(&[  I1:X-U8.=X5MK!K4Y3S3,5
M^H:36A,@?'#(JKTJK2V1J03)\)I,FRW9JTD#7>-,!._IJA\OW^_QSJ:^2"=W
M88\64Q,@>W5]O;P;V_-Q]CG_A//TD,:4@DK,<?".)U!11D!F'5@7?) ^,"W&
MRQA\=IM3F_K'2_\)D(8111.H^FVQ?D>$+#]^POG[>?X_&9=;TS-'ZQ3+((S,
MH'QQ$,@= 6FL,)$+.FSCW9W/;G-J5 T$A2<0&T8N1T/L2UZ&Q7!.P0XEK^;I
M,7T?_U[4_[IE'%D41CB1 (TEQJ4H(1CD8)EE,L44S.ZPNG/Z"GVV/O4->RXP
MGD]^3>C %\A[0R;)8_IDSBQ7O"1735_I'*!@%F)P0NA -.)XUVV_O4_MXTX$
MT%,DV!9"=RE1*2?-E0#ZOU1]."1*R%4'C\PK%#ZDQ,?'XC&H.Z-O>W;4G2*5
M1J[HDYRS=P\I>+%$C%Q*8JBI_6@YV=4R"(A1!YF4DD9?2-K"NVE;[#?D-D\
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M__;_ 5!+ 0(4 Q0    ( -U[75CPY-A<&P@  ,<5   <              "
M 0    !E>#DY,FEN9&5P96YD96YT875D:71O<G,N:'1M4$L! A0#%     @
MW7M=6-0VJ'$: P  = 4  !P              ( !50@  &5X.3DS875D:71O
M<G-I;F1E<&5N9&5N8RYH=&U02P$"% ,4    " #=>UU8N-M#2,8'  "T$P
M$P              @ &I"P  97AH:6)I=#DY,6%P<#1D+FAT;5!+ 0(4 Q0
M   ( -U[75@../:83HH"  ,Z'@ 1              "  : 3  !M97-O+3(P
M,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( -U[75C?V>C,&"0  .RT 0 1
M      "  1V> @!M97-O+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( -U[75B9
MSGFT["X  %_* 0 5              "  63" @!M97-O+3(P,C,Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " #=>UU8 HX1!U9W  "Z704 %0
M@ &#\0( ;65S;RTR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ W7M=6([K
M>!MQ/ $ @RH- !4              ( !#&D# &UE<V\M,C R,S$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( -U[75@$?V97IL   ,F\"  5              "
M ;"E! !M97-O+3(P,C,Q,C,Q7W!R92YX;6Q02P4&      D "0!? @  B68%
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>meso-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:meso="http://www.mesoblast.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meso-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfGainsAndLossesFromInvestmentsInEquityInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:InvestmentRevaluationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManufacturingAndCommercializationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManufacturingAndCommercializationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManagementAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">meso:ManagementAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="meso:IncomeStatementLocationsAxis">meso:IncomeStatementFunctionalExpenseCategoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RegulatoryEnvironmentsAxis">meso:ClinicalManufacturingRegulatoryAndReimbursementApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:GrunenthalGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TaslyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TaslyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TaslyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:License1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:TiGenixNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:JCRPharmaceuticalsCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:JCRPharmaceuticalsCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:ManufacturingCommercializationExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:ManufacturingCommercializationExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:QuarterlyPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">meso:RefinancingAndExpansionOfSeniorDebtFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:November2021WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:November2021WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-05</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-05</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-05</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:December2022WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-05</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">meso:UnlistedEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">meso:UnlistedEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:ContingentConsiderationProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:ContingentConsiderationProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:NovaQuestCapitalManagementLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedUnitSalesPriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedUnitSalesPriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">meso:ExpectedSalesVolumeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">meso:ExpectedSalesVolumeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedSalesVolumesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SalesChannelsAxis">meso:ExpectedSalesVolumeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ExpectedSalesVolumesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:PaymentAssumptionsMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:ProbabilityOfSuccessMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProbabilityOfDefaultAxis">ifrs-full:ProbabilityOfDefaultMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">meso:PaymentAssumptionsMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">meso:WarrantsFairValueAtGrantDateDecember222022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CreationDateAxis">meso:WarrantsFairValueAtGrantDateDecember222022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MethodsOfGenerationAxis">meso:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">meso:November2021WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:OaktreeCapitalManagementLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositoryReceiptMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-05</startDate>
            <endDate>2024-01-05</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-05</startDate>
            <endDate>2024-01-05</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">meso:CurrentMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:CardiovascularProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:CardiovascularProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:IntravenousProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:IntravenousProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:MSCProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">meso:MSCProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ValuationTechniquesUsedInFairValueMeasurementAxis">ifrs-full:DiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:EmployeeBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:ProvisionForLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">meso:ProvisionForLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:TaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">meso:IntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:PlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:PlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:MesoblastEmployeeShareTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ReservesWithinEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-05</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">meso:PrivatePlacementOfSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">srt:OtherCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CommodityPriceRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CommodityPriceRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">meso:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">meso:LonzaBioscienceSingaporePteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:ManufacturingServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001345099</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ServiceConcessionArrangementsAxis">meso:ManufacturingServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="aud">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="audPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:AUD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="milestone">
        <measure>meso:milestone</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="year">
        <measure>meso:Year</measure>
    </unit>
    <unit id="segment">
        <measure>meso:segment</measure>
    </unit>
    <unit id="lawsuit">
        <measure>meso:lawsuit</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-10">0001345099</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-11">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-12">false</dei:AmendmentFlag>
    <meso:ConversionRatioOfWarrants
      contextRef="c-42"
      decimals="INF"
      id="f-229"
      unitRef="number">0.25</meso:ConversionRatioOfWarrants>
    <meso:OutstandingCommonShareCapitalPercentage
      contextRef="c-185"
      decimals="INF"
      id="f-723"
      unitRef="number">5</meso:OutstandingCommonShareCapitalPercentage>
    <meso:OutstandingCommonShareCapitalPercentage
      contextRef="c-186"
      decimals="INF"
      id="f-724"
      unitRef="number">10</meso:OutstandingCommonShareCapitalPercentage>
    <meso:ConversionRatioOfWarrants
      contextRef="c-283"
      decimals="INF"
      id="f-990"
      unitRef="number">0.25</meso:ConversionRatioOfWarrants>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="c-1" id="f-3">001-37626</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">Mesoblast Limited</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-5">Level 38</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-6">55 Collins Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-7">Melbourne</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-8">3000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-9">AU</dei:EntityAddressCountry>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-13" unitRef="usd">3388000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-3" id="f-14" unitRef="usd">3422000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-15" unitRef="usd">12647000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2" decimals="-3" id="f-16" unitRef="usd">13430000</ifrs-full:ResearchAndDevelopmentExpense>
    <meso:ManufacturingCommercialization contextRef="c-1" decimals="-3" id="f-17" unitRef="usd">6746000</meso:ManufacturingCommercialization>
    <meso:ManufacturingCommercialization contextRef="c-2" decimals="-3" id="f-18" unitRef="usd">12760000</meso:ManufacturingCommercialization>
    <meso:ManagementAndAdministrationExpense contextRef="c-1" decimals="-3" id="f-19" unitRef="usd">11482000</meso:ManagementAndAdministrationExpense>
    <meso:ManagementAndAdministrationExpense contextRef="c-2" decimals="-3" id="f-20" unitRef="usd">13281000</meso:ManagementAndAdministrationExpense>
    <meso:FairValueRemeasurementOfContingentConsideration contextRef="c-1" decimals="-3" id="f-21" unitRef="usd">337000</meso:FairValueRemeasurementOfContingentConsideration>
    <meso:FairValueRemeasurementOfContingentConsideration contextRef="c-2" decimals="-3" id="f-22" unitRef="usd">-5989000</meso:FairValueRemeasurementOfContingentConsideration>
    <meso:FairValueRemeasurementOfWarrantLiability contextRef="c-1" decimals="-3" id="f-23" unitRef="usd">-4434000</meso:FairValueRemeasurementOfWarrantLiability>
    <meso:FairValueRemeasurementOfWarrantLiability contextRef="c-2" decimals="-3" id="f-24" unitRef="usd">712000</meso:FairValueRemeasurementOfWarrantLiability>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-25" unitRef="usd">1068000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-2" decimals="-3" id="f-26" unitRef="usd">-39000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-27" unitRef="usd">10319000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-2" decimals="-3" id="f-28" unitRef="usd">10685000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-29" unitRef="usd">-32641000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-2" decimals="-3" id="f-30" unitRef="usd">-41496000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-31" unitRef="usd">-102000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-2" decimals="-3" id="f-32" unitRef="usd">-126000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-33" unitRef="usd">-32539000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-34" unitRef="usd">-41370000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="4"
      id="f-35"
      unitRef="usdPerShare">-0.0382</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-2"
      decimals="4"
      id="f-36"
      unitRef="usdPerShare">-0.0564</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="4"
      id="f-37"
      unitRef="usdPerShare">-0.0382</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-2"
      decimals="4"
      id="f-38"
      unitRef="usdPerShare">-0.0564</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-39" unitRef="usd">-32539000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-40" unitRef="usd">-41370000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax contextRef="c-1" decimals="-3" id="f-41" unitRef="usd">-1164000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax contextRef="c-2" decimals="-3" id="f-42" unitRef="usd">-100000</ifrs-full:ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-43" unitRef="usd">931000</ifrs-full:ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax>
    <ifrs-full:ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax contextRef="c-2" decimals="-3" id="f-44" unitRef="usd">-192000</ifrs-full:ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-3" id="f-45" unitRef="usd">233000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-2" decimals="-3" id="f-46" unitRef="usd">292000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-47" unitRef="usd">-32306000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-48" unitRef="usd">-41078000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">1165309000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">97924000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">-542000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-52" unitRef="usd">-39700000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-53" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-3" id="f-54" unitRef="usd">-738916000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-55" unitRef="usd">497044000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-10" decimals="-3" id="f-56" unitRef="usd">-41370000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-2" decimals="-3" id="f-57" unitRef="usd">-41370000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-11" decimals="-3" id="f-58" unitRef="usd">192000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-12" decimals="-3" id="f-59" unitRef="usd">100000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-2" decimals="-3" id="f-60" unitRef="usd">292000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-11" decimals="-3" id="f-61" unitRef="usd">192000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-12" decimals="-3" id="f-62" unitRef="usd">100000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-10" decimals="-3" id="f-63" unitRef="usd">-41370000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-2" decimals="-3" id="f-64" unitRef="usd">-41078000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners contextRef="c-13" decimals="-3" id="f-65" unitRef="usd">42405000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners contextRef="c-2" decimals="-3" id="f-66" unitRef="usd">42405000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-13" decimals="-3" id="f-67" unitRef="usd">42405000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-2" decimals="-3" id="f-68" unitRef="usd">42405000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <meso:TaxCreditedOrDebitedToEquity contextRef="c-14" decimals="-3" id="f-69" unitRef="usd">126000</meso:TaxCreditedOrDebitedToEquity>
    <meso:TaxCreditedOrDebitedToEquity contextRef="c-2" decimals="-3" id="f-70" unitRef="usd">126000</meso:TaxCreditedOrDebitedToEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-13" decimals="-3" id="f-71" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-14" decimals="-3" id="f-72" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-2" decimals="-3" id="f-73" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-14" decimals="-3" id="f-74" unitRef="usd">1757000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-2" decimals="-3" id="f-75" unitRef="usd">1757000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ChangesInEquity contextRef="c-13" decimals="-3" id="f-76" unitRef="usd">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="c-14" decimals="-3" id="f-77" unitRef="usd">1631000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="c-15" decimals="-3" id="f-78" unitRef="usd">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="c-2" decimals="-3" id="f-79" unitRef="usd">1631000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity contextRef="c-16" decimals="-3" id="f-80" unitRef="usd">1207714000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-17" decimals="-3" id="f-81" unitRef="usd">99555000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-18" decimals="-3" id="f-82" unitRef="usd">-350000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-19" decimals="-3" id="f-83" unitRef="usd">-39600000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-84" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-85" unitRef="usd">-780286000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-86" unitRef="usd">500002000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-87" unitRef="usd">1249123000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-88" unitRef="usd">101367000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-3" id="f-89" unitRef="usd">-543000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-3" id="f-90" unitRef="usd">-40273000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-27" decimals="-3" id="f-91" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-28" decimals="-3" id="f-92" unitRef="usd">-820805000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-3" id="f-93" unitRef="usd">501838000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-30" decimals="-3" id="f-94" unitRef="usd">-32539000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">-32539000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-31" decimals="-3" id="f-96" unitRef="usd">-931000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-32" decimals="-3" id="f-97" unitRef="usd">1164000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">233000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-31" decimals="-3" id="f-99" unitRef="usd">-931000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-32" decimals="-3" id="f-100" unitRef="usd">1164000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-30" decimals="-3" id="f-101" unitRef="usd">-32539000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">-32306000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners contextRef="c-33" decimals="-3" id="f-103" unitRef="usd">37106000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">37106000</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-33" decimals="-3" id="f-105" unitRef="usd">37106000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">37106000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <meso:TaxCreditedOrDebitedToEquity contextRef="c-34" decimals="-3" id="f-107" unitRef="usd">102000</meso:TaxCreditedOrDebitedToEquity>
    <meso:TaxCreditedOrDebitedToEquity contextRef="c-1" decimals="-3" id="f-108" unitRef="usd">102000</meso:TaxCreditedOrDebitedToEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-33" decimals="-3" id="f-109" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-34" decimals="-3" id="f-110" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-34" decimals="-3" id="f-111" unitRef="usd">2195000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">2195000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ChangesInEquity contextRef="c-33" decimals="-3" id="f-113" unitRef="usd">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="c-34" decimals="-3" id="f-114" unitRef="usd">2093000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">2093000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity contextRef="c-35" decimals="-3" id="f-116" unitRef="usd">1286229000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-117" unitRef="usd">103460000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-118" unitRef="usd">-1474000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-3" id="f-119" unitRef="usd">-39109000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-39" decimals="-3" id="f-120" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-40" decimals="-3" id="f-121" unitRef="usd">-853344000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-41" decimals="-3" id="f-122" unitRef="usd">508731000</ifrs-full:Equity>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-123" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-124" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-41" decimals="-3" id="f-125" unitRef="usd">3998000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-29" decimals="-3" id="f-126" unitRef="usd">6998000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments contextRef="c-41" decimals="-3" id="f-127" unitRef="usd">3602000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments contextRef="c-29" decimals="-3" id="f-128" unitRef="usd">3342000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentAssets contextRef="c-41" decimals="-3" id="f-129" unitRef="usd">85154000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-29" decimals="-3" id="f-130" unitRef="usd">81658000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-41" decimals="-3" id="f-131" unitRef="usd">1171000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-29" decimals="-3" id="f-132" unitRef="usd">1357000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-41" decimals="-3" id="f-133" unitRef="usd">4329000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-29" decimals="-3" id="f-134" unitRef="usd">5134000</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-41" decimals="-3" id="f-135" unitRef="usd">826000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-29" decimals="-3" id="f-136" unitRef="usd">1757000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-41" decimals="-3" id="f-137" unitRef="usd">2241000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c-29" decimals="-3" id="f-138" unitRef="usd">2326000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-41" decimals="-3" id="f-139" unitRef="usd">576564000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-29" decimals="-3" id="f-140" unitRef="usd">577183000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:NoncurrentAssets contextRef="c-41" decimals="-3" id="f-141" unitRef="usd">585131000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-29" decimals="-3" id="f-142" unitRef="usd">587757000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c-41" decimals="-3" id="f-143" unitRef="usd">670285000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-29" decimals="-3" id="f-144" unitRef="usd">669415000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-41" decimals="-3" id="f-145" unitRef="usd">10760000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-29" decimals="-3" id="f-146" unitRef="usd">20145000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentProvisions contextRef="c-41" decimals="-3" id="f-147" unitRef="usd">8230000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions contextRef="c-29" decimals="-3" id="f-148" unitRef="usd">6399000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="c-41" decimals="-3" id="f-149" unitRef="usd">8534000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="c-29" decimals="-3" id="f-150" unitRef="usd">5952000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-41" decimals="-3" id="f-151" unitRef="usd">2851000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-29" decimals="-3" id="f-152" unitRef="usd">4060000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-153" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-154" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:CurrentLiabilities contextRef="c-41" decimals="-3" id="f-155" unitRef="usd">31367000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-29" decimals="-3" id="f-156" unitRef="usd">41982000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentProvisions contextRef="c-41" decimals="-3" id="f-157" unitRef="usd">17073000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-29" decimals="-3" id="f-158" unitRef="usd">16612000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:LongtermBorrowings contextRef="c-41" decimals="-3" id="f-159" unitRef="usd">107228000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-29" decimals="-3" id="f-160" unitRef="usd">102811000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-41" decimals="-3" id="f-161" unitRef="usd">3386000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-29" decimals="-3" id="f-162" unitRef="usd">3672000</ifrs-full:NoncurrentLeaseLiabilities>
    <meso:DeferredConsiderationNonCurrent contextRef="c-41" decimals="-3" id="f-163" unitRef="usd">2500000</meso:DeferredConsiderationNonCurrent>
    <meso:DeferredConsiderationNonCurrent contextRef="c-29" decimals="-3" id="f-164" unitRef="usd">2500000</meso:DeferredConsiderationNonCurrent>
    <ifrs-full:NoncurrentLiabilities contextRef="c-41" decimals="-3" id="f-165" unitRef="usd">130187000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-29" decimals="-3" id="f-166" unitRef="usd">125595000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c-41" decimals="-3" id="f-167" unitRef="usd">161554000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-29" decimals="-3" id="f-168" unitRef="usd">167577000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-41" decimals="-3" id="f-169" unitRef="usd">508731000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities contextRef="c-29" decimals="-3" id="f-170" unitRef="usd">501838000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:IssuedCapital contextRef="c-41" decimals="-3" id="f-171" unitRef="usd">1286229000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-29" decimals="-3" id="f-172" unitRef="usd">1249123000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves contextRef="c-41" decimals="-3" id="f-173" unitRef="usd">75846000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-29" decimals="-3" id="f-174" unitRef="usd">73520000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings contextRef="c-41" decimals="-3" id="f-175" unitRef="usd">-853344000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-29" decimals="-3" id="f-176" unitRef="usd">-820805000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c-41" decimals="-3" id="f-177" unitRef="usd">508731000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-29" decimals="-3" id="f-178" unitRef="usd">501838000</ifrs-full:Equity>
    <meso:CommercializationRevenueReceived contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">3971000</meso:CommercializationRevenueReceived>
    <meso:CommercializationRevenueReceived contextRef="c-2" decimals="-3" id="f-180" unitRef="usd">3667000</meso:CommercializationRevenueReceived>
    <meso:GovernmentGrantsAndTaxIncentivesAndCreditsReceived contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">2565000</meso:GovernmentGrantsAndTaxIncentivesAndCreditsReceived>
    <meso:GovernmentGrantsAndTaxIncentivesAndCreditsReceived contextRef="c-2" decimals="-3" id="f-182" unitRef="usd">18000</meso:GovernmentGrantsAndTaxIncentivesAndCreditsReceived>
    <meso:PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">33994000</meso:PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax>
    <meso:PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax contextRef="c-2" decimals="-3" id="f-184" unitRef="usd">34633000</meso:PaymentsToSuppliersAndEmployeesInclusiveOfGoodsAndServicesTax>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">887000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c-2" decimals="-3" id="f-186" unitRef="usd">207000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">1000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-2" decimals="-3" id="f-188" unitRef="usd">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-26572000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-2" decimals="-3" id="f-190" unitRef="usd">-30741000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <meso:InvestmentInFixedAssets contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-194000</meso:InvestmentInFixedAssets>
    <meso:InvestmentInFixedAssets contextRef="c-2" decimals="-3" id="f-192" unitRef="usd">-187000</meso:InvestmentInFixedAssets>
    <meso:ReceiptsFromInvestmentInSublease contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">116000</meso:ReceiptsFromInvestmentInSublease>
    <meso:ReceiptsFromInvestmentInSublease contextRef="c-2" decimals="-3" id="f-194" unitRef="usd">0</meso:ReceiptsFromInvestmentInSublease>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">10000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c-2" decimals="-3" id="f-196" unitRef="usd">50000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-88000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-2" decimals="-3" id="f-198" unitRef="usd">-237000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <meso:PaymentsOfTransactionCostsFromBorrowings contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">540000</meso:PaymentsOfTransactionCostsFromBorrowings>
    <meso:PaymentsOfTransactionCostsFromBorrowings contextRef="c-2" decimals="-3" id="f-200" unitRef="usd">217000</meso:PaymentsOfTransactionCostsFromBorrowings>
    <meso:InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">2845000</meso:InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities>
    <meso:InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities contextRef="c-2" decimals="-3" id="f-202" unitRef="usd">2807000</meso:InterestAndOtherCostsOfFinancePaidClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">39708000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-2" decimals="-3" id="f-204" unitRef="usd">45065000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">2578000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-2" decimals="-3" id="f-206" unitRef="usd">2646000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">2145000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-2" decimals="-3" id="f-208" unitRef="usd">1109000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">31600000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-2" decimals="-3" id="f-210" unitRef="usd">38286000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">4940000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-2" decimals="-3" id="f-212" unitRef="usd">7308000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-213" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-9" decimals="-3" id="f-214" unitRef="usd">60447000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">1296000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-216" unitRef="usd">-136000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-217" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-22" decimals="-3" id="f-218" unitRef="usd">67619000</ifrs-full:CashAndCashEquivalents>
    <meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock contextRef="c-1" id="f-220">Basis of preparation&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. The condensed consolidated financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Accounting Standard IAS 34 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), and are unaudited. These condensed interim financial statements do not include all of the notes and disclosures required by International Financial Reporting Standards, as issued by the IASB, for annual consolidated financial statements and should therefore be read in conjunction with our annual report on Form 20-F for the year ended June&#160;30, 2023. In the opinion of management, the interim financial data includes all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the results for the interim periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Going concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Group held total cash reserves of $77.6 million. During the six months ended December 31, 2023, the Group executed on reprioritization of projects and operational streamlining activities and as a result has reduced net cash usage for operating activities, which was $26.6 million the six months ended December&#160;31, 2023, a reduction of 14% compared to the prior period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In line with the Group's overall commercial strategy to complete additional pivotal clinical studies for both the Group's chronic lower back pain and steroid-refractory acute graft versus host disease ("SR-aGVHD") product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#x201c;PCAOB&#x201d;) standards) on the Group&#x2019;s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Historical cost convention&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income, financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;New and amended standards adopted by the Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new or amended standards adopted by the Group in the six months ended December&#160;31, 2023. These interim financial statements follow the same accounting policies as compared to the June&#160;30, 2023 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;New accounting standards and interpretations not yet adopted by the Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting standards and interpretations not yet adopted by the Group for the December&#160;31, 2023 reporting period that are expected to materially impact the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(v)&#160;&#160;&#160;&#160;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(vi)&#160;&#160;&#160;&#160;Impact of after effects of COVID-19 and geopolitical instability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group&#x2019;s significant accounting estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with relevant collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the effects of the COVID-19 pandemic and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group&#x2019;s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.&lt;/span&gt;&lt;/div&gt;</meso:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatoryPolicyTextBlock>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-219">Basis of preparation&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mesoblast Limited is a for-profit entity for the purpose of preparing the financial statements. The condensed consolidated financial statements of Mesoblast Limited and its subsidiaries have been prepared in accordance with International Accounting Standard IAS 34 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;), and are unaudited. These condensed interim financial statements do not include all of the notes and disclosures required by International Financial Reporting Standards, as issued by the IASB, for annual consolidated financial statements and should therefore be read in conjunction with our annual report on Form 20-F for the year ended June&#160;30, 2023. In the opinion of management, the interim financial data includes all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the results for the interim periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Going concern &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Group held total cash reserves of $77.6 million. During the six months ended December 31, 2023, the Group executed on reprioritization of projects and operational streamlining activities and as a result has reduced net cash usage for operating activities, which was $26.6 million the six months ended December&#160;31, 2023, a reduction of 14% compared to the prior period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In line with the Group's overall commercial strategy to complete additional pivotal clinical studies for both the Group's chronic lower back pain and steroid-refractory acute graft versus host disease ("SR-aGVHD") product candidates, additional inflows from capital markets, royalty monetization, strategic partnerships or product specific financing will be required to meet the Group's projected expenditure consistent with the Group's business strategy over at least the next 12 months. As a result of these matters, there is material uncertainty related to events or conditions that may cast significant doubt (or raise substantial doubt as contemplated by Public Company Accounting Oversight Board (&#x201c;PCAOB&#x201d;) standards) on the Group&#x2019;s ability to continue as a going concern and, therefore, that the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Historical cost convention&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets at fair value through other comprehensive income, financial assets and liabilities (including derivative instruments) at fair value through profit or loss, certain classes of property, plant and equipment and investment property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;New and amended standards adopted by the Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new or amended standards adopted by the Group in the six months ended December&#160;31, 2023. These interim financial statements follow the same accounting policies as compared to the June&#160;30, 2023 consolidated financial statements and related notes as filed with the Australian Securities Exchange and the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;New accounting standards and interpretations not yet adopted by the Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting standards and interpretations not yet adopted by the Group for the December&#160;31, 2023 reporting period that are expected to materially impact the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(v)&#160;&#160;&#160;&#160;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these consolidated financial statements requires the Group to make estimates and judgments that affect the reported amounts of assets, liabilities, income and expenses and related disclosures. On an ongoing basis, the Group evaluates its significant accounting policies and estimates. Estimates are based on historical experience and on various market-specific and other relevant assumptions that the Group believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(vi)&#160;&#160;&#160;&#160;Impact of after effects of COVID-19 and geopolitical instability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the after effects of the COVID-19 pandemic could have on the Group&#x2019;s significant accounting estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is having to account for the after effects of the COVID-19 pandemic on healthcare network, which have been and may continue to be impacted by the pandemic with respect to patient care, operations/staffing, financials, and health and safety protocols. These impacts change the way that Mesoblast will have to engage with relevant collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the effects of the COVID-19 pandemic and recent geopolitical instability, countries in which the Group has operations have experienced some challenges in the ability of the Group&#x2019;s suppliers and contractors to source, supply or acquire raw materials or components needed for its manufacturing process and supply chain. As a result, the manufacturing and commercialization of remestemcel-L and other product candidates could be adversely affected.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-5" id="f-221" unitRef="usd">77600000</ifrs-full:CashAndCashEquivalents>
    <meso:MaximumAmountInCashOutflowsFromOperatingActivities contextRef="c-1" decimals="-5" id="f-222" unitRef="usd">26600000</meso:MaximumAmountInCashOutflowsFromOperatingActivities>
    <meso:PercentageOfReductionInCashOutflowsFromOperatingActivities contextRef="c-1" decimals="2" id="f-223" unitRef="number">0.14</meso:PercentageOfReductionInCashOutflowsFromOperatingActivities>
    <meso:DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock contextRef="c-1" id="f-224">Significant changes in the current reporting period&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Significant events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial position and performance of the Group was affected by the following event during the six months ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;In August 2023, the FDA provided a complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD and requires more data to support marketing approval, including potency assay or clinical data. In line with the Group's overall commercial strategy to progress to adult populations, the Group intends to conduct a targeted, controlled study in the highest-risk adults with the greatest mortality. Assumptions associated with SR-aGVHD are included within the impairment assessment of MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. The Group assessed and included the impact of the FDA's complete response to the Group's BLA resubmission for remestemcel-L for the treatment of pediatric SR-aGVHD in these areas within the Form 20-F for the year ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;In September 2023, the Group provided an update on the path to approval for lead-product candidate remestemcel-L in the treatment of pediatric and adult SR-aGvHD, following a Type A meeting held with FDA.  Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD within the impairment assessment of MSC products within in-process research and development and goodwill, contingent consideration, pre-launch inventory and the NovaQuest borrowings on the consolidated balance sheet and forecast net operating cash usage. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;In December 2023 the Group completed an institutional placement together with a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing eligible shareholders, raising A$60.3&#160;million at an issue price of A$0.30 per share. In December 2023, proceeds of $39.7&#160;million (A$60.3&#160;million) were received and recognized in cash and cash equivalents.</meso:DisclosureOfSignificantChangesInCurrentReportingPeriodExplanatoryTextBlock>
    <meso:NumberOfSharesIssuedAndFullyPaidValue contextRef="c-42" decimals="-5" id="f-225" unitRef="aud">60300000</meso:NumberOfSharesIssuedAndFullyPaidValue>
    <ifrs-full:ParValuePerShare
      contextRef="c-42"
      decimals="2"
      id="f-226"
      unitRef="audPerShare">0.30</ifrs-full:ParValuePerShare>
    <meso:ProceedsFromPrivatePlacement contextRef="c-1" decimals="-5" id="f-227" unitRef="usd">39700000</meso:ProceedsFromPrivatePlacement>
    <meso:NumberOfSharesIssuedAndFullyPaidValue contextRef="c-42" decimals="-5" id="f-228" unitRef="aud">60300000</meso:NumberOfSharesIssuedAndFullyPaidValue>
    <meso:DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock contextRef="c-1" id="f-230">Loss before income tax&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercialization revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,422&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical trial and research &amp;amp; development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(4,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing production &amp;amp; development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salaries and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined contribution superannuation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity settled share-based payment transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(12,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation and amortization of non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plant and equipment depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Depreciation and amortization of non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Management &amp;amp; administration expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Overheads &amp;amp; administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,594)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consultancy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal and other professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property expenses (excluding the amount amortized above)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Other Management &amp;amp; administration expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Fair value remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance (costs)/gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of borrowing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Finance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(10,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(10,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total loss before income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(32,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(41,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Share-based payment transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December&#160;31, 2023 and 2022, the share-based payment transactions have been reflected in the Consolidated Income Statement functional expense categories as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,104,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;797,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing and commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(183,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,043,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,143,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity settled share-based payment transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,195,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,756,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Change in comparative figures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December 31, 2022, the Group reclassified immaterial amounts within Other Management and administration expenses. The Group does not believe these reclassifications to be material to the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gr&#xfc;nenthal arrangement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Group entered into a strategic partnership with Gr&#xfc;nenthal for the development and commercialization in Europe and Latin America of the Group&#x2019;s allogeneic mesenchymal precursor cell (&#x201c;MPC&#x201d;) product, MPC-06-ID, receiving exclusive rights to the Phase 3 allogeneic product candidate for the treatment of low back pain due to degenerative disc disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group received a non-refundable upfront payment of $15.0 million in October 2019, on signing of the contract with Gr&#xfc;nenthal. The Group received a milestone payment in December 2019 of $2.5 million in relation to meeting a milestone event as part of the strategic partnership with Gr&#xfc;nenthal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Group announced its intention to leverage the results from a planned US trial to support potential product approvals in both the US and EU by including 20% EU patients in order to provide regulatory harmonization, cost efficiencies and streamlined timelines, without initiating an EU trial. As a result, the strategic partnership with Gr&#xfc;nenthal has been amended, and milestone payments relating to R&amp;amp;D and CMC services and other development services which were linked to the Europe trial have been removed, instead the Group is eligible to receive payments up to US$112.5 million prior to product launch in the EU, inclusive of US$17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved. Cumulative milestone payments could reach US$1 billion depending on the final outcome of Phase 3 studies and patient adoption. The Group will also receive tiered double-digit royalties on product sales as per the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $2.5 million milestone payment received in December 2019 from Gr&#xfc;nenthal was considered deferred consideration as of December&#160;31, 2023. The performance obligation for the $2.5 million was previously satisfied under the original agreement, however under the amended agreement with Gr&#xfc;nenthal it is subject to repayment to Gr&#xfc;nenthal. Revenue will be recognized when the clinical trial has recruited the required amount of European patients, as the $2.5 million will no longer be subject to repayment to Gr&#xfc;nenthal. For the six months ended December&#160;31, 2023 and 2022, respectively, no milestone revenue was recognized in relation to this strategic partnership with Gr&#xfc;nenthal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tasly arrangement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Group entered into a strategic alliance with Tasly Pharmaceutical Group (&#x201c;Tasly&#x201d;) for the development, manufacture and commercialization in China of the Group&#x2019;s allogeneic mesenchymal precursor cell (&#x201c;MPC&#x201d;) products, MPC-150-IM and MPC-25-IC. Tasly received all exclusive rights for MPC-150-IM and MPC-25-IC in China and Tasly will fund all development, manufacturing and commercialization activities in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group received a $20.0 million up-front technology access fee from Tasly upon closing of this strategic alliance in October 2018. The Group recognized  $10.0 million from this $20.0 million up-front technology access fee at closing in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;October 2018 and the remaining $10.0 million was recognized in revenue in February 2020. The Group is also entitled to receive $25.0 million on product regulatory approvals in China, double-digit escalating royalties on net product sales and up to six escalating milestone payments when the product candidates reach certain sales thresholds in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December&#160;31, 2023 and 2022, respectively, no revenue was recognized in relation to this strategic alliance with Tasly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TiGenix arrangement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Group entered into a patent license agreement with TiGenix NV (&#x201c;TiGenix&#x201d;), now a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), which granted Takeda exclusive access to certain of our patents to support global commercialization of the adipose-derived mesenchymal stem cell (&#x201c;MSC") product, Alofisel&#xae; a registered trademark of TiGenix, previously known as Cx601, for the local treatment of fistulae. The agreement includes the right for Takeda to grant sub-licenses to affiliates and third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group received a $5.9&#160;million (&#x20ac;5.0&#160;million) up-front payment upon entering the patent license agreement and a further payment of $5.9&#160;million (&#x20ac;5.0&#160;million) 12 months after the patent license agreement date. In September 2021, the Group received a milestone payment of $1.2&#160;million (&#x20ac;1.0&#160;million) upon Takeda receiving approval to manufacture and market Alofisel&#xae; in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's Disease. The Group is entitled to further payments up to &#x20ac;9.0 million when Takeda reaches certain product regulatory milestones. Additionally, the Group receives single digit royalties on net sales of Alofisel&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December&#160;31, 2023 and 2022, the Group earned $0.2 million and $0.2 million, respectively, of royalty income on sales of Alofisel&#xae; in Europe by our licensee Takeda.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December&#160;31, 2023 and 2022, respectively, no milestone revenue was recognized in relation to the Group's patent license agreement with Takeda. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;JCR arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Group acquired all of the culture-expanded, MSC-based assets from Osiris Therapeutics, Inc. These assets included assumption of a collaboration agreement with JCR, a research and development oriented pharmaceutical company in Japan. Revenue recognized under this agreement is limited to the amount of cash received or for which the Group is entitled, as JCR has the right to terminate the agreement at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the JCR Agreement, JCR is responsible for all development and manufacturing costs including sales and marketing expenses. Under the JCR Agreement, JCR has the right to develop our MSCs in two fields for the Japanese market: exclusive in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow, or the First JCR Field; and non-exclusive for developing assays that use liver cells for non-clinical drug screening and evaluation, or the Second JCR Field. With respect to the First JCR Field, the Group are entitled to payments when JCR reaches certain commercial milestones and to escalating double-digit royalties. These royalties are subject to possible renegotiation downward in the event of competition from non-infringing products in Japan. With respect to the Second JCR Field, the Group are entitled to a double-digit profit share. The Group expanded our partnership with JCR in Japan for two new indications: for wound healing in patients with Epidermolysis Bullosa (&#x201c;EB&#x201d;) in October 2018 and for hypoxic ischemic encephalopathy (&#x201c;HIE&#x201d;), a condition suffered by newborns who lack sufficient blood supply and oxygen to the brain, in June 2020. The Group will receive royalties on TEMCELL&#xae; Hs. Inj. (&#x201c;TEMCELL&#x201d;), a registered trademark of JCR product sales for EB and HIE, if and when JCR begins selling TEMCELL for such indications in Japan. The Group apply the sales-based and usage-based royalty exception for licenses of intellectual property and therefore recognizes royalty revenue at the later of when the subsequent sale or usage occurs and the associated performance obligation has been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the six months ended December&#160;31, 2023, the Group recognized $3.2 million in commercialization revenue relating to royalty income earned on sales of TEMCELL in Japan by our licensee JCR, compared with $3.2 million for the six months ended December&#160;31, 2022. These amounts were recorded in revenue as there are no further performance obligations required in regard to these items. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are included in the financial statements at the lower of cost (including raw materials, direct labor, other direct costs and related production overheads) and net realizable value. Pre-launch inventory is held as an asset when there is a high probability of regulatory approval for the product in accordance with IAS 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Before that point, a provision is made against the carrying value to its recoverable amount in accordance with IAS 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; the provision is then reversed at the point when a high probability of regulatory approval is determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group considers a number of factors in determining the probability of the product candidate realizing future economic benefit, including the product candidate&#x2019;s current status in the regulatory approval process, results from the related pivotal clinical trial, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, the market need, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, commercialization and market trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When a provision is made against the carrying value of pre-launch inventory the costs are recognized within Manufacturing Commercialization expenses. When the high probability threshold is met, the provision will be reversed through Manufacturing Commercialization expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All inventory costs are currently fully provided for and are recognized within Manufacturing Commercialization expenses. Where it is determined that the pre-launch inventory will be used within a clinical trial, that amount is removed from the cost of pre-launch inventory. There is no impact on the consolidated income statement as the carrying value has been previously fully provided for.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $21.6 million of pre-launch inventory recognized on the balance sheet that was fully provided for, compared with $22.4 million at June&#160;30, 2023. The future commercial use of the pre-launch inventory recognized on the consolidated balance sheet will be dependent on future discussions with the FDA and remains fully provided for.  &lt;/span&gt;&lt;/div&gt;For the six months ended December&#160;31, 2023, the Group reversed $0.8 million of pre-launch inventory costs within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory, primarily due to a reallocation of pre-launch inventory costs for use in clinical trials. For the six months ended December 31, 2022, $1.6 million of pre-launch inventory costs have been recognized within Manufacturing Commercialization expenses in relation to the provision against the carrying value of pre-launch inventory.</meso:DisclosureOfDetailedInformationAboutLossBeforeIncomeTaxExplanatoryTextBlock>
    <meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock contextRef="c-1" id="f-231">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercialization revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,422&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical trial and research &amp;amp; development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(4,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing production &amp;amp; development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salaries and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defined contribution superannuation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity settled share-based payment transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(12,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Depreciation and amortization of non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plant and equipment depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Depreciation and amortization of non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Management &amp;amp; administration expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Overheads &amp;amp; administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,594)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consultancy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal and other professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property expenses (excluding the amount amortized above)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Other Management &amp;amp; administration expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(8,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Fair value remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,989&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Fair value remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains/(losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Other operating income and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,068&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance (costs)/gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of borrowing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Finance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(10,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(10,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total loss before income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(32,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(41,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Share-based payment transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December&#160;31, 2023 and 2022, the share-based payment transactions have been reflected in the Consolidated Income Statement functional expense categories as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,104,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;797,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Manufacturing and commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(183,720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,043,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,143,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity settled share-based payment transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,195,436&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,756,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Change in comparative figures&lt;/span&gt;&lt;/div&gt;For the six months ended December 31, 2022, the Group reclassified immaterial amounts within Other Management and administration expenses. The Group does not believe these reclassifications to be material to the consolidated financial statements.</meso:DisclosureOfLossBeforeIncomeTaxExplanatoryTableTextBlock>
    <meso:CommercializationRevenue contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">3388000</meso:CommercializationRevenue>
    <meso:CommercializationRevenue contextRef="c-2" decimals="-3" id="f-233" unitRef="usd">3422000</meso:CommercializationRevenue>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">3388000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-3" id="f-235" unitRef="usd">3422000</ifrs-full:Revenue>
    <meso:ClinicalTrialRelatedResearchAndDevelopment contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">2045000</meso:ClinicalTrialRelatedResearchAndDevelopment>
    <meso:ClinicalTrialRelatedResearchAndDevelopment contextRef="c-2" decimals="-3" id="f-237" unitRef="usd">4067000</meso:ClinicalTrialRelatedResearchAndDevelopment>
    <meso:ManufacturingProductionAndDevelopment contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">5484000</meso:ManufacturingProductionAndDevelopment>
    <meso:ManufacturingProductionAndDevelopment contextRef="c-2" decimals="-3" id="f-239" unitRef="usd">11717000</meso:ManufacturingProductionAndDevelopment>
    <ifrs-full:WagesAndSalaries contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">10096000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="c-2" decimals="-3" id="f-241" unitRef="usd">9842000</ifrs-full:WagesAndSalaries>
    <meso:DefinedContributionSuperannuationExpenses contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">199000</meso:DefinedContributionSuperannuationExpenses>
    <meso:DefinedContributionSuperannuationExpenses contextRef="c-2" decimals="-3" id="f-243" unitRef="usd">186000</meso:DefinedContributionSuperannuationExpenses>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">2195000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-2" decimals="-3" id="f-245" unitRef="usd">1757000</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">12490000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-2" decimals="-3" id="f-247" unitRef="usd">11785000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">281000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-249" unitRef="usd">565000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">1420000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-2" decimals="-3" id="f-251" unitRef="usd">875000</ifrs-full:DepreciationRightofuseAssets>
    <meso:IntellectualPropertyAmortization contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">742000</meso:IntellectualPropertyAmortization>
    <meso:IntellectualPropertyAmortization contextRef="c-2" decimals="-3" id="f-253" unitRef="usd">750000</meso:IntellectualPropertyAmortization>
    <ifrs-full:AmortisationExpense contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">2443000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-2" decimals="-3" id="f-255" unitRef="usd">2190000</ifrs-full:AmortisationExpense>
    <meso:OverheadsAndAdministrationExpenses contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">4594000</meso:OverheadsAndAdministrationExpenses>
    <meso:OverheadsAndAdministrationExpenses contextRef="c-2" decimals="-3" id="f-257" unitRef="usd">5187000</meso:OverheadsAndAdministrationExpenses>
    <meso:ConsultancyExpenses contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">1285000</meso:ConsultancyExpenses>
    <meso:ConsultancyExpenses contextRef="c-2" decimals="-3" id="f-259" unitRef="usd">1967000</meso:ConsultancyExpenses>
    <meso:LegalAndOtherProfessionalFees contextRef="c-1" decimals="-3" id="f-260" unitRef="usd">1124000</meso:LegalAndOtherProfessionalFees>
    <meso:LegalAndOtherProfessionalFees contextRef="c-2" decimals="-3" id="f-261" unitRef="usd">1053000</meso:LegalAndOtherProfessionalFees>
    <meso:IntellectualPropertyExpenses contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">1410000</meso:IntellectualPropertyExpenses>
    <meso:IntellectualPropertyExpenses contextRef="c-2" decimals="-3" id="f-263" unitRef="usd">1505000</meso:IntellectualPropertyExpenses>
    <meso:OtherManagementAndAdministrationExpenses contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">8413000</meso:OtherManagementAndAdministrationExpenses>
    <meso:OtherManagementAndAdministrationExpenses contextRef="c-2" decimals="-3" id="f-265" unitRef="usd">9712000</meso:OtherManagementAndAdministrationExpenses>
    <meso:LossGainOnRemeasurementOfContingentConsideration contextRef="c-1" decimals="-3" id="f-266" unitRef="usd">337000</meso:LossGainOnRemeasurementOfContingentConsideration>
    <meso:LossGainOnRemeasurementOfContingentConsideration contextRef="c-2" decimals="-3" id="f-267" unitRef="usd">-5989000</meso:LossGainOnRemeasurementOfContingentConsideration>
    <meso:FairValueRemeasurementOfContingentConsideration contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">337000</meso:FairValueRemeasurementOfContingentConsideration>
    <meso:FairValueRemeasurementOfContingentConsideration contextRef="c-2" decimals="-3" id="f-269" unitRef="usd">-5989000</meso:FairValueRemeasurementOfContingentConsideration>
    <meso:LossGainOnRemeasurementOfWarrantLiability contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">-4434000</meso:LossGainOnRemeasurementOfWarrantLiability>
    <meso:LossGainOnRemeasurementOfWarrantLiability contextRef="c-2" decimals="-3" id="f-271" unitRef="usd">712000</meso:LossGainOnRemeasurementOfWarrantLiability>
    <meso:FairValueRemeasurementOfWarrantLiability contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">-4434000</meso:FairValueRemeasurementOfWarrantLiability>
    <meso:FairValueRemeasurementOfWarrantLiability contextRef="c-2" decimals="-3" id="f-273" unitRef="usd">712000</meso:FairValueRemeasurementOfWarrantLiability>
    <ifrs-full:RevenueFromInterest contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">903000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c-2" decimals="-3" id="f-275" unitRef="usd">214000</ifrs-full:RevenueFromInterest>
    <meso:ForeignExchangeGainsLosses contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">165000</meso:ForeignExchangeGainsLosses>
    <meso:ForeignExchangeGainsLosses contextRef="c-2" decimals="-3" id="f-277" unitRef="usd">-253000</meso:ForeignExchangeGainsLosses>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-278" unitRef="usd">1068000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense contextRef="c-2" decimals="-3" id="f-279" unitRef="usd">-39000</ifrs-full:OtherOperatingIncomeExpense>
    <meso:FinanceCostsGainsOnRemeasurementOfBorrowingArrangements contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">-120000</meso:FinanceCostsGainsOnRemeasurementOfBorrowingArrangements>
    <meso:FinanceCostsGainsOnRemeasurementOfBorrowingArrangements contextRef="c-2" decimals="-3" id="f-281" unitRef="usd">-1230000</meso:FinanceCostsGainsOnRemeasurementOfBorrowingArrangements>
    <ifrs-full:InterestExpense contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">10199000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c-2" decimals="-3" id="f-283" unitRef="usd">9455000</ifrs-full:InterestExpense>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">10319000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-2" decimals="-3" id="f-285" unitRef="usd">10685000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-32641000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-2" decimals="-3" id="f-287" unitRef="usd">-41496000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-43" decimals="0" id="f-288" unitRef="usd">1104007</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-44" decimals="0" id="f-289" unitRef="usd">797058</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-45" decimals="0" id="f-290" unitRef="usd">48064</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-46" decimals="0" id="f-291" unitRef="usd">-183720</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-47" decimals="0" id="f-292" unitRef="usd">1043365</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-48" decimals="0" id="f-293" unitRef="usd">1143560</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-49" decimals="0" id="f-294" unitRef="usd">2195436</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions contextRef="c-50" decimals="0" id="f-295" unitRef="usd">1756898</ifrs-full:DecreaseIncreaseThroughTaxOnSharebasedPaymentTransactions>
    <meso:NonRefundableUpFrontPaymentReceived contextRef="c-51" decimals="-5" id="f-296" unitRef="usd">15000000</meso:NonRefundableUpFrontPaymentReceived>
    <meso:MilestonePaymentReceived contextRef="c-52" decimals="-5" id="f-297" unitRef="usd">2500000</meso:MilestonePaymentReceived>
    <meso:PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines contextRef="c-53" decimals="2" id="f-298" unitRef="number">0.20</meso:PercentageOfPatientsToProvideRegulatoryHarmonizationCostEfficienciesAndStreamlinedTimelines>
    <meso:AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved contextRef="c-54" decimals="-5" id="f-299" unitRef="usd">112500000</meso:AmountEntitledToBeReceivedUponReachingProductClinicalAndRegulatoryMilestonesAndReimbursementTargetsAreAchieved>
    <meso:NonRefundableUpfrontPaymentsReceivable contextRef="c-53" decimals="-5" id="f-300" unitRef="usd">17500000</meso:NonRefundableUpfrontPaymentsReceivable>
    <meso:CumulativeMilestonePaymentsReachableAmount contextRef="c-53" decimals="-9" id="f-301" unitRef="usd">1000000000</meso:CumulativeMilestonePaymentsReachableAmount>
    <meso:MilestonePaymentReceived contextRef="c-52" decimals="-5" id="f-302" unitRef="usd">2500000</meso:MilestonePaymentReceived>
    <meso:MilestonePaymentReceived contextRef="c-52" decimals="-5" id="f-303" unitRef="usd">2500000</meso:MilestonePaymentReceived>
    <meso:MilestonePaymentReceived contextRef="c-52" decimals="-5" id="f-304" unitRef="usd">2500000</meso:MilestonePaymentReceived>
    <meso:RevenueRecognizedForRightOfUseLicenseOfIP contextRef="c-55" decimals="INF" id="f-305" unitRef="usd">0</meso:RevenueRecognizedForRightOfUseLicenseOfIP>
    <meso:RevenueRecognizedForRightOfUseLicenseOfIP contextRef="c-56" decimals="INF" id="f-306" unitRef="usd">0</meso:RevenueRecognizedForRightOfUseLicenseOfIP>
    <meso:DeferredConsiderationMilestoneConsiderationRecognized contextRef="c-57" decimals="-5" id="f-307" unitRef="usd">20000000</meso:DeferredConsiderationMilestoneConsiderationRecognized>
    <meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration contextRef="c-57" decimals="-5" id="f-308" unitRef="usd">10000000</meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration>
    <meso:DeferredConsiderationMilestoneConsiderationRecognized contextRef="c-57" decimals="-5" id="f-309" unitRef="usd">20000000</meso:DeferredConsiderationMilestoneConsiderationRecognized>
    <meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration contextRef="c-58" decimals="-5" id="f-310" unitRef="usd">10000000</meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration>
    <meso:AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone contextRef="c-59" decimals="-5" id="f-311" unitRef="usd">25000000</meso:AmountEntitledToBeReceivedOnNonRefundableUpfrontPaymentUponReachingProductRegulatoryMilestone>
    <meso:NumberOfEscalatingMilestonePayments
      contextRef="c-59"
      decimals="INF"
      id="f-312"
      unitRef="milestone">6</meso:NumberOfEscalatingMilestonePayments>
    <meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration contextRef="c-60" decimals="INF" id="f-313" unitRef="usd">0</meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration>
    <meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration contextRef="c-61" decimals="INF" id="f-314" unitRef="usd">0</meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration>
    <ifrs-full:CurrentContractLiabilities contextRef="c-62" decimals="-5" id="f-315" unitRef="usd">5900000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-62" decimals="-5" id="f-316" unitRef="eur">5000000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-62" decimals="-5" id="f-317" unitRef="usd">5900000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-62" decimals="-5" id="f-318" unitRef="eur">5000000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-63" decimals="-5" id="f-319" unitRef="usd">1200000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-63" decimals="-5" id="f-320" unitRef="eur">1000000</ifrs-full:RevenueFromContractsWithCustomers>
    <meso:RevenueRemainingPerformanceObligationVariableConsiderationAmount contextRef="c-64" decimals="-5" id="f-321" unitRef="eur">9000000</meso:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <ifrs-full:RevenueFromRoyalties contextRef="c-65" decimals="-5" id="f-322" unitRef="usd">200000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="c-66" decimals="-5" id="f-323" unitRef="usd">200000</ifrs-full:RevenueFromRoyalties>
    <meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration contextRef="c-60" decimals="INF" id="f-324" unitRef="usd">0</meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration>
    <meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration contextRef="c-61" decimals="INF" id="f-325" unitRef="usd">0</meso:RevenueRecognizedFromUpfrontPaymentAsDeferredConsideration>
    <meso:RoyaltiesReceivableUnderSalesBasedMilestones contextRef="c-67" decimals="-5" id="f-326" unitRef="usd">3200000</meso:RoyaltiesReceivableUnderSalesBasedMilestones>
    <meso:RoyaltiesReceivableUnderSalesBasedMilestones contextRef="c-68" decimals="-5" id="f-327" unitRef="usd">3200000</meso:RoyaltiesReceivableUnderSalesBasedMilestones>
    <meso:PreLaunchInventoryRecognized contextRef="c-41" decimals="-5" id="f-328" unitRef="usd">21600000</meso:PreLaunchInventoryRecognized>
    <meso:PreLaunchInventoryRecognized contextRef="c-29" decimals="-5" id="f-329" unitRef="usd">22400000</meso:PreLaunchInventoryRecognized>
    <meso:PreLaunchInventoryRecognized contextRef="c-69" decimals="-5" id="f-330" unitRef="usd">-800000</meso:PreLaunchInventoryRecognized>
    <meso:PreLaunchInventoryRecognized contextRef="c-70" decimals="-5" id="f-331" unitRef="usd">1600000</meso:PreLaunchInventoryRecognized>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-332">Income tax benefit/(expense)&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total current tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Increase)/decrease in deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Decrease)/increase in deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets have been brought to account only to the extent that it is foreseeable that they are recoverable against future tax liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized for unused tax losses to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilized. Deferred tax assets are offset against taxable temporary &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;differences (deferred tax liabilities) when the deferred tax balances relate to the same tax jurisdiction in accordance with our accounting policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred taxes are measured at the rate in which they are expected to settle within the respective jurisdictions, which can change based on factors such as new legislation or timing of utilization and reversal of associated assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets not brought to account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unused tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential tax benefit at local tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential tax benefit at local tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential tax benefit at local tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;151,699&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;141,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total current tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Increase)/decrease in deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Decrease)/increase in deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income tax (benefit)/expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutIncomeTaxExplanatoryTableTextBlock>
    <meso:IncreaseDecreaseInCurrentTax contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">0</meso:IncreaseDecreaseInCurrentTax>
    <meso:IncreaseDecreaseInCurrentTax contextRef="c-2" decimals="-3" id="f-335" unitRef="usd">0</meso:IncreaseDecreaseInCurrentTax>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">0</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods contextRef="c-2" decimals="-3" id="f-337" unitRef="usd">0</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <meso:IncreaseDecreaseInDeferredTaxAssets contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">22000</meso:IncreaseDecreaseInDeferredTaxAssets>
    <meso:IncreaseDecreaseInDeferredTaxAssets contextRef="c-2" decimals="-3" id="f-339" unitRef="usd">0</meso:IncreaseDecreaseInDeferredTaxAssets>
    <meso:IncreaseDecreaseInDeferredTaxLiabilities contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">-124000</meso:IncreaseDecreaseInDeferredTaxLiabilities>
    <meso:IncreaseDecreaseInDeferredTaxLiabilities contextRef="c-2" decimals="-3" id="f-341" unitRef="usd">-126000</meso:IncreaseDecreaseInDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">-102000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c-2" decimals="-3" id="f-343" unitRef="usd">-126000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">-102000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-2" decimals="-3" id="f-345" unitRef="usd">-126000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <meso:DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets not brought to account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unused tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential tax benefit at local tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;125,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential tax benefit at local tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential tax benefit at local tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;151,699&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;141,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfDeferredTaxAssetsNotBroughtToAccountExplanatoryTableTextBlock>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-41" decimals="-3" id="f-347" unitRef="usd">134682000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-29" decimals="-3" id="f-348" unitRef="usd">125728000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c-41" decimals="-3" id="f-349" unitRef="usd">13797000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures contextRef="c-29" decimals="-3" id="f-350" unitRef="usd">12318000</ifrs-full:TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures>
    <meso:OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-41" decimals="-3" id="f-351" unitRef="usd">3220000</meso:OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <meso:OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-29" decimals="-3" id="f-352" unitRef="usd">3220000</meso:OtherTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <meso:DeferredTaxAssetsNotBroughtToAccount contextRef="c-41" decimals="-3" id="f-353" unitRef="usd">151699000</meso:DeferredTaxAssetsNotBroughtToAccount>
    <meso:DeferredTaxAssetsNotBroughtToAccount contextRef="c-29" decimals="-3" id="f-354" unitRef="usd">141266000</meso:DeferredTaxAssetsNotBroughtToAccount>
    <meso:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock contextRef="c-1" id="f-355">Financial assets and liabilities&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This note provides information about the Group's financial instruments, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;an overview of all financial instruments held by the Group;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;specific information about each type of financial instrument;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;accounting policies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;information used to determine the fair value of the instruments, including judgments and estimation uncertainty involved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group holds the following financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial assets&lt;br/&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVTPL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets at &lt;br/&gt;amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash &amp;amp; cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade &amp;amp; other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;83,793&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;84,619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash &amp;amp; cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade &amp;amp; other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;80,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;82,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through profit or loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;br/&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVTPL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities at &lt;br/&gt;amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;126,522&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;145,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;128,908&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;151,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through other comprehensive income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through profit or loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group&#x2019;s exposure to various risks associated with the financial instruments is discussed in Note 9. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits at call&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;77,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;71,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;As of December&#160;31, 2023 and June&#160;30, 2023, interest-bearing deposits at call include amounts of $0.4 million and $0.4 million, respectively, held as security and restricted for use.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Classification as cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&#160;&#160;&#160;&#160;Trade and other receivables and prepayments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Trade and other receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade debtors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax incentives recoverable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign withholding tax recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment in sublease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recoverable taxes (Goods and services tax and value-added tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,998&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,998&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(1) Research and development tax incentive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group's research and development activities are eligible under the Australian government's Innovation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Australia Research and Development Tax Incentive program for research and development activities conducted in relation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia. The tax incentives recoverable as of December 31, 2023 pertains to an estimate for the year ended June 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Prepayments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial research and development expenditure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance and subscriptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,602&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Classification as trade and other receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade receivables and other receivables represent the principal amounts due at balance date less, where applicable, any provision for expected credit losses. The Group uses the simplified approach to measuring expected credit losses, which uses a lifetime expected credit loss allowance. Debts which are known to be uncollectible are written off in the consolidated income statement. All trade receivables and other receivables are recognized at the value of the amounts receivable, as they are due for settlement within 60 days and therefore do not require remeasurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;Fair values of trade and other receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of the current receivables, their carrying amount is assumed to be the same as their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(v)&#160;&#160;&#160;&#160;Impairment and risk exposure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information about the impairment of trade and other receivables, their credit quality and the Group&#x2019;s exposure to credit risk, foreign currency risk and interest rate risk can be found in Note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c.&#160;&#160;&#160;&#160;Trade and other payables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,760&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;20,145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of trade and other payables are assumed to be the same as their fair values, due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;d.&#160;&#160;&#160;&#160;Borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Secured liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of carrying amount, net of payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;115,762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;108,763&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - Oaktree&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - Oaktree&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;107,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;102,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;115,762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;108,763&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Borrowing arrangements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Funds associated with Oaktree Capital Management, L.P. (&#x201c;Oaktree&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Group entered into a $90.0 million five-year senior debt facility provided by funds associated with Oaktree. The Group drew the first tranche of $60.0 million on closing. The conditions required to draw down the additional $30.0 million tranche have not been met. The facility has a three-year interest only period, at a fixed rate of  9.75% per annum, after which time 40% of the principal amortizes over two years and a final payment is due no later than November 2026. The facility also allowed the Group to make quarterly payments of interest at a rate of 8.0% per annum for the first two years, and the unpaid interest portion (1.75% per annum) has been added to the outstanding loan balance and currently accrues further interest at a fixed rate of 9.75% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On November&#160;19, 2021, Oaktree were also granted warrants to purchase 1,769,669 American Depositary Shares (&#x201c;ADSs&#x201d;) at US$7.26 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the debt facility was signed; consequently, a liability for the warrants was recognized in November 2021. The warrants were legally issued on January&#160;11, 2022 and may be exercised within 7 years of issuance. On the issuance date of the Oaktree facility and the warrants, the warrants were initially measured at fair value and the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Oaktree borrowing liability measured as the difference between the $60.0 million received from the Oaktree facility and the fair value of the warrants. In December 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP. The Group determined that an obligation to issue the warrants arose from the time the first amendment to the loan agreement was signed; consequently, a liability for the warrants was recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance.  Refer to Note 5(e)(vi) for more details on warrants issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 5, 2024, the ratio under Mesoblast's American Depository Receipt ("ADR") program was changed from 5 ordinary shares representing 1 ADS (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADS (10:1 ratio). As a result of this ratio change and as a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the number and exercise price for the warrants was adjusted in accordance with the terms of these warrants. The warrants issued in November 2021 changed from 1,769,669 ADSs at US$7.26 per ADS to 884,838 ADSs at US$14.36 per ADS. The warrants issued in December 2022 changed from 455,000 ADSs at US$3.70 per ADS to 227,502 ADSs at US$7.24 per ADS.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the six months ended December&#160;31, 2023, the Group recognized a minimal loss in the Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of the financial liability to reflect the revised estimated future cash flows from the credit facility. In the six months ended December&#160;31, 2022 the Group recognized a loss of $1.4 million in the Income Statement as remeasurement of borrowing arrangements within finance costs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Within this &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$1.4 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; loss, $1.0&#160;million relates to the remeasurement due to additional warrants being issued to Oaktree as a result of the first amendment to the loan agreement and $0.4&#160;million relates to the adjustment of the carrying amount of the financial liability to reflect the revised estimated future cash flows from the credit facility&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Group has pledged substantially all of its assets as collateral under the loan facility with Oaktree. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NovaQuest Capital Management, L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;29, 2018, the Group entered into an eight-year, $40.0 million loan and security agreement with NovaQuest before drawing the first tranche of $30.0 million of the principal in July 2018. The additional $10.0&#160;million from the loan will be drawn on marketing approval of remestemcel-L for the treatment of pediatric patients with SR-aGVHD by the FDA. The loan term included an interest only period of approximately four years through until July 8, 2022. All interest and principal payments (i.e. the amortization period) are deferred until the earlier of loan maturity or from after the first commercial sale of remestemcel-L for the treatment in pediatric patients with SR-aGVHD in the United States and other geographies excluding Asia ("remestemcel-L for pediatric SR-aGVHD"). Principal is repayable in equal quarterly instalments over the amortization period of the loan and is subject to the payment cap described below. The loan has a fixed interest rate of 15% per annum. If there are no net sales of remestemcel-L for pediatric SR-aGVHD, the loan is only repayable at maturity. The Group can elect to prepay all outstanding amounts owing at any time prior to maturity, subject to a prepayment charge. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following approval and first commercial sales, repayments commence based on a percentage of net sales and are limited by a payment cap which is equal to the principal due for the next 12 months, plus accumulated unpaid principal and accrued unpaid interest.  During the four-year period commencing July 8, 2022, principal amortizes in equal quarterly instalments payable only after approval and first commercial sales. If in any quarterly period, 25% of net sales of remestemcel-L for pediatric SR-aGVHD exceed the annual payment cap, the Group will pay the payment cap and an additional portion of excess sales which will be used towards the prepayment amount in the event there is an early prepayment of the loan. If in any quarterly period 25% of net sales of remestemcel-L for pediatric SR-aGVHD is less than the annual payment cap, then the payment is limited to 25% of net sales of remestemcel-L for pediatric SR-aGVHD. Any unpaid interest will be added to the principal amounts owing and shall accrue further interest. At maturity date, any unpaid loan balances are repaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of this relationship of net sales and repayments, changes in our estimated net sales may trigger an adjustment of the carrying amount of the financial liability to reflect the revised estimated cash flows. The carrying amount is recalculated by computing the present value of the revised estimated future cash flows at the financial instrument&#x2019;s original effective interest rate. The adjustment is recognized in the Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the six months ended December&#160;31, 2023 and 2022, the Group recognized a loss of $0.1 million and a gain of $0.2 million, respectively, in the Income Statement as remeasurement of borrowing arrangements within finance costs in relation to the adjustment of the carrying amount of our financial liability to reflect the revised estimated future cash flows as a net result of changes to the key assumptions in development timelines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group recognizes a liability as current based on repayments linked to estimates of sales of remestemcel-L. However, if sales of remestemcel-L are higher than estimated, actual repayments will exceed this amount, subject to the annual payment cap described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the loan and security agreement with NovaQuest is subordinated to the Group&#x2019;s fixed rate loan with the senior creditor, Oaktree. The Group have pledged a portion of our assets relating to the SR-aGVHD product candidate as collateral under the loan facility with NovaQuest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Compliance with loan covenants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loan facilities with Oaktree and NovaQuest contain a number of covenants that impose operating restrictions on us, which may restrict our ability to respond to changes in our business or take specified actions. The Group has an operating objective to at all times maintain unrestricted cash reserves in excess of six months liquidity. The objective aligns with our loan and security agreement with Oaktree where the Group is currently obliged to maintain a minimum unrestricted cash balance of $35.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has complied with the financial and other restrictive covenants of its borrowing facilities during the six months ended December&#160;31, 2023 and during the year ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Net Debt Reconciliation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(115,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(108,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(50,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross debt - fixed interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(121,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross debt - variable interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(50,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Net debt amount includes leases and borrowing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities from financing activities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Borrowings &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Warrant liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sub-total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and cash&lt;br/&gt;equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Debt as at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(108,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(121,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash Flows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Changes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Debt as at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(115,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(6,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(122,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;77,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Other changes include modification of leases and accrued interest expenses for borrowings and leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;Fair values of borrowing arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the borrowings at amortized cost in accordance with our accounting policy is a reasonable approximation of fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;e.&#160;&#160;&#160;&#160;Recognized fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Fair value hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of December&#160;31, 2023 and June&#160;30, 2023 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities - biotech sector&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities - biotech sector&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between any of the levels for recurring fair value measurements during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group&#x2019;s policy is to recognize transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of financial instruments traded in active markets (such as publicly traded derivatives, trading and financial assets at fair value through other comprehensive income securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The fair value of financial instruments that are not traded in an active market (for example, foreign exchange contracts) is determined using valuation techniques which maximize the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for provisions (contingent consideration), equity securities (unlisted) and warrant liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Valuation techniques used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group did not hold any level 1 and level 2 financial instruments as at December&#160;31, 2023 or June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group&#x2019;s level 3 assets consists of an investment in unlisted equity securities in the biotechnology sector. Level 3 assets were 100% of total assets measured at fair value as at December&#160;31, 2023 and June&#160;30, 2023. The Group&#x2019;s level 3 liabilities consist of a contingent consideration provision related to the acquisition of the MSC assets and warrant liabilities related to the warrants granted to Oaktree as part of the debt facility. Level 3 liabilities were 100% of total liabilities measured at fair value as at December&#160;31, 2023 and June&#160;30, 2023. The Group used discounted cash flow analysis to determine the fair value measurements of contingent consideration and used the Black-Scholes valuation method to determine the fair value of warrant liabilities. Refer to Note 5(e)(vi) for the fair value measurement and movements in warrant liability for the period ended December&#160;31, 2023 and June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Fair value measurements using significant unobservable inputs (level 3)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in level 3 instruments for the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contingent&lt;br/&gt;consideration&lt;br/&gt;provision&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance - July 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassification during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to consolidated income statement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing balance - June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance - July 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to consolidated income statement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing balance - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In the year ended June&#160;30, 2023 a gain of $8.8 million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, developmental timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines were updated to reflect expectations as a result of the complete response.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In the six months ended December&#160;31, 2023 a minimal gain was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation such as development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;Valuation inputs and relationship to fair &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Range of inputs&lt;br/&gt;(weighted average)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value &lt;br/&gt;as of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value &lt;br/&gt;as of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Valuation &lt;br/&gt;technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unobservable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Relationship of &lt;br/&gt;unobservable inputs to &lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Discounted cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Risk adjusted discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11%-13%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(12.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11%-13%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(12.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the discount rate by 0.5% would increase/decrease the fair value by an insignificant amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.01%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Expected unit sales price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Expected sales volumes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Probability of success and payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 10.0% and 20.0%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8% and 16%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;There were no significant inter-relationships between unobservable inputs that materially affect fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(v)&#160;&#160;&#160;&#160;Valuation processes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the MSC assets on October 11, 2013 (the &#x201c;acquisition date&#x201d;), an independent valuation of the contingent consideration was carried out by an independent valuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023, the Group has adopted a process to value contingent consideration internally. This valuation has been completed by the Group&#x2019;s internal valuation team and reviewed by the interim Chief Financial Officer (the "CFO"). The valuation team is responsible for the valuation model. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. For each indication we determine the probability of success based on the current development status within each jurisdiction and payment provisions within the agreement. Cash flows relevant to each jurisdiction are discounted appropriately based on the discount rate assumed. The remeasurement charged to the consolidated income statement in the six months ended December&#160;31, 2023 was a net result of changing the key assumptions of the contingent consideration valuation such as development timelines and the increase &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration. Future discussions with the FDA could lead to a change in the assumptions associated with SR-aGVHD and a remeasurement of contingent consideration, up or down, could occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;The fair value of contingent consideration&lt;br/&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of royalty payments from commercialization of the intellectual property acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The main level 3 inputs used by the Group are evaluated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk adjusted discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used in the valuation has been determined based on required rates of returns of listed companies in the biotechnology industry (having regards to their stage of development, their size and number of projects) and the indicative rates of return required by suppliers of venture capital for investments with similar technical and commercial risks. This assumption is reviewed as part of the valuation process outlined above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected unit sales prices:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected market sale price of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected sales volumes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected sales volumes of the most comparable products currently available in the market place. This assumption is reviewed as part of the valuation process outlined above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of success and payment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected cash flows used to measure contingent consideration are risk adjusted for the probability of successful development of products and payment provisions within the agreement. This assumption is reviewed as part of the valuation process outlined above.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(vi)&#160;&#160;&#160;&#160;Warrant liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants fair value at grant date - December 22, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, in connection with the $60.0 million drawdown of the Oaktree debt, Oaktree were granted the right to warrants to purchase 1,769,669 ADSs at $7.26 per ADS, a 15% premium to the 30-day VWAP. Given that Oaktree received an unconditional right to the warrants on November&#160;19, 2021, this date has been determined as the measurement date. The warrants instruments were issued on January&#160;11, 2022, following the required administrative process, and these warrants may be exercised within 7 years of issuance of the warrant instruments. The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 22, 2022, the Group amended the terms of the loan agreement with Oaktree and in connection with the loan amendment, Oaktree was granted warrants to purchase 455,000 ADSs at $3.70 per ADS, a 15% premium to the 30-day VWAP.  We determined that an obligation to issue the warrants has arisen from the time the first amendment to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loan agreement was signed; consequently, a liability for the warrants has been recognized in December 2022. The warrants were legally issued on March 8, 2023 and may be exercised within 7 years of issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2024, the ratio under Mesoblast's ADR program was changed from 5 ordinary shares representing 1 ADS (5:1 ratio) to a new ratio of 10 ordinary shares representing 1 ADS (10:1 ratio). As a result of this ratio change and as a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the number and exercise price for the warrants was adjusted in accordance with the terms of these warrants. The warrants issued in November 2021 changed from 1,769,669 ADSs at US$7.26 per ADS to 884,838 ADSs at US$14.36 per ADS. The warrants issued in December 2022 changed from 455,000 ADSs at US$3.70 per ADS to 227,502 ADSs at US$7.24 per ADS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of the warrants will be received in U.S. dollars, which is different to Mesoblast Limited&#x2019;s functional currency of Australian dollars which gives rise to variability in the cash flow. As a result, the warrants are classified as a financial liability in accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IAS32 Financial Instruments: Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The financial liability is recorded in warrant liability at fair value at grant date and subsequently remeasured at each reporting period with changes being recorded in the Income Statement as remeasurement of warrant liability. The warrant liabilities are considered level 3 liabilities as the determination of fair value includes various assumptions about the share prices and historical volatility as inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2023, and June&#160;30, 2023 the fair value of the warrant liability was $1.0 million and $5.4 million, respectively. During the six months ended December 31,  2023, a remeasurement gain of $4.4 million was recognized on the remeasurement of warrant liability. During the six months ended December 31, 2022, a remeasurement loss of $0.7 million was recognized on the remeasurement of warrant liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(vii)&#160;&#160;&#160;&#160;Fair value of warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants granted are not traded in an active market and therefore the fair value has been estimated by using the Black-Scholes valuation method based on the following assumptions. Key terms of the warrants are included below. The following assumptions were based on observable market conditions that existed at the issue date and as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.513%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, except percent data and as otherwise noted) &lt;br/&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of&lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rationale&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Closing share price on valuation date from external market source&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.70 to $7.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.70 to $7.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As per subscription agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As per subscription agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on Company&#x2019;s nil dividend history&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on historical volatility data for the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.01%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the closing U.S treasury issued 7 year bonds on valuation date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.4000 to $0.6248&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3103 to $2.9401&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determined using Black-Scholes valuation model with the inputs above&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$992,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5,426,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of 2,224,669 warrants of $992,233 and $5,426,212 as of December&#160;31, 2023 and June&#160;30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatoryTextBlock>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-356">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group holds the following financial instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial assets&lt;br/&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVTPL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets at &lt;br/&gt;amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash &amp;amp; cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade &amp;amp; other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;83,793&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;84,619&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash &amp;amp; cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade &amp;amp; other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;80,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;82,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through profit or loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;br/&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;FVTPL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities at &lt;br/&gt;amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;115,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;126,522&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;145,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(d)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;108,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;128,908&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;151,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Fair value through other comprehensive income &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;Fair value through profit or loss</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:CashAndCashEquivalents contextRef="c-71" decimals="-3" id="f-357" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-358" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-71" decimals="-3" id="f-359" unitRef="usd">3998000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-41" decimals="-3" id="f-360" unitRef="usd">3998000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-72" decimals="-3" id="f-361" unitRef="usd">826000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-41" decimals="-3" id="f-362" unitRef="usd">826000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-71" decimals="-3" id="f-363" unitRef="usd">2241000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-41" decimals="-3" id="f-364" unitRef="usd">2241000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-72" decimals="-3" id="f-365" unitRef="usd">826000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-71" decimals="-3" id="f-366" unitRef="usd">83793000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-41" decimals="-3" id="f-367" unitRef="usd">84619000</ifrs-full:FinancialAssets>
    <ifrs-full:CashAndCashEquivalents contextRef="c-73" decimals="-3" id="f-368" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-369" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-73" decimals="-3" id="f-370" unitRef="usd">6998000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables contextRef="c-29" decimals="-3" id="f-371" unitRef="usd">6998000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-74" decimals="-3" id="f-372" unitRef="usd">1757000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome contextRef="c-29" decimals="-3" id="f-373" unitRef="usd">1757000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-73" decimals="-3" id="f-374" unitRef="usd">2326000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c-29" decimals="-3" id="f-375" unitRef="usd">2326000</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-74" decimals="-3" id="f-376" unitRef="usd">1757000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-73" decimals="-3" id="f-377" unitRef="usd">80642000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-29" decimals="-3" id="f-378" unitRef="usd">82399000</ifrs-full:FinancialAssets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-75" decimals="-3" id="f-379" unitRef="usd">10760000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-41" decimals="-3" id="f-380" unitRef="usd">10760000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:Borrowings contextRef="c-75" decimals="-3" id="f-381" unitRef="usd">115762000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-41" decimals="-3" id="f-382" unitRef="usd">115762000</ifrs-full:Borrowings>
    <meso:ContingentConsiderations contextRef="c-76" decimals="-3" id="f-383" unitRef="usd">17536000</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-41" decimals="-3" id="f-384" unitRef="usd">17536000</meso:ContingentConsiderations>
    <ifrs-full:WarrantLiability contextRef="c-76" decimals="-3" id="f-385" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-386" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:FinancialLiabilities contextRef="c-76" decimals="-3" id="f-387" unitRef="usd">18528000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-75" decimals="-3" id="f-388" unitRef="usd">126522000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-41" decimals="-3" id="f-389" unitRef="usd">145050000</ifrs-full:FinancialLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-77" decimals="-3" id="f-390" unitRef="usd">20145000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-29" decimals="-3" id="f-391" unitRef="usd">20145000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:Borrowings contextRef="c-77" decimals="-3" id="f-392" unitRef="usd">108763000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-29" decimals="-3" id="f-393" unitRef="usd">108763000</ifrs-full:Borrowings>
    <meso:ContingentConsiderations contextRef="c-78" decimals="-3" id="f-394" unitRef="usd">17199000</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-29" decimals="-3" id="f-395" unitRef="usd">17199000</meso:ContingentConsiderations>
    <ifrs-full:WarrantLiability contextRef="c-78" decimals="-3" id="f-396" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-397" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:FinancialLiabilities contextRef="c-78" decimals="-3" id="f-398" unitRef="usd">22625000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-77" decimals="-3" id="f-399" unitRef="usd">128908000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-29" decimals="-3" id="f-400" unitRef="usd">151533000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c-1" id="f-401">&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits at call&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;77,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;71,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;As of December&#160;31, 2023 and June&#160;30, 2023, interest-bearing deposits at call include amounts of $0.4 million and $0.4 million, respectively, held as security and restricted for use.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:BalancesWithBanks contextRef="c-41" decimals="-3" id="f-402" unitRef="usd">77144000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks contextRef="c-29" decimals="-3" id="f-403" unitRef="usd">70920000</ifrs-full:BalancesWithBanks>
    <meso:DepositsAtCall contextRef="c-41" decimals="-3" id="f-404" unitRef="usd">410000</meso:DepositsAtCall>
    <meso:DepositsAtCall contextRef="c-29" decimals="-3" id="f-405" unitRef="usd">398000</meso:DepositsAtCall>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-406" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-407" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <meso:InterestBearingDepositsAtCallHeldAsSecurity contextRef="c-41" decimals="-5" id="f-408" unitRef="usd">400000</meso:InterestBearingDepositsAtCallHeldAsSecurity>
    <meso:InterestBearingDepositsAtCallHeldAsSecurity contextRef="c-29" decimals="-5" id="f-409" unitRef="usd">400000</meso:InterestBearingDepositsAtCallHeldAsSecurity>
    <meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock contextRef="c-1" id="f-410">&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&#160;&#160;&#160;&#160;Trade and other receivables and prepayments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Trade and other receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade debtors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax incentives recoverable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign withholding tax recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net investment in sublease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recoverable taxes (Goods and services tax and value-added tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,998&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,998&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(1) Research and development tax incentive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group's research and development activities are eligible under the Australian government's Innovation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Australia Research and Development Tax Incentive program for research and development activities conducted in relation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;to qualifying research that meets the regulatory criteria. Management has assessed these activities and expenditures to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;determine which costs are likely to be eligible under the incentive scheme. The Group assesses, on an annual basis, the&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;quantum of previous research and development tax claims and on-going eligibility to claim this tax incentive in Australia. The tax incentives recoverable as of December 31, 2023 pertains to an estimate for the year ended June 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Prepayments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial research and development expenditure&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid insurance and subscriptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,602&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfTradeAndOtherReceivablesAndPrepaymentsExplanatoryTableTextBlock>
    <ifrs-full:TradeReceivables contextRef="c-41" decimals="-3" id="f-411" unitRef="usd">1804000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="c-29" decimals="-3" id="f-412" unitRef="usd">2276000</ifrs-full:TradeReceivables>
    <meso:ResearchAndDevelopmentTaxIncentiveCreditReceivable contextRef="c-41" decimals="-3" id="f-413" unitRef="usd">1271000</meso:ResearchAndDevelopmentTaxIncentiveCreditReceivable>
    <meso:ResearchAndDevelopmentTaxIncentiveCreditReceivable contextRef="c-29" decimals="-3" id="f-414" unitRef="usd">2363000</meso:ResearchAndDevelopmentTaxIncentiveCreditReceivable>
    <meso:ForeignWithholdingTaxRecoverable contextRef="c-41" decimals="-3" id="f-415" unitRef="usd">471000</meso:ForeignWithholdingTaxRecoverable>
    <meso:ForeignWithholdingTaxRecoverable contextRef="c-29" decimals="-3" id="f-416" unitRef="usd">471000</meso:ForeignWithholdingTaxRecoverable>
    <meso:ReceivableFromTaxCredits contextRef="c-41" decimals="-3" id="f-417" unitRef="usd">0</meso:ReceivableFromTaxCredits>
    <meso:ReceivableFromTaxCredits contextRef="c-29" decimals="-3" id="f-418" unitRef="usd">1473000</meso:ReceivableFromTaxCredits>
    <ifrs-full:NetInvestmentInFinanceLease contextRef="c-41" decimals="-3" id="f-419" unitRef="usd">216000</ifrs-full:NetInvestmentInFinanceLease>
    <ifrs-full:NetInvestmentInFinanceLease contextRef="c-29" decimals="-3" id="f-420" unitRef="usd">195000</ifrs-full:NetInvestmentInFinanceLease>
    <ifrs-full:CurrentInterestReceivable contextRef="c-41" decimals="-3" id="f-421" unitRef="usd">11000</ifrs-full:CurrentInterestReceivable>
    <ifrs-full:CurrentInterestReceivable contextRef="c-29" decimals="-3" id="f-422" unitRef="usd">18000</ifrs-full:CurrentInterestReceivable>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax contextRef="c-41" decimals="-3" id="f-423" unitRef="usd">225000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax contextRef="c-29" decimals="-3" id="f-424" unitRef="usd">202000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-41" decimals="-3" id="f-425" unitRef="usd">3998000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-29" decimals="-3" id="f-426" unitRef="usd">6998000</ifrs-full:TradeAndOtherCurrentReceivables>
    <meso:ClinicalTrialResearchAndDevelopmentExpenditure contextRef="c-41" decimals="-3" id="f-427" unitRef="usd">23000</meso:ClinicalTrialResearchAndDevelopmentExpenditure>
    <meso:ClinicalTrialResearchAndDevelopmentExpenditure contextRef="c-29" decimals="-3" id="f-428" unitRef="usd">950000</meso:ClinicalTrialResearchAndDevelopmentExpenditure>
    <meso:PrepaidInsuranceAndSubscriptions contextRef="c-41" decimals="-3" id="f-429" unitRef="usd">3219000</meso:PrepaidInsuranceAndSubscriptions>
    <meso:PrepaidInsuranceAndSubscriptions contextRef="c-29" decimals="-3" id="f-430" unitRef="usd">2025000</meso:PrepaidInsuranceAndSubscriptions>
    <meso:OtherPrepayments contextRef="c-41" decimals="-3" id="f-431" unitRef="usd">360000</meso:OtherPrepayments>
    <meso:OtherPrepayments contextRef="c-29" decimals="-3" id="f-432" unitRef="usd">367000</meso:OtherPrepayments>
    <ifrs-full:Prepayments contextRef="c-41" decimals="-3" id="f-433" unitRef="usd">3602000</ifrs-full:Prepayments>
    <ifrs-full:Prepayments contextRef="c-29" decimals="-3" id="f-434" unitRef="usd">3342000</ifrs-full:Prepayments>
    <meso:TradeReceivablesSettlementPeriod contextRef="c-79" id="f-435">P60D</meso:TradeReceivablesSettlementPeriod>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c-1" id="f-436">&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c.&#160;&#160;&#160;&#160;Trade and other payables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,760&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;20,145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-41" decimals="-3" id="f-437" unitRef="usd">10760000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-29" decimals="-3" id="f-438" unitRef="usd">20145000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-41" decimals="-3" id="f-439" unitRef="usd">10760000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c-29" decimals="-3" id="f-440" unitRef="usd">20145000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="c-1" id="f-441">&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;d.&#160;&#160;&#160;&#160;Borrowings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Secured liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowing arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of carrying amount, net of payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;115,762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;108,763&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - Oaktree&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,952&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - Oaktree&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;107,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;102,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;115,762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;108,763&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:SecuredBankLoansReceived contextRef="c-41" decimals="-3" id="f-442" unitRef="usd">81919000</ifrs-full:SecuredBankLoansReceived>
    <ifrs-full:SecuredBankLoansReceived contextRef="c-29" decimals="-3" id="f-443" unitRef="usd">81919000</ifrs-full:SecuredBankLoansReceived>
    <ifrs-full:BorrowingCostsRecognisedAsExpense contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">9215000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <ifrs-full:BorrowingCostsRecognisedAsExpense contextRef="c-80" decimals="-3" id="f-445" unitRef="usd">8740000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <ifrs-full:BorrowingCostsCapitalised contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">43058000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:BorrowingCostsCapitalised contextRef="c-80" decimals="-3" id="f-447" unitRef="usd">35584000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:Borrowings contextRef="c-41" decimals="-3" id="f-448" unitRef="usd">115762000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-29" decimals="-3" id="f-449" unitRef="usd">108763000</ifrs-full:Borrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-81" decimals="-3" id="f-450" unitRef="usd">367000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-82" decimals="-3" id="f-451" unitRef="usd">336000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-83" decimals="-3" id="f-452" unitRef="usd">8167000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-84" decimals="-3" id="f-453" unitRef="usd">5616000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-41" decimals="-3" id="f-454" unitRef="usd">8534000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-29" decimals="-3" id="f-455" unitRef="usd">5952000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-81" decimals="-3" id="f-456" unitRef="usd">60878000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-82" decimals="-3" id="f-457" unitRef="usd">55739000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-83" decimals="-3" id="f-458" unitRef="usd">46350000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-84" decimals="-3" id="f-459" unitRef="usd">47072000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-41" decimals="-3" id="f-460" unitRef="usd">107228000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-29" decimals="-3" id="f-461" unitRef="usd">102811000</ifrs-full:LongtermBorrowings>
    <ifrs-full:Borrowings contextRef="c-41" decimals="-3" id="f-462" unitRef="usd">115762000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-29" decimals="-3" id="f-463" unitRef="usd">108763000</ifrs-full:Borrowings>
    <meso:BorrowingsPrincipalAmount contextRef="c-85" decimals="-5" id="f-464" unitRef="usd">90000000</meso:BorrowingsPrincipalAmount>
    <meso:BorrowingsTerm contextRef="c-86" id="f-465">P5Y</meso:BorrowingsTerm>
    <ifrs-full:Borrowings contextRef="c-87" decimals="-5" id="f-466" unitRef="usd">60000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-88" decimals="-5" id="f-467" unitRef="usd">30000000</ifrs-full:Borrowings>
    <meso:BorrowingsInterestOnlyPeriod contextRef="c-86" id="f-468">P3Y</meso:BorrowingsInterestOnlyPeriod>
    <ifrs-full:BorrowingsInterestRate
      contextRef="c-87"
      decimals="INF"
      id="f-469"
      unitRef="number">0.0975</ifrs-full:BorrowingsInterestRate>
    <meso:PercentageOfBorrowingPrincipalAmountPayableOverTwoYear contextRef="c-85" decimals="2" id="f-470" unitRef="number">0.40</meso:PercentageOfBorrowingPrincipalAmountPayableOverTwoYear>
    <meso:BorrowingsPrincipalAmortizationPeriod contextRef="c-85" id="f-471">P2Y</meso:BorrowingsPrincipalAmortizationPeriod>
    <ifrs-full:BorrowingsInterestRate contextRef="c-89" decimals="3" id="f-472" unitRef="number">0.080</ifrs-full:BorrowingsInterestRate>
    <meso:BorrowingsPrincipalAmortizationPeriod contextRef="c-85" id="f-473">P2Y</meso:BorrowingsPrincipalAmortizationPeriod>
    <meso:UnpaidInterestPortionPerAnnum
      contextRef="c-86"
      decimals="INF"
      id="f-474"
      unitRef="number">0.0175</meso:UnpaidInterestPortionPerAnnum>
    <ifrs-full:BorrowingsInterestRate contextRef="c-85" decimals="4" id="f-475" unitRef="number">0.0975</ifrs-full:BorrowingsInterestRate>
    <meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares
      contextRef="c-90"
      decimals="INF"
      id="f-476"
      unitRef="shares">1769669</meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-91"
      decimals="2"
      id="f-477"
      unitRef="usdPerShare">7.26</ifrs-full:ParValuePerShare>
    <meso:PercentageOfPremiumForVolumeWeightedAveragePrice contextRef="c-92" decimals="2" id="f-478" unitRef="number">0.15</meso:PercentageOfPremiumForVolumeWeightedAveragePrice>
    <meso:IssuanceWarrantsExercisedPeriod contextRef="c-92" id="f-479">P7Y</meso:IssuanceWarrantsExercisedPeriod>
    <ifrs-full:Borrowings contextRef="c-93" decimals="-5" id="f-480" unitRef="usd">60000000</ifrs-full:Borrowings>
    <meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares
      contextRef="c-94"
      decimals="INF"
      id="f-481"
      unitRef="shares">455000</meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-95"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">3.70</ifrs-full:ParValuePerShare>
    <meso:PercentageOfSharePremiumPrice contextRef="c-96" decimals="2" id="f-483" unitRef="number">0.15</meso:PercentageOfSharePremiumPrice>
    <meso:WarrantExerciseTerm contextRef="c-97" id="f-484">P7Y</meso:WarrantExerciseTerm>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-98" decimals="0" id="f-485" unitRef="shares">1769669</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-99"
      decimals="2"
      id="f-486"
      unitRef="usdPerShare">7.26</ifrs-full:ParValuePerShare>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-100" decimals="0" id="f-487" unitRef="shares">884838</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-101"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">14.36</ifrs-full:ParValuePerShare>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-102" decimals="0" id="f-489" unitRef="shares">455000</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-103"
      decimals="2"
      id="f-490"
      unitRef="usdPerShare">3.70</ifrs-full:ParValuePerShare>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-104" decimals="0" id="f-491" unitRef="shares">227502</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-105"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">7.24</ifrs-full:ParValuePerShare>
    <meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements contextRef="c-106" decimals="INF" id="f-493" unitRef="usd">-1400000</meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements>
    <meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements contextRef="c-106" decimals="INF" id="f-494" unitRef="usd">-1400000</meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements>
    <meso:FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued contextRef="c-106" decimals="-5" id="f-495" unitRef="usd">1000000</meso:FinanceCostsGainsLossOnRemeasurementDueToAdditionalWarrantsIssued>
    <meso:FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability contextRef="c-106" decimals="-5" id="f-496" unitRef="usd">400000</meso:FinanceCostsGainsLossOnAdjustmentOfCarryingAmountOnFinancialLiability>
    <meso:BorrowingsTerm contextRef="c-107" id="f-497">P8Y</meso:BorrowingsTerm>
    <meso:BorrowingsPrincipalAmount contextRef="c-108" decimals="-5" id="f-498" unitRef="usd">40000000</meso:BorrowingsPrincipalAmount>
    <ifrs-full:Borrowings contextRef="c-109" decimals="-5" id="f-499" unitRef="usd">30000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-110" decimals="-5" id="f-500" unitRef="usd">10000000</ifrs-full:Borrowings>
    <meso:BorrowingsInterestOnlyPeriod contextRef="c-107" id="f-501">P4Y</meso:BorrowingsInterestOnlyPeriod>
    <ifrs-full:BorrowingsInterestRate contextRef="c-108" decimals="2" id="f-502" unitRef="number">0.15</ifrs-full:BorrowingsInterestRate>
    <meso:BorrowingsInterestOnlyPeriod contextRef="c-107" id="f-503">P4Y</meso:BorrowingsInterestOnlyPeriod>
    <meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold contextRef="c-111" decimals="2" id="f-504" unitRef="number">0.25</meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold>
    <meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold contextRef="c-111" decimals="2" id="f-505" unitRef="number">0.25</meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold>
    <meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold contextRef="c-111" decimals="2" id="f-506" unitRef="number">0.25</meso:PercentageOfEntitysRevenueAnnualPaymentCapThreshold>
    <meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements contextRef="c-112" decimals="-5" id="f-507" unitRef="usd">-100000</meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements>
    <meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements contextRef="c-113" decimals="-5" id="f-508" unitRef="usd">200000</meso:FinanceCostsGainsLossOnRemeasurementOfBorrowingArrangements>
    <meso:MinimumUnrestrictedCashBalance contextRef="c-114" decimals="-5" id="f-509" unitRef="usd">35000000</meso:MinimumUnrestrictedCashBalance>
    <meso:DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Net Debt Reconciliation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(115,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(108,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(50,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross debt - fixed interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(121,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(116,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross debt - variable interest rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(50,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Net debt amount includes leases and borrowing arrangements.&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutNetDebtExplanatoryTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-511" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-512" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Borrowings contextRef="c-41" decimals="-3" id="f-513" unitRef="usd">115762000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-29" decimals="-3" id="f-514" unitRef="usd">108763000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities contextRef="c-41" decimals="-3" id="f-515" unitRef="usd">6237000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-29" decimals="-3" id="f-516" unitRef="usd">7732000</ifrs-full:LeaseLiabilities>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-517" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-518" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:NetDebt contextRef="c-41" decimals="-3" id="f-519" unitRef="usd">45437000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt contextRef="c-29" decimals="-3" id="f-520" unitRef="usd">50603000</ifrs-full:NetDebt>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-521" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-522" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Borrowings contextRef="c-115" decimals="-3" id="f-523" unitRef="usd">121999000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-116" decimals="-3" id="f-524" unitRef="usd">116495000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-117" decimals="-3" id="f-525" unitRef="usd">0</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-118" decimals="-3" id="f-526" unitRef="usd">0</ifrs-full:Borrowings>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-527" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-528" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:NetDebt contextRef="c-41" decimals="-3" id="f-529" unitRef="usd">45437000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt contextRef="c-29" decimals="-3" id="f-530" unitRef="usd">50603000</ifrs-full:NetDebt>
    <meso:DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities from financing activities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Borrowings &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Warrant liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Sub-total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and cash&lt;br/&gt;equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net Debt as at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(108,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(121,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(50,603)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash Flows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Changes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Debt as at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(115,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(6,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(122,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;77,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,437)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Cash flows include the payments of borrowings, lease liabilities, interest and debt transaction costs which are presented as financing cash flows in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Other changes include modification of leases and accrued interest expenses for borrowings and leases.&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutNetDebtReconciliationExplanatoryTableTextBlock>
    <ifrs-full:Borrowings contextRef="c-29" decimals="-3" id="f-532" unitRef="usd">108763000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities contextRef="c-29" decimals="-3" id="f-533" unitRef="usd">7732000</ifrs-full:LeaseLiabilities>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-534" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-29" decimals="-3" id="f-535" unitRef="usd">121921000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-536" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NetDebt contextRef="c-29" decimals="-3" id="f-537" unitRef="usd">50603000</ifrs-full:NetDebt>
    <meso:CashFlowsAdjustmentsOnDebt contextRef="c-1" decimals="-3" id="f-538" unitRef="usd">3163000</meso:CashFlowsAdjustmentsOnDebt>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-539" unitRef="usd">2337000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <meso:IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-540" unitRef="usd">0</meso:IncreaseDecreaseInWarrantLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-541" unitRef="usd">5500000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-1" decimals="-3" id="f-542" unitRef="usd">4940000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-543" unitRef="usd">10440000</ifrs-full:IncreaseDecreaseInLiabilitiesArisingFromFinancingActivities>
    <meso:RemeasurementAdjustmentsOnDebt contextRef="c-1" decimals="-3" id="f-544" unitRef="usd">-120000</meso:RemeasurementAdjustmentsOnDebt>
    <meso:RemeasurementAdjustmentsOnWarrants contextRef="c-1" decimals="-3" id="f-545" unitRef="usd">4434000</meso:RemeasurementAdjustmentsOnWarrants>
    <meso:RemeasurementAdjustmentsOnDebtAndWarrants contextRef="c-1" decimals="-3" id="f-546" unitRef="usd">4314000</meso:RemeasurementAdjustmentsOnDebtAndWarrants>
    <meso:RemeasurementAdjustmentsOnDebtAndWarrants contextRef="c-1" decimals="-3" id="f-547" unitRef="usd">4314000</meso:RemeasurementAdjustmentsOnDebtAndWarrants>
    <meso:IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-548" unitRef="usd">-10042000</meso:IncreaseDecreaseInBorrowingLiabilitiesClassifiedAsFinancingActivities>
    <meso:IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-549" unitRef="usd">-782000</meso:IncreaseDecreaseInLeaseLiabilitiesArisingFromFinancingActivities>
    <meso:OtherChangesOnDebtAndLeases contextRef="c-1" decimals="-3" id="f-550" unitRef="usd">-10824000</meso:OtherChangesOnDebtAndLeases>
    <meso:OtherChangesOnDebtAndLeases contextRef="c-1" decimals="-3" id="f-551" unitRef="usd">-10824000</meso:OtherChangesOnDebtAndLeases>
    <meso:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases contextRef="c-1" decimals="-3" id="f-552" unitRef="usd">-60000</meso:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromLeases>
    <meso:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants contextRef="c-1" decimals="-3" id="f-553" unitRef="usd">0</meso:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromWarrants>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-554" unitRef="usd">-60000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-555" unitRef="usd">1296000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <meso:EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-556" unitRef="usd">1236000</meso:EffectOfForeignExchangeAdjustmentsOnLiabilitiesArisingFromFinancingActivitiesAndCashAndCashEquivalents>
    <ifrs-full:Borrowings contextRef="c-41" decimals="-3" id="f-557" unitRef="usd">115762000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities contextRef="c-41" decimals="-3" id="f-558" unitRef="usd">6237000</ifrs-full:LeaseLiabilities>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-559" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="c-41" decimals="-3" id="f-560" unitRef="usd">122991000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-561" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:NetDebt contextRef="c-41" decimals="-3" id="f-562" unitRef="usd">45437000</ifrs-full:NetDebt>
    <meso:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock contextRef="c-1" id="f-563">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Group's financial assets and financial liabilities measured and recognized at fair value as of December&#160;31, 2023 and June&#160;30, 2023 on a recurring basis, categorized by level according to the significance of the inputs used in making the measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities - biotech sector&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;826&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.061%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets at fair value through other comprehensive income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities - biotech sector&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities at fair value through profit or loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(iii)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5(e)(vi)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutFairValueMeasurementExplanatoryTableTextBlock>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-119" decimals="-3" id="f-564" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-120" decimals="-3" id="f-565" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-121" decimals="-3" id="f-566" unitRef="usd">826000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-122" decimals="-3" id="f-567" unitRef="usd">826000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-123" decimals="-3" id="f-568" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-124" decimals="-3" id="f-569" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-125" decimals="-3" id="f-570" unitRef="usd">826000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-41" decimals="-3" id="f-571" unitRef="usd">826000</ifrs-full:FinancialAssetsAtFairValue>
    <meso:ContingentConsiderations contextRef="c-123" decimals="-3" id="f-572" unitRef="usd">0</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-124" decimals="-3" id="f-573" unitRef="usd">0</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-125" decimals="-3" id="f-574" unitRef="usd">17536000</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-41" decimals="-3" id="f-575" unitRef="usd">17536000</meso:ContingentConsiderations>
    <ifrs-full:WarrantLiability contextRef="c-123" decimals="-3" id="f-576" unitRef="usd">0</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-124" decimals="-3" id="f-577" unitRef="usd">0</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-125" decimals="-3" id="f-578" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-579" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-123" decimals="-3" id="f-580" unitRef="usd">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-124" decimals="-3" id="f-581" unitRef="usd">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-125" decimals="-3" id="f-582" unitRef="usd">18528000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-41" decimals="-3" id="f-583" unitRef="usd">18528000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-126" decimals="-3" id="f-584" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-127" decimals="-3" id="f-585" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-128" decimals="-3" id="f-586" unitRef="usd">1757000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-129" decimals="-3" id="f-587" unitRef="usd">1757000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-130" decimals="-3" id="f-588" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-131" decimals="-3" id="f-589" unitRef="usd">0</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-132" decimals="-3" id="f-590" unitRef="usd">1757000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue contextRef="c-29" decimals="-3" id="f-591" unitRef="usd">1757000</ifrs-full:FinancialAssetsAtFairValue>
    <meso:ContingentConsiderations contextRef="c-130" decimals="-3" id="f-592" unitRef="usd">0</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-131" decimals="-3" id="f-593" unitRef="usd">0</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-132" decimals="-3" id="f-594" unitRef="usd">17199000</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-29" decimals="-3" id="f-595" unitRef="usd">17199000</meso:ContingentConsiderations>
    <ifrs-full:WarrantLiability contextRef="c-130" decimals="-3" id="f-596" unitRef="usd">0</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-131" decimals="-3" id="f-597" unitRef="usd">0</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-132" decimals="-3" id="f-598" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-599" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-130" decimals="-3" id="f-600" unitRef="usd">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-131" decimals="-3" id="f-601" unitRef="usd">0</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-132" decimals="-3" id="f-602" unitRef="usd">22625000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="c-29" decimals="-3" id="f-603" unitRef="usd">22625000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialAssets contextRef="c-133" decimals="INF" id="f-604" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-134" decimals="INF" id="f-605" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-135" decimals="INF" id="f-606" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-134" decimals="INF" id="f-607" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets contextRef="c-136" decimals="INF" id="f-608" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c-135" decimals="INF" id="f-609" unitRef="usd">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities contextRef="c-133" decimals="INF" id="f-610" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="c-136" decimals="INF" id="f-611" unitRef="usd">0</ifrs-full:FinancialLiabilities>
    <meso:PercentageOfAssetsMeasuredAtFairValue contextRef="c-137" decimals="2" id="f-612" unitRef="number">1</meso:PercentageOfAssetsMeasuredAtFairValue>
    <meso:PercentageOfAssetsMeasuredAtFairValue contextRef="c-138" decimals="2" id="f-613" unitRef="number">1</meso:PercentageOfAssetsMeasuredAtFairValue>
    <meso:PercentageOfLiabilitiesMeasuredAtFairValue contextRef="c-139" decimals="2" id="f-614" unitRef="number">1</meso:PercentageOfLiabilitiesMeasuredAtFairValue>
    <meso:PercentageOfLiabilitiesMeasuredAtFairValue contextRef="c-140" decimals="2" id="f-615" unitRef="number">1</meso:PercentageOfLiabilitiesMeasuredAtFairValue>
    <meso:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-616">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in level 3 instruments for the six months ended December&#160;31, 2023 and the year ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contingent&lt;br/&gt;consideration&lt;br/&gt;provision&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance - July 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassification during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to consolidated income statement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing balance - June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance - July 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to consolidated income statement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing balance - December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In the year ended June&#160;30, 2023 a gain of $8.8 million was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing the key assumptions of the contingent consideration valuation such as probability of payment, developmental timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration, including the impact from the complete response from the FDA on the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD in August 2023. The assumptions relating to development timelines were updated to reflect expectations as a result of the complete response.  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In the six months ended December&#160;31, 2023 a minimal gain was recognized on the remeasurement of contingent consideration pertaining to the acquisition of the MSC assets. This remeasurement was a net result of changing key assumptions of the contingent consideration valuation such as development timelines and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfAssetsAndLiabilitiesExplanatoryTableTextBlock>
    <meso:ContingentConsiderationProvision contextRef="c-141" decimals="-3" id="f-617" unitRef="usd">23284000</meso:ContingentConsiderationProvision>
    <meso:ContingentConsiderationProvisionAmountUsed contextRef="c-142" decimals="-3" id="f-618" unitRef="usd">-2686000</meso:ContingentConsiderationProvisionAmountUsed>
    <meso:LossGainOnRemeasurementOfContingentConsideration contextRef="c-142" decimals="-3" id="f-619" unitRef="usd">-8771000</meso:LossGainOnRemeasurementOfContingentConsideration>
    <meso:ContingentConsiderationProvision contextRef="c-132" decimals="-3" id="f-620" unitRef="usd">17199000</meso:ContingentConsiderationProvision>
    <meso:ContingentConsiderationProvision contextRef="c-132" decimals="-3" id="f-621" unitRef="usd">17199000</meso:ContingentConsiderationProvision>
    <meso:LossGainOnRemeasurementOfContingentConsideration contextRef="c-143" decimals="-3" id="f-622" unitRef="usd">337000</meso:LossGainOnRemeasurementOfContingentConsideration>
    <meso:ContingentConsiderationProvision contextRef="c-125" decimals="-3" id="f-623" unitRef="usd">17536000</meso:ContingentConsiderationProvision>
    <meso:GainLossOnReMeasurementOfContingentConsiderationProvision contextRef="c-142" decimals="-5" id="f-624" unitRef="usd">8800000</meso:GainLossOnReMeasurementOfContingentConsiderationProvision>
    <meso:DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the quantitative information about the significant unobservable inputs used in level 3 fair value measurements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Range of inputs&lt;br/&gt;(weighted average)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value &lt;br/&gt;as of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value &lt;br/&gt;as of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Valuation &lt;br/&gt;technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unobservable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Relationship of &lt;br/&gt;unobservable inputs to &lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Discounted cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Risk adjusted discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11%-13%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(12.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;11%-13%&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(12.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the discount rate by 0.5% would increase/decrease the fair value by an insignificant amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the discount rate by 0.5% would increase/decrease the fair value by 0.01%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Expected unit sales price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the price assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Expected sales volumes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the volume assumptions by 10% would increase/decrease the fair value by 0.1%.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Probability of success and payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Six months ended December 31,  2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 10.0% and 20.0%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Year ended 30 June, 2023: A change in the probability of success and payment assumptions by 10% and 20% would increase/decrease the fair value by 8% and 16%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;There were no significant inter-relationships between unobservable inputs that materially affect fair values.&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfQuantitativeInformationAboutSignificantUnobservableInputsUsedInFairValueMeasurementsExplanatoryTableTextBlock>
    <meso:ContingentConsiderationProvision contextRef="c-144" decimals="-3" id="f-626" unitRef="usd">17536000</meso:ContingentConsiderationProvision>
    <meso:ContingentConsiderationProvision contextRef="c-145" decimals="-3" id="f-627" unitRef="usd">17199000</meso:ContingentConsiderationProvision>
    <ifrs-full:DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities contextRef="c-146" id="f-628">Discounted cash flows</ifrs-full:DescriptionOfValuationTechniquesUsedInFairValueMeasurementLiabilities>
    <ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities contextRef="c-146" id="f-629">Risk adjusted discount rate</ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities>
    <meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities contextRef="c-147" decimals="2" id="f-630" unitRef="number">0.11</meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities>
    <meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities contextRef="c-148" decimals="2" id="f-631" unitRef="number">0.13</meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities>
    <meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities contextRef="c-149" decimals="3" id="f-632" unitRef="number">-0.125</meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities>
    <meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities contextRef="c-150" decimals="2" id="f-633" unitRef="number">0.11</meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities>
    <meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities contextRef="c-151" decimals="2" id="f-634" unitRef="number">0.13</meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities>
    <meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities contextRef="c-152" decimals="3" id="f-635" unitRef="number">-0.125</meso:PercentageOfWeightedAverageOfSignificantUnobservableInputsLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-153" decimals="3" id="f-636" unitRef="number">0.005</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-154" decimals="3" id="f-637" unitRef="number">0.005</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-154" decimals="4" id="f-638" unitRef="number">0.0001</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities contextRef="c-143" id="f-639">Expected unit sales price</ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-155" decimals="2" id="f-640" unitRef="number">0.10</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-155" decimals="3" id="f-641" unitRef="number">0.001</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-156" decimals="2" id="f-642" unitRef="number">0.10</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-156" decimals="3" id="f-643" unitRef="number">0.001</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities contextRef="c-157" id="f-644">Expected sales volumes</ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-158" decimals="2" id="f-645" unitRef="number">0.10</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-158" decimals="3" id="f-646" unitRef="number">0.001</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-159" decimals="2" id="f-647" unitRef="number">0.10</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-159" decimals="3" id="f-648" unitRef="number">0.001</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities contextRef="c-160" id="f-649">Probability of success and payment</ifrs-full:DescriptionOfInputsUsedInFairValueMeasurementLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-161" decimals="2" id="f-650" unitRef="number">0.10</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-162" decimals="2" id="f-651" unitRef="number">0.20</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-161" decimals="3" id="f-652" unitRef="number">0.100</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-162" decimals="3" id="f-653" unitRef="number">0.200</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-163" decimals="2" id="f-654" unitRef="number">0.10</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities contextRef="c-164" decimals="2" id="f-655" unitRef="number">0.20</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-163" decimals="2" id="f-656" unitRef="number">0.08</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities contextRef="c-164" decimals="2" id="f-657" unitRef="number">0.16</meso:PercentageOfReasonablyPossibleIncreaseDecreaseInFairValueMeasurementDueToChangeInUnobservableInputLiabilities>
    <meso:DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock contextRef="c-1" id="f-658">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;The fair value of contingent consideration&lt;br/&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of royalty payments from commercialization of the intellectual property acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutValuationProcessesOfContingentConsiderationAtFairValueExplanatoryTableTextBlock>
    <meso:CashOrStockPayableAtFairValueLiabilities contextRef="c-41" decimals="-3" id="f-659" unitRef="usd">16924000</meso:CashOrStockPayableAtFairValueLiabilities>
    <meso:CashOrStockPayableAtFairValueLiabilities contextRef="c-29" decimals="-3" id="f-660" unitRef="usd">16606000</meso:CashOrStockPayableAtFairValueLiabilities>
    <meso:RoyaltyPaymentsAtFairValueLiabilities contextRef="c-41" decimals="-3" id="f-661" unitRef="usd">612000</meso:RoyaltyPaymentsAtFairValueLiabilities>
    <meso:RoyaltyPaymentsAtFairValueLiabilities contextRef="c-29" decimals="-3" id="f-662" unitRef="usd">593000</meso:RoyaltyPaymentsAtFairValueLiabilities>
    <meso:ContingentConsiderations contextRef="c-41" decimals="-3" id="f-663" unitRef="usd">17536000</meso:ContingentConsiderations>
    <meso:ContingentConsiderations contextRef="c-29" decimals="-3" id="f-664" unitRef="usd">17199000</meso:ContingentConsiderations>
    <meso:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock contextRef="c-1" id="f-665">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants fair value at grant date - December 22, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;5,426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutWarrantLiabilityExplanatoryTableTextBlock>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-666" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-9" decimals="-3" id="f-667" unitRef="usd">2185000</ifrs-full:WarrantLiability>
    <meso:WarrantsFairValueAtIssueDate contextRef="c-165" decimals="-3" id="f-668" unitRef="usd">0</meso:WarrantsFairValueAtIssueDate>
    <meso:WarrantsFairValueAtIssueDate contextRef="c-166" decimals="-3" id="f-669" unitRef="usd">1036000</meso:WarrantsFairValueAtIssueDate>
    <meso:RemeasurementOfWarrantLiability contextRef="c-1" decimals="-3" id="f-670" unitRef="usd">-4434000</meso:RemeasurementOfWarrantLiability>
    <meso:RemeasurementOfWarrantLiability contextRef="c-80" decimals="-3" id="f-671" unitRef="usd">2205000</meso:RemeasurementOfWarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-672" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-673" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <ifrs-full:Borrowings contextRef="c-167" decimals="-5" id="f-674" unitRef="usd">60000000</ifrs-full:Borrowings>
    <meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares
      contextRef="c-90"
      decimals="INF"
      id="f-675"
      unitRef="shares">1769669</meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-91"
      decimals="2"
      id="f-676"
      unitRef="usdPerShare">7.26</ifrs-full:ParValuePerShare>
    <meso:PercentageOfPremiumForVolumeWeightedAveragePrice contextRef="c-92" decimals="2" id="f-677" unitRef="number">0.15</meso:PercentageOfPremiumForVolumeWeightedAveragePrice>
    <meso:IssuanceWarrantsExercisedPeriod contextRef="c-92" id="f-678">P7Y</meso:IssuanceWarrantsExercisedPeriod>
    <meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares
      contextRef="c-168"
      decimals="INF"
      id="f-679"
      unitRef="shares">455000</meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-169"
      decimals="2"
      id="f-680"
      unitRef="usdPerShare">3.70</ifrs-full:ParValuePerShare>
    <meso:PercentageOfPremiumForVolumeWeightedAveragePrice contextRef="c-170" decimals="2" id="f-681" unitRef="number">0.15</meso:PercentageOfPremiumForVolumeWeightedAveragePrice>
    <meso:IssuanceWarrantsExercisedPeriod contextRef="c-171" id="f-682">P7Y</meso:IssuanceWarrantsExercisedPeriod>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-98" decimals="0" id="f-683" unitRef="shares">1769669</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-99"
      decimals="2"
      id="f-684"
      unitRef="usdPerShare">7.26</ifrs-full:ParValuePerShare>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-172" decimals="0" id="f-685" unitRef="shares">884838</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-101"
      decimals="2"
      id="f-686"
      unitRef="usdPerShare">14.36</ifrs-full:ParValuePerShare>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-102" decimals="0" id="f-687" unitRef="shares">455000</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-103"
      decimals="2"
      id="f-688"
      unitRef="usdPerShare">3.70</ifrs-full:ParValuePerShare>
    <meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares contextRef="c-104" decimals="0" id="f-689" unitRef="shares">227502</meso:NumberOfWarrantsIssuedToPurchaseAmericanDepositaryShares>
    <ifrs-full:ParValuePerShare
      contextRef="c-105"
      decimals="2"
      id="f-690"
      unitRef="usdPerShare">7.24</ifrs-full:ParValuePerShare>
    <meso:WarrantsFairValueAtIssueDate contextRef="c-1" decimals="-5" id="f-691" unitRef="usd">1000000</meso:WarrantsFairValueAtIssueDate>
    <meso:WarrantsFairValueAtIssueDate contextRef="c-80" decimals="-5" id="f-692" unitRef="usd">5400000</meso:WarrantsFairValueAtIssueDate>
    <meso:GainLossOnRemeasurementOfWarrantLiability contextRef="c-1" decimals="-5" id="f-693" unitRef="usd">-4400000</meso:GainLossOnRemeasurementOfWarrantLiability>
    <meso:GainLossOnRemeasurementOfWarrantLiability contextRef="c-2" decimals="-5" id="f-694" unitRef="usd">-700000</meso:GainLossOnRemeasurementOfWarrantLiability>
    <meso:DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock contextRef="c-1" id="f-695">The following assumptions were based on observable market conditions that existed at the issue date and as of December&#160;31, 2023.&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.513%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, except percent data and as otherwise noted) &lt;br/&gt;Assumption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of&lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Rationale&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Closing share price on valuation date from external market source&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.70 to $7.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.70 to $7.26&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As per subscription agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 to 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As per subscription agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on Company&#x2019;s nil dividend history&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.26%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on historical volatility data for the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk Free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.01%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the closing U.S treasury issued 7 year bonds on valuation date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.4000 to $0.6248&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3103 to $2.9401&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determined using Black-Scholes valuation model with the inputs above&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$992,233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5,426,212&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of 2,224,669 warrants of $992,233 and $5,426,212 as of December&#160;31, 2023 and June&#160;30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfDetailedInformationAboutFairValueOfWarrantsExplanatoryTableTextBlock>
    <meso:WarrantsPricePerShare
      contextRef="c-173"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">1.10</meso:WarrantsPricePerShare>
    <meso:WarrantsPricePerShare
      contextRef="c-174"
      decimals="2"
      id="f-697"
      unitRef="usdPerShare">3.91</meso:WarrantsPricePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-175"
      decimals="2"
      id="f-698"
      unitRef="usdPerShare">3.70</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-176"
      decimals="2"
      id="f-699"
      unitRef="usdPerShare">7.26</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-175"
      decimals="2"
      id="f-700"
      unitRef="usdPerShare">3.70</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-177"
      decimals="2"
      id="f-701"
      unitRef="usdPerShare">7.26</ifrs-full:ParValuePerShare>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-178" decimals="0" id="f-702" unitRef="year">5</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-179" decimals="0" id="f-703" unitRef="year">7</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-180" decimals="0" id="f-704" unitRef="year">6</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-181" decimals="0" id="f-705" unitRef="year">7</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-173" decimals="2" id="f-706" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-174" decimals="2" id="f-707" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-173" decimals="4" id="f-708" unitRef="number">0.8671</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-174" decimals="4" id="f-709" unitRef="number">0.8126</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-173" decimals="4" id="f-710" unitRef="number">0.0388</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-174" decimals="4" id="f-711" unitRef="number">0.0401</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <meso:IssuanceWarrantsExercisedPeriod contextRef="c-1" id="f-712">P7Y</meso:IssuanceWarrantsExercisedPeriod>
    <meso:FairValuePerWarrant
      contextRef="c-175"
      decimals="4"
      id="f-713"
      unitRef="usdPerShare">0.4000</meso:FairValuePerWarrant>
    <meso:FairValuePerWarrant
      contextRef="c-176"
      decimals="4"
      id="f-714"
      unitRef="usdPerShare">0.6248</meso:FairValuePerWarrant>
    <meso:FairValuePerWarrant
      contextRef="c-182"
      decimals="INF"
      id="f-715"
      unitRef="usdPerShare">2.3103</meso:FairValuePerWarrant>
    <meso:FairValuePerWarrant
      contextRef="c-177"
      decimals="INF"
      id="f-716"
      unitRef="usdPerShare">2.9401</meso:FairValuePerWarrant>
    <meso:FairValueOfWarrants contextRef="c-183" decimals="0" id="f-717" unitRef="usd">992233</meso:FairValueOfWarrants>
    <meso:FairValueOfWarrants contextRef="c-184" decimals="0" id="f-718" unitRef="usd">5426212</meso:FairValueOfWarrants>
    <meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares contextRef="c-183" decimals="0" id="f-719" unitRef="shares">2224669</meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares>
    <meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares contextRef="c-184" decimals="0" id="f-720" unitRef="shares">2224669</meso:NumberOfWarrantsGrantedToPurchaseAmericanDepositaryShares>
    <meso:FairValueOfWarrants contextRef="c-183" decimals="0" id="f-721" unitRef="usd">992233</meso:FairValueOfWarrants>
    <meso:FairValueOfWarrants contextRef="c-184" decimals="0" id="f-722" unitRef="usd">5426212</meso:FairValueOfWarrants>
    <meso:DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock contextRef="c-187" id="f-725">Non-financial assets and liabilities&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&#160;&#160;&#160;&#160;Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Acquired licenses&lt;br/&gt;to patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In-process&lt;br/&gt;research and&lt;br/&gt;development&lt;br/&gt;acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current marketed&lt;br/&gt;products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;578,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;577,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;489,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;651,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;577,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;577,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;576,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;489,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;651,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;576,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Carrying value of in-process research and development acquired by product&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiovascular products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;254,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;254,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intravenous products for metabolic diseases and inflammatory/immunologic conditions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MSC products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Includes remestemcel-L for the treatment of adults and children with SR-aGVHD and remestemcel-L for the treatment of Crohn&#x2019;s disease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all products included within the above balances, the underlying currency of each item recorded is US$.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Significant estimate: Impairment of goodwill and assets with an indefinite useful life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group tests annually, or more frequently if events or changes in circumstances indicate that they might be impaired, whether goodwill and its assets with indefinite useful lives have suffered any impairment in accordance with its accounting policy stated in Note 23(j) in the Form 20-F for the year ended June 30, 2023. The recoverable amounts of these assets and cash-generating units have been determined based on fair value less costs to dispose calculations, which require the use of market-participant assumptions that are based on development strategies using external data sources as well as past experience. The full annual impairment assessment was performed at March 31, 2023 and no impairment of the in-process research and development and goodwill were identified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the FDA issued a complete response to the Group's BLA for remestemcel-L for the treatment of pediatric SR-aGVHD and the Group considered this to be an impairment indicator that could cause the carrying amount of its intangible assets to exceed its recoverable amounts. As a result, the Group completed an impairment assessment on its MSC products intangible asset and goodwill. The assumptions used in the impairment assessment were updated from the March 31, 2023 impairment assessment and included changes to the market population and penetration, product pricing and launch timings. There were no other significant changes in key assumptions, including the probability of success. No impairment to the in-process research and development and goodwill was identified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Impairment tests for goodwill and intangible assets with an indefinite useful life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development acquired is considered to be an indefinite life intangible asset on the basis that it is incomplete and cannot be used in its current form (see Note 23(p)(iii) in the Form 20-F for the year ended June 30, 2023). The intangible asset&#x2019;s life will remain indefinite until such time it is completed and commercialized or impaired. The carrying value of in-process research and development is a separate asset which has been subject to impairment testing at the cash generating unit level, which has been determined to be at the product level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On acquisition, goodwill was not able to be allocated to the cash generating unit (&#x201c;CGU&#x201d;) level or to a group of CGU given the synergies of the underlying research and development. For the purpose of impairment testing, goodwill is monitored by management at the operating segment level. The Group is managed as one operating segment, being the development of cell technology platform for commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recoverable amount of both goodwill and in-process research and development was assessed as of March 31, 2023 based on the fair value less costs to dispose. As a result of the receipt of the complete response from the FDA in August 2023, an impairment assessment was performed over the in-process research and development value of the MSC asset and goodwill. No impairment was identified as a result of these impairment assessments. Management assessed assets for indicators of impairment as at December&#160;31, 2023 including considering events up to the date of the approval of the financial statements and no indicators of impairment were identified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;Key assumptions used for fair value less costs to dispose calculations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the fair value less costs to dispose the Group has given consideration to the following internal and external indicators:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;discounted expected future cash flows of programs valued by the Group&#x2019;s internal valuation team and reviewed by the interim CFO. The valuation team also manages a process to continually refine the key assumptions within the model. This is done with input from the relevant business units. The key assumptions in the model have been clearly defined and the responsibility for refining those assumptions has been assigned to the most relevant business units. When determining key assumptions, the business units refer to both external sources and past experience as appropriate. The valuation is considered to be level 3 in the fair value hierarchy due to unobservable inputs used in the valuation; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;the scientific results and progress of the trials since acquisition;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;the market capitalization of the Group on the ASX (ASX:MSB); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;the valuation of the Group&#x2019;s assets from an independent valuation. An independent valuation was obtained for all assets at March 31, 2023 and for the MSC products an impairment assessment was performed as a result of the receipt of the complete response.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs of disposal were assumed to be immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounted cash-flows used a real post-tax discount rate range of 13.8% to 15.5%, and include estimated real cash inflows and outflows for each program through to expected patent expiry which ranges from 9 to 25 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In relation to cash outflows consideration has been given to cost of goods sold, selling costs and clinical trial schedules including estimates of numbers of patients and per patient costs. Associated expenses such as regulatory fees and patent maintenance have been included as well as any further preclinical development if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In relation to cash inflows consideration has been given to product pricing, market population and penetration, sales rebates and discounts, launch timings and probability of success in the relevant applicable markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no standard growth rates applied, other than our estimates of market penetration which increase initially, plateau and then decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assessment of the recoverable amount of each product has been made in accordance with the discounted cash-flow assumptions outlined above. The assessments showed that the recoverable amount of each product exceeds the carrying amount and therefore there is no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assessment of goodwill showed the recoverable amount of the Group's operating segment, including goodwill and remaining in-process research and development, exceeds carrying amounts, and therefore there is no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(v)&#160;&#160;&#160;&#160;Impact of possible changes in key assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has considered and assessed reasonably possible changes in the key assumptions and has not identified any instances that could cause the carrying amount of our intangible assets to exceed its recoverable amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whilst there is no impairment, the key sensitivities in the valuation are dependent on the continued successful development of our technology platforms. Future discussion with the FDA could change the  assumptions used within the impairment assessments. If the Group is unable to successfully develop its technology platforms, an impairment of the carrying amount of our intangible assets may result.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&#160;&#160;&#160;&#160;Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.024%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;25,303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;16,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;23,011&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The classification of contingent consideration as current represents the expected payments within the next 12 months based on current development timelines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Information about individual provisions and significant estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration provision relates to the Group&#x2019;s liability for certain milestones and royalty achievements pertaining to the acquired MSC assets. Further disclosures can be found in Note 5(e)(iii).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for employee benefits relates to the Group&#x2019;s liability for annual leave, short term incentives and long service leave.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits include accrued annual leave. As at December&#160;31, 2023 and June&#160;30, 2023, the entire amount of the annual leave accrual was $1.2 million and $1.1 million respectively, and is presented as current, since the Group does not have an unconditional right to defer settlement for any of these obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Movements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration provision relates to the Group&#x2019;s liability for certain milestones and royalty achievements. Refer to Note 5(e)(iii) for movements in contingent consideration for the period ended December&#160;31, 2023 and June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c.&#160;&#160;&#160;&#160;Deferred tax balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Deferred tax balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance comprises temporary differences attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance comprises temporary differences attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Movements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Tax losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(DTA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;temporary&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;differences&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(DTA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;assets (DTL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total (DTL) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(80,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;88,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- directly to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(76,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- directly to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(74,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(13,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Deferred tax assets are netted against deferred tax liabilities&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfNonFinancialAssetsAndNonFinancialLiabilitiesExplanatoryTextBlock>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c-1" id="f-726">Intangible assets&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Acquired licenses&lt;br/&gt;to patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;In-process&lt;br/&gt;research and&lt;br/&gt;development&lt;br/&gt;acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current marketed&lt;br/&gt;products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;578,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;577,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;489,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;651,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;577,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Six Months Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;427,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;577,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(727)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;576,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;489,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;651,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;134,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;576,564&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-188" decimals="-3" id="f-727" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-189" decimals="-3" id="f-728" unitRef="usd">1632000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-190" decimals="-3" id="f-729" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-191" decimals="-3" id="f-730" unitRef="usd">14788000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-9" decimals="-3" id="f-731" unitRef="usd">578652000</ifrs-full:IntangibleAssetsAndGoodwill>
    <meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-192" decimals="-3" id="f-732" unitRef="usd">23000</meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-733" unitRef="usd">23000</meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-192" decimals="-3" id="f-734" unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-193" decimals="-3" id="f-735" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-736" unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-192" decimals="-3" id="f-737" unitRef="usd">38000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-193" decimals="-3" id="f-738" unitRef="usd">1455000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-80" decimals="-3" id="f-739" unitRef="usd">1493000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-194" decimals="-3" id="f-740" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-195" decimals="-3" id="f-741" unitRef="usd">1618000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-196" decimals="-3" id="f-742" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-197" decimals="-3" id="f-743" unitRef="usd">13333000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-29" decimals="-3" id="f-744" unitRef="usd">577183000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-198" decimals="-3" id="f-745" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-199" decimals="-3" id="f-746" unitRef="usd">2993000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-200" decimals="-3" id="f-747" unitRef="usd">489698000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-201" decimals="-3" id="f-748" unitRef="usd">23999000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-202" decimals="-3" id="f-749" unitRef="usd">651143000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-203" decimals="-3" id="f-750" unitRef="usd">-1375000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-204" decimals="-3" id="f-751" unitRef="usd">-10666000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-205" decimals="-3" id="f-752" unitRef="usd">-12041000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-206" decimals="-3" id="f-753" unitRef="usd">-61919000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-207" decimals="-3" id="f-754" unitRef="usd">-61919000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-194" decimals="-3" id="f-755" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-195" decimals="-3" id="f-756" unitRef="usd">1618000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-196" decimals="-3" id="f-757" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-197" decimals="-3" id="f-758" unitRef="usd">13333000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-29" decimals="-3" id="f-759" unitRef="usd">577183000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-194" decimals="-3" id="f-760" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-195" decimals="-3" id="f-761" unitRef="usd">1618000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-196" decimals="-3" id="f-762" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-197" decimals="-3" id="f-763" unitRef="usd">13333000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-29" decimals="-3" id="f-764" unitRef="usd">577183000</ifrs-full:IntangibleAssetsAndGoodwill>
    <meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-208" decimals="-3" id="f-765" unitRef="usd">122000</meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-766" unitRef="usd">122000</meso:AdditionsReversalOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-208" decimals="-3" id="f-767" unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-209" decimals="-3" id="f-768" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-210" decimals="-3" id="f-769" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-770" unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-208" decimals="-3" id="f-771" unitRef="usd">15000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-210" decimals="-3" id="f-772" unitRef="usd">727000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-1" decimals="-3" id="f-773" unitRef="usd">742000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-211" decimals="-3" id="f-774" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-212" decimals="-3" id="f-775" unitRef="usd">1726000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-213" decimals="-3" id="f-776" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-214" decimals="-3" id="f-777" unitRef="usd">12606000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-41" decimals="-3" id="f-778" unitRef="usd">576564000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-215" decimals="-3" id="f-779" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-216" decimals="-3" id="f-780" unitRef="usd">3131000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-217" decimals="-3" id="f-781" unitRef="usd">489698000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-218" decimals="-3" id="f-782" unitRef="usd">24000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-219" decimals="-3" id="f-783" unitRef="usd">651282000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-220" decimals="-3" id="f-784" unitRef="usd">-1405000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-221" decimals="-3" id="f-785" unitRef="usd">-11394000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-222" decimals="-3" id="f-786" unitRef="usd">-12799000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-223" decimals="-3" id="f-787" unitRef="usd">-61919000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-224" decimals="-3" id="f-788" unitRef="usd">-61919000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-211" decimals="-3" id="f-789" unitRef="usd">134453000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-212" decimals="-3" id="f-790" unitRef="usd">1726000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-213" decimals="-3" id="f-791" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-214" decimals="-3" id="f-792" unitRef="usd">12606000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-41" decimals="-3" id="f-793" unitRef="usd">576564000</ifrs-full:IntangibleAssetsAndGoodwill>
    <meso:DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock contextRef="c-1" id="f-794">Carrying value of in-process research and development acquired by product&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiovascular products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;254,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;254,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intravenous products for metabolic diseases and inflammatory/immunologic conditions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MSC products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;427,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Includes MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;Includes remestemcel-L for the treatment of adults and children with SR-aGVHD and remestemcel-L for the treatment of Crohn&#x2019;s disease</meso:DisclosureOfCarryingValueOfInProcessResearchAndDevelopmentAcquiredByProductExplanatoryTableTextBlock>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-225" decimals="-3" id="f-795" unitRef="usd">254351000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-226" decimals="-3" id="f-796" unitRef="usd">254351000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-227" decimals="-3" id="f-797" unitRef="usd">70730000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-228" decimals="-3" id="f-798" unitRef="usd">70730000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-229" decimals="-3" id="f-799" unitRef="usd">102698000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-230" decimals="-3" id="f-800" unitRef="usd">102698000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-213" decimals="-3" id="f-801" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c-196" decimals="-3" id="f-802" unitRef="usd">427779000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossOnFinancialAssets contextRef="c-231" decimals="INF" id="f-803" unitRef="usd">0</ifrs-full:ImpairmentLossOnFinancialAssets>
    <ifrs-full:ImpairmentLossOnFinancialAssets contextRef="c-232" decimals="INF" id="f-804" unitRef="usd">0</ifrs-full:ImpairmentLossOnFinancialAssets>
    <ifrs-full:ImpairmentLossOnFinancialAssets contextRef="c-232" decimals="INF" id="f-805" unitRef="usd">0</ifrs-full:ImpairmentLossOnFinancialAssets>
    <ifrs-full:ImpairmentLossOnFinancialAssets contextRef="c-231" decimals="INF" id="f-806" unitRef="usd">0</ifrs-full:ImpairmentLossOnFinancialAssets>
    <meso:PostTaxDiscountRates contextRef="c-233" decimals="3" id="f-807" unitRef="number">0.138</meso:PostTaxDiscountRates>
    <meso:PostTaxDiscountRates contextRef="c-234" decimals="3" id="f-808" unitRef="number">0.155</meso:PostTaxDiscountRates>
    <meso:ExpectedPatentExpiry contextRef="c-233" id="f-809">P9Y</meso:ExpectedPatentExpiry>
    <meso:ExpectedPatentExpiry contextRef="c-234" id="f-810">P25Y</meso:ExpectedPatentExpiry>
    <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="c-1" id="f-811">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.024%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for license agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,230&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;17,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;25,303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;16,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;23,011&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The classification of contingent consideration as current represents the expected payments within the next 12 months based on current development timelines.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
    <ifrs-full:CurrentProvisions contextRef="c-235" decimals="-3" id="f-812" unitRef="usd">500000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-235" decimals="-3" id="f-813" unitRef="usd">17036000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-235" decimals="-3" id="f-814" unitRef="usd">17536000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-236" decimals="-3" id="f-815" unitRef="usd">636000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-236" decimals="-3" id="f-816" unitRef="usd">16563000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-236" decimals="-3" id="f-817" unitRef="usd">17199000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-237" decimals="-3" id="f-818" unitRef="usd">3980000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-237" decimals="-3" id="f-819" unitRef="usd">37000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-237" decimals="-3" id="f-820" unitRef="usd">4017000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-238" decimals="-3" id="f-821" unitRef="usd">2013000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-238" decimals="-3" id="f-822" unitRef="usd">49000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-238" decimals="-3" id="f-823" unitRef="usd">2062000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-239" decimals="-3" id="f-824" unitRef="usd">3750000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-239" decimals="-3" id="f-825" unitRef="usd">0</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-239" decimals="-3" id="f-826" unitRef="usd">3750000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-240" decimals="-3" id="f-827" unitRef="usd">3750000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-240" decimals="-3" id="f-828" unitRef="usd">0</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-240" decimals="-3" id="f-829" unitRef="usd">3750000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-41" decimals="-3" id="f-830" unitRef="usd">8230000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-41" decimals="-3" id="f-831" unitRef="usd">17073000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-41" decimals="-3" id="f-832" unitRef="usd">25303000</ifrs-full:Provisions>
    <ifrs-full:CurrentProvisions contextRef="c-29" decimals="-3" id="f-833" unitRef="usd">6399000</ifrs-full:CurrentProvisions>
    <ifrs-full:NoncurrentProvisions contextRef="c-29" decimals="-3" id="f-834" unitRef="usd">16612000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:Provisions contextRef="c-29" decimals="-3" id="f-835" unitRef="usd">23011000</ifrs-full:Provisions>
    <meso:CurrentProvisionsForAccruedAnnualLeave contextRef="c-237" decimals="-5" id="f-836" unitRef="usd">1200000</meso:CurrentProvisionsForAccruedAnnualLeave>
    <meso:CurrentProvisionsForAccruedAnnualLeave contextRef="c-238" decimals="-5" id="f-837" unitRef="usd">1100000</meso:CurrentProvisionsForAccruedAnnualLeave>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory contextRef="c-1" id="f-838">Deferred tax balances&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance comprises temporary differences attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance comprises temporary differences attributable to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses contextRef="c-41" decimals="-3" id="f-839" unitRef="usd">74684000</meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses>
    <meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses contextRef="c-29" decimals="-3" id="f-840" unitRef="usd">76020000</meso:DeferredTaxAssetsAttributableToTemporaryDifferencesFromTaxLosses>
    <meso:DeferredTaxAssetsAttributableToOtherTemporaryDifferences contextRef="c-41" decimals="-3" id="f-841" unitRef="usd">13185000</meso:DeferredTaxAssetsAttributableToOtherTemporaryDifferences>
    <meso:DeferredTaxAssetsAttributableToOtherTemporaryDifferences contextRef="c-29" decimals="-3" id="f-842" unitRef="usd">11972000</meso:DeferredTaxAssetsAttributableToOtherTemporaryDifferences>
    <ifrs-full:DeferredTaxAssets contextRef="c-41" decimals="-3" id="f-843" unitRef="usd">87869000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-29" decimals="-3" id="f-844" unitRef="usd">87992000</ifrs-full:DeferredTaxAssets>
    <meso:DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets contextRef="c-41" decimals="-3" id="f-845" unitRef="usd">87869000</meso:DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets>
    <meso:DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets contextRef="c-29" decimals="-3" id="f-846" unitRef="usd">87992000</meso:DeferredTaxLiabilitiesAttributableToTemporaryDifferencesFromIntangibleAssets>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-41" decimals="-3" id="f-847" unitRef="usd">87869000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="c-29" decimals="-3" id="f-848" unitRef="usd">87992000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-41" decimals="-3" id="f-849" unitRef="usd">0</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c-29" decimals="-3" id="f-850" unitRef="usd">0</ifrs-full:NetDeferredTaxLiabilities>
    <meso:DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock contextRef="c-1" id="f-851">Movements &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Tax losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(DTA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;temporary&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;differences&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(DTA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intangible&lt;br/&gt;assets (DTL)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total (DTL) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(80,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;88,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- directly to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;212&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(76,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(11,972)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,992&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charged/(credited) to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- directly to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(74,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(13,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;87,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Deferred tax assets are netted against deferred tax liabilities&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfNetMovementRelatedToDeferredTaxAssetsAndLiabilitiesExplanatoryTableTextBlock>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-241" decimals="-3" id="f-852" unitRef="usd">-80411000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-242" decimals="-3" id="f-853" unitRef="usd">-7831000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-243" decimals="-3" id="f-854" unitRef="usd">88242000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-9" decimals="-3" id="f-855" unitRef="usd">0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-244" decimals="-3" id="f-856" unitRef="usd">4179000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-245" decimals="-3" id="f-857" unitRef="usd">-4141000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-246" decimals="-3" id="f-858" unitRef="usd">-250000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-80" decimals="-3" id="f-859" unitRef="usd">-212000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-244" decimals="-3" id="f-860" unitRef="usd">212000</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-245" decimals="-3" id="f-861" unitRef="usd">0</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-246" decimals="-3" id="f-862" unitRef="usd">0</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-80" decimals="-3" id="f-863" unitRef="usd">212000</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-247" decimals="-3" id="f-864" unitRef="usd">-76020000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-248" decimals="-3" id="f-865" unitRef="usd">-11972000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-249" decimals="-3" id="f-866" unitRef="usd">87992000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-29" decimals="-3" id="f-867" unitRef="usd">0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-250" decimals="-3" id="f-868" unitRef="usd">1234000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-251" decimals="-3" id="f-869" unitRef="usd">-1213000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-252" decimals="-3" id="f-870" unitRef="usd">-123000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax contextRef="c-1" decimals="-3" id="f-871" unitRef="usd">-102000</ifrs-full:NetMovementInRegulatoryDeferralAccountBalancesRelatedToProfitOrLossAndNetMovementInRelatedDeferredTax>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-250" decimals="-3" id="f-872" unitRef="usd">102000</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-251" decimals="-3" id="f-873" unitRef="usd">0</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-252" decimals="-3" id="f-874" unitRef="usd">0</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity contextRef="c-1" decimals="-3" id="f-875" unitRef="usd">102000</meso:NetMovementInRegulatoryDeferralAccountBalancesRelatedToDirectlyToEquity>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-253" decimals="-3" id="f-876" unitRef="usd">-74684000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-254" decimals="-3" id="f-877" unitRef="usd">-13185000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-255" decimals="-3" id="f-878" unitRef="usd">87869000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-41" decimals="-3" id="f-879" unitRef="usd">0</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="c-1" id="f-880">Cash flow information&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;br/&gt;(a) Reconciliation of cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits at call&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;77,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;71,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(b) Reconciliation of net cash flows used in operations with loss after income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Add/(deduct) net loss for non-cash items as follows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange (gains)/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity settled share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Change in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease/(increase) in trade and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease/(increase) in prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease/(increase) in tax incentive recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase/(decrease) in trade creditors and accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase/(decrease) in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash outflows used in operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(26,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(30,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock contextRef="c-1" id="f-881">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;br/&gt;(a) Reconciliation of cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash at bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deposits at call&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;77,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;71,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(b) Reconciliation of net cash flows used in operations with loss after income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Add/(deduct) net loss for non-cash items as follows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange (gains)/losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remeasurement of warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity settled share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Change in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease/(increase) in trade and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease/(increase) in prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Decrease/(increase) in tax incentive recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase/(decrease) in trade creditors and accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase/(decrease) in provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash outflows used in operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(26,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(30,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfSummaryOfCashFlowInformationExplanatoryTableTextBlock>
    <ifrs-full:BalancesWithBanks contextRef="c-41" decimals="-3" id="f-882" unitRef="usd">77144000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks contextRef="c-29" decimals="-3" id="f-883" unitRef="usd">70920000</ifrs-full:BalancesWithBanks>
    <meso:DepositsAtCall contextRef="c-41" decimals="-3" id="f-884" unitRef="usd">410000</meso:DepositsAtCall>
    <meso:DepositsAtCall contextRef="c-29" decimals="-3" id="f-885" unitRef="usd">398000</meso:DepositsAtCall>
    <ifrs-full:CashAndCashEquivalents contextRef="c-41" decimals="-3" id="f-886" unitRef="usd">77554000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-29" decimals="-3" id="f-887" unitRef="usd">71318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-888" unitRef="usd">-32539000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-889" unitRef="usd">-41370000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-890" unitRef="usd">2443000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-2" decimals="-3" id="f-891" unitRef="usd">2190000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-3" id="f-892" unitRef="usd">-159000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-2" decimals="-3" id="f-893" unitRef="usd">193000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c-1" decimals="-3" id="f-894" unitRef="usd">-10319000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c-2" decimals="-3" id="f-895" unitRef="usd">-10685000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <meso:FairValueRemeasurementOfContingentConsiderationAfterTax contextRef="c-1" decimals="-3" id="f-896" unitRef="usd">337000</meso:FairValueRemeasurementOfContingentConsiderationAfterTax>
    <meso:FairValueRemeasurementOfContingentConsiderationAfterTax contextRef="c-2" decimals="-3" id="f-897" unitRef="usd">-5989000</meso:FairValueRemeasurementOfContingentConsiderationAfterTax>
    <meso:RemeasurementOfWarrantLiability contextRef="c-1" decimals="-3" id="f-898" unitRef="usd">-4434000</meso:RemeasurementOfWarrantLiability>
    <meso:RemeasurementOfWarrantLiability contextRef="c-2" decimals="-3" id="f-899" unitRef="usd">712000</meso:RemeasurementOfWarrantLiability>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-900" unitRef="usd">2195000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-2" decimals="-3" id="f-901" unitRef="usd">1757000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-1" decimals="-3" id="f-902" unitRef="usd">-102000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="c-2" decimals="-3" id="f-903" unitRef="usd">-126000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-1" decimals="-3" id="f-904" unitRef="usd">2084000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="c-2" decimals="-3" id="f-905" unitRef="usd">-743000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <meso:AdjustmentsForIncreaseDecreaseInPrepayments contextRef="c-1" decimals="-3" id="f-906" unitRef="usd">-131000</meso:AdjustmentsForIncreaseDecreaseInPrepayments>
    <meso:AdjustmentsForIncreaseDecreaseInPrepayments contextRef="c-2" decimals="-3" id="f-907" unitRef="usd">-424000</meso:AdjustmentsForIncreaseDecreaseInPrepayments>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="c-1" decimals="-3" id="f-908" unitRef="usd">-1094000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset contextRef="c-2" decimals="-3" id="f-909" unitRef="usd">0</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <meso:AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals contextRef="c-1" decimals="-3" id="f-910" unitRef="usd">-9500000</meso:AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals>
    <meso:AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals contextRef="c-2" decimals="-3" id="f-911" unitRef="usd">2608000</meso:AdjustmentsForIncreaseDecreaseInTradeCreditorsAndAccruals>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-1" decimals="-3" id="f-912" unitRef="usd">1821000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions contextRef="c-2" decimals="-3" id="f-913" unitRef="usd">-234000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-914" unitRef="usd">-26572000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-2" decimals="-3" id="f-915" unitRef="usd">-30741000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-916">Equity&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&#160;&#160;&#160;&#160;Contributed equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Share capital &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares No. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contributed equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Share capital&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,015,342,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;737,121,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,286,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Treasury Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(542,903)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(542,903)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Contributed Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,014,799,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;736,578,315&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,286,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,207,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Movements in ordinary share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares No.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(U.S. dollars, in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;814,204,825&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;650,454,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,249,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,165,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Issues of ordinary shares during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Placement of shares under a share placement agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201,137,412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,666,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs arising on share issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total contributions of equity during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201,137,412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,666,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,405&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share options reserve transferred to equity on exercise of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,015,342,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;737,121,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,286,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,207,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;During the six months ended December 31,  2023, 201,137,412 shares were issued in a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing shareholders in Australia and certain other countries together with an institutional placement of new fully paid ordinary shares in Mesoblast Limited, at A$0.30 per share.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;During the six months ended December 31, 2022, 86,666,667 shares were issued in an equity purchase of Mesoblast Limited at A$0.75 per share to existing and new institutional investors.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Movements of shares in share trust &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares No. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Movement of shares in share trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise of share options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. From July 1, 2020, unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. Prior to July 1, 2020, the shares issued and share capital received on the exercise of options were recorded in ordinary share capital.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&#160;&#160;&#160;&#160;Warrant reserve&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Movement during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Group completed a A$138.0 million (US$110.0 million) private placement of 60,109,290 new fully-paid ordinary shares at a price of A$2.30. As part of this placement, the Group also issued one warrant for every four ordinary shares issued in the placement, which resulted in a further 15,027,327 warrants issued. Each warrant has an exercise price of A$2.88 per share and a 7-year term.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has a right to compel exercise of the warrants at any time, subject to the price of the Group&#x2019;s ordinary shares trading at least A$4.32 for 45 consecutive days on the ASX. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The warrants do not confer any rights to dividends or a right to participate in a new issue without exercising the warrant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s a result of completing the pro-rata accelerated non-renounceable rights issue in December 2023, the exercise price for the warrants was adjusted from A$2.88 per share to A$2.86 per share with effect from January 5, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the warrants include certain anti-dilution clauses, which adjust the exercise price or conversion ratio in the event of a rights issue or bonus issue. Management analyzed these clauses and determined the fixed-for-fixed requirement was still satisfied because the relative rights of shareholders and warrant holders were maintained. Therefore the warrants were classified as equity. The warrants were initially measured in equity at fair value, which was determined using a Monte Carlo simulation (refer to Note 7(b)(iv) in the Form 20-F for the year ended June 30, 2023 for more details), with the residual consideration being attributed to the ordinary shares issued in the same transaction. The warrants are not remeasured for subsequent changes in fair value.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-917">Share capital &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares No. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contributed equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Share capital&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,015,342,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;737,121,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,286,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,207,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Treasury Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(542,903)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(542,903)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Contributed Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,014,799,334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;736,578,315&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,286,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,207,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-256"
      decimals="INF"
      id="f-918"
      unitRef="shares">1015342237</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-257"
      decimals="INF"
      id="f-919"
      unitRef="shares">737121218</ifrs-full:NumberOfSharesIssued>
    <meso:OrdinarySharesPurchasedValue contextRef="c-256" decimals="-3" id="f-920" unitRef="usd">1286229000</meso:OrdinarySharesPurchasedValue>
    <meso:OrdinarySharesPurchasedValue contextRef="c-257" decimals="-3" id="f-921" unitRef="usd">1207714000</meso:OrdinarySharesPurchasedValue>
    <meso:TreasurySharesPurchased
      contextRef="c-256"
      decimals="INF"
      id="f-922"
      unitRef="shares">542903</meso:TreasurySharesPurchased>
    <meso:TreasurySharesPurchased
      contextRef="c-257"
      decimals="INF"
      id="f-923"
      unitRef="shares">542903</meso:TreasurySharesPurchased>
    <meso:TreasurySharesPurchasedValue contextRef="c-256" decimals="-3" id="f-924" unitRef="usd">0</meso:TreasurySharesPurchasedValue>
    <meso:TreasurySharesPurchasedValue contextRef="c-257" decimals="-3" id="f-925" unitRef="usd">0</meso:TreasurySharesPurchasedValue>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-256"
      decimals="INF"
      id="f-926"
      unitRef="shares">1014799334</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-257"
      decimals="INF"
      id="f-927"
      unitRef="shares">736578315</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-256" decimals="-3" id="f-928" unitRef="usd">1286229000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-257" decimals="-3" id="f-929" unitRef="usd">1207714000</ifrs-full:Equity>
    <meso:DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock contextRef="c-1" id="f-930">Movements in ordinary share capital&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares No.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(U.S. dollars, in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;814,204,825&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;650,454,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,249,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,165,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Issues of ordinary shares during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Placement of shares under a share placement agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201,137,412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,666,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs arising on share issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total contributions of equity during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201,137,412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,666,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,405&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share options reserve transferred to equity on exercise of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,015,342,237&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;737,121,218&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,286,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,207,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;During the six months ended December 31,  2023, 201,137,412 shares were issued in a 1 for 4 pro-rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Mesoblast Limited to existing shareholders in Australia and certain other countries together with an institutional placement of new fully paid ordinary shares in Mesoblast Limited, at A$0.30 per share.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;During the six months ended December 31, 2022, 86,666,667 shares were issued in an equity purchase of Mesoblast Limited at A$0.75 per share to existing and new institutional investors.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfMovementsInOrdinaryShareCapitalExplanatoryTableTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-258"
      decimals="INF"
      id="f-931"
      unitRef="shares">814204825</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-259"
      decimals="INF"
      id="f-932"
      unitRef="shares">650454551</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-258" decimals="-3" id="f-933" unitRef="usd">1249123000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-259" decimals="-3" id="f-934" unitRef="usd">1165309000</ifrs-full:Equity>
    <meso:SharesAvailableForIssuanceUnderIssuancePlan
      contextRef="c-260"
      decimals="INF"
      id="f-935"
      unitRef="shares">201137412</meso:SharesAvailableForIssuanceUnderIssuancePlan>
    <meso:SharesAvailableForIssuanceUnderIssuancePlan
      contextRef="c-261"
      decimals="INF"
      id="f-936"
      unitRef="shares">86666667</meso:SharesAvailableForIssuanceUnderIssuancePlan>
    <meso:SharesIssuedInPlacementsValue contextRef="c-260" decimals="-3" id="f-937" unitRef="usd">39708000</meso:SharesIssuedInPlacementsValue>
    <meso:SharesIssuedInPlacementsValue contextRef="c-261" decimals="-3" id="f-938" unitRef="usd">45065000</meso:SharesIssuedInPlacementsValue>
    <meso:TransactionCostsArisingOnShareIssueShare
      contextRef="c-262"
      decimals="INF"
      id="f-939"
      unitRef="shares">0</meso:TransactionCostsArisingOnShareIssueShare>
    <meso:TransactionCostsArisingOnShareIssueShare
      contextRef="c-263"
      decimals="INF"
      id="f-940"
      unitRef="shares">0</meso:TransactionCostsArisingOnShareIssueShare>
    <meso:TransactionCostsArisingOnShareIssue contextRef="c-262" decimals="-3" id="f-941" unitRef="usd">2602000</meso:TransactionCostsArisingOnShareIssue>
    <meso:TransactionCostsArisingOnShareIssue contextRef="c-263" decimals="-3" id="f-942" unitRef="usd">2660000</meso:TransactionCostsArisingOnShareIssue>
    <meso:ContributionsOfEquityDuringPeriod
      contextRef="c-262"
      decimals="INF"
      id="f-943"
      unitRef="shares">201137412</meso:ContributionsOfEquityDuringPeriod>
    <meso:ContributionsOfEquityDuringPeriod
      contextRef="c-263"
      decimals="INF"
      id="f-944"
      unitRef="shares">86666667</meso:ContributionsOfEquityDuringPeriod>
    <meso:ContributionsOfValueForEquityDuringPeriod contextRef="c-262" decimals="-3" id="f-945" unitRef="usd">37106000</meso:ContributionsOfValueForEquityDuringPeriod>
    <meso:ContributionsOfValueForEquityDuringPeriod contextRef="c-263" decimals="-3" id="f-946" unitRef="usd">42405000</meso:ContributionsOfValueForEquityDuringPeriod>
    <meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare
      contextRef="c-262"
      decimals="INF"
      id="f-947"
      unitRef="shares">0</meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare>
    <meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare
      contextRef="c-263"
      decimals="INF"
      id="f-948"
      unitRef="shares">0</meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsShare>
    <meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue contextRef="c-262" decimals="-3" id="f-949" unitRef="usd">0</meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue>
    <meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue contextRef="c-263" decimals="-3" id="f-950" unitRef="usd">0</meso:ShareOptionsReserveTransferredToEquityOnExerciseOfOptionsValue>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-256"
      decimals="INF"
      id="f-951"
      unitRef="shares">1015342237</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-257"
      decimals="INF"
      id="f-952"
      unitRef="shares">737121218</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-256" decimals="-3" id="f-953" unitRef="usd">1286229000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-257" decimals="-3" id="f-954" unitRef="usd">1207714000</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesIssuedButNotFullyPaid
      contextRef="c-42"
      decimals="INF"
      id="f-955"
      unitRef="shares">201137412</ifrs-full:NumberOfSharesIssuedButNotFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="c-42"
      decimals="INF"
      id="f-956"
      unitRef="audPerShare">0.30</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssuedButNotFullyPaid
      contextRef="c-264"
      decimals="INF"
      id="f-957"
      unitRef="shares">86666667</ifrs-full:NumberOfSharesIssuedButNotFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="c-264"
      decimals="INF"
      id="f-958"
      unitRef="audPerShare">0.75</ifrs-full:ParValuePerShare>
    <meso:DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock contextRef="c-1" id="f-959">Movements of shares in share trust &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;br/&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares No. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Movement of shares in share trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise of share options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;542,903&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Options are issued to employees, directors and consultants in accordance with the Mesoblast Employee Share Option Plan. From July 1, 2020, unpaid shares are issued to the share trust to enable future option exercises to be settled. On exercise of options, the proceeds of the exercise are recorded in ordinary share capital in Mesoblast Limited and the exercise is settled by transfer of the shares from the share trust to the employee. Prior to July 1, 2020, the shares issued and share capital received on the exercise of options were recorded in ordinary share capital.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfMovementsOfSharesInShareTrustExplanatoryTableTextBlock>
    <meso:SharesHeldInTrust
      contextRef="c-265"
      decimals="INF"
      id="f-960"
      unitRef="shares">542903</meso:SharesHeldInTrust>
    <meso:SharesHeldInTrust
      contextRef="c-266"
      decimals="INF"
      id="f-961"
      unitRef="shares">542903</meso:SharesHeldInTrust>
    <meso:SharesHeldInTrustValue contextRef="c-265" decimals="INF" id="f-962" unitRef="usd">0</meso:SharesHeldInTrustValue>
    <meso:SharesHeldInTrustValue contextRef="c-266" decimals="INF" id="f-963" unitRef="usd">0</meso:SharesHeldInTrustValue>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-267"
      decimals="INF"
      id="f-964"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c-268"
      decimals="INF"
      id="f-965"
      unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-267" decimals="INF" id="f-966" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-268" decimals="INF" id="f-967" unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <meso:SharesHeldInTrust
      contextRef="c-269"
      decimals="INF"
      id="f-968"
      unitRef="shares">542903</meso:SharesHeldInTrust>
    <meso:SharesHeldInTrust
      contextRef="c-270"
      decimals="INF"
      id="f-969"
      unitRef="shares">542903</meso:SharesHeldInTrust>
    <meso:SharesHeldInTrustValue contextRef="c-269" decimals="INF" id="f-970" unitRef="usd">0</meso:SharesHeldInTrustValue>
    <meso:SharesHeldInTrustValue contextRef="c-270" decimals="INF" id="f-971" unitRef="usd">0</meso:SharesHeldInTrustValue>
    <meso:DisclosureOfWarrantReserveExplanatoryTableTextBlock contextRef="c-1" id="f-972">Warrant reserve&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrant reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Movement during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Closing Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;12,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfWarrantReserveExplanatoryTableTextBlock>
    <ifrs-full:Equity contextRef="c-271" decimals="-3" id="f-973" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-272" decimals="-3" id="f-974" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:ChangesInEquity contextRef="c-273" decimals="-3" id="f-975" unitRef="usd">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="c-274" decimals="-3" id="f-976" unitRef="usd">0</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity contextRef="c-275" decimals="-3" id="f-977" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-271" decimals="-3" id="f-978" unitRef="usd">12969000</ifrs-full:Equity>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-276" decimals="-5" id="f-979" unitRef="aud">138000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-276" decimals="-5" id="f-980" unitRef="usd">110000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-277"
      decimals="INF"
      id="f-981"
      unitRef="shares">60109290</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="c-277"
      decimals="2"
      id="f-982"
      unitRef="audPerShare">2.30</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-278"
      decimals="INF"
      id="f-983"
      unitRef="shares">15027327</ifrs-full:NumberOfSharesIssued>
    <meso:WarrantExercisePricePerShare
      contextRef="c-278"
      decimals="INF"
      id="f-984"
      unitRef="audPerShare">2.88</meso:WarrantExercisePricePerShare>
    <meso:WarrantExerciseTerm contextRef="c-279" id="f-985">P7Y</meso:WarrantExerciseTerm>
    <meso:SharesPrice
      contextRef="c-280"
      decimals="2"
      id="f-986"
      unitRef="audPerShare">4.32</meso:SharesPrice>
    <meso:SharePriceMinimumConsecutiveDay contextRef="c-278" id="f-987">P45D</meso:SharePriceMinimumConsecutiveDay>
    <meso:WarrantExercisePricePerShare
      contextRef="c-281"
      decimals="INF"
      id="f-988"
      unitRef="audPerShare">2.88</meso:WarrantExercisePricePerShare>
    <meso:WarrantExercisePricePerShare
      contextRef="c-282"
      decimals="INF"
      id="f-989"
      unitRef="audPerShare">2.86</meso:WarrantExercisePricePerShare>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="c-1" id="f-991">Financial risk management&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This note explains the Group&#x2019;s exposure to financial risks and how these risks could affect the Group&#x2019;s future financial performance. Current year profit and loss information has been included where relevant to add further context.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exposure arising from&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Management&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; currency risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future commercial transactions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flow forecasting&lt;br/&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; interest rate risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term deposits at fixed rates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposits at variable rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; price risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; share price risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future exercise of warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise. Therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents, and trade and other receivables and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aging analysis&lt;br/&gt;Credit ratings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rolling cash flow forecasts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future cash flow requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group&#x2019;s future commitments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&#160;&#160;&#160;&#160;Market risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(i)&#160;&#160;&#160;&#160;Currency risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group has foreign currency amounts owing relating to clinical, regulatory and overhead activities and foreign currency deposits held primarily in the Group&#x2019;s Australian based entity, whose functional currency is the A$. The Group also has foreign currency amounts owing &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Group&#x2019;s Swiss and Singapore based entities, whose functional currencies are the US$.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Group also has foreign currency amounts owing in various other non-US$ currencies in A$ and US$ functional currency entities in the Group relating to clinical, regulatory and overhead activities. These foreign currency balances give rise to a currency risk, which is the risk of the exchange rate moving, in either direction, and the impact it may have on the Group&#x2019;s financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Currency risk is minimized by ensuring the proportion of cash reserves held in each currency matches the expected rate of spend of each currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Group held 68% of its cash in US$, 31% in A$ and 1% in other currencies. As of June&#160;30, 2023, the Group held 67% of its cash in US$, and 33% in A$.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(ii)&#160;&#160;&#160;&#160;Cash flow and fair value interest rate risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is exposed to interest rate movements which impacts interest income earned on its deposits and at call accounts. The interest rate risk is managed by spreading the maturity date of our deposits across various periods. The Group ensures that sufficient funds are available, in at call accounts, to meet the working capital requirements of the Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of December&#160;31, 2023 and June&#160;30, 2023. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds invested - US$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate increase by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate decrease by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Australian dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;A$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;A$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds invested - A$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate increase by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate decrease by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) A$ deposits held as of June 30, 2023  have been updated to reflect the increasing impact of higher interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iii)&#160;&#160;&#160;&#160;Price risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Price risk is the risk that future cash flows derived from financial instruments will be altered as a result of a market price movement, which is defined as movements other than foreign currency rates and interest rates. The Group is exposed to price risk which arises from long-term borrowings under its facility with NovaQuest, where the timing and amounts of principal and interest payments is dependent on net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia. As net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in these territories increase/decrease, the timing and amount of principal and interest payments relating to this type of financing arrangement will also fluctuate, resulting in an adjustment to the carrying amount of the financial liability. The adjustment is recognized in the Consolidated Income Statement as remeasurement of borrowing arrangements within finance costs in the period the revision is made.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exposure of the Group&#x2019;s borrowing to price rate changes are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% of total&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% of total&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-current borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;61,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;56,075&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2023, all other factors held constant, a +/- 20% increase/decrease in the forecast net sales of remestemcel-L for the treatment of SR-aGVHD in pediatric patients in the United States and other territories excluding Asia would not have a significant impact on non-current borrowing and profit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is also exposed to price risk on contingent consideration provision balances, as expected unit revenues are a significant unobservable input used in the level 3 fair value measurements. As at December&#160;31, 2023, all other factors held constant, the increase/decrease in price assumptions adopted in the fair value measurements of the contingent consideration provision are discussed in Note 5(e)(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;iv&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group does not consider it has any exposure to price risk other than those already described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(iv)&#160;&#160;&#160;&#160;Share price risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group's exposure to share price risk arises from warrant liabilities held by the Group and classified in the statement of financial position at fair value through profit or loss. The future exercise of these warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise, therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the impact of the increase/decrease of Mesoblast's share price on the Group's profit or loss during the period, based on the assumption that the share price had increased/decreased by 10% and 10% with all other variables held constant as of December&#160;31, 2023 and June&#160;30, 2023 respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impact on profit or (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share price increase by 10% (2023: 10%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share price decrease by 10% (2023: 10%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&#160;&#160;&#160;&#160;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk that one party to a financial instrument will fail to discharge its obligation and cause financial loss to the other party. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets as mentioned in Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;c.&#160;&#160;&#160;&#160;Liquidity risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk is the risk that the Group will not be able to pay its debts as and when they fall due. Liquidity risk has been assessed in Note 1(i). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All financial liabilities, excluding contingent consideration, borrowings and lease liabilities held by the Group as of December&#160;31, 2023 and June&#160;30, 2023 mature within 6 months. Trade payables and contingent consideration held by the Group as of December&#160;31, 2023 and June&#160;30, 2023 are non-interest bearing. The total contractual cash flows associated with trade payables equate to the carrying amount disclosed within the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which therefore differs from the carrying value, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Within &lt;br/&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Between &lt;br/&gt;1-2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Between &lt;br/&gt;2-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over &lt;br/&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;br/&gt;contractual &lt;br/&gt;cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(143,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(171,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(115,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(28,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(22,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(144,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(195,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(133,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at December&#160;31, 2023 without taking into account drawdowns of further tranches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD in the United States and other territories excluding Asia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. Product royalties will be payable in cash which will be funded from royalties received from net sales. With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Group commenced production under its manufacturing service agreement with Lonza for the supply of commercial product for the potential approval and launch of remestemcel-L for the treatment of pediatric SR-aGVHD in the US market. This agreement contains lease and non-lease components. As of December&#160;31, 2023, the agreement contains a minimum remaining financial commitment of the non-lease component of $12.7 million, payable until June 2025, which is cancellable in limited circumstances. The Group has accounted for the lease component within the agreement as a lease liability separately from the non-lease components. As of December&#160;31, 2023, the lease component is $2.5 million on an undiscounted basis, as disclosed within the total contractual cash flows as lease liabilities in Note 9(c). At the Group's discretion, the minimum financial commitment under this manufacturing services agreement can be reduced by $7.4&#160;million under certain conditions, with $1.5&#160;million of this reduction relating to the lease component and $5.9&#160;million relating to the non-lease component of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group have agreements with third parties related to contract manufacturing and other goods and services. As of December&#160;31, 2023, the Group had $5.7 million of non-cancellable purchase commitments related to raw materials, manufacturing agreements and other goods and services (excluding those with Lonza). This amount represents our minimum contractual obligations, including termination fees. Certain agreements provide for termination rights subject to termination fees. Under such agreements, the Group are contractually obligated to make certain payments, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation.&lt;/span&gt;&lt;/div&gt;The Group did not have any other purchase commitments as of December&#160;31, 2023.</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <meso:DisclosureOfExposureToFinancialRisksTableTextBlock contextRef="c-1" id="f-992">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This note explains the Group&#x2019;s exposure to financial risks and how these risks could affect the Group&#x2019;s future financial performance. Current year profit and loss information has been included where relevant to add further context.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exposure arising from&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Management&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; currency risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future commercial transactions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognized financial assets and liabilities not denominated in the functional currency of each entity within the Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flow forecasting&lt;br/&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future cash flows of each currency are forecast and the quantum of cash reserves held for each currency are managed in line with future forecasted requirements. Cross currency swaps are undertaken as required.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; interest rate risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Term deposits at fixed rates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposits at variable rates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vary length of term deposits, utilize interest bearing accounts and periodically review interest rates available to ensure we earn interest at market rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; price risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forecasts of net sales of the product underlying the NovaQuest borrowing arrangement are updated on a quarterly basis to evaluate the impact on the carrying amount of the financial liability. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market risk &#x2013; share price risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sensitivity analysis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future exercise of warrants will not impact the Group's future cash flows significantly given the warrants will be paid in shares upon exercise. Therefore there are no significant cashflow risks associated with these warrants. The Group monitors the impact on profit or loss that share price movements have on the valuation of the warrant liability each period. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents, and trade and other receivables and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aging analysis&lt;br/&gt;Credit ratings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transact primarily with the best risk rated banks available in each region giving consideration to the products required, the quantum of cash reserves held and future forecasted requirements.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents, borrowings, trade payables, lease liabilities and contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rolling cash flow forecasts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future cash flow requirements are forecasted and capital raising strategies are planned to ensure sufficient cash balances are maintained to meet the Group&#x2019;s future commitments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfExposureToFinancialRisksTableTextBlock>
    <meso:PercentageOfCashHeld contextRef="c-284" decimals="2" id="f-993" unitRef="number">0.68</meso:PercentageOfCashHeld>
    <meso:PercentageOfCashHeld contextRef="c-285" decimals="2" id="f-994" unitRef="number">0.31</meso:PercentageOfCashHeld>
    <meso:PercentageOfCashHeld contextRef="c-286" decimals="2" id="f-995" unitRef="number">0.01</meso:PercentageOfCashHeld>
    <meso:PercentageOfCashHeld contextRef="c-287" decimals="2" id="f-996" unitRef="number">0.67</meso:PercentageOfCashHeld>
    <meso:PercentageOfCashHeld contextRef="c-288" decimals="2" id="f-997" unitRef="number">0.33</meso:PercentageOfCashHeld>
    <meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock contextRef="c-1" id="f-998">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deposits held which derive interest revenue are described in the table below, together with the maximum and minimum interest rates being earned as of December&#160;31, 2023 and June&#160;30, 2023. The effect on profit is shown if interest rates change by 10%, in either direction, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.515%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.319%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.898%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.424%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds invested - US$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate increase by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate decrease by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;June 30, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in Australian dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;A$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Low &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;High &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;A$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds invested - A$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate increase by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rate decrease by 10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) A$ deposits held as of June 30, 2023  have been updated to reflect the increasing impact of higher interest rates.&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfDepositsHeldWhichDeriveInterestRevenueWithMaximumAndMinimumInterestRatesBeingEarnedExplanatoryTableTextBlock>
    <meso:EffectOnProfitFromChangeInInterestRate
      contextRef="c-289"
      decimals="INF"
      id="f-999"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRate>
    <meso:EffectOnProfitFromChangeInInterestRate
      contextRef="c-290"
      decimals="INF"
      id="f-1000"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRate>
    <meso:FundsInvestedPercentage
      contextRef="c-291"
      decimals="4"
      id="f-1001"
      unitRef="number">0.0184</meso:FundsInvestedPercentage>
    <meso:FundsInvestedPercentage
      contextRef="c-292"
      decimals="4"
      id="f-1002"
      unitRef="number">0.0184</meso:FundsInvestedPercentage>
    <meso:FundsInvestedWhichDerivesInterestRevenue contextRef="c-293" decimals="-3" id="f-1003" unitRef="usd">49950000</meso:FundsInvestedWhichDerivesInterestRevenue>
    <meso:FundsInvestedPercentage
      contextRef="c-294"
      decimals="4"
      id="f-1004"
      unitRef="number">0.0179</meso:FundsInvestedPercentage>
    <meso:FundsInvestedPercentage
      contextRef="c-295"
      decimals="4"
      id="f-1005"
      unitRef="number">0.0179</meso:FundsInvestedPercentage>
    <meso:FundsInvestedWhichDerivesInterestRevenue contextRef="c-296" decimals="-3" id="f-1006" unitRef="usd">40569000</meso:FundsInvestedWhichDerivesInterestRevenue>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-293"
      decimals="INF"
      id="f-1007"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-296"
      decimals="INF"
      id="f-1008"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-291"
      decimals="4"
      id="f-1009"
      unitRef="number">0.0202</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-292"
      decimals="4"
      id="f-1010"
      unitRef="number">0.0202</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-293" decimals="-3" id="f-1011" unitRef="usd">92000</meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-294"
      decimals="4"
      id="f-1012"
      unitRef="number">0.0197</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-295"
      decimals="4"
      id="f-1013"
      unitRef="number">0.0197</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-296" decimals="-3" id="f-1014" unitRef="usd">73000</meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-293"
      decimals="INF"
      id="f-1015"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-296"
      decimals="INF"
      id="f-1016"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-291"
      decimals="4"
      id="f-1017"
      unitRef="number">0.0166</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-292"
      decimals="4"
      id="f-1018"
      unitRef="number">0.0166</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-293" decimals="-3" id="f-1019" unitRef="usd">92000</meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-294"
      decimals="4"
      id="f-1020"
      unitRef="number">0.0161</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-295"
      decimals="4"
      id="f-1021"
      unitRef="number">0.0161</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-296" decimals="-3" id="f-1022" unitRef="usd">73000</meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:FundsInvestedPercentage
      contextRef="c-297"
      decimals="4"
      id="f-1023"
      unitRef="number">0.0385</meso:FundsInvestedPercentage>
    <meso:FundsInvestedPercentage
      contextRef="c-298"
      decimals="4"
      id="f-1024"
      unitRef="number">0.0488</meso:FundsInvestedPercentage>
    <meso:FundsInvestedWhichDerivesInterestRevenue contextRef="c-299" decimals="-3" id="f-1025" unitRef="aud">35466000</meso:FundsInvestedWhichDerivesInterestRevenue>
    <meso:FundsInvestedPercentage
      contextRef="c-300"
      decimals="4"
      id="f-1026"
      unitRef="number">0.0360</meso:FundsInvestedPercentage>
    <meso:FundsInvestedPercentage
      contextRef="c-301"
      decimals="4"
      id="f-1027"
      unitRef="number">0.0459</meso:FundsInvestedPercentage>
    <meso:FundsInvestedWhichDerivesInterestRevenue contextRef="c-302" decimals="-3" id="f-1028" unitRef="aud">35707000</meso:FundsInvestedWhichDerivesInterestRevenue>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-302"
      decimals="INF"
      id="f-1029"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-299"
      decimals="INF"
      id="f-1030"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-297"
      decimals="4"
      id="f-1031"
      unitRef="number">0.0424</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-298"
      decimals="4"
      id="f-1032"
      unitRef="number">0.0537</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-299" decimals="-3" id="f-1033" unitRef="aud">151000</meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-300"
      decimals="4"
      id="f-1034"
      unitRef="number">0.0396</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRatePercentage
      contextRef="c-301"
      decimals="4"
      id="f-1035"
      unitRef="number">0.0505</meso:IncreaseInInterestRatePercentage>
    <meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-302" decimals="-3" id="f-1036" unitRef="aud">143000</meso:IncreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-299"
      decimals="INF"
      id="f-1037"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease
      contextRef="c-302"
      decimals="INF"
      id="f-1038"
      unitRef="number">0.10</meso:EffectOnProfitFromChangeInInterestRateIncreaseOrDecrease>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-297"
      decimals="4"
      id="f-1039"
      unitRef="number">0.0347</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-298"
      decimals="4"
      id="f-1040"
      unitRef="number">0.0439</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-299" decimals="-3" id="f-1041" unitRef="aud">151000</meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-300"
      decimals="4"
      id="f-1042"
      unitRef="number">0.0324</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRatePercentage
      contextRef="c-301"
      decimals="4"
      id="f-1043"
      unitRef="number">0.0413</meso:DecreaseInInterestRatePercentage>
    <meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue contextRef="c-302" decimals="-3" id="f-1044" unitRef="aud">143000</meso:DecreaseInInterestRateOnFundsInvestedWhichDerivesInterestRevenue>
    <meso:DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock contextRef="c-1" id="f-1045">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exposure of the Group&#x2019;s borrowing to price rate changes are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands, except percent data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% of total&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;% of total&lt;br/&gt;borrowings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-current borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings - NovaQuest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;61,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;56,075&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfBorrowingsDerivingPriceRiskExplanatoryTableTextBlock>
    <ifrs-full:ShorttermBorrowings contextRef="c-303" decimals="-3" id="f-1046" unitRef="usd">367000</ifrs-full:ShorttermBorrowings>
    <meso:PercentageOfPriceRateChangesInCurrentBorrowings
      contextRef="c-303"
      decimals="2"
      id="f-1047"
      unitRef="number">0</meso:PercentageOfPriceRateChangesInCurrentBorrowings>
    <ifrs-full:ShorttermBorrowings contextRef="c-304" decimals="-3" id="f-1048" unitRef="usd">336000</ifrs-full:ShorttermBorrowings>
    <meso:PercentageOfPriceRateChangesInCurrentBorrowings
      contextRef="c-304"
      decimals="2"
      id="f-1049"
      unitRef="number">0</meso:PercentageOfPriceRateChangesInCurrentBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-303" decimals="-3" id="f-1050" unitRef="usd">60878000</ifrs-full:LongtermBorrowings>
    <meso:PercentageOfPriceRateChangesInNonCurrentBorrowings
      contextRef="c-303"
      decimals="2"
      id="f-1051"
      unitRef="number">0.53</meso:PercentageOfPriceRateChangesInNonCurrentBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-304" decimals="-3" id="f-1052" unitRef="usd">55739000</ifrs-full:LongtermBorrowings>
    <meso:PercentageOfPriceRateChangesInNonCurrentBorrowings
      contextRef="c-304"
      decimals="2"
      id="f-1053"
      unitRef="number">0.51</meso:PercentageOfPriceRateChangesInNonCurrentBorrowings>
    <ifrs-full:Borrowings contextRef="c-303" decimals="-3" id="f-1054" unitRef="usd">61245000</ifrs-full:Borrowings>
    <meso:PercentageOfPriceRateChangesInBorrowings
      contextRef="c-303"
      decimals="2"
      id="f-1055"
      unitRef="number">0.53</meso:PercentageOfPriceRateChangesInBorrowings>
    <ifrs-full:Borrowings contextRef="c-304" decimals="-3" id="f-1056" unitRef="usd">56075000</ifrs-full:Borrowings>
    <meso:PercentageOfPriceRateChangesInBorrowings
      contextRef="c-304"
      decimals="2"
      id="f-1057"
      unitRef="number">0.51</meso:PercentageOfPriceRateChangesInBorrowings>
    <meso:PercentageOfForecastNetSales contextRef="c-1" decimals="2" id="f-1058" unitRef="number">0.20</meso:PercentageOfForecastNetSales>
    <meso:DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock contextRef="c-1" id="f-1059">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the impact of the increase/decrease of Mesoblast's share price on the Group's profit or loss during the period, based on the assumption that the share price had increased/decreased by 10% and 10% with all other variables held constant as of December&#160;31, 2023 and June&#160;30, 2023 respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.626%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of &lt;br/&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impact on profit or (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share price increase by 10% (2023: 10%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share price decrease by 10% (2023: 10%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</meso:DisclosureOfSensitivityAnalysisEffectOfIncreaseDecreaseInSharePriceTableTextBlock>
    <meso:PercentageOfIncreaseAndDecreaseInSharePrice contextRef="c-41" decimals="2" id="f-1060" unitRef="number">0.10</meso:PercentageOfIncreaseAndDecreaseInSharePrice>
    <meso:PercentageOfIncreaseAndDecreaseInSharePrice contextRef="c-29" decimals="2" id="f-1061" unitRef="number">0.10</meso:PercentageOfIncreaseAndDecreaseInSharePrice>
    <ifrs-full:WarrantLiability contextRef="c-41" decimals="-3" id="f-1062" unitRef="usd">992000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-29" decimals="-3" id="f-1063" unitRef="usd">5426000</ifrs-full:WarrantLiability>
    <meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice contextRef="c-305" decimals="0" id="f-1064" unitRef="usd">-144000</meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice>
    <meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice contextRef="c-306" decimals="0" id="f-1065" unitRef="usd">-698000</meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnIncreaseInSharePrice>
    <meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice contextRef="c-307" decimals="0" id="f-1066" unitRef="usd">140000</meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice>
    <meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice contextRef="c-308" decimals="0" id="f-1067" unitRef="usd">686000</meso:SensitivityAnalysisForTypesOfNetIncomeRiskBasedOnDecreaseInSharePrice>
    <meso:NonInterestBearingFinancialLiabilitiesMaturityPeriod contextRef="c-309" id="f-1068">P6M</meso:NonInterestBearingFinancialLiabilitiesMaturityPeriod>
    <meso:NonInterestBearingFinancialLiabilitiesMaturityPeriod contextRef="c-310" id="f-1069">P6M</meso:NonInterestBearingFinancialLiabilitiesMaturityPeriod>
    <ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities contextRef="c-1" id="f-1070">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maturity profile of the anticipated future contractual cash flows on an undiscounted basis and removing probability adjustments as applicable for contingent consideration, and which therefore differs from the carrying value, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Within &lt;br/&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Between &lt;br/&gt;1-2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Between &lt;br/&gt;2-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over &lt;br/&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total &lt;br/&gt;contractual &lt;br/&gt;cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying &lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(143,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(171,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(115,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(28,630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(22,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(144,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(195,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(133,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;Contractual cash flows include payments of principal, interest and other charges. Interest is calculated based on debt held at December&#160;31, 2023 without taking into account drawdowns of further tranches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In relation to the contractual maturities of the NovaQuest borrowings, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of pediatric SR-aGVHD in the United States and other territories excluding Asia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt"&gt;In relation to the contractual maturities of the royalty payments related to contingent consideration, there is variability in the maturity profile of the anticipated future contractual cash flows given the timing and amount of payments are calculated based on our estimated net sales of remestemcel-L for the treatment of children and adults with aGVHD. Product royalties will be payable in cash which will be funded from royalties received from net sales. With respect to future milestone payments, contingent consideration will be payable in cash or shares at our discretion. The carrying amount reflects the discounted and probability adjusted contractual balance related to royalty payments.&lt;/span&gt;&lt;/div&gt;</ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-311" decimals="-3" id="f-1071" unitRef="usd">-9739000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-312" decimals="-3" id="f-1072" unitRef="usd">-18242000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-313" decimals="-3" id="f-1073" unitRef="usd">-143701000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-314" decimals="-3" id="f-1074" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-315" decimals="-3" id="f-1075" unitRef="usd">-171682000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:GrossLoanCommitments contextRef="c-315" decimals="-3" id="f-1076" unitRef="usd">115763000</ifrs-full:GrossLoanCommitments>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-316" decimals="-3" id="f-1077" unitRef="usd">-10760000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-317" decimals="-3" id="f-1078" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-318" decimals="-3" id="f-1079" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-319" decimals="-3" id="f-1080" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-320" decimals="-3" id="f-1081" unitRef="usd">-10760000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:GrossLoanCommitments contextRef="c-320" decimals="-3" id="f-1082" unitRef="usd">10760000</ifrs-full:GrossLoanCommitments>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-321" decimals="-3" id="f-1083" unitRef="usd">-3131000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-322" decimals="-3" id="f-1084" unitRef="usd">-2877000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-323" decimals="-3" id="f-1085" unitRef="usd">-613000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-324" decimals="-3" id="f-1086" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-325" decimals="-3" id="f-1087" unitRef="usd">-6621000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:GrossLoanCommitments contextRef="c-325" decimals="-3" id="f-1088" unitRef="usd">6237000</ifrs-full:GrossLoanCommitments>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-326" decimals="-3" id="f-1089" unitRef="usd">-5000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-327" decimals="-3" id="f-1090" unitRef="usd">-881000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-328" decimals="-3" id="f-1091" unitRef="usd">-141000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-329" decimals="-3" id="f-1092" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-330" decimals="-3" id="f-1093" unitRef="usd">-6022000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:GrossLoanCommitments contextRef="c-330" decimals="-3" id="f-1094" unitRef="usd">612000</ifrs-full:GrossLoanCommitments>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-331" decimals="-3" id="f-1095" unitRef="usd">-28630000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-332" decimals="-3" id="f-1096" unitRef="usd">-22000000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-333" decimals="-3" id="f-1097" unitRef="usd">-144455000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-334" decimals="-3" id="f-1098" unitRef="usd">0</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows contextRef="c-41" decimals="-3" id="f-1099" unitRef="usd">-195085000</ifrs-full:DerivativeFinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:GrossLoanCommitments contextRef="c-41" decimals="-3" id="f-1100" unitRef="usd">133372000</ifrs-full:GrossLoanCommitments>
    <meso:MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm contextRef="c-335" decimals="-5" id="f-1101" unitRef="usd">12700000</meso:MinimumRemainingFinancialCommitmentOfNonLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm>
    <meso:MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm contextRef="c-335" decimals="-5" id="f-1102" unitRef="usd">2500000</meso:MinimumFinancialCommitmentOfLeaseComponentOnExerciseOfOptionToExtendNonCancellableTerm>
    <meso:MinimumFinancialCommitmentReductionAmount contextRef="c-336" decimals="-5" id="f-1103" unitRef="usd">7400000</meso:MinimumFinancialCommitmentReductionAmount>
    <meso:MinimumFinancialCommitmentReductionAmountOnLeaseComponent contextRef="c-336" decimals="-5" id="f-1104" unitRef="usd">1500000</meso:MinimumFinancialCommitmentReductionAmountOnLeaseComponent>
    <meso:MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent contextRef="c-336" decimals="-5" id="f-1105" unitRef="usd">5900000</meso:MinimumFinancialCommitmentReductionAmountOnNonLeaseComponent>
    <meso:NonCancellablePurchaseCommitments contextRef="c-41" decimals="-5" id="f-1106" unitRef="usd">5700000</meso:NonCancellablePurchaseCommitments>
    <meso:OtherPurchaseCommitments contextRef="c-41" decimals="INF" id="f-1107" unitRef="usd">0</meso:OtherPurchaseCommitments>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-1108">(Losses) per share&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in cents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a) Basic (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From continuing operations attributable to the ordinary equity holders of the company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total basic (losses) per share attributable to the ordinary equity holders of the company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b) Diluted (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From continuing operations attributable to the ordinary equity holders of the company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(c) (Losses) used in calculating (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Diluted (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Losses) from continuing operations attributable to the ordinary equity holders of the company:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Used in calculating basic (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In Shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In Shares)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares used as the denominator in calculating basic losses per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851,464,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;733,282,900&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851,464,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;733,282,900&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees and warrants are considered to be potential ordinary shares. These securities have been excluded from the determination of basic losses per share in the six months ended December&#160;31, 2023 and 2022. Shares that may be paid as contingent consideration have also been excluded from basic losses per share. They have been excluded from the calculation of diluted losses per share because they are anti-dilutive for the six months ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;The calculations for the six months ended December&#160;31, 2023 and 2022 have been adjusted to reflect the bonus element in the entitlement offer to existing eligible shareholders which occurred during December 2023.</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-1109">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in cents)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a) Basic (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From continuing operations attributable to the ordinary equity holders of the company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total basic (losses) per share attributable to the ordinary equity holders of the company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b) Diluted (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From continuing operations attributable to the ordinary equity holders of the company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total diluted (losses) per share attributable to the&#160;ordinary equity holders of the&#160;company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3.82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(c) (Losses) used in calculating (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in U.S. dollars, in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Losses) attributable to the ordinary equity holders of the company used in calculating basic (losses) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Diluted (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Losses) from continuing operations attributable to the ordinary equity holders of the company:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Used in calculating basic (losses) per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Losses) attributable to the ordinary equity holders of the company used in calculating diluted losses per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In Shares)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(In Shares)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares used as the denominator in calculating basic losses per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851,464,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;733,282,900&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares and potential ordinary shares used in calculating diluted losses per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;851,464,145&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;733,282,900&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="4"
      id="f-1110"
      unitRef="usdPerShare">-0.0382</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShareFromContinuingOperations
      contextRef="c-2"
      decimals="4"
      id="f-1111"
      unitRef="usdPerShare">-0.0564</ifrs-full:BasicEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="4"
      id="f-1112"
      unitRef="usdPerShare">-0.0382</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-2"
      decimals="4"
      id="f-1113"
      unitRef="usdPerShare">-0.0564</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-1"
      decimals="4"
      id="f-1114"
      unitRef="usdPerShare">-0.0382</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations
      contextRef="c-2"
      decimals="4"
      id="f-1115"
      unitRef="usdPerShare">-0.0564</ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="4"
      id="f-1116"
      unitRef="usdPerShare">-0.0382</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-2"
      decimals="4"
      id="f-1117"
      unitRef="usdPerShare">-0.0564</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-1" decimals="-3" id="f-1118" unitRef="usd">-32539000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity contextRef="c-2" decimals="-3" id="f-1119" unitRef="usd">-41370000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c-1" decimals="-3" id="f-1120" unitRef="usd">-32539000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c-2" decimals="-3" id="f-1121" unitRef="usd">-41370000</ifrs-full:ProfitLossFromContinuingOperationsAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c-1" decimals="-3" id="f-1122" unitRef="usd">-32539000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects contextRef="c-2" decimals="-3" id="f-1123" unitRef="usd">-41370000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-1124" unitRef="shares">851464145</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-2" decimals="0" id="f-1125" unitRef="shares">733282900</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-1126" unitRef="shares">851464145</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-2" decimals="0" id="f-1127" unitRef="shares">733282900</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1128">Events occurring after the reporting periodThere were no events that have occurred after December&#160;31, 2023 and prior to the signing of this financial report that would likely have a material impact on the financial results presented.</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-1129">Segment information&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified on the basis of whether the allocation of resources and/or the assessment of performance of a particular component of the Company&#x2019;s activities are regularly reviewed by the Company&#x2019;s chief operating decision maker as a separate operating segment. By these criteria, the activities of the Company are considered to be one segment being the development of adult stem cell technology platform for commercialization, and the segmental analysis is the same as the analysis for the Company as a whole. The chief operating decision maker (Chief Executive Officer) reviews the consolidated income statement, balance sheet, and statement of cash flows regularly to make decisions about the Company&#x2019;s resources and to assess overall performance.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <meso:NumberOfOperatingSegment
      contextRef="c-1"
      decimals="INF"
      id="f-1130"
      unitRef="segment">1</meso:NumberOfOperatingSegment>
    <meso:DisclosureOfLegalProceedingsExplanatoryTextBlock contextRef="c-1" id="f-1131">Legal proceedings&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A class action proceeding in the Federal Court of Australia was served on the Company in May 2022 by the law firm William Roberts Lawyers on behalf of persons who, between February 22, 2018, and December 17, 2020, acquired an interest in Mesoblast shares, American Depository Receipts, and/or related equity swap arrangements. In June 2022, the firm Phi Finney McDonald commenced a second shareholder class action against the Company in the Federal Court of Australia asserting similar claims arising during the same period. Like the class action lawsuit from October 2020 filed in the U.S. Federal District Court for the Southern District of New York (which had court approval for settlement in August 2022), the Australian class actions relate to the Complete Response Letter released by the FDA in September 2020 in relation to the Company's GvHD product candidate; they also relate to certain representations made by the Company in relation to our COVID-19 product candidate and the decline in the market price of the Company's ordinary shares in December 2020. The Australian class actions have been consolidated into one lawsuit. The Company will continue to vigorously defend against the proceedings. The Company cannot provide any assurance as to the possible outcome or cost to us from the lawsuit, particularly as it is at an early stage, nor how long it may take to resolve such lawsuit. Thus, the Company has not accrued any amounts in connection with such legal proceedings.&lt;/span&gt;&lt;/div&gt;</meso:DisclosureOfLegalProceedingsExplanatoryTextBlock>
    <meso:NumberOfClassActionLawsuits
      contextRef="c-41"
      decimals="INF"
      id="f-1132"
      unitRef="lawsuit">1</meso:NumberOfClassActionLawsuits>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
